<SEC-DOCUMENT>0001628280-25-033606.txt : 20250701
<SEC-HEADER>0001628280-25-033606.hdr.sgml : 20250701
<ACCEPTANCE-DATETIME>20250630215050
ACCESSION NUMBER:		0001628280-25-033606
CONFORMED SUBMISSION TYPE:	40-F
PUBLIC DOCUMENT COUNT:		109
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250701
DATE AS OF CHANGE:		20250630

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBIN INC.
		CENTRAL INDEX KEY:			0001833141
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		40-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40673
		FILM NUMBER:		251094018

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
		BUSINESS PHONE:		(908) 764-8385

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
</SEC-HEADER>
<DOCUMENT>
<TYPE>40-F
<SEQUENCE>1
<FILENAME>cybn-20250331_d2.htm
<DESCRIPTION>40-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:517b8eb5-c396-4287-8f5e-af5641b4b385,g:1e9b6c9c-673a-419d-ac9f-76e5a6c29d23,d:f4e1c98d36f4414fb4a68955892ed48f-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:cybn="http://cybin.com/20250331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cybn-20250331_d2</title></head><body><div id="if4e1c98d36f4414fb4a68955892ed48f_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt"><span><br/></span></div></div><div><span><br/></span></div><div><img src="cybn-20250331_g4.jpg" alt="Image_0.jpg" style="height:2px;margin-bottom:5pt;vertical-align:text-bottom;width:624px" id="i-7"/></div><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/>Washington, D.C. 20549</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">____________________</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:145%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1173">40-F</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentRegistrationStatement" format="ixt:fixed-false" id="f-1174">[   ]</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registration statement pursuant to Section 12 of the Securities Exchange Act of 1934</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">or</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-1175">[X]</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="margin-top:0.1pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.149%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the fiscal year ended</span></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-1176"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-1177">March 31</ix:nonNumeric>, 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commission File Number</span></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-1178">001-40673</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">____________________</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-1179">Cybin Inc.</ix:nonNumeric><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-1180">Ontario</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityPrimarySicNumber" id="f-1181">2834</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Province or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Primary Standard Industrial Classification</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer </span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identification Number)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Code Number)</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-1182">100 King Street West</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-1183">Suite 5600</ix:nonNumeric><br/><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-1184">Toronto</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-1185">Ontario</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-1186">Canada</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-1187">M5X 1C9</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-1188">908</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-1189">764-8385</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>(Address and telephone number of Registrant&#8217;s principal executive offices)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">____________________</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-428" name="dei:ContactPersonnelName" id="f-1190">C T Corporation System</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-428" name="dei:EntityAddressAddressLine1" id="f-1191">1015 15th Street N.W.</ix:nonNumeric>, <ix:nonNumeric contextRef="c-428" name="dei:EntityAddressAddressLine2" id="f-1192">Suite 1000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-428" name="dei:EntityAddressCityOrTown" id="f-1193">Washington</ix:nonNumeric>, <ix:nonNumeric contextRef="c-428" name="dei:EntityAddressStateOrProvince" id="f-1194">DC</ix:nonNumeric> <ix:nonNumeric contextRef="c-428" name="dei:EntityAddressPostalZipCode" id="f-1195">20005</ix:nonNumeric></span></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-428" name="dei:CityAreaCode" id="f-1196">202</ix:nonNumeric>) <ix:nonNumeric contextRef="c-428" name="dei:LocalPhoneNumber" id="f-1197">572-3133</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>(Name, address (including zip code) and telephone number (including<br/>area code) of agent for service in the United States)</span></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">____________________</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered or to be registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.460%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-1198">Common Shares, no par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-1199">CYBN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-1200">NYSE American LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For annual reports, indicate by check mark the information filed with this Form:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AnnualInformationForm" format="ixt:fixed-true" id="f-1201">[X] Annual information form</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AuditedAnnualFinancialStatements" format="ixt:fixed-true" id="f-1202">[X] Audited annual financial statements</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report:&#160;As at March 31, 2025, Cybin Inc. had <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1203">21,601,208</ix:nonFraction> common shares outstanding. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. [&#160;X ] <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-1204">Yes</ix:nonNumeric> [  ] No</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). [X] <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-1205">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160; [  ] No</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company [<ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-1206">X</ix:nonNumeric>]</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange Act. [&#160; <ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-1207"></ix:nonNumeric>]</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224; The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. [&#160; ]</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. [&#160; <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-1208"></ix:nonNumeric>]</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-(b). [&#160; ]</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXPLANATORY NOTE</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybin Inc. (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is a Canadian issuer that is permitted, under the multijurisdictional disclosure system adopted in the United States, to prepare this Annual Report on Form 40-F (this &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Report</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), in accordance with Canadian disclosure requirements, which are different from those of the United States. The Company is a &#8220;foreign private issuer&#8221; as defined in Rule 3b-4 under the Exchange Act and Rule 405 under the Securities Act of 1933, as amended. Equity securities of the Company are accordingly exempt from Sections 14(a), 14(b), 14(c), 14(f) and 16 of the Exchange Act pursuant to Rule 3a12-3 thereunder.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD LOOKING STATEMENTS</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report, including the documents incorporated by reference herein, may contain &#8220;forward-looking information&#8221; or &#8220;forward-looking statements&#8221; within the meaning of applicable securities laws (collectively referred to herein as &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">forward-looking statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). All statements other than statements of historical fact, including, without limitation, those regarding the future financial position and results of operations, strategy, plans, objectives, goals, targets and future developments of the Registrant in the markets where the Registrant participates or is seeking to participate, and any statements preceded by, followed by or that include the words &#8220;considers&#8221;, &#8220;plans&#8221;, &#8220;expects&#8221; or &#8220;does not expect&#8221;, &#8220;is expected&#8221;, &#8220;budget&#8221;, &#8220;scheduled&#8221;, &#8220;estimates&#8221;, &#8220;forecasts&#8221;, &#8220;intends&#8221;, &#8220;anticipates&#8221; or &#8220;does not anticipate&#8221;, or &#8220;believes&#8221;, or variations of such words and phrases or statements that certain actions, events or results &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;might&#8221; or &#8220;will be taken&#8221;, &#8220;occur&#8221; or &#8220;be achieved&#8221; or the negative of these terms or comparable terminology, are forward-looking statements. These statements reflect management&#8217;s beliefs with respect to future events and are based on information available to management as of the respective dates of this Annual Report and the document incorporated by reference herein, including reasonable assumptions, estimates, internal and external analysis and opinions of management considering its experience, perception of trends, current conditions and expected developments as well as other factors that management believed to be relevant as at the date such statements were made.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated or implied in such forward-looking statements, including, without limitation, those described in the Registrant&#8217;s Annual Information Form for the year ended March 31, 2025, attached hereto as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 99.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant and management caution readers not to place undue reliance on any forward-looking statements, which speak only as of the date made. Although the Registrant believes that the expectations reflected in the forward-looking statements were reasonable as of the time such forward-looking statements were made, it can give no assurance that such expectations will prove to have been correct. The Registrant and management assume no obligation to update or revise them to reflect new events or circumstances except as required by applicable securities laws.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DIFFERENCES IN UNITED STATES AND CANADIAN REPORTING PRACTICES</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant is permitted, under a multijurisdictional disclosure system adopted by the United States Securities and Exchange Commission (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), to prepare this report in accordance with Canadian disclosure requirements, which are different from those of the United States. The Registrant prepares its consolidated financial statements, which are filed as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 99.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to this Annual Report, in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board and the audit is subject to Canadian auditing and auditor independence standards.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENCY</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, all dollar amounts in this Annual Report are in Canadian dollars. The exchange rate of United States dollars into Canadian dollars, on March 31, 2025, based upon the daily exchange rate as quoted by the Bank of Canada was USD$1.00 = CAD$1.4376.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRINCIPAL DOCUMENTS</span></div><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents have been filed as part of this Annual Report:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A. Annual Information Form</span></div><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant&#8217;s Annual Information Form for the fiscal year ended March 31, 2025 (the &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AIF</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is attached as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 99.1</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to this Annual Report and is incorporated by reference herein.</span></div><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B. Audited Annual Financial Statements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant&#8217;s consolidated audited annual financial statements for the fiscal year ended March 31, 2025, including the reports of the independent registered public accounting firm with respect thereto are attached as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 99.2</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to this Annual Report and are incorporated by reference herein.</span></div><div style="margin-bottom:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C. Management&#8217;s Discussion and Analysis</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant&#8217;s management&#8217;s discussion and analysis of financial condition and operating performance for the fiscal year ended March 31, 2025 (the &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MD&amp;A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is attached as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 99.3</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to this Annual Report and is incorporated by reference herein.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TAX MATTERS</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchasing, holding, or disposing of the Company&#8217;s securities may have tax consequences under the laws of the United States and Canada that are not described in this Annual Report.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DISCLOSURE CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this Annual Report, the Company carried out an evaluation, under the supervision of the Company's Chief Executive Officer (the &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CEO</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and Chief Financial Officer (the &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CFO</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), of the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act). Based upon that evaluation, the Company&#8217;s CEO and CFO have concluded that, as of the end of the period covered by this Annual Report, the Company&#8217;s disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (ii) accumulated and communicated to the Company&#8217;s management, including its principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company&#8217;s principal executive officer and principal financial officer believe that the Company&#8217;s disclosure controls and procedures provide a reasonable level of assurance that they are effective, they do not expect that the Company&#8217;s disclosure controls and procedures or internal control over financial reporting will prevent all errors or fraud. A control system, no matter how well conceived or operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S ANNUAL REPORT ON<br/>INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including the CEO and CFO, is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Exchange Act. The Company&#8217;s management has employed a framework consistent with Exchange Act Rule 13a-15(c), to evaluate the Company&#8217;s internal control over financial reporting described below. A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, that accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with applicable IFRS, and that receipts and expenditures of the company are only being made in accordance with authorizations of management and directors of the company; and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. It should be noted that a control system, no matter how well designed or operated, can provide only reasonable assurance, not absolute assurance of achieving the desired control objectives. These inherent limitations include, among other items: (i) that management&#8217;s assumptions and judgments could ultimately prove to be incorrect under varying conditions and circumstances; (ii) the impact of any undetected errors; and (iii) that controls may be circumvented by the unauthorized acts of individuals, by collusion of two or more people, or by management override.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that any design will not succeed in achieving its stated goals under all potential future conditions. Accordingly, because of the inherent limitations in a cost effective control system, misstatements due to error or fraud may occur and not be detected.  </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management, including the CEO and CFO, is responsible for establishing and maintaining adequate internal control over financial reporting, and used the framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013)(COSO) to evaluate the effectiveness of our controls. Based on this evaluation, management concluded that the Company&#8217;s internal controls over financial reporting were effective as of March 31, 2025.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ATTESTATION REPORT OF THE REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an "emerging growth company" under the Jumpstart our Business Startups Act, the Company is exempt from Section 404(b) of the Sarbanes-Oxley Act of 2002, which requires that a public company's registered public accounting firm provide an attestation report relating to management' assessment of internal control over financial reporting.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-bottom:0.1pt;text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in the Registrant&#8217;s internal control over financial reporting during the fiscal year ended March 31, 2025, that has materially affected, or is reasonably likely to materially affect, the Registrant&#8217;s internal control over financial reporting.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTICES PURSUANT TO REGULATION BTR</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no notices required by Rule 104 of Regulation BTR that the Company sent during the year ended March 31, 2025 concerning any equity security subject to a blackout period under Rule 101 of Regulation BTR.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center;text-indent:-0.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CORPORATE GOVERNANCE</span></div><div style="margin-bottom:5pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Board of Directors (the &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is responsible for the Company&#8217;s corporate governance and has the following independent designated standing committees: the Compensation Committee, the Governance and Nomination Committee and Audit Committee. The charters of each committee can be viewed on the Company's corporate website at&#160;https://ir.cybin.com/investors/governance/governance-documents/. In addition, the Company's Audit Committee Charter is attached as Exhibit "A" to the AIF, which is filed as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 99.1</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to this Annual Report.</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AUDIT COMMITTEE</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board has established an independent Audit Committee for the purpose of overseeing our accounting and financial reporting processes and the audit of our annual financial statements. The Audit Committee is composed entirely of independent directors who meet the independence and experience requirements of the NYSE American LLC (the &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NYSE American</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the&#160;Toronto&#160;Stock Exchange, SEC rules and National Instrument 52-110 adopted by Canadian securities regulators, as amended.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee is composed of Mark Lawson (Chair), Eric Hoskins, Theresa Firestone and Grant Froese.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Audit Committee Financia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">l Experts</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board has determined that each member of the audit committee qualifies as a financial expert (as defined in Item 407(d)(5)(ii) of Regulation S-K under the Exchange Act) and that all members are independent (as d</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">etermined under Exchange Act Rule 10A-3 and Section 803.A(2) of the NYSE American Company Guide).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC has indicated that the designation or identification of a person as an audit committee financial expert does not make such person an &#8220;expert&#8221; for any purpose, impose any duties, obligations or liability on such person that are greater than those imposed on members of the audit committee and the board of directors who do not carry this designation or identification, or affect the duties, obligations or liability of any other member of the audit committee or board of directors.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CODE OF ETHICS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted a code of ethics (the &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Business Conduct</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) that applies to all employees and officers, and directors. The Code of Business Conduct is available on the Company's corporate website at&#160;https://ir.cybin.com/investors/governance/governance-documents</span><span style="background-color:#ffffff;color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> [Any amendments to the Code of Business Conduct will be posted at the Company&#8217;s Internet website at the address listed above.] No waivers were granted from the Code of Business Conduct during the year ended March 31, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tabular disclosure of the amounts billed to us by our independent auditors for each of our last two fiscal years ended March 31</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as Audit Fees, Audit-Related Fees, Tax Fees and All Other Fees, is made o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n page 122 of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the AIF, filed as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 99.1</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to this Annual Report and is incorporated by reference herein.</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRE-APPROVAL OF AUDIT AND NON-AUDIT SERVICES PROVIDED BY</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee Charter sets out responsibilities regarding the provision of non-audit services by the Registrant&#8217;s external auditors and requires the Audit Committee to pre-approve all permitted non-audit services to be provided by the Registrant&#8217;s external auditors, in accordance with applicable law.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Audit Committee Charter is attached as Exhibit "A" to the AIF, which is filed as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 99.1</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to this Annual Report and is incorporated by reference herein.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's description of off-balance sheet arrangements is provided in the section entitled &#8220;Off-balance sheet arrangements" contained in the MD&amp;A filed as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 99.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to this Annual Report is incorporated by reference herein.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTRACTUAL OBLIGATIONS</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's description of contractual and other obligations is provided in the section entitled &#8220;Contractual obligations and commitments" contained in the MD&amp;A filed as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 99.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to this Annual Report is incorporated by reference herein.</span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NYSE AMERICAN CORPORATE GOVERNANCE</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s common shares are listed on the NYSE American. Section 110 of the NYSE American Company Guide (the &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Guide</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) permits the NYSE American to consider the laws, customs and practices of foreign issuers in permitting deviations from certain NYSE American listing criteria, and to grant exemptions from certain NYSE American listing criteria based on these considerations. A company seeking relief under these provisions is </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">required to provide written certification from independent local counsel that the non-complying practice is not prohibited by home country law. A description of the significant ways in which the Company&#8217;s governance practices differ from those followed by United States domestic companies pursuant to the Company Guide is set forth below.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Quorum for Shareholders&#8217; Meetings</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company Guide requires that a listed company&#8217;s bylaws provide for a quorum of not less than 33 1/3 percent of such company&#8217;s shares issued and outstanding and entitled to vote at a meeting of shareholders. The Company&#8217;s quorum requirements, as set forth in its by-laws, provide that the quorum for a shareholders&#8217; meeting shall be two (2) individuals present in person, each of whom is either a shareholder entitled to attend and vote at such meeting or the proxyholder of such a shareholder appointed by means of a valid proxy, holding or representing by proxy not less than five percent (5%) of the total number of the issued shares of the Company for the time being enjoying voting rights at such meeting unless a greater number of shareholders and/or a greater number of shares are required by the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Corporations Act </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Ontario) or by the articles or the by-laws).</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Board Composition</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company Guide requires that a listed company have a board of directors consisting of at least a majority of members who satisfy applicable independence standards under the Company Guide. The Company&#8217;s Board is currently composed of 7 members, 4 of whom qualify as independent under applicable independence standards under the Company Guide</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Governance and Nominating Committee.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company Guide requires board of director nominees to be selected or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recommended by either a Nominating Committee comprised solely of independent directors or by a majority of such company&#8217;s independent directors. The Company&#8217;s Governance and Nominating Committee is currently composed of 3 members, 3 of whom qualify as independent under applicable independence standards under the Company Guide.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation Committee. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company Guide requires the compensation of a listed company&#8217;s chief executive officer to be determined or recommended to the board of directors for determination, either by a Compensation Committee comprised of independent directors o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r by a majority of such company&#8217;s independent directors. The Company&#8217;s Compensation Committee consists of 3 directors, of which 3 are ind</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ependent under applicable independence standards under the Company Guide</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Shareholder Approval Requirements. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company Guide requires a listed company to obtain the approval of its shareholders for certain types of securities issuances, including private placements that may result in the issuance of common shares (or securities convertible into common shares) equal to 20 percent or more of presently outstanding shares for less than the greater of book or market value of the shares. The Company may seek a waiver from NYSE American&#8217;s shareholder approval requirements in circumstances where the securities issuance would not trigger such a requirement under Ontario law or under the rules of the Cboe Canada (the &#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cboe</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), on which the Company&#8217;s common shares are also listed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Proxy Delivery.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company Guide requires the solicitation of proxies and delivery of proxy statements for all shareholder meetings of a listed company and requires that these proxies be solicited pursuant to a proxy statement that conforms to SEC proxy rules. The Company is a &#8220;foreign private issuer&#8221; under Rule 3b-4 of the Exchange Act, and the equity securities of the Company are accordingly exempt from the proxy rules set forth in Sections 14(a), 14(b), 14(c) and 14(f) of the Exchange Act. The Company solicits proxies in accordance with applicable rules and regulations in Canada.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing is consistent with the laws, customs and practices in Canada and the rules of the Cboe. In addition, the Company may from time-to-time seek relief from the NYSE American corporate governance requirements on specific transactions under Section 110 of the Company Guide by providing written certification from independent local counsel that the non-complying practice is not prohibited by its home country law, in which case, the Company shall make the disclosure of such transactions available on its website at www.cybin.com. Information contained on, or accessible through, our website is not part of this Annual Report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MINE SAFETY DISCLOSURE</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDERTAKING</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company undertakes to make available, in person or by telephone, representatives to respond to inquiries made by the SEC staff, and to furnish promptly, when requested to do so by the SEC staff, information relating to: the securities registered pursuant to Form 40-F; the securities in relation to which the obligation to file an annual report on Form 40-F arises; or transactions in said securities.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT TO SERVICE OF PROCESS</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant previously filed with the SEC a written consent to service of process on Form F-X. Any change to the name or address of the Registrant&#8217;s agent for service shall be communicated promptly to the SEC by amendment to the Form F-X referencing the file number of the Registrant. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Exchange Act, the Registrant certifies that it meets all of the requirements for filing on Form 40-F and has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.783%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cybin Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Greg Cavers</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name: Greg Cavers</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Date: June 30,  2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title: Chief Financial Officer</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:12pt;margin-top:0.1pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The following documents are being filed with the SEC as Exhibits to this </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Form 40-F</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:130%">: </span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.357%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.52pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.37pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cybin-incentivecompensatio.htm">Incentive Compensation Recovery Policy</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;padding-right:3.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.37pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cybin-annualinformationfor.htm">Annual Information Form for the fiscal year ended March 31, 2025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;padding-right:3.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.37pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cybn-20250331.htm">Audited Annual Consolidated Financial Statements for the fiscal years ended March 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cybn-20250331.htm">5</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cybn-20250331.htm"> and March 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cybn-20250331.htm">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;padding-right:3.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.3</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:3.37pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cybin-mdaxq4x25xmarch31202.htm">Management&#8217;s Discussion and Analysis of Financial Condition and Operating Performance for the fiscal year ended March 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cybin-mdaxq4x25xmarch31202.htm">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;padding-right:3.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:3.35pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;text-decoration:underline" href="cybin-40xfxexhibit994xceo.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14 of the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;padding-right:3.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.5</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:3.35pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;text-decoration:underline" href="cybin-40xfxexhibit995cfo.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14 of the Securities Exchange Act of 1934, as amended </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;padding-right:3.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:3.35pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;text-decoration:underline" href="cybin-40xfxex996xceo906.htm">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;padding-right:3.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.7</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt;padding-right:3.35pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;text-decoration:underline" href="cybin-40xfxex997xcfo906.htm">Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;padding-right:3.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.8</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:3.35pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:145%;text-decoration:underline" href="cybin-consentform40xfannua.htm">Consent of Zeifmans LLP and Laurence W. Zeifman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.52pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance &#8211; the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.52pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.52pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.52pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.52pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.52pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.52pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt 2px 4.37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-top:0.1pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>2
<FILENAME>cybin-incentivecompensatio.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i9f85a51350e948b0b45fc50b8453b001_1"></div><div style="min-height:90.72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.35pt"><font><br></font></div><div style="padding-left:106.22pt;padding-right:106.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cybin Inc.</font></div><div style="margin-top:13.7pt;text-align:center"><font><br></font></div><div style="margin-top:0.05pt;padding-left:0.25pt;padding-right:0.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">INCENTIVE COMPENSATION RECOVERY POLICY</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:0.1pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:14.75pt;text-align:center"><font><br></font></div><div style="padding-left:101.77pt;padding-right:101.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">August 2023</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                                                                   </font><img alt="image_0b.jpg" src="image_0b.jpg" style="height:79px;margin-bottom:5pt;vertical-align:text-bottom;width:132px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="height:13.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9f85a51350e948b0b45fc50b8453b001_4"></div><hr style="page-break-after:always"><div style="min-height:87.84pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.75pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC.</font></div><div><font><br></font></div><div style="padding-left:0.47pt;padding-right:0.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INCENTIVE COMPENSATION RECOVERY POLICY</font></div><div style="margin-top:10.2pt"><font><br></font></div><div style="padding-left:50.95pt;text-indent:-26.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:17.95pt;text-decoration:underline">Introduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Board of Directors of Cybin Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) believe that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company's compensation philosophy. The Board has therefore adopted this policy, which provides for the recovery of erroneously awarded incentive compensation if the Company is required to prepare an accounting restatement due to material non-compliance of the Company with any financial reporting requirements under applicable securities laws (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). This Policy is designed to comply with Section 10D of the United States Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), related rules and the listing standards of the NYSE American or any other securities exchange on which the Company&#8217;s shares are listed in the future.</font></div><div style="margin-top:12pt;padding-left:50.95pt;text-indent:-26.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:17.95pt;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy shall be administered by the Board or, if so designated by the Board, the Governance &#38; Nomination Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in which case, all references herein to the Board shall be deemed references to the Committee. Any determinations made by the Board shall be final and binding on all affected individuals.</font></div><div style="margin-top:12.05pt;padding-left:50.95pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt;text-decoration:underline">Covered Executives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</font></div><div style="margin-top:12pt;padding-left:5.95pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless and until the Board determines otherwise, for purposes of this Policy, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Covered Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a current or former employee who is or was identified by the Company as the Company&#8217;s president, principal financial officer, principal compliance officer, a division head of the Company in charge of a principal business unit, division, or function (such as sales, legal, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company&#8217;s subsidiaries are deemed &#8220;Covered Executives&#8221; if they perform such policy-making functions for the Company. &#8220;Policy-making function&#8221; is not intended to include policy-making functions that are not significant. &#8220;Covered Executives&#8221; will include, at minimum, the executive officers identified by the Company pursuant to Item 401(b) of Regulation S-K of the Exchange Act. For the avoidance of doubt, &#8220;Covered Executives&#8221; will include at least the following Company officers&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Chief Executive Officer, President, Chief Operating Officer, Chief Financial Officer, Chief Compliance, Ethics &#38; Administrative Officer, Chief Growth Officer, Chief Scientific Officer, Chief Medical Officer and Chief Legal Officer.</font></div><div><font><br></font></div><div style="margin-top:11.1pt"><img alt="image_1b.jpg" src="image_1b.jpg" style="height:1px;margin-bottom:5pt;vertical-align:text-bottom;width:192px"></div><div style="margin-top:5.65pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:700;line-height:117%;position:relative;top:-3.32pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:117%"> </font><font style="color:#212b45;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:117%">&#8220;Covered Executive&#8221; is based on the definition of &#8220;officer&#8221; under Rule 16a-1(f) of the Exchange Act as presented in the listings standards.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                                                                                            </font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                                                                                                                                                      </font><img alt="image_0b.jpg" src="image_0b.jpg" style="height:34px;margin-bottom:5pt;vertical-align:text-bottom;width:57px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">   </font></div><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                                                                                     1   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">                                                                                                                      </font></div></div></div><div id="i9f85a51350e948b0b45fc50b8453b001_7"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.95pt;padding-left:6pt;padding-right:5.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy covers Incentive Compensation (defined below) received by a person after beginning service as a Covered Executive and who served as a Covered Executive at any time during the performance period for that Incentive Compensation.</font></div><div style="margin-top:12pt;padding-left:50.95pt;text-indent:-26.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:17.95pt;text-decoration:underline">Recovery&#58; Accounting Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event the Company is required to prepare an accounting restatement of its financial statements filed with the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) due to the Company&#8217;s material noncompliance with any financial reporting requirements under applicable securities laws (including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period) (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accounting Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Company will recover reasonably promptly any excess Incentive Compensation (defined below) received by any Covered Executive during the three completed fiscal years immediately preceding the date on which the Company is required to prepare an Accounting Restatement, including transition periods resulting from a change in the Company&#8217;s fiscal year as provided in Rule 10D-1 of the Exchange Act. Incentive Compensation is deemed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;received&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in the Company&#8217;s fiscal period during which the financial reporting measure specified in the Incentive Compensation award is attained, even if the payment or grant of the Incentive Compensation occurs after the end of that period. The determination of the time when the Company is &#8220;required&#8221; to prepare an Accounting Restatement shall be made in accordance with applicable SEC and national securities exchange rules and regulations.</font></div><div style="margin-top:12.05pt;padding-left:77.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.65pt;text-decoration:underline">Definition of Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:78pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this Policy, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a &#8220;financial reporting measure&#8221; (as defined in paragraph (b) below), including, for example, bonuses or awards under the Company&#8217;s short and long-term incentive plans, grants and awards under the Company&#8217;s equity incentive plans, and contributions of such bonuses or awards to the Company&#8217;s deferred compensation plans or other employee benefit plans that are not tax-qualified plans. For avoidance of doubt, Incentive Compensation that is deferred (either mandatorily or voluntarily) under the Company&#8217;s non-qualified deferred compensation plans, as well as any matching amounts and earnings thereon, are subject to this Policy. Incentive Compensation does not include awards which are granted, earned and vested without regard to attainment of financial reporting measures, such as time- vesting awards, discretionary awards and awards based wholly on subjective standards, strategic measures or operational measures.</font></div><div style="margin-top:12pt;padding-left:77.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.97pt;text-decoration:underline">Financial Reporting Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:78pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Financial reporting measures are those that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements (including non-GAAP financial measures) and any measures derived wholly or in part from such financial measures. For the avoidance of </font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                                                                                            </font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                                                                                                                                                      </font><img alt="image_0b.jpg" src="image_0b.jpg" style="height:34px;margin-bottom:5pt;vertical-align:text-bottom;width:57px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">   </font></div><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                                                                                     2   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">                                                                                                                      </font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:78pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">doubt, financial reporting measures include stock price and total shareholder return. </font></div><div style="margin-top:3.95pt;padding-left:78pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> A measure need not be presented within the financial statements or included in a filing with the SEC to constitute a financial reporting measure for purposes of this Policy.</font></div><div style="margin-top:12pt;padding-left:77.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.65pt;text-decoration:underline">Excess Incentive Compensation&#58; Amount Subject to Recovery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:78pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The amount(s) to be recovered from the Covered Executive will be the amount(s) by which the Covered Executive&#8217;s Incentive Compensation for the relevant period(s) exceeded the amount(s) that the Covered Executive otherwise would have received had such Incentive Compensation been determined based on the restated amounts contained in the Accounting Restatement. All amounts shall be computed without regard to taxes paid.</font></div><div style="margin-top:12pt;padding-left:78pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For Incentive Compensation based on financial reporting measures such as stock price or total shareholder return, where the amount of excess compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Board will calculate the amount to be reimbursed based on a reasonable estimate of the effect of the Accounting Restatement on such financial reporting measure upon which the Incentive Compensation was received. The Company will maintain documentation of that reasonable estimate and will provide such documentation to the applicable national securities exchange.</font></div><div style="margin-top:12pt;padding-left:77.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.97pt;text-decoration:underline">Method of Recovery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:78pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Board will determine, in its sole discretion, the method(s) for recovering as soon as practicable excess Incentive Compensation hereunder. Such methods may include, without limitation&#58;</font></div><div style="margin-top:12.05pt;padding-left:113.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.64pt">requiring reimbursement of Incentive Compensation previously paid&#59;</font></div><div style="margin-top:12pt;padding-left:114pt;padding-right:41.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">forfeiting any Incentive Compensation contribution made under the Company&#8217;s deferred compensation plans&#59;</font></div><div style="margin-top:11.95pt;padding-left:114pt;padding-right:15pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">offsetting the recovered amount from any compensation or Incentive Compensation that the Covered Executive may earn or be awarded in the future&#59;</font></div><div style="margin-top:12.05pt;padding-left:113.95pt;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.64pt">some combination of the foregoing&#59; or</font></div><div style="margin-top:11.95pt;padding-left:114pt;padding-right:45.05pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">taking any other remedial and recovery action permitted by law, as determined by the Board.</font></div><div style="margin-top:12pt;padding-left:42pt;padding-right:45.05pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:12pt;padding-left:50.95pt;padding-right:45.05pt;text-indent:-26.95pt"><font><br></font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                                                                                            </font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                                                                                                                                                      </font><img alt="image_0b.jpg" src="image_0b.jpg" style="height:34px;margin-bottom:5pt;vertical-align:text-bottom;width:57px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">   </font></div><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                                                                                     3   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">                                                                                                                      </font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.05pt;padding-left:50.95pt;text-indent:-26.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:17.95pt;text-decoration:underline">No Indemnification or Advance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:7.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to applicable law, the Company shall not indemnify, including by paying or reimbursing for premiums for any insurance policy covering any potential losses, any Covered Executives against the loss of any erroneously awarded Incentive Compensation, nor shall the Company advance any costs or expenses to any Covered Executives in connection with any action to recover excess Incentive Compensation.</font></div><div style="margin-top:12pt;padding-left:50.95pt;padding-right:7.8pt;text-indent:-26.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">6.&#160;&#160;&#160;&#160;      Interpretation.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:7.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Board is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act and any applicable rules or standards adopted by the SEC or any national securities exchange on which the Company's securities are listed.</font></div><div style="margin-top:12pt;padding-left:14.95pt;text-indent:-8.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">7.&#160;&#160;&#160;&#160;Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The effective date of this Policy is August 11, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). This Policy applies to Incentive Compensation received by Covered Executives on or after the Effective Date that results from attainment of a financial reporting measure based on or derived from financial information for any fiscal period ending on or after the Effective Date. In addition, this Policy is intended to be and will be incorporated as an essential term and condition of any Incentive Compensation agreement, plan or program that the Company establishes or maintains on or after the Effective Date.</font></div><div style="margin-top:12pt;padding-left:14.95pt;text-indent:-8.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amendment and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Board may amend this Policy from time to time at its discretion, and shall amend this Policy as it deems necessary to reflect changes in regulations adopted by the SEC under Section 10D of the Exchange Act and to comply with any rules or standards adopted by the NYSE American or any other United States securities exchange on which the Company&#8217;s shares are listed in the future.</font></div><div style="margin-top:12pt;padding-left:14.95pt;text-indent:-8.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">9.&#160;&#160;&#160;&#160;Other Recovery Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12.05pt;padding-left:6pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Board intends that this Policy will be applied to the fullest extent of the law. The Board may require that any employment agreement or similar agreement relating to Incentive Compensation entered into on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, require a Covered Executive to agree to abide by the terms of this Policy. Any right of recovery under this Policy is in addition to, and not in lieu of, any (i) other remedies or rights of compensation recovery that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, or similar agreement relating to Incentive Compensation, unless any such agreement expressly prohibits such right of recovery, and (ii) any other legal remedies available to the Company. The provisions of this Policy are in addition to (and not in lieu of) any rights to repayment the Company may have under Section 304 of the Sarbanes-Oxley Act of 2002 and other applicable laws.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                                                                                            </font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                                                                                                                                                      </font><img alt="image_0b.jpg" src="image_0b.jpg" style="height:34px;margin-bottom:5pt;vertical-align:text-bottom;width:57px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">   </font></div><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                                                                                     4   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">                                                                                                                      </font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:14.95pt;text-indent:-8.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">10.&#160;&#160;&#160;&#160;Impracticability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:6pt;padding-right:5.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company shall recover any excess Incentive Compensation in accordance with this Policy, except to the extent that certain conditions are met and the Board has determined that such recovery would be impracticable, all in accordance with Rule 10D-1 of the Exchange Act and the NYSE American or any other securities exchange on which the Company&#8217;s shares are listed in the future.</font></div><div style="margin-top:3.95pt;padding-left:14.95pt;text-indent:-8.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">11.&#160;&#160;&#160;&#160;Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy shall be binding upon and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators, or other legal representatives.</font></div><div style="height:58.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                                                                                            </font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                                                                                                                                                      </font><img alt="image_0b.jpg" src="image_0b.jpg" style="height:34px;margin-bottom:5pt;vertical-align:text-bottom;width:57px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">   </font></div><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">                                                                                     5   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">                                                                                                                      </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>cybin-annualinformationfor.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="if1a3b9b71ce54ff2b8fe30144be67c76_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:18pt;text-align:center"><font><br></font></div><div style="margin-bottom:18pt;margin-top:174pt;text-align:center"><img alt="image_0c.jpg" src="image_0c.jpg" style="height:90px;margin-bottom:5pt;vertical-align:text-bottom;width:155px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><br></font></div><div style="margin-bottom:18pt;margin-top:30pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CYBIN INC. </font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ANNUAL INFORMATION FORM</font></div><div style="margin-bottom:156pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FOR THE YEAR ENDED MARCH 31, 2025  </font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">JUNE 30, 2025</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_4"></div><hr style="page-break-after:always"><div style="min-height:114.48pt;width:100%"><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center"><font><br></font></div><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Page</font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">GENERAL</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_10" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">MARKET AND INDUSTRY DATA</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_13" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_16" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">REGULATORY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_16" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_16" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">GLOSSARY OF TERMS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_19" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_22" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">CORPORATE STRUCTURE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_22" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">14</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_22" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">GENERAL DEVELOPMENT OF THE BUSINESS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_22" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">16</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_25" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">DESCRIPTION OF THE BUSINESS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_25" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">27</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_28" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">RISK FACTORS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_28" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">76</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_7" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">DIVIDEND AND DISTRIBUTIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_31" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">110</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_34" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">DESCRIPTION OF CAPITAL STRUCTURE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_34" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">110</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">MARKET FOR SECURITIES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_37" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">111</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_40" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">DIRECTORS AND EXECUTIVE OFFICERS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_40" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">113</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_43" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">CEASE TRADE ORDERS, BANKRUPTCIES, PENALTIES OR SANCTIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_43" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">118</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_46" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">CONFLICTS OF INTEREST</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_46" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">119</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">LEGAL PROCEEDINGS AND REGULATORY ACTIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_49" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">119</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_52" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_52" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">119</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_55" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AUDITOR, TRANSFER AGENT AND REGISTRAR</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_55" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">120</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_58" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">MATERIAL CONTRACTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_58" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">120</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_61" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">INTERESTS OF EXPERTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_61" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">120</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_64" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AUDIT COMMITTEE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_64" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">120</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_67" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">COMPLIANCE PROGRAM</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_67" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">122</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_70" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">INSIDER TRADING POLICY AND CODE OF ETHICS AND BUSINESS CONDUCT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_70" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">123</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_73" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ADDITIONAL INFORMATION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_73" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">124</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_76" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EXHIBIT &#8220;A&#8221; AUDIT COMMITTEE CHARTER</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:0.02pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if1a3b9b71ce54ff2b8fe30144be67c76_76" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">A-1</a></font></div></td></tr></table></div><div><font><br></font></div><div style="height:74.16pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:1.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:43.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.435%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-i-</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:1.5pt"><font><br></font></div><div><font><br></font></div></div></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GENERAL</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In this annual information form (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AIF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) unless otherwise noted or the context indicates otherwise, references to the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">we</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">us</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">our</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; refer to Cybin Inc. and its subsidiaries.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All financial information in this AIF is prepared in Canadian dollars and using International Financial Reporting Standards as issued by the International Accounting Standards Board. Unless otherwise noted herein, this AIF applies to the business activities and operations of the Company for the year ended March 31, 2025, as updated to June 30, 2025, unless otherwise indicated.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All dollar amounts in this AIF are expressed in thousands of Canadian dollars, except as otherwise indicated. References to US$ or &#8220;U.S. dollars&#8221; are to thousands of United States dollars, unless otherwise indicated. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On September 19, 2024, the outstanding common shares in the capital of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Common Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) were consolidated on the basis of one new Common Share for every 38 existing Common Shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2024</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). As a result, all figures related to shares, warrants and options presented in this AIF have been restated retrospectively for all periods to reflect the Consolidation unless otherwise indicated.</font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_10"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This AIF, and certain documents incorporated by reference in this AIF, contain</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">forward-looking information and forward-looking statements within the meaning of Canadian securities legislation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">forward-looking statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). All statements other than statements of historical fact contained in this AIF and in documents incorporated by reference in this AIF, including, without limitation, those regarding the Company&#8217;s future financial position, business strategy, budgets, research and development, plans and objectives of management for future operations, and any statements preceded by, followed by or that include the words &#8220;expect,&#8221; &#8220;likely&#8221;, &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; or &#8220;anticipate,&#8221; &#8220;potential,&#8221; &#8220;proposed,&#8221; &#8220;estimate&#8221; and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions &#8220;may&#8221; or &#8220;will&#8221; happen, or by discussions of strategy, are forward-looking statements. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Forward-looking statements and information include, without limitation, the information concerning possible or assumed future results of operations of the Company set out under &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, including statements regarding&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">assumptions and expectations described in the Company&#8217;s critical accounting policies and estimates&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the Company&#8217;s expectations regarding the adoption and impact of certain accounting pronouncements&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the Company&#8217;s expectations regarding the market for psilocybin products&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the Company&#8217;s expectations regarding legislation, regulations and licensing related to the import, export, processing and sale of psilocybin products&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the approval of regulatory bodies of psychedelic substances including psilocybin, for the treatment of various health conditions&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the healthcare industry in Canada, the United States, the Netherlands, the European Union (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), Ireland and the United Kingdom&#59;  </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the ability to enter and participate in international market opportunities&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the ability to secure inventory through long-term supply contracts or otherwise&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">product diversification and future corporate development&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">anticipated results of research and development&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">production capacity expectations including discussions of plans or potential for expansion of capacity at existing or new facilities&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">expectations with respect to future expenditures and capital activities&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">statements about expected use of proceeds from fundraising activities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These statements are not historical facts, but instead represent only the Company&#8217;s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Management provides forward-looking statements because it believes they provide useful information to readers when considering their investment objectives and cautions readers that the information may not be appropriate for other purposes. Consequently, all of the forward-looking statements made in this AIF and in documents incorporated by reference in this AIF are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this AIF and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The forward-looking statements in this AIF and in documents incorporated by reference in this AIF are based on numerous assumptions regarding the Company&#8217;s present and future business strategies and the environment in which the Company will operate in the future, including assumptions regarding business and operating strategies, and the Company&#8217;s ability to operate on a profitable basis. The Company does not undertake any obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this report, except as may be required by law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Some of the risks which could affect future results and could cause results to differ materially from those expressed in the forward-looking statements contained herein include&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Risks Related to the Company&#8217;s Business and Industry&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">limited operating history&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">achieving publicly announced milestones&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">speculative nature of investment risk&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">early stage of the industry and product development&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">regulatory risks and uncertainties&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">risks of operating in European countries&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">&#8220;foreign private issuer&#8221; status under the U.S. securities laws&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">plans for growth&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">limited products&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">limited marketing and sales capabilities&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">no assurance of commercial success&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">no profits or significant revenues&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">reliance on third parties for clinical development activities&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">risks related to third party relationships&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">reliance on contract manufacturers&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">safety and efficacy of products&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">clinical testing and commercializing products&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">completion of clinical trials&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">commercial grade product manufacturing&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">nature of regulatory approvals&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">unfavourable publicity or consumer perception&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">social media&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">biotechnology and pharmaceutical market competition&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">reliance on key executives and scientists&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">employee misconduct&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">business expansion and growth&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">negative results of external clinical trials or studies&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">product liability&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">enforcing contracts&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">distribution and supply chain interruption&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">difficulty to forecast&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">promoting the brand&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">product viability&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">success of quality control systems&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">reliance on key inputs&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">liability arising from fraudulent or illegal activity&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">operating risk and insurance coverage&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">costs of operating as public company&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">management of growth&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">conflicts of interest&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">foreign operations&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">exchange rate fluctuations </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">cybersecurity and privacy risk&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">environmental regulation and risks&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">decriminalisation of psychedelics&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">forward-looking statements may prove to be inaccurate&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">effects of inflation&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">political and economic conditions&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">application and interpretation of tax laws&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">enforcement of civil liabilities&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">pandemics&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Risks Related to Intellectual Property&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">trademark protection&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">trade secrets&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">patent law reform&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">patent litigation and intellectual property&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">protection of intellectual property&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">third-party licenses&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial and Accounting Risks&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">substantial number of authorized but unissued Common Shares (as defined herein)&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">dilution&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">negative cash flow from operating activities&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">additional capital requirements&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">lack of significant product revenue&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">estimates or judgments relating to critical accounting policies&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">inadequate internal controls&#59;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Risks related to the Common Shares&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">market for the Common Shares&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">significant sales of Common Shares&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">volatile market price for the Common Shares&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">tax issues&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">no dividends.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Although the forward-looking statements contained in this AIF are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. In particular, the Company has made assumptions regarding, among other things&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">substantial fluctuation of losses from quarter to quarter and year to year due to numerous external risk factors, and anticipation that we will continue to incur significant losses in the future&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">uncertainty as to the Company&#8217;s ability to raise additional funding to support operations&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the Company&#8217;s ability to access additional funding&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the fluctuation of foreign exchange rates&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the risks associated with pandemics&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the risks associated with the development of the Company&#8217;s product candidates which are at early stages of development&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">reliance upon industry publications as the Company&#8217;s primary sources for third-party industry data and forecasts&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">reliance on third parties to plan, conduct and monitor the Company&#8217;s preclinical studies and clinical trials&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">reliance on third party contract manufacturers to deliver quality clinical and preclinical materials&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the Company&#8217;s product candidates may fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or may not otherwise produce positive results&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">risks related to filing investigational new drug applications to commence clinical trials and to continue clinical trials if approved&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the risks of delays and inability to complete clinical trials due to difficulties enrolling patients&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">competition from other biotechnology and pharmaceutical companies&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the Company&#8217;s reliance on the capabilities and experience of the Company&#8217;s key executives and scientists and the resulting loss of any of these individuals&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the Company&#8217;s ability to fully realize the benefits of acquisitions&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the Company&#8217;s ability to adequately protect the Company&#8217;s intellectual property and trade secrets&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the risk of patent-related or other litigation&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the risk of unforeseen changes to the laws or regulations in the United States, the United Kingdom, Canada, the Netherlands, Ireland and other jurisdictions in which the Company operates.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Drug development involves long lead times, is very expensive and involves many variables of uncertainty. Anticipated timelines regarding drug development are based on reasonable assumptions </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">informed by current knowledge and information available to the Company. Every patient treated on future studies can change those assumptions either positively (to indicate a faster timeline to new drug applications and other approvals) or negatively (to indicate a slower timeline to new drug applications and other approvals). This AIF contains certain forward-looking statements regarding anticipated or possible drug development timelines. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company&#8217;s development efforts to date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition to the factors set out above and those identified in this AIF under &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, other factors not currently viewed as material could cause actual results to differ materially from those described in the forward-looking statements. Although Cybin has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be anticipated, estimated or intended. Accordingly, readers should not place any undue reliance on forward-looking statements.</font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_13"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MARKET AND INDUSTRY DATA</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This AIF includes market and industry data that has been obtained from third-party sources, including industry publications. The Company believes that the industry data is accurate and that its estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third-party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this AIF or ascertained the underlying economic assumptions relied upon by such sources. The Company does not intend, and undertakes no obligation, to update or revise any such information or data, whether as a result of new information, future events or otherwise, except as, and to the extent required by, applicable Canadian securities laws.</font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_16"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">REGULATORY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s current business focuses on conducting and sponsoring research and development on psychedelic molecules, including psilocybin, and is focused on developing and commercializing psychedelic-inspired regulated medicines. No product will be commercialized prior to applicable legal or regulatory approval. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Canadian and United States federal governments regulate drugs through the CDSA (as defined herein) and the CSA (as defined herein), respectively, which place controlled substances in a schedule. Under the CDSA, psilocybin is currently a Schedule III drug under CDSA and a Schedule I drug under the CSA. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In both Canada and the United States, the applicable federal government is responsible for regulating, among other things, the approval, import, sale and marketing of drugs, including any psychedelic substances, whether natural or novel. Health Canada, and the FDA (as defined herein), have not approved psilocybin as a drug for any indication. The Company does not deal with psychedelic substances except indirectly within laboratory and clinical trial settings conducted within approved regulatory frameworks in order to identify and develop potential treatments for medical conditions and, further, does not have </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any direct or indirect involvement with illegal selling, production or distribution of any substances in jurisdictions in which it operates. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the EU, the INCB (as defined herein), a United Nations entity, oversees the enforcement of international restrictions on controlled substances. EU legislation specifically addresses the regulation of precursors or substances used in the illicit production of drugs through Regulation (EC) No. 273&#47;2004 and Council Regulation (EC) No. 111&#47;2005. However, the EU does not classify different narcotic drugs or psychotropic substances directly. Instead, the Council Decision 2005&#47;387&#47;JHA allows for a decision that can mandate EU member states to impose national controls on a drug, aligning with INCB standards. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EU member states have agreed to prohibit the use of DMT, and in limited and specific cases, inter alia for scientific or medical purposes, regulate the use of DMT. There are specific regulatory requirements in each specific and relevant EU member state, similar to regulating the specific regulatory requirements for the approval of clinical trials at an EU member state level. It is noteworthy to mention that the EU is planning to adopt a pharmaceutical legislation package.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The key legislation in the UK includes MDA (as defined herein), and the MDR (as defined herein), and, if a product is a &#8220;medicinal product&#8221;, by the Human Medicines Regulations 2012. In the UK, substances like psilocin and its esters, including psilocybin, are classified as Class A drugs under the MDA and Schedule 1 drugs under the MDR, meaning they are considered highly dangerous and subject to the strictest controls and penalties. Their legal manufacture, production, possession, and supply require a special licence from the UK Home Office. DMT is similarly classified as a Class A and Schedule 1 drug under these regulations. The manufacturing and marketing of &#8220;medicinal products&#8221; requires additional authorisation and licences from the MHRA (as defined herein). </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company oversees and monitors compliance with applicable laws in each jurisdiction in which it operates. In addition to the Company&#8217;s senior executives and the employees responsible for overseeing compliance, the Company has local counsel engaged in every jurisdiction in which it operates. See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Compliance Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;. Additionally, the Company has received legal opinions or advice in each jurisdiction where it currently operates regarding (a) compliance with applicable regulatory frameworks and (b) potential exposure and implications arising from applicable laws in jurisdictions where the Company has operations or intends to operate. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For these reasons, the Company may be (a) subject to heightened scrutiny by regulators, stock exchanges, clearing agencies and other authorities, (b) susceptible to regulatory changes or other changes in law, and (c) subject to risks related to drug development, among other things. There are a number of risks associated with the business of the Company. See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; herein.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company makes no medical, treatment or health benefit claims about the Company&#8217;s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamines, tryptamine derivatives or other psychedelic compounds. The efficacy of such products have not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamines, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company&#8217;s performance and operations.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div><div style="text-align:center"><font><br></font></div></div></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GLOSSARY OF TERMS</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition to terms defined elsewhere in this AIF, the following terms, when used in this AIF, will have the following meanings (unless otherwise indicated)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2010 Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2021 Base Shelf Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022 ATM Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Distribution Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 ATM Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 Base Shelf Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 Distribution Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2024 Consolidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2025 ATM Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2025 Distribution Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Adelia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Corporate Structure &#8211; Name, Address and Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Adelia Shareholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Corporate Structure &#8211; Name, Address and Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Adelia Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Corporate Structure &#8211; Name, Address and Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ADME</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Absorption, Distribution, Metabolism, and Excretion. </font></div><div style="margin-bottom:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a company that is affiliated with another company as described below. A company is an &#8220;affiliate&#8221; of another company if&#58;</font></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;one of them is the subsidiary of the other, or</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;each of them is controlled by the same person.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A company is &#8220;controlled&#8221; by a person if&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;voting securities of the company are held, other than by way of security only, by or for the benefit of that person, and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the voting securities, if voted, entitle the person to elect a majority of the directors of the company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A person beneficially owns securities that are beneficially owned by&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;a company controlled by that person, or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;an affiliate of that person or an affiliate of any company controlled by that person.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Agents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amalco</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the company resulting from the amalgamation of Cybin and Subco pursuant to the Amalgamation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amalgamation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the amalgamation of Subco and Cybin pursuant to Section 174 of the OBCA on the terms and subject to the conditions of the Amalgamation Agreement, which resulted in the reverse takeover of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amalgamation Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Amalgamation Agreement dated as of June 26, 2020 among Cybin, Clarmin and Subco relating to the Amalgamation, as amended on October 21, 2020, a copy of which is available under the Company&#8217;s profile on SEDAR+ at www.sedarplus.ca.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">APPROACH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Corporate Structure &#8211; Name, Address, and Incorporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Arrangement Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Corporate Structure &#8211; Name, Address, and Incorporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Asset Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Associate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in Section 1(1) of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Securities Act </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Ontario), RSO 1990, c.S.5.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">August 2023 Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">August 2023 Underwriting Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">August 2023 Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">August 2023 Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">BCBCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Business Corporations Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (British Columbia), as amended.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the board of directors of Clarmin prior to the Transaction and the board of directors of the Company following the Transaction.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">BTD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Canadian FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Stage of Development of Principal Products.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CCMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Regulatory Environment &#8211; Europe (Netherlands).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CDSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> Controlled Drugs and Substances Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (Canada).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">cGMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Stage of Development of Principal Products.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Charter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Audit Committee.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CHDR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CIPO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors &#8211; Risks Related to Intellectual Property &#8211; Patent Law Reform.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Clarmin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Clarmin Explorations Inc., as a company existing, prior to the Transaction, under the BCBCA via articles of incorporation dated October 13, 2016, and continued under the OBCA on November 4, 2020 in connection with the Transaction.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Clarmin Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the authorized common shares in the capital of Clarmin, as constituted prior to the Consolidation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Class B Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Intercorporate Relationships.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Clinilabs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Stage of Development of Principal Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CMDh</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Regulatory Environment &#8211; Europe (Netherlands).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CMOs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors - Reliance on Contract Manufacturers.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CNS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Insider Trading Policy and Code of Ethics And Business Conduct &#8211; Code of Business Conduct.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Common Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Cybin Inc., a company existing under the OBCA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Corporate Structure &#8211; Name, Address and Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contribution Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Court</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Significant Acquisitions and Dispositions.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Controlled Substances Act </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(21 U.S.C. &#167; 811, et. seq.). </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CSE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Canadian Securities Exchange.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CTA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Clinical Trial Application.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CTAG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Regulatory Environment &#8211; EU (Netherlands).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CTR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Regulatory Environment &#8211; EU (Netherlands).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cybin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Cybin Corp., prior to giving effect to the Transaction, a corporation existing under the OBCA, which, pursuant to the Transaction, amalgamated with Subco to form Amalco under the name &#8220;Cybin Corp.&#8221; and became a wholly-owned subsidiary of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cybin Ireland</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Cybin IRL Limited, a corporation existing under the laws of Ireland and a wholly-owned subsidiary of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cybin Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the common shares in the capital of Cybin.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cybin U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Cybin U.S. Holdings Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">DEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">DMT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means N, N-dimethyltryptamine. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">dDMT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Dutch Opium Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Regulatory Environment &#8211; Europe (Netherlands).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Equity Incentive Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Company&#8217;s omnibus equity incentive plan adopted by the Board on November 5, 2020.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Regulatory Environment &#8211; Europe (Netherlands).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EMBRACE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Entheon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Cautionary Note Regarding Forward-Looking Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXTEND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8211; Regulatory Environment &#8211; United States.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FFDCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Stage of Development of Principal Products. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">forward-looking statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Cautionary Note Regarding Forward-Looking Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GDP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Regulatory Environment - United Kingdom.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Stage of Development of Principal Products. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Stage of Development of Principal Products. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HPFB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Regulatory Environment &#8211; Canada.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IFRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means International Financial Reporting Standards, as adopted by the International Accounting Standards Board, as amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IMPD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Regulatory Environment &#8211; EU (Netherlands).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Regulatory Environment &#8211; United Kingdom.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INCB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Regulatory Environment &#8211; EU (Netherlands) </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">including</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means including without limitation, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">include</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">includes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; each have a corresponding meaning.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Insiders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Insider Trading Policy and Code of Ethics and Business Conduct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Interim Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Significant Acquisitions and Dispositions.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IRB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ireland MDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Research and Development &#8211; Ireland.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ireland MDR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Research and Development &#8211; Ireland.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Listing Statement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Cboe Canada Form 1 Listing Statement dated November 9, 2020, as filed on SEDAR+ November 9, 2020, which has been filed as required in accordance with the policies of Cboe Canada.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LottoGopher</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Corporate Cease Trade Orders or Bankruptcies&#59; Penalties or Sanctions&#59; Personal Bankruptcies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LPC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LPC Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MADRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Montgomery-Asberg Depression Rating Scale.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">March 2024 Agency Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">March 2024 Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">May 2023 Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Regulatory Environment &#8211; United Kingdom.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MDD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MDR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Regulatory Environment &#8211; United Kingdom.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MHRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Regulatory Environment &#8211; United Kingdom.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MIA(IMP)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Regulatory Environment &#8211; United Kingdom.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Mindset</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Natures Journey&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means Natures Journey Inc., an Ontario corporation incorporated as a wholly-owned subsidiary of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Research and Development &#8211; United States.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NDS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Research and Development &#8211; Canada.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NI 51-102</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means National Instrument 51-102 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Continuous Disclosure Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of the Canadian Securities Administrators.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NI 52-109</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means National Instrument 52-109 &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Certification of Disclosure in Issuers&#8217; Annual and Interim Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NI 52-110</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means National Instrument 52-110 &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Audit Committees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">November 2023 Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">November 2023 Underwriting Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">November 2023 Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">November 2023 Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NYSE American</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OBCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Business Corporations Act </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Ontario), as amended.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an option to purchase Common Shares granted pursuant to the Equity Incentive Plan. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Corporate Cease Trade Orders or Bankruptcies&#59; Penalties or Sanctions&#59; Personal Bankruptcies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OTCQB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PCT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means pharmacodynamic. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PDD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors - Risks Related To The Company&#8217;s Business and Industry - Early Stage of the Industry and Product Development.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PIPEDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors - Cybersecurity and Privacy Risk.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means pharmacokinetic. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PRV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means pulse rate variability.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reverse Takeover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in NI 51-102.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Research and Development &#8211; EU (Netherlands).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Regulatory Environment &#8211; Canada.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 56 Exemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Regulatory Environment &#8211; Canada.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Serenity Life</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Serenity Life Sciences Inc., an Ontario corporation incorporated as a wholly-owned subsidiary of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Small Pharma</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Corporate Structure &#8211; Name, Address and Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Small Pharma Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Significant Acquisitions and Dispositions.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SSRIs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means selective serotonin reuptake inhibitors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Subco</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means 2762898 Ontario Inc., a wholly-owned subsidiary of Clarmin, incorporated for the purposes of effecting the Amalgamation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Support Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Corporate Governance &#8211; Intercorporate Relationships.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TPD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Regulatory Environment &#8211; Canada.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the three-cornered amalgamation among Clarmin, Cybin and Subco pursuant to the terms of the Amalgamation Agreement, which constituted a Reverse Takeover of Clarmin by Cybin.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TSXV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the TSX Venture Exchange.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the United Nations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">United Kingdom</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the&#160;United Kingdom of Great Britain and Northern Ireland.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the United States of America, its territories and possessions, any state of the United States and the District of Columbia.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">USPTO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the U.S. Patent and Trademark Office.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Warrant Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means warrants to purchase Common Shares. </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13</font></div><div style="text-align:center"><font><br></font></div></div></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_22"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CORPORATE STRUCTURE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Name, Address and Incorporation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cybin Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) was incorporated under the BCBCA on October 13, 2016 under the name &#8220;Clarmin Explorations Inc.&#8221;. On January 8, 2018, the Company completed its initial public offering of Common Shares, pursuant to which the Company issued 3,500,000 Common Shares at a price of $0.10 per Common Share (pre-2024 Consolidation) for gross proceeds of $350. The Common Shares were listed on the TSXV on January 8, 2018 under the symbol &#8220;CX&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subco was incorporated under the OBCA on June 26, 2020 for the purposes of effecting the Amalgamation. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On November 2, 2020, in connection with the Transaction, Clarmin consolidated its outstanding Clarmin Shares on a 6.672 old for one (1) new basis (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon closing of the Transaction, on November 5, 2020&#58; (i) the Company (then Clarmin) and Cybin completed a series of transactions resulting in a reorganization of Cybin and the Company and pursuant to which the Company became the direct parent and sole shareholder of Cybin&#59; (ii) the Company changed its year end from July 31 to March 31&#59; and (iii) the Company was continued under the OBCA by Certificate and Articles of Continuance and changed its name to &#8220;Cybin Inc.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Transaction constituted a Reverse Takeover of the Company by Cybin, with Cybin as the reverse takeover acquirer and the Company as the reverse takeover acquiree, under applicable securities laws and for accounting purposes under IFRS.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Clarmin Shares were listed on the TSXV until November 5, 2020 when they were delisted from the TSXV in connection with the completion of the Transaction. The Common Shares commenced trading on Cboe Canada on November 10, 2020, under the symbol &#8220;CYBN&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 8, 2021, the Company announced that its Common Shares had commenced trading on the OTCQB&#174; Venture Market (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OTCQB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) under the symbol &#8220;CLXPF&#8221;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On August 5, 2021, the Common Shares commenced trading on the NYSE American LLC stock exchange (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NYSE American</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) under the symbol &#8220;CYBN&#8221;. Concurrent with the commencement of trading on the NYSE American, the Common Shares ceased to be quoted on the OTCQB.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On October 23, 2023, the Company announced the completion of the acquisition by Cybin of Small Pharma Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Small Pharma</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) by way of a statutory plan of arrangement under the provisions of the BCBCA (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The Arrangement was completed pursuant to the terms of an arrangement agreement entered into between the Company and Small Pharma dated August 28, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Arrangement Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). As a result of the Arrangement, Small Pharma became a wholly-owned subsidiary of Cybin. For further information see &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Significant Acquisitions and Dispositions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On September 19, 2024, the Company completed the 2024 Consolidation. As a result, all figures related to shares, warrants and options presented in this AIF have been restated retrospectively for all periods to reflect the 2024 Consolidation unless otherwise indicated.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s registered office and head office is located at 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Intercorporate Relationships</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cybin was incorporated under the OBCA on October 22, 2019. Pursuant to the Amalgamation, Cybin amalgamated with Subco to form Amalco under the name &#8220;Cybin Corp.&#8221;, which is a wholly-owned subsidiary of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Natures Journey, a wholly-owned, subsidiary of the Company, was formed under the OBCA on November 6, 2019. Effective June 4, 2025, the Company completed the voluntary dissolution of Natures Journey under the OBCA. This entity was non-operational prior to its dissolution. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Serenity Life, a wholly-owned, subsidiary of the Company, was formed under the OBCA on November 6, 2019. Effective June 4, 2025, the Company completed the voluntary dissolution of Serenity Life under the OBCA. This entity was non-operational prior to its dissolution.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cybin U.S., a fully-controlled subsidiary of the Company, was formed under the law of the State of Nevada on December 4, 2020. Certain of the Company&#8217;s business operations pertaining to psilocybin research and development are conducted through Cybin U.S. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On December 4, 2020, the Company entered into a contribution agreement, as amended on September 24, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contribution Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) with Cybin, Cybin U.S. and all of the shareholders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Adelia Shareholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of Adelia Therapeutics Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Adelia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) whereby Cybin U.S. agreed to purchase from the Adelia Shareholders all of the issued and outstanding Adelia shares in exchange for the Class B Shares (as defined herein) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Adelia Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Under the Contribution Agreement, the Adelia Shareholders are entitled to Class B Shares upon the occurrence of certain milestones, as set out in the Contribution Agreement. Pursuant to the Contribution Agreement and the support agreement entered into among Cybin U.S. and the Adelia Shareholders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Support Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the Adelia Shareholders received 868,833</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">non-voting Class B common shares in the capital of Cybin U.S. (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Class B Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), which are exchangeable for Common Shares, on a 0</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26316</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Common Shares for 1 Class B Share basis, at the option of the holder thereof, subject to customary adjustments.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cybin Ireland, a wholly-owned subsidiary of the Company, was formed under the Companies Act of 2014 in the country of Ireland on May 6, 2021. In connection with the formation of Cybin Ireland, the Company transferred its intellectual property assets to this entity. In addition, certain of the Company&#8217;s business operations, including European operations and research activities with various academic and clinical research organizations, are conducted through Cybin Ireland.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On October 23, 2023, the Company announced the completion of the acquisition by Cybin of Small Pharma by way of the Arrangement. As a result of the Arrangement, Small Pharma became a wholly-owned subsidiary of Cybin. On April 1, 2024, pursuant to the provisions of the OBCA, Small Pharma completed a horizontal amalgamation with Cybin Corp., with Cybin Corp. being the resulting entity. As a result of this amalgamation, Cybin UK Limited is now a wholly-owned subsidiary of Cybin Corp. (See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">s&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following chart sets out all the Company&#8217;s material subsidiaries as at the date hereof, their jurisdictions of incorporation and the Company&#8217;s direct and indirect voting interest in each of these subsidiaries.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><img alt="image_1.jpg" src="image_1.jpg" style="height:328px;margin-bottom:5pt;vertical-align:text-bottom;width:496px"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Note&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The Adelia Shareholders hold certain non-voting securities of Cybin U.S. For further information see &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GENERAL DEVELOPMENT OF THE BUSINESS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On November 5, 2020, Cybin completed its Reverse Takeover of Clarmin pursuant to the terms of the Amalgamation Agreement. The Transaction was completed by way of a &#8220;three-cornered&#8221; amalgamation pursuant to the provisions of the OBCA whereby Cybin amalgamated with Subco to form an amalgamated corporation and a wholly owned subsidiary of the Company. With the completion of the Transaction the Common Shares became listed for trading on Cboe Canada under the trading symbol &#8220;CYBN&#8221; and were delisted from the facilities of the TSXV. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additional details regarding the Transaction and the business of the Company can be found in the Listing Statement as filed on SEDAR+ on November 9, 2020.</font></div><div style="margin-bottom:12pt;margin-top:11.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%;text-decoration:underline">Three Year History</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:700;line-height:133%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Year ended March 31, 2023</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April 1, 2022, Adelia achieved the milestone identified as Year 2, Q2 (iv), as contemplated by the terms of the Contribution Agreement. Accordingly, 22,428.3 Class B Shares having an aggregate value of approximately $229 were issued to the Adelia Shareholders, at a price per Class B Share of $10.20. These Class B Shares are exchangeable for a total of 5,902 Common Shares, representing an effective issue price of $38.76 per Common Share. In consideration for the milestone achieved, an additional amount of approximately $5 is issuable at a price per share to be determined in accordance with the terms of the Contribution Agreement and applicable securities laws. </font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> All quarter references in this section are based on calendar year-end.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April 8, 2022, the Company announced that the World Intellectual Property Organization published an international patent application covering a range of inhalation delivery methods across multiple psychedelic molecules (Patent Cooperation Treaty (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PCT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) patent application no. PCT&#47;EP2021&#47;077057). The PCT application titled &#8220;Methods For Delivery Of Psychedelic Medications By Inhalation And Systems For Performing The Methods&#8221; allows the Company to pursue patent applications and seek protection for multiple inhaled forms of psychedelic molecules that are currently being researched and developed, or may be developed by the Company in the future.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April 13, 2022, the Company announced positive preclinical data from a PK study evaluating its proprietary deuterated DMT molecule, CYB004, delivered via inhalation. Specifically, inhaled CYB004 demonstrated significant advantages over both IV DMT and inhaled DMT, including longer duration of action, and improved bioavailability. The study also demonstrated that inhaled CYB004 showed a similar onset of effect and dose profile to IV DMT. These data may support the potential for inhalation as a viable and well-controlled delivery system of therapeutic psychedelics. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April 21, 2022, the Company announced that it has partnered with Clinilabs Drug Development Corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Clinilabs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), a global, full-service contract research organization with expertise in central nervous system drug development, to carry out the Company&#8217;s Phase 1&#47;2a clinical trial of CYB003, its proprietary deuterated psilocybin analog. CYB003 will be the first psilocybin analog to be evaluated in Phase 1&#47;2a development for the treatment of major depressive disorder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MDD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On May 31, 2022, the Company announced the submission of an Investigational New Drug (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) application to the U.S. Food and Drug Administration (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) for its Phase 1&#47;2a first-in-human clinical trial evaluating CYB003, a proprietary deuterated psilocybin analog, for the treatment of MDD.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On June 3, 2022, the Company announced that Adelia achieved the Milestones identified as Y2, Q2 (i), (vi), Y2, Q3 (ii), Year 2 Q4 (i) and Year 3 Q1 (i), (ii), (iii), as contemplated by the terms of the Contribution Agreement. Accordingly, Class B Shares having an aggregate value of approximately $2,034 became due to be issued to the Adelia Shareholders, at a price per share to be determined in accordance with the terms of the Contribution Agreement and applicable securities laws.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On June 7, 2022, the Company announced that, through its wholly-owned subsidiary, Cybin Ireland, it entered into an agreement to acquire a Phase 1 DMT study from Entheon Biomedical Corp. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Entheon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to accelerate the clinical development path for CYB004, the Company&#8217;s proprietary deuterated DMT molecule for the potential treatment of anxiety disorders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Asset Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The purchase price of the Asset Acquisition is $1,000, a portion of which will be a deposit with the balance payable on closing of the Asset Acquisition (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). In addition, the Company may pay up to $480 for consulting services to be provided from Entheon over a period of up to twelve months following Closing. The Company expects the Asset Acquisition to close within 30 days, subject to the completion of certain conditions and obtaining all necessary approvals.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On June 9, 2022, the Company announced that it has received Institutional Review Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IRB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) approval to begin the first-in-human Phase 1&#47;2a clinical trial evaluating CYB003, its proprietary deuterated psilocybin analog, for the treatment of MDD.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On June 27, 2022, the Company announced that it has received a &#8220;may proceed letter&#8221; and IND application clearance from the FDA for its Phase 1&#47;2a first-in-human clinical trial evaluating CYB003. This milestone marks the industry&#8217;s first ever novel psilocybin analog to enter clinical development.&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On June 27, 2022, the Company announced that Adelia achieved the Milestone identified as Y2, Q3 (i), as contemplated by the terms of the Adelia Contribution Agreement. Accordingly, 37,366.2 Class B Shares having an aggregate value of approximately $280 were issued to the Adelia Shareholders, at a price per Class B Share of $7.50. These Class B Shares are exchangeable for a total of 9,833 Common Shares, representing an effective issue price of $28.50 per Common Share.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On July 11, 2022, the Company announced that the Asset Acquisition was completed. The Phase 1 study, previously identified as EBRX-101 and now named CYB004-E. Entheon acted as external consultants to the Company for approximately 10 months after the Asset Acquisition.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On July 12, 2022, the Company announced that its partner, Clinilabs, had begun enrollment in a Phase 1&#47;2a clinical trial of CYB003, the first novel psilocybin analog to be evaluated in Phase 1&#47;2a development for the treatment of MDD.&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On August 8, 2022, the Company established an at-the-market equity program (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ATM Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that allowed the Company to issue and sell up to US$35,000 of Common Shares, from time to time, which was qualified by way of a prospectus supplement dated August 8, 2022, to the Company&#8217;s short form base shelf prospectus dated July 5, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2021 Base Shelf Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The 2021 Base Shelf Prospectus was effective for a period of 25 months, ending on August 5, 2023. Distributions of Common Shares under the 2022 ATM Program were made pursuant to the terms and conditions of an &#8220;at-the-market equity&#8221; distribution agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Distribution Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) dated August 8, 2022, entered into by and among the Company, Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald &#38; Co. The 2022 ATM Program was effective until August 5, 2023 when it automatically terminated in accordance with the terms of the Distribution Agreement following the lapse date of the 2021 Base Shelf Prospectus.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On August 17, 2022, the Company, and its partner Clinilabs, announced that the U.S. Drug Enforcement Administration (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">DEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) has granted a Schedule I license to support the first-in-human Phase 1&#47;2a clinical trial of CYB003, a proprietary deuterated psilocybin analog that is being developed for the treatment MDD.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On August 30, 2022, the Company announced that the first two participants have been dosed in its Phase 1&#47;2a trial evaluating CYB003 for the treatment of MDD.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On August 31, 2022, the Company announced that Adelia has achieved the final milestone identified as Y2, Q4(ii) as contemplated by the terms of the Adelia Contribution Agreement. Accordingly, 33,190.1 Class B Shares having an aggregate value of approximately $468 were issued to the Adelia Shareholders, at a price per Class B Share of $14.10. These Class B Shares are exchangeable for a total of 8,734 Common Shares, representing an effective issue price of $53.58 per Common Share. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On September 27, 2022, the Company entered into an agreement, as amended, with Mindset Pharma Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Mindset</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to acquire an exclusive license to an extensive targeted class of tryptamine-based molecules. The agreement includes an initial license fee payment by Cybin to Mindset of US$500 as well as additional clinical development milestone payments of up to US$9,500, with the first milestone payment, in the amount of US$500, payable upon completion of a Phase 1 clinical trial. At the sole discretion of Cybin, the milestones may be paid in cash or in Common Shares, or a combination thereof, subject to the approval of Cboe Canada. There is no assurance that the aforementioned milestones will be met. The agreement also contemplates a sales royalty of approximately 2% for all commercialized licensed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">products within the scope of the agreement, which is customary for drug licensing agreements of this nature.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On November 10, 2022, the Company announced that its CYB004-E Phase 1 trial evaluating intravenous (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) DMT has completed dosing for four out of five participant cohorts and that the Safety Review Committee has confirmed no clinically significant safety or toxicity issues. The CYB004-E Phase 1 trial was acquired from Entheon in July 2022.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On January 12, 2023, the Company announced that it has selected Generalized Anxiety Disorder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) with or without MDD as the target indication for its proprietary deuterated DMT molecule, CYB004.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 1, 2023, the Company announced that it has received approval from an independent ethics committee in the Netherlands to initiate first-in-human dosing of its proprietary deuterated DMT molecule CYB004 through a protocol amendment to its ongoing CYB004-E Phase 1 trial. This clinical advancement marks the first time a deuterated DMT molecule will be evaluated in humans and further reduces Cybin&#8217;s time-to-clinic with CYB004.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 22, 2023, the Company announced a streamlining plan aimed at maximizing the Company&#8217;s operating efficiency and to allow the Company to focus on critical clinical trials. The Company released approximately 15% of its workforce that previously held roles that were not of a clinical priority or were not directly involved with any of the Company&#8217;s clinical trial initiatives. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 28, 2023, the Company provided interim findings from the Company&#8217;s ongoing Phase 1&#47;2a clinical trial evaluating CYB003. The findings demonstrated positive observations, including a rapid and short-acting psychedelic response in participants. Participants received single oral doses of CYB003 at 1 milligram (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">mg</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), 3mg, 8mg, and 10mg, respectively, and all doses were well-tolerated with no serious adverse events reported. Most notably, participants reported meaningful and robust psychedelic effects at the 8mg and 10mg doses, confirming a complete mystical experience was achieved. These interim findings demonstrate that CYB003 was rapid and short acting, had low variability in plasma levels, and reached a psychedelic effect at low doses, while maintaining a safe and well-tolerated therapeutic profile.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 28, 2023, the Company provided an update on its Phase 1 CYB004-E trial evaluating IV DMT in healthy volunteers. Per a protocol amendment to the initial trial design, the Company has established a three-part study to include Part A (IV DMT infusion), Part B (IV DMT bolus + infusion) and Part C (CYB004) in healthy volunteers, which will allow the Company to initiate first-in-human dosing of CYB004 sooner than initially planned. Data from the new Parts B and C of the trial will serve to build a more robust PK and PD model to optimize dose selection and formulation development for future clinical studies. As of February 28, 2023, Part A of the trial evaluating IV DMT in participants was complete, and IV DMT at the evaluated dose ranges was demonstrated to be safe and well-tolerated. The Phase 1 CYB004-E trial has dosed 40 participants in Part A and dosing has commenced in Part B. </font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The material factors and assumption underlying this forward-looking statement are based on anticipated timelines regarding drug development which are in turn based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company&#8217;s development efforts to date. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Year ended March 31, 2024</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April 12, 2023, the Company announced the launch of EMBARK Open Access, an online foundational training course that offers psychedelic facilitation training for healthcare professionals and people interested in offering psychological support.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On May 9, 2023, the Company announced the completion of dosing the last subject in Part B of the Phase 1 CYB004-E trial. With the completion of Part B, the Company announced on May 24, 2023 that it initiated dosing of CYB004 in Part C which will evaluate IV bolus + infusion regimens of CYB004 in a crossover design. Results from Parts B and C are expected to provide a more robust PK and PD model to optimize dose selection and formulation development for future clinical studies. The Company expects to report top-line results from the completed Phase 1 CYB004-E clinical trial in the third quarter of calendar year 2023.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">3</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On May 30, 2023, the Company announced that it has entered into a common share purchase agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LPC Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LPC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Subject to the terms and conditions of the LPC Purchase Agreement, the Company has the right to sell, and LPC is obligated to purchase, up to US$30 million (approximately C$41 million) of Common Shares over a 36-month period at prices that are based on the market price at the time of each sale to LPC. The Company, in its sole discretion, controls the timing and amount of all sales of Common Shares under the LPC Purchase Agreement. The sale of Common Shares under the LPC Purchase Agreement will be made pursuant to and qualified by way of a prospectus supplement dated May 30, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">May 2023 Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), to the Company&#8217;s short form base shelf prospectus dated July 5, 2021 filed with the securities commissions in each of the provinces and territories of Canada. The May 2023 Prospectus was also filed with the Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) as part of a registration statement on Form F-10, which was declared effective by the SEC on October 8, 2021, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has the right to terminate the LPC Purchase Agreement at any time at no cost or penalty. LPC has agreed not to engage in any short selling or hedging activity of any kind in the Common Shares. As consideration for LPC&#8217;s obligation to purchase Common Shares from the Company at its direction under the LPC Purchase Agreement, the Company issued 66,812 Common Shares to LPC as a commitment fee. The LPC Purchase Agreement provides that the Company may not issue or sell any Common Shares to LPC under the LPC Purchase Agreement which, when aggregated with all other Common Shares then beneficially owned by LPC and its affiliates (as calculated pursuant to Section 13(d) of the U.S. Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and Rule 13d-3 thereunder), would result in LPC beneficially owning more than 9.99% of the outstanding Common Shares. On July 31, 2023, the Company announced that it had suspended all sales under the LPC Purchase Agreement in connection with the August 2023 Offering, as defined below. On August 23, 2023, the Company also announced the filing of a prospectus supplement to the Company&#8217;s base shelf prospectus dated August 17, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 Base Shelf Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), requalifying the Company&#8217;s LPC Purchase Agreement on the same terms as those entered into on May 30, 2023 with LPC. On November 9, 2023, the Company announced that it has, again, suspended all sales under the LPC Purchase Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On June 5, 2023, the Company announced changes to its scientific management team. Following the achievement of the final milestones as contemplated by the terms of the Contribution Agreement, Michael Palfreyman Ph.D. and Brett Greene, who joined the Company following the Adelia Transaction, will leave their roles as Chief R&#38;D Officer and Chief Innovations Officer, respectively, and transition into </font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8221; for further information.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">advisory roles at the Company. Alex Nivorozhkin Ph.D., one of Adelia&#8217;s founders, will continue in his role as Chief Scientific Officer of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On June 27, 2023, the Company announced the appointment of Sanford R. Climan as a strategic advisor.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On June 29, 2023, the Company announced the appointment of Aaron Bartlone as Chief Operating Officer of Cybin Inc., effective July 1, 2023. Mr. Bartlone has served as Chief Operating Officer of Cybin&#8217;s U.S. subsidiary, Cybin US Holdings, Inc., since March 2021. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On July 12, 2023, the Company announced that it had commenced the development of a streamlined, scalable version of its EMBARK Training Program, known as EMBARK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">CT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On July 26, 2023, the Company announced that it had partnered with Worldwide Clinical Trials, a global, full-service contract research organization with deep expertise managing clinical trials for mental health conditions, including major depressive disorder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On August 4, 2023, the Company completed a public offering (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">August 2023 Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of 638,545 units of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">August 2023 Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) at a price of US$12.92 per August 2023 Unit for gross proceeds of $11,018 (US$8,250) pursuant to a supplement to the Company&#8217;s short form base shelf prospectus dated July 5, 2021. Each August 2023 Unit is comprised of one Common Share and one Common Share purchase warrant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">August 2023 Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Each August 2023 Warrant is exercisable to acquire one Common Share at a price of US$15.20 for a period of 60 months from issuance, subject to acceleration in certain circumstances. The August 2023 Warrants are governed by a warrant indenture dated August 4, 2023, entered into with Odyssey Trust Company, as warrant agent (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Warrant Indenture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The August 2023 Offering was completed pursuant to an underwriting agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">August 2023 Underwriting Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) among the Company, Cantor Fitzgerald &#38; Co. as the sole book-running manager, and A.G.P.&#47;Alliance Global Partners as lead manager. In connection with the August 2023 Offering, Cybin paid the underwriters a cash commission of $506 (US$379) and incurred additional share issuance costs, being professional fees of $622 (US$465). </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On August 15, 2023, the Company announced that the USPTO had granted U.S. patent 11,724,985, to a deuterated psilocybin analog in the Company&#8217;s CYB003 investigational drug program. The patent, which is expected to provide exclusivity until 2041, includes composition of matter claims to deuterated tryptamines in support of the Company&#8217;s clinical-stage programs, CYB003, a proprietary deuterated psilocybin analog, and CYB004, a proprietary deuterated (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">dDMT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), in addition to other of the Company&#8217;s pre-clinical programs, as well as claims directed towards methods of treating MDD and treatment-resistant depression.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On August 23, 2023, the Company announced the filing of a prospectus supplement under the 2023 Base Shelf Prospectus to renew its previously established at-the-market equity program (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 ATM Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that allowed the Company to issue and sell up to US$35,000 of Common Shares from treasury to the public, from time to time. Distributions of Common Shares under the 2023 ATM Program were made pursuant to the terms and conditions of an at-the-market equity distribution agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 Distribution Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) dated August 23, 2023 among the Company, Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald &#38; Co. The 2023 ATM Program was effective until February 10, 2025, when it was terminated in accordance with the terms of the 2023 Distribution Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On August 28, 2023, the Company entered into the Arrangement Agreement with Small Pharma pursuant to which Cybin agreed to acquire all of the issued and outstanding shares of Small Pharma (each, a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Small Pharma Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in an all-equity business combination transaction to be completed by way the Arrangement. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On September 5, 2023, the Company announced that the USPTO had granted U.S. patent 11,746,088, covering composition of matter for deuterated tryptamine compounds and pharmaceutical compositions thereof, with exclusivity until 2041.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On September 13, 2023, Small Pharma was granted an interim order (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Interim Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) by the Supreme Court of British Columbia (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Court</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) regarding the Arrangement. The Interim Order authorized Small Pharma to proceed with various matters relating to the Arrangement, including the holding of a special meeting of Small Pharma shareholders to consider and vote on the Arrangement. Completion of the Arrangement was conditional upon receipt of a final order by the Court. Small Pharma was granted a final order by the Court on October 17, 2023.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On September 26, 2023, the Company announced an agreement with Fluence, a leading continuing education organization in psychedelic therapy, to support the streamlining and scaling of Cybin&#8217;s EMBARK facilitator training program in preparation for a multi-site, global Phase 3 trial of CYB003, its proprietary deuterated psilocybin analog in development for the potential treatment of MDD.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On October 12, 2023, the Company held an annual and special meeting of shareholders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Special Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in connection with, among other things, the Arrangement. At the Special Meeting, shareholders of the Company passed an ordinary resolution approving the issuance by the Company of up to such number of Common Shares as may be required to be issued pursuant to the Arrangement in accordance with the terms of the Arrangement Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On October 23, 2023, the Company completed the Arrangement and issued 0.00634 Common Shares for every one Small Pharma Share outstanding, resulting in a total of 2,130,138 Common Shares being issued to Small Pharma shareholders. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On October 25, 2023, the Company announced that the United States Patent and Trademark Office has issued two patent grants that offer protection for its deuterated DMT program. These patents are United States patent no. 11,771,681, which provides composition of matter protection for certain deuterated analogs of DMT&#59; and United States patent no. 11,773,062, which provides protection for the medical use and the novel, efficient and scalable synthesis of certain analogs of DMT.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On October 26, 2023, the Company announced that the European Patent Office had granted a patent protecting Cybin&#8217;s proprietary deuterated psilocybin analog and DMT programs. EP patent no. 4,031,529 provides composition of matter protection for certain deuterated tryptamine compounds, including deuterated psilocybin analogs within the CYB003 program and deuterated analogs of DMT within Cybin&#8217;s DMT program, as well as their medical use.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On October 31, 2023, the Company announced positive Phase 2 interim results for CYB003, its proprietary deuterated psilocybin analog, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single 12mg dose compared to placebo. At the 3-week primary efficacy endpoint, the reduction in MDD symptoms, defined as change from baseline in MADRS total score, was superior in participants assigned to CYB003 compared to the participants who received placebo by 14.08 points (p&#61;0.0005, Cohen&#8217;s d&#61;2.15).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On November 14, 2023, the Company completed a public offering (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">November 2023 Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of 1,754,386 units of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">November 2023 Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) at a price of US$17.10 per November </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023 Unit for gross proceeds of $41,107 (US$30,000) pursuant to a supplement to the Company&#8217;s short form base shelf prospectus dated August 17, 2023. Each November 2023 Unit is comprised of one Common Share and one Common Share purchase warrant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">November 2023 Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Each November 2023 Warrant is exercisable to acquire one Common Share at a price of $27.86 (US$19.38) between May 14, 2024, and May 14, 2029, subject to acceleration in certain circumstances. The November 2023 Offering was completed pursuant to an underwriting agreement between the Company A.G.P.&#47;Alliance Global Partners, acting as the sole book-running manager. In connection with the November 2023 Offering, Cybin paid the underwriter a cash commission of $2,096 (US$1,530) and incurred additional share issuance costs being professional fees of $339 (US$247).  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On November 30, 2023, the Company announced positive Phase 2 topline safety and efficacy data for CYB003, its proprietary deuterated psilocybin analog, being developed for the treatment of MDD. At 6 weeks, incremental MADRS score reductions were seen with 79% of patients in remission from depression after just two doses of CYB003 (12mg). CYB003 demonstrated an excellent safety profile in doses tested, with all reported adverse events mild to moderate and self&#8211;limiting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On December 6, 2023, the Company announced that the USPTO had granted U.S. patent 11,834,410 in support of its CYB003 program. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On January 8, 2024, the Company announced positive topline results from its Phase 1 studies of its proprietary deuterated DMT molecules, CYB004 and SPL028. The Phase 1 CYB004 study results showed that IV CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT. These psychedelic effects were rapid in onset when administered as an IV bolus over five minutes and persisted for about 40 minutes after the bolus without the need for an extended infusion. The Phase 1 SPL028 study identified an intramuscular (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IM&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) dose of SPL028 that resulted in a breakthrough psychedelic experience, with a total duration ranging from 55 to 120 minutes. Both CYB004 (IV) and SPL028 (IM and IV) were well-tolerated with no serious adverse events, and the majority of adverse events were mild to moderate and self-limiting. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On January 23, 2024, the Company announced that it had received FDA clearance to initiate a Phase 2 study of CYB004 in GAD.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 7, 2024, the Company announced that the Japan Patent Office has granted JP patents 2023-500532 and 2023-533436. The patents, which are expected to provide exclusivity until at least 2040 and 2041, respectively, include protection for a synthesis method for the preparation of DMT and dDMT and injectable formulations within the Company&#8217;s proprietary DMT program in clinical development for the treatment of GAD.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 13, 2024, the Company announced that the FDA had granted Breakthrough Therapy Designation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">BTD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to its CYB003 program for the adjunctive treatment of MDD. The BTD provides an expedited review pathway, as well as increased access to FDA guidance on trial design, with the potential to reduce drug development timelines. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 14, 2024, the Company announced a positive End-of-Phase 2 meeting with the FDA for CYB003, its deuterated psilocybin analog for the adjunctive treatment of MDD.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 13, 2024, the Company reported positive four-month durability data from the Phase 2a study of CYB003 in MDD. These results showed robust, sustained and statistically significant improvements in depression symptoms at four months with two doses of CYB003 (12mg or 16mg). The mean reduction from baseline in the MADRS total score was approximately 22 points from baseline in both dosing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">cohorts. Additionally, 60% of patients on 12 mg and 75% on 16 mg were in remission from depression following 2 doses (MADRS score &#60;&#47;&#61; 10).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 15, 2024, the Company announced that it had initiated a Phase 2 study of IM CYB004 in participants with moderate to severe GAD.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 19, 2024, the Company completed a private placement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">March 2024 Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of 9,179,927 Common Shares at a price of US$16.34 per Common Share for gross proceeds of $202,995 (US$150,000). Pursuant to the terms of the March 2024 Offering, on April 8, 2024, the Company amended the 2023 Base Shelf Prospectus to provide that the securities that may be offered and issued thereunder will include distributions by various selling securityholders. Further, on April 17, 2024, the Company filed a prospectus supplement to the 2023 Base Shelf Prospectus, in order to qualify the periodic resale of 8,763,941 Common Shares issued to certain non-Canadian investors pursuant to the March 2024 Offering (See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">s&#8221;). The March 2024 Offering was completed pursuant to an agency agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">March 2024 Agency Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) among the Company, Bloom Burton Securities Inc. as the lead agent, and Haywood Securities Inc. In connection with the March 2024 Offering, Cybin paid the agents a cash commission of $11,726 (US$8,665) and incurred additional share issuance costs being professional fees of $504.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Year ended March 31, 2025</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April 1, 2024, pursuant to the provisions of the OBCA, Small Pharma completed a horizontal amalgamation with Cybin Corp., with Cybin Corp. being the resulting entity. As a result of this amalgamation, Cybin UK Limited is now a wholly-owned subsidiary of Cybin Corp. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April 5, 2024, the Company granted options to purchase up to 308,294 Common Shares, of which 134,872 were granted to employees, 144,738 were granted to officers of the Company and 28,684 were granted to consultants. The granted options have an exercise price of $21.28 per Common Share. All of the options expire on April 5, 2029. The granted options are subject to different vesting schedules. 38,536 options vested immediately and 269,758 options vest over two years. The aggregate estimated grant date fair value of these options was determined to be $4,619, calculated using the Black-Scholes option pricing model.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April 8, 2024, the Company amended the 2023 Base Shelf Prospectus to provide that the securities that may be offered and issued thereunder will include distributions by various selling securityholders.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April 16, 2024, the Company announced that the United States Patent and Trademark Office granted U.S. patent 11,958,807 in support of its CYB003 program in MDD. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April 17, 2024, the Company filed a prospectus supplement to the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023 Base Shelf Prospectus, in order to qualify the periodic resale of 8,763,941 Common Shares issued to certain non-Canadian investors pursuant to the March 2024 Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April 18, 2024, the Company announced that its research manuscript, entitled &#8220;Synthesis and Structure-Activity Relationships of 2,5-dimethoxy-4-substituted phenethylamines and the discovery of CYB210010&#58; A potent, orally bioavailable and long-acting serotonin 5-HT2 receptor agonist,&#8221; was published in the Journal of Medicinal Chemistry, a prestigious bi-weekly peer-reviewed publication.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On May 5, 2024, the Company cancelled options to purchase up to 1,199,655 Common Shares with exercise prices ranging from $27.17 to $119.70. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">24</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On June 11, 2024, the Company announced that Dr. Atul R. Mahableshwarkar M.D., DLFAPA, joined the Company as Senior Vice President, Clinical Development. Dr. Mahableshwarkar will lead the development of the CYB003 program.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On August 13, 2024, the Company announced that it held a Type B Initial Comprehensive Breakthrough Therapy Meeting with the FDA. Further to recent industry discussions around the subject of functional unblinding, the Company plans to implement multiple measures to attempt to mitigate the risk of functional unblinding in its pivotal study program. In addition, the studies will include manual and real time artificial intelligence screening of monitoring sessions to ensure monitor fidelity and patient safety.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On September 19, 2024, the Company announced the appointment of Dr. Atul R. Mahableshwarkar, and Dr. Tom Macek to lead the Company&#8217;s CYB003 and CYB004 programs, respectively.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On September 19, 2024, the Company announced</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that it had filed articles of amendment to complete the 2024 Consolidation. The 2024 Consolidation was effective at the opening of trading on September 19, 2024. &#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On October 1, 2024, the Company announced the appointment of senior clinical team leaders, Dr. Mirza Rahman as Senior Vice President, Patient Safety &#38; Pharmacovigilance and Dr. Marcelo Gutierrez, Vice President, Clinical Pharmacology, as well as the expansion of its clinical operations team.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On October 24, 2024, the Company announced that the USPTO had granted U.S. patent 12,122,741 (&#8216;741) with claims to the composition of matter of lead preclinical candidates in the Company&#8217;s CYB005 phenethylamines program.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On November 13, 2024, the Company announced that it had initiated PARADIGM, a multinational pivotal Phase 3 program evaluating the efficacy and safety&#160;of CYB003 for the adjunctive treatment of MDD.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On November 18, 2024, the Company reported positive Phase 2 data for CYB003, demonstrating 12-month efficacy in treating MDD. At 12 months after two 16 mg doses, 100% of participants were responsive to treatment and 71% of participants were in remission. The mean change from baseline in MADRS was approximately -23 points at 12 months after two 16 mg doses. CYB003 demonstrated an excellent safety and tolerability profile. No new adverse events were reported in the 12-month follow up, including no reports of suicidality.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On January 6, 2025, the Company filed amendment No. 3 to the 2023 Base Shelf Prospectus to increase the aggregate amount of securities that may be offered from time to time under the 2023 Base Shelf Prospectus from $400,000 to $650,000.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On January 15, 2025, the Company announced the launch of its first strategic partnership agreement with Segal Trials in furtherance of the Company&#8217;s multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of MDD.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 10, 2025, the Company launched a new at-the-market equity program (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2025 ATM Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to allow the Company to issue and sell up to US$100,000 of Common Shares from treasury to the public. In connection with the 2025 ATM Program, the Company entered into an at-the-market equity distribution agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2025 Distribution Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) dated February 10, 2025, among the Company, Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald &#38; Co. The 2025 ATM Program is to be effective until the earlier of the issuance and sale of all of the Common Shares issuable pursuant to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the 2025 ATM Program and September 17, 2025, unless earlier terminated in accordance with the terms of the 2025 Distribution Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April 21, 2025, the Company announced a strategic partnership with Osmind. Through this partnership, the Company will leverage Osmind&#8217;s 800-clinic network, point-of-care software, and real-world data to support the commercial preparation for its clinical-stage pipeline.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April 23, 2025, the Company announced the addition of CenExel iResearch Atlanta and Cedar Clinical Research to its strategic partnership agreement program bringing the total to 18 clinical sites engaged to advance Cybin&#8217;s multinational Phase 3 PARADIGM program evaluating CYB003 for the adjunctive treatment of MDD. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On May 8, 2025, the Company announced that the USPTO had granted U.S. patent 12,291,499 in support of its CYB003 program in MDD.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On May 15, 2025, the Company announced that it has engaged Thermo Fisher Scientific to provide U.S.-based manufacturing for the CYB003 program. The production of both drug substance and drug product will be performed at Thermo Fisher&#8217;s U.S. pharma services manufacturing sites. The Company is working with Thermo Fisher&#8217;s pharma services sites in Florence, South Carolina, for Phase 3 clinical supply and future commercialization, and Cincinnati, Ohio, for Phase 3 capsule production and commercialization.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On June 3, 2025, the Company announced that the USPTO had granted U.S. patent 12,318,477 in support of its CYB004 deuterated DMT program in development for the treatment of GAD.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On June 4, 2025, the Company completed the voluntary dissolution of its wholly-owned subsidiaries, Natures Journey Inc. and Serenity Life Sciences Inc. These entities were non-operational prior to their dissolution.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On June 30, 2025, the Company announced that it has entered into a securities purchase agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Securities Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) with High Trail Special Situations LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">High Trail</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), pursuant to which the Company agreed to sell and issue to High Trail up to US$500,000 aggregate principal amount of unsecured convertible debentures (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Convertible Debentures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). The sale and issue of US$50,000 principal amount of Convertible Debentures was completed on June 30, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Convertible Debenture Private Placement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). The sale and issue of US$450,000 principal amount of Convertible Debentures shall be determined at a future date, upon mutual agreement of the parties.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Convertible Debentures will have a two-year term from the closing date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Convertible Denture Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). The Company shall pay guaranteed interest equal to 5.5% of the principal per annum for the Convertible Debenture Term. Such interest would be pre-paid on closing. Upon the occurrence of an event of default, interest shall increase to a rate of 18% on the outstanding principal balance. Pursuant to the terms of the Securities Purchase Agreement, the Company and High Tail may, upon mutual consent, enter into subsequent securities purchase agreements for the purchase and sale of up to an additional US$450,000 principal amount of Convertible Debentures, in tranches, in amounts on such dates as may be mutually agreed and each subsequent tranche shall include prepaid interest at a rate of 9.5%.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Subject to the terms of the Securities Purchase Agreement and the Convertible Debentures, High Trail will be entitled to convert the principal amount of, and accrued and unpaid interest, if any, on each Convertible Debenture, in whole or in part, from time to time, into Common Shares at a conversion price per Common Share equal to the lower of (a) 130% of the volume weighted average price (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">VWAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) of the Common Shares on the day prior to the initial issuance of the Convertible Debentures, or (b) the VWAP of the Common Shares during the five trading days immediately prior to the date of conversion.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company, in its sole discretion, may prepay any outstanding amount under the Convertible Debentures, in whole or in part, in cash by providing High Trail with advance written notice at least five trading days prior to such prepayment. The prepayment shall include, (i) if paid during the first year after closing, a 5% prepayment premium on the amount of the prepayment or (ii) if paid during the second year after closing, a 3% prepayment premium on the amount of the prepayment.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The terms of the Convertible Debentures restrict the conversion of Convertible Debentures by High Trail if such a conversion or exercise would cause High Trail, together with any affiliate thereof, to beneficially own in excess of 4.99% of the number of Common Shares outstanding immediately after giving effect to such conversion. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In connection with the offering, the Company and High Trail entered into a customary Registration Rights Agreement (&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Registration Rights Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#34;) pursuant to which the Company has agreed to provide certain registration rights to High Trail under the U.S. Securities Act of 1933, as amended. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company intends to use the net proceeds from the Convertible Debenture Private Placement for working capital and general corporate purposes.   </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Significant Acquisitions and Dispositions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has not completed any significant acquisitions or dispositions during the fiscal year ended March 31, 2025 for which disclosure is required under Part 8 of NI 51-102. </font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_25"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">DESCRIPTION OF THE BUSINESS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin is a clinical-stage breakthrough neuropsychiatry company on a mission to create safe and effective next-generation therapeutics to address the unmet need for new and innovative treatment options for people who suffer from mental health conditions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin&#8217;s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens. Cybin is currently developing CYB003, a proprietary deuterated psilocin molecule for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the Company on X, LinkedIn, YouTube and Instagram.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Advancement of Mental Healthcare</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is conducting research and development of next-generation neuropsychiatry therapeutics that aim to address unmet needs in the treatment of mental health conditions. This comprehensive development work is predicated on structural modifications of known tryptamine and phenethylamine derivatives to improve their pharmacokinetic properties while maintaining their respective pharmacology. Across its extensive research and development programs, Cybin is evaluating a wide array of novel, synthetic active pharmaceutical ingredients (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">API</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) intended to be delivered through innovative drug delivery systems including via inhalation, via intravenous  (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and intramuscular, or subcutaneous.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">   </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company intends to apply for regulatory approval for therapies targeting indications such as MDD, alcohol use disorder, GAD and potentially other various mental health conditions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Company is also developing compounds that may have the potential to address neuroinflammation, central nervous system (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CNS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) disorders, and psychiatric disorders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">6</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, over the next 12-month period, the Company will continue to seek to establish strategic partnerships that advance the Company&#8217;s scientific research and intellectual property (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) for new novel compounds and novel delivery mechanisms.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Company will also continue to sponsor select internal and partner-related clinical trials that advance the understanding of safety and efficacy for various psychedelic agents that target mental health conditions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stage of Development of Principal Products </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Like most life sciences and pharmaceutical companies, the Company&#8217;s neuropsychiatry business is focused on research and development and any future revenue will be dependent on a number of factors, including the outcome of the Company&#8217;s sponsored clinical trials and the receipt of all necessary regulatory approvals. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In order to establish its business operations, the Company intends to leverage the extensive professional network of its management to build working partnerships with (i) existing producers of products based in Canada, the United States, the European Union and the United Kingdom to source the pharmaceutical products the Company intends to develop and distribute under its specific brand, and (ii) to explore options to facilitate the development and distribution and sale of its specific brand of pharmaceutical products.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">9</font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See footnote 8.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:122%;position:relative;top:-3.15pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:122%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">See footnote 8. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See footnote 8.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A material factor and assumption underlying this forward-looking statement is that the Company will be able to successfully negotiate strategic partnerships.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The material factors and assumptions underlying this forward-looking statement are&#58; (a) that the Company will be able to successfully negotiate strategic partnerships&#59; and (b) all necessary approvals for the studies will be obtained. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> At this time the Company has not entered into commercial supply agreements and has no control over price or conditions. The Company&#8217;s assumption is that it will be able to enter into agreements at such a time when there will be sufficient competition in the market which will render prices reasonable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prescription drugs are classified and regulated under the federal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Food and Drugs Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (Canada) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Canadian FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Labeling, marketing and selling of any prescription drug must comply with the Canadian FDA, including by ensuring that the Company&#8217;s products are not packaged or marketed in a manner that is misleading or deceptive to a consumer. See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Environment &#8211; Canada&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the United States, foods, drugs and dietary supplements are subject to extensive regulation. The </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Federal Food, Drug, and Cosmetic Act </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FFDCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacturing, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. The Company must ensure that all promotion and marketing, distribution, and labeling of any pharmaceutical products comply with the U.S. regulations, including the FFDCA and the FDA. See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Environment &#8211; United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On November 4, 2021, the Company announced that it had been granted a Schedule I manufacturing license from the DEA. The DEA license is for the Company&#8217;s research lab in the Boston area. The license allows the Company to further become a hub for innovation and drug discovery. Previously, the Company conducted much of its research and development work through globally licensed research organizations in the U.S., Canada, and the UK, and through certain in-house capabilities. With the DEA license, the Company expanded its internal R&#38;D capabilities to support innovative drug discovery and delivery involving Schedule I compounds.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 13, 2024, the Company announced that it had been granted BTD by the FDA in respect of CYB003. The BTD provides an expedited review pathway, as well as increased access to FDA guidance on trial design, which has the potential to significantly reduce drug development timelines. The designation includes all &#8220;fast track&#8221; program features, as well as more intensive FDA guidance and discussion of the CYB003 development program, including planned clinical trials and plans for expediting the manufacturing development strategy.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Non-Revenue Generating Projects</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company currently has three significant projects, which have not yet generated revenue&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt">Deuterated Psilocin Program (CYB003)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:9.75pt">Deuterated Dimethyltryptamine Program (CYB004)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt">Phenethylamine Derivatives Program (CYB005)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company was previously exploring a fourth program, the Technology Program&#59; however, in March 2025, the Company concluded that it would no longer be progressing with this program in order to prioritize the progression of its core clinical development programs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has developed EMBARK, a psychological support model that integrates leading clinical approaches to promote supportive healing with pharmacological interventions for neuropsychiatry. EMBARK&#8217;s six clinical domains (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">xistential-Spiritual, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">indfulness, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">ody Aware, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">ffective-Cognitive, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">elational, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">eeping Momentum) represent the broad spectrum of ways in which therapeutic benefits may arise in treatment and the equally broad training needed to prepare therapists to support them all. The Company launched its EMBARK training program in June 2021, which prepares facilitators to work within all of these domains, while inviting facilitators to bring in their own therapeutic training and </font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> All quarter references in this section are based on calendar year-end.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">expertise in a flexible, yet structured way. The EMBARK curriculum additionally emphasizes trauma-informed, culturally competent, and ethically rigorous care. On April 12, 2023, the Company announced the launch of EMBARK Open Access, a free online foundational training course for facilitation. EMBARK Open Access is the first and only free massive open online course that offers foundational facilitation training for healthcare professionals and people interested in offering psychological support. On July 12, 2023, the Company announced that it has commenced the development of a streamlined, scalable version of its EMBARK Training Program, known as EMBARK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">CT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">, which is designed for individuals with existing knowledge, skills, and experience in facilitation. The EMBARK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">CT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> training program is expected to enable the Company to effectively screen, qualify, and train facilitators on a multi-site, international level, to provide support and in-person monitoring for study participants receiving the Company&#8217;s investigational therapeutics in larger pivotal trials.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a description of each program, including a description of the Company&#8217;s plan for such programs, the status of the objectives related to the Company&#8217;s plan for such program and anticipated expenditures to advance the program to the next stage of pipeline development.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The allocation of capital towards the Company&#8217;s ongoing projects and programs is largely dependent on the success, or difficulties encountered, in any particular portion of the process and therefore the time involved in completing it&#59; in turn the time and costs associated with completing each step are highly dependent on the incremental results of each step and the results of other programs, and the Company&#8217;s need to be flexible to rapidly reallocate capital to projects whose results show the greatest potential. As such, it is difficult for the Company to anticipate the timing and costs associated with taking the projects to their next planned stage, and the Company cannot make assurances that the estimates reflected in this AIF will prove to be accurate, as actual results and future events could differ materially from those anticipated. Accordingly, investors are cautioned not to put undue reliance on the estimates reflected in this AIF. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moreover, identifying the timing and costs of such projects beyond their immediate next steps go to the core differentiating factors with respect to the Company and its competitors. The disclosure of prospective costs and timing other than as already disclosed by the Company would negatively impact shareholder value and undermine the Company&#8217;s proprietary technology. In keeping with pharmaceutical industry practice, it is the Company&#8217;s policy to disclose these details in conjunction with its financial statements, and to publicly disclose published patent applications, published scientific papers, scientific symposia and the attainment of key milestones only. In addition, the premature disclosure of proprietary data would have a material and adverse effect on the Company&#8217;s patent and other intellectual property rights and could result in the breach of confidentiality obligations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">About the Deuterated Psilocin Program (CYB003)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has been investigating the development of short-acting tryptamines with the aim of creating clinical development candidates, utilizing (i) the chemical modification of tryptamine derivatives through the selective substitution of hydrogen atoms with deuterium (i.e. deuteration)&#59; and (ii) the combination of such deuterated tryptamine derivative molecules with selected drug delivery methods, including but not limited to oral, inhalation methods, IV and intramuscular delivery.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s lead program, CYB003, is an orally delivered deuterated psilocin molecule that has been granted FDA BTD for the adjunctive treatment of MDD. CYB003 aims to address the limitations of oral psilocin, including side effects, scalability and accessibility of treatment.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company completed its CYB003 IND-enabling preclinical studies and Chemistry, Manufacturing and Control (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">CMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> development, including the production of clinical materials required for clinical trials, in the second quarter of calendar 2022. In the same period, the Company submitted an IND application to the FDA and received a &#8220;may proceed letter&#8221; and IND application clearance from the FDA as well as IRB approval in the U.S. to commence its first-in-human Phase 1&#47;2a study of CYB003 in participants with moderate to severe MDD. The Company had engaged Clinilabs, a full-service contract research organization with deep expertise in central nervous system drug development, to carry out the Phase 1&#47;2a clinical trial of CYB003. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:130%">About the Completed CYB003 Phase 1&#47;2a Clinical Trial</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:128%">The Phase 1&#47;2a trial was a randomized, double-blind, placebo-controlled study evaluating CYB003 in participants with moderate to severe MDD and in healthy volunteers. Per a protocol amendment to the initial Phase 1&#47;2a study design that was announced on February 28, 2023, the study introduced healthy volunteers for the lower (sub-therapeutic) dose cohorts and added a bioequivalence cohort to facilitate the transition to pivotal studies. Healthy volunteers received two administrations (placebo&#47;active and active&#47;active) one week apart, and measures of pharmacological effect were assessed after each dose. Participants with MDD received two administrations (placebo&#47;active and active&#47;active) three weeks apart and response&#47;remission were assessed three weeks after each dose. MDD participants in the trial that were being treated with antidepressants were allowed to remain on their antidepressant medication.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:128%">The study investigated the safety, tolerability, pharmacokinetics and pharmacodynamics, and pharmacological effect of ascending oral doses of CYB003. In participants with MDD, the trial evaluated rapid onset of antidepressant effect on the day of dosing, using MADRS, and evaluated the incremental benefit of a second dose of CYB003 when administered at Week 3. The study included an optional period of assessment to evaluate the durability of treatment effect out to 12 months. The study is listed on ClinicalTrials.gov under Identifier&#58; NCT05385783. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:128%">On August 30, 2022, the Company announced that the first two participants had been dosed in the Phase 1&#47;2a study.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On February 28, 2023, the Company announced positive interim safety and pharmacokinetics and pharmacodynamics data from the Phase 1&#47;2a study of CYB003. Interim findings showed that CYB003 exhibited rapid, short-acting effects, low variability in plasma levels, and achieved a psychedelic effect at low doses. At the 8mg and 10mg dose levels, most of the participants reported robust and meaningful psychedelic effects, confirming a complete mystical experience was achieved. All doses evaluated (single oral doses of CYB003 up to 10mg) were well-tolerated with no serious adverse events reported. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:128%">On July 24, 2023, the Company announced that it had completed dosing in Cohort 5 of the Phase 2a portion of the study with no serious adverse events or other adverse events that may preclude continued </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">31</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:128%">dosing, with recruitment underway for Cohort 6. The Phase 2a trial, consisting of completed Cohorts 4 and 5 as of the date of the announcement, evaluated two 12mg doses of CYB003. On August 2, 2023, the Company announced that it had initiated dosing in Cohort 6, the final cohort of the CYB003 Phase 2a study.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:128%">On September 21, 2023, the Company announced that it had completed enrollment in its Phase 2a study of CYB003, its proprietary deuterated psilocin molecule program being developed for the potential treatment of MDD. All participants in the sixth, and final, cohort received at least one dose (placebo or 16mg of CYB003) with several second doses already administered, and no serious adverse events observed in participants. As of that date, CYB003 demonstrated a favorable safety and tolerability profile at all doses evaluated in the five completed cohorts (1mg, 3mg, 8mg, 10mg, and 12mg). </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:128%">On October 3, 2023, the Company announced that it had completed dosing in Cohort 6 of its Phase 2a study of CYB003. The following doses were evaluated in the six cohorts that comprised the Phase 2a study&#58; 1mg, 3mg, 8mg, 10mg, 12mg, and 16mg. As of that date, CYB003 has been shown to be safe and tolerable at all doses evaluated with no serious adverse events or discontinuations due to adverse events having been observed in the final dose cohort.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On October 31, 2023, the Company announced Phase 2a interim results for CYB003, its proprietary deuterated psilocin molecule, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single 12mg dose compared to placebo, in participants with moderate to severe MDD. At the 3-week primary efficacy endpoint, the reduction in MDD symptoms, defined as change from baseline in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">MADRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> total score, was superior in participants assigned to CYB003 compared to the participants who received placebo by 14.08 points (p&#61;0.0005, Cohen&#8217;s d&#61;2.15). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On November 30, 2023, the Company announced positive Phase 2a topline results for CYB003, showing rapid and robust improvements in symptoms of depression after single doses of CYB003, with an average 13.75 point difference in MADRS score reduction between CYB003 and placebo which was statistically significant at 3 weeks (p&#60;0.0001). The study also demonstrated a clear incremental benefit of a second dose, with a further 5.8 point improvement on the MADRS total score with a second dose of CYB003 (12mg) at 6 weeks, and 79% of patients were in remission from depression at 6 weeks after two doses of CYB003 (12mg). CYB003 exhibited a favorable safety and tolerability profile with no treatment-related serious adverse events at 12mg and 16mg doses. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On March 13, 2024, the Company announced that the FDA had granted BTD to its CYB003 program for the adjunctive treatment of MDD. The BTD provides an expedited review pathway, as well as increased access to FDA guidance on trial design, with the potential to reduce drug development timelines. On March 13, 2024, the Company also reported positive four-month durability data from the Phase 2a study of CYB003 in MDD. These results showed robust, sustained and statistically significant improvements in depression symptoms at four months with two doses of CYB003 (12mg or 16mg)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">Average mean reduction from baseline in the MADRS total score across 2 cohorts was approximately 22 points from baseline in both dosing cohorts.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">60% of patients on 12 mg and 75% on 16 mg were in remission from depression following 2 doses (MADRS score &#60;&#47;&#61; 10).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On August 13, 2024, the Company announced that it held a Type B Initial Comprehensive Breakthrough Therapy Meeting with the FDA. Further to recent industry discussions around the subject of functional unblinding, the Company plans to implement multiple measures to attempt to mitigate the risk of functional unblinding in its pivotal study program, as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">the pivotal study program will include a study with a three-arm design with a high dose, mid-dose, and placebo arm. Patients will not know if they received the therapeutic high dose or the sub therapeutic mid-dose, mitigating the unblinding to an extent and addressing potential expectancy bias&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">the studies will utilize remote, independent, blinded raters who will not have any information on the dose received or the participant&#8217;s dosing experience&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">the reporting of effects during the dosing session will be fire-walled to ensure that the study team stays blinded&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">the studies will recruit participants who are largely psychedelic na&#239;ve to reduce the impact of expectancy bias&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">the studies will assess long-term efficacy data points up to one year, to outlast any potential expectancy effects.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In addition, the studies will include manual and real time artificial intelligence screening of monitoring sessions to ensure monitor fidelity and patient safety.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On November 18, 2024, the Company reported positive Phase 2 data for CYB003, demonstrating 12-month efficacy in treating MDD. At 12 months after two 16 mg doses, 100% of participants were responsive to treatment and 71% of participants were in remission. The mean change from baseline in MADRS was approximately -23 points at 12 months after two 16 mg doses. CYB003 demonstrated an excellent safety and tolerability profile. No new adverse events were reported in the 12-month follow up, including no reports of suicidality.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">About the Phase 3 PARADIGM Pivotal Program</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s Phase 3 program comprises three pivotal efficacy studies as outlined below. Dosing is underway in APPROACH, the first pivotal study.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Pivotal study 1&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">APPROACH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">hase III, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">lacebo-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">ontrolled, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">andomized, Double-Blind Trial of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">ral Doses of CYB003 to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">ssess </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">ombined Safety and Efficacy in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">umans with Major Depressive Disorder) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">APPROACH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">Participants (n&#61;220) will be randomized 1&#58;1 to receive either 16 mg of CYB003 (n&#61;110) or inactive placebo (n&#61;110). Each study arm will evaluate a two-dose regimen, with doses administered three weeks apart. The study will enroll patients suffering from moderate to severe MDD (MADRS&#8805;24) who are on a stable dose of antidepressant medication but are responding inadequately. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">The primary endpoint will be change in depressive symptoms as measured by change in MADRS from baseline at six weeks after the first dose.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">APPROACH will enroll participants at approximately 45 clinical sites across the U.S.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Pivotal study 2&#58; EMBRACE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (An </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">fficacy and Safety, Phase III, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">ulti-center, Double-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">lind, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">andomized Controlled Study Comparing 2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">ctive and 1 Inactive Oral Doses of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">YB003 in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">ligible Participants with Major Depressive Disorder) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">EMBRACE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">Participants (n&#61;330) will be randomized 1&#58;1&#58;1 to receive 16 mg of CYB003 (n&#61;110), 8 mg of CYB003 (n&#61;110), or inactive placebo (n&#61;110). Each arm will evaluate a two-dose regimen, with doses administered three weeks apart. The study will enroll patients suffering from moderate to severe MDD (MADRS&#8805;24) who are on a stable dose of antidepressant medication but are responding inadequately.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">The primary endpoint will be change in depressive symptoms as measured by change in MADRS from baseline at six weeks after the first dose. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">EMBRACE is expected to enroll at approximately 60 clinical sites, with minimal site overlap with the APPROACH study.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Pivotal study 3&#58; EXTEND </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(A Phase III Open Label </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Exten</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">sion Study with Optional Additional Doses of CYB003 to Assess the Safety and Long-term Efficacy in Participants With Major </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">epressive Disorder)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">EXTEND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">Participants from APPROACH and EMBRACE will roll over into EXTEND (up to n&#61;550) after the completion of the 12-week, double-blind, placebo-controlled treatment periods. During EXTEND, all participants who did not respond to treatment in the APPROACH and EMBRACE studies or who relapse during the EXTEND study will be eligible to receive an additional two doses of CYB003 (16 mg) administered three weeks apart. Participants who do not respond to these two doses or relapse again will be eligible to receive an additional single 16 mg dose of CYB003. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Across all three studies, raters will be remote, independent, and blinded with no information on the dose received or the participant&#8217;s dosing experience. Effects during the dosing session will be firewalled to ensure that the study team stays blinded.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">34</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On November 13, 2024, the Company announced that it had initiated PARADIGM, a multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of MDD.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On January 15, 2025, the Company announced the launch of its first strategic partnership agreement with Segal Trials in furtherance of the Company&#8217;s multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of MDD. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The Company spent approximately $42,306 on the Deuterated Psilocin Program during the year ended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">March&#160;31, 2025.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">As the Company continues to progress through the CYB003 program, additional milestones related to its clinical development have been identified. The Company intends to&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Initiate the second Phase 3 study, EMBRACE, around mid-year 2025.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">11</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">Initiate the Phase 3 extension study, EXTEND, around mid-year 2025.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font></div><div style="margin-bottom:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">Provide topline efficacy data readout from the first Phase 3 study, APPROACH, in 2026.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company expects to spend approximately $8,620</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> to initiate the second Phase 3 study, EMBRACE, around mid-year 2025 of which approximately $5,094 was spent during the year ended March&#160;31, 2025 resulting in an approximate remaining spend as of March&#160;31, 2025 of $3,526 by around mid-year 2025.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company expects to spend approximately $11,048</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> to initiate the Phase 3 extension study, EXTEND, around mid-year 2025 of which approximately $6,701 was spent during the year ended </font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> There is no assurance that this timeline will be met or that the program will advance to clinical trials, at all. Drug development involves long lead times, is very expensive and involves many variables of uncertainty. Anticipated timelines regarding drug development and recruitment of patients for participation in clinical trials are dependent on various factors and are based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, eligibility and exclusion criteria for the trial, design of the clinical trial, competition with other companies for clinical sites or patients, perceived risks and benefits of the prescription drug product candidate, the number, availability, location and accessibility of clinical trial sites, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company&#8217;s development efforts to date. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See footnote 11.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See footnote 11.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The Company had previously estimated that its spending to complete this milestone would be $5,484. Anticipated timing and spending regarding drug development is based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company&#8217;s development efforts to date. See also footnote 11.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See footnote 11.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The Company had previously estimated that its spending to complete this milestone would be $13,450. Anticipated timing and spending regarding drug development is based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company&#8217;s development efforts to date. See also footnote 11.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">35</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">March&#160;31, 2025 resulting in an approximate remaining spend as of March&#160;31, 2025 of $4,347 by around mid-year 2025.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company expects to spend approximately $55,792</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> to provide topline efficacy data readout from the first Phase 3 study, APPROACH, in 2026 of which approximately $5,171 was spent during the year ended March&#160;31, 2025 resulting in an approximate remaining spend as of March&#160;31, 2025 of $50,621 by the milestone completion in 2026.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company intends to continue funding the Deuterated Psilocin (CYB003) Program.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company intends to complete future clinical trials for this program in the U.S., Canada, and&#47;or Europe.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">About the Deuterated Dimethyltryptamine Program  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The Company&#8217;s proprietary dDMT program CYB004 is being developed as an intermittent treatment with the potential for less invasive, more convenient and patient-friendly dosing methods for the potential treatment of GAD. A single IM dose is expected to result in acute psychedelic effects lasting an average of 90 minutes.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin has leveraged clinical data from its completed DMT and dDMT trials, which collectively form one of the most advanced and extensive DMT&#47;dDMT data portfolio in the psychedelic drug development sector, to inform and optimize the development of the CYB004 program. To date, Cybin has completed five clinical trials across four molecules&#58; CYB004 (IV dDMT), SPL028 (IV&#47;IM dDMT), SPL026 (IV&#47;IM DMT), and DMT, demonstrating proof-of-concept in potentially treating depression, supporting the development of dDMT for the potential treatment of anxiety disorders, and providing important dosing insights.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Key findings from these completed studies are as follows&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%;padding-left:14.15pt">Phase 2a safety and efficacy data for SPL026 (IV DMT) in 34 participants with MDD, demonstrating a clinically relevant and statistically significant reduction in depression symptoms at two weeks after dosing (-7.4 point difference in MADRS between SPL026 and placebo). Durable antidepressant response and remission rates were observed at six months. Among </font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See footnote 11.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The Company had previously estimated that its spending to complete this milestone would be $32,680. Anticipated timing and spending regarding drug development is based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company&#8217;s development efforts to date. See also footnote 11.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See footnote 11.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">participants who had achieved remission within three months with SPL026, 64% sustained remission to six months.</font></div><div style="margin-bottom:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">Phase 1 study evaluating IM SPL026 supporting IM administration for patient-friendly dosing. The study demonstrated that IM DMT is well-tolerated and generates a breakthrough psychedelic experience lasting approximately 45 minutes.</font></div><div style="margin-bottom:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">Phase 1 study evaluating IM SPL028 supporting IM administration for patient-friendly dosing. The completed Phase 1 study of IV&#47;IM SPL028 in healthy volunteers showed that SPL028 is safe and well-tolerated, and demonstrated that IM dosing of SPL028 produced robust psychedelic effects lasting a short duration (average approximately 90 minutes) in the majority of subjects.</font></div><div style="margin-bottom:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">Phase 1b study evaluating the safety and efficacy of SPL026 in conjunction with SSRIs in 17 participants with MDD, demonstrating no relevant drug-drug interactions, a favorable safety profile and enhanced efficacy when SPL026 was administered with SSRIs, and a 92% remission rate at 4 weeks in the DMT + SSRI combination cohort (n&#61;12).</font></div><div style="margin-bottom:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">Phase 1 results for IV CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as a short-acting, scalable treatment.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Exploratory analysis of the Phase 2a and Phase 1b data for SPL026 also shows significant improvements in symptoms of anxiety, as measured using the State Trait Anxiety Inventory &#8211; Trait version (STAI-T), with a 23 point improvement from baseline at the two week endpoint, in the DMT+ SSRI combination group.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The Company is currently advancing CYB004, a deuterated version of DMT, for the potential treatment of GAD. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">DMT activates the serotonin 5-HT2A receptor, which is believed to mediate the potential therapeutic effects of DMT. In its regular form, DMT is an unstable molecule rapidly metabolized in the body, which significantly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> reduces</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> its bioavailability. CYB004, as a deuterated molecule, has the potential to overcome the therapeutic limitations of native DMT. To date, CYB004 has demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as a short-acting, scalable treatment. Additionally, learnings from Phase 1 studies of IM SPL028 have supported IM administration as a viable dosing method for deuterated DMT, suggesting the potential for CYB004 to offer more convenient and patient-friendly dosing methods. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">CYB004 is secured by a U.S. composition of matter patent with protection through 2041. The patent covers a range of deuteration forms of DMT and protects CYB004 as a putative new chemical entity.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">On June 7, 2022, the Company announced it had entered into an agreement to acquire a Phase 1 DMT study from Entheon Biomedical Corp. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Entheon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;) to accelerate the clinical development path for CYB004. On July 11, 2022, the Company announced that the Asset Acquisition was completed. The Phase 1 study, previously identified as EBRX-101 and now named CYB004-E, was conducted in the Netherlands. Entheon acted as external consultants to the Company for approximately 10 months after the Asset Acquisition. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">On January 12, 2023, the Company announced that it has selected GAD as the target indication for its proprietary deuterated DMT molecule, CYB004. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">37</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:130%">About the Phase 1 CYB004-E DMT Study</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Phase 1 trial was a three-part study evaluating the safety, pharmacokinetics, and pharmacodynamics of escalating doses of DMT and CYB004 in healthy volunteers. The three-part study design was established in a protocol amendment to the initial study design, allowing the Company to commence first-in-human dosing of CYB004 sooner than initially planned. The study provided essential safety and dosing optimization data informing the clinical path forward for CYB004. The CYB004-E study was conducted at the Centre for Human Drug Research in the Netherlands and is one of the largest Phase 1 DMT clinical trials to date.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">On November 10, 2022, the Company announced that its CYB004-E Phase 1 trial evaluating IV DMT completed dosing for four out of five cohorts and that the Safety Review Committee had confirmed no safety issues. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">On February 1, 2023, the Company announced that it had received approval from an independent ethics committee in the Netherlands to initiate first-in-human dosing of CYB004 through a protocol amendment to its ongoing Phase 1 CYB004-E study. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">On February 28, 2023, the Company announced a protocol amendment to the initial Phase 1 study design that would allow the Company to initiate first-in-human dosing of CYB004 sooner than initially planned. Per the protocol amendment, Cybin established a three-part study to include Part A (IV DMT infusion), Part B (IV DMT bolus + infusion) and Part C (IV CYB004 bolus + infusion) in healthy volunteers. The Company was able to rely upon completed preclinical data to gain regulatory authorization to add CYB004 to the CYB004-E DMT Study. The Company also announced confirmatory data from Part A, the single ascending dose portion of the CYB004-E study, which assessed a continuous IV DMT infusion. The Part A data showed a dose-proportional increase in exposure and dose-related increase in behavioral measures of subjective psychedelic experience with IV DMT. IV DMT was also well-tolerated with no safety issues and no serious adverse events within the dose range evaluated. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">On May 9, 2023, the Company announced that it had completed dosing for the last subject in Part B of the Phase 1 CYB004-E trial.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">On May 24, 2023, the Company announced that it had initiated first-in-human dosing of CYB004 in Part C of the Phase 1 CYB004-E trial. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">On January 8, 2024, the Company announced positive topline results from its Phase 1 studies of its proprietary deuterated DMT molecules, CYB004 and SPL028. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;padding-left:14.15pt">The Phase 1 CYB004 study results showed that IV CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT. These psychedelic effects were rapid in onset when administered as an IV bolus over five minutes and persisted for about 40 minutes after the bolus without the need for an extended infusion.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;padding-left:14.15pt">The Phase 1 SPL028 study identified an IM dose of SPL028 that resulted in a breakthrough psychedelic experience, with a total duration ranging from 55 to 120 minutes.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;padding-left:14.15pt">Both CYB004 (IV) and SPL028 (IM and IV) were well-tolerated with no serious adverse events, and the majority of adverse events were mild to moderate and self-limiting. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">On January 23, 2024, the Company announced that it had received FDA clearance to initiate a Phase 2 study of CYB004 in GAD.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">On March 15, 2024, the Company announced that it had initiated a Phase 2 study of IM CYB004 in participants with moderate to severe GAD. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:130%">About the Phase 2 CYB004 Study in GAD</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The CYB004-002 Phase 2 study is a randomized, double-blind study which will evaluate the safety and efficacy of CYB004 in participants with moderate to severe GAD (GAD-7 score &#8805;10), with concomitant antidepressant&#47;anxiolytic treatment and co-morbid depression allowed. The study will recruit approximately 36 participants, who will be randomized in a double-blind manner, into two groups. The first group will receive two IM doses of CYB004, three weeks apart, while the second group will receive two low-dose control administrations of sub-therapeutic doses of CYB004. The primary endpoint is a change in the Hamilton Anxiety Rating Scale score from baseline at six weeks following the second dose. Other endpoints include the HAM-D (Hamilton Depression Rating Scale), safety assessments, MEQ30 (psychedelic experience assessment) and EQ-5D-5L (quality of life assessment). Participants will be followed for up to a year. Results from this study are expected to provide proof of concept for CYB004&#8217;s efficacy in GAD, the time to onset of effects, as well as durability of effects to one year.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company spent approximately $13,345 on its Deuterated Dimethyltryptamine Program during the year ended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">March&#160;31, 2025</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">, related to the milestones detailed below. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">As the Company continues to progress its Deuterated Dimethyltryptamine Program, additional milestones related to its clinical development have been identified. The Company intends to&#58;</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">Complete the Phase 2 GAD study, around mid-year 2025.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">20</font></div><div style="margin-bottom:0.1pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company expects to spend approximately $10,744</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> to complete the Phase 2 GAD study around mid-year 2025 of which approximately $6,940 was spent during the year ended March&#160;31, 2025 and approximately $58 was spent during the financial year ended March 31, 2024, resulting in an approximate remaining spend as of March&#160;31, 2025 of $3,746 by around mid-year 2025.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> The Company has updated this milestone. The Company had previously expected it would complete this milestone by the first half of 2025. There was a minor change in anticipated timing due to updates to the study. Anticipated spending and timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to the Company. See also footnote 11.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The Company had previously estimated that its spending to complete this milestone would be $10,014. Anticipated timing and spending regarding drug development is based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company&#8217;s development efforts to date. See also footnote 11.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See footnote 11.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company intends to continue funding the Deuterated Dimethyltryptamine (CYB004) Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:161%;text-decoration:underline">About the Phenethylamine Derivatives Program (CYB005)</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s Phenethylamine Derivatives Program (CYB005) is focused on the development of therapeutic phenethylamine derivatives. Multiple phenethylamines have been shown to have psychedelic properties and several, such as MDMA, have shown promise as therapeutics. Cybin&#8217;s proprietary approach to phenethylamines modification with novel chemistry, proprietary formulations and directed delivery systems has yielded a number of novel, IP-protected leads with significant therapeutic potential. Several compounds are now being further studied both in vitro and in vivo for selection of the best development candidates, including evaluating the benefits of sub-psychedelic, chronic dosing. The Company is investigating the effects of phenethylamine derivatives on neuroplasticity, and for the potential treatment of CNS disorders, neuroinflammation and other neurological conditions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> The Company is investigating novel molecules within the CYB005 program at non-hallucinogenic doses for a range of CNS disorders. In addition, the Company is continuing to explore non-hallucinogenic neuroplastogens within its broader discovery pipeline, as well as targeted serotonin 5-HT1A and 5-HT2C receptor agonists.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">24</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In order to assess the feasibility and viability of these phenethylamine derivatives entering clinical studies, the Company has and will continue to contract with reputable and licensed third-party vendors to undertake extensive preclinical characterization of target molecules on the Company&#8217;s behalf. These activities include, but are not limited to&#58; the synthesis of such molecules as API at laboratory scale, the development and optimization of production processes for such APIs, the development of stable formulations utilizing these APIs, the development and validation of analytical methods for such formulations, the scale up of API production processes beyond laboratory scale to deliver Good Laboratory Practice&#160;(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) and Good Manufacturing Practices (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) material suitable for entry into animal and human studies, studies of the stability of such formulations suitable for human studies, the development of Chemistry, Manufacturing and Controls to meet Current Good Manufacturing Practices (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">cGMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;).</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> This statement is based on the following material factors and assumptions&#58; (a) the Company assumes it will enter into a contract with a licensed third-party vendor to undertake extensive preclinical characterization of target molecules on the Company&#8217;s behalf&#59; (b) the Company anticipates to complete a number of animal models and the completion of ADME profiles&#59; (c) the Company assumes to enter into third party agreements in order to complete a range of additional preclinical programs including but not limited to dose-ranging studies in multiple animal species, toxicity studies in multiple animal species, genotoxicity studies, teratogenicity studies, along with neuropharmacological, pulmonary, and cardiovascular profiling before the final selection of drug candidates for entry into human trials&#59; and (d) obtain an IND and&#47;or a CTA to enter into clinical trials. As of the date hereof, it has not yet completed the aforementioned items. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company&#8217;s development efforts to date.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See footnotes 11 and 23.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In addition, utilizing the expertise of selected third parties, the Company intends to oversee the study of the pharmacokinetic profiles of its formulations in a number of animal models and the completion of ADME profiles. Further, the Company&#8217;s licensed third party vendors will be responsible for completing a range of additional preclinical programs including, but not limited to, dose-ranging studies in multiple animal species, toxicity studies in multiple animal species, genotoxicity studies, along with neuropharmacological, pulmonary, and cardiovascular profiling, before the final selection of drug candidates for entry into human trials. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company intends to complete these studies, and collect further relevant safety and toxicity data, prior to the filing for any IND application with the FDA, a CTA with Health Canada, or other similar application with regulatory bodies in other jurisdictions. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company spent approximately $97 on its preclinical Phenethylamine Derivatives Program during the twelve months ended March 31, 2025.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company is currently identifying a viable drug candidate and completing its assessment of the potential path forward for this candidate, including whether it will be developed internally or by way of potential third party partners. The Company anticipates that its phenethylamine program may deliver a drug candidate suitable for entry into clinical studies by Q1 2026.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">25</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The Company expects to spend approximately $1,113</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:130%;position:relative;top:-3.85pt;vertical-align:baseline">26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"> to complete preclinical development of a phenethylamine drug candidate by Q1 2026,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:130%;position:relative;top:-3.85pt;vertical-align:baseline">27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"> of which approximately $97 was spent in the year ended March&#160;31, 2025, approximately $83 was spent during the twelve months ended March&#160;31, 2024, and approximately $782 was spent during the financial year ended March 31, 2023 resulting in an approximate remaining spend as of March&#160;31, 2025 of $151. The Company intends to continue funding the Phenethylamine Derivatives Program (CYB005) Program. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Technology Programs </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has historically had two technology programs (a) Digital Therapy Platform which was intended to support patients undergoing psychedelic therapies to memorialize the learning from their treatment sessions and to assist with the integration of such learnings into the patient&#8217;s psychotherapy program&#59; and (b) Kernel Collaboration to evaluate the use of wearable neuroimaging technology during </font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:122%;position:relative;top:-3.15pt;vertical-align:baseline">25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%"> The Company has updated the anticipated timeline for completion of this milestone. The Company had previously expected it would complete this milestone in Q4 2024. Due to the Company prioritizing the progression of its Deuterated Psilocin Program and Deuterated Dimethyltryptamine Program, it now expects to complete preclinical development of a phenethylamine drug candidate in Q1 2026. See also footnote 11.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:130%"> Reflects actual spend during the financial year ended March 31, 2024, the year ended March&#160;31, 2025, and expected spend during the period from April 1, 2025 until the achievement of preclinical development of a phenethylamine drug candidate by Q1 2026. The Company had previously estimated that its spending to complete this milestone would be $900. Anticipated timing and spending regarding drug development is based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company&#8217;s development efforts to date.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> See footnote 25.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">41</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">psychedelic therapy. In March 2025, the Company decided to not proceed with its technology programs in order to prioritize the progression of its clinical development programs. The Company had previously indicated that it was evaluating the path forward for both the Digital Therapy Platform and the Kernel Collaboration.</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company no longer expects to complete the technology programs and is expecting to spend $NIL on these programs. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Relationships with Third Parties</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The Company&#8217;s research and development of its psychedelic pharmaceutical products is conducted by way of licensed partners. The Company also intends to sponsor clinical and other studies at various clinical trial sites. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Clinilabs Drug Development Corporation</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On April 21, 2022, the Company announced that it had partnered with Clinilabs, a global, full-service contract research organization with deep expertise in central nervous system drug development, to carry out the Company&#8217;s Phase 1&#47;2a clinical trial of CYB003, its proprietary deuterated psilocin program. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Entheon Biomedical Corp.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On July 11, 2022, the Company completed the acquisition of a Phase 1 DMT study from Entheon. As part of the Asset Acquisition, Entheon assigned its rights under the Master Services Agreement between Entheon and Centre For Human Drug Research (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">CHDR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) to the Company. The Company now maintains a direct contractual relationship with CHDR to conduct the CYB004-E trial. CHDR is an independent institute in the Netherlands specializing in innovative early-stage clinical drug research. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Mindset Pharma Inc.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On September 27, 2022, the Company entered into an agreement, as amended, with Mindset to acquire an exclusive license to an extensive targeted class of tryptamine-based molecules. The agreement includes an initial license fee payment by Cybin to Mindset of US$500 as well as additional clinical development milestone payments of up to US$9,500, with the first milestone payment, in the amount of US$500, payable upon completion of a Phase 1 clinical trial. At the sole discretion of Cybin, the milestones may be paid in cash or in Common Shares, or a combination thereof, subject to the approval of Cboe Canada. There is no assurance that the aforementioned milestones will be met. The agreement also contemplates a sales royalty of approximately 2% for all commercialized licensed products within the scope of the agreement, which is customary for drug licensing agreements of this nature. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Segal Trials</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On January 15, 2025, the Company launched its first strategic partnership agreement with Segal Trials in furtherance of Cybin&#8217;s multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of MDD. Segal Trials is a privately held company with a network of six research sites throughout South Florida. Segal Trials has extensive experience conducting research trials with an emphasis on psychiatry, neurology, addiction and psychedelics research.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">42</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Worldwide Clinical Trials</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On July 26, 2023, the Company announced that it has partnered with Worldwide Clinical Trials, a global, full-service contract research organization with deep expertise managing clinical trials for mental health conditions, including MDD. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Other Third-Party Partners</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has established contractual sources of synthetic GMP (as defined below) and non-GMP raw materials to support its development operations through licensed third-party suppliers located in Canada, the United States, the UK and Europe. Such raw materials are expected to be, in general, readily available and in adequate supply to meet the Company&#8217;s need for development quantities, or custom manufactured on the Company&#8217;s behalf.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> The prices of research quantities of novel tryptamine compounds are generally higher than commercial supply prices at significantly larger scale and the Company, therefore, expects its supply prices to reduce over time. Development and production of the Company&#8217;s proprietary novel compounds is performed under confidential contractual agreements.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has conducted due diligence on each such third party, including but not limited to the review of necessary licences and the regulatory framework enacted in the jurisdiction of operation.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The allocation of capital towards the Company&#8217;s ongoing projects and programs is largely dependent on the success, or difficulties encountered, in any particular portion of the process and therefore the time involved in completing it&#59; in turn the time and costs associated with completing each step are highly dependent on the incremental results of each step and the results of other programs, and the Company&#8217;s need to be flexible to rapidly reallocate capital to projects whose results show the greatest potential. As such, it is difficult for the Company to anticipate the timing and costs associated with taking the projects to their next planned stage, and the Company cannot make assurances that the foregoing estimates will prove to be accurate, as actual results and future events could differ materially from those anticipated. Accordingly, investors are cautioned not to put undue reliance on the foregoing estimates. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Moreover, identifying the timing and costs of such projects beyond their immediate next steps go to the core differentiating factors with respect to the Company and its competitors. The disclosure of prospective costs and timing other than as already disclosed by the Company would negatively impact shareholder value and undermine the Company&#8217;s proprietary technology. In keeping with pharmaceutical industry practice, it is the Company&#8217;s policy to disclose these details in conjunction with its financial statements, and to publicly disclose published patent applications, published scientific papers, scientific symposia and the attainment of key milestones only. In addition, the premature disclosure of proprietary data would have a material and adverse effect on the Company&#8217;s patent and other intellectual property rights and could result in the breach of confidentiality obligations.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The material factors or assumptions used to develop the estimated costs disclosed above are included in the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:130%">Cautionary Note Regarding Forward-Looking Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221; section above. The actual amount that </font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:122%;position:relative;top:-3.15pt;vertical-align:baseline">28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%"> At this time the Company has not entered into commercial supply agreements and has no control over price or conditions. The Company has assumed that it will be able to enter into commercial supply agreements at such a time when there will be sufficient competition in the market which will render prices reasonable. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">43</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">the Company spends in connection with each of the intended uses of proceeds will depend on a number of factors, including those listed under &#8220;Risk Factors&#8221; in this AIF or unforeseen events. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has negative cash flow from operating activities and has historically incurred net losses. To the extent that the Company has negative operating cash flows in future periods, it may need to deploy a portion of its existing working capital to fund such negative cash flows. The Company will be required to raise additional funds through the issuance of additional equity securities, through loan financing, or other means, such as through partnerships with other companies and research and development reimbursements. There is no assurance that additional capital or other types of financing will be available if needed or that these financings will be on terms at least as favourable to the Company as those previously obtained. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Regulatory Environment</font></div><div style="padding-left:3.8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:25.078%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Business Segment</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current&#47;Proposed Location of Operation</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Summary of Applicable Regulatory Frameworks </font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:2.77pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research, development and commercialization of psychedelic-inspired regulation medicines.</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canada, United Kingdom, United States, Netherlands</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Canadian and United States federal governments regulate drugs through the CDSA and the CSA, respectively, which place controlled substances in a schedule.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The United Kingdom regulates drugs through the MDA (through allocation of classes of risk) and MDR (which places controlled substances in a schedule). The Netherlands regulates drugs under the Dutch Opium Act (as defined herein). </font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the CDSA, psilocybin is currently a Schedule III drug.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the CSA, psilocybin is currently a Schedule I drug.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the MDA, psilocybin is currently a Class A drug under the MDA and a Schedule 1 drug under the MDR.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </font></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div><div style="margin-bottom:1.5pt;padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Dutch Opium Act, DMT is classified in the Netherlands as a List 1 Drug </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:7.1pt;padding-right:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Notes&#58;</font></div><div style="padding-left:35.45pt;padding-right:14.4pt;text-align:justify;text-indent:-14.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;In both Canada and the United States, the applicable federal government is responsible for regulating, among other things, the approval, import, sale and marketing of drugs, including any psychedelic substances, whether natural or novel. Health Canada and the FDA have not approved psilocybin as a drug for any indication. It is illegal to possess such substances without a prescription. The Company does not directly engage in any activities that would trigger the need to comply with any federal laws related to psychedelic substances. See </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Regulatory Environment &#8211; Research and Development&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:35.45pt;padding-right:14.4pt;text-align:justify;text-indent:-14.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;For further information on the Canadian regulatory framework, see </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Regulatory Environment &#8211; Canada&#8221;. </font></div><div style="padding-left:35.45pt;padding-right:14.4pt;text-align:justify;text-indent:-14.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;For further information on the United States regulatory framework, see </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Regulatory Environment &#8211; United States&#8221;.</font></div><div style="padding-left:35.45pt;padding-right:14.4pt;text-align:justify;text-indent:-14.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;For further information on the United Kingdom regulatory framework, see &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Environment &#8211; United Kingdom</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8221;. </font></div><div style="padding-left:35.45pt;padding-right:14.4pt;text-align:justify;text-indent:-14.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;For further information on the Netherlands regulatory framework, see </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Regulatory Environment &#8211; Europe (Netherlands)&#8221;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:35.45pt;padding-right:14.4pt;text-align:justify;text-indent:-14.15pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Canada </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In Canada, oversight of healthcare is divided between the federal and provincial governments. The federal government is responsible for regulating, among other things, the approval, import, sale, and marketing of drugs such as psilocin and other psychedelic substances, whether natural or novel. The provincial&#47;territorial level of government has authority over the delivery of health care services, including regulating </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">44</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">health facilities, administering health insurance plans such as the Ontario Health Insurance Plan, distributing prescription drugs within the province, and regulating health professionals such as doctors, psychologists, psychotherapists and nurse practitioners. Regulation is generally overseen by various colleges formed for that purpose, such as the College of Physicians and Surgeons of Ontario.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Certain psychoactive compounds, such as psilocin, are considered controlled substances under Schedule III of the CDSA. In order to conduct any scientific research, including preclinical and clinical trials, using psychoactive compounds listed as controlled substances under the CDSA, an exemption under Section 56 of the CDSA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 56 Exemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is required. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Health Canada has not approved psilocin as a drug for any indication. However, there are legal routes through which psilocin may be accessed for medical or scientific purposes. The Canadian Minister of Health can grant Section 56 Exemptions if it is deemed to be necessary for a medical or scientific purpose or is otherwise in the public interest. The Company has not applied for a Section 56 Exemption from Health Canada. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Health Canada&#8217;s Special Access Program (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) was designed to provide Canadians to access certain restricted drugs before they are formally approved for use in Canada. In January 2022, certain amendments to the SAP came into force to permit medical practitioners treating patients with serious or life-threatening conditions to request access to restricted drugs that have not yet been approved for sale in Canada when conventional therapies have failed, are unsuitable, or unavailable in Canada. Such amendments create a means of legally accessing psilocin through the SAP. The Company has not applied for access under the SAP.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The possession, sale or distribution of controlled substances is prohibited unless specifically permitted by the government. A party may seek government approval for a Section 56 Exemption to allow for the possession, transport or production of a controlled substance for medical or scientific purposes. Products that contain a controlled substance such as psilocin cannot be made, transported or sold without proper authorization from the government. A party can apply for a Dealer&#8217;s Licence under the Food and Drug Regulations (Part J). In order to qualify as a licensed dealer, a party must meet all regulatory requirements mandated by the regulations including having compliant facilities, compliant materials and staff that meet the qualifications under the regulations of a senior person in charge and a qualified person in charge. Assuming compliance with all relevant laws (Controlled Drugs and Substances Act, Food and Drugs Regulations) and subject to any restrictions placed on the licence by Health Canada, an entity with a Dealer&#8217;s Licence may produce, assemble, sell, provide, transport, send, deliver, import or export a restricted drug (as listed in Part J in the Food and Drugs Regulations &#8211; which includes psilocybin and psilocin) (see s. J.01.009 (1) of the Food and Drug Regulations).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company intends to sponsor and work with licensed third parties to conduct any clinical trials and research and does not handle controlled substances. If the Company were to conduct this work without the reliance on third parties, it would need to obtain additional licences and approvals described above.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Please see &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Research and Development&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for additional information concerning the regulation applicable to the process required before prescription drug product candidates may be marketed in Canada.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">United States</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The FDA and other federal, state, local and foreign regulatory agencies impose substantial requirements upon the clinical development, clinical testing, approval, labeling, manufacture, marketing and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">distribution of drug products. These agencies regulate, among other things, research and development activities and the testing, approval, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, advertising and promotion of any prescription drug product candidates or commercial products. The regulatory approval process is generally lengthy and expensive, with no guarantee of a positive result. Moreover, failure to comply with applicable FDA or other requirements may result in civil or criminal penalties, recall or seizure of products, injunctive relief including partial or total suspension of production, or withdrawal of a product from the market. Anticipated timelines related to regulatory filings are based on reasonable assumptions informed by current knowledge and information available to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Psilocybin, psilocin, DMT, and 5-Methoxy-DMT are strictly controlled under the federal CSA as Schedule I substances. Schedule I substances by definition have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse. Schedule I and II drugs are subject to the strictest controls under the CSA, including manufacturing and procurement quotas, security requirements and criteria for importation. Anyone wishing to conduct research on substances listed in Schedule I under the CSA must register with the DEA and obtain DEA approval of the research proposal. A majority of state laws in the United States also classify psilocybin and psilocin as Schedule I controlled substances. For any product containing psilocin or any Schedule I substance to be available for commercial marketing in the United States, such substance must be rescheduled, or the product itself must be scheduled, by the DEA to Schedule II, III, IV or V. Scheduling determinations by the DEA are dependent on FDA approval of a substance or a specific formulation of a substance.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Please see &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business &#8211; Research and Development&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for additional information concerning the regulation applicable to the process required before prescription drug product candidates may be marketed in the United States.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Europe (Netherlands)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The International Narcotics Control Board (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INCB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), a UN entity, monitors enforcement of restrictions on controlled substances. The INCB&#8217;s authority is defined by three international UN treaties &#8211; the UN Single Convention on Narcotic Drugs of 1961, the UN Psychotropic Convention of 1971 (referred to herein as the UN71), and the UN Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988, which contains provisions related to the control of controlled substance precursors. EU Member States, including the Netherlands, that have agreed to abide by the provisions of these treaties, each create responsible agencies and enact laws or regulations to implement the requirements of these conventions.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Specific EU legislation establishing different classes of controlled substances is limited to EU regulations that define classes of precursors, or substances used in the illicit manufacture of controlled substances, including Regulation (EC) No. 273&#47;2004 of the European Parliament and the Council of February 11, 2004 and the Council Regulation (EC) No. 111&#47;2005 of December 22, 2004. While EU legislation does not establish different classes of narcotic drugs or psychotropic substances, the Council Decision 2005&#47;387&#47;JHA of May 10, 2005 (which applies only in certain limited situations)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> can provoke a Council </font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Decision 2005&#47;387&#47;JHA was repealed (by Directive (EU) 2017&#47;2103 of the European Parliament and of the Council of November 15, 2017 amending Council Framework Decision 2004&#47;757&#47;JHA in order to include new psychoactive substances in the definition of &#8216;drug&#8217; and repealing Council Decision 2005&#47;387&#47;JHA), but still continues to apply to new psychoactive substances in respect of which a Joint Report (as referred to in Article 5 of that Decision) has been submitted before November 23, 2018.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">46</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Decision requiring EU member states to put a drug under national controls equivalent to those of the INCB. DMT is currently classified as a Schedule I substance under the UN71&#59; the EU member states that are party to the UN71, including the Netherlands, have agreed to the following in respect of Schedule I substances&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">prohibit all use except for scientific and very limited medical purposes by duly authorized persons, in medical or scientific establishments which are directly under the control of their Governments or specifically approved by them&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">require that manufacture, trade, distribution and possession be under a special licence or prior authorization&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">provide for close supervision of the activities and acts mentioned in paragraphs (a) and (b)&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">restrict the amount supplied to a duly authorized person to the quantity required for his authorized purpose&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">require that persons performing medical or scientific functions keep records concerning the acquisition of the substances and the details of their use, such records to be preserved for at least two years after the last use recorded therein&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">prohibit export and import except when both the exporter and importer are the competent authorities or agencies of the exporting and importing country or region, respectively, or other persons or enterprises which are specifically authorized by the competent authorities of their country or region for the purpose.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As classification of controlled substances may vary among different EU member states, sponsors must be aware of the prevailing legislation in each country where a clinical trial may be conducted. Prior to operating or conducting any preclinical or clinical studies in any other EU member state, Cybin will investigate the specific regulatory requirements of such EU member state. As referenced above, a licence is required for individuals and entities who wish to produce, dispense, import, or export Schedule I substances (including DMT), but the specific requirements vary from country to country. Currently, DMT is classified in the Netherlands as a List 1 Drug under the Dutch Opium Act (Opiumwet) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Dutch Opium Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and as such, subject to express authorization being obtained, the production, trade and possession of DMT are prohibited. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition to the Dutch Opium Act, two other Dutch Acts may be relevant when it comes to drugs&#58; the Medicines Act and the Commodities Act.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The specific regulatory processes and approvals required may vary among different EU member states and are set forth in the respective legislation of each country. For the Netherlands, there are specific regulatory requirements for the approval of clinical trials that need to be met. Firstly, a CTA dossier containing the preclinical and any clinical information along with the proposed clinical trial design must be submitted to an accredited Ethics Committee and to the Central Commission on Research in Humans (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CCMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), which is also known as the Competent Authority in The Netherlands. In Dutch, the CCMO is called the &#8216;Centrale Commissie Mensgebonden Onderzoek&#8217;. In cases where the study involves a substance subject to the Dutch Opium Act (such as DMT), an official exemption by Farmatec is needed, which needs to be included in the CTA. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Specific rules for the submission, assessment and conduct of clinical trials with medicinal products are set out in, among others, the EU Clinical Trial Regulation 536&#47;2014 (CTR), which is applicable in the EU as of January 31, 2022 and the Medical Research (Human Subjects) Act (Wet medisch-wetenschappelijk onderzoek met mensen).  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">47</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April 26, 2023, the European Commission introduced a comprehensive &#8220;pharmaceutical package&#8221; aimed at revising the EU&#8217;s pharmaceutical legislation. This package includes proposals for a new directive and regulation designed to enhance the availability, accessibility, and affordability of medicines. Additionally, it seeks to boost the competitiveness and attractiveness of the EU pharmaceutical industry while imposing higher environmental standards. The European Parliament has recently looked at these proposals to renovate the EU pharmaceutical legislation, and a newly elected Parliament will take up the proposal following the European elections of June 6-9, 2024. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Ireland </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In Ireland, psilocin is a controlled substance under the Misuse of Drugs Act, 1977, 1984 and 2015 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ireland MDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the Misuse of Drugs Regulations 2017 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ireland MDR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and the Criminal Justice (Psychoactive Substances) Act 2010 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2010 Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). These are the primary legislative instruments which govern controlled substances in Ireland. This legislation regulates the use, possession, supply, licensing, and administration of listed scheduled substances and establishes the offences and penalties for infringement of the legislation. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any substance, product or preparation (whether natural or otherwise) including a fungus of any kind or description, which contains psilocin, or an ester of psilocin, is classed as a Schedule 1 controlled substance under the Ireland MDA and the Ireland MDR. Accordingly, psilocin is subject to the strict regime of control that applies. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a Schedule 1 controlled substance under the Ireland MDA, unlawful manufacturing, production, preparation, importation, exportation, supply, or distribution of psilocin carries onerous obligations and harsh punishments for contravention&#59; this includes prohibition orders, closure orders, fines and&#47;or terms of imprisonment of up to 14 years. The Garda&#237; and Customs officials are granted powers to search persons, vehicles, premises and postal packages suspected of possessing&#47;containing a Schedule 1 controlled substance and&#47;or a psychoactive substance for human consumption.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the Ireland MDA, in certain circumstances, the Minister for Health &#8220;may grant licences or issue permits or authorizations for any of the purposes of this Act, attach conditions to any such licence, permit or authorization, vary such conditions and revoke any such licence, permit or authorization&#8221;. Where licences are granted, there are very strict conditions imposed on licence holders. For example, strict conditions can be placed regarding the security, storage and documenting controlled substances. Further, the 2010 Act permits the Minister to make an order declaring that the Act shall not apply in relation to any &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">substance, product, preparation, plant, fungus or natural</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">organism</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; as specified in the order.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company does not currently engage in any activities in Ireland that are regulated by such laws. If the Company were to engage in such activities, it would need to obtain the appropriate licences and authorization to do so. The Company intends to constantly review its Irish operations to ensure compliance with all applicable laws as the operations evolve.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Irish Government&#8217;s Legislative Programme for Summer 2025 does not contain any proposed amendments to the above-mentioned legislation which currently govern controlled substances.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">United Kingdom </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the UK, there are two main &#8220;layers&#8221; of regulation with which products containing controlled substances must comply. These are&#58; (i) controlled drugs legislation, which applies to all products </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">48</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">irrespective of the type of product, and (ii) the regulatory frameworks applicable to a specific category of products, in this case, pharmaceuticals and food&#47;food supplements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The main UK controlled drugs legislation is the Misuse of Drugs Act 1971 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and the Misuse of Drugs Regulations 2001 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MDR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), each as amended. The MDA sets out the penalties for unlawful production, possession and supply of controlled drugs based on three classes of risk (A, B and C). The MDR sets out the permitted uses of controlled drugs based on which Schedule (1 to 5) they fall within.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the United Kingdom, &#8220;Fungus (of any kind) which contains psilocin or an ester of psilocin&#8221; is controlled as a Class A drug under the MDA and Schedule 1 drug under the MDR. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the United Kingdom, Class A drugs are deemed to be the most dangerous, and so carry the harshest punishments for unlawful manufacture, production, possession and supply. Schedule 1 drugs can only be lawfully manufactured, produced, possessed and supplied under a controlled drugs domestic licence, which specifies the specific activities to which it relates together with any applicable conditions, issued by the UK Home Office. While exemptions do exist, none are applicable to the API. DMT is also considered a Class A drug under the MDA and as a Schedule I drug under the MDR. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company previously mentioned that it intended to file a clinical trial application with the U.K. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Medical and Healthcare Products Regulatory Agency (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MHRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) related to the Deuterated Psilocybin Analog Program upon completion of its pre-clinical studies and CMC development. The Company has since decided that it will first proceed in the U.S. and will reevaluate other applications at a later date. Anticipated timelines related to regulatory filings are based on reasonable assumptions informed by current knowledge and information available to the Company. Small Pharma has a controlled drug licence in respect of the offices at 50 Featherstone St, which was issued on June 6, 2024 and expired on June 5, 2025. An application for 2025 renewal has been made in good time prior to expiration. Although the new certificate has not yet been issued for 2025-2026, the Home Office has advised that the Company may continue to handle controlled drugs on the same terms and subject to the same conditions of the 2024-2025 licence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Licensing Requirements</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company obtains CYB003 API from a pharmaceutical ingredient provider who is FDA-registered and based in the United States. The API itself has been manufactured and packaged in FDA-registered facilities in the United States. The API is expected to be sent directly to the Company&#8217;s partners for research and development purposes in the United States, Canada and the UK and to its clinical trial site in the U.S.  As a part of the Asset Acquisition, the Company also acquired API. The CYB004-E API was manufactured in the Netherlands by a pharmaceutical ingredient provider that is US FDA-inspected.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">30</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As mentioned above, in order to produce, possess and supply the API at a UK-based facility, the facility must also hold a domestic licence issued by the Home Office covering the manufacture, production, possession and supply of a controlled substance. For export of the API to the United States, an export licence is required for each API shipment. The export application must include details of the importer and any import licence required by the local authorities in the United States. Moreover, as set out below in more detail under the heading &#34;Pharmaceutical Products&#34;, depending on how the API is developed and </font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:122%;position:relative;top:-3.15pt;vertical-align:baseline">30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:122%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%">As a result of the Asset Acquisition, including the existing API, the Company did not direct the manufacturing of the API for CYB004-E and proceeded in reliance upon the representations of Entheon and the Company&#8217;s acquisition diligence. While the Company believes the CYB004-E API meets all required specifications, the Company did not oversee or direct the manufacture of the DMT API being used in CYB004-E.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">49</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">supplied, certain authorizations and licenses from the MHRA may be required to authorize some of the activities carried on at the UK-based facilities in relation to the API .</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All premises that are Home Office licensed, or are intending to be licensed, in connection with the possession, and&#47;or supply and&#47;or production of controlled drugs should consider certain security measures.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">31</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Typically, when controlled drugs are being transported between licensees, responsibility for their security remains with the owner and does not transfer to either the courier or the customer until the drugs arrive at their destination and are signed for. However, where a third party is involved in the transit and&#47;or storage of controlled drugs, even if they are not the legal owners, this party also carries responsibility for their security by virtue of being &#8216;in possession&#8217; of them. The MDA requires that every person in possession of controlled drugs holds an appropriate Home Office Licence and under the Home Office guidance, each organization involved in the movement of controlled drugs should have a standard operating procedure covering their responsibilities, record keeping, reconciliation and reporting of thefts&#47;losses.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">32</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Small Pharma holds the appropriate UK Home Office licence required to sponsor clinical trials using Schedule I compounds.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmaceutical Products</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A product is regulated as a &#8220;medicinal product&#8221; under UK legislation (the Human Medicines Regulations 2012, as amended) if (i) it is a substance or combination of substances presented as having properties of preventing or treating disease in human beings (e.g., in marketing claims) or (ii) it is a substance or combination of substances that may be used by or administered to human beings with a view to (a) restoring, correcting or modifying a physiological function by exerting a pharmacological, immunological or metabolic action, or (b) making a medical diagnosis.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In respect of psilocybin&#47;psilocin and DMT, whether a specific product restores, corrects or modifies a physiological function by exerting a pharmacological, immunological or metabolic action will depend on factors such as the concentration of the psilocybin&#47;psilocin or DMT (as applicable) and the mode of action of any psilocybin&#47;psilocin or DMT (as applicable) absorbed in the body. This requires scientific analysis.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If a product is a medicinal product, the Human Medicines Regulations 2012 require that a marketing authorization for the product granted by the UK Licensing Authority should be in place before the product is placed on the market in the UK (other, more limited, licensing options are available, such as a conditional marketing authorization), unless the product falls within one of the specified exemptions, such as supply in response to an unsolicited request from a healthcare professional to meet the special clinical needs of a particular patient under his&#47;her care. Following the UK&#8217;s exit from the EU and the end of the transitional period, up to (and including) December 31, 2024, there were separate licensing routes and licences for products supplied&#58; (i) in Great Britain only&#59; (ii) in Northern Ireland only&#59; and (iii) across the UK. From January 1, 2025, the UK Licensing Authority now licenses products across the whole of the UK through UK-wide licenses, removing the separate licensing routes for Great Britain and Northern Ireland for many medicinal products. The process for obtaining a standard marketing authorization generally involves submitting preclinical and clinical data as well as quality and manufacturing </font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:122%;position:relative;top:-3.15pt;vertical-align:baseline">31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%"> Home Office guidance&#59; Security guidance for all existing or prospective Home Office Controlled Drug Licensees and&#47;or Precursor Chemical Licensees or Registrants&#59; 2022&#59;  https&#58;&#47;&#47;assets.publishing.service.gov.uk&#47;media&#47;63a1b6c8e90e075874d91825&#47;Security_Guidance_for_all_Businesses_and_Other_Organisations_v1.5_Nov_2022.pdf.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:122%;position:relative;top:-3.15pt;vertical-align:baseline">32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:122%"> Home Office guidance&#59; Guidelines for Standard Operating Procedures (SOPs)&#59; https&#58;&#47;&#47;assets.publishing.service.gov.uk&#47;government&#47;uploads&#47;system&#47;uploads&#47;attachment_data&#47;file&#47;480572&#47;StandardOpProcedure.pdf.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">50</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">information in the form of a common technical document to the MHRA. In addition to a marketing authorization for the product itself, companies carrying out activities involving medicinal products, such as manufacturing, distribution and wholesaling, need to meet defined standards (GMP) and&#47;or Good Distribution Practice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GDP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and to hold a related licence from the MHRA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">How the API is subsequently processed will determine the licences (in addition to any applicable Home Office licenses as referred to above) that the UK-based facility must hold. In particular&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">if the API is just one &#8216;ingredient&#8217; (i.e. active substance) of the investigational medicinal product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) which is used in the clinical trial then the UK-based facility must apply to be registered with the MHRA and provide the MHRA with 60 days&#8217; notice of the intended start of manufacture, import or distribution of the API, and comply with GMP and GDP for active substances&#59; furthermore, an MHRA inspection may be required&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">conversely, if the API will itself constitute the IMP, the manufacturer must, except in certain limited circumstances, hold a Manufacturer&#8217;s Authorizations for IMPs licence (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MIA(IMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)&#8221;) granted by the MHRA. In this scenario, assuming the IMP is manufactured or assembled in the UK, an MIA(IMP) would be required regardless of whether the IMP is for use in clinical trials in the UK, an EEA Member State or a third country (such as the United States or Canada). GMP, GDP and inspection requirements will apply.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Some products fall on the borderline between medicines and other categories of regulated products such as medical devices, cosmetics or food supplements. The regulatory status of the product will be determined by i) the actual effect of the product on the body&#59; and ii) any claims made about the effect of the product.&#160;Where a product is potentially both a medicinal product and another category of product, the legal position in the UK and EU is that it will be regulated as a medicinal product.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is focused on development of psychedelic medicines and other products, through research and development of novel chemical compounds and delivery mechanisms and study of such compounds in clinical environments around the world. The Company anticipates growing its pipeline of psychedelic pharmaceutical products inspired medicines through its internal research, development, proprietary discovery programs, mergers and acquisitions, joint ventures and collaborative development agreements. For the time being, the Company maintains intellectual property generated by its R&#38;D programs through patent filings and as trade secrets. The Company anticipates that as these programs mature more patent applications will be filed and more details about these programs will be disclosed at such time. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Psychedelics are a class of drug whose primary action is to trigger psychedelic experiences by way of serotonin receptor agonism, causing thought, visual and auditory changes, and altered state of consciousness. Major psychedelic drugs include mescaline, LSD, psilocin, and DMT. Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms. The most potent are members of the genus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Psilocybe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, such as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> P. azurescens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">P. semilanceata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">P. cyanescens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, but psilocybin has also been isolated from about a dozen other genera. As a prodrug, psilocybin is quickly converted by the body to psilocin, which has mind-altering effects. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">51</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The pharmacokinetics, pharmacology and human metabolism of psilocin are well known and well characterized. In conjunction with psychotherapy, psilocin has been utilized broadly in phase II clinical trials.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Psilocybin found in certain species of mushrooms is a non-habit forming naturally occurring psychedelic compound. Once ingested, psilocybin is rapidly metabolized to psilocin, which then acts on serotonin receptors in the brain. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cybin has commenced research and development on the delivery of synthetic psilocin and other psychedelics through mechanisms such as sublingual film delivery, IV, and by way of inhalation. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development is led by the Company&#8217;s North American Chief Scientific Officer, Alex Nivorozhkin Ph.D., a seasoned medicinal chemist, drug delivery expert and founder of multiple biotech companies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s research and development must be conducted in strict compliance with the regulations of federal, state, local and regulatory agencies in Canada, the United States and the UK, and the equivalent regulatory agencies in the other jurisdictions in which the Company operates. These regulatory authorities regulate, among other things, the research, manufacture, promotion and distribution of drugs in specific jurisdictions under applicable laws and regulations. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Canada</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The process required before a prescription drug product candidate may be marketed in Canada generally involves&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Chemical and Biological Research </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- Laboratory tests are carried out on tissue cultures and with a variety of small animals to determine the effects of the drug. If the results are promising, the manufacturer will proceed to the next step of development.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Pre-clinical Development &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Animals are given the drug in varying amounts over differing periods of time. If it can be shown that the drug causes no serious or unexpected harm at the doses required to have an effect, the manufacturer will proceed to clinical trials.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Clinical Trials &#8212; Phase 1 - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The first administration in humans is to test if people can tolerate the drug. If this testing is to take place in Canada, the manufacturer must prepare a clinical trial application for the Therapeutic Products Directorate of Health Canada (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TPD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). This includes the results of the first two steps and a proposal for testing in humans. If the information is sufficient, the Health Products and Food Branch of Health Canada (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HPFB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) grants permission to start testing the drug, generally first on healthy volunteers. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Clinical Trials &#8212; Phase 2 - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Phase 2 trials are carried out on people with the target condition, who are usually otherwise healthy, with no other medical condition. Trials carried out in Canada must be approved by the TPD. In phase 2, the objective of the trials is to continue to gather information on the safety of the drug and begin to determine its effectiveness.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Clinical Trials &#8212; Phase 3 - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the results from phase 2 show promise, the manufacturer provides an updated clinical trial application to the TPD for Phase 3 trials. The objectives of phase 3 include determining whether the drug can be shown to be effective, and have an acceptable side effect profile, in people who better represent the general population. Further information will also </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">52</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">be obtained on how the drug should be used, the optimal dosage regimen and the possible side effects.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">New Drug Submission - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the results from phase 3 continue to be favourable, the drug manufacturer can submit a new drug submission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NDS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to the TPD. A drug manufacturer can submit an NDS regardless of whether the clinical trials were carried out in Canada. The TPD reviews all the information gathered during the development of the drug and assesses the risks and benefits of the drug. If it is judged that, for a specific patient population and specific conditions of use, the benefits of the drug outweigh the known risks, the HPFB will approve the drug by issuing a notice of compliance.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">United States</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because psilocybin, psilocin, DMT, and 5-Methoxy-DMT are listed as Schedule I substances under the CSA, for any product containing psilocin or any Schedule I substance to be available for commercial marketing in the United States, such substance must be rescheduled, or the product itself must be scheduled, by the DEA to Schedule II, III, IV or V.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The process required before a prescription drug product candidate may be marketed in the United States generally involves&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">completion of extensive nonclinical laboratory tests, animal studies and formulation studies, all performed in accordance with the FDA&#8217;s GLP, Good Clinical and&#47;or GMP regulations&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">submission to the FDA of an IND Application, which the FDA must approve before human clinical trials may begin&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">approval by an IRB or independent ethics committee at each clinical trial site before each trial may be initiated&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">for nearly all new pharmaceutical products, performance of adequate and well-controlled human clinical trials in accordance with the FDA&#8217;s regulations, including Good Clinical Practices, to establish the safety and efficacy of the prescription drug product candidate for each proposed indication&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">submission to the FDA of an NDA&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality, and purity&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">FDA review and approval of the NDA prior to any commercial marketing, sale or shipment of the drug.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The testing and approval process requires substantial time, effort and financial resources, and the Company cannot be certain that the DEA will schedule or reschedule any Schedule I substance or product candidate to Schedule II, III, IV or V, or that approvals for its prescription drug product candidates will be granted on a timely basis, if at all.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-clinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animals and other animal studies or through FDA-accepted alternative methods (New Approach Methodologies or NAMs). The results of non-clinical tests, together with manufacturing information and analytical data, are submitted as part of an IND to the FDA. Some non-clinical testing may continue even after an IND is submitted. The IND also includes one or more </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">53</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">protocols for the initial clinical trial or trials and an investigator&#8217;s brochure. An IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions relating to the proposed clinical trials as outlined in the IND and places the clinical trial on a clinical hold. In such cases, the IND sponsor and the FDA must resolve any outstanding concerns or questions before any clinical trials can begin. Clinical trial holds also may be imposed at any time before or during studies due to safety concerns or non-compliance with regulatory requirements. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">An IRB board, at each of the clinical centers proposing to conduct the clinical trial must review and approve the plan for any clinical trial before it commences at that center. An IRB board considers, among other things, whether the risks to individuals participating in the trials are minimized and are reasonable in relation to anticipated benefits. The IRB board also approves the consent form signed by the trial participants and must monitor the study until completed.&#160;The FDA, the independent IRB, or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trials to public registries. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The FDA offers a number of regulatory mechanisms that provide expedited or accelerated approval procedures for selected drugs and indications which are designed to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These include programs such as BTDs, Fast Track designations, Priority Review and Accelerated Approval, which the Company may need to rely upon in order to receive timely approval or to be competitive.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company may plan to seek orphan drug designation for certain indications qualified for such designation. The U.S., E.U. and other jurisdictions may grant orphan drug designation to drugs intended to treat a &#8220;rare disease or condition,&#8221; which, in the U.S., is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or 200,000 or more individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug available in the United States for this type of disease or condition will be recovered from sales of the product. In the E.U., orphan drug designation can be granted if&#58; the disease is life threatening or chronically debilitating and affects no more than 50 in 100,000 persons in the E.U.&#59; without incentive it is unlikely that the drug would generate sufficient return to justify the necessary investment&#59; and no satisfactory method of treatment for the condition exists or, if it does, the new drug will provide a significant benefit to those affected by the condition. Orphan drug designation must be requested before submitting an NDA. If a product that has an orphan drug designation subsequently receives the first regulatory approval for the indication for which it has such designation, the product is entitled to orphan exclusivity, meaning that the applicable regulatory authority may not approve any other applications to market the same drug for the same indication, except in very limited circumstances, for a period of seven years in the U.S. and 10 years in the E.U. Orphan drug designation does not prevent competitors from developing or marketing different drugs for the same indication or the same drug for different indications. After orphan drug designation is granted, the identity of the therapeutic agent and its potential orphan use are publicly disclosed. Orphan drug designation does not convey an advantage in, or shorten the duration of, the development, review and approval process. However, this designation provides an exemption from marketing and authorization fees.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Drugs manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, reporting of adverse experiences with the product, and complying with promotion and advertising requirements. The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-market testing, including </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">54</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">phase IV clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. In addition, drug manufacturers and their subcontractors involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including current Good Manufacturing Practices, which impose certain procedural and documentation requirements. Failure to comply with statutory and regulatory requirements may subject a manufacturer to legal or regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties or criminal prosecution. There is also a continuing, annual prescription drug product program user fee.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, requirements for post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a risk evaluation and mitigation strategy.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the United States, pharmaceutical manufacturers are subject to complex laws and regulations pertaining to healthcare &#8220;fraud and abuse,&#8221; including, but not limited to, the Anti-Kickback Statute, the federal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">False Claims Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and other state and federal laws and regulations. The Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase, order, or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The FCA prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to or approval by the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Violations of the FCA can result in very significant monetary penalties and treble damages. The federal government is using the FCA, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical companies throughout the country, for example, in connection with the promotion of products for unapproved uses and other sales and marketing practices. The government has obtained multi-million and multi-billion dollar settlements under the FCA in addition to individual criminal convictions under applicable criminal statutes. In addition, the federal civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers&#8217; and manufacturers&#8217; compliance with applicable fraud and abuse laws.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There are also an increasing number of state laws that require manufacturers to make reports to states on pricing and marketing information. In addition, a similar federal requirement Section 6002 of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or the Affordable Care Act, commonly referred to as the &#8220;Physician Payments Sunshine Act&#8221; requires applicable manufacturers to track and report to the federal government certain payments and &#8220;transfers of value&#8221; made to physicians and teaching hospitals, as well as ownership and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">55</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">investment interests held by physicians and their immediate family members, made in the previous calendar year. There are a number of states that have various types of additional reporting requirements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Controlled Substances</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The CSA and its implementing regulations establish a &#8220;closed system&#8221; of regulations for controlled substances. The CSA imposes registration, security, recordkeeping and reporting, storage, manufacturing, distribution, importation and other requirements under the oversight of the DEA. The DEA is responsible for regulating controlled substances, and requires those individuals or entities that manufacture, import, export, distribute, research, or dispense controlled substances to comply with the regulatory requirements in order to prevent the diversion of controlled substances to illicit channels of commerce.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The DEA categorizes controlled substances into one of five schedules&#8201;&#8212;&#8201;Schedule I, II, III, IV or V&#8201;&#8212;&#8201;with varying qualifications for listing in each schedule. Schedule I substances by definition have a high potential for abuse, have no currently accepted medical use in treatment in the United States and lack accepted safety for use under medical supervision. For any product containing a Schedule I substance, such as psilocin to be available for commercial marketing in the United States, such substance must be rescheduled, or the product itself must be scheduled, by the DEA to Schedule II, III, IV or V. Scheduling determinations by the DEA are dependent on FDA approval of a substance or a specific formulation of a substance.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Facilities that research, manufacture, distribute, import or export any controlled substance must register annually with the DEA. The DEA registration is specific to the particular location, activity(ies) and controlled substance schedule(s). For example, separate registrations are needed for import and manufacturing, and each registration will specify which schedules of controlled substances are authorized.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The DEA may inspect all research and manufacturing facilities to review security, recordkeeping, reporting and handling prior to issuing a controlled substance registration and periodically to ensure continued compliance. The specific security requirements vary by the type of business activity and the schedule and quantity of controlled substances handled. The most stringent requirements apply to researchers and manufacturers of Schedule I and Schedule II substances. Required security measures commonly include background checks on employees and physical control of controlled substances through storage in approved vaults, safes and cages, and through use of alarm systems and surveillance cameras. Once registered, manufacturing facilities must maintain records documenting the manufacture, receipt and distribution of all controlled substances. Manufacturers must submit periodic reports to the DEA of the distribution of Schedule I and II controlled substances, Schedule III narcotic substances, and other designated substances. Registrants must also report any controlled substance thefts or significant losses, and must obtain authorization to destroy or dispose of controlled substances. Imports of Schedule I and II controlled substances for commercial purposes are generally restricted to substances not already available from a domestic supplier or where there is not adequate competition among domestic suppliers. In addition to an importer or exporter registration, importers and exporters must obtain a permit for every import or export of a Schedule I and II substance or Schedule III, IV and V narcotic, and submit import or export declarations for Schedule III, IV and V non-narcotics. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For drugs manufactured in the United States, the DEA establishes annually an aggregate quota for the amount of substances within Schedules I and II that may be manufactured or produced in the United States based on the DEA&#8217;s estimate of the quantity needed to meet legitimate medical, scientific, research and industrial needs. The quotas apply equally to the manufacturing of the active pharmaceutical ingredient and production of dosage forms. The DEA may adjust aggregate production quotas a few times </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">per year, and individual manufacturing or procurement quotas from time to time during the year, although the DEA has substantial discretion in whether or not to make such adjustments for individual companies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Individual U.S. states also establish and maintain separate controlled substance laws and regulations, including licensing, recordkeeping, security, distribution, and dispensing requirements. A majority of state laws in the United States classify psilocybin and psilocin as Schedule I controlled substances. State authorities, including boards of pharmacy, regulate use of controlled substances in each state, including state specific controlled substance registration requirements. Failure to obtain applicable registrations or maintain compliance with applicable requirements, particularly as manifested in the loss or diversion of controlled substances, can result in enforcement action that could have a material adverse effect on the Company&#8217;s business, operations and financial condition. The DEA and&#47;or state regulatory agencies may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances, violations could lead to criminal prosecution.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EU (Netherlands)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Regulation (EU) No 536&#47;2014 on Clinical Trials on Medicinal Products for Human Use (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CTR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is applicable as of January 31, 2022, harmonizing the laws, regulations and administrative provisions of the EU Member States relating to the implementation of Good Clinical Practice in the conduct of clinical trials on medicinal products for human use.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> EU Member States have transformed the requirements outlined in the Clinical Trials Directive into the respective national laws. Pursuant to the CTR, as of January 31, 2023 sponsors are obliged to use the Clinical Trials Information System (CTSI) for regularity submission, authorization and supervision of clinical trials in the EU and the EEA. CTIS will thus serve as the single-entry point for submissions by sponsors and for regulatory assessment. In addition to this obligation, sponsors must transfer any ongoing (approved) trials under the CTR to CTIS by January 2025.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, the European Medicines Agency (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) adopted on October 5, 2023, the &#8220;Revised CTIS Transparency Rules&#8221; on publishing information about clinical trials submitted through CTIS. To increase transparency, EMA removed the deferral mechanism which allowed sponsors to delay certain data and document publication for up to seven years after the end of their trial. Annex I of the revised rules outlines the timing of information publication for each category of clinical trial and patient population. These new rules became applicable on June 18, 2024, the same day of the launch of the new CTIS portal. In order to smoothen the process of transitioning clinical trials from the Clinical Trial Directive to the CTR, a non-binding guide named &#8220;Guidance for the Transition of clinical trials from the Clinical Trials Directive to the Clinical Trials Regulation&#8221; (version 4) dated May 2024 is published.      </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CTIS and the practical aspects thereof are also discussed and explained (among other relevant topics relating to clinical trials) in a quick guide on the rules and procedures of the EU Clinical Trials Regulation called &#8220;Clinical Trials Regulation (EU) 536&#47;2014 in practice&#8221;, which is published by the Clinical Trials Coordination and Advisory Group (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CTAG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) on December 8, 2023. The objective of the rules is to provide sponsors and investigators a quick guide on the rules and procedures of the CTR with a view to facilitating implementation. In addition to the quick guide, CTAG also published a non-binding Questions &#38; Answers (Version 7.1) that should be read in conjunction with the quick guide and with the &#8220;Clinical Trials Information System (CTIS)&#58; online training modules&#8221; in order to gain a better understanding of the legislative changes that are effected by the CTR.</font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The CTR does not apply in the UK and UK law on clinical trials is currently based on old EU law (the Clinical Trials Directive), transposed into UK law via the Medicines for Human Use (Clinical Trials) Regulations 2004. An overhaul of UK law on clinical trials has been on-going for a few years, and new legislation on clinical trials in the UK, the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2024, has been signed into law and is due to come into effect from mid-April 2026.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">57</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Investigational Medicinal Product Dossier (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IMPD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is one of several regulatory documents required for conducting a clinical trial of a pharmacologically API intended for one or more EU Member States. The IMPD includes summaries of information related to the quality, manufacture and control of any IMP (including reference product and placebo), and data from non-clinical and clinical studies. Guidance concerning IMPDs is based on the CTR and on the approximation of laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use (also commonly referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Clinical Trials Directive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The content of the IMPD may be adapted to the existing level of knowledge and the product&#8217;s phase of development. When applying for a clinical trial authorization, a full IMPD is required when little or no information about an API has been previously submitted to competent authorities, when it is not possible to cross-refer to data submitted by another sponsor and&#47;or when there is no authorization for sale in the EU. However, a simplified IMPD may be submitted if information has been assessed previously as part of a Marketing Authorization or a clinical trial to that competent authority. Although the format is not obligatory, the components of an IMPD are largely equivalent to clinical trial applications in Canada and the United States. The IMPD need not be a large document as the amount of information to be contained in the dossier is dependent on various factors such as product type, indication, development phase etc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The assessment of an IMPD is focused on patient safety and any risks associated with the IMP. Whenever any potential new risks are identified the IMPD must be amended to reflect the changes. Certain amendments are considered substantial in which case the competent authority must be informed of the substantial amendment. This may be the case for changes in IMP impurities, microbial contamination, viral safety, transmissible spongiform encephalopathies (e.g. mad cow disease) and in some particular cases to stability when toxic degradation products may be generated.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With the completion of the Asset Acquisition, the Company has an ongoing phase I study to obtain preliminary evidence of the safety and efficacy of infused DMT. Prior to the Asset Acquisition, an investigator&#8217;s brochure (including prior safety, preclinical and clinical data), and an IMPD document that includes CMC information and a clinical study protocol and supporting information had been prepared. Approval by the Dutch ethics committee of the Phase 1 Study, planned to be conducted by CHDR will be based on the vast amount of published human and animal studies of DMT. Prior to the Asset Acquisition, preclinical data was not provided as part of the application package&#59; however, limited additional in vivo and in vitro data to support the rationale for human dosing and safety had been included. CHDR and its partner GMP-licensed pharmacy that will be involved in the Phase 1 Study, the Leiden University Medical Center, have all the required approvals to possess and handle DMT for the Phase 1 Study. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Failure of the Company to receive the necessary regulatory approvals required to conduct the Phase 1 Study would have an adverse impact on its business plans and financial condition for a number of reasons including, without limitation&#58; (i) it would cause delays in the Company&#8217;s research and development plans&#59; (ii) it may require the Company to expend additional financial and human resources on revising its application package or creating a new one&#59; or (iii) it may require the Company to approach an entirely different regulatory authority in a new jurisdiction, in which case the Company would have to expend a substantial amount of capital and other resources on engaging the appropriate research and development partners and creating an application package that complies with the regulations of that new jurisdiction. Additionally, the Company would be required to spend capital on transferring the DMT materials to the new jurisdiction. All of the foregoing would likely have a negative impact on the Company&#8217;s business and financial condition.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">58</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Pharmaceutical Products</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In accordance with the Dutch Medicines Act (Geneesmiddelenwet), &#8220;medicinal products&#8221; are defined as&#58; a substance or a combination of substances that is intended to be administered or used for, or is presented in any way as being suitable for, use&#58; (i) the cure or prevention of any disease, defect, wound or pain in human beings, (ii) the making of a medical diagnosis in human beings, or (iii) restoring, improving or otherwise modifying physiological functions in humans by exerting a pharmacological, immunological or metabolic effect. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If a product constitutes a medicinal product, a marketing authorization for the product is required before the product may be placed on the market in the Netherlands. In the EU, marketing authorizations may be obtained through the Centralized procedure, the Decentralized or Mutual Recognition procedures and&#47;or the national procedure. The Centralized procedure is compulsory for medicines intended to treat i.e. cancer, AIDS, neurodegenerative diseases and diabetes and optional (only) for medicines comprising of new active substances not previously approved for the EEA. When applying for a marketing authorization through the Centralized procedure, applications are submitted with the EMA. Where the Centralized procedure is not available but a medicinal product is intended for several EU&#47;EEA Member States, an application for a marketing authorization may be submitted with the competent authority of a single EU&#47;EEA Member State in accordance with the Decentralized procedure. When the assessment of the application results in a decision to grant the marketing authorization, this decision will be recognized by the competent authorities of the other Member States for which the marketing authorization is applied. The Mutual Recognition procedure is similar to the Decentralised procedure, but applies to applications where the medicinal product is already the subject of a marketing authorization in another EU&#47;EEA Member State. Finally, should a medicinal product be intended for the Netherlands only, then the national procedure may be followed by submitting an application with the Dutch Medicines Evaluation Board. It may be remarked that the national procedure is unavailable in case the Centralized procedure is compulsory or in case an applicant has already submitted an application for and&#47;or obtained a marketing authorization in another Member State. In that case, applications must follow the Mutual Recognition procedure instead.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Companies that manufacture or trade in medicinal products and&#47;or active pharmaceutical ingredients in the Netherlands require a manufacturing authorization or a wholesale distribution authorization. A manufacturing authorization is required for the preparation, trading in, import and export of medicinal products and&#47;or active substances. Here, &#8216;preparation&#8217; means the total or partial manufacture of medicinal products and&#47;or active substances or the packaging or labelling thereof. &#8216;Importing&#8217; means the import of medicinal products or active substances from a country outside the EEA into the Dutch territory, while &#8216;exporting&#8217; means the export of medicinal products or active substances from the Dutch territory to a country outside the EEA. A wholesale distribution authorization is required for one or more activities within the wholesale business, such as procuring, holding, supplying, delivering or exporting medicinal products or active substances which are prepared or imported by a third party. It may be noted that holders of wholesale distribution authorization, other than holders of marketing authorizations, are not authorized to import medicinal products from countries outside the EEA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Only a natural or legal person established in the Netherlands may obtain either a Dutch marketing authorization or a wholesale distribution authorization. These authorizations concern national permits, meaning that these authorizations are not automatically valid in other EU Member States. Furthermore, in the Netherlands applicants of marketing authorizations and wholesale distributions authorizations must be registered with Farmatec and comply with GDP norms.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">59</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Marketing Authorization Regulatory Process </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Under the Centralized procedure, pharmaceutical companies submit a single marketing authorization application to the EMA, which provides the basis of a legally binding recommendation that will be provided by the EMA to the European Commission, the authorizing body for all centrally authorized products. This allows the marketing-authorization holder to market the medicine and make it available to patients and healthcare professionals throughout the EU on the basis of a single marketing authorization. EMA&#8217;s Committee for Medicinal products for Human Use or Committee for Medicinal Products for Veterinary Use carry out a scientific assessment of the application and give a recommendation on whether the medicine should be marketed or not, under any particular dosing regime. Although, under EU law, the EMA has no authority to permit marketing in the different EU countries, the European Commission is the authorizing body for all centrally authorized products, who takes a legally binding decision based on EMA&#8217;s recommendation. Once granted by the European Commission, the centralized marketing authorization is valid in all EU Member States as well as in the European Economic Area countries Iceland, Liechtenstein and Norway. European Commission decisions are published in the Community Register of medicinal products for human use. Once a medicine has been authorized for use in the EU, the EMA and the EU Member States constantly monitor its safety and take action if new information indicates that the medicine is no longer as safe and effective as previously thought. The safety monitoring of medicines involves a number of routine activities ranging from&#58; assessing the way risks associated with a medicine will be managed and monitored once it is authorized&#59; continuously monitoring suspected side effects reported by patients and healthcare professionals, identified in new clinical studies or reported in scientific publications&#59; regularly assessing reports submitted by the Company holding the marketing authorization on the benefit-risk balance of a medicine in real life&#59; and assessing the design and results of post-authorization safety studies which were required at the time of authorization. The EMA can also carry out a review of a medicine or a class of medicines upon request of a Member State or the European Commission. These are called EU referral procedures&#59; they are usually triggered by concerns in relation to a medicine&#8217;s safety, the effectiveness of risk minimization measures or the benefit-risk balance of the medicine. The EMA has a dedicated committee responsible for assessing and monitoring the safety of medicines, the Pharmacovigilance Risk Assessment Committee. This ensures that EMA and the EU Member States can move very quickly once an issue is detected and take any necessary action, such as amending the information available to patients and healthcare professionals, restricting use or suspending a medicine, in a timely manner in order to protect patients.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Besides the Centralized procedure, pharmaceutical companies may also submit marketing authorization applications through the Decentralized procedure with the competent authority of a Member State. As the Centralized procedure is compulsory for medicines intended to treat specified diseases i.e. cancer, AIDS, neurodegenerative diseases and diabetes and only optional for medicines comprising of new active substances not previously approved for the EU&#47;EEA, in all other circumstances the Decentralized procedure should be used instead if a marketing authorization is to be obtained for several EU&#47;EEA Member States. When following the Decentralized procedure, the applicant requests one country to be the Reference Member State (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in the procedure. After having shared draft assessment reports to which both the applicant and the competent authorities of other Member States may respond, the to be granted marketing authorization will eventually go through the Mutual recognition procedure. In the Mutual recognition procedure other Member States generally adopt the RMS&#8217;s assessment, unless there are important objections on the grounds of a potentially serious risk to public health. In such situations, further discussions will also be held in the Co-ordination group for Mutual recognition and Decentralised procedures (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CMDh</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). When all Member States involved decide on a positive opinion on products in the CMDh, Dutch translations of the summary of product characteristics, package leaflet, labelling texts and mock-ups are submitted and a national marketing authorization is issued.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">60</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Compliance with Applicable Laws</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company oversees and monitors compliance with applicable laws in each jurisdiction in which it operates. In addition to the Company&#8217;s senior executives and the employees responsible for overseeing compliance, the Company has local counsel engaged in every jurisdiction in which it operates and has received legal opinions or advice in each of these jurisdictions regarding (a) compliance with applicable regulatory frameworks, and (b) potential exposure to, and implications arising from, applicable laws in jurisdictions in which the Company has operations or intends to operate. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company works with third parties who require regulatory licensing to handle scheduled drugs. The Company continuously updates its compliance and channel programs to maintain regulatory standards set for drug development. The Company also works with clinical research organizations who maintain batch records and data storage for the Company&#8217;s clinical programs.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, the Company has established a Medical &#38; Clinical Advisory Team, a Research, Clinical and Regulatory Team and a Government Relations and Communications Team with cross-functional expertise in business, neuroscience, pharmaceuticals, mental health and psychedelics to advise management. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In conjunction with the Company&#8217;s human resources and operations departments, the Company oversees and implements training on the Company&#8217;s protocols. The Company will continue to work closely with external counsel and other compliance experts, and is evaluating the engagement of one or more independent third party providers to further develop, enhance and improve its compliance and risk management and mitigation processes and procedures in furtherance of continued compliance with the laws of the jurisdictions in which the Company operates. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The programs currently in place include monitoring by executives of the Company to ensure that operations conform to and comply with required laws, regulations and operating procedures. The Company is currently in compliance with the laws and regulations in all jurisdictions and the related licensing framework applicable to its business activities. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company and, to its knowledge, each of its third-party researchers, suppliers and manufacturers have not received any non-compliance, citations or notices of violation which may have an impact on the Company&#8217;s licences, business activities or operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company conducts due diligence on third-party researchers, medical professionals, clinics, cultivators, processors and others as applicable, with whom it engages. Such due diligence includes but is not limited to the review of necessary licenses and the regulatory framework enacted in the jurisdiction of operation. Further, the Company generally obtains, under its contractual arrangements, representations and warranties from such third parties pertaining to compliance with applicable licensing requirements and the regulatory framework enacted in the jurisdiction of operation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Patent Cooperation Treaty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Patent Cooperation Treaty (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PCT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) facilitates filing for patent recognition in multiple jurisdictions simultaneously using a single uniform patent application. 157 countries, including Canada and the United States have ratified the PCT.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">61</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ultimately, patents are still granted in each country individually. As such, the PCT procedure consists of two phases&#58; filing of an international application, and national evaluation under the patent laws in force in each country where a patent is sought.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Within 12 months of filing a provisional patent application at the United States Patent and Trademark Office, the Company may elect to file a regular utility patent application in the United States in tandem with filing a PCT application with the World Intellectual Property Office, in each case claiming priority to the provisional patent application. Within 30 months of the provisional filing date, deadlines begin for a PCT application to enter the national phase in desired jurisdictions globally, such as Canada (30 months) and Europe (31 months), in each case claiming priority to the provisional patent application. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">While the Company is focused on programs using psychedelic-inspired compounds, the Company does not have any direct or indirect involvement with the illegal selling, production or distribution of any substances in the jurisdictions in which it operates. The Company is exploring drug development within approved laboratory clinical trial settings conducted within approved regulatory frameworks. Though highly speculative, should any prescription drug product be developed by the Company (which, if it does occur, would not be for several years), such drug product will not be commercialized prior to receipt of applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended use(s) is successfully developed. The Company may also employ non-prescription drugs, where appropriate.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Objectives of the Company </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Key elements of the Company&#8217;s growth strategy include&#58; (i) progressing its psychedelic division through the development and commercialization of key psychedelic molecules (including tryptamines and phenethylamines) and delivery mechanisms&#59; (ii) working to develop the synthetic production of deuterated psychedelic active pharmaceutical ingredients&#59; (iii) obtaining regulatory approval for an approved psilocybin product targeting MDD&#59; (iv) establishing strategic partnerships to advance its scientific research and to develop patented or trade secret intellectual property for the Company&#8217;s new psychedelic chemical compounds and processes related to psychedelics&#59; and (v) sponsoring clinical studies to determine the safety and efficacy of delivery mechanisms, chemically synthesized psychedelic compounds and screening protocols. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Production and Raw Materials </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has established contractual sources of synthetic GMP and non-GMP raw materials to support its development operations through licensed third-party suppliers located in Canada, the United States, the United Kingdom and Europe. Such raw materials are expected to be, in general, readily available and in adequate supply to meet the Company&#8217;s need for development quantities, or custom manufactured on the Company&#8217;s behalf. The prices of research quantities of psilocybin and novel psychedelic compounds are generally higher than commercial supply prices at significantly larger scale and the Company, therefore, expects its supply prices to reduce over time. Development and production of the Company&#8217;s proprietary novel compounds is performed under confidential contractual agreements. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Operations</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s management is located in Canada</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ireland</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">United Kingdom</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and the United States led by others in local jurisdictions. The Company psilocybin raw materials are expected to be sourced from a supplier in the United States and are expected to be manufactured and packaged in FDA registered facilities in the United Kingdom. Such raw materials are expected to be sent directly to the Company&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">62</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">partners for research and development purposes pursuant to its corresponding agreements, subject to receipt of all necessary approvals. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company conducts its international operations to conform to local variations, economic realities, market customs, consumer habits and regulatory environments. The Company will modify its products (including labeling of such products) and its distribution and marketing programs in response to local and foreign legal requirements and customer preferences.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s international operations are subject to many of the same risks that its domestic operations face. These include competition and the strength of the relevant economy. In addition, international operations are subject to certain risks inherent in conducting business abroad, including foreign regulatory restrictions, fluctuations in monetary exchange rates, import-export controls and the economic and political policies of foreign governments. Government regulations in foreign countries may prevent or delay the introduction, or require the reformulation, of certain of its products. Compliance with such foreign governmental regulations is generally the responsibility of the Company&#8217;s distributors in those countries. These distributors are independent contractors whom the Company does not control. The importance of these risks increases as the Company&#8217;s international operations grow and expand. See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Market for Products </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Market Segment, Market Acceptance and Geographic Areas</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is focused on developing novel compounds and improving the bioavailability and pharmacokinetic profiles of existing compounds to target psychiatric and neurological conditions. The Company is focused on progressing its novel psychedelic compounds, delivery mechanisms and supportive treatment platforms.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Marketing Plan and Strategies</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s marketing strategy will be initially driven through a digital marketing strategy composed of digital advertising and influencer marketing. The Company expects to also retain a sales force to complement its digital strategy by targeting wholesale and retail distribution.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Specialized Skills and Knowledge</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s directors and officers possess a wide range of professional skills and experience relevant to pursuing and executing on the Company&#8217;s business strategy. Drawing on significant experience in various industries and sectors, the Company believes its management has a demonstrated track record of bringing together all of the key components for a successful psychedelic medicine company, such as strong technical skills, expertise in planning and financial controls, ability to execute on business development opportunities, and capital markets expertise. The operational skills of the Company&#8217;s management include valuable knowledge and ability to analyze demographics and consumer purchasing habits, and tailor product brands and consumer retail experiences based on relevant demographic data.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By leveraging the strengths and experiences of its management team (i.e., individuals who possess a wealth of combined knowledge and experience necessary for the research and development, sales, marketing, and distribution of psychedelic pharmaceutical products) the Company intends to, over time, establish itself as a leader in the psychedelic pharmaceutical industry. The Company will continue to build out its team with specialists on an &#8220;as-needed&#8221; basis.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">63</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s current directors, officers and key executives have significant collective experience with psychedelic molecules, medicinal chemistry, pre-clinical and clinical operations, clinical psychology, quality and regulatory affairs, in addition to a track record of growing pharmaceutical companies including aspects of commercial operations, securities and capital markets. Collectively, the Company believes that it has adequate access to the current and future skill sets required to grow and sustain its business.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cyclical or Seasonality of Business</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s business is not expected to be cyclical or seasonal.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Employees</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At the current stage of development, the Company is focused on maintaining a lean corporate structure, utilizing a highly experienced core team of senior executives and managers, while leveraging a cost-effective ecosystem of independent contractors, consultants and advisors, on an &#8220;as needed&#8221; basis. The Company employs less than 50 current full-time staff. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intellectual Property  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Cybin has title to twenty four granted US patents and seventy four granted national (non-US) patents, including claims directed to compositions of matter and methods of use in support of its research and development and preclinical and clinical trial programs. Granted European patents are counted as a single granted patent (as opposed to multiple patents in each European territory in which the patent is in force). </font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:3.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Number</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,242,318</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives And Methods Of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,724,985</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives And Methods Of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,746,088</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives And Methods Of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,834,410</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives And Methods Of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,958,807</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives And Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,110,272</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives And Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,240,813</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives And Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,291,499</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives And Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,122,741</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2018311307</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crystalline Forms of Hydroxynorketamine</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020378647</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020381103</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021334933</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021204158</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020286709</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120220221983</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3104072</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Drug Substance Compositions Comprising N,N-Dimethyltryptamine</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3160337</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3179161</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3142290</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">64</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:3.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Number</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3160334</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3179335</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202080087091.0</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202080087092.5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202180044031.5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202180046463.X</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202080050439.9</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202180090269.1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46951</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eurasian Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48675</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eurasian Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49402</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eurasian Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49106</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eurasian Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3463323</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid Oral Dosage Forms of 2R,6R-Hydroxynorketamine or Derivatives Thereof</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3687515</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid Oral Dosage Forms of Ketamine Derivatives</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3532457</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crystalline Forms of Hydroxynorketamine</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3826632</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3844147</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3873883</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3902541</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4031529</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4138818</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4149460</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40042383</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40035970</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid Oral Dosage Forms of Ketamine Derivatives</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40056359</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40060666</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40065709</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40064531</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40045846</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40060891</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40078818</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40089095</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507114</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">528813</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">65</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:3.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Number</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292753</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds, Compositions Comprising Same, and Uses Thereof in the Treatment of Psychiatric or <br>Neurological Disorders </font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288617</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298542</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7288154</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7422474</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7423131</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7422474</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7523474</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A therapeutic composition comprising a deuterated or partially deuterated N,N-dimethyltryptamine compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7579888</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202180044031.5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Macao</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202080087092.5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Macao</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202180046463.X</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Macao</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202080050439.9</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Macao</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404310</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411316</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">412331</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">415678</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">788543</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dimethyltryptamine derivatives and their use in psychedelic-assisted psychotherapy</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">794833</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">793361</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">794813</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Form</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2589605</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Republic of Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2636385</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Republic of Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023&#47;01086</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2585978</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">I860478</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taiwan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2586940</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2592822</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2595776</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,377,416</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crystalline Forms of Hydroxynorketamine</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,771,681</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,773,062</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,643,390</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthesis of N,N-Dimethyltryptamine-Type Compounds, Methods, and Uses</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,471,417</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,406,619</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,697,638</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5-Methoxy-N,N-Dimethyltryptamine Crystalline Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,660,289</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,578,039</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,042,564</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">66</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:3.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Number</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,076,311</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,084,417</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthesis of N,N-Dimethyltryptamine-Type Compounds, Methods, and Uses</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12157723</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12251371</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12318477</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In addition, Cybin has title to three provisional patent applications, thirty three US non-provisional patent applications, two hundred and six national (non-US) patent applications, and six Patent Cooperation Treaty (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">PCT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) applications, including claims directed to compositions of matter and methods of use in support of its research and development and preclinical and clinical trial programs.  </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Application Number</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;056,958</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;041,728</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;027,810</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;547,100</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;561,152</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations of Psilocybin</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;576,487</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Integrated Data Collection Devices for Use in Various Therapeutic and Wellness Applications</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;588,132</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods of Treating Disorders with a Psilocybin Analog</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PCT&#47;EP2024&#47;054897</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WIPO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods of Treating Disorders with a Psilocybin Analog</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;688,125</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination Drug Therapies</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PCT&#47;EP2024&#47;062406</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WIPO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Pharmaceutical Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;707,825</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PCT&#47;EP2024&#47;065453</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WIPO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Companion Animal Treatments</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;720,922</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PCT&#47;EP2024&#47;067458</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WIPO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Processes For Preparing Phenethylamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;730,397</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;730,423</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;825,122</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;883,262</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;850,356</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;852,115</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination of Nitrous Oxide and 5-HT2A Receptor Agonists</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;867,231 </font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid Dispersions of Psilocybin</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#47;020,095</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#47;106,551</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compounds, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#47;119,308</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Compounds, Compositions, and Methods of Use</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">67</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Application Number</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#47;170,327</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#47;822,926</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacture of Psilocin or Deuterated Psilocin Salts</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">793553</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">812214</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297492</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312785</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3177454</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NC2022&#47;0016662</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Colombia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MX&#47;a&#47;2022&#47;014605</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MX&#47;a&#47;2024&#47;006467</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202203191</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2022-7040243</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Republic of Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2024-7019118</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Republic of Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EP21808464.8</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24175524.8</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202180036163.3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202410728550.9</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120220235658</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021276656</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024203974</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11202254530T</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10202401521X</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202213256</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2201007493</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1-2022-553135</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1-2024-551326</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202227065770</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022-571175</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-080101</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62023078320.6</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42024099806.2</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3186357</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2023-7003815</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021327136</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-512063</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21766581.9</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62023079716.4</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3186359</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">68</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Application Number</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2023-7006128</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021328671</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-512107</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21763068</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62023079718</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21786852</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2023-7007858</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021354006</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-519831</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3194558</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62023079720.6</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">802136</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305457</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3212563</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NC2023&#47;0013714</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Columbia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MX&#47;a&#47;2023&#47;010843</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202302731</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202501220</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2023-7032581</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22716857.2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202280022029.2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120230188946</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022239825</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11202305618U</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202309486</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2301005753</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1-2023-552572</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202327063524</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">69</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Application Number</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-556906</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62024086011.9</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022277515</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations of Psilocybin</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3216799</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations of Psilocybin</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22729558.1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations of Psilocybin</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202327074210</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations of Psilocybin</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-571283</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations of Psilocybin</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2023-7041239</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations of Psilocybin</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62024089505.7</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations of Psilocybin</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022342266</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination Drug Therapies</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3231021</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination Drug Therapies</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22716971.1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination Drug Therapies</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-515026</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination Drug Therapies</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2024-7008355</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination Drug Therapies</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62024094405.3</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination Drug Therapies</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022381220</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120240088332</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3236624</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202280073355.6</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22783493.4</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202417038272</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312175</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-526529</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2024-7017594</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">810005</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120242311</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saudi Arabia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62024097476.1</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023207801</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120240139522</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3259235</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202380016531.7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23700949.3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313889</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202417058417</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-541809</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2024-7026687</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MX&#47;a&#47;2024&#47;008691</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PI2024003160</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Malaysia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">811765</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120243886</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saudi Arabia</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">70</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Application Number</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62024099899.2</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023222397</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3244275</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23705529.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-547671</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2024-7028837</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62024101488.0</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023222126</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3244130</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23705530.6</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-547667</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2024-7028843</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62024101490.6</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023246690</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3246274</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23715813.4</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-557460</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2024-7032719</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">815769</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62025103102.2</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023242469</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination of Nitrous Oxide and 5-HT2A Receptor Agonists</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3247035</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination of Nitrous Oxide and 5-HT2A Receptor Agonists</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23717049.3</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination of Nitrous Oxide and 5-HT2A Receptor Agonists</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-557455</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination of Nitrous Oxide and 5-HT2A Receptor Agonists</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813800</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination of Nitrous Oxide and 5-HT2A Receptor Agonists</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62025103101.4</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination of Nitrous Oxide and 5-HT2A Receptor Agonists</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023331937</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compounds, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3265884</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compounds, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23764241.8</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compounds, Compositions, and Methods of Use</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">71</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Application Number</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025-512678</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compounds, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2025-7007259</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compounds, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023366306</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Compounds, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3271746</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Compounds, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202380075041.4</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Compounds, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23798713.6</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Compounds, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025-524528</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Compounds, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2025-7014590</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Compounds, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120253030</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saudi Arabia</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Compounds, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120220089198</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202217028822</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds, Compositions Comprising Same, and Uses Thereof in the Treatment of Psychiatric or Neurological Disorders</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-202672</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2023-7033500</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Republic of Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;921,515</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110143066</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taiwan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021391581</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3203020</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202180090269.1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Macao</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23198784.3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42024091001.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202317043169</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303288</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-533243</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800961</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 816489.5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;252,949</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;056,771</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022393234</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 2024 009571 1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3238583</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">72</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Application Number</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 818741.5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62025102900</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202417045861</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312859</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-529536</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2024-7020007</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MX&#47;a&#47;2024&#47;005955</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">811102</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11202403174T</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024&#47;03906</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PI 2024002791</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Malaysia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120242659</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saudi Arabia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202401452</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2401003192</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12024551165</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;711,130</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#47;192,691</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NC2024&#47;0007518</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Colombia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202280084101.4</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24194778.7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42025103259.5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298129</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PI 2023000584</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Malaysia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11202300697X</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#47;806,526</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#47;202,059</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;619,547</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Administration</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PCT&#47;EP2024&#47;058587</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WIPO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination Comprising a Monoamine Antidepressant Agent and a Short-Duration Psychedelic Agent</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PCT&#47;EP2024&#47;051569</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WIPO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treatment of Psychiatric or Neurological Disorders by Parenteral Administration of a Single, Effective Parenteral Dose of A Short-Acting Psychedelic Agent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22214748</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202217028688</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292754</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21203394.8</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid Oral Dosage Forms of 2R,6R-Hydroxynorketamine or Derivatives Thereof</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;602,171</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthesis of N,N-Dimethyltryptamine-Type Compounds, Methods, and Uses</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120220245661</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">73</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Application Number</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42023070531.1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202217076779</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298541</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120210243330</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22173907.1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">783166</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2021-7043410</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Republic of Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2024-7030292</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Republic of Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;779,611</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021284861</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Form</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202217076899</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Form</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023361184</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Administration of a Parenteral Formulation Comprising a Psychedelic Agent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,270,486</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Administration of a Parenteral Formulation Comprising a Psychedelic Agent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TBD</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Administration of a Parenteral Formulation Comprising a Psychedelic Agent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 790574.0</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Administration of a Parenteral Formulation Comprising a Psychedelic Agent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025-521004</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Administration of a Parenteral Formulation Comprising a Psychedelic Agent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2025-7015515</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Republic of Korea</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Administration of a Parenteral Formulation Comprising a Psychedelic Agent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#47;119,888</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Administration of a Parenteral Formulation Comprising a Psychedelic Agent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3118556</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202180046533.1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;748,483</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 215587.7</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#47;699,449</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical Compositions Comprising Deuterated N,N-Dimethyltryptamine</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#47;723,250</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical Compositions Comprising Deuterated  N,N-Dimethyltryptamine</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cybin&#8217;s patent applications cover a wide range of novel psychedelic compounds from different classes, including those with targeted structural modifications for improved pharmacokinetic characteristics and safety profiles without altering their receptor binding. The patent applications also cover novel synthetic routes, pharmaceutical formulations, methods of use, and methods of administration. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, the Company has entered into multiple licensing agreements that provide the Company with additional access to IP, including the acquisition of an exclusive license to a targeted class of tryptamine-based molecules from Mindset. The licensing agreements collectively provide the Company with access </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">74</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to a broad range of preclinical molecule combinations for its library of psychedelic derivative drug development candidates.  </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company owns or has filed applications for registration of thirty-four trademarks, including APPROACH&#174;, CYBIN&#174;, EMBARK&#174;, EMBRACE&#174;, PARADIGM&#174;, and REVOLUTIONIZING MENTAL HEALTHCARE&#174;.  </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s mission to discover, develop and deploy psychedelic inspired medicines encompasses the research and development of potential new and improved psychedelic inspired medicines ranging from proprietary psychedelic compounds for use as API, specific formulations thereof, and specific uses for compounds and formulations. As the Company generates new data it will continue to file or acquire additional patent applications throughout the Company&#8217;s development program. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Environmental Protections</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is committed to minimizing any environmental impact of its operations and operating its business in a way that will foster sustainable use of the world&#8217;s natural resources. At this time, the Company&#8217;s business does not materially impact environmental conditions. However, prior to commencing any operations that the Company expects to impact environmental conditions, the Company will establish internal policies to comply with all applicable environmental protection laws and regulations. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company does not expect that there will be any financial or operational effects as a result of environmental protection requirements on its capital expenditures, profit or loss, or its competitive positions in the current fiscal year or in future years. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Competitive Conditions </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s proposed development of psychoactive compounds for use in medical research will compete with other entities that are developing or supplying psychoactive compounds for use in medical research, including clinical trials. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The industry within which the Company intends to operate will become intensely competitive in all its phases, and the Company will face intense competition from other companies, some of which can be expected to have more financial resources and retail, formulation, research, processing, and marketing experience than the Company. Although the Company has access to capital, a management team with specialized skills and knowledge, and an IP portfolio that positions it well among its competitors, there can be no assurance that potential competitors of the Company, which may have greater financial, formulation, research, production, sales and marketing experience, and personnel and resources than the Company, are not currently developing, or will not in the future develop, products and strategies that are equally or more effective and&#47;or economical as any products or strategies developed by the Company or which would otherwise render the Company&#8217;s business, products and strategies, as applicable, ineffective, or obsolete. Increased competition by larger and better financed competitors could materially and adversely affect the business, financial condition and results of operations of the Company. See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">75</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Negative Operating Cash Flow</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Since inception, the Company has had negative operating cash flow and incurred losses. The Company&#8217;s negative operating cash flow and losses may continue for the foreseeable future. The Company cannot predict when it will reach positive operating cash flow, if ever. Due to the expected continuation of negative operating cash flow, the Company will be reliant on future financings in order to meet its cash needs. There is no assurance that such future financings will be available on acceptable terms or at all. See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="text-align:justify"><font><br></font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_28"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RISK FACTORS </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There are various risk factors that could cause the Company&#8217;s future results to differ materially from those described in this AIF. The risks and uncertainties described below are those the Company currently believes to be material, but they are not the only ones it faces. If any of the following risks, or any other risks and uncertainties that the Company has not yet identified or that it currently considers not to be material, actually occur or become material risks, the Company&#8217;s business, financial condition, results of operations and cash flows, and consequently the price of the Common Shares, could be materially and adversely affected. The risks discussed below also include forward-looking statements and the Company&#8217;s actual results may differ substantially from those discussed in these forward-looking statements. See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Note Regarding Forward-Looking Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; in this AIF.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RISKS RELATED TO THE COMPANY&#8217;S BUSINESS AND INDUSTRY</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Limited Operating History</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Common Shares commenced trading on Cboe Canada on November 10, 2020 on a post-Transaction basis and therefore the Company has a limited operating history as a public company. To operate effectively, the Company will be required to continue to implement changes in certain aspects of its business, improve information systems and develop, manage and train management-level and other employees to comply with ongoing public company requirements. Failure to take such actions, or delay in implementation thereof, could adversely affect the business, financial condition, liquidity and results of operations of the Company and, more specifically, could result in regulatory penalties, market criticism or the imposition of cease trade orders in respect of the Common Shares. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company will be subject to all of the business risks and uncertainties associated with any new business enterprise, including the risk that it will not achieve its operating goals. In order for the Company to meet future operating and debt service requirements, it will need to be successful in its growth, marketing and sales efforts. Additionally, where the Company experiences increased production and future sales, its current operational infrastructure may require changes to scale its business efficiently and effectively to keep pace with demand and achieve long-term profitability. If the Company&#8217;s products and services are not accepted by new customers, the Company&#8217;s operating results may be materially and adversely affected.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Achieving Publicly Announced Milestones</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From time to time, the Company may announce the timing of certain events it expects to occur, such as the anticipated timing of results from clinical trials. These statements are forward-looking and are based on the best estimates of management at the time relating to the occurrence of such events. However, the actual timing of such events may differ from what has been publicly disclosed. The timing of events such as initiation or completion of a clinical trial, filing of an application to obtain regulatory approval, or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">76</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">announcement of additional clinical trials for a prescription drug product candidate may ultimately vary from what is publicly disclosed. See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Commercial Scale Product Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Safety and Efficacy of Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Clinical Testing and Commercializing Product Candidates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Completion of Clinical Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Nature of Regulatory Approvals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; as discussed under this heading &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; for further disclosure of risks and events that may affect the timing of certain events the Company may announce.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company undertakes no obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise, except as otherwise required by-law. Any variation in the timing of previously announced milestones could have a material adverse effect on the Company&#8217;s business plan, financial condition or operating results and the trading price of the Common Shares.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Speculative Nature of Investment Risk</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">An investment in the securities of the Company carries a high degree of risk and should be considered as a speculative investment. The Company has no history of earnings, limited cash reserves, limited operating history, has not paid dividends, and is unlikely to pay dividends in the immediate or near future.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Early Stage of the Industry and Product Development </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Given the early stage of its prescription drug product development, the Company can make no assurance that its research and development programs will result in regulatory approval or commercially viable products. To achieve profitable operations, the Company, alone or with others, must successfully develop, gain regulatory approval for, and market its future products. The Company currently has no products that have been approved by Health Canada, the FDA, the MHRA, the EMA, the Pharmaceutical Drugs Directorate (formerly the Therapeutic Drugs Directorate) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PDD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) or any similar regulatory authority. To obtain regulatory approvals for its prescription drug product candidates being developed and to achieve commercial success, clinical trials must demonstrate that the prescription drug product candidates are safe for human use and that they demonstrate efficacy. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Many prescription drug product candidates never reach the stage of clinical testing and even those that do have only a small chance of successfully completing clinical development and gaining regulatory approval. Prescription drug product candidates can fail for a number of reasons, including, but not limited to, being unsafe for human use or due to the failure to provide therapeutic benefits equal to or better than the current standard of treatment at the time of testing. Unsatisfactory results obtained from a particular study relating to a research and development program may cause the Company or its collaborators to abandon commitments to that program. Positive results of early preclinical research may not be indicative of the results that will be obtained in later stages of preclinical or clinical research. Similarly, positive results from early-stage clinical trials may not be indicative of favourable outcomes in later-stage clinical trials, and the Company can make no assurance that any future studies, if undertaken, will yield favourable results.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The early stage of the Company&#8217;s product development makes it particularly uncertain whether any of its product development efforts will prove to be successful and meet applicable regulatory requirements, and whether any of its prescription drug product candidates will receive the requisite regulatory approvals, be capable of being manufactured at a reasonable cost or be successfully marketed. If the Company is successful in developing its current and future prescription drug product candidates into approved products, it will still experience many potential obstacles, which would affect its ability to successfully market and commercialize such approved products, such as the need to develop or obtain manufacturing, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">77</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">marketing and distribution capabilities, price pressures from third-party payors, or proposed changes in health care systems. If the Company is unable to successfully market and commercialize any of its products, its financial condition and results of operations may be materially and adversely affected.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company can make no assurance that any future studies, if undertaken, will yield favorable results. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later-stage clinical trials after achieving positive results in early-stage development, and the Company cannot be certain that it will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in clinical trials, including previously unreported adverse events or latent defects in the manufactured drug product or the formulation or stability thereof. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their prescription drug product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain Health Canada, FDA or EMA approval. If the Company fails to produce positive results in future clinical trials and other programs, the development timeline and regulatory approval and commercialization prospects for the Company&#8217;s leading prescription drug product candidates, and, correspondingly, its business and financial prospects, would be materially adversely affected.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Preclinical testing and clinical trials for the Company&#8217;s products may not achieve the desired results. The results of preclinical testing and clinical trials are uncertain. Product approvals are subject to a number of contingencies and may not be obtained in the time expected or at all. The Company&#8217;s products may not attract a following among patients, retailers and&#47;or providers. The Company expects to face an inherent risk of exposure to product liability claims, regulatory action and litigation if the products it plans to distribute are alleged to have caused loss or injury. There can be no assurance that the Company will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s business relies on its ability to access, develop, and sell psilocybin, psilocin, DMT-based compounds and other psychedelic compounds. Psilocybin, psilocin, DMT-based compounds and other psychedelic compounds are controlled substances in many jurisdictions, including in Canada under Schedule III of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Controlled Drugs and Substances Act </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and in the United States. The Company may face difficulty accessing the public capital markets in Canada as a result of the response of regulators, stock exchanges, and other market participants to the Company&#8217;s development and sale of a controlled substance. The Company may also have limited access to traditional banking services, as well as limited access to debt financing from traditional institutional lenders. The medical efficacy of psilocybin, DMT-based compounds and other psychedelic compounds has not been confirmed and requires further study and scientific rigour.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Regulatory Risks and Uncertainties</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In Canada, certain psychedelic drugs, including psilocybin&#47;psilocin, are classified as Schedule III drugs under the CDSA and as such, medical and recreational use is illegal under Canadian federal laws. In the United States, certain psychedelic drugs, including psilocybin, psilocin, DMT, and 5-Methoxy-DMT, are classified as Schedule I drugs under the CSA and the Controlled Substances Import and Export Act and as such, medical and recreational use is illegal under the U.S. federal laws. Anyone wishing to conduct research on substances listed in Schedule I under the CSA must register with the DEA and obtain DEA approval of the research proposal. The EU member states currently classify DMT as a Schedule I substance under the UN 71 and, as such, a licence is required to produce, dispense, import or export any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">78</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule I substances, but the specific requirements vary from country to country. Currently in the Netherlands, DMT is classified as a List 1 Drug under the Dutch Opium Act and, as such, subject to express authorization being obtained, the production, trade and possession of DMT are prohibited. In the United Kingdom, &#8220;Fungus (of any kind) which contains psilocin or an ester of psilocin&#8221; is controlled as a Class A drug under the MDA and Schedule 1 drug under the MDR. As psilocybin is a phosphate ester of psilocin, even if it is isolated from psilocin, it will still be treated as a Class A drug under the MDA and as a Schedule 1 drug under the MDR. Schedule 1 drugs can only be lawfully manufactured, produced, possessed and supplied under a controlled drugs domestic licence issued by the UK Home Office.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There is no guarantee that psychedelic drugs or psychedelic inspired drugs will ever be approved as medicines in any jurisdiction in which the Company operates. All activities involving such substances by or on behalf of the Company are conducted in accordance with applicable federal, provincial, state and local laws. Further, all facilities engaged with such substances by or on behalf of the Company do so under current licences and permits issued by appropriate federal, provincial and local governmental agencies. While the Company is focused on programs using psychedelic inspired compounds, the Company does not have any direct or indirect involvement with the illegal selling, production or distribution of any substances in the jurisdictions in which it operates and does not intend to have any such involvement. However, the laws and regulations generally applicable to the industry in which the Company is involved in may change in ways currently unforeseen. Any amendment to or replacement of existing laws or regulations, including the classification or re-classification of the substances the Company is developing or working with, which are matters beyond the Company&#8217;s control, may cause the Company&#8217;s business, financial condition, results of operations and prospects to be adversely affected or may cause the Company to incur significant costs in complying with such changes or it may be unable to comply therewith. A violation of any applicable laws and regulations of the jurisdictions in which the Company operates could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings initiated by either government entities in the jurisdictions in which the Company operates, or private citizens or criminal charges. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The loss of the necessary licences and permits for any of the above scheduled drugs could have an adverse effect on the Company&#8217;s operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The psychedelic drug industry is a fairly new industry and the Company cannot predict the impact of the ever-evolving compliance regime in respect of this industry. Similarly, the Company cannot predict the time required to secure all appropriate regulatory approvals for future products, or the extent of testing and documentation that may, from time to time, be required by governmental authorities. The impact of compliance regimes, any delays in obtaining, or failure to obtain regulatory approvals may significantly delay or impact the development of markets, its business and products, and sales initiatives and could have a material adverse effect on the business, financial condition and operating results of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The success of the Company&#8217;s business is dependent on the reform of controlled substances laws pertaining to psilocybin. If controlled substances laws are not favourably reformed in Canada, the United States, the Netherlands, the UK, and other global jurisdictions, the commercial opportunity that the Company is pursuing may be highly limited.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company makes no medical, treatment or health benefit claims about the Company&#8217;s proposed products. The FDA, Health Canada, the EMA or other similar regulatory authorities have not evaluated claims regarding psilocybin, DMT, psilocybin analogues, or other psychedelic compounds. The efficacy of such products have not been confirmed by approved research. There is no assurance that the use of psilocybin, DMT, psilocybin analogues, or other psychedelic compounds can diagnose, treat, cure or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">79</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company&#8217;s performance and operations. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks of Operating in European Countries</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is subject to additional risks related to operating in countries in Europe including&#58; (i) differing regulatory requirements in Europe&#59; (ii) unexpected changes in price and exchange controls and other regulatory requirements&#59; (iii) increased difficulties in managing the logistics and transportation of collecting and shipping patient material&#59; (iv) import and export requirements and restrictions&#59; (v) compliance with tax, employment, immigration and labour laws for employees living or traveling abroad&#59; (vi) foreign taxes, including withholding of payroll taxes&#59; (vii) foreign currency fluctuations, which could result in increased operating expenses, and other obligations incident to doing business in another country&#59; (viii) difficulties staffing and managing foreign operations&#59; (ix) potential liability under the Corruption of Foreign Public Officials Act of Canada or comparable foreign regulations&#59; (x) challenges enforcing its contractual and intellectual property rights, especially in those European countries that do not respect and protect intellectual property rights to the same extent as Canada or the United States&#59; (xi) production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#59; and (xii) business interruptions resulting from geo-political actions, including war and terrorism.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These and other risks associated with the Company&#8217;s international operations may materially adversely affect its ability to attain or maintain profitable operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Foreign Private Issuer&#8221; Status Under the U.S. Securities Laws</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is a &#8220;foreign private issuer&#8221;, under applicable U.S. federal securities laws, and is, therefore, not subject to the same requirements that are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, the Company is subject to reporting obligations that, in certain respects, are less detailed and less frequent than those of U.S. domestic reporting companies. As a result, the Company does not file the same reports that a U.S. domestic issuer would file with the SEC, although the Company is required to file with or furnish to the SEC the continuous disclosure documents that it is required to file in Canada under Canadian securities laws. In addition, the Company&#8217;s officers, directors, and principal shareholders are exempt from the reporting and short-swing profit recovery provisions of Section 16 of the Exchange Act. Therefore, the Company&#8217;s shareholders may not know on as timely a basis when the Company&#8217;s officers, directors and principal shareholders purchase or sell Common Shares, as the reporting periods under the corresponding Canadian insider reporting requirements are longer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a foreign private issuer, the Company is exempt from the rules and regulations under the Exchange Act related to the furnishing and content of proxy statements. The Company is also exempt from Regulation FD, which prohibits issuers from making selective disclosures of material non-public information. While the Company complies with the corresponding requirements relating to proxy statements and disclosure of material non-public information under Canadian securities laws, these requirements differ from those under the Exchange Act and Regulation FD and shareholders should not expect to receive the same information at the same time as such information is provided by U.S. domestic companies. In addition, the Company may not be required under the Exchange Act to file annual and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">80</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">quarterly reports with the SEC as promptly as U.S. domestic companies whose securities are registered under the Exchange Act.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Plans for Growth</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company intends to continue to advance its research and development programs and operations over the next 12 to 24 months. This advancement will place a significant strain on the Company&#8217;s management systems and resources. The Company may not be able to implement its business strategy in a rapidly evolving market. In particular, the Company may be required to manage multiple relationships with various strategic industry participants and other third parties, which relationships could be strained. Similarly, an increase in the number of third-party relationships the Company has, may lead to management of the Company being unable to manage growth effectively. The occurrence of such events may result in the Company being unable to successfully identify, manage and exploit existing and potential market opportunities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Limited Products</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company will be heavily reliant on the production and distribution of psychedelics and related products. If they do not achieve sufficient market acceptance, it will be difficult for the Company to achieve profitability.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s revenue will be derived almost exclusively from sales of psychedelic pharmaceutical products, and the Company expects that its psychedelic pharmaceutical products will account for substantially all of its revenue for the foreseeable future. If the psychedelic pharmaceutical market declines or psychedelics fail to achieve substantially greater market acceptance than it currently enjoys, the Company will not be able to grow its revenues sufficiently for it to achieve consistent profitability.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Even if products to be distributed by the Company conform to international safety and quality standards, sales could be adversely affected if consumers in target markets lose confidence in the safety, efficacy, and quality of psychedelic pharmaceutical products. Adverse publicity about psychedelic pharmaceutical products that the Company sells may discourage consumers from buying products distributed by the Company. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Limited Marketing and Sales Capabilities</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company will, for the immediate future, have limited marketing and sales capabilities, and there can be no assurance that it will be able to develop or acquire these capabilities at the level needed to produce and deliver for sale, through industry partners, its products in sufficient commercial quantities. Further, there can be no assurance that the Company, either on its own or through arrangements with other industry participants, will be able to develop or acquire such capabilities on a cost-effective basis, or at all. Finally, there can be no assurance that the Company&#8217;s industry partners will be able to market or sell the Company&#8217;s products in compliance with requisite regulatory protocols or on a cost-effective basis. The Company&#8217;s dependence upon third parties for the production, and marketing or sale, as applicable, of the Company&#8217;s products could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">No Assurance of Commercial Success</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The successful commercialization of the Company&#8217;s products will depend on many factors, including, the Company&#8217;s ability to establish and maintain working partnerships with industry participants in order to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">81</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">market its products, the Company&#8217;s ability to supply a sufficient amount of its products to meet market demand, and the number of competitors within each jurisdiction within which the Company may from time to time be engaged. There can be no assurance that the Company or its industry partners will be successful in their respective efforts to develop and implement, or assist the Company in developing and implementing, a commercialization strategy for the Company&#8217;s products.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">No Profits or Significant Revenues</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has no history upon which to evaluate its performance and future prospects. The Company&#8217;s proposed operations are subject to all the business risks associated with new enterprises. These include likely fluctuations in operating results as the Company makes significant investments in research, development and product opportunities, and reacts to developments in its market, including purchasing patterns of customers, and the entry of competitors into the market. The Company will only be able to pay dividends on any shares once its directors determine that it is financially able to do so. The Company cannot make any assurance that it will be profitable in the next three years or generate sufficient revenues to pay dividends to the holders of the Common Shares.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reliance on Third Parties for Clinical Development Activities</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company relies and will continue to rely on third parties to conduct a significant portion of its preclinical and clinical development activities. For example, clinical development activities include trial design, regulatory submissions, clinical patient recruitment, clinical trial monitoring, clinical data management and analysis, safety monitoring and project management. If there is any dispute or disruption in its relationship with third parties, or if it is unable to provide quality services in a timely manner and at a feasible cost, the Company&#8217;s active development programs will face delays. Further, if any of these third parties fails to perform as the Company expects or if their work fails to meet regulatory requirements, the Company&#8217;s testing could be delayed, cancelled or rendered ineffective.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Third Party Relationships</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company intends to enter into strategic alliances with third parties that the Company believes will complement or augment its proposed business or will have a beneficial impact on the Company. Strategic alliances could present unforeseen integration obstacles or costs, may not enhance the Company&#8217;s business, and may involve risks that could adversely affect the Company, including significant amounts of management time that may be diverted from operations in order to pursue and complete such transactions or maintain such strategic alliances. Future strategic alliances could result in the incurrence of additional debt, costs and contingent liabilities, and there can be no assurance that future strategic alliances will achieve, or that the Company&#8217;s existing strategic alliances will continue to achieve, the expected benefits to the Company&#8217;s business or that the Company will be able to consummate future strategic alliances on satisfactory terms, or at all. Any of the foregoing could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition to the foregoing, the success of the Company&#8217;s business will depend, in large part, on the Company&#8217;s ability to enter into, and maintain collaborative arrangements with various participants in the psychedelic pharmaceutical industry. There can be no assurance that the Company will be able to enter into collaborative arrangements in the future on acceptable terms, if at all. There can be no assurance that such arrangements will be successful, that the parties with which the Company has or may establish arrangements will adequately or successfully perform their obligations under such arrangements, that potential partners will not compete with the Company by seeking or prioritizing alternate, competitor </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">82</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">products. The termination or cancellation of any such collaborative arrangement or the failure of the Company and&#47;or the other parties to these arrangements to fulfill their obligations could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations. In addition, disagreements between the Company and any of its industry partners could lead to delays or time consuming and expensive legal proceedings, which could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reliance on Contract Manufacturers</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has limited manufacturing experience and relies on contract manufacturing organizations (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CMOs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) to manufacture its prescription drug product candidates for preclinical studies and clinical trials. The Company relies on CMOs for manufacturing, filling, packaging, storing and shipping of drug product in compliance with cGMP regulations applicable to its products. All applicable jurisdictions, including Health Canada, the FDA, the MHRA the EMA, and the PDD, ensure the quality of food, drug products and dietary supplements by carefully monitoring drug manufacturers&#8217; compliance with cGMP regulations. The cGMP regulations for drugs contain minimum requirements for the methods, facilities and controls used in manufacturing, processing and packing of a drug product. There can be no assurances that CMOs will be able to meet the Company&#8217;s timetable and requirements. The Company has not contracted with alternate suppliers for drug substance production in the event that the current provider is unable to scale up production, or if it otherwise experiences any other significant problems. If the Company is unable to arrange for alternative third-party manufacturing sources on commercially reasonable terms or in a timely manner, the Company may be delayed in the development of its prescription drug product candidates. Further, CMOs must operate in compliance with cGMP and ensure that their appropriate permits and licences remain in good standing and failure to do so could result in, among other things, the disruption of product supplies. The Company&#8217;s dependence upon third parties for the manufacture of its products may adversely affect its profit margins and its ability to develop and deliver products on a timely and competitive basis.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Safety and Efficacy of Products </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of the Company&#8217;s prescription drug product candidates, the Company must conduct preclinical studies in animals and extensive clinical trials in humans to demonstrate the safety and efficacy of the prescription drug product candidates. Clinical testing is expensive and difficult to design and implement, can take many years to complete and has uncertain outcomes. The outcome of preclinical studies and early clinical trials may not predict the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier trials. The Company does not know whether the clinical trials it may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market any of its prescription drug product candidates in any jurisdiction. A major risk the Company faces is the possibility that none of its prescription drug product candidates under development will successfully gain market approval from Health Canada, the FDA, the MHRA, the EMA, the PDD or other regulatory authorities, resulting in the Company being unable to derive any commercial revenue from them after investing significant amounts of capital in their development.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Clinical trials are conducted in representative samples of the potential patient population which may have significant variability. Clinical trials are by design based on a limited number of subjects and of limited duration for exposure to the product used to determine whether, on a potentially statistically significant </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">83</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">basis, the planned safety and efficacy of any such product can be achieved. As with the results of any statistical sampling, the Company cannot be sure that all side effects of its products may be uncovered, and it may be the case that only with a significantly larger number of patients exposed to such product for a longer duration, may a more complete safety profile be identified. Further, even larger clinical trials may not identify rare serious adverse effects, or the duration of such studies may not be sufficient to identify when those events may occur. There have been products that have been approved by the regulatory authorities but for which safety concerns have been uncovered following approval. Such safety concerns have led to labelling changes or withdrawal of such products from the market, and the Company&#8217;s products may be subject to similar risks. The Company might have to withdraw or recall its products from the marketplace. The Company may also experience a significant drop in the potential future sales of its products if and when regulatory approvals for such products are obtained, experience harm to its reputation in the marketplace or become subject to lawsuits, including class actions. Any of these results could decrease or prevent any sales of the Company&#8217;s products, or substantially increase the costs and expenses of commercializing and marketing its products.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Clinical Testing and Commercializing Products </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of the Company&#8217;s prescription drug product candidates, it must conduct pre-clinical studies in animals and extensive clinical trials in humans to demonstrate the safety and efficacy of the prescription drug product candidates. Clinical testing is expensive and difficult to design and implement, can take many years to complete and has uncertain outcomes. The outcome of pre-clinical studies and early clinical trials may not predict the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier trails. The Company does not know whether the clinical trials it may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market any of its prescription drug product candidates in any jurisdiction. A prescription drug product candidate may fail for safety or efficacy reasons at any stage of the testing process. A major risk the Company faces is the possibility that none of its prescription drug product candidates under development will successfully gain market approval from the FDA, or other regulatory authorities, resulting in the Company being unable to derive any commercial revenue from this business segment after investing significant amounts of capital in its development. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company cannot predict whether any clinical trials will begin as planned, will need to be restructured, or will be completed on schedule, or at all. The Company&#8217;s product development costs will increase if it experiences delays in clinical testing. Significant clinical trial delays could shorten any periods during which the Company may have the exclusive right to commercialize its prescription drug product candidates or allow its competitors to bring products to market before the Company, which would impair the Company&#8217;s ability to successfully commercialize its prescription drug product candidates and may harm its financial condition, results of operations and prospects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The commencement and completion of clinical trials for the Company&#8217;s prescription drug product candidates may be delayed for a number of reasons, including but not limited, to&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">failure by regulatory authorities to grant permission to proceed or placing clinical trials on hold&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">84</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">suspension or termination of clinical trials by regulators for many reasons, including concerns about patient safety or failure of the Company&#8217;s CMOs to comply with cGMP requirements or latent defects in product quality&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">any changes to the Company&#8217;s manufacturing process that may be necessary or desired, delays or failure to obtain clinical supply from CMOs of the Company&#8217;s products necessary to conduct clinical trials&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">prescription drug product candidates demonstrating a lack of safety or efficacy during clinical trials, reports of clinical testing on similar technologies and products raising safety or efficacy concerns&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">clinical investigators not performing the Company&#8217;s clinical trials on their anticipated schedule, dropping out of a trial, or employing methods not consistent with the clinical trial protocol, regulatory requirements or other third parties not performing data collection and analysis in a timely or accurate manner&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">failure of the Company&#8217;s contract research organizations to satisfy their contractual duties or meet expected deadlines&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">inspections of clinical trial sites by regulatory authorities&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">regulatory authorities or ethics committees finding regulatory violations that require the Company to undertake corrective action, resulting in suspension or termination of one or more sites or the imposition of a clinical hold on the entire study&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">one or more regulatory authorities or ethics committees rejecting, suspending or terminating the study at an investigational site, precluding enrollment of additional subjects, or withdrawing its approval of the trial&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">failure to reach agreement on acceptable terms with prospective clinical trial sites.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s product development costs will increase if it experiences delays in testing or approval or if the Company needs to perform more or larger clinical trials than planned. Additionally, changes in regulatory requirements and policies may occur, and the Company may need to amend study protocols to reflect these changes. Amendments may require the Company to resubmit its study protocols to regulatory authorities or ethics committees for re-examination, which may impact the cost, timing or successful completion of that trial. Delays or increased product development costs may have a material adverse effect on the Company&#8217;s business, financial condition and prospects.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prior to commencing clinical trials in Canada, the United States, the UK, the Netherlands or other jurisdictions, for any prescription drug product candidates developed by the Company, it may be required to have an IND (or equivalent) for each prescription drug product candidate and to file additional INDs prior to initiating any additional clinical trials. The Company believes that the data from its studies will support the filing of additional INDs to enable the Company to undertake additional clinical studies as it has planned. However, submission of an IND (or equivalent) may not result in the FDA (or equivalent authorities) allowing further clinical trials to begin and, once begun, issues may arise that will require the Company to suspend or terminate such clinical trials.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, even if relevant regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, these regulatory authorities may change their requirements in the future. Failure to submit or have effective INDs (or equivalent) and commence or continue clinical programs will significantly limit its opportunity to generate revenue.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">85</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Completion of Clinical Trials</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As the Company&#8217;s prescription drug product candidates advance from preclinical testing to clinical testing, and then through progressively larger and more complex clinical trials, the Company will need to enroll an increasing number of patients that meet its eligibility criteria. There is significant competition for recruiting patients in clinical trials, and the Company may be unable to enroll the patients it needs to complete clinical trials on a timely basis or at all. The factors that affect the Company&#8217;s ability to enroll patients are largely uncontrollable and include, but are not limited to, the size and nature of the patient population, eligibility and exclusion criteria for the trial, design of the clinical trial, competition with other companies for clinical sites or patients, perceived risks and benefits of the prescription drug product candidate, and the number, availability, location and accessibility of clinical trial sites.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Commercial Grade Product Manufacturing </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s prescription drug products will be manufactured in small quantities for pre-clinical studies and clinical trials by third party manufacturers. In order to commercialize its product, the Company needs to manufacture commercial quality drug supply for use in registration clinical trials. Most, if not all, of the clinical material used in phase III&#47;pivotal&#47;registration studies must be derived from the defined commercial process including scale, manufacturing site, process controls and batch size. If the Company has not scaled up and validated the commercial production of its product prior to the commencement of pivotal clinical trials, it may have to employ a bridging strategy during the trial to demonstrate equivalency of early-stage material to commercial drug product, or potentially delay the initiation or completion of the trial until drug supply is available. The manufacturing of commercial quality product may have long lead times, may be very expensive and requires significant efforts including, but not limited to, scale-up of production to anticipated commercial scale, process characterization and validation, analytical method validation, identification of critical process parameters and product quality attributes, and multiple process performance and validation runs. If the Company does not have commercial drug supply available when needed for pivotal clinical trials, the Company&#8217;s regulatory and commercial progress may be delayed, and it may incur increased product development costs. This may have a material adverse effect on the Company&#8217;s business, financial condition and prospects, and may delay marketing of the product.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Nature of Regulatory Approvals </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s development and commercialization activities and prescription drug product candidates are significantly regulated by a number of governmental entities, including Health Canada, the FDA, the MHRA, the EMA and the PDD. Regulatory approvals are required prior to each clinical trial and the Company may fail to obtain the necessary approvals to commence or continue clinical testing. The Company must comply with regulations concerning the manufacture, testing, safety, effectiveness, labeling, documentation, advertising, and sale of products and prescription drug product candidates and ultimately must obtain regulatory approval before it can commercialize a prescription drug product candidate. The time required to obtain approval by such regulatory authorities is unpredictable but typically takes many years following the commencement of preclinical studies and clinical trials. Any analysis of data from clinical activities the Company performs is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. Even if the Company believes results from its sponsored clinical trials are favorable to support the marketing of its prescription drug product candidates, Health Canada, the FDA, the MHRA, the EMA, the PDD or other regulatory authorities may disagree. In addition, approval policies, regulations, or the type and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">86</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">amount of clinical data necessary to gain approval may change during the course of a prescription drug product candidate&#8217;s clinical development and may vary among jurisdictions.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has not obtained regulatory approval for any prescription drug product candidate and it is possible that none of its existing prescription drug product candidates or any future prescription drug product candidates will ever obtain regulatory approval. The Company could fail to receive regulatory approval for its prescription drug product candidates for many reasons, including, but not limited to failure to demonstrate that a prescription drug product candidate is safe and effective for its proposed indication, failure of clinical trials to meet the level of statistical significance required for approval, failure to demonstrate that a prescription drug product candidate&#8217;s clinical and other benefits outweigh its safety risks, or deficiencies in the manufacturing processes or the failure of facilities of CMOs with whom the Company contracts for clinical and commercial supplies to pass a pre-approval inspection.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A regulatory authority may require more information, including additional preclinical or clinical data to support approval, which may delay or prevent approval and the Company&#8217;s commercialization plans, or the Company may decide to abandon the development program. If the Company were to obtain approval, regulatory authorities may approve any of its prescription drug product candidates for fewer or more limited indications than the Company request, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a prescription drug product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that prescription drug product candidate. Moreover, depending on any safety issues associated with the Company&#8217;s prescription drug product candidates that garner approval, Health Canada, the FDA, the MHRA, the EMA, the PDD or other regulatory authorities may impose a risk evaluation and mitigation strategy, thereby imposing certain restrictions on the sale and marketability of such products. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If there are changes in the application of legislation, regulations or regulatory policies, or if problems are discovered with the Company products, or if one of its distributors, licensees or co-marketers fails to comply with regulatory requirements, the regulators could take various actions. These include imposing fines on the Company, imposing restrictions on the Company&#8217;s products or its manufacture and requiring the Company to recall or remove its products from the market. The regulators could also suspend or withdraw the Company&#8217;s Co-marketing authorizations, requiring it to conduct additional clinical trials, change its labeling or submit additional applications for marketing authorization. If any of these events occurs, the Company&#8217;s ability to sell its products may be impaired, and it may incur substantial additional expense to comply with regulatory requirements, which could materially adversely affect its business, financial condition and results of operations.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Market Access and Acceptance</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company may never have a product that is commercially successful. To date, the Company has no product authorized for marketing. The Company&#8217;s future products require further clinical investigation, regulatory review, significant market access and marketing efforts and substantial investment before it can produce any revenue. Furthermore, if approved, the Company&#8217;s product may not achieve an adequate level of acceptance by payors, health technology assessment bodies, healthcare professionals, patients and the medical community at large, and the Company may not become profitable. The level of acceptance the Company ultimately achieves may be affected by negative public perceptions and historic media coverage of psychedelic substances. Because of this history, efforts to educate the medical community and third-party payors and health technologies assessment bodies on the benefits of company&#8217;s product compounds may require significant resources and may never be successful, which would prevent the Company from generating significant revenue or becoming profitable. Market acceptance of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">87</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Company&#8217;s future products by healthcare professionals, patients, healthcare payors and health technology assessment bodies will depend on a number of factors, many of which are beyond the Company&#8217;s control, including, but not limited to, the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.15pt"> acceptance by healthcare professionals, patients and healthcare payors of each product as safe, effective and cost-effective&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.15pt"> changes in the standard of care for the targeted indications for any product&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.15pt"> the strength of sales, marketing and distribution support&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.15pt"> potential product liability claims&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.15pt">the product&#8217;s relative convenience, ease of use, ease of administration and other perceived advantages over alternatives&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.15pt">the prevalence and severity of adverse events or publicity&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.15pt">limitations, precautions or warnings listed in the summary of product characteristics, patient information leaflet, package labeling or instructions for use&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.15pt">the cost of treatment with the Company&#8217;s product in relation to alternatives&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.15pt">the steps that prescribers and dispensers must take, as well as the perceived risks based upon its controlled substance status&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.15pt">the ability to manufacture the Company&#8217;s product in sufficient quantities and yields with adequate purity&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.15pt">the availability and amount of coverage and reimbursement from healthcare payors, and the willingness of patients to pay out of pocket in the absence of healthcare payor coverage or adequate reimbursement&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.15pt">the willingness of the target patient population to try, and of healthcare professionals to prescribe, the product&#59;</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.15pt">any potential unfavorable publicity, including negative publicity associated with recreational use or abuse of psilocybin, DMT-based compounds and other psychedelic compounds&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:14.15pt">any restrictions on the use, sale or distribution of the Company&#8217;s future products.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the Company&#8217;s future products fail to gain market access and acceptance, this will have a material adverse impact on the Company&#8217;s ability to generate revenue to provide a satisfactory, or any, return on the Company&#8217;s investments. Even if some products achieve market access and acceptance, the market may prove not to be large enough to allow the Company to generate significant revenue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company must rely largely on its own market research to forecast sales as detailed forecasts are not generally obtainable from other sources at this early stage of the psychedelic industry. A failure in the demand for the Company&#8217;s psychedelic based products to materialize as a result of competition, technological change or other factors could have a material adverse effect on the business, results of operations and financial condition of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">88</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unfavourable Publicity or Consumer Perception</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company believes the psychedelic pharmaceutical industry is highly dependent upon consumer perception regarding the safety, efficacy and quality of psychedelic pharmaceutical products. Consumer perception of the Company&#8217;s psychedelic pharmaceutical products can be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of psychedelics. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favourable to the psychedelic pharmaceutical industry or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favourable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for the Company&#8217;s psychedelic products and the business, results of operations, financial condition and cash flows of the Company. The Company&#8217;s dependence upon consumer perceptions means that adverse scientific research reports, findings, regulatory proceedings, litigation, media attention or other publicity, whether or not accurate or with merit, could have a material adverse effect on the Company, the demand for the Company&#8217;s psychedelic products, and the business, results of operations, financial condition and cash flows of the Company. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of psychedelic products in general, or the Company&#8217;s psychedelic products and services specifically or associating the consumption of psychedelics with illness or other negative effects or events, could have such a material adverse effect. Such adverse publicity reports or other media attention could arise even if the adverse effects associated with such products resulted from consumers&#8217; failure to consume such products legally, appropriately or as directed.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The psychedelic medicine industry is highly dependent upon consumer perception regarding the medical benefits, safety, efficacy and quality of the psychedelic medicine distributed for medical purposes to such consumers. There can be no assurance that future scientific research or findings on the medical benefits, viability, safety, efficacy and dosing of psilocybin, DMT or isolated constituents, regulatory proceedings, litigation, media attention or other research findings or publicity will be favourable to the industry or the Company or any particular product, or consistent with earlier publicity. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Social Media</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There has been a marked increase in the use of social media platforms and similar channels that provide individuals with access to a broad audience of consumers and other interested persons. The availability and impact of information on social media platforms is virtually immediate and many social media platforms publish user-generated content without filters or independent verification as to the accuracy of the content posted. Information posted about the Company may be adverse to the Company&#8217;s interests or may be inaccurate, each of which may harm the Company&#8217;s business, financial condition and results of operations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Biotechnology and Pharmaceutical Market Competition</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. The Company&#8217;s competitors include large, well-established pharmaceutical companies, biotechnology companies, and academic and research institutions developing therapeutics for the same indications the Company is targeting and competitors with existing marketed therapies. Many other companies are developing or commercializing therapies to treat the same diseases or indications for which the Company&#8217;s prescription drug product candidates may be useful. Although </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">89</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">there are no approved therapies that specifically target opioid addiction, some competitors use therapeutic approaches that may compete directly with the Company&#8217;s prescription drug product candidates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Many of the Company&#8217;s competitors have substantially greater financial, technical and human resources than the Company does and have significantly greater experience than the Company in conducting preclinical testing and human clinical trials of product candidates, scaling up manufacturing operations and obtaining regulatory approvals of products. Accordingly, the Company&#8217;s competitors may succeed in obtaining regulatory approval for products more rapidly than the Company does. The Company&#8217;s ability to compete successfully will largely depend on&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the efficacy and safety profile of its prescription drug product candidates relative to marketed products and other prescription drug product candidates in development&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the Company&#8217;s ability to develop and maintain a competitive position in the product categories and technologies on which it focuses&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the time it takes for the Company&#8217;s prescription drug product candidates to complete clinical development and receive marketing approval&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the Company&#8217;s ability to obtain required regulatory approvals&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the Company&#8217;s ability to commercialize any of its prescription drug product candidates that receive regulatory approval&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">the Company&#8217;s ability to establish, maintain and protect intellectual property rights related to its prescription drug product candidates&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:32.15pt">acceptance of any of the Company&#8217;s prescription drug product candidates that receive regulatory approval by physicians and other healthcare providers and payers.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Competitors have developed and may develop technologies that could be the basis for products that challenge the discovery research capabilities of prescription drug product candidates the Company is developing. Some of those products may have an entirely different approach or means of accomplishing the same desired therapeutic effect than the Company&#8217;s prescription drug product candidates and may be more effective or less costly than its prescription drug product candidates. The success of the Company&#8217;s competitors and their products and technologies relative to the Company&#8217;s technological capabilities and competitiveness could have a material adverse effect on the future preclinical studies and clinical trials of the Company&#8217;s prescription drug product candidates, including its ability to obtain the necessary regulatory approvals for the conduct of such clinical trials. This may further negatively impact the Company&#8217;s ability to generate future product development programs using psychedelic based compounds.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the Company is not able to compete effectively against its current and future competitors, the Company&#8217;s business will not grow, and its financial condition and operations will substantially suffer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, there can be no assurance that potential competitors of the Company, which may have greater financial, cultivation, production, sales and marketing experience, and personnel and resources than the Company, are not currently developing, or will not in the future develop, products and strategies that are equally or more effective and&#47;or economical as any products or strategies developed by the Company or which would otherwise render the Company&#8217;s business, products and strategies, as applicable, ineffective, or obsolete. Increased competition by larger and better financed competitors could materially and adversely affect the business, financial condition and results of operations of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">90</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reliance on Key Executives and Scientists</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The loss of key members of the Company&#8217;s staff, could harm the Company. The Company does not have employment agreements with all members of its staff, although such employment agreements do not guarantee their retention. The Company also depends on its scientific and clinical collaborators and advisors, all of whom have outside commitments that may limit their availability to the Company. In addition, the Company believes that its future success will depend in large part upon its ability to attract and retain highly skilled scientific, managerial, medical, manufacturing, clinical and regulatory personnel, particularly as the Company expands its activities and seeks regulatory approvals for clinical trials. The Company enters into agreements with its scientific and clinical collaborators and advisors, key opinion leaders and academic partners in the ordinary course of its business. Should key academic and scientific personnel including employees or collaborative partners who work on the development of the Company&#8217;s research activities leave, the Company&#8217;s current and future development programs may be delayed or adversely affected. Notwithstanding these arrangements, the Company faces significant competition for these types of personnel from other companies, research and academic institutions, government entities and other organizations. The Company cannot predict its success in hiring or retaining the personnel it requires for continued growth. In addition, due to limited financial resources, the Company may not be able to successfully expand its operations due to challenges in recruiting and training qualified new staff. Expansion of personnel may result in significant diversion of management time and resources. The loss of the services of any of the Company&#8217;s executive officers or other key personnel could potentially harm its business, operating results or financial condition.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Employee Misconduct</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding having established an insider trading policy and code of ethics and business conduct, the Company is exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include failures to comply with Health Canada, the FDA the MHRA the EMA the PDD, and other comparable international authorities&#8217; regulations, provide accurate information to Health Canada, the FDA the MHRA, the EMA, and&#47;or the PDD provide accurate information to Health Canada, the FDA, the MHRA, the EMA and the PDD, comply with manufacturing standards the Company has established, comply with federal and provincial healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to the Company. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to the Company&#8217;s reputation. If any such actions are instituted against the Company, and the Company is not successful in defending itself or asserting its rights, those actions could have a substantial impact on the Company&#8217;s business and results of operations, including the imposition of substantial fines or other sanctions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Expansion and Growth</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company may in the future seek to expand its pipeline and capabilities by acquiring one or more companies or businesses, entering into collaborations, or in-licensing one or more prescription drug product candidates. Acquisitions, collaborations and in-licences involve numerous risks, including, but not limited to substantial cash expenditures, technology development risks, potentially dilutive issuances of equity securities, incurrence of debt and contingent liabilities, some of which may be difficult or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">91</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">impossible to identify at the time of acquisition, difficulties in assimilating the operations of the acquired companies, entering markets in which the Company has limited or no direct experience, and potential loss of the Company&#8217;s key employees or key employees of the acquired companies or businesses.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has experience in making acquisitions, entering collaborations and in-licensing prescription drug product candidates&#59; however, the Company cannot provide assurance that any acquisition, collaboration or in-licence will result in short-term or long-term benefits to it. The Company may incorrectly judge the value or worth of an acquired company or business or in-licensed prescription drug product candidate. In addition, the Company&#8217;s future success would depend in part on its ability to manage the rapid growth associated with some of these acquisitions, collaborations and in-licences. The Company cannot provide assurance that it would be able to successfully combine its business with that of acquired businesses, manage a collaboration or integrate in-licensed prescription drug product candidates. Furthermore, the development or expansion of the Company&#8217;s business may require a substantial capital investment by the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Negative Results of External Clinical Trials or Studies</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">From time to time, studies or clinical trials on various aspects of breakthrough neuropsychiatry products are conducted by academic researchers, competitors or others. The results of these studies or trials, when published, may have a significant effect on the market for the breakthrough neuropsychiatry product that is the subject of the study. The publication of negative results of studies or clinical trials or adverse safety events related to the Company&#8217;s prescription drug product candidates, or the therapeutic areas in which the Company&#8217;s prescription drug product candidates compete, could adversely affect its share price and the Company&#8217;s ability to finance future development of its prescription drug product candidates, and its business and financial results could be materially and adversely affected.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Liability</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company currently does not carry any product liability insurance coverage. Even though the Company is not aware of any product liability claims at this time, its business exposes itself to potential product liability, recalls and other liability risks that are inherent in the sale of consumer products. The Company can provide no assurance that such potential claims will not be asserted against it. A successful liability claim or series of claims brought against the Company could have a material adverse effect on its business, financial condition and results of operations. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Although the Company intends to obtain adequate product liability insurance, it cannot provide any assurances that it will be able to obtain or maintain adequate product liability insurance of on acceptable terms, if at all, or that such insurance will provide adequate coverage against potential liabilities. Claims or losses in excess of any product liability cover that may be obtained by the Company could have a material adverse effect on its business, financial conditional and results of operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Some of the Company&#8217;s agreements with third parties might require it to maintain product liability insurance. If the Company cannot obtain acceptable amounts of coverage on commercially reasonable terms in accordance with the terms set forth in these agreements, the corresponding agreements would be subject to termination, which could have a material adverse impact on its operations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Enforcing Contracts</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Due to the nature of the business of the Company and the fact that certain of its contracts involve psilocybin&#47;psilocin, the use of which is not legal under Canadian or U.S. federal law and in certain other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">92</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">jurisdictions, the Company may face difficulties in enforcing its contracts in Canadian or U.S. federal and state courts. The inability to enforce any of its contracts could have a material adverse effect on its business, operating results, financial condition or prospects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In order to manage its contracts with contractors, the Company will ensure that such contractors are appropriately licensed. Were such contractors to operate outside the terms of these licenses, the Company may experience an adverse effect on its business, including the pace of development of its product.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product and Material Recalls</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Manufacturers, producers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety storage deficiencies and inadequate or inaccurate labelling disclosure. If any of the Company&#8217;s products are recalled due to an alleged product defect or for any other reason, the Company could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. The Company may have to recall material being used in a clinical trial resulting in delays to the trial and additional manufacturing expenses, if further drug product is required. If the product is already commercialized, the Company may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Although the Company&#8217;s suppliers have detailed procedures in place for testing its products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. Additionally, if the Company is subject to recall, the image of the Company could be harmed. A recall for any of the foregoing reasons could lead to decreased demand for the Company&#8217;s products and could have a material adverse effect on the results of operations and financial condition of the Company. Additionally, product recalls may lead to increased scrutiny of the Company&#8217;s operations by regulatory agencies, requiring further management attention, potential loss of applicable licences and potential legal fees and other expenses.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Distribution and Supply Chain Interruption</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is susceptible to risks relating to distributor and supply chain interruptions. Distribution in the U.S., Canada, the EU, the UK and other jurisdictions will be largely accomplished through independent contractors, therefore, an interruption (e.g., a labour strike) for any length of time affecting such independent contractors may have a significant impact on the Company&#8217;s ability to sell or manufacture its products. Supply chain interruptions, including a production or inventory disruption, could impact product quality and availability. Inherent to producing products is a potential for shortages or surpluses in future years if demand and supply are materially different from long-term forecasts. The Company monitors category trends and regularly reviews maturing inventory levels.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Difficulty to Forecast</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company must rely largely on its own market research to forecast sales as detailed forecasts are not generally obtainable from other sources at this early stage of the psychedelic pharmaceutical industry. A failure in the demand for the Company&#8217;s psychedelic pharmaceutical industry products to materialize as a result of competition, technological change or other factors could have a material adverse effect on the business, results of operations and financial condition of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">93</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Promoting the Brand</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Promoting the Company&#8217;s brand will be critical to creating and expanding a customer base. Promoting the brand will depend largely on the Company&#8217;s ability to provide psychedelic pharmaceutical products to the market. Further, the Company may, in the future, introduce new products or services that its customers do not like, which may negatively affect the brand and reputation. If the Company fails to successfully promote its brand or if it incurs excessive expenses in this effort, its business and financial results from operations could be materially adversely affected. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If there are changes in the applicable regulatory framework governing the promotion, branding and marketing of the Company&#8217;s products, the Company&#8217;s ability to promote and sell its products may be impaired, and it may incur substantial additional expense to comply with regulatory requirements, which could materially adversely affect its business, financial condition and results of operations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Viability</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the Company&#8217;s psychedelic pharmaceutical products are not perceived to have the effects intended by the end user, the Company&#8217;s business may suffer. In general, psychedelic pharmaceutical products have minimal long-term data with respect to efficacy, unknown side effects and&#47;or interaction with individual human biochemistry or other supplements or medications. As a result, the Company&#8217;s psychedelic pharmaceutical products could have certain side effects if not used as directed or if taken by an end user that has certain known or unknown medical conditions. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Success of Quality Control Systems</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The quality and safety of the Company&#8217;s products are critical to the success of its business and operations. As such, it is imperative that the Company (and its service providers&#8217;) quality control systems operate effectively and successfully. Quality control systems can be negatively impacted by the design of the quality control systems, the quality of training programs and adherence by employees to quality control guidelines. Any significant failure or deterioration of such quality control systems could have a material adverse effect on the Company&#8217;s business and operating results.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reliance on Key Inputs</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s business is expected to be dependent on a number of key inputs and their related costs including raw materials and supplies. Any significant interruption or negative change in the availability or economics of the supply chain for key inputs could materially impact the business, financial condition and operating results of the Company. Any inability to secure required supplies and services or to do so on appropriate terms could have a materially adverse impact on the business, financial condition and operating results of the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Liability Arising from Fraudulent or Illegal Activity</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is exposed to the risk that its employees, independent contractors, consultants, service providers and licensors may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional undertakings of unauthorized activities, or reckless or negligent undertakings of authorized activities, in each case on the Company&#8217;s behalf or in its service that violate (i) various laws and regulations, including healthcare laws and regulations, (ii) laws that require the true, complete and accurate reporting of financial information or data, (iii) the terms of the Company&#8217;s agreements with third parties. Such misconduct could expose the Company to, among other things, class actions and other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">94</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">litigation, increased regulatory inspections and related sanctions, and lost sales and revenue or reputational damage.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The precautions taken by the Company to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting the Company from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Such misconduct may result in legal action, significant fines or other sanctions and could result in loss of any regulatory licence held by the Company at such time. The Company may be subject to security breaches at its facilities or in respect of electronic document or data storage, which could lead to breaches of applicable privacy laws and associated sanctions or civil or criminal penalties&#59; events, including those beyond the control of the Company, may damage its operations. In addition, these events may negatively affect customers&#8217; demand for the Company&#8217;s products. Such events include, but are not limited to, non-performance by third party contractors&#59; increases in materials or labour costs&#59; breakdown or failure of equipment&#59; failure of quality control processes&#59; contractor or operator errors&#59; and major incidents and&#47;or catastrophic events such as fires, explosions, earthquakes or storms. As a result, there is a risk that the Company may not have the capacity to meet customer demand or to meet future demand when it arises. Failure to comply with health and safety laws and regulations may result in additional costs for corrective measures, penalties or in restrictions on the Company&#8217;s manufacturing operations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Operating Risk and Insurance Coverage</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has directors and officers insurance to protect its assets, operations and employees. The Company&#8217;s insurance is subject to coverage limits and exclusions and may not be available for the risks and hazards to which the Company is expected to be exposed. In addition, no assurance can be given that such insurance will be adequate to cover the Company&#8217;s liabilities or will be generally available in the future, or if available, that premiums will be commercially justifiable. If the Company were to incur substantial liability and such damages were not covered by insurance or were in excess of policy limits, or if the Company were to incur such liability at a time when it is not able to obtain liability insurance, its business, results of operations and financial condition could be materially adversely affected.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Costs of Operating as Public Company</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a public company, the Company will incur significant legal, accounting and other expenses. As a public company, the Company is subject to various securities rules and regulations, which impose various requirements on the Company, including the requirement to establish and maintain effective disclosure and financial controls and corporate governance practices. The Company&#8217;s management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase the Company&#8217;s legal and financial compliance costs and make some activities more time-consuming and costly.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Management of Growth</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company may be subject to growth-related risks, including capacity constraints and pressure on its internal systems and controls. The ability of the Company to manage growth effectively will require it to continue to implement and improve its operational and financial systems and to expand, train and manage its employee base. The inability of the Company to deal with this growth may have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and prospects.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">95</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Conflicts of Interest</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company may be subject to various potential conflicts of interest because of the fact that some of its officers and directors may be engaged in a range of business activities. The Company&#8217;s executive officers and directors may devote time to their outside business interests, so long as such activities do not materially or adversely interfere with their duties to the Company. In some cases, the Company&#8217;s executive officers and directors may have fiduciary obligations associated with these business interests that interfere with their ability to devote time to the Company&#8217;s business and affairs and that could adversely affect the Company&#8217;s operations. These outside business interests could require significant time and attention of the Company&#8217;s executive officers and directors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, the Company may also become involved in other transactions which conflict with the interests of its directors and the officers who may from time-to-time deal with persons, firms, institutions or companies with which the Company may be dealing, or which may be seeking investments similar to those desired by it. The interests of these persons could conflict with those of the Company, and from time to time, these persons may be competing with the Company for available investment opportunities.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Conflicts of interest, if any, will be subject to the procedures and remedies provided under applicable laws. In particular, in the event that such a conflict of interest arises at a meeting of the Company&#8217;s directors, a director who has such a conflict will abstain from voting for or against the approval of such participation or such terms. In accordance with applicable laws, the directors of the Company are required to act honestly, in good faith and in the best interests of the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Operations</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition to operations carried out in Canada and the UK, the Company intends to carry out international operations through an office in Ireland. As a result, the Company may be subject to political, economic and other uncertainties, including, but not limited to, additional implications that may have a material impact on the Company&#8217;s ability to operate in other jurisdictions, including&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">differences in the regulatory requirements for drug approvals&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">differing requirements for securing, maintaining or obtaining freedom to operate&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">the potential for reduced protection for intellectual property rights&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">challenges with compliance to different regulations and court systems of multiple jurisdictions and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">compliance with a wide variety of foreign laws, treaties and regulations&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">differing reimbursement regimes and price controls in certain international markets&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">differing labor relations that create challenges with staffing and managing international operations&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">impacts on manufacturing capabilities leading to production shortages.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s international operations may also be adversely affected by laws and policies of Canada affecting foreign trade, taxation and investment. In the event of a dispute arising in connection with its foreign operations, the Company may be subject to the exclusive jurisdiction of foreign courts or may not be successful in subjecting foreign persons to the jurisdiction of courts in Canada or enforcing Canadian judgments in foreign jurisdictions.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Similarly, to the extent that the Company&#8217;s assets are located outside of Canada, investors may have difficulty collecting from the Company any judgments obtained in the Canadian courts and predicated on the civil liability provisions of securities laws. Consequently, investors may be effectively prevented from </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">96</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">pursuing remedies against the Company under Canadian securities laws or otherwise. The Company may also be hindered or prevented from enforcing its rights with respect to a governmental entity or instrumentality because of the doctrine of sovereign immunity.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exchange Rate Fluctuations</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Due to the international scope of the Company&#8217;s current and future operations, the Company&#8217;s assets, future earnings and cash flows may be influenced by movements in exchange rates of several currencies, particularly the British Pound, the U.S. dollar, Canadian Dollar and the Euro. The Company&#8217;s reporting currency is denominated in Canadian dollars and the Company&#8217;s functional currency is the Canadian dollar and the majority of the Company&#8217;s operating expenses are paid in Canadian dollars. The Company may also regularly acquire services, consumables and materials in British Pounds, U.S. dollars, Canadian dollars and other currencies. Further, future revenue may be derived from abroad. As a result, the Company&#8217;s business and the price of the Company&#8217;s products may be affected by fluctuations in foreign exchange rates between the British Pound, the U.S. dollar, the Canadian dollar and other currencies, which may also have a significant impact on the Company&#8217;s results of operations and cash flows from period to period. Currently, the Company does not have any exchange rate hedging arrangements in place.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cybersecurity and Privacy Risk</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s information systems and any third-party service providers and vendors are vulnerable to an increasing threat of continually evolving cybersecurity risks. These risks may take the form of malware, computer viruses, cyber threats, extortion, employee error, malfeasance, system errors or other types of risks, and may occur from inside or outside of the respective organizations. Cybersecurity risk is increasingly difficult to identify and quantify and cannot be fully mitigated because of the rapidly evolving nature of the threats, targets and consequences. Additionally, unauthorized parties may attempt to gain access to these systems through fraud or other means of deceiving third-party service providers, employees or vendors. The Company&#8217;s operations depend, in part, on how well networks, equipment, IT systems and software are protected against damage from a number of threats. These operations also depend on the timely maintenance, upgrade and replacement of networks, equipment, IT systems and software, as well as pre-emptive expenses to mitigate the risks of failures. However, if the Company is unable or delayed in maintaining, upgrading or replacing IT systems and software, the risk of a cybersecurity incident could materially increase. Any of these and other events could result in information system failures, delays and&#47;or increases in capital expenses. The failure of information systems or a component of information systems could, depending on the nature of any such failure, adversely impact the Company&#8217;s reputation and results of operations. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company may collect and store certain personal information about customers and are responsible for protecting such information from privacy breaches. A privacy breach may occur through procedural or process failure, information technology malfunction, or deliberate unauthorized intrusions. In addition, theft of data is an ongoing risk whether perpetrated via employee collusion or negligence or through deliberate cyber-attack. Any such privacy breach or theft could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, there are a number of laws protecting the confidentiality of certain patient health information, including patient records, and restricting the use and disclosure of that protected information. In particular, the privacy rules under the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Personal Information Protection and Electronics Documents Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (Canada) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PIPEDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and where applicable, provincial legislation governing personal health information, protect medical records and other personal health information by limiting their use and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">97</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">disclosure of health information to the minimum level reasonably necessary to accomplish the intended purpose. If the Company were found to be in violation of the privacy or security rules under PIPEDA or other laws protecting the confidentiality of medical patients health information, the Company could be subject to sanctions and civil or criminal penalties, which could increase its liabilities, harm its reputation and have a material adverse effect on the Company&#8217;s business, financial condition and results of operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Environmental Regulation and Risks</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s operations are subject to environmental regulations that mandate, among other things, the maintenance of air and water quality standards and land reclamation. They also set forth limitations on the generation, transportation, storage and disposal of solid and hazardous waste. Environmental legislation is evolving in a manner which could include stricter standards and enforcement, increased fines and penalties for non-compliance, more stringent environmental assessments of proposed projects and a heightened degree of responsibility for companies and their officers, directors and employees. There is no assurance that future changes in environmental regulation, if any, will not adversely affect the Company&#8217;s operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Failure to comply with applicable laws, regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment, or remedial actions. The Company may be required to compensate those suffering loss or damage by reason of its operations and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amendments to current laws, regulations and permits governing psychedelics and related products, or more stringent implementation thereof, could have a material adverse impact on the Company and cause increases in expenses, capital expenditures or production costs or reduction in levels of production or require abandonment or delays in development.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Decriminalization of Psychedelics</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Despite the current status of many psychotropic substances as a Schedule II and Schedule I controlled substances in the United States and Canada, respectively, there may be changes in the status of some of these substances under the laws of certain jurisdictions. Possession of psilocybin, for example, was voted to be decriminalized in May 2019 in Denver and in November 2020, voters in Oregon approved the legal medical use of &#8220;psilocybin products,&#8221; including magic mushrooms, to treat mental health conditions in licensed facilities with registered therapists (Measure 109). The legalization of psychedelics with inadequate regulatory oversight may lead to the development of psychotropic tourism in such states in clinics without proper therapeutic infrastructure or adequate clinical research. The expansion of such an industry which could put patients at risk may bring reputational and regulatory risk to the entire industry, leading to challenges for the Company to achieve regulatory approval. The legalization of psilocybin, DMT and potentially other psychotropic compounds in the future may also impact commercial sales for the Company due to a reduced barrier to entry leading to a risk of increasing competition.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-looking statements May Prove to be Inaccurate </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investors should not place undue reliance on forward-looking statements. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, of both general and specific nature, that could cause actual results to differ materially from those suggested by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">98</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">forward-looking statements or contribute to the possibility that predictions, forecasts or projections will prove to be materially inaccurate.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Effects of Inflation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Global markets have experienced increased rates of inflation. Inflation itself, as well as certain governmental efforts to combat inflation, may have significant negative effects on any economy which the Company does business. Past governmental efforts to curb inflation have involved certain drastic economic measures, which had a materially adverse impact on the level of economic activity in these countries. Any future economic measures to curb inflation could be expected to have similar adverse effects on the level of economic activity in the market which the Company does business and, in turn, on the operations of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Political and Economic Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Political and economic conditions directly affect the Company&#8217;s business and can result in a material adverse effect on the Company. Macroeconomic policies imposed by foreign governments could have significant impact on the Company. As certain global markets experience increased inflation, certain government actions to control inflation may have significant impact on the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company cannot control or predict foreign government implementation of changes to existing policies that may impact the Company&#8217;s operations in foreign markets and, consequently, its business. The Company&#8217;s business, operating results and financial condition and prospects, as well as the market price of its securities, may be adversely affected by changes in government public policies, whether federal, state or local, that affect, without limitation&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">inflation&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">fluctuations in exchange rates&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">exchange controls and restrictions on remittances abroad&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">interest rates and monetary policies&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">import and export controls&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">liquidity of domestic capital, credit and financial markets&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">expansion or contraction of foreign economies, as measured by rates of growth in gross domestic product&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">fiscal policies&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">other political, social and economic developments in or affecting foreign markets.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Government policies and measures to combat inflation, along with public speculation about such policies and measures, have often had adverse effects on global economies, have contributed to economic uncertainty and may increase volatility in foreign securities markets. Government action to control inflation may involve actions such as price and salary controls, currency devaluations, capital limitations, limits on imports and other actions which could significantly impact the operations of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other policies and measures adopted by governments, include interest rate adjustments, intervention in the currency markets or actions to adjust or fix the value of the local currency may adversely affect the target market&#8217;s economy, the Company&#8217;s business and results of operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Uncertainty over whether federal governments will implement reforms or changes in policy or regulation affecting these or other factors in the future may affect economic performance and contribute to economic </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">99</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">uncertainty in markets that the Company operates or relies on, which may in turn have adverse effects on the Company&#8217;s operations in the market and consequently on the results of its operations. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Application and Interpretation of Tax Laws</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is subject to direct and indirect taxes in various foreign jurisdictions. The amount of tax that the Company pays, directly or indirectly, is subject to the interpretation of applicable tax laws in the jurisdictions of operations in which the Company has interests. The Company has taken and will continue to take tax positions based on the application and interpretation of tax laws, but tax accounting often involves complex matters and judgment is required in determining the Company&#8217;s foreign provisions for taxes and other tax liabilities. There can be no assurance that a taxing authority will not have a different interpretation of the law and assess the Company, or the operations in which the Company has interests, with additional taxes. Further, the Company&#8217;s future effective tax rates could be impacted by changes in tax laws or regulations, and changing interpretation of existing laws or regulations. Both domestic and international tax laws, and interpretation of the tax laws, are subject to change as a result of changes in fiscal policy, changes in legislation, evolution of regulation and court rulings. The application of these tax laws and related regulations is subject to legal and factual interpretation, judgment and uncertainty.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Enforcement of Civil Liabilities</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s subsidiaries and assets are located outside of Canada. Accordingly, it may be difficult for investors to enforce within Canada any judgments obtained against the Company, including judgments predicated upon the civil liability provisions of applicable Canadian securities laws or otherwise. Consequently, investors may be effectively prevented from pursuing remedies against the Company under Canadian securities laws or otherwise. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has subsidiaries incorporated in the United States and Ireland. It may not be possible for shareholders to effect service of process outside of Canada against the directors and officers of the Company who are not resident in Canada. In the event a judgment is obtained in a Canadian court against one or more of such persons for violations of Canadian securities laws or otherwise, it may not be possible to enforce such judgment against persons not resident in Canada. Additionally, it may be difficult for an investor, or any other person or entity, to assert Canadian securities law or other claims in original actions instituted in the United States and Ireland. Courts in such jurisdictions may refuse to hear a claim based on a violation of Canadian securities laws or otherwise on the grounds that such jurisdiction is not the most appropriate forum to bring such a claim. Even if a foreign court agrees to hear a claim, it may determine that the local law, and not Canadian law, is applicable to the claim. If Canadian law is found to be applicable, the content of applicable Canadian law must be proven as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be governed by foreign law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pandemics, Epidemics and Other Health Risks</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pandemics, epidemics and other health risks could have an adverse effect on the Company&#8217;s business. Pandemics, epidemics and other health risks could occur, which could adversely affect the Company&#8217;s ability to conduct its operations as currently conducted, or the ability of suppliers to provide the Company with products and services needed to operate the business.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pandemics, epidemics and other health risks could have an adverse effect on the economy and financial markets, resulting in a decline of commercial activity. Any of these events could have an adverse effect on the Company&#8217;s business and financial performance.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">100</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RISKS RELATED TO INTELLECTUAL PROPERTY</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Trademark Protection</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Failure to register trademarks for the Company or its products could require the Company to rebrand its products resulting in a material adverse impact on its business.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Trade Secrets</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company relies on third parties to develop its products and as a result, must share trade secrets with them. The Company seeks to protect its proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with its collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically restrict the ability of the Company&#8217;s collaborators, advisors, employees and consultants to publish data potentially relating to its trade secrets. Its academic and clinical collaborators typically have rights to publish data, provided that the Company is notified in advance and may delay publication for a specified time in order to secure any intellectual property rights arising from the collaboration. In other cases, publication rights are controlled exclusively by the Company, although in some cases the Company may share these rights with other parties. The Company may also conduct joint research and development programs which may require it to share trade secrets under the terms of research and development collaboration or similar agreements. Despite the Company&#8217;s efforts to protect its trade secrets, the Company&#8217;s competitors may discover its trade secrets, either through breach of these agreements, independent development or publication of information. A competitor&#8217;s discovery of the Company&#8217;s trade secrets may impair its competitive position and could have a material adverse effect on its business and financial condition.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Patent Law Reform </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s commercial success depends in part on obtaining and maintaining patents and other forms of intellectual property rights for its current and future therapeutic candidates and associated therapies, digital therapies, methods used to manufacture the underlying therapeutic substances, and the methods for treating patients using those substances and therapies, or on licensing in such rights. Failure to obtain, maintain, protect, enforce or extend adequate patent and other intellectual property rights could materially adversely affect the Company&#8217;s ability to develop and market its current and future therapeutic candidates. The Company also relies on trade secrets and know-how to develop and maintain its proprietary and intellectual property position. Any failure to protect its trade secrets and know-how could adversely affect the Company&#8217;s operations and prospects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company cannot be certain that patents will be issued or granted with respect to patent applications that are currently pending, or that issued or granted patents will not later be found to be invalid or unenforceable. The patent position of companies like the Company is generally uncertain because it involves complex legal and factual considerations. The standards applied by the UK Intellectual Property Office, the European Patent Office, the USPTO, the Canadian Intellectual Property Office (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CIPO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in pharmaceutical patents. Consequently, patents may not issue from the Company&#8217;s pending patent applications, and even if they do issue, such patents may not issue in a form that effectively prevents others from developing or commercializing competing therapies. As such, the Company does not know the degree of future protection that it will have on its proprietary therapies.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">101</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The patent prosecution process is expensive, complex and time-consuming, and the Company, its current or future third-party partners, licensors, licensees, or collaboration partners may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that the Company or its licensors, licensees or collaboration partners will fail to identify patentable aspects of inventions made in the course of research, development or commercialization activities before it is too late to pursue patent protection on them. In addition, although the Company enters into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of its R&#38;D output, such as its employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing the Company&#8217;s ability to seek patent protection. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the UK and other jurisdictions are typically not published until 18 months after filing, or in some cases not published until and unless granted. Therefore, the Company cannot be certain that it is the first to make the inventions claimed in its patents or pending patent applications, or that it was the first to file for patent protection of such inventions. Similarly, the Company cannot be certain that for any licensed patents or pending patent applications, the named applicant(s) were the first to make the inventions claimed in such patents or pending patent applications or that the named applicant(s) were the first to file for patent protection for such inventions.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, the issuance, scope, validity, enforceability and commercial value of the Company&#8217;s and its current or future licensors&#8217;, licensees&#8217; or collaboration partners&#8217; patent rights are highly uncertain. The Company and any potential licensors&#8217; pending and future patent applications may not result in patents being issued that protect the Company&#8217;s therapies, in whole or in part, or that effectively prevent others from commercializing competitive technologies and therapies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Moreover, in some circumstances, the Company may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain such patents, should the Company&#8217;s license technology from or to third parties and would be reliant on its licensors, licensees or collaboration partners. If the Company engages with licensors, licensees or collaboration partners and they fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If such licensors, licensees or collaboration partners were not fully cooperative or disagree with the Company as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The patent examination process may require the Company or its licensors, licensees or collaboration partners to narrow the scope of the claims of the Company or the Company&#8217;s licensors&#8217;, licensees&#8217; or collaboration partners&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. The Company cannot guarantee that all of the potentially relevant prior art relating to its patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and the Company&#8217;s patents may be challenged in the courts or patent offices in the UK and abroad. Even if patents do successfully issue and even if such patents cover the Company&#8217;s current and future therapeutic candidates, third parties may initiate an opposition, interference, re-examination, post-grant review, inter parties review, nullification or derivation proceedings in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">102</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company and the Company&#8217;s licensors&#8217;, licensees&#8217; or collaboration partners&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology. In addition, patents and other intellectual property rights also will not protect the Company&#8217;s current and any future therapeutic candidates if third parties, including the Company&#8217;s competitors, design around the Company&#8217;s protected technology and the Company&#8217;s current and any future therapeutic candidates without infringing, misappropriating or otherwise violating the Company&#8217;s patents or other intellectual property rights. Moreover, some of the Company&#8217;s patents and patent applications may in the future be co-owned with third parties. If the Company is unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including the Company&#8217;s competitors, and the Company&#8217;s competitors could market competing therapies and technology. In addition, the Company may need the cooperation of any such co-owners of its patents in order to enforce such patents against third parties, and such cooperation may not be provided. Any of the foregoing could have a material adverse effect on the Company&#8217;s competitive position, business, financial conditions, results of operations, and prospects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Because patent applications are confidential for a period of time after filing, and some remain so until issued, the Company cannot be certain that the Company or its current or future licensors, licensees or collaborators were or will be the first to file any patent application related to a therapeutic candidate. Even where the Company has a valid and enforceable patent, it may not be able to exclude others from practicing the Company&#8217;s invention where the other party can show that they used the invention in commerce before the Company&#8217;s filing date or the other party benefits from a compulsory license. In addition, the Company may be subject to third-party challenges regarding the Company&#8217;s exclusive ownership of the Company&#8217;s intellectual property. If a third party were successful in challenging the Company&#8217;s exclusive ownership of any of the Company&#8217;s intellectual property, the Company may lose its right to use such intellectual property, such third party may be able to license such intellectual property to other third parties, including the Company&#8217;s competitors, and the Company&#8217;s competitors could market competing therapies and technology. Any of the foregoing could have a material adverse effect on the Company&#8217;s competitive position, business, financial conditions, results of operations, and prospects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As is the case with other biotechnology and pharmaceutical companies, the Company&#8217;s success is heavily dependent on intellectual property rights, particularly patents. Obtaining and enforcing patents in the breakthrough neuropsychiatry industry is a technologically and legally complex process, and obtaining and enforcing breakthrough neuropsychiatry patents is costly, time consuming and inherently uncertain. Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of the Company&#8217;s and its licensors&#8217; or collaborators&#8217; patent applications and the enforcement or defense of the Company or its licensors&#8217; or collaborators&#8217; issued patents.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Patent Litigation and Intellectual Property</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As disclosed under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Description of the Business -</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Company has filed a number of provisional patent applications but even if regular patent applications are filed claiming priority to one or more of the provisional patent applications, there can be no assurance that any or all of these patent applications will issue into a valid patent. Such failure to issue could have a material adverse effect on the Company. In the event that a patent issued to the Company is challenged, any of the Company&#8217;s patents may be invalidated. The Company could also become involved in interference or impeachment proceedings in connection with one or more of its patents or patent applications to determine priority of invention.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">103</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Patent litigation is widespread in the pharmaceutical industry and the Company cannot predict how this will affect its efforts to form strategic alliances, conduct clinical testing, or manufacture and market any of its prescription drug product candidates that it may successfully develop. If the Company becomes involved in any litigation, interference, impeachment or other administrative proceedings, it will likely incur substantial expenses and the efforts of its technical and management personnel will be significantly diverted. The Company cannot make any assurances that it will have the financial or other resources necessary to enforce or defend a patent infringement or proprietary rights violation action. Moreover, if the Company&#8217;s products infringe patents, trademarks or proprietary rights of others, it could, in certain circumstances, become liable for substantial damages, which also could have a material adverse effect on the business of the Company, its financial condition and results of operation. Patent litigation is less likely during development as many jurisdictions contain exemptions from patent infringement for the purpose of obtaining regulatory approval of a product. Where there is any sharing of patent rights either through co-ownership or different licensed &#8220;fields of use&#8221;, one owner&#8217;s actions could lead to the invalidity of the entire patent. If the Company is unable to avoid infringing the patent rights of others, the Company may be required to seek a licence, defend an infringement action or challenge the validity of the patents in court. Such results could have a material adverse effect on the Company. Regardless of the outcome, patent litigation is costly and time consuming. In some cases, the Company may not have sufficient resources to bring these actions to a successful conclusion, and, even if the Company is successful in these proceedings, it may incur substantial costs and divert management time and attention in pursuing these proceedings, which could have a material adverse effect on the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any infringement or misappropriation of the Company&#8217;s intellectual property could damage its value and limit its ability to compete. In addition, the Company&#8217;s ability to enforce and protect its intellectual property rights may be limited in certain countries outside the U.S., which could make it easier for competitors to capture market position in such countries by utilizing technologies that are similar to those developed or licensed by the Company. Competitors may also harm the Company&#8217;s sales by designing products that mirror the capabilities of its products or technology without infringing on its intellectual property rights. If the Company does not obtain sufficient protection for its intellectual property, or if it is unable to effectively enforce its intellectual property rights, its competitiveness could be impaired, which would limit its growth and future revenue. The Company may also find it necessary to bring infringement or other actions against third parties to seek to protect its intellectual property rights. Litigation of this nature, even if successful, is often expensive and time- consuming to prosecute and there can be no assurance that the Company will have the financial or other resources to enforce its rights or be able to enforce its rights or prevent other parties from developing similar technology or designing around its intellectual property.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is not aware of any infringement by it of any person&#8217;s or entity&#8217;s intellectual property rights. In the event that products sold by the Company are deemed to infringe upon the patents or proprietary rights of others, the Company could be required to modify its products or obtain a licence for the manufacture and&#47;or sale of such products or cease selling such products. In such event, there can be no assurance that the Company would be able to do so in a timely manner, upon acceptable terms and conditions, or at all, and the failure to do any of the foregoing could have a material adverse effect upon the Company&#8217;s business. If the Company&#8217;s products or proposed products are deemed to infringe or likely to infringe upon the patents or proprietary rights of others, the Company could be subject to injunctive relief and, under certain circumstances, become liable for damages, which could also have a material adverse effect on the Company&#8217;s business and its financial condition.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Protection of Intellectual Property</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company will be able to protect its intellectual property from unauthorized use by third parties only to the extent that the Company&#8217;s proprietary technologies, key products and any future products are covered by valid and enforceable intellectual property rights including patents or are effectively maintained as trade secrets and provided the Company has the funds to enforce its rights, if necessary.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To protect the Company&#8217;s competitive position, the Company may from time to time need to resort to litigation in order to enforce or defend any patents or other intellectual property rights owned by or licensed to the Company from time to time, or to determine or challenge the scope or validity of patents or other intellectual property rights of third parties. Enforcement of intellectual property rights is difficult, unpredictable and expensive, and many of the Company&#8217;s or the Company&#8217;s licensors&#8217; or collaboration partners&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than the Company or the Company&#8217;s licensors or collaboration partners can. Accordingly, despite the Company&#8217;s or the Company&#8217;s licensors&#8217; or collaboration partners&#8217; efforts, the Company or the Company&#8217;s licensors or collaboration partners may not prevent third parties from infringing upon, misappropriating or otherwise violating intellectual property rights. In the event that products sold by the Company own or control, particularly in countries where the laws may not protect those rights as fully as in the UK, EU, the US and Canada. The Company may fail in enforcing its rights, in which case the Company&#8217;s competitors and other third parties may be permitted to use the Company&#8217;s therapies without payment to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, litigation involving the Company&#8217;s licensed patents carries the risk that one or more of the Company&#8217;s licensed patents will be narrowed, held invalid (in whole or in part, on a claim-by-claim basis) or held unenforceable. Such an adverse court ruling could allow third parties to commercialize the Company&#8217;s therapies, and then compete directly with the Company, without payment to the Company. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the Company were to initiate legal proceedings against a third party to enforce a patent covering one of the Company&#8217;s investigational therapies, the defendant could counterclaim that the Company&#8217;s patent is invalid or unenforceable. In patent litigation in the UK, EU, the US or Canada, defendant counterclaims alleging invalidity or unenforceability are commonplace. A claim for a validity challenge may be based on failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. A claim for unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the UK Intellectual Property Office, European Patent Office, the USPTO, the CIPO or made a misleading statement, during prosecution. Third parties may also raise challenges to the validity of the Company&#8217;s patent claims before administrative bodies in the US or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (i.e., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to the Company&#8217;s patents in such a way that they no longer cover the Company&#8217;s current or any future therapeutic candidates. The outcome following legal assertions of invalidity and unenforceability during patent litigation or other proceedings is unpredictable. With respect to the validity question, for example, the Company cannot be certain that there is no invalidating prior art, of which the Company and the patent examiner were unaware during prosecution. If a defendant or third party were to prevail on a legal assertion of invalidity or unenforceability, the Company would lose at least part, and perhaps all, of the patent protection on the Company&#8217;s current or one or more of any future therapeutic candidates. Such a loss of patent protection could have a material adverse impact on the Company&#8217;s business financial condition, results of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">105</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">operations, and prospects. Further, litigation could result in substantial costs and diversion of management resources, regardless of the outcome, and this could harm the Company&#8217;s business and financial results.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Third-Party Licences</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A substantial number of patents have already been issued to other biotechnology and pharmaceutical companies. To the extent that valid third-party patent rights cover the Company&#8217;s products or services, the Company or its strategic collaborators would be required to seek licences from the holders of these patents in order to manufacture, use or sell these products and services and payments under them would reduce the Company&#8217;s profits from these products and services. The Company is currently unable to predict the extent to which it may wish or be required to acquire rights under such patents, the availability and cost of acquiring such rights and whether a licence to such patents will be available on acceptable terms or at all. There may be patents in the U.S. or in foreign countries or patents issued in the future that are unavailable to licence on acceptable terms. The Company&#8217;s inability to obtain such licences may hinder or eliminate its ability to manufacture and market its products.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further, if the Company obtains third-party licences but fails to pay annual maintenance fees, development and sales milestones, or it is determined that the Company does not use commercially reasonable efforts to commercialize licensed products, the Company could lose its licences which could have a material adverse effect on its business and financial condition.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Periodic maintenance and annuity fees on any issued patent are due to be paid to the UK Intellectual Property Office, the European Patent Office, the USPTO, the CIPO and foreign patent agencies in several stages over the lifetime of the patent. The European Patent Office, the USPTO, the CIPO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, the Company may rely on collaboration partners to pay these fees due to US and comparable foreign patent agencies and take the necessary action to comply with such requirements with respect to the Company&#8217;s intellectual property. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If the Company, its licensors or collaboration partners fail to maintain the patents and patent applications covering the Company&#8217;s investigational therapies, third parties, including its competitors might be able to enter the market with similar or identical therapies or technologies, which would have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, and prospects.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FINANCIAL AND ACCOUNTING RISKS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Substantial Number of Authorized but Unissued Common Shares</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has an unlimited number of Common Shares that may be issued by the Board without further action or approval of the Shareholders. While the Board will be required to fulfill its fiduciary obligations in connection with the issuance of such Common Shares, the Common Shares may be issued in transactions with which not all of the shareholders of the Company agree, and the issuance of such Common Shares will cause dilution to the ownership interests of the shareholders of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">106</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Dilution</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company may issue additional Common Shares in subsequent offerings (including through the sale of securities convertible into or exchangeable for Common Shares) and on the exercise of stock options or other securities exercisable for Common Shares. The Company cannot predict the size of future issuances of Common Shares or the effect that future issuances and sales of Common Shares will have on the market price of the Common Shares. Issuances of a substantial number of additional Common Shares, or the perception that such issuances could occur, may adversely affect prevailing market prices for the Common Shares. With any additional issuance of Common Shares, investors will suffer dilution to their voting power and the Company may experience dilution in its earnings per share.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Negative Cash Flow from Operating Activities</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has had negative cash flow from operating activities since inception. Drug development involves long lead times, is very expensive and involves many variables of uncertainty. As such, significant capital investment will be required to achieve the Company&#8217;s existing plans. The Company&#8217;s net losses have had and will continue to have an adverse effect on, among other things, shareholder equity, total assets and working capital. The Company expects that losses may fluctuate from quarter to quarter and year to year, and that such fluctuations may be substantial based on the stage of development of its principal programs. The Company cannot predict when it will become profitable, if at all. Accordingly, the Company may be required to obtain additional financing in order to meet its future cash commitments. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Additional Capital Requirements</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a research and development company, the Company expects to spend substantial funds to continue the research, development and testing of its prescription drug product candidates and to prepare to commercialize products subject to applicable regulatory approval. Substantial additional financing may be required if the Company is to be successful in continuing to develop its business and its products. No assurances can be given that the Company will be able to raise the additional capital that it may require for its anticipated future development. Any additional equity financing may be dilutive to investors and debt financing, if available, may involve restrictions on financing and operating activities. There is no assurance that additional financing will be available on terms acceptable to the Company, if at all. If the Company is unable to obtain additional financing as needed, it may be required to reduce the scope of its operations or anticipated expansion. The Company&#8217;s ability to successfully raise additional capital and maintain liquidity may by impaired by factors outside of its control, such as a shift in consumer attitudes towards certain therapeutic methods or a downturn in the economy. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Heightened regulatory scrutiny could have a negative impact on the Company&#8217;s ability to raise capital. The Company&#8217;s business activities rely on developing laws and regulations in multiple jurisdictions. It is impossible to determine the extent of the impact of any new laws, regulations or initiatives that may be proposed, or whether any proposals will become law. The regulatory uncertainty surrounding the Company&#8217;s current or any future products may adversely affect the Company&#8217;s business and operations, including without limitation, the Company&#8217;s ability to raise additional capital.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, the Company may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving its business objectives. The Company will eventually need to transition from a company with a development focus to a company capable of supporting commercial activities. The Company may not be successful in such a transition.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">107</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lack of Significant Product Revenue</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To date, the Company has generated little product revenue and cannot predict when and if it will generate significant product revenue. The Company&#8217;s ability to generate significant product revenue and ultimately become profitable depends upon its ability, alone or with partners, to successfully develop its prescription drug product candidates, obtain regulatory approval and commercialize products, including any of its current prescription drug product candidates or other prescription drug product candidates that it may develop, in-license or acquire in the future. The Company does not anticipate generating revenue from the sale of products for the foreseeable future. The Company expects its research and development expenses to increase in connection with its ongoing activities, particularly as it advances its prescription drug product candidates through clinical trials.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Estimates or Judgments Relating to Critical Accounting Policies</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with the International Financial Reporting Standards requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, as provided in the notes to the financial statements of the Company, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. The Company&#8217;s operating results may be adversely affected if the assumptions change or if actual circumstances differ from those in the assumptions, which could cause its operating results to fall below the expectations of securities analysts and investors, resulting in a decline in the share price of the Company. Significant assumptions and estimates used in preparing the financial statements include those related to income tax credits receivable, share based payments, impairment of non-financial assets, fair value of biological assets, as well as cost recognition.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inadequate Internal Controls</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the Company fails to maintain an effective system of internal controls, the Company might not be able to report its financial results accurately or prevent misstatement&#59; and in that case, the Company&#8217;s shareholders could lose confidence in its financial reporting, which would harm its business and could negatively impact the value of its shares. While the Company believes that it has sufficient personnel and review procedures to allow it to maintain an effective system of internal controls, there can be no assurance that the Company will always successfully detect misstatements or implement necessary improvements in a timely fashion.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RISKS RELATED TO THE COMMON SHARES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Market for the Common Shares</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There can be no assurance that an active trading market for the Common Shares will develop or, if developed, that any market will be sustained. The Company cannot predict the prices at which the Common Shares will trade. Fluctuations in the market price of the Common Shares could cause an investor to lose all or part of its investment in Common Shares. Factors that could cause fluctuations in the trading price of the Common Shares include&#58; (i) announcements of new offerings, products, services or technologies&#59; commercial relationships, acquisitions or other events by the Company or its competitors&#59; (ii) price and volume fluctuations in the overall stock market from time to time&#59; (iii) significant volatility in the market price and trading volume of companies commercializing psychedelic pharmaceuticals&#59; (iv) fluctuations in the trading volume of the Common Shares or the size of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">108</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Company&#8217;s public float&#59; (v) actual or anticipated changes or fluctuations in the Company&#8217;s results of operations&#59; (vi) whether the Company&#8217;s results of operations meet the expectations of securities analysts or investors&#59; (vii) actual or anticipated changes in the expectations of investors or securities analysts&#59; (viii) litigation involving the Company, its industry, or both&#59; (ix) regulatory developments&#59; (x) general economic conditions and trends&#59; (xi) major catastrophic events&#59; (xii) escrow releases, sales of large blocks of the Common Shares&#59; (xiii) departures of key employees or members of management&#59; or (xiv) an adverse impact on the Company from any of the other risks cited herein.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Significant Sales of the Common Shares</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Although Common Shares held by existing shareholders of the Company will be freely tradable under applicable securities legislation, the Common Shares held by the Company&#8217;s directors, executive officers, Control persons and certain other security holders may be subject to contractual lock-up restrictions and may also be subject to escrow restrictions pursuant to the policies of Cboe Canada. Sales of a substantial number of the Common Shares in the public market after the expiry of lock-up or escrow restrictions, or the perception that these sales could occur, could adversely affect the market price of the Common Shares and may make it more difficult for investors to sell Common Shares at a favourable time and price.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Volatile Market Price for the Common Shares</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The securities market in Canada has experienced a high level of price and volume volatility, and the market prices of securities of many companies have experienced wide fluctuations in price which have not necessarily been related to the operating performance, underlying asset values or prospects of such companies. There can be no assurance that continual fluctuations in price will not occur. It may be anticipated that any market for the Common Shares will be subject to market trends generally, notwithstanding any potential success of the Company. The value of the Common Shares distributed hereunder will be affected by such volatility.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The volatility of the Common Shares may affect the ability of holders to sell the Common Shares at an advantageous price or at all. Market price fluctuations in the Common Shares may be adversely affected by a variety of factors relating to the Company&#8217;s business, including fluctuations in the Company&#8217;s operating and financial results, such results failing to meet the expectations of securities analysts or investors and downward revisions in securities analysis&#8217; estimates in connection therewith, sales of additional Common Shares, governmental regulatory action, adverse change in general market conditions or economic trends, acquisitions, dispositions or other material public announcements by the Company or its competitors, along with a variety of additional factors, including, without limitation, those set forth under the heading &#8220;Cautionary Note Regarding Forward-Looking Information&#8221;. In addition, the market price for securities on stock markets, including Cboe Canada is subject to significant price and trading fluctuations. These fluctuations have resulted in volatility in the market prices of securities that often has been unrelated or disproportionate to changes in operating performance. These broad market fluctuations may materially adversely affect the market price of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, the value of the Common Shares is subject to market value fluctuations based upon factors that influence the Company&#8217;s operations, such as legislative or regulatory developments, competition, technological change and changes in interest rates or foreign exchange rates. There can be no assurance that the market price of the Common Shares will not experience significant fluctuations in the future, including fluctuations that are unrelated to the Company&#8217;s performance.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">109</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tax Issues</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There may be income tax consequences in relation to the Common Shares, which will vary according to circumstances. Independent advice from tax and legal advisers should be obtained.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">No Dividends</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s current policy is, and will be, to retain earnings to finance the development and enhancement of its products and to otherwise reinvest in the Company. Therefore, the Company does not anticipate paying cash dividends on the Common Shares in the foreseeable future. The Company&#8217;s dividend policy will be reviewed from time to time by the Board in the context of its earnings, financial condition and other relevant factors. Until the time that the Company does pay dividends, which it might never do, its shareholders will not be able to receive a return on their Common Shares unless they sell them.</font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_31"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">DIVIDEND AND DISTRIBUTIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company does not currently intend to declare any dividends payable to the holders of the Common Shares. The Company has no restrictions on paying dividends, but if the Company generates earnings in the foreseeable future, it expects that they will be retained to finance growth. The Board will determine if and when dividends should be declared and paid in the future based upon the Company&#8217;s financial position at the relevant time.</font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_34"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">DESCRIPTION OF CAPITAL STRUCTURE</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of the date of this AIF, the authorized share capital of the Company consists of an unlimited number of Common Shares of which 23,023,631 are issued and outstanding, and an unlimited number of preferred shares, issuable in series, none of which are issued and outstanding. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, the Company has agreed to issue Common Shares in connection with the Adelia Transaction. The Common Shares are issuable upon exchange of Class B Shares in the capital of Cybin U.S. on the basis of 0.26316 Common Shares for 1 Class B Share, subject to customary adjustments. The Adelia Shareholders are also entitled to Class B Shares upon the occurrence of certain milestones. No Class B Shares were exchangeable prior to the first anniversary of closing of the Adelia Transaction, and not more than&#58; (i) 33 1&#47;3% of the Class B Shares were exchangeable prior to the second anniversary of the Adelia Transaction&#59; and (ii) 66 2&#47;3% of the Class B Shares were exchangeable prior to the third anniversary of the Adelia Transaction. Currently, 100% of the Class B Shares are exchangeable. As at March&#160;31, 2025, 36,084.7 Class B Shares were outstanding and are exchangeable for a total of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9,496 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Common Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of the date of this AIF, all of the milestones have been completed and 1,591,625.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Class B Shares, have been issued to the Adelia Shareholders, with 1,555,540.6 of the Class B Shares having been exchanged into Common Shares. For further information see &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">General Development of the Business &#8211; Three Year History</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Prior Sales &#8211; Exchangeable Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Holders of Common Shares are entitled to one vote for each Common Share held at all meetings of shareholders of the Company, to receive dividends if, as and when declared by the Board, and to participate ratably in any distribution of property or assets upon the liquidation, winding-up or other dissolution of the Company. The Common Shares carry no pre-emptive rights, conversion or exchange rights, or redemption, retraction, repurchase, sinking fund or purchase fund provisions. There are no provisions requiring a holder of Common Shares to contribute additional capital, and no restrictions on </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">110</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the issuance of additional securities by the Company. There are no restrictions on the repurchase or redemption of Common Shares by the Company except to the extent that any such repurchase or redemption would render the Company insolvent.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The aim of the Equity Incentive Plan is to attract and retain employees, directors and consultants, and to ensure that interests of key persons are aligned with the success of the Company and its affiliates. The maximum number of options to purchase Common Shares reserved for issuance under the Equity Incentive Plan pursuant to options not intended as incentive stock options shall be 20% of the issued and outstanding Common Shares from time to time, on a non-diluted basis. The maximum number of Common Shares reserved for issuance under the Equity Incentive Plan pursuant to incentive stock options is 3,998,381. For the avoidance of doubt, long-term incentive options are excluded from the Equity Incentive Plan maximum. Common Shares in respect of Options that have been exercised, cancelled, surrendered, or terminated or that expire without being exercised shall again be available for issuance under the Equity Incentive Plan.</font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_37"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MARKET FOR SECURITIES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Trading Price and Volume</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prior to the closing of the Transaction on November 5, 2020, the Common Shares were listed for trading on the TSXV. Trading on the TSXV was halted on June 29, 2020, in connection with the announcement of the Transaction. The Common Shares commenced trading on Cboe Canada following the completion of the Transaction on a post-Consolidation basis under the stock symbol &#8220;CYBN&#8221; on November 10, 2020, and were voluntarily de-listed from the TSXV. The following table sets forth, for the periods indicated, the reported high and low prices and the trading volume of the Common Shares on Cboe Canada and the NYSE American&#58; </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.896%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cboe Canada Price Range</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.39pt;padding-right:2.39pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Month</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">High</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ($)</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Low </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">($)</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Volume</font></div></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.32</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.10</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,784</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2024</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.76</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.91</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,286</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2024</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.62</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.78</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,950</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2024</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.00</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.73</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,807</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2024</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.20</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.59</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,135</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2024</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.43</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622,414</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2024</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.95</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.25</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,904</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2024</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.46</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.88</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658,562</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2024</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.50</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.25</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,739</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2025</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.55</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.45</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,121</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.27</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.15</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,579</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.14</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.91</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,695</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-21.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#58;</font></div><div style="padding-left:36pt;padding-right:35.65pt;text-align:justify;text-indent:-14.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Source&#58; Cboe Canada trading data as of the date of this AIF. All figures related to securities are represented on a post-2024 Consolidation basis.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">111</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As the close of business on June 30, 2025, the date of this AIF, the price of the Common Shares as quoted by Cboe Canada was $11.40 per Common Share. </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.896%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NYSE American Price Range</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.39pt;padding-right:2.39pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Month</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">High</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (US$)</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Low </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(US$)</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Volume</font></div></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2024</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8562</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8136</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,316,709</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2024</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.44</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5514</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445,190</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2024</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.30</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.405</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,135,767</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2024</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.768</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.405</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,657,895</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2024</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.716</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7381</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,478,612</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 2024</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.628</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,478,558</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2024</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6597</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2852</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,140,648</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2024</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.88</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1612</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,981,742</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2024</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.08</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.386</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,976,111</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2025</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.73</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.625</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926,388</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2025</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7199</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8001</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,083,405</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4747</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.20</font></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:1.99pt;padding-right:1.99pt;text-align:center"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,701,307</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-21.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#58;</font></div><div style="padding-left:36pt;padding-right:35.65pt;text-align:justify;text-indent:-14.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Source&#58; NYSE as of the date of this AIF. All figures related to securities are represented on a post-2024 Consolidation basis.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As the close of business on June 30, 2025, the date of this AIF, the price of the Common Shares as quoted by the NYSE American was US$8.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">per Common Share. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Prior Sales</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables summarize details of the following securities that are not listed or quoted on a marketplace issued by the Company during the most recently completed financial year end&#58; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Options</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date Granted</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-1.28pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Options</font></div></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price ($)</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiry Date</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-right:-1.28pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 5, 2024</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)-(7)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,294</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$21.28</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 5, 2029</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-right:-1.28pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 15, 2024</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(8)-(11)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061,232</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$13.11</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 15, 2034</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 27, 2024</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,100</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$14.37</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 27, 2034</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 7, 2025</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,000</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.45</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 7, 2035</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Notes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">On August 9, 2024, 988 options were terminated as a result of the optionee no longer being eligible under the Equity Incentive Plan.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">On November 7, 2024, 328 options were terminated as a result of the optionee no longer being eligible under the Equity Incentive Plan.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">On December 1, 2024, 5,593 options were terminated as a result of the optionee no longer being eligible under the Equity Incentive Plan.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">On January 6, 2025, 988 options were terminated as a result of the optionee no longer being eligible under the Equity Incentive Plan.  &#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">112</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">On February 28, 2025, 988 options were terminated as a result of the optionee no longer being eligible under the Equity Incentive Plan.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">On March 1, 2025, 3,354 options were terminated as a result of the optionee no longer being eligible under the Equity Incentive Plan.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">On March 7, 2025, the Board determined that the grant of 3,947 Options did not achieve the goal of incentivizing the optionees in accordance with the Equity Incentive Plan and cancelled the options effective March 7, 2025.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">On November 11, 2024, 576 options were terminated as a result of the optionee no longer being eligible under the Equity Incentive Plan.  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">On January 6, 2025, 988 options were terminated as a result of the optionee no longer being eligible under the Equity Incentive Plan.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">On February 9, 2025, 82 options were terminated as a result of the optionee no longer being eligible under the Equity Incentive Plan.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(11)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">On March 7, 2025, the Board determined that the grant of 1,974 Options did not achieve the goal of incentivizing the optionees in accordance with the Equity Incentive Plan and cancelled the options effective March 7, 2025.</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exchangeable Securities</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">During the year ended March 31, 2025, no additional Class B shares were issued. As of March 31, 2025, all Milestones were achieved, and all eligible Class B shares were issued.</font></div><div><font><br></font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_40"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">DIRECTORS AND EXECUTIVE OFFICERS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table lists the names and municipalities of residence of the directors and officers of the Company, their positions and offices to be held with the Company, their principal occupations during the past five years and the number of securities of the Company that are beneficially owned, directly or indirectly, or over which control or direction will be exercised by each such director or officer. Each of the directors is elected to hold office until the next annual meeting of the shareholders of the Company or until a successor is duly elected or appointed. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name, Municipality of Residence and Position Held</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupation for the Past Five Years</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Appointed to Position Held</font></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number and Percentage of Securities Beneficially Owned or Controlled</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Douglas Drysdale, Somerville, Massachusetts, United States</font></div><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:2.17pt"><font><br></font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer, Cybin</font></div><div style="padding-left:0.02pt;padding-right:0.02pt"><font><br></font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer, Tedor Pharma Inc.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,154</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.02%)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Greg Cavers, </font></div><div style="padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Toronto, Ontario, Canada</font></div><div style="padding-left:0.02pt;padding-right:2.17pt"><font><br></font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer, Cybin</font></div><div style="padding-left:0.02pt;padding-right:0.02pt"><font><br></font></div><div style="padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim Chief Financial Officer, LottoGopher Holdings Inc.</font></div><div style="padding-left:0.02pt;padding-right:0.02pt"><font><br></font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt"><font><br></font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,632</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.01%)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gabriel Fahel, Ottawa, Ontario, Canada</font></div><div style="padding-left:0.02pt;padding-right:2.17pt"><font><br></font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Legal Officer</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Legal Officer, Cybin</font></div><div style="padding-left:0.02pt;padding-right:0.02pt"><font><br></font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal Counsel, Government of Canada</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,610</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.05%)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">113</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name, Municipality of Residence and Position Held</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupation for the Past Five Years</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Appointed to Position Held</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number and Percentage of Securities Beneficially Owned or Controlled</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aaron Bartlone</font></div><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milton, Georgia, United States</font></div><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:2.17pt"><font><br></font></div><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Operating Officer</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Operating Officer, Cybin</font></div><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font><br></font></div><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer and President, Georgia Health Dynamix</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2023</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,712</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</font></div><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.10%)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paul Glavine, United Arab Emirates</font></div><div style="padding-left:0.02pt;padding-right:2.17pt"><font><br></font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director and Chief Growth Officer</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Growth Officer, Cybin</font></div><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font><br></font></div><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Former Chief Operating Officer and Chief Executive Officer, Cybin</font></div><div style="padding-left:0.02pt;padding-right:0.02pt"><font><br></font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt"><font><br></font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 2020</font></div><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2021</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">299,674</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.30%)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eric So, </font></div><div style="padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Arab Emirates </font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:2.17pt"><font><br></font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director and President</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President, Cybin</font></div><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font><br></font></div><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managing Director, Trinity Venture Partners</font></div><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font><br></font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">311,116</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.35%)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Theresa Firestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)(4)</font></div><div style="padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Toronto, Ontario, Canada</font></div><div style="padding-left:0.02pt;padding-right:2.17pt"><font><br></font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Independent Board Director</font></div><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font><br></font></div><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SVP, Health and Wellness, Shoppers Drug Mart</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2021</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,059</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">)</font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.005%)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant Froese</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Toronto, Ontario, Canada</font></div><div style="padding-left:0.02pt;padding-right:2.17pt"><font><br></font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal, Greywolf Management Services Inc.</font></div><div style="padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font><br></font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director and Chief Executive Officer, Harvest One Cannabis Inc.</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,263</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(12)</font></div><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.02%)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eric Hoskins</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Toronto, Ontario, Canada</font></div><div style="padding-left:0.02pt;padding-right:2.17pt"><font><br></font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner, Maverix Private Equity</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,632</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">)</font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.01%)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">114</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name, Municipality of Residence and Position Held</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupation for the Past Five Years</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Appointed to Position Held</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number and Percentage of Securities Beneficially Owned or Controlled</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mark Lawson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Toronto, Ontario, Canada</font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Growth Officer, Invert Inc.<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managing Partner, Clermont Capital Partners</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2020</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,026</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(14)</font></div><div style="margin-bottom:1.5pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.01%)</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">George Tziras</font></div><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">London, United Kingdom</font></div><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:2.17pt"><font><br></font></div><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:2.17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director and Chief Business Officer</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Business Officer, Cybin</font></div><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font><br></font></div><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer and Chief Business Officer, Small Pharma Ltd.</font></div><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font><br></font></div><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Director, Goldman Sachs International</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,072</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(15)</font></div><div style="margin-top:2.15pt;padding-left:0.02pt;padding-right:0.02pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.15%)</font></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Notes&#58;</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Member of the Audit Committee.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Member of the Compensation Committee.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Member of Governance and Nominating Committee.</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Lead independent director</font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Excludes 225,501 Options to acquire 225,501 Common Shares.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;Excludes 69,079 Options to acquire 69,079 Common Shares.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7) &#160;&#160;&#160;&#160;Excludes 80,395 Options to acquire 80,395 Common Shares. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)&#160;&#160;&#160;&#160;Excludes 70,132 Options to acquire 70,132 Common Shares.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)&#160;&#160;&#160;&#160;Excludes 105,263 Warrants to acquire 105,263 Common Shares and 791,421 Options to acquire 791,421 Common Shares.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)&#160;&#160;&#160;&#160;Excludes 105,264 Warrants to acquire 105,263 Common Shares and 791,421 Options to acquire 791,421 Common Shares. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(11)&#160;&#160;&#160;&#160;Excludes 30,000 Options to acquire 30,000 Common Shares. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12)&#160;&#160;&#160;&#160;Excludes 30,000 Options to acquire 30,000 Common Shares and 19,737 Warrants to acquire 19,737 Common Shares.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(13)&#160;&#160;&#160;&#160;Excludes 30,000 Options to acquire 30,000 Common Shares and 30,263 Warrants to acquire 30,263 Common Shares.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(14)&#160;&#160;&#160;&#160;Excludes 30,789 Options to acquire 30,789 Common Shares. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(15)&#160;&#160;&#160;&#160;Excludes 39,474 Options to acquire 39,474 Common Shares.</font></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of the date of this AIF, all promoters, directors, officers and insiders, as a group, beneficially own, directly or indirectly, an aggregate of 697,950 Common Shares on a non-diluted basis, representing 3.03% of the Company&#8217;s capitalization on a fully diluted basis. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Board of Directors &#38; Management </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Douglas Drysdale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Chief Executive Officer, Age 54</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Douglas Drysdale is the Chief Executive Officer of the Company. Mr. Drysdale has more than 30 years of experience in the health care sector. As a skillful corporate director, in early 2014, Mr. Drysdale led the recapitalization of a NASDAQ-listed pharmaceutical company, Pernix Therapeutics Inc., raising $65 million. Within the first year of taking the helm as Chairman and CEO, Mr. Drysdale rebuilt the management team and board of directors, and built a 220-person sales team, complete with supporting functions (marketing, sales training, sales operations, and analytics). Mr. Drysdale&#8217;s efforts grew the company&#8217;s enterprise value exponentially from $80 million to around $800 million. Under Mr. Drysdale&#8217;s leadership, the pharmaceutical company raised $465 million of capital. Mr. Drysdale was also the founding CEO of Alvogen in 2008, leading the company from inception through an expansion to 35 countries and revenues of approximately $500 million in 5 years.&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">115</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Earlier in his career, Mr. Drysdale served as Head of M&#38;A at Actavis Group, leading 15 corporate acquisitions across three continents, between 2004 and 2008, including a high-profile public hostile takeover attempt in Central Eastern Europe. Over this period, Mr. Drysdale raised approximately $3 billion of capital and managed lending syndicates, including over 25 banks, to fund its growth. Actavis was sold to Watson Pharmaceuticals in 2012 for &#8364;4.25 billion.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Greg Cavers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Chief Financial Officer, Age 55</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Greg Cavers has over 20 years&#8217; experience specializing in transforming and revitalizing corporate finance departments. Mr. Cavers has experience in service operations in varying stages of growth&#59; leading business unit start-ups, restructuring, system implementations and merger integrations while increasing profitability, minimizing risk and dedicated to meeting financial reporting, IFRS&#59; as well as regulatory reporting OSFI, MFDA requirements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Gabriel Fahel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Chief Legal Officer and Corporate Secretary, Age 50</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gabe Fahel brings extensive experience in corporate commercial matters and government relations with more than 25 years as counsel with law firms, private and public companies, and government and non-governmental organizations. Gabe has a broad range of experience managing multijurisdictional and multidisciplinary teams in fast-paced and politically charged environments. He has been engaged in complex and intractable areas of international law and advanced novel legal issues of law before every level of court in Canada, including the Supreme Court of Canada. Gabe is also a founding board member of PsyCan (The Canadian Psychedelic Businesses Association).</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Aaron Bartlone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Chief Operation Officer, Age 58</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Aaron Bartlone is an accomplished and highly regarded biopharmaceutical executive with an impressive track record of driving disruptive therapies to worldwide markets. Prior to joining the Company, Aaron served UCB for 12 years as Senior Vice President of Quality Assurance, Patient Safety and Enterprise Risk Management, where he delivered functional results, clinical pipeline progression and regulatory marketing approvals for products in neurology, gastroenterology and immunology. Aaron also served as President of the US Commercial Operations where he delivered double-digit growth on a +US$2 billion P&#38;L while concurrently restructuring the business units and supporting compliance infrastructure. Before UCB, Aaron spent 14 years with Eli Lilly &#38; Company across a myriad of US and global roles spanning Quality Assurance, Regulatory Affairs and CMC Product Development, where he drove successful neurology, oncology, diabetes, and cardiovascular drug candidates and combination products through the clinical phases to global markets. Aaron holds a bachelor&#8217;s degree in Chemistry &#38; Mathematics from Youngstown State University and a master&#8217;s degree in Analytical Chemistry from the University of Notre Dame. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Paul Glavine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Director and Chief Growth Officer, Age 36</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Paul Glavine is a Co-founder, the Chief Growth Officer, and a Director of the Company, with extensive expertise as a serial entrepreneur and investor in the biotech and life sciences sectors. As the founding CEO of Cybin, he has been instrumental in advancing psychedelic therapeutics. Additionally, he co-founded Truverra, which focuses on cannabinoid-based therapies for pain management, which was acquired by Supreme Cannabis Company. Over the past six years, Paul has successfully raised and completed financings and mergers &#38; acquisitions totaling over $450 million.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">116</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Eric So</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Director and President, Age 49</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Eric So is a veteran founder and operator of various public and private companies over the last 20 years and has led corporate strategy, development and finance at all stages of the business life cycle from start-up to high growth and large multi-national.&#160;A trusted advisor he began his career practicing in the areas of corporate commercial, securities, finance and mergers and acquisitions at a leading international law firm.&#160;He has focused on sectors which have profound global impact in critical areas such as mental health and addiction.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">George Tziras</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Chief Business Officer, Age 44</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mr. Tziras has over 15 years of experience in investment banking and international capital markets having worked at a number of global financial institutions including Goldman Sachs, Credit Suisse, Nomura, Lehman Brothers and CIBC. Mr. Tziras has worked on a broad range of transactions including debt and equity financings&#59; mergers, disposals and acquisitions&#59; private equity buyouts and debt restructurings. He has also worked across a number of industries, including healthcare. Mr. Tziras holds a BA degree from the University of Oxford and a MA degree from Johns Hopkins.&#160;Mr. Tziras Joined Small Pharma Inc in 2021 as Chief Business Officer and on July 20, 2022, transitioned to Chief Executive Officer of Small Pharma Inc until it was acquired by the Company on October 23, 2023. Mr. Tziras has been a director of Small Pharma Ltd (now renamed to Cybin UK Ltd.) since 2015. Mr Tziras joined Cybin on October 24, 2023 as a Director and Chief Business Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Theresa Firestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Director, Age 69</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ms. Theresa Firestone is a senior healthcare executive with over 35 years&#8217; experience in pharmaceuticals, health &#38; wellness and government and has extensive P&#38;L, strategy development and operations expertise. Ms. Firestone has held executive leadership positions in Canada, Europe and Asia and led teams in 15 different countries. Prior to retirement in 2021, she was Senior Vice President, Health and Wellness at Shoppers Drug Mart (SDM), Canada&#8217;s largest retail pharmacy chain. Prior to Shoppers, Ms. Firestone was Regional President of Emerging Markets Asia with Pfizer Inc (Shanghai and HK). She was also General Manager of the Established Products Business Unit, Pfizer Canada, Country Manager, Pfizer Austria, VP Sales and VP of Government Affairs with Pfizer Canada. She currently sits on the Board of Aurora and a number of private&#160;boards&#160;including&#160;Apotex, Orion Biotechnology and Prollenium Medical Technologies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Grant Froese</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Director, Age 63</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Grant Froese completed a 38-year career with Canadian retail giant Loblaw Companies Limited where he last served as Chief Operating Officer until his retirement. During his career at Loblaw, he led operations, merchandising and had oversight of supply chain, ecommerce, and marketing functions. After retirement Grant was the CEO of Harvest One &#47; Delivra Health Brands until 2020. &#160;Currently, Grant is the principal consultant at Grey Wolf Management Services Inc. and sits on the board of several companies. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Eric Hoskins</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Director, Age 64</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dr. Eric Hoskins is a Partner at Maverix Private Equity. He is the former Ontario Health Minister (2014-2018) responsible for one of the largest health care systems in North America. He is a former elected Member of Ontario Provincial Parliament holding Cabinet positions in Health, Economic </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">117</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Development and Trade, Children and Youth Services, and Immigration. Dr. Hoskins is a physician and public health specialist with more than thirty years&#8217; experience in health care and public policy.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Mark Lawson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Director, Age 52</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mark Lawson is a private equity and investment banking executive with over 20 years of experience in Canada, the United States, and in the emerging markets. He is currently the Head of Carbon Acquisition for Invert, a company that funds global carbon reduction and removal projects. From 2009 to 2023 Mr. Lawson was the Managing Partner of Clermont Capital Partners, a Toronto based merchant bank and advisory firm focused on the technology and healthcare sectors. From 2004 to 2008 he was an investment banker with Morgan Stanley in New York, where he was involved in the execution of over $6 billion worth of mergers and acquisitions, $8 billion worth of debt offerings and $500 million of equity financings in the healthcare, technology, and telecom sectors. Mr. Lawson is also currently a director of various publicly traded companies in North America. Mr. Lawson received his Bachelor of Arts in Statistical Sciences from The University of Western Ontario, Canada and his MBA from The Richard Ivey School of Business, University of Western Ontario, Canada. Mr. Lawson is a member of the Economic Club of New York and is a Director of the Hugh and Ilene Lawson Charitable Organization.</font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_43"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CEASE TRADE ORDERS, BANKRUPTCIES, PENALTIES OR SANCTIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except as disclosed below, no director or executive officer of the Company is, as at the date of this AIF, or has been within the last ten years, a director, chief executive officer or chief financial officer of any company (including the Company) that&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;was subject to a cease trade order, an order similar to a cease trade order, or an order that denied the relevant company access to any exemption under securities legislation, and which in all cases was in effect for a period of more than 30 consecutive days (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), which Order was issued while the director or executive officer was acting in the capacity as director, chief executive officer or chief financial officer of such company&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;was subject to an Order that was issued after the director or executive officer ceased to be a director, chief executive officer or chief financial officer and which resulted from an event that occurred while that person was acting in the capacity as director, chief executive officer or chief financial officer of such company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To the knowledge of the Company, no director or executive officer of the Company or any shareholder holding a sufficient number of Common Shares to affect materially the control of the Company&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;is, as at the date of this AIF, or has been within the last ten years, a director or executive officer of any company (including the Company) that, while that person was acting in that capacity, or within a year of that person ceasing to act in that capacity, became bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;has, within the last ten years, become bankrupt, made a proposal under any legislation relating to bankruptcy or insolvency or become subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold his assets&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">118</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;has been subject to any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;has been subject to any penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable investor in making an investment decision regarding the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Greg Cavers was the interim Chief Financial Officer of LottoGopher Holdings Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LottoGopher</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), a CSE-listed company, until January 2020. Preceding his position, LottoGopher had been subject to a cease trade order on December 5, 2018 for failing to file interim financial report, management&#8217;s discussion and analysis and certification of the filings pursuant to NI 52-109.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The foregoing information, not being within the knowledge of the Company, has been furnished by the respective directors and executive officers.</font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_46"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONFLICTS OF INTEREST</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To the best of the Company&#8217;s knowledge, other than as disclosed herein, there are no known existing or potential material conflicts of interest between the Company and any directors or officers of the Company, except that certain of the directors and officers serve as directors, officers, promoters and members of management of other public companies and therefore it is possible that a conflict may arise between their duties as a director or officer of the Company and their duties as a director, officer, promoter or member of management of such other companies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The directors and officers of the Company are aware of the existence of laws governing accountability of directors and officers for corporate opportunity and requiring disclosures by directors of conflicts of interest and the Company will rely upon such laws in respect of any directors and officers&#8217; conflicts of interest or in respect of any breaches of duty by any of its directors or officers. All such conflicts will be disclosed by such directors or officers in accordance with the OBCA and they will govern themselves in respect thereof to the best of their ability in accordance with the obligations imposed upon them by law.</font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_49"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LEGAL PROCEEDINGS AND REGULATORY ACTIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To the Company&#8217;s knowledge, there are no legal proceedings or regulatory actions material to the Company to which it is a party, or has been a party to, or of which any of its property is or was the subject matter, and no such proceedings or actions are known by the Company to be contemplated.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There have been no penalties or sanctions imposed against the Company by a court or regulatory authority, and the Company has not entered into any settlement agreements before any court relating to provincial or territorial securities legislation, or with any securities regulatory authority, in the three years prior to the date of this AIF.</font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_52"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other than as disclosed below, and elsewhere in this AIF, no director, executive officer or unitholder or shareholder that beneficially owns, or controls or directs, directly or indirectly, more than 10% of the voting securities of the Company, or any of their respective Associates or affiliates, has any material interest, direct or indirect, in any transaction within the three years before the date of this AIF which has </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">119</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">materially affected or is reasonably expected to materially affect the Company or a subsidiary of the Company.</font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_55"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AUDITOR, TRANSFER AGENT AND REGISTRAR</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Odyssey Trust Company, at its Calgary, Alberta office, acts as the Company&#8217;s transfer agent and registrar and Zeifmans LLP, at its Toronto, Ontario office, acts as the Company&#8217;s auditor. </font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_58"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MATERIAL CONTRACTS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Material contracts of the Company, other than contracts entered into in the ordinary course of business, that were entered into within the last financial year or before the last financial year but are still in effect&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Contribution Agreement&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b) &#160;&#160;&#160;&#160;Support Agreement&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Warrant Indenture&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;LPC Purchase Agreement&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Arrangement Agreement&#59;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;March 2024 Agency Agreement&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;2025 Distribution Agreement&#59; </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;Securities Purchase Agreement&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Registration Rights Agreement</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company&#8217;s material contracts described above are filed under the Company&#8217;s profile on SEDAR+ at www.sedarplus.ca. </font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_61"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INTERESTS OF EXPERTS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No person or corporation whose profession or business gives authority to a statement made by the person or corporation and who is named as having prepared or certified a part of this AIF or as having prepared or certified a report or valuation described or included in this AIF holds any beneficial interest, direct or indirect, in any securities or property of the Company or of an Associate or affiliate of the Company and no such person is expected to be elected, appointed or employed as a director, senior officer or employee of the Company or of an Associate or affiliate of the Company and no such person is a promoter of the Company or an Associate or affiliate of the Company. Zeifmans LLP is independent of the Company in accordance with the rules of professional conduct of the Institute of Chartered Professional Accountants of Ontario.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_64"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AUDIT COMMITTEE</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Audit Committee&#8217;s Charter</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The charter (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Charter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) of the Company&#8217;s Audit Committee is reproduced as Exhibit &#8220;A&#8221;.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Composition of Audit Committee</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As at the date of this AIF, the Audit Committee is composed of Mark Lawson (Chair), Eric Hoskins, Theresa Firestone and Grant Froese, each of whom is a director of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">120</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All of the members of the Audit Committee are &#8220;independent&#8221; as such term is defined in NI 52-110. The Company is of the opinion that all three members of the Audit Committee are &#8220;financially literate&#8221; as such term is defined in NI 52-110.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Relevant Education and Experience</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All the members of the Audit Committee have the education and&#47;or practical experience required to understand and evaluate financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of issues that can reasonably be expected to be raised by the Company&#8217;s financial statements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Mark Lawson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; Mr. Lawson was previously an investment banker with Morgan Stanley in New York where he was involved in the execution of over $6 billion worth of mergers and acquisitions, $8 billion worth of debt offerings and $500 million of equity financings in the healthcare, energy, technology, and media &#38; telecom sector. He received his Bachelor of Arts in Statistical Sciences from The University of Western Ontario, Canada, and his MBA in Finance from&#160;The Richard Ivey School of Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;University of Western Ontario, Canada. Mr. Lawson was previously the Chief Financial Officer of a TSX Venture listed company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Eric Hoskins</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; Dr. Hoskins served as the Minister of Health for Ontario for 4 years and was responsible for creating, overseeing and administering a $55 billion budget. He was also a member of the Ontario government Cabinet for ten years regularly reviewing and commenting on budgets and financial statements. Dr. Hoskins was the Chief Financial Officer of War Child Canada, a $20 million charity, for 8 years. Dr Hoskins is currently on the audit committee of Canada Health Infowa. He also has a degree in Health Economics and a ICD.D (Institute for Corporate Directors) diploma from the Rotman School of Management.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Theresa Firestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; Ms. Firestone is a senior healthcare executive with over 35 years experience in pharmaceuticals, health &#38; wellness and government and has extensive P&#38;L, strategy development and operations expertise. Ms. Firestone has held executive leadership positions in Canada, Europe and Asia and led teams in 15 different countries. Prior to retirement in 2021, she was Senior Vice President, Health and Wellness at Shoppers Drug Mart (SDM), Canada&#8217;s largest retail pharmacy chain. Ms Firestone is and has been a member of audit committees in public and private companies for a number of years and has had overall responsibility for numerous complex businesses including P&#38;Ls, in Canada, Europe and Asia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Grant Froese</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; Mr. Froese had a 38-year career with retail giant Loblaw Companies Limited, including 3 years as Chief Operating Officer responsible for all levels of operations and merchandising, as well as oversight of information technology, supply chain, digital&#47;e-commerce, marketing and industry-leading control brands. In his capacity as Chief Operating Officer, Mr. Froese was responsible for financial budgeting, operational P&#47;L and annual revenues of approximately $30 million. Mr. Froese served as Chief Executive Officer of Harvest One Cannabis Inc., where he was responsible for oversight of all aspects of the company&#8217;s production, operations and financial matters including, the review and approval of quarterly and annual financial statements, AIF, MD&#38;A, and related corporate disclosures.&#160;Mr. Froese has a Diploma in Business Administration.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">121</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Audit Committee Oversight</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At no time since the commencement of the Company&#8217;s most recently completed financial year have any recommendations by the Audit Committee respecting the nomination and&#47;or compensation of the Company&#8217;s external auditors not been adopted by the board of directors.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pre-Approval Policies and Procedures</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the terms of the Audit Committee Charter, the Audit Committee shall pre-approve all non-audit services to be provided to the Company or its subsidiary entities by the Company&#8217;s external auditor.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">External Auditor Service Fees (By Category) </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The aggregate fees billed by the Company&#8217;s external auditors during the financial years ended March 31, 2025 and March 31, 2024 were as follows&#58; </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Period Ending</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Audit Fees ($)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Audit Related Fees ($)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Tax Fees ($)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">All Other Fees ($)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$405,725</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$73,746</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$380,611</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1.01pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$30,100</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Notes&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;&#8220;Audit Fees&#8221; includes fees necessary to perform the annual audit of the Company&#8217;s financial statements. These services include reviewing interim financial statements and disclosure documents related to financings and other attest services required by legislation or regulation, such as comfort letters, consents, reviews of securities filings and statutory audits.  &#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;&#8220;Audit-Related Fees&#8221; include services that are traditionally performed by the auditor.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;&#8220;Tax Fees&#8221; include fees for all tax services other than those included in &#8220;Audit Fees&#8221; and &#8220;Audit-Related Fees&#8221;. This category includes fees for tax compliance, tax planning and tax advice. Tax planning and tax advice includes assistance with tax audits and appeals, tax advice related to mergers and acquisitions, and requests for rulings or technical advice from tax authorities.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;&#8220;All Other Fees&#8221; include all other non-audit services, the aggregate fees billed for products and services, other than the services reported under notes (1), (2) and (3) above.</font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_67"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">COMPLIANCE PROGRAM</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company oversees and monitors compliance with applicable laws in each jurisdiction in which it operates. In addition to the Company&#8217;s senior executives and the employees responsible for overseeing compliance, the Company has local counsel engaged in every jurisdiction in which it operates and has received legal opinions or advice in each of these jurisdiction regarding (a) compliance with applicable regulatory frameworks, and (b) potential exposure to, and implications arising from, applicable laws in jurisdictions where the Company has operations or intends to operate. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company works with third parties who require regulatory licensing in order to handle scheduled drugs.&#160;The Company continuously updates its compliance and channel programs to maintain regulatory standards set for drug development.&#160;The Company also works with clinical research organizations who maintain batch records and data storage for the Company&#8217;s clinical programs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, the Company has established a Medical &#38; Clinical Advisory Team, a Research, Clinical and Regulatory Team and a Government Relations and Communications Team with cross-functional </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">122</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expertise in business, neuroscience, pharmaceuticals, mental health and psychedelics to advise management. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In conjunction with the Company&#8217;s human resources and operations departments, the Company oversees and implements training on the Company&#8217;s protocols. The Company will continue to work closely with external counsel and other compliance experts, and is evaluating the engagement of one or more independent third party providers to further develop, enhance and improve its compliance and risk management and mitigation processes and procedures in furtherance of continued compliance with the laws of the jurisdictions in which the Company operates. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The programs currently in place include monitoring by executives of the Company to ensure that all operations materially conform to and comply with required laws, regulations and operating procedures. The Company is currently in compliance with the laws and regulations in all jurisdictions and the related licencing framework applicable to its business activities. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company and, to its knowledge, each of its third-party researchers, suppliers and manufacturers have not received any non-compliance, citations or notices of violation which may have an impact on the Company&#8217;s licences, business activities or operations. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company conducts due diligence on third-party researchers, medical professionals, clinics, cultivators, processors and others as applicable, with whom it engages. Such due diligence includes but is not limited to the review of necessary licenses and the regulatory framework enacted in the jurisdiction of operation. Further, the Company generally obtains, under its contractual arrangements, representations and warranties from such third parties pertaining to compliance with applicable licensing requirements and the regulatory framework enacted in the jurisdiction of operation.  </font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_70"></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INSIDER TRADING POLICY AND CODE OF ETHICS AND BUSINESS CONDUCT</font></div><div style="margin-bottom:0.1pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Insider Trading Policy </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has adopted an insider trading policy to set forth basic guidelines for trading in the Company&#8217;s securities (including, without limitation, its Common Shares) to avoid any situation that might have the potential to damage the Company&#8217;s reputation or which could constitute a violation of federal or provincial securities law by the Company, its officers, directors, employees, consultants, affiliates and certain family members of such individuals (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Insiders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Under this policy, Insiders are prohibited from trading in Common Shares and other securities on the basis of material, non-public information relating to the Company until after the information has been disclosed to the public or during a blackout period. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The obligation not to trade on inside information applies not only to the Insiders, but also to persons who obtain such information from Insiders and use it to their advantage. Thus, liability may be imposed upon the Company, its Insiders and also outsiders who are the source of leaks of material information not yet disclosed to the public and the leaks coincide with purchases or sales of the Company&#8217;s securities by such insiders, outsiders or by &#8220;tippees&#8221;. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In order to provide a degree of certainty as to when insider trading is permissible, the policy imposes mandatory blackout periods during the period commencing on the first day following the end of each fiscal quarter or year-end and ending at the close of business on the first trading day following the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">123</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">dissemination by the Company of such quarterly and annual results. In addition, no Insider is permitted to trade any securities of the Company until two trading days after the issuance of any news release in which material information is released to the public. The Company may, from time to time, issue a general blackout period for a specific or indefinite period covering Insiders or specific employees or groups. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The policy also outlines the Company&#8217;s reporting obligations for changes in Common Shares owned by Insiders as well as the penalties for violating such policy and applicable laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Code of Business Conduct </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has adopted a Code of Business Conduct (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The Code sets forth standards designed to reasonably deter wrongdoing, promote honest and ethical conduct, promote prompt internal reporting of violations of the Code and promote accountability. All personnel, in discharging their duties, must comply with applicable laws and regulations, the rules of the stock exchange(s) on which the Common Shares are listed as well as the Company&#8217;s internal policies. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Code sets the expectation that personnel learn about laws, rules and regulations that affect what they do at the Company, and raise any questions concerning the applicability, existence or interpretation of any law or regulation or conduct with their supervisor or the legal department of the Company. The Code prohibits personnel from making or participating in making any payments designed to cause or improperly influence the decisions of an individual, a company or a governmental official to act in a way that gives the Company or its personnel an advantage or soliciting, encouraging or actually receiving any bribe or other payment, contribution, gifts or favor that could influence your or another&#8217;s decision.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Code encourages personnel to report any actual or suspected fraud or securities law violations to the Chief Compliance Officer. The Code mandates a safe work environment and a no tolerance policy towards harassment and violence in the workplace. The Code provides guidance on avoiding conflicts of interest and acting in the best interest of the Company. The Code also outlines the requirements or personnel as it relates to disclosure of Company information, confidentiality and maintaining the integrity of the Company&#8217;s books and records and intellectual property. </font></div><div style="text-align:justify"><font><br></font></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_73"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ADDITIONAL INFORMATION</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additional information relating to the Company can be found under the Company&#8217;s profile on SEDAR+ at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.sedarplus.ca</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and on the Company&#8217;s website at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.cybin.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Additional information, including directors&#8217; and officers&#8217; remuneration and indebtedness, principal holders of the Company&#8217;s securities and securities authorized for issuance under equity compensation plans, will be contained in the Company&#8217;s information circular for its most recent annual meeting of shareholders. Additional financial information is provided in the Company&#8217;s consolidated financial statements for the most recently completed financial year and the related MD&#38;A.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">124</font></div><div style="text-align:center"><font><br></font></div></div></div><div id="if1a3b9b71ce54ff2b8fe30144be67c76_76"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT &#8220;A&#8221;<br>AUDIT COMMITTEE CHARTER</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CYBIN INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(the &#8220;Corporation&#8221;)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AUDIT COMMITTEE CHARTER</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Implemented pursuant to National Instrument 52-110 &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Audit Committees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">National Instrument 52-110 &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Audit Committees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Instrument</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) relating to the composition and function of audit committees was implemented for reporting issuers and, accordingly, applies to every CBOE Canada listed company, including the Corporation. The Instrument requires all affected issuers to have a written audit committee charter which must be disclosed, as stipulated by Form 52-110F2, in the management information circular of the Corporation wherein management solicits proxies from the security holders of the Corporation for the purpose of electing directors to the board of directors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Charter has been adopted by the board of directors in order to comply with the Instrument and to more properly define the role of the Committee in the oversight of the financial reporting process of the Corporation. Nothing in this Charter is intended to restrict the ability of the board of directors or Committee to alter or vary procedures in order to comply more fully with the Instrument, as amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Part 1</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Purpose&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The purpose of the Committee is to&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;improve the quality of the Corporation&#8217;s financial reporting&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;assist the board of directors to properly and fully discharge its responsibilities&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;provide an avenue of enhanced communication between the directors and external auditors&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;enhance the external auditor&#8217;s independence&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;increase the credibility and objectivity of financial reports&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;strengthen the role of the directors by facilitating in depth discussions between directors, management and external auditors.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Definitions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">accounting principles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to it in National Instrument 52-107 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Acceptable Accounting Principles and Auditing Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A-1</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a Corporation that is a subsidiary of another Corporation or companies that are controlled by the same entity&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">audit services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the professional services rendered by the Corporation&#8217;s external auditor for the audit and review of the Corporation&#8217;s financial statements or services that are normally provided by the external auditor in connection with statutory and regulatory filings or engagements&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Charter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means this audit committee charter&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the committee established by and among certain members of the board of directors for the purpose of overseeing the accounting and financial reporting processes of the Corporation and audits of the financial statements of the Corporation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Control Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any individual or company that holds or is one of a combination of individuals or companies that holds a sufficient number of any of the securities of the Corporation so as to affect materially the control of the Corporation, or that holds more than 20% of the outstanding voting shares of the Corporation except where there is evidence showing that the holder of those securities does not materially affect the control of the Corporation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">financially literate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Section 1.2&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">immediate family member</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an individual&#8217;s spouse, parent, child, sibling, mother or father-in-law, son or daughter-in-law, brother or sister-in-law, and anyone (other than an employee of either the individual or the individual&#8217;s immediate family member) who shares the individual&#8217;s home&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;independent&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> means independent only as determined by both the Instrument and the CBOE Canada Listing Manual&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Instrument</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means National Instrument 52-110 &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Audit Committees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MD&#38;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning ascribed to it in National Instrument 51-102&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Member</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a member of the Committee&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">National Instrument 51-102</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means National Instrument 51-102 - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Continuous Disclosure Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">non-audit services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means services other than audit services.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt">Meaning of Financially Literate</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the purposes of this Charter, an individual is financially literate if he or she has the ability to read and understand a set of financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by the Corporation&#8217;s financial statements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A-2</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Part 2</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.1 &#160;&#160;&#160;&#160;Audit Committee</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The board of directors has hereby established the Committee for, among other purposes, compliance with the Instrument.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.2&#160;&#160;&#160;&#160;Relationship with External Auditors</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Corporation will require its external auditor to report directly to the Committee and the Members shall ensure that such is the case.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.3&#160;&#160;&#160;&#160;Committee Responsibilities</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">The Committee shall be responsible for making the following recommendations to the board of directors&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">the external auditor to be nominated for the purpose of preparing or issuing an auditor&#8217;s report or performing other audit, review or attest services for the Corporation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">the compensation of the external auditor.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">The Committee shall be directly responsible for overseeing the work of the external auditor engaged for the purpose of preparing or issuing an auditor&#8217;s report or performing other audit, review or attest services for the Corporation, including the resolution of disagreements between management and the external auditor regarding financial reporting. This responsibility shall include&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">reviewing the audit plan with management and the external auditor&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">reviewing with management and the external auditor any proposed changes in major accounting policies, the presentation and impact of significant risks and uncertainties, and key estimates and judgements of management that may be material to financial reporting&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">questioning management and the external auditor regarding significant financial reporting issues discussed during the fiscal period and the method of resolution&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">reviewing any problems experienced by the external auditor in performing the audit, including any restrictions imposed by management or significant accounting issues on which there was a disagreement with management&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">reviewing audited annual financial statements, in conjunction with the report of the external auditor, and obtaining an explanation from management of all significant variances between comparative reporting periods&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.02pt">reviewing the post-audit or management letter, containing the recommendations of the external auditor, and management&#8217;s response and subsequent follow up to any identified weakness&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">reviewing interim unaudited financial statements before release to the public&#59;</font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A-3</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">reviewing all public disclosure documents containing audited or unaudited financial information before release, including any prospectus, the annual report and management&#8217;s discussion and analysis&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">reviewing the evaluation of internal controls by the external auditor, together with management&#8217;s response&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">reviewing the terms of reference of the internal auditor, if any&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">reviewing the reports issued by the internal auditor, if any, and management&#8217;s response and subsequent follow up to any identified weaknesses&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:25.63pt">reviewing the appointments of the chief financial officer and any key financial executives involved in the financial reporting process, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">The Committee shall pre-approve all non-audit services to be provided to the Corporation or its subsidiary entities by the issuer&#8217;s external auditor.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">The Committee shall review the Corporation&#8217;s financial statements, MD&#38;A, and annual and interim earnings press releases before the Corporation publicly discloses this information.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">The Committee shall ensure that adequate procedures are in place for the review of the Corporation&#8217;s public disclosure of financial information extracted or derived from the Corporation&#8217;s financial statements, and shall periodically assess the adequacy of those procedures.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">When there is to be a change of auditor, the Committee shall review all issues related to the change, including the information to be included in the notice of change of auditor called for under National Instrument 51-102, and the planned steps for an orderly transition.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">The Committee shall review all reportable events, including disagreements, unresolved issues and consultations, as defined in National Instrument 51-102, on a routine basis, whether or not there is to be a change of auditor.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">The Committee shall, as applicable, establish procedures for&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">the receipt, retention and treatment of complaints received by the issuer regarding accounting, internal accounting controls, or auditing matters&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">the confidential, anonymous submission by employees of the issuer of concerns regarding questionable accounting or auditing matters.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">As applicable, the Committee shall establish, periodically review and approve the Corporation&#8217;s hiring policies regarding partners, employees and former partners and employees of the present and former external auditor of the issuer.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:22.25pt">The responsibilities outlined in this Charter are not intended to be exhaustive. Members should consider any additional areas which may require oversight when discharging their responsibilities.</font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A-4</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.4&#160;&#160;&#160;&#160;De Minimis Non-Audit Services</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Committee shall satisfy the pre-approval requirement in subsection (2.3(3)) if&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">the aggregate amount of all the non-audit services that were not pre-approved is reasonably expected to constitute no more than five per cent of the total amount of fees paid by the issuer and its subsidiary entities to the issuer&#8217;s external auditor during the financial year in which the services are provided&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">the Corporation or the subsidiary of the Corporation, as the case may be, did not recognize the services as non-audit services at the time of the engagement&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">the services are promptly brought to the attention of the Committee and approved by the Committee or by one or more of its Members to whom authority to grant such approvals has been delegated by the Committee, prior to the completion of the audit.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.5&#160;&#160;&#160;&#160;Delegation of Pre-Approval Function</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">The Committee may delegate to one or more independent Members the authority to pre-approve non-audit services in satisfaction of the requirement in subsection (2.3(3)).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">The pre-approval of non-audit services by any Member to whom authority has been delegated pursuant to subsection (2.5(1)) must be presented to the Committee at its first scheduled meeting following such pre-approval.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Part 3</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.1&#160;&#160;&#160;&#160;Composition</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">The Committee shall be composed of a minimum of three Members.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">Every Member shall be a director of the issuer.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">Every Member shall be independent.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">Every Member shall be financially literate.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">The board of directors of the Corporation shall appoint or re-appoint the Members after each annual meeting of shareholders of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Part 4</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.1&#160;&#160;&#160;&#160;Authority</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Until the replacement of this Charter, the Committee shall have the authority to&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">engage independent counsel and other advisors as it determines necessary to carry out its duties&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">set and pay the compensation for any advisors employed by the Committee&#59;</font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A-5</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;padding-left:5.75pt;padding-right:5.75pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.8pt">communicate directly with the internal and external auditors&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:23.18pt">recommend the amendment or approval of audited and interim financial statements to the board of directors.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Part 5</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.1&#160;&#160;&#160;&#160;Required Disclosure</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Corporation must include in its Annual Information Form the disclosure required by Form 52-110F1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.2&#160;&#160;&#160;&#160;Disclosure in Information Circular</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If management of the Corporation solicits proxies from the security holders of the Corporation for the purpose of electing directors to the board of directors, the Corporation shall include in its management information circular a cross-reference to the sections in the Corporation&#8217;s Annual Information Form that contain the information required by section 5.1.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Part 6</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.1 &#160;&#160;&#160;&#160;Meetings</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">Meetings of the Committee shall be scheduled to take place at regular intervals and, in any event, not less frequently than quarterly.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">Opportunities shall be afforded periodically to the external auditor, the internal auditor and to members of senior management to meet separately with the Members.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:27.75pt">Minutes shall be kept of all meetings of the Committee.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A-6</font></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>cybn-20250331.htm
<DESCRIPTION>EX-99.2
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:517b8eb5-c396-4287-8f5e-af5641b4b385,g:1e9b6c9c-673a-419d-ac9f-76e5a6c29d23,d:f8fb0108db0244bfbc2227aa1b3f68fe-->
<html xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:cybn="http://cybin.com/20250331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cybn-20250331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="cybn:NumberOfCommonSharePurchaseWarrants" id="f-969">0.5</ix:nonFraction><ix:nonNumeric contextRef="c-426" name="cybn:DebtInstrumentConvertibleDebentureThresholdTradingDays" id="f-1169">P5D</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-1209">0001833141</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-1210">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-1211">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-1212">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cybn-20250331.xsd"/></ix:references><ix:resources><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:unit id="cadPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="subsidiary"><xbrli:measure>cybn:subsidiary</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="patent_family"><xbrli:measure>cybn:patent_family</xbrli:measure></xbrli:unit><xbrli:unit id="application"><xbrli:measure>cybn:application</xbrli:measure></xbrli:unit><xbrli:unit id="patent"><xbrli:measure>cybn:patent</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="y"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit><xbrli:unit id="option"><xbrli:measure>cybn:option</xbrli:measure></xbrli:unit><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cybn:LPCPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cybn:LPCPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">cybn:CybinCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">cybn:JourneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">cybn:SerenityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">cybn:CybinUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">cybn:AdeliaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">cybn:CybinIRLLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">cybn:CybinUKLtd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cybn:SmallPharmaInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cybn:SmallPharmaInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cybn:SmallPharmaInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cybn:SmallPharmaInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-23</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:LPCPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:LPCPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-30</xbrli:startDate><xbrli:endDate>2023-05-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:LPCPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:LPCPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-30</xbrli:startDate><xbrli:endDate>2023-05-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-30</xbrli:startDate><xbrli:endDate>2023-05-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:LPCPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-04</xbrli:startDate><xbrli:endDate>2023-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:August2023CompensationCommonShareWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:August2023CompensationCommonShareWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-04</xbrli:startDate><xbrli:endDate>2023-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:November2023CompensationCommonShareWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-14</xbrli:startDate><xbrli:endDate>2023-11-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:November2023CompensationCommonShareWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:November2023CompensationCommonShareWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-04</xbrli:startDate><xbrli:endDate>2023-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-19</xbrli:startDate><xbrli:endDate>2024-03-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:March2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-19</xbrli:startDate><xbrli:endDate>2024-03-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:March2024PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-19</xbrli:startDate><xbrli:endDate>2024-03-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">cybn:ClassBSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">cybn:ClassBSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">cybn:ClassBSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">cybn:ClassBSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">cybn:ClassBSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:UnitPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:UnitPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:UnitPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:UnitPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:November2023CompensationCommonShareWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-14</xbrli:startDate><xbrli:endDate>2023-11-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:WarrantExpirationPeriodAxis">cybn:WarrantExpirationPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:WarrantExpirationPeriodAxis">cybn:WarrantExpirationPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:WarrantExpirationPeriodAxis">cybn:WarrantExpirationPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:WarrantExpirationPeriodAxis">cybn:WarrantExpirationPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:WarrantExpirationPeriodAxis">cybn:WarrantExpirationPeriodFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToOfficersAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-05</xbrli:startDate><xbrli:endDate>2024-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-05</xbrli:startDate><xbrli:endDate>2024-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-05</xbrli:startDate><xbrli:endDate>2024-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-05</xbrli:startDate><xbrli:endDate>2024-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-05</xbrli:startDate><xbrli:endDate>2024-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-05</xbrli:startDate><xbrli:endDate>2024-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-05</xbrli:startDate><xbrli:endDate>2024-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-05</xbrli:startDate><xbrli:endDate>2024-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-05</xbrli:startDate><xbrli:endDate>2024-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-05</xbrli:startDate><xbrli:endDate>2024-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-05</xbrli:startDate><xbrli:endDate>2024-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-05</xbrli:startDate><xbrli:endDate>2024-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-05</xbrli:startDate><xbrli:endDate>2024-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-15</xbrli:startDate><xbrli:endDate>2024-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-15</xbrli:startDate><xbrli:endDate>2024-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToOfficersAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-15</xbrli:startDate><xbrli:endDate>2024-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-15</xbrli:startDate><xbrli:endDate>2024-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-15</xbrli:startDate><xbrli:endDate>2024-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-15</xbrli:startDate><xbrli:endDate>2024-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-15</xbrli:startDate><xbrli:endDate>2024-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-15</xbrli:startDate><xbrli:endDate>2024-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-27</xbrli:startDate><xbrli:endDate>2024-11-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-27</xbrli:startDate><xbrli:endDate>2024-11-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-27</xbrli:startDate><xbrli:endDate>2024-11-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-27</xbrli:startDate><xbrli:endDate>2024-11-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-27</xbrli:startDate><xbrli:endDate>2024-11-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-27</xbrli:startDate><xbrli:endDate>2024-11-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-27</xbrli:startDate><xbrli:endDate>2024-11-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-27</xbrli:startDate><xbrli:endDate>2024-11-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-07</xbrli:startDate><xbrli:endDate>2025-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-07</xbrli:startDate><xbrli:endDate>2025-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-07</xbrli:startDate><xbrli:endDate>2025-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-07</xbrli:startDate><xbrli:endDate>2025-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-29</xbrli:startDate><xbrli:endDate>2023-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-29</xbrli:startDate><xbrli:endDate>2023-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-29</xbrli:startDate><xbrli:endDate>2023-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-29</xbrli:startDate><xbrli:endDate>2023-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-29</xbrli:startDate><xbrli:endDate>2023-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-29</xbrli:startDate><xbrli:endDate>2023-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-29</xbrli:startDate><xbrli:endDate>2023-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingThirdTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingThirdTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-29</xbrli:startDate><xbrli:endDate>2023-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFourthTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFourthTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-29</xbrli:startDate><xbrli:endDate>2023-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-29</xbrli:startDate><xbrli:endDate>2023-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingThirdTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingThirdTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFourthTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFourthTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFifthTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFifthTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-16</xbrli:startDate><xbrli:endDate>2023-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-16</xbrli:startDate><xbrli:endDate>2023-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-16</xbrli:startDate><xbrli:endDate>2023-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-16</xbrli:startDate><xbrli:endDate>2023-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-16</xbrli:startDate><xbrli:endDate>2023-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySevenAndThirtyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-16</xbrli:startDate><xbrli:endDate>2023-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-16</xbrli:startDate><xbrli:endDate>2023-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-16</xbrli:startDate><xbrli:endDate>2023-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySevenAndThirtyEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySevenAndThirtyEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySevenAndThirtyEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-16</xbrli:startDate><xbrli:endDate>2023-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySevenAndThirtyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-16</xbrli:startDate><xbrli:endDate>2023-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-16</xbrli:startDate><xbrli:endDate>2023-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-20</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-20</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-20</xbrli:startDate><xbrli:endDate>2024-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodSixteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodSixteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodSeventeenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodSeventeenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodEighteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodEighteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:ShareBasedPaymentArrangementOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:ShareBasedPaymentArrangementOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:IncomeStatementLocationAxis">cybn:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:IncomeStatementLocationAxis">cybn:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:IncomeStatementLocationAxis">cybn:ResearchComponentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cybn:IncomeStatementLocationAxis">cybn:ResearchComponentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ItemsOfContingentLiabilitiesAxis">ifrs-full:OtherContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">cybn:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">cybn:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">cybn:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">cybn:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ClassesOfFinancialAssetsAndLiabilitiesAxis">cybn:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ClassesOfFinancialAssetsAndLiabilitiesAxis">cybn:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ClassesOfFinancialAssetsAndLiabilitiesAxis">cybn:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ClassesOfFinancialAssetsAndLiabilitiesAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ClassesOfFinancialAssetsAndLiabilitiesAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ClassesOfFinancialAssetsAndLiabilitiesAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ClassesOfFinancialAssetsAndLiabilitiesAxis">cybn:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ClassesOfFinancialAssetsAndLiabilitiesAxis">cybn:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ClassesOfFinancialAssetsAndLiabilitiesAxis">cybn:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cybn:DeferredCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cybn:DeferredCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cybn:RDExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cybn:RDExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cybn:ShareIssuanceCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cybn:ShareIssuanceCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cybn:PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cybn:PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2042Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2042Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A20402041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2042Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ClassesOfDebtInstrumentsAxis">cybn:ConvertibleDebenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ClassesOfDebtInstrumentsAxis">cybn:ConvertibleDebenturePrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cybn:ClassesOfDebtInstrumentsAxis">cybn:ConvertibleDebenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-30</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001833141</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_1"></div><div style="min-height:126pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="cybn-20250331_g1.jpg" alt="Image_0.jpg" style="height:105px;margin-bottom:5pt;vertical-align:text-bottom;width:180px" id="i-1"/></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:24pt;font-weight:700;line-height:139%">CYBIN INC.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:139%">Consolidated Financial Statements </span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:139%">MARCH&#160;31, 2025 AND 2024</span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_4"></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Responsibility for Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Company&#8217;s management is responsible for the integrity and fairness of presentation of these consolidated financial statements. The consolidated financial statements have been prepared by management, in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, for approval by the Board of Directors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Where necessary, management has made judgements and estimates in preparing the consolidated financial statements and such statements have been prepared within acceptable limits of materiality. Management maintains a system of internal accounting controls to ensure, on a reasonable and cost-effective basis, that the financial information is timely reported and is accurate and reliable in all material respects and that the Company&#8217;s assets are appropriately accounted for and adequately safeguarded.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">A firm of independent Chartered Professional Accountants, <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-1">Zeifmans LLP</ix:nonNumeric>, appointed by the shareholders, audited the consolidated financial statements in accordance with Canadian generally accepted auditing standards and provided an independent professional opinion on the consolidated financial statements.</span></div><div><span><br/></span></div><div style="margin-top:20pt;padding-left:288pt;text-indent:-288pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">/s/ Doug Drysdale</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Chief Executive Officer                                              </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">June&#160;30, 2025</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_722"></div><hr style="page-break-after:always"/><div style="min-height:81.36pt;width:100%"><div><img src="cybn-20250331_g2.jpg" alt="ziefmans.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:162px" id="i-2"/></div><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">INDEPENDENT AUDITORS&#8217; REPORT</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders of Cybin Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the consolidated financial statements of Cybin Inc. and its subsidiaries (together, the &#8220;Company&#8221;), which comprise the consolidated statements of financial position as at March 31, 2025 and 2024, and the consolidated statements of loss and comprehensive loss, changes in shareholders&#8217; equity and cash flows for the years then ended, and notes to the consolidated financial statements, including material accounting policy information. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as at March 31, 2025 and 2024 and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with IFRS Accounting Standards  as issued by the International Accounting Standards Board (&#8220;IASB&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with Canadian generally accepted auditing standards (&#8220;GAAS&#8221;). Our responsibilities under those standards are further described in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Auditors&#8217; Responsibilities for the Audits of the Consolidated Financial Statements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audits of the consolidated financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Key Audit Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements as at and for the year ended March 31, 2025. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined the matter described below to be the key audit matter to be communicated in our report. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81.36pt;width:100%"><div><img src="cybn-20250331_g2.jpg" alt="ziefmans.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:162px" id="i-3"/></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#c5e0b3;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Key audit matter</span></td><td colspan="3" style="background-color:#c5e0b3;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:justify;vertical-align:top"><span style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">How are audit addressed the key audit matter</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><span style="color:#70ad47;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assessment of impairment of goodwill and intangible assets </span></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><span><br/></span></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Refer to note 2 &#8211; Material accounting policy information, note 6 - Intangible assets and note 8 - Goodwill </span></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><span><br/></span></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with IAS 36, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Assets, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management is required to test goodwill and intangible assets not yet available for use for impairment annually, or when facts and circumstances suggest they may be impaired. Goodwill arising from business combinations is allocated to each of the Company&#8217;s cash-generating units (&#8220;CGU&#8221;) that is expected to benefit from the synergies of the combination. The recoverable amount of the CGU to which the goodwill and intangible assets have been allocated is tested for impairment at the same time every year. As at March 31, 2025 the Company had goodwill of $51.5 million and intangible assets of $41.0 million before the impairment test. The annual impairment test has been performed as of March 31, 2025, and no impairment was recognized. </span></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><span><br/></span></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purpose of the impairment test, the recoverable amount of the Company&#8217;s CGU has been determined by management based on an assessment of its value in use following a discounted cash flow approach over a period of thirteen years. Management made certain assumptions in determining the cash flow projections based on its internally approved budgets and include management&#8217;s best estimates of expected market conditions. The future cash flows used in the model are inherently uncertain and could materially change over time as a result of changes to the key assumptions estimated by management including revenue growth, discount rate, terminal growth rate, costs, future tax, risk premiums applicable to the CGU&#8217;s operations and future capital expenditure. </span></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><span><br/></span></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We considered this a key audit matter due to the subjectivity and complexity in performing procedures to test the key assumptions used by management in determining the recoverable amount of the Company&#8217;s CGU, which involved significant judgment from management. </span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach to addressing the matter included the following procedures, among others:</span></div><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><span><br/></span></div><div style="padding-left:20.07pt;padding-right:2.77pt;text-align:justify;text-indent:-17.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We evaluated the appropriateness of the value-in-use and discounted cash flow forecast models;</span></div><div style="padding-left:20.07pt;padding-right:2.77pt;text-align:justify;text-indent:-17.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We reviewed the controls and methodology used to develop information for assessing the recoverable amount including the risk assessment process, and the nature and extent of oversight and governance over financial reporting;</span></div><div style="padding-left:20.07pt;padding-right:2.77pt;text-align:justify;text-indent:-17.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We evaluated the assumptions applied to key inputs, such as forecasted revenues, gross margin, operating expenses, long-term growth rates and discount rates used by management in the discounted cash flow forecast models and value-in-use determination;</span></div><div style="padding-left:20.07pt;padding-right:2.77pt;text-align:justify;text-indent:-17.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We performed a retrospective review to compare management&#8217;s assumptions in the prior year&#8217;s expected future cash flows to the actual result to assess the Company&#8217;s budgeting process;</span></div><div style="padding-left:20.07pt;padding-right:2.77pt;text-align:justify;text-indent:-17.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We tested the mathematical accuracy of management&#8217;s impairment model and supporting calculations;</span></div><div style="padding-left:20.07pt;padding-right:2.77pt;text-align:justify;text-indent:-17.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">With the assistance of a valuation specialist, we evaluated the reasonableness of the Company&#8217;s impairment model and the discount rates by comparing the Company&#8217;s weighted average cost of capital against publicly available market data; and </span></div><div style="padding-left:20.07pt;padding-right:2.77pt;text-align:justify;text-indent:-17.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We assessed the appropriateness of the disclosure of the assumptions used in the impairment assessment in the notes to the consolidated financial statements. </span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81.36pt;width:100%"><div><img src="cybn-20250331_g2.jpg" alt="ziefmans.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:162px" id="i-4"/></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Information </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for the other information. The other information comprises the information included in the Management Discussion and Analysis (&#8220;MD&amp;A&#8221;) but does not include the consolidated financial statements and our auditors&#8217; report thereon.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our opinion on the consolidated financial statements does not cover the MD&amp;A and we do not express any form of assurance conclusion thereon. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our audits of the consolidated financial statements, our responsibility is to read the MD&amp;A identified above and, in doing so, consider whether the MD&amp;A is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audits, or otherwise appears to be materially misstated. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained the MD&amp;A prior to the date of this auditors&#8217; report. If, based on the work we have performed on this MD&amp;A, we conclude that there is a material misstatement of this MD&amp;A, we are required to report that fact in this auditors&#8217; report. We have nothing to report in this regard. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with IFRS Accounting Standards as issued by the IASB, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements, management is responsible for assessing the Company&#8217;s ability to continue as a going concern, disclosing, as applicable, matters relating to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those charged with governance are responsible for overseeing the Company&#8217;s financial reporting process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Auditors&#8217; Responsibilities for the Audits of the Consolidated Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors&#8217; report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements. As part of an audit in accordance with GAAS, we exercise professional judgment and maintain professional skepticism throughout the audits. We also:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Obtain an understanding of internal control relevant to the audits in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the Company&#8217;s internal control. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81.36pt;width:100%"><div><img src="cybn-20250331_g2.jpg" alt="ziefmans.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:162px" id="i-5"/></div><div><span><br/></span></div></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Conclude on the appropriateness of management&#8217;s use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company&#8217;s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors&#8217; report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors&#8217; report. However, future events or conditions may cause the Company to cease to continue as a going concern. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%;padding-left:14.5pt">Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audits. We remain solely responsible for our audit opinion. </span></div><div style="margin-bottom:8pt;padding-left:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audits and significant audit findings, including any significant deficiencies in internal control that we identify during our audits. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors&#8217; report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The engagement partner on the audits resulting in this independent auditors&#8217; report is Laurence W. Zeifman, CPA, CA. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:right"><img src="cybn-20250331_g3.jpg" alt="Zeifmans Signature.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:192px" id="i-6"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-2">Toronto, Ontario</ix:nonNumeric>&#160;&#160;&#160;&#160;Chartered Professional Accountants</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2025&#160;&#160;&#160;&#160;Licensed Public Accountants</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                                                  <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-3">1149</ix:nonNumeric>  </span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_7"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC.  </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF FINANCIAL POSITION  </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars)</span></div></td></tr></table></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.735%"/><td style="width:0.1%"/></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:139%">As at</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Notes</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:139%">Current</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Cash</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="3" id="f-4">135,022</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="3" id="f-5">208,992</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Accounts receivable</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="f-6">5,885</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivables" format="ixt:num-dot-decimal" scale="3" id="f-7">4,476</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Prepaid expenses</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-8">22,156</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-9">2,891</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other current assets</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-10">2,909</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:OtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-11">2,177</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:3pt;font-weight:400;line-height:139%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Current Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-12">165,972</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-13">218,536</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:139%">Non-current</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Equipment </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">5</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-14">141</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-15">266</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Intangible assets </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">6</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-16">41,018</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-17">35,465</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Right-of-use asset </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">7</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-18">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-19">281</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Goodwill</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">8</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-20">51,487</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-21">47,475</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:3pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:3pt;font-weight:400;line-height:139%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Non-Current Assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-22">92,646</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-23">83,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d9d9d9;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL ASSETS</span></td><td colspan="3" style="background-color:#d9d9d9;padding:0 1pt"/><td colspan="2" style="background-color:#d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-24">258,618</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d9d9d9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-25">302,023</ix:nonFraction>&#160;</span></td><td style="background-color:#d9d9d9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:139%">Current</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Accounts payable and accrued liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-26">21,418</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-27">9,805</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">7</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-28">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="f-29"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="f-30">291</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total  Liabilities</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-31">21,418</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-32">10,096</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Share capital </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="f-33">464,364</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="f-34"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="f-35">443,877</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Contributed surplus</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="f-36">44,414</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="f-37"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="f-38">11,750</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Options reserve </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:ReserveOfSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-39">47,427</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:ReserveOfSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-40"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:ReserveOfSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-41">39,177</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Warrants reserve </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:WarrantReserve" format="ixt:num-dot-decimal" scale="3" id="f-42">27,594</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:WarrantReserve" format="ixt:num-dot-decimal" scale="3" id="f-43"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:WarrantReserve" format="ixt:num-dot-decimal" scale="3" id="f-44">25,639</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Accumulated other comprehensive loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:AccumulatedOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-45">7,231</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" sign="-" name="ifrs-full:AccumulatedOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-46"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" sign="-" name="ifrs-full:AccumulatedOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-47">2,285</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Deficit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-48">339,368</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-49">226,231</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:3pt;font-weight:400;line-height:139%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 3.77pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#d9d9d9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-50">237,200</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9d9d9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d9d9d9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-51">291,927</ix:nonFraction>&#160;</span></td><td style="background-color:#d9d9d9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#d9d9d9;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-52">258,618</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d9d9d9;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#d9d9d9;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-53">302,023</ix:nonFraction>&#160;</span></td><td style="background-color:#d9d9d9;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Corporate information (note 1); Contracts, commitments and contingencies (note 13); Subsequent events (note 17)</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">These consolidated financial statements were approved for issue on June&#160;30, 2025 by the board of directors and signed on its behalf by:</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">/s/ Paul Glavine</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">  Director&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;  </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">/s/ Eric So</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> Director</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_10"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts) </span></div></td></tr></table></div></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.735%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Notes</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EXPENSES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Research</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-54">54,910</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-55">32,362</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">General and administrative costs </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-56">45,368</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-57">32,588</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Share-based compensation </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-58">42,869</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-59">13,886</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL EXPENSES</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-60">143,147</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:OperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-61">78,836</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OTHER INCOME (EXPENSES)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Foreign currency translation gain</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-62">21,749</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" scale="3" id="f-63">137</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Interest income</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:RevenueFromInterest" format="ixt:num-dot-decimal" scale="3" id="f-64">8,289</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:RevenueFromInterest" scale="3" id="f-65">619</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Other loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:OtherExpenseByNature" scale="3" id="f-66">28</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:OtherExpenseByNature" format="ixt:fixed-zero" scale="3" id="f-67">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL OTHER INCOME</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:OtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-68">30,010</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:OtherIncome" scale="3" id="f-69">756</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NET LOSS FOR THE YEAR</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-70">113,137</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-71">78,080</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OTHER COMPREHENSIVE  LOSS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:9pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Foreign currency translation differences for foreign operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="f-72">4,946</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-73">250</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">COMPREHENSIVE LOSS FOR THE YEAR</span></td><td colspan="3" style="background-color:#d9d9d9;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-74">118,083</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-75">78,330</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic loss per share for the year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" id="f-76">5.59</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="c-5" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" id="f-77">9.41</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average number of common shares outstanding - basic</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" id="f-78">20,222,493</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" id="f-79">8,297,370</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_13"></div><hr style="page-break-after:always"/><div style="min-height:115.2pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC.</span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the years ended March 31, 2025 and 2024</span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share amounts)</span></div></td></tr></table></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.339%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.778%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reserves</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contributed surplus</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">#</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as at March 31, 2023</span></td><td colspan="3" style="background-color:#d9d9d9;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d9d9d9;border-top:1pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" id="f-80">5,279,846</ix:nonFraction></span></td><td colspan="3" style="background-color:#d9d9d9;border-top:1pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-6" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-81">158,162</ix:nonFraction></span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d9d9d9;border-top:1pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-82">10,873</ix:nonFraction></span></td><td colspan="3" style="background-color:#d9d9d9;border-top:1pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-83">27,283</ix:nonFraction></span></td><td colspan="3" style="background-color:#d9d9d9;border-top:1pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="cad" contextRef="c-9" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-84">2,102</ix:nonFraction></span></td><td colspan="3" style="background-color:#d9d9d9;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d9d9d9;border-top:1pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="cad" contextRef="c-10" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-85">148,151</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d9d9d9;border-top:1pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="cad" contextRef="c-11" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-86">2,035</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#d9d9d9;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#d9d9d9;border-top:1pt solid #000000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="cad" contextRef="c-12" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-87">48,234</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">At-the-market offering - net of share issuance costs</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="cybn:NumberOfSharesIssuedThroughShareOfferingEquity" format="ixt:num-dot-decimal" id="f-88">898,434</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-13" decimals="-3" name="cybn:IncreaseDecreaseThroughShareOfferingEquity" format="ixt:num-dot-decimal" scale="3" id="f-89">14,700</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:IncreaseDecreaseThroughShareOfferingEquity" format="ixt:num-dot-decimal" scale="3" id="f-90">14,700</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued through common share purchase agreement - net of share issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="cybn:NumberOfSharesIssuedNetOfIssuanceCosts" format="ixt:num-dot-decimal" id="f-91">11,572,858</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-13" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-92">217,311</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-14" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-93">22,442</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-94">239,753</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share issuance on business acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="cybn:NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity" format="ixt:num-dot-decimal" id="f-95">2,130,138</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-13" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary" format="ixt:num-dot-decimal" scale="3" id="f-96">53,481</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary" format="ixt:num-dot-decimal" scale="3" id="f-97">53,481</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common shares as commitment fee for future financing</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="cybn:NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing" format="ixt:num-dot-decimal" id="f-98">66,812</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued through LPC purchase  agreement - net of share issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="cybn:NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity" format="ixt:num-dot-decimal" id="f-99">50,658</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-15" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary" scale="3" id="f-100">147</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-16" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary" scale="3" id="f-101">147</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-17" decimals="-3" sign="-" name="cybn:IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity" format="ixt:num-dot-decimal" scale="3" id="f-102">1,992</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-18" decimals="-3" name="cybn:IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity" format="ixt:num-dot-decimal" scale="3" id="f-103">1,992</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity" format="ixt:fixed-zero" scale="3" id="f-104">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="cybn:NumberOfSharesIssuedThroughExerciseOfWarrantsEquity" format="ixt:num-dot-decimal" id="f-105">2,658</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-13" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="f-106">76</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-14" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="f-107">20</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="f-108">56</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Warrants expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-14" decimals="-3" sign="-" name="cybn:IncreaseDecreaseThroughExpirationOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="f-109">7,656</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-18" decimals="-3" name="cybn:IncreaseDecreaseThroughExpirationOfWarrantsEquity" format="ixt:num-dot-decimal" scale="3" id="f-110">7,656</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:IncreaseDecreaseThroughExpirationOfWarrantsEquity" format="ixt:fixed-zero" scale="3" id="f-111">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-17" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-112">13,886</ix:nonFraction></span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-113">13,886</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss  on translation of foreign operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-19" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-114">250</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-115">250</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Net loss for the year</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-20" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-116">78,080</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-117">78,080</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="0" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" id="f-118">20,001,404</ix:nonFraction></span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-21" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-119">443,877</ix:nonFraction></span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-22" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-120">25,639</ix:nonFraction></span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-23" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-121">39,177</ix:nonFraction></span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-24" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-122">11,750</ix:nonFraction></span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-25" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-123">226,231</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-26" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-124">2,285</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-125">291,927</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustment for fractional shares upon share consolidation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-27" decimals="0" name="cybn:IncreaseDecreaseThroughShareConsolidationEquity" id="f-126">2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">At-the-market offering - net of share issuance costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="cybn:NumberOfSharesIssuedThroughShareOfferingEquity" format="ixt:num-dot-decimal" id="f-127">1,609,298</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-27" decimals="-3" name="cybn:IncreaseDecreaseThroughShareOfferingEquity" format="ixt:num-dot-decimal" scale="3" id="f-128">20,983</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:IncreaseDecreaseThroughShareOfferingEquity" format="ixt:num-dot-decimal" scale="3" id="f-129">20,983</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share issuance costs</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-27" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-130">496</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-131">496</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Options forfeited/expired</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-28" decimals="-3" sign="-" name="cybn:IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity" format="ixt:num-dot-decimal" scale="3" id="f-132">32,664</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-29" decimals="-3" name="cybn:IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity" format="ixt:num-dot-decimal" scale="3" id="f-133">32,664</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity" format="ixt:fixed-zero" scale="3" id="f-134">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Share-based compensation</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-30" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-135">1,955</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-28" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-136">40,914</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-137">42,869</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Unrealized loss on translation of foreign operations</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-31" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="f-138">4,946</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" format="ixt:num-dot-decimal" scale="3" id="f-139">4,946</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Net loss for the year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-32" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-140">113,137</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-141">113,137</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.02pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as at March&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#d9d9d9;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#D9D9D9;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="0" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" id="f-142">21,610,704</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#D9D9D9;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#D9D9D9;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-33" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-143">464,364</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#D9D9D9;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#D9D9D9;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-34" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-144">27,594</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#D9D9D9;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#D9D9D9;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-35" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-145">47,427</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#D9D9D9;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#D9D9D9;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-36" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-146">44,414</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#D9D9D9;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#D9D9D9;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#D9D9D9;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-37" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-147">339,368</ix:nonFraction>)</span></td><td style="background-color:#D9D9D9;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#D9D9D9;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-38" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-148">7,231</ix:nonFraction>)</span></td><td style="background-color:#D9D9D9;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#D9D9D9;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-149">237,200</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#D9D9D9;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_16"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC.</span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars)</span></div></td></tr></table></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.329%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the year ended March&#160;31,</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Notes</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OPERATING ACTIVITIES</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss for the year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-150">113,137</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-151">78,080</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjustments for items not affecting cash:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:18pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">&#160;Depreciation and amortization</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">5,6,7</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="f-152">475</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="f-153">424</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Share-based compensation</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-154">42,869</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-155">13,886</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Lease interest accretion</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">7</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:AdjustmentForLeaseInterest" scale="3" id="f-156">7</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:AdjustmentForLeaseInterest" scale="3" id="f-157">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.02pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">7</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:AdjustmentsForOtherLossesGains" scale="3" id="f-158">28</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:AdjustmentsForOtherLossesGains" format="ixt:fixed-zero" scale="3" id="f-159">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Computer equipment write-down</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-160">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="f-161">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.77pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unrealized foreign currency translation gain </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation" format="ixt:num-dot-decimal" scale="3" id="f-162">21,749</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation" scale="3" id="f-163">137</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-164">91,507</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-165">63,881</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net changes in non-cash working capital items:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Accounts receivable</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" format="ixt:num-dot-decimal" scale="3" id="f-166">1,409</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" format="ixt:num-dot-decimal" scale="3" id="f-167">1,089</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Prepaid expenses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-168">19,265</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" scale="3" id="f-169">986</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" scale="3" id="f-170">732</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" scale="3" id="f-171">408</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Accounts payable and accrued liabilities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-172">11,613</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" sign="-" name="cybn:AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-173">2,544</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash flows used in operating activities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-174">101,300</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-175">68,908</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">INVESTING ACTIVITIES</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash acquired on acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" format="ixt:fixed-zero" scale="3" id="f-176">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" format="ixt:num-dot-decimal" scale="3" id="f-177">7,632</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of equipment and intangible assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">5,6</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-178">1,966</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="f-179">710</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash flows provided by (used in) investing activities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-180">1,966</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-181">6,922</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">FINANCING ACTIVITIES</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds on issuance of common shares, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">9</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="f-182">20,487</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="f-183">254,600</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds on exercise of warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="f-184">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" scale="3" id="f-185">56</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 21.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">7</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="f-186">290</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="f-187">149</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash flows provided by financing activities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-188">20,197</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-189">254,507</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effects of exchange rate changes on cash</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-190">9,099</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="f-191">162</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net increase (decrease) in cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-192">73,970</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-193">192,359</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, beginning of year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-194">208,992</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-12" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-195">16,633</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, end of year</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-196">135,022</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-197">208,992</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_405"></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CYBIN INC. </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">March 31, 2025 and 2024 </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those amounts indicated as being in US dollars, Euros or Great Britain Pounds which are in thousands.)</span></div></td></tr></table></div></div><div><span><br/></span></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_22"></div><div style="padding-left:17.85pt;text-indent:-17.85pt"><span style="color:#2d5f91;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBasisOfConsolidationExplanatory" id="f-198" continuedAt="f-198-1" escape="true">CORPORATE INFORMATION</ix:nonNumeric></span></div><ix:continuation id="f-198-1"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Cybin Inc. (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Cybin</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;), was incorporated under the Business Corporations Act (British Columbia) on October 13, 2016. These consolidated financial statements include the accounts of Cybin&#8217;s <ix:nonFraction unitRef="subsidiary" contextRef="c-2" decimals="INF" name="cybn:NumberOfSubsidiaries" format="ixt-sec:numwordsen" scale="0" id="f-199">seven</ix:nonFraction> subsidiaries (together with Cybin, the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Company</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;): Cybin Corp., Natures Journey Inc. (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Journey</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;), Serenity Life Sciences Inc. (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Serenity</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;), Cybin US Holdings Inc. (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Cybin</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">US</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;), Adelia Therapeutics Inc. (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Adelia</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;) Cybin IRL Limited (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Cybin</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">IRL</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;) and Cybin UK Ltd.  Cybin&#8217;s head office, principal address and registered address and records office is 100 King Street West, Suite 5600, Toronto, Ontario M5X 1C9. The Company acquired Small Pharma Inc. (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Small</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Pharma</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;) and its subsidiary Small Pharma Ltd. on October 23, 2023. On April 1, 2024, Small Pharma Inc. was amalgamated with Cybin Corp. and continued as Cybin Corp. Effective on December 16, 2023, Small Pharma Ltd.'s name was changed to Cybin UK Ltd. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit.  These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">These consolidated financial statements as at, and for the year ended March 31, 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">were approved and authorized for issue by the board of directors on June&#160;30, 2025.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%;text-decoration:underline">Stock exchange listings</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Cybin&#8217;s common shares (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Common Shares</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;) are listed for trading on Cboe Canada Inc. (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Cboe Canada</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">") and NYSE American LLC under the symbol &#8220;CYBN&#8221; and on the Frankfurt Stock Exchange under the symbol &#8220;R7E1&#8221;.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Share consolidation</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On September 19, 2024, the Company consolidated its outstanding Common Shares on the basis of <ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="cybn:OrdinarySharesConsolidationNewSharesIssued" format="ixt-sec:numwordsen" scale="0" id="f-200">one</ix:nonFraction> new Common Share for every <ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="cybn:OrdinarySharesConsolidationSharesIssuedPreviously" scale="0" id="f-201">38</ix:nonFraction> previously existing Common Shares (the "</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Consolidation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">"). As a result, the number of Common Shares, warrants, options and earnings per share presented in these consolidated financial statements have been restated retrospectively for all the years to reflect the Consolidation.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_25"></div><div style="margin-top:10pt"><span><br/></span></div><div style="padding-left:17.85pt;text-indent:-17.85pt"><span style="color:#2d5f91;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory" id="f-202" continuedAt="f-202-1" escape="true">MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="f-202-1" continuedAt="f-202-2"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Statement of compliance </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:StatementOfIFRSCompliance" id="f-203" continuedAt="f-203-1" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%">The Company&#8217;s consolidated financial statements have been prepared in accordance with IFRS Accounting Standards (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:124%">IFRS</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%">&#8221;) as issued by the International Accounting Standards Board (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:124%">IASB</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%">&#8221;). </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%">The policies applied to these consolidated financial statements are based on IFRS, which have been applied consistently to all periods presented. These consolidated financial statements were issued and effective as at June&#160;30, 2025, the date the Board of Directors approved these consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 11 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-202-2" continuedAt="f-202-3"><ix:continuation id="f-203-1"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company&#8217;s board of directors has the power to amend the consolidated financial statements after issuance.</span></div></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="cybn:DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock" id="f-204" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Basis of measurement</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">These consolidated financial statements have been prepared on a going concern basis, under the historical cost convention, except for certain financial instruments classified at fair value upon initial recognition.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory" id="f-205" escape="true"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Functional and presentation currency</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The functional currency of a company is the currency of the primary economic environment in which the company operates. The presentation currency for a company is the currency in which the company chooses to present its financial statements.</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">These consolidated financial statements are presented in Canadian dollars, the Company&#8217;s presentation currency. <ix:nonNumeric contextRef="c-1" name="cybn:DetailDescriptionOfFunctionalCurrenciesTableTextBlock" id="f-206" continuedAt="f-206-1" escape="true">The subsidiaries&#8217; functional currencies are as follows:</ix:nonNumeric></span></div><ix:continuation id="f-206-1"><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:37.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.400%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Entity</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ownership</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cybin Corp.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollars</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-40" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" format="ixt:num-dot-decimal" id="f-207">100</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Journey</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-41" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" format="ixt:num-dot-decimal" id="f-208">100</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serenity</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-42" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" format="ixt:num-dot-decimal" id="f-209">100</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybin US</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-43" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" format="ixt:num-dot-decimal" id="f-210">100</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adelia</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-44" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" format="ixt:num-dot-decimal" id="f-211">100</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cybin IRL </span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-45" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" format="ixt:num-dot-decimal" id="f-212">100</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybin UK Ltd</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Great Britain pounds</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-46" decimals="INF" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" format="ixt:num-dot-decimal" id="f-213">100</ix:nonFraction>%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> For accounting purposes, Cybin US is a wholly-owned subsidiary of Cybin. Certain former Adelia Shareholders hold Class B Shares (defined below) in Cybin US.</span></div></ix:continuation></ix:nonNumeric><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"> <ix:nonNumeric contextRef="c-1" name="cybn:DisclosureOfBasisOfConsolidationPolicyTextBlock" id="f-214" continuedAt="f-214-1" escape="true">Basis of consolidation </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-214-1" continuedAt="f-214-2"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company consolidates entities which it controls. Control exists when the Company has the power, directly and indirectly to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. </span></div></ix:continuation><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:continuation id="f-214-2">Intercompany balances, and any unrealized gains and losses or income and expenses arising from transactions with controlled entities are eliminated to the extent of the Company&#8217;s interest in the entity.</ix:continuation> </span></div><div style="padding-left:18pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" id="f-215" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Cash and cash equivalents</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash and cash equivalents are comprised of cash on deposit and highly liquid short-term interest-bearing variable rate investments with an original maturity of three months or less, or which are readily convertible into a known amount of cash with no significant changes. As at March&#160;31, 2025 and March&#160;31, 2024 there were <ix:nonFraction unitRef="cad" contextRef="c-3" decimals="INF" name="ifrs-full:CashEquivalents" format="ixt:fixed-zero" scale="0" id="f-216"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="INF" name="ifrs-full:CashEquivalents" format="ixt:fixed-zero" scale="0" id="f-217">no</ix:nonFraction></ix:nonFraction> cash equivalents.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 12 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-202-3" continuedAt="f-202-4"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories" id="f-218" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Inventories</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inventories include raw materials and finished goods. Raw materials are stated at the lower of cost and replacement cost with cost determined on a first-in, first-out basis. The Company monitors the shelf life and expiry of finished goods to determine when inventory values are not recoverable and a write-down is necessary.</span></div></ix:nonNumeric><div style="padding-left:18pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="f-219" continuedAt="f-219-1" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Equipment</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Equipment consists of lab and computer equipment and are recorded at cost less accumulated depreciation and accumulated impairment losses. Cost includes all expenditures incurred to bring the asset to the location and condition necessary for them to be operating in the manner intended by management. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Depreciation is recognized based on the cost of the item less its estimated residual value, over its estimated useful life on a straight-line basis at the following rates:</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Lab equipment &#8211; <ix:nonNumeric contextRef="c-47" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-220">5</ix:nonNumeric> years</span></div><div style="padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Computer equipment &#8211; <ix:nonNumeric contextRef="c-48" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" format="ixt-sec:duryear" id="f-221">3</ix:nonNumeric> years</span></div></ix:nonNumeric><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:continuation id="f-219-1">An item of equipment and any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the consolidated statement of loss and comprehensive loss when the asset is derecognized. The assets&#8217; residual values, useful lives and methods of depreciation are reviewed at each reporting date and adjusted prospectively if appropriate.</ix:continuation> </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" id="f-222" continuedAt="f-222-1" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Intangible Assets</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Intangible assets include expenditures related to obtaining patents, software related items and in-process research and development (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">IPR&amp;D</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;). The amortization of software related items begins when the software is in use and will be amortized on a straight-line basis over a period of <ix:nonNumeric contextRef="c-49" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-223">3</ix:nonNumeric> years. The amortization of patent costs commences when the associated products are available for commercial sale and is amortized on a straight-line basis over its respective legal lives or economic life, if shorter. Patents have an estimated useful life of <ix:nonNumeric contextRef="c-50" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-224">17</ix:nonNumeric> years. Amortization methods, useful lives, and residual values are reviewed at each reporting date and adjusted if appropriate. Acquired IPR&amp;D is capitalized based on technical feasibility and remains on the balance sheet, subject to impairment. Acquired IPR&amp;D is initially measured at fair value and recognized as an indefinite-lived intangible asset until completion or abandonment of the related project. Amortization commences when the assets become available for use. Expenditures on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in operations as incurred. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Development activities involve a plan or design for the production of new, or substantially improved, products or processes related to the Company&#8217;s development of psychedelic-based therapeutics. Development expenditures are capitalized only if the relevant IFRS criteria are met. Capitalized development expenditures </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 13 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-202-4" continuedAt="f-202-5"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:continuation id="f-222-1">are amortized from the beginning of commercial production and sales and are amortized on a straight-line basis over the remaining useful life of the related patents. Development expenditures, in relation to the Company&#8217;s psychedelic-based therapeutics, have not satisfied the above criteria and are recognized in operations as incurred.</ix:continuation> </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory" id="f-225" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Goodwill</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Goodwill represents the excess of the consideration transferred for the acquisition of an entity over the fair value of the net identifiable assets. Goodwill is initially measured at cost, and subsequently recorded at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Company&#8217;s cash-generating units (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">CGUs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those CGUs. The Company tests for impairment annually, or when indications of impairment exist.  Impairment is determined for goodwill by assessing if the carrying value of CGUs, including goodwill, exceeds its recoverable amount determined as the greater of the estimated fair value less costs of disposal and the value in use. Impairment losses recognized in respect of the CGUs are first allocated to the carrying value of goodwill and any excess is allocated to the carrying amount of assets in the CGUs. Any goodwill impairment is recorded in the consolidated statement of loss and comprehensive loss.</span></div></ix:nonNumeric><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" id="f-226" continuedAt="f-226-1" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Impairment of long-lived assets</span></div></ix:nonNumeric><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:continuation id="f-226-1">Long-lived assets, including equipment and intangible assets, are reviewed for impairment at each consolidated statement of financial position date or whenever events or changes in circumstances indicate that the carrying amount of the asset exceeds its recoverable amount. Where the carrying value of an asset exceeds its recoverable amount, which is the higher of value in use and fair value less costs to sell, the asset is written down accordingly. Where it is not possible to estimate the recoverable amount of an individual asset, the impairment test is carried out on the asset&#8217;s cash-generating unit, which is the lowest group of assets in which the asset belongs for which there are separate cash inflows that are largely independent of the cash inflows from other assets. An impairment loss is charged to operations.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" id="f-227" continuedAt="f-227-1" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Financial instruments</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Recognition and initial measurement</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company initially recognizes financial instruments on the trade date, which is the date on which the Company becomes a party to the contractual provisions of the instrument. A financial asset or financial liability is measured initially at fair value plus/minus, for an item not at fair value through profit or loss (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">FVTPL</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;), transaction costs that are directly attributable to its acquisition or use.</span></div></ix:nonNumeric></ix:continuation><div style="padding-left:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 14 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-227-1" continuedAt="f-227-2"><ix:continuation id="f-202-5" continuedAt="f-202-6"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Classification</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Financial asset</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On initial recognition, a financial asset is classified as measured at: amortized cost, fair value through other comprehensive income (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">FVOCI</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;), or FVTPL.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">A financial asset is measured at amortized cost if it meets both of the following conditions and is not designated as at FVTPL:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company currently measures accounts receivable at amortized cost. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">A debt instrument is measured at FVOCI only if it meets both of the following conditions and is not designated as at FVTPL:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in FVOCI. This election is made on an investment-by-investment basis. The Company has not elected to present any assets as FVOCI.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash is measured at FVTPL.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In addition, on initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortized cost as FVOCI or FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Business model assessment</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company makes an assessment of the objective of a business model in which an asset is held at a portfolio level because this best reflects the way the business is managed and information is provided to management. The information considered includes:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The stated policies and objectives for the portfolio and the operation of those policies in practice. In particular, whether management&#8217;s strategy focuses on earning contractual interest revenue, maintaining a particular interest rate profile, matching the duration of the financial assets to the </span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 15 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-227-2" continuedAt="f-227-3"><ix:continuation id="f-202-6" continuedAt="f-202-7"><div style="padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">duration of the liabilities that are funding those assets or realizing cash flows through the sale of the assets;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">How the performance of the portfolio is evaluated and reported to the Company&#8217;s management;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">How managers of the business are compensated (e.g. whether compensation is based on the fair value of the assets managed or the contractual cash flows collected); and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The frequency, volume and timing of sales in prior periods, the reasons for such sales and its expectation about future sales activity. However, information about sales activity is not considered in isolation, but as part of an overall assessment of the Company&#8217;s stated objective for managing the financial asset is achieved and how cash flows are realized. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Assessment whether contractual cash flows are solely payments of principal and interest</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">For the purpose of this assessment, &#8216;principal&#8217; is defined as the fair value of the financial asset on initial recognition. &#8216;Interest&#8217; is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g. liquidity risk and administrative costs), as well as profit margin. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In assessing whether the contractual cash flows are solely payments of principal and interest, the Company considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of the contractual cash flows such that it would not meet this condition. In making the assessment, the Company considers:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">contingent events that would change the amount and timing of cash flows;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">leverage features;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">prepayment and extension terms;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">terms that limit the Company&#8217;s claim to cash flows from specified assets (e.g. non-recourse asset arrangements); and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">features that modify consideration of the time value of money (e.g. periodical rest of interest rates).</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Reclassifications</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company would reclassify a financial asset when the Company changes its business model for managing the financial asset. All reclassifications are recorded at fair value at the date of the reclassification, which becomes the new carrying value. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Financial assets are not reclassified subsequent to their initial recognition, except in the period after the Company changes its business model for managing financial assets. </span></div></ix:continuation></ix:continuation><div style="padding-left:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 16 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-227-3" continuedAt="f-227-4"><ix:continuation id="f-202-7" continuedAt="f-202-8"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Financial liabilities</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company classifies its financial liabilities at amortized cost or FVTPL. The Company currently measures accounts payable, lease liabilities and accrued liabilities at amortized cost.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Derecognition </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Financial assets</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transition in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and it does not retain control of the financial asset. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On derecognition of a financial asset, the difference between the carrying amount of the asset (or the carrying amount allocated to the portion of the asset derecognized) and the sum of (i) the consideration received (including any new assets obtained less any new liability assumed) and (ii) cumulative gain or loss that had been recognized in other comprehensive income is recognized in profit or loss. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Financial liabilities </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled, or expire. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Modifications of financial assets and financial liabilities </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Financial assets</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If the terms of a financial asset are modified, the Company evaluates whether the cash flows of the modified asset are substantially different. If the cash flows are substantially different, then the contractual rights to cash flows from the original financial asset are deemed to have expired. In this case, the original financial asset is derecognized and a new financial asset is recognized at fair value. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If the cash flows of the modified asset carried at amortized cost are not substantially different, then the modification does not result in derecognition of the financial asset. In this case, the Company recalculates the gross carrying amount of the financial asset and recognizes the amount arising from adjusting the gross carrying amount as a modification gain or loss in profit or loss. If such a modification is carried out because of financial difficulties of the borrower, then the gain or loss is presented together with impairment losses. In other cases, it is presented as interest income. </span></div></ix:continuation></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 17 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-227-4" continuedAt="f-227-5"><ix:continuation id="f-202-8" continuedAt="f-202-9"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Financial liabilities</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company derecognizes a financial liability when its terms are modified and the cash flows of the modified liability are substantially different. In this case, a new financial liability based on the modified terms is recognized at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognized in profit or loss. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Offsetting</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Financial assets and financial liabilities are offset and the net amount presented in the consolidated statement of financial position when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Income and expenses are presented on a net basis only when permitted under IFRS, or for gains and losses arising from a group of similar transactions. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Fair value measurement</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or, in its absence, the most advantageous market to which the Company has access at that date. The fair value of a liability reflects its non-performance risk. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">When one is available, the Company measures the fair value of an instrument using the quoted price in an active market for that instrument. A market is regarded as active if transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If there is no quoted price in an active market, then the Company uses valuation techniques that maximize the use of relevant observable inputs and minimize the use of unobservable inputs. The chosen valuation technique incorporates all of the factors that market participants would take into account in pricing a transaction. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The best evidence of the fair value of a financial instrument on initial recognition is normally the transaction price (i.e. the fair value of the consideration given or received). If the Company determines that the fair value on initial recognition differs from the transaction price and the fair value is evidenced neither by a quoted price in an active market for an identical asset or liability nor based on a valuation technique for which any observable inputs are judged to be insignificant in relation to the measurement, then the financial instrument is initially measured at fair value, adjusted to defer the difference between the fair value on initial recognition and the transaction price. Subsequently, that difference is recognized in profit or loss on an appropriate basis over the life of the instrument but no later than when the valuation is wholly supported by observable market data or the transaction is closed out. </span></div></ix:continuation></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 18 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-227-5" continuedAt="f-227-6"><ix:continuation id="f-202-9" continuedAt="f-202-10"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If an asset or a liability at fair value has a bid price and an ask price, then the Company measures assets and long positions at bid price and liabilities and short positions at an ask price. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Portfolio of financial assets and financial liabilities that are exposed to market risk and credit risk that are managed by the Company on the basis of the net exposure to either market or credit risk are measured on the basis of a price that would be received to sell a net long position (or paid to transfer a net short position) for the particular risk exposure. Portfolio-level adjustment e.g. bid-ask adjustment or credit risk adjustments that reflect the measurement on the basis of the net exposure are allocated to the individual assets and liabilities on the basis of the relative risk adjustment of each of the individual instruments in the portfolio.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The fair value of a financial liability with a demand feature is not less than the amount payable on demand, discounted from the first date on which the amount could be required to be paid. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period during which the change has occurred.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:130%">  </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Impairment</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Credit-impaired financial assets</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">At each reporting date, the Company assesses whether financial assets carried at amortized costs and debt financial assets carried at FVOCI are credit-impaired. A financial asset is &#8216;credit-impaired&#8217; when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Evidence that a financial asset is credit-impaired includes the following observable data: </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">Significant financial difficulty of the borrower or issuer;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">A breach of contract such as a default of past due event;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The restructuring of a loan or advance by the Company on terms that the Company would not consider otherwise;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">It is becoming probable that the borrower will enter bankruptcy or other financial reorganization; or </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The disappearance of an active market for a security because of financial difficulties. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">A loan that has been renegotiated due to a deterioration in the borrower&#8217;s condition is usually considered to be credit-impaired unless there is evidence that the risk of not receiving contractual cash flows has reduced significantly and there are no other indicators of impairment. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Recognition of allowance of expected credit losses (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">ECL</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">&#8221;) in the consolidated statement of financial position</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company recognizes a loss allowance for ECL on trade receivables that are measured at amortized cost. The Company&#8217;s applied the simplified approach for trade receivables and recognizes the lifetime ECL for these assets. The ECL on trade receivables is estimated using a provision matrix based on the Company&#8217;s historical credit loss experience, adjusted for factors that are specific to the customers, general economic conditions and </span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 19 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-202-10" continuedAt="f-202-11"><ix:continuation id="f-227-6" continuedAt="f-227-7"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">an assessment of both the current as well as the forecast direction of conditions at the reporting date, including time value of money where appropriate. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">For all other financial assets measured at amortized cost of FVOCI, the Company recognizes lifetime ECL only when there has been a significant increase in credit risk since initial recognition. If the credit risk on such financial instruments has not increased significantly since initial recognition, the Company measures the loss allowance on those financial instruments at an amount equal to 12-months ECL. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Lifetime ECL represents the ECL that will result from all possible default events over the expected life of a financial asset. In contrast, 12-month ECL represents the portion of lifetime ECL that is expected to result from default events on a financial asset that are possible within 12 months after the reporting date. In assessing whether the credit risk on a financial asset has increased significantly since initial recognition, the Company compares the risk of default occurring on the financial asset at the reporting date with the risk of default occurring at the initial recognition. The Company considers both quantitative and qualitative factors that are supportable, including historical experience and forward-looking information that is available without undue cost or effort. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Irrespective of the above assessment, the Company presumes that the credit risk on a financial asset has increased significantly since initial recognition when contractual payments are more than 30 days past due, unless the Company has reasonable and supportable information that demonstrates otherwise. Despite the foregoing, the Company presumes that the credit risk on a financial asset has not increased significantly since initial recognition if the financial asset is determined to have low credit risk at the reporting date. </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company regularly monitors the effectiveness of the criteria used to identify whether there has been a significant increase in credit risk and revises them as appropriate to ensure that the criteria are capable of identifying significant increase in credit risk before the amount becomes pas due. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Definition of default</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">For internal credit risk management purposes, the Company considers a financial asset not recoverable if the customer balance owing is 180 days past due and information obtained from the customer and other external factors indicate that the customer is unlikely to pay its creditors in full.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Write-off</span></div></ix:continuation><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:continuation id="f-227-7">Financial assets are written off (either partially or in full) when there is no realistic prospect of recovery. This is generally the case when the Company determines that the counterparty does not have assets or sources of income that could general sufficient cash flows to repay the amounts subject to the write-off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Company&#8217;s procedures for recovery of amounts due.</ix:continuation> </span></div></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 20 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-202-11" continuedAt="f-202-12"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" id="f-228" continuedAt="f-228-1" escape="true"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Taxation</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Income tax comprises current and deferred tax. Income tax is recognized in the consolidated statement of loss and comprehensive loss except to the extent that it relates to items recognized directly in equity, in which case the income tax is also recognized directly in equity.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Current income tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted, at the end of the reporting period, and any adjustment to tax payable in respect of previous years.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from audits by taxing authorities. Where the outcome of these tax-related matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Deferred income tax is recorded using the asset and liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences do not result in deferred tax assets or liabilities: the initial recognized of assets or liabilities that affect neither accounting or taxable loss; or difference relating to investment in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the consolidated statement of financial position date.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized. </span></div></ix:nonNumeric><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:continuation id="f-228-1">Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its correct tax assets and liabilities on a net basis.</ix:continuation> </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" id="f-229" continuedAt="f-229-1" escape="true"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Share capital</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Equity instruments are contracts that give a residual interest in the net assets of the Company. Financial instruments issued by the Company are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Common Shares and the Company&#8217;s Common Share purchase warrants and options are classified as equity instruments. </span></div></ix:nonNumeric><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:continuation id="f-229-1">Incremental costs directly attributable to the issue of new Common Shares or warrants are shown in equity as a deduction, net of tax, from the proceeds.</ix:continuation> </span></div></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 21 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-202-12" continuedAt="f-202-13"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="f-230" continuedAt="f-230-1" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Share-based compensation</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Under the Company&#8217;s equity incentive plan, all stock options granted may have graded vesting periods and are exercisable up to a maximum of <ix:nonNumeric contextRef="c-1" name="cybn:ShareBasedCompensationArrangementExpirationPeriod" format="ixt-sec:duryear" id="f-231">10</ix:nonNumeric> years form the date of grant. Each tranche of an award with graded vesting periods is considered a separate grant at each grant date for the calculation of fair value, and the resulting fair value is amortized over the vesting period of the respective tranches. The fair value of the options granted is measured using the Black-Scholes option pricing model taking into account the terms and conditions upon which the options were granted, the estimated volatility, estimated risk free rate and estimated forfeitures. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If a grant of the share-based payments is cancelled or settled during the vesting period (other than a grant cancelled by forfeiture when the vesting conditions are not satisfied or options granted in error and cancelled retroactively), the Company accounts for the cancellation or settlement as an acceleration of vesting, and recognizes immediately the amount that otherwise would have been recognized for services over the remainder of the vesting period. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The amount recognized for goods or services received during the vesting period is based on the best available estimate of the number of equity instruments anticipated to vest. The Company revises that estimate, if necessary, if subsequent information indicates that the number of share options anticipated to vest differs from previous estimates. On the vesting date, the Company revises the estimate to equal the number of equity instrument that ultimately vested. After the vesting date, the Company makes no subsequent adjustment to total equity for goods or services received if the share options are later forfeited or they expire at the end of the share option&#8217;s life. Upon expiration of options, the amount applicable to expired options is moved to contributed surplus.</span></div></ix:nonNumeric><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><ix:continuation id="f-230-1" continuedAt="f-230-2"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If a grant of the share based payment is modified during the vesting period (other than a grant cancelled by forfeiture when</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:130%">  </span></ix:continuation><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:continuation id="f-230-2">the vesting conditions are not satisfied) and the fair value of the new instruments is higher than the fair value of the original instrument, the incremental fair value granted is included in the measurement of the amount recognized for services received over the period from modification date until the date when the modified equity instruments vests, in addition to the amount based on the grant date fair value of the original equity instruments, which is recognized over the remainder of the original vesting period of the original instrument.</ix:continuation> </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForWarrantsExplanatory" id="f-232" continuedAt="f-232-1" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Warrants</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company follows the relative fair value method with respect to the measurement of Common Shares and warrants issued as units. The proceeds from the issuance of units are allocated between share capital and warrants. The warrant component is recorded in equity reserve. Unit proceeds are allocated to Common Shares and warrants using the Black-Scholes option pricing model and the share price at the time of financing. If and when the warrants are exercised, consideration paid by the warrant holder, together with the amount previously recognized in warrant reserve, is recorded as an increase to share capital. A forfeiture rate is estimated on the grant date and is adjusted to reflect the actual number of warrants that vest. When stock options or warrants are cancelled, they are treated as if they have vested on the date of collation and any cost </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 22 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-202-13" continuedAt="f-202-14"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:continuation id="f-232-1">not yet recognized in profit or loss is immediately expensed. Upon expiration of warrants, the amount applicable to expired warrants is moved to contributed surplus.</ix:continuation> </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" id="f-233" escape="true"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Loss per share</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Basic loss per share is calculated using the weighted-average number of shares outstanding during the period. The diluted earnings (loss) per share reflects the potential dilution of Common Share equivalents, such as outstanding stock options and warrants, in the weighted average number of Common Shares outstanding during the period, if they are dilutive.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="f-234" continuedAt="f-234-1" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Currency translation</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">All figures presented in the consolidated financial statements are reflected in Canadian dollars unless otherwise noted.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Foreign currency transactions are translated into Canadian dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the consolidated statement of financial position date are translated to Canadian dollars at the foreign exchange rate applicable as that date. Realized and unrealized exchange gains and losses are recognized through profit or loss. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The assets and liabilities of foreign operations are translated into Canadian dollars at period-end exchange rates. Income and expenses, and cash flows of foreign operations are translated into Canadian dollars using average exchange rates. Exchange differences resulting from translating foreign operations are recognized in other comprehensive income (loss) and accumulated separately in shareholders&#8217; equity. </span></div></ix:nonNumeric><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:continuation id="f-234-1">Foreign currency translation gains or losses arising from a monetary item receivable or payable to a foreign operation, the settlement of which is neither planned nor likely to occur in the foreseeable future and which in substance is considered to form part of the net investment in the foreign operation, are recognized in other comprehensive income (loss) in the translation reserve.</ix:continuation> </span></div><div style="padding-left:18pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" id="f-235" continuedAt="f-235-1" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Provisions</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Provisions are recorded when a present legal or constructive obligation exists as a result of past events where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and a reliable estimate of the amount of the obligation can be made.</span></div></ix:nonNumeric><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:continuation id="f-235-1">The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the consolidated statement of financial position date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows. When some or all of the economic benefits required to settle, a provision is expected to be recovered from a third party, the receivable is recognized as an asset if it is virtually certain that reimbursement will be received and the amount receivable can be measured reliably.</ix:continuation> </span></div></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 23 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations" id="f-236" escape="true"><ix:continuation id="f-202-14"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">New standards and interpretations</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The IASB has issued certain amendments to accounting and financial reporting standards effective for annual reporting periods beginning on or after January 1, 2024.</span></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">IAS 1, Presentation of Financial Statements ("IAS 1") - Classification of Liabilities as Current or Non-Current</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In January 2020, the IASB issued amendments to IAS 1. The amendments aim to promote consistency in applying the requirements by helping companies determine whether, in the consolidated statements of financial position, debt and other liabilities with an uncertain settlement date should be classified as current (due or potentially due to be settled within one year) or non-current. The amendments include clarifying the classification requirements for debt a company might settle by converting it into equity. The amendments are effective for annual reporting periods beginning on or after January 1, 2024.  The Company has determined that adoption of these amendments has no significant effect on the Company's consolidated financial statements.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">New standards and interpretations not yet adopted </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">IFRS 18, Presentation and Disclosure in Financial Statements</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In April 2024, the IASB issued IFRS 18 that is to replace IAS 1, Presentation of Financial Statements. The new standard aims to improve the quality of financial reporting by: (i) requiring defined subtotals in the statement of profit or loss; (ii) requiring disclosure about management defined performance measures; and (iii) adding new principles for aggregation and disaggregation of information.  The standard is effective for the annual reporting periods beginning on or after January 1, 2027, with early application permitted. The Company is in the process of assessing the impact of this new standard on its consolidated financial statements.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">IFRS 9, Financial Instruments (&#8220;IFRS 9&#8221;) and IFRS 7, Financial Instruments: Disclosures (&#8220;IFRS 7&#8221;)</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In May 2024, the IASB issued targeted amendments to IFRS 9 and IFRS 7 in response to practical implementation issues and to introduce new requirements applicable to both financial institutions and corporate entities. These amendments aim to enhance the clarity and consistency of financial reporting for various types of financial instruments and their related disclosures by (i) clarifying the date of recognition and derecognition for certain financial assets and liabilities, including a new exception for financial liabilities settled through an electronic cash transfer system (ii) providing help to determine whether a financial asset meets the Solely Payments of Principal and Interest criterion (iii) introducing new disclosures for instruments with contractual terms that may alter cash flows, such as financial instruments linked to the achievement of environmental, social, and governance targets, and (iv) updating the disclosure requirements for equity instruments designated at FVTOCI. The new standard is to be effective for annual periods beginning on or after January 1, 2026. The Company is in the process of assessing the impact of the standard on its consolidated financial statements.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">All other IFRSs and amendments issued but not yet effective have been assessed by the Company and are not expected to have a material impact on the Company's consolidated financial statements.</span></div></ix:continuation></ix:nonNumeric><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 24 of 52</span></div></div></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_496"></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify"><span style="color:#2d5f91;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">3.    <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" id="f-237" continuedAt="f-237-1" escape="true">CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS </ix:nonNumeric></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-237-1" continuedAt="f-237-2"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The preparation of these consolidated financial statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting year. Actual outcomes could differ from these estimates. These consolidated financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the year in which the estimate is revised and future years if the revision affects both current and future years. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Judgments, estimates and assumptions that have the most significant effect on the amounts recognized in the consolidated financial statements include warrants and fair value of share-based payments (note 9) and the fair value of financial instruments (note 15).</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Ability to continue as a going concern</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In order to assess whether it is appropriate for the Company to continue as a going concern, management is required to apply judgment and make estimates with respect to future cash flow projections. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In arriving at this judgment, there were a number of assumptions and estimates involved in calculating these future cash flow projections. This includes making estimates regarding the timing and amounts of future expenditures and the ability and timing of raising additional financing. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Business combinations</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">A business combination is a transaction or event in which an acquirer obtains control of one or more businesses and is accounted for using the acquisition method. The total consideration paid for the acquisition is the aggregate of the fair values of assets given, liabilities incurred or assumed, and equity instruments issued in exchange for control of the acquiree at the acquisition date. The acquisition date is the date where the Company obtains control of the acquiree. The identifiable assets acquired and liabilities assumed are recognized at their acquisition date fair values, except for deferred taxes and share-based payment awards where IFRS provides exceptions to recording the amounts at fair value. Acquisition costs are expensed to profit or loss.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combination. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as an asset or a liability is remeasured at subsequent reporting dates in accordance with IFRS 9, or IAS 37 Provisions, Contingent Liabilities and Contingent Assets, as appropriate, with the corresponding gain or loss being recognized in profit or loss.</span></div></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 25 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-237-2" continuedAt="f-237-3"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Non-controlling interest in the acquiree, if any, is recognized either at fair value or at the non-controlling interest&#8217;s proportionate share of the acquiree&#8217;s net assets, determined on an acquisition-by-acquisition basis. For each acquisition, the excess of total consideration, the fair value of previously held equity interest prior to obtaining control and the non-controlling interest in the acquiree, over the fair value of the identifiable net asset acquired, is recorded as goodwill.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Certain fair values may be estimated at the acquisition date pending confirmation or completion of the valuation process. Where provisional values are used in accounting for a business combination, they may be adjusted retrospectively in subsequent periods. The measurement period is the period from the acquisition date to the date complete information about facts and circumstances that existed as of the acquisition date is received. However, the measurement period does not exceed one year from the acquisition date. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Acquisitions that do not meet the definition of a business combination are accounted for as an asset acquisition. Consideration paid for an asset acquisition is allocated to the individual identifiable assets acquired and liabilities assumed based on their relative fair values.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Share based payments</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The fair value of share-based compensation expenses are estimated using the Black-Scholes option pricing model and rely on a number of estimates, such as the expected life of the option, the volatility of the underlying share price, the risk-free rate of return, and the estimated rate of forfeiture of options or warrants granted.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Impairment of non-financial assets</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Impairment exists when the carrying value of an asset or cash generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The fair value less costs of disposal calculation is based on available data from binding sales transactions, conducted at arm&#8217;s length, for similar assets or observable market prices less incremental costs of disposing of the asset. The value in use calculation is based on a discounted cash flow (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">DCF</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) model. The cash flows are derived from the forecast for the next ten years and do not include restructuring activities that the Company is not yet committed to or significant future investments that will enhance the performance of the assets of the CGU being tested. The determination of the Company&#8217;s CGUs is based on management&#8217;s judgement. The recoverable amount is sensitive to the discount rate used for the DCF model as well as the expected future cash-inflows and the growth rate used for extrapolation purposes. These estimates are most relevant to goodwill and other intangibles with indefinite useful lives recognized by the Company.  Future events could cause the assumptions used in the impairment review to change with a consequential adverse effect on the results of the Company. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Income taxes</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company computed an income tax provision in accordance with the applicable income tax laws. However, actual amounts of income tax expense only become final upon filing and acceptance of the tax return by the relevant authorities, which occurs subsequent to the issuance of the consolidated financial statements. Additionally, estimation of income taxes includes evaluation the recoverability of deferred tax assets based on </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 26 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-237-3" continuedAt="f-237-4"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">an assessment of the ability to use the underlying future tax deductions before they expire against future taxable income. The assessment is based upon existing tax laws and estimates of future taxable income. The income tax provision is based on estimates of full-year earnings by jurisdiction. The average annual effective income tax rates are re-estimated at the end of each reporting period. To the extent that estimates and forecasts  differ from actual results, adjustments are recorded in subsequent periods. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">The useful life and recoverability of long-lived assets:</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Management estimates the useful life of long-lived assets based on the period during which the assets are expected to be available for use. The amounts and timing of recorded expenses for amortization and depreciation are affected by these estimated useful lives. The estimates are reviewed at least annually and are updated if expectations change as a result of technical or commercial obsolescence, and legal or other limits to use. It is possible that changes in these factors may cause significant changes in the estimated useful lives of the Company&#8217;s long-lived assets in the future. </span></div></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:continuation id="f-237-4">The Company estimates the useful lives and selects methods used to allocate amortization and depreciation amounts of long-lived assets on a systematic basis. Technical obsolescence of intangible and tangible assets could significantly impact estimated residual useful lives and, in turn, carrying values being over or understated. The estimates of the useful lives of long-lived assets are reviewed on an annual basis. Amortization and depreciation are adjusted on a prospective basis, if and when required.</ix:continuation> </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_513"></div><div><span style="color:#2d5f91;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.  <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBusinessCombinationsExplanatory" id="f-238" continuedAt="f-238-1" escape="true">ACQUISITION</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-238-1" continuedAt="f-238-2"><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On October 23, 2023, Cybin completed the acquisition of Small Pharma and its wholly-owned subsidiary Small Pharma Ltd. (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Acquisition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) and issued <ix:nonFraction unitRef="number" contextRef="c-51" decimals="5" name="cybn:RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-239">0.00634</ix:nonFraction> Common Shares for every one common share of Small Pharma outstanding, resulting in a total of <ix:nonFraction unitRef="shares" contextRef="c-51" decimals="4" name="ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable" format="ixt:num-dot-decimal" scale="0" id="f-240">2,130,138</ix:nonFraction> Common Shares being issued to Small Pharma shareholders. As a result of the Acquisition, Small Pharma became a wholly-owned subsidiary of Cybin. On December 16, 2023 the Company changed the name of Small Pharma Ltd. to Cybin UK Ltd. </span></div><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In connection with the Acquisition, all unvested options of Small Pharma were vested and holders were able to exercise their options prior to the close of the Acquisition. All stock options of Small Pharma remaining unexercised at October 23, 2023 were cancelled and compensation of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-51" decimals="3" name="cybn:UnexercisedStockOptionsInSubsidiaryCompensationForCancellation" format="ixt:num-dot-decimal" scale="0" id="f-241">0.001</ix:nonFraction> per stock option was paid to the optionees.</span></div><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">As at October 23, 2023  Small Pharma&#8217;s patent portfolio consisted of <ix:nonFraction unitRef="patent_family" contextRef="c-51" decimals="INF" name="cybn:NumberOfActivePatentFamilies" scale="0" id="f-242">17</ix:nonFraction> active patent families with <ix:nonFraction unitRef="application" contextRef="c-51" decimals="INF" name="cybn:NumberOfPendingPatentApplications" scale="0" id="f-243">92</ix:nonFraction> pending applications and <ix:nonFraction unitRef="patent" contextRef="c-51" decimals="INF" name="cybn:NumberOfGrantedPatents" scale="0" id="f-244">30</ix:nonFraction> granted patents across its psychedelic and non-psychedelic portfolio.</span></div><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company determined that the Acquisition was a business combination under IFRS. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" id="f-245" continuedAt="f-245-1" escape="true">The consideration for the acquisition and measurement of assets acquired and liabilities assumed, as well as goodwill, in accordance with IFRS 3 - Business Combinations, is as follows:</ix:nonNumeric></span></div></ix:continuation><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 27 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-238-2"><ix:continuation id="f-245-1" continuedAt="f-245-2"><div style="padding-left:13.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"/><td style="width:38.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.206%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.464%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acquisition Summary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Consideration</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-51" decimals="-3" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" format="ixt:num-dot-decimal" scale="3" id="f-246">53,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of purchaser consideration</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-51" decimals="-3" name="ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred" format="ixt:num-dot-decimal" scale="3" id="f-247">53,481</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of Purchase Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-51" decimals="-3" name="cybn:CashRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="3" id="f-248">7,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-51" decimals="-3" name="ifrs-full:CurrentAssetsRecognisedAsOfAcquisitionDate" scale="3" id="f-249">510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-51" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" scale="3" id="f-250">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-51" decimals="-3" name="ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="3" id="f-251">29,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-51" decimals="-3" name="cybn:RightOfUseAssetRecognisedAsOfAcquisitionDate" scale="3" id="f-252">412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-51" decimals="-3" name="cybn:LeaseLiabilitiesRecognisedAsOfAcquisitionDate" scale="3" id="f-253">415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-51" decimals="-3" name="ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="3" id="f-254">6,686</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-51" decimals="-3" name="ifrs-full:GoodwillRecognisedAsOfAcquisitionDate" format="ixt:num-dot-decimal" scale="3" id="f-255">22,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total allocation of purchase price</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-51" decimals="-3" name="ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed" format="ixt:num-dot-decimal" scale="3" id="f-256">53,481</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:continuation><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A professional valuator was engaged by the Company to estimate the value of the assets of Small Pharma for the purpose of the final purchase price allocation. Accordingly, the purchase price allocation was subject to change as at March 31, 2024. The final purchase price allocation was completed within the required one-year measurement period and did not result in any changes from the provisional amounts previously reported. As such, the allocation of the purchase consideration to the identifiable assets acquired and liabilities assumed remains unchanged.</span></div><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">As at February 28, 2023, Small Pharma had Canadian loss carry forwards of $<ix:nonFraction unitRef="cad" contextRef="c-52" decimals="-3" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-257">9,393</ix:nonFraction> and UK loss carry forwards (stated in Canadian dollars) of $<ix:nonFraction unitRef="cad" contextRef="c-53" decimals="-3" sign="-" name="ifrs-full:DeferredTaxLiabilityAsset" format="ixt:num-dot-decimal" scale="3" id="f-258">46,631</ix:nonFraction>. No value has been ascribed to loss carry forwards in these  consolidated financial statements. Tax values of assets acquired may differ from their accounting values.</span></div><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-245-2"><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The following revenue and net loss is attributable to Small Pharma for the period from the Acquisition date to March 31, 2024 and included in these consolidated financial statements for the comparative year.</span></div><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> </span></div><div style="padding-left:13.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"/><td style="width:38.668%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-54" decimals="-3" name="ifrs-full:Revenue" format="ixt:fixed-zero" scale="3" id="f-259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-54" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-260">1,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 28 of 52</span></div></div></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_28"></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><div style="margin-top:10pt;padding-left:17.85pt;text-align:justify;text-indent:-17.85pt"><span><br/></span></div><div style="padding-left:17.85pt;text-align:justify;text-indent:-17.85pt"><span style="color:#2d5f91;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="f-261" continuedAt="f-261-1" escape="true">EQUIPMENT</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="f-262" escape="true"><ix:continuation id="f-261-1"><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:38.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lab Equipment</span></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-55" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-263">664</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-56" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-264">239</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-57" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-265">903</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Small Pharma</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-58" decimals="-3" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-266">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-59" decimals="-3" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-267">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-60" decimals="-3" name="ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-268">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-58" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-269">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-59" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-270">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-60" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-271">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment write-down</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-59" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="f-272">33</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-60" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="f-273">33</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-58" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-274">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-59" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-275">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-60" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-276">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-61" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-277">664</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-62" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-278">266</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-63" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-279">930</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-64" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-280">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-65" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-281">35</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-66" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-282">35</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment write-down</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-64" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="f-283">19</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-66" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="f-284">19</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-64" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-285">41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-65" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-286">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-66" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-287">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31,  2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-67" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-288">686</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-68" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-289">302</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-69" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-290">988</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at   March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-70" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-291">290</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-71" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-292">163</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-72" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-293">453</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation charge</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-73" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-294">137</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-74" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-295">86</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-75" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-296">223</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment write-down</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-74" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="f-297">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-75" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="f-298">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-73" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-299">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-74" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-300">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-75" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-301">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-76" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-302">430</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-77" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-303">234</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-78" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-304">664</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation charge</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-79" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-305">146</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-80" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-306">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-81" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-307">172</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment write-down</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-79" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="f-308">19</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-81" decimals="-3" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" scale="3" id="f-309">19</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-79" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-310">30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-80" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-311">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-81" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="3" id="f-312">30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31,  2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-82" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-313">587</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-83" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-314">260</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-84" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-315">847</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-85" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-316">234</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-86" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-317">32</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-318">266</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value as at March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-87" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-319">99</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-88" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-320">42</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-321">141</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 29 of 52</span></div></div></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_31"></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:139%">CYBIN INC. </span></div><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.77pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.77pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#2d5f91;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIntangibleAssetsExplanatory" id="f-322" continuedAt="f-322-1" escape="true">INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="f-322-1" continuedAt="f-322-2"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" id="f-323" escape="true"><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:40.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.069%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IP Research &amp; Development </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patents</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">License</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-89" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-324">3,076</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-90" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-325">978</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-91" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-326">1,379</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-92" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-327">74</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-57" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-328">5,507</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Small Pharma</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-93" decimals="-3" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-329">29,339</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-94" decimals="-3" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-330">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-95" decimals="-3" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-331">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-96" decimals="-3" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-332">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-60" decimals="-3" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-333">29,339</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-93" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-334">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-94" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="f-335">689</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-95" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-336">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-96" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-60" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="f-338">689</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-93" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-339">25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-94" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-340">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-95" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-341">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-96" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-342">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-60" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-343">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-97" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-344">32,440</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-98" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-345">1,668</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-99" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-346">1,381</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-100" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-347">74</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-63" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-348">35,563</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-101" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-349">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-102" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-350">1,931</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-103" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-351">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-104" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-66" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-353">1,931</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-101" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-354">3,411</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-102" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-355">195</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-103" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-356">84</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-104" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-357">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-66" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-358">3,690</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-105" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-359">35,851</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-106" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-360">3,794</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-107" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-361">1,465</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-108" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-362">74</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-69" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-363">41,184</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-109" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-364">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-110" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-365">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-111" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-366">19</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-112" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-367">18</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-72" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-368">37</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization charge</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-113" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-369">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-114" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-370">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-115" decimals="-3" sign="-" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-371">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-116" decimals="-3" sign="-" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-372">24</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-75" decimals="-3" sign="-" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-373">61</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-117" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-374">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-118" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-375">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-119" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-376">56</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-120" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-377">42</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-78" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-378">98</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization charge</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-121" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-379">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-122" decimals="-3" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-123" decimals="-3" sign="-" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-381">39</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-124" decimals="-3" sign="-" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-382">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-81" decimals="-3" sign="-" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="3" id="f-383">65</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-121" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-384">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-122" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-385">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-123" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-386">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-124" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-387">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-81" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" scale="3" id="f-388">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-125" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-389">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-126" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-390">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-127" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-391">98</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-128" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-392">68</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-84" decimals="-3" sign="-" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-393">166</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-129" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-394">32,440</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-130" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-395">1,668</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-131" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-396">1,325</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-132" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-397">32</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-398">35,465</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value as at March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-133" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-399">35,851</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-134" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-400">3,794</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-135" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-401">1,367</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-136" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="f-402">6</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-403">41,018</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">IP Research &amp; Development</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Refer to note 4 for information on the Small Pharma Acquisition.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Patents</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Costs associated with patent procurement.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company performed its annual impairment test of intangible assets not yet in use at March 31, 2025. The recoverable amount was determined based on the relief from royalty method to arrive at the value-in-use (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">VIU</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;). The Company considered an estimate of future revenues and a reasonable royalty rate to apply to financial projections based on the current budget and future commercialization plans. In assessing the VIU, estimated future cash flows are discounted to their present value using a discount rate that reflects the assessment of royalty and business opportunities and risk as well as the market potential. The VIU calculations were performed using a pre-tax discount rate of <ix:nonFraction unitRef="number" contextRef="c-137" decimals="3" name="ifrs-full:SignificantUnobservableInputAssets" format="ixt:num-dot-decimal" scale="-2" id="f-404">20.3</ix:nonFraction>% (2024 - <ix:nonFraction unitRef="number" contextRef="c-138" decimals="3" name="ifrs-full:SignificantUnobservableInputAssets" format="ixt:num-dot-decimal" scale="-2" id="f-405">15.7</ix:nonFraction>%) and an estimated useful life of <ix:nonNumeric contextRef="c-139" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-406">15</ix:nonNumeric> year</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 30 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:continuation id="f-322-2">s (2024 - <ix:nonNumeric contextRef="c-140" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" format="ixt-sec:duryear" id="f-407">15</ix:nonNumeric> years). Based on the Company&#8217;s assessment, the recoverable amount is higher than the carrying value and therefore no impairment loss was recorded for the years ended March&#160;31, 2025 or 2024.</ix:continuation> </span></div><div style="padding-left:18pt"><span><br/></span></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_699"></div><div><span style="color:#2d5f91;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.     <ix:nonNumeric contextRef="c-1" name="cybn:DisclosureOfLeasesAndRightOfUseAssetsTextBlock" id="f-408" continuedAt="f-408-1" escape="true">RIGHT-OF-USE ASSETS AND LEASE LIABILITIES</ix:nonNumeric></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-408-1" continuedAt="f-408-2"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">During the year ended March&#160;31, 2025, the Company terminated its lease early, resulting in a loss on the derecognition of its right-of-use assets of $<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="cybn:GainLossOnDerecognitionOfRightOfUseAssets" scale="3" id="f-409">52</ix:nonFraction> and a gain on derecognition of lease liabilities of $<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:GainLossOnDerecognitionOfLeaseLiability" scale="3" id="f-410">24</ix:nonFraction>. The loss on the derecognition of its right-of-use assets reflects the difference between the carrying value of the right-of-use asset and the recoverable amount at the time of derecognition. The gain on derecognition of lease liabilities was calculated as the difference between the carrying amount of the lease liability immediately before the termination and the payment made to settle the lease obligation. The net loss of $<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:OtherExpenseByNature" scale="3" id="f-411">28</ix:nonFraction> has been recognized as "other loss" in the consolidated statement of loss and comprehensive loss. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">a)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:9.96pt;text-decoration:underline">Right-of-use assets</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" id="f-412" escape="true"><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:38.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:59.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-57" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-413">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-60" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" id="f-414">412</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-60" decimals="-3" name="cybn:EffectOfForeignExchangeRightOfUseAssets" scale="3" id="f-415">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-63" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-416">424</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-66" decimals="-3" name="cybn:EffectOfForeignExchangeRightOfUseAssets" scale="3" id="f-417">24</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-66" decimals="-3" name="ifrs-full:DisposalsRightofuseAssets" scale="3" id="f-418">448</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-69" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-419">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31,  2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-72" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-420">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-75" decimals="-3" sign="-" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="f-421">140</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-75" decimals="-3" sign="-" name="cybn:EffectOfForeignExchangeRightOfUseAssets" scale="3" id="f-422">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-78" decimals="-3" sign="-" name="ifrs-full:RightofuseAssets" scale="3" id="f-423">143</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-81" decimals="-3" sign="-" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="f-424">238</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-81" decimals="-3" sign="-" name="cybn:EffectOfForeignExchangeRightOfUseAssets" scale="3" id="f-425">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-81" decimals="-3" name="ifrs-full:DisposalsRightofuseAssets" scale="3" id="f-426">395</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-84" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-427">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-428">281</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value as at  March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:RightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-429">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 31 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-408-2"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">b)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.53pt;text-decoration:underline">Lease Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" id="f-430" escape="true"><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:38.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:59.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-12" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-431">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:AdditionsToLeaseLiabilities" scale="3" id="f-432">415</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest accretion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="f-433">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:EffectOfForeignExchangeLeaseLiabilities" scale="3" id="f-434">17</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:PaymentsOfLeaseLiabilities" scale="3" id="f-435">149</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="f-436">291</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest accretion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="f-437">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:EffectOfForeignExchangeLeaseLiabilities" scale="3" id="f-438">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on derecognition</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:GainLossOnDerecognitionOfLeaseLiability" scale="3" id="f-439">24</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination penalty payment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:PaymentForTerminationPenaltyLeaseLiability" scale="3" id="f-440">31</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:PaymentsOfLeaseLiabilities" scale="3" id="f-441">259</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-442">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">     </span></div><div style="padding-left:17.85pt;text-align:justify;text-indent:-17.85pt"><span><br/></span></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_530"></div><div style="text-align:justify"><span style="color:#2d5f91;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.    <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGoodwillExplanatory" id="f-443" continuedAt="f-443-1" escape="true">GOODWILL</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-443-1"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory" id="f-444" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill is recognized at the acquisition date when total consideration exceeds the net identifiable assets acquired. </span></div><div><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:38.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:59.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-141" decimals="-3" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-445">24,792</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition from Small Pharma</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-142" decimals="-3" name="ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-446">22,652</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-142" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" scale="3" id="f-447">31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31,  2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-143" decimals="-3" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-448">47,475</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-144" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-449">4,012</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31,  2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-145" decimals="-3" name="ifrs-full:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-450">51,487</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Impairment</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">For purposes of the Company&#8217;s goodwill impairment testing, the Company has grouped certain CGUs to test at the lowest level at which management monitors goodwill for internal management purposes, which is the Company wide level.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company performed its annual impairment test of goodwill at March&#160;31, 2025. The recoverable amount was determined based on value-in-use (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">VIU</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) and considered the cash flows of the group of CGUs based on the current budget and future commercialization plans. In assessing the VIU, estimated future cash flows are discounted to their present value using a discount rate that reflects market assessments of the time value of money and the risks specific to the CGUs. The VIU calculations were performed using a pre-tax discount rate of <ix:nonFraction unitRef="number" contextRef="c-146" decimals="3" name="ifrs-full:SignificantUnobservableInputAssets" format="ixt:num-dot-decimal" scale="-2" id="f-451">20.3</ix:nonFraction>% (March&#160;31, 2024 - <ix:nonFraction unitRef="number" contextRef="c-147" decimals="3" name="ifrs-full:SignificantUnobservableInputAssets" format="ixt:num-dot-decimal" scale="-2" id="f-452">15.7</ix:nonFraction>%). The Company utilized the run-off method, and no terminal period cash flows were considered. Based on the Company&#8217;s assessment, the recoverable amount is higher than the carrying value and therefore <ix:nonFraction unitRef="cad" contextRef="c-1" decimals="INF" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill" format="ixt:fixed-zero" scale="0" id="f-453"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="INF" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill" format="ixt:fixed-zero" scale="0" id="f-454">no</ix:nonFraction></ix:nonFraction> impairment loss was recorded for the year ended March&#160;31, 2025 or March&#160;31, 2024.</span></div></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 32 of 52</span></div></div></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_548"></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#2d5f91;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="f-455" continuedAt="f-455-1" escape="true">SHARE CAPITAL</ix:nonNumeric></span></div><ix:continuation id="f-455-1" continuedAt="f-455-2"><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">a)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:9.96pt;text-decoration:underline">Authorized share capital</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On September 19, 2024, the Company completed the Consolidation.  As a result, the number of Common Shares, warrants, options and earnings per share presented in these consolidated financial statements have been restated retrospectively for all the years to reflect the Consolidation.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The authorized share capital of Cybin consists of an unlimited number of Common Shares and an unlimited number of preferred shares without par value. The board of directors of Cybin would determine the designation, rights, privileges, and conditions attached to any preferred shares prior to issuance.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">b)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:9.53pt;text-decoration:underline">Issued share capital</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Common Shares</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As at March&#160;31, 2025, the Company had <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="cybn:NumberOfCommonSharesHeldInEscrow" format="ixt:num-dot-decimal" scale="0" id="f-456">23,364</ix:nonFraction> Common Shares subject to transfer restrictions (March 31, 2024: <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="cybn:NumberOfCommonSharesHeldInEscrow" format="ixt:num-dot-decimal" scale="0" id="f-457">415,985</ix:nonFraction>). </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">During the year ended March 31, 2025, the Company completed the following share issuances:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On February 10, 2025, the Company established a new at-the-market equity program (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">2025 ATM Program</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221; and together with the 2023 ATM Program (see below), the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">ATM Programs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) that allow the Company to issue and sell up to US$<ix:nonFraction unitRef="cad" contextRef="c-148" decimals="-3" name="cybn:CommonStockSharesAuthorizedValue" format="ixt:num-dot-decimal" scale="0" id="f-458">100,000</ix:nonFraction> of Common Shares from treasury to the public, from time to time. Distributions of Common Shares under the 2025 ATM Program are made pursuant to the terms and conditions of an at-the-market equity distribution agreement (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">2025 Distribution Agreement</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) dated February 10, 2025, among the Company, Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald &amp; Co. The 2025 ATM Program is to be effective until the earlier of the issuance and sale of all of the Common Shares issuable pursuant to the 2025 ATM Program and September 17, 2025, unless earlier terminated in accordance with the terms of the 2025 Distribution Agreement.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">During the year ended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="cybn:NumberOfSharesIssuedThroughShareOfferingEquity" format="ixt:num-dot-decimal" scale="0" id="f-459">1,609,298</ix:nonFraction> Common Shares under the ATM Programs at an average price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-149" decimals="2" name="cybn:SharePricePerCommonShare" format="ixt:num-dot-decimal" scale="0" id="f-460">13.62</ix:nonFraction> (US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-149" decimals="2" name="cybn:SharePricePerCommonShare" format="ixt:num-dot-decimal" scale="0" id="f-461">9.52</ix:nonFraction>) per Common Share, for aggregate gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-149" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-462">21,924</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-463">15,322</ix:nonFraction>). Share issuance costs related to the ATM Programs for the year were $<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" scale="3" id="f-464">941</ix:nonFraction>.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">There were <ix:nonFraction unitRef="cad" contextRef="c-27" decimals="0" name="cybn:IncreaseDecreaseThroughShareConsolidationEquity" format="ixt-sec:numwordsen" scale="0" id="f-465">two</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> Common Shares issued in connection with the Consolidation as a result of rounding.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">During the year ended March 31, 2024, the Company completed the following share issuances:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On August 23, 2023, the Company established a new at-the-market equity program (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">2023 ATM Program</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221; and together with the 2022 at-the-market equity program, the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Prior</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">ATM Programs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) that allows the Company to issue and sell up to US$<ix:nonFraction unitRef="cad" contextRef="c-150" decimals="-3" name="cybn:CommonStockSharesAuthorizedValue" format="ixt:num-dot-decimal" scale="0" id="f-466">35,000</ix:nonFraction> of Common Shares from treasury to the public, from time to time. Distributions of Common Shares under the 2023 ATM Program are made pursuant to the terms and conditions of an at-the-market equity distribution agreement (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">2023 Distribution Agreement</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) dated August 23, 2023, among the Company, Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald &amp; Co. The 2023 ATM Program was terminated on February 10, 2025.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 33 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-455-2" continuedAt="f-455-3"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">During the year ended March 31, 2024, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-151" decimals="0" name="cybn:NumberOfSharesIssuedThroughShareOfferingEquity" format="ixt:num-dot-decimal" scale="0" id="f-467">898,434</ix:nonFraction> Common Shares under the Prior ATM Programs at an average price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-151" decimals="2" name="cybn:SharePricePerCommonShare" format="ixt:num-dot-decimal" scale="0" id="f-468">17.29</ix:nonFraction> (US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="2" name="cybn:SharePricePerCommonShare" format="ixt:num-dot-decimal" scale="0" id="f-469">12.82</ix:nonFraction>) per Common Share, for aggregate gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-151" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-470">15,532</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-471">11,518</ix:nonFraction>). Share issuance costs related to the ATM Programs for the year were $<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" scale="3" id="f-472">832</ix:nonFraction>.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On May 30, 2023, the Company entered into an agreement (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">LPC Agreement</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">LPC</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;). Subject to the terms and conditions of the LPC Agreement, the Company has the right to sell, and LPC is obligated to purchase, up to US$<ix:nonFraction unitRef="cad" contextRef="c-152" decimals="-3" name="cybn:CommonStockSharesAuthorizedValue" format="ixt:num-dot-decimal" scale="3" id="f-473">30,000</ix:nonFraction> of Common Shares over a <ix:nonNumeric contextRef="c-153" name="cybn:CommonSharesPurchasePeriodTerm" format="ixt-sec:durwordsen" id="f-474">36-month</ix:nonNumeric> period at prices that are based on the market price at the time of each sale to LPC. Cybin, in its sole discretion, controls the timing and amount of all sales of Common Shares under the LPC Agreement. During the year ended March 31, 2024, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-154" decimals="0" name="cybn:NumberOfSharesIssuedThroughShareOfferingEquity" format="ixt:num-dot-decimal" scale="0" id="f-475">50,658</ix:nonFraction> Common Shares, at an average price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-154" decimals="2" name="cybn:SharePricePerCommonShare" format="ixt:num-dot-decimal" scale="0" id="f-476">12.30</ix:nonFraction> (US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-154" decimals="2" name="cybn:SharePricePerCommonShare" format="ixt:num-dot-decimal" scale="0" id="f-477">9.18</ix:nonFraction>) per Common Shares, for aggregate gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-154" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="3" id="f-478">623</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="3" id="f-479">465</ix:nonFraction>) pursuant to the LPC Agreement. Share issuance costs related to the LPC Agreement for the year ended March  31, 2024 were $<ix:nonFraction unitRef="cad" contextRef="c-155" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="3" id="f-480">476</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="3" id="f-481">351</ix:nonFraction>).</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cybin has the right to terminate the LPC Agreement at any time at no cost or penalty. LPC has agreed not to engage in any short selling or hedging activity of any kind in the Common Shares. As consideration for LPC&#8217;s obligation to purchase Common Shares from the Company at its direction under the LPC Agreement, Cybin issued <ix:nonFraction unitRef="shares" contextRef="c-156" decimals="0" name="cybn:NumberOfSharesIssuedThroughShareOfferingEquity" format="ixt:num-dot-decimal" scale="0" id="f-482">66,812</ix:nonFraction> Common Shares to LPC as a commitment fee on May 30, 2023.  The LPC Agreement provides that Cybin may not issue or sell any Common Shares to LPC under the LPC Agreement which, when aggregated with all other Common Shares then beneficially owned by LPC and its affiliates (as calculated pursuant to Section 13(d) of the U.S. Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder), would result in LPC beneficially owning more than <ix:nonFraction unitRef="number" contextRef="c-157" decimals="4" name="cybn:PercentageOfOutstandingCommonSharesOwn" format="ixt:num-dot-decimal" scale="-2" id="f-483">9.99</ix:nonFraction>% of the outstanding Common Shares. On July 31, 2023, Cybin announced that it had suspended all sales under the LPC Agreement. On August 23, 2023, the Company filed a prospectus supplement to the base shelf prospectus dated August 17, 2023 to re-qualify sales of up to US$<ix:nonFraction unitRef="cad" contextRef="c-158" decimals="-3" name="cybn:CommonStockSharesAuthorizedValue" format="ixt:num-dot-decimal" scale="3" id="f-484">30,000</ix:nonFraction> of the Company&#8217;s Common Shares pursuant to the LPC Agreement. On November 9, 2023, the Company announced that it has, again, suspended all sales under the LPC Agreement. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On August 4, 2023, the Company completed a public offering (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">August 2023 Offering</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) of <ix:nonFraction unitRef="shares" contextRef="c-159" decimals="0" name="cybn:NumberOfSharesIssuedThroughShareOfferingEquity" format="ixt:num-dot-decimal" scale="0" id="f-485">638,545</ix:nonFraction> units of the Company (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">August 2023 Units</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) at a price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-159" decimals="2" name="cybn:SharePricePerCommonShare" format="ixt:num-dot-decimal" scale="0" id="f-486">12.92</ix:nonFraction> per August 2023 Unit for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-159" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-487">11,018</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-488">8,250</ix:nonFraction>) pursuant to a supplement to the Company&#8217;s short form base shelf prospectus dated July 5, 2021. Each August 2023 Unit is comprised of <ix:nonFraction unitRef="shares" contextRef="c-160" decimals="0" name="cybn:NumberOfCommonShares" format="ixt-sec:numwordsen" scale="0" id="f-489">one</ix:nonFraction> Common Share and <ix:nonFraction unitRef="shares" contextRef="c-160" decimals="0" name="cybn:NumberOfCommonSharePurchaseWarrants" format="ixt-sec:numwordsen" scale="0" id="f-490">one</ix:nonFraction> Common Share purchase warrant (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">August 2023 Warrants</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;). Each August 2023 Warrant is exercisable to acquire <ix:nonFraction unitRef="shares" contextRef="c-160" decimals="INF" name="cybn:NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement" format="ixt-sec:numwordsen" scale="0" id="f-491">one</ix:nonFraction> Common Share at a price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-160" decimals="2" name="cybn:ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-492">21.85</ix:nonFraction> (US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-160" decimals="2" name="cybn:ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-493">15.20</ix:nonFraction>) for a period of <ix:nonNumeric contextRef="c-161" name="cybn:PeriodToExerciseWarrantsInShareBasedPaymentArrangement" format="ixt-sec:durmonth" id="f-494">60</ix:nonNumeric> months from issuance, subject to acceleration in certain circumstances. In connection with the Offering, Cybin paid the underwriters a cash commission of $<ix:nonFraction unitRef="cad" contextRef="c-161" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" scale="3" id="f-495">506</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" scale="3" id="f-496">379</ix:nonFraction>) and incurred additional share issuance costs, being professional fees of $<ix:nonFraction unitRef="cad" contextRef="c-161" decimals="-3" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="f-497">622</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="f-498">465</ix:nonFraction>).</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On November 14, 2023, the Company completed a public offering (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">November 2023 Offering</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) of <ix:nonFraction unitRef="shares" contextRef="c-162" decimals="0" name="cybn:NumberOfSharesIssuedThroughShareOfferingEquity" format="ixt:num-dot-decimal" scale="0" id="f-499">1,754,386</ix:nonFraction> units of the Company (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">November 2023 Units</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) at a price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-162" decimals="2" name="cybn:SharePricePerCommonShare" format="ixt:num-dot-decimal" scale="0" id="f-500">17.10</ix:nonFraction> per November 2023 Unit for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-162" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-501">41,107</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-502">30,000</ix:nonFraction>) pursuant to a supplement to the Company&#8217;s short form base shelf prospectus dated August 17, 2023. Each November 2023 Unit is comprised of <ix:nonFraction unitRef="shares" contextRef="c-163" decimals="0" name="cybn:NumberOfCommonShares" format="ixt-sec:numwordsen" scale="0" id="f-503">one</ix:nonFraction> Common Share and <ix:nonFraction unitRef="shares" contextRef="c-163" decimals="0" name="cybn:NumberOfCommonSharePurchaseWarrants" format="ixt-sec:numwordsen" scale="0" id="f-504">one</ix:nonFraction> Common Share purchase warrant (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">November 2023 Warrants</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;). Each November 2023 Warrant is exercisable to acquire <ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="cybn:NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement" format="ixt-sec:numwordsen" scale="0" id="f-505">one</ix:nonFraction> Common Share at a price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-163" decimals="2" name="cybn:ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-506">27.86</ix:nonFraction> (US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-163" decimals="2" name="cybn:ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-507">19.38</ix:nonFraction>) between May 14, 2024 and May 14, 2029, subject to acceleration in certain circumstances. In connection with the November 2023 Offering, Cybin paid the underwriters a cash commission of $<ix:nonFraction unitRef="cad" contextRef="c-164" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" format="ixt:num-dot-decimal" scale="3" id="f-508">2,096</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" format="ixt:num-dot-decimal" scale="3" id="f-509">1,530</ix:nonFraction>) and incurred additional share issuance costs being professional fees of $<ix:nonFraction unitRef="cad" contextRef="c-164" decimals="-3" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="f-510">339</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="f-511">247</ix:nonFraction>).</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 34 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-455-3" continuedAt="f-455-4"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On March 19, 2024, the Company completed a private placement (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">March 2024 Offering</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) of <ix:nonFraction unitRef="shares" contextRef="c-165" decimals="0" name="cybn:NumberOfSharesIssuedThroughShareOfferingEquity" format="ixt:num-dot-decimal" scale="0" id="f-512">9,179,927</ix:nonFraction> Common Shares at a price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-166" decimals="2" name="cybn:SharePricePerCommonShare" format="ixt:num-dot-decimal" scale="0" id="f-513">16.34</ix:nonFraction> per Common Share for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-166" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-514">202,995</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-515">150,000</ix:nonFraction>). <ix:nonFraction unitRef="shares" contextRef="c-166" decimals="1" name="cybn:NumberOfSharesSubjectToResaleRestrictions" format="ixt:num-dot-decimal" scale="0" id="f-516">415,985</ix:nonFraction> Common Shares issued in the March 2024 Offering were subject to resale restrictions until July 20, 2024. In connection with the March  2024 Offering, Cybin paid the agent a cash commission of $<ix:nonFraction unitRef="cad" contextRef="c-167" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" format="ixt:num-dot-decimal" scale="3" id="f-517">11,726</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="ifrs-full:PaymentsForShareIssueCosts" format="ixt:num-dot-decimal" scale="3" id="f-518">8,665</ix:nonFraction>) and incurred additional share issuance costs being professional fees of $<ix:nonFraction unitRef="cad" contextRef="c-167" decimals="-3" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="f-519">504</ix:nonFraction> .</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Preferred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Shares</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As at March&#160;31, 2025,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> the Company had <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-520">no</ix:nonFraction> preferred shares outstanding (2024- <ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-521">nil</ix:nonFraction>).</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="f-522" escape="true"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Cybin US Class B Shares</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:65.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Class B Shares</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-170" decimals="1" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" id="f-523">530,542.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Converted into Common Shares</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-171" decimals="1" sign="-" name="cybn:IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares" format="ixt:num-dot-decimal" id="f-524">494,457.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-172" decimals="1" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" id="f-525">36,084.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-173" decimals="1" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" id="f-526">36,084.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As at March&#160;31, 2025, <ix:nonFraction unitRef="shares" contextRef="c-173" decimals="1" name="ifrs-full:NumberOfSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-527">36,084.7</ix:nonFraction> class B common shares of Cybin US (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Class B Shares</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;) were outstanding, and are exchangeable for a total of <ix:nonFraction unitRef="shares" contextRef="c-173" decimals="0" name="cybn:NumberOfSharesIssuedUponConversionOfConvertibleInstruments" format="ixt:num-dot-decimal" scale="0" id="f-528">9,496</ix:nonFraction> Common Shares. The Class B Shares are exchangeable at the holder&#8217;s option for Common Shares on the basis of <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="5" name="cybn:CommonSharesExchangeRate" format="ixt:num-dot-decimal" scale="0" id="f-529">0.26316</ix:nonFraction> Common Shares for 1 Class B Share. These consolidated financial statements reflect issued Class B Shares on an as-converted basis. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">During the year ended March 31, 2025, <ix:nonFraction unitRef="shares" contextRef="c-174" decimals="1" name="cybn:NumberOfSharesConvertedThroughContingentConsiderationEquity" format="ixt:fixed-zero" scale="0" id="f-530"><ix:nonFraction unitRef="shares" contextRef="c-174" decimals="1" name="cybn:NumberOfSharesIssuedThroughContingentConsiderationEquity" format="ixt:fixed-zero" scale="0" id="f-531">no</ix:nonFraction></ix:nonFraction> Class B Shares were issued or converted.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 35 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-455-4" continuedAt="f-455-5"><div style="margin-top:10pt;padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">c)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%;padding-left:10.56pt;text-decoration:underline">Warrants</span></div><div style="text-align:justify;text-indent:0.15pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="f-532" continuedAt="f-532-1" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The continuity of the outstanding warrants for the years ended March 31, 2025 and 2024, are as follows: </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:61.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Warrants</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Common Share Purchase Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-175" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-533">611,329</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-175" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" id="f-534">49.02</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-176" decimals="0" name="cybn:NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-535">2,392,931</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-176" decimals="2" name="cybn:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement" id="f-536">25.46</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-176" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-537">2,658</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-176" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" id="f-538">20.14</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-176" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-539">205,404</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-176" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" id="f-540">131.86</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-177" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-541">2,796,197</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-177" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" id="f-542">22.74</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-178" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" id="f-543">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-178" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" id="f-544">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-179" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-545">2,796,197</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-179" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" id="f-546">24.03</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-179" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-547">2,796,197</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-179" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" id="f-548">24.03</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unit Purchase Warrants</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-180" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-549">22,862</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-180" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" id="f-550">85.50</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-181" decimals="0" sign="-" name="cybn:NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-551">22,862</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-181" decimals="2" name="cybn:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement" id="f-552">85.50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at March 31, 2024 and March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-182" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" id="f-553"><ix:nonFraction unitRef="shares" contextRef="c-183" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" id="f-554">&#8212;</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-183" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" id="f-555"><ix:nonFraction unitRef="cadPerShare" contextRef="c-182" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" id="f-556">&#8212;</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Certain warrants were issued in USD, the weighted average exercise price is calculated using the closing exchange rate in effect as at the respective dates.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">        </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Each unit consisted of <ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="cybn:NumberOfCommonShares" format="ixt-sec:numwordsen" scale="0" id="f-557">one</ix:nonFraction> Common Share and one half of one Common Share purchase warrant, with each Common Share purchase warrant being exercisable to acquire <ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="cybn:NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement" format="ixt-sec:numwordsen" scale="0" id="f-558">one</ix:nonFraction> Common Share at an exercise price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-183" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" format="ixt:num-dot-decimal" scale="0" id="f-559">123.50</ix:nonFraction> per Common Share.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">During the year ended March 31, 2024, the Company had the following movement in warrants:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended March 31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-176" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-560">2,658</ix:nonFraction> Common Share purchase warrants were exercised by various holders for aggregate proceeds to the Company of $<ix:nonFraction unitRef="cad" contextRef="c-178" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" scale="3" id="f-561">56</ix:nonFraction>. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended March 31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-176" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-562">205,404</ix:nonFraction> warrants with a weighted average exercise price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-176" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" format="ixt:num-dot-decimal" scale="0" id="f-563">131.86</ix:nonFraction> expired unexercised.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">During the year ended March 31, 2024, the Company completed the following warrant issuances: </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On August 4, 2023, Cybin issued <ix:nonFraction unitRef="shares" contextRef="c-161" decimals="0" name="cybn:NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-564">638,545</ix:nonFraction> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">August 2023 Warrants in connection with the August 2023 Offering. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Each August 2023 Warrant is exercisable to acquire <ix:nonFraction unitRef="shares" contextRef="c-160" decimals="INF" name="cybn:NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement" format="ixt-sec:numwordsen" scale="0" id="f-565">one</ix:nonFraction> Common Share at a price of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> US$<ix:nonFraction unitRef="cadPerShare" contextRef="c-161" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" format="ixt:num-dot-decimal" scale="0" id="f-566">15.20</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> per Common Share until August 4, 2028, subject to acceleration in certain circumstances. </span></div></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 36 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-455-5" continuedAt="f-455-6"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" id="f-567" continuedAt="f-567-1" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company estimated the aggregate fair value of the August 2023 Warrants using the Black-Scholes option pricing model to be $<ix:nonFraction unitRef="cad" contextRef="c-161" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-568">4,600</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-569">3,442</ix:nonFraction>) with the following assumptions: </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"/><td style="width:81.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-161" decimals="4" name="cybn:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-570">3.87</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-161" decimals="4" name="cybn:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="f-571">95.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-161" name="cybn:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="f-572">5.00</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-161" decimals="4" name="cybn:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="f-573">0.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-161" decimals="2" name="cybn:SharePricePerCommonShare" format="ixt:num-dot-decimal" scale="0" id="f-574">12.92</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-161" decimals="2" name="cybn:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-575">15.20</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On November 14, 2023, Cybin issued <ix:nonFraction unitRef="shares" contextRef="c-184" decimals="0" name="cybn:NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-576">1,754,386</ix:nonFraction> November 2023 Warrants in connection with the November 2023 Offering. Each November 2023 Warrant is exercisable from May 14, 2024 to May 14, 2029 to acquire <ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="cybn:NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement" format="ixt-sec:numwordsen" scale="0" id="f-577">one</ix:nonFraction> Common Share at a price of </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">US$<ix:nonFraction unitRef="cadPerShare" contextRef="c-184" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" format="ixt:num-dot-decimal" scale="0" id="f-578">19.38</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, subject to acceleration in certain circumstances.  </span></div><div style="padding-left:18pt"><span><br/></span></div><ix:continuation id="f-567-1"><div style="padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company estimated the aggregate fair value of the November 2023 Warrants using the Black-</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Scholes option pricing model to be $<ix:nonFraction unitRef="cad" contextRef="c-184" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-579">17,842</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-580">12,299</ix:nonFraction>) with the following assumptions: </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"/><td style="width:81.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-184" decimals="4" name="cybn:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-581">3.76</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-184" decimals="4" name="cybn:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="f-582">95.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-184" name="cybn:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" format="ixt-sec:duryear" id="f-583">5.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-184" decimals="4" name="cybn:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" scale="-2" id="f-584">0.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-184" decimals="2" name="cybn:SharePricePerCommonShare" format="ixt:num-dot-decimal" scale="0" id="f-585">17.48</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-184" decimals="2" name="cybn:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-586">19.38</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   </span></div><ix:continuation id="f-532-1"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes information about warrants outstanding as at March&#160;31, 2025:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:30.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Expiry</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants outstanding</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants exercisable</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average of exercisable price</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated fair value</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average remaining contractual life</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$000&#8217;s</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2028</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-185" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-587">635,887</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-185" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-588">635,887</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="cadPerShare" contextRef="c-185" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" format="ixt:num-dot-decimal" id="f-589">15.20</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-185" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="3" id="f-590">4,578</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-185" name="cybn:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" format="ixt-sec:duryear" id="f-591">3.35</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 14, 2029</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-186" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-592">1,754,386</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-186" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-593">1,754,386</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="cadPerShare" contextRef="c-186" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" format="ixt:num-dot-decimal" id="f-594">19.38</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-186" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="3" id="f-595">17,842</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-186" name="cybn:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" format="ixt-sec:duryear" id="f-596">4.12</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 15, 2030</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-187" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-597">336,843</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-187" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-598">336,843</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-187" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" id="f-599">9.50</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-187" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="3" id="f-600">3,891</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-187" name="cybn:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" format="ixt-sec:duryear" id="f-601">5.21</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 20, 2030</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-188" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-602">38,818</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-188" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-603">38,818</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-188" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" id="f-604">24.32</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-188" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="3" id="f-605">936</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-188" name="cybn:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" format="ixt-sec:duryear" id="f-606">5.39</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2030</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-189" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-607">30,263</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-189" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-608">30,263</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-189" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" id="f-609">9.50</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-189" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="3" id="f-610">347</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-189" name="cybn:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" format="ixt-sec:duryear" id="f-611">5.63</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-179" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-612">2,796,197</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-179" decimals="0" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-613">2,796,197</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-179" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" id="f-614">24.03</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-179" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="3" id="f-615">27,594</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-179" name="cybn:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" format="ixt-sec:duryear" id="f-616">4.11</ix:nonNumeric></span></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On August 27, 2024, the Company, upon receiving shareholder approval, extended the expiry dates of the warrants originally expiring on June 15, 2025, August 20 , 2025, and November 15, 2025 to June 15, 2030, August 20, 2030, and November 15, 2030, respectively. The Company extended the expiry date of <ix:nonFraction unitRef="shares" contextRef="c-179" decimals="0" name="cybn:NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended" format="ixt:num-dot-decimal" scale="0" id="f-617">405,924</ix:nonFraction> </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 37 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-455-6" continuedAt="f-455-7"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">warrants, of which <ix:nonFraction unitRef="shares" contextRef="c-190" decimals="0" name="cybn:NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended" format="ixt:num-dot-decimal" scale="0" id="f-618">260,527</ix:nonFraction> warrants related to officers and directors of the Company. No other changes to the terms of the warrants were made. As a result of the modification, the Company recorded an additional expense, related to the incremental fair value of the extended warrants, of $<ix:nonFraction unitRef="cad" contextRef="c-30" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-619">1,955</ix:nonFraction> in the statements of loss and comprehensive loss as "Share-based compensation".</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">d</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">)  </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%;text-decoration:underline"> Stock options</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On November 5, 2020, Cybin adopted an equity incentive plan. Under the plan, the board of directors may grant share-based awards to acquire such number of Common Shares as is equal to up to <ix:nonFraction unitRef="number" contextRef="c-191" decimals="2" name="cybn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding" scale="-2" id="f-620">20</ix:nonFraction>% of the total number of issued and outstanding Common Shares at the time such awards are granted. Options granted under the plan vest over a period of time at the discretion of the board of directors. On August 27, 2024, the board of directors and the shareholders re-approved the equity incentive plan and approved certain amendments to the plan, including an increase to the fixed number of Incentive Stock Options (as defined in the plan), certain changes to the board of directors' authority to amend existing awards, and certain other housekeeping amendments.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="f-621" continuedAt="f-621-1" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in options for the years ended March 31, 2025 and 2024 are as follow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s: </span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:66.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Options</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average exercise price</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-622">778,163</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-12" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" id="f-623">51.68</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-624">1,011,711</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-5" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" id="f-625">26.22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="cybn:NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-626">47,735</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-5" decimals="2" name="cybn:WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" id="f-627">44.08</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-628">1,742,139</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-3" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" id="f-629">35.17</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-630">3,484,626</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-1" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" id="f-631">13.84</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="cybn:NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-632">1,270,081</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-1" decimals="2" name="cybn:WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" id="f-633">38.76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-634">3,956,684</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-2" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" id="f-635">15.23</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable as at March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-636">3,591,976</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-2" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" id="f-637">15.19</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">During the year ended March 31, 2025, the Company completed the following option issuances:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On April 5, 2024, the Company granted options to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-192" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-638">308,294</ix:nonFraction> Common Shares, of which <ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-639">134,872</ix:nonFraction> were granted to employees, <ix:nonFraction unitRef="shares" contextRef="c-194" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-640">144,738</ix:nonFraction> were granted to officers of the Company and <ix:nonFraction unitRef="shares" contextRef="c-195" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-641">28,684</ix:nonFraction> were granted to consultants. The granted options have an exercise price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-196" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" format="ixt:num-dot-decimal" scale="0" id="f-642">21.28</ix:nonFraction> per Common Share and expire on April 5, 2029. The granted options have different vesting schedules; <ix:nonFraction unitRef="shares" contextRef="c-197" decimals="INF" name="cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-643">38,536</ix:nonFraction> options vested immediately and <ix:nonFraction unitRef="shares" contextRef="c-198" decimals="INF" name="cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-644">269,758</ix:nonFraction> options vest over <ix:nonNumeric contextRef="c-199" name="cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-645">two years</ix:nonNumeric>. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" id="f-646" continuedAt="f-646-1" escape="true">The aggregate estimated grant date fair value was determined to be $<ix:nonFraction unitRef="cad" contextRef="c-200" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" format="ixt:num-dot-decimal" scale="3" id="f-647">4,619</ix:nonFraction> calculated using the Black-Scholes option pricing model with the following assumptions: </ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 38 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-455-7" continuedAt="f-455-8"><ix:continuation id="f-646-1" continuedAt="f-646-2"><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"/><td style="width:81.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-201" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-648">3.62</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on historical share price of the Company</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-201" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-649">88.13</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="c-201" decimals="2" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" id="f-650">5.00</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-201" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-651">0.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested forfeiture rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-202" decimals="3" name="cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted" scale="-2" id="f-652">0</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-203" decimals="3" name="cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted" format="ixt:num-dot-decimal" scale="-2" id="f-653">3.4</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-201" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-654">21.28</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-201" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-655">21.28</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-top:12pt;padding-left:17.85pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On May 5, 2024, the Company cancelled options to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-204" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-656">1,199,655</ix:nonFraction> Common Shares (exercise prices ranged from $<ix:nonFraction unitRef="cadPerShare" contextRef="c-205" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" format="ixt:num-dot-decimal" scale="0" id="f-657">27.17</ix:nonFraction> to $<ix:nonFraction unitRef="cadPerShare" contextRef="c-206" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" format="ixt:num-dot-decimal" scale="0" id="f-658">119.70</ix:nonFraction>). The unvested options were vested based on an accelerated cancellation criteria which resulted in $<ix:nonFraction unitRef="cad" contextRef="c-207" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-659">1,185</ix:nonFraction> of share based compensation expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On August 15, 2024, the Company granted options to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-208" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-660">3,061,232</ix:nonFraction> Common Shares, of which <ix:nonFraction unitRef="shares" contextRef="c-209" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-661">940,168</ix:nonFraction> were granted to employees, <ix:nonFraction unitRef="shares" contextRef="c-210" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-662">1,980,888</ix:nonFraction> were granted to officers and directors and <ix:nonFraction unitRef="shares" contextRef="c-211" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-663">140,176</ix:nonFraction> were granted to consultants. The granted options have an exercise price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-212" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" format="ixt:num-dot-decimal" scale="0" id="f-664">13.11</ix:nonFraction> per Common Share and expire on August 15, 2034. Certain options vested immediately, while others vest over periods of up to <ix:nonNumeric contextRef="c-213" name="cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-665">two years</ix:nonNumeric>. <ix:continuation id="f-646-2" continuedAt="f-646-3">The aggregate estimated grant date fair value was determined to be $<ix:nonFraction unitRef="cad" contextRef="c-214" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" format="ixt:num-dot-decimal" scale="3" id="f-666">34,822</ix:nonFraction> calculated using the Black-Scholes option pricing model with the following assumptions: </ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-646-3" continuedAt="f-646-4"><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-213" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-667">3.07</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on historical share price of the Company</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-213" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-668">86.69</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="c-213" decimals="2" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" id="f-669">10.00</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-213" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-670">0.00</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested forfeiture rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-215" decimals="3" name="cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted" scale="-2" id="f-671">0</ix:nonFraction>%  - <ix:nonFraction unitRef="number" contextRef="c-216" decimals="3" name="cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted" format="ixt:num-dot-decimal" scale="-2" id="f-672">3.4</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-213" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-673">13.30</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-213" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-674">13.11</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On November 27, 2024, the Company granted options to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-217" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-675">80,100</ix:nonFraction> Common Shares, of which <ix:nonFraction unitRef="shares" contextRef="c-218" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-676">73,100</ix:nonFraction> were granted to employees and <ix:nonFraction unitRef="shares" contextRef="c-219" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-677">7,000</ix:nonFraction> was granted to a consultant. The granted options have an exercise price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-220" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" format="ixt:num-dot-decimal" scale="0" id="f-678">14.37</ix:nonFraction> per Common Share and expire on November 27, 2034. The granted options vest over periods of up to <ix:nonNumeric contextRef="c-221" name="cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-679">two years</ix:nonNumeric>. <ix:continuation id="f-646-4" continuedAt="f-646-5">The aggregate estimated grant date fair value was determined to be $<ix:nonFraction unitRef="cad" contextRef="c-222" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-680">982</ix:nonFraction> calculated using the Black-Scholes option pricing model with the following assumptions: </ix:continuation></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 39 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-455-8" continuedAt="f-455-9"><ix:continuation id="f-646-5" continuedAt="f-646-6"><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:74.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-223" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-681">3.23</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on historical share price of the Company</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-223" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-682">86.06</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="c-223" decimals="2" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" id="f-683">10.00</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-223" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-684">0.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested forfeiture rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-224" decimals="3" name="cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted" scale="-2" id="f-685">0</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-225" decimals="3" name="cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted" format="ixt:num-dot-decimal" scale="-2" id="f-686">3.4</ix:nonFraction>% </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-223" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-687">14.37</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-223" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-688">14.37</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On March 7, 2025, the Company granted options to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-226" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-689">35,000</ix:nonFraction> Common Shares to a consultant. The granted options have an exercise price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-227" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" format="ixt:num-dot-decimal" scale="0" id="f-690">10.45</ix:nonFraction> per Common Share and expire on March 7, 2035. The granted options vest over period of <ix:nonNumeric contextRef="c-228" name="cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-691">one year</ix:nonNumeric>. <ix:continuation id="f-646-6" continuedAt="f-646-7">The aggregate estimated grant date fair value was determined to be $<ix:nonFraction unitRef="cad" contextRef="c-229" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-692">307</ix:nonFraction> calculated using the Black-Scholes option pricing model with the following assumptions: </ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-646-7" continuedAt="f-646-8"><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:74.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-230" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-693">3.03</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on historical share price of the Company</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-230" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-694">83.43</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="c-230" decimals="2" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" id="f-695">10.00</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-230" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-696">0.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested forfeiture rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-230" decimals="2" name="cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted" scale="-2" id="f-697">2</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-230" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-698">10.45</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-230" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-699">10.45</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">D</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">uring the year ended March 31, 2024, the Company completed the following option issuances:</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On June 29, 2023, the Company granted options to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-231" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-700">305,661</ix:nonFraction> Common Shares, of which <ix:nonFraction unitRef="shares" contextRef="c-232" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-701">105,026</ix:nonFraction></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> were granted to employees, <ix:nonFraction unitRef="shares" contextRef="c-233" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-702">99,027</ix:nonFraction> were granted to officers of the Company, <ix:nonFraction unitRef="shares" contextRef="c-234" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-703">80,949</ix:nonFraction> were granted to consultants, and <ix:nonFraction unitRef="shares" contextRef="c-235" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-704">20,659</ix:nonFraction> were granted to directors of the Company. The granted options have an exercise price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-236" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" format="ixt:num-dot-decimal" scale="0" id="f-705">16.72</ix:nonFraction> per Common Share and expire on June 30, 2028. The granted options have different vesting schedules; <ix:nonFraction unitRef="shares" contextRef="c-237" decimals="INF" name="cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-706">39,474</ix:nonFraction> options vested immediately, <ix:nonFraction unitRef="shares" contextRef="c-238" decimals="INF" name="cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-707">18,422</ix:nonFraction> options vest over <ix:nonNumeric contextRef="c-239" name="cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-708">three months</ix:nonNumeric>, <ix:nonFraction unitRef="shares" contextRef="c-240" decimals="INF" name="cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-709">2,632</ix:nonFraction> options vest over <ix:nonNumeric contextRef="c-241" name="cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-710">one year</ix:nonNumeric>, and <ix:nonFraction unitRef="shares" contextRef="c-242" decimals="INF" name="cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-711">245,133</ix:nonFraction> options vest over <ix:nonNumeric contextRef="c-243" name="cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-712">two years</ix:nonNumeric>.  <ix:continuation id="f-646-8" continuedAt="f-646-9">The aggregate estimated grant date fair value was determined to be $<ix:nonFraction unitRef="cad" contextRef="c-244" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" format="ixt:num-dot-decimal" scale="3" id="f-713">4,080</ix:nonFraction>, calculated using the Black-Scholes option pricing model with the following assumptions: </ix:continuation></span></div><ix:continuation id="f-646-9" continuedAt="f-646-10"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"/><td style="width:81.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-245" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-714">3.78</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-245" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-715">95.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="c-245" decimals="2" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" id="f-716">5.00</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-245" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-717">0.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-245" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-718">17.86</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-245" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-719">16.72</ix:nonFraction></span></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On September 26, 2023, the Company granted options to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-246" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-720">31,842</ix:nonFraction> Common Shares, of which <ix:nonFraction unitRef="shares" contextRef="c-247" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-721">3,553</ix:nonFraction> were granted to an employee and, <ix:nonFraction unitRef="shares" contextRef="c-248" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-722">28,289</ix:nonFraction> were granted to consultants. The granted options have an exercise price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-246" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" format="ixt:num-dot-decimal" scale="0" id="f-723">30.02</ix:nonFraction> per Common Share, and <ix:nonFraction unitRef="shares" contextRef="c-249" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-724">25,657</ix:nonFraction> options expire on September 26, 2026 and the re</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 40 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-455-9" continuedAt="f-455-10"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">maining <ix:nonFraction unitRef="shares" contextRef="c-250" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-725">6,185</ix:nonFraction> options expire on September 26, 2028. The granted options have different vesting schedules. <ix:nonFraction unitRef="shares" contextRef="c-251" decimals="INF" name="cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-726">9,868</ix:nonFraction> options vest over <ix:nonNumeric contextRef="c-252" name="cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-727">three months</ix:nonNumeric>, <ix:nonFraction unitRef="shares" contextRef="c-253" decimals="INF" name="cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-728">5,263</ix:nonFraction> options vest over <ix:nonNumeric contextRef="c-254" name="cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-729">six months</ix:nonNumeric>, <ix:nonFraction unitRef="shares" contextRef="c-255" decimals="INF" name="cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-730">10,526</ix:nonFraction> options vest over <ix:nonNumeric contextRef="c-256" name="cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-731">one year</ix:nonNumeric>, <ix:nonFraction unitRef="shares" contextRef="c-257" decimals="INF" name="cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-732">2,632</ix:nonFraction> options vest over <ix:nonNumeric contextRef="c-258" name="cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-733">fifteen months</ix:nonNumeric>, and <ix:nonFraction unitRef="shares" contextRef="c-259" decimals="INF" name="cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-734">3,553</ix:nonFraction> options vest over <ix:nonNumeric contextRef="c-260" name="cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durmonth" id="f-735">18</ix:nonNumeric> months.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-646-10" continuedAt="f-646-11"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> The aggregate estimated grant date fair value was determined to be $<ix:nonFraction unitRef="cad" contextRef="c-261" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-736">577</ix:nonFraction>, calculated using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> Options expiring on September 26, 2026</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"/><td style="width:81.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-262" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-737">4.68</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-262" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-738">85.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="c-262" decimals="2" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" id="f-739">3.00</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-262" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-740">0.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-262" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-741">30.02</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-262" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-742">30.02</ix:nonFraction></span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Options  expiring on September 26, 2028</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"/><td style="width:81.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Risk-free interest rate</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-263" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-743">4.28</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-263" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-744">95.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="c-263" decimals="2" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" id="f-745">5.00</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-263" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-746">0.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-263" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-747">30.02</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-263" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-748">30.02</ix:nonFraction></span></td></tr></table></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On November 16, 2023, the Company granted options to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-264" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-749">673,682</ix:nonFraction> Common Shares, of which <ix:nonFraction unitRef="shares" contextRef="c-265" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-750">584,211</ix:nonFraction> were granted to officers, <ix:nonFraction unitRef="shares" contextRef="c-266" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-751">42,104</ix:nonFraction> were granted to directors, <ix:nonFraction unitRef="shares" contextRef="c-267" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-752">34,209</ix:nonFraction> were granted to employees and <ix:nonFraction unitRef="shares" contextRef="c-268" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-753">13,158</ix:nonFraction> were granted to a consultant. The granted options have an exercise price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-269" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" format="ixt:num-dot-decimal" scale="0" id="f-754">27.17</ix:nonFraction> per Common Share, <ix:nonFraction unitRef="shares" contextRef="c-270" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-755">13,158</ix:nonFraction> options expire on November 16, 2026 and the remaining <ix:nonFraction unitRef="shares" contextRef="c-271" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-756">660,524</ix:nonFraction> options expire on November 16, 2028. The granted options have different vesting schedules. <ix:nonFraction unitRef="shares" contextRef="c-272" decimals="INF" name="cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-757">496,052</ix:nonFraction> options vest immediately and <ix:nonFraction unitRef="shares" contextRef="c-273" decimals="INF" name="cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-758">177,630</ix:nonFraction> options vest over <ix:nonNumeric contextRef="c-274" name="cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-759">two years</ix:nonNumeric>. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-646-11" continuedAt="f-646-12"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The aggregate estimated grant date fair value was determined to be $<ix:nonFraction unitRef="cad" contextRef="c-275" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" format="ixt:num-dot-decimal" scale="3" id="f-760">10,907</ix:nonFraction>, calculated using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Options expiring on November 16, 2026</span></div><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"/><td style="width:81.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-276" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-761">4.28</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-276" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-762">85.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="c-276" decimals="2" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" id="f-763">3.00</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-276" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-764">0.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-276" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-765">22.80</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-276" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-766">27.17</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 41 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-455-10" continuedAt="f-455-11"><ix:continuation id="f-646-12" continuedAt="f-646-13"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Options expiring on November 16, 2028</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"/><td style="width:81.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-277" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-767">4.28</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-277" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-768">95.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="c-277" decimals="2" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" id="f-769">5.00</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-277" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-770">0.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-277" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-771">22.80</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-277" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-772">27.17</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 20, 2024, the Company granted options to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-278" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="f-773">526</ix:nonFraction> Common Shares to an employee with an exercise price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-279" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" format="ixt:num-dot-decimal" scale="0" id="f-774">21.28</ix:nonFraction> per Common Share which expire on March 20, 2029 and vest over <ix:nonNumeric contextRef="c-280" name="cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" format="ixt-sec:durwordsen" id="f-775">two years</ix:nonNumeric>.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-646-13"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The aggregate estimated grant date fair value was determined to be $<ix:nonFraction unitRef="cad" contextRef="c-281" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-776">8</ix:nonFraction>, calculated using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"/><td style="width:81.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-280" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-777">3.52</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-280" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-778">95.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="y" contextRef="c-280" decimals="2" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" id="f-779">5.00</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-280" decimals="4" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" scale="-2" id="f-780">0.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-280" decimals="2" name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" scale="0" id="f-781">21.28</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-280" decimals="2" name="ifrs-full:ExercisePriceShareOptionsGranted2019" scale="0" id="f-782">21.28</ix:nonFraction></span></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">During the year ended March 31, 2024, the Company amended the expiry dates of certain options with former employees and consultants of the Company.  </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-621-1" continuedAt="f-621-2"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The following summarizes information about stock options outstanding on March&#160;31, 2025:</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 42 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-621-2"><ix:continuation id="f-455-11" continuedAt="f-455-12"><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:26.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of options outstanding</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of options exercisable</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated  fair value</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average remaining life</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiry date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$000&#8217;s</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 6, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-282" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" id="f-783">986</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-282" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" id="f-784">986</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-282" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-785">13.11</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-282" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-786">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-283" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-787">0.02</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 6, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-284" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-788">2,372</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-284" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-789">2,372</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-284" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-790">16.72</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-284" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-791">32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-285" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-792">0.02</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 6, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-286" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" id="f-793">986</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-286" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" id="f-794">986</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-286" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-795">21.28</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-286" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-796">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-287" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-797">0.02</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 7, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-288" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-798">1,161</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-288" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-799">1,161</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-288" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-800">66.12</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-288" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-801">55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-289" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-802">0.02</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 15, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-290" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-803">27,631</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-290" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-804">27,631</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-290" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-805">9.50</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-290" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-806">188</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-291" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-807">0.21</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-292" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-808">5,263</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-292" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-809">5,263</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-292" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-810">34.20</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-292" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-811">73</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-293" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-812">0.25</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-294" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-813">7,106</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-294" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-814">7,106</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-294" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-815">28.50</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-294" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-816">97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-295" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-817">0.50</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-296" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-818">25,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-296" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-819">25,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-296" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-820">28.50</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-296" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-821">509</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-297" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-822">0.60</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-298" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-823">9,869</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-298" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-824">9,869</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-298" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-825">28.50</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-298" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-826">110</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-299" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-827">0.63</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-300" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-828">5,263</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-300" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-829">5,263</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-300" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-830">34.58</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-300" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-831">53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-301" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-832">0.63</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 11, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-302" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-833">5,263</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-302" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-834">5,263</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-302" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-835">56.24</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-302" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-836">211</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-303" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-837">0.70</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 14, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-304" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-838">2,829</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-304" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-839">2,829</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-304" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-840">66.12</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-304" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-841">131</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-305" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-842">0.71</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-306" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-843">2,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-306" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-844">2,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-306" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-845">13.11</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-306" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-846">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-307" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-847">0.75</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-308" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-848">3,947</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-308" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-849">3,947</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-308" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-850">16.72</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-308" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-851">53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-309" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-852">0.75</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-310" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-853">5,263</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-310" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-854">5,263</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-310" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-855">21.28</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-310" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-856">79</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-311" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-857">0.75</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-312" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-858">1,974</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-312" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-859">1,974</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-312" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-860">77.14</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-312" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-861">109</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-313" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-862">0.88</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-314" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-863">5,725</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-314" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-864">5,725</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-314" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-865">52.82</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-314" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-866">217</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-315" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-867">0.94</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-316" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-868">7,895</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-316" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-869">7,895</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-316" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-870">58.90</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-316" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-871">360</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-317" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-872">0.96</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-318" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" id="f-873">987</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-318" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" id="f-874">987</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-318" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-875">50.16</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-318" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-876">35</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-319" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-877">0.99</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-320" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-878">4,342</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-320" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-879">4,342</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-320" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-880">13.11</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-320" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-881">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-321" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-882">1.00</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-322" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-883">3,339</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-322" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-884">3,339</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-322" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-885">16.72</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-322" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-886">44</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-323" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-887">1.00</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-324" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" id="f-888">986</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-324" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" id="f-889">986</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-324" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-890">21.28</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-324" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-891">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-325" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-892">1.00</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 28, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-326" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-893">4,475</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-326" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-894">4,475</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-326" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-895">110.20</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-326" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-896">355</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-327" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-897">1.24</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 26, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-328" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-898">25,657</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-328" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-899">25,657</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-328" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-900">30.02</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-328" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-901">439</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-329" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-902">1.49</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-330" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-903">13,158</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-330" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-904">9,868</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-330" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-905">27.17</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-330" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-906">150</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-331" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-907">1.63</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-332" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-908">32,896</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-332" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-909">32,896</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-332" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-910">57.00</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-332" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" format="ixt:num-dot-decimal" scale="3" id="f-911">1,352</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-333" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-912">1.75</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 4, 2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-334" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" id="f-913">526</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-334" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" id="f-914">526</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-334" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-915">42.94</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-334" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-916">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-335" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-917">1.92</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-336" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-918">10,526</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-336" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-919">10,526</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-336" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-920">38.76</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-336" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-921">295</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-337" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-922">1.94</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-338" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-923">277,949</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-338" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-924">277,949</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-338" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-925">16.72</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-338" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" format="ixt:num-dot-decimal" scale="3" id="f-926">3,710</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-339" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-927">3.25</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 26, 2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-340" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-928">2,632</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-340" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-929">2,632</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-340" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-930">30.02</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-340" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-931">59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-341" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-932">3.49</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 20, 2029</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-342" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" id="f-933">526</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-342" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" id="f-934">394</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-342" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-935">21.28</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-342" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-936">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-343" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-937">3.97</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 5, 2029</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-344" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-938">284,873</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-344" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-939">177,994</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-344" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-940">21.28</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-344" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" format="ixt:num-dot-decimal" scale="3" id="f-941">3,742</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-345" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-942">4.01</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2032</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-346" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-943">7,895</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-346" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-944">7,895</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-346" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-945">34.20</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-346" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-946">179</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-347" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-947">7.25</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 15, 2034</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-348" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-948">3,049,784</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-348" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-949">2,877,860</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-348" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-950">13.11</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-348" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" format="ixt:num-dot-decimal" scale="3" id="f-951">34,032</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-349" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-952">9.37</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 27, 2034</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-350" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-953">80,100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-350" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-954">23,867</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-350" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-955">14.37</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-350" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-956">507</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-351" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-957">9.66</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 7, 2035</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-352" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-958">35,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-352" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-959">8,750</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-352" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" id="f-960">10.45</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-352" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="3" id="f-961">109</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-353" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-962">9.93</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-2" decimals="0" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" id="f-963">3,956,684</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="option" contextRef="c-2" decimals="0" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" id="f-964">3,591,976</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" format="ixt:num-dot-decimal" scale="3" id="f-965">47,427</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-966">8.13</ix:nonNumeric></span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 43 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-455-12"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company recognized share-based payments expense related to the issuance of stock options for the year ended March 31, 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">of $<ix:nonFraction unitRef="cad" contextRef="c-28" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-967">40,914</ix:nonFraction> (2024 - $<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:num-dot-decimal" scale="3" id="f-968">13,886</ix:nonFraction>).</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The outstanding options and warrants disclosed above were anti-dilutive for the year ended March 31, 2025 and 2024 and did not impact the calculation of the loss per share.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_37"></div><div><span style="color:#2d5f91;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">10.     <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="f-970" continuedAt="f-970-1" escape="true">RELATED PARTY TRANSACTIONS AND BALANCES</ix:nonNumeric></span></div><ix:continuation id="f-970-1"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Key management personnel include persons having the authority and responsibility for planning, directing, and controlling the activities of the Company as a whole. The Company has determined its key management personnel to be certain executive officers and directors of the Company.</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="f-971" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The remuneration of key management personnel for the years ended March 31, 2025 and 2024 are as follows: </span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:67.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payroll, consulting and benefits</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-972">7,807</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-973">6,406</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 15.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-354" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="f-974">24,937</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-355" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="f-975">8,643</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 15.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-356" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="f-976">1,239</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-357" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:fixed-zero" id="f-977">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="f-978">33,983</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="f-979">15,049</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%;padding-left:8pt"> For the year ended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">March&#160;31, 2025</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%">, includes $</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%"><ix:nonFraction unitRef="cad" contextRef="c-358" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-980">6,640</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%"> (2024 - $<ix:nonFraction unitRef="cad" contextRef="c-359" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-981">5,145</ix:nonFraction>) presented in the consolidated statements of loss and comprehensive loss as a part of &#8220;General and administrative costs&#8221; and $</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%"><ix:nonFraction unitRef="cad" contextRef="c-360" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-982">1,167</ix:nonFraction> (2024 - $<ix:nonFraction unitRef="cad" contextRef="c-361" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-983">1,261</ix:nonFraction>)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%"> presented in the consolidated statements of loss and comprehensive loss as a part of &#8220;Research&#8221;.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_565"></div><div style="text-align:justify"><span style="color:#2d5f91;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.   <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory" id="f-984" continuedAt="f-984-1" escape="true">RESEARCH EXPENSES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="cybn:ScheduleOfResearchExpensesTableTextBlock" id="f-985" escape="true"><ix:continuation id="f-984-1"><div style="padding-left:13.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"/><td style="width:67.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.460%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.248%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advancement of development programs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:AdvancementOfDevelopmentPrograms" format="ixt:num-dot-decimal" scale="3" id="f-986">39,547</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:AdvancementOfDevelopmentPrograms" format="ixt:num-dot-decimal" scale="3" id="f-987">22,799</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:PayrollAndBenefits" format="ixt:num-dot-decimal" scale="3" id="f-988">13,146</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:PayrollAndBenefits" format="ixt:num-dot-decimal" scale="3" id="f-989">8,319</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab and administration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:LabAndAdministration" format="ixt:num-dot-decimal" scale="3" id="f-990">1,933</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:LabAndAdministration" format="ixt:num-dot-decimal" scale="3" id="f-991">1,034</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional and consulting fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:ProfessionalAndConsultingFees" scale="3" id="f-992">284</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:ProfessionalAndConsultingFees" scale="3" id="f-993">210</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-994">54,910</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-995">32,362</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 44 of 52</span></div></div></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_582"></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#2d5f91;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.      <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory" id="f-996" continuedAt="f-996-1" escape="true">GENERAL AND ADMINISTRATIVE EXPENSES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory" id="f-997" escape="true"><ix:continuation id="f-996-1"><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:70.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.068%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:CapitalMarketExpense" format="ixt:num-dot-decimal" scale="3" id="f-998">16,694</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:CapitalMarketExpense" format="ixt:num-dot-decimal" scale="3" id="f-999">11,519</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll, consulting and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-1000">13,146</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-1001">8,248</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and administration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:OccupancyExpense" format="ixt:num-dot-decimal" scale="3" id="f-1002">4,498</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:OccupancyExpense" format="ixt:num-dot-decimal" scale="3" id="f-1003">2,945</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional and consulting fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ProfessionalFeesExpense" format="ixt:num-dot-decimal" scale="3" id="f-1004">4,156</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:ProfessionalFeesExpense" format="ixt:num-dot-decimal" scale="3" id="f-1005">4,918</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:BusinessDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1006">3,305</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:BusinessDevelopmentExpense" scale="3" id="f-1007">896</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investor relations and Marketing media</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:InvestorRelationsSalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-1008">3,286</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:InvestorRelationsSalesAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-1009">3,791</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Listing fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:ListingFeesExpense" scale="3" id="f-1010">283</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:ListingFeesExpense" scale="3" id="f-1011">271</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1012">45,368</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1013">32,588</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="if8fb0108db0244bfbc2227aa1b3f68fe_40"></div><div style="margin-top:10pt"><span style="color:#2d5f91;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">13.   <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" id="f-1014" continuedAt="f-1014-1" escape="true">CONTRACTS, COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-1014-1"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As at March&#160;31, 2025, the Company had entered into agreements for various studies which may require the Company to spend up to an additional $<ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:ContractualCapitalCommitments" format="ixt:num-dot-decimal" scale="3" id="f-1015">85,802</ix:nonFraction>. The Company expects to pay this amount within the 24 months ending March 31, 2027, however the timing and certainty of the payments are contingent on availability of materials and successful completion of certain milestones. The Company has the right to cancel the studies at its discretion, in which case a cancellation fee may apply, however the Company is not liable to pay the full amount of the studies. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition to the above, during the year ended March 31, 2022, the Company entered into an exclusive license agreement with Mindset Pharma Inc. to acquire access to a number of classes of tryptamine-based molecules to support Company&#8217;s early-stage research programs and a fully-paid, perpetual non-exclusive license to a separate class of tryptamine-based molecules. Upon the successful completion of certain milestones contemplated in the exclusive license, the Company may have to pay additional consideration of up to $<ix:nonFraction unitRef="cad" contextRef="c-362" decimals="-3" name="ifrs-full:ContractualCapitalCommitments" format="ixt:num-dot-decimal" scale="3" id="f-1016">13,657</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-362" decimals="-3" name="ifrs-full:ContractualCapitalCommitments" format="ixt:num-dot-decimal" scale="3" id="f-1017">9,500</ix:nonFraction>). At the sole discretion of Cybin, the milestones may be paid in cash or in Common Shares, or a combination thereof, subject to the approval of Cboe Canada. Due to the nature of the arrangement, the timing and probability of future potential payments cannot be determined at this time, and no accrual has been recorded. Further, there is no assurance that the aforementioned milestones will be met at all. The agreement also contemplates a sales royalty of approximately <ix:nonFraction unitRef="number" contextRef="c-363" decimals="2" name="cybn:SalesRoyaltyPercentage" scale="-2" id="f-1018">2</ix:nonFraction>% for all commercialized licensed products within the scope of the agreement. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company is party to certain employee and management contracts that contain severance obligations. These contracts contain clauses requiring additional payments to be made upon the occurrence of involuntary termination. As the likelihood of these events taking place is not determinable, no contingent liabilities have been recorded in the consolidated financial statements.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In the normal course of business, the Company may be subject to legal proceedings and claims. As at March&#160;31, 2025, there was no ongoing litigation and therefore no contingent liabilities have been recorded in the consolidated financial statements.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 45 of 52</span></div></div></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_599"></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#2d5f91;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" id="f-1019" continuedAt="f-1019-1" escape="true">CAPITAL MANAGEMENT</ix:nonNumeric></span></div><ix:continuation id="f-1019-1"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company&#8217;s objectives when managing capital are to safeguard the Company&#8217;s ability to continue as a going concern in order to pursue business opportunities and to maintain a flexible capital structure that optimizes the costs of capital at an acceptable risk. The Company&#8217;s intentions are to (i) provide financial capacity and flexibility in order to preserve its ability to meet its strategic objectives and financial obligations; (ii) maintain a capital structure which allows the Company to respond to changes in economic and marketplace conditions and affords the Company the ability to participate in new investments; (iii) optimize the use of its capital to provide an appropriate investment return to its shareholders equal with the level of risk; and (iv) maintain a flexible capital structure which optimizes the cost of capital at acceptable levels of risk.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company&#8217;s financial strategy is formulated and adapted according to market conditions in order to maintain a flexible capital structure that is consistent with its objectives and the risk characteristics of its underlying assets. The Company manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of its underlying assets. The Company maintains or adjusts its capital level to enable it to meet its objectives by raising capital through the issuance of securities.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company&#8217;s capital management objectives, policies and processes generally remained unchanged during the year ended March 31, 2025.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company requires capital to fund existing and future operations. The Company&#8217;s policy is to maintain adequate levels of capital at all times.</span></div><ix:nonNumeric contextRef="c-1" name="cybn:DisclosureOfCapitalStructureTableTextBlock" id="f-1020" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company&#8217;s capital structure includes the following:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:59.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.734%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity comprised of:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share capital</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="f-1021">464,364</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="f-1022"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="f-1023">443,877</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributed surplus</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="f-1024">44,414</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="f-1025"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:SharePremium" format="ixt:num-dot-decimal" scale="3" id="f-1026">11,750</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options reserve</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:ReserveOfSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-1027">47,427</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:ReserveOfSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-1028"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:ReserveOfSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-1029">39,177</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants reserve</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:WarrantReserve" format="ixt:num-dot-decimal" scale="3" id="f-1030">27,594</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:WarrantReserve" format="ixt:num-dot-decimal" scale="3" id="f-1031"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:WarrantReserve" format="ixt:num-dot-decimal" scale="3" id="f-1032">25,639</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:AccumulatedOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-1033">7,231</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" sign="-" name="ifrs-full:AccumulatedOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-1034"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" sign="-" name="ifrs-full:AccumulatedOtherComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-1035">2,285</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deficit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-1036">339,368</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-1037">226,231</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-1038">237,200</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-1039">291,927</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 46 of 52</span></div></div></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_616"></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#2d5f91;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="f-1040" continuedAt="f-1040-1" escape="true">FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="f-1040-1" continuedAt="f-1040-2"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company&#8217;s financial instruments are exposed to certain financial risks, which include currency risk, credit risk, liquidity risk and interest rate risk.</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialAssetsExplanatory" id="f-1042" escape="true"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory" id="f-1041" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company has classified its financial instruments as follows:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"><tr><td style="width:1.0%"/><td style="width:50.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.129%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.010%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial assets, measured at fair value:</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-364" decimals="-3" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="3" id="f-1043">135,022</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-365" decimals="-3" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="3" id="f-1044">208,992</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial assets, measured at amortized cost:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-366" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="3" id="f-1045">706</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-367" decimals="-3" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="3" id="f-1046">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial liabilities, measured at amortized cost:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-368" decimals="-3" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1047">21,418</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-369" decimals="-3" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1048">9,805</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-1049">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="f-1050"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="f-1051">291</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The carrying value of the Company&#8217;s financial instruments approximate their fair value.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%;text-decoration:underline">Fair value hierarchy of financial instruments</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company has categorized its financial instruments that are carried at fair value, based on the priority of the inputs to the valuation techniques used to measure fair value, into a three-level fair value hierarchy as follows:</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Level 1:  Fair value is based on unadjusted quoted prices for identical assets or liabilities in an active market. The types of assets and liabilities classified as Level 1 generally included cash. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Level 2: Fair value is based on quoted prices for similar assets or liabilities in active markets, valuation that is based on significant observable inputs, or inputs that are derived principally from or corroborated with observable market data through correlation or other means. Currently, the Company has no financial instruments that would be classified as Level 2. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Level 3: Fair value is based on valuation techniques that require one or more significant inputs that are not based on observable market inputs. These unobservable inputs reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability. Currently, the Company has no financial instruments that would be classified as Level 3. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">There were no transfers between levels of the fair value hierarchy for the year ended March 31, 2025.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%;text-decoration:underline">Financial risk management</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Credit risk</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company&#8217;s cash is exposed to credit risk.  The Company reduces its </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 47 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-1040-2" continuedAt="f-1040-3"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">credit risk on cash by placing these instruments with institutions of high creditworthiness. As at March&#160;31, 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">the Company&#8217;s maximum exposure to credit risk is the carrying value of its financial assets. </span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Liquidity risk</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Liquidity risk is the risk that an entity will encounter difficulty in raising funds to meet commitments associated with financial instruments. The Company manages liquidity by maintaining adequate cash balances to meet liabilities as they become due.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As at March&#160;31, 2025, the Company had cash of $<ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="3" id="f-1052">135,022</ix:nonFraction> (March&#160;31, 2024 - $<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:Cash" format="ixt:num-dot-decimal" scale="3" id="f-1053">208,992</ix:nonFraction>) in order to meet current liabilities. Current liabilities include accounts payable and accrued liabilities of $<ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1054">21,418</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(March&#160;31, 2024 - $<ix:nonFraction unitRef="cad" contextRef="c-369" decimals="-3" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1055">9,805</ix:nonFraction>) and lease liabilities of $<ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-1056">nil</ix:nonFraction> (March 31, 2024 - $<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="f-1057"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="f-1058">291</ix:nonFraction></ix:nonFraction>). All amounts are due within the next 12 months. </span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Market risk</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The significant market risks to which the Company is exposed are interest rate risk and currency risk.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%;text-decoration:underline">Interest rate risk</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Interest rate risk is the risk that the fair value or the future cash flows of a financial instrument will fluctuate because of changes in market interest rates. In seeking to minimize the risks from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities.  Assuming that all other variables remain constant, as at March&#160;31, 2025, a <ix:nonFraction unitRef="number" contextRef="c-2" decimals="2" sign="-" name="cybn:InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash" scale="-2" id="f-1059">1</ix:nonFraction>% decline on the interest rate generated on cash would have resulted in a reduction of interest income of $<ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" sign="-" name="cybn:InterestRateRiskIncreaseDecreaseInInterestIncome" format="ixt:num-dot-decimal" scale="3" id="f-1060">1,145</ix:nonFraction> over a <ix:nonNumeric contextRef="c-1" name="cybn:InterestRateRiskTerm" format="ixt-sec:durwordsen" id="f-1061">one-year</ix:nonNumeric> period.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%;text-decoration:underline">Currency risk</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company is exposed to currency risk to the extent that monetary operational expenses are denominated in both CAD and USD while the functional currency of CAD is used for reporting.  The Company has not entered into any foreign currency contracts to mitigate this risk.</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" id="f-1062" continuedAt="f-1062-1" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">At March&#160;31, 2025 the Company had the following balances in monetary assets and monetary liabilities which are subject to fluctuation against CAD:</span></div></ix:nonNumeric></ix:continuation><div style="padding-left:18pt;text-align:justify"><ix:continuation id="f-1062-1"><ix:continuation id="f-1040-3" continuedAt="f-1040-4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.673%"><tr><td style="width:1.0%"/><td style="width:48.481%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.817%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominated in:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">US$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GBP</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EUR</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-3" name="cybn:FinancialAssetsAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1063">92,416</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="c-371" decimals="-3" name="cybn:FinancialAssetsAndLiabilities" scale="3" id="f-1064">76</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-372" decimals="-3" name="cybn:FinancialAssetsAndLiabilities" scale="3" id="f-1065">676</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-3" name="cybn:FinancialAssetsAndLiabilities" scale="3" id="f-1066">353</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="c-374" decimals="-3" name="cybn:FinancialAssetsAndLiabilities" format="ixt:fixed-zero" scale="3" id="f-1067">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-375" decimals="-3" name="cybn:FinancialAssetsAndLiabilities" format="ixt:fixed-zero" scale="3" id="f-1068">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-3" sign="-" name="cybn:FinancialAssetsAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1069">1,841</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="gbp" contextRef="c-377" decimals="-3" sign="-" name="cybn:FinancialAssetsAndLiabilities" scale="3" id="f-1070">415</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-378" decimals="-3" sign="-" name="cybn:FinancialAssetsAndLiabilities" scale="3" id="f-1071">58</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3" name="cybn:FinancialAssetsAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1072">90,928</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="gbp" contextRef="c-380" decimals="-3" sign="-" name="cybn:FinancialAssetsAndLiabilities" scale="3" id="f-1073">339</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-381" decimals="-3" name="cybn:FinancialAssetsAndLiabilities" scale="3" id="f-1074">618</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-379" decimals="4" name="ifrs-full:ClosingForeignExchangeRate" id="f-1075">1.4376</ix:nonFraction></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-380" decimals="4" name="ifrs-full:ClosingForeignExchangeRate" id="f-1076">1.8571</ix:nonFraction></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-381" decimals="4" name="ifrs-full:ClosingForeignExchangeRate" id="f-1077">1.5540</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equivalent in Canadian dollars</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-379" decimals="-3" name="cybn:FinancialAssetsAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1078">130,718</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-380" decimals="-3" sign="-" name="cybn:FinancialAssetsAndLiabilities" scale="3" id="f-1079">630</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-381" decimals="-3" name="cybn:FinancialAssetsAndLiabilities" scale="3" id="f-1080">960</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Impact of 10% change in exchange rate</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-379" decimals="-3" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" format="ixt:num-dot-decimal" scale="3" id="f-1081">13,072</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-380" decimals="-3" sign="-" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="f-1082">63</ix:nonFraction>)</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-381" decimals="-3" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="f-1083">96</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1040-4">Such analysis excludes any indirect economic or geo-political effects of such currency fluctuations.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 48 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span></div><div id="if8fb0108db0244bfbc2227aa1b3f68fe_43"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#2d5f91;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="f-1084" continuedAt="f-1084-1" escape="true">INCOME TAX </ix:nonNumeric></span></div><ix:continuation id="f-1084-1" continuedAt="f-1084-2"><ix:nonNumeric contextRef="c-1" name="cybn:DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock" id="f-1085" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Major items causing the Company&#8217;s income tax rate to differ from the Canadian statutory rate of approximately 26.5% are as follows:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:47.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended March 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 3.77pt 0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 3.77pt 0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 3.77pt 0 1pt"/><td colspan="3" style="padding:0 3.77pt 0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 3.75pt 0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-1086">113,137</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-1087">78,080</ix:nonFraction>)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected recovery at statutory rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-1088">29,981</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-1089">20,691</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital losses acquired on acquisition of subsidiary</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset" format="ixt:fixed-zero" scale="3" id="f-1090">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset" format="ixt:num-dot-decimal" scale="3" id="f-1091">11,658</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:TaxEffectOfShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1092">10,497</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:TaxEffectOfShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1093">3,680</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issuance costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:TaxEffectOfShareIssuanceCosts" scale="3" id="f-1094">122</ix:nonFraction></span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:TaxEffectOfShareIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-1095">4,420</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Difference between Canadian and foreign tax rates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:TaxEffectOfForeignTaxRates" format="ixt:num-dot-decimal" scale="3" id="f-1096">9,317</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:TaxEffectOfForeignTaxRates" format="ixt:num-dot-decimal" scale="3" id="f-1097">5,440</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange on unbooked deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" scale="3" id="f-1098">351</ix:nonFraction></span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" scale="3" id="f-1099">112</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" scale="3" id="f-1100">103</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" scale="3" id="f-1101">132</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrecognized deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="cybn:TaxEffectOfChangeInDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-1102">10,537</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="cybn:TaxEffectOfChangeInDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-1103">27,405</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax recovery</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 3.77pt 0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 3.77pt 0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:fixed-zero" scale="3" id="f-1104">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" format="ixt:fixed-zero" scale="3" id="f-1105">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" id="f-1106" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The significant components of the Company&#8217;s deferred tax assets resulting from temporary differences, unused tax credits and unused tax losses, that have not been included on the consolidated statement of financial position, are as follows:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"/><td style="width:59.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital loss carryforwards - Canada</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-382" decimals="-3" name="cybn:GrossDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-1107">22,310</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-383" decimals="-3" name="cybn:GrossDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-1108">20,168</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital loss carryforwards - United States</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-384" decimals="-3" name="cybn:GrossDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-1109">2,533</ix:nonFraction></span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-385" decimals="-3" name="cybn:GrossDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-1110">2,344</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital loss carryforwards - Ireland</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-386" decimals="-3" name="cybn:GrossDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-1111">18,327</ix:nonFraction></span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-387" decimals="-3" name="cybn:GrossDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-1112">10,391</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital loss carryforwards - United Kingdom</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-388" decimals="-3" name="cybn:GrossDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-1113">10,767</ix:nonFraction></span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-389" decimals="-3" name="cybn:GrossDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-1114">10,282</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-390" decimals="-3" name="cybn:GrossDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-1115">1,653</ix:nonFraction></span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-391" decimals="-3" name="cybn:GrossDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-1116">1,474</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development expenditures</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-392" decimals="-3" name="cybn:GrossDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-1117">2,538</ix:nonFraction></span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-393" decimals="-3" name="cybn:GrossDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-1118">1,681</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issuance costs</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-394" decimals="-3" name="cybn:GrossDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-1119">3,102</ix:nonFraction></span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-395" decimals="-3" name="cybn:GrossDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-1120">4,361</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation/Capital cost allowance differences</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-396" decimals="-3" name="cybn:GrossDeferredTaxAssets" scale="3" id="f-1121">15</ix:nonFraction></span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-397" decimals="-3" name="cybn:GrossDeferredTaxAssets" scale="3" id="f-1122">7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="cybn:GrossDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-1123">61,245</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="cybn:GrossDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-1124">50,708</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="cybn:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1125">61,245</ix:nonFraction>)</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="cybn:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1126">50,708</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:fixed-zero" scale="3" id="f-1127">&#8212;</ix:nonFraction></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:DeferredTaxAssets" format="ixt:fixed-zero" scale="3" id="f-1128">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 49 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-1084-2" continuedAt="f-1084-3"><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Non-capital loss balance</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As at March&#160;31, 2025, the Company has non-capital losses in Canada, which under certain circumstances can be used to reduce taxable income of future years. <ix:nonNumeric contextRef="c-1" name="cybn:DisclosureOfExpirationOfNonCapitalLossesTableTextBlock" id="f-1129" continuedAt="f-1129-1" escape="true">The non-capital losses expire as follows:</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-1129-1" continuedAt="f-1129-2"><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year of expiry</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-398" decimals="-3" name="cybn:NonCapitalLossCarryforward" scale="3" id="f-1130">1</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-399" decimals="-3" name="cybn:NonCapitalLossCarryforward" scale="3" id="f-1131">62</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-400" decimals="-3" name="cybn:NonCapitalLossCarryforward" scale="3" id="f-1132">32</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-401" decimals="-3" name="cybn:NonCapitalLossCarryforward" scale="3" id="f-1133">115</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-402" decimals="-3" name="cybn:NonCapitalLossCarryforward" scale="3" id="f-1134">863</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-403" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1135">21,856</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-404" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1136">16,019</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-405" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1137">10,704</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-406" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1138">24,397</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2045</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-407" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1139">10,105</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-408" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1140">84,154</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As at March&#160;31, 2025, the Company has non-capital losses in the United States and Massachusetts of $<ix:nonFraction unitRef="cad" contextRef="c-409" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1141">12,064</ix:nonFraction>, which under certain circumstances can be used to reduce the taxable income of future years. The federal losses have no expiry but are subject to limitations on utilization as laid out below. The Massachusetts non-capital losses, stated in Canadian dollars expire as follows:</span></div><ix:continuation id="f-1129-2" continuedAt="f-1129-3"><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.993%"><tr><td style="width:1.0%"/><td style="width:82.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year of expiry</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-410" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1142">1,053</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-411" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1143">1,543</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-412" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1144">4,979</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-413" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1145">1,593</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-414" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1146">1,425</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2045</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-415" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1147">1,471</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-409" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1148">12,064</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="padding-left:18pt"><span style="background-color:#ffde0f;color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:139%"> </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Although the US federal losses carryforward indefinitely, they are subject to restrictions on their deductibility. For federal purposes the deductibility of $<ix:nonFraction unitRef="cad" contextRef="c-416" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1149">2,596</ix:nonFraction> is restricted to 80% of taxable income in the year of deduction. The deductibility of $<ix:nonFraction unitRef="cad" contextRef="c-410" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1150">1,053</ix:nonFraction> is further restricted to an annual limitation under Section 382. As at March&#160;31, 2025, the annual limitation was $<ix:nonFraction unitRef="cad" contextRef="c-2" decimals="-3" name="cybn:Section382Limitation" scale="3" id="f-1151">153</ix:nonFraction>.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As at March&#160;31, 2025, the Company has non-capital losses in Ireland, which under certain circumstances can be used to reduce taxable income of future years. <ix:continuation id="f-1129-3" continuedAt="f-1129-4">The non-capital losses in Ireland, stated in Canadian Dollars, expire as follows:</ix:continuation></span></div><ix:continuation id="f-1129-4" continuedAt="f-1129-5"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"> </span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 50 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><ix:continuation id="f-1084-3"><ix:continuation id="f-1129-5"><div style="margin-bottom:10pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.275%"><tr><td style="width:1.0%"/><td style="width:81.272%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.528%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year of expiry</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2042</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-417" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1152">22,965</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2043</span></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-418" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1153">23,017</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2044</span></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-419" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1154">33,857</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2045</span></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-420" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1155">57,875</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-421" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1156">137,714</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">As at March&#160;31, 2025 the Company had $<ix:nonFraction unitRef="cad" contextRef="c-422" decimals="-3" name="cybn:NonCapitalLossCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-1157">43,208</ix:nonFraction> of non-capital losses in UK which under certain circumstances can be used to reduce the taxable income of future years. These losses do not expire.</span></div></ix:continuation><div id="if8fb0108db0244bfbc2227aa1b3f68fe_633"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#2d5f91;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">17. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" id="f-1158" continuedAt="f-1158-1" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="f-1158-1" continuedAt="f-1158-2"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">ATM Program</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">During the period from April 1, 2025 to June&#160;30, 2025, the Company sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:nonFraction unitRef="shares" contextRef="c-423" decimals="0" name="cybn:NumberOfSharesIssuedThroughShareOfferingEquity" format="ixt:num-dot-decimal" scale="0" id="f-1159">1,422,423</ix:nonFraction> Common Shares, at an average price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-423" decimals="2" name="cybn:SharePricePerCommonShare" format="ixt:num-dot-decimal" scale="0" id="f-1160">7.36</ix:nonFraction> per Common Share, for aggregate gross proceeds of US$<ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-1161">10,465</ix:nonFraction>, through its 2025 ATM Program.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Convertible Debentures</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On June 30, 2025, the Company entered into a securities purchase agreement (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">SPA</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) with High Trail Special Situations LLC (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">High Trail</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;), pursuant to which the Company agreed to issue to High Trail up to US$<ix:nonFraction unitRef="cad" contextRef="c-424" decimals="-3" name="ifrs-full:DebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1162">500,000</ix:nonFraction> of unsecured convertible debentures (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Convertible Debentures</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;). The sale and issuance of US$<ix:nonFraction unitRef="cad" contextRef="c-425" decimals="-3" name="ifrs-full:DebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-1163">50,000</ix:nonFraction> principal amount of Convertible Debentures was completed on June 30, 2025. </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Convertible Debentures have a <ix:nonNumeric contextRef="c-426" name="cybn:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1164">two-year</ix:nonNumeric> term (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Convertible Debenture Term</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;). The Company is to pay guaranteed interest equal to <ix:nonFraction unitRef="number" contextRef="c-424" decimals="2" name="cybn:DebtInstrumentGuaranteedInterestPayableRate" scale="-2" id="f-1165">11</ix:nonFraction>% of the amount issued for the Convertible Debenture Term (the equivalent of <ix:nonFraction unitRef="number" contextRef="c-424" decimals="3" name="cybn:DebtInstrumentGuaranteedInterestPayableAnnualRate" format="ixt:num-dot-decimal" scale="-2" id="f-1166">5.5</ix:nonFraction>% per annum). Such interest is to be pre-paid on closing. Upon the occurrence of an event of default, interest would increase to <ix:nonFraction unitRef="number" contextRef="c-424" decimals="2" name="cybn:DebtInstrumentDefaultRate" scale="-2" id="f-1167">18</ix:nonFraction>% per annum on the outstanding principal balance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Subject to the terms of the SPA and the Convertible Debentures, High Trail is to be entitled to convert the principal amount of, and accrued and unpaid interest, if any, in whole or in part, from time to time, into Common Shares at a conversion price per Common Share equal to the lower of (a) <ix:nonFraction unitRef="number" contextRef="c-426" decimals="2" name="cybn:DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-1168">130</ix:nonFraction>% of the volume weighted average price (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">VWAP</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) of the Common Shares on the day prior to the initial issuance of the Convertible Debentures, or (b) the VWAP of the Common Shares during the <span style="-sec-ix-hidden:f-1169">five</span> trading days immediately prior to conversion.  </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company, in its sole discretion, may prepay any outstanding amount under the Convertible Debentures, in whole or in part, in cash by providing High Trail with advance written notice at least five trading days prior to such prepayment. The prepayment is to include, (i) if paid during the first year after closing, a <ix:nonFraction unitRef="number" contextRef="c-426" decimals="2" name="cybn:DebtInstrumentPrepaymentPremiumYearOne" scale="-2" id="f-1170">5</ix:nonFraction>% premium on the amount of the prepayment or (ii) if paid during the second year after closing, a <ix:nonFraction unitRef="number" contextRef="c-426" decimals="2" name="cybn:DebtInstrumentPrepaymentPremiumYearTwo" scale="-2" id="f-1171">3</ix:nonFraction>% premium on the amount of the prepayment.  </span></div></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 51 of 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:126pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #404040;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CYBIN INC. </span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="padding-left:2.75pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;31, 2025 and 2024</span></div><div style="padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(All amounts expressed in thousands of Canadian dollars, except share and per share amounts, and those otherwise stated in US dollars, Euros and Great Britain pounds which are in thousands.)</span></div></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"><ix:continuation id="f-1158-2">The terms of the Convertible Debentures restrict the conversion of Convertible Debentures by High Trail if such a conversion or exercise would cause High Trail, together with any affiliate thereof, to beneficially own in excess of <ix:nonFraction unitRef="number" contextRef="c-427" decimals="4" name="cybn:DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage" format="ixt:num-dot-decimal" scale="-2" id="f-1172">4.99</ix:nonFraction>% of the number of Common Shares outstanding immediately after giving effect to such conversion.</ix:continuation> </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Page 52 of 52</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>5
<FILENAME>cybin-mdaxq4x25xmarch31202.htm
<DESCRIPTION>EX-99.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i2b86e3b0612046f694ccc21dee9687a9_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">                                                                                                                  &#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:center"><img alt="image_0d.jpg" src="image_0d.jpg" style="height:99px;margin-bottom:5pt;vertical-align:text-bottom;width:170px"></div><div style="margin-bottom:0.1pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Cybin Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Management&#8217;s Discussion and Analysis </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">of Financial Condition and Operating Performance</font></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">For the year ended March 31, 2025</font></div><div style="margin-bottom:0.1pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Date&#58; June&#160;30, 2025</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">CYBIN INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">This Management&#8217;s Discussion and Analysis (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">MD&#38;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) has been prepared by management of Cybin Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Cybin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) and should be read in conjunction with Cybin&#8217;s audited  consolidated financial statements and notes for the year ended March&#160;31, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). This MD&#38;A does not address all of the changes to the Company and its business, such changes are addressed in the Company&#8217;s most recently filed annual information form (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">AIF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) on SEDAR+. The Financial Statements have been prepared using International Financial Reporting Standards (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">IFRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) as issued by the International Accounting Standards Board. All amounts are in Canadian dollars unless otherwise indicated. The Financial Statements may be viewed on the SEDAR+ profile of Cybin at www.sedarplus.ca. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">This MD&#38;A contains disclosure related to Cybin occurring up to and including June&#160;30, 2025. Unless otherwise indicated, all amounts in this MD&#38;A are in thousands of Canadian dollars.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Cybin was incorporated under the laws of the Province of British Columbia. Its wholly owned subsidiary, Cybin Corp. was incorporated under the laws of the Province of Ontario. Prior to November 5, 2020, the Company&#8217;s operations were conducted through Cybin Corp. On November 5, 2020, the Company completed a reverse takeover transaction pursuant to the terms of an amalgamation agreement dated June 26, 2020, as amended on October 21, 2020, among the Company, Cybin Corp. and 2762898 Ontario Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">SubCo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), a wholly-owned subsidiary of the Company&#160;(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Reverse Takeover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). The Reverse Takeover was completed by way of a &#8220;three-cornered&#8221; amalgamation pursuant to the provisions of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Business Corporations Act </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(Ontario) whereby Cybin Corp. amalgamated with SubCo to form an amalgamated corporation and a wholly owned subsidiary of the Company. Cybin Corp. is deemed to be the acquirer in the Reverse Takeover. As a result, the consolidated statements of financial position are presented as a continuance of Cybin Corp. and the comparative figures presented are those of Cybin Corp.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On September 19, 2024, the Company consolidated its outstanding Common Shares on the basis of</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">one new Common Share for every 38 existing Common Shares (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Consolidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). As a result,</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">all figures related to shares, warrants, options and earnings per share presented in this MD&#38;A have</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">been restated retrospectively for all periods to reflect the Consolidation.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">FORWARD-LOOKING STATEMENTS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Certain statements contained in this MD&#38;A constitute &#8220;forward-looking information&#8221; and &#8220;forward-looking statements&#8221;. All  statements,  other  than  statements  of  historical  fact,  contained  in  this  MD&#38;A  are  forward-looking  statements,  including,  without  limitation,  statements  regarding  future  financial  position, business strategy, budgets, research and development and plans and objectives of management for future operations.  Such statements can, in some cases, be identified by the use of forward-looking terminology such as &#8220;expect,&#8221; &#8220;likely&#8221;, &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; or &#8220;anticipate,&#8221; &#8220;potential,&#8221; &#8220;proposed,&#8221; &#8220;estimate&#8221; and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions &#8220;may&#8221; or &#8220;will&#8221; happen, or by discussions of strategy. The forward-looking statements included in this MD&#38;A are made only as of the date of this MD&#38;A and the Company assumes no obligation to update or revise </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">them to reflect subsequent information, events or circumstances or otherwise, except as required by applicable securities laws.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Forward-looking statements in this MD&#38;A are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Management provides forward-looking statements because it believes they provide useful information to readers when considering their investment objectives and cautions readers that the information may not be appropriate for other purposes. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Some of the risks which could affect future results and could cause results to differ materially from those expressed in the forward-looking statements contained herein include&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%"> </font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">limited operating history&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">achieving publicly announced milestones&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">speculative nature of investment risk&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">early stage of the industry and product development&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">regulatory risks and uncertainties</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">risks of operating in European countries&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">&#8220;foreign private issuer&#8221; status under U.S. Securities Laws&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">plans for growth&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">limited products&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">limited marketing and sales capabilities&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">no assurance of commercial success&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">no profits or significant revenues&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">reliance on third parties for clinical development activities&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">risks related to third party relationships&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">reliance on contract manufacturers&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">safety and efficacy of products&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">clinical testing and commercializing products&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">completion of clinical trials&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">commercial grade product manufacturing&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">nature of regulatory approvals&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">market access and acceptance&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">unfavourable publicity or consumer perception&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">social media&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">biotechnology and pharmaceutical market competition&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">reliance on key executives and scientists&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">employee misconduct&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">business expansion and growth&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">negative results of external clinical trials or studies&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">product liability&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">enforcing contracts&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">product and material recalls&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">distribution and supply chain interruption&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">difficulty to forecast&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">promoting the brand&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">product viability&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">success of quality control systems&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">reliance on key inputs&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">liability arising from fraudulent or illegal activity&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">operating risk and insurance coverage&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">costs of operating as public company&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">management of growth&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">conflicts of interest&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">foreign operations&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">exchange rate fluctuations&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">cybersecurity and privacy risk&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">environmental regulation and risks&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">decriminalization of psychedelics&#59; </font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">forward-looking statements may prove to be inaccurate&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">effects of inflation&#59; </font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">political and economic conditions&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">application and interpretation of tax laws&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">enforcement of civil liabilities&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">pandemics&#59; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Risks Related to Intellectual Property&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">trademark protection&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">trade secrets&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">patent law reform&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">patent litigation and intellectual property&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">protection of intellectual property&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">third-party licences&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Financial and Accounting Risks&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">substantial number of authorized but unissued Common Shares (as defined herein)&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">dilution&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">negative cash flow from operating activities&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">additional capital requirements&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">lack of significant product revenue&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">estimates or judgments relating to critical accounting policies&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">inadequate internal controls&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Risks related to the Common Shares&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">market for the Common Shares&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">significant sales of Common Shares&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">volatile market price for the Common Shares&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">tax issues&#59; and</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">no dividends.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Although the forward-looking statements contained in this MD&#38;A are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. In particular, the Company has made assumptions regarding, among other things&#58; </font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">substantial fluctuation of losses from quarter to quarter and year to year due to numerous external risk factors, and anticipation that we will continue to incur significant losses in the future&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">uncertainty as to the Company&#8217;s ability to raise additional funding to support operations&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the Company&#8217;s ability to access additional funding&#59; </font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the fluctuation of foreign exchange rates&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the risks associated with pandemics&#59; </font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the risks associated with the development of the Company&#8217;s product candidates which are at early stages of development&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">reliance upon industry publications as the Company&#8217;s primary sources for third-party industry data and forecasts&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">reliance on third parties to plan, conduct and monitor the Company&#8217;s preclinical studies and clinical trials&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">reliance on third party contract manufacturers to deliver quality clinical and preclinical materials&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the Company&#8217;s product candidates may fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or may not otherwise produce positive results&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">risks related to filing investigational new drug applications to commence clinical trials and to continue clinical trials if approved&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the risks of delays and inability to complete clinical trials due to difficulties enrolling patients&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">competition from other biotechnology and pharmaceutical companies&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the Company&#8217;s reliance on the capabilities and experience of the Company&#8217;s key executives and scientists and the resulting loss of any of these individuals&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the Company&#8217;s ability to fully realize the benefits of acquisitions&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the Company&#8217;s ability to adequately protect the Company&#8217;s intellectual property and trade secrets&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the risk of patent-related or other litigation&#59; and</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:13.65pt">the risk of unforeseen changes to the laws or regulations in the United States (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), the United Kingdom (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">United Kingdom</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">UK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), Canada, the Netherlands, Ireland and other jurisdictions in which the Company operates.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Drug development involves long lead times, is very expensive and involves many variables of uncertainty. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to the Company. Every patient treated on future studies can change those assumptions either positively (to indicate a faster timeline to new drug applications and other approvals) or negatively (to indicate a slower timeline to new drug applications and other approvals). This MD&#38;A contains certain forward-looking statements regarding anticipated </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">or possible drug development timelines. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company&#8217;s development efforts to date.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In addition to the factors set out above and those identified in this MD&#38;A under &#8220;Risk Factors&#8221;, other factors not currently viewed as material could cause actual results to differ materially from those described in the forward-looking statements. Although Cybin has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be anticipated, estimated or intended. Accordingly, readers should not place any undue reliance on forward-looking statements.</font></div><div id="i2b86e3b0612046f694ccc21dee9687a9_73"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">CORPORATE STRUCTURE OVERVIEW</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company is a clinical-stage breakthrough neuropsychiatry company focused on advancing next-generation therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On November 5, 2020, the Company completed a reverse takeover transaction pursuant to the terms of an amalgamation agreement dated June 26, 2020, as amended on October 21, 2020, among the Company, Cybin Corp. and SubCo, a wholly-owned subsidiary of the Company. The Reverse Takeover was completed by way of a &#8220;three-cornered&#8221; amalgamation pursuant to the provisions of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Business Corporations Act </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(Ontario) whereby Cybin Corp. amalgamated with SubCo to form an amalgamated corporation and a wholly owned subsidiary of the Company. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">In connection with the Reverse Takeover, Clarmin Explorations Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Clarmin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;) changed its name to &#8220;Cybin Inc.&#8221; and the common shares (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Common Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;) became listed for trading on Cboe Canada Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Cboe Canada</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;) under the trading symbol &#8220;CYBN&#8221;. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On July 8, 2021, the Company announced the scale-up of its European operations and research activities with various academic and clinical research organizations, including the transfer of its intellectual property assets to its wholly owned Ireland subsidiary, Cybin IRL Limited (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Cybin Ireland</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On August 5, 2021, the Common Shares commenced trading on the NYSE American LLC stock exchange (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">NYSE American</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) under the symbol &#8220;CYBN&#8221;. Concurrent with the commencement of trading on the NYSE American, the Common Shares ceased to be quoted on the OTCQB&#174; Venture Market.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">On October 23, 2023, the Company announced the completion of the acquisition by Cybin of Small Pharma Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Small Pharma</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;) by way of a statutory plan of arrangement under the provisions of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:130%">Business Corporations Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"> (British Columbia) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Arrangement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;). The Arrangement was </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">completed pursuant to the terms of an arrangement agreement entered into between the Company and Small Pharma dated August 28, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">Arrangement Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;). As a result of the Arrangement, Small Pharma is now a wholly-owned subsidiary of Cybin.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On September 19, 2024, the Company completed the Consolidation.  As a result, all figures related to shares, warrants, options and earnings per share presented in this MD&#38;A have been restated retrospectively for all periods to reflect the Consolidation.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Please refer to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:130%">General Development of the Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221; in the AIF for additional information on the background and operational highlights of Cybin. The AIF may be viewed under the SEDAR+ profile of Cybin at www.sedarplus.ca.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div id="i2b86e3b0612046f694ccc21dee9687a9_87"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">BUSINESS OVERVIEW</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Cybin is a clinical-stage breakthrough neuropsychiatry company on a mission to create safe and effective next-generation therapeutics to address the unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin&#8217;s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Cybin&#8217;s research and development work focuses on a three-pillar strategy that leverages the Company&#8217;s core competencies in preclinical innovation and clinical development. This strategy supports the creation of intellectual property (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) focused on developing the Company&#8217;s platform technology, the progression of clinical development programs including CYB003, a deuterated psilocin molecule, CYB004, a deuterated version of N, N-dimethyltryptamine (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">DMT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), CYB005, phenethylamine derivatives, and an expansive list of preclinical molecules to facilitate future drug development opportunities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On October 23, 2023, the Company completed the acquisition of Small Pharma by way of the Arrangement pursuant to which Small Pharma became a wholly-owned subsidiary of Cybin. Small Pharma is a biotechnology company focused on developing short-duration therapies for the treatment of mental health conditions. Small Pharma initiated programs across its &#8220;First-generation&#8221; and &#8220;Second-generation&#8221; psychedelics portfolio. First-generation psychedelics refer to the well-known classic psychedelics which includes psilocybin, DMT, and Lysergic acid diethylamide (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">LSD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). Second-generation psychedelics refer to those that have been chemically modified with the aim to optimize their therapeutic benefit. </font></div><div style="text-align:justify"><font><br></font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">This is a forward-looking statement that involves material assumptions by the Company. Drug development involves long lead times, is very expensive and involves many variables of uncertainty. Anticipated timelines regarding drug development and recruitment of patients for participation in clinical trials are dependent on various factors and are based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, eligibility and exclusion criteria for the trial, design of the clinical trial, competition with other companies for clinical sites or patients, perceived risks and benefits of the prescription drug product candidate, the number, availability, location and accessibility of clinical trial sites, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company&#8217;s development efforts to date. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">With a common goal to create novel, optimized psychedelic-based therapeutics, the combination of Cybin and Small Pharma creates a leading international, clinical-stage company with potential to transform the treatment paradigm for mental health conditions. The companies&#8217; combined development portfolios are highly complementary and provide multiple opportunities to create operational and cost synergies.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><br>As a result of the acquisition of Small Pharma by way of the Arrangement, Cybin currently has over 90 granted patents and over 230 pending applications. See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Advancement of Mental Healthcare</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company is conducting research and development of next-generation neuropsychiatry therapeutics that aim to address unmet needs in the treatment of mental health conditions. This comprehensive development work is predicated on structural modifications of known tryptamine and phenethylamine derivatives to improve their pharmacokinetic properties while maintaining their respective pharmacology.    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Across its extensive research and development programs, Cybin is evaluating a wide array of novel, synthetic active pharmaceutical ingredients (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">API</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) intended to be delivered through innovative drug delivery systems including via inhalation, via intravenous  (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), and intramuscular, or subcutaneous administration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">    </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company intends to apply for regulatory approval for therapies targeting indications such as major depressive disorder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">MDD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), alcohol use disorder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">AUD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), generalized anxiety disorder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">GAD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) and potentially other various mental health conditions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> The Company is also developing compounds that may have the potential to address neuroinflammation, central nervous system (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">CNS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) disorders, and psychiatric disorders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">4</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Further, over the next 12-month period, the Company will continue to seek to establish strategic partnerships that advance the Company&#8217;s scientific research and IP for novel compounds and delivery mechanisms.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company will also continue to sponsor select internal and partner-related clinical trials that advance the understanding of safety and efficacy for various psychedelic agents that target mental health conditions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">6</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Stage of Development </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Like most life sciences and pharmaceutical companies, the Company&#8217;s neuropsychiatry business is focused on research and development and any future revenue will be dependent on a number of factors, including the outcome of the Company&#8217;s clinical trials and the receipt of all necessary regulatory approvals.</font></div><div style="text-align:justify"><font><br></font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> See footnote 1. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">See footnote 1. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> See footnote 1.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">A material factor and assumption underlying this forward-looking statement is that the Company will be able to successfully negotiate strategic partnerships.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The material factors and assumptions underlying this forward-looking statement are&#58; (a) that the Company will be able to successfully negotiate strategic partnerships&#59; and (b) all necessary approvals for the studies will be obtained.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In order to establish its business operations, Cybin intends to leverage the extensive professional network of its management to build working partnerships with (i) existing producers of products based in Canada, the United States, the European Union (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) and the UK to source the pharmaceutical products the Company intends to develop and distribute under its specific brand, and (ii) to explore options to facilitate the development and distribution and sale of its specific brand of pharmaceutical products.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">7</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Prescription drugs are classified and regulated under the federal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Food and Drugs Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (Canada) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Canadian FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). Labeling, marketing and selling of any prescription drug must comply with the Canadian FDA, including by ensuring that the Company&#8217;s products are not packaged or marketed in a manner that is misleading or deceptive to a consumer. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In the United States, foods, drugs and dietary supplements are subject to extensive regulation. The </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Federal Food, Drug, and Cosmetic Act </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">FFDCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) and other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacturing, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. The Company must ensure that all promotion and marketing, distribution, and labeling of any pharmaceutical products comply with the U.S. regulations, including the FFDCA and the U.S. Food and Drug Administration (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On November 4, 2021, the Company announced that it had been granted a Schedule I manufacturing license from the U.S. Drug Enforcement Administration (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">DEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). The DEA license is for the Company&#8217;s research lab in the Boston area. The license allows the Company to further become a hub for innovation and drug discovery. Previously, the Company conducted much of its R&#38;D work through globally licensed research organizations in the U.S., Canada, and the UK, and through certain in-house capabilities. With the DEA license, the Company has expanded its internal R&#38;D capabilities to support innovative drug discovery and delivery involving Schedule I compounds. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On March 13, 2024, the Company announced that it had been granted Breakthrough Therapy Designation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">BTD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) by the FDA in respect of CYB003. The BTD provides an expedited review pathway, as well as increased access to FDA guidance on trial design, which has the potential to significantly reduce drug development timelines. The designation includes all &#8220;fast track&#8221; program features, as well as more intensive FDA guidance and discussion of the CYB003 development program, including planned clinical trials and plans for expediting the manufacturing development strategy.</font></div><div style="text-align:justify"><font><br></font></div><div id="i2b86e3b0612046f694ccc21dee9687a9_129"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Non-Revenue Generating Projects</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-style:italic;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">8</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company currently has three significant projects, which have not yet generated revenue&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:9.75pt">Deuterated Psilocin Program (CYB003)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:9.75pt">Deuterated Dimethyltryptamine Program (CYB004)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:9.75pt">Phenethylamine Derivatives Program (CYB005)</font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> At this time the Company has not entered into commercial supply agreements and has no control over price or conditions. The Company&#8217;s assumption is that it will be able to enter into agreements at such a time when there will be sufficient competition in the market which will render prices reasonable.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> All quarter references in this section are based on calendar year-end.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">he Company was previously exploring a fourth program, the Technology Program&#59; however, in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">March 2025, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">the Company concluded that it would no longer be progressing with this program in order to prioritize the progression of its core clinical development programs. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has developed EMBARK, a psychological support model that integrates leading clinical approaches to promote supportive healing with pharmacological interventions for neuropsychiatry. EMBARK&#8217;s six clinical domains (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">xistential-Spiritual, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">indfulness, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">ody Aware, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">ffective-Cognitive, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">elational, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">eeping Momentum) represent the broad spectrum of ways in which therapeutic benefits may arise in treatment and the equally broad training needed to prepare therapists to support them all. The Company launched its EMBARK training program in June 2021, which prepares facilitators to work within all of these domains, while inviting facilitators to bring in their own therapeutic training and expertise in a flexible, yet structured way. The EMBARK curriculum additionally emphasizes trauma-informed, culturally competent, and ethically rigorous care. On April 12, 2023, the Company announced the launch of EMBARK Open Access (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">EMBARK OA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), a free online foundational training course for facilitation. EMBARK Open Access is the first and only free massive open online course that offers foundational facilitation training for healthcare professionals and people interested in offering psychological support. On July 12, 2023, the Company announced that it has commenced the development of a streamlined, scalable version of its EMBARK Training Program, known as EMBARK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">CT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">, which is designed for individuals with existing knowledge, skills, and experience in facilitation. The EMBARK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">CT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> training program is expected to enable the Company to effectively screen, qualify, and train facilitators on a multi-site, international level, to provide support and in-person monitoring for study participants receiving the Company&#8217;s investigational therapeutics in larger pivotal trials.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">About the Deuterated Psilocin Program (CYB003)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has been investigating the development of short-acting tryptamines with the aim of creating clinical development candidates, utilizing (i) the chemical modification of tryptamine derivatives through the selective substitution of hydrogen atoms with deuterium (i.e. deuteration)&#59; and (ii) the combination of such deuterated tryptamine derivative molecules with selected drug delivery methods, including but not limited to oral, inhalation methods, IV and intramuscular delivery.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s lead program, CYB003, is an orally delivered deuterated psilocin molecule that has been granted FDA BTD for the adjunctive treatment of MDD. CYB003 aims to address the limitations of oral psilocin, including side effects, scalability and accessibility of treatment.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company completed its CYB003 Investigational New Drug (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;)-enabling preclinical studies and Chemistry, Manufacturing and Control (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">CMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) development, including the production of clinical materials required for clinical trials, in the second quarter of calendar 2022. In the same period, the Company submitted an IND application to the FDA and received a &#8220;may proceed letter&#8221; and IND application clearance from the FDA as well as Institutional Review Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">IRB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) approval in the U.S. to commence its first-in-human Phase 1&#47;2a study of CYB003 in participants with moderate to severe MDD. The Company had engaged Clinilabs Drug Development Corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Clinilabs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), a full-service contract research organization with deep expertise in central nervous system drug development, to carry out the Phase 1&#47;2a clinical trial of CYB003. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">About the Completed CYB003 Phase 1&#47;2a Clinical Trial</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Phase 1&#47;2a trial was a randomized, double-blind, placebo-controlled study evaluating CYB003 in participants with moderate to severe MDD and in healthy volunteers. Per a protocol amendment to the initial Phase 1&#47;2a study design that was announced on February 28, 2023, the study introduced healthy volunteers for the lower (sub-therapeutic) dose cohorts and added a bioequivalence cohort to facilitate the transition to pivotal studies. Healthy volunteers received two administrations (placebo&#47;active and active&#47;active) one week apart, and measures of pharmacological effect were assessed after each dose. Participants with MDD received two administrations (placebo&#47;active and active&#47;active) three weeks apart and response&#47;remission were assessed three weeks after each dose. MDD participants in the trial that were being treated with antidepressants were allowed to remain on their antidepressant medication.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The study investigated the safety, tolerability, pharmacokinetics (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">PK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) and pharmacodynamics (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">PD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), and pharmacological effect of ascending oral doses of CYB003. In participants with MDD, the trial evaluated rapid onset of antidepressant effect on the day of dosing, using the Montgomery-Asberg Depression Rating Scale (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">MADRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), and evaluated the incremental benefit of a second dose of CYB003 when administered at Week 3. The study included an optional period of assessment to evaluate the durability of treatment effect out to 12 months. The study is listed on ClinicalTrials.gov under Identifier&#58; NCT05385783. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On August 30, 2022, the Company announced that the first two participants had been dosed in the Phase 1&#47;2a study. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On February 28, 2023, the Company announced positive interim safety and pharmacokinetics and pharmacodynamics data from the Phase 1&#47;2a study of CYB003. Interim findings showed that CYB003 exhibited rapid, short-acting effects, low variability in plasma levels, and achieved a psychedelic effect at low doses. At the 8mg and 10mg dose levels, most of the participants reported robust and meaningful psychedelic effects, confirming a complete mystical experience was achieved. All doses evaluated (single oral doses of CYB003 up to 10mg) were well-tolerated with no serious adverse events reported. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On July 24, 2023, the Company announced that it had completed dosing in Cohort 5 of the Phase 2a portion of the study with no serious adverse events or other adverse events that may preclude continued dosing, with recruitment underway for Cohort 6. The Phase 2a trial, consisting of completed Cohorts 4 and 5 as of the date of the announcement, evaluated two 12mg doses of CYB003. On August 2, 2023, the Company announced that it had initiated dosing in Cohort 6, the final cohort of the CYB003 Phase 2a study.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On September 21, 2023, the Company announced that it had completed enrollment in its Phase 2a study of CYB003, its proprietary deuterated psilocin molecule program being developed for the potential treatment of MDD. All participants in the sixth, and final, cohort received at least one dose (placebo or 16mg of CYB003) with several second doses already administered, and no serious adverse events observed in participants. As of that date, CYB003  demonstrated a favorable safety and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">tolerability profile at all doses evaluated in the five completed cohorts (1mg, 3mg, 8mg, 10mg, and 12mg). </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On October 3, 2023, the Company announced that it had completed dosing in Cohort 6 of its Phase 2a study of CYB003. The following doses were evaluated in the six cohorts that comprised the Phase 2a study&#58; 1mg, 3mg, 8mg, 10mg, 12mg, and 16mg. As of that date, CYB003 has been shown to be safe and tolerable at all doses evaluated with no serious adverse events or discontinuations due to adverse events having been observed in the final dose cohort.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On October 31, 2023, the Company announced Phase 2a interim results for CYB003, its proprietary deuterated psilocin molecule, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single 12mg dose compared to placebo, in participants with moderate to severe MDD. At the 3-week primary efficacy endpoint, the reduction in MDD symptoms, defined as change from baseline in the MADRS total score, was superior in participants assigned to CYB003 compared to the participants who received placebo by 14.08 points (p&#61;0.0005, Cohen&#8217;s d&#61;2.15). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On November 30, 2023, the Company announced positive Phase 2a topline results for CYB003, showing rapid and robust improvements in symptoms of depression after single doses of CYB003, with an average 13.75 point difference in MADRS score reduction between CYB003 and placebo which was statistically significant at 3 weeks (p&#60;0.0001). The study also demonstrated a clear incremental benefit of a second dose, with a further 5.8 point improvement on the MADRS total score with a second dose of CYB003 (12mg) at 6 weeks, and 79% of patients were in remission from depression at 6 weeks after two doses of CYB003 (12mg). CYB003 exhibited a favorable safety and tolerability profile with no treatment-related serious adverse events at 12mg and 16mg doses.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On March 13, 2024, the Company announced that the FDA had granted BTD to its CYB003 program for the adjunctive treatment of MDD. The BTD provides an expedited review pathway, as well as increased access to FDA guidance on trial design, with the potential to reduce drug development timelines. On March 13, 2024, the Company also reported positive four-month durability data from the Phase 2a study of CYB003 in MDD. These results showed robust, sustained and statistically significant improvements in depression symptoms at four months with two doses of CYB003 (12mg or 16mg)&#58;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">Average mean reduction from baseline in the MADRS total score across 2 cohorts was approximately 22 points from baseline in both dosing cohorts.</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14pt">60% of patients on 12 mg and 75% on 16 mg were in remission from depression following 2 doses (MADRS score &#60;&#47;&#61; 10).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On August 13, 2024, the Company announced that it held a Type B Initial Comprehensive Breakthrough Therapy Meeting with the FDA. Further to recent industry discussions around the subject of functional unblinding, the Company plans to implement multiple measures to attempt to mitigate the risk of functional unblinding in its pivotal study program, as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">the pivotal study program will include a study with a three-arm design with a high dose, mid-dose, and placebo arm. Patients will not know if they received the therapeutic high dose or the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">sub therapeutic mid-dose, mitigating the unblinding to an extent and addressing potential expectancy bias&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">the studies will utilize remote, independent, blinded raters who will not have any information on the dose received or the participant&#8217;s dosing experience&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">the reporting of effects during the dosing session will be fire-walled to ensure that the study team stays blinded&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">the studies will recruit participants who are largely psychedelic na&#239;ve to reduce the impact of expectancy bias&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">the studies will assess long-term efficacy data points up to one year, to outlast any potential expectancy effects.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In addition, the studies will include manual and real time artificial intelligence screening of monitoring sessions to ensure monitor fidelity and patient safety.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On November 18, 2024, the Company reported positive Phase 2 data for CYB003, demonstrating 12-month efficacy in treating MDD. At 12 months after two 16 mg doses, 100% of participants were responsive to treatment and 71% of participants were in remission. The mean change from baseline in MADRS was approximately -23 points at 12 months after two 16 mg doses. CYB003 demonstrated an excellent safety and tolerability profile. No new adverse events were reported in the 12-month follow up, including no reports of suicidality.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">About the Phase 3 PARADIGM Pivotal Program</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s Phase 3 program comprises three pivotal efficacy studies as outlined below. Dosing is underway in APPROACH, the first pivotal study.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Pivotal study 1&#58; APPROACH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline"> TM </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">A P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">hase III, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">lacebo-Controlled, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">andomized, Double-Blind Trial of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">ral Doses of CYB003 to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">ssess </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">ombined Safety and Efficacy in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">H</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">umans with Major Depressive Disorder)(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">APPROACH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">Participants (n&#61;220) will be randomized 1&#58;1 to receive either 16 mg of CYB003 (n&#61;110) or inactive placebo (n&#61;110). Each study arm will evaluate a two-dose regimen, with doses administered three weeks apart. The study will enroll patients suffering from moderate to severe MDD (MADRS&#8805;24) who are on a stable dose of antidepressant medication but are responding inadequately. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">The primary endpoint will be change in depressive symptoms as measured by change in MADRS from baseline at six weeks after the first dose.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">APPROACH will enroll participants at approximately 45 clinical sites across the U.S.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Pivotal study 2&#58; EMBRACE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(An </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">fficacy and Safety, Phase III, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">ulti-center, Double-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">lind, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">andomized Controlled Study Comparing 2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">ctive and 1 Inactive Oral Doses of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">YB003 in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">ligible Participants with Major Depressive Disorder) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">EMBRACE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">Participants (n&#61;330) will be randomized 1&#58;1&#58;1 to receive 16 mg of CYB003 (n&#61;110), 8 mg of CYB003 (n&#61;110), or inactive placebo (n&#61;110). Each arm will evaluate a two-dose regimen, with doses administered three weeks apart. The study will enroll patients suffering from </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">moderate to severe MDD (MADRS&#8805;24) who are on a stable dose of antidepressant medication but are responding inadequately.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">The primary endpoint will be change in depressive symptoms as measured by change in MADRS from baseline at six weeks after the first dose. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">EMBRACE is expected to enroll at approximately 60 clinical sites, with minimal site overlap with the APPROACH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">study.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Pivotal study 3&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">EXTEND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(A Phase III Open Label </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Exten</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">sion Study with Optional Additional Doses of CYB003 to Assess the Safety and Long-term Efficacy in Participants With Major </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">epressive Disorder.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14.15pt">Participants from APPROACH and EMBRACE will roll over into EXTEND (up to n&#61;550) after the completion of the 12-week, double-blind, placebo-controlled treatment periods.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">During EXTEND, all participants who did not respond to treatment in the APPROACH and EMBRACE studies or who relapse during the EXTEND study will be eligible to receive an additional two doses of CYB003 (16 mg) administered three weeks apart. Participants who do not respond to these two doses or relapse again will be eligible to receive an additional single 16 mg dose of CYB003. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Across all three studies, raters will be remote, independent, and blinded with no information on the dose received or the participant&#8217;s dosing experience. Effects during the dosing session will be firewalled to ensure that the study team stays blinded.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On November 13, 2024, the Company announced that it had initiated PARADIGM, a multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of MDD.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On January 15, 2025, the Company announced the launch of its first strategic partnership agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">SPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) with Segal Trials in furtherance of the Company&#8217;s multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of MDD.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company spent approximately $42,306 on the Deuterated Psilocin Program during the year ended March&#160;31, 2025.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">As the Company continues to progress through the CYB003 program, additional milestones related its clinical development have been identified. The Company intends to&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">Initiate the second Phase 3 study, EMBRACE, around mid-year 2025.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">9 </font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">There is no assurance that this timeline will be met or that the program will advance to clinical trials, at all. Drug development involves long lead times, is very expensive and involves many variables of uncertainty. Anticipated timelines regarding drug development and recruitment of patients for participation in clinical trials are dependent on various factors and are based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, eligibility and exclusion criteria for the trial, design of the clinical trial, competition with other companies for clinical sites or patients, perceived risks and benefits of the prescription drug product candidate, the number, availability, location and accessibility of clinical trial sites, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company&#8217;s development efforts to date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14pt">Initiate the Phase 3 extension study, EXTEND, around mid-year 2025.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">10</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:14pt">Provide topline efficacy data readout from the first Phase 3 study, APPROACH, in 2026.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">11</font></div><div style="text-align:justify;text-indent:0.15pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company expects to spend approximately $8,620</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> to initiate the second Phase 3 study, EMBRACE, around mid-year 2025 of which approximately $5,094 was spent during the year ended March&#160;31, 2025 resulting in an approximate remaining spend as of March&#160;31, 2025 of $3,526 by around mid-year 2025.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company expects to spend approximately $11,048</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> to initiate the Phase 3 extension study, EXTEND, around mid-year 2025 of which approximately $6,701 was spent during the year ended March&#160;31, 2025 resulting in an approximate remaining spend as of March&#160;31, 2025 of $4,347 by around mid-year 2025.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company expects to spend approximately $55,792</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> to provide topline efficacy data readout from the first Phase 3 study, APPROACH, in 2026 of which approximately $5,171 was spent during the year ended March&#160;31, 2025 resulting in an approximate remaining spend as of March&#160;31, 2025 of $50,621 by the milestone completion in 2026.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">17</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company intends to continue funding the Deuterated Psilocin (CYB003) Program. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company intends to complete future clinical trials for this program in the U.S., Canada, and&#47;or Europe.</font></div><div style="text-align:justify"><font><br></font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company has updated this milestone. The Company had previously expected it would complete this milestone by the first half of 2025. There was a minor change in anticipated timing due to updates to the study. Anticipated spending and timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to the Company. See also footnote 9.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">See footnote 9.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company had previously estimated that its spending to complete this milestone would be $5,484. Anticipated timing and spending regarding drug development is based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company&#8217;s development efforts to date. See also footnote 9.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">See footnote 9.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company had previously estimated that its spending to complete this milestone would be $13,450. Anticipated timing and spending regarding drug development is based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company&#8217;s development efforts to date. See also footnote 9.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">See footnote 9.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company had previously estimated that its spending to complete this milestone would be $32,680. Anticipated timing and spending regarding drug development is based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company&#8217;s development efforts to date. See also footnote 9.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">See footnote 9.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">About the Deuterated Dimethyltryptamine Program</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s proprietary deuterated dimethyltryptamine (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">dDMT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) program CYB004 is being developed as an intermittent treatment with the potential for less invasive, more convenient and patient-friendly dosing methods for the potential treatment of GAD. A single intramuscular (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">IM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) dose is expected to result in acute psychedelic effects lasting an average of 90 minutes.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Cybin has leveraged clinical data from its completed DMT and dDMT trials, which collectively form one of the most advanced and extensive DMT&#47;dDMT data portfolio in the psychedelic drug development sector, to inform and optimize the development of the CYB004 program. To date, Cybin has completed five clinical trials across four molecules&#58; CYB004 (IV dDMT), SPL028 (IV&#47;IM dDMT), SPL026 (IV&#47;IM DMT), and DMT, demonstrating proof-of-concept in potentially treating depression, supporting the development of dDMT for the potential treatment of anxiety disorders, and providing important dosing insights.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Key findings from these completed studies are as follows&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">Phase 2a safety and efficacy data for SPL026 (IV DMT) in 34 participants with MDD, demonstrating a clinically relevant and statistically significant reduction in depression symptoms at two weeks after dosing (-7.4 point difference in MADRS between SPL026 and placebo). Durable antidepressant response and remission rates were observed at six months. Among participants who had achieved remission within three months with SPL026, 64% sustained remission to six months.</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">Phase 1 study evaluating IM SPL026 supporting IM administration for patient-friendly dosing. The study demonstrated that IM DMT is well-tolerated and generates a breakthrough psychedelic experience lasting approximately 45 minutes.</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">Phase 1 study evaluating IM SPL028 supporting IM administration for patient-friendly dosing. The completed Phase 1 study of IV&#47;IM SPL028 in healthy volunteers showed that SPL028 is safe and well-tolerated, and demonstrated that IM dosing of SPL028 produced robust psychedelic effects lasting a short duration (average approximately 90 minutes) in the majority of subjects.</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">Phase 1b study evaluating the safety and efficacy of SPL026 in conjunction with selective serotonin reuptake inhibitors (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">SSRIs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) in 17 participants with MDD, demonstrating no relevant drug-drug interactions, a favorable safety profile and enhanced efficacy when SPL026 was administered with SSRIs, and a 92% remission rate at 4 weeks in the DMT + SSRI combination cohort (n&#61;12).</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">Phase 1 results for IV CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as a short-acting, scalable treatment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Exploratory analysis of the Phase 2a and Phase 1b data for SPL026 also shows significant improvements in symptoms of anxiety, as measured using the State Trait Anxiety Inventory &#8211; Trait version (STAI-T), with a 23 point improvement from baseline at the two week endpoint, in the DMT+ SSRI combination group.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company is currently advancing CYB004, a deuterated version of DMT, for the potential treatment of GAD. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">DMT activates the serotonin 5-HT</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:1.55pt;vertical-align:baseline">2A</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> receptor, which is believed to mediate the potential therapeutic effects of DMT. In its regular form, DMT is an unstable molecule rapidly metabolized in the body, which significantly</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> reduces</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> its bioavailability. CYB004, as a deuterated molecule, has the potential to overcome the therapeutic limitations of native DMT. To date, CYB004 has demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as a short-acting, scalable treatment. Additionally, learnings from Phase 1 studies of IM SPL028 have supported IM administration as a viable dosing method for deuterated DMT, suggesting the potential for CYB004 to offer more convenient and patient-friendly dosing methods. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">CYB004 is secured by a U.S. composition of matter patent with protection through 2041. The patent covers a range of deuteration forms of DMT and protects CYB004 as a putative new chemical entity.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On June 7, 2022, the Company announced it had entered into an agreement to acquire a Phase 1 DMT study (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Asset Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) from Entheon Biomedical Corp. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Entheon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) to accelerate the clinical development path for CYB004. On July 11, 2022, the Company announced that the Asset Acquisition was completed. The Phase 1 study, previously identified as EBRX-101 and now named CYB004-E, was conducted in the Netherlands. Entheon acted as external consultants to the Company for approximately 10 months after the Asset Acquisition. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On January 12, 2023, the Company announced that it has selected GAD as the target indication for its proprietary deuterated DMT molecule, CYB004. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">About the Phase 1 CYB004-E DMT Study</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Phase 1 trial was a three-part study evaluating the safety, pharmacokinetics, and pharmacodynamics of escalating doses of DMT and CYB004 in healthy volunteers. The three-part study design was established in a protocol amendment to the initial study design, allowing the Company to commence first-in-human dosing of CYB004 sooner than initially planned. The study provided essential safety and dosing optimization data informing the clinical path forward for CYB004. The CYB004-E study was conducted at the Centre for Human Drug Research in the Netherlands and is one of the largest Phase 1 DMT clinical trials to date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On November 10, 2022, the Company announced that its CYB004-E Phase 1 trial evaluating IV DMT completed dosing for four out of five cohorts and that the Safety Review Committee had confirmed no safety issues. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On February 1, 2023, the Company announced that it had received approval from an independent ethics committee in the Netherlands to initiate first-in-human dosing of CYB004 through a protocol amendment to its ongoing Phase 1 CYB004-E study. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On February 28, 2023, the Company announced a protocol amendment to the initial Phase 1 study design that would allow the Company to initiate first-in-human dosing of CYB004 sooner than initially planned. Per the protocol amendment, Cybin established a three-part study to include Part A (IV DMT infusion), Part B (IV DMT bolus + infusion) and Part C (IV CYB004 bolus + infusion) in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">healthy volunteers. The Company was able to rely upon completed preclinical data to gain regulatory authorization to add CYB004 to the CYB004-E DMT Study. The Company also announced confirmatory data from Part A, the single ascending dose portion of the CYB004-E study, which assessed a continuous IV DMT infusion. The Part A data showed a dose-proportional increase in exposure and dose-related increase in behavioral measures of subjective psychedelic experience with IV DMT. IV DMT was also well-tolerated with no safety issues and no serious adverse events within the dose range evaluated. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On May 9, 2023, the Company announced that it had completed dosing for the last subject in Part B of the Phase 1 CYB004-E trial.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On May 24, 2023, the Company announced that it had initiated first-in-human dosing of CYB004 in Part C of the Phase 1 CYB004-E trial. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On January 8, 2024, the Company announced positive topline results from its Phase 1 studies of its proprietary deuterated DMT molecules, CYB004 and SPL028. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">The Phase 1 CYB004 study results showed that IV CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT. These psychedelic effects were rapid in onset when administered as an IV bolus over five minutes and persisted for about 40 minutes after the bolus without the need for an extended infusion.</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">The Phase 1 SPL028 study identified an IM dose of SPL028 that resulted in a breakthrough psychedelic experience, with a total duration ranging from 55 to 120 minutes.</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">Both CYB004 (IV) and SPL028 (IM and IV) were well-tolerated with no serious adverse events, and the majority of adverse events were mild to moderate and self-limiting. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On January 23, 2024, the Company announced that it had received FDA clearance to initiate a Phase 2 study of CYB004 in GAD.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On March 15, 2024, the Company announced that it had initiated a Phase 2 study of IM CYB004 in participants with moderate to severe GAD. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">About the Phase 2 CYB004 Study in GAD</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The CYB004-002 Phase 2 study is a randomized, double-blind study which will evaluate the safety and efficacy of CYB004 in participants with moderate to severe GAD (GAD-7 score &#8805;10), with concomitant antidepressant&#47;anxiolytic treatment and co-morbid depression allowed. The study will recruit approximately 36 participants, who will be randomized in a double-blind manner, into two groups. The first group will receive two IM doses of CYB004, three weeks apart, while the second group will receive two low-dose control administrations of sub-therapeutic doses of CYB004. The primary endpoint is a change in the Hamilton Anxiety Rating Scale score from baseline at six weeks following the second dose. Other endpoints include the HAM-D (Hamilton Depression Rating Scale), safety assessments, MEQ30 (psychedelic experience assessment) and EQ-5D-5L (quality of life assessment). Participants will be followed for up to a year. Results from this study are expected to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">provide proof of concept for CYB004&#8217;s efficacy in GAD, the time to onset of effects, as well as durability of effects to one year.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company spent approximately $13,345 on its Deuterated Dimethyltryptamine Program during the year ended March&#160;31, 2025 related to the milestones detailed below. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">As the Company continues to progress its Deuterated Dimethyltryptamine Program, additional milestones related to its clinical development have been identified. The Company intends to&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">Complete the Phase 2 GAD study, around mid-year 2025.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">18</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company expects to spend approximately $10,744</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> to complete the Phase 2 GAD study, around mid-year 2025 of which approximately $6,940 was spent during the year ended March&#160;31, 2025 and approximately $58 was spent during the financial year ended March 31, 2024, resulting in an approximate remaining spend as of March&#160;31, 2025 of $3,746 by around mid-year 2025.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company intends to continue funding the Deuterated Dimethyltryptamine (CYB004) Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">About the Phenethylamine Derivatives Program (CYB005)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s Phenethylamine Derivatives Program (CYB005) is focused on the development of therapeutic phenethylamine derivatives. Multiple phenethylamines have been shown to have psychedelic properties and several, such as MDMA, have shown promise as therapeutics. Cybin&#8217;s proprietary approach to phenethylamines modification with novel chemistry, proprietary formulations and directed delivery systems has yielded a number of novel, IP-protected leads with significant therapeutic potential. Several compounds are now being further studied both in vitro and in vivo for selection of the best development candidates, including evaluating the benefits of sub-psychedelic, chronic dosing. The Company is investigating the effects of phenethylamine derivatives on neuroplasticity, and for the potential treatment of CNS disorders, neuroinflammation and other </font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> The Company has updated this milestone. The Company had previously expected it would complete this milestone by the first half of 2025. There was a minor change in anticipated timing due to updates to the study. Anticipated spending and timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to the Company. See also footnote 9.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company had previously estimated that its spending to complete this milestone would be $10,014. Anticipated timing and spending regarding drug development is based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company&#8217;s development efforts to date. See also footnote 9.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:139%;position:relative;top:-3.15pt;vertical-align:baseline">20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%"> See footnote 9.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">neurological conditions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">21 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company is investigating novel molecules within the CYB005 program at non-hallucinogenic doses for a range of CNS disorders. In addition, the Company is continuing to explore non-hallucinogenic neuroplastogens within its broader discovery pipeline, as well as targeted serotonin 5-HT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:1.55pt;vertical-align:baseline">1A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> and 5-HT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:1.55pt;vertical-align:baseline">2C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> receptor agonists.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">22</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In order to assess the feasibility and viability of these phenethylamine derivatives entering clinical studies, the Company has and will continue to contract with reputable and licensed third-party vendors to undertake extensive preclinical characterization of target molecules on the Company&#8217;s behalf. These activities include, but are not limited to&#58; the synthesis of such molecules as API at laboratory scale, the development and optimization of production processes for such APIs, the development of stable formulations utilizing these APIs, the development and validation of analytical methods for such formulations, the scale up of API production processes beyond laboratory scale to deliver GLP and GMP material suitable for entry into animal and human studies, studies of the stability of such formulations suitable for human studies, the development of Chemistry, Manufacturing and Controls to meet Current Good Manufacturing Practices  (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">cGMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In addition, utilizing the expertise of selected third parties, the Company intends to oversee the study of the pharmacokinetic profiles of its formulations in a number of animal models and the completion of Absorption, Distribution, Metabolism, and Excretion (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">ADME</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) profiles. Further, the Company&#8217;s licensed third party vendors will be responsible for completing a range of additional preclinical programs including, but not limited to, dose-ranging studies in multiple animal species, toxicity studies in multiple animal species, genotoxicity studies, along with neuropharmacological, pulmonary, and cardiovascular profiling, before the final selection of drug candidates for entry into human trials. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company intends to complete these studies, and collect further relevant safety and toxicity data, prior to the filing for any IND application with the FDA, a CTA with Health Canada, or other similar application with regulatory bodies in other jurisdictions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On October 24, 2024, the Company announced that the United States Patent and Trademark Office granted U.S. patent 12,122,741 with claims to the composition of matter of lead preclinical candidates in the Company&#8217;s CYB005 phenethylamines program. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company spent approximately $97 on its preclinical Phenethylamine Derivatives Program during the year ended March&#160;31, 2025.</font></div><div style="text-align:justify"><font><br></font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> This statement is based on the following material factors and assumptions&#58; (a) the Company assumes it will enter into a contract with a licensed third-party vendor to undertake extensive preclinical characterization of target molecules on the Company&#8217;s behalf&#59; (b) the Company anticipates to complete a number of animal models and the completion of ADME profiles&#59; (c) the Company assumes to enter into third party agreements in order to complete a range of additional preclinical programs including but not limited to dose-ranging studies in multiple animal species, toxicity studies in multiple animal species, genotoxicity studies, teratogenicity studies, along with neuropharmacological, pulmonary, and cardiovascular profiling before the final selection of drug candidates for entry into human trials&#59; and (d) obtain an IND and&#47;or a CTA to enter into clinical trials. As of the date hereof, it has not yet completed the aforementioned items. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company&#8217;s development efforts to date.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">See footnotes 9 and 21.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company is currently identifying a viable drug candidate and completing its assessment of the potential path forward for this candidate, including whether it will be developed internally or by way of potential third party partners. The Company anticipates that its phenethylamine program may deliver a drug candidate suitable for entry into clinical studies by Q1 2026.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">23</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company expects to spend approximately $1,113</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> to complete preclinical development of a phenethylamine drug candidate by Q1 2026,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> of which approximately $97 was spent in the year ended March&#160;31, 2025, approximately $83 was spent during the twelve months ended March&#160;31, 2024, and approximately $782 was spent during the financial year ended March 31, 2023 resulting in an approximate remaining spend as of March&#160;31, 2025 of $151. The Company intends to continue funding the Phenethylamine Derivatives Program (CYB005) Program. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Technology Programs</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has historically had two technology programs (a) Digital Therapy Platform which was intended to support patients undergoing psychedelic therapies to memorialize the learning from their treatment sessions and to assist with the integration of such learnings into the patient&#8217;s psychotherapy program&#59; and (b) Kernel </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Collaboration to evaluate the use of wearable neuroimaging technology during psychedelic therapy. In March 2025, the Company decided to not proceed with its technology programs in order to prioritize the progression of its clinical development programs. The Company had previously indicated that it was evaluating the path forward for both the Digital Therapy Platform and the Kernel Collaboration. The Company no longer e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">xpects to complete the technology programs and is expecting to spend $NIL on these programs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%;text-decoration:underline">Relationships with Third Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%;text-decoration:underline"> </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The Company&#8217;s research and development of its psychedelic pharmaceutical products is conducted by way of licensed partners. The Company also intends to sponsor clinical and other studies at various clinical trial sites. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Clinilabs Drug Development Corporation</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On April 21, 2022, the Company announced that it had partnered with Clinilabs, a global, full-service contract research organization with deep expertise in central nervous system drug development, to </font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> The Company has updated the anticipated timeline for completion of this milestone. The Company had previously expected it would complete this milestone in Q4 2024. Due to the Corporation prioritizing the progression of its Deuterated Psilocybin Analog Program and Deuterated Dimethyltryptamine Program, it now expects to complete preclinical development of a phenethylamine drug candidate in Q1 2026. See also footnote 9.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Reflects actual spend during the financial year ended March 31, 2024, the year ended March&#160;31, 2025, and expected spend during the period from April 1, 2025 until the achievement of preclinical development of a phenethylamine drug candidate by Q1 2026. The Company had previously estimated that its spending to complete this milestone would be $900. Anticipated timing and spending regarding drug development is based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company&#8217;s development efforts to date.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">25 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company has updated the anticipated timeline for completion of this milestone. The Company had previously expected it would complete this milestone in Q4 2024. Due to the Corporation prioritizing the progression of its Deuterated Psilocybin Analog Program and Deuterated Dimethyltryptamine Program, it now expects to complete preclinical development of a phenethylamine drug candidate in Q1 2026. See also footnote 9.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">carry out the Company&#8217;s Phase 1&#47;2a clinical trial of CYB003, its proprietary deuterated psilocin program. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Entheon Biomedical Corp.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On July 11, 2022, the Company completed the acquisition of a Phase 1 DMT study from Entheon. As part of the Asset Acquisition, Entheon assigned its rights under the Master Services Agreement between Entheon and Centre For Human Drug Research (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">CHDR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) to the Company. The Company now maintains a direct contractual relationship with CHDR to conduct the CYB004-E trial. CHDR is an independent institute in the Netherlands specializing in innovative early-stage clinical drug research. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Mindset Pharma Inc.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On September 27, 2022, the Company entered into an agreement, as amended, with Mindset Pharma Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Mindset</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) to acquire an exclusive license to an extensive targeted class of tryptamine-based molecules. The agreement includes an initial license fee payment by Cybin to Mindset of US$500 as well as additional clinical development milestone payments of up to US$9,500, with the first milestone payment, in the amount of US$500, payable upon completion of a Phase 1 clinical trial. At the sole discretion of Cybin, the milestones may be paid in cash or in Common Shares, or a combination thereof, subject to the approval of the Cboe Canada. There is no assurance that the aforementioned milestones will be met. The agreement also contemplates a sales royalty of approximately 2% for all commercialized licensed products within the scope of the agreement, which is customary for drug licensing agreements of this nature. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Segal Trials</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On January 15, 2025, the Company launched its first strategic partnership agreement  with Segal Trials in furtherance of Cybin&#8217;s multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of MDD. Segal Trials is a privately held company with a network of six research sites throughout South Florida. Segal Trials has extensive experience conducting research trials with an emphasis on psychiatry, neurology, addiction, and psychedelics research. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Worldwide Clinical Trials</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On July 26, 2023, the Company announced that it has partnered with Worldwide Clinical Trials, a global, full-service contract research organization with deep expertise managing clinical trials for mental health conditions, including MDD. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Other Third-Party Partners</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has established contractual sources of synthetic GMP (as defined below) and non-GMP raw materials to support its development operations through licensed third-party suppliers located in Canada, the United States, the UK and Europe. Such raw materials are expected to be, in general, readily available and in adequate supply to meet the Company&#8217;s need for development quantities, or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">custom manufactured on the Company&#8217;s behalf.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> The prices of research quantities of novel tryptamine compounds are generally higher than commercial supply prices at significantly larger scale and the Company, therefore, expects its supply prices to reduce over time. Development and production of the Company&#8217;s proprietary novel compounds is performed under confidential contractual agreements.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has conducted due diligence on each such third party, including but not limited to the review of necessary licences and the regulatory framework enacted in the jurisdiction of operation.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The allocation of capital towards the Company&#8217;s ongoing projects and programs is largely dependent on the success, or difficulties encountered, in any particular portion of the process and therefore the time involved in completing it&#59; in turn the time and costs associated with completing each step are highly dependent on the incremental results of each step and the results of other programs, and the Company&#8217;s need to be flexible to rapidly reallocate capital to projects whose results show the greatest potential. As such, it is difficult for the Company to anticipate the timing and costs associated with taking the projects to their next planned stage, and the Company cannot make assurances that the foregoing estimates will prove to be accurate, as actual results and future events could differ materially from those anticipated. Accordingly, investors are cautioned not to put undue reliance on the foregoing estimates. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Moreover, identifying the timing and costs of such projects beyond their immediate next steps go to the core differentiating factors with respect to the Company and its competitors. The disclosure of prospective costs and timing other than as already disclosed by the Company would negatively impact shareholder value and undermine the Company&#8217;s proprietary technology. In keeping with pharmaceutical industry practice, it is the Company&#8217;s policy to disclose these details in conjunction with its financial statements, and to publicly disclose published patent applications, published scientific papers, scientific symposia and the attainment of key milestones only. In addition, the premature disclosure of proprietary data would have a material and adverse effect on the Company&#8217;s patent and other intellectual property rights and could result in the breach of confidentiality obligations.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The material factors or assumptions used to develop the estimated costs disclosed above are included in the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:130%">Cautionary Note Regarding Forward-Looking Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221; section above. The actual amount that the Company spends in connection with each of the intended uses of proceeds will depend on a number of factors, including those listed under &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:130%">Risk Factors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221; in this MD&#38;A or unforeseen events. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Other than as described in the AIF and herein, to the knowledge of management, there are no other particular significant events or milestones that must occur for the Company&#8217;s  business objectives in the next 12 months to be accomplished. However, there is no guarantee that the Company will meet its business objectives or milestones described above within the specific time periods, within the estimated costs or at all. The Company may, for sound business reasons, reallocate its time or capital resources, or both, differently than as described above.</font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> At this time the Company has not entered into commercial supply agreements and has no control over price or conditions. The Company has assumed that it will be able to enter into commercial supply agreements at such a time when there will be sufficient competition in the market which will render prices reasonable. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has negative cash flow from operating activities and has historically incurred net losses. To the extent that the Company has negative operating cash flows in future periods, it may need to deploy a portion of its existing working capital to fund such negative cash flows.  The Company will be required to raise additional funds through the issuance of additional equity securities, through loan financing, or other means, such as through partnerships with other companies and research and development reimbursements.  There is no assurance that additional capital or other types of financing will be available if needed or that these financings will be on terms at least as favourable to the Company as those previously obtained. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div id="i2b86e3b0612046f694ccc21dee9687a9_143"></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Intellectual Property</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Cybin has title to twenty four granted US patents and seventy four granted national (non-US) patents, including claims directed to compositions of matter and methods of use in support of its research and development and preclinical and clinical trial programs. Granted European patents are counted as a single granted patent (as opposed to multiple patents in each European territory in which the patent is in force). </font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Number</font></td><td colspan="3" style="background-color:#bfbfbf;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#bfbfbf;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,242,318</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives And Methods Of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,724,985</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives And Methods Of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,746,088</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives And Methods Of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,834,410</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives And Methods Of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,958,807</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives And Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,110,272</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives And Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,240,813</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives And Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,291,499</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives And Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,122,741</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2018311307</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crystalline Forms of Hydroxynorketamine</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020378647</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020381103</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021334933</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021204158</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020286709</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds </font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120220221983</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3104072</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Drug Substance Compositions Comprising N,N-Dimethyltryptamine</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3160337</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3179161</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3142290</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3160334</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3179335</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202080087091.0</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202080087092.5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202180044031.5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202180046463.X</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202080050439.9</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202180090269.1</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Number</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">046951</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eurasian Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">048675</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eurasian Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">049402</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eurasian Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">049106</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eurasian Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3463323</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid Oral Dosage Forms of 2R,6R-Hydroxynorketamine or Derivatives Thereof</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3687515</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid Oral Dosage Forms of Ketamine Derivatives</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3532457</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crystalline Forms of Hydroxynorketamine</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3826632</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3844147</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3873883</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3902541</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4031529</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4138818</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4149460</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40042383</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40035970</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid Oral Dosage Forms of Ketamine Derivatives</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40056359</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40060666</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40065709</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40064531</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40045846</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40060891</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40078818</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40089095</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507114</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">528813</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292753</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds, Compositions Comprising Same, and Uses Thereof in the Treatment of Psychiatric or </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neurological Disorders </font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288617</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298542</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7288154</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7422474</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7423131</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7422474</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7523474</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A therapeutic composition comprising a deuterated or partially deuterated N,N-dimethyltryptamine compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7579888</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202180044031.5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Macao</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202080087092.5</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Macao</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Number</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202180046463.X</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Macao</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZL202080050439.9</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Macao</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404310</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">411316</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">412331</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">415678</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">788543</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dimethyltryptamine derivatives and their use in psychedelic-assisted psychotherapy</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">794833</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">793361</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">794813</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Form</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2589605</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Republic of Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2636385</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Republic of Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023&#47;01086</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2585978</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">I860478</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taiwan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2586940</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2592822</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2595776</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,377,416</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Crystalline Forms of Hydroxynorketamine</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,771,681</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,773,062</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,643,390</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthesis of N,N-Dimethyltryptamine-Type Compounds, Methods, and Uses</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,471,417</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,406,619</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,697,638</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5-Methoxy-N,N-Dimethyltryptamine Crystalline Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,660,289</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,578,039</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,042,564</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,076,311</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds </font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,084,417</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthesis of N,N-Dimethyltryptamine-Type Compounds, Methods, and Uses</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12157723</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12251371</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12318477</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></div></td></tr></table></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In addition, Cybin has title to three provisional patent applications, thirty three US non-provisional patent applications, two hundred and six national (non-US) patent applications, and six Patent Cooperation Treaty (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">PCT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) applications, including claims directed to compositions of matter and methods of use in support of its research and development and preclinical and clinical trial programs.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Application Number</font></td><td colspan="3" style="background-color:#bfbfbf;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#bfbfbf;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Status</font></td><td colspan="3" style="background-color:#bfbfbf;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;056,958</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Application Number</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Status</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;041,728</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;027,810</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;547,100</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;561,152</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations of Psilocybin</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;576,487</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Integrated Data Collection Devices for Use in Various Therapeutic and Wellness Applications</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;588,132</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods of Treating Disorders with a Psilocybin Analog</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PCT&#47;EP2024&#47;054897</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WIPO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods of Treating Disorders with a Psilocybin Analog</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;688,125</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination Drug Therapies</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PCT&#47;EP2024&#47;062406</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WIPO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Pharmaceutical Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;707,825</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PCT&#47;EP2024&#47;065453</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WIPO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Companion Animal Treatments</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;720,922</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PCT&#47;EP2024&#47;067458</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WIPO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Processes For Preparing Phenethylamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;730,397</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;730,423</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;825,122</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;883,262 </font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;850,356</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;852,115 </font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination of Nitrous Oxide and 5-HT2A Receptor Agonists</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;867,231 </font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid Dispersions of Psilocybin</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#47;020,095</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#47;106,551</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compounds, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#47;119,308 </font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Compounds, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#47;170,327</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#47;822,926</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Manufacture of Psilocin or Deuterated Psilocin Salts</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">793553</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">812214</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297492</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312785</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3177454</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NC2022&#47;0016662</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Colombia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MX&#47;a&#47;2022&#47;014605</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Application Number</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Status</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MX&#47;a&#47;2024&#47;006467</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202203191</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2022-7040243</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Republic of Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2024-7019118</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Republic of Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EP21808464.8</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24175524.8</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202180036163.3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202410728550.9</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120220235658</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021276656</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024203974</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11202254530T</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10202401521X</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202213256</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2201007493</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1-2022-553135</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1-2024-551326</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202227065770</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022-571175</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-080101</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62023078320.6</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42024099806.2</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Tryptamine Derivatives and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3186357</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2023-7003815</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021327136</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-512063</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21766581.9</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62023079716.4</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3186359</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2023-7006128</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021328671</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Application Number</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Status</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-512107</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21763068.0</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62023079718.0</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21786852.0</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2023-7007858</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021354006</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-519831</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3194558</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62023079720.6</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">802136</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">305457</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3212563</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NC2023&#47;0013714</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Columbia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MX&#47;a&#47;2023&#47;010843</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202302731</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202501220</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2023-7032581</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22716857.2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202280022029.2</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120230188946</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022239825</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11202305618U</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202309486</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2301005753</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1-2023-552572</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202327063524</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-556906</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62024086011.9</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Psilocybin Analogs, Salts, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022277515</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations of Psilocybin</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Application Number</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Status</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3216799</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations of Psilocybin</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22729558.1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations of Psilocybin</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202327074210</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations of Psilocybin</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-571283</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations of Psilocybin</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2023-7041239</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations of Psilocybin</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62024089505.7</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations of Psilocybin</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022342266</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination Drug Therapies</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3231021</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination Drug Therapies</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22716971.1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination Drug Therapies</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-515026</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination Drug Therapies</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2024-7008355</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination Drug Therapies</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62024094405.3</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination Drug Therapies</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022381220</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120240088332</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3236624</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202280073355.6</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22783493.4</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202417038272</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312175</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-526529</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2024-7017594</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">810005</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120242311</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saudi Arabia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62024097476.1</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Formulations Of Psilocybin Analogs and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023207801</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120240139522</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3259235</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202380016531.7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23700949.3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313889</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202417058417</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-541809</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2024-7026687</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MX&#47;a&#47;2024&#47;008691</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PI2024003160</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Malaysia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">811765</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120243886</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saudi Arabia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62024099899.2</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compositions and Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023222397</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3244275</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Application Number</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Status</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23705529.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-547671</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2024-7028837</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62024101488.0</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Phenethylamine Compositions and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023222126</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3244130</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23705530.6</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-547667</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2024-7028843</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62024101490.6</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Derivatives, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023246690</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3246274</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23715813.4</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-557460</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2024-7032719</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">815769</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62025103102.2</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Methods For Delivery of Psychedelic Medications By Inhalation and Systems For Performing the Methods</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023242469</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination of Nitrous Oxide and 5-HT2A Receptor Agonists</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3247035</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination of Nitrous Oxide and 5-HT2A Receptor Agonists</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23717049.3</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination of Nitrous Oxide and 5-HT2A Receptor Agonists</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-557455</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination of Nitrous Oxide and 5-HT2A Receptor Agonists</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813800</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination of Nitrous Oxide and 5-HT2A Receptor Agonists</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62025103101.4</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination of Nitrous Oxide and 5-HT2A Receptor Agonists</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023331937</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compounds, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3265884</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compounds, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23764241.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compounds, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025-512678</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compounds, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2025-7007259</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tryptamine Compounds, Compositions, and Methods of Use</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Application Number</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Status</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023366306</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Compounds, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3271746</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Compounds, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202380075041.4</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Compounds, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23798713.6</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Compounds, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025-524528</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Compounds, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2025-7014590</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Compounds, Compositions, and Methods of Use</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120253030</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saudi Arabia</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phenethylamine Compounds, Compositions, and Methods of Use</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120220089198</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202217028822</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds, Compositions Comprising Same, and Uses Thereof in the Treatment of Psychiatric or Neurological Disorders</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-202672</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2023-7033500</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Republic of Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;921,515</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compounds</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110143066</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taiwan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021391581</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3203020</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202180090269.1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Macao</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23198784.3</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42024091001.8</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202317043169</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303288</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023-533243</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800961</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 816489.5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;252,949</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;056,771</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022393234</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 2024 009571 1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3238583</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 818741.5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62025102900.0</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202417045861</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312859</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024-529536</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2024-7020007</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MX&#47;a&#47;2024&#47;005955</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">811102</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Application Number</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Status</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11202403174T</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024&#47;03906</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PI 2024002791</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Malaysia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120242659</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saudi Arabia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202401452</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2401003192</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12024551165</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;711,130</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#47;192,691</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NC2024&#47;0007518</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Colombia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202280084101.4</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable and Inhalable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24194778.7</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42025103259.5</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298129</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PI 2023000584</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Malaysia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11202300697X</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulation</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#47;806,526</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#47;202,059</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Injectable Formulations</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;619,547</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Administration</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PCT&#47;EP2024&#47;058587</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WIPO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Combination Comprising a Monoamine Antidepressant Agent and a Short-Duration Psychedelic Agent</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PCT&#47;EP2024&#47;051569</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WIPO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treatment of Psychiatric or Neurological Disorders by Parenteral Administration of a Single, Effective Parenteral Dose of A Short-Acting Psychedelic Agent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22214748.0</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202217028688</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292754</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Synthesis</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21203394.8</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid Oral Dosage Forms of 2R,6R-Hydroxynorketamine or Derivatives Thereof</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;602,171</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthesis of N,N-Dimethyltryptamine-Type Compounds, Methods, and Uses</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120220245661</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42023070531.1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202217076779</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298541</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1120210243330</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22173907.1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">783166</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Patent Application Number</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction of Filing</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Status</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2021-7043410</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Republic of Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2024-7030292</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Republic of Korea</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;779,611</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,N-Dimethyltryptamine Compounds</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021284861</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Form</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202217076899</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Form</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023361184</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Administration of a Parenteral Formulation Comprising a Psychedelic Agent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,270,486</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Administration of a Parenteral Formulation Comprising a Psychedelic Agent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TBD</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Administration of a Parenteral Formulation Comprising a Psychedelic Agent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23 790574.0</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Administration of a Parenteral Formulation Comprising a Psychedelic Agent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025-521004</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Administration of a Parenteral Formulation Comprising a Psychedelic Agent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-2025-7015515</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Republic of Korea</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Administration of a Parenteral Formulation Comprising a Psychedelic Agent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#47;119,888</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method of Administration of a Parenteral Formulation Comprising a Psychedelic Agent</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3118556</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202180046533.1</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#47;748,483</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 215587.7</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Patent Office</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Therapeutic Solid Dosage Forms</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#47;699,449</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical Compositions Comprising Deuterated N,N-Dimethyltryptamine</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#47;723,250</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States of America</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pending</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical Compositions Comprising Deuterated  N,N-Dimethyltryptamine</font></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Cybin&#8217;s patent applications cover a wide range of novel psychedelic compounds from different classes, including those with targeted structural modifications for improved pharmacokinetic characteristics and safety profiles without altering their receptor binding. The patent applications also cover novel synthetic routes, pharmaceutical formulations, methods of use, and methods of administration. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Additionally, the Company has entered into multiple licensing agreements that provide the Company with additional access to IP, including the acquisition of an exclusive license to a targeted class of tryptamine-based molecules from Mindset. The licensing agreements collectively provide the Company with access to a broad range of preclinical molecule combinations for its library of psychedelic derivative drug development candidates.  </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company owns or has filed applications for registration of thirty-four trademarks, including APPROACH&#174;, CYBIN&#174;, EMBARK&#174;, EMBRACE&#174;, PARADIGM&#174;, and REVOLUTIONIZING MENTAL HEALTHCARE&#174;.  </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s mission to discover, develop and deploy psychedelic inspired medicines encompasses the research and development of potential new and improved psychedelic inspired medicines ranging </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">from proprietary psychedelic compounds for use as API, specific formulations thereof, and specific uses for compounds and formulations. As the Company generates new data it will continue to file or acquire additional patent applications throughout the Company&#8217;s development program. </font></div><div style="text-align:justify"><font><br></font></div><div id="i2b86e3b0612046f694ccc21dee9687a9_157"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Regulatory Framework and Licensing Regime</font></div><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Canada</font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In Canada, oversight of healthcare is divided between the federal and provincial governments. The federal government is responsible for regulating, among other things, the approval, import, sale, and marketing of drugs such as psilocin and other psychedelic substances, whether natural or novel. The provincial&#47;territorial level of government has authority over the delivery of health care services, including regulating health facilities, administering health insurance plans such as the Ontario Health Insurance Plan, distributing prescription drugs within the province, and regulating health professionals such as doctors, psychologists, psychotherapists and nurse practitioners. Regulation is generally overseen by various colleges formed for that purpose, such as the College of Physicians and Surgeons of Ontario.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Certain psychoactive compounds, such as psilocin, are considered controlled substances under Schedule III of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Controlled Drugs and Substances Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (Canada) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">CDSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;).  In order to conduct any scientific research, including preclinical and clinical trials, using psychoactive compounds listed as controlled substances under the CDSA, an exemption under Section 56 of the CDSA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Section 56 Exemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) is required. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Health Canada has not approved psilocin as a drug for any indication. However, there are legal routes through which psilocin may be accessed for medical or scientific purposes. The Canadian Minister of  Health can grant exemptions under section 56 of the CDSA to use controlled substances if it is deemed to be necessary for a medical or scientific purpose or is otherwise in the public interest.  The Company has not applied for a Section 56 Exemption from Health Canada. Health Canada&#8217;s Special Access Program (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">SAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;) was designed to provide Canadians to access certain restricted drugs before they are formally approved for use in Canada. In January 2022, certain amendments to the SAP came into force to permit medical practitioners treating patients with serious or life-threatening conditions to request access to restricted drugs that have not yet been approved for sale in Canada when conventional therapies have failed, are unsuitable, or unavailable in Canada. Such amendments create a means of legally accessing psilocin through the SAP. The Company has not applied for access under the SAP.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The possession, sale or distribution of controlled substances is prohibited unless specifically permitted by the government. A party may seek government approval for a Section 56 Exemption to allow for the possession, transport or production of a controlled substance for medical or scientific purposes. Products that contain a controlled substance such as psilocin cannot be made, transported or sold without proper authorization from the government. A party can apply for a Dealer&#8217;s Licence under the Food and Drug Regulations (Part J). In order to qualify as a licensed dealer, a party must meet all regulatory requirements mandated by the regulations including having compliant facilities, compliant materials and staff that meet the qualifications under the regulations of a senior person in charge and a qualified person in charge. Assuming compliance with all relevant laws (Controlled Drugs and Substances Act, Food and Drugs Regulations) and subject to any restrictions placed on the licence by Health Canada, an entity with a Dealer&#8217;s Licence may produce, assemble, sell, provide, transport, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">send, deliver, import or export a restricted drug (as listed in Part J in the Food and Drugs Regulations &#8211; which includes psilocybin and psilocin) (see s. J.01.009 (1) of the Food and Drug Regulations).</font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company intends to sponsor and work with licensed third parties to conduct any clinical trials and research and does not handle controlled substances. If the Company were to conduct this work without the reliance on third parties, it would need to obtain additional licences and approvals described above.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">United States </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The FDA and other federal, state, local and foreign regulatory agencies impose substantial requirements upon the clinical development, clinical testing, approval, labeling, manufacture, marketing and distribution of drug products. These agencies regulate, among other things, research and development activities and the testing, approval, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, advertising and promotion of any prescription drug product candidates or commercial products. The regulatory approval process is generally lengthy and expensive, with no guarantee of a positive result. Moreover, failure to comply with applicable FDA or other requirements may result in civil or criminal penalties, recall or seizure of products, injunctive relief including partial or total suspension of production, or withdrawal of a product from the market. Anticipated timelines related to regulatory filings are based on reasonable assumptions informed by current knowledge and information available to the Company. </font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Psilocybin, psilocin, DMT, and 5-Methoxy-DMT are strictly controlled under the federal Controlled Substances Act, 21 U.S.C. &#167;801, et. seq. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">CSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) as Schedule I substances. Schedule I substances by definition have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse. Schedule I and II drugs are subject to the strictest controls under the CSA, including manufacturing and procurement quotas, security requirements and criteria for importation. Anyone wishing to conduct research on substances listed in Schedule I under the CSA must register with the DEA and obtain DEA approval of the research proposal. A majority of state laws in the United States also classify psilocybin and psilocin as Schedule I controlled substances. For any product containing psilocin or any Schedule I substance to be available for commercial marketing in the United States, such substance must be rescheduled, or the product itself must be scheduled, by the DEA to Schedule II, III, IV or V. Scheduling determinations by the DEA are dependent on FDA approval of a substance or a specific formulation of a substance.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Europe&#47;Netherlands </font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The International Narcotics Control Board (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">INCB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), a United Nations (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">UN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) entity, monitors enforcement of restrictions on controlled substances. The INCB&#8217;s authority is defined by three international UN treaties &#8211; the UN Single Convention on Narcotic Drugs of 1961, the UN Psychotropic Convention of 1971 (referred to herein as the UN71), and the UN Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988, which contains provisions related to the control of controlled substance precursors. EU Member States, including the Netherlands, that have agreed to abide by the provisions of these treaties, each create responsible agencies and enact laws or regulations to implement the requirements of these conventions. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Specific EU legislation establishing different classes of controlled substances is limited to EU regulations that define classes of precursors, or substances used in the illicit manufacture of controlled substances, including Regulation (EC) No. 273&#47;2004 of the European Parliament and the Council of February 11, 2004 and the Council Regulation (EC) No. 111&#47;2005 of December 22, 2004. While EU legislation does not establish different classes of narcotic drugs or psychotropic substances, the Council Decision 2005&#47;387&#47;JHA of May 10, 2005 (which applies only in certain limited situations)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> can provoke a Council Decision requiring EU member states to put a drug under national controls equivalent to those of the INCB. DMT is currently classified as a Schedule I substance under the UN71&#59; the EU member states that are party to the UN71, including the Netherlands, have agreed to the following in respect of Schedule I substances&#58;</font></div><div><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">prohibit all use except for scientific and very limited medical purposes by duly authorized persons, in medical or scientific establishments which are directly under the control of their Governments or specifically approved by them&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">require that manufacture, trade, distribution and possession be under a special licence or prior authorization&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">provide for close supervision of the activities and acts mentioned in paragraphs (a) and (b)&#59; </font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">restrict the amount supplied to a duly authorized person to the quantity required for his authorized purpose&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">require that persons performing medical or scientific functions keep records concerning the acquisition of the substances and the details of their use, such records to be preserved for at least two years after the last use recorded therein&#59; and</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">prohibit export and import except when both the exporter and importer are the competent authorities or agencies of the exporting and importing country or region, respectively, or other persons or enterprises which are specifically authorized by the competent authorities of their country or region for the purpose.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">As classification of controlled substances may vary among different EU member states, sponsors must be aware of the prevailing legislation in each country where a clinical trial may be conducted. Prior to operating or conducting any preclinical or clinical studies in any other EU member state, Cybin will investigate the specific regulatory requirements of such EU member state. As referenced above, a licence is required for individuals and entities who wish to produce, dispense, import, or export Schedule I substances (including DMT), but the specific requirements vary from country to country. Currently, DMT is classified in the Netherlands as a List 1 Drug under the Dutch Opium Act (Opiumwet) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Dutch Opium Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) and as such, subject to express authorization being obtained, the production, trade and possession of DMT are prohibited. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In addition to the Dutch Opium Act, two other Dutch Acts may be relevant when it comes to drugs&#58; the Medicines Act and the Commodities Act.</font></div><div><font><br></font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Decision 2005&#47;387&#47;JHA was repealed (by Directive (EU) 2017&#47;2103 of the European Parliament and of the Council of November 15, 2017 amending Council Framework Decision 2004&#47;757&#47;JHA in order to include new psychoactive substances in the definition of &#8216;drug&#8217; and repealing Council Decision 2005&#47;387&#47;JHA), but still continues to apply to new psychoactive substances in respect of which a Joint Report (as referred to in Article 5 of that Decision) has been submitted before November 23, 2018.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The specific regulatory processes and approvals required may vary among different EU member states and are set forth in the respective legislation of each country. For the Netherlands, there are specific regulatory requirements for the approval of clinical trials that need to be met. Firstly, a CTA (Clinical Trial Application) dossier containing the preclinical and any clinical information along with the proposed clinical trial design must be submitted to an accredited Ethics Committee and to the Central Commission on Research in Humans (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">CCMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), which is also known as the Competent Authority in The Netherlands. In Dutch, the CCMO is called the &#8216;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Centrale Commissie Mensgebonden Onderzoek</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8217;. In cases where the study involves a substance subject to the Dutch Opium Act (such as DMT), an official exemption by Farmatec is needed, which needs to be included in the CTA. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Specific rules for the submission, assessment and conduct of clinical trials with medicinal products are set out in, among others, the EU Clinical Trial Regulation 536&#47;2014 (CTR), which is applicable in the EU as of January 31, 2022 and the Medical Research (Human Subjects) Act (Wet medisch-wetenschappelijk onderzoek met mensen). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On April 26, 2023, the European Commission introduced a comprehensive &#8220;pharmaceutical package&#8221; aimed at revising the EU&#8217;s pharmaceutical legislation. This package includes proposals for a new directive and regulation designed to enhance the availability, accessibility, and affordability of medicines. Additionally, it seeks to boost the competitiveness and attractiveness of the EU pharmaceutical industry while imposing higher environmental standards. The European Parliament has recently looked at these proposals to renovate the EU pharmaceutical legislation, and a newly elected Parliament will take up the proposal following the European elections of June 6-9, 2024. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">United Kingdom </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In the UK, there are two main &#8220;layers&#8221; of regulation with which products containing controlled substances must comply. These are&#58; (i) controlled drugs legislation, which applies to all products irrespective of the type of product, and (ii) the regulatory frameworks applicable to a specific category of products, in this case, pharmaceuticals and food&#47;food supplements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The main UK controlled drugs legislation is the Misuse of Drugs Act 1971 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">MDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) and the Misuse of Drugs Regulations 2001 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">MDR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), each as amended. The MDA sets out the penalties for unlawful production, possession and supply of controlled drugs based on three classes of risk (A, B and C). The MDR sets out the permitted uses of controlled drugs based on which Schedule (1 to 5) they fall within.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In the United Kingdom, &#8220;Fungus (of any kind) which contains psilocin or an ester of psilocin&#8221; is controlled as a Class A drug under the MDA and Schedule 1 drug under the MDR. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In the United Kingdom, Class A drugs are deemed to be the most dangerous, and so carry the harshest punishments for unlawful manufacture, production, possession and supply. Schedule 1 drugs can only be lawfully manufactured, produced, possessed and supplied under a controlled drugs domestic licence, which specifies the specific activities to which it relates together with any applicable conditions, issued by the UK Home Office. While exemptions do exist, none are applicable to the API. DMT is also considered a Class A drug under the MDA and as a Schedule I drug under the MDR. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company previously mentioned that it intended to file a clinical trial application with the U.K. Medicines and Healthcare products Regulatory Agency (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">MHRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) related to the Deuterated Psilocin Program upon completion of its pre-clinical studies and CMC development. The Company has since decided that it will first proceed in the U.S. and will reevaluate other applications at a later date. Anticipated timelines related to regulatory filings are based on reasonable assumptions informed by current knowledge and information available to the Company. Small Pharma has a controlled drug licence in respect of the offices at 50 Featherstone St </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">which was issued on</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">June 6, 2024 and expired on June 5, 2025.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> An application for 2025 renewal has been made in good time prior to expiration. Although the new certificate has not yet been issued for 2025-2026, the Home Office has advised that the Company may continue to handle controlled drugs on the same terms and subject to the same conditions of the 2024-2025 licence. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Licensing Requirements </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The Company obtains CYB003 API from a pharmaceutical ingredient provider who is FDA-registered and based in the United States. The API itself has been manufactured and packaged in FDA-registered facilities in the United States. The API is expected to be sent directly to the Company&#8217;s partners for research and development purposes in the United States, Canada and the UK and to its clinical trial site in the U.S.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">As a part of the Asset Acquisition, the Company also acquired API.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:130%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The CYB004-E API was manufactured in the Netherlands by a pharmaceutical ingredient provider that is US FDA-inspected.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:130%;position:relative;top:-3.85pt;vertical-align:baseline">28</font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">As mentioned above, in order to produce, possess and supply the API at a UK-based facility, the facility must also hold a domestic licence issued by the Home Office covering the manufacture, production, possession and supply of a controlled substance. For export of the API to the United States, an export licence is required for each API shipment. The export application must include details of the importer and any import licence required by the local authorities in the United States. Moreover, as set out below in more detail under the heading &#34;Pharmaceutical Products&#34;, depending on how the API is developed and supplied, certain authorizations and licenses from the MHRA may be required to authorize some of the activities carried on at the UK-based facilities in relation to the API.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">All premises that are Home Office licensed, or are intending to be licensed, in connection with the possession, and&#47;or supply and&#47;or production of controlled drugs should consider certain security measures.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:130%;position:relative;top:-3.85pt;vertical-align:baseline">29</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Typically, when controlled drugs are being transported between licensees, responsibility for their security remains with the owner and does not transfer to either the courier or the customer until the drugs arrive at their destination and are signed for. However, where a third party is involved in the transit and&#47;or storage of controlled drugs, even if they are not the legal owners, this party also carries responsibility for their security by virtue of being &#8216;in possession&#8217; of them. The MDA requires that every person in possession of controlled drugs holds an appropriate Home Office License and under </font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">As a result of the Asset Acquisition, including the existing API, the Company did not direct the manufacturing of the API for CYB004-E and proceeded in reliance upon the representations of Entheon and the Company's acquisition diligence.  While the Company believes the CYB004-E API meets all required specifications, the Company did not oversee or direct the manufacture of the DMT API being used in CYB004-E.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">  Home Office guidance&#59; Security guidance for all existing or prospective Home Office Controlled Drug Licensees and&#47;or Precursor Chemical Licensees or Registrants&#59; 2022&#59; https&#58;&#47;&#47;assets.publishing.service.gov.uk&#47;media&#47;63a1b6c8e90e075874d91825&#47;Security_Guidance_for_all_Businesses_and_Other_Organisations_v1.5_Nov_2022.pdf </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">the Home Office guidance, each organization involved in the movement of controlled drugs should have a standard operating procedure covering their responsibilities, record keeping, reconciliation and reporting of thefts&#47;losses.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:139%;position:relative;top:-3.85pt;vertical-align:baseline">30</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Small Pharma holds the appropriate UK Home Office licence required to sponsor clinical trials using Schedule I compounds. </font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Pharmaceutical Products</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">A product is regulated as a &#8220;medicinal product&#8221; under UK legislation (the Human Medicines Regulations 2012, as amended) if (i) it is a substance or combination of substances presented as having properties of preventing or treating disease in human beings (e.g., in marketing claims) or (ii) it is a substance or combination of substances that may be used by or administered to human beings with a view to (a) restoring, correcting or modifying a physiological function by exerting a pharmacological, immunological or metabolic action, or (b) making a medical diagnosis.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In respect of psilocybin&#47;psilocin and DMT, whether a specific product restores, corrects or modifies a physiological function by exerting a pharmacological, immunological or metabolic action will depend on factors such as the concentration of the psilocybin&#47;psilocin or DMT (as applicable) and the mode of action of any psilocybin&#47;psilocin or DMT (as applicable) absorbed in the body. This requires scientific analysis.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">If a product is a medicinal product, the Human Medicines Regulations 2012 require that a marketing authorization for the product granted by the UK Licensing Authority should be in place before the product is placed on the market in the UK (other, more limited, licensing options are available, such as a conditional marketing authorization), unless the product falls within one of the specified exemptions, such as supply in response to an unsolicited request from a healthcare professional to meet the special clinical needs of a particular patient under his&#47;her care ). Following the UK&#8217;s exit from the EU and the end of the transitional period, up to (and including) December 31, 2024, there were separate licensing routes and licences for products supplied&#58; (i) in Great Britain only&#59; (ii) in Northern Ireland only&#59; and (iii) across the UK. From 1 January 2025, the UK Licensing Authority now licenses products across the whole of the UK through UK-wide licenses, removing the separate licensing routes for Great Britain and Northern Ireland for many medicinal products. The process for obtaining a standard marketing authorization generally involves submitting preclinical and clinical data as well as quality and manufacturing information in the form of a common technical document to the MHRA. In addition to a marketing authorization for the product itself, companies carrying out activities involving medicinal products, such as manufacturing, distribution and wholesaling, need to meet defined standards (Good Manufacturing Practices (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;)) and&#47;or Good Distribution Practice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">GDP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) and to hold a related licence from the MHRA.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">How the API is subsequently processed will determine the licences (in addition to any applicable Home Office licences as referred to above) that the UK-based facility must hold. In particular&#58;</font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">  Home Office guidance&#59; Guidelines for Standard Operating Procedures (SOPs)&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">https&#58;&#47;&#47;assets.publishing.service.gov.uk&#47;government&#47;uploads&#47;system&#47;uploads&#47;attachment_data&#47;file&#47;480572&#47;StandardOpProcedure.pdf.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">if the API is just one &#8216;ingredient&#8217; (i.e. active substance) of the investigational medicinal product (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">IMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) which is used in the clinical trial then the UK-based facility must apply to be registered with the MHRA and provide the MHRA with 60 days&#8217; notice of the intended start of manufacture, import or distribution of the API, and comply with GMP and GDP for active substances. Furthermore, an MHRA inspection may be required&#59; and</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">conversely, if the API will itself constitute the IMP, the manufacturer must, except in certain limited circumstances, hold a Manufacturer&#8217;s Authorizations for IMPs licence (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">MIA(IMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">)&#8221;) granted by the MHRA. In this scenario, assuming the IMP is manufactured or assembled in the UK, an MIA(IMP) would be required regardless of whether the IMP is for use in clinical trials in the UK, an EEA Member State or a third country (such as the United States or Canada). GMP, GDP and inspection requirements will apply.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Some products fall on the borderline between medicines and other categories of regulate products such as medical devices, cosmetics or food supplements. The regulatory status of the product will be determined by i) the actual effect of the product on the body&#59; and ii) any claims made about the effect of the product.&#160;Where a product is potentially both a medicinal product and another category of product, the legal position in the UK and EU is that it will be regulated as a medicinal product.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Research and Development</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company is focused on development of psychedelic medicines and other products, through research and development of novel chemical compounds and delivery mechanisms and study of such compounds in clinical environments around the world. The Company anticipates growing its pipeline of psychedelic pharmaceutical products inspired medicines through its internal research, development, proprietary discovery programs, mergers and acquisitions, joint ventures and collaborative development agreements. For the time being, the Company maintains intellectual property generated by its R&#38;D programs through patent filings and as trade secrets. The Company anticipates that as these programs mature more patent applications will be filed and more details about these programs will be disclosed at such time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Psychedelics are a class of drug whose primary action is to trigger psychedelic experiences by way of serotonin receptor agonism, causing thought, visual and auditory changes, and altered state of consciousness. Major psychedelic drugs include mescaline, LSD, psilocin, and DMT. Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms. The most potent are members of the genus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Psilocybe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">, such as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">P. azurescens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">P. semilanceata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">P. cyanescens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">, but psilocybin has also been isolated from about a dozen other genera. As a prodrug, psilocybin is quickly converted by the body to psilocin, which has mind-altering effects.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The pharmacokinetics, pharmacology and human metabolism of psilocin are well known and well characterized. In conjunction with psychotherapy, psilocin has been utilized broadly in phase II clinical trials.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Psilocybin found in certain species of mushrooms is a non-habit forming naturally occurring psychedelic compound. Once ingested, psilocybin is rapidly metabolized to psilocin, which then acts on serotonin receptors in the brain. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:124%">Cybin has commenced research and development on the delivery of synthetic psilocin and other psychedelics through mechanisms such as sublingual film delivery, IV, and by way of inhalation. </font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Research and development is led by the Company&#8217;s North American Chief Scientific Officer, Alex Nivorozhkin Ph.D., a seasoned medicinal chemist, drug delivery expert and founder of multiple biotech companies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s research and development must be conducted in strict compliance with the regulations of federal, state, local and regulatory agencies in Canada, the United States, and the UK, and the equivalent regulatory agencies in the other jurisdictions in which the Company operates. These regulatory authorities regulate, among other things, the research, manufacture, promotion and distribution of drugs in specific jurisdictions under applicable laws and regulations. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Canada</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The process required before a prescription drug product candidate may be marketed in Canada generally involves&#58;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%;padding-left:12.38pt">Chemical and Biological Research &#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> Laboratory tests are carried out on tissue cultures and with a variety of small animals to determine the effects of the drug. If the results are promising, the manufacturer will proceed to the next step of development.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%;padding-left:12.38pt">Preclinical Development &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Animals are given the drug in varying amounts over differing periods of time. If it can be shown that the drug causes no serious or unexpected harm at the doses required to have an effect, the manufacturer will proceed to clinical trials.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%;padding-left:12.38pt">Clinical Trials &#8211; Phase 1 - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The first administration in humans is to test if people can tolerate the drug. If this testing is to take place in Canada, the manufacturer must prepare a clinical trial application for the Therapeutic Products Directorate of Health Canada (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">TPD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). This includes the results of the first two steps and a proposal for testing in humans. If the information is sufficient, the Health Products and Food Branch of Health Canada (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">HPFB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) grants permission to start testing the drug, generally first on healthy volunteers.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%;padding-left:12.38pt">Clinical Trials &#8211; Phase 2 - Phase 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> trials are carried out on people with the target condition, who are usually otherwise healthy, with no other medical condition. Trials carried out in Canada must be approved by the TPD. In phase II, the objective of the trials is to continue to gather information on the safety of the drug and begin to determine its effectiveness.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%;padding-left:12.38pt">Clinical Trials &#8211; Phase 3 - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">If the results from phase II show promise, the manufacturer provides an updated clinical trial application to the TPD for phase III trials. The objectives of phase III include determining whether the drug can be shown to be effective, and have an acceptable side effect profile, in people who better represent the general population. Further information will also be obtained on how the drug should be used, the optimal dosage regimen and the possible side effects.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%;padding-left:12.38pt">New Drug Submission &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">If the results from phase III continue to be favourable, the drug manufacturer can submit a new drug submission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">NDS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) to the TPD. A drug manufacturer can submit an NDS regardless of whether the clinical trials were carried out in Canada. The TPD reviews all the information gathered during the development of the drug and assesses the risks and benefits of the drug. If it is judged that, for a specific patient population and specific conditions of use, the benefits of the drug outweigh the known risks, the HPFB will approve the drug by issuing a notice of compliance.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:145%">United States</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Because psilocybin, psilocin, DMT, and 5-Methoxy-DMT are listed as Schedule I substances under the CSA, for any product containing psilocin or any Schedule I substance to be available for commercial marketing in the United States, such substance must be rescheduled, or the product itself must be scheduled, by the DEA to Schedule II, III, IV or V.</font></div><div style="margin-bottom:0.1pt"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The process required before a prescription drug product candidate may be marketed in the United States generally involves&#58;</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">completion of extensive non-clinical laboratory tests, animal studies and formulation studies, all performed in accordance with the FDA&#8217;s Good Laboratory, Good Clinical and&#47;or Good Manufacturing Practice regulations&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">submission to the FDA of an IND Application, which the FDA must approve before human clinical trials may begin&#59; </font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">approval by an IRB or independent ethics committee at each clinical trial site before each trial may be initiated&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">for nearly all new pharmaceutical products, performance of adequate and well-controlled human clinical trials in accordance with the FDA&#8217;s regulations, including Good Clinical Practices, to establish the safety and efficacy of the prescription drug product candidate for each proposed indication&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">submission to the FDA of a New Drug Application (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;)&#59; </font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality, and purity&#59; and</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">FDA review and approval of the NDA prior to any commercial marketing, sale or shipment of the drug.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The testing and approval process requires substantial time, effort and financial resources, and the Company cannot be certain that the DEA will schedule or reschedule any Schedule I substance or product candidate to Schedule II, III, IV, or V, or that approvals for its prescription drug product candidates will be granted on a timely basis, if at all.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Non-clinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animals and other animal studies or through FDA-accepted alternative methods (New Approach Methodologies or NAMs). The results of non-clinical tests, together with manufacturing information and analytical data, are submitted as part of an IND to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">FDA. Some non-clinical testing may continue even after an IND is submitted. The IND also includes one or more protocols for the initial clinical trial or trials and an investigator&#8217;s brochure. An IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions relating to the proposed clinical trials as outlined in the IND and places the clinical trial on a clinical hold. In such cases, the IND sponsor and the FDA must resolve any outstanding concerns or questions before any clinical trials can begin. Clinical trial holds also may be imposed at any time before or during studies due to safety concerns or non-compliance with regulatory requirements. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">An IRB board, at each of the clinical centers proposing to conduct the clinical trial, must review and approve the plan for any clinical trial before it commences at that center. An IRB board considers, among other things, whether the risks to individuals participating in the trials are minimized and are reasonable in relation to anticipated benefits. The IRB board also approves the consent form signed by the trial participants and must monitor the study until completed.&#160;The FDA, the independent IRB, or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trials to public registries. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The FDA offers a number of regulatory mechanisms that provide expedited or accelerated approval procedures for selected drugs and indications which are designed to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These include programs such as BTDs, Fast Track designations, Priority Review and Accelerated Approval, which the Company may need to rely upon in order to receive timely approval or to be competitive.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company may plan to seek orphan drug designation for certain indications qualified for such designation. The U.S., E.U. and other jurisdictions may grant orphan drug designation to drugs intended to treat a &#8220;rare disease or condition,&#8221; which, in the U.S., is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or 200,000 or more individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug available in the United States for this type of disease or condition will be recovered from sales of the product.&#160;In the E.U., orphan drug designation can be granted if&#58; the disease is life threatening or chronically debilitating and affects no more than 50 in 100,000 persons in the E.U.&#59; without incentive it is unlikely that the drug would generate sufficient return to justify the necessary investment&#59; and no satisfactory method of treatment for the condition exists or, if it does, the new drug will provide a significant benefit to those affected by the condition. Orphan drug designation must be requested before submitting an NDA. If a product that has an orphan drug designation subsequently receives the first regulatory approval for the indication for which it has such designation, the product is entitled to orphan exclusivity, meaning that the applicable regulatory authority may not approve any other applications to market the same drug for the same indication, except in very limited circumstances, for a period of seven years in the U.S. and 10 years in the E.U. Orphan drug designation does not prevent competitors from developing or marketing different drugs for the same indication or the same drug for different indications. After orphan drug designation is granted, the identity of the therapeutic agent and its potential orphan use are publicly disclosed. Orphan drug designation does not convey an advantage in, or shorten the duration of, the development, review and approval process. However, this designation provides an exemption from marketing and authorization fees.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Drugs manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, reporting of adverse experiences with the product, and complying with promotion and advertising requirements. The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-market testing, including phase IV clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. In addition, drug manufacturers and their subcontractors involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including current Good Manufacturing Practices, which impose certain procedural and documentation requirements. Failure to comply with statutory and regulatory requirements may subject a manufacturer to legal or regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties or criminal prosecution. There is also a continuing, annual prescription drug product program user fee.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, requirements for post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a risk evaluation and mitigation strategy.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In the United States, pharmaceutical manufacturers are subject to complex laws and regulations pertaining to healthcare &#8220;fraud and abuse,&#8221; including, but not limited to, the Anti-Kickback Statute, the federal </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">False Claims Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">FCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), and other state and federal laws and regulations. The Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase, order, or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The FCA prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment to or approval by the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Violations of the FCA can result in very significant monetary penalties and treble damages. The federal government is using the FCA, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical companies throughout the country, for example, in connection with the promotion of products for unapproved uses and other sales and marketing practices.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The government has obtained multi-million and multi-billion dollar settlements under the FCA in addition to individual criminal convictions under applicable criminal statutes. In addition, the federal civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">for an item or service that was not provided as claimed or is false or fraudulent.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers&#8217; and manufacturers&#8217; compliance with applicable fraud and abuse laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">There are also an increasing number of state laws that require manufacturers to make reports to states on pricing and marketing information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In addition, a similar federal requirement Section 6002 of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or the Affordable Care Act, commonly referred to as the &#8220;Physician Payments Sunshine Act&#8221; requires applicable manufacturers to track and report to the federal government certain payments and &#8220;transfers of value&#8221; made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members, made in the previous calendar year. There are a number of states that have various types of additional reporting requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Controlled Substances</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The CSA and its implementing regulations establish a &#8220;closed system&#8221; of regulations for controlled substances. The CSA imposes registration, security, recordkeeping and reporting, storage, manufacturing, distribution, importation and other requirements under the oversight of the DEA. The DEA is responsible for regulating controlled substances, and requires those individuals or entities that manufacture, import, export, distribute, research, or dispense controlled substances to comply with the regulatory requirements in order to prevent the diversion of controlled substances to illicit channels of commerce.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The DEA categorizes controlled substances into one of five schedules&#8201;&#8212;&#8201;Schedule I, II, III, IV or V&#8201;&#8212;&#8201;with varying qualifications for listing in each schedule. Schedule I substances by definition have a high potential for abuse, have no currently accepted medical use in treatment in the United States and lack accepted safety for use under medical supervision. For any product containing a Schedule I substance, such as psilocin, to be available for commercial marketing in the United States, such substance must be rescheduled, or the product itself must be scheduled, by the DEA to Schedule II, III, IV or V. Scheduling determinations by the DEA are dependent on FDA approval of a substance or a specific formulation of a substance.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Facilities that research, manufacture, distribute, import or export any controlled substance must register annually with the DEA. The DEA registration is specific to the particular location, activity(ies) and controlled substance schedule(s). For example, separate registrations are needed for import and manufacturing, and each registration will specify which schedules of controlled substances are authorized.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The DEA may inspect all research and manufacturing facilities to review security, recordkeeping, reporting and handling prior to issuing a controlled substance registration and periodically to ensure continued compliance.  The specific security requirements vary by the type of business activity and the schedule and quantity of controlled substances handled. The most stringent requirements apply to researchers and manufacturers of Schedule I and Schedule II substances. Required security measures </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">commonly include background checks on employees and physical control of controlled substances through storage in approved vaults, safes and cages, and through use of alarm systems and surveillance cameras. Once registered, manufacturing facilities must maintain records documenting the manufacture, receipt and distribution of all controlled substances. Manufacturers must submit periodic reports to the DEA of the distribution of Schedule I and II controlled substances, Schedule III narcotic substances, and other designated substances. Registrants must also report any controlled substance thefts or significant losses, and must obtain authorization to destroy or dispose of controlled substances. Imports of Schedule I and II controlled substances for commercial purposes are generally restricted to substances not already available from a domestic supplier or where there is not adequate competition among domestic suppliers. In addition to an importer or exporter registration, importers and exporters must obtain a permit for every import or export of a Schedule I and II substance or Schedule III, IV and V narcotic, and submit import or export declarations for Schedule III, IV and V non-narcotics. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">For drugs manufactured in the United States, the DEA establishes annually an aggregate quota for the amount of substances within Schedules I and II that may be manufactured or produced in the United States based on the DEA&#8217;s estimate of the quantity needed to meet legitimate medical, scientific, research and industrial needs. The quotas apply equally to the manufacturing of the active pharmaceutical ingredient and production of dosage forms. The DEA may adjust aggregate production quotas a few times per year, and individual manufacturing or procurement quotas from time to time during the year, although the DEA has substantial discretion in whether or not to make such adjustments for individual companies.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Individual U.S. states also establish and maintain separate controlled substance laws and regulations, including licensing, recordkeeping, security, distribution, and dispensing requirements. A majority of state laws in the United States classify psilocybin and psilocin as Schedule I controlled substances. State authorities, including boards of pharmacy, regulate use of controlled substances in each state, including state specific controlled substance registration requirements. Failure to obtain applicable registrations or maintain compliance with applicable requirements, particularly as manifested in the loss or diversion of controlled substances, can result in enforcement action that could have a material adverse effect on the Company&#8217;s business, operations and financial condition. The DEA and&#47;or state regulatory agencies may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances, violations could lead to criminal prosecution. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">EU (Netherlands) </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Regulation (EU) No 536&#47;2014 on Clinical Trials on Medicinal Products for Human Use ( the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">CTR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;) is applicable as of January 31, 2022, harmonizing the laws, regulations and administrative provisions of the EU Member States relating to the implementation of Good Clinical Practice in the conduct of clinical trials on medicinal products for human use.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:130%;position:relative;top:-3.85pt;vertical-align:baseline">31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"> EU Member States have transformed the </font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The CTR does not apply in the UK and UK law on clinical trials is currently based on old EU law (the Clinical Trials Directive), transposed into UK law via the Medicines for Human Use (Clinical Trials) Regulations 2004. An overhaul of UK law on clinical trials has been on-going for a few years, and new legislation on clinical trials in the UK, the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2024, has been signed into law and is due to come into effect from mid-April 2026.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">requirements outlined in the Clinical Trials Directive into the respective national laws.  Pursuant to the CTR, as of January 31, 2023 sponsors are obliged to use the Clinical Trials Information System (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">CTSI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;) for regularity submission, authorization and supervision of clinical trials in the EU and the EEA. CTIS will thus serve as the single-entry point for submissions by sponsors and for regulatory assessment. In addition to this obligation, sponsors must transfer any ongoing (approved) trials under the CTR to CTIS by January 2025. Further, EMA adopted on October 5, 2023, the &#8220;Revised CTIS Transparency Rules&#8221; on publishing information about clinical trials submitted through CTIS. To increase transparency, EMA removed the deferral mechanism which allowed sponsors to delay certain data and document publication for up to seven years after the end of their trial. Annex I of the revised rules outlines the timing of information publication for each category of clinical trial and patient population. These new rules became applicable on June 18, 2024, the same day of the launch of the new CTIS portal. In order to smoothen the process of transitioning clinical trials from the Clinical Trial Directive to the CTR, a non-binding guide named &#8220;Guidance for the Transition of clinical trials from the Clinical Trials Directive to the Clinical Trials Regulation&#8221; (version 4) dated May 2024 is published. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">CTIS and the practical aspects thereof are also discussed and explained (among other relevant topics relating to clinical trials) in a quick guide on the rules and procedures of the EU Clinical Trials Regulation called &#8220;Clinical Trials Regulation (EU) 536&#47;2014 in practice&#8221;, which is published by the Clinical Trials Coordination and Advisory Group (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">CTAG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) on December 8, 2023. The objective of the rules is to provide sponsors and investigators a quick guide on the rules and procedures of the CTR with a view to facilitating implementation. In addition to the quick guide, CTAG also published a non-binding Questions &#38; Answers (Version 7.1) that should be read in conjunction with the quick guide and with the &#8220;Clinical Trials Information System (CTIS)&#58; online training modules&#8221; in order to gain a better understanding of the legislative changes that are effected by the CTR.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Investigational Medicinal Product Dossier (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">IMPD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) is one of several regulatory documents required for conducting a clinical trial of a pharmacologically API intended for one or more EU Member States. The IMPD includes summaries of information related to the quality, manufacture and control of any IMP (including reference product and placebo), and data from non-clinical and clinical studies. Guidance concerning IMPDs is based on the CTR and on the approximation of laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use (also commonly referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Clinical Trials Directive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The content of the IMPD may be adapted to the existing level of knowledge and the product&#8217;s phase of development. When applying for a clinical trial authorization, a full IMPD is required when little or no information about an API has been previously submitted to competent authorities, when it is not possible to cross-refer to data submitted by another sponsor and&#47;or when there is no authorization for sale in the EU. However, a simplified IMPD may be submitted if information has been assessed previously as part of a Marketing Authorization or a clinical trial to that competent authority. Although the format is not obligatory, the components of an IMPD are largely equivalent to clinical trial applications in Canada and the United States. The IMPD need not be a large document as the amount of information to be contained in the dossier is dependent on various factors such as product type, indication, development phase etc.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The assessment of an IMPD is focused on patient safety and any risks associated with the IMP. Whenever any potential new risks are identified the IMPD must be amended to reflect the changes. Certain amendments are considered substantial in which case the competent authority must be informed of the substantial amendment. This may be the case for changes in IMP impurities, microbial contamination, viral safety, transmissible spongiform encephalopathies (e.g. mad cow disease) and in some particular cases to stability when toxic degradation products may be generated.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">With the completion of the Asset Acquisition, the Company has an ongoing phase I study to obtain preliminary evidence of the safety and efficacy of infused DMT. Prior to the Asset Acquisition, an investigator&#8217;s brochure (including prior safety, preclinical and clinical data), and an IMPD document that includes CMC information and a clinical study protocol and supporting information had been prepared.  Approval by the Dutch ethics committee of the Phase 1 Study, planned to be conducted by CHDR will be based on the vast amount of published human and animal studies of DMT. Prior to the Asset Acquisition, preclinical data was not provided as part of the application package&#59; however, limited additional in vivo and in vitro data to support the rationale for human dosing and safety had been included. CHDR and its partner GMP-licensed pharmacy that will be involved in the Phase 1 Study, the Leiden University Medical Center, have all the required approvals to possess and handle DMT for the Phase 1 Study. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Failure of the Company to receive the necessary regulatory approvals required to conduct the Phase 1 Study would have an adverse impact on its business plans and financial condition for a number of reasons including, without limitation&#58; (i) it would cause delays in the Company&#8217;s research and development plans&#59; (ii) it may require the Company to expend additional financial and human resources on revising its application package or creating a new one&#59; or (iii) it may require the Company to approach an entirely different regulatory authority in a new jurisdiction, in which case the Company would have to expend a substantial amount of capital and other resources on engaging the appropriate research and development partners and creating an application package that complies with the regulations of that new jurisdiction. Additionally, the Company would be required to spend capital on transferring the DMT materials to the new jurisdiction. All of the foregoing would likely have a negative impact on the Company&#8217;s business and financial condition. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Pharmaceutical Products</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In accordance with the Dutch Medicines Act (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Geneesmiddelenwet</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">), &#8220;medicinal products&#8221; are defined as&#58; a substance or a combination of substances that is intended to be administered or used for, or is presented in any way as being suitable for, use&#58; (i) the cure or prevention of any disease, defect, wound or pain in human beings, (ii) the making of a medical diagnosis in human beings, or (iii) restoring, improving or otherwise modifying physiological functions in humans by exerting a pharmacological, immunological or metabolic effect. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">If a product constitutes a medicinal product, a marketing authorization for the product is required before the product may be placed on the market in the Netherlands. In the EU, marketing authorizations may be obtained through the Centralized procedure, the Decentralized or Mutual Recognition procedures and&#47;or the national procedure. The Centralized procedure is compulsory for medicines intended to treat i.e. cancer, AIDS, neurodegenerative diseases and diabetes and optional (only) for medicines comprising of new active substances not previously approved for the EEA. When </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">applying for a marketing authorization through the Centralized procedure, applications are submitted with the European Medicines Agency (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;). Where the Centralized procedure is not available but a medicinal product is intended for several EU&#47;EEA Member States, an application for a marketing authorization may be submitted with the competent authority of a single EU&#47;EEA Member State in accordance with the Decentralized procedure. When the assessment of the application results in a decision to grant the marketing authorization, this decision will be recognized by the competent authorities of the other Member States for which the marketing authorization is applied. The Mutual Recognition procedure is similar to the Decentralised procedure, but applies to applications where the medicinal product is already the subject of a marketing authorization in another EU&#47;EEA Member State. Finally, should a medicinal product be intended for the Netherlands only, then the national procedure may be followed by submitting an application with the Dutch Medicines Evaluation Board. It may be remarked that the national procedure is unavailable in case the Centralized procedure is compulsory or in case an applicant has already submitted an application for and&#47;or obtained a marketing authorization in another Member State. In that case, applications must follow the Mutual Recognition procedure instead.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Companies that manufacture or trade in medicinal products and&#47;or active pharmaceutical ingredients in the Netherlands require a manufacturing authorization or a wholesale distribution authorization. A manufacturing authorization is required for the preparation, trading in, import and export of medicinal products and&#47;or active substances. Here, &#8216;preparation&#8217; means the total or partial manufacture of medicinal products and&#47;or active substances or the packaging or labelling thereof. &#8216;Importing&#8217; means the import of medicinal products or active substances from a country outside the EEA into the Dutch territory, while &#8216;exporting&#8217; means the export of medicinal products or active substances from the Dutch territory to a country outside the EEA. A wholesale distribution authorization is required for one or more activities within the wholesale business, such as procuring, holding, supplying, delivering or exporting medicinal products or active substances which are prepared or imported by a third party. It may be noted that holders of wholesale distribution authorization, other than holders of marketing authorizations, are not authorized to import medicinal products from countries outside the EEA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Only a natural or legal person established in the Netherlands may obtain either a Dutch marketing authorization or a  wholesale distribution authorization. These authorizations concern national permits, meaning that these authorizations are not automatically valid in other EU Member States. Furthermore, in the Netherlands applicants of marketing authorizations and wholesale distributions authorizations must be registered with Farmatec and comply with GDP norms.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Marketing Authorization Regulatory Process </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Under the Centralized procedure, pharmaceutical companies submit a single marketing authorization application to the EMA, which provides the basis of a legally binding recommendation that will be provided by the EMA to the European Commission, the authorizing body for all centrally authorized products. This allows the marketing-authorization holder to market the medicine and make it available to patients and healthcare professionals throughout the EU on the basis of a single marketing authorization. EMA&#8217;s Committee for Medicinal products for Human Use or Committee for Medicinal Products for Veterinary Use carry out a scientific assessment of the application and give a recommendation on whether the medicine should be marketed or not, under any particular dosing regime. Although, under EU law, the EMA has no authority to permit marketing in the different EU countries, the European Commission is the authorizing body for all centrally authorized products, who </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">takes a legally binding decision based on EMA&#8217;s recommendation. Once granted by the European Commission, the centralized marketing authorization is valid in all EU Member States as well as in the European Economic Area countries Iceland, Liechtenstein and Norway. European Commission decisions are published in the Community Register of medicinal products for human use. Once a medicine has been authorized for use in the EU, the EMA and the EU Member States constantly monitor its safety and take action if new information indicates that the medicine is no longer as safe and effective as previously thought. The safety monitoring of medicines involves a number of routine activities ranging from&#58; assessing the way risks associated with a medicine will be managed and monitored once it is authorized&#59; continuously monitoring suspected side effects reported by patients and healthcare professionals, identified in new clinical studies or reported in scientific publications&#59; regularly assessing reports submitted by the Company holding the marketing authorization on the benefit-risk balance of a medicine in real life&#59; and assessing the design and results of post-authorization safety studies which were required at the time of authorization. The EMA can also carry out a review of a medicine or a class of medicines upon request of a Member State or the European Commission. These are called EU referral procedures&#59; they are usually triggered by concerns in relation to a medicine&#8217;s safety, the effectiveness of risk minimization measures or the benefit-risk balance of the medicine. The EMA has a dedicated committee responsible for assessing and monitoring the safety of medicines, the Pharmacovigilance Risk Assessment Committee. This ensures that EMA and the EU Member States can move very quickly once an issue is detected and take any necessary action, such as amending the information available to patients and healthcare professionals, restricting use or suspending a medicine, in a timely manner in order to protect patients.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Besides the Centralized procedure, pharmaceutical companies may also submit marketing authorization applications through the Decentralized procedure with the competent authority of a Member State. As the Centralized procedure is compulsory for medicines intended to treat specified diseases i.e. cancer, AIDS, neurodegenerative diseases and diabetes and only optional for medicines comprising of new active substances not previously approved for the EU&#47;EEA, in all other circumstances the Decentralized procedure should be used instead if a marketing authorization is to be obtained for several EU&#47;EEA Member States. When following the Decentralized procedure, the applicant requests one country to be the Reference Member State (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">RMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) in the procedure. After having shared draft assessment reports to which both the applicant and the competent authorities of other Member States may respond, the to be granted marketing authorization will eventually go through the Mutual recognition procedure. In the Mutual recognition procedure other Member States generally adopt the RMS&#8217;s assessment, unless there are important objections on the grounds of a potentially serious risk to public health. In such situations, further discussions will also be held in the Co-ordination group for Mutual recognition and Decentralised procedures (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">CMDh</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). When all Member States involved decide on a positive opinion on products in the CMDh, Dutch translations of the summary of product characteristics, package leaflet, labelling texts and mock-ups are submitted and a national marketing authorization is issued.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Ireland</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In Ireland, psilocin is a controlled substance under the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Misuse of Drugs Act, 1977, 1984 and 2015</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Ireland</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">MDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Misuse of Drugs Regulations 2017</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Ireland</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">MDR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) and the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Criminal Justice (Psychoactive Substances) Act 2010 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">2010 Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). These are the primary legislative </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">instruments which govern controlled substances in Ireland. This legislation regulates the use, possession, supply, licensing, and administration of listed scheduled substances and establishes the offences and penalties for infringement of the legislation. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Any substance, product or preparation (whether natural or otherwise) including a fungus of any kind or description, which contains psilocin or an ester of psilocin is classed as a Schedule 1 controlled substance under the Ireland MDA and the Ireland MDR. Accordingly, psilocin is subject to the strict regime of control that applies. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">As a Schedule 1 controlled substance under the Ireland MDA, unlawful manufacturing, production, preparation, importation, exportation, supply, or distribution of psilocin carries onerous obligations and harsh punishments for contravention&#59; this includes prohibition orders, closure orders, fines and&#47;or terms of imprisonment of up to 14 years. The Garda&#237; and Customs officials are granted powers to search persons, vehicles, premises and postal packages suspected of possessing&#47;containing a Schedule 1 controlled substance and&#47;or a psychoactive substance for human consumption.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Pursuant to the Ireland MDA, in certain circumstances, the Minister for Health &#8220;may grant licences or issue permits or authorizations for any of the purposes of this Act, attach conditions to any such licence, permit or authorization, vary such conditions and revoke any such licence, permit or authorization&#8221;. Where licences are granted, there are very strict conditions imposed on licence holders. For example, strict conditions can be placed regarding the security, storage and documenting controlled substances. Further, the 2010 Act permits the Minister to make an order declaring that the Act shall not apply in relation to any &#8220;substance, product, preparation, plant, fungus or natural organism&#8221; as specified in the order.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company does not currently engage in any activities in Ireland that are regulated by such laws. If the Company were to engage in such activities, it would need to obtain the appropriate licences and authorization to do so. The Company intends to constantly review its Irish operations to ensure compliance with all applicable laws as the operations evolve.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Irish Government&#8217;s Legislative Programme for Summer 2025 does not contain any proposed amendments to the above-mentioned legislation which currently govern controlled substances.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Compliance with Applicable Laws</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The Company oversees and monitors compliance with applicable laws in each jurisdiction in which it operates. In addition to the Company&#8217;s senior executives and the employees responsible for overseeing compliance, the Company has local counsel engaged in every jurisdiction in which it operates and has received legal opinions or advice in each of these jurisdictions regarding (a) compliance with applicable regulatory frameworks, and (b) potential exposure to, and implications arising from, applicable laws in jurisdictions in which the Company has operations or intends to operate. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company works with third parties who require regulatory licensing to handle scheduled drugs.  The Company continuously updates its compliance and channel programs to maintain regulatory </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">standards set for drug development.  The Company also works with clinical research organizations who maintain batch records and data storage for the Company&#8217;s clinical programs.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Additionally, the Company has established a Medical &#38; Clinical Advisory Team, a Research, Clinical and Regulatory Team and a Government Relations and Communications Team with cross-functional expertise in business, neuroscience, pharmaceuticals, mental health and psychedelics to advise management. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">In conjunction with the Company&#8217;s human resources and operations departments, the Company oversees and implements training on the Company&#8217;s protocols. The Company will continue to work closely with external counsel and other compliance experts, and is evaluating the engagement of one or more independent third party providers to further develop, enhance and improve its compliance and risk management and mitigation processes and procedures in furtherance of continued compliance with the laws of the jurisdictions in which the Company operates. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The programs currently in place include monitoring by executives of the Company to ensure that operations conform to and comply with required laws, regulations and operating procedures. The Company is currently in compliance with the laws and regulations in all jurisdictions and the related licensing framework applicable to its business activities. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company and, to its knowledge, each of its third-party researchers, suppliers and manufacturers have not received any non-compliance, citations or notices of violation which may have an impact on the Company&#8217;s licences, business activities or operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company conducts due diligence on third-party researchers, medical professionals, clinics, cultivators, processors and others as applicable, with whom it engages. Such due diligence includes but is not limited to the review of necessary licenses and the regulatory framework enacted in the jurisdiction of operation. Further, the Company generally obtains, under its contractual arrangements, representations and warranties from such third parties pertaining to compliance with applicable licensing requirements and the regulatory framework enacted in the jurisdiction of operation.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Patent Cooperation Treaty </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The PCT facilitates filing for patent recognition in multiple jurisdictions simultaneously using a single uniform patent application. 157 countries, including Canada and the United States have ratified the PCT.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Ultimately, patents are still granted in each country individually. As such, the PCT procedure consists of two phases&#58; filing of an international application, and national evaluation under the patent laws in force in each country where a patent is sought.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Within 12 months of filing a provisional patent application at the USPTO, the Company may elect to file a regular utility patent application in the United States in tandem with filing a PCT application with the World Intellectual Property Office, in each case claiming priority to the provisional patent application. Within 30 months of the provisional filing date, deadlines begin for a PCT application to enter the national phase in desired jurisdictions globally, such as Canada (30 months) and Europe (31 months), in each case claiming priority to the provisional patent application. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">While the Company is focused on programs using psychedelic-inspired compounds, the Company does not have any direct or indirect involvement with the illegal selling, production or distribution of any substances in the jurisdictions in which it operates. The Company is exploring drug development within approved laboratory clinical trial settings conducted within approved regulatory frameworks. Though highly speculative, should any prescription drug product be developed by the Company (which, if it does occur, would not be for several years), such drug product will not be commercialized prior to receipt of applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended use(s) is successfully developed. The Company may also employ non-prescription drugs, where appropriate.</font></div><div id="i2b86e3b0612046f694ccc21dee9687a9_171"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Selected Quarterly Information</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The following table sets forth selected consolidated financial information for the periods indicated that are derived</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> f</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">rom, and should be read in conjunction with, the Financial Statements and related notes thereto.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.847%"><tr><td style="width:1.0%"></td><td style="width:17.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:100%">(Canadian dollars in thousands, except per share and share figures)</font></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">March 31, 2025</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">December 31, 2024</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">September 30, 2024</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">June 30, 2024</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">March 31, 2024</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">December 31, 2023</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">September 30, 2023</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">June 30, 2023</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Revenues ($)</font></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Operating Expenses ($)</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">33,272</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">31,304&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">58,254&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">20,317&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">25,195&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">27,024&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">13,910&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">12,707&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Net loss ($)</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(30,579)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(10,542)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(57,192)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(14,824)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(21,346)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(30,330)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(11,890)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(14,514)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:17pt"><font><br></font></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Weighted Average Shares - Basic</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">20,898,038</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">20,001,406&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">20,001,406&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">20,001,406&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">12,045,467&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,468,579&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6,173,270&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5,425,205&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Loss per share ($)</font></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(1.46)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.53)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(2.86)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.74)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1.77)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(3.20)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1.93)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(2.68)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Weighted Average Shares - Diluted</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">20,898,038</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">20,001,406&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">20,001,406&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">20,001,406&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">12,045,467&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,468,579&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">6,173,270&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">5,425,205&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Loss per share ($)</font></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">(1.46)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.53)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(2.86)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(0.74)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1.77)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(3.20)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(1.93)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(2.68)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Cash and cash equivalents</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">135,022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">136,290&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">154,318&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">183,275&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">208,992&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">38,999&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">18,118&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">9,349&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total Assets ($)</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">258,618</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">253,546&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">262,391&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">284,647&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">302,023&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">129,724&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">57,627&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">45,691&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Total Non-Current Liabilities ($)</font></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">42&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Selected Annual Information</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The following table presenting the Company&#8217;s results of operations as at and for the three most recently completed financial years ending March 31 should be read in conjunction with the Financial Statements and related notes thereto.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s selected financial information as at and for the three most recently completed financial years ended March 31, are summarized as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.847%"><tr><td style="width:1.0%"></td><td style="width:38.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Canadian dollars in thousands, except per share and share figures)</font></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the year ended<br>March 31, 2025</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the year ended March 31, 2024</font></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the year ended<br>March 31, 2023</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues ($)</font></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Expenses ($)</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">143,147</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,836&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,518&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss ($)</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(113,137)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78,080)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,490)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:17pt"><font><br></font></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Shares - Basic</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,222,493</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,297,370&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,879,704&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss per share ($'s)</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5.59)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.41)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.73)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Shares - Diluted</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,222,493</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,297,370&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,879,704&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss per share ($'s)</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5.59)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.41)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.73)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">135,022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208,992&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,633&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Assets ($)</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">258,618</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302,023&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,897&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Non-Current Liabilities ($)</font></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has not paid dividends on the Common Shares and does not anticipate declaring any dividends in the near future.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Assets</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Total assets decreased by $43,405 from April 1, 2024 to March&#160;31, 2025 mainly as a result of a decrease in cash as the Company continues to progress its operations. The decrease is partially offset by an increase of prepaid expenses. As at March&#160;31, 2025, the Company had prepaid expenses related to future clinical work of $16,051 (US$11,165).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Results of Operations </font></div><div style="margin-bottom:0.1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.847%"><tr><td style="width:1.0%"></td><td style="width:45.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.044%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.047%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</font></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended March 31, </font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">EXPENSES</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Research</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18,969</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,843&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">54,910</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,362</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">General and administrative costs </font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,210</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,083&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">45,368</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,588</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Share-based compensation </font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,093</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,269&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">42,869</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,886</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL EXPENSES</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">33,272</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,195&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">143,147</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,836&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OTHER INCOME (EXPENSES)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Foreign currency translation gain</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,252</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,507&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,749</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Interest income</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,441</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,289</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.75pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Other loss</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(28)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL OTHER INCOME </font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,693</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,849&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30,010</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">756&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NET LOSS FOR THE PERIOD</font></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(30,579)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,346)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(113,137)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78,080)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic loss per share for the period</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1.46)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.77)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5.59)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9.41)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average number of common shares outstanding - basic</font></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,898,038</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,045,467&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,222,493</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,297,370&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">For t</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">he three month period ended March 31, 2025 and the year ended March 31, 2025, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Cybin incurred net losses of $30,579 and $113,137, respectively, compared to net losses of $21,346 and $78,080, respectively, during the same periods in the prior year. The net losses for th</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">e three and twelve month periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> include</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> a non-cash component</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> related to share-based compensation of $2,093 and $42,869, respectively, compared to $1,269 and $13,886, respectively, during the same periods in the prior year.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">During the year ended March 31, 2025, the Company was focused on progressing its various research programs, with a focus on its Deuterated Psilocin Analog Program (CYB003) and Deuterated Dimethyltryptamine Program (CYB004), and raising awareness of the Company and its industry. During such period, both the CYB003 and the CYB004 clinical programs have progressed towards the milestones noted above. See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Non-Revenue Generating Projects</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:2pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Operating expenses</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">For the three month period ended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">March&#160;31, 2025</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">, operating expenses totaled $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">33,272</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (2024 - $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">25,195</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">). The operating expenses include a non-cash component of $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">2,093</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (2024 - $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">1,269</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">) related to share-based compensation. The remaining operating expenses were incurred to support raising capital, research &#38; development and the overall development of the Company. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">For the year ended March 31, 2025, operating expenses totaled $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">143,147</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (2024 - $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">78,836</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">). The operating expenses include a non-cash component of $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">42,869</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (2024 - $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">13,886</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">) related to share-based compensation. The remaining operating expenses were incurred to support raising capital, research &#38; development and the overall development of the Company. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Research</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%"> </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">For the three month period ended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">March&#160;31, 2025</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">, the Company&#8217;s research expenses totaled $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">18,969</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> compared to $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">11,843</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> during the same period in the prior year. Research expenses for the three month period are comprised of advancement of the development programs of $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">14,369</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (2024 - $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">8,209</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">), payroll related expenses of $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">4,879</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (2024 - $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">3,316</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">), lab and administration expenses of  $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">448</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (2024 - $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">256</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">), and professional and consulting fees of $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(727)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (2024 - $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">62).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">For the year ended March 31, 2025, the Company&#8217;s research expenses totaled $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">54,910</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> compared to $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">32,362</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> during the same period in the prior year. Research expenses for the year are comprised of advancement of the development programs of $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">39,547</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (2024 - $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">22,799</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">), payroll related expenses of $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">13,146</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (2024 - $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">8,319</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">), lab and administration expenses of  $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">1,933</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (2024 - $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">1,034</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">) and professional and consulting fees of $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">284</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (2023 - $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">210</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The overall increase in research ex</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">penses, for both the three and twelve month periods, is due to the progression of the Company&#8217;s various research programs, primarily related to the advancement of its clinical trials for both its Deuterated Psilocin Analog Program (CYB003) and Deuterated Dimethyltryptamine Program (CYB004). Both of the Company&#8217;s proprietary clinical programs, CYB003 and CYB004, have shown positive phase 2 safety and efficacy results. Furthermore, CYB003, which has been granted FDA BTD, has initiated phase 3 studies.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">General and Administration Costs </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">For the three month period ended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">March&#160;31, 2025</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> general and administrative expenses were $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">12,210</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> compared to $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">12,083</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> during the same period in the prior year. General and administrative expenses for the three month period are comprised of payroll related expenses of $4,443 (2024 - $3,861), capital market expenses of $2,709 (2024 - $3,919), business development expenses of $1,410 (2024 - $203), professional and consulting fees of $1,231 (2024 -$1,838),  investor relations and marketing media fees of $1,212 (2024 - $1,366), office and administration expenses of $1,144 (2024 - $843),  and listing fe</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">es of $61 (2024 - $53). The overall increase in general and administrative expenses for the three month period ended March&#160;31, 2025 is due to the overall growth of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">For the year ended March 31, 2025 general and administrative expenses were $45,368 compared to $32,588 during the same period in the prior year. General and administrative expenses for the year are comprised of capital market expenses of $16,694 (2024 - $11,519), payroll related expenses of $13,146 (2024 - $8,248), office and administration expenses of $4,498 (2024 - $2,945), professional </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">and consulting fees of $4,156 (2024 -$4,918), business development expenses of $3,305 (2024 - $896), investor relations and marketing media fees of $3,286 (2024 - $3,791),  and listing fees of $283 (2024 - $271). T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">he overall increase in general and administrative expenses for the </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">year ended March 31, 2025 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">is largely due to an increase in capital market spend and investor relations spend as the Company continues to raise awareness of the Company and its industry. In addition, payroll related expenses have increased due to both the acquisition of Small Pharma and the overall growth of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Share-Based Compensation</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">For the three month period ended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">March&#160;31, 2025 and the year ended March 31 2025</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">, the Company recorded share-based compensation expenses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">of $2,093 and $42,869, respectively, compared to $1,269 and $13,886, respectively, during the same periods in the prior year. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The increase is largely related to the new options grants issued to consultants, officers, directors and employees.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The share-based compensation expense was recorded based on the fair value using a Black Scholes Model. On exercise of warrants and options the equity reserve balances will be moved to share capital.   </font></div><div style="margin-bottom:12pt;margin-top:2pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Other Income (Expenses)</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Foreign Exchange Gain </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">For the three month period ended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">March&#160;31, 2025 and the year ended March 31, 2025,</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> the Company incurred foreign currency translation gains from operations and revaluations of balance sheet assets and liabilities held in foreign currencies of $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">1,252 and $21,749, respectively. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company holds assets and liabilities in Canadian dollars, U.S. dollars, Euros, and British pounds. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;text-decoration:underline">Interest Income</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">For the three month period ended March&#160;31, 2025 and the year ended March 31, 2025, the Company recorded interest income of $1,441 and $8,289, respectively, compared to $342 and $619, respectively, during the same periods in the prior year. The increase is largely related to an increase on interest rates and the average cash balance earning interest. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">58</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:130%">Liquidity, Capital Resources and Cash Flows</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.514%"><tr><td style="width:1.0%"></td><td style="width:28.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended March 31, </font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Canadian dollars in thousands)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</font></td><td colspan="2" style="border-top:1pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(21,113)</font></td><td style="border-top:1pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,707)</font></td><td style="border-top:1pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(406)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(101,300)</font></td><td style="border-top:1pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68,908)</font></td><td style="border-top:1pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,392)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) from investing activities</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,084)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(215)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(869)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,966)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,922&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,888)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash from financing activities</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,981</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190,861&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(169,880)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(89)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,197</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254,507&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(234,310)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(92)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase (decrease) in cash</font></td><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,216)</font></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169,939&#160;</font></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(171,155)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(83,069)</font></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,521&#160;</font></td><td style="border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(275,590)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143)</font></td><td style="background-color:#dbdbdb;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net foreign exchange difference</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(52)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(106)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9,099</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(162)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,261&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5717)</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">136,290</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,999&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,291&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">208,992</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,633&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,359&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1156&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</font></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">135,022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208,992&#160;</font></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,970)</font></td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</font></td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">135,022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208,992&#160;</font></td><td style="border-bottom:1pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,970)</font></td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;border-top:1pt solid #929292;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</font></td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000000;border-top:1pt solid #929292;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.847%"><tr><td style="width:1.0%"></td><td style="width:20.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.169%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months ended March 31</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended March 31</font></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</font></td><td colspan="6" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Primarily relates to cash used for operating expenses including research and development expenses, salaries, and other general and administration expenses. Cash flows from operating activities exclude expenses not affecting cash, such as share based compensation expense, depreciation and amortization, lease interest, unrealized foreign exchange gains or losses, and net changes in non-cash balances relating to operations. </font></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For the three month period ended March 31, 2025, cash used in operating activities was $21,113 driven by a net loss for the period of $30,579, and a non-cash unrealized foreign exchange gain of  $1,252, partially offset by the following non-cash items&#58; an increase in working capital of $8,563,  share-based compensation of $2,093 and depreciation and amortization of $62.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the year ended March 31, 2025, cash used in operating activities was $101,300 driven by a net loss for the period of $113,137, a non-cash unrealized foreign exchange gain of  $21,749, and a decrease in working capital of $9,793,  partially offset by the following non-cash items&#58; share-based compensation of $42,869, depreciation and amortization of $475, other loss of $28 and lease interest of $7.</font></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For the three month period ended March 31, 2025, cash used in investing activities was driven by the purchase of intangible assets and equipment of $1,084.</font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For the year ended March 31, 2025, cash used in investing activities was driven by the purchase of intangible assets and equipment of $1,966.</font></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash from financing activities</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For the three month period ended March 31, 2025, cash from financing activities was driven by net proceeds on the issuance of common shares of share issuance costs of $20,981.</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">For the year ended March 31, 2025, cash from financing activities was driven by net proceeds on the issuance of common shares  of $20,487, partially offset by lease payments of $290.</font></div></td></tr></table></div><div style="margin-top:0.1pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">2022 ATM Program</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On August 8, 2022, the Company established an at-the-market program (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">2022 ATM Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) that allowed the Company to issue and sell up to US$35,000 of Common Shares in the capital of the Company from treasury to the public, from time to time, which was qualified by way of a prospectus supplement dated August 8, 2022, to the Company&#8217;s short form base shelf prospectus dated July 5, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">2021 Base Shelf Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). The 2021 Base Shelf Prospectus was effective for a period of 25 months, ending on August 5, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Lapse</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;).</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Distributions of Common Shares under the 2022 ATM Program were made pursuant to the terms and conditions of the Distribution Agreement. The 2022 ATM Program was effective until August 5, 2023 when it automatically terminated in accordance with the terms of the Distribution Agreement following the Lapse Date of the 2021 Base Shelf Prospectus. The Company was not obligated to make any sales of Common Shares under the 2022 ATM Program. The volume and timing of distributions under the 2022 ATM Program were determined in Cybin&#8217;s sole discretion and in accordance with the Distribution Agreement. As any Common Shares distributed under the 2022 ATM Program were issued and sold at the prevailing market price at the time of the applicable sale, prices varied among purchasers through the duration of the 2022 ATM Program. The Company sold 825,791 Common Shares under the 2022 ATM Program at an average price of $22.67 (US$16.89) per Common Share, for aggregate gross proceeds of $18,723 (US$13,949). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">LPC Agreement</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On May 30, 2023, the Company entered into a Common Share purchase agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">LPC Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">LPC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). Subject to the terms and conditions of the LPC Purchase Agreement, the Company has the right to sell, and LPC is obligated to purchase, up to US$30,000 of Common Shares over a 36-month period at prices that are based on the market price at the time of each sale to LPC. Cybin, in its sole discretion, controls the timing and amount of all sales of Common Shares under the LPC Purchase Agreement. Cybin has the right to terminate the LPC Purchase Agreement at any time at no cost or penalty. LPC has agreed not to engage in any short selling or hedging activity of any kind in the Common Shares. As consideration for LPC&#8217;s obligation to purchase Common Shares from the Company at its direction under the LPC Purchase Agreement, Cybin issued 66,812 Common Shares to LPC as a commitment fee on May 30, 2023.  The LPC Purchase Agreement provides that Cybin may not issue or sell any Common Shares to LPC under the LPC Purchase Agreement which, when aggregated with all other Common Shares then beneficially owned by LPC and its affiliates (as calculated pursuant to Section 13(d) of the U.S. Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder), would result in LPC beneficially owning more than 9.99% of the outstanding Common Shares. On July 31, 2023, Cybin announced that it had suspended all sales under the LPC Purchase Agreement in connection with the August 2023 Offering (as defined herein). On August 23, 2023, the Company also announced the filing of a prospectus supplement under the 2023 Base Shelf Prospectus, requalifying the LPC Purchase Agreement on the same terms as those entered into on May 30, 2023, with LPC. On November 9, 2023, the Company announced that it has, again, suspended all sales under the LPC Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">During the year ended March&#160;31, 2025, no Common Shares were issued under the LPC Purchase Agreement. As at March&#160;31, 2025, the Company has sold 50,658 Common Shares, at an average price of  $12.30 (US$9.18) per Common Share, for aggregate gross proceeds of  $623 (US$465) pursuant to the LPC Purchase Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">60</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">2023 ATM Program</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On August 23, 2023, the Company announced the filing of a prospectus supplement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">ATM Prospectus Supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) under the 2023 Base Shelf Prospectus to renew its previously established at-the-market equity program (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">2023 ATM Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) that allowed the Company to issue and sell up to US$35,000 of Common Shares from treasury to the public, from time to time. Distributions of Common Shares under the 2023 ATM Program were made pursuant to the terms and conditions of an at-the-market equity distribution agreement dated August 23, 2023 among the Company, Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald &#38; Co. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">2023 Distribution Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;)  The 2023 ATM Program was effective until February 10, 2025 when it was terminated in accordance with the terms of the 2023 Distribution Agreement. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">From August 23, 2023, being the date of the launch of the 2023 ATM Program to February 10, 2025 the Company sold 1,653,320 Common Shares under the 2023 ATM Program, at an average price of $15.44 (US$11.05) per Common Share, for aggregate gross proceeds of $25,531 (US$18,265). Share issuance costs related to the 2023 ATM Program were $1,159 (US$829). During the year ended March&#160;31, 2025, the Company sold 1,034,516 Common Shares under the 2023 ATM Program at an average price of $14.08 (US$9.82) per Common Share, for aggregate gross proceeds of $14,569 (US$10,156).</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">2025 ATM Program</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On February 10, 2025, the Company launched a new at-the-market equity program (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">2025 ATM Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) to allow the Company to issue and sell up to US$100,000 of Common Shares from treasury to the public. In connection with the 2025 ATM Program, the Company entered into an at-the-market equity distribution agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">2025 Distribution Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) dated February 10, 2025, among the Company, Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald &#38; Co. The 2025 ATM Program is to be effective until the earlier of the issuance and sale of all of the Common Shares issuable pursuant to the 2025 ATM Program and September 17, 2025, unless earlier terminated in accordance with the terms of the 2025 Distribution Agreement. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">From February 10, 2025, being the date of the launch of the 2025 ATM Program to March&#160;31, 2025 the Company sold 574,782 Common Shares under the 2025 ATM Program, at an average price of $12.80 (US$8.99) per Common Share, for aggregate gross proceeds of $7,355 (US$5,166). Share issuance costs related to the 2025 ATM Program were $504 (US$354). See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Subsequent Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">61</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Equity Offerings </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;margin-top:2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On August 4, 2023, the Company completed a public offering (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">August 2023 Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) of 638,545 units of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">August</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">2023 Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) at a price of US$12.92 per August 2023 Unit for gross proceeds of US$8,250 pursuant to the Company&#8217;s prospectus supplement dated August 1, 2023, to the 2021 Base Shelf Prospectus . Each August 2023 Unit is comprised of one Common Share and one Common Share purchase warrant (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">&#8220;August 2023 Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). Each August 2023 Warrant is exercisable to acquire one Common Share at a price of US$15.20 per Common Share for a period of 60 months from issuance, subject to acceleration in certain circumstances. In connection with the August 2023 Offering, Cybin paid the underwriters a cash commission of US$379 and incurred additional share issuance costs related to professional fees of US$465.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On November 14, 2023, the Company completed a public offering (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">November 2023 Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) of 1,754,386 units of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">November 2023 Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) at a price of US$17.10 per November 2023 Unit for gross proceeds of $41,107 (US$30,000) pursuant to the November Prospectus Supplement to the 2023 Base Shelf Prospectus. Each November 2023 Unit is comprised of one Common Share and one Common Share purchase warrant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">November 2023 Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). Each November 2023 Warrant is exercisable to acquire one Common Share at a price of $27.86 (US$19.38) per Common Share between May 14, 2024 and May 14, 2029, subject to acceleration in certain circumstances. In connection with the November 2023 Offering, Cybin paid the underwriters a cash commission of $2,096 (US$1,530) and incurred additional share issuance costs related to professional fees of $339 (US$247).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">On March 19, 2024, the Company completed a private placement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">March 2024 Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;) of 9,179,927 Common Shares at a price of US$16.34 per Common Share for gross proceeds of $202,995 (US$150,000). Pursuant to the terms of the March 2024 Offering, on April 8, 2024, the Company amended the 2023 Base Shelf Prospectus to provide that the securities that may be offered and issued thereunder will include distributions by various selling security holders. Further, on April 17, 2024, the Company filed a prospectus supplement to the 2023 Base Shelf Prospectus, in order to qualify the periodic resale of 8,763,941 Common Shares issued to certain non-Canadian investors pursuant to the March 2024 Offering. In connection with the March 2024 Offering, Cybin paid the agents a cash commission of $11,726 (US$8,665) and incurred additional share issuance costs being professional fees of $504.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:139%">Overview</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s main use for liquidity is to fund the development of its research programs as noted above. The primary source of liquidity has been from public financing to date. The ability to fund operations, to make planned capital expenditures and execute the growth&#47;acquisition strategy depends on the future operating performance and cash flows, which are subject to prevailing economic conditions, regulatory and financial, business and other factors, some of which are beyond the Company&#8217;s control.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">As at March&#160;31, 2025 the Company had working capital of $144,554. The Company is a pre-operative stage as it researches and develops its IP portfolio in anticipation of manufacturing in the near future. Therefore the Company will not be able to generate sufficient amounts of cash and cash equivalents from its operations in the short term. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">62</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company intends to continue to advance its non-revenue generating programs over the next twelve to twenty-four months. These intended advancements, along with the expectation of operating at a loss for at minimum the next 12 months, will  diminish the Company&#8217;s working capital. As such, further financings may be required to develop the Company&#8217;s pipeline, make acquisitions, meet ongoing obligations, and discharge its liabilities in the normal course of business. There is no assurance that additional funds can be raised upon terms acceptable to the Company, or at all, as funding for small companies remains challenging.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s ability to access both public and private capital is dependent upon, among other things, general market conditions and the capital markets generally, market perceptions about the Company and its business operations, and the trading prices of the Company&#8217;s securities from time to time. When additional capital is required, the Company intends to raise funds through the issuance of equity or debt securities. Other possible sources include the exercise of stock options and warrants of the Company. There can be no assurance that additional funds can be raised upon terms acceptable to the Company, or at all, as funding for early-stage companies remain challenging generally. Given the nature of the Company&#8217;s business as of the date of this MD&#38;A, and in particular, the fact that its operations are undertaken exclusively within a foreign jurisdiction, the Company may face difficulty in accessing traditional sources of financing, notwithstanding that its business operations are conducted in a regulatory environment within which the Company&#8217;s activities are neither illegal nor subject to conflicting laws.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s current expenditure obligations include commitments for those projects described in the section entitled </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Non-Revenue Generating Projects</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> in this MD&#38;A. The Company expects to continue funding these projects with available cash and cash equivalents, and therefore, is subject to risks including, but not limited to, an inability to raise additional funds through debt and&#47;or equity financing to support the Company&#8217;s continued development, including capital expenditure requirements, operating requirements and to meet its liabilities and commitments as they become due.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company constantly monitors and manages its capital resources to assess the liquidity necessary to fund operations and capacity expansion. As at March&#160;31, 2025, the Company had a cash balance of $135,022 and current liabilities of $21,418. The Company&#8217;s current resources are sufficient to settle its current liabilities. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Management continues to raise the capital necessary to become a fully operational enterprise. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has negative cash flow from operating activities and has historically incurred net losses. To the extent that the Company has negative operating cash flows in future periods, it may need to deploy a portion of its existing working capital to fund such negative cash flows.  The Company will be required to raise additional funds through the issuance of additional equity securities, through loan financing, or other means, such as through partnerships with other companies and research and development reimbursements.  There is no assurance that additional capital or other types of financing will be available if needed or that these financings will be on terms at least as favourable to the Company as those previously obtained. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">63</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s primary capital needs are funds to advance its research and development activities and for working capital purposes. These activities include staffing, preclinical studies, clinical trials and administrative costs. The Company has experienced operating losses and cash outflows from operations since incorporation and will require ongoing financing to continue its research and development. The Company has not earned any revenue or reached successful commercialization of any products. The Company&#8217;s success is dependent upon the ability to finance its cash requirements to continue its activities. There is no assurance that additional capital or other types of financing will be available if needed or that these financings will be on terms at least as favourable to the Company as those previously obtained, or at all. See &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Risk Factors&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company is focused on research and has not seen any major changes to its ability to complete those activities. The Company intends to assess its business and operational needs, and implement cost reductions as needed. The Company is currently focused on the research stage of its projects and will not be generating significant revenues in the short term. The Company believes it has sufficient working capital to manage its short- and long-term cash flow needs as it continues to invest into its intellectual property.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Contractual Obligations and Commitments</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">As at March&#160;31, 2025, the Company had also entered into agreements for various studies which may require the Company to spend up to an additional </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">$85,802</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. The Company expects to pay this amount within the next 24 months, however the timing and certainty of the payments are contingent on availability of materials and successful completion of certain milestones. The Company has the right to cancel the studies at its discretion, in which case a cancellation fee may apply, however the Company is not liable to pay the full amount of the study. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In addition to the above, the Company has entered into an exclusive license agreement with Mindset to acquire an extensive targeted class of tryptamine-based molecules. Upon the successful completion of certain milestones contemplated in the agreement, the Company may have to pay additional consideration of up to US$9,500. At the sole discretion of Cybin, the milestones may be paid in cash or in Common Shares, or a combination thereof, subject to the approval of the Cboe Canada. There is no assurance that the aforementioned milestones will be met.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company is party to certain employee and management contracts that contain severance obligations. These contracts contain clauses requiring additional payments to be made upon the occurrence of involuntary termination. As the likelihood of these events taking place is not determinable, no contingent liabilities have been recorded in the consolidated financial statements.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In the normal course of business, the Company may be subject to legal proceedings and claims. As at March&#160;31, 2025, there was no ongoing litigation and therefore no contingent liabilities have been recorded.</font></div><div style="text-align:justify"><font><br></font></div><div id="i2b86e3b0612046f694ccc21dee9687a9_200"></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">64</font></div></div></div><div id="i2b86e3b0612046f694ccc21dee9687a9_185"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Outstanding Share Data </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On September 19, 2024, the Company completed the Consolidation. As a result, all figures related to shares, warrants, options and earnings per share presented in this MD&#38;A have been restated retrospectively for all periods to reflect the Consolidation.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The table below sets out the outstanding share capital of the Company as at March&#160;31, 2025, and as of the date of this MD&#38;A&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%"> </font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Class of Security</font></td><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of  March&#160;31, 2025</font></div><div style="text-align:center"><font><br></font></div></td><td colspan="3" style="background-color:#dbdbdb;border-left:0.25pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of the date of this MD&#38;A</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Shares</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,601,208</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,023,631</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,956,684</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,945,916</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Share purchase warrants</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,796,197</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,796,197</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;margin-top:1.15pt;padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Class B Shares (as defined below)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:139%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,084.7</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,084.7</font></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:139%;text-decoration:underline">Note&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">The</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:139%">Class B Shares are exchangeable for Common Shares, on the basis of 0.26316 Common Shares for each Class B Share, at the option of the holder thereof, subject to customary adjustments.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Common Shares</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The authorized capital of the Company consists of an unlimited number of Common Shares without par value and an unlimited number of preferred shares. As of March&#160;31, 2025, 21,601,208 Common Shares were outstanding and no preferred shares were issued and outstanding. As of the date of this MD&#38;A 23,023,631</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Common Shares were outstanding and no preferred shares were issued and outstanding.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Stock Options</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">As of March&#160;31, 2025 options to purchase up to 3,956,684 Common Shares were outstanding under Cybin&#8217;s equity incentive plan. As of the date of this MD&#38;A options to purchase up to 3,945,916 Common Shares were outstanding under Cybin&#8217;s equity incentive plan.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Common Share Purchase Warrants</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">As of March&#160;31, 2025, and the date of this MD&#38;A, warrants to purchase up to 2,796,197</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Common Shares were outstanding, exercisable at weighted average exercise price of $24.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">per Common Share.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Class B Shares</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In connection with the Adelia Transaction (see &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Acquisitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), Cybin U.S. (a subsidiary of the Company) has issued 1,591,625.3 Class B Shares. The Class B Shares are exchangeable at the holder&#8217;s option for Common Shares on the basis of 0.26316 Common Shares for 1 Class B Share, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">65</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">subject to customary adjustments. As of March&#160;31, 2025, and the date of this MD&#38;A, 36,084.7 Class B Shares were outstanding. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Adelia Acquisition </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On December 4, 2020, Cybin entered into a contribution agreement, as amended on September 24, 2021, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Contribution Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) with Cybin Corp., Cybin U.S. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Acquiror</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), a newly formed fully-controlled subsidiary of Cybin created for the purposes of the Adelia Transaction, and all of the shareholders of Adelia (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Adelia Shareholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) whereby the Acquiror has agreed to purchase from the Adelia Shareholders all of the issued and outstanding common shares of Adelia (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Adelia Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) in exchange for non-voting Class B common shares in the capital of the Acquiror (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Class B Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). The Adelia Transaction closed on December 14, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Pursuant to the Contribution Agreement, the Adelia Shareholders contributed all of the Adelia Shares to the Acquiror as a capital contribution in exchange for the Acquiror issuing to them, in the aggregate, 868,833 Class B Shares in accordance with their respective pro rata percentages at a price per Class B Share equal to $12.40 (approximately US$9.69). The aggregate value of the Class B Shares to be issued to the Adelia Shareholders on the Closing was $19,549 (approximately USD$15.28 million).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Class B Shares issued by the Acquiror to the Adelia Shareholders are exchangeable for Common Shares on a 0.26316 Common Shares for 1 Class B Share basis, at the option of the holder thereof, subject to customary adjustments. The purpose of issuing exchangeable Class B Shares to the Adelia Shareholders is to allow the Adelia Shareholders to defer a taxable event, which occurs on the exchange of shares of a United States company for the shares of a Canadian company. Notwithstanding the foregoing, no Class B Shares were exchangeable prior to the first anniversary of the Closing and not more than&#58; (i) 33 1&#47;3% of the Class B Shares were exchangeable prior to the second anniversary of Closing&#59; (ii) 66 2&#47;3% of the Class B Shares were exchangeable prior to the third anniversary of Closing&#59; and (iii) thereafter, 100% of the Class B Shares will be exchangeable ((i), (ii) and (iii), collectively, the &#8220;Hold Periods&#8221;). The Class B Shares issued to the Adelia Shareholders upon the Closing are exchangeable for a total of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">228,640</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> Common Shares, resulting in an effective issue price of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">$47.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> per Cybin Share.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On the occurrence of certain milestones as set out in the Contribution Agreement (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), the Acquiror will issue to the Adelia Shareholders in accordance with their pro rata percentage, within five business days following the relevant date at which there is agreement as to the achievement of the Milestone (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Milestone Determination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), such number of Class B Shares as shall be determined by dividing the applicable Milestone consideration, as set out in the Contribution Agreement (or where some, but not all, of such sub-Milestone&#8217;s in the relevant fiscal quarter are achieved, such lesser potion of such milestone consideration) as is determined in accordance with applicable Milestone, by the greater of&#58; (i) $28.50&#59; (ii) the 10 day volume weighted average trading price of the Common Shares on the Cboe Canada (or, in the event that the Common Shares are no longer traded on the Cboe Canada, such other nationally recognized exchange as the Common Shares may at the applicable time be trading)&#59; and (iii) the closing market price of the Common Shares on the Cboe Canada (or, in the event that the Common Shares are no longer traded </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">66</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">on the Cboe Canada, such other nationally recognized exchange as the Common may at the applicable time be trading) in each case, on the close of business on the last business day preceding the Milestone Determination Date. If a particular Milestone has not been achieved by the close of the quarter immediately following the quarter in which such Milestone is scheduled for completion pursuant to the Contribution Agreement, the Acquiror&#8217;s obligation to issue Class B Shares on the occurrence of the applicable Milestone shall expire. The total value of the Class B Shares issuable pursuant to the Milestones is up to $9,388 (approximately US$7.33 million). As of the date of this MD&#38;A, all of the Milestones have been completed, 1,591,625.3 Class B Shares have been issued, and 1,555,540.6 Class B Shares have been exchanged into Common Shares. Pursuant to the Contribution Agreement, Cybin, the Acquiror and the Adelia Shareholders also entered into a support agreement dated December 14, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Support Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), which for the purpose of Canadian securities law, is deemed a &#8220;security&#8221; as it is a document evidencing an interest in or to a security (i.e. the Common Shares), and, as such, constitutes a security of Cybin. Upon the signing of the Support Agreement, given that each of the Adelia Shareholders are an &#8220;accredited investor&#8221;, the prescribed restricted period (of (4) months and one (1) day after the date of issuance) as required under Canadian securities law on the Common Shares (which are exchangeable for Class B Shares at a future date) will commence. Therefore, upon the exchange of the Class B Shares for the Common Shares, subject to the Hold Periods, such Common Shares will no longer be within a restrictive period as prescribed under applicable securities law and free trading securities. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On January 11, 2021, the Company announced the achievement of the first Milestone for the period commencing November 15, 2020, as contemplated by the terms of the Contribution Agreement. The achievement included the successful synthesis of multiple tryptamine derivatives in sufficient quantities to initiate in vitro &#8220;Proof of Principle&#8221;&#59; establish a ADME&#47;PK has been completed&#59; and to demonstrate &#8220;In Vitro&#8221; ADME &#8220;Proof of Principle&#8221; that specific synthesis modifies the metabolism of a psychedelic tryptamine. Pursuant to the terms of the Contribution Agreement, an aggregate of 51,163 Class B Shares were issued to the Adelia Shareholders in satisfaction of $1,018 due to them upon meeting such Milestones.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">   </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On March 9, 2021, the Company announced the achievement of certain Milestones for the period commencing January 1, 2021, as contemplated by the terms of the Contribution Agreement. The achievement included API Synthesis and optimization to demonstrate that two or more deuterated tryptamines show significant in vivo modifications of PK consistent with proof of concept, nomination of two deuterated candidates for full IND enabling studies, and completion of a certain API Manufacturing Contract. Pursuant to the terms of the Contribution Agreement, an aggregate of 42,247.3 Class B Shares were issued to the Adelia Shareholders in satisfaction of $686 due to them upon meeting such Milestones.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On June 28, 2021, Adelia completed the remaining requirements of the second Milestone as listed in the Contribution Agreement. Accordingly, 15,777.1 Class B Shares were issued to the Adelia Shareholders, amounting to $458. The Class B Shares are exchangeable for a total of 4,152 Common Shares, representing an effective issue price of $110.20 per Common Share.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On August 17, 2021, an additional 18,788.5 Class B Shares were issued to the Adelia Shareholders due to the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">achievement of certain requirements of the third and fourth Milestones, amounting to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">67</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">$633. The Class B Shares are exchangeable for a total of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">4,944</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> Common Shares, representing an effective issue price of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">$128.06 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">per Common Share. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On August 31, 2021, the remaining requirements of the third Milestone were achieved. Accordingly, 9,392.6 Class B Shares were issued to the Adelia Shareholders, amounting to $317. The Class B Shares are exchangeable for a total of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">2,472</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> Common Shares, representing an effective issue price of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">$128.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> per Common Share. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On November 18, 2021, an additional 28,903 Class B Shares were issued to the Adelia Shareholders due to the achievement of certain requirements of the fourth and fifth Milestones, amounting to $706. These Class B Shares are exchangeable for a total of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">7,606</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> Common Shares, representing an effective issue price of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">$92.72</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> per Common Share.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On November 29, 2021, an additional 31,721.5 Class B Shares were issued to the Adelia Shareholders due to the achievement of certain requirements of the fourth and fifth Milestones, amounting to $629. These Class B Shares are exchangeable for a total of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">8,348</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> Common Shares, representing an effective issue price of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">$75.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> per Common Share.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On January 6, 2022, an additional 15,611.4 Class B Shares were issued to the Adelia Shareholders due to the achievement of the Milestone identified as Year 2 Q1 (v), as contemplated by the terms of the Contribution Agreement, amounting to $236. These Class B Shares are exchangeable for a total of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">4,108</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> Common Shares, representing an effective issue price of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">$57.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> per Common Share.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On February 14, 2022, an additional 41,028.2 Class B Shares were issued to the Adelia Shareholders due to the achievement of the Milestones identified as Y1, Q4 (iv), Y1, Q4 (v) and Y2, Q1 (vi), as contemplated by the terms of the Contribution Agreement, amounting to $551 at a price per Class B Share of $13.43. These Class B Shares are exchangeable for a total of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">10,797</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> Common Shares, representing an effective issue price of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">$50.92</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> per Common Share.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On February 18, 2022, an additional 17,239.5 Class B Shares were issued to the Adelia Shareholders due to the achievement of certain Milestones identified as Y2, Q2 (iii), as contemplated by the terms of the Contribution Agreement, having an aggregate value of $233 at a price per Class B Share of $13.54. These Class B Shares are exchangeable for a total of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">4,537</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> Common Shares, representing an effective issue price of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">$51.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> per Common Share.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On March 25, 2022, an additional</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">90,546.0 Class B Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">were issued to Adelia Shareholders due to the achievement of certain Milestones identified as Year 1 Q4 (vi)&#59; Year 2 Q2 (ii)&#59; Year 2 Q2 (v) and Year 2, Q3 (iii), as contemplated by the terms of the Contribution Agreement, having an aggregate value of $905 at a price per Class B Share of $9.994. These Class B Shares are exchangeable for a total of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">23,828</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> Common Shares, representing an effective issue price of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">$38.00</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> per Common Share.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On April 1, 2022, an additional 22,428.3 Class B Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">were issued to Former Adelia Shareholders due to the achievement of the Milestone identified as Year 2 Q2 (iv), as contemplated by the terms of the Contribution Agreement, having an aggregate value of $229 at a price per Class B Share of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">68</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">$10.20. These Class B Shares are exchangeable for a total of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">5,902</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> Common Shares, representing an effective issue price of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">$38.76</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> per Common Share. In consideration for the Milestone achieved, on June 22, 2022, an additional 456.5 Class B shares having an aggregate value of $5 were issued to Former Adelia Shareholders.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On June 24, 2022,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">an additional 266,933.1 Class B Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">were issued to Former Adelia Shareholders due to the achievement of certain Milestones identified as Y2, Q2 (i), (vi), Y2, Q3 (ii), Year 2 Q4 (i) and Year 3 Q1 (i), (ii), (iii), as contemplated by the terms of the Adelia Contribution Agreement, having an aggregate value of $2,034 at a price per Class B Share of $7.62. These Class B Shares are exchangeable for a total of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">70,246</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> Common Shares, representing an effective issue price of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">$28.96</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> per Common Share. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On June 27, 2022, an additional 37,366.2 Class B Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">were issued to Former Adelia Shareholders due to the achievement of the Milestone identified as Y2, Q3 (i), as contemplated by the terms of the Adelia Contribution Agreement, having an aggregate value of $280 at a price per Class B Share of $7.50. These Class B Shares are exchangeable for a total of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">9,833</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> Common Shares, representing an effective issue price of $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">28.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> per Common Share. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On August 31, 2022, an additional 33,190.1 Class B Shares were issued to Former Adelia Shareholders due to the achievement of the Milestone identified as Y2, Q4 (ii), as contemplated by the terms of the Adelia Contribution Agreement, having an aggregate value of $468 at a price per Class B Share of $14.10. These Class B Shares are exchangeable for a total of 8,734 Common Shares, representing an effective issue price of $53.58 per Common Share. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">As of August 31, 2022, all of the Milestones contemplated by the terms of the Adelia Contribution Agreement were successfully achieved. The Milestones focused on bringing Cybin&#8217;s psychedelic programs from the lab to the clinic. As Cybin has advanced its research and development pipeline, these milestone achievements have contributed to discovering potential new drug formulations and delivery methods, creating clinical protocols for psychedelic compounds, and most recently, supporting clinical-stage development of the Company&#8217;s CYB003 and CYB004 programs for MDD and anxiety disorders, respectively. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Pursuant to the Contribution Agreement certain members of Adelia entered into advisory and&#47;or executive employment arrangements with Cybin upon the Closing and, in such capacity, received, in the aggregate, a grant of options to purchase up to 59,055 to acquire Common Shares, pursuant to Cybin&#8217;s equity incentive plan, exercisable for a period of five (5) years and subject to vesting, at an exercise price of $66.12 per Cybin Share. An additional 14,629 options to acquire Common Shares were issued to eligible participants at the direction of the Adelia Shareholders following the Closing.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Following the achievement of the final milestones as contemplated by the terms of the Contribution Agreement, Michael Palfreyman Ph.D. and Brett Greene, who joined the Company following the Adelia Transaction, left their roles as Chief R&#38;D Officer and Chief Innovations Officer, respectively, and transition into advisory roles at the Company. Alex Nivorozhkin Ph.D., one of Adelia&#8217;s founders, is continuing in his role as Chief Scientific Officer of Cybin.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">69</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Small Pharma Acquisition</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On August 28, 2023, the Company entered into the Arrangement Agreement with Small Pharma pursuant to which Cybin agreed to acquire all of the issued and outstanding shares of Small Pharma (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Small Pharma Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) in an all-equity business combination transaction to be completed by way the Arrangement. </font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On September 13, 2023, Small Pharma was granted an interim order (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Interim Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) by the Supreme Court of British Columbia (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Court</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) regarding the Arrangement. The Interim Order authorized Small Pharma to proceed with various matters relating to the Arrangement, including the holding of a special meeting of Small Pharma shareholders to consider and vote on the Arrangement. Completion of the Arrangement was conditional upon receipt of a final order by the Court. Small Pharma was granted a final order by the Court on October 17, 2023.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On October 12, 2023, the Company held an annual and special meeting of shareholders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Special</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) in connection with, among other things, the Arrangement. At the Special Meeting, shareholders of the Company passed an ordinary resolution approving the issuance by the Company of up to such number of Common Shares as may be required to be issued pursuant to the Arrangement in accordance with the terms of the Arrangement Agreement.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">On October 23, 2023, the Company completed the Arrangement and issued 0.00634 Common Shares for every one Small Pharma Share outstanding, resulting in a total of 2,130,138 Common Shares being issued to Small Pharma shareholders. As a result of the Arrangement, Small Pharma is now a wholly-owned subsidiary of Cybin. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Off-Balance Sheet Arrangements</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">As at March&#160;31, 2025 and the date of this MD&#38;A, other than these contractual obligations and commitments disclosed in note 13 of the Financial Statements, the Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the results of operations or financial condition of the Company.   </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Transactions Between Related Parties</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:135%">Key management personnel  of the Company are the board of directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:135%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:135%">&#8221;), the President, Chief Executive Officer, Chief Financial Officer, Chief Operating Officer, Chief Growth Officer, Chief Legal Officer, and Chief Business Officer. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Compensation for key management personnel of the Company for the three month period ended March&#160;31, 2025 and the year ended March 31, 2025 consisted of consulting fees, short term benefits and other compensation of $3,095 and $33,983, respectively (three month period ended March 31, 2024 - 3,538, year ended March 31, 2025 - $15,049).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Critical Accounting Estimates</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The preparation of the Financial Statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">70</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">financial statements and reported amounts of expenses during the reporting year. Actual outcomes could differ from these estimates. The Financial Statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the Financial Statements and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the year in which the estimate is revised and future years if the revision affects both current and future years. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The Company&#8217;s significant accounting estimates and assumptions are reported in</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> note 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> of the Financial Statements found on SEDAR+ at www.sedarplus.ca.</font></div><div><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Summary Of Significant Accounting Policies</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s significant accounting policies are set out in </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">note 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> of the Company&#8217;s annual consolidated financial statements for the year ended March 31, 2025, found on SEDAR+ at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">www.sedarplus.ca</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">. This MD&#38;A should be read in conjunction with the Financial Statements. Other accounting standards or amendments to existing accounting standards that have been issued, but have future effective dates, are either not applicable or are not expected to have a significant impact on the Financial Statements.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Disclosure Controls and Procedures</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In accordance with the requirements of National Instrument 52-109&#8211;Certification of Disclosure in Issuers&#8217; Annual and Interim Filings, the Company&#8217;s management, including the Company&#8217;s Chief Executive Officer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">CEO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) and the Company&#8217;s Chief Financial Officer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">CFO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), have evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures. Based upon the results of the evaluation, the CEO and the CFO have concluded that as at March 31, 2025, the Company&#8217;s disclosure controls and procedures to provide reasonable assurance that the information required to be disclosed by the Company in reports it files is recorded, processed, summarized and reported within the appropriate time periods and forms were effective. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Internal Control Over Financial Reporting</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with applicable IFRS.  Internal control over financial reporting should include those policies and procedures that establish the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">maintenance of records in reasonable detail, that accurately and fairly reflect the transactions and dispositions of assets&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with applicable IFRS&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">receipts and expenditures are only being made in accordance with authorizations of management or the Board&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">71</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the financial instruments.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The Company&#8217;s management, with the participation of the CEO and the CFO, assessed the effectiveness of the Company&#8217;s internal controls over financial reporting and concluded that as at March 31, 2025, the Company&#8217;s internal control over financial reporting was effective.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">During the period ended March&#160;31, 2025, the Company did not make any significant changes to its internal controls over financial reporting that would have materially affected, or reasonably likely to materially affect, its internal controls over financial reporting. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Limitations of Disclosure Controls and Procedures and Internal Control Over Financial Reporting</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s management, including the CEO and the CFO, believe that due to inherent limitations, any disclosure controls and procedures or internal control over financial reporting, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives. These inherent limitations include, among other items&#58; (i) that management&#8217;s assumptions and judgments could ultimately prove to be incorrect under varying conditions and circumstances&#59; (ii) the impact of any undetected errors&#59; and (iii) that controls may be circumvented by the unauthorized acts of individuals, by collusion of two or more people, or by management override.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Accordingly, because of the inherent limitations in a cost effective control system, misstatements due to error or fraud may occur and not be detected. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">New Accounting Standards and Interpretations Not Yet Adopted</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IFRS 18, Presentation and Disclosure in Financial Statements</font></div><div style="padding-left:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In April 2024, the IASB issued IFRS 18 that will replace IAS 1, Presentation of Financial Statements. The new standard aims to improve the quality of financial reporting by&#58; (i) requiring defined subtotals in the statement of profit or loss&#59; (ii) requiring disclosure about management defined performance measures&#59; and (iii) adding new principles for aggregation and disaggregation of information.  The standard is effective for the annual reporting periods beginning on or after January 1, 2027, with early application permitted. The Company is in the process of assessing the impact of this new standard on its consolidated financial statements.</font></div><div style="padding-left:18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IFRS 9, Financial Instruments (&#8220;IFRS 9&#8221;) and IFRS 7, Financial Instruments&#58; Disclosures (&#8220;IFRS 7&#8221;)</font></div><div style="padding-left:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In May 2024, the IASB issued targeted amendments to IFRS 9 and IFRS 7 in response to practical implementation issues and to introduce new requirements applicable to both financial institutions and corporate entities. These amendments aim to enhance the clarity and consistency of financial reporting for various types of financial instruments and their related disclosures by (i) clarifying the date of recognition and derecognition for certain financial assets and liabilities, including a new exception for financial liabilities settled through an electronic cash transfer system (ii) providing help to determine </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">72</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">whether a financial asset meets the Solely Payments of Principal and Interest criterion (iii) introducing new disclosures for instruments with contractual terms that may alter cash flows, such as financial instruments linked to the achievement of environmental, social, and governance targets, and (iv) updating the disclosure requirements for equity instruments designated at FVTOCI. The new standard will be effective for annual periods beginning on or after January 1, 2026. The Company is in the process of assessing the impact of the standard on the consolidated financial statements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">All other IFRSs and amendments issued but not yet effective have been assessed by the Company and are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Financial and Risk Management</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company is exposed to a variety of financial instrument related risks and is exposed to liquidity risk, credit risk, interest rate risk, foreign exchange risk, equity price risk, asset forfeiture risk and banking risk. Management, in conjunction with the Board, mitigates these risks by assessing, monitoring and approving the Company&#8217;s risk management processes. See note 13, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Financial Instruments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> in the Financial Statements for the Company&#8217;s financial instruments, financial risk factors, and other instruments. The Company&#8217;s financial risk activities are governed by the appropriate policy and procedures and financial risks are identified, measured and managed in accordance with the Company&#8217;s policies and risk appetite.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In addition, the Company noted the following risks specific to the psychedelic industry that it is exposed to&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Liquidity Risk</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company is a development stage company and is reliant on external fundraising to support its operations. Once funds have been raised, the Company manages liquidity risk by continuously monitoring actual and projected cash flows. The Board reviews and approves the Company&#8217;s operating and capital budgets, as well as any material transactions not in the ordinary course of business.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Regulatory Risk</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Regulatory risk pertains to the risk that the Company&#8217;s business objectives are contingent, in part, upon the compliance with regulatory requirements. Due to the nature of the industry, regulatory requirements can be more stringent than other industries and may also be punitive in nature. Any delays in obtaining, or failure to obtain regulatory approvals can significantly delay operational and product development and can have a material adverse effect on the Company&#8217;s business, results of operation, and financial condition. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company routinely monitors regulatory changes occurring in the psychedelic industry at the city, state, and national levels. Although the general regulatory outlook for the psychedelic industry has been moving in a positive direction, unforeseen regulatory changes could have a material adverse effect on the business as a whole.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">73</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Currency Risk</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company is exposed to currency risk related to the fluctuation of foreign exchange rates and the degree of volatility of those rates. Currency risk is limited to the portion of the Company&#8217;s business transactions and balances denominated in currencies other than the Canadian dollar.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Subsequent Events</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">During the period from January 1, 2025 to June&#160;30, 2025 the Company sold 1,422,423 Common Shares under the 2023 ATM Program, at an average price of US$7.36 per Common Share, for aggregate gross proceeds of US$10,465. On February 10, 2025, the Company, Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald &#38; Co terminated the 2023 Distribution Agreement and ended its 2023 ATM Program.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On April 21, 2025, the Company announced a strategic partnership with Osmind, a leading service provider advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Through this partnership, the Company will leverage Osmind&#8217;s 800-clinic network, point-of-care software, and real-world data to support the commercial preparation for its clinical-stage pipeline.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On April 23, 2025, the Company announced the addition of CenExel iResearch Atlanta and Cedar Clinical Research to its SPA program, bringing the total to 18 clinical sites engaged to advance Cybin&#8217;s multinational Phase 3 PARADIGM program evaluating CYB003 for the adjunctive treatment of MDD. The APPROACH study is expected to include approximately 45 clinical sites.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On May 8, 2025, the Company announced that the USPTO has granted U.S. patent 12,291,499 in support of its CYB003 program in MDD.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On May 15, 2025, the Company announced that it has engaged Thermo Fisher Scientific to provide U.S.-based manufacturing for the CYB003 program. The production of both drug substance and drug product will be performed at Thermo Fisher&#8217;s U.S. pharma services manufacturing sites. The Company is working with Thermo Fisher&#8217;s pharma services sites in Florence, South Carolina, for  Phase 3 clinical supply and future commercialization, and Cincinnati, Ohio, for Phase 3 capsule production and commercialization.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On June 3, 2025, the Company announced that the USPTO has granted U.S. patent 12,318,477 in support of its CYB004 deuterated DMT program in development for the treatment of GAD.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On June 4, 2025, the Company completed the formal dissolution of the wholly-owned subsidiaries Natures Journey Inc. and Serenity Life Sciences Inc. These entities were non-operational prior to their dissolution and had no material impact on the Company&#8217;s consolidated financial statements as of March 31, 2025.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">On June 30, 2025, the Company announced that it has entered into a securities purchase agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Securities Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) with High Trail Special Situations LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">High Trail</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;), </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">74</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">pursuant to which the Company agreed to sell and issue to High Trail up to US$500,000 aggregate principal amount of unsecured convertible debentures (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Convertible Debentures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). The sale and issue of US$50,000 principal amount of Convertible Debentures was completed on June 30, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Convertible Debenture Private Placement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). The sale and issue of US$450,000 principal amount of Convertible Debentures shall be determined at a future date, upon mutual agreement of the parties.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Convertible Debentures will have a two-year term from the closing date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">Convertible Denture Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;). The Company shall pay guaranteed interest equal to 5.5% of the principal per annum for the Convertible Debenture Term. Such interest would be pre-paid on closing. Upon the occurrence of an event of default, interest shall increase to a rate of 18% on the outstanding principal balance. Pursuant to the terms of the Securities Purchase Agreement, the Company and High Tail may, upon mutual consent, enter into subsequent securities purchase agreements for the purchase and sale of up to an additional US$450,000 principal amount of Convertible Debentures, in tranches, in amounts on such dates as may be mutually agreed and each subsequent tranche shall include prepaid interest at a rate of 9.5%.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Subject to the terms of the Securities Purchase Agreement and the Convertible Debentures, High Trail will be entitled to convert the principal amount of, and accrued and unpaid interest, if any, on each Convertible Debenture, in whole or in part, from time to time, into Common Shares at a conversion price per Common Share equal to the lower of (a) 130% of the volume weighted average price (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">VWAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) of the Common Shares on the day prior to the initial issuance of the Convertible Debentures, or (b) the VWAP of the Common Shares during the five trading days immediately prior to the date of conversion.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company, in its sole discretion, may prepay any outstanding amount under the Convertible Debentures, in whole or in part, in cash by providing High Trail with advance written notice at least five trading days prior to such prepayment. The prepayment shall include, (i) if paid during the first year after closing, a 5% prepayment premium on the amount of the prepayment or (ii) if paid during the second year after closing, a 3% prepayment premium on the amount of the prepayment.  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The terms of the Convertible Debentures restrict the conversion of Convertible Debentures by High Trail if such a conversion or exercise would cause High Trail, together with any affiliate thereof, to beneficially own in excess of 4.99% of the number of Common Shares outstanding immediately after giving effect to such conversion. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In connection with the offering, the Company and High Trail entered into a customary Registration Rights Agreement pursuant to which the Company has agreed to provide certain registration rights to High Trail under the U.S. Securities Act of 1933, as amended. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company intends to use the net proceeds from the Convertible Debenture Private Placement for working capital and general corporate purposes.   </font></div><div style="text-align:justify"><font><br></font></div><div id="i2b86e3b0612046f694ccc21dee9687a9_101"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">RISK FACTORS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In addition to the risks described herein, reference is made to the section entitled &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Risk Factors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221; in the AIF, which is incorporated herein by reference. The risks described herein are not the only risks faced </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">75</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">by the Company and securityholders of the Company. Additional risks and uncertainties not currently known to the Company, or that the Company currently deems immaterial, may also materially and adversely affect its business. The business, financial condition, revenues or profitability of the Company could be materially adversely affected by any of the risks set forth in this MD&#38;A. The trading price of the Common Shares could decline due to any of these risks and investors could lose all or part of their investment. This MD&#38;A contains forward-looking statements that involve risks and uncertainties. The Company&#8217;s actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks faced by the Company described below and elsewhere in this MD&#38;A. No inference should be drawn, nor should an investor place undue importance on, the risk factors that are included in this MD&#38;A as compared to those included in other documents publicly filed by the Company, as all risk factors are important and should be carefully considered by a potential investor.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Risks Related to the Company&#8217;s Business and Industry</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Limited Operating History</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Common Shares commenced trading on Cboe Canada on November 10, 2020 on a post-Reverse Takeover basis and therefore the Company has a limited operating history as a public company. To operate effectively, the Company will be required to continue to implement changes in certain aspects of its business, improve information systems and develop, manage and train management-level and other employees to comply with ongoing public company requirements. Failure to take such actions, or delay in implementation thereof, could adversely affect the business, financial condition, liquidity and results of operations of the Company and, more specifically, could result in regulatory penalties, market criticism or the imposition of cease trade orders in respect of the Common Shares. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company will be subject to all of the business risks and uncertainties associated with any new business enterprise, including the risk that it will not achieve its operating goals. In order for the Company to meet future operating and debt service requirements, it will need to be successful in its growth, marketing and sales efforts. Additionally, where the Company experiences increased production and future sales, its current operational infrastructure may require changes to scale its business efficiently and effectively to keep pace with demand and achieve long-term profitability. If the Company&#8217;s products and services are not accepted by new customers, the Company&#8217;s operating results may be materially and adversely affected.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Achieving Publicly Announced Milestones</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">From time to time, the Company may announce the timing of certain events it expects to occur, such as the anticipated timing of results from clinical trials. These statements are forward-looking and are based on the best estimates of management at the time relating to the occurrence of such events. However, the actual timing of such events may differ from what has been publicly disclosed. The timing of events such as initiation or completion of a clinical trial, filing of an application to obtain regulatory approval, or announcement of additional clinical trials for a prescription drug product candidate may ultimately vary from what is publicly disclosed. See &#8220;Commercial Scale Product Manufacturing&#8221;, &#8220;Safety and Efficacy of Products&#8221;, &#8220;Clinical Testing and Commercializing Product </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">76</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Candidates&#8221;, &#8220;Completion of Clinical Trials&#8221;, and &#8220;Nature of Regulatory Approvals&#8221; as discussed under this heading &#8220;Risk Factors&#8221; for further disclosure of risks and events that may affect the timing of certain events the Company may announce.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company undertakes no obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise, except as otherwise required by-law. Any variation in the timing of previously announced milestones could have a material adverse effect on the Company&#8217;s business plan, financial condition or operating results and the trading price of the Common Shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Speculative Nature of Investment Risk</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">An investment in the securities of the Company carries a high degree of risk and should be considered as a speculative investment. The Company has no history of earnings, limited cash reserves, limited operating history, has not paid dividends, and is unlikely to pay dividends in the immediate or near future.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Early Stage of the Industry and Product Development </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Given the early stage of its prescription drug product development, the Company can make no assurance that its research and development programs will result in regulatory approval or commercially viable products. To achieve profitable operations, the Company, alone or with others, must successfully develop, gain regulatory approval for, and market its future products. The Company currently has no products that have been approved by Health Canada, the FDA, the MHRA, the EMA, the Pharmaceutical Drugs Directorate (formerly the Therapeutic Drugs Directorate) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">PDD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) or any similar regulatory authority. To obtain regulatory approvals for its prescription drug product candidates being developed and to achieve commercial success, clinical trials must demonstrate that the prescription drug product candidates are safe for human use and that they demonstrate efficacy. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Many prescription drug product candidates never reach the stage of clinical testing and even those that do have only a small chance of successfully completing clinical development and gaining regulatory approval. Prescription drug product candidates can fail for a number of reasons, including, but not limited to, being unsafe for human use or due to the failure to provide therapeutic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">benefits equal to or better than the current standard of treatment at the time of testing. Unsatisfactory results obtained from a particular study relating to a research and development program may cause the Company or its collaborators to abandon commitments to that program. Positive results of early preclinical research may not be indicative of the results that will be obtained in later stages of preclinical or clinical research. Similarly, positive results from early-stage clinical trials may not be indicative of favourable outcomes in later-stage clinical trials, and the Company can make no assurance that any future studies, if undertaken, will yield favourable results.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The early stage of the Company&#8217;s product development makes it particularly uncertain whether any of its product development efforts will prove to be successful and meet applicable regulatory requirements, and whether any of its prescription drug product candidates will receive the requisite regulatory approvals, be capable of being manufactured at a reasonable cost or be successfully </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">77</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">marketed. If the Company is successful in developing its current and future prescription drug product candidates into approved products, it will still experience many potential obstacles, which would affect its ability to successfully market and commercialize such approved products, such as the need to develop or obtain manufacturing, marketing and distribution capabilities, price pressures from third-party payors, or proposed changes in health care systems. If the Company is unable to successfully market and commercialize any of its products, its financial condition and results of operations may be materially and adversely affected.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company can make no assurance that any future studies, if undertaken, will yield favorable results. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later-stage clinical trials after achieving positive results in early-stage development, and the Company cannot be certain that it will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in clinical trials, including previously unreported adverse events or latent defects in the manufactured drug product or the formulation or stability thereof. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their prescription drug product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain Health Canada, FDA or EMA approval. If the Company fails to produce positive results in future clinical trials and other programs, the development timeline and regulatory approval and commercialization prospects for the Company&#8217;s leading prescription drug product candidates, and, correspondingly, its business and financial prospects, would be materially adversely affected.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Preclinical testing and clinical trials for the Company&#8217;s products may not achieve the desired results. The results of preclinical testing and clinical trials are uncertain. Product approvals are subject to a number of contingencies and may not be obtained in the time expected or at all. The Company&#8217;s products may not attract a following among patients, retailers and&#47;or providers. The Company expects to face an inherent risk of exposure to product liability claims, regulatory action and litigation if the products it plans to distribute are alleged to have caused loss or injury. There can be no assurance that the Company will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s business relies on its ability to access, develop, and sell psilocybin, psilocin, DMT-based compounds and other psychedelic compounds. Psilocybin, psilocin, DMT-based compounds and other psychedelic compounds are controlled substances in many jurisdictions, including in Canada under Schedule III of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Controlled Drugs and Substances Act </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">and in the United States. The Company may face difficulty accessing  the public capital markets in Canada as a result of the response of regulators, stock exchanges, and other market participants to the Company&#8217;s development and sale of a controlled substance. The Company may also have limited access to traditional banking services, as well as limited access to debt financing from traditional institutional lenders. The medical efficacy of psilocybin, DMT-based compounds and other psychedelic compounds has not been confirmed and requires further study and scientific rigour.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">78</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Regulatory Risks and Uncertainties</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">In Canada, certain psychedelic drugs, including psilocybin&#47;psilocin, are classified as Schedule III drugs under the CDSA and as such, medical and recreational use is illegal under Canadian federal laws. In the United States, certain psychedelic drugs, including psilocybin, psilocin, DMT, and 5-Methoxy-DMT, are classified as Schedule I drugs under the CSA and the Controlled Substances Import and Export Act and as such, medical and recreational use is illegal under the U.S. federal laws. Anyone wishing to conduct research on substances listed in Schedule I under the CSA must register with the DEA and obtain DEA approval of the research proposal. The EU member states currently classify DMT as a Schedule I substance under the UN 71 and, as such, a licence is required to produce, dispense, import or export any Schedule I substances, but the specific requirements vary from country to country. Currently in the Netherlands, DMT is classified as a List 1 Drug under the Dutch Opium Act and, as such, subject to express authorization being obtained, the production, trade and possession of DMT are prohibited. In the United Kingdom, &#8220;Fungus (of any kind) which contains psilocin or an ester of psilocin&#8221; is controlled as a Class A drug under the MDA and Schedule 1 drug under the MDR. As psilocybin is a phosphate ester of psilocin, even if it is isolated from psilocin, it will still be treated as a Class A drug under the MDA and as a Schedule 1 drug under the MDR. Schedule 1 drugs can only be lawfully manufactured, produced, possessed and supplied under a controlled drugs domestic licence issued by the UK Home Office.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">There is no guarantee that psychedelic drugs or psychedelic inspired drugs will ever be approved as medicines in any jurisdiction in which the Company operates. All activities involving such substances by or on behalf of the Company are conducted in accordance with applicable federal, provincial, state and local laws. Further, all facilities engaged with such substances by or on behalf of the Company do so under current licences and permits issued by appropriate federal, provincial and local governmental agencies. While the Company is focused on programs using psychedelic inspired compounds, the Company does not have any direct or indirect involvement with the illegal selling, production or distribution of any substances in the jurisdictions in which it operates and does not intend to have any such involvement. However, the laws and regulations generally applicable to the industry in which the Company is involved in may change in ways currently unforeseen. Any amendment to or replacement of existing laws or regulations, including the classification or re-classification of the substances the Company is developing or working with, which are matters beyond the Company&#8217;s control, may cause the Company&#8217;s business, financial condition, results of operations and prospects to be adversely affected or may cause the Company to incur significant costs in complying with such changes or it may be unable to comply therewith. A violation of any applicable laws and regulations of the jurisdictions in which the Company operates could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings initiated by either government entities in the jurisdictions in which the Company operates, or private citizens or criminal charges. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The loss of the necessary licences and permits for any of the above scheduled drugs could have an adverse effect on the Company&#8217;s operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The psychedelic drug industry is a fairly new industry and the Company cannot predict the impact of the ever-evolving compliance regime in respect of this industry. Similarly, the Company cannot predict the time required to secure all appropriate regulatory approvals for future products, or the extent of testing and documentation that may, from time to time, be required by governmental authorities. The impact of compliance regimes, any delays in obtaining, or failure to obtain regulatory </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">79</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">approvals may significantly delay or impact the development of markets, its business and products, and sales initiatives and could have a material adverse effect on the business, financial condition and operating results of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The success of the Company&#8217;s business is dependent on the reform of controlled substances laws pertaining to psilocybin. If controlled substances laws are not favourably reformed in Canada, the United States, the Netherlands, the UK, and other global jurisdictions, the commercial opportunity that the Company is pursuing may be highly limited.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company makes no medical, treatment or health benefit claims about the Company&#8217;s proposed products. The FDA, Health Canada, the EMA or other similar regulatory authorities have not evaluated claims regarding psilocybin, DMT, psilocybin analogues, or other psychedelic compounds. The efficacy of such products have not been confirmed by approved research. There is no assurance that the use of psilocybin, DMT, psilocybin analogues, or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company&#8217;s performance and operations. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:122%">Risks of Operating in European Countries</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company is subject to additional risks related to operating in countries in Europe including&#58; (i) differing regulatory requirements in Europe&#59; (ii) unexpected changes in price and exchange controls and other regulatory requirements&#59; (iii) increased difficulties in managing the logistics and transportation of collecting and shipping patient material&#59; (iv) import and export requirements and restrictions&#59; (v) compliance with tax, employment, immigration and labour laws for employees living or traveling abroad&#59; (vi) foreign taxes, including withholding of payroll taxes&#59; (vii) foreign currency fluctuations, which could result in increased operating expenses, and other obligations incident to doing business in another country&#59; (viii) difficulties staffing and managing foreign operations&#59; (ix) potential liability under the Corruption of Foreign Public Officials Act of Canada or comparable foreign regulations&#59; (x) challenges enforcing its contractual and intellectual property rights, especially in those European countries that do not respect and protect intellectual property rights to the same extent as Canada or the United States&#59; (xi) production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#59; and (xii) business interruptions resulting from geo-political actions, including war and terrorism.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">These and other risks associated with the Company&#8217;s international operations may materially adversely affect its ability to attain or maintain profitable operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">&#8220;Foreign Private Issuer&#8221; Status Under the U.S. Securities Laws</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The Company is a &#8220;foreign private issuer&#8221;, under applicable U.S. federal securities laws, and is, therefore, not subject to the same requirements that are imposed upon U.S. domestic issuers by the Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;). Under the Exchange Act, the Company is subject to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">80</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">reporting obligations that, in certain respects, are less detailed and less frequent than those of U.S. domestic reporting companies. As a result, the Company does not file the same reports that a U.S. domestic issuer would file with the SEC, although the Company is required to file with or furnish to the SEC the continuous disclosure documents that it is required to file in Canada under Canadian securities laws. In addition, the Company&#8217;s officers, directors, and principal shareholders are exempt from the reporting and short-swing profit recovery provisions of Section 16 of the Exchange Act. Therefore, the Company&#8217;s shareholders may not know on as timely a basis when the Company&#8217;s officers, directors and principal shareholders purchase or sell Common Shares, as the reporting periods under the corresponding Canadian insider reporting requirements are longer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">As a foreign private issuer, the Company is exempt from the rules and regulations under the Exchange Act related to the furnishing and content of proxy statements. The Company is also exempt from Regulation FD, which prohibits issuers from making selective disclosures of material non-public information. While the Company complies with the corresponding requirements relating to proxy statements and disclosure of material non-public information under Canadian securities laws, these requirements differ from those under the Exchange Act and Regulation FD and shareholders should not expect to receive the same information at the same time as such information is provided by U.S. domestic companies. In addition, the Company may not be required under the Exchange Act to file annual and quarterly reports with the SEC as promptly as U.S. domestic companies whose securities are registered under the Exchange Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Plans for Growth </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company intends to continue to advance its research and development programs and operations over the next 12 to 24 months. This advancement will place a significant strain on the Company&#8217;s management systems and resources. The Company may not be able to implement its business strategy in a rapidly evolving market. In particular, the Company may be required to manage multiple relationships with various strategic industry participants and other third parties, which relationships could be strained. Similarly, an increase in the number of third-party relationships the Company has, may lead to management of the Company being unable to manage growth effectively. The occurrence of such events may result in the Company being unable to successfully identify, manage and exploit existing and potential market opportunities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Limited Products</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company will be heavily reliant on the production and distribution of psychedelics and related products. If they do not achieve sufficient market acceptance, it will be difficult for the Company to achieve profitability.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s revenue will be derived almost exclusively from sales of psychedelic pharmaceutical products, and the Company expects that its psychedelic pharmaceutical products will account for substantially all of its revenue for the foreseeable future. If the psychedelic pharmaceutical market declines or psychedelics fail to achieve substantially greater market acceptance than it currently enjoys, the Company will not be able to grow its revenues sufficiently for it to achieve consistent profitability.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">81</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Even if products to be distributed by the Company conform to international safety and quality standards, sales could be adversely affected if consumers in target markets lose confidence in the safety, efficacy, and quality of psychedelic pharmaceutical products. Adverse publicity about psychedelic pharmaceutical products that the Company sells may discourage consumers from buying products distributed by the Company. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Limited Marketing and Sales Capabilities</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company will, for the immediate future, have limited marketing and sales capabilities, and there can be no assurance that it will be able to develop or acquire these capabilities at the level needed to produce and deliver for sale, through industry partners, its products in sufficient commercial quantities. Further, there can be no assurance that the Company, either on its own or through arrangements with other industry participants, will be able to develop or acquire such capabilities on a cost-effective basis, or at all. Finally, there can be no assurance that the Company&#8217;s industry partners will be able to market or sell the Company&#8217;s products in compliance with requisite regulatory protocols or on a cost-effective basis. The Company&#8217;s dependence upon third parties for the production, and marketing or sale, as applicable, of the Company&#8217;s products could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">No Assurance of Commercial Success</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The successful commercialization of the Company&#8217;s products will depend on many factors, including, the Company&#8217;s ability to establish and maintain working partnerships with industry participants in order to market its products, the Company&#8217;s ability to supply a sufficient amount of its products to meet market demand, and the number of competitors within each jurisdiction within which the Company may from time to time be engaged. There can be no assurance that the Company or its industry partners will be successful in their respective efforts to develop and implement, or assist the Company in developing and implementing, a commercialization strategy for the Company&#8217;s products.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">No Profits or Significant Revenues</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has no history upon which to evaluate its performance and future prospects. The Company&#8217;s proposed operations are subject to all the business risks associated with new enterprises. These include likely fluctuations in operating results as the Company makes significant investments in research, development and product opportunities, and reacts to developments in its market, including purchasing patterns of customers, and the entry of competitors into the market. The Company will only be able to pay dividends on any shares once its directors determine that it is financially able to do so. The Company cannot make any assurance that it will be profitable in the next three years or generate sufficient revenues to pay dividends to the holders of the Common Shares.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Reliance on Third Parties for Clinical Development Activities</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company relies and will continue to rely on third parties to conduct a significant portion of its preclinical and clinical development activities. For example, clinical development activities include trial design, regulatory submissions, clinical patient recruitment, clinical trial monitoring, clinical data </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">82</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">management and analysis, safety monitoring and project management. If there is any dispute or disruption in its relationship with third parties, or if it is unable to provide quality services in a timely manner and at a feasible cost, the Company&#8217;s active development programs will face delays. Further, if any of these third parties fails to perform as the Company expects or if their work fails to meet regulatory requirements, the Company&#8217;s testing could be delayed, cancelled or rendered ineffective.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Risks Related to Third Party Relationships</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company intends to enter into strategic alliances with third parties that the Company believes will complement or augment its proposed business or will have a beneficial impact on the Company. Strategic alliances could present unforeseen integration obstacles or costs, may not enhance the Company&#8217;s business, and may involve risks that could adversely affect the Company, including significant amounts of management time that may be diverted from operations in order to pursue and complete such transactions or maintain such strategic alliances. Future strategic alliances could result in the incurrence of additional debt, costs and contingent liabilities, and there can be no assurance that future strategic alliances will achieve, or that the Company&#8217;s existing strategic alliances will continue to achieve, the expected benefits to the Company&#8217;s business or that the Company will be able to consummate future strategic alliances on satisfactory terms, or at all. Any of the foregoing could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In addition to the foregoing, the success of the Company&#8217;s business will depend, in large part, on the Company&#8217;s ability to enter into, and maintain collaborative arrangements with various participants in the psychedelic pharmaceutical industry. There can be no assurance that the Company will be able to enter into collaborative arrangements in the future on acceptable terms, if at all. There can be no assurance that such arrangements will be successful, that the parties with which the Company has or may establish arrangements will adequately or successfully perform their obligations under such arrangements, that potential partners will not compete with the Company by seeking or prioritizing alternate, competitor products. The termination or cancellation of any such collaborative arrangement or the failure of the Company and&#47;or the other parties to these arrangements to fulfill their obligations could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations. In addition, disagreements between the Company and any of its industry partners could lead to delays or time consuming and expensive legal proceedings, which could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Reliance on Contract Manufacturers</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has limited manufacturing experience and relies on contract manufacturing organizations (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">CMOs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) to manufacture its prescription drug product candidates for preclinical studies and clinical trials. The Company relies on CMOs for manufacturing, filling, packaging, storing and shipping of drug product in compliance with cGMP regulations applicable to its products. All applicable jurisdictions, including Health Canada, the FDA,the MHRA the EMA,and the PDD, ensure the quality of food, drug products and dietary supplements by carefully monitoring drug manufacturers&#8217; compliance with cGMP regulations. The cGMP regulations for drugs contain minimum requirements for the methods, facilities and controls used in manufacturing, processing and packing of a drug product. There can be no assurances that CMOs will be able to meet the Company&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">83</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">timetable and requirements. The Company has not contracted with alternate suppliers for drug substance production in the event that the current provider is unable to scale up production, or if it otherwise experiences any other significant problems. If the Company is unable to arrange for alternative third-party manufacturing sources on commercially reasonable terms or in a timely manner, the Company may be delayed in the development of its prescription drug product candidates. Further, CMOs must operate in compliance with cGMP and ensure that their appropriate permits and licences remain in good standing and failure to do so could result in, among other things, the disruption of product supplies. The Company&#8217;s dependence upon third parties for the manufacture of its products may adversely affect its profit margins and its ability to develop and deliver products on a timely and competitive basis.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Safety and Efficacy of Products </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Before obtaining marketing approval from regulatory authorities for the sale of the Company&#8217;s prescription drug product candidates, the Company must conduct preclinical studies in animals and extensive clinical trials in humans to demonstrate the safety and efficacy of the prescription drug product candidates. Clinical testing is expensive and difficult to design and implement, can take many years to complete and has uncertain outcomes. The outcome of preclinical studies and early clinical trials may not predict the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier trials. The Company does not know whether the clinical trials it may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market any of its prescription drug product candidates in any jurisdiction. A prescription drug product candidate may fail for safety or efficacy reasons at any stage of the testing process. A major risk the Company faces is the possibility that none of its prescription drug product candidates under development will successfully gain market approval from Health Canada, the FDA, the MHRA, the EMA,the PDD or other regulatory authorities, resulting in the Company being unable to derive any commercial revenue from them after investing significant amounts of capital in their development.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Clinical trials are conducted in representative samples of the potential patient population which may have significant variability. Clinical trials are by design based on a limited number of subjects and of limited duration for exposure to the product used to determine whether, on a potentially statistically significant basis, the planned safety and efficacy of any such product can be achieved. As with the results of any statistical sampling, the Company cannot be sure that all side effects of its products may be uncovered, and it may be the case that only with a significantly larger number of patients exposed to such product for a longer duration, may a more complete safety profile be identified. Further, even larger clinical trials may not identify rare serious adverse effects, or the duration of such studies may not be sufficient to identify when those events may occur. There have been products that have been approved by the regulatory authorities but for which safety concerns have been uncovered following approval. Such safety concerns have led to labelling changes or withdrawal of such products from the market, and the Company&#8217;s products may be subject to similar risks. The Company might have to withdraw or recall its products from the marketplace. The Company may also experience a significant drop in the potential future sales of its products if and when regulatory approvals for such products are </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">84</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">obtained, experience harm to its reputation in the marketplace or become subject to lawsuits, including class actions. Any of these results could decrease or prevent any sales of the Company&#8217;s products, or substantially increase the costs and expenses of commercializing and marketing its products.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Clinical Testing and Commercializing Products </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Before obtaining marketing approval from regulatory authorities for the sale of the Company&#8217;s prescription drug product candidates, it must conduct preclinical studies in animals and extensive clinical trials in humans to demonstrate the safety and efficacy of the prescription drug product candidates. Clinical testing is expensive and difficult to design and implement, can take many years to complete and has uncertain outcomes. The outcome of preclinical studies and early clinical trials may not predict the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier trails. The Company does not know whether the clinical trials it may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market any of its prescription drug product candidates in any jurisdiction. A prescription drug product candidate may fail for safety or efficacy reasons at any stage of the testing process. A major risk the Company faces is the possibility that none of its prescription drug product candidates under development will successfully gain market approval from the FDA, or other regulatory authorities, resulting in the Company being unable to derive any commercial revenue from this business segment after investing significant amounts of capital in its development. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company cannot predict whether any clinical trials will begin as planned, will need to be restructured, or will be completed on schedule, or at all. The Company&#8217;s product development costs will increase if it experiences delays in clinical testing. Significant clinical trial delays could shorten any periods during which the Company may have the exclusive right to commercialize its prescription drug product candidates or allow its competitors to bring products to market before the Company, which would impair the Company&#8217;s ability to successfully commercialize its prescription drug product candidates and may harm its financial condition, results of operations and prospects.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The commencement and completion of clinical trials for the Company&#8217;s prescription drug product candidates may be delayed for a number of reasons, including but not limited, to&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">failure by regulatory authorities to grant permission to proceed or placing clinical trials on hold&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">suspension or termination of clinical trials by regulators for many reasons, including concerns about patient safety or failure of the Company&#8217;s CMOs to comply with cGMP requirements or latent defects in product quality&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">any changes to the Company&#8217;s manufacturing process that may be necessary or desired, delays or failure to obtain clinical supply from CMOs of the Company&#8217;s products necessary to conduct clinical trials&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">85</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">prescription drug product candidates demonstrating a lack of safety or efficacy during clinical trials, reports of clinical testing on similar technologies and products raising safety or efficacy concerns&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">clinical investigators not performing the Company&#8217;s clinical trials on their anticipated schedule, dropping out of a trial, or employing methods not consistent with the clinical trial protocol, regulatory requirements or other third parties not performing data collection and analysis in a timely or accurate manner&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">failure of the Company&#8217;s contract research organizations to satisfy their contractual duties or meet expected deadlines&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">inspections of clinical trial sites by regulatory authorities&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">regulatory authorities or ethics committees finding regulatory violations that require the Company to undertake corrective action, resulting in suspension or termination of one or more sites or the imposition of a clinical hold on the entire study&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">one or more regulatory authorities or ethics committees rejecting, suspending or terminating the study at an investigational site, precluding enrollment of additional subjects, or withdrawing its approval of the trial&#59; or</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">failure to reach agreement on acceptable terms with prospective clinical trial sites.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s product development costs will increase if it experiences delays in testing or approval or if the Company needs to perform more or larger clinical trials than planned. Additionally, changes in regulatory requirements and policies may occur, and the Company may need to amend study protocols to reflect these changes. Amendments may require the Company to resubmit its study protocols to regulatory authorities or ethics committees for re-examination, which may impact the cost, timing or successful completion of that trial. Delays or increased product development costs may have a material adverse effect on the Company&#8217;s business, financial condition and prospects.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Prior to commencing clinical trials in Canada, the United States, the UK, the Netherlands, or other jurisdictions, for any prescription drug product candidates developed by the Company, it may be required to have an IND (or equivalent) for each prescription drug product candidate and to file additional INDs prior to initiating any additional clinical trials. The Company believes that the data from its studies will support the filing of additional INDs to enable the Company to undertake additional clinical studies as it has planned. However, submission of an IND (or equivalent) may not result in the FDA (or equivalent authorities) allowing further clinical trials to begin and, once begun, issues may arise that will require the Company to suspend or terminate such clinical trials.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Additionally, even if relevant regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, these regulatory authorities may change their requirements in the future. Failure to submit or have effective INDs (or equivalent) and commence or continue clinical programs will significantly limit its opportunity to generate revenue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Completion of Clinical Trials</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">As the Company&#8217;s prescription drug product candidates advance from preclinical testing to clinical testing, and then through progressively larger and more complex clinical trials, the Company will need to enroll an increasing number of patients that meet its eligibility criteria. There is significant competition for recruiting patients in clinical trials, and the Company may be unable to enroll the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">86</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">patients it needs to complete clinical trials on a timely basis or at all. The factors that affect the Company&#8217;s ability to enroll patients are largely uncontrollable and include, but are not limited to, the size and nature of the patient population, eligibility and exclusion criteria for the trial, design of the clinical trial, competition with other companies for clinical sites or patients, perceived risks and benefits of the prescription drug product candidate, and the number, availability, location and accessibility of clinical trial sites.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Commercial Grade Product Manufacturing </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s prescription drug products will be manufactured in small quantities for preclinical studies and clinical trials by third party manufacturers. In order to commercialize its product, the Company needs to manufacture commercial quality drug supply for use in registration clinical trials. Most, if not all, of the clinical material used in phase III&#47;pivotal&#47;registration studies must be derived from the defined commercial process including scale, manufacturing site, process controls and batch size. If the Company has not scaled up and validated the commercial production of its product prior to the commencement of pivotal clinical trials, it may have to employ a bridging strategy during the trial to demonstrate equivalency of early-stage material to commercial drug product, or potentially delay the initiation or completion of the trial until drug supply is available. The manufacturing of commercial quality product may have long lead times, may be very expensive and requires significant efforts including, but not limited to, scale-up of production to anticipated commercial scale, process characterization and validation, analytical method validation, identification of critical process parameters and product quality attributes, and multiple process performance and validation runs. If the Company does not have commercial drug supply available when needed for pivotal clinical trials, the Company&#8217;s regulatory and commercial progress may be delayed, and it may incur increased product development costs. This may have a material adverse effect on the Company&#8217;s business, financial condition and prospects, and may delay marketing of the product.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Nature of Regulatory Approvals </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s development and commercialization activities and prescription drug product candidates are significantly regulated by a number of governmental entities, including Health Canada, the FDA, the MHRA, the EMA and the PDD. Regulatory approvals are required prior to each clinical trial and the Company may fail to obtain the necessary approvals to commence or continue clinical testing. The Company must comply with regulations concerning the manufacture, testing, safety, effectiveness, labeling, documentation, advertising, and sale of products and prescription drug product candidates and ultimately must obtain regulatory approval before it can commercialize a prescription drug product candidate. The time required to obtain approval by such regulatory authorities is unpredictable but typically takes many years following the commencement of preclinical studies and clinical trials. Any analysis of data from clinical activities the Company performs is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. Even if the Company believes results from its sponsored clinical trials are favorable to support the marketing of its prescription drug product candidates, Health Canada, the FDA, the MHRA, the EMA  the PDD or other regulatory authorities may disagree. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">87</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">change during the course of a prescription drug product candidate&#8217;s clinical development and may vary among jurisdictions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has not obtained regulatory approval for any prescription drug product candidate and it is possible that none of its existing prescription drug product candidates or any future prescription drug product candidates will ever obtain regulatory approval. The Company could fail to receive regulatory approval for its prescription drug product candidates for many reasons, including, but not limited to failure to demonstrate that a prescription drug product candidate is safe and effective for its proposed indication, failure of clinical trials to meet the level of statistical significance required for approval, failure to demonstrate that a prescription drug product candidate&#8217;s clinical and other benefits outweigh its safety risks, or deficiencies in the manufacturing processes or the failure of facilities of CMOs with whom the Company contracts for clinical and commercial supplies to pass a pre-approval inspection.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">A regulatory authority may require more information, including additional preclinical or clinical data to support approval, which may delay or prevent approval and the Company&#8217;s commercialization plans, or the Company may decide to abandon the development program. If the Company were to obtain approval, regulatory authorities may approve any of its prescription drug product candidates for fewer or more limited indications than the Company request, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a prescription drug product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that prescription drug product candidate. Moreover, depending on any safety issues associated with the Company&#8217;s prescription drug product candidates that garner approval, Health Canada, the FDA, the MHRA, the EMA,the PDD or other regulatory authorities may impose a risk evaluation and mitigation strategy, thereby imposing certain restrictions on the sale and marketability of such products.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">If there are changes in the application of legislation, regulations or regulatory policies, or if problems are discovered with the Company products, or if one of its distributors, licensees or co-marketers fails to comply with regulatory requirements, the regulators could take various actions. These include imposing fines on the Company, imposing restrictions on the Company&#8217;s products or its manufacture and requiring the Company to recall or remove its products from the market. The regulators could also suspend or withdraw the Company&#8217;s Co-marketing authorizations, requiring it to conduct additional clinical trials, change its labeling or submit additional applications for marketing authorization. If any of these events occurs, the Company&#8217;s ability to sell its products may be impaired, and it may incur substantial additional expense to comply with regulatory requirements, which could materially adversely affect its business, financial condition and results of operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Market Access and Acceptance</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company may never have a product that is commercially successful. To date, the Company has no product authorized for marketing. The Company&#8217;s future products require further clinical investigation, regulatory review, significant market access and marketing efforts and substantial investment before it can produce any revenue. Furthermore, if approved, the Company&#8217;s product may not achieve an adequate level of acceptance by payors, health technology assessment bodies, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">88</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">healthcare professionals, patients and the medical community at large, and the Company may not become profitable. The level of acceptance the Company ultimately achieves may be affected by negative public perceptions and historic media coverage of psychedelic substances. Because of this history, efforts to educate the medical community and third-party payors and health technologies assessment bodies on the benefits of company&#8217;s product compounds may require significant resources and may never be successful, which would prevent the Company from generating significant revenue or becoming profitable. Market acceptance of the Company&#8217;s future products by healthcare professionals, patients, healthcare payors and health technology assessment bodies will depend on a number of factors, many of which are beyond the Company&#8217;s control, including, but not limited to, the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">acceptance by healthcare professionals, patients and healthcare payors of each product as safe, effective and cost-effective&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">changes in the standard of care for the targeted indications for any product&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the strength of sales, marketing and distribution support&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">potential product liability claims&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the product&#8217;s relative convenience, ease of use, ease of administration and other perceived advantages over alternatives&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the prevalence and severity of adverse events or publicity&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">limitations, precautions or warnings listed in the summary of product characteristics, patient information leaflet, package labeling or instructions for use&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the cost of treatment with the Company&#8217;s product in relation to alternatives&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the steps that prescribers and dispensers must take, as well as the perceived risks based upon its controlled substance status&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the ability to manufacture the Company&#8217;s product in sufficient quantities and yields with adequate purity&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the availability and amount of coverage and reimbursement from healthcare payors, and the willingness of patients to pay out of pocket in the absence of healthcare payor coverage or adequate reimbursement&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the willingness of the target patient population to try, and of healthcare professionals to prescribe, the product&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">any potential unfavorable publicity, including negative publicity associated with recreational use or abuse of psilocybin, psilocin, DMT-based compounds and other psychedelic compounds&#59; and</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">any restrictions on the use, sale or distribution of the Company&#8217;s future products.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">If the Company&#8217;s future products fail to gain market access and acceptance, this will have a material adverse impact on the Company&#8217;s ability to generate revenue to provide a satisfactory, or any, return on the Company&#8217;s investments. Even if some products achieve market access and acceptance, the market may prove not to be large enough to allow the Company to generate significant revenue.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company must rely largely on its own market research to forecast sales as detailed forecasts are not generally obtainable from other sources at this early stage of the psychedelic industry. A failure in the demand for the Company&#8217;s psychedelic based products to materialize as a result of competition, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">89</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">technological change or other factors could have a material adverse effect on the business, results of operations and financial condition of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Unfavourable Publicity or Consumer Perception</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company believes the psychedelic pharmaceutical industry is highly dependent upon consumer perception regarding the safety, efficacy and quality of psychedelic pharmaceutical products. Consumer perception of the Company&#8217;s psychedelic pharmaceutical products can be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of psychedelics. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favourable to the psychedelic pharmaceutical industry or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favourable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for the Company&#8217;s psychedelic products and the business, results of operations, financial condition and cash flows of the Company. The Company&#8217;s dependence upon consumer perceptions means that adverse scientific research reports, findings, regulatory proceedings, litigation, media attention or other publicity, whether or not accurate or with merit, could have a material adverse effect on the Company, the demand for the Company&#8217;s psychedelic products, and the business, results of operations, financial condition and cash flows of the Company. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of psychedelic products in general, or the Company&#8217;s psychedelic products and services specifically or associating the consumption of psychedelics with illness or other negative effects or events, could have such a material adverse effect. Such adverse publicity reports or other media attention could arise even if the adverse effects associated with such products resulted from consumers&#8217; failure to consume such products legally, appropriately or as directed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The psychedelic medicine industry is highly dependent upon consumer perception regarding the medical benefits, safety, efficacy and quality of the psychedelic medicine distributed for medical purposes to such consumers. There can be no assurance that future scientific research or findings on the medical benefits, viability, safety, efficacy and dosing of psilocybin, psilocin, DMT or isolated constituents, regulatory proceedings, litigation, media attention or other research findings or publicity will be favourable to the industry or the Company or any particular product, or consistent with earlier publicity.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Social Media</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">There has been a marked increase in the use of social media platforms and similar channels that provide individuals with access to a broad audience of consumers and other interested persons. The availability and impact of information on social media platforms is virtually immediate and many social media platforms publish user-generated content without filters or independent verification as to the accuracy of the content posted. Information posted about the Company may be adverse to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">90</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Company&#8217;s interests or may be inaccurate, each of which may harm the Company&#8217;s business, financial condition and results of operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Biotechnology and Pharmaceutical Market Competition</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. The Company&#8217;s competitors include large, well-established pharmaceutical companies, biotechnology companies, and academic and research institutions developing therapeutics for the same indications the Company is targeting and competitors with existing marketed therapies. Many other companies are developing or commercializing therapies to treat the same diseases or indications for which the Company&#8217;s prescription drug product candidates may be useful. Although there are no approved therapies that specifically target opioid addiction, some competitors use therapeutic approaches that may compete directly with the Company&#8217;s prescription drug product candidates.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Many of the Company&#8217;s competitors have substantially greater financial, technical and human resources than the Company does and have significantly greater experience than the Company in conducting preclinical testing and human clinical trials of product candidates, scaling up manufacturing operations and obtaining regulatory approvals of products. Accordingly, the Company&#8217;s competitors may succeed in obtaining regulatory approval for products more rapidly than the Company does. The Company&#8217;s ability to compete successfully will largely depend on&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the efficacy and safety profile of its prescription drug product candidates relative to marketed products and other prescription drug product candidates in development&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the Company&#8217;s ability to develop and maintain a competitive position in the product categories and technologies on which it focuses&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the time it takes for the Company&#8217;s prescription drug product candidates to complete clinical development and receive marketing approval&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the Company&#8217;s ability to obtain required regulatory approvals&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the Company&#8217;s ability to commercialize any of its prescription drug product candidates that receive regulatory approval&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the Company&#8217;s ability to establish, maintain and protect intellectual property rights related to its prescription drug product candidates&#59; and</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">acceptance of any of the Company&#8217;s prescription drug product candidates that receive regulatory approval by physicians and other healthcare providers and payers.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Competitors have developed and may develop technologies that could be the basis for products that challenge the discovery research capabilities of prescription drug product candidates the Company is developing. Some of those products may have an entirely different approach or means of accomplishing the same desired therapeutic effect than the Company&#8217;s prescription drug product candidates and may be more effective or less costly than its prescription drug product candidates. The success of the Company&#8217;s competitors and their products and technologies relative to the Company&#8217;s technological capabilities and competitiveness could have a material adverse effect on the future preclinical studies and clinical trials of the Company&#8217;s prescription drug product candidates, including its ability to obtain the necessary regulatory approvals for the conduct of such clinical trials. This may </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">91</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">further negatively impact the Company&#8217;s ability to generate future product development programs using psychedelic based compounds.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">If the Company is not able to compete effectively against its current and future competitors, the Company&#8217;s business will not grow, and its financial condition and operations will substantially suffer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Further, there can be no assurance that potential competitors of the Company, which may have greater financial, cultivation, production, sales and marketing experience, and personnel and resources than the Company, are not currently developing, or will not in the future develop, products and strategies that are equally or more effective and&#47;or economical as any products or strategies developed by the Company or which would otherwise render the Company&#8217;s business, products and strategies, as applicable, ineffective, or obsolete. Increased competition by larger and better financed competitors could materially and adversely affect the business, financial condition and results of operations of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Reliance on Key Executives and Scientists</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The loss of key members of the Company&#8217;s staff, could harm the Company. The Company does not have employment agreements with all members of its staff, although such employment agreements do not guarantee their retention. The Company also depends on its scientific and clinical collaborators and advisors, all of whom have outside commitments that may limit their availability to the Company. In addition, the Company believes that its future success will depend in large part upon its ability to attract and retain highly skilled scientific, managerial, medical, manufacturing, clinical and regulatory personnel, particularly as the Company expands its activities and seeks regulatory approvals for clinical trials. The Company enters into agreements with its scientific and clinical collaborators and advisors, key opinion leaders and academic partners in the ordinary course of its business. Should key academic and scientific personnel including employees or collaborative partners who work on the development of the Company&#8217;s research activities leave, the Company&#8217;s current and future development programs may be delayed or adversely affected. Notwithstanding these arrangements, the Company faces significant competition for these types of personnel from other companies, research and academic institutions, government entities and other organizations. The Company cannot predict its success in hiring or retaining the personnel it requires for continued growth. In addition, due to limited financial resources, the Company may not be able to successfully expand its operations due to challenges in recruiting and training qualified new staff. Expansion of personnel may result in significant diversion of management time and resources. The loss of the services of any of the Company&#8217;s executive officers or other key personnel could potentially harm its business, operating results or financial condition.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Employee Misconduct</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Notwithstanding having established an insider trading policy and code of ethics and business conduct (see the AIF for further details), the Company is exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include failures to comply with Health Canada, the FDA the MHRA the EMA the PDD, and other comparable international authorities&#8217; regulations, provide accurate information to Health Canada, the FDA the MHRA, the EMA, and&#47;or the PDD provide </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">92</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">accurate information to Health Canada, the FDA, the MHRA, the EMA and the PDD, comply with manufacturing standards the Company has established, comply with federal and provincial healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to the Company. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to the Company&#8217;s reputation. If any such actions are instituted against the Company, and the Company is not successful in defending itself or asserting its rights, those actions could have a substantial impact on the Company&#8217;s business and results of operations, including the imposition of substantial fines or other sanctions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Business Expansion and Growth</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company may in the future seek to expand its pipeline and capabilities by acquiring one or more companies or businesses, entering into collaborations, or in-licensing one or more prescription drug product candidates. Acquisitions, collaborations and in-licences involve numerous risks, including, but not limited to substantial cash expenditures, technology development risks, potentially dilutive issuances of equity securities, incurrence of debt and contingent liabilities, some of which may be difficult or impossible to identify at the time of acquisition, difficulties in assimilating the operations of the acquired companies, entering markets in which the Company has limited or no direct experience, and potential loss of the Company&#8217;s key employees or key employees of the acquired companies or businesses.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has experience in making acquisitions, entering collaborations and in-licensing prescription drug product candidates&#59; however, the Company cannot provide assurance that any acquisition, collaboration or in-licence will result in short-term or long-term benefits to it. The Company may incorrectly judge the value or worth of an acquired company or business or in-licensed prescription drug product candidate. In addition, the Company&#8217;s future success would depend in part on its ability to manage the rapid growth associated with some of these acquisitions, collaborations and in-licences. The Company cannot provide assurance that it would be able to successfully combine its business with that of acquired businesses, manage a collaboration or integrate in-licensed prescription drug product candidates. Furthermore, the development or expansion of the Company&#8217;s business may require a substantial capital investment by the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Negative Results of External Clinical Trials or Studies</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">From time to time, studies or clinical trials on various aspects of breakthrough neuropsychiatry products are conducted by academic researchers, competitors or others. The results of these studies or trials, when published, may have a significant effect on the market for the breakthrough neuropsychiatry product that is the subject of the study. The publication of negative results of studies or clinical trials or adverse safety events related to the Company&#8217;s prescription drug product candidates, or the therapeutic areas in which the Company&#8217;s prescription drug product candidates </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">93</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">compete, could adversely affect its share price and the Company&#8217;s ability to finance future development of its prescription drug product candidates, and its business and financial results could be materially and adversely affected.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Product Liability</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company currently does not carry any product liability insurance coverage. Even though the Company is not aware of any product liability claims at this time, its business exposes itself to potential product liability, recalls and other liability risks that are inherent in the sale of consumer products. The Company can provide no assurance that such potential claims will not be asserted against it. A successful liability claim or series of claims brought against the Company could have a material adverse effect on its business, financial condition and results of operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Although the Company intends to obtain adequate product liability insurance, it cannot provide any assurances that it will be able to obtain or maintain adequate product liability insurance of on acceptable terms, if at all, or that such insurance will provide adequate coverage against potential liabilities. Claims or losses in excess of any product liability cover that may be obtained by the Company could have a material adverse effect on its business, financial conditional and results of operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Some of the Company&#8217;s agreements with third parties might require it to maintain product liability insurance. If the Company cannot obtain acceptable amounts of coverage on commercially reasonable terms in accordance with the terms set forth in these agreements, the corresponding agreements would be subject to termination, which could have a material adverse impact on its operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Enforcing Contracts</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Due to the nature of the business of the Company and the fact that certain of its contracts involve psilocybin&#47;psilocin, the use of which is not legal under Canadian or U.S. federal law and in certain other jurisdictions, the Company may face difficulties in enforcing its contracts in Canadian or U.S. federal and state courts. The inability to enforce any of its contracts could have a material adverse effect on its business, operating results, financial condition or prospects.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In order to manage its contracts with contractors, the Company will ensure that such contractors are appropriately licensed. Were such contractors to operate outside the terms of these licences, the Company may experience an adverse effect on its business, including the pace of development of its product.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Product and Material Recalls</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Manufacturers, producers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety storage deficiencies and inadequate or inaccurate labelling disclosure. If any of the Company&#8217;s products are recalled due to an alleged product defect or for any other reason, the Company could be required to incur the unexpected </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">94</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">expense of the recall and any legal proceedings that might arise in connection with the recall. Company may have to recall material being used in a clinical trial resulting in delays to the trial and additional manufacturing expenses, if further drug product is required. If the product is already commercialized, the Company may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Although the Company&#8217;s suppliers have detailed procedures in place for testing its products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. Additionally, if the Company is subject to recall, the image of the Company could be harmed. A recall for any of the foregoing reasons could lead to decreased demand for the Company&#8217;s products and could have a material adverse effect on the results of operations and financial condition of the Company. Additionally, product recalls may lead to increased scrutiny of the Company&#8217;s operations by regulatory agencies, requiring further management attention, potential loss of applicable licences and potential legal fees and other expenses.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Distribution and Supply Chain Interruption</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company is susceptible to risks relating to distributor and supply chain interruptions. Distribution in the U.S., Canada the EU, the UK and other jurisdictions will be largely accomplished through independent contractors, therefore, an interruption (e.g., a labour strike) for any length of time affecting such independent contractors may have a significant impact on the Company&#8217;s ability to sell or manufacture its products. Supply chain interruptions, including a production or inventory disruption, could impact product quality and availability. Inherent to producing products is a potential for shortages or surpluses in future years if demand and supply are materially different from long-term forecasts. The Company monitors category trends and regularly reviews maturing inventory levels.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Difficulty to Forecast</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company must rely largely on its own market research to forecast sales as detailed forecasts are not generally obtainable from other sources at this early stage of the psychedelic pharmaceutical industry. A failure in the demand for the Company&#8217;s psychedelic pharmaceutical industry products to materialize as a result of competition, technological change or other factors could have a material adverse effect on the business, results of operations and financial condition of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Promoting the Brand</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Promoting the Company&#8217;s brand will be critical to creating and expanding a customer base. Promoting the brand will depend largely on the Company&#8217;s ability to provide psychedelic pharmaceutical products to the market. Further, the Company may, in the future, introduce new products or services that its customers do not like, which may negatively affect the brand and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">95</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">reputation. If the Company fails to successfully promote its brand or if it incurs excessive expenses in this effort, its business and financial results from operations could be materially adversely affected. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">If there are changes in the applicable regulatory framework governing the promotion, branding and marketing of the Company&#8217;s products, the Company&#8217;s ability to promote and sell its products may be impaired, and it may incur substantial additional expense to comply with regulatory requirements, which could materially adversely affect its business, financial condition and results of operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Product Viability</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">If the Company&#8217;s psychedelic pharmaceutical products are not perceived to have the effects intended by the end user, the Company&#8217;s business may suffer. In general, psychedelic pharmaceutical products have minimal long-term data with respect to efficacy, unknown side effects and&#47;or interaction with individual human biochemistry or other supplements or medications. As a result, the Company&#8217;s psychedelic pharmaceutical products could have certain side effects if not used as directed or if taken by an end user that has certain known or unknown medical conditions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Success of Quality Control Systems</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The quality and safety of the Company&#8217;s products are critical to the success of its business and operations. As such, it is imperative that the Company (and its service providers&#8217;) quality control systems operate effectively and successfully. Quality control systems can be negatively impacted by the design of the quality control systems, the quality of training programs and adherence by employees to quality control guidelines. Any significant failure or deterioration of such quality control systems could have a material adverse effect on the Company&#8217;s business and operating results.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Reliance on Key Inputs</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s business is expected to be dependent on a number of key inputs and their related costs including raw materials and supplies. Any significant interruption or negative change in the availability or economics of the supply chain for key inputs could materially impact the business, financial condition and operating results of the Company. Any inability to secure required supplies and services or to do so on appropriate terms could have a materially adverse impact on the business, financial condition and operating results of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Liability Arising from Fraudulent or Illegal Activity</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company is exposed to the risk that its employees, independent contractors, consultants, service providers and licensors may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional undertakings of unauthorized activities, or reckless or negligent undertakings of authorized activities, in each case on the Company&#8217;s behalf or in its service that violate (i) various laws and regulations, including healthcare laws and regulations, (ii) laws that require the true, complete and accurate reporting of financial information or data, (iii) the terms of the Company&#8217;s agreements with third parties. Such misconduct could expose the Company to, among other things, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">96</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">class actions and other litigation, increased regulatory inspections and related sanctions, and lost sales and revenue or reputational damage.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The precautions taken by the Company to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting the Company from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Such misconduct may result in legal action, significant fines or other sanctions and could result in loss of any regulatory licence held by the Company at such time. The Company may be subject to security breaches at its facilities or in respect of electronic document or data storage, which could lead to breaches of applicable privacy laws and associated sanctions or civil or criminal penalties&#59; events, including those beyond the control of the Company, may damage its operations. In addition, these events may negatively affect customers&#8217; demand for the Company&#8217;s products. Such events include, but are not limited to, non-performance by third party contractors&#59; increases in materials or labour costs&#59; breakdown or failure of equipment&#59; failure of quality control processes&#59; contractor or operator errors&#59; and major incidents and&#47;or catastrophic events such as fires, explosions, earthquakes or storms. As a result, there is a risk that the Company may not have the capacity to meet customer demand or to meet future demand when it arises. Failure to comply with health and safety laws and regulations may result in additional costs for corrective measures, penalties or in restrictions on the Company&#8217;s manufacturing operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Operating Risk and Insurance Coverage</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has directors and officers insurance to protect its assets, operations and employees. The Company&#8217;s insurance is subject to coverage limits and exclusions and may not be available for the risks and hazards to which the Company is expected to be exposed. In addition, no assurance can be given that such insurance will be adequate to cover the Company&#8217;s liabilities or will be generally available in the future, or if available, that premiums will be commercially justifiable. If the Company were to incur substantial liability and such damages were not covered by insurance or were in excess of policy limits, or if the Company were to incur such liability at a time when it is not able to obtain liability insurance, its business, results of operations and financial condition could be materially adversely affected.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Costs of Operating as Public Company</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">As a public company, the Company will incur significant legal, accounting and other expenses. As a public company, the Company is subject to various securities rules and regulations, which impose various requirements on the Company, including the requirement to establish and maintain effective disclosure and financial controls and corporate governance practices. The Company&#8217;s management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase the Company&#8217;s legal and financial compliance costs and make some activities more time-consuming and costly.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">97</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Management of Growth</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company may be subject to growth-related risks, including capacity constraints and pressure on its internal systems and controls. The ability of the Company to manage growth effectively will require it to continue to implement and improve its operational and financial systems and to expand, train and manage its employee base. The inability of the Company to deal with this growth may have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and prospects.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Conflicts of Interest</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company may be subject to various potential conflicts of interest because of the fact that some of its officers and directors may be engaged in a range of business activities. The Company&#8217;s executive officers and directors may devote time to their outside business interests, so long as such activities do not materially or adversely interfere with their duties to the Company. In some cases, the Company&#8217;s executive officers and directors may have fiduciary obligations associated with these business interests that interfere with their ability to devote time to the Company&#8217;s business and affairs and that could adversely affect the Company&#8217;s operations. These outside business interests could require significant time and attention of the Company&#8217;s executive officers and directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In addition, the Company may also become involved in other transactions which conflict with the interests of its directors and the officers who may from time-to-time deal with persons, firms, institutions or companies with which the Company may be dealing, or which may be seeking investments similar to those desired by it. The interests of these persons could conflict with those of the Company, and from time to time, these persons may be competing with the Company for available investment opportunities.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Conflicts of interest, if any, will be subject to the procedures and remedies provided under applicable laws. In particular, in the event that such a conflict of interest arises at a meeting of the Company&#8217;s directors, a director who has such a conflict will abstain from voting for or against the approval of such participation or such terms. In accordance with applicable laws, the Board is required to act honestly, in good faith and in the best interests of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Foreign Operations</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In addition to operations carried out in Canada and the UK, the Company intends to carry out international operations through an office in Ireland. As a result, the Company may be subject to political, economic and other uncertainties, including, but not  limited  to, additional implications that may have a material impact on the Company&#8217;s ability to operate in other jurisdictions including&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">differences in the regulatory requirements for drug approvals&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">differing requirements for securing, maintaining or obtaining freedom to operate&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">the potential for reduced protection for intellectual property rights&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">challenges with compliance to different regulations and court systems of multiple jurisdictions and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">98</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">compliance with a wide variety of foreign laws, treaties and regulations&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">differing reimbursement regimes and price controls in certain international markets&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">differing labor relations that create challenges with staffing and managing international operations&#59; and</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">impacts on manufacturing capabilities leading to production shortages.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s international operations may also be adversely affected by laws and policies of Canada affecting foreign trade, taxation and investment. In the event  of  a  dispute  arising  in  connection  with  its  foreign  operations,  the Company  may  be  subject  to  the  exclusive  jurisdiction of foreign courts or may not be successful in subjecting foreign persons to the jurisdiction of courts in Canada or enforcing Canadian judgments in foreign jurisdictions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Similarly, to the extent that the Company&#8217;s assets are located outside of Canada, investors may have difficulty collecting from the Company any judgments obtained in the Canadian courts and predicated on the civil liability provisions of securities laws. Consequently, investors may be effectively prevented from pursuing remedies against the Company under Canadian securities laws or otherwise. The Company may also be hindered or prevented from enforcing its rights with respect to a governmental entity or instrumentality because of the doctrine of sovereign immunity.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Exchange Rate Fluctuations</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Due to the international scope of the Company&#8217;s current and future operations, the Company&#8217;s assets, future earnings and cash flows may be influenced by movements in exchange rates of several currencies, particularly the British Pound, the U.S. dollar, Canadian Dollar and the Euro. The Company&#8217;s reporting currency is denominated in Canadian dollars and the Company&#8217;s functional currency is the Canadian dollar and the majority of the Company&#8217;s operating expenses are paid in Canadian dollars. The Company may also regularly acquire services, consumables and materials in British Pounds, U.S. dollars, Canadian dollars and other currencies. Further, future revenue may be derived from abroad. As a result, the Company&#8217;s business and the price of the Company&#8217;s products may be affected by fluctuations in foreign exchange rates between the British Pound, the U.S. dollar, the Canadian dollar and other currencies, which may also have a significant impact on the Company&#8217;s results of operations and cash flows from period to period. Currently, the Company does not have any exchange rate hedging arrangements in place.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Cybersecurity and Privacy Risk</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s information systems and any third-party service providers and vendors are vulnerable to an increasing threat of continually evolving cybersecurity risks. These risks may take the form of malware, computer viruses, cyber threats, extortion, employee error, malfeasance, system errors or other types of risks, and may occur from inside or outside of the respective organizations. Cybersecurity risk is increasingly difficult to identify and quantify and cannot be fully mitigated because of the rapidly evolving nature of the threats, targets and consequences. Additionally, unauthorized parties may attempt to gain access to these systems through fraud or other means of deceiving third-party service providers, employees or vendors. The Company&#8217;s operations depend, in part, on how well networks, equipment, IT systems and software are protected against damage from a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">99</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">number of threats. These operations also depend on the timely maintenance, upgrade and replacement of networks, equipment, IT systems and software, as well as pre-emptive expenses to mitigate the risks of failures. However, if the Company is unable or delayed in maintaining, upgrading or replacing IT systems and software, the risk of a cybersecurity incident could materially increase. Any of these and other events could result in information system failures, delays and&#47;or increases in capital expenses. The failure of information systems or a component of information systems could, depending on the nature of any such failure, adversely impact the Company&#8217;s reputation and results of operations. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company may collect and store certain personal information about customers and are responsible for protecting such information from privacy breaches. A privacy breach may occur through procedural or process failure, information technology malfunction, or deliberate unauthorized intrusions. In addition, theft of data is an ongoing risk whether perpetrated via employee collusion or negligence or through deliberate cyber-attack. Any such privacy breach or theft could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In addition, there are a number of laws protecting the confidentiality of certain patient health information, including patient records, and restricting the use and disclosure of that protected information. In particular, the privacy rules under the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">Personal Information Protection and Electronics Documents Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%"> (Canada) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">PIPEDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8221;) and where applicable, provincial legislation governing personal health information, protect medical records and other personal health information by limiting their use and disclosure of health information to the minimum level reasonably necessary to accomplish the intended purpose. If the Company were found to be in violation of the privacy or security rules under PIPEDA or other laws protecting the confidentiality of medical patients health information, the Company could be subject to sanctions and civil or criminal penalties, which could increase its liabilities, harm its reputation and have a material adverse effect on the Company&#8217;s business, financial condition and results of operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Environmental Regulation and Risks</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s operations are subject to environmental regulations that mandate, among other things, the maintenance of air and water quality standards and land reclamation. They also set forth limitations on the generation, transportation, storage and disposal of solid and hazardous waste. Environmental legislation is evolving in a manner which could include stricter standards and enforcement, increased fines and penalties for non-compliance, more stringent environmental assessments of proposed projects and a heightened degree of responsibility for companies and their officers, directors and employees. There is no assurance that future changes in environmental regulation, if any, will not adversely affect the Company&#8217;s operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Failure to comply with applicable laws, regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment, or remedial actions. The Company may be required to compensate those suffering loss or damage by reason of its operations and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">100</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Amendments to current laws, regulations and permits governing psychedelics and related products, or more stringent implementation thereof, could have a material adverse impact on the Company and cause increases in expenses, capital expenditures or production costs or reduction in levels of production or require abandonment or delays in development.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Decriminalization of Psychedelics</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Despite the current status of many psychotropic substances as a Schedule II and Schedule I controlled substances in the United States and Canada, respectively, there may be changes in the status of some of these substances under the laws of certain jurisdictions. Possession of psilocybin, for example, was voted to be decriminalized in May 2019 in Denver and in November 2020, voters in Oregon approved the legal medical use of &#8220;psilocybin products,&#8221; including magic mushrooms, to treat mental health conditions in licensed facilities with registered therapists (Measure 109). The legalization of psychedelics with inadequate regulatory oversight may lead to the development of psychotropic tourism in such states in clinics without proper therapeutic infrastructure or adequate clinical research. The expansion of such an industry which could put patients at risk may bring reputational and regulatory risk to the entire industry, leading to challenges for the Company to achieve regulatory approval. The legalization of psilocybin, psilocin, DMT,and potentially other psychotropic compounds in the future may also impact commercial sales for the Company due to a reduced barrier to entry leading to a risk of increasing competition.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Forward-Looking Statements May Prove to be Inaccurate </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Investors should not place undue reliance on forward-looking statements. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, of both general and specific nature, that could cause actual results to differ materially from those suggested by the forward-looking statements or contribute to the possibility that predictions, forecasts or projections will prove to be materially inaccurate.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Effects of Inflation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Global markets have experienced increased rates of inflation. Inflation itself, as well as certain governmental efforts to combat inflation, may have significant negative effects on any economy which the Company does business. Past governmental efforts to curb inflation have involved certain drastic economic measures, which had a materially adverse impact on the level of economic activity in these countries. Any future economic measures to curb inflation could be expected to have similar adverse effects on the level of economic activity in the market which the Company does business and, in turn, on the operations of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">101</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Political and Economic Conditions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Political and economic conditions directly affect the Company&#8217;s business and can result in a material adverse effect on the Company. Macroeconomic policies imposed by foreign governments could have significant impact on the Company. As certain global markets experience increased inflation, certain government actions to control inflation may have significant impact on the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company cannot control or predict foreign government implementation of changes to existing policies that may impact the Company&#8217;s operations in foreign markets and, consequently, its business. The Company&#8217;s business, operating results and financial condition and prospects, as well as the market price of its securities, may be adversely affected by changes in government public policies, whether federal, state or local, that affect, without limitation&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">inflation&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">fluctuations in exchange rates&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">exchange controls and restrictions on remittances abroad&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">interest rates and monetary policies&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">import and export controls&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">liquidity of domestic capital, credit and financial markets&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">expansion or contraction of foreign economies, as measured by rates of growth in gross domestic product&#59;</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">fiscal policies&#59; and</font></div><div style="padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;padding-left:12.38pt">other political, social and economic developments in or affecting foreign markets.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Government policies and measures to combat inflation, along with public speculation about such policies and measures, have often had adverse effects on global economies, have contributed to economic uncertainty and may increase volatility in foreign securities markets. Government action to control inflation may involve actions such as price and salary controls, currency devaluations, capital limitations, limits on imports and other actions which could significantly impact the operations of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Other policies and measures adopted by governments, include interest rate adjustments, intervention in the currency markets or actions to adjust or fix the value of the local currency may adversely affect the target market&#8217;s economy, the Company&#8217;s business and results of operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Uncertainty over whether federal governments will implement reforms or changes in policy or regulation affecting these or other factors in the future may affect economic performance and contribute to economic uncertainty in markets that the Company operates or relies on, which may in turn have adverse effects on the Company&#8217;s operations in the market and consequently on the results of its operations. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Application and Interpretation of Tax Laws</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company is subject to direct and indirect taxes in various foreign jurisdictions. The amount of tax that the Company pays, directly or indirectly, is subject to the interpretation of applicable tax laws in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">102</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">the jurisdictions of operations in which the Company has interests. The Company has taken and will continue to take tax positions based on the application and interpretation of tax laws, but tax accounting often involves complex matters and judgment is required in determining the Company&#8217;s foreign provisions for taxes and other tax liabilities. There can be no assurance that a taxing authority will not have a different interpretation of the law and assess the Company, or the operations in which the Company has interests, with additional taxes. Further, the Company&#8217;s future effective tax rates could be impacted by changes in tax laws or regulations, and changing interpretation of existing laws or regulations. Both domestic and international tax laws, and interpretation of the tax laws, are subject to change as a result of changes in fiscal policy, changes in legislation, evolution of regulation and court rulings. The application of these tax laws and related regulations is subject to legal and factual interpretation, judgment and uncertainty.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Enforcement of Civil Liabilities</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Certain of the Company&#8217;s subsidiaries and assets are located outside of Canada. Accordingly, it may be difficult for investors to enforce within Canada any judgments obtained against the Company, including judgments predicated upon the civil liability provisions of applicable Canadian securities laws or otherwise. Consequently, investors may be effectively prevented from pursuing remedies against the Company under Canadian securities laws or otherwise.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has subsidiaries incorporated in the United States and Ireland. It may not be possible for shareholders to effect service of process outside of Canada against the directors and officers of the Company who are not resident in Canada. In the event a judgment is obtained in a Canadian court against one or more of such persons for violations of Canadian securities laws or otherwise, it may not be possible to enforce such judgment against persons not resident in Canada. Additionally, it may be difficult for an investor, or any other person or entity, to assert Canadian securities law or other claims in original actions instituted in the United States and Ireland. Courts in such jurisdictions may refuse to hear a claim based on a violation of Canadian securities laws or otherwise on the grounds that such jurisdiction is not the most appropriate forum to bring such a claim. Even if a foreign court agrees to hear a claim, it may determine that the local law, and not Canadian law, is applicable to the claim. If Canadian law is found to be applicable, the content of applicable Canadian law must be proven as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be governed by foreign law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Pandemics, Epidemics and Other Health Risks</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Pandemics, epidemics and other health risks could have an adverse effect on the Company&#8217;s business. Pandemics, epidemics and other health risks could occur, which could adversely affect the Company&#8217;s ability to conduct its operations as currently conducted, or the ability of suppliers to provide the Company with products and services needed to operate the business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Pandemics, epidemics and other health risks could have an adverse effect on the economy and financial markets, resulting in a decline of commercial activity. Any of these events could have an adverse effect on the Company&#8217;s business and financial performance.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">103</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Risks Related to Intellectual Property</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Trademark Protection</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Failure to register trademarks for the Company or its products could require the Company to rebrand its products resulting in a material adverse impact on its business.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Trade Secrets</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company relies on third parties to develop its products and, as a result, must share trade secrets with them. The Company seeks to protect its proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with its collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically restrict the ability of the Company&#8217;s collaborators, advisors, employees and consultants to publish data potentially relating to its trade secrets. Its academic and clinical collaborators typically have rights to publish data, provided that the Company is notified in advance and may delay publication for a specified time in order to secure any intellectual property rights arising from the collaboration. In other cases, publication rights are controlled exclusively by the Company, although in some cases the Company may share these rights with other parties. The Company may also conduct joint research and development programs which may require it to share trade secrets under the terms of research and development collaboration or similar agreements. Despite the Company&#8217;s efforts to protect its trade secrets, the Company&#8217;s competitors may discover its trade secrets, either through breach of these agreements, independent development or publication of information. A competitor&#8217;s discovery of the Company&#8217;s trade secrets may impair its competitive position and could have a material adverse effect on its business and financial condition.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Patent Law Reform</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The Company&#8217;s commercial success depends in part on obtaining and maintaining patents and other forms of intellectual property rights for its current and future therapeutic candidates and associated therapies, digital therapies, methods used to manufacture the underlying therapeutic substances, and the methods for treating patients using those substances and therapies, or on licensing in such rights. Failure to obtain, maintain, protect, enforce or extend adequate patent and other intellectual property rights could materially adversely affect the Company&#8217;s ability to develop and market its current and future therapeutic candidates. The Company also relies on trade secrets and know-how to develop and maintain its proprietary and intellectual property position. Any failure to protect its trade secrets and know-how could adversely affect the Company&#8217;s operations and prospects.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The Company cannot be certain that patents will be issued or granted with respect to patent applications that are currently pending, or that issued or granted patents will not later be found to be invalid or unenforceable. The patent position of companies like the Company is generally uncertain because it involves complex legal and factual considerations. The standards applied by the UK Intellectual Property Office, the European Patent Office, the USPTO, the Canadian Intellectual Property Office (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:130%">CIPO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8221;) and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in pharmaceutical patents. Consequently, patents may </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">104</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">not issue from the Company&#8217;s pending patent applications, and even if they do issue, such patents may not issue in a form that effectively prevents others from developing or commercializing competing therapies. As such, the Company does not know the degree of future protection that it will have on its proprietary therapies.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The patent prosecution process is expensive, complex and time-consuming, and the Company, its current or future third-party partners, licensors, licensees, or collaboration partners may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that the Company or its licensors, licensees or collaboration partners will fail to identify patentable aspects of inventions made in the course of research, development or commercialization activities before it is too late to pursue patent protection on them. In addition, although the Company enters into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of its R&#38;D output, such as its employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing the Company&#8217;s ability to seek patent protection. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the UK and other jurisdictions are typically not published until 18 months after filing, or in some cases not published until and unless granted. Therefore, the Company cannot be certain that it is the first to make the inventions claimed in its patents or pending patent applications, or that it was the first to file for patent protection of such inventions. Similarly, the Company cannot be certain that for any licensed patents or pending patent applications, the named applicant(s) were the first to make the inventions claimed in such patents or pending patent applications or that the named applicant(s) were the first to file for patent protection for such inventions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Further, the issuance, scope, validity, enforceability and commercial value of the Company&#8217;s and its current or future licensors&#8217;, licensees&#8217; or collaboration partners&#8217; patent rights are highly uncertain. The Company and any potential licensors&#8217; pending and future patent applications may not result in patents being issued that protect the Company&#8217;s therapies, in whole or in part, or that effectively prevent others from commercializing competitive technologies and therapies.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Moreover, in some circumstances, the Company may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain such patents, should the Company&#8217;s license technology from or to third parties and would be reliant on its licensors, licensees or collaboration partners. If the Company engages with licensors, licensees or collaboration partners and they fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If such licensors, licensees or collaboration partners were not fully cooperative or disagree with the Company as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The patent examination process may require the Company or its licensors, licensees or collaboration partners to narrow the scope of the claims of the Company or the Company&#8217;s licensors&#8217;, licensees&#8217; or collaboration partners&#8217; pending and future patent applications, which may limit the scope of patent protection that may be obtained. The Company cannot guarantee that all of the potentially relevant prior art relating to its patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">105</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and the Company&#8217;s patents may be challenged in the courts or patent offices in the UK and abroad. Even if patents do successfully issue and even if such patents cover the Company&#8217;s current and future therapeutic candidates, third parties may initiate an opposition, interference, re-examination, post-grant review, inter parties review, nullification or derivation proceedings in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">The Company and the Company&#8217;s licensors&#8217;, licensees&#8217; or collaboration partners&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology. In addition, patents and other intellectual property rights also will not protect the Company&#8217;s current and any future therapeutic candidates if third parties, including the Company&#8217;s competitors, design around the Company&#8217;s protected technology and the Company&#8217;s current and any future therapeutic candidates without infringing, misappropriating or otherwise violating the Company&#8217;s patents or other intellectual property rights. Moreover, some of the Company&#8217;s patents and patent applications may in the future be co-owned with third parties. If the Company is unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including the Company&#8217;s competitors, and the Company&#8217;s competitors could market competing therapies and technology. In addition, the Company may need the cooperation of any such co-owners of its patents in order to enforce such patents against third parties, and such cooperation may not be provided. Any of the foregoing could have a material adverse effect on the Company&#8217;s competitive position, business, financial conditions, results of operations, and prospects.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Because patent applications are confidential for a period of time after filing, and some remain so until issued, the Company cannot be certain that the Company or its current or future licensors, licensees or collaborators were or will be the first to file any patent application related to a therapeutic candidate. Even where the Company has a valid and enforceable patent, it may not be able to exclude others from practicing the Company&#8217;s invention where the other party can show that they used the invention in commerce before the Company&#8217;s filing date or the other party benefits from a compulsory license. In addition, the Company may be subject to third-party challenges regarding the Company&#8217;s exclusive ownership of the Company&#8217;s intellectual property. If a third party were successful in challenging the Company&#8217;s exclusive ownership of any of the Company&#8217;s intellectual property, the Company may lose its right to use such intellectual property, such third party may be able to license such intellectual property to other third parties, including the Company&#8217;s competitors, and the Company&#8217;s competitors could market competing therapies and technology. Any of the foregoing could have a material adverse effect on the Company&#8217;s competitive position, business, financial conditions, results of operations, and prospects.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">As is the case with other biotechnology and pharmaceutical companies, the Company&#8217;s success is heavily dependent on intellectual property rights, particularly patents. Obtaining and enforcing patents in the breakthrough neuropsychiatry industry is a technologically and legally complex process, and obtaining and enforcing breakthrough neuropsychiatry patents is costly, time consuming and inherently uncertain. Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of the Company&#8217;s and its licensors&#8217; or collaborators&#8217; patent applications and the enforcement or defense of the Company or its licensors&#8217; or collaborators&#8217; issued patents.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">106</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Patent Litigation and Intellectual Property</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has filed a number of provisional patent applications but even if regular patent applications are filed claiming priority to one or more of the provisional patent applications, there can be no assurance that any or all of these patent applications will issue into a valid patent. Such failure to issue could have a material adverse effect on the Company. In the event that a patent issued to the Company is challenged, any of the Company&#8217;s patents may be invalidated. The Company could also become involved in interference or impeachment proceedings in connection with one or more of its patents or patent applications to determine priority of invention.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Patent litigation is widespread in the pharmaceutical industry and the Company cannot predict how this will affect its efforts to form strategic alliances, conduct clinical testing, or manufacture and market any of its prescription drug product candidates that it may successfully develop. If the Company becomes involved in any litigation, interference, impeachment or other administrative proceedings, it will likely incur substantial expenses and the efforts of its technical and management personnel will be significantly diverted. The Company cannot make any assurances that it will have the financial or other resources necessary to enforce or defend a patent infringement or proprietary rights violation action. Moreover, if the Company&#8217;s products infringe patents, trademarks or proprietary rights of others, it could, in certain circumstances, become liable for substantial damages, which also could have a material adverse effect on the business of the Company, its financial condition and results of operation. Patent litigation is less likely during development as many jurisdictions contain exemptions from patent infringement for the purpose of obtaining regulatory approval of a product. Where there is any sharing of patent rights either through co-ownership or different licensed &#8220;fields of use&#8221;, one owner&#8217;s actions could lead to the invalidity of the entire patent. If the Company is unable to avoid infringing the patent rights of others, the Company may be required to seek a licence, defend an infringement action or challenge the validity of the patents in court. Such results could have a material adverse effect on the Company. Regardless of the outcome, patent litigation is costly and time consuming. In some cases, the Company may not have sufficient resources to bring these actions to a successful conclusion, and, even if the Company is successful in these proceedings, it may incur substantial costs and divert management time and attention in pursuing these proceedings, which could have a material adverse effect on the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Any infringement or misappropriation of the Company&#8217;s intellectual property could damage its value and limit its ability to compete. In addition, the Company&#8217;s ability to enforce and protect its intellectual property rights may be limited in certain countries outside the U.S., which could make it easier for competitors to capture market position in such countries by utilizing technologies that are similar to those developed or licensed by the Company. Competitors may also harm the Company&#8217;s sales by designing products that mirror the capabilities of its products or technology without infringing on its intellectual property rights. If the Company does not obtain sufficient protection for its intellectual property, or if it is unable to effectively enforce its intellectual property rights, its competitiveness could be impaired, which would limit its growth and future revenue. The Company may also find it necessary to bring infringement or other actions against third parties to seek to protect its intellectual property rights. Litigation of this nature, even if successful, is often expensive and time- consuming to prosecute and there can be no assurance that the Company will have the financial or other resources to enforce its rights or be able to enforce its rights or prevent other parties from developing similar technology or designing around its intellectual property.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">107</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company is not aware of any infringement by it of any person&#8217;s or entity&#8217;s intellectual property rights. In the event that products sold by the Company are deemed to infringe upon the patents or proprietary rights of others, the Company could be required to modify its products or obtain a licence for the manufacture and&#47;or sale of such products or cease selling such products. In such event, there can be no assurance that the Company would be able to do so in a timely manner, upon acceptable terms and conditions, or at all, and the failure to do any of the foregoing could have a material adverse effect upon the Company&#8217;s business. If the Company&#8217;s products or proposed products are deemed to infringe or likely to infringe upon the patents or proprietary rights of others, the Company could be subject to injunctive relief and, under certain circumstances, become liable for damages, which could also have a material adverse effect on the Company&#8217;s business and its financial condition.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Protection of Intellectual Property</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company will be able to protect its intellectual property from unauthorized use by third parties only to the extent that the Company&#8217;s proprietary technologies, key products and any future products are covered by valid and enforceable intellectual property rights including patents or are effectively maintained as trade secrets and provided the Company has the funds to enforce its rights, if necessary.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">To protect the Company&#8217;s competitive position, the Company may from time to time need to resort to litigation in order to enforce or defend any patents or other intellectual property rights owned by or licensed to the Company from time to time, or to determine or challenge the scope or validity of patents or other intellectual property rights of third parties. Enforcement of intellectual property rights is difficult, unpredictable and expensive, and many of the Company&#8217;s or the Company&#8217;s licensors&#8217; or collaboration partners&#8217; adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than the Company or the Company&#8217;s licensors or collaboration partners can. Accordingly, despite the Company&#8217;s or the Company&#8217;s licensors&#8217; or collaboration partners&#8217; efforts, the Company or the Company&#8217;s licensors or collaboration partners may not prevent third parties from infringing upon, misappropriating or otherwise violating intellectual property rights. In the event that products sold by the Company own or control, particularly in countries where the laws may not protect those rights as fully as in the UK, EU, the US and Canada. The Company may fail in enforcing its rights, in which case the Company&#8217;s competitors and other third parties may be permitted to use the Company&#8217;s therapies without payment to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">In addition, litigation involving the Company&#8217;s licensed patents carries the risk that one or more of the Company&#8217;s licensed patents will be narrowed, held invalid (in whole or in part, on a claim-by-claim basis) or held unenforceable. Such an adverse court ruling could allow third parties to commercialize the Company&#8217;s therapies, and then compete directly with the Company, without payment to the Company. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">If the Company were to initiate legal proceedings against a third party to enforce a patent covering one of the Company&#8217;s investigational therapies, the defendant could counterclaim that the Company&#8217;s patent is invalid or unenforceable. In patent litigation in the UK, EU, the US or Canada, defendant counterclaims alleging invalidity or unenforceability are commonplace. A claim for a validity challenge may be based on failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. A claim for unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the UK Intellectual Property Office, European Patent Office, the USPTO, the CIPO or made a misleading </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">108</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">statement, during prosecution. Third parties may also raise challenges to the validity of the Company&#8217;s patent claims before administrative bodies in the US or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (i.e., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to the Company&#8217;s patents in such a way that they no longer cover the Company&#8217;s current or any future therapeutic candidates. The outcome following legal assertions of invalidity and unenforceability during patent litigation or other proceedings is unpredictable. With respect to the validity question, for example, the Company cannot be certain that there is no invalidating prior art, of which the Company and the patent examiner were unaware during prosecution. If a defendant or third party were to prevail on a legal assertion of invalidity or unenforceability, the Company would lose at least part, and perhaps all, of the patent protection on the Company&#8217;s current or one or more of any future therapeutic candidates. Such a loss of patent protection could have a material adverse impact on the Company&#8217;s business financial condition, results of operations, and prospects. Further, litigation could result in substantial costs and diversion of management resources, regardless of the outcome, and this could harm the Company&#8217;s business and financial results.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Third-Party Licences</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">A substantial number of patents have already been issued to other biotechnology and pharmaceutical companies. To the extent that valid third-party patent rights cover the Company&#8217;s products or services, the Company or its strategic collaborators would be required to seek licences from the holders of these patents in order to manufacture, use or sell these products and services and payments under them would reduce the Company&#8217;s profits from these products and services. The Company is currently unable to predict the extent to which it may wish or be required to acquire rights under such patents, the availability and cost of acquiring such rights and whether a licence to such patents will be available on acceptable terms or at all. There may be patents in the U.S. or in foreign countries or patents issued in the future that are unavailable to licence on acceptable terms. The Company&#8217;s inability to obtain such licences may hinder or eliminate its ability to manufacture and market its products.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Further, if the Company obtains third-party licences but fails to pay annual maintenance fees, development and sales milestones, or it is determined that the Company does not use commercially reasonable efforts to commercialize licensed products, the Company could lose its licences which could have a material adverse effect on its business and financial condition.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">Periodic maintenance and annuity fees on any issued patent are due to be paid to the UK Intellectual Property Office, the European Patent Office, the USPTO, the CIPO and foreign patent agencies in several stages over the lifetime of the patent. The European Patent Office, the USPTO, the CIPO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, the Company may rely on collaboration partners to pay these fees due to US and comparable foreign patent agencies and take the necessary action to comply with such requirements with respect to the Company&#8217;s intellectual property. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">109</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If the Company, its licensors or collaboration partners fail to maintain the patents and patent applications covering the Company&#8217;s investigational therapies, third parties, including its competitors might be able to enter the market with similar or identical therapies or technologies, which would have a material adverse effect on the Company&#8217;s business, financial condition, results of operations, and prospects.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Financial and Accounting Risks</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Substantial Number of Authorized but Unissued Common Shares</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has an unlimited number of Common Shares that may be issued by the Board without further action or approval of the Shareholders. While the Board will be required to fulfill its fiduciary obligations in connection with the issuance of such Common Shares, the Common Shares may be issued in transactions with which not all of the shareholders of the Company agree, and the issuance of such Common Shares will cause dilution to the ownership interests of the shareholders of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Dilution</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company may issue additional Common Shares in subsequent offerings (including through the sale of securities convertible into or exchangeable for Common Shares) and on the exercise of stock options or other securities exercisable for Common Shares. The Company cannot predict the size of future issuances of Common Shares or the effect that future issuances and sales of Common Shares will have on the market price of the Common Shares. Issuances of a substantial number of additional Common Shares, or the perception that such issuances could occur, may adversely affect prevailing market prices for the Common Shares. With any additional issuance of Common Shares, investors will suffer dilution to their voting power and the Company may experience dilution in its earnings per share.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Negative Cash Flow from Operating Activities</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company has had negative cash flow from operating activities since inception. Drug development involves long lead times, is very expensive and involves many variables of uncertainty.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">As such, significant capital investment will be required to achieve the Company&#8217;s existing plans. The Company&#8217;s net losses have had and will continue to have an adverse effect on, among other things, shareholder equity, total assets and working capital. The Company expects that losses may fluctuate from quarter to quarter and year to year, and that such fluctuations may be substantial based on the stage of development of its principal programs. The Company cannot predict when it will become profitable, if at all. Accordingly, the Company may be required to obtain additional financing in order to meet its future cash commitments. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">110</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Additional Capital Requirements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">As a research and development company, the Company expects to spend substantial funds to continue the research, development and testing of its prescription drug product candidates and to prepare to commercialize products subject to applicable regulatory approval. Substantial additional financing may be required if the Company is to be successful in continuing to develop its business and its products. No assurances can be given that the Company will be able to raise the additional capital that it may require for its anticipated future development. Any additional equity financing may be dilutive to investors and debt financing, if available, may involve restrictions on financing and operating activities. There is no assurance that additional financing will be available on terms acceptable to the Company, if at all. If the Company is unable to obtain additional financing as needed, it may be required to reduce the scope of its operations or anticipated expansion. The Company&#8217;s ability to successfully raise additional capital and maintain liquidity may by impaired by factors outside of its control, such as a shift in consumer attitudes towards certain therapeutic methods or a downturn in the economy.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Heightened regulatory scrutiny could have a negative impact on the Company&#8217;s ability to raise capital. The Company&#8217;s business activities rely on developing laws and regulations in multiple jurisdictions. It is impossible to determine the extent of the impact of any new laws, regulations or initiatives that may be proposed, or whether any proposals will become law. The regulatory uncertainty surrounding the Company&#8217;s current or any future products may adversely affect the Company&#8217;s business and operations, including without limitation, the Company&#8217;s ability to raise additional capital.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">In addition, the Company may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving its business objectives. The Company will eventually need to transition from a company with a development focus to a company capable of supporting commercial activities. The Company may not be successful in such a transition.</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Lack of Significant Product Revenue</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">To date, the Company has generated little product revenue and cannot predict when and if it will generate significant product revenue. The Company&#8217;s ability to generate significant product revenue and ultimately become profitable depends upon its ability, alone or with partners, to successfully develop its prescription drug product candidates, obtain regulatory approval and commercialize products, including any of its current prescription drug product candidates or other prescription drug product candidates that it may develop, in-license or acquire in the future. The Company does not anticipate generating revenue from the sale of products for the foreseeable future. The Company expects its research and development expenses to increase in connection with its ongoing activities, particularly as it advances its prescription drug product candidates through clinical trials.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Estimates or Judgments Relating to Critical Accounting Policies</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The preparation of Financial Statements in conformity with the International Financial Reporting Standards requires management to make estimates and assumptions that affect the amounts reported </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">111</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">in the Financial Statements and accompanying notes. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, as provided in the notes to the Financial Statements, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. The Company&#8217;s operating results may be adversely affected if the assumptions change or if actual circumstances differ from those in the assumptions, which could cause its operating results to fall below the expectations of securities analysts and investors, resulting in a decline in the share price of the Company. Significant assumptions and estimates used in preparing the Financial Statements include those related to income tax credits receivable, share based payments, impairment of non-financial assets, fair value of biological assets, as well as cost recognition.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Inadequate Internal Controls</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">If the Company fails to maintain an effective system of internal controls, the Company might not be able to report its financial results accurately or prevent misstatement&#59; and in that case, the Company&#8217;s shareholders could lose confidence in its financial reporting, which would harm its business and could negatively impact the value of its shares. While the Company believes that it has sufficient personnel and review procedures to allow it to maintain an effective system of internal controls, there can be no assurance that the Company will always successfully detect misstatements or implement necessary improvements in a timely fashion.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Risks Related to the Common Shares</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Market for the Common Shares</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">There can be no assurance that an active trading market for the Common Shares will develop or, if developed, that any market will be sustained. The Company cannot predict the prices at which the Common Shares will trade. Fluctuations in the market price of the Common Shares could cause an investor to lose all or part of its investment in Common Shares. Factors that could cause fluctuations in the trading price of the Common Shares include&#58; (i) announcements of new offerings, products, services or technologies&#59; commercial relationships, acquisitions or other events by the Company or its competitors&#59; (ii) price and volume fluctuations in the overall stock market from time to time&#59; (iii) significant volatility in the market price and trading volume of companies commercializing psychedelic pharmaceuticals&#59; (iv) fluctuations in the trading volume of the Common Shares or the size of the Company&#8217;s public float&#59; (v) actual or anticipated changes or fluctuations in the Company&#8217;s results of operations&#59; (vi) whether the Company&#8217;s results of operations meet the expectations of securities analysts or investors&#59; (vii) actual or anticipated changes in the expectations of investors or securities analysts&#59; (viii) litigation involving the Company, its industry, or both&#59; (ix) regulatory developments&#59; (x) general economic conditions and trends&#59; (xi) major catastrophic events&#59; (xii) escrow releases, sales of large blocks of the Common Shares&#59; (xiii) departures of key employees or members of management&#59; or (xiv) an adverse impact on the Company from any of the other risks cited herein.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">112</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Significant Sales of the Common Shares</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Although Common Shares held by existing shareholders of the Company will be freely tradable under applicable securities legislation, the Common Shares held by the Company&#8217;s directors, executive officers, Control persons and certain other security holders may be subject to contractual lock-up restrictions and may also be subject to escrow restrictions pursuant to the policies of Cboe Canada. Sales of a substantial number of the Common Shares in the public market after the expiry of lock-up or escrow restrictions, or the perception that these sales could occur, could adversely affect the market price of the Common Shares and may make it more difficult for investors to sell Common Shares at a favourable time and price.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Volatile Market Price for the Common Shares</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The securities market in Canada has experienced a high level of price and volume volatility, and the market prices of securities of many companies have experienced wide fluctuations in price which have not necessarily been related to the operating performance, underlying asset values or prospects of such companies. There can be no assurance that continual fluctuations in price will not occur. It may be anticipated that any market for the Common Shares will be subject to market trends generally, notwithstanding any potential success of the Company. The value of the Common Shares distributed hereunder will be affected by such volatility.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The volatility of the Common Shares may affect the ability of holders to sell the Common Shares at an advantageous price or at all. Market price fluctuations in the Common Shares may be adversely affected by a variety of factors relating to the Company&#8217;s business, including fluctuations in the Company&#8217;s operating and financial results, such results failing to meet the expectations of securities analysts or investors and downward revisions in securities analysis&#8217; estimates in connection therewith, sales of additional Common Shares, governmental regulatory action, adverse change in general market conditions or economic trends, acquisitions, dispositions or other material public announcements by the Company or its competitors, along with a variety of additional factors, including, without limitation, those set forth under the heading &#8220;Cautionary Note Regarding Forward-Looking Information&#8221;. In addition, the market price for securities on stock markets, including Cboe Canada is subject to significant price and trading fluctuations. These fluctuations have resulted in volatility in the market prices of securities that often has been unrelated or disproportionate to changes in operating performance. These broad market fluctuations may materially adversely affect the market price of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Additionally, the value of the Common Shares is subject to market value fluctuations based upon factors that influence the Company&#8217;s operations, such as legislative or regulatory developments, competition, technological change and changes in interest rates or foreign exchange rates. There can be no assurance that the market price of the Common Shares will not experience significant fluctuations in the future, including fluctuations that are unrelated to the Company&#8217;s performance.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">Tax Issues</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">There may be income tax consequences in relation to the Common Shares, which will vary according to circumstances. Independent advice from tax and legal advisers should be obtained.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">113</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:139%">No Dividends</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Company&#8217;s current policy is, and will be, to retain earnings to finance the development and enhancement of its products and to otherwise reinvest in the Company. Therefore, the Company does not anticipate paying cash dividends on the Common Shares in the foreseeable future. The Company&#8217;s dividend policy will be reviewed from time to time by the Board in the context of its earnings, financial condition and other relevant factors. Until the time that the Company does pay dividends, which it might never do, its shareholders will not be able to receive a return on their Common Shares unless they sell them.</font></div><div style="margin-bottom:0.1pt;text-align:center"><font><br></font></div><div id="i2b86e3b0612046f694ccc21dee9687a9_115"></div><div style="margin-bottom:0.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%">ADDITIONAL INFORMATION</font></div><div style="margin-bottom:0.1pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Additional information on the Company has been filed electronically through SEDAR+ and is available online at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:139%">www.sedarplus.ca</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:139%;text-decoration:underline">Approval</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">The Board has approved the disclosure in this MD&#38;A.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">114</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>6
<FILENAME>cybin-40xfxexhibit994xceo.htm
<DESCRIPTION>EX-99.4
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia66c5e3989e440acab0b1b8f0a61d72d_1"></div><div style="min-height:36pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:20pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.4</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Doug Drysdale, certify that&#58;</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 40-F of Cybin Inc.&#59;</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.&#160;&#160;&#160;&#160;The issuer&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the issuer and have&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:10.5pt"><font><br></font></div><div style="text-indent:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:10.5pt"><font><br></font></div><div style="text-indent:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Evaluated the effectiveness of the issuer&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:10.5pt"><font><br></font></div><div style="text-indent:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Disclosed in this report any change in the issuer&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the issuer&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:10.5pt"><font><br></font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;The issuer&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the issuer&#8217;s auditor and the audit committee of the issuer&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;text-indent:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the issuer&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;text-indent:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the issuer&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:20pt;margin-top:20pt;padding-left:288pt;text-indent:-288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; June 30, 2025&#160;&#160;&#160;&#160;By&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Doug Drysdale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br>Doug Drysdale<br>Chief Executive Officer<br>(Principal Executive Officer)</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>7
<FILENAME>cybin-40xfxexhibit995cfo.htm
<DESCRIPTION>EX-99.5
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i9d74d5376af24e70b54c9082351e9fe9_1"></div><div style="min-height:36pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:20pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.5</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATION</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I, Greg Cavers, certify that&#58;</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 40-F of Cybin Inc.&#59;</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.&#160;&#160;&#160;&#160;The issuer&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the issuer and have&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:10.5pt"><font><br></font></div><div style="text-indent:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:10.5pt"><font><br></font></div><div style="text-indent:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Evaluated the effectiveness of the issuer&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:10.5pt"><font><br></font></div><div style="text-indent:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Disclosed in this report any change in the issuer&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the issuer&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:10.5pt"><font><br></font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;The issuer&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the issuer&#8217;s auditor and the audit committee of the issuer&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;text-indent:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the issuer&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;text-indent:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the issuer&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:20pt;margin-top:20pt;padding-left:288pt;text-indent:-288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; June 30, 2025&#160;&#160;&#160;&#160;By&#58; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Greg Cavers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br>Greg Cavers<br>Chief Financial Officer<br>(Principal Financial and Accounting Officer)</font></div><div style="margin-bottom:20pt;text-align:right"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>8
<FILENAME>cybin-40xfxex996xceo906.htm
<DESCRIPTION>EX-99.6
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i24c98be7b6884373803336337a73d496_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div style="margin-bottom:20pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.6</font></div><div style="margin-bottom:20pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CERTIFICATION PURSUANT TO<br>18 U.S.C. &#167;1350,<br>AS ADOPTED PURSUANT TO<br>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In connection with the Annual Report of Cybin Inc. (the &#8220;Company&#8221;) on Form 40-F for the period ended March 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Doug Drysdale, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:6pt;text-indent:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:6pt;text-indent:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:20pt;margin-top:20pt;padding-left:288pt;text-indent:-288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2025&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Doug Drysdale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br>Doug Drysdale<br>Chief Executive Officer<br>(Principal Executive Officer)</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A signed original of this written statement required by Section 906 has been provided to Cybin Inc. and will be retained by Cybin Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="margin-bottom:20pt;text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.7
<SEQUENCE>9
<FILENAME>cybin-40xfxex997xcfo906.htm
<DESCRIPTION>EX-99.7
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i3f4bdfcf98a748958506256a8db6a6df_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Exhibit 99.7</font></div><div style="margin-bottom:20pt;text-align:center"><font><br></font></div><div style="margin-bottom:20pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CERTIFICATION PURSUANT TO<br>18 U.S.C. &#167;1350,<br>AS ADOPTED PURSUANT TO<br>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In connection with the Annual Report of Cybin Inc. (the &#8220;Company&#8221;) on Form 40-F for the period ended March 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Greg Cavers, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:6pt;text-indent:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:6pt;text-indent:10.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt;text-indent:10.5pt"><font><br></font></div><div style="padding-left:288pt;text-indent:-288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30,  2025</font></div><div style="padding-left:288pt;text-indent:-288pt"><font><br></font></div><div style="padding-left:288pt;text-indent:-288pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:292.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Greg Cavers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> <br>Greg Cavers<br>Chief Financial Officer<br>(Principal Financial and Accounting Officer)</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="padding-left:288pt;text-indent:-288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A signed original of this written statement required by Section 906 has been provided to Cybin Inc. and will be retained by Cybin Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.8
<SEQUENCE>10
<FILENAME>cybin-consentform40xfannua.htm
<DESCRIPTION>EX-99.8
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ib3b04a825b5f40988c3e462ca5ab8880_1"></div><div style="min-height:14.4pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:162px"></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%">To the United States Securities and Exchange Commission </font></div><div style="margin-top:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">We consent to the incorporation by reference in the Annual Report on Form 40-F of Cybin Inc. (the &#8220;Company&#8221;) of our report dated June 30, 2025, with respect to the consolidated statement of financial position of the Company as at March 31, 2025 and March 31, 2024 and the consolidated statements of loss and comprehensive loss, changes in shareholders&#8217; equity and cash flows for the years then ended, and notes to the consolidated financial statements, including material accounting policy information. </font></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">   &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_1a.jpg" src="image_1a.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:219px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Toronto, Canada&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;           &#160;       Chartered Professional Accountants</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 30, 2025&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;                   Licensed Public Accountants</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="ziefmans3.jpg" src="ziefmans3.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:672px"></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>cybn-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:517b8eb5-c396-4287-8f5e-af5641b4b385,g:1e9b6c9c-673a-419d-ac9f-76e5a6c29d23-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cybn="http://cybin.com/20250331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cybin.com/20250331">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cybn-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cybn-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cybn-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cybn-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="COVER" roleURI="http://cybin.com/role/COVER">
        <link:definition>0000001 - Document - COVER</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AUDITINFORMATION" roleURI="http://cybin.com/role/AUDITINFORMATION">
        <link:definition>0000002 - Document - AUDIT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" roleURI="http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION">
        <link:definition>9952151 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" roleURI="http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS">
        <link:definition>9952152 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" roleURI="http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
        <link:definition>9952153 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTOFCASHFLOWS" roleURI="http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS">
        <link:definition>9952154 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CORPORATEINFORMATION" roleURI="http://cybin.com/role/CORPORATEINFORMATION">
        <link:definition>9952155 - Disclosure - CORPORATE INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATION" roleURI="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATION">
        <link:definition>9952156 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CRITICALACCOUNTINGESTIMATESANDJUDGEMENTS" roleURI="http://cybin.com/role/CRITICALACCOUNTINGESTIMATESANDJUDGEMENTS">
        <link:definition>9952157 - Disclosure - CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITION" roleURI="http://cybin.com/role/ACQUISITION">
        <link:definition>9952158 - Disclosure - ACQUISITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUIPMENT" roleURI="http://cybin.com/role/EQUIPMENT">
        <link:definition>9952159 - Disclosure - EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETS" roleURI="http://cybin.com/role/INTANGIBLEASSETS">
        <link:definition>9952160 - Disclosure - INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RIGHTOFUSEASSETSANDLEASELIABILITIES" roleURI="http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIES">
        <link:definition>9952161 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILL" roleURI="http://cybin.com/role/GOODWILL">
        <link:definition>9952162 - Disclosure - GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITAL" roleURI="http://cybin.com/role/SHARECAPITAL">
        <link:definition>9952163 - Disclosure - SHARE CAPITAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSANDBALANCES" roleURI="http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCES">
        <link:definition>9952164 - Disclosure - RELATED PARTY TRANSACTIONS AND BALANCES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHEXPENSES" roleURI="http://cybin.com/role/RESEARCHEXPENSES">
        <link:definition>9952165 - Disclosure - RESEARCH EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GENERALANDADMINISTRATIVEEXPENSES" roleURI="http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSES">
        <link:definition>9952166 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONTRACTSCOMMITMENTSANDCONTINGENCIES" roleURI="http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIES">
        <link:definition>9952167 - Disclosure - CONTRACTS, COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALMANAGEMENT" roleURI="http://cybin.com/role/CAPITALMANAGEMENT">
        <link:definition>9952168 - Disclosure - CAPITAL MANAGEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTS" roleURI="http://cybin.com/role/FINANCIALINSTRUMENTS">
        <link:definition>9952169 - Disclosure - FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAX" roleURI="http://cybin.com/role/INCOMETAX">
        <link:definition>9952170 - Disclosure - INCOME TAX</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://cybin.com/role/SUBSEQUENTEVENTS">
        <link:definition>9952171 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies" roleURI="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies">
        <link:definition>9955511 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONTables" roleURI="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONTables">
        <link:definition>9955512 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONTables" roleURI="http://cybin.com/role/ACQUISITIONTables">
        <link:definition>9955513 - Disclosure - ACQUISITION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUIPMENTTables" roleURI="http://cybin.com/role/EQUIPMENTTables">
        <link:definition>9955514 - Disclosure - EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSTables" roleURI="http://cybin.com/role/INTANGIBLEASSETSTables">
        <link:definition>9955515 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RIGHTOFUSEASSETSANDLEASELIABILITIESTables" roleURI="http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESTables">
        <link:definition>9955516 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLTables" roleURI="http://cybin.com/role/GOODWILLTables">
        <link:definition>9955517 - Disclosure - GOODWILL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALTables" roleURI="http://cybin.com/role/SHARECAPITALTables">
        <link:definition>9955518 - Disclosure - SHARE CAPITAL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSANDBALANCESTables" roleURI="http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESTables">
        <link:definition>9955519 - Disclosure - RELATED PARTY TRANSACTIONS AND BALANCES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHEXPENSESTables" roleURI="http://cybin.com/role/RESEARCHEXPENSESTables">
        <link:definition>9955520 - Disclosure - RESEARCH EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GENERALANDADMINISTRATIVEEXPENSESTables" roleURI="http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESTables">
        <link:definition>9955521 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALMANAGEMENTTables" roleURI="http://cybin.com/role/CAPITALMANAGEMENTTables">
        <link:definition>9955522 - Disclosure - CAPITAL MANAGEMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSTables" roleURI="http://cybin.com/role/FINANCIALINSTRUMENTSTables">
        <link:definition>9955523 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXTables" roleURI="http://cybin.com/role/INCOMETAXTables">
        <link:definition>9955524 - Disclosure - INCOME TAX (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CORPORATEINFORMATIONDetails" roleURI="http://cybin.com/role/CORPORATEINFORMATIONDetails">
        <link:definition>9955525 - Disclosure - CORPORATE INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails" roleURI="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails">
        <link:definition>9955526 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Functional and presentation currency (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONCashandcashequivalentsDetails" roleURI="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONCashandcashequivalentsDetails">
        <link:definition>9955527 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Cash and cash equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails" roleURI="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails">
        <link:definition>9955528 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Equipment and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONSharebasedcompensationDetails" roleURI="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONSharebasedcompensationDetails">
        <link:definition>9955529 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Share-based compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONNarrativeDetails" roleURI="http://cybin.com/role/ACQUISITIONNarrativeDetails">
        <link:definition>9955530 - Disclosure - ACQUISITION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONDetailsofacquisitionDetails" roleURI="http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails">
        <link:definition>9955531 - Disclosure - ACQUISITION - Details of acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONResultssinceacquisitionDetails" roleURI="http://cybin.com/role/ACQUISITIONResultssinceacquisitionDetails">
        <link:definition>9955532 - Disclosure - ACQUISITION - Results since acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUIPMENTDetails" roleURI="http://cybin.com/role/EQUIPMENTDetails">
        <link:definition>9955533 - Disclosure - EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSDetails" roleURI="http://cybin.com/role/INTANGIBLEASSETSDetails">
        <link:definition>9955534 - Disclosure - INTANGIBLE ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RIGHTOFUSEASSETSANDLEASELIABILITIESNarrativeDetails" roleURI="http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESNarrativeDetails">
        <link:definition>9955535 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails" roleURI="http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails">
        <link:definition>9955536 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Right of use assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RIGHTOFUSEASSETSANDLEASELIABILITIESLeaseliabilitiesDetails" roleURI="http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESLeaseliabilitiesDetails">
        <link:definition>9955537 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLDetails" roleURI="http://cybin.com/role/GOODWILLDetails">
        <link:definition>9955538 - Disclosure - GOODWILL (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALNarrativeIssuedShareCapitalDetails" roleURI="http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails">
        <link:definition>9955539 - Disclosure - SHARE CAPITAL - Narrative - Issued Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALSummaryofsharecapitalDetails" roleURI="http://cybin.com/role/SHARECAPITALSummaryofsharecapitalDetails">
        <link:definition>9955540 - Disclosure - SHARE CAPITAL - Summary of share capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALSummaryofwarrantsDetails" roleURI="http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails">
        <link:definition>9955541 - Disclosure - SHARE CAPITAL - Summary of warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALNarrativeWarrantsDetails" roleURI="http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails">
        <link:definition>9955542 - Disclosure - SHARE CAPITAL - Narrative - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails" roleURI="http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails">
        <link:definition>9955543 - Disclosure - SHARE CAPITAL - Summary of significant unobservable inputs used, equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails" roleURI="http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails">
        <link:definition>9955544 - Disclosure - SHARE CAPITAL - Summary of warrants by expiry period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALNarrativeStockoptionsDetails" roleURI="http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails">
        <link:definition>9955545 - Disclosure - SHARE CAPITAL - Narrative - Stock options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALSummaryofnumberandweightedaverageexercisepricesofshareoptionsDetails" roleURI="http://cybin.com/role/SHARECAPITALSummaryofnumberandweightedaverageexercisepricesofshareoptionsDetails">
        <link:definition>9955546 - Disclosure - SHARE CAPITAL - Summary of number and weighted average exercise prices of share options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails" roleURI="http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails">
        <link:definition>9955547 - Disclosure - SHARE CAPITAL - Summary of measurement of stock option fair value assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHARECAPITALSummaryofstockoptioninformationDetails" roleURI="http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails">
        <link:definition>9955548 - Disclosure - SHARE CAPITAL - Summary of stock option information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails" roleURI="http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails">
        <link:definition>9955549 - Disclosure - RELATED PARTY TRANSACTIONS AND BALANCES - Schedule of Remuneration of Key Management Personnel (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHEXPENSESDetails" roleURI="http://cybin.com/role/RESEARCHEXPENSESDetails">
        <link:definition>9955550 - Disclosure - RESEARCH EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GENERALANDADMINISTRATIVEEXPENSESDetails" roleURI="http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails">
        <link:definition>9955551 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONTRACTSCOMMITMENTSANDCONTINGENCIESDetails" roleURI="http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>9955552 - Disclosure - CONTRACTS, COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALMANAGEMENTDetails" roleURI="http://cybin.com/role/CAPITALMANAGEMENTDetails">
        <link:definition>9955553 - Disclosure - CAPITAL MANAGEMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails" roleURI="http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails">
        <link:definition>9955554 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Financial Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSNarrativeDetails" roleURI="http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails">
        <link:definition>9955555 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails" roleURI="http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails">
        <link:definition>9955556 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Monetary Assets and Liabilities Currency Risk Fluctuations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXIncomeTaxRateReconciliationDetails" roleURI="http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails">
        <link:definition>9955557 - Disclosure - INCOME TAX - Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXDeferredTaxAssetsDetails" roleURI="http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails">
        <link:definition>9955558 - Disclosure - INCOME TAX - Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXNoncapitalLossesExpirationDetails" roleURI="http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails">
        <link:definition>9955559 - Disclosure - INCOME TAX - Non-capital Losses Expiration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXAdditionalInformationDetails" roleURI="http://cybin.com/role/INCOMETAXAdditionalInformationDetails">
        <link:definition>9955560 - Disclosure - INCOME TAX - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://cybin.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>9955561 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cybn_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_MiscellaneousIncomeExpenseAbstract" abstract="true" name="MiscellaneousIncomeExpenseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_LPCPurchaseAgreementMember" abstract="true" name="LPCPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_NumberOfSharesIssuedThroughShareOfferingEquity" abstract="false" name="NumberOfSharesIssuedThroughShareOfferingEquity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_IncreaseDecreaseThroughShareOfferingEquity" abstract="false" name="IncreaseDecreaseThroughShareOfferingEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_IncreaseDecreaseThroughShareConsolidationEquity" abstract="false" name="IncreaseDecreaseThroughShareConsolidationEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_NumberOfSharesIssuedNetOfIssuanceCosts" abstract="false" name="NumberOfSharesIssuedNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity" abstract="false" name="NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing" abstract="false" name="NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity" abstract="false" name="IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity" abstract="false" name="IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity" abstract="false" name="NumberOfSharesIssuedThroughExerciseOfWarrantsEquity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity" abstract="false" name="IncreaseDecreaseThroughExpirationOfWarrantsEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_AdjustmentForLeaseInterest" abstract="false" name="AdjustmentForLeaseInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_AdjustmentsForOtherLossesGains" abstract="false" name="AdjustmentsForOtherLossesGains" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation" abstract="false" name="AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_AdjustmentsForWorkingCapitalAbstract" abstract="true" name="AdjustmentsForWorkingCapitalAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities" abstract="false" name="AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" abstract="false" name="PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_AccountingPoliciesAbstract" abstract="true" name="AccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_CriticalAccountingEstimatesAndJudgementsAbstract" abstract="true" name="CriticalAccountingEstimatesAndJudgementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_PropertyPlantAndEquipment1Abstract" abstract="true" name="PropertyPlantAndEquipment1Abstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_IntangibleAssetsAbstract" abstract="true" name="IntangibleAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_DisclosureOfLeasesAndRightOfUseAssetsTextBlock" abstract="false" name="DisclosureOfLeasesAndRightOfUseAssetsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cybn_GoodwillAbstract" abstract="true" name="GoodwillAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_ShareCapitalReservesAndOtherEquityInterestAbstract" abstract="true" name="ShareCapitalReservesAndOtherEquityInterestAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_RelatedPartyAbstract" abstract="true" name="RelatedPartyAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_CommitmentsAbstract" abstract="true" name="CommitmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_CapitalManagementAbstract" abstract="true" name="CapitalManagementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_FinancialInstrumentsAbstract" abstract="true" name="FinancialInstrumentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_IncomeTaxesAbstract" abstract="true" name="IncomeTaxesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_EventsAfterReportingPeriodAbstract" abstract="true" name="EventsAfterReportingPeriodAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock" abstract="false" name="DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cybn_DisclosureOfBasisOfConsolidationPolicyTextBlock" abstract="false" name="DisclosureOfBasisOfConsolidationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cybn_DetailDescriptionOfFunctionalCurrenciesTableTextBlock" abstract="false" name="DetailDescriptionOfFunctionalCurrenciesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="cybn_ScheduleOfResearchExpensesTableTextBlock" abstract="false" name="ScheduleOfResearchExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cybn_DisclosureOfCapitalStructureTableTextBlock" abstract="false" name="DisclosureOfCapitalStructureTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="cybn_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock" abstract="false" name="DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="cybn_DisclosureOfExpirationOfNonCapitalLossesTableTextBlock" abstract="false" name="DisclosureOfExpirationOfNonCapitalLossesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="cybn_NumberOfSubsidiaries" abstract="false" name="NumberOfSubsidiaries" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cybn_OrdinarySharesConsolidationNewSharesIssued" abstract="false" name="OrdinarySharesConsolidationNewSharesIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_OrdinarySharesConsolidationSharesIssuedPreviously" abstract="false" name="OrdinarySharesConsolidationSharesIssuedPreviously" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_WorkingCapital" abstract="false" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_CybinCorpMember" abstract="true" name="CybinCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_JourneyMember" abstract="true" name="JourneyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_SerenityMember" abstract="true" name="SerenityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_CybinUSMember" abstract="true" name="CybinUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_AdeliaMember" abstract="true" name="AdeliaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_CybinIRLLimitedMember" abstract="true" name="CybinIRLLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_CybinUKLtd.Member" abstract="true" name="CybinUKLtd.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_ShareBasedCompensationArrangementExpirationPeriod" abstract="false" name="ShareBasedCompensationArrangementExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cybn_SmallPharmaInc.Member" abstract="true" name="SmallPharmaInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding" abstract="false" name="RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation" abstract="false" name="UnexercisedStockOptionsInSubsidiaryCompensationForCancellation" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="cybn_NumberOfActivePatentFamilies" abstract="false" name="NumberOfActivePatentFamilies" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cybn_NumberOfPendingPatentApplications" abstract="false" name="NumberOfPendingPatentApplications" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cybn_NumberOfGrantedPatents" abstract="false" name="NumberOfGrantedPatents" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cybn_CashRecognisedAsOfAcquisitionDate" abstract="false" name="CashRecognisedAsOfAcquisitionDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate" abstract="false" name="RightOfUseAssetRecognisedAsOfAcquisitionDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate" abstract="false" name="LeaseLiabilitiesRecognisedAsOfAcquisitionDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_GainLossOnDerecognitionOfRightOfUseAssets" abstract="false" name="GainLossOnDerecognitionOfRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_GainLossOnDerecognitionOfLeaseLiability" abstract="false" name="GainLossOnDerecognitionOfLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_EffectOfForeignExchangeRightOfUseAssets" abstract="false" name="EffectOfForeignExchangeRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_AdditionsToLeaseLiabilities" abstract="false" name="AdditionsToLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_EffectOfForeignExchangeLeaseLiabilities" abstract="false" name="EffectOfForeignExchangeLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_PaymentForTerminationPenaltyLeaseLiability" abstract="false" name="PaymentForTerminationPenaltyLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_PaymentsOfLeaseLiabilities" abstract="false" name="PaymentsOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_ClassBSharesMember" abstract="true" name="ClassBSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_August2023CompensationCommonShareWarrantMember" abstract="true" name="August2023CompensationCommonShareWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_November2023CompensationCommonShareWarrantMember" abstract="true" name="November2023CompensationCommonShareWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_March2024PrivatePlacementMember" abstract="true" name="March2024PrivatePlacementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_NumberOfCommonSharesHeldInEscrow" abstract="false" name="NumberOfCommonSharesHeldInEscrow" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_CommonStockSharesAuthorizedValue" abstract="false" name="CommonStockSharesAuthorizedValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_SharePricePerCommonShare" abstract="false" name="SharePricePerCommonShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="cybn_CommonSharesPurchasePeriodTerm" abstract="false" name="CommonSharesPurchasePeriodTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cybn_PercentageOfOutstandingCommonSharesOwn" abstract="false" name="PercentageOfOutstandingCommonSharesOwn" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement" abstract="false" name="NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement" abstract="false" name="ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement" abstract="false" name="PeriodToExerciseWarrantsInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cybn_NumberOfCommonShares" abstract="false" name="NumberOfCommonShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_NumberOfCommonSharePurchaseWarrants" abstract="false" name="NumberOfCommonSharePurchaseWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_NumberOfSharesSubjectToResaleRestrictions" abstract="false" name="NumberOfSharesSubjectToResaleRestrictions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments" abstract="false" name="NumberOfSharesIssuedUponConversionOfConvertibleInstruments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_CommonSharesExchangeRate" abstract="false" name="CommonSharesExchangeRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity" abstract="false" name="NumberOfSharesConvertedThroughContingentConsiderationEquity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity" abstract="false" name="NumberOfSharesIssuedThroughContingentConsiderationEquity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares" abstract="false" name="IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_CommonSharePurchaseWarrantsMember" abstract="true" name="CommonSharePurchaseWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_UnitPurchaseWarrantsMember" abstract="true" name="UnitPurchaseWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_WarrantsNumberOfSharesRollForward" abstract="true" name="WarrantsNumberOfSharesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement" abstract="false" name="NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_WarrantsWeightedAverageExercisePriceRollForward" abstract="true" name="WarrantsWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement" abstract="false" name="WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="cybn_GrantedToOfficersAndDirectorsMember" abstract="true" name="GrantedToOfficersAndDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended" abstract="false" name="NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted" abstract="false" name="RiskFreeInterestRateOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cybn_ExpectedVolatilityOtherEquityInstrumentsGranted" abstract="false" name="ExpectedVolatilityOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" abstract="false" name="OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" abstract="false" name="ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" abstract="false" name="WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="cybn_WarrantExpirationPeriodAxis" abstract="true" name="WarrantExpirationPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cybn_WarrantExpirationPeriodDomain" abstract="true" name="WarrantExpirationPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_WarrantExpirationPeriodOneMember" abstract="true" name="WarrantExpirationPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_WarrantExpirationPeriodTwoMember" abstract="true" name="WarrantExpirationPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_WarrantExpirationPeriodThreeMember" abstract="true" name="WarrantExpirationPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_WarrantExpirationPeriodFourMember" abstract="true" name="WarrantExpirationPeriodFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_WarrantExpirationPeriodFiveMember" abstract="true" name="WarrantExpirationPeriodFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" abstract="false" name="WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cybn_GrantedToOfficersMember" abstract="true" name="GrantedToOfficersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_GrantedToDirectorsMember" abstract="true" name="GrantedToDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_GrantedToEmployeesMember" abstract="true" name="GrantedToEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_GrantedToConsultantsMember" abstract="true" name="GrantedToConsultantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodAxis" abstract="true" name="OptionExpirationPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodDomain" abstract="true" name="OptionExpirationPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodThirtyTwoMember" abstract="true" name="OptionExpirationPeriodThirtyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodThirtyFourMember" abstract="true" name="OptionExpirationPeriodThirtyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodThirtyFiveMember" abstract="true" name="OptionExpirationPeriodThirtyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodThirtySixMember" abstract="true" name="OptionExpirationPeriodThirtySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodTwentyNineMember" abstract="true" name="OptionExpirationPeriodTwentyNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodTwentyFourAndThirtyMember" abstract="true" name="OptionExpirationPeriodTwentyFourAndThirtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodTwentyFourMember" abstract="true" name="OptionExpirationPeriodTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodThirtyMember" abstract="true" name="OptionExpirationPeriodThirtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember" abstract="true" name="OptionExpirationPeriodThirtySevenAndThirtyEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodThirtySevenMember" abstract="true" name="OptionExpirationPeriodThirtySevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodThirtyEightMember" abstract="true" name="OptionExpirationPeriodThirtyEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodThirtyOneMember" abstract="true" name="OptionExpirationPeriodThirtyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_ShareBasedPaymentVestingPeriodAxis" abstract="true" name="ShareBasedPaymentVestingPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cybn_ShareBasedPaymentVestingPeriodDomain" abstract="true" name="ShareBasedPaymentVestingPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_ShareOptionsVestingFirstTrancheMember" abstract="true" name="ShareOptionsVestingFirstTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_ShareOptionsVestingSecondTrancheMember" abstract="true" name="ShareOptionsVestingSecondTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_ShareOptionsVestingThirdTrancheMember" abstract="true" name="ShareOptionsVestingThirdTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_ShareOptionsVestingFourthTrancheMember" abstract="true" name="ShareOptionsVestingFourthTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_ShareOptionsVestingFifthTrancheMember" abstract="true" name="ShareOptionsVestingFifthTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" abstract="false" name="NumberOfShareOptionsVestedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" abstract="false" name="VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cybn_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" abstract="false" name="NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="cybn_WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" abstract="false" name="WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted" abstract="false" name="UnvestedForfeitureRateAsPercentageShareOptionsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodOneMember" abstract="true" name="OptionExpirationPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodTwoMember" abstract="true" name="OptionExpirationPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodThreeMember" abstract="true" name="OptionExpirationPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodFourMember" abstract="true" name="OptionExpirationPeriodFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodFiveMember" abstract="true" name="OptionExpirationPeriodFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodSixMember" abstract="true" name="OptionExpirationPeriodSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodSevenMember" abstract="true" name="OptionExpirationPeriodSevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodEightMember" abstract="true" name="OptionExpirationPeriodEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodNineMember" abstract="true" name="OptionExpirationPeriodNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodTenMember" abstract="true" name="OptionExpirationPeriodTenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodElevenMember" abstract="true" name="OptionExpirationPeriodElevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodTwelveMember" abstract="true" name="OptionExpirationPeriodTwelveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodThirteenMember" abstract="true" name="OptionExpirationPeriodThirteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodFourteenMember" abstract="true" name="OptionExpirationPeriodFourteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodFifteenMember" abstract="true" name="OptionExpirationPeriodFifteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodSixteenMember" abstract="true" name="OptionExpirationPeriodSixteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodSeventeenMember" abstract="true" name="OptionExpirationPeriodSeventeenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodEighteenMember" abstract="true" name="OptionExpirationPeriodEighteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodNineteenMember" abstract="true" name="OptionExpirationPeriodNineteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodTwentyMember" abstract="true" name="OptionExpirationPeriodTwentyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodTwentyOneMember" abstract="true" name="OptionExpirationPeriodTwentyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodTwentyTwoMember" abstract="true" name="OptionExpirationPeriodTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodTwentyThreeMember" abstract="true" name="OptionExpirationPeriodTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodTwentyFiveMember" abstract="true" name="OptionExpirationPeriodTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodTwentySixMember" abstract="true" name="OptionExpirationPeriodTwentySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodTwentySevenMember" abstract="true" name="OptionExpirationPeriodTwentySevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodTwentyEightMember" abstract="true" name="OptionExpirationPeriodTwentyEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_OptionExpirationPeriodThirtyThreeMember" abstract="true" name="OptionExpirationPeriodThirtyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_ShareBasedPaymentArrangementOptionMember" abstract="true" name="ShareBasedPaymentArrangementOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_IncomeStatementLocationAxis" abstract="true" name="IncomeStatementLocationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cybn_IncomeStatementLocationDomain" abstract="true" name="IncomeStatementLocationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_GeneralAndAdministrativeExpenseMember" abstract="true" name="GeneralAndAdministrativeExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_ResearchComponentMember" abstract="true" name="ResearchComponentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_AdvancementOfDevelopmentPrograms" abstract="false" name="AdvancementOfDevelopmentPrograms" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_PayrollAndBenefits" abstract="false" name="PayrollAndBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_LabAndAdministration" abstract="false" name="LabAndAdministration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_ProfessionalAndConsultingFees" abstract="false" name="ProfessionalAndConsultingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_CapitalMarketExpense" abstract="false" name="CapitalMarketExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_BusinessDevelopmentExpense" abstract="false" name="BusinessDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_InvestorRelationsSalesAndMarketingExpense" abstract="false" name="InvestorRelationsSalesAndMarketingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_ListingFeesExpense" abstract="false" name="ListingFeesExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_COMMITMENTSTable" abstract="true" name="COMMITMENTSTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cybn_COMMITMENTSLineItems" abstract="true" name="COMMITMENTSLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_SalesRoyaltyPercentage" abstract="false" name="SalesRoyaltyPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable" abstract="true" name="DisclosureOfFinancialAssetsAndLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cybn_CashMember" abstract="true" name="CashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_AccountsPayableAndAccruedLiabilitiesMember" abstract="true" name="AccountsPayableAndAccruedLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" abstract="true" name="DisclosureOfFinancialAssetsAndLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent" abstract="false" name="SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss" abstract="false" name="SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash" abstract="false" name="InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="cybn_InterestRateRiskIncreaseDecreaseInInterestIncome" abstract="false" name="InterestRateRiskIncreaseDecreaseInInterestIncome" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_InterestRateRiskTerm" abstract="false" name="InterestRateRiskTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis" abstract="true" name="ClassesOfFinancialAssetsAndLiabilitiesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain" abstract="true" name="ClassesOfFinancialAssetsAndLiabilitiesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_FinancialAssetsAndLiabilities" abstract="false" name="FinancialAssetsAndLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_TaxEffectOfShareBasedCompensation" abstract="false" name="TaxEffectOfShareBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_TaxEffectOfShareIssuanceCosts" abstract="false" name="TaxEffectOfShareIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_TaxEffectOfChangeInDeferredTaxAssets" abstract="false" name="TaxEffectOfChangeInDeferredTaxAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_DeferredCompensationMember" abstract="true" name="DeferredCompensationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_RDExpendituresMember" abstract="true" name="RDExpendituresMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_ShareIssuanceCostsMember" abstract="true" name="ShareIssuanceCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember" abstract="true" name="PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_GrossDeferredTaxAssets" abstract="false" name="GrossDeferredTaxAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_DeferredTaxAssetsValuationAllowance" abstract="false" name="DeferredTaxAssetsValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_DisclosureOfNonCapitalLossesExpirationTable" abstract="true" name="DisclosureOfNonCapitalLossesExpirationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cybn_LossCarryforwardExpirationAxis" abstract="true" name="LossCarryforwardExpirationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cybn_LossCarryforwardExpirationDomain" abstract="true" name="LossCarryforwardExpirationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cybn_A2036Member" abstract="true" name="A2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_A2037Member" abstract="true" name="A2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_A2038Member" abstract="true" name="A2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_A2039Member" abstract="true" name="A2039Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_A2040Member" abstract="true" name="A2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_A2041Member" abstract="true" name="A2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_A2042Member" abstract="true" name="A2042Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_A2043Member" abstract="true" name="A2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_A2044Member" abstract="true" name="A2044Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_A2045Member" abstract="true" name="A2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_DisclosureOfNonCapitalLossesExpirationLineItems" abstract="true" name="DisclosureOfNonCapitalLossesExpirationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cybn_NonCapitalLossCarryforward" abstract="false" name="NonCapitalLossCarryforward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_A20402041Member" abstract="true" name="A20402041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_Section382Limitation" abstract="false" name="Section382Limitation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cybn_ClassesOfDebtInstrumentsAxis" abstract="true" name="ClassesOfDebtInstrumentsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cybn_ClassesOfDebtInstrumentsDomain" abstract="true" name="ClassesOfDebtInstrumentsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_ConvertibleDebenturesMember" abstract="true" name="ConvertibleDebenturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_ConvertibleDebenturePrivatePlacementMember" abstract="true" name="ConvertibleDebenturePrivatePlacementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cybn_DebtInstrumentTerm" abstract="false" name="DebtInstrumentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cybn_DebtInstrumentGuaranteedInterestPayableRate" abstract="false" name="DebtInstrumentGuaranteedInterestPayableRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate" abstract="false" name="DebtInstrumentGuaranteedInterestPayableAnnualRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cybn_DebtInstrumentDefaultRate" abstract="false" name="DebtInstrumentDefaultRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger" abstract="false" name="DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays" abstract="false" name="DebtInstrumentConvertibleDebentureThresholdTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cybn_DebtInstrumentPrepaymentPremiumYearOne" abstract="false" name="DebtInstrumentPrepaymentPremiumYearOne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cybn_DebtInstrumentPrepaymentPremiumYearTwo" abstract="false" name="DebtInstrumentPrepaymentPremiumYearTwo" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage" abstract="false" name="DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>cybn-20250331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:517b8eb5-c396-4287-8f5e-af5641b4b385,g:1e9b6c9c-673a-419d-ac9f-76e5a6c29d23-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="cybn-20250331.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:calculationLink xlink:role="http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_af27d692-88cf-4c7f-b4b5-55190ea60746" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_4e0460e4-41cb-49ee-8642-f754e3a72d53" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_af27d692-88cf-4c7f-b4b5-55190ea60746" xlink:to="loc_ifrs-full_Cash_4e0460e4-41cb-49ee-8642-f754e3a72d53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_2801d55c-bd89-4c79-a11f-10f69936db98" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_af27d692-88cf-4c7f-b4b5-55190ea60746" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_2801d55c-bd89-4c79-a11f-10f69936db98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_f3c720b9-dcd2-4fbd-8e00-748ac1f079f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_af27d692-88cf-4c7f-b4b5-55190ea60746" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_f3c720b9-dcd2-4fbd-8e00-748ac1f079f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_11df62de-fed0-4b4c-a7b6-157529aa841b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_af27d692-88cf-4c7f-b4b5-55190ea60746" xlink:to="loc_ifrs-full_OtherCurrentAssets_11df62de-fed0-4b4c-a7b6-157529aa841b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_f9674a4c-4c67-4430-80a7-9ff2beb60b3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_038c47e6-0352-4f4b-9a9a-7ee597775071" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_f9674a4c-4c67-4430-80a7-9ff2beb60b3c" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_038c47e6-0352-4f4b-9a9a-7ee597775071" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_3eb8c146-0c02-4ab0-9722-7ecb8a8bc4c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_f9674a4c-4c67-4430-80a7-9ff2beb60b3c" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_3eb8c146-0c02-4ab0-9722-7ecb8a8bc4c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_069c8d70-5f0b-4d0c-8358-b63c13b183f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_c285e3b0-0cf4-47e2-a1a3-9b5bf016be4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_069c8d70-5f0b-4d0c-8358-b63c13b183f9" xlink:to="loc_ifrs-full_NoncurrentAssets_c285e3b0-0cf4-47e2-a1a3-9b5bf016be4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_6dc65df1-856f-4ae2-b5be-02f96d82022d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_069c8d70-5f0b-4d0c-8358-b63c13b183f9" xlink:to="loc_ifrs-full_CurrentAssets_6dc65df1-856f-4ae2-b5be-02f96d82022d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_dcbc5f86-f098-450e-995c-0a13e6cb35fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_1c103dc3-4f29-4174-a612-707b1af3e339" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_dcbc5f86-f098-450e-995c-0a13e6cb35fe" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_1c103dc3-4f29-4174-a612-707b1af3e339" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_8b9f01be-d768-402d-9738-1e44078faac7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_dcbc5f86-f098-450e-995c-0a13e6cb35fe" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_8b9f01be-d768-402d-9738-1e44078faac7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_1121e061-60e7-43ad-b5e6-a9355cf9403f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_dcbc5f86-f098-450e-995c-0a13e6cb35fe" xlink:to="loc_ifrs-full_RightofuseAssets_1121e061-60e7-43ad-b5e6-a9355cf9403f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_24c0fd62-703b-4c78-ab38-7143d5cff296" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_NoncurrentAssets_dcbc5f86-f098-450e-995c-0a13e6cb35fe" xlink:to="loc_ifrs-full_Goodwill_24c0fd62-703b-4c78-ab38-7143d5cff296" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_5a467f07-c7c5-4be7-966f-9461a42cfaeb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_3240356e-db0f-4320-99d4-4acd47c99f0d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_5a467f07-c7c5-4be7-966f-9461a42cfaeb" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_3240356e-db0f-4320-99d4-4acd47c99f0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium_68f64990-66d1-41d5-aee1-26f05018ec60" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_5a467f07-c7c5-4be7-966f-9461a42cfaeb" xlink:to="loc_ifrs-full_SharePremium_68f64990-66d1-41d5-aee1-26f05018ec60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantReserve_cf541664-4633-4679-ad2c-3d43cb9499a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantReserve"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_5a467f07-c7c5-4be7-966f-9461a42cfaeb" xlink:to="loc_ifrs-full_WarrantReserve_cf541664-4633-4679-ad2c-3d43cb9499a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPayments_d48d1ba9-149a-459f-b6cc-0809bd763607" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_5a467f07-c7c5-4be7-966f-9461a42cfaeb" xlink:to="loc_ifrs-full_ReserveOfSharebasedPayments_d48d1ba9-149a-459f-b6cc-0809bd763607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_6ef0abbc-76db-44ee-a776-635bfc7c298f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_5a467f07-c7c5-4be7-966f-9461a42cfaeb" xlink:to="loc_ifrs-full_IssuedCapital_6ef0abbc-76db-44ee-a776-635bfc7c298f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_2f2d6dab-07b0-48eb-bf14-4aa46f04c811" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_5a467f07-c7c5-4be7-966f-9461a42cfaeb" xlink:to="loc_ifrs-full_RetainedEarnings_2f2d6dab-07b0-48eb-bf14-4aa46f04c811" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_7b1d0bf5-6a8c-4f25-a549-e9a16a392e7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_bcb02164-c900-46f3-8e30-60dc813d08d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_7b1d0bf5-6a8c-4f25-a549-e9a16a392e7c" xlink:to="loc_ifrs-full_Equity_bcb02164-c900-46f3-8e30-60dc813d08d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_69aff2e8-0701-4765-86d9-1341adce11e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_7b1d0bf5-6a8c-4f25-a549-e9a16a392e7c" xlink:to="loc_ifrs-full_CurrentLiabilities_69aff2e8-0701-4765-86d9-1341adce11e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="cybn-20250331.xsd#CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_ffe6c033-50e0-42ad-8743-2f509a6b6b37" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromInterest_5f80c328-d121-4458-987d-852f2cb9a1c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherIncome_ffe6c033-50e0-42ad-8743-2f509a6b6b37" xlink:to="loc_ifrs-full_RevenueFromInterest_5f80c328-d121-4458-987d-852f2cb9a1c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_49722d17-1663-4557-b8f1-b89d0fc26cad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherIncome_ffe6c033-50e0-42ad-8743-2f509a6b6b37" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_49722d17-1663-4557-b8f1-b89d0fc26cad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherExpenseByNature_e403597e-f05a-4466-9202-2a989cd1d337" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherExpenseByNature"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OtherIncome_ffe6c033-50e0-42ad-8743-2f509a6b6b37" xlink:to="loc_ifrs-full_OtherExpenseByNature_e403597e-f05a-4466-9202-2a989cd1d337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_1a09b11e-66ac-473d-831f-d376170a63e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_ca698d8b-7670-4ebb-8d37-747876ce72ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_1a09b11e-66ac-473d-831f-d376170a63e0" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_ca698d8b-7670-4ebb-8d37-747876ce72ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_de59a6b9-c0d6-455d-bd31-f1aaefa5f66f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_1a09b11e-66ac-473d-831f-d376170a63e0" xlink:to="loc_ifrs-full_ProfitLoss_de59a6b9-c0d6-455d-bd31-f1aaefa5f66f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_33c875ee-9923-4d8a-bd3a-8ad8fd7dfd38" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_f7c7cb65-3589-4e38-a273-c99b81569728" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_33c875ee-9923-4d8a-bd3a-8ad8fd7dfd38" xlink:to="loc_ifrs-full_OperatingExpense_f7c7cb65-3589-4e38-a273-c99b81569728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_ca981be6-13ac-43bf-aed8-51e26c70e1d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_33c875ee-9923-4d8a-bd3a-8ad8fd7dfd38" xlink:to="loc_ifrs-full_OtherIncome_ca981be6-13ac-43bf-aed8-51e26c70e1d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_39a4554b-d006-49d5-befc-e8b9fd16f4a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_576a4cd7-45ef-4831-88cb-1f0980a6a67e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_39a4554b-d006-49d5-befc-e8b9fd16f4a8" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_576a4cd7-45ef-4831-88cb-1f0980a6a67e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_6c521530-f5ec-47e5-906d-77127bc79138" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_39a4554b-d006-49d5-befc-e8b9fd16f4a8" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_6c521530-f5ec-47e5-906d-77127bc79138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_38f43d61-60a7-4868-bf53-7b1a1c2e1942" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_OperatingExpense_39a4554b-d006-49d5-befc-e8b9fd16f4a8" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_38f43d61-60a7-4868-bf53-7b1a1c2e1942" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="simple" xlink:href="cybn-20250331.xsd#CONSOLIDATEDSTATEMENTOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_617c0bce-59f2-4d6d-9116-a55617c423a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_c5d46adb-9e9b-4e34-9634-4906ef13c4bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_617c0bce-59f2-4d6d-9116-a55617c423a5" xlink:to="loc_ifrs-full_ProfitLoss_c5d46adb-9e9b-4e34-9634-4906ef13c4bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_2c3adeb1-522a-48af-a078-81faeb35c654" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_617c0bce-59f2-4d6d-9116-a55617c423a5" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_2c3adeb1-522a-48af-a078-81faeb35c654" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_eaf85c91-05dd-4a38-8096-19d35acc7599" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_617c0bce-59f2-4d6d-9116-a55617c423a5" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_eaf85c91-05dd-4a38-8096-19d35acc7599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdjustmentForLeaseInterest_66c7f41a-9dd0-4ff4-a6fe-fd0cdaa17a02" xlink:href="cybn-20250331.xsd#cybn_AdjustmentForLeaseInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_617c0bce-59f2-4d6d-9116-a55617c423a5" xlink:to="loc_cybn_AdjustmentForLeaseInterest_66c7f41a-9dd0-4ff4-a6fe-fd0cdaa17a02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdjustmentsForOtherLossesGains_89b2e7fc-77ef-4671-80f8-eb604bf18d82" xlink:href="cybn-20250331.xsd#cybn_AdjustmentsForOtherLossesGains"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_617c0bce-59f2-4d6d-9116-a55617c423a5" xlink:to="loc_cybn_AdjustmentsForOtherLossesGains_89b2e7fc-77ef-4671-80f8-eb604bf18d82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_c96cdf14-a262-4fb1-b530-4a58c1b1bfb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_617c0bce-59f2-4d6d-9116-a55617c423a5" xlink:to="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_c96cdf14-a262-4fb1-b530-4a58c1b1bfb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation_53565022-1ac4-4576-a090-e5f70e01da9d" xlink:href="cybn-20250331.xsd#cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_617c0bce-59f2-4d6d-9116-a55617c423a5" xlink:to="loc_cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation_53565022-1ac4-4576-a090-e5f70e01da9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_b5330a4a-31e4-44eb-bac2-015551835d89" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9f80e40a-409e-4cc1-804b-2f1eda326a6f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_b5330a4a-31e4-44eb-bac2-015551835d89" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_9f80e40a-409e-4cc1-804b-2f1eda326a6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_cd753b7d-859d-4806-beb0-8a2fa8cd24a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_b5330a4a-31e4-44eb-bac2-015551835d89" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_cd753b7d-859d-4806-beb0-8a2fa8cd24a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_3e2e69ac-8e7e-4552-8f09-5513c219ae05" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_b5330a4a-31e4-44eb-bac2-015551835d89" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_3e2e69ac-8e7e-4552-8f09-5513c219ae05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_8cda8015-641d-4285-8cdf-6fc739c314f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_b5330a4a-31e4-44eb-bac2-015551835d89" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_8cda8015-641d-4285-8cdf-6fc739c314f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities_ce527752-0f46-4921-8114-297dc11cfc69" xlink:href="cybn-20250331.xsd#cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_b5330a4a-31e4-44eb-bac2-015551835d89" xlink:to="loc_cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities_ce527752-0f46-4921-8114-297dc11cfc69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_d86b1b7d-506b-4b3b-91fc-49f053fea07c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_cdeaeb61-b2d3-48d1-95cb-4ab1e7d8afb1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_d86b1b7d-506b-4b3b-91fc-49f053fea07c" xlink:to="loc_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_cdeaeb61-b2d3-48d1-95cb-4ab1e7d8afb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_97208ffd-a100-4f6d-900a-687a423bff88" xlink:href="cybn-20250331.xsd#cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_d86b1b7d-506b-4b3b-91fc-49f053fea07c" xlink:to="loc_cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_97208ffd-a100-4f6d-900a-687a423bff88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_dceb621a-d90c-4e54-8aa9-541eaf45ed53" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_846a90cb-bf06-4984-a95f-18c14be54ea5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_dceb621a-d90c-4e54-8aa9-541eaf45ed53" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_846a90cb-bf06-4984-a95f-18c14be54ea5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_ec22ada5-657a-471b-8afb-2b20eb5fc5b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_dceb621a-d90c-4e54-8aa9-541eaf45ed53" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_ec22ada5-657a-471b-8afb-2b20eb5fc5b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_706aed21-1def-4b85-84dd-cf3dea1d6e36" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_dceb621a-d90c-4e54-8aa9-541eaf45ed53" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_706aed21-1def-4b85-84dd-cf3dea1d6e36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_5a80befc-966f-4dd5-8430-7794066261b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_dceb621a-d90c-4e54-8aa9-541eaf45ed53" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_5a80befc-966f-4dd5-8430-7794066261b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_8502bd76-e180-4ae6-9c38-c42d84000d7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_a32ebb6a-b36c-4156-a0cb-764882429998" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_8502bd76-e180-4ae6-9c38-c42d84000d7f" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_a32ebb6a-b36c-4156-a0cb-764882429998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_0d1e40ae-14a7-41bc-a4fb-bfb5c54a9d5d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_8502bd76-e180-4ae6-9c38-c42d84000d7f" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_0d1e40ae-14a7-41bc-a4fb-bfb5c54a9d5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_52edddd0-2318-4db6-8bdc-5b332992a635" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_8502bd76-e180-4ae6-9c38-c42d84000d7f" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_52edddd0-2318-4db6-8bdc-5b332992a635" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#ACQUISITIONDetailsofacquisitionDetails"/>
  <link:calculationLink xlink:role="http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_f5b8ff07-ffe7-466c-bfa4-8c7cec5a6a02" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_207932f3-6f33-4bae-a9f0-0b63db52aed3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_f5b8ff07-ffe7-466c-bfa4-8c7cec5a6a02" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_207932f3-6f33-4bae-a9f0-0b63db52aed3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_13b17c29-9af8-4e85-ad22-9d03fc977661" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_f5b8ff07-ffe7-466c-bfa4-8c7cec5a6a02" xlink:to="loc_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_13b17c29-9af8-4e85-ad22-9d03fc977661" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_398f630a-9b53-4b6e-89dd-31ad3b0c4457" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_f5b8ff07-ffe7-466c-bfa4-8c7cec5a6a02" xlink:to="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_398f630a-9b53-4b6e-89dd-31ad3b0c4457" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_1572b923-d10e-4646-bca9-9acf78244539" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_f5b8ff07-ffe7-466c-bfa4-8c7cec5a6a02" xlink:to="loc_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_1572b923-d10e-4646-bca9-9acf78244539" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate_c8c618d4-dc9e-4d78-a5a7-2a18d6bf01bd" xlink:href="cybn-20250331.xsd#cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_f5b8ff07-ffe7-466c-bfa4-8c7cec5a6a02" xlink:to="loc_cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate_c8c618d4-dc9e-4d78-a5a7-2a18d6bf01bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate_34d8249e-24c6-4381-be15-b919993e6338" xlink:href="cybn-20250331.xsd#cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_f5b8ff07-ffe7-466c-bfa4-8c7cec5a6a02" xlink:to="loc_cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate_34d8249e-24c6-4381-be15-b919993e6338" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_9379e09c-f189-4160-9a8a-4d4087e4cbad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_f5b8ff07-ffe7-466c-bfa4-8c7cec5a6a02" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_9379e09c-f189-4160-9a8a-4d4087e4cbad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CashRecognisedAsOfAcquisitionDate_5d7c77bd-d84c-4bc6-a1d8-360e0b5ee0ec" xlink:href="cybn-20250331.xsd#cybn_CashRecognisedAsOfAcquisitionDate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_f5b8ff07-ffe7-466c-bfa4-8c7cec5a6a02" xlink:to="loc_cybn_CashRecognisedAsOfAcquisitionDate_5d7c77bd-d84c-4bc6-a1d8-360e0b5ee0ec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails"/>
  <link:calculationLink xlink:role="http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_983df9f1-0868-47e0-8949-0dae4a6b78ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_a22e55c8-0eeb-45d7-b44f-22ddd0223003" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_983df9f1-0868-47e0-8949-0dae4a6b78ea" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_a22e55c8-0eeb-45d7-b44f-22ddd0223003" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_cd046e28-8d73-4296-af7a-0a70cb3bc114" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_983df9f1-0868-47e0-8949-0dae4a6b78ea" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_cd046e28-8d73-4296-af7a-0a70cb3bc114" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cybin.com/role/RESEARCHEXPENSESDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#RESEARCHEXPENSESDetails"/>
  <link:calculationLink xlink:role="http://cybin.com/role/RESEARCHEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_0a12d8e8-1644-4601-ab50-74a3008eaff6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LabAndAdministration_78c12ce5-3c72-42ba-834d-9f12f454807c" xlink:href="cybn-20250331.xsd#cybn_LabAndAdministration"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_0a12d8e8-1644-4601-ab50-74a3008eaff6" xlink:to="loc_cybn_LabAndAdministration_78c12ce5-3c72-42ba-834d-9f12f454807c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdvancementOfDevelopmentPrograms_36063f20-b612-4c35-b99e-a9b406f4d0ce" xlink:href="cybn-20250331.xsd#cybn_AdvancementOfDevelopmentPrograms"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_0a12d8e8-1644-4601-ab50-74a3008eaff6" xlink:to="loc_cybn_AdvancementOfDevelopmentPrograms_36063f20-b612-4c35-b99e-a9b406f4d0ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ProfessionalAndConsultingFees_ce83d188-6814-4429-8bf0-5915f9154020" xlink:href="cybn-20250331.xsd#cybn_ProfessionalAndConsultingFees"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_0a12d8e8-1644-4601-ab50-74a3008eaff6" xlink:to="loc_cybn_ProfessionalAndConsultingFees_ce83d188-6814-4429-8bf0-5915f9154020" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PayrollAndBenefits_c9473602-3c96-4a41-8cd7-87458d02b3c2" xlink:href="cybn-20250331.xsd#cybn_PayrollAndBenefits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense_0a12d8e8-1644-4601-ab50-74a3008eaff6" xlink:to="loc_cybn_PayrollAndBenefits_c9473602-3c96-4a41-8cd7-87458d02b3c2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#GENERALANDADMINISTRATIVEEXPENSESDetails"/>
  <link:calculationLink xlink:role="http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_c1b03771-d8aa-4536-b277-4bdfbd783dd0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_77e5e220-b648-41ba-995c-a5d76929415e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense_c1b03771-d8aa-4536-b277-4bdfbd783dd0" xlink:to="loc_ifrs-full_ProfessionalFeesExpense_77e5e220-b648-41ba-995c-a5d76929415e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OccupancyExpense_ba05bbc4-363f-4e9b-a71b-9d3efafc1bbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OccupancyExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense_c1b03771-d8aa-4536-b277-4bdfbd783dd0" xlink:to="loc_ifrs-full_OccupancyExpense_ba05bbc4-363f-4e9b-a71b-9d3efafc1bbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CapitalMarketExpense_b78d6255-6f1f-419c-9891-f4e24edc23c4" xlink:href="cybn-20250331.xsd#cybn_CapitalMarketExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense_c1b03771-d8aa-4536-b277-4bdfbd783dd0" xlink:to="loc_cybn_CapitalMarketExpense_b78d6255-6f1f-419c-9891-f4e24edc23c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ListingFeesExpense_8f881696-36cf-4bd7-bbba-c4b4128f3307" xlink:href="cybn-20250331.xsd#cybn_ListingFeesExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense_c1b03771-d8aa-4536-b277-4bdfbd783dd0" xlink:to="loc_cybn_ListingFeesExpense_8f881696-36cf-4bd7-bbba-c4b4128f3307" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_5b6f7a02-5c1c-4964-8cbe-4cd2df05f566" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense_c1b03771-d8aa-4536-b277-4bdfbd783dd0" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_5b6f7a02-5c1c-4964-8cbe-4cd2df05f566" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_BusinessDevelopmentExpense_107e8c58-240b-443f-b3af-68d1c7b61e80" xlink:href="cybn-20250331.xsd#cybn_BusinessDevelopmentExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense_c1b03771-d8aa-4536-b277-4bdfbd783dd0" xlink:to="loc_cybn_BusinessDevelopmentExpense_107e8c58-240b-443f-b3af-68d1c7b61e80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_InvestorRelationsSalesAndMarketingExpense_01f3e4a1-3121-4460-ab43-e3595a091d82" xlink:href="cybn-20250331.xsd#cybn_InvestorRelationsSalesAndMarketingExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense_c1b03771-d8aa-4536-b277-4bdfbd783dd0" xlink:to="loc_cybn_InvestorRelationsSalesAndMarketingExpense_01f3e4a1-3121-4460-ab43-e3595a091d82" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#INCOMETAXIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_583f47f4-e1cb-49fc-a56c-c3ff58bce1b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_TaxEffectOfShareIssuanceCosts_5f4310e9-d149-4633-ba41-6a770b61ec15" xlink:href="cybn-20250331.xsd#cybn_TaxEffectOfShareIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_583f47f4-e1cb-49fc-a56c-c3ff58bce1b6" xlink:to="loc_cybn_TaxEffectOfShareIssuanceCosts_5f4310e9-d149-4633-ba41-6a770b61ec15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_cbcc3ab5-a0fb-405b-819a-f40978c1536a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_583f47f4-e1cb-49fc-a56c-c3ff58bce1b6" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_cbcc3ab5-a0fb-405b-819a-f40978c1536a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_TaxEffectOfShareBasedCompensation_159adde1-676c-4947-817f-ed15be6c8ab7" xlink:href="cybn-20250331.xsd#cybn_TaxEffectOfShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_583f47f4-e1cb-49fc-a56c-c3ff58bce1b6" xlink:to="loc_cybn_TaxEffectOfShareBasedCompensation_159adde1-676c-4947-817f-ed15be6c8ab7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset_1d8180f2-f796-4dac-9ed3-ba7c455ecbbe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_583f47f4-e1cb-49fc-a56c-c3ff58bce1b6" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset_1d8180f2-f796-4dac-9ed3-ba7c455ecbbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_e2a931f0-96f8-4e5a-9bac-87e039a1d4e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_583f47f4-e1cb-49fc-a56c-c3ff58bce1b6" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_e2a931f0-96f8-4e5a-9bac-87e039a1d4e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset_2e94f3e1-4adc-4a35-9663-202cf28b9a97" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_583f47f4-e1cb-49fc-a56c-c3ff58bce1b6" xlink:to="loc_ifrs-full_ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset_2e94f3e1-4adc-4a35-9663-202cf28b9a97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_f7d0099e-5aca-46ea-96eb-33b533f1c00f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_583f47f4-e1cb-49fc-a56c-c3ff58bce1b6" xlink:to="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_f7d0099e-5aca-46ea-96eb-33b533f1c00f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_TaxEffectOfChangeInDeferredTaxAssets_435530e6-1865-4e04-99bd-ce6e6f5b52a7" xlink:href="cybn-20250331.xsd#cybn_TaxEffectOfChangeInDeferredTaxAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_583f47f4-e1cb-49fc-a56c-c3ff58bce1b6" xlink:to="loc_cybn_TaxEffectOfChangeInDeferredTaxAssets_435530e6-1865-4e04-99bd-ce6e6f5b52a7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#INCOMETAXDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_faaeac6e-a03a-43df-8ab1-14c036866574" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrossDeferredTaxAssets_20538a84-6bc5-4ba3-9f83-35419de5863f" xlink:href="cybn-20250331.xsd#cybn_GrossDeferredTaxAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DeferredTaxAssets_faaeac6e-a03a-43df-8ab1-14c036866574" xlink:to="loc_cybn_GrossDeferredTaxAssets_20538a84-6bc5-4ba3-9f83-35419de5863f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DeferredTaxAssetsValuationAllowance_c5bf85f4-63f3-4aaf-bdbe-28002aa26b4d" xlink:href="cybn-20250331.xsd#cybn_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_DeferredTaxAssets_faaeac6e-a03a-43df-8ab1-14c036866574" xlink:to="loc_cybn_DeferredTaxAssetsValuationAllowance_c5bf85f4-63f3-4aaf-bdbe-28002aa26b4d" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>cybn-20250331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:517b8eb5-c396-4287-8f5e-af5641b4b385,g:1e9b6c9c-673a-419d-ac9f-76e5a6c29d23-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://cybin.com/role/COVER" xlink:type="simple" xlink:href="cybn-20250331.xsd#COVER"/>
  <link:definitionLink xlink:role="http://cybin.com/role/COVER" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable_12905258-9533-4b8e-ac0c-db6f621e2680" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityAddressesTable_12905258-9533-4b8e-ac0c-db6f621e2680" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_60370fe5-ca70-4d16-91a9-1f7cf511f15b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntityAddressesTable_12905258-9533-4b8e-ac0c-db6f621e2680" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_60370fe5-ca70-4d16-91a9-1f7cf511f15b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_60370fe5-ca70-4d16-91a9-1f7cf511f15b_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_60370fe5-ca70-4d16-91a9-1f7cf511f15b" xlink:to="loc_dei_AddressTypeDomain_60370fe5-ca70-4d16-91a9-1f7cf511f15b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_2c9845ab-3da8-414a-b916-e780150a4b95" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_60370fe5-ca70-4d16-91a9-1f7cf511f15b" xlink:to="loc_dei_AddressTypeDomain_2c9845ab-3da8-414a-b916-e780150a4b95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_d4715ab9-7008-4b1a-ad5c-faeb56e5ed86" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_2c9845ab-3da8-414a-b916-e780150a4b95" xlink:to="loc_dei_BusinessContactMember_d4715ab9-7008-4b1a-ad5c-faeb56e5ed86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e2863752-7a9d-44e7-b87e-42ac75870233" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_DocumentType_e2863752-7a9d-44e7-b87e-42ac75870233" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_04f37acd-7f66-4a1d-a601-0fc46bf509ea" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_DocumentRegistrationStatement_04f37acd-7f66-4a1d-a601-0fc46bf509ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_f8c6b4a4-d88e-4673-91f2-985edf0aeeb2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_DocumentAnnualReport_f8c6b4a4-d88e-4673-91f2-985edf0aeeb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_3b144ee4-f0e6-4437-9d26-ef6fccb7e1d1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_CurrentFiscalYearEndDate_3b144ee4-f0e6-4437-9d26-ef6fccb7e1d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c2c0d1c2-5acc-48f4-a5a2-5c231f22ae6b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_DocumentPeriodEndDate_c2c0d1c2-5acc-48f4-a5a2-5c231f22ae6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7926dcb6-3026-4d78-92d9-7b5158a0680e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityFileNumber_7926dcb6-3026-4d78-92d9-7b5158a0680e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d4cd1f26-8e4b-46ec-86e6-7234050d4f53" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityRegistrantName_d4cd1f26-8e4b-46ec-86e6-7234050d4f53" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_71398c1a-be58-4089-b738-d2608e1cbfab" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_71398c1a-be58-4089-b738-d2608e1cbfab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPrimarySicNumber_7b7234ae-d5c1-4e36-9c15-0035fc5407a6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityPrimarySicNumber_7b7234ae-d5c1-4e36-9c15-0035fc5407a6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_0392992e-0380-4b62-8fcc-96434568cf29" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_ContactPersonnelName_0392992e-0380-4b62-8fcc-96434568cf29" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cda3e75b-b114-47ba-98d9-a78db1708004" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityAddressAddressLine1_cda3e75b-b114-47ba-98d9-a78db1708004" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_d371498e-31cb-4739-be67-9db487b562b4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityAddressAddressLine2_d371498e-31cb-4739-be67-9db487b562b4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_29b3bc8f-c410-4742-ab1f-0ac4efaae74d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityAddressCityOrTown_29b3bc8f-c410-4742-ab1f-0ac4efaae74d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e5729b80-75f4-4891-8843-ed4253734754" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityAddressStateOrProvince_e5729b80-75f4-4891-8843-ed4253734754" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_c50a7cfe-7343-43d4-99da-9d9cf9cdc3cc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityAddressCountry_c50a7cfe-7343-43d4-99da-9d9cf9cdc3cc" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_783dbf54-d0a8-4959-98e5-461218abd661" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityAddressPostalZipCode_783dbf54-d0a8-4959-98e5-461218abd661" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6922f85a-b6dc-44b5-b447-5ef019676fbd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_CityAreaCode_6922f85a-b6dc-44b5-b447-5ef019676fbd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_aa51c987-2c1b-4673-bb2a-a90905e0d275" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_LocalPhoneNumber_aa51c987-2c1b-4673-bb2a-a90905e0d275" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8cf4cdc3-fdc3-465b-a474-c52b618ebb48" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_Security12bTitle_8cf4cdc3-fdc3-465b-a474-c52b618ebb48" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2cacc591-bb72-42aa-85f7-b7b64d513128" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_TradingSymbol_2cacc591-bb72-42aa-85f7-b7b64d513128" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_fc8801e2-0898-44ec-ae97-b9816df1becf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_SecurityExchangeName_fc8801e2-0898-44ec-ae97-b9816df1becf" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AnnualInformationForm_35dec144-e7b5-4c25-9039-0c969b02890f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_AnnualInformationForm_35dec144-e7b5-4c25-9039-0c969b02890f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditedAnnualFinancialStatements_44a4435f-0495-449b-b24f-29dd7efb4cca" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_AuditedAnnualFinancialStatements_44a4435f-0495-449b-b24f-29dd7efb4cca" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_464950f0-1b86-4c04-8e1d-92d792d9613a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_464950f0-1b86-4c04-8e1d-92d792d9613a" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3bbd8caa-875d-4245-b1c1-4508935f95df" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityCurrentReportingStatus_3bbd8caa-875d-4245-b1c1-4508935f95df" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a37411ae-559d-4548-8974-c3f4b1034fc0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityInteractiveDataCurrent_a37411ae-559d-4548-8974-c3f4b1034fc0" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c2c2ec66-dd18-4495-b177-583e4e1d3077" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityEmergingGrowthCompany_c2c2ec66-dd18-4495-b177-583e4e1d3077" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_aa97d29a-d9bf-4e9d-bece-773610a0befc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityExTransitionPeriod_aa97d29a-d9bf-4e9d-bece-773610a0befc" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_67ffb4bf-3e75-40e7-9b56-ca25d2a2ed2d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_67ffb4bf-3e75-40e7-9b56-ca25d2a2ed2d" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1f5adf89-d342-43c7-bf06-4c31b70317c9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityCentralIndexKey_1f5adf89-d342-43c7-bf06-4c31b70317c9" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_be6392f1-0383-4ef9-ab8f-11f6035b47ec" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_DocumentFiscalYearFocus_be6392f1-0383-4ef9-ab8f-11f6035b47ec" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_51feb906-baa2-48bd-860d-4feaadfaa1e8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_51feb906-baa2-48bd-860d-4feaadfaa1e8" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5bce8361-9b44-4a5a-a347-b76ccfb5ea23" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_AmendmentFlag_5bce8361-9b44-4a5a-a347-b76ccfb5ea23" xlink:type="arc" order="32"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="cybn-20250331.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_79a7686d-485b-4a28-9b10-9e2baa59156c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_f5b1d19e-9991-476b-899c-c249e9e8fb45" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79a7686d-485b-4a28-9b10-9e2baa59156c" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_f5b1d19e-9991-476b-899c-c249e9e8fb45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_be4a5343-af25-4e39-b5c3-dd7bf334308a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_f5b1d19e-9991-476b-899c-c249e9e8fb45" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_be4a5343-af25-4e39-b5c3-dd7bf334308a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_be4a5343-af25-4e39-b5c3-dd7bf334308a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_be4a5343-af25-4e39-b5c3-dd7bf334308a" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_be4a5343-af25-4e39-b5c3-dd7bf334308a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_f52739cb-3bc5-4115-84ab-9e90e618b958" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_be4a5343-af25-4e39-b5c3-dd7bf334308a" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_f52739cb-3bc5-4115-84ab-9e90e618b958" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_d86f60c7-5a28-4333-a310-6bf51fa11aa4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_f52739cb-3bc5-4115-84ab-9e90e618b958" xlink:to="loc_ifrs-full_IssuedCapitalMember_d86f60c7-5a28-4333-a310-6bf51fa11aa4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantReserveMember_a128d3a8-3ce0-4fa7-bfb1-76e28c0134d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantReserveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_f52739cb-3bc5-4115-84ab-9e90e618b958" xlink:to="loc_ifrs-full_WarrantReserveMember_a128d3a8-3ce0-4fa7-bfb1-76e28c0134d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_33975d6f-5058-4756-97e8-2ffc2eeb7425" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_f52739cb-3bc5-4115-84ab-9e90e618b958" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_33975d6f-5058-4756-97e8-2ffc2eeb7425" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_b22af51a-365f-496a-937c-f4736a530616" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_f52739cb-3bc5-4115-84ab-9e90e618b958" xlink:to="loc_ifrs-full_SharePremiumMember_b22af51a-365f-496a-937c-f4736a530616" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_f69dd227-57a9-4976-8d7a-8f68726860c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_f52739cb-3bc5-4115-84ab-9e90e618b958" xlink:to="loc_ifrs-full_RetainedEarningsMember_f69dd227-57a9-4976-8d7a-8f68726860c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_13c700e9-d17e-4f35-99f2-894355ffb556" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_f52739cb-3bc5-4115-84ab-9e90e618b958" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_13c700e9-d17e-4f35-99f2-894355ffb556" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_ddcfb63a-331e-4193-b255-2ab3c8ee2b75" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_f5b1d19e-9991-476b-899c-c249e9e8fb45" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_ddcfb63a-331e-4193-b255-2ab3c8ee2b75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_ddcfb63a-331e-4193-b255-2ab3c8ee2b75_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_ddcfb63a-331e-4193-b255-2ab3c8ee2b75" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_ddcfb63a-331e-4193-b255-2ab3c8ee2b75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_7ebc8ee2-cd7f-4cf5-bdf3-73357fc82783" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_ddcfb63a-331e-4193-b255-2ab3c8ee2b75" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_7ebc8ee2-cd7f-4cf5-bdf3-73357fc82783" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LPCPurchaseAgreementMember_1d92b51d-9aa5-47c3-9983-43600f047ca4" xlink:href="cybn-20250331.xsd#cybn_LPCPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_7ebc8ee2-cd7f-4cf5-bdf3-73357fc82783" xlink:to="loc_cybn_LPCPurchaseAgreementMember_1d92b51d-9aa5-47c3-9983-43600f047ca4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ChangesInEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79a7686d-485b-4a28-9b10-9e2baa59156c" xlink:to="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_8c0384cc-c785-4c1e-8ec5-0cb2da81f385" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_8c0384cc-c785-4c1e-8ec5-0cb2da81f385" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_4432d933-9901-41ac-a543-1d60bc517ad4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_Equity_4432d933-9901-41ac-a543-1d60bc517ad4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughShareOfferingEquity_d635640d-fe30-4ff9-9c4f-c1407e342b87" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughShareOfferingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_NumberOfSharesIssuedThroughShareOfferingEquity_d635640d-fe30-4ff9-9c4f-c1407e342b87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughShareOfferingEquity_803b705e-c3bd-4bb2-a4f5-c3be191710be" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughShareOfferingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_IncreaseDecreaseThroughShareOfferingEquity_803b705e-c3bd-4bb2-a4f5-c3be191710be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_c225a6c7-e58e-4d3c-9a3a-6b289994d4e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_c225a6c7-e58e-4d3c-9a3a-6b289994d4e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughShareConsolidationEquity_d99f3b0f-14eb-4747-9eb6-9961fd9a8fa5" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughShareConsolidationEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_IncreaseDecreaseThroughShareConsolidationEquity_d99f3b0f-14eb-4747-9eb6-9961fd9a8fa5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedNetOfIssuanceCosts_918dd503-f181-42fb-ad7e-054006ff644b" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_NumberOfSharesIssuedNetOfIssuanceCosts_918dd503-f181-42fb-ad7e-054006ff644b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_33f79d93-de3e-4853-9bc7-d731ecc297f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_IssueOfEquity_33f79d93-de3e-4853-9bc7-d731ecc297f5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity_c1e065c0-5f92-4cf1-a613-654c0c4f6062" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity_c1e065c0-5f92-4cf1-a613-654c0c4f6062" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary_bd158aff-9f45-46ff-9799-8b7038b20ece" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary_bd158aff-9f45-46ff-9799-8b7038b20ece" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing_968acd7b-d2db-446e-8d9c-0b856783b3a8" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing_968acd7b-d2db-446e-8d9c-0b856783b3a8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity_b20a3d5f-7363-4783-b33d-90e6ecf486d8" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity_b20a3d5f-7363-4783-b33d-90e6ecf486d8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity_92c1ad3a-b7c4-414f-abf8-9d1cbd5606b1" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity_92c1ad3a-b7c4-414f-abf8-9d1cbd5606b1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity_c65c01fb-15a8-446e-a8fd-23a41fefef68" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity_c65c01fb-15a8-446e-a8fd-23a41fefef68" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_4e4824c9-9e71-4431-bdeb-5b2145ae12f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_4e4824c9-9e71-4431-bdeb-5b2145ae12f5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity_edb50f04-cd4c-4f61-8c49-e2367add5f97" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity_edb50f04-cd4c-4f61-8c49-e2367add5f97" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_5f67fb0d-1d2e-4cc4-892c-d0bca0949fa3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_5f67fb0d-1d2e-4cc4-892c-d0bca0949fa3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_c7c77628-12a1-4755-9956-84d8d5241472" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_c7c77628-12a1-4755-9956-84d8d5241472" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_4cab11f4-fbf8-414c-b153-320f0d006929" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_ProfitLoss_4cab11f4-fbf8-414c-b153-320f0d006929" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_9cecfa87-7405-41e5-ba47-ffeffeba4351" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_76f2a08f-e3b3-4666-882f-7d82cf0bb692" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_5f3b70df-f399-441c-b966-a2f5aa45e0a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ba816c89-6f29-4f9b-9f4e-e08d4548b872" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_5f3b70df-f399-441c-b966-a2f5aa45e0a2" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ba816c89-6f29-4f9b-9f4e-e08d4548b872" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5741d226-38c1-49d5-acac-04ae63e951a9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ba816c89-6f29-4f9b-9f4e-e08d4548b872" xlink:to="loc_srt_OwnershipAxis_5741d226-38c1-49d5-acac-04ae63e951a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_5741d226-38c1-49d5-acac-04ae63e951a9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_5741d226-38c1-49d5-acac-04ae63e951a9" xlink:to="loc_srt_OwnershipDomain_5741d226-38c1-49d5-acac-04ae63e951a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ac03c333-1149-4d27-97cc-70ead15e6726" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_5741d226-38c1-49d5-acac-04ae63e951a9" xlink:to="loc_srt_OwnershipDomain_ac03c333-1149-4d27-97cc-70ead15e6726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CybinCorpMember_ae242c1c-f275-4908-a2b5-edabc1f7fa4b" xlink:href="cybn-20250331.xsd#cybn_CybinCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_ac03c333-1149-4d27-97cc-70ead15e6726" xlink:to="loc_cybn_CybinCorpMember_ae242c1c-f275-4908-a2b5-edabc1f7fa4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_JourneyMember_9b998682-e2ed-4f0d-80dd-0769ad59821b" xlink:href="cybn-20250331.xsd#cybn_JourneyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_ac03c333-1149-4d27-97cc-70ead15e6726" xlink:to="loc_cybn_JourneyMember_9b998682-e2ed-4f0d-80dd-0769ad59821b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SerenityMember_0ad4b76d-3ac2-4813-ad7a-177f908c88a4" xlink:href="cybn-20250331.xsd#cybn_SerenityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_ac03c333-1149-4d27-97cc-70ead15e6726" xlink:to="loc_cybn_SerenityMember_0ad4b76d-3ac2-4813-ad7a-177f908c88a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CybinUSMember_21360080-522a-4b2b-99b2-5810f0a173fc" xlink:href="cybn-20250331.xsd#cybn_CybinUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_ac03c333-1149-4d27-97cc-70ead15e6726" xlink:to="loc_cybn_CybinUSMember_21360080-522a-4b2b-99b2-5810f0a173fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdeliaMember_259104f5-04ab-45fd-a166-cceb99d92e21" xlink:href="cybn-20250331.xsd#cybn_AdeliaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_ac03c333-1149-4d27-97cc-70ead15e6726" xlink:to="loc_cybn_AdeliaMember_259104f5-04ab-45fd-a166-cceb99d92e21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CybinIRLLimitedMember_7aff2efe-f422-4b87-96e8-62d7fbd9e236" xlink:href="cybn-20250331.xsd#cybn_CybinIRLLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_ac03c333-1149-4d27-97cc-70ead15e6726" xlink:to="loc_cybn_CybinIRLLimitedMember_7aff2efe-f422-4b87-96e8-62d7fbd9e236" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CybinUKLtd.Member_c954e7f4-a1eb-4fa7-847f-f09cce7217ae" xlink:href="cybn-20250331.xsd#cybn_CybinUKLtd.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_ac03c333-1149-4d27-97cc-70ead15e6726" xlink:to="loc_cybn_CybinUKLtd.Member_c954e7f4-a1eb-4fa7-847f-f09cce7217ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_84198505-366f-4906-b6dc-9c931a4b28ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_5f3b70df-f399-441c-b966-a2f5aa45e0a2" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_84198505-366f-4906-b6dc-9c931a4b28ff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0c0916f3-f8a7-4bcf-8728-79b2aa3da2b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4c3addbc-baeb-478a-92b4-281254bc78d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0c0916f3-f8a7-4bcf-8728-79b2aa3da2b6" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4c3addbc-baeb-478a-92b4-281254bc78d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_bb3ad254-7f3d-4fd8-877f-3eed13a80e16" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4c3addbc-baeb-478a-92b4-281254bc78d9" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_bb3ad254-7f3d-4fd8-877f-3eed13a80e16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_bb3ad254-7f3d-4fd8-877f-3eed13a80e16_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_bb3ad254-7f3d-4fd8-877f-3eed13a80e16" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_bb3ad254-7f3d-4fd8-877f-3eed13a80e16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_7818b6cc-ad92-43e0-bbed-18eea2b010ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_bb3ad254-7f3d-4fd8-877f-3eed13a80e16" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_7818b6cc-ad92-43e0-bbed-18eea2b010ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LaboratoryEquipmentMember_f4064429-5fec-4f23-aee1-22f2d72a7e5f" xlink:href="cybn-20250331.xsd#cybn_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_7818b6cc-ad92-43e0-bbed-18eea2b010ea" xlink:to="loc_cybn_LaboratoryEquipmentMember_f4064429-5fec-4f23-aee1-22f2d72a7e5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_1943770e-0d5d-4d55-88a9-5a72859595f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_7818b6cc-ad92-43e0-bbed-18eea2b010ea" xlink:to="loc_ifrs-full_ComputerEquipmentMember_1943770e-0d5d-4d55-88a9-5a72859595f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_c8356aef-b118-49a2-acbf-50938f8292b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4c3addbc-baeb-478a-92b4-281254bc78d9" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_c8356aef-b118-49a2-acbf-50938f8292b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_c8356aef-b118-49a2-acbf-50938f8292b9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_c8356aef-b118-49a2-acbf-50938f8292b9" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_c8356aef-b118-49a2-acbf-50938f8292b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_c174605d-7d4e-4294-ad4b-c90fe3c1d5d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_c8356aef-b118-49a2-acbf-50938f8292b9" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_c174605d-7d4e-4294-ad4b-c90fe3c1d5d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_2c1f6776-50ed-41ef-b7e2-af2fcf5d18f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_c174605d-7d4e-4294-ad4b-c90fe3c1d5d3" xlink:to="loc_ifrs-full_ComputerSoftwareMember_2c1f6776-50ed-41ef-b7e2-af2fcf5d18f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_731c23a7-070c-484f-a86c-5324659c1f2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_c174605d-7d4e-4294-ad4b-c90fe3c1d5d3" xlink:to="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_731c23a7-070c-484f-a86c-5324659c1f2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_413debd7-94fb-4643-86ae-38d6a6f9579a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0c0916f3-f8a7-4bcf-8728-79b2aa3da2b6" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_413debd7-94fb-4643-86ae-38d6a6f9579a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_2fad0b19-0be0-49b1-b51b-611207157882" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0c0916f3-f8a7-4bcf-8728-79b2aa3da2b6" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_2fad0b19-0be0-49b1-b51b-611207157882" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/ACQUISITIONNarrativeDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#ACQUISITIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/ACQUISITIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ce5cc1ee-175e-498a-9108-0f7936006ba3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ce5cc1ee-175e-498a-9108-0f7936006ba3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_78d9bc93-e47d-475c-9aa9-1f18030ca2f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ce5cc1ee-175e-498a-9108-0f7936006ba3" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_78d9bc93-e47d-475c-9aa9-1f18030ca2f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_78d9bc93-e47d-475c-9aa9-1f18030ca2f5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_78d9bc93-e47d-475c-9aa9-1f18030ca2f5" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_78d9bc93-e47d-475c-9aa9-1f18030ca2f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_b4abdb4f-0ece-424b-99a9-02aeb2e59c54" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_78d9bc93-e47d-475c-9aa9-1f18030ca2f5" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_b4abdb4f-0ece-424b-99a9-02aeb2e59c54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SmallPharmaInc.Member_62c59c38-8294-4a22-ac54-629a9a7e07e4" xlink:href="cybn-20250331.xsd#cybn_SmallPharmaInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_b4abdb4f-0ece-424b-99a9-02aeb2e59c54" xlink:to="loc_cybn_SmallPharmaInc.Member_62c59c38-8294-4a22-ac54-629a9a7e07e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1b2e1d4a-c7d8-4d09-8558-476b5b75159a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ce5cc1ee-175e-498a-9108-0f7936006ba3" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1b2e1d4a-c7d8-4d09-8558-476b5b75159a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_1b2e1d4a-c7d8-4d09-8558-476b5b75159a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1b2e1d4a-c7d8-4d09-8558-476b5b75159a" xlink:to="loc_ifrs-full_GeographicalAreasDomain_1b2e1d4a-c7d8-4d09-8558-476b5b75159a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_8d3ceb55-cb4a-42ee-843b-6aa0a9e81133" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1b2e1d4a-c7d8-4d09-8558-476b5b75159a" xlink:to="loc_ifrs-full_GeographicalAreasDomain_8d3ceb55-cb4a-42ee-843b-6aa0a9e81133" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_8f962d30-c0e3-43f3-8bbf-c9192bf16e1b" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_8d3ceb55-cb4a-42ee-843b-6aa0a9e81133" xlink:to="loc_country_CA_8f962d30-c0e3-43f3-8bbf-c9192bf16e1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_025666d1-9d56-478d-a28d-412b33408b2d" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_8d3ceb55-cb4a-42ee-843b-6aa0a9e81133" xlink:to="loc_country_GB_025666d1-9d56-478d-a28d-412b33408b2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding_11c569c1-1434-4165-ada2-db55fade180a" xlink:href="cybn-20250331.xsd#cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:to="loc_cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding_11c569c1-1434-4165-ada2-db55fade180a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_e6587a29-e515-492f-af17-e01afc5c668e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:to="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_e6587a29-e515-492f-af17-e01afc5c668e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation_b618caa8-28de-4718-aded-546c4d0ff872" xlink:href="cybn-20250331.xsd#cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:to="loc_cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation_b618caa8-28de-4718-aded-546c4d0ff872" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfActivePatentFamilies_33e263eb-4108-4fc0-8a09-812e661693dd" xlink:href="cybn-20250331.xsd#cybn_NumberOfActivePatentFamilies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:to="loc_cybn_NumberOfActivePatentFamilies_33e263eb-4108-4fc0-8a09-812e661693dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfPendingPatentApplications_9e321ce0-c55e-4fc5-8490-2a87c3c0a787" xlink:href="cybn-20250331.xsd#cybn_NumberOfPendingPatentApplications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:to="loc_cybn_NumberOfPendingPatentApplications_9e321ce0-c55e-4fc5-8490-2a87c3c0a787" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfGrantedPatents_bda1b504-1205-423f-8a23-d374814337e5" xlink:href="cybn-20250331.xsd#cybn_NumberOfGrantedPatents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:to="loc_cybn_NumberOfGrantedPatents_bda1b504-1205-423f-8a23-d374814337e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_7515c412-4e45-476d-83ed-7bbdbeae9be4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:to="loc_ifrs-full_ProfitLoss_7515c412-4e45-476d-83ed-7bbdbeae9be4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_50f0754a-e3f9-47e5-887b-8d125edaadb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_50f0754a-e3f9-47e5-887b-8d125edaadb9" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#ACQUISITIONDetailsofacquisitionDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_4d9f55cc-9266-4950-a418-85b662405090" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_4d9f55cc-9266-4950-a418-85b662405090" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_acb700bb-649e-4011-b2dd-526f0ad7af60" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_4d9f55cc-9266-4950-a418-85b662405090" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_acb700bb-649e-4011-b2dd-526f0ad7af60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_acb700bb-649e-4011-b2dd-526f0ad7af60_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_acb700bb-649e-4011-b2dd-526f0ad7af60" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_acb700bb-649e-4011-b2dd-526f0ad7af60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_72268257-d34b-4381-a188-d934dd396051" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_acb700bb-649e-4011-b2dd-526f0ad7af60" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_72268257-d34b-4381-a188-d934dd396051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SmallPharmaInc.Member_0c1529cb-571c-44f5-b2b6-148cdbcc38bd" xlink:href="cybn-20250331.xsd#cybn_SmallPharmaInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_72268257-d34b-4381-a188-d934dd396051" xlink:to="loc_cybn_SmallPharmaInc.Member_0c1529cb-571c-44f5-b2b6-148cdbcc38bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_2bfeed9e-191e-447d-975e-8e38e1f865c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_2bfeed9e-191e-447d-975e-8e38e1f865c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CashRecognisedAsOfAcquisitionDate_3c576dd6-7449-44e9-bbab-4300b875f3dd" xlink:href="cybn-20250331.xsd#cybn_CashRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_cybn_CashRecognisedAsOfAcquisitionDate_3c576dd6-7449-44e9-bbab-4300b875f3dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_b18ed717-42cf-48d3-86c8-cbdb56209b1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_b18ed717-42cf-48d3-86c8-cbdb56209b1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_11e68a06-69bd-41d2-8196-87bffba83477" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_11e68a06-69bd-41d2-8196-87bffba83477" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_f9c715fa-98f0-4605-a086-9b88cc3672c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_f9c715fa-98f0-4605-a086-9b88cc3672c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate_082e0ab6-b4c9-416e-b832-3cba84bab6cd" xlink:href="cybn-20250331.xsd#cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate_082e0ab6-b4c9-416e-b832-3cba84bab6cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate_6b218e07-f7e1-4583-af09-c9331604b2d3" xlink:href="cybn-20250331.xsd#cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate_6b218e07-f7e1-4583-af09-c9331604b2d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_b5f99f4d-865b-4186-ae86-6c14ad6c4c8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_b5f99f4d-865b-4186-ae86-6c14ad6c4c8a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_5f7194c0-55b5-4287-99d3-841637d40836" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_5f7194c0-55b5-4287-99d3-841637d40836" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_2d6b67e4-71a0-47fa-a744-833684446363" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_2d6b67e4-71a0-47fa-a744-833684446363" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/ACQUISITIONResultssinceacquisitionDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#ACQUISITIONResultssinceacquisitionDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/ACQUISITIONResultssinceacquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_4f50ca43-51ac-46a1-b369-f9d817bc02b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_c7bc3553-723b-4d15-98a9-3365c10afe2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_4f50ca43-51ac-46a1-b369-f9d817bc02b9" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_c7bc3553-723b-4d15-98a9-3365c10afe2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_bc020ee8-73a1-45c1-8500-8aba4fc762e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_c7bc3553-723b-4d15-98a9-3365c10afe2c" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_bc020ee8-73a1-45c1-8500-8aba4fc762e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_bc020ee8-73a1-45c1-8500-8aba4fc762e6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_bc020ee8-73a1-45c1-8500-8aba4fc762e6" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_bc020ee8-73a1-45c1-8500-8aba4fc762e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_7d692414-9765-4417-b653-58ec7984e63e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_bc020ee8-73a1-45c1-8500-8aba4fc762e6" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_7d692414-9765-4417-b653-58ec7984e63e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SmallPharmaInc.Member_d75f942c-1c31-4ce9-a1bf-808ab5e4b774" xlink:href="cybn-20250331.xsd#cybn_SmallPharmaInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_7d692414-9765-4417-b653-58ec7984e63e" xlink:to="loc_cybn_SmallPharmaInc.Member_d75f942c-1c31-4ce9-a1bf-808ab5e4b774" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_3182ebd1-7292-41a5-a899-87c2d782c87d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_4f50ca43-51ac-46a1-b369-f9d817bc02b9" xlink:to="loc_ifrs-full_Revenue_3182ebd1-7292-41a5-a899-87c2d782c87d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_10b47667-678d-4ccf-83cc-15c34e76af7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_4f50ca43-51ac-46a1-b369-f9d817bc02b9" xlink:to="loc_ifrs-full_ProfitLoss_10b47667-678d-4ccf-83cc-15c34e76af7c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/EQUIPMENTDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#EQUIPMENTDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/EQUIPMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_62f2d3b0-8ab8-448d-9905-42dce88d7a4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_84495ee5-2d1e-4062-9555-ce2437b97801" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_62f2d3b0-8ab8-448d-9905-42dce88d7a4c" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_84495ee5-2d1e-4062-9555-ce2437b97801" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_e90a3df3-f5c4-4b10-a67d-33b90e635fc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_84495ee5-2d1e-4062-9555-ce2437b97801" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_e90a3df3-f5c4-4b10-a67d-33b90e635fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_e90a3df3-f5c4-4b10-a67d-33b90e635fc3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_e90a3df3-f5c4-4b10-a67d-33b90e635fc3" xlink:to="loc_ifrs-full_CarryingAmountMember_e90a3df3-f5c4-4b10-a67d-33b90e635fc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_880bc53a-4e11-48de-a83c-3c38bfdf1b90" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_e90a3df3-f5c4-4b10-a67d-33b90e635fc3" xlink:to="loc_ifrs-full_CarryingAmountMember_880bc53a-4e11-48de-a83c-3c38bfdf1b90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_513e83af-dd35-4442-8efc-71bdbc8b34ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_880bc53a-4e11-48de-a83c-3c38bfdf1b90" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_513e83af-dd35-4442-8efc-71bdbc8b34ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_670359ae-ea2e-49ad-bd6c-d415565a3396" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_880bc53a-4e11-48de-a83c-3c38bfdf1b90" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_670359ae-ea2e-49ad-bd6c-d415565a3396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_71526c85-ecdd-4780-b3e5-00475919d3aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_84495ee5-2d1e-4062-9555-ce2437b97801" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_71526c85-ecdd-4780-b3e5-00475919d3aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_71526c85-ecdd-4780-b3e5-00475919d3aa_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_71526c85-ecdd-4780-b3e5-00475919d3aa" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_71526c85-ecdd-4780-b3e5-00475919d3aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_cead900f-60e1-4814-bb05-eee1b960e1e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_71526c85-ecdd-4780-b3e5-00475919d3aa" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_cead900f-60e1-4814-bb05-eee1b960e1e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LaboratoryEquipmentMember_ff8b67f9-686e-4cfc-a876-495c74b66165" xlink:href="cybn-20250331.xsd#cybn_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_cead900f-60e1-4814-bb05-eee1b960e1e4" xlink:to="loc_cybn_LaboratoryEquipmentMember_ff8b67f9-686e-4cfc-a876-495c74b66165" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_b3aa9ea2-9b3a-4147-b39f-640b9510c863" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_cead900f-60e1-4814-bb05-eee1b960e1e4" xlink:to="loc_ifrs-full_ComputerEquipmentMember_b3aa9ea2-9b3a-4147-b39f-640b9510c863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_429776f0-159a-4536-95ad-03c574f895ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_62f2d3b0-8ab8-448d-9905-42dce88d7a4c" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_429776f0-159a-4536-95ad-03c574f895ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_6bbcc87e-6f8e-45da-a476-400332129337" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_429776f0-159a-4536-95ad-03c574f895ab" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_6bbcc87e-6f8e-45da-a476-400332129337" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_8807c196-3da3-4278-a362-189022c3f1e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_429776f0-159a-4536-95ad-03c574f895ab" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_8807c196-3da3-4278-a362-189022c3f1e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_18003e19-ae7c-4629-a294-1c2b82131199" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_429776f0-159a-4536-95ad-03c574f895ab" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_18003e19-ae7c-4629-a294-1c2b82131199" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_f7c364c3-0168-4dd2-b06f-9400a2a4d388" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_429776f0-159a-4536-95ad-03c574f895ab" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_f7c364c3-0168-4dd2-b06f-9400a2a4d388" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_70f92b26-0a4a-4d21-ab30-7907b87a1730" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_429776f0-159a-4536-95ad-03c574f895ab" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_70f92b26-0a4a-4d21-ab30-7907b87a1730" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_1f1af418-bd41-47f5-b43f-1195b464bf75" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_429776f0-159a-4536-95ad-03c574f895ab" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_1f1af418-bd41-47f5-b43f-1195b464bf75" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_9f771399-7611-4ec7-9be4-7f4987ff6aaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_180e9783-b5ec-4a4f-a40e-14256360c35f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/INTANGIBLEASSETSDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#INTANGIBLEASSETSDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/INTANGIBLEASSETSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_021d17c6-f8e5-46a0-b9da-cb7cd2e2e215" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_11946242-9757-48cd-a93f-72284f8afade" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_021d17c6-f8e5-46a0-b9da-cb7cd2e2e215" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_11946242-9757-48cd-a93f-72284f8afade" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fb09541c-2f8a-4096-913c-fceaa6824e00" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_11946242-9757-48cd-a93f-72284f8afade" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fb09541c-2f8a-4096-913c-fceaa6824e00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_fb09541c-2f8a-4096-913c-fceaa6824e00_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fb09541c-2f8a-4096-913c-fceaa6824e00" xlink:to="loc_ifrs-full_CarryingAmountMember_fb09541c-2f8a-4096-913c-fceaa6824e00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_aa5b11ff-98ff-4743-8b70-9d7f06ee9fcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fb09541c-2f8a-4096-913c-fceaa6824e00" xlink:to="loc_ifrs-full_CarryingAmountMember_aa5b11ff-98ff-4743-8b70-9d7f06ee9fcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_af485f6d-ae72-4a75-9c40-86b6c8c1d5a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_aa5b11ff-98ff-4743-8b70-9d7f06ee9fcf" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_af485f6d-ae72-4a75-9c40-86b6c8c1d5a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_1e30031e-f05a-4927-bbf9-35034e719db6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_aa5b11ff-98ff-4743-8b70-9d7f06ee9fcf" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_1e30031e-f05a-4927-bbf9-35034e719db6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_aa25a898-cdfc-4d7b-b0e6-ffc0cfd90892" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_11946242-9757-48cd-a93f-72284f8afade" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_aa25a898-cdfc-4d7b-b0e6-ffc0cfd90892" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_aa25a898-cdfc-4d7b-b0e6-ffc0cfd90892_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_aa25a898-cdfc-4d7b-b0e6-ffc0cfd90892" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_aa25a898-cdfc-4d7b-b0e6-ffc0cfd90892_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_1add896e-5934-4492-bc4f-a49486c943c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_aa25a898-cdfc-4d7b-b0e6-ffc0cfd90892" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_1add896e-5934-4492-bc4f-a49486c943c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_38994f85-1af8-4bf5-9a7c-ec83013e3689" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_1add896e-5934-4492-bc4f-a49486c943c0" xlink:to="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_38994f85-1af8-4bf5-9a7c-ec83013e3689" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_bea168fd-fb80-485d-ae56-f8cccb544fae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_1add896e-5934-4492-bc4f-a49486c943c0" xlink:to="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_bea168fd-fb80-485d-ae56-f8cccb544fae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicencesMember_c94ea0f8-e463-445b-a9fd-fa4aa70799e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LicencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_1add896e-5934-4492-bc4f-a49486c943c0" xlink:to="loc_ifrs-full_LicencesMember_c94ea0f8-e463-445b-a9fd-fa4aa70799e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_972a30a5-99a3-45b6-b949-93bc1bf40b47" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_1add896e-5934-4492-bc4f-a49486c943c0" xlink:to="loc_ifrs-full_ComputerSoftwareMember_972a30a5-99a3-45b6-b949-93bc1bf40b47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_de961345-c976-4991-b8c3-256028f9a4bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_11946242-9757-48cd-a93f-72284f8afade" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_de961345-c976-4991-b8c3-256028f9a4bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_de961345-c976-4991-b8c3-256028f9a4bf_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_de961345-c976-4991-b8c3-256028f9a4bf" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_de961345-c976-4991-b8c3-256028f9a4bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_27ab10c3-3a36-4d58-9f66-f0583401cce7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_de961345-c976-4991-b8c3-256028f9a4bf" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_27ab10c3-3a36-4d58-9f66-f0583401cce7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1c4ccce2-def8-4028-9870-a1d34853e22f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_27ab10c3-3a36-4d58-9f66-f0583401cce7" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1c4ccce2-def8-4028-9870-a1d34853e22f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_db653c35-dcdc-41aa-aef2-615b3b74dfce" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_11946242-9757-48cd-a93f-72284f8afade" xlink:to="loc_ifrs-full_UnobservableInputsAxis_db653c35-dcdc-41aa-aef2-615b3b74dfce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_db653c35-dcdc-41aa-aef2-615b3b74dfce_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_db653c35-dcdc-41aa-aef2-615b3b74dfce" xlink:to="loc_ifrs-full_UnobservableInputsDomain_db653c35-dcdc-41aa-aef2-615b3b74dfce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_0df21af0-3734-47e1-acab-154b20cac804" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_db653c35-dcdc-41aa-aef2-615b3b74dfce" xlink:to="loc_ifrs-full_UnobservableInputsDomain_0df21af0-3734-47e1-acab-154b20cac804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember_8af7e745-2ae7-49d5-9cc8-e10867347f75" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DiscountRateMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_0df21af0-3734-47e1-acab-154b20cac804" xlink:to="loc_ifrs-full_DiscountRateMeasurementInputMember_8af7e745-2ae7-49d5-9cc8-e10867347f75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_76ccbcfa-e86a-46c9-b142-aa7f1031c196" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_021d17c6-f8e5-46a0-b9da-cb7cd2e2e215" xlink:to="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_76ccbcfa-e86a-46c9-b142-aa7f1031c196" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_ec6503e2-3dd3-4535-a5a7-e473ba30f431" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_76ccbcfa-e86a-46c9-b142-aa7f1031c196" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_ec6503e2-3dd3-4535-a5a7-e473ba30f431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_ae55e1ff-0049-4d71-9fe7-a5847f581c87" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_76ccbcfa-e86a-46c9-b142-aa7f1031c196" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_ae55e1ff-0049-4d71-9fe7-a5847f581c87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_8ca575ea-2524-4ec6-b441-eb460708bc58" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_76ccbcfa-e86a-46c9-b142-aa7f1031c196" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_8ca575ea-2524-4ec6-b441-eb460708bc58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_911cb76e-cd64-4fd0-ae5d-c30d53cf700d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_76ccbcfa-e86a-46c9-b142-aa7f1031c196" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_911cb76e-cd64-4fd0-ae5d-c30d53cf700d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_6a5ee886-3971-4473-906c-31e7bb6a0695" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_76ccbcfa-e86a-46c9-b142-aa7f1031c196" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_6a5ee886-3971-4473-906c-31e7bb6a0695" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_3a10d331-03aa-4f4b-807c-cbd6e47c30d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputAssets_4e500f88-3c0f-47d5-9f7e-1e0032543943" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantUnobservableInputAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_021d17c6-f8e5-46a0-b9da-cb7cd2e2e215" xlink:to="loc_ifrs-full_SignificantUnobservableInputAssets_4e500f88-3c0f-47d5-9f7e-1e0032543943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_a5c9ecdd-c333-4ae7-9079-143b36a31522" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_021d17c6-f8e5-46a0-b9da-cb7cd2e2e215" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_a5c9ecdd-c333-4ae7-9079-143b36a31522" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_7a91f427-fda4-47bb-9ddb-9e59ccd5aed7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_c1e6e5cf-ba1f-461c-886e-33513bace0e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_7a91f427-fda4-47bb-9ddb-9e59ccd5aed7" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_c1e6e5cf-ba1f-461c-886e-33513bace0e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_eac35f7e-579e-4227-a0f2-aedaa85d3551" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_c1e6e5cf-ba1f-461c-886e-33513bace0e7" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_eac35f7e-579e-4227-a0f2-aedaa85d3551" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_eac35f7e-579e-4227-a0f2-aedaa85d3551_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_eac35f7e-579e-4227-a0f2-aedaa85d3551" xlink:to="loc_ifrs-full_CarryingAmountMember_eac35f7e-579e-4227-a0f2-aedaa85d3551_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_0ea41083-2893-4df4-9c5f-1855e06ed530" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_eac35f7e-579e-4227-a0f2-aedaa85d3551" xlink:to="loc_ifrs-full_CarryingAmountMember_0ea41083-2893-4df4-9c5f-1855e06ed530" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_d6c0ba82-036e-4644-9971-449313f21ff2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_0ea41083-2893-4df4-9c5f-1855e06ed530" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_d6c0ba82-036e-4644-9971-449313f21ff2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_c66541e3-4f0a-4e65-a195-2757d74c689e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_0ea41083-2893-4df4-9c5f-1855e06ed530" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_c66541e3-4f0a-4e65-a195-2757d74c689e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_cd0af7f8-f025-4138-945a-d36094addd55" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_7a91f427-fda4-47bb-9ddb-9e59ccd5aed7" xlink:to="loc_ifrs-full_RightofuseAssets_cd0af7f8-f025-4138-945a-d36094addd55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_2ce5e022-75c2-4d8a-9b77-de08275943ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_7a91f427-fda4-47bb-9ddb-9e59ccd5aed7" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_2ce5e022-75c2-4d8a-9b77-de08275943ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_EffectOfForeignExchangeRightOfUseAssets_8683ea33-4a4e-45cc-ac80-88c411ce0366" xlink:href="cybn-20250331.xsd#cybn_EffectOfForeignExchangeRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_7a91f427-fda4-47bb-9ddb-9e59ccd5aed7" xlink:to="loc_cybn_EffectOfForeignExchangeRightOfUseAssets_8683ea33-4a4e-45cc-ac80-88c411ce0366" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsRightofuseAssets_f22addcb-6830-4739-811c-11b4b169be63" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_7a91f427-fda4-47bb-9ddb-9e59ccd5aed7" xlink:to="loc_ifrs-full_DisposalsRightofuseAssets_f22addcb-6830-4739-811c-11b4b169be63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_4ef6583a-1f16-410a-9865-bb1be2eebcbd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_7a91f427-fda4-47bb-9ddb-9e59ccd5aed7" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_4ef6583a-1f16-410a-9865-bb1be2eebcbd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_296c4f39-0902-40b1-8a72-d178b2324438" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/GOODWILLDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#GOODWILLDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/GOODWILLDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_999850b2-d1f7-449c-bf09-b87a670562bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_6bc7ec0a-a5a1-422d-8e1e-77a121d49d52" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_999850b2-d1f7-449c-bf09-b87a670562bf" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_6bc7ec0a-a5a1-422d-8e1e-77a121d49d52" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ae68e498-f657-4a53-b305-0dc681ae8ad5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_6bc7ec0a-a5a1-422d-8e1e-77a121d49d52" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ae68e498-f657-4a53-b305-0dc681ae8ad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain_ae68e498-f657-4a53-b305-0dc681ae8ad5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ae68e498-f657-4a53-b305-0dc681ae8ad5" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain_ae68e498-f657-4a53-b305-0dc681ae8ad5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain_6067b9ac-c9c9-4c0c-8462-93ffc3d4e826" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ae68e498-f657-4a53-b305-0dc681ae8ad5" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain_6067b9ac-c9c9-4c0c-8462-93ffc3d4e826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember_d128de12-31b9-4fc7-847e-46698cbf97d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain_6067b9ac-c9c9-4c0c-8462-93ffc3d4e826" xlink:to="loc_ifrs-full_GoodwillMember_d128de12-31b9-4fc7-847e-46698cbf97d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_3a9fa964-3546-4ed8-b199-4381e257e745" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_6bc7ec0a-a5a1-422d-8e1e-77a121d49d52" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_3a9fa964-3546-4ed8-b199-4381e257e745" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_3a9fa964-3546-4ed8-b199-4381e257e745_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_3a9fa964-3546-4ed8-b199-4381e257e745" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_3a9fa964-3546-4ed8-b199-4381e257e745_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_2bd17d61-beb3-4291-b7f3-e19dc6152f01" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_3a9fa964-3546-4ed8-b199-4381e257e745" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_2bd17d61-beb3-4291-b7f3-e19dc6152f01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember_bf1a46c9-df0e-4ee9-b773-3b320f3088da" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodwillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_2bd17d61-beb3-4291-b7f3-e19dc6152f01" xlink:to="loc_ifrs-full_GoodwillMember_bf1a46c9-df0e-4ee9-b773-3b320f3088da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_a65cf71c-dafa-430a-9492-2e9b2b0a7430" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_6bc7ec0a-a5a1-422d-8e1e-77a121d49d52" xlink:to="loc_ifrs-full_UnobservableInputsAxis_a65cf71c-dafa-430a-9492-2e9b2b0a7430" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_a65cf71c-dafa-430a-9492-2e9b2b0a7430_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_UnobservableInputsAxis_a65cf71c-dafa-430a-9492-2e9b2b0a7430" xlink:to="loc_ifrs-full_UnobservableInputsDomain_a65cf71c-dafa-430a-9492-2e9b2b0a7430_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_bca530af-92df-478b-bc89-71d642b8289e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_UnobservableInputsAxis_a65cf71c-dafa-430a-9492-2e9b2b0a7430" xlink:to="loc_ifrs-full_UnobservableInputsDomain_bca530af-92df-478b-bc89-71d642b8289e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember_29e2ae26-289f-4294-9dd6-8247c104964e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DiscountRateMeasurementInputMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_UnobservableInputsDomain_bca530af-92df-478b-bc89-71d642b8289e" xlink:to="loc_ifrs-full_DiscountRateMeasurementInputMember_29e2ae26-289f-4294-9dd6-8247c104964e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract_2572ce3d-bcb2-4f63-bff1-7f44c0b5c67c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_999850b2-d1f7-449c-bf09-b87a670562bf" xlink:to="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract_2572ce3d-bcb2-4f63-bff1-7f44c0b5c67c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_e2aa4aa2-5554-4bf0-b98c-3f11a48788b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract_2572ce3d-bcb2-4f63-bff1-7f44c0b5c67c" xlink:to="loc_ifrs-full_Goodwill_e2aa4aa2-5554-4bf0-b98c-3f11a48788b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_b3c200b6-dd53-48bd-b7ce-121511c5b13f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract_2572ce3d-bcb2-4f63-bff1-7f44c0b5c67c" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_b3c200b6-dd53-48bd-b7ce-121511c5b13f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_3067c5ad-5be0-451c-8f89-4101fda3fe57" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract_2572ce3d-bcb2-4f63-bff1-7f44c0b5c67c" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_3067c5ad-5be0-451c-8f89-4101fda3fe57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_1435059d-c050-4765-a54e-0f88148d5ce2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputAssets_4cf1bbff-466f-4d5a-92f6-dc9f078df569" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantUnobservableInputAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_999850b2-d1f7-449c-bf09-b87a670562bf" xlink:to="loc_ifrs-full_SignificantUnobservableInputAssets_4cf1bbff-466f-4d5a-92f6-dc9f078df569" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_5dd17671-efe8-4df8-8425-5891d90eaa0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_999850b2-d1f7-449c-bf09-b87a670562bf" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_5dd17671-efe8-4df8-8425-5891d90eaa0a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALNarrativeIssuedShareCapitalDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_f01e5a71-7699-4558-987c-1272297d854d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_f01e5a71-7699-4558-987c-1272297d854d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_2910c021-f9c7-44ad-b713-43b61fc119ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_f01e5a71-7699-4558-987c-1272297d854d" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_2910c021-f9c7-44ad-b713-43b61fc119ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_2910c021-f9c7-44ad-b713-43b61fc119ec_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_2910c021-f9c7-44ad-b713-43b61fc119ec" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_2910c021-f9c7-44ad-b713-43b61fc119ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_dec052ab-49c2-4ab0-bea8-867140920496" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_2910c021-f9c7-44ad-b713-43b61fc119ec" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_dec052ab-49c2-4ab0-bea8-867140920496" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_46125989-5db9-483c-b78f-ced8ab04a6e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_dec052ab-49c2-4ab0-bea8-867140920496" xlink:to="loc_ifrs-full_IssuedCapitalMember_46125989-5db9-483c-b78f-ced8ab04a6e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_8c127ff0-d497-4e06-9e4b-07ae6f92a9bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_f01e5a71-7699-4558-987c-1272297d854d" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_8c127ff0-d497-4e06-9e4b-07ae6f92a9bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_8c127ff0-d497-4e06-9e4b-07ae6f92a9bb_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_8c127ff0-d497-4e06-9e4b-07ae6f92a9bb" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_8c127ff0-d497-4e06-9e4b-07ae6f92a9bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_2414782e-d8ad-400d-8f3b-f96fccc2bdea" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_8c127ff0-d497-4e06-9e4b-07ae6f92a9bb" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_2414782e-d8ad-400d-8f3b-f96fccc2bdea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_09a4083d-53f0-4fd9-83e1-2a87e7207ab1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_2414782e-d8ad-400d-8f3b-f96fccc2bdea" xlink:to="loc_ifrs-full_OrdinarySharesMember_09a4083d-53f0-4fd9-83e1-2a87e7207ab1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PreferenceSharesMember_4bb62c60-4451-4c99-9761-a46a547c369a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PreferenceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_2414782e-d8ad-400d-8f3b-f96fccc2bdea" xlink:to="loc_ifrs-full_PreferenceSharesMember_4bb62c60-4451-4c99-9761-a46a547c369a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassBSharesMember_796e6c9c-dac7-437f-b629-c0e296ae1742" xlink:href="cybn-20250331.xsd#cybn_ClassBSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_2414782e-d8ad-400d-8f3b-f96fccc2bdea" xlink:to="loc_cybn_ClassBSharesMember_796e6c9c-dac7-437f-b629-c0e296ae1742" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_8cf2423a-b207-4454-813c-19e49d9db341" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_f01e5a71-7699-4558-987c-1272297d854d" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_8cf2423a-b207-4454-813c-19e49d9db341" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_8cf2423a-b207-4454-813c-19e49d9db341_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_8cf2423a-b207-4454-813c-19e49d9db341" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_8cf2423a-b207-4454-813c-19e49d9db341_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6e7f331e-45bc-4b4c-95b1-ca4e0693df46" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_8cf2423a-b207-4454-813c-19e49d9db341" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6e7f331e-45bc-4b4c-95b1-ca4e0693df46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LPCPurchaseAgreementMember_ba2534d7-d1a8-4932-9983-46c7da3c8db8" xlink:href="cybn-20250331.xsd#cybn_LPCPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6e7f331e-45bc-4b4c-95b1-ca4e0693df46" xlink:to="loc_cybn_LPCPurchaseAgreementMember_ba2534d7-d1a8-4932-9983-46c7da3c8db8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_August2023CompensationCommonShareWarrantMember_e9b4dcb3-c207-4f02-acf6-289ba11df994" xlink:href="cybn-20250331.xsd#cybn_August2023CompensationCommonShareWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6e7f331e-45bc-4b4c-95b1-ca4e0693df46" xlink:to="loc_cybn_August2023CompensationCommonShareWarrantMember_e9b4dcb3-c207-4f02-acf6-289ba11df994" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_November2023CompensationCommonShareWarrantMember_c971d1a0-b3a5-43a3-bd10-9fe3377a1c1b" xlink:href="cybn-20250331.xsd#cybn_November2023CompensationCommonShareWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6e7f331e-45bc-4b4c-95b1-ca4e0693df46" xlink:to="loc_cybn_November2023CompensationCommonShareWarrantMember_c971d1a0-b3a5-43a3-bd10-9fe3377a1c1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_March2024PrivatePlacementMember_b3770b95-a298-4761-94f2-53bd3344df26" xlink:href="cybn-20250331.xsd#cybn_March2024PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6e7f331e-45bc-4b4c-95b1-ca4e0693df46" xlink:to="loc_cybn_March2024PrivatePlacementMember_b3770b95-a298-4761-94f2-53bd3344df26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfCommonSharesHeldInEscrow_23e70713-5134-4b9b-b31a-3f7c70042cd9" xlink:href="cybn-20250331.xsd#cybn_NumberOfCommonSharesHeldInEscrow"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_NumberOfCommonSharesHeldInEscrow_23e70713-5134-4b9b-b31a-3f7c70042cd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommonStockSharesAuthorizedValue_48be67bf-948d-4eb2-be8a-d249e8ef11ef" xlink:href="cybn-20250331.xsd#cybn_CommonStockSharesAuthorizedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_CommonStockSharesAuthorizedValue_48be67bf-948d-4eb2-be8a-d249e8ef11ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughShareOfferingEquity_c508c8eb-644a-4aac-a59b-712be43391c3" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughShareOfferingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_NumberOfSharesIssuedThroughShareOfferingEquity_c508c8eb-644a-4aac-a59b-712be43391c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SharePricePerCommonShare_6def5f15-8400-4f32-b2a7-b03e17687442" xlink:href="cybn-20250331.xsd#cybn_SharePricePerCommonShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_SharePricePerCommonShare_6def5f15-8400-4f32-b2a7-b03e17687442" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_7b9ef9c8-f8ec-48cc-ad64-c1e0bdf303b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_7b9ef9c8-f8ec-48cc-ad64-c1e0bdf303b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_cf6c4c8a-156b-4d06-8f95-c2a51ec50601" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_cf6c4c8a-156b-4d06-8f95-c2a51ec50601" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughShareConsolidationEquity_ce228016-c4f8-495b-879a-be9d68c4f0f6" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughShareConsolidationEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_IncreaseDecreaseThroughShareConsolidationEquity_ce228016-c4f8-495b-879a-be9d68c4f0f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommonSharesPurchasePeriodTerm_3a38ea32-ee1e-4716-b0f0-8594e0c59974" xlink:href="cybn-20250331.xsd#cybn_CommonSharesPurchasePeriodTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_CommonSharesPurchasePeriodTerm_3a38ea32-ee1e-4716-b0f0-8594e0c59974" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PercentageOfOutstandingCommonSharesOwn_bb55a4c6-e46c-478e-bc58-1f5d2d1963c5" xlink:href="cybn-20250331.xsd#cybn_PercentageOfOutstandingCommonSharesOwn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_PercentageOfOutstandingCommonSharesOwn_bb55a4c6-e46c-478e-bc58-1f5d2d1963c5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement_74978a8d-37f6-4250-824a-e6648892b50d" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement_74978a8d-37f6-4250-824a-e6648892b50d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement_e9b3b574-d1be-45e4-8855-6a0d1cc40f99" xlink:href="cybn-20250331.xsd#cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement_e9b3b574-d1be-45e4-8855-6a0d1cc40f99" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement_279867c8-2c9d-4aaa-a226-e6b928e2e59a" xlink:href="cybn-20250331.xsd#cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement_279867c8-2c9d-4aaa-a226-e6b928e2e59a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_55988720-26bc-49bd-aebe-865a909e402f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_ifrs-full_ProfessionalFeesExpense_55988720-26bc-49bd-aebe-865a909e402f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfCommonShares_144c819e-d085-4d9a-b2c0-de2fe26e52c5" xlink:href="cybn-20250331.xsd#cybn_NumberOfCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_NumberOfCommonShares_144c819e-d085-4d9a-b2c0-de2fe26e52c5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfCommonSharePurchaseWarrants_5555ba96-99ad-44df-a18e-a831f0e8cf7d" xlink:href="cybn-20250331.xsd#cybn_NumberOfCommonSharePurchaseWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_NumberOfCommonSharePurchaseWarrants_5555ba96-99ad-44df-a18e-a831f0e8cf7d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesSubjectToResaleRestrictions_d2f4b7f9-44ec-4018-9e92-ccd367baa554" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesSubjectToResaleRestrictions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_NumberOfSharesSubjectToResaleRestrictions_d2f4b7f9-44ec-4018-9e92-ccd367baa554" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_129f059a-c4b4-43fc-beea-fcd9c884a80e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_129f059a-c4b4-43fc-beea-fcd9c884a80e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments_146f50cb-a7ff-48a2-b746-955282faaf96" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments_146f50cb-a7ff-48a2-b746-955282faaf96" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommonSharesExchangeRate_2d07df63-a0db-4fd7-8adb-42a8a81911be" xlink:href="cybn-20250331.xsd#cybn_CommonSharesExchangeRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_CommonSharesExchangeRate_2d07df63-a0db-4fd7-8adb-42a8a81911be" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity_79fcd894-b5f1-4304-869a-44f0e585b0ab" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity_79fcd894-b5f1-4304-869a-44f0e585b0ab" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity_0464711f-cab5-453b-a442-0f621c755cc4" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity_0464711f-cab5-453b-a442-0f621c755cc4" xlink:type="arc" order="20"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALSummaryofsharecapitalDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALSummaryofsharecapitalDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/SHARECAPITALSummaryofsharecapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e518f3f-79b8-443a-91cc-f9741a0da24b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_eb342b97-2c02-4346-aee4-a8b5cbcf2d54" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e518f3f-79b8-443a-91cc-f9741a0da24b" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_eb342b97-2c02-4346-aee4-a8b5cbcf2d54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_d58a6d6e-8e20-4acd-9381-02cf195bb9ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_eb342b97-2c02-4346-aee4-a8b5cbcf2d54" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_d58a6d6e-8e20-4acd-9381-02cf195bb9ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_d58a6d6e-8e20-4acd-9381-02cf195bb9ae_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_d58a6d6e-8e20-4acd-9381-02cf195bb9ae" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_d58a6d6e-8e20-4acd-9381-02cf195bb9ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_54ea4c81-df52-4221-b30d-2d9f97653475" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_d58a6d6e-8e20-4acd-9381-02cf195bb9ae" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_54ea4c81-df52-4221-b30d-2d9f97653475" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassBSharesMember_ab1207bb-800a-4cb1-b4c1-d10dbdbb74a6" xlink:href="cybn-20250331.xsd#cybn_ClassBSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_54ea4c81-df52-4221-b30d-2d9f97653475" xlink:to="loc_cybn_ClassBSharesMember_ab1207bb-800a-4cb1-b4c1-d10dbdbb74a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_e7633d0b-b846-479a-b478-b06dd121371c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e518f3f-79b8-443a-91cc-f9741a0da24b" xlink:to="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_e7633d0b-b846-479a-b478-b06dd121371c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_1419fa0d-bd1a-4564-ad35-21d3349d8152" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_e7633d0b-b846-479a-b478-b06dd121371c" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_1419fa0d-bd1a-4564-ad35-21d3349d8152" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares_ac219544-4652-4270-ad5b-36fb3dbdefeb" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_e7633d0b-b846-479a-b478-b06dd121371c" xlink:to="loc_cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares_ac219544-4652-4270-ad5b-36fb3dbdefeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_cd669531-8e69-4591-a613-646965f29643" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALSummaryofwarrantsDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec0a83b4-fc23-4702-aef7-c7c3955c4437" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_4aa0fcdc-f367-4f8f-a7ac-10dd6ad2b2cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec0a83b4-fc23-4702-aef7-c7c3955c4437" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_4aa0fcdc-f367-4f8f-a7ac-10dd6ad2b2cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fa5b7b9d-2691-4bc1-90e9-58ce56d52a4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_4aa0fcdc-f367-4f8f-a7ac-10dd6ad2b2cc" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fa5b7b9d-2691-4bc1-90e9-58ce56d52a4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_fa5b7b9d-2691-4bc1-90e9-58ce56d52a4c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fa5b7b9d-2691-4bc1-90e9-58ce56d52a4c" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_fa5b7b9d-2691-4bc1-90e9-58ce56d52a4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_1c66b12f-a381-47c2-978e-8f860b2d28c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fa5b7b9d-2691-4bc1-90e9-58ce56d52a4c" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_1c66b12f-a381-47c2-978e-8f860b2d28c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommonSharePurchaseWarrantsMember_c47f0b2b-5044-4c7a-9f48-6a3c5a5178c7" xlink:href="cybn-20250331.xsd#cybn_CommonSharePurchaseWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_1c66b12f-a381-47c2-978e-8f860b2d28c5" xlink:to="loc_cybn_CommonSharePurchaseWarrantsMember_c47f0b2b-5044-4c7a-9f48-6a3c5a5178c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_UnitPurchaseWarrantsMember_d2ce4c42-3508-403f-83cc-a55632183c39" xlink:href="cybn-20250331.xsd#cybn_UnitPurchaseWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_1c66b12f-a381-47c2-978e-8f860b2d28c5" xlink:to="loc_cybn_UnitPurchaseWarrantsMember_d2ce4c42-3508-403f-83cc-a55632183c39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantsNumberOfSharesRollForward_09e8333e-02f1-484d-b608-d9a834686ae1" xlink:href="cybn-20250331.xsd#cybn_WarrantsNumberOfSharesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec0a83b4-fc23-4702-aef7-c7c3955c4437" xlink:to="loc_cybn_WarrantsNumberOfSharesRollForward_09e8333e-02f1-484d-b608-d9a834686ae1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_7f31b9eb-5b7b-4339-ae37-b9f5e51ffa53" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_WarrantsNumberOfSharesRollForward_09e8333e-02f1-484d-b608-d9a834686ae1" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_7f31b9eb-5b7b-4339-ae37-b9f5e51ffa53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement_e5a0bd37-4a00-4e88-8d02-bdc8cd84f3e0" xlink:href="cybn-20250331.xsd#cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_WarrantsNumberOfSharesRollForward_09e8333e-02f1-484d-b608-d9a834686ae1" xlink:to="loc_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement_e5a0bd37-4a00-4e88-8d02-bdc8cd84f3e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_debea07f-b9e5-4e5a-9a46-eff05d18ab32" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_WarrantsNumberOfSharesRollForward_09e8333e-02f1-484d-b608-d9a834686ae1" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_debea07f-b9e5-4e5a-9a46-eff05d18ab32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_5f1b3be6-c318-41ac-83e5-6e4f360d841e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_WarrantsNumberOfSharesRollForward_09e8333e-02f1-484d-b608-d9a834686ae1" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_5f1b3be6-c318-41ac-83e5-6e4f360d841e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_d12e1b20-fe47-44ff-a2eb-cc1a333ed5ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_a70c27fc-895d-48a1-8c76-ed565b724ab4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec0a83b4-fc23-4702-aef7-c7c3955c4437" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_a70c27fc-895d-48a1-8c76-ed565b724ab4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantsWeightedAverageExercisePriceRollForward_503b14fe-d905-4758-8ed5-a6d0d8e29005" xlink:href="cybn-20250331.xsd#cybn_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec0a83b4-fc23-4702-aef7-c7c3955c4437" xlink:to="loc_cybn_WarrantsWeightedAverageExercisePriceRollForward_503b14fe-d905-4758-8ed5-a6d0d8e29005" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_6b83a1e8-abcd-4148-b2f0-064e27137e9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_WarrantsWeightedAverageExercisePriceRollForward_503b14fe-d905-4758-8ed5-a6d0d8e29005" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_6b83a1e8-abcd-4148-b2f0-064e27137e9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement_000c5194-98f4-4577-a245-4f082847b0e7" xlink:href="cybn-20250331.xsd#cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_WarrantsWeightedAverageExercisePriceRollForward_503b14fe-d905-4758-8ed5-a6d0d8e29005" xlink:to="loc_cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement_000c5194-98f4-4577-a245-4f082847b0e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_4ec808c6-8275-42b4-a7da-6bad9b838e6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_WarrantsWeightedAverageExercisePriceRollForward_503b14fe-d905-4758-8ed5-a6d0d8e29005" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_4ec808c6-8275-42b4-a7da-6bad9b838e6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_702cb618-bef2-449b-87cd-1c5cb5c04661" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_WarrantsWeightedAverageExercisePriceRollForward_503b14fe-d905-4758-8ed5-a6d0d8e29005" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_702cb618-bef2-449b-87cd-1c5cb5c04661" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_193d87ef-8e80-4ab3-840c-c9ffa221a5cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfCommonShares_1133b24a-25c2-4f7b-b5aa-d7c69ac87f0f" xlink:href="cybn-20250331.xsd#cybn_NumberOfCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec0a83b4-fc23-4702-aef7-c7c3955c4437" xlink:to="loc_cybn_NumberOfCommonShares_1133b24a-25c2-4f7b-b5aa-d7c69ac87f0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfCommonSharePurchaseWarrants_a340ef2b-5922-494d-be0b-c1a5a30d1870" xlink:href="cybn-20250331.xsd#cybn_NumberOfCommonSharePurchaseWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec0a83b4-fc23-4702-aef7-c7c3955c4437" xlink:to="loc_cybn_NumberOfCommonSharePurchaseWarrants_a340ef2b-5922-494d-be0b-c1a5a30d1870" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement_a733ba28-8b8a-4209-8a98-ffe7fbdf6fe1" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec0a83b4-fc23-4702-aef7-c7c3955c4437" xlink:to="loc_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement_a733ba28-8b8a-4209-8a98-ffe7fbdf6fe1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_c2e83792-bf4a-4241-bb7c-1d50dcc84be5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec0a83b4-fc23-4702-aef7-c7c3955c4437" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_c2e83792-bf4a-4241-bb7c-1d50dcc84be5" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALNarrativeWarrantsDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c2eb40b9-5226-4613-a697-5437561e0207" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c2eb40b9-5226-4613-a697-5437561e0207" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ab3047ce-10b2-4ced-b17e-97423365d06f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c2eb40b9-5226-4613-a697-5437561e0207" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ab3047ce-10b2-4ced-b17e-97423365d06f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_ab3047ce-10b2-4ced-b17e-97423365d06f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ab3047ce-10b2-4ced-b17e-97423365d06f" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_ab3047ce-10b2-4ced-b17e-97423365d06f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_2399f078-c350-4455-b0c5-a8e1ef21e733" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ab3047ce-10b2-4ced-b17e-97423365d06f" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_2399f078-c350-4455-b0c5-a8e1ef21e733" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommonSharePurchaseWarrantsMember_6a1625a8-11f7-41b4-9a50-ef5011bf590b" xlink:href="cybn-20250331.xsd#cybn_CommonSharePurchaseWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_2399f078-c350-4455-b0c5-a8e1ef21e733" xlink:to="loc_cybn_CommonSharePurchaseWarrantsMember_6a1625a8-11f7-41b4-9a50-ef5011bf590b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_August2023CompensationCommonShareWarrantMember_5b0c4c56-8118-43e2-8923-f5529b59a5f0" xlink:href="cybn-20250331.xsd#cybn_August2023CompensationCommonShareWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_2399f078-c350-4455-b0c5-a8e1ef21e733" xlink:to="loc_cybn_August2023CompensationCommonShareWarrantMember_5b0c4c56-8118-43e2-8923-f5529b59a5f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_November2023CompensationCommonShareWarrantMember_e555e1e8-8e17-487a-bcac-e9b488cc7d7a" xlink:href="cybn-20250331.xsd#cybn_November2023CompensationCommonShareWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_2399f078-c350-4455-b0c5-a8e1ef21e733" xlink:to="loc_cybn_November2023CompensationCommonShareWarrantMember_e555e1e8-8e17-487a-bcac-e9b488cc7d7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrantedToOfficersAndDirectorsMember_1a82daf2-4db8-4841-a577-e142c0b6b883" xlink:href="cybn-20250331.xsd#cybn_GrantedToOfficersAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_2399f078-c350-4455-b0c5-a8e1ef21e733" xlink:to="loc_cybn_GrantedToOfficersAndDirectorsMember_1a82daf2-4db8-4841-a577-e142c0b6b883" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_bdb4b59a-dbe9-4cb3-8b60-28824cd3cf7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c2eb40b9-5226-4613-a697-5437561e0207" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_bdb4b59a-dbe9-4cb3-8b60-28824cd3cf7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_bdb4b59a-dbe9-4cb3-8b60-28824cd3cf7a_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_bdb4b59a-dbe9-4cb3-8b60-28824cd3cf7a" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_bdb4b59a-dbe9-4cb3-8b60-28824cd3cf7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_4ee999b8-9168-488c-8975-dfb98aec5f83" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_bdb4b59a-dbe9-4cb3-8b60-28824cd3cf7a" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_4ee999b8-9168-488c-8975-dfb98aec5f83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantReserveMember_8a2d82ae-ff84-4215-b9b6-537fbc4da19e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantReserveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_4ee999b8-9168-488c-8975-dfb98aec5f83" xlink:to="loc_ifrs-full_WarrantReserveMember_8a2d82ae-ff84-4215-b9b6-537fbc4da19e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_6d83fb8c-faaf-4b18-98c0-35f50a2ddac0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_6d83fb8c-faaf-4b18-98c0-35f50a2ddac0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_2d49e21f-08b4-437a-a18a-6f6b78fe14c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_2d49e21f-08b4-437a-a18a-6f6b78fe14c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_6c1b92f1-5c86-4cdd-ac3b-540db1767273" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_6c1b92f1-5c86-4cdd-ac3b-540db1767273" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_de07152d-dc14-4de4-b978-4ef0a9087d29" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_de07152d-dc14-4de4-b978-4ef0a9087d29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement_5f3b353f-5aea-44b2-94c5-3326a3ab10de" xlink:href="cybn-20250331.xsd#cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement_5f3b353f-5aea-44b2-94c5-3326a3ab10de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_59ca9a01-7620-4026-bbbf-c1ef9310bb03" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_59ca9a01-7620-4026-bbbf-c1ef9310bb03" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement_9ee0a0ac-ee58-4353-b737-fd659601d736" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement_9ee0a0ac-ee58-4353-b737-fd659601d736" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended_c3630154-5d53-40d5-a3e3-31e8645676c5" xlink:href="cybn-20250331.xsd#cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended_c3630154-5d53-40d5-a3e3-31e8645676c5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_4d48f21f-db95-4b9b-aec7-4a930a805371" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_4d48f21f-db95-4b9b-aec7-4a930a805371" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6144a17d-fab3-4d76-9f76-c463d66b8a6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_666c6c3c-bc51-4ef7-a689-7e6476876258" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6144a17d-fab3-4d76-9f76-c463d66b8a6e" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_666c6c3c-bc51-4ef7-a689-7e6476876258" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_693bd09f-64b7-44c4-a232-9d231c77c862" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_666c6c3c-bc51-4ef7-a689-7e6476876258" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_693bd09f-64b7-44c4-a232-9d231c77c862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_693bd09f-64b7-44c4-a232-9d231c77c862_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_693bd09f-64b7-44c4-a232-9d231c77c862" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_693bd09f-64b7-44c4-a232-9d231c77c862_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_96efb358-764b-4896-a3e0-2dde6bc67350" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_693bd09f-64b7-44c4-a232-9d231c77c862" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_96efb358-764b-4896-a3e0-2dde6bc67350" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_August2023CompensationCommonShareWarrantMember_a860a5d5-e48d-4c8d-a366-86f35e80e6a8" xlink:href="cybn-20250331.xsd#cybn_August2023CompensationCommonShareWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_96efb358-764b-4896-a3e0-2dde6bc67350" xlink:to="loc_cybn_August2023CompensationCommonShareWarrantMember_a860a5d5-e48d-4c8d-a366-86f35e80e6a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_November2023CompensationCommonShareWarrantMember_1a984f23-892d-4704-898f-d51e026afc8e" xlink:href="cybn-20250331.xsd#cybn_November2023CompensationCommonShareWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_96efb358-764b-4896-a3e0-2dde6bc67350" xlink:to="loc_cybn_November2023CompensationCommonShareWarrantMember_1a984f23-892d-4704-898f-d51e026afc8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_9c0c8f86-0c1a-4469-93ae-210d8d39b890" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6144a17d-fab3-4d76-9f76-c463d66b8a6e" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_9c0c8f86-0c1a-4469-93ae-210d8d39b890" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted_c6517dec-ff6c-4a95-8e66-64505dbd4f39" xlink:href="cybn-20250331.xsd#cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6144a17d-fab3-4d76-9f76-c463d66b8a6e" xlink:to="loc_cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted_c6517dec-ff6c-4a95-8e66-64505dbd4f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ExpectedVolatilityOtherEquityInstrumentsGranted_a55162e4-ca42-4f8d-a9ee-74f336582b41" xlink:href="cybn-20250331.xsd#cybn_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6144a17d-fab3-4d76-9f76-c463d66b8a6e" xlink:to="loc_cybn_ExpectedVolatilityOtherEquityInstrumentsGranted_a55162e4-ca42-4f8d-a9ee-74f336582b41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_906a2ac7-8e08-4344-a8b9-46be6e18f2a5" xlink:href="cybn-20250331.xsd#cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6144a17d-fab3-4d76-9f76-c463d66b8a6e" xlink:to="loc_cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_906a2ac7-8e08-4344-a8b9-46be6e18f2a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_40714cd0-66da-44f3-8b6c-cbadb424dc5a" xlink:href="cybn-20250331.xsd#cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6144a17d-fab3-4d76-9f76-c463d66b8a6e" xlink:to="loc_cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_40714cd0-66da-44f3-8b6c-cbadb424dc5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SharePricePerCommonShare_5e5e7c7a-53dd-4f11-8bb3-61e9c3a6ffd7" xlink:href="cybn-20250331.xsd#cybn_SharePricePerCommonShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6144a17d-fab3-4d76-9f76-c463d66b8a6e" xlink:to="loc_cybn_SharePricePerCommonShare_5e5e7c7a-53dd-4f11-8bb3-61e9c3a6ffd7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_0b32b68f-5b34-4775-a3ff-c535ef22d938" xlink:href="cybn-20250331.xsd#cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6144a17d-fab3-4d76-9f76-c463d66b8a6e" xlink:to="loc_cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_0b32b68f-5b34-4775-a3ff-c535ef22d938" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_658e0bad-65b7-4579-ae7b-172c09e8b190" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ebca30ec-ed68-4c6e-9824-0a68d4dc1713" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_658e0bad-65b7-4579-ae7b-172c09e8b190" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ebca30ec-ed68-4c6e-9824-0a68d4dc1713" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f20fbef7-ec3f-481b-8e7c-0e23c06995da" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ebca30ec-ed68-4c6e-9824-0a68d4dc1713" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f20fbef7-ec3f-481b-8e7c-0e23c06995da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f20fbef7-ec3f-481b-8e7c-0e23c06995da_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f20fbef7-ec3f-481b-8e7c-0e23c06995da" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_f20fbef7-ec3f-481b-8e7c-0e23c06995da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_72f7f226-ab41-4f73-a3cf-4c30b466b5f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f20fbef7-ec3f-481b-8e7c-0e23c06995da" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_72f7f226-ab41-4f73-a3cf-4c30b466b5f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommonSharePurchaseWarrantsMember_c906f519-1ab9-46d6-8787-0ad594307e78" xlink:href="cybn-20250331.xsd#cybn_CommonSharePurchaseWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_72f7f226-ab41-4f73-a3cf-4c30b466b5f9" xlink:to="loc_cybn_CommonSharePurchaseWarrantsMember_c906f519-1ab9-46d6-8787-0ad594307e78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodAxis_22b04dc4-cd49-4141-9236-ba2e35c70c59" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ebca30ec-ed68-4c6e-9824-0a68d4dc1713" xlink:to="loc_cybn_WarrantExpirationPeriodAxis_22b04dc4-cd49-4141-9236-ba2e35c70c59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodDomain_22b04dc4-cd49-4141-9236-ba2e35c70c59_default" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cybn_WarrantExpirationPeriodAxis_22b04dc4-cd49-4141-9236-ba2e35c70c59" xlink:to="loc_cybn_WarrantExpirationPeriodDomain_22b04dc4-cd49-4141-9236-ba2e35c70c59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodDomain_b1f2e209-c213-41e3-80f2-b375cc571f75" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cybn_WarrantExpirationPeriodAxis_22b04dc4-cd49-4141-9236-ba2e35c70c59" xlink:to="loc_cybn_WarrantExpirationPeriodDomain_b1f2e209-c213-41e3-80f2-b375cc571f75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodOneMember_aa616630-1267-4bf3-b9eb-632480ce65ab" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_WarrantExpirationPeriodDomain_b1f2e209-c213-41e3-80f2-b375cc571f75" xlink:to="loc_cybn_WarrantExpirationPeriodOneMember_aa616630-1267-4bf3-b9eb-632480ce65ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodTwoMember_bc7a56bf-ddbe-4fd0-8d5b-d1ebba59021c" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_WarrantExpirationPeriodDomain_b1f2e209-c213-41e3-80f2-b375cc571f75" xlink:to="loc_cybn_WarrantExpirationPeriodTwoMember_bc7a56bf-ddbe-4fd0-8d5b-d1ebba59021c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodThreeMember_44adf6d9-31f9-41db-868f-0695c27dfa16" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_WarrantExpirationPeriodDomain_b1f2e209-c213-41e3-80f2-b375cc571f75" xlink:to="loc_cybn_WarrantExpirationPeriodThreeMember_44adf6d9-31f9-41db-868f-0695c27dfa16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodFourMember_504695d5-2ba6-4b00-91b5-2f2e4f33b14b" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_WarrantExpirationPeriodDomain_b1f2e209-c213-41e3-80f2-b375cc571f75" xlink:to="loc_cybn_WarrantExpirationPeriodFourMember_504695d5-2ba6-4b00-91b5-2f2e4f33b14b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodFiveMember_9c577e8d-0dd0-40e3-b59a-dc0238a52d20" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_WarrantExpirationPeriodDomain_b1f2e209-c213-41e3-80f2-b375cc571f75" xlink:to="loc_cybn_WarrantExpirationPeriodFiveMember_9c577e8d-0dd0-40e3-b59a-dc0238a52d20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_d2b7fa9d-cdff-4506-ab36-dde3032fdef8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_658e0bad-65b7-4579-ae7b-172c09e8b190" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_d2b7fa9d-cdff-4506-ab36-dde3032fdef8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_27372f55-bd31-4b75-81ef-c9d8ba92112a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_658e0bad-65b7-4579-ae7b-172c09e8b190" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_27372f55-bd31-4b75-81ef-c9d8ba92112a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_c4d0fd91-12f5-4636-af3b-6a6cbe466d52" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_658e0bad-65b7-4579-ae7b-172c09e8b190" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_c4d0fd91-12f5-4636-af3b-6a6cbe466d52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_ce850e46-d18a-46cb-bb17-71785b26dde3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_658e0bad-65b7-4579-ae7b-172c09e8b190" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_ce850e46-d18a-46cb-bb17-71785b26dde3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_729c3960-3124-42a6-b623-2be9ce5e29d7" xlink:href="cybn-20250331.xsd#cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_658e0bad-65b7-4579-ae7b-172c09e8b190" xlink:to="loc_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_729c3960-3124-42a6-b623-2be9ce5e29d7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALNarrativeStockoptionsDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_708ed013-0b72-4c75-b78b-cd82d1c9d4a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_708ed013-0b72-4c75-b78b-cd82d1c9d4a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_91f86017-f412-4ea7-8877-bc95dccaa528" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_708ed013-0b72-4c75-b78b-cd82d1c9d4a0" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_91f86017-f412-4ea7-8877-bc95dccaa528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_91f86017-f412-4ea7-8877-bc95dccaa528_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_91f86017-f412-4ea7-8877-bc95dccaa528" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_91f86017-f412-4ea7-8877-bc95dccaa528_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_1162b8ef-909d-4489-8d42-6ceb06aa8b4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_91f86017-f412-4ea7-8877-bc95dccaa528" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_1162b8ef-909d-4489-8d42-6ceb06aa8b4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_811775fe-d056-4d5c-a867-9ae21631fd03" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_1162b8ef-909d-4489-8d42-6ceb06aa8b4f" xlink:to="loc_ifrs-full_OrdinarySharesMember_811775fe-d056-4d5c-a867-9ae21631fd03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b53fc96d-3624-4bbb-a7c2-2d213e30bae1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_708ed013-0b72-4c75-b78b-cd82d1c9d4a0" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b53fc96d-3624-4bbb-a7c2-2d213e30bae1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b53fc96d-3624-4bbb-a7c2-2d213e30bae1_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b53fc96d-3624-4bbb-a7c2-2d213e30bae1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b53fc96d-3624-4bbb-a7c2-2d213e30bae1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_32ad40a2-bf25-4ea1-9f02-c4dda086d389" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b53fc96d-3624-4bbb-a7c2-2d213e30bae1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_32ad40a2-bf25-4ea1-9f02-c4dda086d389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrantedToOfficersAndDirectorsMember_0219c5ab-bbdd-4f01-8cfb-96355d64a3a0" xlink:href="cybn-20250331.xsd#cybn_GrantedToOfficersAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_32ad40a2-bf25-4ea1-9f02-c4dda086d389" xlink:to="loc_cybn_GrantedToOfficersAndDirectorsMember_0219c5ab-bbdd-4f01-8cfb-96355d64a3a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrantedToOfficersMember_bc260a0c-71f6-45cd-8b5b-d423e9aeb0bb" xlink:href="cybn-20250331.xsd#cybn_GrantedToOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_GrantedToOfficersAndDirectorsMember_0219c5ab-bbdd-4f01-8cfb-96355d64a3a0" xlink:to="loc_cybn_GrantedToOfficersMember_bc260a0c-71f6-45cd-8b5b-d423e9aeb0bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrantedToDirectorsMember_f2eb564a-e558-449f-b40f-2c7d24552fa1" xlink:href="cybn-20250331.xsd#cybn_GrantedToDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_GrantedToOfficersMember_bc260a0c-71f6-45cd-8b5b-d423e9aeb0bb" xlink:to="loc_cybn_GrantedToDirectorsMember_f2eb564a-e558-449f-b40f-2c7d24552fa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrantedToEmployeesMember_6857e26d-be6c-4672-b741-b5542a68be9f" xlink:href="cybn-20250331.xsd#cybn_GrantedToEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_32ad40a2-bf25-4ea1-9f02-c4dda086d389" xlink:to="loc_cybn_GrantedToEmployeesMember_6857e26d-be6c-4672-b741-b5542a68be9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrantedToConsultantsMember_8971c981-6b2f-4a88-816e-2446fa77ac36" xlink:href="cybn-20250331.xsd#cybn_GrantedToConsultantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_32ad40a2-bf25-4ea1-9f02-c4dda086d389" xlink:to="loc_cybn_GrantedToConsultantsMember_8971c981-6b2f-4a88-816e-2446fa77ac36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodAxis_c070af11-0bf7-41d0-97e1-67d5845a94c8" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_708ed013-0b72-4c75-b78b-cd82d1c9d4a0" xlink:to="loc_cybn_OptionExpirationPeriodAxis_c070af11-0bf7-41d0-97e1-67d5845a94c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodDomain_c070af11-0bf7-41d0-97e1-67d5845a94c8_default" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cybn_OptionExpirationPeriodAxis_c070af11-0bf7-41d0-97e1-67d5845a94c8" xlink:to="loc_cybn_OptionExpirationPeriodDomain_c070af11-0bf7-41d0-97e1-67d5845a94c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cybn_OptionExpirationPeriodAxis_c070af11-0bf7-41d0-97e1-67d5845a94c8" xlink:to="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyTwoMember_745ff73c-b5a4-43b7-ac6b-5619ed57da11" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:to="loc_cybn_OptionExpirationPeriodThirtyTwoMember_745ff73c-b5a4-43b7-ac6b-5619ed57da11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyFourMember_e4dcd4c0-6ce9-46ad-b2c0-c3472c310893" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:to="loc_cybn_OptionExpirationPeriodThirtyFourMember_e4dcd4c0-6ce9-46ad-b2c0-c3472c310893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyFiveMember_738cfd63-a84f-455e-ae4c-ecfac282bddf" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:to="loc_cybn_OptionExpirationPeriodThirtyFiveMember_738cfd63-a84f-455e-ae4c-ecfac282bddf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtySixMember_b4966145-bdb6-4141-98bd-12e971802abd" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:to="loc_cybn_OptionExpirationPeriodThirtySixMember_b4966145-bdb6-4141-98bd-12e971802abd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyNineMember_73f73d7b-7117-4a59-aca2-c4dfb4b84b2c" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:to="loc_cybn_OptionExpirationPeriodTwentyNineMember_73f73d7b-7117-4a59-aca2-c4dfb4b84b2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyFourAndThirtyMember_eb12ea27-e690-442c-9d3f-191b380435b3" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyFourAndThirtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:to="loc_cybn_OptionExpirationPeriodTwentyFourAndThirtyMember_eb12ea27-e690-442c-9d3f-191b380435b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyFourMember_017c37eb-9b9e-434f-8d41-fae3b0cc5a85" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodTwentyFourAndThirtyMember_eb12ea27-e690-442c-9d3f-191b380435b3" xlink:to="loc_cybn_OptionExpirationPeriodTwentyFourMember_017c37eb-9b9e-434f-8d41-fae3b0cc5a85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyMember_8e93bea2-6f7f-4af3-b1f6-2f2e8c161c53" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodTwentyFourAndThirtyMember_eb12ea27-e690-442c-9d3f-191b380435b3" xlink:to="loc_cybn_OptionExpirationPeriodThirtyMember_8e93bea2-6f7f-4af3-b1f6-2f2e8c161c53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember_dd45916e-4e79-40e7-bf91-e590ba4ed8fe" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:to="loc_cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember_dd45916e-4e79-40e7-bf91-e590ba4ed8fe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtySevenMember_51d61e5b-eba0-4403-8984-5ffcc6d5082d" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember_dd45916e-4e79-40e7-bf91-e590ba4ed8fe" xlink:to="loc_cybn_OptionExpirationPeriodThirtySevenMember_51d61e5b-eba0-4403-8984-5ffcc6d5082d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyEightMember_c13b7101-8e90-41b7-a3f0-793283e5a470" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember_dd45916e-4e79-40e7-bf91-e590ba4ed8fe" xlink:to="loc_cybn_OptionExpirationPeriodThirtyEightMember_c13b7101-8e90-41b7-a3f0-793283e5a470" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyOneMember_e6df09d8-6d89-4e29-bc01-776bb70ae909" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:to="loc_cybn_OptionExpirationPeriodThirtyOneMember_e6df09d8-6d89-4e29-bc01-776bb70ae909" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareBasedPaymentVestingPeriodAxis_dd22acea-507e-49a3-afc9-e1418f5a4fe3" xlink:href="cybn-20250331.xsd#cybn_ShareBasedPaymentVestingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_708ed013-0b72-4c75-b78b-cd82d1c9d4a0" xlink:to="loc_cybn_ShareBasedPaymentVestingPeriodAxis_dd22acea-507e-49a3-afc9-e1418f5a4fe3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareBasedPaymentVestingPeriodDomain_dd22acea-507e-49a3-afc9-e1418f5a4fe3_default" xlink:href="cybn-20250331.xsd#cybn_ShareBasedPaymentVestingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cybn_ShareBasedPaymentVestingPeriodAxis_dd22acea-507e-49a3-afc9-e1418f5a4fe3" xlink:to="loc_cybn_ShareBasedPaymentVestingPeriodDomain_dd22acea-507e-49a3-afc9-e1418f5a4fe3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareBasedPaymentVestingPeriodDomain_fc07e688-d505-4ee6-9c09-e9892c5b780a" xlink:href="cybn-20250331.xsd#cybn_ShareBasedPaymentVestingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cybn_ShareBasedPaymentVestingPeriodAxis_dd22acea-507e-49a3-afc9-e1418f5a4fe3" xlink:to="loc_cybn_ShareBasedPaymentVestingPeriodDomain_fc07e688-d505-4ee6-9c09-e9892c5b780a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareOptionsVestingFirstTrancheMember_a2bdcdcd-a4ab-431c-ba3c-ef9615c25a66" xlink:href="cybn-20250331.xsd#cybn_ShareOptionsVestingFirstTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_ShareBasedPaymentVestingPeriodDomain_fc07e688-d505-4ee6-9c09-e9892c5b780a" xlink:to="loc_cybn_ShareOptionsVestingFirstTrancheMember_a2bdcdcd-a4ab-431c-ba3c-ef9615c25a66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareOptionsVestingSecondTrancheMember_08c35e10-551e-45be-bfb5-10d2c161056a" xlink:href="cybn-20250331.xsd#cybn_ShareOptionsVestingSecondTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_ShareBasedPaymentVestingPeriodDomain_fc07e688-d505-4ee6-9c09-e9892c5b780a" xlink:to="loc_cybn_ShareOptionsVestingSecondTrancheMember_08c35e10-551e-45be-bfb5-10d2c161056a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareOptionsVestingThirdTrancheMember_4b9289ea-b8c1-4f38-add3-bd02084771ea" xlink:href="cybn-20250331.xsd#cybn_ShareOptionsVestingThirdTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_ShareBasedPaymentVestingPeriodDomain_fc07e688-d505-4ee6-9c09-e9892c5b780a" xlink:to="loc_cybn_ShareOptionsVestingThirdTrancheMember_4b9289ea-b8c1-4f38-add3-bd02084771ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareOptionsVestingFourthTrancheMember_423ae738-9282-4553-98b1-9113b14375cf" xlink:href="cybn-20250331.xsd#cybn_ShareOptionsVestingFourthTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_ShareBasedPaymentVestingPeriodDomain_fc07e688-d505-4ee6-9c09-e9892c5b780a" xlink:to="loc_cybn_ShareOptionsVestingFourthTrancheMember_423ae738-9282-4553-98b1-9113b14375cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareOptionsVestingFifthTrancheMember_69f680db-e817-4d51-8ef3-7b9d84fce8d5" xlink:href="cybn-20250331.xsd#cybn_ShareOptionsVestingFifthTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_ShareBasedPaymentVestingPeriodDomain_fc07e688-d505-4ee6-9c09-e9892c5b780a" xlink:to="loc_cybn_ShareOptionsVestingFifthTrancheMember_69f680db-e817-4d51-8ef3-7b9d84fce8d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8d1d8c29-6037-410f-8ba8-8c12d2de47f3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_708ed013-0b72-4c75-b78b-cd82d1c9d4a0" xlink:to="loc_srt_RangeAxis_8d1d8c29-6037-410f-8ba8-8c12d2de47f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8d1d8c29-6037-410f-8ba8-8c12d2de47f3_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8d1d8c29-6037-410f-8ba8-8c12d2de47f3" xlink:to="loc_srt_RangeMember_8d1d8c29-6037-410f-8ba8-8c12d2de47f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0da49e7d-9dc3-4e70-8b98-8cb221169cee" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8d1d8c29-6037-410f-8ba8-8c12d2de47f3" xlink:to="loc_srt_RangeMember_0da49e7d-9dc3-4e70-8b98-8cb221169cee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f6d28ceb-c93c-4071-b42c-7d6c9d910f94" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0da49e7d-9dc3-4e70-8b98-8cb221169cee" xlink:to="loc_srt_MinimumMember_f6d28ceb-c93c-4071-b42c-7d6c9d910f94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_96b73b7d-2cb7-48d2-8581-f75fa6c22c4b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0da49e7d-9dc3-4e70-8b98-8cb221169cee" xlink:to="loc_srt_MaximumMember_96b73b7d-2cb7-48d2-8581-f75fa6c22c4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding_18de1af7-68f7-4f6d-befe-6f6c693fbc6e" xlink:href="cybn-20250331.xsd#cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding_18de1af7-68f7-4f6d-befe-6f6c693fbc6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_2074f17f-3dfb-44f0-8b6c-84330e5a39b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_2074f17f-3dfb-44f0-8b6c-84330e5a39b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_ae0624fc-38e3-48c5-b7a5-f301951c6a02" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_ae0624fc-38e3-48c5-b7a5-f301951c6a02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_9007d759-37fa-4dbc-9686-5cf206cab8cd" xlink:href="cybn-20250331.xsd#cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_9007d759-37fa-4dbc-9686-5cf206cab8cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_9af8a8a5-87d9-4ba5-81c1-7e71b3c7b40d" xlink:href="cybn-20250331.xsd#cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_9af8a8a5-87d9-4ba5-81c1-7e71b3c7b40d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_6869c68f-9003-426a-b3d2-de007ccdc17c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_6869c68f-9003-426a-b3d2-de007ccdc17c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_ecfedb6b-7da1-419c-b0a6-30a840ff32d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_ecfedb6b-7da1-419c-b0a6-30a840ff32d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_7fe90b03-c815-45e9-b5a5-7352b22cb951" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_7fe90b03-c815-45e9-b5a5-7352b22cb951" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_a8b926bf-dcde-4108-83ee-0267d910aedd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_a8b926bf-dcde-4108-83ee-0267d910aedd" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f53b3081-9a0c-4fc7-9174-e4acf370e2ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_39e6cf99-6c91-4d8c-9462-2eae6b740d5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f53b3081-9a0c-4fc7-9174-e4acf370e2ec" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_39e6cf99-6c91-4d8c-9462-2eae6b740d5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodAxis_bd0d3872-060c-4bd8-9d83-45b54a5a6ad4" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_39e6cf99-6c91-4d8c-9462-2eae6b740d5b" xlink:to="loc_cybn_OptionExpirationPeriodAxis_bd0d3872-060c-4bd8-9d83-45b54a5a6ad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodDomain_bd0d3872-060c-4bd8-9d83-45b54a5a6ad4_default" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cybn_OptionExpirationPeriodAxis_bd0d3872-060c-4bd8-9d83-45b54a5a6ad4" xlink:to="loc_cybn_OptionExpirationPeriodDomain_bd0d3872-060c-4bd8-9d83-45b54a5a6ad4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cybn_OptionExpirationPeriodAxis_bd0d3872-060c-4bd8-9d83-45b54a5a6ad4" xlink:to="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyTwoMember_a6b41361-5322-4a23-9ee3-6f3f7e504b36" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodThirtyTwoMember_a6b41361-5322-4a23-9ee3-6f3f7e504b36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyFourMember_95c3578d-b261-48ff-8313-3d6bf467211e" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodThirtyFourMember_95c3578d-b261-48ff-8313-3d6bf467211e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyFiveMember_de78136e-648a-493b-af2a-8ce6afa0f252" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodThirtyFiveMember_de78136e-648a-493b-af2a-8ce6afa0f252" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtySixMember_ec23ff4d-ea8d-4296-b034-81a7265cd115" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodThirtySixMember_ec23ff4d-ea8d-4296-b034-81a7265cd115" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyNineMember_22ed1c6d-ac80-4bb7-ac12-ed0788c2aa6b" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodTwentyNineMember_22ed1c6d-ac80-4bb7-ac12-ed0788c2aa6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyFourMember_3f488394-692c-413d-bc0c-dbb4e14c8dc8" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodTwentyFourMember_3f488394-692c-413d-bc0c-dbb4e14c8dc8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyMember_a74ed0e1-2273-4e7f-9e46-920f5895e498" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodThirtyMember_a74ed0e1-2273-4e7f-9e46-920f5895e498" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtySevenMember_ae42d48f-e9ca-459e-b27d-48dbea9d6dcd" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodThirtySevenMember_ae42d48f-e9ca-459e-b27d-48dbea9d6dcd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyEightMember_82c0666b-a84c-46d3-a38f-f4e6a8892aa7" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodThirtyEightMember_82c0666b-a84c-46d3-a38f-f4e6a8892aa7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyOneMember_25d92c3d-c233-4622-8c37-d11764266bb4" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodThirtyOneMember_25d92c3d-c233-4622-8c37-d11764266bb4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5798694e-b0d2-4271-a856-c82152a4488c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_39e6cf99-6c91-4d8c-9462-2eae6b740d5b" xlink:to="loc_srt_RangeAxis_5798694e-b0d2-4271-a856-c82152a4488c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5798694e-b0d2-4271-a856-c82152a4488c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5798694e-b0d2-4271-a856-c82152a4488c" xlink:to="loc_srt_RangeMember_5798694e-b0d2-4271-a856-c82152a4488c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fcc81119-2fa2-4fba-9209-96d8d83fcd8c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5798694e-b0d2-4271-a856-c82152a4488c" xlink:to="loc_srt_RangeMember_fcc81119-2fa2-4fba-9209-96d8d83fcd8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f11f6559-2a68-4eaa-a067-f2d389415b34" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fcc81119-2fa2-4fba-9209-96d8d83fcd8c" xlink:to="loc_srt_MinimumMember_f11f6559-2a68-4eaa-a067-f2d389415b34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_762c0ded-6c3e-400d-bcb2-9bab0b16558b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fcc81119-2fa2-4fba-9209-96d8d83fcd8c" xlink:to="loc_srt_MaximumMember_762c0ded-6c3e-400d-bcb2-9bab0b16558b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_dc003637-ddbf-4d0b-99e2-225531ca42af" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f53b3081-9a0c-4fc7-9174-e4acf370e2ec" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_dc003637-ddbf-4d0b-99e2-225531ca42af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_52254ec7-f618-408c-a038-a7019b824c93" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f53b3081-9a0c-4fc7-9174-e4acf370e2ec" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_52254ec7-f618-408c-a038-a7019b824c93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_f904a1b6-c25c-47d0-a51b-eb6bf438c2a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f53b3081-9a0c-4fc7-9174-e4acf370e2ec" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_f904a1b6-c25c-47d0-a51b-eb6bf438c2a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_aa072334-5c8e-4a71-921d-53345449efbe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f53b3081-9a0c-4fc7-9174-e4acf370e2ec" xlink:to="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_aa072334-5c8e-4a71-921d-53345449efbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted_f8cdafca-0da0-4548-8fcc-2f712c509adc" xlink:href="cybn-20250331.xsd#cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f53b3081-9a0c-4fc7-9174-e4acf370e2ec" xlink:to="loc_cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted_f8cdafca-0da0-4548-8fcc-2f712c509adc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_329a1047-b5f2-4c0a-8644-1a45a708ba39" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f53b3081-9a0c-4fc7-9174-e4acf370e2ec" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_329a1047-b5f2-4c0a-8644-1a45a708ba39" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_6308bbe7-d22e-42fd-a312-5c2a4636f538" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f53b3081-9a0c-4fc7-9174-e4acf370e2ec" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_6308bbe7-d22e-42fd-a312-5c2a4636f538" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALSummaryofstockoptioninformationDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_db85a482-30e2-471c-a0ee-73413230d1e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_680a7f79-4c65-41b9-bc38-f20b81ce371d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_db85a482-30e2-471c-a0ee-73413230d1e2" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_680a7f79-4c65-41b9-bc38-f20b81ce371d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodAxis_8b35601a-d1a8-4c62-8ee1-e6e78fd7f3b9" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_680a7f79-4c65-41b9-bc38-f20b81ce371d" xlink:to="loc_cybn_OptionExpirationPeriodAxis_8b35601a-d1a8-4c62-8ee1-e6e78fd7f3b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodDomain_8b35601a-d1a8-4c62-8ee1-e6e78fd7f3b9_default" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cybn_OptionExpirationPeriodAxis_8b35601a-d1a8-4c62-8ee1-e6e78fd7f3b9" xlink:to="loc_cybn_OptionExpirationPeriodDomain_8b35601a-d1a8-4c62-8ee1-e6e78fd7f3b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cybn_OptionExpirationPeriodAxis_8b35601a-d1a8-4c62-8ee1-e6e78fd7f3b9" xlink:to="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodOneMember_89945b29-03da-4f53-a0ec-2916ffb2a9ba" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodOneMember_89945b29-03da-4f53-a0ec-2916ffb2a9ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwoMember_e19ba77e-4ce4-4fa1-a3d0-9da0ee317ffc" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwoMember_e19ba77e-4ce4-4fa1-a3d0-9da0ee317ffc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThreeMember_b76e7d7e-6f9a-400e-8e5c-916d59801374" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodThreeMember_b76e7d7e-6f9a-400e-8e5c-916d59801374" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodFourMember_21ec41bd-4ae4-48c3-b1c3-a254660b1fb9" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodFourMember_21ec41bd-4ae4-48c3-b1c3-a254660b1fb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodFiveMember_10aaa2d8-24ce-4406-80e3-2353528206e5" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodFiveMember_10aaa2d8-24ce-4406-80e3-2353528206e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodSixMember_3d9c4fa4-bffb-49e1-9fa0-f943ba045efe" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodSixMember_3d9c4fa4-bffb-49e1-9fa0-f943ba045efe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodSevenMember_e7fd849f-e358-4210-800d-c3d4db15be73" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodSevenMember_e7fd849f-e358-4210-800d-c3d4db15be73" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodEightMember_a978a60b-fc32-4113-a8dc-d0a1fd55ea03" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodEightMember_a978a60b-fc32-4113-a8dc-d0a1fd55ea03" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodNineMember_29ec9dcb-c36f-4eb7-9da5-3a6f0bbbed14" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodNineMember_29ec9dcb-c36f-4eb7-9da5-3a6f0bbbed14" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTenMember_ef6d5a56-94d1-4360-a7b3-d649b07b9d68" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTenMember_ef6d5a56-94d1-4360-a7b3-d649b07b9d68" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodElevenMember_a49f795c-27c0-46ff-8464-d821a6147f4f" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodElevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodElevenMember_a49f795c-27c0-46ff-8464-d821a6147f4f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwelveMember_72bf97ef-1b8f-4378-a1bd-d08c1e7188fa" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwelveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwelveMember_72bf97ef-1b8f-4378-a1bd-d08c1e7188fa" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirteenMember_1ba05a0f-0eaa-409f-a5cc-8bbaafe70e14" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodThirteenMember_1ba05a0f-0eaa-409f-a5cc-8bbaafe70e14" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodFourteenMember_d0986393-0b98-4769-b47a-ee3ada3c2281" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodFourteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodFourteenMember_d0986393-0b98-4769-b47a-ee3ada3c2281" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodFifteenMember_099f1b16-f313-4781-967b-c7649b446a8d" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodFifteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodFifteenMember_099f1b16-f313-4781-967b-c7649b446a8d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodSixteenMember_e0c1923a-1651-4828-95c5-ca536c13217f" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodSixteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodSixteenMember_e0c1923a-1651-4828-95c5-ca536c13217f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodSeventeenMember_e9b9dc58-620a-4aa2-a3ba-13e233fd91e7" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodSeventeenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodSeventeenMember_e9b9dc58-620a-4aa2-a3ba-13e233fd91e7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodEighteenMember_289545a0-c74f-46b8-8c96-2c722247b0ce" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodEighteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodEighteenMember_289545a0-c74f-46b8-8c96-2c722247b0ce" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodNineteenMember_ae40c267-36f1-4d67-9206-5f535aa42f95" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodNineteenMember_ae40c267-36f1-4d67-9206-5f535aa42f95" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyMember_5d71c3a0-c640-436c-b950-8b56632ff6f8" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentyMember_5d71c3a0-c640-436c-b950-8b56632ff6f8" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyOneMember_15c7ff6f-6f9f-482f-9c20-a16252b35d57" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentyOneMember_15c7ff6f-6f9f-482f-9c20-a16252b35d57" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyTwoMember_e3ec032f-43f7-4589-96c5-49f8af0847ba" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentyTwoMember_e3ec032f-43f7-4589-96c5-49f8af0847ba" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyThreeMember_5b826138-34d4-4426-add6-1612f43d74e9" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentyThreeMember_5b826138-34d4-4426-add6-1612f43d74e9" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyFourMember_f058e294-ce6c-456f-9061-9ee5451a32a8" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentyFourMember_f058e294-ce6c-456f-9061-9ee5451a32a8" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyFiveMember_00bd4cb9-1c9c-4642-9bbf-abd51875f968" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentyFiveMember_00bd4cb9-1c9c-4642-9bbf-abd51875f968" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentySixMember_991570a4-f6c0-4e8e-a9ae-4aa8b295eee2" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentySixMember_991570a4-f6c0-4e8e-a9ae-4aa8b295eee2" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentySevenMember_040b9671-996a-41fb-9a35-d89a090bdf28" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentySevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentySevenMember_040b9671-996a-41fb-9a35-d89a090bdf28" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyEightMember_bbb1a3b5-4d6e-404c-865e-220e98f53f4f" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentyEightMember_bbb1a3b5-4d6e-404c-865e-220e98f53f4f" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyNineMember_0fead762-2c83-4230-aef4-bbf4a9092c79" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentyNineMember_0fead762-2c83-4230-aef4-bbf4a9092c79" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyMember_3f51ebb1-4d1a-453b-b4bf-b92de47a1861" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodThirtyMember_3f51ebb1-4d1a-453b-b4bf-b92de47a1861" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyOneMember_38882e4a-df5e-44b9-abc4-7eb3cb69ad43" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodThirtyOneMember_38882e4a-df5e-44b9-abc4-7eb3cb69ad43" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyTwoMember_042b9db6-cef3-49f9-a603-0db532755210" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodThirtyTwoMember_042b9db6-cef3-49f9-a603-0db532755210" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyThreeMember_2638d2f5-ef30-4f74-8aee-0ff9f6aadfea" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodThirtyThreeMember_2638d2f5-ef30-4f74-8aee-0ff9f6aadfea" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyFourMember_04b71c01-a0ed-45ee-80be-49d576681ecc" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodThirtyFourMember_04b71c01-a0ed-45ee-80be-49d576681ecc" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyFiveMember_a1a8767b-731c-4958-99e5-b6c938671c66" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodThirtyFiveMember_a1a8767b-731c-4958-99e5-b6c938671c66" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtySixMember_5da4eb7d-be0d-42de-aa4f-6357ac9be247" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodThirtySixMember_5da4eb7d-be0d-42de-aa4f-6357ac9be247" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_85bf7935-1fa0-4c8c-a843-20c29b79c4e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_db85a482-30e2-471c-a0ee-73413230d1e2" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_85bf7935-1fa0-4c8c-a843-20c29b79c4e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_eea00655-d2d7-41d7-8701-a85f957abfde" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_db85a482-30e2-471c-a0ee-73413230d1e2" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_eea00655-d2d7-41d7-8701-a85f957abfde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_4744dc1b-d1a3-421b-bd04-73e4bc898bf8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_db85a482-30e2-471c-a0ee-73413230d1e2" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_4744dc1b-d1a3-421b-bd04-73e4bc898bf8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_1b9f4db6-f100-470d-a0af-24a3734d0374" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_db85a482-30e2-471c-a0ee-73413230d1e2" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_1b9f4db6-f100-470d-a0af-24a3734d0374" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_ee429980-df25-4189-bae8-6baf2eafc008" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_db85a482-30e2-471c-a0ee-73413230d1e2" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_ee429980-df25-4189-bae8-6baf2eafc008" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_4b3582b7-d939-42d7-a37b-9f057fd87afd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_952751e7-0309-4130-a7de-16af201001b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_4b3582b7-d939-42d7-a37b-9f057fd87afd" xlink:to="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_952751e7-0309-4130-a7de-16af201001b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4bb8fb84-1e09-494f-98e5-b6af9d7047d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_952751e7-0309-4130-a7de-16af201001b9" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4bb8fb84-1e09-494f-98e5-b6af9d7047d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4bb8fb84-1e09-494f-98e5-b6af9d7047d9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4bb8fb84-1e09-494f-98e5-b6af9d7047d9" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4bb8fb84-1e09-494f-98e5-b6af9d7047d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_e19eb9c6-3116-460b-a70b-f0cef61e8930" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4bb8fb84-1e09-494f-98e5-b6af9d7047d9" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_e19eb9c6-3116-460b-a70b-f0cef61e8930" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareBasedPaymentArrangementOptionMember_09dd2813-6c0e-4e17-92a5-8b90577a50fa" xlink:href="cybn-20250331.xsd#cybn_ShareBasedPaymentArrangementOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_e19eb9c6-3116-460b-a70b-f0cef61e8930" xlink:to="loc_cybn_ShareBasedPaymentArrangementOptionMember_09dd2813-6c0e-4e17-92a5-8b90577a50fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_876c1dfe-4d98-4b1d-8656-80682fc44b0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_e19eb9c6-3116-460b-a70b-f0cef61e8930" xlink:to="loc_ifrs-full_WarrantsMember_876c1dfe-4d98-4b1d-8656-80682fc44b0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncomeStatementLocationAxis_f73ad67d-96a2-4dca-9df0-3a37026f3ae7" xlink:href="cybn-20250331.xsd#cybn_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_952751e7-0309-4130-a7de-16af201001b9" xlink:to="loc_cybn_IncomeStatementLocationAxis_f73ad67d-96a2-4dca-9df0-3a37026f3ae7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncomeStatementLocationDomain_f73ad67d-96a2-4dca-9df0-3a37026f3ae7_default" xlink:href="cybn-20250331.xsd#cybn_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cybn_IncomeStatementLocationAxis_f73ad67d-96a2-4dca-9df0-3a37026f3ae7" xlink:to="loc_cybn_IncomeStatementLocationDomain_f73ad67d-96a2-4dca-9df0-3a37026f3ae7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncomeStatementLocationDomain_e53c8ab8-9628-434a-9e27-a973cff471aa" xlink:href="cybn-20250331.xsd#cybn_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cybn_IncomeStatementLocationAxis_f73ad67d-96a2-4dca-9df0-3a37026f3ae7" xlink:to="loc_cybn_IncomeStatementLocationDomain_e53c8ab8-9628-434a-9e27-a973cff471aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GeneralAndAdministrativeExpenseMember_56b6456e-7be6-4fb8-bc7e-afb9f2b3f55c" xlink:href="cybn-20250331.xsd#cybn_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_IncomeStatementLocationDomain_e53c8ab8-9628-434a-9e27-a973cff471aa" xlink:to="loc_cybn_GeneralAndAdministrativeExpenseMember_56b6456e-7be6-4fb8-bc7e-afb9f2b3f55c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ResearchComponentMember_9e6168a9-0d69-474f-b1a4-12ee4a8eeb9b" xlink:href="cybn-20250331.xsd#cybn_ResearchComponentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_IncomeStatementLocationDomain_e53c8ab8-9628-434a-9e27-a973cff471aa" xlink:to="loc_cybn_ResearchComponentMember_9e6168a9-0d69-474f-b1a4-12ee4a8eeb9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_303a7b4e-af29-4244-a030-1e61d8893e9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_4b3582b7-d939-42d7-a37b-9f057fd87afd" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_303a7b4e-af29-4244-a030-1e61d8893e9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_3f114bbc-1b7e-4204-af04-392127273f2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_4b3582b7-d939-42d7-a37b-9f057fd87afd" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_3f114bbc-1b7e-4204-af04-392127273f2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_5ee5a475-0329-4fdf-8561-69f2adba77a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_4b3582b7-d939-42d7-a37b-9f057fd87afd" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_5ee5a475-0329-4fdf-8561-69f2adba77a1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#CONTRACTSCOMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_COMMITMENTSLineItems_b5a3ca18-aece-411b-aef6-ef983cdf3f97" xlink:href="cybn-20250331.xsd#cybn_COMMITMENTSLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_COMMITMENTSTable_a8f96588-a3b8-4f5d-b9e9-1f4f3655712c" xlink:href="cybn-20250331.xsd#cybn_COMMITMENTSTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cybn_COMMITMENTSLineItems_b5a3ca18-aece-411b-aef6-ef983cdf3f97" xlink:to="loc_cybn_COMMITMENTSTable_a8f96588-a3b8-4f5d-b9e9-1f4f3655712c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ItemsOfContingentLiabilitiesAxis_004d793c-ad92-4b00-b00b-cc92bd84e544" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ItemsOfContingentLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cybn_COMMITMENTSTable_a8f96588-a3b8-4f5d-b9e9-1f4f3655712c" xlink:to="loc_ifrs-full_ItemsOfContingentLiabilitiesAxis_004d793c-ad92-4b00-b00b-cc92bd84e544" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ItemsOfContingentLiabilitiesDomain_004d793c-ad92-4b00-b00b-cc92bd84e544_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ItemsOfContingentLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ItemsOfContingentLiabilitiesAxis_004d793c-ad92-4b00-b00b-cc92bd84e544" xlink:to="loc_ifrs-full_ItemsOfContingentLiabilitiesDomain_004d793c-ad92-4b00-b00b-cc92bd84e544_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ItemsOfContingentLiabilitiesDomain_64e9996e-c0dc-4c14-8856-e9cede5381af" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ItemsOfContingentLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ItemsOfContingentLiabilitiesAxis_004d793c-ad92-4b00-b00b-cc92bd84e544" xlink:to="loc_ifrs-full_ItemsOfContingentLiabilitiesDomain_64e9996e-c0dc-4c14-8856-e9cede5381af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherContingentLiabilitiesMember_e06f60a7-4ec9-4af0-8ac9-77de9044f708" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherContingentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ItemsOfContingentLiabilitiesDomain_64e9996e-c0dc-4c14-8856-e9cede5381af" xlink:to="loc_ifrs-full_OtherContingentLiabilitiesMember_e06f60a7-4ec9-4af0-8ac9-77de9044f708" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCapitalCommitments_76f78418-8ccc-4768-b5df-2c8bf99051c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractualCapitalCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_COMMITMENTSLineItems_b5a3ca18-aece-411b-aef6-ef983cdf3f97" xlink:to="loc_ifrs-full_ContractualCapitalCommitments_76f78418-8ccc-4768-b5df-2c8bf99051c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SalesRoyaltyPercentage_54d3f044-854c-4ac2-a8a5-8c64f07b52ea" xlink:href="cybn-20250331.xsd#cybn_SalesRoyaltyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_COMMITMENTSLineItems_b5a3ca18-aece-411b-aef6-ef983cdf3f97" xlink:to="loc_cybn_SalesRoyaltyPercentage_54d3f044-854c-4ac2-a8a5-8c64f07b52ea" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_6390f1b0-0cbb-4600-9682-6ec7d50f571f" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_7914a5fe-3fac-4110-9497-257b0ed808db" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_6390f1b0-0cbb-4600-9682-6ec7d50f571f" xlink:to="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_7914a5fe-3fac-4110-9497-257b0ed808db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_86b07139-1f5a-4984-80d7-e63544b1f4a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_7914a5fe-3fac-4110-9497-257b0ed808db" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_86b07139-1f5a-4984-80d7-e63544b1f4a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_86b07139-1f5a-4984-80d7-e63544b1f4a9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_86b07139-1f5a-4984-80d7-e63544b1f4a9" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_86b07139-1f5a-4984-80d7-e63544b1f4a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_78eec2b6-6189-4f51-9e9f-a6e21d596cfe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_86b07139-1f5a-4984-80d7-e63544b1f4a9" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_78eec2b6-6189-4f51-9e9f-a6e21d596cfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_db41c549-2608-42c1-a169-629a82f605a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_78eec2b6-6189-4f51-9e9f-a6e21d596cfe" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_db41c549-2608-42c1-a169-629a82f605a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_5dfb721d-5aaa-4e68-a471-bb745f89a5ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_78eec2b6-6189-4f51-9e9f-a6e21d596cfe" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_5dfb721d-5aaa-4e68-a471-bb745f89a5ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_71f78bc3-40c6-4dfe-9385-6af92fa1e6fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_7914a5fe-3fac-4110-9497-257b0ed808db" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_71f78bc3-40c6-4dfe-9385-6af92fa1e6fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_71f78bc3-40c6-4dfe-9385-6af92fa1e6fa_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_71f78bc3-40c6-4dfe-9385-6af92fa1e6fa" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_71f78bc3-40c6-4dfe-9385-6af92fa1e6fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_0c641725-5655-4558-9281-564e83ed57c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_71f78bc3-40c6-4dfe-9385-6af92fa1e6fa" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_0c641725-5655-4558-9281-564e83ed57c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CashMember_a9daacc2-f19c-453b-9e44-0d8981241bb2" xlink:href="cybn-20250331.xsd#cybn_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_0c641725-5655-4558-9281-564e83ed57c4" xlink:to="loc_cybn_CashMember_a9daacc2-f19c-453b-9e44-0d8981241bb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember_c9b8a0cd-ecd2-4fb7-acf2-8d6e2cbaff85" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_0c641725-5655-4558-9281-564e83ed57c4" xlink:to="loc_ifrs-full_TradeReceivablesMember_c9b8a0cd-ecd2-4fb7-acf2-8d6e2cbaff85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_6b1b8360-0444-4295-8995-80bac112983b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_7914a5fe-3fac-4110-9497-257b0ed808db" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_6b1b8360-0444-4295-8995-80bac112983b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_6b1b8360-0444-4295-8995-80bac112983b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_6b1b8360-0444-4295-8995-80bac112983b" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_6b1b8360-0444-4295-8995-80bac112983b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_eaac8f6e-7d73-4b21-97f5-c736811d74dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_6b1b8360-0444-4295-8995-80bac112983b" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_eaac8f6e-7d73-4b21-97f5-c736811d74dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_4a22e53b-b8db-4324-b62e-ea2a56aca5ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_eaac8f6e-7d73-4b21-97f5-c736811d74dd" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_4a22e53b-b8db-4324-b62e-ea2a56aca5ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_41209467-671f-4572-8f3c-7d29d7ccc0f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_7914a5fe-3fac-4110-9497-257b0ed808db" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_41209467-671f-4572-8f3c-7d29d7ccc0f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_41209467-671f-4572-8f3c-7d29d7ccc0f7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_41209467-671f-4572-8f3c-7d29d7ccc0f7" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_41209467-671f-4572-8f3c-7d29d7ccc0f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f0d14633-e018-4b61-b4c5-d16f46cfa913" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_41209467-671f-4572-8f3c-7d29d7ccc0f7" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f0d14633-e018-4b61-b4c5-d16f46cfa913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AccountsPayableAndAccruedLiabilitiesMember_407697f8-30d9-4e7c-8fe0-017c578c2049" xlink:href="cybn-20250331.xsd#cybn_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f0d14633-e018-4b61-b4c5-d16f46cfa913" xlink:to="loc_cybn_AccountsPayableAndAccruedLiabilitiesMember_407697f8-30d9-4e7c-8fe0-017c578c2049" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_59c699e8-fdbb-4545-baae-c71d57834d55" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f0d14633-e018-4b61-b4c5-d16f46cfa913" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_59c699e8-fdbb-4545-baae-c71d57834d55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_dde08be9-bd56-4c29-be77-fa6d6c8abb7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_6390f1b0-0cbb-4600-9682-6ec7d50f571f" xlink:to="loc_ifrs-full_Cash_dde08be9-bd56-4c29-be77-fa6d6c8abb7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_65f79035-cf27-49d8-b198-8e30a425060d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_6390f1b0-0cbb-4600-9682-6ec7d50f571f" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_65f79035-cf27-49d8-b198-8e30a425060d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_a2130a81-98c2-40eb-89a8-0afed941ca00" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_6390f1b0-0cbb-4600-9682-6ec7d50f571f" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_a2130a81-98c2-40eb-89a8-0afed941ca00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_2e948b32-397f-4e77-b9fd-281858335a23" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_6390f1b0-0cbb-4600-9682-6ec7d50f571f" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_2e948b32-397f-4e77-b9fd-281858335a23" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#FINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_54a39549-acef-4788-a565-6aa1a2a40c02" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:to="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_54a39549-acef-4788-a565-6aa1a2a40c02" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_63b1c960-8530-4d99-8777-b287d33359e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_54a39549-acef-4788-a565-6aa1a2a40c02" xlink:to="loc_ifrs-full_TypesOfRisksAxis_63b1c960-8530-4d99-8777-b287d33359e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksDomain_63b1c960-8530-4d99-8777-b287d33359e4_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_63b1c960-8530-4d99-8777-b287d33359e4" xlink:to="loc_ifrs-full_TypesOfRisksDomain_63b1c960-8530-4d99-8777-b287d33359e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksDomain_4cab5e24-4fb1-4d75-bccf-416a33a673d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_63b1c960-8530-4d99-8777-b287d33359e4" xlink:to="loc_ifrs-full_TypesOfRisksDomain_4cab5e24-4fb1-4d75-bccf-416a33a673d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_4349aa9b-d7f3-47e0-8dc0-cfa6729cd8b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksDomain_4cab5e24-4fb1-4d75-bccf-416a33a673d7" xlink:to="loc_ifrs-full_CurrencyRiskMember_4349aa9b-d7f3-47e0-8dc0-cfa6729cd8b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_60b118f7-74b1-4649-9aab-94d7941123b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:to="loc_ifrs-full_Cash_60b118f7-74b1-4649-9aab-94d7941123b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_23729e75-f7e1-4e54-92df-169864fe5fb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:to="loc_ifrs-full_CurrentLiabilities_23729e75-f7e1-4e54-92df-169864fe5fb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_afe4bbed-66aa-4441-bb99-cd4e416130c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_afe4bbed-66aa-4441-bb99-cd4e416130c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent_9466682d-0c10-4aca-b113-19d532fe1784" xlink:href="cybn-20250331.xsd#cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:to="loc_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent_9466682d-0c10-4aca-b113-19d532fe1784" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss_7b012ac3-2ded-4332-8adc-e181aa485f87" xlink:href="cybn-20250331.xsd#cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:to="loc_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss_7b012ac3-2ded-4332-8adc-e181aa485f87" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash_6c7562eb-6fe8-44e3-b89f-0dfc80f34eb8" xlink:href="cybn-20250331.xsd#cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:to="loc_cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash_6c7562eb-6fe8-44e3-b89f-0dfc80f34eb8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_InterestRateRiskIncreaseDecreaseInInterestIncome_0ebf8d5e-9ce7-48c8-a7bf-e59496b1d697" xlink:href="cybn-20250331.xsd#cybn_InterestRateRiskIncreaseDecreaseInInterestIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:to="loc_cybn_InterestRateRiskIncreaseDecreaseInInterestIncome_0ebf8d5e-9ce7-48c8-a7bf-e59496b1d697" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_InterestRateRiskTerm_c6058572-f529-4086-a04c-711cd83fd199" xlink:href="cybn-20250331.xsd#cybn_InterestRateRiskTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:to="loc_cybn_InterestRateRiskTerm_c6058572-f529-4086-a04c-711cd83fd199" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_c211eb95-98be-460c-8847-f5adc5f5c144" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c925c40d-1193-4196-83fd-95c00891334d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_c211eb95-98be-460c-8847-f5adc5f5c144" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c925c40d-1193-4196-83fd-95c00891334d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_4c08c406-675b-4f4a-b6ed-a7de75784566" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c925c40d-1193-4196-83fd-95c00891334d" xlink:to="loc_srt_CurrencyAxis_4c08c406-675b-4f4a-b6ed-a7de75784566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_4c08c406-675b-4f4a-b6ed-a7de75784566_default" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_4c08c406-675b-4f4a-b6ed-a7de75784566" xlink:to="loc_currency_AllCurrenciesDomain_4c08c406-675b-4f4a-b6ed-a7de75784566_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_1efdd05f-1d11-4835-b8b9-7c9ae1f17148" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_4c08c406-675b-4f4a-b6ed-a7de75784566" xlink:to="loc_currency_AllCurrenciesDomain_1efdd05f-1d11-4835-b8b9-7c9ae1f17148" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_dad29d3e-ced4-4ff8-bf38-b223ff33ff93" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1efdd05f-1d11-4835-b8b9-7c9ae1f17148" xlink:to="loc_currency_USD_dad29d3e-ced4-4ff8-bf38-b223ff33ff93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_762f56cc-0c5d-4dd5-b9a7-f5f0c5b49d87" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1efdd05f-1d11-4835-b8b9-7c9ae1f17148" xlink:to="loc_currency_GBP_762f56cc-0c5d-4dd5-b9a7-f5f0c5b49d87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_adca0c4d-a8c2-4b49-a054-73e61be3a4d2" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_1efdd05f-1d11-4835-b8b9-7c9ae1f17148" xlink:to="loc_currency_EUR_adca0c4d-a8c2-4b49-a054-73e61be3a4d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis_1c4284d0-8174-4437-a0a5-f663838fd237" xlink:href="cybn-20250331.xsd#cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c925c40d-1193-4196-83fd-95c00891334d" xlink:to="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis_1c4284d0-8174-4437-a0a5-f663838fd237" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain_1c4284d0-8174-4437-a0a5-f663838fd237_default" xlink:href="cybn-20250331.xsd#cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis_1c4284d0-8174-4437-a0a5-f663838fd237" xlink:to="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain_1c4284d0-8174-4437-a0a5-f663838fd237_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain_af54d291-d2a3-4cb9-93c8-5a2a27b24e25" xlink:href="cybn-20250331.xsd#cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis_1c4284d0-8174-4437-a0a5-f663838fd237" xlink:to="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain_af54d291-d2a3-4cb9-93c8-5a2a27b24e25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CashMember_38b6140d-8438-4194-911a-9a59ce522fd5" xlink:href="cybn-20250331.xsd#cybn_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain_af54d291-d2a3-4cb9-93c8-5a2a27b24e25" xlink:to="loc_cybn_CashMember_38b6140d-8438-4194-911a-9a59ce522fd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember_3f81474f-08d5-4b97-8e05-f694696798d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain_af54d291-d2a3-4cb9-93c8-5a2a27b24e25" xlink:to="loc_ifrs-full_TradeReceivablesMember_3f81474f-08d5-4b97-8e05-f694696798d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AccountsPayableAndAccruedLiabilitiesMember_4bc4b2c2-9fda-4998-a73d-55263439ccb8" xlink:href="cybn-20250331.xsd#cybn_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain_af54d291-d2a3-4cb9-93c8-5a2a27b24e25" xlink:to="loc_cybn_AccountsPayableAndAccruedLiabilitiesMember_4bc4b2c2-9fda-4998-a73d-55263439ccb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_52596111-ff4b-4612-a48a-a2e097c4ce44" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain_af54d291-d2a3-4cb9-93c8-5a2a27b24e25" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_52596111-ff4b-4612-a48a-a2e097c4ce44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_FinancialAssetsAndLiabilities_129d9b50-6034-4f1a-bfaa-7b59c16bf086" xlink:href="cybn-20250331.xsd#cybn_FinancialAssetsAndLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_c211eb95-98be-460c-8847-f5adc5f5c144" xlink:to="loc_cybn_FinancialAssetsAndLiabilities_129d9b50-6034-4f1a-bfaa-7b59c16bf086" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_69170b91-c973-4274-86be-cd875757e8b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_c211eb95-98be-460c-8847-f5adc5f5c144" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_69170b91-c973-4274-86be-cd875757e8b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_a5e78a84-47d4-4faa-b0a7-b93a3d00c545" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_c211eb95-98be-460c-8847-f5adc5f5c144" xlink:to="loc_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_a5e78a84-47d4-4faa-b0a7-b93a3d00c545" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#INCOMETAXDeferredTaxAssetsDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_47a3475e-c99f-432e-992a-7fa3cddb641d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f25e1188-3a25-4102-b940-012fcce5fb71" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_47a3475e-c99f-432e-992a-7fa3cddb641d" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f25e1188-3a25-4102-b940-012fcce5fb71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_7de7dd9f-9af4-4122-ad74-50ca10e223d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f25e1188-3a25-4102-b940-012fcce5fb71" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_7de7dd9f-9af4-4122-ad74-50ca10e223d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_7de7dd9f-9af4-4122-ad74-50ca10e223d5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_7de7dd9f-9af4-4122-ad74-50ca10e223d5" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_7de7dd9f-9af4-4122-ad74-50ca10e223d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_25312568-bfe7-4d9d-83c2-c7bcb1096a89" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_7de7dd9f-9af4-4122-ad74-50ca10e223d5" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_25312568-bfe7-4d9d-83c2-c7bcb1096a89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_1504a2a9-a6e6-4200-b6b9-824c472525c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_25312568-bfe7-4d9d-83c2-c7bcb1096a89" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_1504a2a9-a6e6-4200-b6b9-824c472525c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DeferredCompensationMember_4a9591b7-5774-4797-a956-c60e1ca9efa6" xlink:href="cybn-20250331.xsd#cybn_DeferredCompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_25312568-bfe7-4d9d-83c2-c7bcb1096a89" xlink:to="loc_cybn_DeferredCompensationMember_4a9591b7-5774-4797-a956-c60e1ca9efa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_RDExpendituresMember_c2bffc26-8b31-47e8-84fe-7c2e8765912e" xlink:href="cybn-20250331.xsd#cybn_RDExpendituresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_25312568-bfe7-4d9d-83c2-c7bcb1096a89" xlink:to="loc_cybn_RDExpendituresMember_c2bffc26-8b31-47e8-84fe-7c2e8765912e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareIssuanceCostsMember_7cdfc7b9-4b47-480f-a6c2-f36f61fd181d" xlink:href="cybn-20250331.xsd#cybn_ShareIssuanceCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_25312568-bfe7-4d9d-83c2-c7bcb1096a89" xlink:to="loc_cybn_ShareIssuanceCostsMember_7cdfc7b9-4b47-480f-a6c2-f36f61fd181d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember_eec14e49-2dc0-4dba-b6a3-38cd9d3aad3d" xlink:href="cybn-20250331.xsd#cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_25312568-bfe7-4d9d-83c2-c7bcb1096a89" xlink:to="loc_cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember_eec14e49-2dc0-4dba-b6a3-38cd9d3aad3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8a4909a0-267d-40e9-b3d1-b484af43ab6d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f25e1188-3a25-4102-b940-012fcce5fb71" xlink:to="loc_srt_StatementGeographicalAxis_8a4909a0-267d-40e9-b3d1-b484af43ab6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8a4909a0-267d-40e9-b3d1-b484af43ab6d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8a4909a0-267d-40e9-b3d1-b484af43ab6d" xlink:to="loc_srt_SegmentGeographicalDomain_8a4909a0-267d-40e9-b3d1-b484af43ab6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e246ac3f-3251-40a7-9b08-f34859399b40" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8a4909a0-267d-40e9-b3d1-b484af43ab6d" xlink:to="loc_srt_SegmentGeographicalDomain_e246ac3f-3251-40a7-9b08-f34859399b40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_ab99f890-8eb3-4814-bab8-ebd13c03460a" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e246ac3f-3251-40a7-9b08-f34859399b40" xlink:to="loc_country_CA_ab99f890-8eb3-4814-bab8-ebd13c03460a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ab615412-9443-4a3c-9079-18c86dda5a9e" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e246ac3f-3251-40a7-9b08-f34859399b40" xlink:to="loc_country_US_ab615412-9443-4a3c-9079-18c86dda5a9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_8a9ffdb7-bbec-4c8e-b6c0-54abb1c448ea" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e246ac3f-3251-40a7-9b08-f34859399b40" xlink:to="loc_country_IE_8a9ffdb7-bbec-4c8e-b6c0-54abb1c448ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_1de04e4a-f19d-46cd-998d-3104937b648e" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e246ac3f-3251-40a7-9b08-f34859399b40" xlink:to="loc_country_GB_1de04e4a-f19d-46cd-998d-3104937b648e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrossDeferredTaxAssets_8a1c1735-5c39-4abe-95f3-c40be3365508" xlink:href="cybn-20250331.xsd#cybn_GrossDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_47a3475e-c99f-432e-992a-7fa3cddb641d" xlink:to="loc_cybn_GrossDeferredTaxAssets_8a1c1735-5c39-4abe-95f3-c40be3365508" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DeferredTaxAssetsValuationAllowance_630bd1ce-ffe9-4094-b5ad-c83c4d60e1f8" xlink:href="cybn-20250331.xsd#cybn_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_47a3475e-c99f-432e-992a-7fa3cddb641d" xlink:to="loc_cybn_DeferredTaxAssetsValuationAllowance_630bd1ce-ffe9-4094-b5ad-c83c4d60e1f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_d0f44e2b-17af-46b1-ab01-507110909ad4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_47a3475e-c99f-432e-992a-7fa3cddb641d" xlink:to="loc_ifrs-full_DeferredTaxAssets_d0f44e2b-17af-46b1-ab01-507110909ad4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#INCOMETAXNoncapitalLossesExpirationDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfNonCapitalLossesExpirationLineItems_00f90855-fe8f-438e-bde0-a5e7f7f6f753" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfNonCapitalLossesExpirationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable_e5f785e9-8276-41cc-b6b3-ddb9e45f0268" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfNonCapitalLossesExpirationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationLineItems_00f90855-fe8f-438e-bde0-a5e7f7f6f753" xlink:to="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable_e5f785e9-8276-41cc-b6b3-ddb9e45f0268" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LossCarryforwardExpirationAxis_3c2f4e85-c908-4f30-832b-1bb6604b79bf" xlink:href="cybn-20250331.xsd#cybn_LossCarryforwardExpirationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable_e5f785e9-8276-41cc-b6b3-ddb9e45f0268" xlink:to="loc_cybn_LossCarryforwardExpirationAxis_3c2f4e85-c908-4f30-832b-1bb6604b79bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LossCarryforwardExpirationDomain_3c2f4e85-c908-4f30-832b-1bb6604b79bf_default" xlink:href="cybn-20250331.xsd#cybn_LossCarryforwardExpirationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cybn_LossCarryforwardExpirationAxis_3c2f4e85-c908-4f30-832b-1bb6604b79bf" xlink:to="loc_cybn_LossCarryforwardExpirationDomain_3c2f4e85-c908-4f30-832b-1bb6604b79bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:href="cybn-20250331.xsd#cybn_LossCarryforwardExpirationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cybn_LossCarryforwardExpirationAxis_3c2f4e85-c908-4f30-832b-1bb6604b79bf" xlink:to="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2036Member_32bbee4a-d61d-4c70-809c-3c0c6fc285f3" xlink:href="cybn-20250331.xsd#cybn_A2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2036Member_32bbee4a-d61d-4c70-809c-3c0c6fc285f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2037Member_39c81b44-8ba4-4cb1-82b7-9dcf2262d033" xlink:href="cybn-20250331.xsd#cybn_A2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2037Member_39c81b44-8ba4-4cb1-82b7-9dcf2262d033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2038Member_ba60715e-2e01-4fd7-aaf6-ce587e1c2cad" xlink:href="cybn-20250331.xsd#cybn_A2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2038Member_ba60715e-2e01-4fd7-aaf6-ce587e1c2cad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2039Member_260d3dca-b588-4075-805e-451c12889872" xlink:href="cybn-20250331.xsd#cybn_A2039Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2039Member_260d3dca-b588-4075-805e-451c12889872" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2040Member_68f66e6e-a84e-4069-a79a-2e82cc6d3efc" xlink:href="cybn-20250331.xsd#cybn_A2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2040Member_68f66e6e-a84e-4069-a79a-2e82cc6d3efc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2041Member_91b21b40-bbd2-404f-8b52-ef84a8b4ee46" xlink:href="cybn-20250331.xsd#cybn_A2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2041Member_91b21b40-bbd2-404f-8b52-ef84a8b4ee46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2042Member_f10ed48f-8b8d-4017-9b81-b3f38a4af6a6" xlink:href="cybn-20250331.xsd#cybn_A2042Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2042Member_f10ed48f-8b8d-4017-9b81-b3f38a4af6a6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2043Member_8f6ef45b-d26c-4634-a7c2-517a5685a2b1" xlink:href="cybn-20250331.xsd#cybn_A2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2043Member_8f6ef45b-d26c-4634-a7c2-517a5685a2b1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2044Member_0b38c33d-ba7d-427f-9146-454bddd9bccd" xlink:href="cybn-20250331.xsd#cybn_A2044Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2044Member_0b38c33d-ba7d-427f-9146-454bddd9bccd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2045Member_d2c74987-6c74-4258-9d1f-8b4dee26f61e" xlink:href="cybn-20250331.xsd#cybn_A2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2045Member_d2c74987-6c74-4258-9d1f-8b4dee26f61e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_777a6f23-e94e-4633-ac4a-9ffbfbf4247a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable_e5f785e9-8276-41cc-b6b3-ddb9e45f0268" xlink:to="loc_srt_StatementGeographicalAxis_777a6f23-e94e-4633-ac4a-9ffbfbf4247a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_777a6f23-e94e-4633-ac4a-9ffbfbf4247a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_777a6f23-e94e-4633-ac4a-9ffbfbf4247a" xlink:to="loc_srt_SegmentGeographicalDomain_777a6f23-e94e-4633-ac4a-9ffbfbf4247a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ca930b70-8d81-4af2-a032-7dbedad9eaaf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_777a6f23-e94e-4633-ac4a-9ffbfbf4247a" xlink:to="loc_srt_SegmentGeographicalDomain_ca930b70-8d81-4af2-a032-7dbedad9eaaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_287a7bfd-9966-41d0-bef4-0eeae4e125a9" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca930b70-8d81-4af2-a032-7dbedad9eaaf" xlink:to="loc_country_CA_287a7bfd-9966-41d0-bef4-0eeae4e125a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0cb6b2ce-cb3e-4d88-945c-0d69591cf823" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca930b70-8d81-4af2-a032-7dbedad9eaaf" xlink:to="loc_country_US_0cb6b2ce-cb3e-4d88-945c-0d69591cf823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_d7109f96-835e-4a8e-a9e3-ed46b430ffa4" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca930b70-8d81-4af2-a032-7dbedad9eaaf" xlink:to="loc_country_IE_d7109f96-835e-4a8e-a9e3-ed46b430ffa4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_2083d2c1-a0f2-414c-95ab-ba55fd0aefc6" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ca930b70-8d81-4af2-a032-7dbedad9eaaf" xlink:to="loc_country_GB_2083d2c1-a0f2-414c-95ab-ba55fd0aefc6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NonCapitalLossCarryforward_1bd84b2d-dafe-425b-9ac8-dc3ff22929a5" xlink:href="cybn-20250331.xsd#cybn_NonCapitalLossCarryforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationLineItems_00f90855-fe8f-438e-bde0-a5e7f7f6f753" xlink:to="loc_cybn_NonCapitalLossCarryforward_1bd84b2d-dafe-425b-9ac8-dc3ff22929a5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/INCOMETAXAdditionalInformationDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#INCOMETAXAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/INCOMETAXAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfNonCapitalLossesExpirationLineItems_d1ab2306-fabd-44cd-becf-a9439aa60b38" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfNonCapitalLossesExpirationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable_b57e1f2b-6e4e-436f-984a-06ba2002d232" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfNonCapitalLossesExpirationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationLineItems_d1ab2306-fabd-44cd-becf-a9439aa60b38" xlink:to="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable_b57e1f2b-6e4e-436f-984a-06ba2002d232" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4b42b825-bbae-41a5-acb7-bdd3863a8b44" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable_b57e1f2b-6e4e-436f-984a-06ba2002d232" xlink:to="loc_srt_StatementGeographicalAxis_4b42b825-bbae-41a5-acb7-bdd3863a8b44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4b42b825-bbae-41a5-acb7-bdd3863a8b44_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4b42b825-bbae-41a5-acb7-bdd3863a8b44" xlink:to="loc_srt_SegmentGeographicalDomain_4b42b825-bbae-41a5-acb7-bdd3863a8b44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_94f2f334-8fcf-4767-81ad-907ff26f3395" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4b42b825-bbae-41a5-acb7-bdd3863a8b44" xlink:to="loc_srt_SegmentGeographicalDomain_94f2f334-8fcf-4767-81ad-907ff26f3395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_734f2450-d8e0-417c-93c2-b04d6f3452d9" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_94f2f334-8fcf-4767-81ad-907ff26f3395" xlink:to="loc_country_GB_734f2450-d8e0-417c-93c2-b04d6f3452d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_92f11202-a5a1-49e9-b3e6-5ab6f3c8a8c8" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_94f2f334-8fcf-4767-81ad-907ff26f3395" xlink:to="loc_country_US_92f11202-a5a1-49e9-b3e6-5ab6f3c8a8c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LossCarryforwardExpirationAxis_8d9bdf84-b178-4402-8729-ac9381cc53db" xlink:href="cybn-20250331.xsd#cybn_LossCarryforwardExpirationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable_b57e1f2b-6e4e-436f-984a-06ba2002d232" xlink:to="loc_cybn_LossCarryforwardExpirationAxis_8d9bdf84-b178-4402-8729-ac9381cc53db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LossCarryforwardExpirationDomain_8d9bdf84-b178-4402-8729-ac9381cc53db_default" xlink:href="cybn-20250331.xsd#cybn_LossCarryforwardExpirationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cybn_LossCarryforwardExpirationAxis_8d9bdf84-b178-4402-8729-ac9381cc53db" xlink:to="loc_cybn_LossCarryforwardExpirationDomain_8d9bdf84-b178-4402-8729-ac9381cc53db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LossCarryforwardExpirationDomain_8af9d68e-3ec6-488a-b9bc-00fb68a6bb98" xlink:href="cybn-20250331.xsd#cybn_LossCarryforwardExpirationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cybn_LossCarryforwardExpirationAxis_8d9bdf84-b178-4402-8729-ac9381cc53db" xlink:to="loc_cybn_LossCarryforwardExpirationDomain_8af9d68e-3ec6-488a-b9bc-00fb68a6bb98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A20402041Member_12b9b08b-85f0-4112-9b04-7f2d05f8b138" xlink:href="cybn-20250331.xsd#cybn_A20402041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_8af9d68e-3ec6-488a-b9bc-00fb68a6bb98" xlink:to="loc_cybn_A20402041Member_12b9b08b-85f0-4112-9b04-7f2d05f8b138" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2040Member_519e25ac-9e99-4237-aacf-a7ea6b7017e9" xlink:href="cybn-20250331.xsd#cybn_A2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_8af9d68e-3ec6-488a-b9bc-00fb68a6bb98" xlink:to="loc_cybn_A2040Member_519e25ac-9e99-4237-aacf-a7ea6b7017e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NonCapitalLossCarryforward_e489b5d5-84a7-4280-ba5c-9dc446287abb" xlink:href="cybn-20250331.xsd#cybn_NonCapitalLossCarryforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationLineItems_d1ab2306-fabd-44cd-becf-a9439aa60b38" xlink:to="loc_cybn_NonCapitalLossCarryforward_e489b5d5-84a7-4280-ba5c-9dc446287abb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_Section382Limitation_346b2062-b2a4-4a0f-9174-4f2926a3b3f1" xlink:href="cybn-20250331.xsd#cybn_Section382Limitation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationLineItems_d1ab2306-fabd-44cd-becf-a9439aa60b38" xlink:to="loc_cybn_Section382Limitation_346b2062-b2a4-4a0f-9174-4f2926a3b3f1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cybin.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://cybin.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_41105518-258b-482a-a243-81ce2135017c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_41105518-258b-482a-a243-81ce2135017c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_5b810831-8268-4d55-8f5e-c14d91694d83" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_41105518-258b-482a-a243-81ce2135017c" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_5b810831-8268-4d55-8f5e-c14d91694d83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_5b810831-8268-4d55-8f5e-c14d91694d83_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_5b810831-8268-4d55-8f5e-c14d91694d83" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_5b810831-8268-4d55-8f5e-c14d91694d83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_7df0c10b-3440-44b8-b020-a608e962a7ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_5b810831-8268-4d55-8f5e-c14d91694d83" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_7df0c10b-3440-44b8-b020-a608e962a7ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_fb2b0c63-3fe4-4e06-94ca-391192444600" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_7df0c10b-3440-44b8-b020-a608e962a7ac" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_fb2b0c63-3fe4-4e06-94ca-391192444600" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_0b3f848d-ce22-4502-a1bc-363ba96424da" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_41105518-258b-482a-a243-81ce2135017c" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_0b3f848d-ce22-4502-a1bc-363ba96424da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_0b3f848d-ce22-4502-a1bc-363ba96424da_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_0b3f848d-ce22-4502-a1bc-363ba96424da" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_0b3f848d-ce22-4502-a1bc-363ba96424da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_8f38e12d-e846-4847-b34f-352d8735ce18" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_0b3f848d-ce22-4502-a1bc-363ba96424da" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_8f38e12d-e846-4847-b34f-352d8735ce18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_18efe883-af7f-43ea-9330-8992ecb2fa49" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_8f38e12d-e846-4847-b34f-352d8735ce18" xlink:to="loc_ifrs-full_OrdinarySharesMember_18efe883-af7f-43ea-9330-8992ecb2fa49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassesOfDebtInstrumentsAxis_0a9b4a6a-f441-4d71-8343-57f0a3adf377" xlink:href="cybn-20250331.xsd#cybn_ClassesOfDebtInstrumentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_41105518-258b-482a-a243-81ce2135017c" xlink:to="loc_cybn_ClassesOfDebtInstrumentsAxis_0a9b4a6a-f441-4d71-8343-57f0a3adf377" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassesOfDebtInstrumentsDomain_0a9b4a6a-f441-4d71-8343-57f0a3adf377_default" xlink:href="cybn-20250331.xsd#cybn_ClassesOfDebtInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cybn_ClassesOfDebtInstrumentsAxis_0a9b4a6a-f441-4d71-8343-57f0a3adf377" xlink:to="loc_cybn_ClassesOfDebtInstrumentsDomain_0a9b4a6a-f441-4d71-8343-57f0a3adf377_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassesOfDebtInstrumentsDomain_fecf2630-af7b-4549-ade5-00a5f988c2b3" xlink:href="cybn-20250331.xsd#cybn_ClassesOfDebtInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cybn_ClassesOfDebtInstrumentsAxis_0a9b4a6a-f441-4d71-8343-57f0a3adf377" xlink:to="loc_cybn_ClassesOfDebtInstrumentsDomain_fecf2630-af7b-4549-ade5-00a5f988c2b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ConvertibleDebenturesMember_3a5e54e2-a5f2-491d-b916-cc116fb7e305" xlink:href="cybn-20250331.xsd#cybn_ConvertibleDebenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_ClassesOfDebtInstrumentsDomain_fecf2630-af7b-4549-ade5-00a5f988c2b3" xlink:to="loc_cybn_ConvertibleDebenturesMember_3a5e54e2-a5f2-491d-b916-cc116fb7e305" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ConvertibleDebenturePrivatePlacementMember_dc7a99ad-e519-40df-8c69-c46c3396141a" xlink:href="cybn-20250331.xsd#cybn_ConvertibleDebenturePrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cybn_ConvertibleDebenturesMember_3a5e54e2-a5f2-491d-b916-cc116fb7e305" xlink:to="loc_cybn_ConvertibleDebenturePrivatePlacementMember_dc7a99ad-e519-40df-8c69-c46c3396141a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughShareOfferingEquity_a5cd18e2-624f-4c09-8463-d1693b6fc9ce" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughShareOfferingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_NumberOfSharesIssuedThroughShareOfferingEquity_a5cd18e2-624f-4c09-8463-d1693b6fc9ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SharePricePerCommonShare_1408bb01-73f4-48c2-923d-1cf15d78e600" xlink:href="cybn-20250331.xsd#cybn_SharePricePerCommonShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_SharePricePerCommonShare_1408bb01-73f4-48c2-923d-1cf15d78e600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_986fa520-2430-430f-a912-ea8913dd4bde" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_986fa520-2430-430f-a912-ea8913dd4bde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtSecurities_13ede7ad-b91b-4544-8106-a3092c041559" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_ifrs-full_DebtSecurities_13ede7ad-b91b-4544-8106-a3092c041559" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentTerm_831be623-d32c-4cc0-b711-9bb0250c28b5" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_DebtInstrumentTerm_831be623-d32c-4cc0-b711-9bb0250c28b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentGuaranteedInterestPayableRate_5f13ff18-f045-4be6-9f4e-56553fbb6e6d" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentGuaranteedInterestPayableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_DebtInstrumentGuaranteedInterestPayableRate_5f13ff18-f045-4be6-9f4e-56553fbb6e6d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate_5fa0baf5-f71b-4ed2-8c49-ac9b6948f80b" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate_5fa0baf5-f71b-4ed2-8c49-ac9b6948f80b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentDefaultRate_118864a8-86dc-4e6e-b548-ebcd595c91ea" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentDefaultRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_DebtInstrumentDefaultRate_118864a8-86dc-4e6e-b548-ebcd595c91ea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger_c006fe35-8aa9-4b8a-93ce-43f7edd02b0a" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger_c006fe35-8aa9-4b8a-93ce-43f7edd02b0a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays_c6e49b9e-1f7c-4109-9624-d9c3ab954f2e" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays_c6e49b9e-1f7c-4109-9624-d9c3ab954f2e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentPrepaymentPremiumYearOne_60eb6d48-ec59-4c69-a640-98afa6ae513c" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentPrepaymentPremiumYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_DebtInstrumentPrepaymentPremiumYearOne_60eb6d48-ec59-4c69-a640-98afa6ae513c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentPrepaymentPremiumYearTwo_359909f0-3e75-4f6f-9646-38d6dd0b8f06" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentPrepaymentPremiumYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_DebtInstrumentPrepaymentPremiumYearTwo_359909f0-3e75-4f6f-9646-38d6dd0b8f06" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage_6eb25ccc-6a2d-4ed4-8869-ed9f659579da" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage_6eb25ccc-6a2d-4ed4-8869-ed9f659579da" xlink:type="arc" order="12"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>cybn-20250331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:517b8eb5-c396-4287-8f5e-af5641b4b385,g:1e9b6c9c-673a-419d-ac9f-76e5a6c29d23-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis_68d79fd1-279a-4ac6-b212-bdcf800e4f3d_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_4e3bee86-ca2a-4269-be77-babbd6e4fcdf_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_2a6e6492-60dd-4d74-a2a1-3ac20ef72f0a_verboseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortisation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b8411b3c-dbd6-445a-a5ea-5b776ec9cf85_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a1ee2f02-16e6-402e-84c3-c4e0b2ea580b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_GrantedToEmployeesMember_2fed4eb3-5265-4eee-aa08-b3371b1f617a_terseLabel_en-US" xlink:label="lab_cybn_GrantedToEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted to employees</link:label>
    <link:label id="lab_cybn_GrantedToEmployeesMember_label_en-US" xlink:label="lab_cybn_GrantedToEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted To Employees [Member]</link:label>
    <link:label id="lab_cybn_GrantedToEmployeesMember_documentation_en-US" xlink:label="lab_cybn_GrantedToEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Granted To Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrantedToEmployeesMember" xlink:href="cybn-20250331.xsd#cybn_GrantedToEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_GrantedToEmployeesMember" xlink:to="lab_cybn_GrantedToEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_PercentageOfOutstandingCommonSharesOwn_dd9f8ee0-fc5b-4039-a40d-fdc9f63c2875_terseLabel_en-US" xlink:label="lab_cybn_PercentageOfOutstandingCommonSharesOwn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of outstanding common shares</link:label>
    <link:label id="lab_cybn_PercentageOfOutstandingCommonSharesOwn_label_en-US" xlink:label="lab_cybn_PercentageOfOutstandingCommonSharesOwn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Outstanding Common Shares Own</link:label>
    <link:label id="lab_cybn_PercentageOfOutstandingCommonSharesOwn_documentation_en-US" xlink:label="lab_cybn_PercentageOfOutstandingCommonSharesOwn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Outstanding Common Shares Own</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PercentageOfOutstandingCommonSharesOwn" xlink:href="cybn-20250331.xsd#cybn_PercentageOfOutstandingCommonSharesOwn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_PercentageOfOutstandingCommonSharesOwn" xlink:to="lab_cybn_PercentageOfOutstandingCommonSharesOwn" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_e961cadd-4a55-4199-8b2e-574befb11b92_terseLabel_en-US" xlink:label="lab_cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Dividend As Percentage, Other Equity Instruments Granted</link:label>
    <link:label id="lab_cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Dividend As Percentage, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:href="cybn-20250331.xsd#cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:to="lab_cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_35addd4b-9827-43d0-a746-d36ea23a6af9_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issue of ordinary shares</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issue of ordinary shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems_dcd79764-12cd-42d0-b0e6-f2cc3411b405_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_CommonSharesExchangeRate_5e6b0b26-2bd4-4f4c-8cc7-54fd8c46bcdd_terseLabel_en-US" xlink:label="lab_cybn_CommonSharesExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares exchange rate</link:label>
    <link:label id="lab_cybn_CommonSharesExchangeRate_label_en-US" xlink:label="lab_cybn_CommonSharesExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Shares, Exchange Rate</link:label>
    <link:label id="lab_cybn_CommonSharesExchangeRate_documentation_en-US" xlink:label="lab_cybn_CommonSharesExchangeRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Shares, Exchange Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommonSharesExchangeRate" xlink:href="cybn-20250331.xsd#cybn_CommonSharesExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_CommonSharesExchangeRate" xlink:to="lab_cybn_CommonSharesExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_412c0922-2c42-48b1-9a39-da973daa541a_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_401d6e54-bfc5-4790-92d6-0079267a412f_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended_e155f962-e0cd-4be4-9e6a-a9dc01d08939_terseLabel_en-US" xlink:label="lab_cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants with extended expiry dates (in shares)</link:label>
    <link:label id="lab_cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended_label_en-US" xlink:label="lab_cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Other Equity Instruments In Share-Based Payment Arrangement, Expiry Date Extended</link:label>
    <link:label id="lab_cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended_documentation_en-US" xlink:label="lab_cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Other Equity Instruments In Share-Based Payment Arrangement, Expiry Date Extended</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended" xlink:href="cybn-20250331.xsd#cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended" xlink:to="lab_cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ab84500e-ba90-417e-88c4-135250f37646_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ShareBasedCompensationArrangementExpirationPeriod_30c10848-e903-4844-8a1b-c789d8b4408d_terseLabel_en-US" xlink:label="lab_cybn_ShareBasedCompensationArrangementExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable period</link:label>
    <link:label id="lab_cybn_ShareBasedCompensationArrangementExpirationPeriod_label_en-US" xlink:label="lab_cybn_ShareBasedCompensationArrangementExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement, Expiration Period</link:label>
    <link:label id="lab_cybn_ShareBasedCompensationArrangementExpirationPeriod_documentation_en-US" xlink:label="lab_cybn_ShareBasedCompensationArrangementExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareBasedCompensationArrangementExpirationPeriod" xlink:href="cybn-20250331.xsd#cybn_ShareBasedCompensationArrangementExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ShareBasedCompensationArrangementExpirationPeriod" xlink:to="lab_cybn_ShareBasedCompensationArrangementExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGoodwillExplanatory_ae4f448b-37db-49a5-9bc8-1221901d16e5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GOODWILL</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGoodwillExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate_7ca9ea9c-c46f-4faa-9d7f-a48721b29f08_terseLabel_en-US" xlink:label="lab_cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right Of Use Asset Recognised As Of Acquisition Date</link:label>
    <link:label id="lab_cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate_documentation_en-US" xlink:label="lab_cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right Of Use Asset Recognised As Of Acquisition Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate" xlink:href="cybn-20250331.xsd#cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate" xlink:to="lab_cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_0b37b7aa-8608-4b8f-b7d9-91922d6de166_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_3c8a9206-3e9f-4ae8-b491-b1ff54e623b4_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets, measured at amortized cost:</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at amortised cost, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_3a852e46-7a0f-4855-ad21-eef071fef8ff_terseLabel_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares</link:label>
    <link:label id="lab_ifrs-full_OrdinarySharesMember_label_en-US" xlink:label="lab_ifrs-full_OrdinarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OrdinarySharesMember" xlink:to="lab_ifrs-full_OrdinarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_42d0c5e2-e6fa-4eda-83e5-44771b40fe57_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_3d97d7b7-67bd-421b-ac14-13040d522f32_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of intangible assets and goodwill [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets and goodwill [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeographicalAreasDomain_8905019b-62c3-4283-8dc8-b69cd35f7e1b_terseLabel_en-US" xlink:label="lab_ifrs-full_GeographicalAreasDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical areas [domain]</link:label>
    <link:label id="lab_ifrs-full_GeographicalAreasDomain_label_en-US" xlink:label="lab_ifrs-full_GeographicalAreasDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasDomain" xlink:to="lab_ifrs-full_GeographicalAreasDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_adad50db-f9d5-40e1-b6ad-a97ac6a38c03_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of number and weighted average exercise prices of share options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyFourAndThirtyMember_216ed69a-c361-4c25-9e09-57ecb10f087f_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyFourAndThirtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Four And Thirty</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyFourAndThirtyMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyFourAndThirtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Four And Thirty [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyFourAndThirtyMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyFourAndThirtyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Four And Thirty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyFourAndThirtyMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyFourAndThirtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodTwentyFourAndThirtyMember" xlink:to="lab_cybn_OptionExpirationPeriodTwentyFourAndThirtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyFourMember_cf9cdab9-e7f6-43eb-941f-cc990541cf6c_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Four</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyFourMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Four [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyFourMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyFourMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodTwentyFourMember" xlink:to="lab_cybn_OptionExpirationPeriodTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_WarrantsNumberOfSharesRollForward_3ad4930d-c1ce-433f-8e65-cba15bd33343_terseLabel_en-US" xlink:label="lab_cybn_WarrantsNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Warrants</link:label>
    <link:label id="lab_cybn_WarrantsNumberOfSharesRollForward_label_en-US" xlink:label="lab_cybn_WarrantsNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_cybn_WarrantsNumberOfSharesRollForward_documentation_en-US" xlink:label="lab_cybn_WarrantsNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantsNumberOfSharesRollForward" xlink:href="cybn-20250331.xsd#cybn_WarrantsNumberOfSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_WarrantsNumberOfSharesRollForward" xlink:to="lab_cybn_WarrantsNumberOfSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DebtInstrumentDefaultRate_0fe7e6ec-d82c-4114-973f-83c049ce62f7_terseLabel_en-US" xlink:label="lab_cybn_DebtInstrumentDefaultRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, default rate</link:label>
    <link:label id="lab_cybn_DebtInstrumentDefaultRate_label_en-US" xlink:label="lab_cybn_DebtInstrumentDefaultRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Default Rate</link:label>
    <link:label id="lab_cybn_DebtInstrumentDefaultRate_documentation_en-US" xlink:label="lab_cybn_DebtInstrumentDefaultRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Default Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentDefaultRate" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentDefaultRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DebtInstrumentDefaultRate" xlink:to="lab_cybn_DebtInstrumentDefaultRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_a6e190ad-d33c-4415-afba-e013489b898a_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditedAnnualFinancialStatements_49286033-88ef-42df-8db9-348ec0046105_terseLabel_en-US" xlink:label="lab_dei_AuditedAnnualFinancialStatements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Audited Annual Financial Statements</link:label>
    <link:label id="lab_dei_AuditedAnnualFinancialStatements_label_en-US" xlink:label="lab_dei_AuditedAnnualFinancialStatements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audited Annual Financial Statements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditedAnnualFinancialStatements" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditedAnnualFinancialStatements" xlink:to="lab_dei_AuditedAnnualFinancialStatements" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_IncomeStatementLocationAxis_2d4e01da-4812-434e-bea2-5480f1f46211_terseLabel_en-US" xlink:label="lab_cybn_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_cybn_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_cybn_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_cybn_IncomeStatementLocationAxis_documentation_en-US" xlink:label="lab_cybn_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncomeStatementLocationAxis" xlink:href="cybn-20250331.xsd#cybn_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_IncomeStatementLocationAxis" xlink:to="lab_cybn_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate_f2743e40-39d2-4420-a32d-ba54227f250f_negatedTerseLabel_en-US" xlink:label="lab_cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Liabilities Recognised As Of Acquisition Date</link:label>
    <link:label id="lab_cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate_documentation_en-US" xlink:label="lab_cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Liabilities Recognised As Of Acquisition Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:href="cybn-20250331.xsd#cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lab_cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_4f7cb380-beff-4438-9cc6-d48a4ea8e887_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_8a3b2e42-9b68-43ca-8f3a-2d763edc4e59_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DisclosureOfBasisOfConsolidationPolicyTextBlock_ad96a537-3729-43a6-8c4e-dffb0282ba3b_terseLabel_en-US" xlink:label="lab_cybn_DisclosureOfBasisOfConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of consolidation</link:label>
    <link:label id="lab_cybn_DisclosureOfBasisOfConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_cybn_DisclosureOfBasisOfConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Basis Of Consolidation [Policy Text Block]</link:label>
    <link:label id="lab_cybn_DisclosureOfBasisOfConsolidationPolicyTextBlock_documentation_en-US" xlink:label="lab_cybn_DisclosureOfBasisOfConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Basis Of Consolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfBasisOfConsolidationPolicyTextBlock" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfBasisOfConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DisclosureOfBasisOfConsolidationPolicyTextBlock" xlink:to="lab_cybn_DisclosureOfBasisOfConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_CybinIRLLimitedMember_401bda1c-14ca-4ecf-a33f-55fc0b8c6ee2_terseLabel_en-US" xlink:label="lab_cybn_CybinIRLLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cybin IRL</link:label>
    <link:label id="lab_cybn_CybinIRLLimitedMember_label_en-US" xlink:label="lab_cybn_CybinIRLLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cybin IRL Limited [Member]</link:label>
    <link:label id="lab_cybn_CybinIRLLimitedMember_documentation_en-US" xlink:label="lab_cybn_CybinIRLLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cybin IRL Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CybinIRLLimitedMember" xlink:href="cybn-20250331.xsd#cybn_CybinIRLLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_CybinIRLLimitedMember" xlink:to="lab_cybn_CybinIRLLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_9ed2323c-8b2f-4a71-9c76-9a596e2b68d4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_IncreaseDecreaseThroughShareConsolidationEquity_114094c3-f802-47b8-ba34-da669249063e_terseLabel_en-US" xlink:label="lab_cybn_IncreaseDecreaseThroughShareConsolidationEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment for fractional shares upon share consolidation (in shares)</link:label>
    <link:label id="lab_cybn_IncreaseDecreaseThroughShareConsolidationEquity_label_en-US" xlink:label="lab_cybn_IncreaseDecreaseThroughShareConsolidationEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share Consolidation, Equity</link:label>
    <link:label id="lab_cybn_IncreaseDecreaseThroughShareConsolidationEquity_documentation_en-US" xlink:label="lab_cybn_IncreaseDecreaseThroughShareConsolidationEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share Consolidation, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughShareConsolidationEquity" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughShareConsolidationEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_IncreaseDecreaseThroughShareConsolidationEquity" xlink:to="lab_cybn_IncreaseDecreaseThroughShareConsolidationEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_30780b17-4490-4f12-832b-2a5cac953921_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RESEARCH EXPENSES</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of research and development expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_WarrantExpirationPeriodOneMember_19c17191-36b5-4172-b776-db14aaddeff1_terseLabel_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">August 4, 2028</link:label>
    <link:label id="lab_cybn_WarrantExpirationPeriodOneMember_label_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Expiration Period One [Member]</link:label>
    <link:label id="lab_cybn_WarrantExpirationPeriodOneMember_documentation_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Expiration Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodOneMember" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_WarrantExpirationPeriodOneMember" xlink:to="lab_cybn_WarrantExpirationPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodThirteenMember_a4a98ddb-8f8d-426f-b995-d41ffa1d2a22_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirteen</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirteenMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirteen [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirteenMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirteen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirteenMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodThirteenMember" xlink:to="lab_cybn_OptionExpirationPeriodThirteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksDomain_ff81eeff-646c-4d82-8200-55cf566b47bc_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of risks [domain]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of risks [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksDomain" xlink:to="lab_ifrs-full_TypesOfRisksDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_SalesRoyaltyPercentage_b9b4865b-8df1-47d9-9dab-09c0c35ed209_terseLabel_en-US" xlink:label="lab_cybn_SalesRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales royalty percentage</link:label>
    <link:label id="lab_cybn_SalesRoyaltyPercentage_label_en-US" xlink:label="lab_cybn_SalesRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Royalty, Percentage</link:label>
    <link:label id="lab_cybn_SalesRoyaltyPercentage_documentation_en-US" xlink:label="lab_cybn_SalesRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Royalty, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SalesRoyaltyPercentage" xlink:href="cybn-20250331.xsd#cybn_SalesRoyaltyPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_SalesRoyaltyPercentage" xlink:to="lab_cybn_SalesRoyaltyPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityDomain_978a3624-e364-4008-815a-3633d68915fa_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [domain]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityDomain_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain" xlink:to="lab_ifrs-full_ComponentsOfEquityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_820a5cf8-3ce7-4d41-9889-e7cd1aa7d146_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_WarrantExpirationPeriodDomain_8c52d21f-2d67-4464-b8f5-f3a99a4f7422_terseLabel_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Expiration Period [Domain]</link:label>
    <link:label id="lab_cybn_WarrantExpirationPeriodDomain_label_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Expiration Period [Domain]</link:label>
    <link:label id="lab_cybn_WarrantExpirationPeriodDomain_documentation_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Expiration Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodDomain" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_WarrantExpirationPeriodDomain" xlink:to="lab_cybn_WarrantExpirationPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_AdjustmentForLeaseInterest_4c471ba5-6e83-42db-802d-e115a4dd3f75_terseLabel_en-US" xlink:label="lab_cybn_AdjustmentForLeaseInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease interest accretion</link:label>
    <link:label id="lab_cybn_AdjustmentForLeaseInterest_label_en-US" xlink:label="lab_cybn_AdjustmentForLeaseInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment For Lease Interest</link:label>
    <link:label id="lab_cybn_AdjustmentForLeaseInterest_documentation_en-US" xlink:label="lab_cybn_AdjustmentForLeaseInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustment For Lease Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdjustmentForLeaseInterest" xlink:href="cybn-20250331.xsd#cybn_AdjustmentForLeaseInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_AdjustmentForLeaseInterest" xlink:to="lab_cybn_AdjustmentForLeaseInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodFourteenMember_fb26fc4b-e6db-4641-b45b-6c357d85088f_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodFourteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Fourteen</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodFourteenMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodFourteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Fourteen [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodFourteenMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodFourteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Fourteen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodFourteenMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodFourteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodFourteenMember" xlink:to="lab_cybn_OptionExpirationPeriodFourteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DetailDescriptionOfFunctionalCurrenciesTableTextBlock_e438cfe3-60d1-4ec7-bc78-b2b902771431_terseLabel_en-US" xlink:label="lab_cybn_DetailDescriptionOfFunctionalCurrenciesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of subsidiaries and functional currencies</link:label>
    <link:label id="lab_cybn_DetailDescriptionOfFunctionalCurrenciesTableTextBlock_label_en-US" xlink:label="lab_cybn_DetailDescriptionOfFunctionalCurrenciesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Detail Description Of Functional Currencies [Table Text Block]</link:label>
    <link:label id="lab_cybn_DetailDescriptionOfFunctionalCurrenciesTableTextBlock_documentation_en-US" xlink:label="lab_cybn_DetailDescriptionOfFunctionalCurrenciesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Detail Description Of Functional Currencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DetailDescriptionOfFunctionalCurrenciesTableTextBlock" xlink:href="cybn-20250331.xsd#cybn_DetailDescriptionOfFunctionalCurrenciesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DetailDescriptionOfFunctionalCurrenciesTableTextBlock" xlink:to="lab_cybn_DetailDescriptionOfFunctionalCurrenciesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DiscountRateMeasurementInputMember_78fb1eb7-1e62-4f95-8a66-3bdf87373296_terseLabel_en-US" xlink:label="lab_ifrs-full_DiscountRateMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_ifrs-full_DiscountRateMeasurementInputMember_label_en-US" xlink:label="lab_ifrs-full_DiscountRateMeasurementInputMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount rate, measurement input [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DiscountRateMeasurementInputMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DiscountRateMeasurementInputMember" xlink:to="lab_ifrs-full_DiscountRateMeasurementInputMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_MiscellaneousIncomeExpenseAbstract_c5cd3b42-f9df-4573-bf0f-31b0bd13d020_terseLabel_en-US" xlink:label="lab_cybn_MiscellaneousIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER INCOME (EXPENSES)</link:label>
    <link:label id="lab_cybn_MiscellaneousIncomeExpenseAbstract_label_en-US" xlink:label="lab_cybn_MiscellaneousIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous Income (Expense) [Abstract]</link:label>
    <link:label id="lab_cybn_MiscellaneousIncomeExpenseAbstract_documentation_en-US" xlink:label="lab_cybn_MiscellaneousIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Miscellaneous Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_MiscellaneousIncomeExpenseAbstract" xlink:href="cybn-20250331.xsd#cybn_MiscellaneousIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_MiscellaneousIncomeExpenseAbstract" xlink:to="lab_cybn_MiscellaneousIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_99b1f978-8497-48af-9047-5700b98922d5_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expected recovery at statutory rate</link:label>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income) at applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_fe04ae5b-fef4-4857-b543-77c984e9620e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_SerenityMember_a389872d-8aef-4601-b2f7-e3404dfab14a_terseLabel_en-US" xlink:label="lab_cybn_SerenityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Serenity</link:label>
    <link:label id="lab_cybn_SerenityMember_label_en-US" xlink:label="lab_cybn_SerenityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Serenity [Member]</link:label>
    <link:label id="lab_cybn_SerenityMember_documentation_en-US" xlink:label="lab_cybn_SerenityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Serenity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SerenityMember" xlink:href="cybn-20250331.xsd#cybn_SerenityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_SerenityMember" xlink:to="lab_cybn_SerenityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SignificantUnobservableInputAssets_5ca3102b-8635-4ff3-a582-bb193e1608a7_terseLabel_en-US" xlink:label="lab_ifrs-full_SignificantUnobservableInputAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant unobservable input, assets</link:label>
    <link:label id="lab_ifrs-full_SignificantUnobservableInputAssets_label_en-US" xlink:label="lab_ifrs-full_SignificantUnobservableInputAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant unobservable input, assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantUnobservableInputAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SignificantUnobservableInputAssets" xlink:to="lab_ifrs-full_SignificantUnobservableInputAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_A2041Member_9f08544c-10f9-4af1-aeb7-243134bcc42e_terseLabel_en-US" xlink:label="lab_cybn_A2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2041</link:label>
    <link:label id="lab_cybn_A2041Member_label_en-US" xlink:label="lab_cybn_A2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2041 [Member]</link:label>
    <link:label id="lab_cybn_A2041Member_documentation_en-US" xlink:label="lab_cybn_A2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2041</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2041Member" xlink:href="cybn-20250331.xsd#cybn_A2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_A2041Member" xlink:to="lab_cybn_A2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_GrossDeferredTaxAssets_77e9c7b2-a5ce-4afe-8ff9-74c748bd057f_terseLabel_en-US" xlink:label="lab_cybn_GrossDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_cybn_GrossDeferredTaxAssets_label_en-US" xlink:label="lab_cybn_GrossDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Deferred Tax Assets</link:label>
    <link:label id="lab_cybn_GrossDeferredTaxAssets_documentation_en-US" xlink:label="lab_cybn_GrossDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gross Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrossDeferredTaxAssets" xlink:href="cybn-20250331.xsd#cybn_GrossDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_GrossDeferredTaxAssets" xlink:to="lab_cybn_GrossDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_e991f6e3-1dcb-4989-8a3d-944f0a3f5171_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_96b7140f-4eee-4c99-8066-4eae50511f2f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ShareOptionsVestingThirdTrancheMember_41e84d1d-2fa5-40c3-8c42-bfd1e1c59c4d_terseLabel_en-US" xlink:label="lab_cybn_ShareOptionsVestingThirdTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Options, Vesting, Third Tranche</link:label>
    <link:label id="lab_cybn_ShareOptionsVestingThirdTrancheMember_label_en-US" xlink:label="lab_cybn_ShareOptionsVestingThirdTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Options, Vesting, Third Tranche [Member]</link:label>
    <link:label id="lab_cybn_ShareOptionsVestingThirdTrancheMember_documentation_en-US" xlink:label="lab_cybn_ShareOptionsVestingThirdTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Options, Vesting, Third Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareOptionsVestingThirdTrancheMember" xlink:href="cybn-20250331.xsd#cybn_ShareOptionsVestingThirdTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ShareOptionsVestingThirdTrancheMember" xlink:to="lab_cybn_ShareOptionsVestingThirdTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_730beb97-e480-4fd5-8032-981c754b346e_terseLabel_en-US" xlink:label="lab_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_label_en-US" xlink:label="lab_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Vesting Period</link:label>
    <link:label id="lab_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_documentation_en-US" xlink:label="lab_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Requirements For Share-Based Payment Arrangement, Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:href="cybn-20250331.xsd#cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:to="lab_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_AdjustmentsForOtherLossesGains_5917b3cb-812f-4727-8ab8-35776a644f90_terseLabel_en-US" xlink:label="lab_cybn_AdjustmentsForOtherLossesGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other loss</link:label>
    <link:label id="lab_cybn_AdjustmentsForOtherLossesGains_label_en-US" xlink:label="lab_cybn_AdjustmentsForOtherLossesGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Other Losses (Gains)</link:label>
    <link:label id="lab_cybn_AdjustmentsForOtherLossesGains_documentation_en-US" xlink:label="lab_cybn_AdjustmentsForOtherLossesGains" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Other Losses (Gains)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdjustmentsForOtherLossesGains" xlink:href="cybn-20250331.xsd#cybn_AdjustmentsForOtherLossesGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_AdjustmentsForOtherLossesGains" xlink:to="lab_cybn_AdjustmentsForOtherLossesGains" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ProfessionalAndConsultingFees_2e558efb-775d-415b-99af-ea2b0d7ab46a_terseLabel_en-US" xlink:label="lab_cybn_ProfessionalAndConsultingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional and consulting fees</link:label>
    <link:label id="lab_cybn_ProfessionalAndConsultingFees_label_en-US" xlink:label="lab_cybn_ProfessionalAndConsultingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional And Consulting Fees</link:label>
    <link:label id="lab_cybn_ProfessionalAndConsultingFees_documentation_en-US" xlink:label="lab_cybn_ProfessionalAndConsultingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Professional And Consulting Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ProfessionalAndConsultingFees" xlink:href="cybn-20250331.xsd#cybn_ProfessionalAndConsultingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ProfessionalAndConsultingFees" xlink:to="lab_cybn_ProfessionalAndConsultingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RevenueFromInterest_ae55648c-2850-43c2-908a-d914683b4a93_terseLabel_en-US" xlink:label="lab_ifrs-full_RevenueFromInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_ifrs-full_RevenueFromInterest_label_en-US" xlink:label="lab_ifrs-full_RevenueFromInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RevenueFromInterest" xlink:to="lab_ifrs-full_RevenueFromInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_373e26a2-49fa-4c99-82e8-6f20fcd06779_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement_cd7dc2a4-7111-4d7f-a320-46ef2b0e3df3_negatedLabel_en-US" xlink:label="lab_cybn_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of share options forfeited/expired in share-based payment arrangement (in shares)</link:label>
    <link:label id="lab_cybn_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_cybn_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share Options Forfeited And Expired In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_cybn_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_cybn_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Share Options Forfeited And Expired In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:href="cybn-20250331.xsd#cybn_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:to="lab_cybn_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_38fd1182-45d0-4931-ba41-982c512919f5_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for depreciation and amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_5f6b24c0-93a4-496e-ac3b-643bf1e441fa_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option life, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_20447743-b063-4c6d-b838-d7d2a293f162_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a0b26c09-93d6-46db-87c4-2b5e8e98177e_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_3452725d-aecb-4f74-adcd-f6d5235f28eb_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_b7c173a5-c479-4cfd-984b-f197d67af4c8_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining life</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_CybinCorpMember_79ba609b-6fa0-46b4-8f2c-65137194794b_terseLabel_en-US" xlink:label="lab_cybn_CybinCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cybin Corp.</link:label>
    <link:label id="lab_cybn_CybinCorpMember_label_en-US" xlink:label="lab_cybn_CybinCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cybin Corp [Member]</link:label>
    <link:label id="lab_cybn_CybinCorpMember_documentation_en-US" xlink:label="lab_cybn_CybinCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cybin Corp</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CybinCorpMember" xlink:href="cybn-20250331.xsd#cybn_CybinCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_CybinCorpMember" xlink:to="lab_cybn_CybinCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_43dc55fe-f1b2-4d82-a7e1-018bcbed1f65_terseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation charge</link:label>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodSixteenMember_3327ee9c-94a5-41e7-8f5c-cc138c5b411e_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodSixteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Sixteen</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodSixteenMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodSixteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Sixteen [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodSixteenMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodSixteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Sixteen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodSixteenMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodSixteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodSixteenMember" xlink:to="lab_cybn_OptionExpirationPeriodSixteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesAbstract_5990414f-221f-4af2-8034-54a6aa51ee52_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesAbstract" xlink:to="lab_ifrs-full_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary_ae8f5739-a5cb-46f1-83ef-253bc6164414_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issuance on business acquisition</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through acquisition of subsidiary, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyMember_d676b5b8-7956-446d-8c89-16bd23f644bb_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodThirtyMember" xlink:to="lab_cybn_OptionExpirationPeriodThirtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory_43c1db14-3906-49b4-813f-5a95a490de6b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant unobservable inputs used, equity</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of significant unobservable inputs used in fair value measurement of equity [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_2df90ee7-0b6f-4a1f-bfa0-9ec25daa2e0b_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerEquipmentMember" xlink:to="lab_ifrs-full_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_6a102869-91f4-4937-a75c-dc2c6bc94084_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAX</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted_3215e56e-d88d-496a-81b0-0bf226b3b356_terseLabel_en-US" xlink:label="lab_cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk Free Interest Rate, Other Equity Instruments Granted</link:label>
    <link:label id="lab_cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Risk Free Interest Rate, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:href="cybn-20250331.xsd#cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:to="lab_cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain_7c9f78fa-c330-473f-aba0-5362db5c0bdc_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of intangible assets and goodwill [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets and goodwill [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_CybinUKLtd.Member_2c1cfe02-8d44-4fab-945f-c3e4ab5a8a21_terseLabel_en-US" xlink:label="lab_cybn_CybinUKLtd.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cybin UK Ltd.</link:label>
    <link:label id="lab_cybn_CybinUKLtd.Member_label_en-US" xlink:label="lab_cybn_CybinUKLtd.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cybin UK Ltd. [Member]</link:label>
    <link:label id="lab_cybn_CybinUKLtd.Member_documentation_en-US" xlink:label="lab_cybn_CybinUKLtd.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cybin UK Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CybinUKLtd.Member" xlink:href="cybn-20250331.xsd#cybn_CybinUKLtd.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_CybinUKLtd.Member" xlink:to="lab_cybn_CybinUKLtd.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_6424ce21-0fcd-4720-9571-b7aeadd1742e_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by (used in) investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_label_en-US" xlink:label="lab_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital, Reserves, and Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_documentation_en-US" xlink:label="lab_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Capital, Reserves, and Other Equity Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:href="cybn-20250331.xsd#cybn_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:to="lab_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_61b70aeb-f789-4492-9907-500305a0251d_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis" xlink:to="lab_ifrs-full_TypesOfRisksAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity_c25d921b-8e53-4318-8074-274f9fc36497_terseLabel_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issuance on business acquisition (in shares)</link:label>
    <link:label id="lab_cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity_label_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Issued Through Acquisition Of Subsidiary, Equity</link:label>
    <link:label id="lab_cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity_documentation_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares Issued Through Acquisition Of Subsidiary, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity" xlink:to="lab_cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_InterestRateRiskIncreaseDecreaseInInterestIncome_40ec65f6-fcd1-49a2-a393-45f4a23e5f04_negatedTerseLabel_en-US" xlink:label="lab_cybn_InterestRateRiskIncreaseDecreaseInInterestIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reduction in interest income due to interest rate decline</link:label>
    <link:label id="lab_cybn_InterestRateRiskIncreaseDecreaseInInterestIncome_label_en-US" xlink:label="lab_cybn_InterestRateRiskIncreaseDecreaseInInterestIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Risk, Increase (Decrease) In Interest Income</link:label>
    <link:label id="lab_cybn_InterestRateRiskIncreaseDecreaseInInterestIncome_documentation_en-US" xlink:label="lab_cybn_InterestRateRiskIncreaseDecreaseInInterestIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Risk, Increase (Decrease) In Interest Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_InterestRateRiskIncreaseDecreaseInInterestIncome" xlink:href="cybn-20250331.xsd#cybn_InterestRateRiskIncreaseDecreaseInInterestIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_InterestRateRiskIncreaseDecreaseInInterestIncome" xlink:to="lab_cybn_InterestRateRiskIncreaseDecreaseInInterestIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_FinancialInstrumentsAbstract_label_en-US" xlink:label="lab_cybn_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_cybn_FinancialInstrumentsAbstract_documentation_en-US" xlink:label="lab_cybn_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_FinancialInstrumentsAbstract" xlink:href="cybn-20250331.xsd#cybn_FinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_FinancialInstrumentsAbstract" xlink:to="lab_cybn_FinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement_0c976c2d-a297-42c7-aa4a-68e4c1e3338e_terseLabel_en-US" xlink:label="lab_cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period to exercise warrant</link:label>
    <link:label id="lab_cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period To Exercise Warrants In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period To Exercise Warrants In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement" xlink:href="cybn-20250331.xsd#cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement" xlink:to="lab_cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_037b7644-47fc-42c5-a237-bd808e3d996f_terseLabel_en-US" xlink:label="lab_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining of outstanding contractual life</link:label>
    <link:label id="lab_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_label_en-US" xlink:label="lab_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life of Other Equity Instruments</link:label>
    <link:label id="lab_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_documentation_en-US" xlink:label="lab_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life of Other Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" xlink:href="cybn-20250331.xsd#cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" xlink:to="lab_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_A2043Member_e5206a91-8f7c-4ff0-ab9a-2194773d4d3c_terseLabel_en-US" xlink:label="lab_cybn_A2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2043</link:label>
    <link:label id="lab_cybn_A2043Member_label_en-US" xlink:label="lab_cybn_A2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2043 [Member]</link:label>
    <link:label id="lab_cybn_A2043Member_documentation_en-US" xlink:label="lab_cybn_A2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2043Member" xlink:href="cybn-20250331.xsd#cybn_A2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_A2043Member" xlink:to="lab_cybn_A2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_A2038Member_3e0c293e-2ac6-4cf3-9f56-7ba43e1d4a1a_terseLabel_en-US" xlink:label="lab_cybn_A2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2038</link:label>
    <link:label id="lab_cybn_A2038Member_label_en-US" xlink:label="lab_cybn_A2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2038 [Member]</link:label>
    <link:label id="lab_cybn_A2038Member_documentation_en-US" xlink:label="lab_cybn_A2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2038</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2038Member" xlink:href="cybn-20250331.xsd#cybn_A2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_A2038Member" xlink:to="lab_cybn_A2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_RelatedPartyAbstract_label_en-US" xlink:label="lab_cybn_RelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Abstract]</link:label>
    <link:label id="lab_cybn_RelatedPartyAbstract_documentation_en-US" xlink:label="lab_cybn_RelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_RelatedPartyAbstract" xlink:href="cybn-20250331.xsd#cybn_RelatedPartyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_RelatedPartyAbstract" xlink:to="lab_cybn_RelatedPartyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_d77bf30e-d26b-4211-908a-6fab86dfa3d3_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_1b58e0c8-f45a-4600-a0fd-a8b8a221a6de_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_5981d908-d832-49a1-95ef-b68dc2ef4ecf_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_b86a82df-7c4c-49ee-8649-2370a7f2ca8b_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Equipment write-down</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodTenMember_bb290200-34c5-4efa-a378-6a6f35df9ad3_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Ten</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTenMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Ten [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTenMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Ten</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTenMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodTenMember" xlink:to="lab_cybn_OptionExpirationPeriodTenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_07acc52d-b197-4fbf-9c6a-3845e94d3581_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of measurement of stock option fair value assumptions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity_a48ae1ec-bcb3-41b9-ac79-fd16ea8a6c76_terseLabel_en-US" xlink:label="lab_cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants expired</link:label>
    <link:label id="lab_cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity_label_en-US" xlink:label="lab_cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Expiration Of Warrants, Equity</link:label>
    <link:label id="lab_cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity_documentation_en-US" xlink:label="lab_cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Expiration Of Warrants, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity" xlink:to="lab_cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_cf3ff8b6-3c9b-4984-becb-b6a04e359aec_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted_0d43c9b1-e4ff-46d7-89c6-67c421fb2bf5_terseLabel_en-US" xlink:label="lab_cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested forfeiture rate</link:label>
    <link:label id="lab_cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted_label_en-US" xlink:label="lab_cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unvested Forfeiture Rate, As Percentage, Share Options Granted</link:label>
    <link:label id="lab_cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted_documentation_en-US" xlink:label="lab_cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unvested Forfeiture Rate, As Percentage, Share Options Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted" xlink:href="cybn-20250331.xsd#cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted" xlink:to="lab_cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_a1a7f4b1-d06e-4a80-95be-53c5eb94b5ae_periodStartLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in CAD per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_43d2232f-f1d4-4f89-a2ed-0f109f4f41c5_periodEndLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in CAD per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentRegistrationStatement_aa0100c3-9c45-4e3b-aa84-dc20f016fddc_terseLabel_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Registration Statement</link:label>
    <link:label id="lab_dei_DocumentRegistrationStatement_label_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfWarrants_faf3ee0b-2048-4173-b4d1-b5d455a4d8d5_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds on exercise of warrants</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfWarrants_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OrdinarySharesConsolidationSharesIssuedPreviously_e7143132-07d1-4e81-a8fc-5fcd8f032fc7_terseLabel_en-US" xlink:label="lab_cybn_OrdinarySharesConsolidationSharesIssuedPreviously" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share consolidation, shares issued previously (in shares)</link:label>
    <link:label id="lab_cybn_OrdinarySharesConsolidationSharesIssuedPreviously_label_en-US" xlink:label="lab_cybn_OrdinarySharesConsolidationSharesIssuedPreviously" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary Shares, Consolidation, Shares Issued Previously</link:label>
    <link:label id="lab_cybn_OrdinarySharesConsolidationSharesIssuedPreviously_documentation_en-US" xlink:label="lab_cybn_OrdinarySharesConsolidationSharesIssuedPreviously" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ordinary Shares, Consolidation, Shares Issued Previously</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OrdinarySharesConsolidationSharesIssuedPreviously" xlink:href="cybn-20250331.xsd#cybn_OrdinarySharesConsolidationSharesIssuedPreviously"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OrdinarySharesConsolidationSharesIssuedPreviously" xlink:to="lab_cybn_OrdinarySharesConsolidationSharesIssuedPreviously" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8b5fc090-95a4-4df2-9896-5d0c79d873af_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesMember_4da96750-074d-4754-9dec-91c9348dc583_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesMember" xlink:to="lab_ifrs-full_LeaseLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_a3f60bfb-97e0-4aa5-a3c2-f28ba92f3de8_periodStartLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_8a9b5500-677d-4916-865e-85b95f2f6fdc_periodEndLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, ending balance (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_d19cc5c4-f257-4e66-8935-c970c80d1a6f_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_5d186a18-22d8-454c-806c-e025e144e90b_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilities_6cf7bdcb-7c69-40b8-bad9-5003ef9a4dba_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, beginning of period</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_ae0db914-e4da-4dc2-9ccf-eb7b1a76df7f_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, end of period</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodFiveMember_8bc33696-5dbb-4426-9fce-e13a2ad64c53_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Five</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodFiveMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Five [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodFiveMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodFiveMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodFiveMember" xlink:to="lab_cybn_OptionExpirationPeriodFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_d9418d27-493d-412f-b7a3-ff6660b29596_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_UnitPurchaseWarrantsMember_e192f1b5-dc30-4b6b-ad27-31fe1929f98e_terseLabel_en-US" xlink:label="lab_cybn_UnitPurchaseWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unit Purchase Warrants</link:label>
    <link:label id="lab_cybn_UnitPurchaseWarrantsMember_label_en-US" xlink:label="lab_cybn_UnitPurchaseWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unit Purchase Warrants [Member]</link:label>
    <link:label id="lab_cybn_UnitPurchaseWarrantsMember_documentation_en-US" xlink:label="lab_cybn_UnitPurchaseWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unit Purchase Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_UnitPurchaseWarrantsMember" xlink:href="cybn-20250331.xsd#cybn_UnitPurchaseWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_UnitPurchaseWarrantsMember" xlink:to="lab_cybn_UnitPurchaseWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity_3371e48f-78f4-4383-b8dd-fa461f24c1ec_terseLabel_en-US" xlink:label="lab_cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options forfeited/expired</link:label>
    <link:label id="lab_cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity_label_en-US" xlink:label="lab_cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share Options Forfeited And Expired In Share Based Payment Award, Equity</link:label>
    <link:label id="lab_cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity_documentation_en-US" xlink:label="lab_cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share Options Forfeited And Expired In Share Based Payment Award, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity" xlink:to="lab_cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_d995ec6f-a62e-40df-a557-d900ca7af626_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_42f8c781-8fce-4d20-9df3-16816563bf09_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition from Small Pharma</link:label>
    <link:label id="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_AdditionsToLeaseLiabilities_b4b9f130-cd8f-4d08-b86e-ef6bde316567_terseLabel_en-US" xlink:label="lab_cybn_AdditionsToLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_cybn_AdditionsToLeaseLiabilities_label_en-US" xlink:label="lab_cybn_AdditionsToLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions To Lease Liabilities</link:label>
    <link:label id="lab_cybn_AdditionsToLeaseLiabilities_documentation_en-US" xlink:label="lab_cybn_AdditionsToLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additions To Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdditionsToLeaseLiabilities" xlink:href="cybn-20250331.xsd#cybn_AdditionsToLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_AdditionsToLeaseLiabilities" xlink:to="lab_cybn_AdditionsToLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_6d0e713f-cf0a-42ad-8b03-95ee5160323e_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Difference between Canadian and foreign tax rates</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax effect of foreign tax rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfForeignTaxRates" xlink:to="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ItemsOfContingentLiabilitiesDomain_cb61bea6-9a92-4aee-b666-03a7e25a9e09_terseLabel_en-US" xlink:label="lab_ifrs-full_ItemsOfContingentLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Items of contingent liabilities [domain]</link:label>
    <link:label id="lab_ifrs-full_ItemsOfContingentLiabilitiesDomain_label_en-US" xlink:label="lab_ifrs-full_ItemsOfContingentLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Items of contingent liabilities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ItemsOfContingentLiabilitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ItemsOfContingentLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ItemsOfContingentLiabilitiesDomain" xlink:to="lab_ifrs-full_ItemsOfContingentLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset_feb8e7a0-07aa-4516-868e-84d19686a6ee_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-capital loss acquired on acquisition of subsidiary</link:label>
    <link:label id="lab_ifrs-full_ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset_label_en-US" xlink:label="lab_ifrs-full_ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in amount recognised for pre-acquisition deferred tax asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset" xlink:to="lab_ifrs-full_ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesTable_0f98ae96-b02f-4d0e-b2d6-fe52838341b9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Addresses [Table]</link:label>
    <link:label id="lab_dei_EntityAddressesTable_label_en-US" xlink:label="lab_dei_EntityAddressesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Addresses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesTable" xlink:to="lab_dei_EntityAddressesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsExplanatory_fcade540-25a1-48a5-b9f7-b4bcb5a13c82_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACQUISITION</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of business combinations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_d53a97d7-ae65-48a8-b6bd-cba152ec72f0_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [domain]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_WarrantsWeightedAverageExercisePriceRollForward_39dbc2b1-b0f9-4df6-84e7-5a2c0000f2a4_terseLabel_en-US" xlink:label="lab_cybn_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_cybn_WarrantsWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_cybn_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_cybn_WarrantsWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_cybn_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantsWeightedAverageExercisePriceRollForward" xlink:href="cybn-20250331.xsd#cybn_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_WarrantsWeightedAverageExercisePriceRollForward" xlink:to="lab_cybn_WarrantsWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_CommonSharePurchaseWarrantsMember_b6480bd1-41a2-4b9d-a2eb-08553bf66cac_terseLabel_en-US" xlink:label="lab_cybn_CommonSharePurchaseWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Share Purchase Warrants</link:label>
    <link:label id="lab_cybn_CommonSharePurchaseWarrantsMember_label_en-US" xlink:label="lab_cybn_CommonSharePurchaseWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Share Purchase Warrants [Member]</link:label>
    <link:label id="lab_cybn_CommonSharePurchaseWarrantsMember_documentation_en-US" xlink:label="lab_cybn_CommonSharePurchaseWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Share Purchase Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommonSharePurchaseWarrantsMember" xlink:href="cybn-20250331.xsd#cybn_CommonSharePurchaseWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_CommonSharePurchaseWarrantsMember" xlink:to="lab_cybn_CommonSharePurchaseWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory_bd5acde9-5ffa-41f9-a86b-fc4c82858210_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Monetary Assets and Liabilities Currency Risk Fluctuations</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentReceivables_73782e04-25f8-409a-bd30-485b15217006_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentReceivables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other current receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_EffectOfForeignExchangeLeaseLiabilities_6f3eedab-4691-41d6-99f7-9c4f3edd112f_terseLabel_en-US" xlink:label="lab_cybn_EffectOfForeignExchangeLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of foreign exchange</link:label>
    <link:label id="lab_cybn_EffectOfForeignExchangeLeaseLiabilities_label_en-US" xlink:label="lab_cybn_EffectOfForeignExchangeLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect Of Foreign Exchange, Lease Liabilities</link:label>
    <link:label id="lab_cybn_EffectOfForeignExchangeLeaseLiabilities_documentation_en-US" xlink:label="lab_cybn_EffectOfForeignExchangeLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effect Of Foreign Exchange, Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_EffectOfForeignExchangeLeaseLiabilities" xlink:href="cybn-20250331.xsd#cybn_EffectOfForeignExchangeLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_EffectOfForeignExchangeLeaseLiabilities" xlink:to="lab_cybn_EffectOfForeignExchangeLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_abaa1017-4384-49ce-8d31-d3971d3293cc_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options granted in share-based payment arrangement (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_828db746-600c-4708-9370-b7064c2add98_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of instruments or interests issued or issuable (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of instruments or interests issued or issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:to="lab_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory_c1760b16-4aac-4e90-b105-fe374c4d4c68_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of goodwill</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_d4ddd5dd-f91b-4539-acdc-43fe571ac72c_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_a44774f6-f5b9-4143-ae0a-c9df9428b857_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_b0878b90-e5cc-49f8-88f8-9ef3bbb31c9e_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnobservableInputsAxis_2ce0e1e7-aaa8-4e5c-befa-3c9865db9bde_terseLabel_en-US" xlink:label="lab_ifrs-full_UnobservableInputsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable inputs [axis]</link:label>
    <link:label id="lab_ifrs-full_UnobservableInputsAxis_label_en-US" xlink:label="lab_ifrs-full_UnobservableInputsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unobservable inputs [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnobservableInputsAxis" xlink:to="lab_ifrs-full_UnobservableInputsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_WarrantExpirationPeriodAxis_a2d49664-cd6d-40de-81c1-1f1001d65daa_terseLabel_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Expiration Period [Axis]</link:label>
    <link:label id="lab_cybn_WarrantExpirationPeriodAxis_label_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Expiration Period [Axis]</link:label>
    <link:label id="lab_cybn_WarrantExpirationPeriodAxis_documentation_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodAxis" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_WarrantExpirationPeriodAxis" xlink:to="lab_cybn_WarrantExpirationPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfSharesSubjectToResaleRestrictions_7f361f2b-fed2-4c67-85a4-46eda337135b_terseLabel_en-US" xlink:label="lab_cybn_NumberOfSharesSubjectToResaleRestrictions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares subject to resale restrictions (in shares)</link:label>
    <link:label id="lab_cybn_NumberOfSharesSubjectToResaleRestrictions_label_en-US" xlink:label="lab_cybn_NumberOfSharesSubjectToResaleRestrictions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Subject To Resale Restrictions</link:label>
    <link:label id="lab_cybn_NumberOfSharesSubjectToResaleRestrictions_documentation_en-US" xlink:label="lab_cybn_NumberOfSharesSubjectToResaleRestrictions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares Subject To Resale Restrictions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesSubjectToResaleRestrictions" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesSubjectToResaleRestrictions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfSharesSubjectToResaleRestrictions" xlink:to="lab_cybn_NumberOfSharesSubjectToResaleRestrictions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_3cfe0a7f-f8eb-496c-b56b-ad60dc701b54_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of lease liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_e97bde51-1454-403a-862d-be11b3db40b9_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for items not affecting cash:</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="lab_ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_3dd4e671-3c8f-466c-a7f9-0b1342ba1955_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_March2024PrivatePlacementMember_4fbcdbfc-823b-43be-865b-77367e2c5b4c_terseLabel_en-US" xlink:label="lab_cybn_March2024PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">March 2024 private placement</link:label>
    <link:label id="lab_cybn_March2024PrivatePlacementMember_label_en-US" xlink:label="lab_cybn_March2024PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">March 2024 Private Placement [Member]</link:label>
    <link:label id="lab_cybn_March2024PrivatePlacementMember_documentation_en-US" xlink:label="lab_cybn_March2024PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">March 2024 Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_March2024PrivatePlacementMember" xlink:href="cybn-20250331.xsd#cybn_March2024PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_March2024PrivatePlacementMember" xlink:to="lab_cybn_March2024PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding_a29c4f12-45df-49aa-bdae-526e2645d3d4_terseLabel_en-US" xlink:label="lab_cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for grant, percent of total shares outstanding (up to)</link:label>
    <link:label id="lab_cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding_label_en-US" xlink:label="lab_cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant, Percent Of Total Shares Outstanding</link:label>
    <link:label id="lab_cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding_documentation_en-US" xlink:label="lab_cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant, Percent Of Total Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding" xlink:href="cybn-20250331.xsd#cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding" xlink:to="lab_cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_58eb64f1-caa5-47ed-9fb7-e4f5050dc867_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share issuance costs</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_label_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share issue related cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost" xlink:to="lab_ifrs-full_ShareIssueRelatedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_1e5e3cb1-4532-49c5-b836-1d84f1e7c964_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected annual volatility, based on historical share price of the Company</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_89c88ffd-1ca9-4831-a91f-7f81406666ac_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss_a5c375d7-2428-4ad6-88ab-76faff530a40_terseLabel_en-US" xlink:label="lab_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reasonably possible change in risk variable, impact on net loss</link:label>
    <link:label id="lab_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss_label_en-US" xlink:label="lab_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Risks, Reasonably Possible Change In Risk Variable, Impact On Profit (Loss)</link:label>
    <link:label id="lab_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss_documentation_en-US" xlink:label="lab_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Risks, Reasonably Possible Change In Risk Variable, Impact On Profit (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss" xlink:href="cybn-20250331.xsd#cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss" xlink:to="lab_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfessionalFeesExpense_f766722e-619c-415d-a9ce-48e38d0b6c9d_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfessionalFeesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional and consulting fees</link:label>
    <link:label id="lab_ifrs-full_ProfessionalFeesExpense_label_en-US" xlink:label="lab_ifrs-full_ProfessionalFeesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional fees expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfessionalFeesExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfessionalFeesExpense" xlink:to="lab_ifrs-full_ProfessionalFeesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelName_05969248-1022-4867-b18c-b79b3e41982c_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:label id="lab_dei_ContactPersonnelName_label_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_EventsAfterReportingPeriodAbstract_label_en-US" xlink:label="lab_cybn_EventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Events after reporting period [Abstract]</link:label>
    <link:label id="lab_cybn_EventsAfterReportingPeriodAbstract_documentation_en-US" xlink:label="lab_cybn_EventsAfterReportingPeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Events after reporting period [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_EventsAfterReportingPeriodAbstract" xlink:href="cybn-20250331.xsd#cybn_EventsAfterReportingPeriodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_EventsAfterReportingPeriodAbstract" xlink:to="lab_cybn_EventsAfterReportingPeriodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodEightMember_a46b1a1f-fe5b-44a3-8035-97f6ca8f395c_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Eight</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodEightMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Eight [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodEightMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Eight</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodEightMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodEightMember" xlink:to="lab_cybn_OptionExpirationPeriodEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsTable_8bdbf032-dc0f-497c-93dd-4e0e83e729e3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssets_0c5e1e8c-471f-4e0a-88b2-60db2799e11c_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_8bb36254-1834-4540-a472-73ddb730beb7_periodStartLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, beginning of period</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_342244bd-2d93-48e8-99e2-4216dc6061fe_periodEndLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, end of period</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtySevenMember_d4d1d5ed-a258-4b25-a756-97b296b8bf94_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Seven</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtySevenMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Seven [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtySevenMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtySevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Seven</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtySevenMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtySevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodThirtySevenMember" xlink:to="lab_cybn_OptionExpirationPeriodThirtySevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ShareOptionsVestingFifthTrancheMember_6fdf53e2-5e75-4308-bb35-87e7288c76a8_terseLabel_en-US" xlink:label="lab_cybn_ShareOptionsVestingFifthTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Options, Vesting, Fifth Tranche</link:label>
    <link:label id="lab_cybn_ShareOptionsVestingFifthTrancheMember_label_en-US" xlink:label="lab_cybn_ShareOptionsVestingFifthTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Options, Vesting, Fifth Tranche [Member]</link:label>
    <link:label id="lab_cybn_ShareOptionsVestingFifthTrancheMember_documentation_en-US" xlink:label="lab_cybn_ShareOptionsVestingFifthTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Options, Vesting, Fifth Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareOptionsVestingFifthTrancheMember" xlink:href="cybn-20250331.xsd#cybn_ShareOptionsVestingFifthTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ShareOptionsVestingFifthTrancheMember" xlink:to="lab_cybn_ShareOptionsVestingFifthTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_4abe1986-603c-4f76-a45c-e4512cc4f1a1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_850a637d-2bd9-40ad-8695-23baa407f49b_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_bb5c3443-b33c-4aeb-b060-3d62f7fd9477_verboseLabel_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_ifrs-full_ComputerSoftwareMember_label_en-US" xlink:label="lab_ifrs-full_ComputerSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer software [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerSoftwareMember" xlink:to="lab_ifrs-full_ComputerSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyFiveMember_5a1ef691-0caa-436e-9a66-e4ea3b6c3412_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Five</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyFiveMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Five [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyFiveMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyFiveMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodThirtyFiveMember" xlink:to="lab_cybn_OptionExpirationPeriodThirtyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_807ef3fe-f344-4142-9376-e47a4e9dedb3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CAPITAL MANAGEMENT</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of objectives, policies and processes for managing capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_c302d8cf-88f4-4de9-91ca-4d01a08dbd82_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_21c3e02e-cf64-4690-8c8b-8cb972f03271_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation_ecfcbbac-ec13-4e44-a894-c7594ce4a8ca_negatedTerseLabel_en-US" xlink:label="lab_cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign currency translation gain</link:label>
    <link:label id="lab_cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation_label_en-US" xlink:label="lab_cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Unrealized Gain (Loss) On Foreign Currency Translation</link:label>
    <link:label id="lab_cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation_documentation_en-US" xlink:label="lab_cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Unrealized Gain (Loss) On Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation" xlink:href="cybn-20250331.xsd#cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation" xlink:to="lab_cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesLineItems_042dd0d9-a90d-430f-95e4-679b1ff5564f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
    <link:label id="lab_dei_EntityAddressesLineItems_label_en-US" xlink:label="lab_dei_EntityAddressesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesLineItems" xlink:to="lab_dei_EntityAddressesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_SharePricePerCommonShare_2c1e7a6c-69a4-448c-b663-be812bc5f3a5_terseLabel_en-US" xlink:label="lab_cybn_SharePricePerCommonShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in CAD/USD per share)</link:label>
    <link:label id="lab_cybn_SharePricePerCommonShare_9e775fd6-5592-4c33-89a0-ec5737635aa3_verboseLabel_en-US" xlink:label="lab_cybn_SharePricePerCommonShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share price (in USD per share)</link:label>
    <link:label id="lab_cybn_SharePricePerCommonShare_label_en-US" xlink:label="lab_cybn_SharePricePerCommonShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price per Common Share</link:label>
    <link:label id="lab_cybn_SharePricePerCommonShare_documentation_en-US" xlink:label="lab_cybn_SharePricePerCommonShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Price per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SharePricePerCommonShare" xlink:href="cybn-20250331.xsd#cybn_SharePricePerCommonShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_SharePricePerCommonShare" xlink:to="lab_cybn_SharePricePerCommonShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c8c960b3-7d31-4100-812b-4bb165e94f08_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_WarrantExpirationPeriodFiveMember_97e28557-557b-427d-80cd-b0643e87de81_terseLabel_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">November 15, 2030</link:label>
    <link:label id="lab_cybn_WarrantExpirationPeriodFiveMember_label_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Expiration Period Five [Member]</link:label>
    <link:label id="lab_cybn_WarrantExpirationPeriodFiveMember_documentation_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Expiration Period Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodFiveMember" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_WarrantExpirationPeriodFiveMember" xlink:to="lab_cybn_WarrantExpirationPeriodFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfSharesIssuedThroughShareOfferingEquity_a9e45166-1b26-4d77-9fb1-6b7d1cf0de60_terseLabel_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedThroughShareOfferingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-the-market offering - net of share issuance costs (in shares)</link:label>
    <link:label id="lab_cybn_NumberOfSharesIssuedThroughShareOfferingEquity_label_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedThroughShareOfferingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Issued Through Share Offering, Equity</link:label>
    <link:label id="lab_cybn_NumberOfSharesIssuedThroughShareOfferingEquity_documentation_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedThroughShareOfferingEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares Issued Through Share Offering, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughShareOfferingEquity" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughShareOfferingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfSharesIssuedThroughShareOfferingEquity" xlink:to="lab_cybn_NumberOfSharesIssuedThroughShareOfferingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory_644bf42a-b86b-406d-97a8-d5d4be1df7fc_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_e98c112d-6e66-4733-ba63-22f025a79be4_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_2d68023f-727a-4b2f-b04a-0efc42559af5_terseLabel_en-US" xlink:label="lab_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Financial Assets and Liabilities [Line Items]</link:label>
    <link:label id="lab_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_label_en-US" xlink:label="lab_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Financial Assets and Liabilities [Line Items]</link:label>
    <link:label id="lab_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_documentation_en-US" xlink:label="lab_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of Financial Assets and Liabilities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:to="lab_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_7010de12-0c6f-4908-b8bc-77f985aeded9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SHARE CAPITAL</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_GainLossOnDerecognitionOfRightOfUseAssets_8fcecea5-14b6-4486-9af2-fb49cd62f8ec_negatedLabel_en-US" xlink:label="lab_cybn_GainLossOnDerecognitionOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on derecognition of right-of-use assets</link:label>
    <link:label id="lab_cybn_GainLossOnDerecognitionOfRightOfUseAssets_label_en-US" xlink:label="lab_cybn_GainLossOnDerecognitionOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Derecognition of Right-Of-Use Assets</link:label>
    <link:label id="lab_cybn_GainLossOnDerecognitionOfRightOfUseAssets_documentation_en-US" xlink:label="lab_cybn_GainLossOnDerecognitionOfRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Derecognition of Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GainLossOnDerecognitionOfRightOfUseAssets" xlink:href="cybn-20250331.xsd#cybn_GainLossOnDerecognitionOfRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_GainLossOnDerecognitionOfRightOfUseAssets" xlink:to="lab_cybn_GainLossOnDerecognitionOfRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_290c716b-5022-44b0-a2b0-e3c0757bae27_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_0ba33368-5341-401f-9177-e56e6dbbfee2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory_02a357c0-3eac-475c-b0a3-f5058e30480c_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Functional and presentation currency</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for functional currency [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_eb7eb45e-521a-4845-8b20-f158049ff80b_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashEquivalents_177a3e00-10fe-4ae7-99ee-129bd0ff3894_terseLabel_en-US" xlink:label="lab_ifrs-full_CashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashEquivalents" xlink:to="lab_ifrs-full_CashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:to="lab_ifrs-full_DisclosureOfBusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_JourneyMember_d875a97d-268e-4fa7-89af-3df220923110_terseLabel_en-US" xlink:label="lab_cybn_JourneyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Journey</link:label>
    <link:label id="lab_cybn_JourneyMember_label_en-US" xlink:label="lab_cybn_JourneyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Journey [Member]</link:label>
    <link:label id="lab_cybn_JourneyMember_documentation_en-US" xlink:label="lab_cybn_JourneyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Journey</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_JourneyMember" xlink:href="cybn-20250331.xsd#cybn_JourneyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_JourneyMember" xlink:to="lab_cybn_JourneyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfSharesIssuedNetOfIssuanceCosts_91b352ea-1837-457c-8edc-d897ed2100a7_terseLabel_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued through common share purchase agreement - net of share issuance costs (in shares)</link:label>
    <link:label id="lab_cybn_NumberOfSharesIssuedNetOfIssuanceCosts_label_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Issued, Net Of Issuance Costs</link:label>
    <link:label id="lab_cybn_NumberOfSharesIssuedNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares Issued, Net Of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedNetOfIssuanceCosts" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfSharesIssuedNetOfIssuanceCosts" xlink:to="lab_cybn_NumberOfSharesIssuedNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock_feab3d22-a567-4137-9faf-4e407bee3fb2_terseLabel_en-US" xlink:label="lab_cybn_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major items causing the income tax rate to differ from the Canadian statutory rate</link:label>
    <link:label id="lab_cybn_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock_label_en-US" xlink:label="lab_cybn_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates [Table Text Block]</link:label>
    <link:label id="lab_cybn_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock_documentation_en-US" xlink:label="lab_cybn_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock" xlink:to="lab_cybn_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_2adc7e01-cde5-4cd7-a60f-ffcbd824870d_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity_7759ecd4-42ab-4d76-8cae-5a494a7903b9_terseLabel_en-US" xlink:label="lab_cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options expired</link:label>
    <link:label id="lab_cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity_label_en-US" xlink:label="lab_cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share Options Expired In Share Based Payment Award, Equity</link:label>
    <link:label id="lab_cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity_documentation_en-US" xlink:label="lab_cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share Options Expired In Share Based Payment Award, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity" xlink:to="lab_cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Cash_18fb18c4-2240-4cd0-b583-3b0ca6450791_terseLabel_en-US" xlink:label="lab_ifrs-full_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_ifrs-full_Cash_label_en-US" xlink:label="lab_ifrs-full_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Cash" xlink:to="lab_ifrs-full_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_8fcd35b5-ef64-498b-9ca9-6f2e0d82e7f6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ShareOptionsVestingFirstTrancheMember_705ff800-de07-4106-82be-26534ded9f64_terseLabel_en-US" xlink:label="lab_cybn_ShareOptionsVestingFirstTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Options, Vesting, First Tranche</link:label>
    <link:label id="lab_cybn_ShareOptionsVestingFirstTrancheMember_label_en-US" xlink:label="lab_cybn_ShareOptionsVestingFirstTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Options, Vesting, First Tranche [Member]</link:label>
    <link:label id="lab_cybn_ShareOptionsVestingFirstTrancheMember_documentation_en-US" xlink:label="lab_cybn_ShareOptionsVestingFirstTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Options, Vesting, First Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareOptionsVestingFirstTrancheMember" xlink:href="cybn-20250331.xsd#cybn_ShareOptionsVestingFirstTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ShareOptionsVestingFirstTrancheMember" xlink:to="lab_cybn_ShareOptionsVestingFirstTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyOneMember_d130dfe8-17e3-42e9-b9da-c80c93ca6742_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty One</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyOneMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty One [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyOneMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyOneMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodTwentyOneMember" xlink:to="lab_cybn_OptionExpirationPeriodTwentyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_8a19b46c-7c75-4ee0-afe1-3b825ddcb618_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_75ca9137-cc1b-47a0-9c47-d3de7140be3f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0a704ec7-d321-4a9c-a90b-df5616a115c0_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_6f1997ee-c155-4cbf-851e-51bb51bc50a9_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of foreign exchange</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_4face6eb-0eb5-41c0-b087-449b115625a6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of general and administrative expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_7bb9271e-01aa-4f68-9f32-ecd2c7ee55d7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement_ea057a2d-aec8-4b3f-a399-3f5846632b73_terseLabel_en-US" xlink:label="lab_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares acquired upon exercise of warrant (in shares)</link:label>
    <link:label id="lab_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Acquired Upon Exercise Of Warrant In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares Acquired Upon Exercise Of Warrant In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement" xlink:to="lab_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ShareOptionsVestingFourthTrancheMember_991bf77c-a290-4828-bed9-ac7b8b785d4f_terseLabel_en-US" xlink:label="lab_cybn_ShareOptionsVestingFourthTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Options, Vesting, Fourth Tranche</link:label>
    <link:label id="lab_cybn_ShareOptionsVestingFourthTrancheMember_label_en-US" xlink:label="lab_cybn_ShareOptionsVestingFourthTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Options, Vesting, Fourth Tranche [Member]</link:label>
    <link:label id="lab_cybn_ShareOptionsVestingFourthTrancheMember_documentation_en-US" xlink:label="lab_cybn_ShareOptionsVestingFourthTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Options, Vesting, Fourth Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareOptionsVestingFourthTrancheMember" xlink:href="cybn-20250331.xsd#cybn_ShareOptionsVestingFourthTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ShareOptionsVestingFourthTrancheMember" xlink:to="lab_cybn_ShareOptionsVestingFourthTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding_841f666f-50eb-412e-afd3-665adcb945fc_terseLabel_en-US" xlink:label="lab_cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ratio of common shares issued</link:label>
    <link:label id="lab_cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding_label_en-US" xlink:label="lab_cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ratio Of Common Shares Issued To Every One Share Of Subsidiary Outstanding</link:label>
    <link:label id="lab_cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding_documentation_en-US" xlink:label="lab_cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ratio Of Common Shares Issued To Every One Share Of Subsidiary Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding" xlink:href="cybn-20250331.xsd#cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding" xlink:to="lab_cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GoodwillMember_65eed5e8-efe3-4af7-830e-fad56137d6aa_terseLabel_en-US" xlink:label="lab_ifrs-full_GoodwillMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_GoodwillMember_label_en-US" xlink:label="lab_ifrs-full_GoodwillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodwillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GoodwillMember" xlink:to="lab_ifrs-full_GoodwillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BusinessCombinationsAxis_b19801a7-d1ef-4f24-a5ca-7ce334a62f50_terseLabel_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combinations [axis]</link:label>
    <link:label id="lab_ifrs-full_BusinessCombinationsAxis_label_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business combinations [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BusinessCombinationsAxis" xlink:to="lab_ifrs-full_BusinessCombinationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AnnualInformationForm_0769fc36-8cf9-4167-8909-f0d9c2c7e869_terseLabel_en-US" xlink:label="lab_dei_AnnualInformationForm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual Information Form</link:label>
    <link:label id="lab_dei_AnnualInformationForm_label_en-US" xlink:label="lab_dei_AnnualInformationForm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Information Form</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AnnualInformationForm" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AnnualInformationForm" xlink:to="lab_dei_AnnualInformationForm" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_IncomeStatementLocationDomain_9a3d4fc2-08fd-4bc6-9b96-ddec38cce612_terseLabel_en-US" xlink:label="lab_cybn_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_cybn_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_cybn_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_cybn_IncomeStatementLocationDomain_documentation_en-US" xlink:label="lab_cybn_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncomeStatementLocationDomain" xlink:href="cybn-20250331.xsd#cybn_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_IncomeStatementLocationDomain" xlink:to="lab_cybn_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyTwoMember_0e868c13-1ef5-4a39-9a2b-59105c48b5af_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Two</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyTwoMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Two [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyTwoMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyTwoMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodTwentyTwoMember" xlink:to="lab_cybn_OptionExpirationPeriodTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodTwoMember_5807b156-ee66-448d-9f35-54b855a4ca90_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Two</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwoMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Two [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwoMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwoMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodTwoMember" xlink:to="lab_cybn_OptionExpirationPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_cybn_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_cybn_AccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_cybn_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AccountingPoliciesAbstract" xlink:href="cybn-20250331.xsd#cybn_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_AccountingPoliciesAbstract" xlink:to="lab_cybn_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_WarrantExpirationPeriodThreeMember_2dd0a4e8-2ecd-4839-9728-60dd5fe612c4_terseLabel_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">June 15, 2030</link:label>
    <link:label id="lab_cybn_WarrantExpirationPeriodThreeMember_label_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Expiration Period Three [Member]</link:label>
    <link:label id="lab_cybn_WarrantExpirationPeriodThreeMember_documentation_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Expiration Period Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodThreeMember" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_WarrantExpirationPeriodThreeMember" xlink:to="lab_cybn_WarrantExpirationPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DisclosureOfLeasesAndRightOfUseAssetsTextBlock_935550fb-efc0-4561-a20a-917f12386a9d_terseLabel_en-US" xlink:label="lab_cybn_DisclosureOfLeasesAndRightOfUseAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RIGHT-OF-USE ASSETS AND LEASE LIABILITIES</link:label>
    <link:label id="lab_cybn_DisclosureOfLeasesAndRightOfUseAssetsTextBlock_label_en-US" xlink:label="lab_cybn_DisclosureOfLeasesAndRightOfUseAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Leases And Right-Of-Use Assets [Text Block]</link:label>
    <link:label id="lab_cybn_DisclosureOfLeasesAndRightOfUseAssetsTextBlock_documentation_en-US" xlink:label="lab_cybn_DisclosureOfLeasesAndRightOfUseAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Leases And Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfLeasesAndRightOfUseAssetsTextBlock" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfLeasesAndRightOfUseAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DisclosureOfLeasesAndRightOfUseAssetsTextBlock" xlink:to="lab_cybn_DisclosureOfLeasesAndRightOfUseAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d44dfe57-c0e6-445b-b7b4-bce093ff0d88_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarnings_abb4d4c1-3c55-49d0-923b-8582e218cbe3_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deficit</link:label>
    <link:label id="lab_ifrs-full_RetainedEarnings_05267b56-13e4-40ca-803e-154ef67ab7c4_negatedLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deficit</link:label>
    <link:label id="lab_ifrs-full_RetainedEarnings_label_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings" xlink:to="lab_ifrs-full_RetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsForShareIssueCosts_22311e22-7972-4299-ad1f-02cac9e12c59_terseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for share issue costs</link:label>
    <link:label id="lab_ifrs-full_PaymentsForShareIssueCosts_label_en-US" xlink:label="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for share issue costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsForShareIssueCosts" xlink:to="lab_ifrs-full_PaymentsForShareIssueCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_2fbc3245-1335-4ff6-8a46-18f87be46792_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_2512585d-d67a-4226-a8bc-b69a6428bb7a_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value at measurement date, share options granted</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_cd11bf02-f3b0-4478-a36f-cdc628dc8cdd_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated grant date fair value</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average fair value at measurement date, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtySixMember_6c68ad26-9f62-41a9-9d76-dd207418a869_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Six</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtySixMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Six [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtySixMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtySixMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodThirtySixMember" xlink:to="lab_cybn_OptionExpirationPeriodThirtySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_2d215238-3f86-46be-b2c9-87307034a4ad_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_c973268d-9a4d-4e9f-9e96-83e8865fe5a3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of intangible assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_label_en-US" xlink:label="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate information and statement of IFRS compliance [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:to="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_11706ef9-dfaa-441c-a3ad-52fbebcc364e_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_78e236e7-a969-45a3-bcf2-8318cc602dbd_periodStartLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_88c19c11-8767-47c9-9b15-56fa4719bbc6_periodEndLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountMember_aa539889-9240-47f0-918f-eccf2b7d5b0d_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_1b0de639-ff07-4894-bf2e-94b347897cdd_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_483d1ce9-988a-418f-a7f6-8ab40ea28abf_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [domain]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodNineMember_87ffcb26-56cc-4c5d-bb36-e84cc0c8dd14_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Nine</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodNineMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Nine [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodNineMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Nine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodNineMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodNineMember" xlink:to="lab_cybn_OptionExpirationPeriodNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_966990b3-dfb1-4ed4-aa13-f9722851a384_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_ef2848fd-8dba-4b87-ae5f-83d5505d80c0_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_df81604c-439b-4092-bd9a-2b8d12334c60_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New standards and interpretations not yet adopted</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_6c1fa58c-cdb2-4a31-9d40-c8c1fca0d250_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_97512274-3d20-4f70-9e5f-2a9b243d3b4b_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_7b3df0ae-69ce-4d0e-b521-6a2437d3a279_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory_e4d0b391-ba19-4991-bb38-80b3c8a8634f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of General and Administrative Expenses</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of attribution of expenses by nature to their function [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_73daa608-3e96-4ade-90cf-a643bbac7570_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_3868c348-2615-4861-95f0-a207fe2b14b8_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Goodwill_7ead41dc-dca9-4b7c-8528-7cc80a10247f_terseLabel_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_Goodwill_55c90936-0076-4e73-8dce-ef2f104b2415_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_ifrs-full_Goodwill_6da7a8e1-23ea-438f-adfe-01a696d5b1e7_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_ifrs-full_Goodwill_label_en-US" xlink:label="lab_ifrs-full_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Goodwill" xlink:to="lab_ifrs-full_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ConvertibleDebenturesMember_e6634555-1d1e-40ef-837c-fcedb956aaa3_terseLabel_en-US" xlink:label="lab_cybn_ConvertibleDebenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debentures</link:label>
    <link:label id="lab_cybn_ConvertibleDebenturesMember_label_en-US" xlink:label="lab_cybn_ConvertibleDebenturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debentures [Member]</link:label>
    <link:label id="lab_cybn_ConvertibleDebenturesMember_documentation_en-US" xlink:label="lab_cybn_ConvertibleDebenturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Debentures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ConvertibleDebenturesMember" xlink:href="cybn-20250331.xsd#cybn_ConvertibleDebenturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ConvertibleDebenturesMember" xlink:to="lab_cybn_ConvertibleDebenturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodElevenMember_b5c409a4-cb89-4884-ae09-eae567d50099_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodElevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Eleven</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodElevenMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodElevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Eleven [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodElevenMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodElevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Eleven</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodElevenMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodElevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodElevenMember" xlink:to="lab_cybn_OptionExpirationPeriodElevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0fbc0709-31aa-49ad-873b-04552e315f98_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_InterestRateRiskTerm_8a58a941-a06d-4cee-b7c3-8f8409fc390c_terseLabel_en-US" xlink:label="lab_cybn_InterestRateRiskTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate risk, term</link:label>
    <link:label id="lab_cybn_InterestRateRiskTerm_label_en-US" xlink:label="lab_cybn_InterestRateRiskTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Risk, Term</link:label>
    <link:label id="lab_cybn_InterestRateRiskTerm_documentation_en-US" xlink:label="lab_cybn_InterestRateRiskTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Risk, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_InterestRateRiskTerm" xlink:href="cybn-20250331.xsd#cybn_InterestRateRiskTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_InterestRateRiskTerm" xlink:to="lab_cybn_InterestRateRiskTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_6ccf3bf4-dacd-4dde-a0c6-50bbaccd572c_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of compliance</link:label>
    <link:label id="lab_ifrs-full_StatementOfIFRSCompliance_label_en-US" xlink:label="lab_ifrs-full_StatementOfIFRSCompliance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of IFRS compliance [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfIFRSCompliance" xlink:to="lab_ifrs-full_StatementOfIFRSCompliance" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_PaymentsOfLeaseLiabilities_3a78b6fe-c017-4d78-aa4b-4f1741a665e2_negatedTerseLabel_en-US" xlink:label="lab_cybn_PaymentsOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_cybn_PaymentsOfLeaseLiabilities_label_en-US" xlink:label="lab_cybn_PaymentsOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Of Lease Liabilities</link:label>
    <link:label id="lab_cybn_PaymentsOfLeaseLiabilities_documentation_en-US" xlink:label="lab_cybn_PaymentsOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments Of Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PaymentsOfLeaseLiabilities" xlink:href="cybn-20250331.xsd#cybn_PaymentsOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_PaymentsOfLeaseLiabilities" xlink:to="lab_cybn_PaymentsOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodOneMember_4b655609-5c2c-4edb-9c71-d89eb3371a2b_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period One</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodOneMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period One [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodOneMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodOneMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodOneMember" xlink:to="lab_cybn_OptionExpirationPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_9d9972b6-281c-414f-bca5-abe3169e9045_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_01480122-3416-4bd0-a737-36c8d7e8df8c_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ScheduleOfResearchExpensesTableTextBlock_d42e4de6-a1c6-4b5f-9d66-aac9a072de76_terseLabel_en-US" xlink:label="lab_cybn_ScheduleOfResearchExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Research Expenses</link:label>
    <link:label id="lab_cybn_ScheduleOfResearchExpensesTableTextBlock_label_en-US" xlink:label="lab_cybn_ScheduleOfResearchExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Research Expenses [Table Text Block]</link:label>
    <link:label id="lab_cybn_ScheduleOfResearchExpensesTableTextBlock_documentation_en-US" xlink:label="lab_cybn_ScheduleOfResearchExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Research Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ScheduleOfResearchExpensesTableTextBlock" xlink:href="cybn-20250331.xsd#cybn_ScheduleOfResearchExpensesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ScheduleOfResearchExpensesTableTextBlock" xlink:to="lab_cybn_ScheduleOfResearchExpensesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract_52c19232-b4e4-4d1a-a028-fc0b9958063f_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in intangible assets and goodwill [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in intangible assets and goodwill [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_IncreaseDecreaseThroughShareOfferingEquity_1f887e41-d189-4417-82bf-570b6f4b9230_terseLabel_en-US" xlink:label="lab_cybn_IncreaseDecreaseThroughShareOfferingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-the-market offering - net of share issuance costs</link:label>
    <link:label id="lab_cybn_IncreaseDecreaseThroughShareOfferingEquity_label_en-US" xlink:label="lab_cybn_IncreaseDecreaseThroughShareOfferingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share Offering, Equity</link:label>
    <link:label id="lab_cybn_IncreaseDecreaseThroughShareOfferingEquity_documentation_en-US" xlink:label="lab_cybn_IncreaseDecreaseThroughShareOfferingEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Share Offering, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughShareOfferingEquity" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughShareOfferingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_IncreaseDecreaseThroughShareOfferingEquity" xlink:to="lab_cybn_IncreaseDecreaseThroughShareOfferingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_0269cc59-02e7-4cbc-aaba-d3d2829706ac_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of number of shares outstanding [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of number of shares outstanding [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract" xlink:to="lab_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_62f7b4a2-e636-4b5a-b1d5-d7cba8530dc9_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds on issuance of common shares, net</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ShareIssuanceCostsMember_dd710574-0678-47d7-83ed-0ffc3b5e6607_terseLabel_en-US" xlink:label="lab_cybn_ShareIssuanceCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issuance costs</link:label>
    <link:label id="lab_cybn_ShareIssuanceCostsMember_label_en-US" xlink:label="lab_cybn_ShareIssuanceCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Issuance Costs [Member]</link:label>
    <link:label id="lab_cybn_ShareIssuanceCostsMember_documentation_en-US" xlink:label="lab_cybn_ShareIssuanceCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareIssuanceCostsMember" xlink:href="cybn-20250331.xsd#cybn_ShareIssuanceCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ShareIssuanceCostsMember" xlink:to="lab_cybn_ShareIssuanceCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfGrantedPatents_70c42bb4-536a-4049-abb4-34533aaca692_terseLabel_en-US" xlink:label="lab_cybn_NumberOfGrantedPatents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of granted patents</link:label>
    <link:label id="lab_cybn_NumberOfGrantedPatents_label_en-US" xlink:label="lab_cybn_NumberOfGrantedPatents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Granted Patents</link:label>
    <link:label id="lab_cybn_NumberOfGrantedPatents_documentation_en-US" xlink:label="lab_cybn_NumberOfGrantedPatents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Granted Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfGrantedPatents" xlink:href="cybn-20250331.xsd#cybn_NumberOfGrantedPatents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfGrantedPatents" xlink:to="lab_cybn_NumberOfGrantedPatents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_27dda9b4-3086-4ad5-a9d1-48f0112579d8_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected dividend as percentage, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_August2023CompensationCommonShareWarrantMember_b6d8fb68-eff6-4f9f-9a4c-76d4b053c133_terseLabel_en-US" xlink:label="lab_cybn_August2023CompensationCommonShareWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">August 2023 compensation common share warrant</link:label>
    <link:label id="lab_cybn_August2023CompensationCommonShareWarrantMember_label_en-US" xlink:label="lab_cybn_August2023CompensationCommonShareWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">August 2023 Compensation Common Share Warrant [Member]</link:label>
    <link:label id="lab_cybn_August2023CompensationCommonShareWarrantMember_documentation_en-US" xlink:label="lab_cybn_August2023CompensationCommonShareWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">August 2023 Compensation Common Share Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_August2023CompensationCommonShareWarrantMember" xlink:href="cybn-20250331.xsd#cybn_August2023CompensationCommonShareWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_August2023CompensationCommonShareWarrantMember" xlink:to="lab_cybn_August2023CompensationCommonShareWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_df7747c8-d279-49ac-ae95-e3f323c27f46_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyNineMember_ada083bf-5837-4cd4-ae57-c20976196407_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Nine</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyNineMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Nine [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyNineMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Nine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyNineMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodTwentyNineMember" xlink:to="lab_cybn_OptionExpirationPeriodTwentyNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_ec58005b-9ab9-4470-b806-7ff4c3c335a5_totalLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxAssets_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxAssets" xlink:to="lab_ifrs-full_DeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_CapitalManagementAbstract_label_en-US" xlink:label="lab_cybn_CapitalManagementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Management [Abstract]</link:label>
    <link:label id="lab_cybn_CapitalManagementAbstract_documentation_en-US" xlink:label="lab_cybn_CapitalManagementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Management [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CapitalManagementAbstract" xlink:href="cybn-20250331.xsd#cybn_CapitalManagementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_CapitalManagementAbstract" xlink:to="lab_cybn_CapitalManagementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_ca569ff2-3118-4248-8468-ef8d970f4bd6_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major ordinary share transactions</link:label>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_label_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major ordinary share transactions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:to="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_GainLossOnDerecognitionOfLeaseLiability_5804a2fd-7ca2-42bf-8191-fe7084a5e038_terseLabel_en-US" xlink:label="lab_cybn_GainLossOnDerecognitionOfLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on derecognition of lease liability</link:label>
    <link:label id="lab_cybn_GainLossOnDerecognitionOfLeaseLiability_541e6995-ee6e-442a-8584-f3a0a9427965_negatedTerseLabel_en-US" xlink:label="lab_cybn_GainLossOnDerecognitionOfLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on derecognition</link:label>
    <link:label id="lab_cybn_GainLossOnDerecognitionOfLeaseLiability_label_en-US" xlink:label="lab_cybn_GainLossOnDerecognitionOfLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Derecognition of Lease Liability</link:label>
    <link:label id="lab_cybn_GainLossOnDerecognitionOfLeaseLiability_documentation_en-US" xlink:label="lab_cybn_GainLossOnDerecognitionOfLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Derecognition of Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GainLossOnDerecognitionOfLeaseLiability" xlink:href="cybn-20250331.xsd#cybn_GainLossOnDerecognitionOfLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_GainLossOnDerecognitionOfLeaseLiability" xlink:to="lab_cybn_GainLossOnDerecognitionOfLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_089b1ea4-e945-4e45-805b-c83dc7289016_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_f376a317-ab8c-428d-832f-0f8c9746831d_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation gain</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on exchange differences on translation of foreign operations, before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate_2decbfaf-c000-4041-9738-dcf3d12a1488_terseLabel_en-US" xlink:label="lab_cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, annual interest rate</link:label>
    <link:label id="lab_cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate_label_en-US" xlink:label="lab_cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Guaranteed Interest Payable, Annual Rate</link:label>
    <link:label id="lab_cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate_documentation_en-US" xlink:label="lab_cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Guaranteed Interest Payable, Annual Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate" xlink:to="lab_cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsDomain_5d676264-2f98-49ea-a9cf-183162785d35_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial assets [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialAssetsDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial assets [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="lab_ifrs-full_ClassesOfFinancialAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_fdad23fa-d180-4be2-a6ef-a87589126762_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for provisions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyFourMember_60992d13-3c0b-439f-882a-b0470e6b571f_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Four</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyFourMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Four [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyFourMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyFourMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodThirtyFourMember" xlink:to="lab_cybn_OptionExpirationPeriodThirtyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6526e3a7-4970-49dc-8c83-f93300bb2812_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_CybinUSMember_8198c72c-077c-462c-86bf-03ddd2c934ae_terseLabel_en-US" xlink:label="lab_cybn_CybinUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cybin US</link:label>
    <link:label id="lab_cybn_CybinUSMember_label_en-US" xlink:label="lab_cybn_CybinUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cybin US [Member]</link:label>
    <link:label id="lab_cybn_CybinUSMember_documentation_en-US" xlink:label="lab_cybn_CybinUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cybin US</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CybinUSMember" xlink:href="cybn-20250331.xsd#cybn_CybinUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_CybinUSMember" xlink:to="lab_cybn_CybinUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_TaxEffectOfChangeInDeferredTaxAssets_ac1a11c8-530e-453f-9d70-032cb3d72136_negatedTerseLabel_en-US" xlink:label="lab_cybn_TaxEffectOfChangeInDeferredTaxAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in unrecognized deferred tax assets</link:label>
    <link:label id="lab_cybn_TaxEffectOfChangeInDeferredTaxAssets_label_en-US" xlink:label="lab_cybn_TaxEffectOfChangeInDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Change In Deferred Tax Assets</link:label>
    <link:label id="lab_cybn_TaxEffectOfChangeInDeferredTaxAssets_documentation_en-US" xlink:label="lab_cybn_TaxEffectOfChangeInDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Change In Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_TaxEffectOfChangeInDeferredTaxAssets" xlink:href="cybn-20250331.xsd#cybn_TaxEffectOfChangeInDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_TaxEffectOfChangeInDeferredTaxAssets" xlink:to="lab_cybn_TaxEffectOfChangeInDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_1ec6f1d7-bfea-4c49-8b7d-65848b0ac288_terseLabel_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss</link:label>
    <link:label id="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_label_en-US" xlink:label="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment loss recognised in profit or loss, goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:to="lab_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_e338f223-663b-4ce6-b25c-5cd140b0a0d3_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash acquired on acquisition</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents in subsidiary or businesses acquired or disposed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:to="lab_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_IntangibleAssetsAbstract_label_en-US" xlink:label="lab_cybn_IntangibleAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets [Abstract]</link:label>
    <link:label id="lab_cybn_IntangibleAssetsAbstract_documentation_en-US" xlink:label="lab_cybn_IntangibleAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IntangibleAssetsAbstract" xlink:href="cybn-20250331.xsd#cybn_IntangibleAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_IntangibleAssetsAbstract" xlink:to="lab_cybn_IntangibleAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ConvertibleDebenturePrivatePlacementMember_b9d2c4ee-fadb-4094-9dc4-284068d3e5a3_terseLabel_en-US" xlink:label="lab_cybn_ConvertibleDebenturePrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debenture Private Placement</link:label>
    <link:label id="lab_cybn_ConvertibleDebenturePrivatePlacementMember_label_en-US" xlink:label="lab_cybn_ConvertibleDebenturePrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debenture Private Placement [Member]</link:label>
    <link:label id="lab_cybn_ConvertibleDebenturePrivatePlacementMember_documentation_en-US" xlink:label="lab_cybn_ConvertibleDebenturePrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Debenture Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ConvertibleDebenturePrivatePlacementMember" xlink:href="cybn-20250331.xsd#cybn_ConvertibleDebenturePrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ConvertibleDebenturePrivatePlacementMember" xlink:to="lab_cybn_ConvertibleDebenturePrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ShareOptionsVestingSecondTrancheMember_6e294401-40dc-4f8e-b637-54f8ebda1850_terseLabel_en-US" xlink:label="lab_cybn_ShareOptionsVestingSecondTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Options, Vesting, Second Tranche</link:label>
    <link:label id="lab_cybn_ShareOptionsVestingSecondTrancheMember_label_en-US" xlink:label="lab_cybn_ShareOptionsVestingSecondTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Options, Vesting, Second Tranche [Member]</link:label>
    <link:label id="lab_cybn_ShareOptionsVestingSecondTrancheMember_documentation_en-US" xlink:label="lab_cybn_ShareOptionsVestingSecondTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Options, Vesting, Second Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareOptionsVestingSecondTrancheMember" xlink:href="cybn-20250331.xsd#cybn_ShareOptionsVestingSecondTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ShareOptionsVestingSecondTrancheMember" xlink:to="lab_cybn_ShareOptionsVestingSecondTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DebtInstrumentGuaranteedInterestPayableRate_9b61ffd7-a2d8-40d5-a517-d21ba98481a4_terseLabel_en-US" xlink:label="lab_cybn_DebtInstrumentGuaranteedInterestPayableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, guaranteed interest payable</link:label>
    <link:label id="lab_cybn_DebtInstrumentGuaranteedInterestPayableRate_label_en-US" xlink:label="lab_cybn_DebtInstrumentGuaranteedInterestPayableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Guaranteed Interest Payable, Rate</link:label>
    <link:label id="lab_cybn_DebtInstrumentGuaranteedInterestPayableRate_documentation_en-US" xlink:label="lab_cybn_DebtInstrumentGuaranteedInterestPayableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Guaranteed Interest Payable, Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentGuaranteedInterestPayableRate" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentGuaranteedInterestPayableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DebtInstrumentGuaranteedInterestPayableRate" xlink:to="lab_cybn_DebtInstrumentGuaranteedInterestPayableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_9a690525-b173-4484-839a-b8565d31388c_totalLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodSixMember_6467f052-7396-4a4c-8979-03d9bd34fd98_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Six</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodSixMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Six [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodSixMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodSixMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodSixMember" xlink:to="lab_cybn_OptionExpirationPeriodSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodFourMember_b93fffa8-b9e6-43ce-9ec9-0dfb7da1e3e5_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Four</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodFourMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Four [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodFourMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodFourMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodFourMember" xlink:to="lab_cybn_OptionExpirationPeriodFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash_884142cb-373b-41ba-853f-7ef55eb757f6_negatedTerseLabel_en-US" xlink:label="lab_cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in interest rate generated on cash</link:label>
    <link:label id="lab_cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash_label_en-US" xlink:label="lab_cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Risk, Increase (Decrease) In Interest Rate Generated On Cash</link:label>
    <link:label id="lab_cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash_documentation_en-US" xlink:label="lab_cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Rate Risk, Increase (Decrease) In Interest Rate Generated On Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash" xlink:href="cybn-20250331.xsd#cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash" xlink:to="lab_cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_633b0ee0-8f9f-4099-8a6a-b516e1a2c2c1_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_554e1edd-00cc-4429-987f-5b40e315b5b7_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic loss per share for the year (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_BusinessDevelopmentExpense_647e229b-e304-4792-a057-f9746f38022e_terseLabel_en-US" xlink:label="lab_cybn_BusinessDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business development</link:label>
    <link:label id="lab_cybn_BusinessDevelopmentExpense_label_en-US" xlink:label="lab_cybn_BusinessDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Development Expense</link:label>
    <link:label id="lab_cybn_BusinessDevelopmentExpense_documentation_en-US" xlink:label="lab_cybn_BusinessDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_BusinessDevelopmentExpense" xlink:href="cybn-20250331.xsd#cybn_BusinessDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_BusinessDevelopmentExpense" xlink:to="lab_cybn_BusinessDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_WorkingCapital_af8900e4-a2f6-46d6-9d0d-54a083b30d6e_terseLabel_en-US" xlink:label="lab_cybn_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_cybn_WorkingCapital_label_en-US" xlink:label="lab_cybn_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_cybn_WorkingCapital_documentation_en-US" xlink:label="lab_cybn_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WorkingCapital" xlink:href="cybn-20250331.xsd#cybn_WorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_WorkingCapital" xlink:to="lab_cybn_WorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyTwoMember_b4066c25-b3b2-4149-b022-cca8a3b32e5d_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Two</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyTwoMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Two [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyTwoMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyTwoMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodThirtyTwoMember" xlink:to="lab_cybn_OptionExpirationPeriodThirtyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_38cf4464-d821-4ee2-a3a1-5bf05607390d_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments_e5daedd4-a21a-4b80-ad4e-8ee06f2e98a6_terseLabel_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued upon conversion of convertible instruments (in shares)</link:label>
    <link:label id="lab_cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments_label_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Shares Issued Upon Conversion of Convertible Instruments</link:label>
    <link:label id="lab_cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments_documentation_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Shares Issued Upon Conversion of Convertible Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments" xlink:to="lab_cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain_c28dbe41-08e3-4d02-bf07-e0f34a00e0a6_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:to="lab_ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseByNatureAbstract_1b224e4d-0c28-4ba4-b462-afeb81e15257_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EXPENSES</link:label>
    <link:label id="lab_ifrs-full_ExpenseByNatureAbstract_label_en-US" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses by nature [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract" xlink:to="lab_ifrs-full_ExpenseByNatureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_f7418050-ee85-464c-9b3b-f27dabf48c2e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_729ff560-96af-4627-97b0-be9183f54e99_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClosingForeignExchangeRate_425d3cdc-cdef-49d1-87ab-0376bddbe5e0_terseLabel_en-US" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency rate</link:label>
    <link:label id="lab_ifrs-full_ClosingForeignExchangeRate_label_en-US" xlink:label="lab_ifrs-full_ClosingForeignExchangeRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Closing foreign exchange rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClosingForeignExchangeRate" xlink:to="lab_ifrs-full_ClosingForeignExchangeRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_995dd6fd-3fe5-408d-b5b6-b08766c3f3e2_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets other than goodwill [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="lab_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_e7bf2ec8-d15c-4b61-b8f0-b3db19981429_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FINANCING ACTIVITIES</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_c11029ce-83cd-4ad2-a2f0-c788084c3cba_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_2e114e21-c78f-44e4-8ea9-a18e048cc3d0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_d64bf084-18d6-4a5e-987a-bab52059e098_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of warrants</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_ecb35f64-0a7c-46bf-a85d-2cfdb18d035e_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_fe03c3d1-0358-474a-a3d3-1dd9910fd918_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET LOSS FOR THE YEAR</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_674f9246-fcfc-42db-bb6c-571b8064d099_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss for the year</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_e1fe8cdf-26d4-44e4-ae86-08a94dc70471_negatedLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_269c50c6-8fb2-4c1b-b80a-d9ecb7059df5_verboseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfCommonSharesHeldInEscrow_7a205c53-79a9-4a4b-88ec-966596e50201_terseLabel_en-US" xlink:label="lab_cybn_NumberOfCommonSharesHeldInEscrow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common shares held in escrow (in shares)</link:label>
    <link:label id="lab_cybn_NumberOfCommonSharesHeldInEscrow_label_en-US" xlink:label="lab_cybn_NumberOfCommonSharesHeldInEscrow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Common Shares Held In Escrow</link:label>
    <link:label id="lab_cybn_NumberOfCommonSharesHeldInEscrow_documentation_en-US" xlink:label="lab_cybn_NumberOfCommonSharesHeldInEscrow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Common Shares Held In Escrow</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfCommonSharesHeldInEscrow" xlink:href="cybn-20250331.xsd#cybn_NumberOfCommonSharesHeldInEscrow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfCommonSharesHeldInEscrow" xlink:to="lab_cybn_NumberOfCommonSharesHeldInEscrow" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_423e1228-7612-4faa-b42f-2d773fe6cb8e_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in other current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_a04b7bbc-26fc-4f58-95e3-501fbf869f4d_totalLabel_en-US" xlink:label="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total allocation of purchase price</link:label>
    <link:label id="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_label_en-US" xlink:label="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable assets acquired (liabilities assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:to="lab_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodDomain_c782bd6e-9ceb-48fa-8bc6-40d164b06344_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period [Domain]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodDomain_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period [Domain]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodDomain_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodDomain" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodDomain" xlink:to="lab_cybn_OptionExpirationPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_af4f7b31-b4e7-4fd7-8088-83066e773a46_terseLabel_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership</link:label>
    <link:label id="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_label_en-US" xlink:label="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proportion of ownership interest in subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="lab_ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_765ee79c-d996-48a2-ae8a-6e28c81768da_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_07c51849-1c04-41a6-a3cd-dc22c2ba8cbe_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentySixMember_4f98941c-c602-4acc-a1e4-e923f3642119_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Six</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentySixMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Six [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentySixMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentySixMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodTwentySixMember" xlink:to="lab_cybn_OptionExpirationPeriodTwentySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_b4dfc86d-3131-4c5d-bfea-e099212b809b_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash flows used in operating activities before net changes in non-cash working capital items</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operations before changes in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_57228f9f-6a18-437d-9403-bae1b9d25196_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalDomain_1e5cb12e-eab2-4b05-a452-cde0bd310a56_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of share capital [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain" xlink:to="lab_ifrs-full_ClassesOfShareCapitalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DisclosureOfNonCapitalLossesExpirationTable_d52820d0-e031-4073-97e5-d0721c9b3ea8_terseLabel_en-US" xlink:label="lab_cybn_DisclosureOfNonCapitalLossesExpirationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-Capital Losses Expiration [Table]</link:label>
    <link:label id="lab_cybn_DisclosureOfNonCapitalLossesExpirationTable_label_en-US" xlink:label="lab_cybn_DisclosureOfNonCapitalLossesExpirationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-Capital Losses Expiration [Table]</link:label>
    <link:label id="lab_cybn_DisclosureOfNonCapitalLossesExpirationTable_documentation_en-US" xlink:label="lab_cybn_DisclosureOfNonCapitalLossesExpirationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-Capital Losses Expiration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfNonCapitalLossesExpirationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable" xlink:to="lab_cybn_DisclosureOfNonCapitalLossesExpirationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodThreeMember_d47abdb1-e05c-46d0-9b1b-126f71a5fcd9_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Three</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThreeMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Three [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThreeMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThreeMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodThreeMember" xlink:to="lab_cybn_OptionExpirationPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_GrantedToConsultantsMember_7ea9bda1-d24c-4f62-ae2a-9a2fd5cb276e_terseLabel_en-US" xlink:label="lab_cybn_GrantedToConsultantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted to consultants</link:label>
    <link:label id="lab_cybn_GrantedToConsultantsMember_label_en-US" xlink:label="lab_cybn_GrantedToConsultantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted To Consultants [Member]</link:label>
    <link:label id="lab_cybn_GrantedToConsultantsMember_documentation_en-US" xlink:label="lab_cybn_GrantedToConsultantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Granted To Consultants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrantedToConsultantsMember" xlink:href="cybn-20250331.xsd#cybn_GrantedToConsultantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_GrantedToConsultantsMember" xlink:to="lab_cybn_GrantedToConsultantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity_97c48430-d9ed-43cf-9382-4de6ecf5b68e_terseLabel_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued on Adelia milestones (in shares)</link:label>
    <link:label id="lab_cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity_label_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Shares Issued Through Contingent Consideration, Equity</link:label>
    <link:label id="lab_cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity_documentation_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Shares Issued Through Contingent Consideration, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity" xlink:to="lab_cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_b22dc805-0436-428c-bb0e-90c9b9cc28f1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about business combination [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ResearchComponentMember_6bcf43c4-e3f6-4b85-b561-3f019bb9ea0c_terseLabel_en-US" xlink:label="lab_cybn_ResearchComponentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research</link:label>
    <link:label id="lab_cybn_ResearchComponentMember_label_en-US" xlink:label="lab_cybn_ResearchComponentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Component [Member]</link:label>
    <link:label id="lab_cybn_ResearchComponentMember_documentation_en-US" xlink:label="lab_cybn_ResearchComponentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ResearchComponentMember" xlink:href="cybn-20250331.xsd#cybn_ResearchComponentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ResearchComponentMember" xlink:to="lab_cybn_ResearchComponentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement_6eb8cbaa-21ec-4226-a1e1-bea3a3345f9b_terseLabel_en-US" xlink:label="lab_cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of other equity instruments (in CAD/USD per share)</link:label>
    <link:label id="lab_cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price of Other Equity Instruments in Share-based Payment Arrangement</link:label>
    <link:label id="lab_cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price of Other Equity Instruments in Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement" xlink:href="cybn-20250331.xsd#cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement" xlink:to="lab_cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_acd73282-1b5d-4ec3-9b3c-4ee1642868fa_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation differences for foreign operations</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_0cff349c-2f04-4270-a745-5578513a7a52_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on translation of foreign operations</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_7af105b8-65e1-49e2-b6e3-d24e3b54c64d_terseLabel_en-US" xlink:label="lab_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of 10% change in foreign currency rate</link:label>
    <link:label id="lab_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_label_en-US" xlink:label="lab_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk exposure associated with instruments sharing characteristic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:to="lab_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation_b174c6bb-ef9c-4e55-b8da-2f4c1f24d8be_terseLabel_en-US" xlink:label="lab_cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unexercised stock options in subsidiary, compensation for cancellation (in CAD per share)</link:label>
    <link:label id="lab_cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation_label_en-US" xlink:label="lab_cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unexercised Stock Options In Subsidiary, Compensation For Cancellation</link:label>
    <link:label id="lab_cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation_documentation_en-US" xlink:label="lab_cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unexercised Stock Options In Subsidiary, Compensation For Cancellation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation" xlink:href="cybn-20250331.xsd#cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation" xlink:to="lab_cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_eb0d6381-4fc3-4987-861e-3386078bab50_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable" xlink:to="lab_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_118b5a87-1631-4011-8998-3f490c8afae0_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_9a661e19-f8c9-49d7-b07f-f670c8c14b06_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of options exercisable (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_5a09290f-239c-48af-ab8a-0d858302125e_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">CORPORATE INFORMATION</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of consolidation [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_400e3d0e-2715-4057-ae21-47d6e50d3793_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CONTRACTS, COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyFiveMember_feeb81a0-36b6-4908-b147-89ef6314a48e_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Five</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyFiveMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Five [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyFiveMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyFiveMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodTwentyFiveMember" xlink:to="lab_cybn_OptionExpirationPeriodTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodEighteenMember_0c85b29c-c0f4-44a1-ab80-51bed1003a50_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodEighteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Eighteen</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodEighteenMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodEighteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Eighteen [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodEighteenMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodEighteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Eighteen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodEighteenMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodEighteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodEighteenMember" xlink:to="lab_cybn_OptionExpirationPeriodEighteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WarrantsMember_1608630f-f6a4-4315-b4fa-905adc26aaf7_terseLabel_en-US" xlink:label="lab_ifrs-full_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_ifrs-full_WarrantsMember_label_en-US" xlink:label="lab_ifrs-full_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WarrantsMember" xlink:to="lab_ifrs-full_WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_b0f24824-6ae8-4992-aaf4-09c2eb93a8e9_terseLabel_en-US" xlink:label="lab_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options vested (in shares)</link:label>
    <link:label id="lab_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share Options Vested In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Share Options Vested In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:href="cybn-20250331.xsd#cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:to="lab_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExercisePriceShareOptionsGranted2019_d69e16dc-01a4-411c-b267-ca3b03e1f699_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price, share options granted (in CAD per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceShareOptionsGranted2019_04be14bf-e9cb-43ba-bc7d-3da43a4518e9_verboseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in CAD per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceShareOptionsGranted2019_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="lab_ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_a2859259-c5b1-46ae-9d86-ad32062fbb09_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition from Small Pharma</link:label>
    <link:label id="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_label_en-US" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, intangible assets and goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:to="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_898835ce-0ae7-48a8-b77a-0bd815423c39_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_4aa21fdd-eaf4-4d7f-905a-afe3d6c8296b_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercisable (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremiumMember_9f5a7fee-c652-463d-9637-01c9218ac0fd_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributed surplus</link:label>
    <link:label id="lab_ifrs-full_SharePremiumMember_label_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share premium [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember" xlink:to="lab_ifrs-full_SharePremiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_7ddeef33-4485-4d44-b3cf-2eb64a783931_terseLabel_en-US" xlink:label="lab_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Financial Assets and Liabilities [Table]</link:label>
    <link:label id="lab_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_label_en-US" xlink:label="lab_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Financial Assets and Liabilities [Table]</link:label>
    <link:label id="lab_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_documentation_en-US" xlink:label="lab_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of Financial Assets and Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable" xlink:to="lab_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DebtSecurities_c0550aec-48e7-4ab3-99e7-caeeae664372_terseLabel_en-US" xlink:label="lab_ifrs-full_DebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instruments issued</link:label>
    <link:label id="lab_ifrs-full_DebtSecurities_label_en-US" xlink:label="lab_ifrs-full_DebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt instruments issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtSecurities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DebtSecurities" xlink:to="lab_ifrs-full_DebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_38f10646-351d-4552-afd7-bbfa21f8df51_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_aab91f4a-1bc0-44af-8eb7-98824b9db0fa_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-capital loss carryforwards - Canada</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax losses [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesMember" xlink:to="lab_ifrs-full_UnusedTaxLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyEightMember_838e50f3-cfe6-45c5-9fca-547973844f61_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Eight</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyEightMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Eight [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyEightMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Eight</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyEightMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodTwentyEightMember" xlink:to="lab_cybn_OptionExpirationPeriodTwentyEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares_5f1de8b3-9c0d-44b8-91b1-c63e0e7e22fe_terseLabel_en-US" xlink:label="lab_cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Converted into Common Shares (in shares)</link:label>
    <link:label id="lab_cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares_label_en-US" xlink:label="lab_cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Conversion of Convertible Instruments, Equity, Shares</link:label>
    <link:label id="lab_cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares_documentation_en-US" xlink:label="lab_cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Conversion of Convertible Instruments, Equity, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares" xlink:to="lab_cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_e882258a-5d8b-4477-b23f-2a0649d4b3fb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MATERIAL ACCOUNTING POLICIES AND BASIS OF PREPARATION</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of material accounting policy information [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_LossCarryforwardExpirationDomain_cbdf456a-995a-4755-8dba-f2126a545685_terseLabel_en-US" xlink:label="lab_cybn_LossCarryforwardExpirationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Carryforward Expiration [Domain]</link:label>
    <link:label id="lab_cybn_LossCarryforwardExpirationDomain_label_en-US" xlink:label="lab_cybn_LossCarryforwardExpirationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Carryforward Expiration [Domain]</link:label>
    <link:label id="lab_cybn_LossCarryforwardExpirationDomain_documentation_en-US" xlink:label="lab_cybn_LossCarryforwardExpirationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Carryforward Expiration [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LossCarryforwardExpirationDomain" xlink:href="cybn-20250331.xsd#cybn_LossCarryforwardExpirationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_LossCarryforwardExpirationDomain" xlink:to="lab_cybn_LossCarryforwardExpirationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_fa51b81d-7840-4aca-808d-c008138c0719_terseLabel_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life of equipment</link:label>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful life measured as period of time, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_InvestorRelationsSalesAndMarketingExpense_69f51d6f-7e6e-41a4-a6b8-c78218578f67_terseLabel_en-US" xlink:label="lab_cybn_InvestorRelationsSalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investor relations and Marketing media</link:label>
    <link:label id="lab_cybn_InvestorRelationsSalesAndMarketingExpense_label_en-US" xlink:label="lab_cybn_InvestorRelationsSalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investor Relations, Sales and Marketing Expense</link:label>
    <link:label id="lab_cybn_InvestorRelationsSalesAndMarketingExpense_documentation_en-US" xlink:label="lab_cybn_InvestorRelationsSalesAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investor Relations, Sales and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_InvestorRelationsSalesAndMarketingExpense" xlink:href="cybn-20250331.xsd#cybn_InvestorRelationsSalesAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_InvestorRelationsSalesAndMarketingExpense" xlink:to="lab_cybn_InvestorRelationsSalesAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_ecfd4aa8-e360-452f-a832-29495b3e7869_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_6fae8c57-1d90-4e27-bd82-f2d632414c60_verboseLabel_en-US" xlink:label="lab_cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in USD per share)</link:label>
    <link:label id="lab_cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted</link:label>
    <link:label id="lab_cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="cybn-20250331.xsd#cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="lab_cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DeferredTaxAssetsValuationAllowance_430ba7dd-1dc0-4431-ae18-5ceb4748bc80_negatedTerseLabel_en-US" xlink:label="lab_cybn_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_cybn_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_cybn_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label id="lab_cybn_DeferredTaxAssetsValuationAllowance_documentation_en-US" xlink:label="lab_cybn_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DeferredTaxAssetsValuationAllowance" xlink:href="cybn-20250331.xsd#cybn_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DeferredTaxAssetsValuationAllowance" xlink:to="lab_cybn_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_08cedd74-b047-4b6c-a2f9-0f95118209fb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_ea94d7f8-c12f-452e-b507-73ed2d2b94c2_terseLabel_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life of intangible assets</link:label>
    <link:label id="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful life measured as period of time, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_A2042Member_7a65bf01-1f85-470f-9774-33df8d6d6a2f_terseLabel_en-US" xlink:label="lab_cybn_A2042Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2042</link:label>
    <link:label id="lab_cybn_A2042Member_label_en-US" xlink:label="lab_cybn_A2042Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2042 [Member]</link:label>
    <link:label id="lab_cybn_A2042Member_documentation_en-US" xlink:label="lab_cybn_A2042Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2042</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2042Member" xlink:href="cybn-20250331.xsd#cybn_A2042Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_A2042Member" xlink:to="lab_cybn_A2042Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_4c79054c-ac7c-4af8-8d5b-e42c97dd4da3_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_9286a950-6b16-4b0f-8e3e-111403c4d933_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement (in CAD per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_64840478-78f3-4ab7-b5d4-fc848380672a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of intangible assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_PropertyPlantAndEquipment1Abstract_label_en-US" xlink:label="lab_cybn_PropertyPlantAndEquipment1Abstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment1 [Abstract]</link:label>
    <link:label id="lab_cybn_PropertyPlantAndEquipment1Abstract_documentation_en-US" xlink:label="lab_cybn_PropertyPlantAndEquipment1Abstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PropertyPlantAndEquipment1Abstract" xlink:href="cybn-20250331.xsd#cybn_PropertyPlantAndEquipment1Abstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_PropertyPlantAndEquipment1Abstract" xlink:to="lab_cybn_PropertyPlantAndEquipment1Abstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_bba7aa1e-d302-4689-96fe-7f1e3b466965_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_100f5071-d3ff-4188-aeae-90c0f7d4d982_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets, measured at fair value:</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets at fair value through other comprehensive income, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:to="lab_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyOneMember_7bce1a00-7701-4717-bd0c-e87e80a0e0b6_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty One</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyOneMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty One [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyOneMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyOneMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodThirtyOneMember" xlink:to="lab_cybn_OptionExpirationPeriodThirtyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodNineteenMember_d8636faf-5cfa-438b-933c-fcf189f807ff_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodNineteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Nineteen</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodNineteenMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodNineteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Nineteen [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodNineteenMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodNineteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Nineteen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodNineteenMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodNineteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodNineteenMember" xlink:to="lab_cybn_OptionExpirationPeriodNineteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_COMMITMENTSTable_bc170c0f-e55d-4342-8b54-6d8b7195623a_terseLabel_en-US" xlink:label="lab_cybn_COMMITMENTSTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS [Table]</link:label>
    <link:label id="lab_cybn_COMMITMENTSTable_label_en-US" xlink:label="lab_cybn_COMMITMENTSTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COMMITMENTS [Table]</link:label>
    <link:label id="lab_cybn_COMMITMENTSTable_documentation_en-US" xlink:label="lab_cybn_COMMITMENTSTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">COMMITMENTS [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_COMMITMENTSTable" xlink:href="cybn-20250331.xsd#cybn_COMMITMENTSTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_COMMITMENTSTable" xlink:to="lab_cybn_COMMITMENTSTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OccupancyExpense_215fe3b4-f557-426f-8ddd-15686c85c80c_terseLabel_en-US" xlink:label="lab_ifrs-full_OccupancyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office and administration</link:label>
    <link:label id="lab_ifrs-full_OccupancyExpense_label_en-US" xlink:label="lab_ifrs-full_OccupancyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Occupancy expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OccupancyExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OccupancyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OccupancyExpense" xlink:to="lab_ifrs-full_OccupancyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_IncomeTaxesAbstract_label_en-US" xlink:label="lab_cybn_IncomeTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Abstract]</link:label>
    <link:label id="lab_cybn_IncomeTaxesAbstract_documentation_en-US" xlink:label="lab_cybn_IncomeTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncomeTaxesAbstract" xlink:href="cybn-20250331.xsd#cybn_IncomeTaxesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_IncomeTaxesAbstract" xlink:to="lab_cybn_IncomeTaxesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ClassesOfDebtInstrumentsAxis_86254a27-c20b-4e75-9d52-8c8248663ae2_terseLabel_en-US" xlink:label="lab_cybn_ClassesOfDebtInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes Of Debt Instruments [Axis]</link:label>
    <link:label id="lab_cybn_ClassesOfDebtInstrumentsAxis_label_en-US" xlink:label="lab_cybn_ClassesOfDebtInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes Of Debt Instruments [Axis]</link:label>
    <link:label id="lab_cybn_ClassesOfDebtInstrumentsAxis_documentation_en-US" xlink:label="lab_cybn_ClassesOfDebtInstrumentsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Classes Of Debt Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassesOfDebtInstrumentsAxis" xlink:href="cybn-20250331.xsd#cybn_ClassesOfDebtInstrumentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ClassesOfDebtInstrumentsAxis" xlink:to="lab_cybn_ClassesOfDebtInstrumentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_AuditInformationAbstract_label_en-US" xlink:label="lab_cybn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_cybn_AuditInformationAbstract_documentation_en-US" xlink:label="lab_cybn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AuditInformationAbstract" xlink:href="cybn-20250331.xsd#cybn_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_AuditInformationAbstract" xlink:to="lab_cybn_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_05ceb891-ae77-4a3d-bae6-c502f11a5baa_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:to="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_96cb18b2-dc8d-4d94-8f78-332180498bb1_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_511ca9ab-329c-43d8-88b5-98c5fd487606_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of remuneration of key management personnel</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_2ffbb9d1-f9af-4bb0-aa3e-917734dd8cd7_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated grant date fair value</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average fair value at measurement date, other equity instruments granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_1c7e99a2-9b44-4030-a669-bbc6474a169f_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INVESTING ACTIVITIES</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2bdbd392-6380-4082-94ed-d72aeeb9b8b1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_753c7348-729c-4ff8-ab3d-191917e6a9e7_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss carryforwards</link:label>
    <link:label id="lab_ifrs-full_DeferredTaxLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeferredTaxLiabilityAsset" xlink:to="lab_ifrs-full_DeferredTaxLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_7ed38e65-60f6-44fa-9452-eec0759aa43d_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Lease payments</link:label>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_689cee31-429d-4575-b83d-189a291bafa3_negatedLabel_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="lab_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_4ad77bb7-d905-4dfb-91de-18f0388553c8_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of Small Pharma</link:label>
    <link:label id="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisitions through business combinations, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ShareBasedPaymentVestingPeriodDomain_7fe914c1-21da-4d0c-805c-671985106183_terseLabel_en-US" xlink:label="lab_cybn_ShareBasedPaymentVestingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment, Vesting Period [Domain]</link:label>
    <link:label id="lab_cybn_ShareBasedPaymentVestingPeriodDomain_label_en-US" xlink:label="lab_cybn_ShareBasedPaymentVestingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment, Vesting Period [Domain]</link:label>
    <link:label id="lab_cybn_ShareBasedPaymentVestingPeriodDomain_documentation_en-US" xlink:label="lab_cybn_ShareBasedPaymentVestingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Payment, Vesting Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareBasedPaymentVestingPeriodDomain" xlink:href="cybn-20250331.xsd#cybn_ShareBasedPaymentVestingPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ShareBasedPaymentVestingPeriodDomain" xlink:to="lab_cybn_ShareBasedPaymentVestingPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WarrantReserve_752a8714-3030-47a6-a753-8ad47fd87dbf_terseLabel_en-US" xlink:label="lab_ifrs-full_WarrantReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants reserve</link:label>
    <link:label id="lab_ifrs-full_WarrantReserve_label_en-US" xlink:label="lab_ifrs-full_WarrantReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantReserve" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WarrantReserve" xlink:to="lab_ifrs-full_WarrantReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_45e1b8c8-e903-41c4-9b26-2499f8336b5b_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_05911ed8-4cd1-4470-a4b7-a34762b908b7_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract" xlink:to="lab_ifrs-full_NoncurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_1c9b7000-ae48-4aa5-ab5e-935a91efb32b_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment write-down</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeographicalAreasAxis_bb447fd2-0590-4b31-9da8-f305b20d20d0_terseLabel_en-US" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical areas [axis]</link:label>
    <link:label id="lab_ifrs-full_GeographicalAreasAxis_label_en-US" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasAxis" xlink:to="lab_ifrs-full_GeographicalAreasAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_LaboratoryEquipmentMember_dafdfd66-5a18-46ca-ac1e-229091c61e74_terseLabel_en-US" xlink:label="lab_cybn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab Equipment</link:label>
    <link:label id="lab_cybn_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_cybn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_cybn_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_cybn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LaboratoryEquipmentMember" xlink:href="cybn-20250331.xsd#cybn_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_LaboratoryEquipmentMember" xlink:to="lab_cybn_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_9db2015f-2d1f-42d4-8802-2287fff77514_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of share capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_78861de7-4c03-4db5-87de-8f7d8632be8a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAbstract_8453590a-16f6-4bac-972d-fcc722617abd_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_ce465ae2-42c3-408a-9d23-2e20ec1fb9c4_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Current Assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_LossCarryforwardExpirationAxis_52444d6f-fe61-4a79-8706-89b5c357d7aa_terseLabel_en-US" xlink:label="lab_cybn_LossCarryforwardExpirationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Carryforward Expiration [Axis]</link:label>
    <link:label id="lab_cybn_LossCarryforwardExpirationAxis_label_en-US" xlink:label="lab_cybn_LossCarryforwardExpirationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Carryforward Expiration [Axis]</link:label>
    <link:label id="lab_cybn_LossCarryforwardExpirationAxis_documentation_en-US" xlink:label="lab_cybn_LossCarryforwardExpirationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Carryforward Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LossCarryforwardExpirationAxis" xlink:href="cybn-20250331.xsd#cybn_LossCarryforwardExpirationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_LossCarryforwardExpirationAxis" xlink:to="lab_cybn_LossCarryforwardExpirationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_7f46bb84-be13-4030-9e58-fb7af7f3f361_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PreferenceSharesMember_d89f941d-e53e-4ecc-ac64-57d5d1cff02b_terseLabel_en-US" xlink:label="lab_ifrs-full_PreferenceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred shares</link:label>
    <link:label id="lab_ifrs-full_PreferenceSharesMember_label_en-US" xlink:label="lab_ifrs-full_PreferenceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preference shares [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PreferenceSharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PreferenceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PreferenceSharesMember" xlink:to="lab_ifrs-full_PreferenceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_140f5a92-fb55-42d4-9bfb-74d56f99d0b0_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsRightofuseAssets_02f974a3-9419-49a8-a342-c4d46206b0d8_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsRightofuseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Disposals</link:label>
    <link:label id="lab_ifrs-full_DisposalsRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_DisposalsRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals, right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsRightofuseAssets" xlink:to="lab_ifrs-full_DisposalsRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BusinessCombinationsDomain_fd580e2c-9367-46a9-a11c-7aa28c046ba8_terseLabel_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business combinations [domain]</link:label>
    <link:label id="lab_ifrs-full_BusinessCombinationsDomain_label_en-US" xlink:label="lab_ifrs-full_BusinessCombinationsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business combinations [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BusinessCombinationsDomain" xlink:to="lab_ifrs-full_BusinessCombinationsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_624a17bf-9ece-475b-9049-c0418d57b0d0_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsDomain_988fe3bc-4327-40f5-8cfa-2521c344ebb3_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of financial assets [domain]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsDomain_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial assets [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:to="lab_ifrs-full_CategoriesOfFinancialAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_8599b07c-c789-4568-87ab-7278885cfc7f_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_86f5851d-409f-4637-bc8c-d7d621a1330e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_GrantedToOfficersAndDirectorsMember_a6987d69-1b72-4266-bbe3-5d959278c8f3_terseLabel_en-US" xlink:label="lab_cybn_GrantedToOfficersAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted to officers and directors</link:label>
    <link:label id="lab_cybn_GrantedToOfficersAndDirectorsMember_label_en-US" xlink:label="lab_cybn_GrantedToOfficersAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted To Officers And Directors [Member]</link:label>
    <link:label id="lab_cybn_GrantedToOfficersAndDirectorsMember_documentation_en-US" xlink:label="lab_cybn_GrantedToOfficersAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Granted To Officers And Directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrantedToOfficersAndDirectorsMember" xlink:href="cybn-20250331.xsd#cybn_GrantedToOfficersAndDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_GrantedToOfficersAndDirectorsMember" xlink:to="lab_cybn_GrantedToOfficersAndDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement_8c02857b-bd78-4494-80e9-b7a02f80acec_terseLabel_en-US" xlink:label="lab_cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:label id="lab_cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price Of Other Equity Instruments Exercised Or Vested In Share-based Payment Arrangement</link:label>
    <link:label id="lab_cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price Of Other Equity Instruments Issued In Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement" xlink:href="cybn-20250331.xsd#cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement" xlink:to="lab_cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfCommonSharePurchaseWarrants_290a1779-bf59-47a9-a881-00d23846ca4b_terseLabel_en-US" xlink:label="lab_cybn_NumberOfCommonSharePurchaseWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common share purchase warrants (in shares)</link:label>
    <link:label id="lab_cybn_NumberOfCommonSharePurchaseWarrants_label_en-US" xlink:label="lab_cybn_NumberOfCommonSharePurchaseWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Common Share Purchase Warrants</link:label>
    <link:label id="lab_cybn_NumberOfCommonSharePurchaseWarrants_documentation_en-US" xlink:label="lab_cybn_NumberOfCommonSharePurchaseWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Common Share Purchase Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfCommonSharePurchaseWarrants" xlink:href="cybn-20250331.xsd#cybn_NumberOfCommonSharePurchaseWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfCommonSharePurchaseWarrants" xlink:to="lab_cybn_NumberOfCommonSharePurchaseWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_10ea4697-24ef-4c86-ba85-65f42ec7e120_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_BusinessContactMember_bc85ce6d-060f-47eb-b19f-9d712357bb25_terseLabel_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Contact</link:label>
    <link:label id="lab_dei_BusinessContactMember_label_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Contact [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent_64474871-1b5e-4f7a-8575-4bc7b809cf60_terseLabel_en-US" xlink:label="lab_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reasonably possible change in risk variable, percent</link:label>
    <link:label id="lab_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent_label_en-US" xlink:label="lab_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Risks, Reasonably Possible Change In Risk Variable, Percent</link:label>
    <link:label id="lab_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent_documentation_en-US" xlink:label="lab_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Risks, Reasonably Possible Change In Risk Variable, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent" xlink:href="cybn-20250331.xsd#cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent" xlink:to="lab_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_TaxEffectOfShareBasedCompensation_fc7b902e-ea56-4f53-8214-84b8c24c26bc_negatedTerseLabel_en-US" xlink:label="lab_cybn_TaxEffectOfShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_cybn_TaxEffectOfShareBasedCompensation_label_en-US" xlink:label="lab_cybn_TaxEffectOfShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Share Based Compensation</link:label>
    <link:label id="lab_cybn_TaxEffectOfShareBasedCompensation_documentation_en-US" xlink:label="lab_cybn_TaxEffectOfShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Share Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_TaxEffectOfShareBasedCompensation" xlink:href="cybn-20250331.xsd#cybn_TaxEffectOfShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_TaxEffectOfShareBasedCompensation" xlink:to="lab_cybn_TaxEffectOfShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LicencesMember_9db180c9-552e-491e-9466-1a8b7668ad8a_terseLabel_en-US" xlink:label="lab_ifrs-full_LicencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_ifrs-full_LicencesMember_label_en-US" xlink:label="lab_ifrs-full_LicencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licences [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicencesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LicencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LicencesMember" xlink:to="lab_ifrs-full_LicencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_47d1d6ea-9551-4775-a2e4-9c2de41d56b0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EQUIPMENT</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_9a3d15e9-043c-4ac2-91aa-0e18fe6790e0_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_b1a8debd-4aa0-4400-bb10-61dc78b7f849_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_5ad09f3f-808c-4e6f-b5b0-9c681ab8e869_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRightofuseAssets" xlink:to="lab_ifrs-full_DepreciationRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_FinancialAssetsAndLiabilities_7f1bf05e-ea5d-4c42-9cd1-826094e523dc_terseLabel_en-US" xlink:label="lab_cybn_FinancialAssetsAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets and liabilities</link:label>
    <link:label id="lab_cybn_FinancialAssetsAndLiabilities_label_en-US" xlink:label="lab_cybn_FinancialAssetsAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Assets And Liabilities</link:label>
    <link:label id="lab_cybn_FinancialAssetsAndLiabilities_documentation_en-US" xlink:label="lab_cybn_FinancialAssetsAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Assets And Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_FinancialAssetsAndLiabilities" xlink:href="cybn-20250331.xsd#cybn_FinancialAssetsAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_FinancialAssetsAndLiabilities" xlink:to="lab_cybn_FinancialAssetsAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherContingentLiabilitiesMember_c1c568cb-287a-4f72-844a-90e3937eca19_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherContingentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other contingent liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherContingentLiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_OtherContingentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other contingent liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherContingentLiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherContingentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherContingentLiabilitiesMember" xlink:to="lab_ifrs-full_OtherContingentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_8a320b2f-5ef9-4bbc-8006-170562d65602_verboseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_a16b3693-af97-47c7-a2d4-5275e9710c3e_periodStartLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_cb36ad5f-498e-4cf5-8ab8-1dd8b7e8001c_periodEndLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_0b5faa61-7ffe-4b67-9731-4e4734599e0b_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net book value</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodSevenMember_2d6354bd-03fb-446d-b8b4-041bddd04629_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodSevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Seven</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodSevenMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Seven [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodSevenMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Seven</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodSevenMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodSevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodSevenMember" xlink:to="lab_cybn_OptionExpirationPeriodSevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_CashMember_0e2b58ac-ffa4-4bca-8ef3-c4b9017c1cd3_terseLabel_en-US" xlink:label="lab_cybn_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_cybn_CashMember_label_en-US" xlink:label="lab_cybn_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash [Member]</link:label>
    <link:label id="lab_cybn_CashMember_documentation_en-US" xlink:label="lab_cybn_CashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CashMember" xlink:href="cybn-20250331.xsd#cybn_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_CashMember" xlink:to="lab_cybn_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember_252104de-7d2a-4ebf-8bef-c2ae3df0e185_terseLabel_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IP Research &amp; Development</link:label>
    <link:label id="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember_label_en-US" xlink:label="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets under development [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:to="lab_ifrs-full_IntangibleAssetsUnderDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity_7764cd23-11fc-436b-b56b-612a50201e37_terseLabel_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity_label_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Issued Through Exercise Of Warrants, Equity</link:label>
    <link:label id="lab_cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity_documentation_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares Issued Through Exercise Of Warrants, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity" xlink:to="lab_cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_31122ad6-b7ea-4cd2-90a3-bff3f1efd6e4_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_GoodwillAbstract_label_en-US" xlink:label="lab_cybn_GoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Abstract]</link:label>
    <link:label id="lab_cybn_GoodwillAbstract_documentation_en-US" xlink:label="lab_cybn_GoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GoodwillAbstract" xlink:href="cybn-20250331.xsd#cybn_GoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_GoodwillAbstract" xlink:to="lab_cybn_GoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_A2045Member_b084efcd-4133-4657-9408-9843086e76bb_terseLabel_en-US" xlink:label="lab_cybn_A2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2045</link:label>
    <link:label id="lab_cybn_A2045Member_label_en-US" xlink:label="lab_cybn_A2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2045 [Member]</link:label>
    <link:label id="lab_cybn_A2045Member_documentation_en-US" xlink:label="lab_cybn_A2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2045</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2045Member" xlink:href="cybn-20250331.xsd#cybn_A2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_A2045Member" xlink:to="lab_cybn_A2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7bcb3721-8f22-4d77-a18f-28b3a0003ae2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DebtInstrumentPrepaymentPremiumYearOne_9fe687cd-36ca-43ef-821a-b46b83a1f511_terseLabel_en-US" xlink:label="lab_cybn_DebtInstrumentPrepaymentPremiumYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment premium, if paid year one</link:label>
    <link:label id="lab_cybn_DebtInstrumentPrepaymentPremiumYearOne_label_en-US" xlink:label="lab_cybn_DebtInstrumentPrepaymentPremiumYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Premium, Year One</link:label>
    <link:label id="lab_cybn_DebtInstrumentPrepaymentPremiumYearOne_documentation_en-US" xlink:label="lab_cybn_DebtInstrumentPrepaymentPremiumYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Premium, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentPrepaymentPremiumYearOne" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentPrepaymentPremiumYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DebtInstrumentPrepaymentPremiumYearOne" xlink:to="lab_cybn_DebtInstrumentPrepaymentPremiumYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_CapitalMarketExpense_2089c776-602f-42b9-8ae5-fceca9ad1f8d_terseLabel_en-US" xlink:label="lab_cybn_CapitalMarketExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital markets</link:label>
    <link:label id="lab_cybn_CapitalMarketExpense_label_en-US" xlink:label="lab_cybn_CapitalMarketExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Market Expense</link:label>
    <link:label id="lab_cybn_CapitalMarketExpense_documentation_en-US" xlink:label="lab_cybn_CapitalMarketExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Market Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CapitalMarketExpense" xlink:href="cybn-20250331.xsd#cybn_CapitalMarketExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_CapitalMarketExpense" xlink:to="lab_cybn_CapitalMarketExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_6b3f0b81-e107-46e7-80b1-16666a900215_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [domain]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IE_7fb9e0a3-0bc5-4c15-9528-ce7787a37d7f_terseLabel_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ireland</link:label>
    <link:label id="lab_country_IE_label_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IRELAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IE" xlink:to="lab_country_IE" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DeferredCompensationMember_0b31f4b6-2bcd-425f-b0ed-26ed97b09014_terseLabel_en-US" xlink:label="lab_cybn_DeferredCompensationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred compensation</link:label>
    <link:label id="lab_cybn_DeferredCompensationMember_label_en-US" xlink:label="lab_cybn_DeferredCompensationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred compensation [Member]</link:label>
    <link:label id="lab_cybn_DeferredCompensationMember_documentation_en-US" xlink:label="lab_cybn_DeferredCompensationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DeferredCompensationMember" xlink:href="cybn-20250331.xsd#cybn_DeferredCompensationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DeferredCompensationMember" xlink:to="lab_cybn_DeferredCompensationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyMember_a0198817-c128-408a-8def-e9ed2ad27e49_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodTwentyMember" xlink:to="lab_cybn_OptionExpirationPeriodTwentyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6a5b4580-6e7d-463b-8b6e-71aa59cbf514_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_6ecff919-054a-4e4d-97e9-b4758c42dce5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_6dfc73aa-8c3b-41de-b7b1-7389f976b3bf_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_AdeliaMember_e1bfc392-3d83-4247-b8eb-b0eef0eea40c_terseLabel_en-US" xlink:label="lab_cybn_AdeliaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adelia</link:label>
    <link:label id="lab_cybn_AdeliaMember_label_en-US" xlink:label="lab_cybn_AdeliaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adelia [Member]</link:label>
    <link:label id="lab_cybn_AdeliaMember_documentation_en-US" xlink:label="lab_cybn_AdeliaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adelia</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdeliaMember" xlink:href="cybn-20250331.xsd#cybn_AdeliaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_AdeliaMember" xlink:to="lab_cybn_AdeliaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DebtInstrumentPrepaymentPremiumYearTwo_1b751c7c-06c0-404b-92df-4be34467f2b0_terseLabel_en-US" xlink:label="lab_cybn_DebtInstrumentPrepaymentPremiumYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment premium, if paid year two</link:label>
    <link:label id="lab_cybn_DebtInstrumentPrepaymentPremiumYearTwo_label_en-US" xlink:label="lab_cybn_DebtInstrumentPrepaymentPremiumYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Premium, Year Two</link:label>
    <link:label id="lab_cybn_DebtInstrumentPrepaymentPremiumYearTwo_documentation_en-US" xlink:label="lab_cybn_DebtInstrumentPrepaymentPremiumYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Premium, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentPrepaymentPremiumYearTwo" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentPrepaymentPremiumYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DebtInstrumentPrepaymentPremiumYearTwo" xlink:to="lab_cybn_DebtInstrumentPrepaymentPremiumYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_a15d4233-7ec3-4206-8b5a-4f182bc7c95b_terseLabel_en-US" xlink:label="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_265c2bf4-bdb4-441b-8e20-01f430329170_verboseLabel_en-US" xlink:label="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_label_en-US" xlink:label="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Copyrights, patents and other industrial property rights, service and operating rights [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:to="lab_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_53c5445d-b7d5-414f-b8cf-1dfad55d6a12_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_a216c8cb-2d89-4009-ba24-35f17902b312_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_WarrantExpirationPeriodTwoMember_6be5e203-d1f7-40b5-ae1c-60752c47d7e9_terseLabel_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">May 14, 2029</link:label>
    <link:label id="lab_cybn_WarrantExpirationPeriodTwoMember_label_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Expiration Period Two [Member]</link:label>
    <link:label id="lab_cybn_WarrantExpirationPeriodTwoMember_documentation_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Expiration Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodTwoMember" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_WarrantExpirationPeriodTwoMember" xlink:to="lab_cybn_WarrantExpirationPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_3ac800e9-1c80-46df-b317-dd4af83a5d7c_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_342dd840-dfc2-469e-878d-ed77f38a0805_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Number of other equity instruments expired in share-based payment arrangement (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_9f31838b-86a6-400d-a25b-1d28432f2f22_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of other equity instruments expired in share-based payment arrangement (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments expired in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DisclosureOfNonCapitalLossesExpirationLineItems_6258e358-7ee7-4cb7-9a06-2b56af19b23d_terseLabel_en-US" xlink:label="lab_cybn_DisclosureOfNonCapitalLossesExpirationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-Capital Losses Expiration [Line Items]</link:label>
    <link:label id="lab_cybn_DisclosureOfNonCapitalLossesExpirationLineItems_label_en-US" xlink:label="lab_cybn_DisclosureOfNonCapitalLossesExpirationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-Capital Losses Expiration [Line Items]</link:label>
    <link:label id="lab_cybn_DisclosureOfNonCapitalLossesExpirationLineItems_documentation_en-US" xlink:label="lab_cybn_DisclosureOfNonCapitalLossesExpirationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Non-Capital Losses Expiration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfNonCapitalLossesExpirationLineItems" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfNonCapitalLossesExpirationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationLineItems" xlink:to="lab_cybn_DisclosureOfNonCapitalLossesExpirationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodTwelveMember_ba23eac2-6853-4f53-8c5d-2ad672430a4b_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwelveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twelve</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwelveMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwelveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twelve [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwelveMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwelveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twelve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwelveMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwelveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodTwelveMember" xlink:to="lab_cybn_OptionExpirationPeriodTwelveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_d5fc926c-bc47-4a49-b617-3ceb66dd5ee7_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, beginning of year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_f791911d-ef19-46a7-ad30-c66c3e74c134_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, end of year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_b9bf3733-bcef-4fe1-97d9-8423df505c46_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial instruments</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_A2044Member_f0b4080b-d3b7-4e3d-b5f6-3a2e9b965af8_terseLabel_en-US" xlink:label="lab_cybn_A2044Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2044</link:label>
    <link:label id="lab_cybn_A2044Member_label_en-US" xlink:label="lab_cybn_A2044Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2044 [Member]</link:label>
    <link:label id="lab_cybn_A2044Member_documentation_en-US" xlink:label="lab_cybn_A2044Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2044</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2044Member" xlink:href="cybn-20250331.xsd#cybn_A2044Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_A2044Member" xlink:to="lab_cybn_A2044Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyEightMember_e4d3df42-dfd5-4734-b10e-f82f98cf2ac1_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Eight</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyEightMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Eight [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyEightMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Eight</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyEightMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodThirtyEightMember" xlink:to="lab_cybn_OptionExpirationPeriodThirtyEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_44c26b4f-1a70-48bb-832b-75e098a69c21_terseLabel_en-US" xlink:label="lab_cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Equity Instruments Life, Other Equity Instruments Granted</link:label>
    <link:label id="lab_cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Equity Instruments Life, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" xlink:href="cybn-20250331.xsd#cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" xlink:to="lab_cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain_151b7352-cd40-41cb-a380-8068507d87f0_terseLabel_en-US" xlink:label="lab_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes Of Financial Assets And Liabilities [Domain]</link:label>
    <link:label id="lab_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain_label_en-US" xlink:label="lab_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes Of Financial Assets And Liabilities [Domain]</link:label>
    <link:label id="lab_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain_documentation_en-US" xlink:label="lab_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Classes Of Financial Assets And Liabilities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain" xlink:href="cybn-20250331.xsd#cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain" xlink:to="lab_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_A2039Member_cae8160d-7eef-4782-849b-0a183c308280_terseLabel_en-US" xlink:label="lab_cybn_A2039Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2039</link:label>
    <link:label id="lab_cybn_A2039Member_label_en-US" xlink:label="lab_cybn_A2039Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2039 [Member]</link:label>
    <link:label id="lab_cybn_A2039Member_documentation_en-US" xlink:label="lab_cybn_A2039Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2039</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2039Member" xlink:href="cybn-20250331.xsd#cybn_A2039Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_A2039Member" xlink:to="lab_cybn_A2039Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfActivePatentFamilies_3b1b9dfe-8419-417c-876b-b229c027ecaf_terseLabel_en-US" xlink:label="lab_cybn_NumberOfActivePatentFamilies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of active patent families</link:label>
    <link:label id="lab_cybn_NumberOfActivePatentFamilies_label_en-US" xlink:label="lab_cybn_NumberOfActivePatentFamilies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Active Patent Families</link:label>
    <link:label id="lab_cybn_NumberOfActivePatentFamilies_documentation_en-US" xlink:label="lab_cybn_NumberOfActivePatentFamilies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Active Patent Families</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfActivePatentFamilies" xlink:href="cybn-20250331.xsd#cybn_NumberOfActivePatentFamilies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfActivePatentFamilies" xlink:to="lab_cybn_NumberOfActivePatentFamilies" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfSubsidiaries_b81330b1-d4b2-4600-8bf8-fbc65a18eaf7_terseLabel_en-US" xlink:label="lab_cybn_NumberOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of subsidiaries</link:label>
    <link:label id="lab_cybn_NumberOfSubsidiaries_label_en-US" xlink:label="lab_cybn_NumberOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Subsidiaries</link:label>
    <link:label id="lab_cybn_NumberOfSubsidiaries_documentation_en-US" xlink:label="lab_cybn_NumberOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSubsidiaries" xlink:href="cybn-20250331.xsd#cybn_NumberOfSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfSubsidiaries" xlink:to="lab_cybn_NumberOfSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_2e6e49e4-9dfc-4b9e-b9c5-f39a0cd95b47_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current accrued expenses and other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_bac773ae-9676-486f-8083-0de17da47bf1_terseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NonCapitalLossCarryforward_5a3e792b-f40d-4fa1-ad68-aa7b11739ea1_terseLabel_en-US" xlink:label="lab_cybn_NonCapitalLossCarryforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-capital losses</link:label>
    <link:label id="lab_cybn_NonCapitalLossCarryforward_label_en-US" xlink:label="lab_cybn_NonCapitalLossCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Capital Loss Carryforward</link:label>
    <link:label id="lab_cybn_NonCapitalLossCarryforward_documentation_en-US" xlink:label="lab_cybn_NonCapitalLossCarryforward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Capital Loss Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NonCapitalLossCarryforward" xlink:href="cybn-20250331.xsd#cybn_NonCapitalLossCarryforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NonCapitalLossCarryforward" xlink:to="lab_cybn_NonCapitalLossCarryforward" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger_6cda1799-3948-434e-b7f0-c559dae346e3_terseLabel_en-US" xlink:label="lab_cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold percentage of stock price trigger</link:label>
    <link:label id="lab_cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Debenture, Threshold Percentage of Stock Price Trigger</link:label>
    <link:label id="lab_cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger_documentation_en-US" xlink:label="lab_cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Debenture, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger" xlink:to="lab_cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_f9760931-23b5-497b-80e9-df900f9d5616_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_70a0d168-fd42-4a4c-95d6-89dbc0cba498_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for impairment of assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyThreeMember_e8bd8160-de97-443e-86a8-23e9d5b6948f_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Three</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyThreeMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Three [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentyThreeMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyThreeMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodTwentyThreeMember" xlink:to="lab_cybn_OptionExpirationPeriodTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset_91f95c42-25f2-404c-8a5f-07bb5ed49d63_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange on unbooked deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, deferred tax liability (asset)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnobservableInputsDomain_ba0238ac-341e-43ac-9fec-625e6665b659_terseLabel_en-US" xlink:label="lab_ifrs-full_UnobservableInputsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unobservable inputs [domain]</link:label>
    <link:label id="lab_ifrs-full_UnobservableInputsDomain_label_en-US" xlink:label="lab_ifrs-full_UnobservableInputsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unobservable inputs [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnobservableInputsDomain" xlink:to="lab_ifrs-full_UnobservableInputsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeReceivablesMember_25c3532e-3120-4ae9-9dff-5eade30dcda8_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_ifrs-full_TradeReceivablesMember_label_en-US" xlink:label="lab_ifrs-full_TradeReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade receivables [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeReceivablesMember" xlink:to="lab_ifrs-full_TradeReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_16aefb2c-8757-4a82-8aeb-cb7596a19c07_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect of foreign exchange</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_Section382Limitation_f5750b8e-0b03-4045-8727-3067854ed574_terseLabel_en-US" xlink:label="lab_cybn_Section382Limitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Section 382 limitation</link:label>
    <link:label id="lab_cybn_Section382Limitation_label_en-US" xlink:label="lab_cybn_Section382Limitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Section 382 Limitation</link:label>
    <link:label id="lab_cybn_Section382Limitation_documentation_en-US" xlink:label="lab_cybn_Section382Limitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Section 382 Limitation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_Section382Limitation" xlink:href="cybn-20250331.xsd#cybn_Section382Limitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_Section382Limitation" xlink:to="lab_cybn_Section382Limitation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_d8f87f08-fb06-48e0-b3dd-95e233d7f732_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of subsidiaries [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="lab_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_af5587e3-f39b-40c5-b724-fdb83c55b68d_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_eb5d9c6c-1e9b-40c6-ab44-6baf0ff663cc_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_62b320ef-6f29-4e2d-afd2-564907ea984f_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesOutstanding_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesOutstanding" xlink:to="lab_ifrs-full_NumberOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory_93ccd8d8-020c-4e1f-8331-b6473214ac33_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for warrants [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_AccountsPayableAndAccruedLiabilitiesMember_632f4b3d-6c1a-4434-bb6d-98a861ca7348_terseLabel_en-US" xlink:label="lab_cybn_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_cybn_AccountsPayableAndAccruedLiabilitiesMember_label_en-US" xlink:label="lab_cybn_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable And Accrued Liabilities [Member]</link:label>
    <link:label id="lab_cybn_AccountsPayableAndAccruedLiabilitiesMember_documentation_en-US" xlink:label="lab_cybn_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable And Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AccountsPayableAndAccruedLiabilitiesMember" xlink:href="cybn-20250331.xsd#cybn_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="lab_cybn_AccountsPayableAndAccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_9acf86aa-d5c8-4a57-926a-df956b439851_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for measuring inventories [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ShareBasedPaymentArrangementOptionMember_e05a93ea-fe33-4a4b-9cff-6d4db73a7bef_terseLabel_en-US" xlink:label="lab_cybn_ShareBasedPaymentArrangementOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_cybn_ShareBasedPaymentArrangementOptionMember_label_en-US" xlink:label="lab_cybn_ShareBasedPaymentArrangementOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label id="lab_cybn_ShareBasedPaymentArrangementOptionMember_documentation_en-US" xlink:label="lab_cybn_ShareBasedPaymentArrangementOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareBasedPaymentArrangementOptionMember" xlink:href="cybn-20250331.xsd#cybn_ShareBasedPaymentArrangementOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ShareBasedPaymentArrangementOptionMember" xlink:to="lab_cybn_ShareBasedPaymentArrangementOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_GeneralAndAdministrativeExpenseMember_48e79689-8f61-4b68-a1b0-39dcccb3c37e_terseLabel_en-US" xlink:label="lab_cybn_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative costs</link:label>
    <link:label id="lab_cybn_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_cybn_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General And Administrative Expense [Member]</link:label>
    <link:label id="lab_cybn_GeneralAndAdministrativeExpenseMember_documentation_en-US" xlink:label="lab_cybn_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General And Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GeneralAndAdministrativeExpenseMember" xlink:href="cybn-20250331.xsd#cybn_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_GeneralAndAdministrativeExpenseMember" xlink:to="lab_cybn_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities_2df3bbd0-8343-4511-89da-88f2a17f5450_terseLabel_en-US" xlink:label="lab_cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities_label_en-US" xlink:label="lab_cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Increase (Decrease) In Accrued And Other Liabilities</link:label>
    <link:label id="lab_cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities_documentation_en-US" xlink:label="lab_cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Increase (Decrease) In Accrued And Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities" xlink:href="cybn-20250331.xsd#cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities" xlink:to="lab_cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DisclosureOfExpirationOfNonCapitalLossesTableTextBlock_01796c5a-a334-4b38-92af-98a71d28ea9f_terseLabel_en-US" xlink:label="lab_cybn_DisclosureOfExpirationOfNonCapitalLossesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-capital losses expiration</link:label>
    <link:label id="lab_cybn_DisclosureOfExpirationOfNonCapitalLossesTableTextBlock_label_en-US" xlink:label="lab_cybn_DisclosureOfExpirationOfNonCapitalLossesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Expiration Of Non Capital Losses [Table Text Block]</link:label>
    <link:label id="lab_cybn_DisclosureOfExpirationOfNonCapitalLossesTableTextBlock_documentation_en-US" xlink:label="lab_cybn_DisclosureOfExpirationOfNonCapitalLossesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Expiration Of Non Capital Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfExpirationOfNonCapitalLossesTableTextBlock" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfExpirationOfNonCapitalLossesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DisclosureOfExpirationOfNonCapitalLossesTableTextBlock" xlink:to="lab_cybn_DisclosureOfExpirationOfNonCapitalLossesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_dc4c07a4-9550-4cc8-931a-86eef0250a1a_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effects of exchange rate changes on cash</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_71b49a0c-31d7-460b-972a-69b5e5826a76_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_8dcb47fc-f861-4086-91e4-7e595eab5d09_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentySevenMember_ecd654fb-9bf4-4540-b163-2f9fbb27e45e_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentySevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Seven</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentySevenMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentySevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Seven [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodTwentySevenMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodTwentySevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Twenty Seven</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentySevenMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentySevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodTwentySevenMember" xlink:to="lab_cybn_OptionExpirationPeriodTwentySevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfCommonShares_711fc67a-5056-4aba-911b-f37194cea6c8_terseLabel_en-US" xlink:label="lab_cybn_NumberOfCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common shares (in shares)</link:label>
    <link:label id="lab_cybn_NumberOfCommonShares_label_en-US" xlink:label="lab_cybn_NumberOfCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Common Shares</link:label>
    <link:label id="lab_cybn_NumberOfCommonShares_documentation_en-US" xlink:label="lab_cybn_NumberOfCommonShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Common Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfCommonShares" xlink:href="cybn-20250331.xsd#cybn_NumberOfCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfCommonShares" xlink:to="lab_cybn_NumberOfCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_f3242076-195e-4d27-9aeb-f62da801c456_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OPERATING ACTIVITIES</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_dec0036f-eb6a-488f-9ed5-3db3f9a4aa66_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_053f538b-abe6-4d01-a5e6-0d13cc9a1f2e_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest accretion</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_e5330fe9-1a9b-45e1-897e-49b8dfa312ab_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of share-based payments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_WarrantExpirationPeriodFourMember_777a7e18-93ef-4509-8f4c-c4ca24a0e36e_terseLabel_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">August 20, 2030</link:label>
    <link:label id="lab_cybn_WarrantExpirationPeriodFourMember_label_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Expiration Period Four [Member]</link:label>
    <link:label id="lab_cybn_WarrantExpirationPeriodFourMember_documentation_en-US" xlink:label="lab_cybn_WarrantExpirationPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Expiration Period Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodFourMember" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_WarrantExpirationPeriodFourMember" xlink:to="lab_cybn_WarrantExpirationPeriodFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_COMMITMENTSLineItems_6aabd40a-182f-43cd-ad0d-6fde6345310f_terseLabel_en-US" xlink:label="lab_cybn_COMMITMENTSLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS [Line Items]</link:label>
    <link:label id="lab_cybn_COMMITMENTSLineItems_label_en-US" xlink:label="lab_cybn_COMMITMENTSLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COMMITMENTS [Line Items]</link:label>
    <link:label id="lab_cybn_COMMITMENTSLineItems_documentation_en-US" xlink:label="lab_cybn_COMMITMENTSLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">COMMITMENTS [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_COMMITMENTSLineItems" xlink:href="cybn-20250331.xsd#cybn_COMMITMENTSLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_COMMITMENTSLineItems" xlink:to="lab_cybn_COMMITMENTSLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_CriticalAccountingEstimatesAndJudgementsAbstract_label_en-US" xlink:label="lab_cybn_CriticalAccountingEstimatesAndJudgementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Critical Accounting Estimates and Judgements [Abstract]</link:label>
    <link:label id="lab_cybn_CriticalAccountingEstimatesAndJudgementsAbstract_documentation_en-US" xlink:label="lab_cybn_CriticalAccountingEstimatesAndJudgementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Critical Accounting Estimates and Judgements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CriticalAccountingEstimatesAndJudgementsAbstract" xlink:href="cybn-20250331.xsd#cybn_CriticalAccountingEstimatesAndJudgementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_CriticalAccountingEstimatesAndJudgementsAbstract" xlink:to="lab_cybn_CriticalAccountingEstimatesAndJudgementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_A2037Member_3dac6980-2796-4a32-95bf-adfe52c57316_terseLabel_en-US" xlink:label="lab_cybn_A2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2037</link:label>
    <link:label id="lab_cybn_A2037Member_label_en-US" xlink:label="lab_cybn_A2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2037 [Member]</link:label>
    <link:label id="lab_cybn_A2037Member_documentation_en-US" xlink:label="lab_cybn_A2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2037</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2037Member" xlink:href="cybn-20250331.xsd#cybn_A2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_A2037Member" xlink:to="lab_cybn_A2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_d922fa6a-2b58-424b-b527-cdc20005541d_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_41d57c68-97d9-4b17-882e-fbe617c250d9_terseLabel_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="lab_ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OrdinarySharesConsolidationNewSharesIssued_a09e08f4-c76b-4266-958f-8ec0050c1347_terseLabel_en-US" xlink:label="lab_cybn_OrdinarySharesConsolidationNewSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share consolidation, new shares issued (in shares)</link:label>
    <link:label id="lab_cybn_OrdinarySharesConsolidationNewSharesIssued_label_en-US" xlink:label="lab_cybn_OrdinarySharesConsolidationNewSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary Shares, Consolidation, New Shares Issued</link:label>
    <link:label id="lab_cybn_OrdinarySharesConsolidationNewSharesIssued_documentation_en-US" xlink:label="lab_cybn_OrdinarySharesConsolidationNewSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ordinary Shares, Consolidation, New Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OrdinarySharesConsolidationNewSharesIssued" xlink:href="cybn-20250331.xsd#cybn_OrdinarySharesConsolidationNewSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OrdinarySharesConsolidationNewSharesIssued" xlink:to="lab_cybn_OrdinarySharesConsolidationNewSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OperatingExpense_d153fead-4e7f-4629-bd50-20ccd8f231c3_totalLabel_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL EXPENSES</link:label>
    <link:label id="lab_ifrs-full_OperatingExpense_label_en-US" xlink:label="lab_ifrs-full_OperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OperatingExpense" xlink:to="lab_ifrs-full_OperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_18645c8b-05d4-48bf-b6ed-aa5e6a50391e_terseLabel_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payroll, consulting and benefits</link:label>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_label_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee benefits expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="lab_ifrs-full_EmployeeBenefitsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_09098ec7-7b36-464a-b3e8-2932913388fb_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_EffectOfForeignExchangeRightOfUseAssets_670f2c04-a093-4492-acee-7bb76f7d8c7f_terseLabel_en-US" xlink:label="lab_cybn_EffectOfForeignExchangeRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of foreign exchange</link:label>
    <link:label id="lab_cybn_EffectOfForeignExchangeRightOfUseAssets_label_en-US" xlink:label="lab_cybn_EffectOfForeignExchangeRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect Of Foreign Exchange, Right Of Use Assets</link:label>
    <link:label id="lab_cybn_EffectOfForeignExchangeRightOfUseAssets_documentation_en-US" xlink:label="lab_cybn_EffectOfForeignExchangeRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effect Of Foreign Exchange, Right Of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_EffectOfForeignExchangeRightOfUseAssets" xlink:href="cybn-20250331.xsd#cybn_EffectOfForeignExchangeRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_EffectOfForeignExchangeRightOfUseAssets" xlink:to="lab_cybn_EffectOfForeignExchangeRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_e58cadc4-0986-4a7a-b8ce-42b9a9c00a3f_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of foreign exchange</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through net exchange differences, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_8bb380d7-802a-4b40-acdd-0afe89face38_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Income tax recovery</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b84ed46c-c5c9-46fb-a24a-8c1c1c764d7f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3e687454-d3fb-4120-9112-9f4584b589c0_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ClassBSharesMember_fbd47d1d-15d8-43f0-b094-0e18575ebefc_terseLabel_en-US" xlink:label="lab_cybn_ClassBSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class B Shares</link:label>
    <link:label id="lab_cybn_ClassBSharesMember_label_en-US" xlink:label="lab_cybn_ClassBSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class B Shares [Member]</link:label>
    <link:label id="lab_cybn_ClassBSharesMember_documentation_en-US" xlink:label="lab_cybn_ClassBSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class B Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassBSharesMember" xlink:href="cybn-20250331.xsd#cybn_ClassBSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ClassBSharesMember" xlink:to="lab_cybn_ClassBSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_54596a8b-059c-4447-955f-d18443887867_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="lab_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_a46ceb07-9bd1-4da5-9b85-747e39a3f5c6_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_5486b0d4-29ad-4643-9952-9b9142e7a51e_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_76d213a5-a3a1-4d1a-81b6-f60455ee59b7_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk free interest rate, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_2c8da099-085d-40b0-87a5-6b0d3d3ca95d_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement (in CAD per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_14d8e9de-923e-4bce-ab8f-8739b842fdfc_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average of exercisable price (in CAD per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_69410050-beca-4c04-ab6e-252d724b808e_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_PaymentForTerminationPenaltyLeaseLiability_b183e364-cded-4bd6-b9e2-2079acaba8ea_negatedTerseLabel_en-US" xlink:label="lab_cybn_PaymentForTerminationPenaltyLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Termination penalty payment</link:label>
    <link:label id="lab_cybn_PaymentForTerminationPenaltyLeaseLiability_label_en-US" xlink:label="lab_cybn_PaymentForTerminationPenaltyLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment For Termination Penalty, Lease Liability</link:label>
    <link:label id="lab_cybn_PaymentForTerminationPenaltyLeaseLiability_documentation_en-US" xlink:label="lab_cybn_PaymentForTerminationPenaltyLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment For Termination Penalty, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PaymentForTerminationPenaltyLeaseLiability" xlink:href="cybn-20250331.xsd#cybn_PaymentForTerminationPenaltyLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_PaymentForTerminationPenaltyLeaseLiability" xlink:to="lab_cybn_PaymentForTerminationPenaltyLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_5911101c-24f1-4457-86d7-97d1fcc10586_negatedTerseLabel_en-US" xlink:label="lab_cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of equipment and intangible assets</link:label>
    <link:label id="lab_cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Of Property, Plant, Equipment And Intangible Assets, Classified As Investing Activities</link:label>
    <link:label id="lab_cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_documentation_en-US" xlink:label="lab_cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Of Property, Plant, Equipment And Intangible Assets, Classified As Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" xlink:href="cybn-20250331.xsd#cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="lab_cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WarrantReserveMember_9f369252-5803-4fad-975e-201c1ef8d96c_terseLabel_en-US" xlink:label="lab_ifrs-full_WarrantReserveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_ifrs-full_WarrantReserveMember_label_en-US" xlink:label="lab_ifrs-full_WarrantReserveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant reserve [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantReserveMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantReserveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WarrantReserveMember" xlink:to="lab_ifrs-full_WarrantReserveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ShareBasedPaymentVestingPeriodAxis_9e1402e6-bc4e-4bf3-889d-ceb6bbff02fe_terseLabel_en-US" xlink:label="lab_cybn_ShareBasedPaymentVestingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_cybn_ShareBasedPaymentVestingPeriodAxis_label_en-US" xlink:label="lab_cybn_ShareBasedPaymentVestingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment, Vesting Period [Axis]</link:label>
    <link:label id="lab_cybn_ShareBasedPaymentVestingPeriodAxis_documentation_en-US" xlink:label="lab_cybn_ShareBasedPaymentVestingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Payment, Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareBasedPaymentVestingPeriodAxis" xlink:href="cybn-20250331.xsd#cybn_ShareBasedPaymentVestingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ShareBasedPaymentVestingPeriodAxis" xlink:to="lab_cybn_ShareBasedPaymentVestingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_3e045571-7d74-4745-b905-20f7d0c3e493_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_c263960d-e0ba-4777-8971-76e5c89f79b0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RELATED PARTY TRANSACTIONS AND BALANCES</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage_bc867601-8481-4b7a-ad18-a28fea4b89a2_terseLabel_en-US" xlink:label="lab_cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum affiliate ownership percentage</link:label>
    <link:label id="lab_cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage_label_en-US" xlink:label="lab_cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Debenture, Maximum Affiliate Ownership Percentage</link:label>
    <link:label id="lab_cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage_documentation_en-US" xlink:label="lab_cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Debenture, Maximum Affiliate Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage" xlink:to="lab_cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPayments_5e4bee5e-4312-4c06-bde7-f6c058702df3_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options reserve</link:label>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfSharebasedPayments" xlink:to="lab_ifrs-full_ReserveOfSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_284edc3b-88b5-4248-8c01-d4385acde0b5_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_bb76794f-f6ba-46b1-b3c0-84a81f8305ce_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in CAD per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average share price, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="lab_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_dab3d853-b992-4010-ac28-477b3c5e37a4_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_5761ec34-7f04-4f91-bbbb-f4a4e1060305_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_6aa77902-0250-4107-8385-fae8be8e4906_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_AdvancementOfDevelopmentPrograms_21f66f78-29f4-40c3-91b7-0c2ef2026821_terseLabel_en-US" xlink:label="lab_cybn_AdvancementOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advancement of development programs</link:label>
    <link:label id="lab_cybn_AdvancementOfDevelopmentPrograms_label_en-US" xlink:label="lab_cybn_AdvancementOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advancement Of Development Programs</link:label>
    <link:label id="lab_cybn_AdvancementOfDevelopmentPrograms_documentation_en-US" xlink:label="lab_cybn_AdvancementOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Advancement Of Development Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdvancementOfDevelopmentPrograms" xlink:href="cybn-20250331.xsd#cybn_AdvancementOfDevelopmentPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_AdvancementOfDevelopmentPrograms" xlink:to="lab_cybn_AdvancementOfDevelopmentPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ItemsOfContingentLiabilitiesAxis_e7bfaae0-fd62-490b-95ba-b8b8b8f1846d_terseLabel_en-US" xlink:label="lab_ifrs-full_ItemsOfContingentLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Items of contingent liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ItemsOfContingentLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ItemsOfContingentLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Items of contingent liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ItemsOfContingentLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ItemsOfContingentLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ItemsOfContingentLiabilitiesAxis" xlink:to="lab_ifrs-full_ItemsOfContingentLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ListingFeesExpense_6ee00c67-bd27-468d-b269-74005bcc393f_terseLabel_en-US" xlink:label="lab_cybn_ListingFeesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Listing fees</link:label>
    <link:label id="lab_cybn_ListingFeesExpense_label_en-US" xlink:label="lab_cybn_ListingFeesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Listing Fees Expense</link:label>
    <link:label id="lab_cybn_ListingFeesExpense_documentation_en-US" xlink:label="lab_cybn_ListingFeesExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Listing Fees Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ListingFeesExpense" xlink:href="cybn-20250331.xsd#cybn_ListingFeesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ListingFeesExpense" xlink:to="lab_cybn_ListingFeesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock_ac09c32b-23d0-4b00-b26f-25c412c01d56_terseLabel_en-US" xlink:label="lab_cybn_DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of measurement</link:label>
    <link:label id="lab_cybn_DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock_label_en-US" xlink:label="lab_cybn_DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounting Policy For Basis Of Measurement [Policy Text Block]</link:label>
    <link:label id="lab_cybn_DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock_documentation_en-US" xlink:label="lab_cybn_DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Accounting Policy For Basis Of Measurement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock" xlink:to="lab_cybn_DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis_f60e0b4f-d4f8-4ca2-a746-adc94b18b8a3_terseLabel_en-US" xlink:label="lab_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes Of Financial Assets And Liabilities [Axis]</link:label>
    <link:label id="lab_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis_label_en-US" xlink:label="lab_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes Of Financial Assets And Liabilities [Axis]</link:label>
    <link:label id="lab_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis_documentation_en-US" xlink:label="lab_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Classes Of Financial Assets And Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis" xlink:href="cybn-20250331.xsd#cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis" xlink:to="lab_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_f779a366-4f35-4d32-bc2f-af804f670ad0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_88629de1-afa2-4558-91ef-1e121482eb79_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember_10eca539-fbb5-4019-9c27-d6cfa74aac60_terseLabel_en-US" xlink:label="lab_cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation/Capital cost allowance differences</link:label>
    <link:label id="lab_cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember_label_en-US" xlink:label="lab_cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant And Equipment Related Temporary Differences [Member]</link:label>
    <link:label id="lab_cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember_documentation_en-US" xlink:label="lab_cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant And Equipment Related Temporary Differences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember" xlink:href="cybn-20250331.xsd#cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember" xlink:to="lab_cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_A2036Member_1e3ff40e-334a-4fed-8281-b0154dc68ac5_terseLabel_en-US" xlink:label="lab_cybn_A2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2036</link:label>
    <link:label id="lab_cybn_A2036Member_label_en-US" xlink:label="lab_cybn_A2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2036 [Member]</link:label>
    <link:label id="lab_cybn_A2036Member_documentation_en-US" xlink:label="lab_cybn_A2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2036</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2036Member" xlink:href="cybn-20250331.xsd#cybn_A2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_A2036Member" xlink:to="lab_cybn_A2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement_2aad0c0d-26b9-46e6-a39a-906468c29a18_terseLabel_en-US" xlink:label="lab_cybn_WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</link:label>
    <link:label id="lab_cybn_WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_cybn_WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price Of Share Options Forfeited And Expired In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_cybn_WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_cybn_WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price Of Share Options Forfeited And Expired In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:href="cybn-20250331.xsd#cybn_WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:to="lab_cybn_WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ClassesOfDebtInstrumentsDomain_3a6b6d2e-24eb-4169-b194-1e682668b759_terseLabel_en-US" xlink:label="lab_cybn_ClassesOfDebtInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes Of Debt Instruments [Domain]</link:label>
    <link:label id="lab_cybn_ClassesOfDebtInstrumentsDomain_label_en-US" xlink:label="lab_cybn_ClassesOfDebtInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes Of Debt Instruments [Domain]</link:label>
    <link:label id="lab_cybn_ClassesOfDebtInstrumentsDomain_documentation_en-US" xlink:label="lab_cybn_ClassesOfDebtInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Classes Of Debt Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassesOfDebtInstrumentsDomain" xlink:href="cybn-20250331.xsd#cybn_ClassesOfDebtInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ClassesOfDebtInstrumentsDomain" xlink:to="lab_cybn_ClassesOfDebtInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_62c40fde-d3d0-4887-9f20-e9421640fca4_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_a0275084-030f-4c3c-9538-723af0cea428_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payroll, consulting and benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfPendingPatentApplications_53fdc0ef-8a42-425f-809f-26fdea3f2a04_terseLabel_en-US" xlink:label="lab_cybn_NumberOfPendingPatentApplications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of pending patent applications</link:label>
    <link:label id="lab_cybn_NumberOfPendingPatentApplications_label_en-US" xlink:label="lab_cybn_NumberOfPendingPatentApplications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Pending Patent Applications</link:label>
    <link:label id="lab_cybn_NumberOfPendingPatentApplications_documentation_en-US" xlink:label="lab_cybn_NumberOfPendingPatentApplications" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Pending Patent Applications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfPendingPatentApplications" xlink:href="cybn-20250331.xsd#cybn_NumberOfPendingPatentApplications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfPendingPatentApplications" xlink:to="lab_cybn_NumberOfPendingPatentApplications" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_GrantedToDirectorsMember_ddc832ea-c80e-4483-ab6e-e7469ab9e3cf_terseLabel_en-US" xlink:label="lab_cybn_GrantedToDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted to directors</link:label>
    <link:label id="lab_cybn_GrantedToDirectorsMember_label_en-US" xlink:label="lab_cybn_GrantedToDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted To Directors [Member]</link:label>
    <link:label id="lab_cybn_GrantedToDirectorsMember_documentation_en-US" xlink:label="lab_cybn_GrantedToDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Granted To Directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrantedToDirectorsMember" xlink:href="cybn-20250331.xsd#cybn_GrantedToDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_GrantedToDirectorsMember" xlink:to="lab_cybn_GrantedToDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_CommitmentsAbstract_label_en-US" xlink:label="lab_cybn_CommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments [Abstract]</link:label>
    <link:label id="lab_cybn_CommitmentsAbstract_documentation_en-US" xlink:label="lab_cybn_CommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommitmentsAbstract" xlink:href="cybn-20250331.xsd#cybn_CommitmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_CommitmentsAbstract" xlink:to="lab_cybn_CommitmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_CommonSharesPurchasePeriodTerm_985dc121-9e8c-4406-a8b6-66c0d6ca5f7d_terseLabel_en-US" xlink:label="lab_cybn_CommonSharesPurchasePeriodTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase period, term</link:label>
    <link:label id="lab_cybn_CommonSharesPurchasePeriodTerm_label_en-US" xlink:label="lab_cybn_CommonSharesPurchasePeriodTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Shares Purchase Period, Term</link:label>
    <link:label id="lab_cybn_CommonSharesPurchasePeriodTerm_documentation_en-US" xlink:label="lab_cybn_CommonSharesPurchasePeriodTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Shares Purchase Period, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommonSharesPurchasePeriodTerm" xlink:href="cybn-20250331.xsd#cybn_CommonSharesPurchasePeriodTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_CommonSharesPurchasePeriodTerm" xlink:to="lab_cybn_CommonSharesPurchasePeriodTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DisclosureOfCapitalStructureTableTextBlock_1d8ea302-461c-4a7a-a499-7ec6dc562b81_terseLabel_en-US" xlink:label="lab_cybn_DisclosureOfCapitalStructureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Capital Structure</link:label>
    <link:label id="lab_cybn_DisclosureOfCapitalStructureTableTextBlock_label_en-US" xlink:label="lab_cybn_DisclosureOfCapitalStructureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Capital Structure [Table Text Block]</link:label>
    <link:label id="lab_cybn_DisclosureOfCapitalStructureTableTextBlock_documentation_en-US" xlink:label="lab_cybn_DisclosureOfCapitalStructureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Capital Structure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfCapitalStructureTableTextBlock" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfCapitalStructureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DisclosureOfCapitalStructureTableTextBlock" xlink:to="lab_cybn_DisclosureOfCapitalStructureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_CashRecognisedAsOfAcquisitionDate_2c2ffbc5-022b-4591-9b4c-f17db576c018_terseLabel_en-US" xlink:label="lab_cybn_CashRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_cybn_CashRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_cybn_CashRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Recognised as of Acquisition Date</link:label>
    <link:label id="lab_cybn_CashRecognisedAsOfAcquisitionDate_documentation_en-US" xlink:label="lab_cybn_CashRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Recognised as of Acquisition Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CashRecognisedAsOfAcquisitionDate" xlink:href="cybn-20250331.xsd#cybn_CashRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_CashRecognisedAsOfAcquisitionDate" xlink:to="lab_cybn_CashRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_3732de4d-ca39-4835-b4f2-f1d723951189_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for intangible assets other than goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_label_en-US" xlink:label="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presentation of leases for lessee [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays_9a58f005-627c-4a27-a19f-1c4012da48ed_terseLabel_en-US" xlink:label="lab_cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold trading days</link:label>
    <link:label id="lab_cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays_label_en-US" xlink:label="lab_cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Debenture, Threshold Trading Days</link:label>
    <link:label id="lab_cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays_documentation_en-US" xlink:label="lab_cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Debenture, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays" xlink:to="lab_cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodFifteenMember_11f7ee4f-10f3-453d-8452-db6e1634d8f0_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Fifteen</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodFifteenMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Fifteen [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodFifteenMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Fifteen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodFifteenMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodFifteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodFifteenMember" xlink:to="lab_cybn_OptionExpirationPeriodFifteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_2a66d037-7185-4c5a-8964-a3ab53951212_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_LabAndAdministration_da452b14-df2b-43da-b891-adf35b573e74_terseLabel_en-US" xlink:label="lab_cybn_LabAndAdministration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab and administration</link:label>
    <link:label id="lab_cybn_LabAndAdministration_label_en-US" xlink:label="lab_cybn_LabAndAdministration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lab And Administration</link:label>
    <link:label id="lab_cybn_LabAndAdministration_documentation_en-US" xlink:label="lab_cybn_LabAndAdministration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lab And Administration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LabAndAdministration" xlink:href="cybn-20250331.xsd#cybn_LabAndAdministration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_LabAndAdministration" xlink:to="lab_cybn_LabAndAdministration" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_a9ea6045-a4e0-476d-b85e-dbf13f0d3c65_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremium_63505c3e-e950-42ed-8797-7cd3c734025c_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributed surplus</link:label>
    <link:label id="lab_ifrs-full_SharePremium_label_en-US" xlink:label="lab_ifrs-full_SharePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremium" xlink:to="lab_ifrs-full_SharePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_4b221c94-8330-4dcd-807d-6e3d3e5c4246_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency risk</link:label>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_label_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember" xlink:to="lab_ifrs-full_CurrencyRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_f2390268-0853-456f-a9f4-a40ae872d57d_terseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_b3b1d10f-0cf5-449a-978e-0f12967f8a25_totalLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_b27691f4-147a-4535-9680-c020c14f17d3_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_RDExpendituresMember_0abe7796-ff08-4444-8ee1-72fd0739cd82_terseLabel_en-US" xlink:label="lab_cybn_RDExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development expenditures</link:label>
    <link:label id="lab_cybn_RDExpendituresMember_label_en-US" xlink:label="lab_cybn_RDExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">R&amp;D expenditures [Member]</link:label>
    <link:label id="lab_cybn_RDExpendituresMember_documentation_en-US" xlink:label="lab_cybn_RDExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">R&amp;D expenditures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_RDExpendituresMember" xlink:href="cybn-20250331.xsd#cybn_RDExpendituresMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_RDExpendituresMember" xlink:to="lab_cybn_RDExpendituresMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_DebtInstrumentTerm_1e9aaf26-34b1-4cbd-a8fa-51ce12bea316_terseLabel_en-US" xlink:label="lab_cybn_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_cybn_DebtInstrumentTerm_label_en-US" xlink:label="lab_cybn_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:label id="lab_cybn_DebtInstrumentTerm_documentation_en-US" xlink:label="lab_cybn_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentTerm" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_DebtInstrumentTerm" xlink:to="lab_cybn_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_A2040Member_97e8f88f-549d-47ae-8332-2c8621935cd9_terseLabel_en-US" xlink:label="lab_cybn_A2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2040</link:label>
    <link:label id="lab_cybn_A2040Member_label_en-US" xlink:label="lab_cybn_A2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2040 [Member]</link:label>
    <link:label id="lab_cybn_A2040Member_documentation_en-US" xlink:label="lab_cybn_A2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2040Member" xlink:href="cybn-20250331.xsd#cybn_A2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_A2040Member" xlink:to="lab_cybn_A2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5b6dc8fc-7cb0-451c-9191-45eaf701c82f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_1b7ae4fe-1fa6-4077-bfbd-a2de14ced623_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for issued capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractualCapitalCommitments_708aef2b-7cad-43c9-8ea0-685a688f8501_terseLabel_en-US" xlink:label="lab_ifrs-full_ContractualCapitalCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual commitments</link:label>
    <link:label id="lab_ifrs-full_ContractualCapitalCommitments_label_en-US" xlink:label="lab_ifrs-full_ContractualCapitalCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual capital commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCapitalCommitments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractualCapitalCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractualCapitalCommitments" xlink:to="lab_ifrs-full_ContractualCapitalCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement_957e098e-0eb9-4142-bfa5-2c80b151fa7e_verboseLabel_en-US" xlink:label="lab_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Other Equity Instruments Issued in Share-Based Payment Arrangement</link:label>
    <link:label id="lab_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Other Equity Instruments Issued in Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement" xlink:href="cybn-20250331.xsd#cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement" xlink:to="lab_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodAxis_750093b1-3ee8-4574-9c78-df7682db927c_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period [Axis]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodAxis_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period [Axis]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodAxis_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodAxis" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodAxis" xlink:to="lab_cybn_OptionExpirationPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_6eff52e9-0644-4914-b0ee-041357652d96_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization charge</link:label>
    <link:label id="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation, intangible assets other than goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="lab_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_LPCPurchaseAgreementMember_d3259181-79da-4739-bbb2-848d10775a87_terseLabel_en-US" xlink:label="lab_cybn_LPCPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LPC Purchase Agreement</link:label>
    <link:label id="lab_cybn_LPCPurchaseAgreementMember_label_en-US" xlink:label="lab_cybn_LPCPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LPC Purchase Agreement [Member]</link:label>
    <link:label id="lab_cybn_LPCPurchaseAgreementMember_documentation_en-US" xlink:label="lab_cybn_LPCPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">LPC Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LPCPurchaseAgreementMember" xlink:href="cybn-20250331.xsd#cybn_LPCPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_LPCPurchaseAgreementMember" xlink:to="lab_cybn_LPCPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_e74c3b9c-b20d-4745-a68f-f4c9c30980d6_terseLabel_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative costs</link:label>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_e35583a6-3cf6-4cd9-9500-3cfea20bfde4_totalLabel_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory_4f978019-fed3-4554-8624-d23795bcc223_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for goodwill [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_8d3a8dd8-41d3-43e1-95ef-5bafcddb2e13_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentAssets_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentAssets" xlink:to="lab_ifrs-full_OtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_ded3ae2e-ace4-4896-a6b9-84d2d93044ff_terseLabel_en-US" xlink:label="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual property</link:label>
    <link:label id="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Identifiable intangible assets recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ChangesInEquityAbstract_8e82a5bf-1e52-4179-89ba-c617403517a9_terseLabel_en-US" xlink:label="lab_ifrs-full_ChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in equity [abstract]</link:label>
    <link:label id="lab_ifrs-full_ChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_ChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ChangesInEquityAbstract" xlink:to="lab_ifrs-full_ChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_PayrollAndBenefits_687849a5-0678-4e44-b050-f75d6872762d_terseLabel_en-US" xlink:label="lab_cybn_PayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payroll and benefits</link:label>
    <link:label id="lab_cybn_PayrollAndBenefits_label_en-US" xlink:label="lab_cybn_PayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payroll And Benefits</link:label>
    <link:label id="lab_cybn_PayrollAndBenefits_documentation_en-US" xlink:label="lab_cybn_PayrollAndBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payroll And Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PayrollAndBenefits" xlink:href="cybn-20250331.xsd#cybn_PayrollAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_PayrollAndBenefits" xlink:to="lab_cybn_PayrollAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing_a62d3cc7-2c6c-4ec7-8b3a-59fdcbeedf0a_terseLabel_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares as commitment fee for equity financing (in shares)</link:label>
    <link:label id="lab_cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing_label_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Issued Through Commitment Fee For Equity Financing</link:label>
    <link:label id="lab_cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing_documentation_en-US" xlink:label="lab_cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares Issued Through Commitment Fee For Equity Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing" xlink:to="lab_cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_03bb1abb-00d2-49aa-8d2e-b108f177fbb3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_6be93a9f-0556-4a77-be82-0bdbb9897845_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of changes in goodwill [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:to="lab_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_CommonStockSharesAuthorizedValue_08f9f723-e80e-45e7-97c7-92541f3440c5_terseLabel_en-US" xlink:label="lab_cybn_CommonStockSharesAuthorizedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares, authorized value</link:label>
    <link:label id="lab_cybn_CommonStockSharesAuthorizedValue_label_en-US" xlink:label="lab_cybn_CommonStockSharesAuthorizedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Shares Authorized Value</link:label>
    <link:label id="lab_cybn_CommonStockSharesAuthorizedValue_documentation_en-US" xlink:label="lab_cybn_CommonStockSharesAuthorizedValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Shares Authorized Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommonStockSharesAuthorizedValue" xlink:href="cybn-20250331.xsd#cybn_CommonStockSharesAuthorizedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_CommonStockSharesAuthorizedValue" xlink:to="lab_cybn_CommonStockSharesAuthorizedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_23d80466-4d69-4124-8c79-5e3dc33f101a_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxation</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_70da82fc-4825-4eda-a121-de042d354880_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_TaxEffectOfShareIssuanceCosts_5785da96-b740-4064-a8c4-e6419b430c9f_terseLabel_en-US" xlink:label="lab_cybn_TaxEffectOfShareIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issuance costs</link:label>
    <link:label id="lab_cybn_TaxEffectOfShareIssuanceCosts_label_en-US" xlink:label="lab_cybn_TaxEffectOfShareIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Share Issuance Costs</link:label>
    <link:label id="lab_cybn_TaxEffectOfShareIssuanceCosts_documentation_en-US" xlink:label="lab_cybn_TaxEffectOfShareIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Share Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_TaxEffectOfShareIssuanceCosts" xlink:href="cybn-20250331.xsd#cybn_TaxEffectOfShareIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_TaxEffectOfShareIssuanceCosts" xlink:to="lab_cybn_TaxEffectOfShareIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e4ffbc00-95bc-4381-86c9-896d8feb742a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_325dd71c-ac89-4e85-8c94-4a5bdf36bf33_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsDomain_a81cbd66-549f-49ab-b443-14985f267d12_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of assets [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of assets [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain" xlink:to="lab_ifrs-full_ClassesOfAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_98d9a08c-a9e8-4d7b-b7d1-b355f050c432_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_4feef1ec-a49f-4831-a532-fdd9738dd2ef_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8ed21bcd-922d-4fb7-9c8d-5a2573905c2d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember_6ae6e68f-5a00-47ba-8462-9b1d3e39a59e_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Seven And Thirty Eight</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Seven And Thirty Eight [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Seven And Thirty Eight</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember" xlink:to="lab_cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_b785c5b1-d4fe-4aae-be78-d4f1d06246f3_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for determining components of cash and cash equivalents [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_ddd84f68-dfd2-4f79-b505-c53e853840e7_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfAssetsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis" xlink:to="lab_ifrs-full_ClassesOfAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_455cb49d-72ac-4147-82d6-35147c46103d_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement (in CAD per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_87859b65-55d5-490f-94c5-ec44600e9083_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherExpenseByNature_086aa694-a0c9-4351-8fcc-d8ef319b82d1_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_OtherExpenseByNature" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other loss</link:label>
    <link:label id="lab_ifrs-full_OtherExpenseByNature_880dce83-bdff-4606-9f83-03e5d60d1621_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherExpenseByNature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other loss</link:label>
    <link:label id="lab_ifrs-full_OtherExpenseByNature_label_en-US" xlink:label="lab_ifrs-full_OtherExpenseByNature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other expenses, by nature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherExpenseByNature" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherExpenseByNature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherExpenseByNature" xlink:to="lab_ifrs-full_OtherExpenseByNature" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_ExpectedVolatilityOtherEquityInstrumentsGranted_4991bba3-3c3f-4945-8213-7edd8677a31a_terseLabel_en-US" xlink:label="lab_cybn_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected annual volatility, based on comparable companies</link:label>
    <link:label id="lab_cybn_ExpectedVolatilityOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_cybn_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Volatility, Other Equity Instruments Granted</link:label>
    <link:label id="lab_cybn_ExpectedVolatilityOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_cybn_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Volatility, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:href="cybn-20250331.xsd#cybn_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:to="lab_cybn_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_AdjustmentsForWorkingCapitalAbstract_8323fe43-3ca3-4e0d-a864-9434953450e9_terseLabel_en-US" xlink:label="lab_cybn_AdjustmentsForWorkingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net changes in non-cash working capital items:</link:label>
    <link:label id="lab_cybn_AdjustmentsForWorkingCapitalAbstract_label_en-US" xlink:label="lab_cybn_AdjustmentsForWorkingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Working Capital [Abstract]</link:label>
    <link:label id="lab_cybn_AdjustmentsForWorkingCapitalAbstract_documentation_en-US" xlink:label="lab_cybn_AdjustmentsForWorkingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Working Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdjustmentsForWorkingCapitalAbstract" xlink:href="cybn-20250331.xsd#cybn_AdjustmentsForWorkingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_AdjustmentsForWorkingCapitalAbstract" xlink:to="lab_cybn_AdjustmentsForWorkingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_6dba5b5a-a217-4f26-9ace-1e4675fb6eed_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deficit</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssueOfEquity_b3bf57db-fbb7-4288-8838-9b6109258c06_terseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued through common share purchase agreement - net of share issuance costs</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_label_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity" xlink:to="lab_ifrs-full_IssueOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_980c2632-d5b2-40e7-ba60-e8bcd31f5f80_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentAssets_c8f7851c-e04d-40f4-817b-48818faf2e78_totalLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Non-Current Assets</link:label>
    <link:label id="lab_ifrs-full_NoncurrentAssets_label_en-US" xlink:label="lab_ifrs-full_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentAssets" xlink:to="lab_ifrs-full_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyThreeMember_474f1596-ef7a-46e5-bb0e-7d94a72bffdc_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Three</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyThreeMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Three [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodThirtyThreeMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodThirtyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Thirty Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyThreeMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodThirtyThreeMember" xlink:to="lab_cybn_OptionExpirationPeriodThirtyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_GrantedToOfficersMember_8f424283-e0a5-449c-a49e-bf0cacb2caba_terseLabel_en-US" xlink:label="lab_cybn_GrantedToOfficersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted to officers</link:label>
    <link:label id="lab_cybn_GrantedToOfficersMember_label_en-US" xlink:label="lab_cybn_GrantedToOfficersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted To Officers [Member]</link:label>
    <link:label id="lab_cybn_GrantedToOfficersMember_documentation_en-US" xlink:label="lab_cybn_GrantedToOfficersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Granted To Officers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrantedToOfficersMember" xlink:href="cybn-20250331.xsd#cybn_GrantedToOfficersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_GrantedToOfficersMember" xlink:to="lab_cybn_GrantedToOfficersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_bc6688d1-1b11-4edb-bbe8-27d340f2b233_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of options, beginning balance (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_b4ca35a3-f176-4ee7-bd09-7c9770ac2b50_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of options, ending balance (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_a46e4ebb-eb27-42f2-8577-ab1158aeb476_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options outstanding (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_label_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_OptionExpirationPeriodSeventeenMember_156e4ba7-412c-496a-b87f-4aed14d9ea31_terseLabel_en-US" xlink:label="lab_cybn_OptionExpirationPeriodSeventeenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Expiration Period Seventeen</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodSeventeenMember_label_en-US" xlink:label="lab_cybn_OptionExpirationPeriodSeventeenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Expiration Period Seventeen [Member]</link:label>
    <link:label id="lab_cybn_OptionExpirationPeriodSeventeenMember_documentation_en-US" xlink:label="lab_cybn_OptionExpirationPeriodSeventeenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option Expiration Period Seventeen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodSeventeenMember" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodSeventeenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_OptionExpirationPeriodSeventeenMember" xlink:to="lab_cybn_OptionExpirationPeriodSeventeenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_4af80dd3-861f-4af4-a96e-a11019c5983c_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">COMPREHENSIVE LOSS FOR THE YEAR</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_6d1ea725-5372-427a-9d3a-383328020da9_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_ifrs-full_Equity_bc8adb0e-4854-44c9-8191-4b230da164d7_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_ifrs-full_Equity_2ecf4600-41f0-4467-b7c4-6bec8960bd34_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_eadb2659-357b-4c68-b8e3-ee537cc1ede9_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in trade accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPrimarySicNumber_f000a9c1-93f8-4c82-9010-e904386950df_terseLabel_en-US" xlink:label="lab_dei_EntityPrimarySicNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Primary SIC Number</link:label>
    <link:label id="lab_dei_EntityPrimarySicNumber_label_en-US" xlink:label="lab_dei_EntityPrimarySicNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Primary SIC Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPrimarySicNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPrimarySicNumber" xlink:to="lab_dei_EntityPrimarySicNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_56d03698-14e5-4b10-a766-d7b9f58c4cce_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_229f3b22-79c2-4e0e-b6b4-2e540a08b8a6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant components of deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_537ef3ff-1468-4852-8a55-aa113adc46db_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Revenue_4f9f02ad-5a12-43da-bf16-3a95a318ec4e_terseLabel_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_ifrs-full_Revenue_label_en-US" xlink:label="lab_ifrs-full_Revenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Revenue" xlink:to="lab_ifrs-full_Revenue" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_A20402041Member_b2b8fe0b-643a-4538-bd3c-a21076ff6c9a_terseLabel_en-US" xlink:label="lab_cybn_A20402041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2040 - 2041</link:label>
    <link:label id="lab_cybn_A20402041Member_label_en-US" xlink:label="lab_cybn_A20402041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2040 - 2041 [Member]</link:label>
    <link:label id="lab_cybn_A20402041Member_documentation_en-US" xlink:label="lab_cybn_A20402041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2040 - 2041</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A20402041Member" xlink:href="cybn-20250331.xsd#cybn_A20402041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_A20402041Member" xlink:to="lab_cybn_A20402041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherIncome_f7f213bf-85fd-447a-880f-2131b7189ba4_totalLabel_en-US" xlink:label="lab_ifrs-full_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL OTHER INCOME</link:label>
    <link:label id="lab_ifrs-full_OtherIncome_label_en-US" xlink:label="lab_ifrs-full_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherIncome" xlink:to="lab_ifrs-full_OtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_November2023CompensationCommonShareWarrantMember_50686e85-e6fd-4801-860b-18d52b252a10_terseLabel_en-US" xlink:label="lab_cybn_November2023CompensationCommonShareWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">November 2023 compensation common share warrant</link:label>
    <link:label id="lab_cybn_November2023CompensationCommonShareWarrantMember_label_en-US" xlink:label="lab_cybn_November2023CompensationCommonShareWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">November 2023 Compensation Common Share Warrant [Member]</link:label>
    <link:label id="lab_cybn_November2023CompensationCommonShareWarrantMember_documentation_en-US" xlink:label="lab_cybn_November2023CompensationCommonShareWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">November 2023 Compensation Common Share Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_November2023CompensationCommonShareWarrantMember" xlink:href="cybn-20250331.xsd#cybn_November2023CompensationCommonShareWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_November2023CompensationCommonShareWarrantMember" xlink:to="lab_cybn_November2023CompensationCommonShareWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity_f2ec5abb-11b8-48f0-b7b8-fe198f8833f6_terseLabel_en-US" xlink:label="lab_cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class B shares converted (in shares)</link:label>
    <link:label id="lab_cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity_label_en-US" xlink:label="lab_cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Shares Converted Through Contingent Consideration, Equity</link:label>
    <link:label id="lab_cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity_documentation_en-US" xlink:label="lab_cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Shares Converted Through Contingent Consideration, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity" xlink:to="lab_cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_2eb55240-e7f0-4d14-a803-6f143c3f054f_terseLabel_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of purchaser consideration</link:label>
    <link:label id="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_label_en-US" xlink:label="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration transferred, acquisition-date fair value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:to="lab_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_cybn_SmallPharmaInc.Member_b4ba9abc-2279-4a8c-9886-51eabec339ba_terseLabel_en-US" xlink:label="lab_cybn_SmallPharmaInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Small Pharma Inc. ("Small Pharma")</link:label>
    <link:label id="lab_cybn_SmallPharmaInc.Member_label_en-US" xlink:label="lab_cybn_SmallPharmaInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Small Pharma Inc. [Member]</link:label>
    <link:label id="lab_cybn_SmallPharmaInc.Member_documentation_en-US" xlink:label="lab_cybn_SmallPharmaInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Small Pharma Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SmallPharmaInc.Member" xlink:href="cybn-20250331.xsd#cybn_SmallPharmaInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cybn_SmallPharmaInc.Member" xlink:to="lab_cybn_SmallPharmaInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_9c0fea8d-56fd-4f61-9d5b-5ee5fe2894fa_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-deductible expenses</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax effect of expense not deductible in determining taxable profit (tax loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:to="lab_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_label_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_f979d36a-5237-43a1-b828-ef5c9457f634_terseLabel_en-US" xlink:label="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_label_en-US" xlink:label="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill recognised as of acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:to="lab_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_5eb424be-c65e-4f4b-92be-f736d7f5e9c4_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in intangible assets other than goodwill [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in intangible assets other than goodwill [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_e48cc768-dffe-4080-ba46-ad90c3fed6e6_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities, measured at amortized cost:</link:label>
    <link:label id="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_label_en-US" xlink:label="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities at amortised cost, category [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:to="lab_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>cybn-20250331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:517b8eb5-c396-4287-8f5e-af5641b4b385,g:1e9b6c9c-673a-419d-ac9f-76e5a6c29d23-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cybin.com/role/COVER" xlink:type="simple" xlink:href="cybn-20250331.xsd#COVER"/>
  <link:presentationLink xlink:role="http://cybin.com/role/COVER" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_57e8aa0c-eadb-409d-a580-1ddf8576ac6f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable_12905258-9533-4b8e-ac0c-db6f621e2680" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_57e8aa0c-eadb-409d-a580-1ddf8576ac6f" xlink:to="loc_dei_EntityAddressesTable_12905258-9533-4b8e-ac0c-db6f621e2680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_60370fe5-ca70-4d16-91a9-1f7cf511f15b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_12905258-9533-4b8e-ac0c-db6f621e2680" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_60370fe5-ca70-4d16-91a9-1f7cf511f15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_2c9845ab-3da8-414a-b916-e780150a4b95" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_60370fe5-ca70-4d16-91a9-1f7cf511f15b" xlink:to="loc_dei_AddressTypeDomain_2c9845ab-3da8-414a-b916-e780150a4b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_d4715ab9-7008-4b1a-ad5c-faeb56e5ed86" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_2c9845ab-3da8-414a-b916-e780150a4b95" xlink:to="loc_dei_BusinessContactMember_d4715ab9-7008-4b1a-ad5c-faeb56e5ed86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_12905258-9533-4b8e-ac0c-db6f621e2680" xlink:to="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e2863752-7a9d-44e7-b87e-42ac75870233" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_DocumentType_e2863752-7a9d-44e7-b87e-42ac75870233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_04f37acd-7f66-4a1d-a601-0fc46bf509ea" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_DocumentRegistrationStatement_04f37acd-7f66-4a1d-a601-0fc46bf509ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_f8c6b4a4-d88e-4673-91f2-985edf0aeeb2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_DocumentAnnualReport_f8c6b4a4-d88e-4673-91f2-985edf0aeeb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_3b144ee4-f0e6-4437-9d26-ef6fccb7e1d1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_CurrentFiscalYearEndDate_3b144ee4-f0e6-4437-9d26-ef6fccb7e1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c2c0d1c2-5acc-48f4-a5a2-5c231f22ae6b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_DocumentPeriodEndDate_c2c0d1c2-5acc-48f4-a5a2-5c231f22ae6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7926dcb6-3026-4d78-92d9-7b5158a0680e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityFileNumber_7926dcb6-3026-4d78-92d9-7b5158a0680e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d4cd1f26-8e4b-46ec-86e6-7234050d4f53" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityRegistrantName_d4cd1f26-8e4b-46ec-86e6-7234050d4f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_71398c1a-be58-4089-b738-d2608e1cbfab" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_71398c1a-be58-4089-b738-d2608e1cbfab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPrimarySicNumber_7b7234ae-d5c1-4e36-9c15-0035fc5407a6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityPrimarySicNumber_7b7234ae-d5c1-4e36-9c15-0035fc5407a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_0392992e-0380-4b62-8fcc-96434568cf29" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_ContactPersonnelName_0392992e-0380-4b62-8fcc-96434568cf29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cda3e75b-b114-47ba-98d9-a78db1708004" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityAddressAddressLine1_cda3e75b-b114-47ba-98d9-a78db1708004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_d371498e-31cb-4739-be67-9db487b562b4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityAddressAddressLine2_d371498e-31cb-4739-be67-9db487b562b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_29b3bc8f-c410-4742-ab1f-0ac4efaae74d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityAddressCityOrTown_29b3bc8f-c410-4742-ab1f-0ac4efaae74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e5729b80-75f4-4891-8843-ed4253734754" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityAddressStateOrProvince_e5729b80-75f4-4891-8843-ed4253734754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_c50a7cfe-7343-43d4-99da-9d9cf9cdc3cc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityAddressCountry_c50a7cfe-7343-43d4-99da-9d9cf9cdc3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_783dbf54-d0a8-4959-98e5-461218abd661" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityAddressPostalZipCode_783dbf54-d0a8-4959-98e5-461218abd661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6922f85a-b6dc-44b5-b447-5ef019676fbd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_CityAreaCode_6922f85a-b6dc-44b5-b447-5ef019676fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_aa51c987-2c1b-4673-bb2a-a90905e0d275" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_LocalPhoneNumber_aa51c987-2c1b-4673-bb2a-a90905e0d275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_8cf4cdc3-fdc3-465b-a474-c52b618ebb48" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_Security12bTitle_8cf4cdc3-fdc3-465b-a474-c52b618ebb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2cacc591-bb72-42aa-85f7-b7b64d513128" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_TradingSymbol_2cacc591-bb72-42aa-85f7-b7b64d513128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_fc8801e2-0898-44ec-ae97-b9816df1becf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_SecurityExchangeName_fc8801e2-0898-44ec-ae97-b9816df1becf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AnnualInformationForm_35dec144-e7b5-4c25-9039-0c969b02890f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_AnnualInformationForm_35dec144-e7b5-4c25-9039-0c969b02890f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditedAnnualFinancialStatements_44a4435f-0495-449b-b24f-29dd7efb4cca" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_AuditedAnnualFinancialStatements_44a4435f-0495-449b-b24f-29dd7efb4cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_464950f0-1b86-4c04-8e1d-92d792d9613a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_464950f0-1b86-4c04-8e1d-92d792d9613a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3bbd8caa-875d-4245-b1c1-4508935f95df" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityCurrentReportingStatus_3bbd8caa-875d-4245-b1c1-4508935f95df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a37411ae-559d-4548-8974-c3f4b1034fc0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityInteractiveDataCurrent_a37411ae-559d-4548-8974-c3f4b1034fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c2c2ec66-dd18-4495-b177-583e4e1d3077" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityEmergingGrowthCompany_c2c2ec66-dd18-4495-b177-583e4e1d3077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_aa97d29a-d9bf-4e9d-bece-773610a0befc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityExTransitionPeriod_aa97d29a-d9bf-4e9d-bece-773610a0befc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_67ffb4bf-3e75-40e7-9b56-ca25d2a2ed2d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_67ffb4bf-3e75-40e7-9b56-ca25d2a2ed2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1f5adf89-d342-43c7-bf06-4c31b70317c9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_EntityCentralIndexKey_1f5adf89-d342-43c7-bf06-4c31b70317c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_be6392f1-0383-4ef9-ab8f-11f6035b47ec" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_DocumentFiscalYearFocus_be6392f1-0383-4ef9-ab8f-11f6035b47ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_51feb906-baa2-48bd-860d-4feaadfaa1e8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_51feb906-baa2-48bd-860d-4feaadfaa1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5bce8361-9b44-4a5a-a347-b76ccfb5ea23" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_822c2e68-6dc4-4378-8bbd-90413b8edc5b" xlink:to="loc_dei_AmendmentFlag_5bce8361-9b44-4a5a-a347-b76ccfb5ea23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/AUDITINFORMATION" xlink:type="simple" xlink:href="cybn-20250331.xsd#AUDITINFORMATION"/>
  <link:presentationLink xlink:role="http://cybin.com/role/AUDITINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AuditInformationAbstract_6ec04696-1a90-4acd-a720-099c16fcf7ed" xlink:href="cybn-20250331.xsd#cybn_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_82fc2d90-5db1-4aa4-a6c1-04a0c2a568b0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AuditInformationAbstract_6ec04696-1a90-4acd-a720-099c16fcf7ed" xlink:to="loc_dei_AuditorName_82fc2d90-5db1-4aa4-a6c1-04a0c2a568b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_9b29e32b-a0e1-4668-8e66-44f08889e3e2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AuditInformationAbstract_6ec04696-1a90-4acd-a720-099c16fcf7ed" xlink:to="loc_dei_AuditorLocation_9b29e32b-a0e1-4668-8e66-44f08889e3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_5c63bf44-b262-4f1d-9fe1-372652d84eb0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AuditInformationAbstract_6ec04696-1a90-4acd-a720-099c16fcf7ed" xlink:to="loc_dei_AuditorFirmId_5c63bf44-b262-4f1d-9fe1-372652d84eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="cybn-20250331.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:presentationLink xlink:role="http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_478b7c3b-779a-45ad-9287-1d6e8caef750" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_ac186c07-05b9-4260-b5c1-b5822ac836a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_478b7c3b-779a-45ad-9287-1d6e8caef750" xlink:to="loc_ifrs-full_AssetsAbstract_ac186c07-05b9-4260-b5c1-b5822ac836a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_cf3d1aa6-6c44-4381-b029-b9349154e880" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_ac186c07-05b9-4260-b5c1-b5822ac836a3" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_cf3d1aa6-6c44-4381-b029-b9349154e880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_85a24c7c-d5e6-48d0-b8ab-c30110a29fb1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_cf3d1aa6-6c44-4381-b029-b9349154e880" xlink:to="loc_ifrs-full_Cash_85a24c7c-d5e6-48d0-b8ab-c30110a29fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_c7256c6f-91b0-43fc-a914-79e97d29cadd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_cf3d1aa6-6c44-4381-b029-b9349154e880" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_c7256c6f-91b0-43fc-a914-79e97d29cadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_2bf7d256-dbb6-4a82-99f7-235e6996eafc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_cf3d1aa6-6c44-4381-b029-b9349154e880" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_2bf7d256-dbb6-4a82-99f7-235e6996eafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentAssets_ff953291-90d7-4060-804b-f7bfa8e36b71" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_cf3d1aa6-6c44-4381-b029-b9349154e880" xlink:to="loc_ifrs-full_OtherCurrentAssets_ff953291-90d7-4060-804b-f7bfa8e36b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_9a279ca5-55e3-4222-9ad2-2e4df6830878" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_cf3d1aa6-6c44-4381-b029-b9349154e880" xlink:to="loc_ifrs-full_CurrentAssets_9a279ca5-55e3-4222-9ad2-2e4df6830878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssetsAbstract_84645ecc-34fd-4f67-8319-6d9c8bef053d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_ac186c07-05b9-4260-b5c1-b5822ac836a3" xlink:to="loc_ifrs-full_NoncurrentAssetsAbstract_84645ecc-34fd-4f67-8319-6d9c8bef053d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_b3c94796-3f1c-43d6-bf98-524cf08985e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_84645ecc-34fd-4f67-8319-6d9c8bef053d" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_b3c94796-3f1c-43d6-bf98-524cf08985e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_d882d64c-b416-41e3-b622-9176e33355c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_84645ecc-34fd-4f67-8319-6d9c8bef053d" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_d882d64c-b416-41e3-b622-9176e33355c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_63c5c8f0-b3b6-4a07-9acc-45b0ce59f9d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_84645ecc-34fd-4f67-8319-6d9c8bef053d" xlink:to="loc_ifrs-full_RightofuseAssets_63c5c8f0-b3b6-4a07-9acc-45b0ce59f9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_e3417b0a-fc73-42f0-8ee1-e63037892ed9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_84645ecc-34fd-4f67-8319-6d9c8bef053d" xlink:to="loc_ifrs-full_Goodwill_e3417b0a-fc73-42f0-8ee1-e63037892ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentAssets_fe41a31b-dd90-4a3f-9788-12376542caad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NoncurrentAssetsAbstract_84645ecc-34fd-4f67-8319-6d9c8bef053d" xlink:to="loc_ifrs-full_NoncurrentAssets_fe41a31b-dd90-4a3f-9788-12376542caad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_87186c1a-4509-4896-923e-3e0701181d7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_ac186c07-05b9-4260-b5c1-b5822ac836a3" xlink:to="loc_ifrs-full_Assets_87186c1a-4509-4896-923e-3e0701181d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesAbstract_9f158869-85e4-49a1-96c2-6599e91fed51" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_478b7c3b-779a-45ad-9287-1d6e8caef750" xlink:to="loc_ifrs-full_LiabilitiesAbstract_9f158869-85e4-49a1-96c2-6599e91fed51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_9bc30883-5004-4cc6-b603-10dd7437cb84" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesAbstract_9f158869-85e4-49a1-96c2-6599e91fed51" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_9bc30883-5004-4cc6-b603-10dd7437cb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_f6278358-d07f-466a-9e3e-2074df4481ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_9bc30883-5004-4cc6-b603-10dd7437cb84" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_f6278358-d07f-466a-9e3e-2074df4481ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_7b8100ee-8f65-4c00-9ce1-64a5b1acc63b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_9bc30883-5004-4cc6-b603-10dd7437cb84" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_7b8100ee-8f65-4c00-9ce1-64a5b1acc63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_45962691-daaf-41c6-ab7d-2cfe7fdf8aeb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_9bc30883-5004-4cc6-b603-10dd7437cb84" xlink:to="loc_ifrs-full_CurrentLiabilities_45962691-daaf-41c6-ab7d-2cfe7fdf8aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_31eaf6cc-bf84-4e7e-a815-d69cba9f4047" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_478b7c3b-779a-45ad-9287-1d6e8caef750" xlink:to="loc_ifrs-full_EquityAbstract_31eaf6cc-bf84-4e7e-a815-d69cba9f4047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_a8344476-69fd-461a-a226-ba167769e7de" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_31eaf6cc-bf84-4e7e-a815-d69cba9f4047" xlink:to="loc_ifrs-full_IssuedCapital_a8344476-69fd-461a-a226-ba167769e7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium_15d31c2c-1719-4f84-9d49-d3a39f603095" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_31eaf6cc-bf84-4e7e-a815-d69cba9f4047" xlink:to="loc_ifrs-full_SharePremium_15d31c2c-1719-4f84-9d49-d3a39f603095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPayments_c67d4a94-56b6-4197-9fbe-7cb17e83c376" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_31eaf6cc-bf84-4e7e-a815-d69cba9f4047" xlink:to="loc_ifrs-full_ReserveOfSharebasedPayments_c67d4a94-56b6-4197-9fbe-7cb17e83c376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantReserve_8faf1869-da2d-4751-bbfd-5751bb16601a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_31eaf6cc-bf84-4e7e-a815-d69cba9f4047" xlink:to="loc_ifrs-full_WarrantReserve_8faf1869-da2d-4751-bbfd-5751bb16601a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_8608e4a6-3754-425c-bf40-7c53366801d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_31eaf6cc-bf84-4e7e-a815-d69cba9f4047" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_8608e4a6-3754-425c-bf40-7c53366801d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_22f69462-f6c8-489f-a4a1-e6404746e64c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_31eaf6cc-bf84-4e7e-a815-d69cba9f4047" xlink:to="loc_ifrs-full_RetainedEarnings_22f69462-f6c8-489f-a4a1-e6404746e64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_7fe5ea9d-db02-47fb-9bb9-feac82de229f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_31eaf6cc-bf84-4e7e-a815-d69cba9f4047" xlink:to="loc_ifrs-full_Equity_7fe5ea9d-db02-47fb-9bb9-feac82de229f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_524e6882-bd64-4e12-90eb-e5d29706a76a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_478b7c3b-779a-45ad-9287-1d6e8caef750" xlink:to="loc_ifrs-full_EquityAndLiabilities_524e6882-bd64-4e12-90eb-e5d29706a76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="cybn-20250331.xsd#CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract_0e6c26eb-7a31-4fa3-bdab-050f0366b614" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_abc3bba4-87e9-489c-b6b1-582638747cfc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0e6c26eb-7a31-4fa3-bdab-050f0366b614" xlink:to="loc_ifrs-full_ExpenseByNatureAbstract_abc3bba4-87e9-489c-b6b1-582638747cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_a3006103-4372-4ad5-8d15-111e37c20447" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_abc3bba4-87e9-489c-b6b1-582638747cfc" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_a3006103-4372-4ad5-8d15-111e37c20447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_3f5ec9ec-19ac-42c4-a7cd-51a2bc21bea5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_abc3bba4-87e9-489c-b6b1-582638747cfc" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_3f5ec9ec-19ac-42c4-a7cd-51a2bc21bea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_f2b65749-945a-4e10-b765-e48dbfa06ef1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_abc3bba4-87e9-489c-b6b1-582638747cfc" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_f2b65749-945a-4e10-b765-e48dbfa06ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OperatingExpense_6e268a4e-184a-4b0c-9d0f-ed8f0aec6d87" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OperatingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_abc3bba4-87e9-489c-b6b1-582638747cfc" xlink:to="loc_ifrs-full_OperatingExpense_6e268a4e-184a-4b0c-9d0f-ed8f0aec6d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_MiscellaneousIncomeExpenseAbstract_f2165ef4-ebaf-41c6-aaca-4ea916ceb2cc" xlink:href="cybn-20250331.xsd#cybn_MiscellaneousIncomeExpenseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0e6c26eb-7a31-4fa3-bdab-050f0366b614" xlink:to="loc_cybn_MiscellaneousIncomeExpenseAbstract_f2165ef4-ebaf-41c6-aaca-4ea916ceb2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_24dfb95d-4ad7-4e44-b1bb-74ca8c6e92b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_MiscellaneousIncomeExpenseAbstract_f2165ef4-ebaf-41c6-aaca-4ea916ceb2cc" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_24dfb95d-4ad7-4e44-b1bb-74ca8c6e92b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RevenueFromInterest_47c8d60f-9328-4f24-ad5b-148bc4fccd55" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_MiscellaneousIncomeExpenseAbstract_f2165ef4-ebaf-41c6-aaca-4ea916ceb2cc" xlink:to="loc_ifrs-full_RevenueFromInterest_47c8d60f-9328-4f24-ad5b-148bc4fccd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherExpenseByNature_e14e0bc8-4e8a-48ee-b836-6f423fd36e13" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherExpenseByNature"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_MiscellaneousIncomeExpenseAbstract_f2165ef4-ebaf-41c6-aaca-4ea916ceb2cc" xlink:to="loc_ifrs-full_OtherExpenseByNature_e14e0bc8-4e8a-48ee-b836-6f423fd36e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherIncome_f8529ef2-cefb-4701-9fb8-59fae4a46485" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_MiscellaneousIncomeExpenseAbstract_f2165ef4-ebaf-41c6-aaca-4ea916ceb2cc" xlink:to="loc_ifrs-full_OtherIncome_f8529ef2-cefb-4701-9fb8-59fae4a46485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_6f430074-5581-4837-80bb-6c85b7b65518" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0e6c26eb-7a31-4fa3-bdab-050f0366b614" xlink:to="loc_ifrs-full_ProfitLoss_6f430074-5581-4837-80bb-6c85b7b65518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_148f6b4d-ad74-47ff-b8eb-307f5d235c40" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0e6c26eb-7a31-4fa3-bdab-050f0366b614" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_148f6b4d-ad74-47ff-b8eb-307f5d235c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_d0505137-2ff4-41d4-bd94-35bc2de778ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_148f6b4d-ad74-47ff-b8eb-307f5d235c40" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_d0505137-2ff4-41d4-bd94-35bc2de778ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_ac35b925-7127-4760-839c-5ead6a001740" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0e6c26eb-7a31-4fa3-bdab-050f0366b614" xlink:to="loc_ifrs-full_ComprehensiveIncome_ac35b925-7127-4760-839c-5ead6a001740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_9c9ea803-f2eb-4cdc-bc29-5e824b47ade9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0e6c26eb-7a31-4fa3-bdab-050f0366b614" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_9c9ea803-f2eb-4cdc-bc29-5e824b47ade9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_be6128d0-1097-4005-af2e-32bf1920380a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_0e6c26eb-7a31-4fa3-bdab-050f0366b614" xlink:to="loc_ifrs-full_WeightedAverageShares_be6128d0-1097-4005-af2e-32bf1920380a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="cybn-20250331.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_8595f41a-3eb7-45e2-8be6-ce1761dcf836" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_f5b1d19e-9991-476b-899c-c249e9e8fb45" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_8595f41a-3eb7-45e2-8be6-ce1761dcf836" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_f5b1d19e-9991-476b-899c-c249e9e8fb45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_be4a5343-af25-4e39-b5c3-dd7bf334308a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_f5b1d19e-9991-476b-899c-c249e9e8fb45" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_be4a5343-af25-4e39-b5c3-dd7bf334308a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_f52739cb-3bc5-4115-84ab-9e90e618b958" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_be4a5343-af25-4e39-b5c3-dd7bf334308a" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_f52739cb-3bc5-4115-84ab-9e90e618b958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_d86f60c7-5a28-4333-a310-6bf51fa11aa4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_f52739cb-3bc5-4115-84ab-9e90e618b958" xlink:to="loc_ifrs-full_IssuedCapitalMember_d86f60c7-5a28-4333-a310-6bf51fa11aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantReserveMember_a128d3a8-3ce0-4fa7-bfb1-76e28c0134d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantReserveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_f52739cb-3bc5-4115-84ab-9e90e618b958" xlink:to="loc_ifrs-full_WarrantReserveMember_a128d3a8-3ce0-4fa7-bfb1-76e28c0134d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_33975d6f-5058-4756-97e8-2ffc2eeb7425" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_f52739cb-3bc5-4115-84ab-9e90e618b958" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_33975d6f-5058-4756-97e8-2ffc2eeb7425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_b22af51a-365f-496a-937c-f4736a530616" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_f52739cb-3bc5-4115-84ab-9e90e618b958" xlink:to="loc_ifrs-full_SharePremiumMember_b22af51a-365f-496a-937c-f4736a530616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_f69dd227-57a9-4976-8d7a-8f68726860c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_f52739cb-3bc5-4115-84ab-9e90e618b958" xlink:to="loc_ifrs-full_RetainedEarningsMember_f69dd227-57a9-4976-8d7a-8f68726860c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_13c700e9-d17e-4f35-99f2-894355ffb556" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_f52739cb-3bc5-4115-84ab-9e90e618b958" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_13c700e9-d17e-4f35-99f2-894355ffb556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_ddcfb63a-331e-4193-b255-2ab3c8ee2b75" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_f5b1d19e-9991-476b-899c-c249e9e8fb45" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_ddcfb63a-331e-4193-b255-2ab3c8ee2b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_7ebc8ee2-cd7f-4cf5-bdf3-73357fc82783" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_ddcfb63a-331e-4193-b255-2ab3c8ee2b75" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_7ebc8ee2-cd7f-4cf5-bdf3-73357fc82783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LPCPurchaseAgreementMember_1d92b51d-9aa5-47c3-9983-43600f047ca4" xlink:href="cybn-20250331.xsd#cybn_LPCPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_7ebc8ee2-cd7f-4cf5-bdf3-73357fc82783" xlink:to="loc_cybn_LPCPurchaseAgreementMember_1d92b51d-9aa5-47c3-9983-43600f047ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_79a7686d-485b-4a28-9b10-9e2baa59156c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_f5b1d19e-9991-476b-899c-c249e9e8fb45" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_79a7686d-485b-4a28-9b10-9e2baa59156c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ChangesInEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_79a7686d-485b-4a28-9b10-9e2baa59156c" xlink:to="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_8c0384cc-c785-4c1e-8ec5-0cb2da81f385" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_8c0384cc-c785-4c1e-8ec5-0cb2da81f385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_4432d933-9901-41ac-a543-1d60bc517ad4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_Equity_4432d933-9901-41ac-a543-1d60bc517ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughShareOfferingEquity_d635640d-fe30-4ff9-9c4f-c1407e342b87" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughShareOfferingEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_NumberOfSharesIssuedThroughShareOfferingEquity_d635640d-fe30-4ff9-9c4f-c1407e342b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughShareOfferingEquity_803b705e-c3bd-4bb2-a4f5-c3be191710be" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughShareOfferingEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_IncreaseDecreaseThroughShareOfferingEquity_803b705e-c3bd-4bb2-a4f5-c3be191710be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_c225a6c7-e58e-4d3c-9a3a-6b289994d4e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_c225a6c7-e58e-4d3c-9a3a-6b289994d4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughShareConsolidationEquity_d99f3b0f-14eb-4747-9eb6-9961fd9a8fa5" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughShareConsolidationEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_IncreaseDecreaseThroughShareConsolidationEquity_d99f3b0f-14eb-4747-9eb6-9961fd9a8fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedNetOfIssuanceCosts_918dd503-f181-42fb-ad7e-054006ff644b" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedNetOfIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_NumberOfSharesIssuedNetOfIssuanceCosts_918dd503-f181-42fb-ad7e-054006ff644b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_33f79d93-de3e-4853-9bc7-d731ecc297f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_IssueOfEquity_33f79d93-de3e-4853-9bc7-d731ecc297f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity_c1e065c0-5f92-4cf1-a613-654c0c4f6062" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity_c1e065c0-5f92-4cf1-a613-654c0c4f6062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary_bd158aff-9f45-46ff-9799-8b7038b20ece" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary_bd158aff-9f45-46ff-9799-8b7038b20ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing_968acd7b-d2db-446e-8d9c-0b856783b3a8" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing_968acd7b-d2db-446e-8d9c-0b856783b3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity_b20a3d5f-7363-4783-b33d-90e6ecf486d8" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity_b20a3d5f-7363-4783-b33d-90e6ecf486d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity_92c1ad3a-b7c4-414f-abf8-9d1cbd5606b1" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity_92c1ad3a-b7c4-414f-abf8-9d1cbd5606b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity_c65c01fb-15a8-446e-a8fd-23a41fefef68" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity_c65c01fb-15a8-446e-a8fd-23a41fefef68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_4e4824c9-9e71-4431-bdeb-5b2145ae12f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_4e4824c9-9e71-4431-bdeb-5b2145ae12f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity_edb50f04-cd4c-4f61-8c49-e2367add5f97" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity_edb50f04-cd4c-4f61-8c49-e2367add5f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_5f67fb0d-1d2e-4cc4-892c-d0bca0949fa3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_5f67fb0d-1d2e-4cc4-892c-d0bca0949fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_c7c77628-12a1-4755-9956-84d8d5241472" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_c7c77628-12a1-4755-9956-84d8d5241472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_4cab11f4-fbf8-414c-b153-320f0d006929" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_ProfitLoss_4cab11f4-fbf8-414c-b153-320f0d006929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_9cecfa87-7405-41e5-ba47-ffeffeba4351" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_9cecfa87-7405-41e5-ba47-ffeffeba4351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_76f2a08f-e3b3-4666-882f-7d82cf0bb692" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ChangesInEquityAbstract_a045ebcc-fd1d-4f02-a734-54b8d9419940" xlink:to="loc_ifrs-full_Equity_76f2a08f-e3b3-4666-882f-7d82cf0bb692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="simple" xlink:href="cybn-20250331.xsd#CONSOLIDATEDSTATEMENTOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_7605ae8e-9233-4947-95ea-79305ef092bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_03a0c2c4-a08b-4ef6-9d8e-86ca6290ae58" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_7605ae8e-9233-4947-95ea-79305ef092bf" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_03a0c2c4-a08b-4ef6-9d8e-86ca6290ae58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_9ccc1edd-8ff3-47c5-8638-838c34eacc91" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_03a0c2c4-a08b-4ef6-9d8e-86ca6290ae58" xlink:to="loc_ifrs-full_ProfitLoss_9ccc1edd-8ff3-47c5-8638-838c34eacc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ca53f7f-e913-40a7-a196-78e83f94d66c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_03a0c2c4-a08b-4ef6-9d8e-86ca6290ae58" xlink:to="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ca53f7f-e913-40a7-a196-78e83f94d66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_06f101ad-ab77-4b2e-8046-5f47c37a1313" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ca53f7f-e913-40a7-a196-78e83f94d66c" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_06f101ad-ab77-4b2e-8046-5f47c37a1313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_1637dde6-0a2c-4434-aeef-7ca06c7b2b4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ca53f7f-e913-40a7-a196-78e83f94d66c" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_1637dde6-0a2c-4434-aeef-7ca06c7b2b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdjustmentForLeaseInterest_1e93d0d4-a071-468e-9521-251b2c99b2e5" xlink:href="cybn-20250331.xsd#cybn_AdjustmentForLeaseInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ca53f7f-e913-40a7-a196-78e83f94d66c" xlink:to="loc_cybn_AdjustmentForLeaseInterest_1e93d0d4-a071-468e-9521-251b2c99b2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdjustmentsForOtherLossesGains_7ccbf8ba-6311-4ed5-bf15-1ae14438f734" xlink:href="cybn-20250331.xsd#cybn_AdjustmentsForOtherLossesGains"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ca53f7f-e913-40a7-a196-78e83f94d66c" xlink:to="loc_cybn_AdjustmentsForOtherLossesGains_7ccbf8ba-6311-4ed5-bf15-1ae14438f734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_acbab75e-a339-4f50-8e73-ed3b783ae748" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ca53f7f-e913-40a7-a196-78e83f94d66c" xlink:to="loc_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_acbab75e-a339-4f50-8e73-ed3b783ae748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation_e131564b-fc06-493d-9305-89788db9de7a" xlink:href="cybn-20250331.xsd#cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AdjustmentsForReconcileProfitLossAbstract_2ca53f7f-e913-40a7-a196-78e83f94d66c" xlink:to="loc_cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation_e131564b-fc06-493d-9305-89788db9de7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_d516e797-79b8-4460-870e-be0cf1d5e1e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_03a0c2c4-a08b-4ef6-9d8e-86ca6290ae58" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_d516e797-79b8-4460-870e-be0cf1d5e1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdjustmentsForWorkingCapitalAbstract_321eba2c-0e74-4337-b581-6634ef6f1bd4" xlink:href="cybn-20250331.xsd#cybn_AdjustmentsForWorkingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_03a0c2c4-a08b-4ef6-9d8e-86ca6290ae58" xlink:to="loc_cybn_AdjustmentsForWorkingCapitalAbstract_321eba2c-0e74-4337-b581-6634ef6f1bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_954faf44-e943-446e-8bf3-b715e2dc9de7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AdjustmentsForWorkingCapitalAbstract_321eba2c-0e74-4337-b581-6634ef6f1bd4" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_954faf44-e943-446e-8bf3-b715e2dc9de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_e514dd72-8904-4850-bccb-a9ecdab3a4e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AdjustmentsForWorkingCapitalAbstract_321eba2c-0e74-4337-b581-6634ef6f1bd4" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_e514dd72-8904-4850-bccb-a9ecdab3a4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_a49259f0-5731-4a9b-be06-afeba34bc986" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AdjustmentsForWorkingCapitalAbstract_321eba2c-0e74-4337-b581-6634ef6f1bd4" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_a49259f0-5731-4a9b-be06-afeba34bc986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities_95e30551-1901-4f22-8a87-e1df6ae49a6d" xlink:href="cybn-20250331.xsd#cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AdjustmentsForWorkingCapitalAbstract_321eba2c-0e74-4337-b581-6634ef6f1bd4" xlink:to="loc_cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities_95e30551-1901-4f22-8a87-e1df6ae49a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_0914dce8-aadb-48b0-9356-fe2d91d77dec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_03a0c2c4-a08b-4ef6-9d8e-86ca6290ae58" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_0914dce8-aadb-48b0-9356-fe2d91d77dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_8d4922a2-2df2-446b-8101-de2d9e78e73a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_7605ae8e-9233-4947-95ea-79305ef092bf" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_8d4922a2-2df2-446b-8101-de2d9e78e73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_08cbce69-7b3a-4a20-b507-3d51ddbbcf8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_8d4922a2-2df2-446b-8101-de2d9e78e73a" xlink:to="loc_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013_08cbce69-7b3a-4a20-b507-3d51ddbbcf8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_ead9b7f8-f990-4072-91b1-590691838508" xlink:href="cybn-20250331.xsd#cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_8d4922a2-2df2-446b-8101-de2d9e78e73a" xlink:to="loc_cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_ead9b7f8-f990-4072-91b1-590691838508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_ba99ff18-325a-42cc-af18-93b09b9e008d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_8d4922a2-2df2-446b-8101-de2d9e78e73a" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_ba99ff18-325a-42cc-af18-93b09b9e008d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_f0a0c02f-077c-412f-bf1c-662f27f5f425" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_7605ae8e-9233-4947-95ea-79305ef092bf" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_f0a0c02f-077c-412f-bf1c-662f27f5f425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_1f019bd5-5646-4d31-938b-203c8a5a1cbe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_f0a0c02f-077c-412f-bf1c-662f27f5f425" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_1f019bd5-5646-4d31-938b-203c8a5a1cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_4720e7ca-ad02-4208-b779-992058d4c1eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_f0a0c02f-077c-412f-bf1c-662f27f5f425" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_4720e7ca-ad02-4208-b779-992058d4c1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_b994943b-65c7-4dc1-842a-b2687b120eab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_f0a0c02f-077c-412f-bf1c-662f27f5f425" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_b994943b-65c7-4dc1-842a-b2687b120eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_3c8befaa-f414-4715-8fff-3510a9adea2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_f0a0c02f-077c-412f-bf1c-662f27f5f425" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_3c8befaa-f414-4715-8fff-3510a9adea2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_f9bbf631-e9cd-4b2f-9842-c59db7305d98" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_7605ae8e-9233-4947-95ea-79305ef092bf" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_f9bbf631-e9cd-4b2f-9842-c59db7305d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_e519f6d1-b681-422d-8538-d00b0757d3ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_7605ae8e-9233-4947-95ea-79305ef092bf" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_e519f6d1-b681-422d-8538-d00b0757d3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_b3befb21-3207-4a5f-bfdd-bb502754b8db" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_7605ae8e-9233-4947-95ea-79305ef092bf" xlink:to="loc_ifrs-full_CashAndCashEquivalents_b3befb21-3207-4a5f-bfdd-bb502754b8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_7a4d7ced-3086-4219-a305-4b663319e4c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_7605ae8e-9233-4947-95ea-79305ef092bf" xlink:to="loc_ifrs-full_CashAndCashEquivalents_7a4d7ced-3086-4219-a305-4b663319e4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/CORPORATEINFORMATION" xlink:type="simple" xlink:href="cybn-20250331.xsd#CORPORATEINFORMATION"/>
  <link:presentationLink xlink:role="http://cybin.com/role/CORPORATEINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_1a3956b6-5a1b-4c45-b7c4-51d3f496aa00" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_371e7455-ec08-43e4-88be-409bfabb08c9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_1a3956b6-5a1b-4c45-b7c4-51d3f496aa00" xlink:to="loc_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_371e7455-ec08-43e4-88be-409bfabb08c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATION" xlink:type="simple" xlink:href="cybn-20250331.xsd#MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATION"/>
  <link:presentationLink xlink:role="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AccountingPoliciesAbstract_e1366654-3e71-4d19-a81e-bfe76c3d0093" xlink:href="cybn-20250331.xsd#cybn_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_2dc2791d-be22-492d-8f9b-013ab98919cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_e1366654-3e71-4d19-a81e-bfe76c3d0093" xlink:to="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_2dc2791d-be22-492d-8f9b-013ab98919cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/CRITICALACCOUNTINGESTIMATESANDJUDGEMENTS" xlink:type="simple" xlink:href="cybn-20250331.xsd#CRITICALACCOUNTINGESTIMATESANDJUDGEMENTS"/>
  <link:presentationLink xlink:role="http://cybin.com/role/CRITICALACCOUNTINGESTIMATESANDJUDGEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CriticalAccountingEstimatesAndJudgementsAbstract_111967a0-a63f-4334-9906-98345e1e6566" xlink:href="cybn-20250331.xsd#cybn_CriticalAccountingEstimatesAndJudgementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_74de51ea-8b6c-470e-83a4-4c6d891efa95" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_CriticalAccountingEstimatesAndJudgementsAbstract_111967a0-a63f-4334-9906-98345e1e6566" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_74de51ea-8b6c-470e-83a4-4c6d891efa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/ACQUISITION" xlink:type="simple" xlink:href="cybn-20250331.xsd#ACQUISITION"/>
  <link:presentationLink xlink:role="http://cybin.com/role/ACQUISITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_79edca75-5591-4acb-af7e-95bf955b3e7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsExplanatory_5b41de55-e461-489c-b1f0-92981c64ecc8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_79edca75-5591-4acb-af7e-95bf955b3e7b" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsExplanatory_5b41de55-e461-489c-b1f0-92981c64ecc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/EQUIPMENT" xlink:type="simple" xlink:href="cybn-20250331.xsd#EQUIPMENT"/>
  <link:presentationLink xlink:role="http://cybin.com/role/EQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PropertyPlantAndEquipment1Abstract_d726bfc4-4ed3-4237-958a-12bf35eee4fd" xlink:href="cybn-20250331.xsd#cybn_PropertyPlantAndEquipment1Abstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_63787116-282d-4cf2-bba1-db2e3cb8d830" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_PropertyPlantAndEquipment1Abstract_d726bfc4-4ed3-4237-958a-12bf35eee4fd" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_63787116-282d-4cf2-bba1-db2e3cb8d830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/INTANGIBLEASSETS" xlink:type="simple" xlink:href="cybn-20250331.xsd#INTANGIBLEASSETS"/>
  <link:presentationLink xlink:role="http://cybin.com/role/INTANGIBLEASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IntangibleAssetsAbstract_8dce215a-5ec2-45e5-b188-fa8f7e269a73" xlink:href="cybn-20250331.xsd#cybn_IntangibleAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_cf7f9f40-ec1c-4c7b-b0b6-71856c79aa94" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IntangibleAssetsAbstract_8dce215a-5ec2-45e5-b188-fa8f7e269a73" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsExplanatory_cf7f9f40-ec1c-4c7b-b0b6-71856c79aa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIES" xlink:type="simple" xlink:href="cybn-20250331.xsd#RIGHTOFUSEASSETSANDLEASELIABILITIES"/>
  <link:presentationLink xlink:role="http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_6bb7f22c-a1d1-4caa-8c27-d84b23f8ec49" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfLeasesAndRightOfUseAssetsTextBlock_2bdd4fc2-8b4a-4013-b7e0-938fb88e620d" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfLeasesAndRightOfUseAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_6bb7f22c-a1d1-4caa-8c27-d84b23f8ec49" xlink:to="loc_cybn_DisclosureOfLeasesAndRightOfUseAssetsTextBlock_2bdd4fc2-8b4a-4013-b7e0-938fb88e620d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/GOODWILL" xlink:type="simple" xlink:href="cybn-20250331.xsd#GOODWILL"/>
  <link:presentationLink xlink:role="http://cybin.com/role/GOODWILL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GoodwillAbstract_fc77ec08-1db9-438c-9db4-0ccae37420a0" xlink:href="cybn-20250331.xsd#cybn_GoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGoodwillExplanatory_7e3f4deb-a09b-46da-b1fb-2446455d33b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGoodwillExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_GoodwillAbstract_fc77ec08-1db9-438c-9db4-0ccae37420a0" xlink:to="loc_ifrs-full_DisclosureOfGoodwillExplanatory_7e3f4deb-a09b-46da-b1fb-2446455d33b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITAL" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITAL"/>
  <link:presentationLink xlink:role="http://cybin.com/role/SHARECAPITAL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_6b5b1c72-c59e-4a1e-940a-d9c67d47199e" xlink:href="cybn-20250331.xsd#cybn_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_56c446e8-faaf-446a-b18d-ae0a2675198c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_6b5b1c72-c59e-4a1e-940a-d9c67d47199e" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_56c446e8-faaf-446a-b18d-ae0a2675198c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory_71a8417b-5bf4-4b0f-b549-e552f23801e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCES" xlink:type="simple" xlink:href="cybn-20250331.xsd#RELATEDPARTYTRANSACTIONSANDBALANCES"/>
  <link:presentationLink xlink:role="http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_RelatedPartyAbstract_f99e0ffd-08cb-4bae-aacd-4024935f25f7" xlink:href="cybn-20250331.xsd#cybn_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_ba47d3df-ec80-40ca-89c3-014cb829b32f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_RelatedPartyAbstract_f99e0ffd-08cb-4bae-aacd-4024935f25f7" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_ba47d3df-ec80-40ca-89c3-014cb829b32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/RESEARCHEXPENSES" xlink:type="simple" xlink:href="cybn-20250331.xsd#RESEARCHEXPENSES"/>
  <link:presentationLink xlink:role="http://cybin.com/role/RESEARCHEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_ad912026-98da-4550-8b6d-b68fdcafaa8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_5dc8d516-29a4-4a4c-af2a-e0a8c38f89f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_ad912026-98da-4550-8b6d-b68fdcafaa8c" xlink:to="loc_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_5dc8d516-29a4-4a4c-af2a-e0a8c38f89f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSES" xlink:type="simple" xlink:href="cybn-20250331.xsd#GENERALANDADMINISTRATIVEEXPENSES"/>
  <link:presentationLink xlink:role="http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_f7f7ea1e-8add-4c04-b006-c48eff15f08d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_9fae93e6-b296-4dbf-a4cc-7fc7a2a31a7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_f7f7ea1e-8add-4c04-b006-c48eff15f08d" xlink:to="loc_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_9fae93e6-b296-4dbf-a4cc-7fc7a2a31a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="cybn-20250331.xsd#CONTRACTSCOMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommitmentsAbstract_5ad5fc43-70a7-4ac6-b75f-acf059c6ef42" xlink:href="cybn-20250331.xsd#cybn_CommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_aebe4a95-97e5-4faf-9b91-1af5e7a2ecee" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_CommitmentsAbstract_5ad5fc43-70a7-4ac6-b75f-acf059c6ef42" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_aebe4a95-97e5-4faf-9b91-1af5e7a2ecee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/CAPITALMANAGEMENT" xlink:type="simple" xlink:href="cybn-20250331.xsd#CAPITALMANAGEMENT"/>
  <link:presentationLink xlink:role="http://cybin.com/role/CAPITALMANAGEMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CapitalManagementAbstract_e63c34bc-6484-448f-818c-b48fde1d7839" xlink:href="cybn-20250331.xsd#cybn_CapitalManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_91b11183-9919-415a-98ae-274826943b5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_CapitalManagementAbstract_e63c34bc-6484-448f-818c-b48fde1d7839" xlink:to="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_91b11183-9919-415a-98ae-274826943b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/FINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="cybn-20250331.xsd#FINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://cybin.com/role/FINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_FinancialInstrumentsAbstract_d899fc90-3451-4278-9feb-c548eb56ed6a" xlink:href="cybn-20250331.xsd#cybn_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_2859d6f6-459d-49a2-a54e-5335cb9f87d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_FinancialInstrumentsAbstract_d899fc90-3451-4278-9feb-c548eb56ed6a" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_2859d6f6-459d-49a2-a54e-5335cb9f87d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/INCOMETAX" xlink:type="simple" xlink:href="cybn-20250331.xsd#INCOMETAX"/>
  <link:presentationLink xlink:role="http://cybin.com/role/INCOMETAX" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncomeTaxesAbstract_1d1f867f-b6e9-4b9f-906f-806d04425b6c" xlink:href="cybn-20250331.xsd#cybn_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_4594e929-ba03-4142-a76f-5785e8a16bcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeTaxesAbstract_1d1f867f-b6e9-4b9f-906f-806d04425b6c" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_4594e929-ba03-4142-a76f-5785e8a16bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="cybn-20250331.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://cybin.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_EventsAfterReportingPeriodAbstract_cbfa29d4-c604-496d-944f-9fe556a9cdcd" xlink:href="cybn-20250331.xsd#cybn_EventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_b5b35da6-b5a9-4d3c-b5da-42f0fa63f1ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_EventsAfterReportingPeriodAbstract_cbfa29d4-c604-496d-944f-9fe556a9cdcd" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_b5b35da6-b5a9-4d3c-b5da-42f0fa63f1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies" xlink:type="simple" xlink:href="cybn-20250331.xsd#MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"/>
  <link:presentationLink xlink:role="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:href="cybn-20250331.xsd#cybn_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfIFRSCompliance_18de008c-8808-4f6c-a835-960dce206d79" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfIFRSCompliance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_ifrs-full_StatementOfIFRSCompliance_18de008c-8808-4f6c-a835-960dce206d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock_e832709b-2623-4beb-a54c-e1f46d8df618" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_cybn_DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock_e832709b-2623-4beb-a54c-e1f46d8df618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory_f69bd857-7958-46bf-8a18-48b29fd075d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory_f69bd857-7958-46bf-8a18-48b29fd075d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfBasisOfConsolidationPolicyTextBlock_35e81a8f-369c-4cb3-8c60-cb8b80f843cf" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfBasisOfConsolidationPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_cybn_DisclosureOfBasisOfConsolidationPolicyTextBlock_35e81a8f-369c-4cb3-8c60-cb8b80f843cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_39ac5313-a9a1-4d30-b49e-bff756fda54b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_39ac5313-a9a1-4d30-b49e-bff756fda54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_3ccbc45b-e2bc-404b-a617-dd5bacf061a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories_3ccbc45b-e2bc-404b-a617-dd5bacf061a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_dc93ce29-37cc-42f4-b819-a4b8d7a523dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_dc93ce29-37cc-42f4-b819-a4b8d7a523dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_846b0881-64a5-4464-bfb2-0b6ac7f6a88b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory_846b0881-64a5-4464-bfb2-0b6ac7f6a88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory_765b132c-1c2d-408b-87d8-46397ec2247d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory_765b132c-1c2d-408b-87d8-46397ec2247d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_e0985ede-4430-4381-9efa-92020a245fcd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_e0985ede-4430-4381-9efa-92020a245fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_3d09d97e-170a-4320-8717-74549f6e21d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_3d09d97e-170a-4320-8717-74549f6e21d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_a9da414e-53d3-41ac-a1f6-eaa2ec834d68" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_a9da414e-53d3-41ac-a1f6-eaa2ec834d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_6351525f-112d-4311-b9ca-904962417d10" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory_6351525f-112d-4311-b9ca-904962417d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_d5f2c30a-1965-467c-b377-e24fed789c90" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_d5f2c30a-1965-467c-b377-e24fed789c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory_e2207f75-f275-47b0-a6ab-dbe81d20b797" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory_e2207f75-f275-47b0-a6ab-dbe81d20b797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_2e31689e-7e80-46b1-8281-026a7ec48e91" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_2e31689e-7e80-46b1-8281-026a7ec48e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_7aa12834-ba47-455d-8a68-a4b72f9e739b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_7aa12834-ba47-455d-8a68-a4b72f9e739b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_d78d2e0f-039d-489f-8078-d48aa0b8d7c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_d78d2e0f-039d-489f-8078-d48aa0b8d7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_9cb399ce-d5ac-403a-9659-b8c3be8387ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_65f3cf4c-f08c-49f4-9aea-206a90665f5b" xlink:to="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_9cb399ce-d5ac-403a-9659-b8c3be8387ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONTables" xlink:type="simple" xlink:href="cybn-20250331.xsd#MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONTables"/>
  <link:presentationLink xlink:role="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AccountingPoliciesAbstract_7957bec1-278f-43eb-9e69-4f5410ba5f91" xlink:href="cybn-20250331.xsd#cybn_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DetailDescriptionOfFunctionalCurrenciesTableTextBlock_e8cdcf84-c4a1-4dd4-8ad3-387c71df9492" xlink:href="cybn-20250331.xsd#cybn_DetailDescriptionOfFunctionalCurrenciesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_7957bec1-278f-43eb-9e69-4f5410ba5f91" xlink:to="loc_cybn_DetailDescriptionOfFunctionalCurrenciesTableTextBlock_e8cdcf84-c4a1-4dd4-8ad3-387c71df9492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/ACQUISITIONTables" xlink:type="simple" xlink:href="cybn-20250331.xsd#ACQUISITIONTables"/>
  <link:presentationLink xlink:role="http://cybin.com/role/ACQUISITIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_0213b9f0-8327-450c-a331-29d4a74b4177" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_824c3975-f800-442d-ace2-a063e5b8a227" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_0213b9f0-8327-450c-a331-29d4a74b4177" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory_824c3975-f800-442d-ace2-a063e5b8a227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/EQUIPMENTTables" xlink:type="simple" xlink:href="cybn-20250331.xsd#EQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://cybin.com/role/EQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PropertyPlantAndEquipment1Abstract_aeb2e299-b085-480d-a261-452d4e34c890" xlink:href="cybn-20250331.xsd#cybn_PropertyPlantAndEquipment1Abstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_a1abfb2d-8738-4f7d-907a-5e81e95d93d2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_PropertyPlantAndEquipment1Abstract_aeb2e299-b085-480d-a261-452d4e34c890" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_a1abfb2d-8738-4f7d-907a-5e81e95d93d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/INTANGIBLEASSETSTables" xlink:type="simple" xlink:href="cybn-20250331.xsd#INTANGIBLEASSETSTables"/>
  <link:presentationLink xlink:role="http://cybin.com/role/INTANGIBLEASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IntangibleAssetsAbstract_0d8ce7c8-8026-4e70-b4e1-3d2ea663c4c6" xlink:href="cybn-20250331.xsd#cybn_IntangibleAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_bd14d987-5b51-48ad-83bd-5fa1ad5fccdf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IntangibleAssetsAbstract_0d8ce7c8-8026-4e70-b4e1-3d2ea663c4c6" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_bd14d987-5b51-48ad-83bd-5fa1ad5fccdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESTables" xlink:type="simple" xlink:href="cybn-20250331.xsd#RIGHTOFUSEASSETSANDLEASELIABILITIESTables"/>
  <link:presentationLink xlink:role="http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_a5c5a756-97ca-4df4-a63e-d27d267602bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_5e8cfd51-0a1a-4656-9381-fa8ed92c0836" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_a5c5a756-97ca-4df4-a63e-d27d267602bf" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_5e8cfd51-0a1a-4656-9381-fa8ed92c0836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_429d98a3-7003-46ee-a98c-fdb79f00d0b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_a5c5a756-97ca-4df4-a63e-d27d267602bf" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_429d98a3-7003-46ee-a98c-fdb79f00d0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/GOODWILLTables" xlink:type="simple" xlink:href="cybn-20250331.xsd#GOODWILLTables"/>
  <link:presentationLink xlink:role="http://cybin.com/role/GOODWILLTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GoodwillAbstract_258108ff-afda-4bfb-ae5f-a6959d9b2ed0" xlink:href="cybn-20250331.xsd#cybn_GoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory_e9ff77bb-3ba5-4bfe-9f2c-5174c868466b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_GoodwillAbstract_258108ff-afda-4bfb-ae5f-a6959d9b2ed0" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory_e9ff77bb-3ba5-4bfe-9f2c-5174c868466b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALTables" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALTables"/>
  <link:presentationLink xlink:role="http://cybin.com/role/SHARECAPITALTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_6772fab9-9c06-439f-9400-0450cdd1435e" xlink:href="cybn-20250331.xsd#cybn_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_32aa3b87-a42b-4af6-a95b-9a03d9ed936b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_6772fab9-9c06-439f-9400-0450cdd1435e" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_32aa3b87-a42b-4af6-a95b-9a03d9ed936b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_04b195f2-4e52-4afb-ac75-6c932465c0ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_6772fab9-9c06-439f-9400-0450cdd1435e" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_04b195f2-4e52-4afb-ac75-6c932465c0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory_29efa4af-42db-445c-ae5f-cf145ef112e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_6772fab9-9c06-439f-9400-0450cdd1435e" xlink:to="loc_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory_29efa4af-42db-445c-ae5f-cf145ef112e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_94417f3d-903d-472d-9d62-abb5dac6f743" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_6772fab9-9c06-439f-9400-0450cdd1435e" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_94417f3d-903d-472d-9d62-abb5dac6f743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_5e6f65be-47d3-4bc5-9c87-1e2530f5ed84" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_6772fab9-9c06-439f-9400-0450cdd1435e" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_5e6f65be-47d3-4bc5-9c87-1e2530f5ed84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESTables" xlink:type="simple" xlink:href="cybn-20250331.xsd#RELATEDPARTYTRANSACTIONSANDBALANCESTables"/>
  <link:presentationLink xlink:role="http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_RelatedPartyAbstract_549b9fb3-ca11-48f8-b70e-a66d807c2d09" xlink:href="cybn-20250331.xsd#cybn_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_8c8c37f2-4827-4fa4-bcc8-9097a4813375" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_RelatedPartyAbstract_549b9fb3-ca11-48f8-b70e-a66d807c2d09" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_8c8c37f2-4827-4fa4-bcc8-9097a4813375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/RESEARCHEXPENSESTables" xlink:type="simple" xlink:href="cybn-20250331.xsd#RESEARCHEXPENSESTables"/>
  <link:presentationLink xlink:role="http://cybin.com/role/RESEARCHEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_1e7dfecc-31fc-4a3f-97a9-d86bf6b93ff6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ScheduleOfResearchExpensesTableTextBlock_f9c66953-e777-48b1-a89d-8b100c639ee9" xlink:href="cybn-20250331.xsd#cybn_ScheduleOfResearchExpensesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_1e7dfecc-31fc-4a3f-97a9-d86bf6b93ff6" xlink:to="loc_cybn_ScheduleOfResearchExpensesTableTextBlock_f9c66953-e777-48b1-a89d-8b100c639ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESTables" xlink:type="simple" xlink:href="cybn-20250331.xsd#GENERALANDADMINISTRATIVEEXPENSESTables"/>
  <link:presentationLink xlink:role="http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_dbf8abe5-a56e-4db5-a97d-956500f35679" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory_6f10603b-732e-49be-9a89-65290578a81b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_dbf8abe5-a56e-4db5-a97d-956500f35679" xlink:to="loc_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory_6f10603b-732e-49be-9a89-65290578a81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/CAPITALMANAGEMENTTables" xlink:type="simple" xlink:href="cybn-20250331.xsd#CAPITALMANAGEMENTTables"/>
  <link:presentationLink xlink:role="http://cybin.com/role/CAPITALMANAGEMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CapitalManagementAbstract_f43fa739-56e8-4002-8d9b-c528d16f7223" xlink:href="cybn-20250331.xsd#cybn_CapitalManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfCapitalStructureTableTextBlock_32552a7a-4247-48ae-95f1-7ff95c6f742f" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfCapitalStructureTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_CapitalManagementAbstract_f43fa739-56e8-4002-8d9b-c528d16f7223" xlink:to="loc_cybn_DisclosureOfCapitalStructureTableTextBlock_32552a7a-4247-48ae-95f1-7ff95c6f742f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/FINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="cybn-20250331.xsd#FINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://cybin.com/role/FINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_FinancialInstrumentsAbstract_de6b4a98-6262-4e18-880b-dca75aee35fb" xlink:href="cybn-20250331.xsd#cybn_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory_6be3068c-d6bd-42b8-8285-591c4ea1b7ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_FinancialInstrumentsAbstract_de6b4a98-6262-4e18-880b-dca75aee35fb" xlink:to="loc_ifrs-full_DisclosureOfFinancialAssetsExplanatory_6be3068c-d6bd-42b8-8285-591c4ea1b7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_4c919b75-4def-4165-8ff9-473bf8ebb760" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_FinancialInstrumentsAbstract_de6b4a98-6262-4e18-880b-dca75aee35fb" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_4c919b75-4def-4165-8ff9-473bf8ebb760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory_479afc5e-0bd4-4d3e-b76b-8e4261941604" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_FinancialInstrumentsAbstract_de6b4a98-6262-4e18-880b-dca75aee35fb" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory_479afc5e-0bd4-4d3e-b76b-8e4261941604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/INCOMETAXTables" xlink:type="simple" xlink:href="cybn-20250331.xsd#INCOMETAXTables"/>
  <link:presentationLink xlink:role="http://cybin.com/role/INCOMETAXTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncomeTaxesAbstract_0d854c97-d028-4aa6-86a9-857f30f36f74" xlink:href="cybn-20250331.xsd#cybn_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock_9c02f0dc-24b5-42a5-9be9-54b4db59b140" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeTaxesAbstract_0d854c97-d028-4aa6-86a9-857f30f36f74" xlink:to="loc_cybn_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock_9c02f0dc-24b5-42a5-9be9-54b4db59b140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_03d29c20-1b5e-4a26-8c30-1c0753741fb6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeTaxesAbstract_0d854c97-d028-4aa6-86a9-857f30f36f74" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_03d29c20-1b5e-4a26-8c30-1c0753741fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfExpirationOfNonCapitalLossesTableTextBlock_eb213472-5f02-4959-91a4-88158854ec5d" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfExpirationOfNonCapitalLossesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeTaxesAbstract_0d854c97-d028-4aa6-86a9-857f30f36f74" xlink:to="loc_cybn_DisclosureOfExpirationOfNonCapitalLossesTableTextBlock_eb213472-5f02-4959-91a4-88158854ec5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/CORPORATEINFORMATIONDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#CORPORATEINFORMATIONDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/CORPORATEINFORMATIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_6abb90ad-0962-42c3-b846-7ddc55872026" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSubsidiaries_62ed48d8-8489-4bd8-a18c-e7b6020ee970" xlink:href="cybn-20250331.xsd#cybn_NumberOfSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_6abb90ad-0962-42c3-b846-7ddc55872026" xlink:to="loc_cybn_NumberOfSubsidiaries_62ed48d8-8489-4bd8-a18c-e7b6020ee970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OrdinarySharesConsolidationNewSharesIssued_84d2af70-5209-4b46-955d-bed8398496d7" xlink:href="cybn-20250331.xsd#cybn_OrdinarySharesConsolidationNewSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_6abb90ad-0962-42c3-b846-7ddc55872026" xlink:to="loc_cybn_OrdinarySharesConsolidationNewSharesIssued_84d2af70-5209-4b46-955d-bed8398496d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OrdinarySharesConsolidationSharesIssuedPreviously_50bcbb57-5171-42b9-95bc-c5adb615d89a" xlink:href="cybn-20250331.xsd#cybn_OrdinarySharesConsolidationSharesIssuedPreviously"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_6abb90ad-0962-42c3-b846-7ddc55872026" xlink:to="loc_cybn_OrdinarySharesConsolidationSharesIssuedPreviously_50bcbb57-5171-42b9-95bc-c5adb615d89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_93b7fe46-8b8b-44e4-8252-79c74cfe8719" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_6abb90ad-0962-42c3-b846-7ddc55872026" xlink:to="loc_ifrs-full_RetainedEarnings_93b7fe46-8b8b-44e4-8252-79c74cfe8719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_c9806ed5-68b5-486c-8fad-d3db135f5d3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_6abb90ad-0962-42c3-b846-7ddc55872026" xlink:to="loc_ifrs-full_Cash_c9806ed5-68b5-486c-8fad-d3db135f5d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WorkingCapital_46784f25-480d-458f-80d7-e0824f03246b" xlink:href="cybn-20250331.xsd#cybn_WorkingCapital"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_6abb90ad-0962-42c3-b846-7ddc55872026" xlink:to="loc_cybn_WorkingCapital_46784f25-480d-458f-80d7-e0824f03246b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_e5cc83b0-ee4d-449d-9991-0cf76c7dae7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_6abb90ad-0962-42c3-b846-7ddc55872026" xlink:to="loc_ifrs-full_ProfitLoss_e5cc83b0-ee4d-449d-9991-0cf76c7dae7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_0c43001b-7902-4999-8e97-71fc57f8a3ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_6abb90ad-0962-42c3-b846-7ddc55872026" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivities_0c43001b-7902-4999-8e97-71fc57f8a3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AccountingPoliciesAbstract_fea5cce8-2817-430e-abd0-727edf4bf2f9" xlink:href="cybn-20250331.xsd#cybn_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ba816c89-6f29-4f9b-9f4e-e08d4548b872" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_fea5cce8-2817-430e-abd0-727edf4bf2f9" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ba816c89-6f29-4f9b-9f4e-e08d4548b872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_5741d226-38c1-49d5-acac-04ae63e951a9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ba816c89-6f29-4f9b-9f4e-e08d4548b872" xlink:to="loc_srt_OwnershipAxis_5741d226-38c1-49d5-acac-04ae63e951a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ac03c333-1149-4d27-97cc-70ead15e6726" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_5741d226-38c1-49d5-acac-04ae63e951a9" xlink:to="loc_srt_OwnershipDomain_ac03c333-1149-4d27-97cc-70ead15e6726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CybinCorpMember_ae242c1c-f275-4908-a2b5-edabc1f7fa4b" xlink:href="cybn-20250331.xsd#cybn_CybinCorpMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_ac03c333-1149-4d27-97cc-70ead15e6726" xlink:to="loc_cybn_CybinCorpMember_ae242c1c-f275-4908-a2b5-edabc1f7fa4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_JourneyMember_9b998682-e2ed-4f0d-80dd-0769ad59821b" xlink:href="cybn-20250331.xsd#cybn_JourneyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_ac03c333-1149-4d27-97cc-70ead15e6726" xlink:to="loc_cybn_JourneyMember_9b998682-e2ed-4f0d-80dd-0769ad59821b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SerenityMember_0ad4b76d-3ac2-4813-ad7a-177f908c88a4" xlink:href="cybn-20250331.xsd#cybn_SerenityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_ac03c333-1149-4d27-97cc-70ead15e6726" xlink:to="loc_cybn_SerenityMember_0ad4b76d-3ac2-4813-ad7a-177f908c88a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CybinUSMember_21360080-522a-4b2b-99b2-5810f0a173fc" xlink:href="cybn-20250331.xsd#cybn_CybinUSMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_ac03c333-1149-4d27-97cc-70ead15e6726" xlink:to="loc_cybn_CybinUSMember_21360080-522a-4b2b-99b2-5810f0a173fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdeliaMember_259104f5-04ab-45fd-a166-cceb99d92e21" xlink:href="cybn-20250331.xsd#cybn_AdeliaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_ac03c333-1149-4d27-97cc-70ead15e6726" xlink:to="loc_cybn_AdeliaMember_259104f5-04ab-45fd-a166-cceb99d92e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CybinIRLLimitedMember_7aff2efe-f422-4b87-96e8-62d7fbd9e236" xlink:href="cybn-20250331.xsd#cybn_CybinIRLLimitedMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_ac03c333-1149-4d27-97cc-70ead15e6726" xlink:to="loc_cybn_CybinIRLLimitedMember_7aff2efe-f422-4b87-96e8-62d7fbd9e236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CybinUKLtd.Member_c954e7f4-a1eb-4fa7-847f-f09cce7217ae" xlink:href="cybn-20250331.xsd#cybn_CybinUKLtd.Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_ac03c333-1149-4d27-97cc-70ead15e6726" xlink:to="loc_cybn_CybinUKLtd.Member_c954e7f4-a1eb-4fa7-847f-f09cce7217ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_5f3b70df-f399-441c-b966-a2f5aa45e0a2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_ba816c89-6f29-4f9b-9f4e-e08d4548b872" xlink:to="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_5f3b70df-f399-441c-b966-a2f5aa45e0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_84198505-366f-4906-b6dc-9c931a4b28ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_5f3b70df-f399-441c-b966-a2f5aa45e0a2" xlink:to="loc_ifrs-full_ProportionOfOwnershipInterestInSubsidiary_84198505-366f-4906-b6dc-9c931a4b28ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONCashandcashequivalentsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONCashandcashequivalentsDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONCashandcashequivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AccountingPoliciesAbstract_886bf62c-6a7e-47bf-90ae-c90bb7d181db" xlink:href="cybn-20250331.xsd#cybn_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents_2ae462a8-1306-441f-90a9-9dec7ca37977" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_886bf62c-6a7e-47bf-90ae-c90bb7d181db" xlink:to="loc_ifrs-full_CashEquivalents_2ae462a8-1306-441f-90a9-9dec7ca37977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AccountingPoliciesAbstract_03c68271-2eae-4e5f-879f-3bd6dd23b2db" xlink:href="cybn-20250331.xsd#cybn_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4c3addbc-baeb-478a-92b4-281254bc78d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_03c68271-2eae-4e5f-879f-3bd6dd23b2db" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4c3addbc-baeb-478a-92b4-281254bc78d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_bb3ad254-7f3d-4fd8-877f-3eed13a80e16" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4c3addbc-baeb-478a-92b4-281254bc78d9" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_bb3ad254-7f3d-4fd8-877f-3eed13a80e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_7818b6cc-ad92-43e0-bbed-18eea2b010ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_bb3ad254-7f3d-4fd8-877f-3eed13a80e16" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_7818b6cc-ad92-43e0-bbed-18eea2b010ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LaboratoryEquipmentMember_f4064429-5fec-4f23-aee1-22f2d72a7e5f" xlink:href="cybn-20250331.xsd#cybn_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_7818b6cc-ad92-43e0-bbed-18eea2b010ea" xlink:to="loc_cybn_LaboratoryEquipmentMember_f4064429-5fec-4f23-aee1-22f2d72a7e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_1943770e-0d5d-4d55-88a9-5a72859595f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_7818b6cc-ad92-43e0-bbed-18eea2b010ea" xlink:to="loc_ifrs-full_ComputerEquipmentMember_1943770e-0d5d-4d55-88a9-5a72859595f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_c8356aef-b118-49a2-acbf-50938f8292b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4c3addbc-baeb-478a-92b4-281254bc78d9" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_c8356aef-b118-49a2-acbf-50938f8292b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_c174605d-7d4e-4294-ad4b-c90fe3c1d5d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_c8356aef-b118-49a2-acbf-50938f8292b9" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_c174605d-7d4e-4294-ad4b-c90fe3c1d5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_2c1f6776-50ed-41ef-b7e2-af2fcf5d18f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_c174605d-7d4e-4294-ad4b-c90fe3c1d5d3" xlink:to="loc_ifrs-full_ComputerSoftwareMember_2c1f6776-50ed-41ef-b7e2-af2fcf5d18f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_731c23a7-070c-484f-a86c-5324659c1f2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_c174605d-7d4e-4294-ad4b-c90fe3c1d5d3" xlink:to="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_731c23a7-070c-484f-a86c-5324659c1f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0c0916f3-f8a7-4bcf-8728-79b2aa3da2b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_4c3addbc-baeb-478a-92b4-281254bc78d9" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0c0916f3-f8a7-4bcf-8728-79b2aa3da2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_413debd7-94fb-4643-86ae-38d6a6f9579a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0c0916f3-f8a7-4bcf-8728-79b2aa3da2b6" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_413debd7-94fb-4643-86ae-38d6a6f9579a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_2fad0b19-0be0-49b1-b51b-611207157882" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0c0916f3-f8a7-4bcf-8728-79b2aa3da2b6" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_2fad0b19-0be0-49b1-b51b-611207157882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONSharebasedcompensationDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONSharebasedcompensationDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONSharebasedcompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AccountingPoliciesAbstract_a51dbb02-9331-42a0-9079-c91411082fae" xlink:href="cybn-20250331.xsd#cybn_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareBasedCompensationArrangementExpirationPeriod_71fd79d2-b5ec-43e4-8e2a-c1f324517344" xlink:href="cybn-20250331.xsd#cybn_ShareBasedCompensationArrangementExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_AccountingPoliciesAbstract_a51dbb02-9331-42a0-9079-c91411082fae" xlink:to="loc_cybn_ShareBasedCompensationArrangementExpirationPeriod_71fd79d2-b5ec-43e4-8e2a-c1f324517344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/ACQUISITIONNarrativeDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#ACQUISITIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/ACQUISITIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_26cc8773-6326-4950-8d28-4c235d977722" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ce5cc1ee-175e-498a-9108-0f7936006ba3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_26cc8773-6326-4950-8d28-4c235d977722" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ce5cc1ee-175e-498a-9108-0f7936006ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_78d9bc93-e47d-475c-9aa9-1f18030ca2f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ce5cc1ee-175e-498a-9108-0f7936006ba3" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_78d9bc93-e47d-475c-9aa9-1f18030ca2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_b4abdb4f-0ece-424b-99a9-02aeb2e59c54" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_78d9bc93-e47d-475c-9aa9-1f18030ca2f5" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_b4abdb4f-0ece-424b-99a9-02aeb2e59c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SmallPharmaInc.Member_62c59c38-8294-4a22-ac54-629a9a7e07e4" xlink:href="cybn-20250331.xsd#cybn_SmallPharmaInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_b4abdb4f-0ece-424b-99a9-02aeb2e59c54" xlink:to="loc_cybn_SmallPharmaInc.Member_62c59c38-8294-4a22-ac54-629a9a7e07e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_1b2e1d4a-c7d8-4d09-8558-476b5b75159a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ce5cc1ee-175e-498a-9108-0f7936006ba3" xlink:to="loc_ifrs-full_GeographicalAreasAxis_1b2e1d4a-c7d8-4d09-8558-476b5b75159a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_8d3ceb55-cb4a-42ee-843b-6aa0a9e81133" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_1b2e1d4a-c7d8-4d09-8558-476b5b75159a" xlink:to="loc_ifrs-full_GeographicalAreasDomain_8d3ceb55-cb4a-42ee-843b-6aa0a9e81133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_8f962d30-c0e3-43f3-8bbf-c9192bf16e1b" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_8d3ceb55-cb4a-42ee-843b-6aa0a9e81133" xlink:to="loc_country_CA_8f962d30-c0e3-43f3-8bbf-c9192bf16e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_025666d1-9d56-478d-a28d-412b33408b2d" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_8d3ceb55-cb4a-42ee-843b-6aa0a9e81133" xlink:to="loc_country_GB_025666d1-9d56-478d-a28d-412b33408b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_ce5cc1ee-175e-498a-9108-0f7936006ba3" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding_11c569c1-1434-4165-ada2-db55fade180a" xlink:href="cybn-20250331.xsd#cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:to="loc_cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding_11c569c1-1434-4165-ada2-db55fade180a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_e6587a29-e515-492f-af17-e01afc5c668e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:to="loc_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable_e6587a29-e515-492f-af17-e01afc5c668e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation_b618caa8-28de-4718-aded-546c4d0ff872" xlink:href="cybn-20250331.xsd#cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:to="loc_cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation_b618caa8-28de-4718-aded-546c4d0ff872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfActivePatentFamilies_33e263eb-4108-4fc0-8a09-812e661693dd" xlink:href="cybn-20250331.xsd#cybn_NumberOfActivePatentFamilies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:to="loc_cybn_NumberOfActivePatentFamilies_33e263eb-4108-4fc0-8a09-812e661693dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfPendingPatentApplications_9e321ce0-c55e-4fc5-8490-2a87c3c0a787" xlink:href="cybn-20250331.xsd#cybn_NumberOfPendingPatentApplications"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:to="loc_cybn_NumberOfPendingPatentApplications_9e321ce0-c55e-4fc5-8490-2a87c3c0a787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfGrantedPatents_bda1b504-1205-423f-8a23-d374814337e5" xlink:href="cybn-20250331.xsd#cybn_NumberOfGrantedPatents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:to="loc_cybn_NumberOfGrantedPatents_bda1b504-1205-423f-8a23-d374814337e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_7515c412-4e45-476d-83ed-7bbdbeae9be4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:to="loc_ifrs-full_ProfitLoss_7515c412-4e45-476d-83ed-7bbdbeae9be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxLiabilityAsset_50f0754a-e3f9-47e5-887b-8d125edaadb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxLiabilityAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_32a36955-157a-4c27-b6e3-553b6656d971" xlink:to="loc_ifrs-full_DeferredTaxLiabilityAsset_50f0754a-e3f9-47e5-887b-8d125edaadb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#ACQUISITIONDetailsofacquisitionDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_8d2808ca-a3ce-49c4-9baf-8d79e5885415" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_4d9f55cc-9266-4950-a418-85b662405090" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_8d2808ca-a3ce-49c4-9baf-8d79e5885415" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_4d9f55cc-9266-4950-a418-85b662405090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_acb700bb-649e-4011-b2dd-526f0ad7af60" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_4d9f55cc-9266-4950-a418-85b662405090" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_acb700bb-649e-4011-b2dd-526f0ad7af60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_72268257-d34b-4381-a188-d934dd396051" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_acb700bb-649e-4011-b2dd-526f0ad7af60" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_72268257-d34b-4381-a188-d934dd396051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SmallPharmaInc.Member_0c1529cb-571c-44f5-b2b6-148cdbcc38bd" xlink:href="cybn-20250331.xsd#cybn_SmallPharmaInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_72268257-d34b-4381-a188-d934dd396051" xlink:to="loc_cybn_SmallPharmaInc.Member_0c1529cb-571c-44f5-b2b6-148cdbcc38bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_4d9f55cc-9266-4950-a418-85b662405090" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_2bfeed9e-191e-447d-975e-8e38e1f865c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred_2bfeed9e-191e-447d-975e-8e38e1f865c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CashRecognisedAsOfAcquisitionDate_3c576dd6-7449-44e9-bbab-4300b875f3dd" xlink:href="cybn-20250331.xsd#cybn_CashRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_cybn_CashRecognisedAsOfAcquisitionDate_3c576dd6-7449-44e9-bbab-4300b875f3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_b18ed717-42cf-48d3-86c8-cbdb56209b1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate_b18ed717-42cf-48d3-86c8-cbdb56209b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_11e68a06-69bd-41d2-8196-87bffba83477" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate_11e68a06-69bd-41d2-8196-87bffba83477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_f9c715fa-98f0-4605-a086-9b88cc3672c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_f9c715fa-98f0-4605-a086-9b88cc3672c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate_082e0ab6-b4c9-416e-b832-3cba84bab6cd" xlink:href="cybn-20250331.xsd#cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate_082e0ab6-b4c9-416e-b832-3cba84bab6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate_6b218e07-f7e1-4583-af09-c9331604b2d3" xlink:href="cybn-20250331.xsd#cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate_6b218e07-f7e1-4583-af09-c9331604b2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_b5f99f4d-865b-4186-ae86-6c14ad6c4c8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate_b5f99f4d-865b-4186-ae86-6c14ad6c4c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_5f7194c0-55b5-4287-99d3-841637d40836" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodwillRecognisedAsOfAcquisitionDate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate_5f7194c0-55b5-4287-99d3-841637d40836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_2d6b67e4-71a0-47fa-a744-833684446363" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_d8ea4151-f07b-4da2-b0a9-5d04d4406312" xlink:to="loc_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed_2d6b67e4-71a0-47fa-a744-833684446363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/ACQUISITIONResultssinceacquisitionDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#ACQUISITIONResultssinceacquisitionDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/ACQUISITIONResultssinceacquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_6eb0a418-a7e7-49d9-8d26-9a47d077f77e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_c7bc3553-723b-4d15-98a9-3365c10afe2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsAbstract_6eb0a418-a7e7-49d9-8d26-9a47d077f77e" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_c7bc3553-723b-4d15-98a9-3365c10afe2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsAxis_bc020ee8-73a1-45c1-8500-8aba4fc762e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_c7bc3553-723b-4d15-98a9-3365c10afe2c" xlink:to="loc_ifrs-full_BusinessCombinationsAxis_bc020ee8-73a1-45c1-8500-8aba4fc762e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BusinessCombinationsDomain_7d692414-9765-4417-b653-58ec7984e63e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BusinessCombinationsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsAxis_bc020ee8-73a1-45c1-8500-8aba4fc762e6" xlink:to="loc_ifrs-full_BusinessCombinationsDomain_7d692414-9765-4417-b653-58ec7984e63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SmallPharmaInc.Member_d75f942c-1c31-4ce9-a1bf-808ab5e4b774" xlink:href="cybn-20250331.xsd#cybn_SmallPharmaInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_BusinessCombinationsDomain_7d692414-9765-4417-b653-58ec7984e63e" xlink:to="loc_cybn_SmallPharmaInc.Member_d75f942c-1c31-4ce9-a1bf-808ab5e4b774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_4f50ca43-51ac-46a1-b369-f9d817bc02b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsTable_c7bc3553-723b-4d15-98a9-3365c10afe2c" xlink:to="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_4f50ca43-51ac-46a1-b369-f9d817bc02b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Revenue_3182ebd1-7292-41a5-a899-87c2d782c87d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_4f50ca43-51ac-46a1-b369-f9d817bc02b9" xlink:to="loc_ifrs-full_Revenue_3182ebd1-7292-41a5-a899-87c2d782c87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_10b47667-678d-4ccf-83cc-15c34e76af7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfBusinessCombinationsLineItems_4f50ca43-51ac-46a1-b369-f9d817bc02b9" xlink:to="loc_ifrs-full_ProfitLoss_10b47667-678d-4ccf-83cc-15c34e76af7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/EQUIPMENTDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#EQUIPMENTDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/EQUIPMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PropertyPlantAndEquipment1Abstract_487d2111-fdc7-4e1d-95d7-3b17ac6f9189" xlink:href="cybn-20250331.xsd#cybn_PropertyPlantAndEquipment1Abstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_84495ee5-2d1e-4062-9555-ce2437b97801" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_PropertyPlantAndEquipment1Abstract_487d2111-fdc7-4e1d-95d7-3b17ac6f9189" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_84495ee5-2d1e-4062-9555-ce2437b97801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_e90a3df3-f5c4-4b10-a67d-33b90e635fc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_84495ee5-2d1e-4062-9555-ce2437b97801" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_e90a3df3-f5c4-4b10-a67d-33b90e635fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_880bc53a-4e11-48de-a83c-3c38bfdf1b90" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_e90a3df3-f5c4-4b10-a67d-33b90e635fc3" xlink:to="loc_ifrs-full_CarryingAmountMember_880bc53a-4e11-48de-a83c-3c38bfdf1b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_513e83af-dd35-4442-8efc-71bdbc8b34ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_880bc53a-4e11-48de-a83c-3c38bfdf1b90" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_513e83af-dd35-4442-8efc-71bdbc8b34ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_670359ae-ea2e-49ad-bd6c-d415565a3396" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_880bc53a-4e11-48de-a83c-3c38bfdf1b90" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_670359ae-ea2e-49ad-bd6c-d415565a3396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_71526c85-ecdd-4780-b3e5-00475919d3aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_84495ee5-2d1e-4062-9555-ce2437b97801" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_71526c85-ecdd-4780-b3e5-00475919d3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_cead900f-60e1-4814-bb05-eee1b960e1e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_71526c85-ecdd-4780-b3e5-00475919d3aa" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_cead900f-60e1-4814-bb05-eee1b960e1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LaboratoryEquipmentMember_ff8b67f9-686e-4cfc-a876-495c74b66165" xlink:href="cybn-20250331.xsd#cybn_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_cead900f-60e1-4814-bb05-eee1b960e1e4" xlink:to="loc_cybn_LaboratoryEquipmentMember_ff8b67f9-686e-4cfc-a876-495c74b66165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_b3aa9ea2-9b3a-4147-b39f-640b9510c863" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_cead900f-60e1-4814-bb05-eee1b960e1e4" xlink:to="loc_ifrs-full_ComputerEquipmentMember_b3aa9ea2-9b3a-4147-b39f-640b9510c863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_62f2d3b0-8ab8-448d-9905-42dce88d7a4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_84495ee5-2d1e-4062-9555-ce2437b97801" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_62f2d3b0-8ab8-448d-9905-42dce88d7a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_429776f0-159a-4536-95ad-03c574f895ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_62f2d3b0-8ab8-448d-9905-42dce88d7a4c" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_429776f0-159a-4536-95ad-03c574f895ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_6bbcc87e-6f8e-45da-a476-400332129337" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_429776f0-159a-4536-95ad-03c574f895ab" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_6bbcc87e-6f8e-45da-a476-400332129337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_8807c196-3da3-4278-a362-189022c3f1e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_429776f0-159a-4536-95ad-03c574f895ab" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_8807c196-3da3-4278-a362-189022c3f1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_18003e19-ae7c-4629-a294-1c2b82131199" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_429776f0-159a-4536-95ad-03c574f895ab" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment_18003e19-ae7c-4629-a294-1c2b82131199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_f7c364c3-0168-4dd2-b06f-9400a2a4d388" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_429776f0-159a-4536-95ad-03c574f895ab" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_f7c364c3-0168-4dd2-b06f-9400a2a4d388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_70f92b26-0a4a-4d21-ab30-7907b87a1730" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_429776f0-159a-4536-95ad-03c574f895ab" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_70f92b26-0a4a-4d21-ab30-7907b87a1730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_1f1af418-bd41-47f5-b43f-1195b464bf75" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_429776f0-159a-4536-95ad-03c574f895ab" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_1f1af418-bd41-47f5-b43f-1195b464bf75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_9f771399-7611-4ec7-9be4-7f4987ff6aaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_429776f0-159a-4536-95ad-03c574f895ab" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_9f771399-7611-4ec7-9be4-7f4987ff6aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_180e9783-b5ec-4a4f-a40e-14256360c35f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_62f2d3b0-8ab8-448d-9905-42dce88d7a4c" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_180e9783-b5ec-4a4f-a40e-14256360c35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/INTANGIBLEASSETSDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#INTANGIBLEASSETSDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/INTANGIBLEASSETSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IntangibleAssetsAbstract_a497ab68-8d2a-47f7-b45e-8f33b72a5b7c" xlink:href="cybn-20250331.xsd#cybn_IntangibleAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_11946242-9757-48cd-a93f-72284f8afade" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IntangibleAssetsAbstract_a497ab68-8d2a-47f7-b45e-8f33b72a5b7c" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_11946242-9757-48cd-a93f-72284f8afade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fb09541c-2f8a-4096-913c-fceaa6824e00" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_11946242-9757-48cd-a93f-72284f8afade" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fb09541c-2f8a-4096-913c-fceaa6824e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_aa5b11ff-98ff-4743-8b70-9d7f06ee9fcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_fb09541c-2f8a-4096-913c-fceaa6824e00" xlink:to="loc_ifrs-full_CarryingAmountMember_aa5b11ff-98ff-4743-8b70-9d7f06ee9fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_af485f6d-ae72-4a75-9c40-86b6c8c1d5a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_aa5b11ff-98ff-4743-8b70-9d7f06ee9fcf" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_af485f6d-ae72-4a75-9c40-86b6c8c1d5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_1e30031e-f05a-4927-bbf9-35034e719db6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_aa5b11ff-98ff-4743-8b70-9d7f06ee9fcf" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_1e30031e-f05a-4927-bbf9-35034e719db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_aa25a898-cdfc-4d7b-b0e6-ffc0cfd90892" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_11946242-9757-48cd-a93f-72284f8afade" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_aa25a898-cdfc-4d7b-b0e6-ffc0cfd90892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_1add896e-5934-4492-bc4f-a49486c943c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_aa25a898-cdfc-4d7b-b0e6-ffc0cfd90892" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_1add896e-5934-4492-bc4f-a49486c943c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_38994f85-1af8-4bf5-9a7c-ec83013e3689" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsUnderDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_1add896e-5934-4492-bc4f-a49486c943c0" xlink:to="loc_ifrs-full_IntangibleAssetsUnderDevelopmentMember_38994f85-1af8-4bf5-9a7c-ec83013e3689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_bea168fd-fb80-485d-ae56-f8cccb544fae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_1add896e-5934-4492-bc4f-a49486c943c0" xlink:to="loc_ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember_bea168fd-fb80-485d-ae56-f8cccb544fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LicencesMember_c94ea0f8-e463-445b-a9fd-fa4aa70799e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LicencesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_1add896e-5934-4492-bc4f-a49486c943c0" xlink:to="loc_ifrs-full_LicencesMember_c94ea0f8-e463-445b-a9fd-fa4aa70799e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerSoftwareMember_972a30a5-99a3-45b6-b949-93bc1bf40b47" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerSoftwareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain_1add896e-5934-4492-bc4f-a49486c943c0" xlink:to="loc_ifrs-full_ComputerSoftwareMember_972a30a5-99a3-45b6-b949-93bc1bf40b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_de961345-c976-4991-b8c3-256028f9a4bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_11946242-9757-48cd-a93f-72284f8afade" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_de961345-c976-4991-b8c3-256028f9a4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_27ab10c3-3a36-4d58-9f66-f0583401cce7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_de961345-c976-4991-b8c3-256028f9a4bf" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_27ab10c3-3a36-4d58-9f66-f0583401cce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1c4ccce2-def8-4028-9870-a1d34853e22f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_27ab10c3-3a36-4d58-9f66-f0583401cce7" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1c4ccce2-def8-4028-9870-a1d34853e22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_db653c35-dcdc-41aa-aef2-615b3b74dfce" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_11946242-9757-48cd-a93f-72284f8afade" xlink:to="loc_ifrs-full_UnobservableInputsAxis_db653c35-dcdc-41aa-aef2-615b3b74dfce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_0df21af0-3734-47e1-acab-154b20cac804" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_db653c35-dcdc-41aa-aef2-615b3b74dfce" xlink:to="loc_ifrs-full_UnobservableInputsDomain_0df21af0-3734-47e1-acab-154b20cac804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember_8af7e745-2ae7-49d5-9cc8-e10867347f75" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DiscountRateMeasurementInputMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_0df21af0-3734-47e1-acab-154b20cac804" xlink:to="loc_ifrs-full_DiscountRateMeasurementInputMember_8af7e745-2ae7-49d5-9cc8-e10867347f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_021d17c6-f8e5-46a0-b9da-cb7cd2e2e215" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsTable_11946242-9757-48cd-a93f-72284f8afade" xlink:to="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_021d17c6-f8e5-46a0-b9da-cb7cd2e2e215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_76ccbcfa-e86a-46c9-b142-aa7f1031c196" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_021d17c6-f8e5-46a0-b9da-cb7cd2e2e215" xlink:to="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_76ccbcfa-e86a-46c9-b142-aa7f1031c196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_ec6503e2-3dd3-4535-a5a7-e473ba30f431" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_76ccbcfa-e86a-46c9-b142-aa7f1031c196" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_ec6503e2-3dd3-4535-a5a7-e473ba30f431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_ae55e1ff-0049-4d71-9fe7-a5847f581c87" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_76ccbcfa-e86a-46c9-b142-aa7f1031c196" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_ae55e1ff-0049-4d71-9fe7-a5847f581c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_8ca575ea-2524-4ec6-b441-eb460708bc58" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_76ccbcfa-e86a-46c9-b142-aa7f1031c196" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_8ca575ea-2524-4ec6-b441-eb460708bc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_911cb76e-cd64-4fd0-ae5d-c30d53cf700d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_76ccbcfa-e86a-46c9-b142-aa7f1031c196" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_911cb76e-cd64-4fd0-ae5d-c30d53cf700d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_6a5ee886-3971-4473-906c-31e7bb6a0695" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_76ccbcfa-e86a-46c9-b142-aa7f1031c196" xlink:to="loc_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_6a5ee886-3971-4473-906c-31e7bb6a0695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_3a10d331-03aa-4f4b-807c-cbd6e47c30d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_76ccbcfa-e86a-46c9-b142-aa7f1031c196" xlink:to="loc_ifrs-full_IntangibleAssetsOtherThanGoodwill_3a10d331-03aa-4f4b-807c-cbd6e47c30d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputAssets_4e500f88-3c0f-47d5-9f7e-1e0032543943" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantUnobservableInputAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_021d17c6-f8e5-46a0-b9da-cb7cd2e2e215" xlink:to="loc_ifrs-full_SignificantUnobservableInputAssets_4e500f88-3c0f-47d5-9f7e-1e0032543943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_a5c9ecdd-c333-4ae7-9079-143b36a31522" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfIntangibleAssetsLineItems_021d17c6-f8e5-46a0-b9da-cb7cd2e2e215" xlink:to="loc_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill_a5c9ecdd-c333-4ae7-9079-143b36a31522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESNarrativeDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#RIGHTOFUSEASSETSANDLEASELIABILITIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_e43faed6-1098-40c3-b8a4-ae2f9e5f3e65" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GainLossOnDerecognitionOfRightOfUseAssets_6c14022c-864f-4cc2-ab7f-d987c13fbb13" xlink:href="cybn-20250331.xsd#cybn_GainLossOnDerecognitionOfRightOfUseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_e43faed6-1098-40c3-b8a4-ae2f9e5f3e65" xlink:to="loc_cybn_GainLossOnDerecognitionOfRightOfUseAssets_6c14022c-864f-4cc2-ab7f-d987c13fbb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GainLossOnDerecognitionOfLeaseLiability_1b4b59ec-701f-4fed-9577-e0c4f3d2e071" xlink:href="cybn-20250331.xsd#cybn_GainLossOnDerecognitionOfLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_e43faed6-1098-40c3-b8a4-ae2f9e5f3e65" xlink:to="loc_cybn_GainLossOnDerecognitionOfLeaseLiability_1b4b59ec-701f-4fed-9577-e0c4f3d2e071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherExpenseByNature_2c869b6c-f4ac-4e72-ab8e-193390101d59" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherExpenseByNature"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_e43faed6-1098-40c3-b8a4-ae2f9e5f3e65" xlink:to="loc_ifrs-full_OtherExpenseByNature_2c869b6c-f4ac-4e72-ab8e-193390101d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_556591f2-8ea7-47c2-be18-6ed3cc8602df" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_c1e6e5cf-ba1f-461c-886e-33513bace0e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_556591f2-8ea7-47c2-be18-6ed3cc8602df" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_c1e6e5cf-ba1f-461c-886e-33513bace0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_eac35f7e-579e-4227-a0f2-aedaa85d3551" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_c1e6e5cf-ba1f-461c-886e-33513bace0e7" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_eac35f7e-579e-4227-a0f2-aedaa85d3551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_0ea41083-2893-4df4-9c5f-1855e06ed530" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_eac35f7e-579e-4227-a0f2-aedaa85d3551" xlink:to="loc_ifrs-full_CarryingAmountMember_0ea41083-2893-4df4-9c5f-1855e06ed530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_d6c0ba82-036e-4644-9971-449313f21ff2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_0ea41083-2893-4df4-9c5f-1855e06ed530" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_d6c0ba82-036e-4644-9971-449313f21ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_c66541e3-4f0a-4e65-a195-2757d74c689e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_0ea41083-2893-4df4-9c5f-1855e06ed530" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_c66541e3-4f0a-4e65-a195-2757d74c689e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_7a91f427-fda4-47bb-9ddb-9e59ccd5aed7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_c1e6e5cf-ba1f-461c-886e-33513bace0e7" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_7a91f427-fda4-47bb-9ddb-9e59ccd5aed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_cd0af7f8-f025-4138-945a-d36094addd55" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_7a91f427-fda4-47bb-9ddb-9e59ccd5aed7" xlink:to="loc_ifrs-full_RightofuseAssets_cd0af7f8-f025-4138-945a-d36094addd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_2ce5e022-75c2-4d8a-9b77-de08275943ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_7a91f427-fda4-47bb-9ddb-9e59ccd5aed7" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_2ce5e022-75c2-4d8a-9b77-de08275943ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_EffectOfForeignExchangeRightOfUseAssets_8683ea33-4a4e-45cc-ac80-88c411ce0366" xlink:href="cybn-20250331.xsd#cybn_EffectOfForeignExchangeRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_7a91f427-fda4-47bb-9ddb-9e59ccd5aed7" xlink:to="loc_cybn_EffectOfForeignExchangeRightOfUseAssets_8683ea33-4a4e-45cc-ac80-88c411ce0366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsRightofuseAssets_f22addcb-6830-4739-811c-11b4b169be63" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsRightofuseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_7a91f427-fda4-47bb-9ddb-9e59ccd5aed7" xlink:to="loc_ifrs-full_DisposalsRightofuseAssets_f22addcb-6830-4739-811c-11b4b169be63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_4ef6583a-1f16-410a-9865-bb1be2eebcbd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_7a91f427-fda4-47bb-9ddb-9e59ccd5aed7" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_4ef6583a-1f16-410a-9865-bb1be2eebcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_296c4f39-0902-40b1-8a72-d178b2324438" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_7a91f427-fda4-47bb-9ddb-9e59ccd5aed7" xlink:to="loc_ifrs-full_RightofuseAssets_296c4f39-0902-40b1-8a72-d178b2324438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESLeaseliabilitiesDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#RIGHTOFUSEASSETSANDLEASELIABILITIESLeaseliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESLeaseliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_fc7718da-bc7a-4f33-b9c8-3a8c2a72e9ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_48031e92-02c9-46af-b114-c3471301e34e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_fc7718da-bc7a-4f33-b9c8-3a8c2a72e9ba" xlink:to="loc_ifrs-full_LeaseLiabilities_48031e92-02c9-46af-b114-c3471301e34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdditionsToLeaseLiabilities_d489a7ba-1e3a-451e-bcf8-3b2856ecc91e" xlink:href="cybn-20250331.xsd#cybn_AdditionsToLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_fc7718da-bc7a-4f33-b9c8-3a8c2a72e9ba" xlink:to="loc_cybn_AdditionsToLeaseLiabilities_d489a7ba-1e3a-451e-bcf8-3b2856ecc91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_e7b02093-bb53-45f0-ac64-b681772642c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_fc7718da-bc7a-4f33-b9c8-3a8c2a72e9ba" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_e7b02093-bb53-45f0-ac64-b681772642c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_EffectOfForeignExchangeLeaseLiabilities_439056bc-a0d3-46b7-af4c-b8a10a17da16" xlink:href="cybn-20250331.xsd#cybn_EffectOfForeignExchangeLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_fc7718da-bc7a-4f33-b9c8-3a8c2a72e9ba" xlink:to="loc_cybn_EffectOfForeignExchangeLeaseLiabilities_439056bc-a0d3-46b7-af4c-b8a10a17da16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GainLossOnDerecognitionOfLeaseLiability_f135d30d-28d6-43e8-83c6-92fd3cfcff4f" xlink:href="cybn-20250331.xsd#cybn_GainLossOnDerecognitionOfLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_fc7718da-bc7a-4f33-b9c8-3a8c2a72e9ba" xlink:to="loc_cybn_GainLossOnDerecognitionOfLeaseLiability_f135d30d-28d6-43e8-83c6-92fd3cfcff4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PaymentForTerminationPenaltyLeaseLiability_09b0a205-c7f1-44b8-90bc-57e900944fa5" xlink:href="cybn-20250331.xsd#cybn_PaymentForTerminationPenaltyLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_fc7718da-bc7a-4f33-b9c8-3a8c2a72e9ba" xlink:to="loc_cybn_PaymentForTerminationPenaltyLeaseLiability_09b0a205-c7f1-44b8-90bc-57e900944fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PaymentsOfLeaseLiabilities_394e1c15-460b-4717-9bf2-3970ee0a1e26" xlink:href="cybn-20250331.xsd#cybn_PaymentsOfLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_fc7718da-bc7a-4f33-b9c8-3a8c2a72e9ba" xlink:to="loc_cybn_PaymentsOfLeaseLiabilities_394e1c15-460b-4717-9bf2-3970ee0a1e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_0bd04296-dc18-4581-93c6-1b3dc6bff071" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_fc7718da-bc7a-4f33-b9c8-3a8c2a72e9ba" xlink:to="loc_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_0bd04296-dc18-4581-93c6-1b3dc6bff071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_fdbf8e68-4f7d-43cf-a2e1-697c2a6330ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_fc7718da-bc7a-4f33-b9c8-3a8c2a72e9ba" xlink:to="loc_ifrs-full_LeaseLiabilities_fdbf8e68-4f7d-43cf-a2e1-697c2a6330ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/GOODWILLDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#GOODWILLDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/GOODWILLDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GoodwillAbstract_c8543bdf-dfc2-4edb-8e20-698ebf0525e7" xlink:href="cybn-20250331.xsd#cybn_GoodwillAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_6bc7ec0a-a5a1-422d-8e1e-77a121d49d52" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_GoodwillAbstract_c8543bdf-dfc2-4edb-8e20-698ebf0525e7" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_6bc7ec0a-a5a1-422d-8e1e-77a121d49d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ae68e498-f657-4a53-b305-0dc681ae8ad5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_6bc7ec0a-a5a1-422d-8e1e-77a121d49d52" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ae68e498-f657-4a53-b305-0dc681ae8ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain_6067b9ac-c9c9-4c0c-8462-93ffc3d4e826" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_ae68e498-f657-4a53-b305-0dc681ae8ad5" xlink:to="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain_6067b9ac-c9c9-4c0c-8462-93ffc3d4e826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember_d128de12-31b9-4fc7-847e-46698cbf97d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain_6067b9ac-c9c9-4c0c-8462-93ffc3d4e826" xlink:to="loc_ifrs-full_GoodwillMember_d128de12-31b9-4fc7-847e-46698cbf97d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsAxis_3a9fa964-3546-4ed8-b199-4381e257e745" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_6bc7ec0a-a5a1-422d-8e1e-77a121d49d52" xlink:to="loc_ifrs-full_ClassesOfAssetsAxis_3a9fa964-3546-4ed8-b199-4381e257e745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfAssetsDomain_2bd17d61-beb3-4291-b7f3-e19dc6152f01" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsAxis_3a9fa964-3546-4ed8-b199-4381e257e745" xlink:to="loc_ifrs-full_ClassesOfAssetsDomain_2bd17d61-beb3-4291-b7f3-e19dc6152f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GoodwillMember_bf1a46c9-df0e-4ee9-b773-3b320f3088da" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodwillMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfAssetsDomain_2bd17d61-beb3-4291-b7f3-e19dc6152f01" xlink:to="loc_ifrs-full_GoodwillMember_bf1a46c9-df0e-4ee9-b773-3b320f3088da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsAxis_a65cf71c-dafa-430a-9492-2e9b2b0a7430" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_6bc7ec0a-a5a1-422d-8e1e-77a121d49d52" xlink:to="loc_ifrs-full_UnobservableInputsAxis_a65cf71c-dafa-430a-9492-2e9b2b0a7430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnobservableInputsDomain_bca530af-92df-478b-bc89-71d642b8289e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsAxis_a65cf71c-dafa-430a-9492-2e9b2b0a7430" xlink:to="loc_ifrs-full_UnobservableInputsDomain_bca530af-92df-478b-bc89-71d642b8289e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DiscountRateMeasurementInputMember_29e2ae26-289f-4294-9dd6-8247c104964e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DiscountRateMeasurementInputMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_UnobservableInputsDomain_bca530af-92df-478b-bc89-71d642b8289e" xlink:to="loc_ifrs-full_DiscountRateMeasurementInputMember_29e2ae26-289f-4294-9dd6-8247c104964e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_999850b2-d1f7-449c-bf09-b87a670562bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable_6bc7ec0a-a5a1-422d-8e1e-77a121d49d52" xlink:to="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_999850b2-d1f7-449c-bf09-b87a670562bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract_2572ce3d-bcb2-4f63-bff1-7f44c0b5c67c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_999850b2-d1f7-449c-bf09-b87a670562bf" xlink:to="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract_2572ce3d-bcb2-4f63-bff1-7f44c0b5c67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_e2aa4aa2-5554-4bf0-b98c-3f11a48788b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract_2572ce3d-bcb2-4f63-bff1-7f44c0b5c67c" xlink:to="loc_ifrs-full_Goodwill_e2aa4aa2-5554-4bf0-b98c-3f11a48788b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_b3c200b6-dd53-48bd-b7ce-121511c5b13f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract_2572ce3d-bcb2-4f63-bff1-7f44c0b5c67c" xlink:to="loc_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill_b3c200b6-dd53-48bd-b7ce-121511c5b13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_3067c5ad-5be0-451c-8f89-4101fda3fe57" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract_2572ce3d-bcb2-4f63-bff1-7f44c0b5c67c" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill_3067c5ad-5be0-451c-8f89-4101fda3fe57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Goodwill_1435059d-c050-4765-a54e-0f88148d5ce2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract_2572ce3d-bcb2-4f63-bff1-7f44c0b5c67c" xlink:to="loc_ifrs-full_Goodwill_1435059d-c050-4765-a54e-0f88148d5ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SignificantUnobservableInputAssets_4cf1bbff-466f-4d5a-92f6-dc9f078df569" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SignificantUnobservableInputAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_999850b2-d1f7-449c-bf09-b87a670562bf" xlink:to="loc_ifrs-full_SignificantUnobservableInputAssets_4cf1bbff-466f-4d5a-92f6-dc9f078df569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_5dd17671-efe8-4df8-8425-5891d90eaa0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems_999850b2-d1f7-449c-bf09-b87a670562bf" xlink:to="loc_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill_5dd17671-efe8-4df8-8425-5891d90eaa0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALNarrativeIssuedShareCapitalDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_c8373b69-002a-408a-8530-b8619de2c41f" xlink:href="cybn-20250331.xsd#cybn_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_f01e5a71-7699-4558-987c-1272297d854d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_c8373b69-002a-408a-8530-b8619de2c41f" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_f01e5a71-7699-4558-987c-1272297d854d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_2910c021-f9c7-44ad-b713-43b61fc119ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_f01e5a71-7699-4558-987c-1272297d854d" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_2910c021-f9c7-44ad-b713-43b61fc119ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_dec052ab-49c2-4ab0-bea8-867140920496" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_2910c021-f9c7-44ad-b713-43b61fc119ec" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_dec052ab-49c2-4ab0-bea8-867140920496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_46125989-5db9-483c-b78f-ced8ab04a6e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_dec052ab-49c2-4ab0-bea8-867140920496" xlink:to="loc_ifrs-full_IssuedCapitalMember_46125989-5db9-483c-b78f-ced8ab04a6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_8c127ff0-d497-4e06-9e4b-07ae6f92a9bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_f01e5a71-7699-4558-987c-1272297d854d" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_8c127ff0-d497-4e06-9e4b-07ae6f92a9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_2414782e-d8ad-400d-8f3b-f96fccc2bdea" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_8c127ff0-d497-4e06-9e4b-07ae6f92a9bb" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_2414782e-d8ad-400d-8f3b-f96fccc2bdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_09a4083d-53f0-4fd9-83e1-2a87e7207ab1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_2414782e-d8ad-400d-8f3b-f96fccc2bdea" xlink:to="loc_ifrs-full_OrdinarySharesMember_09a4083d-53f0-4fd9-83e1-2a87e7207ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PreferenceSharesMember_4bb62c60-4451-4c99-9761-a46a547c369a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PreferenceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_2414782e-d8ad-400d-8f3b-f96fccc2bdea" xlink:to="loc_ifrs-full_PreferenceSharesMember_4bb62c60-4451-4c99-9761-a46a547c369a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassBSharesMember_796e6c9c-dac7-437f-b629-c0e296ae1742" xlink:href="cybn-20250331.xsd#cybn_ClassBSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_2414782e-d8ad-400d-8f3b-f96fccc2bdea" xlink:to="loc_cybn_ClassBSharesMember_796e6c9c-dac7-437f-b629-c0e296ae1742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_8cf2423a-b207-4454-813c-19e49d9db341" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_f01e5a71-7699-4558-987c-1272297d854d" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_8cf2423a-b207-4454-813c-19e49d9db341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6e7f331e-45bc-4b4c-95b1-ca4e0693df46" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_8cf2423a-b207-4454-813c-19e49d9db341" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6e7f331e-45bc-4b4c-95b1-ca4e0693df46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LPCPurchaseAgreementMember_ba2534d7-d1a8-4932-9983-46c7da3c8db8" xlink:href="cybn-20250331.xsd#cybn_LPCPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6e7f331e-45bc-4b4c-95b1-ca4e0693df46" xlink:to="loc_cybn_LPCPurchaseAgreementMember_ba2534d7-d1a8-4932-9983-46c7da3c8db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_August2023CompensationCommonShareWarrantMember_e9b4dcb3-c207-4f02-acf6-289ba11df994" xlink:href="cybn-20250331.xsd#cybn_August2023CompensationCommonShareWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6e7f331e-45bc-4b4c-95b1-ca4e0693df46" xlink:to="loc_cybn_August2023CompensationCommonShareWarrantMember_e9b4dcb3-c207-4f02-acf6-289ba11df994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_November2023CompensationCommonShareWarrantMember_c971d1a0-b3a5-43a3-bd10-9fe3377a1c1b" xlink:href="cybn-20250331.xsd#cybn_November2023CompensationCommonShareWarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6e7f331e-45bc-4b4c-95b1-ca4e0693df46" xlink:to="loc_cybn_November2023CompensationCommonShareWarrantMember_c971d1a0-b3a5-43a3-bd10-9fe3377a1c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_March2024PrivatePlacementMember_b3770b95-a298-4761-94f2-53bd3344df26" xlink:href="cybn-20250331.xsd#cybn_March2024PrivatePlacementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6e7f331e-45bc-4b4c-95b1-ca4e0693df46" xlink:to="loc_cybn_March2024PrivatePlacementMember_b3770b95-a298-4761-94f2-53bd3344df26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_f01e5a71-7699-4558-987c-1272297d854d" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfCommonSharesHeldInEscrow_23e70713-5134-4b9b-b31a-3f7c70042cd9" xlink:href="cybn-20250331.xsd#cybn_NumberOfCommonSharesHeldInEscrow"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_NumberOfCommonSharesHeldInEscrow_23e70713-5134-4b9b-b31a-3f7c70042cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommonStockSharesAuthorizedValue_48be67bf-948d-4eb2-be8a-d249e8ef11ef" xlink:href="cybn-20250331.xsd#cybn_CommonStockSharesAuthorizedValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_CommonStockSharesAuthorizedValue_48be67bf-948d-4eb2-be8a-d249e8ef11ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughShareOfferingEquity_c508c8eb-644a-4aac-a59b-712be43391c3" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughShareOfferingEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_NumberOfSharesIssuedThroughShareOfferingEquity_c508c8eb-644a-4aac-a59b-712be43391c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SharePricePerCommonShare_6def5f15-8400-4f32-b2a7-b03e17687442" xlink:href="cybn-20250331.xsd#cybn_SharePricePerCommonShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_SharePricePerCommonShare_6def5f15-8400-4f32-b2a7-b03e17687442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_7b9ef9c8-f8ec-48cc-ad64-c1e0bdf303b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_7b9ef9c8-f8ec-48cc-ad64-c1e0bdf303b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PaymentsForShareIssueCosts_cf6c4c8a-156b-4d06-8f95-c2a51ec50601" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_ifrs-full_PaymentsForShareIssueCosts_cf6c4c8a-156b-4d06-8f95-c2a51ec50601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughShareConsolidationEquity_ce228016-c4f8-495b-879a-be9d68c4f0f6" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughShareConsolidationEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_IncreaseDecreaseThroughShareConsolidationEquity_ce228016-c4f8-495b-879a-be9d68c4f0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommonSharesPurchasePeriodTerm_3a38ea32-ee1e-4716-b0f0-8594e0c59974" xlink:href="cybn-20250331.xsd#cybn_CommonSharesPurchasePeriodTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_CommonSharesPurchasePeriodTerm_3a38ea32-ee1e-4716-b0f0-8594e0c59974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PercentageOfOutstandingCommonSharesOwn_bb55a4c6-e46c-478e-bc58-1f5d2d1963c5" xlink:href="cybn-20250331.xsd#cybn_PercentageOfOutstandingCommonSharesOwn"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_PercentageOfOutstandingCommonSharesOwn_bb55a4c6-e46c-478e-bc58-1f5d2d1963c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement_74978a8d-37f6-4250-824a-e6648892b50d" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement_74978a8d-37f6-4250-824a-e6648892b50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement_e9b3b574-d1be-45e4-8855-6a0d1cc40f99" xlink:href="cybn-20250331.xsd#cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement_e9b3b574-d1be-45e4-8855-6a0d1cc40f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement_279867c8-2c9d-4aaa-a226-e6b928e2e59a" xlink:href="cybn-20250331.xsd#cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement_279867c8-2c9d-4aaa-a226-e6b928e2e59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_55988720-26bc-49bd-aebe-865a909e402f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_ifrs-full_ProfessionalFeesExpense_55988720-26bc-49bd-aebe-865a909e402f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfCommonShares_144c819e-d085-4d9a-b2c0-de2fe26e52c5" xlink:href="cybn-20250331.xsd#cybn_NumberOfCommonShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_NumberOfCommonShares_144c819e-d085-4d9a-b2c0-de2fe26e52c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfCommonSharePurchaseWarrants_5555ba96-99ad-44df-a18e-a831f0e8cf7d" xlink:href="cybn-20250331.xsd#cybn_NumberOfCommonSharePurchaseWarrants"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_NumberOfCommonSharePurchaseWarrants_5555ba96-99ad-44df-a18e-a831f0e8cf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesSubjectToResaleRestrictions_d2f4b7f9-44ec-4018-9e92-ccd367baa554" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesSubjectToResaleRestrictions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_NumberOfSharesSubjectToResaleRestrictions_d2f4b7f9-44ec-4018-9e92-ccd367baa554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_129f059a-c4b4-43fc-beea-fcd9c884a80e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_129f059a-c4b4-43fc-beea-fcd9c884a80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments_146f50cb-a7ff-48a2-b746-955282faaf96" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments_146f50cb-a7ff-48a2-b746-955282faaf96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommonSharesExchangeRate_2d07df63-a0db-4fd7-8adb-42a8a81911be" xlink:href="cybn-20250331.xsd#cybn_CommonSharesExchangeRate"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_CommonSharesExchangeRate_2d07df63-a0db-4fd7-8adb-42a8a81911be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity_79fcd894-b5f1-4304-869a-44f0e585b0ab" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity_79fcd894-b5f1-4304-869a-44f0e585b0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity_0464711f-cab5-453b-a442-0f621c755cc4" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6a870a2c-6465-4fb5-a2ff-da98b8931d26" xlink:to="loc_cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity_0464711f-cab5-453b-a442-0f621c755cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALSummaryofsharecapitalDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALSummaryofsharecapitalDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/SHARECAPITALSummaryofsharecapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_2dd912d5-8580-438a-a836-24f7fcfe0cad" xlink:href="cybn-20250331.xsd#cybn_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_eb342b97-2c02-4346-aee4-a8b5cbcf2d54" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_2dd912d5-8580-438a-a836-24f7fcfe0cad" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_eb342b97-2c02-4346-aee4-a8b5cbcf2d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_d58a6d6e-8e20-4acd-9381-02cf195bb9ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_eb342b97-2c02-4346-aee4-a8b5cbcf2d54" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_d58a6d6e-8e20-4acd-9381-02cf195bb9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_54ea4c81-df52-4221-b30d-2d9f97653475" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_d58a6d6e-8e20-4acd-9381-02cf195bb9ae" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_54ea4c81-df52-4221-b30d-2d9f97653475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassBSharesMember_ab1207bb-800a-4cb1-b4c1-d10dbdbb74a6" xlink:href="cybn-20250331.xsd#cybn_ClassBSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_54ea4c81-df52-4221-b30d-2d9f97653475" xlink:to="loc_cybn_ClassBSharesMember_ab1207bb-800a-4cb1-b4c1-d10dbdbb74a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e518f3f-79b8-443a-91cc-f9741a0da24b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_eb342b97-2c02-4346-aee4-a8b5cbcf2d54" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e518f3f-79b8-443a-91cc-f9741a0da24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_e7633d0b-b846-479a-b478-b06dd121371c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e518f3f-79b8-443a-91cc-f9741a0da24b" xlink:to="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_e7633d0b-b846-479a-b478-b06dd121371c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_1419fa0d-bd1a-4564-ad35-21d3349d8152" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_e7633d0b-b846-479a-b478-b06dd121371c" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_1419fa0d-bd1a-4564-ad35-21d3349d8152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares_ac219544-4652-4270-ad5b-36fb3dbdefeb" xlink:href="cybn-20250331.xsd#cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_e7633d0b-b846-479a-b478-b06dd121371c" xlink:to="loc_cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares_ac219544-4652-4270-ad5b-36fb3dbdefeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesOutstanding_cd669531-8e69-4591-a613-646965f29643" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract_e7633d0b-b846-479a-b478-b06dd121371c" xlink:to="loc_ifrs-full_NumberOfSharesOutstanding_cd669531-8e69-4591-a613-646965f29643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALSummaryofwarrantsDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_b8afa0da-afe6-4776-a278-a7f9fcce0181" xlink:href="cybn-20250331.xsd#cybn_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_4aa0fcdc-f367-4f8f-a7ac-10dd6ad2b2cc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_b8afa0da-afe6-4776-a278-a7f9fcce0181" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_4aa0fcdc-f367-4f8f-a7ac-10dd6ad2b2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fa5b7b9d-2691-4bc1-90e9-58ce56d52a4c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_4aa0fcdc-f367-4f8f-a7ac-10dd6ad2b2cc" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fa5b7b9d-2691-4bc1-90e9-58ce56d52a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_1c66b12f-a381-47c2-978e-8f860b2d28c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_fa5b7b9d-2691-4bc1-90e9-58ce56d52a4c" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_1c66b12f-a381-47c2-978e-8f860b2d28c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommonSharePurchaseWarrantsMember_c47f0b2b-5044-4c7a-9f48-6a3c5a5178c7" xlink:href="cybn-20250331.xsd#cybn_CommonSharePurchaseWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_1c66b12f-a381-47c2-978e-8f860b2d28c5" xlink:to="loc_cybn_CommonSharePurchaseWarrantsMember_c47f0b2b-5044-4c7a-9f48-6a3c5a5178c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_UnitPurchaseWarrantsMember_d2ce4c42-3508-403f-83cc-a55632183c39" xlink:href="cybn-20250331.xsd#cybn_UnitPurchaseWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_1c66b12f-a381-47c2-978e-8f860b2d28c5" xlink:to="loc_cybn_UnitPurchaseWarrantsMember_d2ce4c42-3508-403f-83cc-a55632183c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec0a83b4-fc23-4702-aef7-c7c3955c4437" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_4aa0fcdc-f367-4f8f-a7ac-10dd6ad2b2cc" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec0a83b4-fc23-4702-aef7-c7c3955c4437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantsNumberOfSharesRollForward_09e8333e-02f1-484d-b608-d9a834686ae1" xlink:href="cybn-20250331.xsd#cybn_WarrantsNumberOfSharesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec0a83b4-fc23-4702-aef7-c7c3955c4437" xlink:to="loc_cybn_WarrantsNumberOfSharesRollForward_09e8333e-02f1-484d-b608-d9a834686ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_7f31b9eb-5b7b-4339-ae37-b9f5e51ffa53" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_WarrantsNumberOfSharesRollForward_09e8333e-02f1-484d-b608-d9a834686ae1" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_7f31b9eb-5b7b-4339-ae37-b9f5e51ffa53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement_e5a0bd37-4a00-4e88-8d02-bdc8cd84f3e0" xlink:href="cybn-20250331.xsd#cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_WarrantsNumberOfSharesRollForward_09e8333e-02f1-484d-b608-d9a834686ae1" xlink:to="loc_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement_e5a0bd37-4a00-4e88-8d02-bdc8cd84f3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_debea07f-b9e5-4e5a-9a46-eff05d18ab32" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_WarrantsNumberOfSharesRollForward_09e8333e-02f1-484d-b608-d9a834686ae1" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_debea07f-b9e5-4e5a-9a46-eff05d18ab32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_5f1b3be6-c318-41ac-83e5-6e4f360d841e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_WarrantsNumberOfSharesRollForward_09e8333e-02f1-484d-b608-d9a834686ae1" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_5f1b3be6-c318-41ac-83e5-6e4f360d841e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_d12e1b20-fe47-44ff-a2eb-cc1a333ed5ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_WarrantsNumberOfSharesRollForward_09e8333e-02f1-484d-b608-d9a834686ae1" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_d12e1b20-fe47-44ff-a2eb-cc1a333ed5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_a70c27fc-895d-48a1-8c76-ed565b724ab4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec0a83b4-fc23-4702-aef7-c7c3955c4437" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_a70c27fc-895d-48a1-8c76-ed565b724ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantsWeightedAverageExercisePriceRollForward_503b14fe-d905-4758-8ed5-a6d0d8e29005" xlink:href="cybn-20250331.xsd#cybn_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec0a83b4-fc23-4702-aef7-c7c3955c4437" xlink:to="loc_cybn_WarrantsWeightedAverageExercisePriceRollForward_503b14fe-d905-4758-8ed5-a6d0d8e29005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_6b83a1e8-abcd-4148-b2f0-064e27137e9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_WarrantsWeightedAverageExercisePriceRollForward_503b14fe-d905-4758-8ed5-a6d0d8e29005" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_6b83a1e8-abcd-4148-b2f0-064e27137e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement_000c5194-98f4-4577-a245-4f082847b0e7" xlink:href="cybn-20250331.xsd#cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_WarrantsWeightedAverageExercisePriceRollForward_503b14fe-d905-4758-8ed5-a6d0d8e29005" xlink:to="loc_cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement_000c5194-98f4-4577-a245-4f082847b0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_4ec808c6-8275-42b4-a7da-6bad9b838e6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_WarrantsWeightedAverageExercisePriceRollForward_503b14fe-d905-4758-8ed5-a6d0d8e29005" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_4ec808c6-8275-42b4-a7da-6bad9b838e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_702cb618-bef2-449b-87cd-1c5cb5c04661" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_WarrantsWeightedAverageExercisePriceRollForward_503b14fe-d905-4758-8ed5-a6d0d8e29005" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_702cb618-bef2-449b-87cd-1c5cb5c04661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_193d87ef-8e80-4ab3-840c-c9ffa221a5cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_WarrantsWeightedAverageExercisePriceRollForward_503b14fe-d905-4758-8ed5-a6d0d8e29005" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_193d87ef-8e80-4ab3-840c-c9ffa221a5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfCommonShares_1133b24a-25c2-4f7b-b5aa-d7c69ac87f0f" xlink:href="cybn-20250331.xsd#cybn_NumberOfCommonShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec0a83b4-fc23-4702-aef7-c7c3955c4437" xlink:to="loc_cybn_NumberOfCommonShares_1133b24a-25c2-4f7b-b5aa-d7c69ac87f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfCommonSharePurchaseWarrants_a340ef2b-5922-494d-be0b-c1a5a30d1870" xlink:href="cybn-20250331.xsd#cybn_NumberOfCommonSharePurchaseWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec0a83b4-fc23-4702-aef7-c7c3955c4437" xlink:to="loc_cybn_NumberOfCommonSharePurchaseWarrants_a340ef2b-5922-494d-be0b-c1a5a30d1870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement_a733ba28-8b8a-4209-8a98-ffe7fbdf6fe1" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec0a83b4-fc23-4702-aef7-c7c3955c4437" xlink:to="loc_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement_a733ba28-8b8a-4209-8a98-ffe7fbdf6fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_c2e83792-bf4a-4241-bb7c-1d50dcc84be5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_ec0a83b4-fc23-4702-aef7-c7c3955c4437" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_c2e83792-bf4a-4241-bb7c-1d50dcc84be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALNarrativeWarrantsDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_5e6f2211-e812-486a-9aaa-1b06a607646b" xlink:href="cybn-20250331.xsd#cybn_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c2eb40b9-5226-4613-a697-5437561e0207" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_5e6f2211-e812-486a-9aaa-1b06a607646b" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c2eb40b9-5226-4613-a697-5437561e0207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ab3047ce-10b2-4ced-b17e-97423365d06f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c2eb40b9-5226-4613-a697-5437561e0207" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ab3047ce-10b2-4ced-b17e-97423365d06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_2399f078-c350-4455-b0c5-a8e1ef21e733" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_ab3047ce-10b2-4ced-b17e-97423365d06f" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_2399f078-c350-4455-b0c5-a8e1ef21e733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommonSharePurchaseWarrantsMember_6a1625a8-11f7-41b4-9a50-ef5011bf590b" xlink:href="cybn-20250331.xsd#cybn_CommonSharePurchaseWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_2399f078-c350-4455-b0c5-a8e1ef21e733" xlink:to="loc_cybn_CommonSharePurchaseWarrantsMember_6a1625a8-11f7-41b4-9a50-ef5011bf590b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_August2023CompensationCommonShareWarrantMember_5b0c4c56-8118-43e2-8923-f5529b59a5f0" xlink:href="cybn-20250331.xsd#cybn_August2023CompensationCommonShareWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_2399f078-c350-4455-b0c5-a8e1ef21e733" xlink:to="loc_cybn_August2023CompensationCommonShareWarrantMember_5b0c4c56-8118-43e2-8923-f5529b59a5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_November2023CompensationCommonShareWarrantMember_e555e1e8-8e17-487a-bcac-e9b488cc7d7a" xlink:href="cybn-20250331.xsd#cybn_November2023CompensationCommonShareWarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_2399f078-c350-4455-b0c5-a8e1ef21e733" xlink:to="loc_cybn_November2023CompensationCommonShareWarrantMember_e555e1e8-8e17-487a-bcac-e9b488cc7d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrantedToOfficersAndDirectorsMember_1a82daf2-4db8-4841-a577-e142c0b6b883" xlink:href="cybn-20250331.xsd#cybn_GrantedToOfficersAndDirectorsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_2399f078-c350-4455-b0c5-a8e1ef21e733" xlink:to="loc_cybn_GrantedToOfficersAndDirectorsMember_1a82daf2-4db8-4841-a577-e142c0b6b883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_bdb4b59a-dbe9-4cb3-8b60-28824cd3cf7a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c2eb40b9-5226-4613-a697-5437561e0207" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_bdb4b59a-dbe9-4cb3-8b60-28824cd3cf7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_4ee999b8-9168-488c-8975-dfb98aec5f83" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_bdb4b59a-dbe9-4cb3-8b60-28824cd3cf7a" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_4ee999b8-9168-488c-8975-dfb98aec5f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantReserveMember_8a2d82ae-ff84-4215-b9b6-537fbc4da19e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantReserveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_4ee999b8-9168-488c-8975-dfb98aec5f83" xlink:to="loc_ifrs-full_WarrantReserveMember_8a2d82ae-ff84-4215-b9b6-537fbc4da19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_c2eb40b9-5226-4613-a697-5437561e0207" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_6d83fb8c-faaf-4b18-98c0-35f50a2ddac0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_6d83fb8c-faaf-4b18-98c0-35f50a2ddac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_2d49e21f-08b4-437a-a18a-6f6b78fe14c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_2d49e21f-08b4-437a-a18a-6f6b78fe14c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_6c1b92f1-5c86-4cdd-ac3b-540db1767273" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_6c1b92f1-5c86-4cdd-ac3b-540db1767273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_de07152d-dc14-4de4-b978-4ef0a9087d29" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_de07152d-dc14-4de4-b978-4ef0a9087d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement_5f3b353f-5aea-44b2-94c5-3326a3ab10de" xlink:href="cybn-20250331.xsd#cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement_5f3b353f-5aea-44b2-94c5-3326a3ab10de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_59ca9a01-7620-4026-bbbf-c1ef9310bb03" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_59ca9a01-7620-4026-bbbf-c1ef9310bb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement_9ee0a0ac-ee58-4353-b737-fd659601d736" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement_9ee0a0ac-ee58-4353-b737-fd659601d736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended_c3630154-5d53-40d5-a3e3-31e8645676c5" xlink:href="cybn-20250331.xsd#cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended_c3630154-5d53-40d5-a3e3-31e8645676c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_4d48f21f-db95-4b9b-aec7-4a930a805371" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_2e64eabe-ec0e-4fa9-b16f-faf757022221" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_4d48f21f-db95-4b9b-aec7-4a930a805371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_6f035690-1e39-4b1a-8736-e7c228150560" xlink:href="cybn-20250331.xsd#cybn_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_666c6c3c-bc51-4ef7-a689-7e6476876258" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_6f035690-1e39-4b1a-8736-e7c228150560" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_666c6c3c-bc51-4ef7-a689-7e6476876258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_693bd09f-64b7-44c4-a232-9d231c77c862" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_666c6c3c-bc51-4ef7-a689-7e6476876258" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_693bd09f-64b7-44c4-a232-9d231c77c862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_96efb358-764b-4896-a3e0-2dde6bc67350" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_693bd09f-64b7-44c4-a232-9d231c77c862" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_96efb358-764b-4896-a3e0-2dde6bc67350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_August2023CompensationCommonShareWarrantMember_a860a5d5-e48d-4c8d-a366-86f35e80e6a8" xlink:href="cybn-20250331.xsd#cybn_August2023CompensationCommonShareWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_96efb358-764b-4896-a3e0-2dde6bc67350" xlink:to="loc_cybn_August2023CompensationCommonShareWarrantMember_a860a5d5-e48d-4c8d-a366-86f35e80e6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_November2023CompensationCommonShareWarrantMember_1a984f23-892d-4704-898f-d51e026afc8e" xlink:href="cybn-20250331.xsd#cybn_November2023CompensationCommonShareWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_96efb358-764b-4896-a3e0-2dde6bc67350" xlink:to="loc_cybn_November2023CompensationCommonShareWarrantMember_1a984f23-892d-4704-898f-d51e026afc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6144a17d-fab3-4d76-9f76-c463d66b8a6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_666c6c3c-bc51-4ef7-a689-7e6476876258" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6144a17d-fab3-4d76-9f76-c463d66b8a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_9c0c8f86-0c1a-4469-93ae-210d8d39b890" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6144a17d-fab3-4d76-9f76-c463d66b8a6e" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_9c0c8f86-0c1a-4469-93ae-210d8d39b890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted_c6517dec-ff6c-4a95-8e66-64505dbd4f39" xlink:href="cybn-20250331.xsd#cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6144a17d-fab3-4d76-9f76-c463d66b8a6e" xlink:to="loc_cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted_c6517dec-ff6c-4a95-8e66-64505dbd4f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ExpectedVolatilityOtherEquityInstrumentsGranted_a55162e4-ca42-4f8d-a9ee-74f336582b41" xlink:href="cybn-20250331.xsd#cybn_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6144a17d-fab3-4d76-9f76-c463d66b8a6e" xlink:to="loc_cybn_ExpectedVolatilityOtherEquityInstrumentsGranted_a55162e4-ca42-4f8d-a9ee-74f336582b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_906a2ac7-8e08-4344-a8b9-46be6e18f2a5" xlink:href="cybn-20250331.xsd#cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6144a17d-fab3-4d76-9f76-c463d66b8a6e" xlink:to="loc_cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_906a2ac7-8e08-4344-a8b9-46be6e18f2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_40714cd0-66da-44f3-8b6c-cbadb424dc5a" xlink:href="cybn-20250331.xsd#cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6144a17d-fab3-4d76-9f76-c463d66b8a6e" xlink:to="loc_cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_40714cd0-66da-44f3-8b6c-cbadb424dc5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SharePricePerCommonShare_5e5e7c7a-53dd-4f11-8bb3-61e9c3a6ffd7" xlink:href="cybn-20250331.xsd#cybn_SharePricePerCommonShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6144a17d-fab3-4d76-9f76-c463d66b8a6e" xlink:to="loc_cybn_SharePricePerCommonShare_5e5e7c7a-53dd-4f11-8bb3-61e9c3a6ffd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_0b32b68f-5b34-4775-a3ff-c535ef22d938" xlink:href="cybn-20250331.xsd#cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6144a17d-fab3-4d76-9f76-c463d66b8a6e" xlink:to="loc_cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_0b32b68f-5b34-4775-a3ff-c535ef22d938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_7661719f-3be0-4f0b-abeb-ce49955a6bfe" xlink:href="cybn-20250331.xsd#cybn_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ebca30ec-ed68-4c6e-9824-0a68d4dc1713" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_7661719f-3be0-4f0b-abeb-ce49955a6bfe" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ebca30ec-ed68-4c6e-9824-0a68d4dc1713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f20fbef7-ec3f-481b-8e7c-0e23c06995da" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ebca30ec-ed68-4c6e-9824-0a68d4dc1713" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f20fbef7-ec3f-481b-8e7c-0e23c06995da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_72f7f226-ab41-4f73-a3cf-4c30b466b5f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_f20fbef7-ec3f-481b-8e7c-0e23c06995da" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_72f7f226-ab41-4f73-a3cf-4c30b466b5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommonSharePurchaseWarrantsMember_c906f519-1ab9-46d6-8787-0ad594307e78" xlink:href="cybn-20250331.xsd#cybn_CommonSharePurchaseWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_72f7f226-ab41-4f73-a3cf-4c30b466b5f9" xlink:to="loc_cybn_CommonSharePurchaseWarrantsMember_c906f519-1ab9-46d6-8787-0ad594307e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodAxis_22b04dc4-cd49-4141-9236-ba2e35c70c59" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ebca30ec-ed68-4c6e-9824-0a68d4dc1713" xlink:to="loc_cybn_WarrantExpirationPeriodAxis_22b04dc4-cd49-4141-9236-ba2e35c70c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodDomain_b1f2e209-c213-41e3-80f2-b375cc571f75" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_WarrantExpirationPeriodAxis_22b04dc4-cd49-4141-9236-ba2e35c70c59" xlink:to="loc_cybn_WarrantExpirationPeriodDomain_b1f2e209-c213-41e3-80f2-b375cc571f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodOneMember_aa616630-1267-4bf3-b9eb-632480ce65ab" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_WarrantExpirationPeriodDomain_b1f2e209-c213-41e3-80f2-b375cc571f75" xlink:to="loc_cybn_WarrantExpirationPeriodOneMember_aa616630-1267-4bf3-b9eb-632480ce65ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodTwoMember_bc7a56bf-ddbe-4fd0-8d5b-d1ebba59021c" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_WarrantExpirationPeriodDomain_b1f2e209-c213-41e3-80f2-b375cc571f75" xlink:to="loc_cybn_WarrantExpirationPeriodTwoMember_bc7a56bf-ddbe-4fd0-8d5b-d1ebba59021c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodThreeMember_44adf6d9-31f9-41db-868f-0695c27dfa16" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_WarrantExpirationPeriodDomain_b1f2e209-c213-41e3-80f2-b375cc571f75" xlink:to="loc_cybn_WarrantExpirationPeriodThreeMember_44adf6d9-31f9-41db-868f-0695c27dfa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodFourMember_504695d5-2ba6-4b00-91b5-2f2e4f33b14b" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_WarrantExpirationPeriodDomain_b1f2e209-c213-41e3-80f2-b375cc571f75" xlink:to="loc_cybn_WarrantExpirationPeriodFourMember_504695d5-2ba6-4b00-91b5-2f2e4f33b14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WarrantExpirationPeriodFiveMember_9c577e8d-0dd0-40e3-b59a-dc0238a52d20" xlink:href="cybn-20250331.xsd#cybn_WarrantExpirationPeriodFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_WarrantExpirationPeriodDomain_b1f2e209-c213-41e3-80f2-b375cc571f75" xlink:to="loc_cybn_WarrantExpirationPeriodFiveMember_9c577e8d-0dd0-40e3-b59a-dc0238a52d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_658e0bad-65b7-4579-ae7b-172c09e8b190" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_ebca30ec-ed68-4c6e-9824-0a68d4dc1713" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_658e0bad-65b7-4579-ae7b-172c09e8b190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_d2b7fa9d-cdff-4506-ab36-dde3032fdef8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_658e0bad-65b7-4579-ae7b-172c09e8b190" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_d2b7fa9d-cdff-4506-ab36-dde3032fdef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_27372f55-bd31-4b75-81ef-c9d8ba92112a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_658e0bad-65b7-4579-ae7b-172c09e8b190" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_27372f55-bd31-4b75-81ef-c9d8ba92112a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_c4d0fd91-12f5-4636-af3b-6a6cbe466d52" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_658e0bad-65b7-4579-ae7b-172c09e8b190" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_c4d0fd91-12f5-4636-af3b-6a6cbe466d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_ce850e46-d18a-46cb-bb17-71785b26dde3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_658e0bad-65b7-4579-ae7b-172c09e8b190" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_ce850e46-d18a-46cb-bb17-71785b26dde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_729c3960-3124-42a6-b623-2be9ce5e29d7" xlink:href="cybn-20250331.xsd#cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_658e0bad-65b7-4579-ae7b-172c09e8b190" xlink:to="loc_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments_729c3960-3124-42a6-b623-2be9ce5e29d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALNarrativeStockoptionsDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_30335969-263d-4a38-ba0b-e18644756d99" xlink:href="cybn-20250331.xsd#cybn_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_708ed013-0b72-4c75-b78b-cd82d1c9d4a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_30335969-263d-4a38-ba0b-e18644756d99" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_708ed013-0b72-4c75-b78b-cd82d1c9d4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_91f86017-f412-4ea7-8877-bc95dccaa528" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_708ed013-0b72-4c75-b78b-cd82d1c9d4a0" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_91f86017-f412-4ea7-8877-bc95dccaa528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_1162b8ef-909d-4489-8d42-6ceb06aa8b4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_91f86017-f412-4ea7-8877-bc95dccaa528" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_1162b8ef-909d-4489-8d42-6ceb06aa8b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_811775fe-d056-4d5c-a867-9ae21631fd03" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_1162b8ef-909d-4489-8d42-6ceb06aa8b4f" xlink:to="loc_ifrs-full_OrdinarySharesMember_811775fe-d056-4d5c-a867-9ae21631fd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b53fc96d-3624-4bbb-a7c2-2d213e30bae1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_708ed013-0b72-4c75-b78b-cd82d1c9d4a0" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b53fc96d-3624-4bbb-a7c2-2d213e30bae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_32ad40a2-bf25-4ea1-9f02-c4dda086d389" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_b53fc96d-3624-4bbb-a7c2-2d213e30bae1" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_32ad40a2-bf25-4ea1-9f02-c4dda086d389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrantedToOfficersAndDirectorsMember_0219c5ab-bbdd-4f01-8cfb-96355d64a3a0" xlink:href="cybn-20250331.xsd#cybn_GrantedToOfficersAndDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_32ad40a2-bf25-4ea1-9f02-c4dda086d389" xlink:to="loc_cybn_GrantedToOfficersAndDirectorsMember_0219c5ab-bbdd-4f01-8cfb-96355d64a3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrantedToOfficersMember_bc260a0c-71f6-45cd-8b5b-d423e9aeb0bb" xlink:href="cybn-20250331.xsd#cybn_GrantedToOfficersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_GrantedToOfficersAndDirectorsMember_0219c5ab-bbdd-4f01-8cfb-96355d64a3a0" xlink:to="loc_cybn_GrantedToOfficersMember_bc260a0c-71f6-45cd-8b5b-d423e9aeb0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrantedToDirectorsMember_f2eb564a-e558-449f-b40f-2c7d24552fa1" xlink:href="cybn-20250331.xsd#cybn_GrantedToDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_GrantedToOfficersMember_bc260a0c-71f6-45cd-8b5b-d423e9aeb0bb" xlink:to="loc_cybn_GrantedToDirectorsMember_f2eb564a-e558-449f-b40f-2c7d24552fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrantedToEmployeesMember_6857e26d-be6c-4672-b741-b5542a68be9f" xlink:href="cybn-20250331.xsd#cybn_GrantedToEmployeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_32ad40a2-bf25-4ea1-9f02-c4dda086d389" xlink:to="loc_cybn_GrantedToEmployeesMember_6857e26d-be6c-4672-b741-b5542a68be9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrantedToConsultantsMember_8971c981-6b2f-4a88-816e-2446fa77ac36" xlink:href="cybn-20250331.xsd#cybn_GrantedToConsultantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_32ad40a2-bf25-4ea1-9f02-c4dda086d389" xlink:to="loc_cybn_GrantedToConsultantsMember_8971c981-6b2f-4a88-816e-2446fa77ac36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodAxis_c070af11-0bf7-41d0-97e1-67d5845a94c8" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_708ed013-0b72-4c75-b78b-cd82d1c9d4a0" xlink:to="loc_cybn_OptionExpirationPeriodAxis_c070af11-0bf7-41d0-97e1-67d5845a94c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodAxis_c070af11-0bf7-41d0-97e1-67d5845a94c8" xlink:to="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyTwoMember_745ff73c-b5a4-43b7-ac6b-5619ed57da11" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:to="loc_cybn_OptionExpirationPeriodThirtyTwoMember_745ff73c-b5a4-43b7-ac6b-5619ed57da11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyFourMember_e4dcd4c0-6ce9-46ad-b2c0-c3472c310893" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyFourMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:to="loc_cybn_OptionExpirationPeriodThirtyFourMember_e4dcd4c0-6ce9-46ad-b2c0-c3472c310893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyFiveMember_738cfd63-a84f-455e-ae4c-ecfac282bddf" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:to="loc_cybn_OptionExpirationPeriodThirtyFiveMember_738cfd63-a84f-455e-ae4c-ecfac282bddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtySixMember_b4966145-bdb6-4141-98bd-12e971802abd" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtySixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:to="loc_cybn_OptionExpirationPeriodThirtySixMember_b4966145-bdb6-4141-98bd-12e971802abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyNineMember_73f73d7b-7117-4a59-aca2-c4dfb4b84b2c" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyNineMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:to="loc_cybn_OptionExpirationPeriodTwentyNineMember_73f73d7b-7117-4a59-aca2-c4dfb4b84b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyFourAndThirtyMember_eb12ea27-e690-442c-9d3f-191b380435b3" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyFourAndThirtyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:to="loc_cybn_OptionExpirationPeriodTwentyFourAndThirtyMember_eb12ea27-e690-442c-9d3f-191b380435b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyFourMember_017c37eb-9b9e-434f-8d41-fae3b0cc5a85" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodTwentyFourAndThirtyMember_eb12ea27-e690-442c-9d3f-191b380435b3" xlink:to="loc_cybn_OptionExpirationPeriodTwentyFourMember_017c37eb-9b9e-434f-8d41-fae3b0cc5a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyMember_8e93bea2-6f7f-4af3-b1f6-2f2e8c161c53" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodTwentyFourAndThirtyMember_eb12ea27-e690-442c-9d3f-191b380435b3" xlink:to="loc_cybn_OptionExpirationPeriodThirtyMember_8e93bea2-6f7f-4af3-b1f6-2f2e8c161c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember_dd45916e-4e79-40e7-bf91-e590ba4ed8fe" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:to="loc_cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember_dd45916e-4e79-40e7-bf91-e590ba4ed8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtySevenMember_51d61e5b-eba0-4403-8984-5ffcc6d5082d" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtySevenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember_dd45916e-4e79-40e7-bf91-e590ba4ed8fe" xlink:to="loc_cybn_OptionExpirationPeriodThirtySevenMember_51d61e5b-eba0-4403-8984-5ffcc6d5082d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyEightMember_c13b7101-8e90-41b7-a3f0-793283e5a470" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyEightMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember_dd45916e-4e79-40e7-bf91-e590ba4ed8fe" xlink:to="loc_cybn_OptionExpirationPeriodThirtyEightMember_c13b7101-8e90-41b7-a3f0-793283e5a470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyOneMember_e6df09d8-6d89-4e29-bc01-776bb70ae909" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyOneMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_3629f0ee-a372-4ecc-a5f8-20754dff49c9" xlink:to="loc_cybn_OptionExpirationPeriodThirtyOneMember_e6df09d8-6d89-4e29-bc01-776bb70ae909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareBasedPaymentVestingPeriodAxis_dd22acea-507e-49a3-afc9-e1418f5a4fe3" xlink:href="cybn-20250331.xsd#cybn_ShareBasedPaymentVestingPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_708ed013-0b72-4c75-b78b-cd82d1c9d4a0" xlink:to="loc_cybn_ShareBasedPaymentVestingPeriodAxis_dd22acea-507e-49a3-afc9-e1418f5a4fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareBasedPaymentVestingPeriodDomain_fc07e688-d505-4ee6-9c09-e9892c5b780a" xlink:href="cybn-20250331.xsd#cybn_ShareBasedPaymentVestingPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareBasedPaymentVestingPeriodAxis_dd22acea-507e-49a3-afc9-e1418f5a4fe3" xlink:to="loc_cybn_ShareBasedPaymentVestingPeriodDomain_fc07e688-d505-4ee6-9c09-e9892c5b780a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareOptionsVestingFirstTrancheMember_a2bdcdcd-a4ab-431c-ba3c-ef9615c25a66" xlink:href="cybn-20250331.xsd#cybn_ShareOptionsVestingFirstTrancheMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareBasedPaymentVestingPeriodDomain_fc07e688-d505-4ee6-9c09-e9892c5b780a" xlink:to="loc_cybn_ShareOptionsVestingFirstTrancheMember_a2bdcdcd-a4ab-431c-ba3c-ef9615c25a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareOptionsVestingSecondTrancheMember_08c35e10-551e-45be-bfb5-10d2c161056a" xlink:href="cybn-20250331.xsd#cybn_ShareOptionsVestingSecondTrancheMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareBasedPaymentVestingPeriodDomain_fc07e688-d505-4ee6-9c09-e9892c5b780a" xlink:to="loc_cybn_ShareOptionsVestingSecondTrancheMember_08c35e10-551e-45be-bfb5-10d2c161056a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareOptionsVestingThirdTrancheMember_4b9289ea-b8c1-4f38-add3-bd02084771ea" xlink:href="cybn-20250331.xsd#cybn_ShareOptionsVestingThirdTrancheMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareBasedPaymentVestingPeriodDomain_fc07e688-d505-4ee6-9c09-e9892c5b780a" xlink:to="loc_cybn_ShareOptionsVestingThirdTrancheMember_4b9289ea-b8c1-4f38-add3-bd02084771ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareOptionsVestingFourthTrancheMember_423ae738-9282-4553-98b1-9113b14375cf" xlink:href="cybn-20250331.xsd#cybn_ShareOptionsVestingFourthTrancheMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareBasedPaymentVestingPeriodDomain_fc07e688-d505-4ee6-9c09-e9892c5b780a" xlink:to="loc_cybn_ShareOptionsVestingFourthTrancheMember_423ae738-9282-4553-98b1-9113b14375cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareOptionsVestingFifthTrancheMember_69f680db-e817-4d51-8ef3-7b9d84fce8d5" xlink:href="cybn-20250331.xsd#cybn_ShareOptionsVestingFifthTrancheMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareBasedPaymentVestingPeriodDomain_fc07e688-d505-4ee6-9c09-e9892c5b780a" xlink:to="loc_cybn_ShareOptionsVestingFifthTrancheMember_69f680db-e817-4d51-8ef3-7b9d84fce8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8d1d8c29-6037-410f-8ba8-8c12d2de47f3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_708ed013-0b72-4c75-b78b-cd82d1c9d4a0" xlink:to="loc_srt_RangeAxis_8d1d8c29-6037-410f-8ba8-8c12d2de47f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0da49e7d-9dc3-4e70-8b98-8cb221169cee" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8d1d8c29-6037-410f-8ba8-8c12d2de47f3" xlink:to="loc_srt_RangeMember_0da49e7d-9dc3-4e70-8b98-8cb221169cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f6d28ceb-c93c-4071-b42c-7d6c9d910f94" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0da49e7d-9dc3-4e70-8b98-8cb221169cee" xlink:to="loc_srt_MinimumMember_f6d28ceb-c93c-4071-b42c-7d6c9d910f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_96b73b7d-2cb7-48d2-8581-f75fa6c22c4b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0da49e7d-9dc3-4e70-8b98-8cb221169cee" xlink:to="loc_srt_MaximumMember_96b73b7d-2cb7-48d2-8581-f75fa6c22c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_708ed013-0b72-4c75-b78b-cd82d1c9d4a0" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding_18de1af7-68f7-4f6d-befe-6f6c693fbc6e" xlink:href="cybn-20250331.xsd#cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding_18de1af7-68f7-4f6d-befe-6f6c693fbc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_2074f17f-3dfb-44f0-8b6c-84330e5a39b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_2074f17f-3dfb-44f0-8b6c-84330e5a39b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_ae0624fc-38e3-48c5-b7a5-f301951c6a02" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_ae0624fc-38e3-48c5-b7a5-f301951c6a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_9007d759-37fa-4dbc-9686-5cf206cab8cd" xlink:href="cybn-20250331.xsd#cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_9007d759-37fa-4dbc-9686-5cf206cab8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_9af8a8a5-87d9-4ba5-81c1-7e71b3c7b40d" xlink:href="cybn-20250331.xsd#cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod_9af8a8a5-87d9-4ba5-81c1-7e71b3c7b40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_6869c68f-9003-426a-b3d2-de007ccdc17c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_6869c68f-9003-426a-b3d2-de007ccdc17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_ecfedb6b-7da1-419c-b0a6-30a840ff32d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_ecfedb6b-7da1-419c-b0a6-30a840ff32d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_7fe90b03-c815-45e9-b5a5-7352b22cb951" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_7fe90b03-c815-45e9-b5a5-7352b22cb951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_a8b926bf-dcde-4108-83ee-0267d910aedd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_31354fea-6d2d-47ac-9811-4e2cd50deab1" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_a8b926bf-dcde-4108-83ee-0267d910aedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALSummaryofnumberandweightedaverageexercisepricesofshareoptionsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALSummaryofnumberandweightedaverageexercisepricesofshareoptionsDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/SHARECAPITALSummaryofnumberandweightedaverageexercisepricesofshareoptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_b039529f-2914-48be-96e9-cdc8ff535f04" xlink:href="cybn-20250331.xsd#cybn_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_9a8300d4-077f-48ea-932d-7c2a9b785fbd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_b039529f-2914-48be-96e9-cdc8ff535f04" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_9a8300d4-077f-48ea-932d-7c2a9b785fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_fa684987-7233-4bbd-b268-2231c005f7f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_b039529f-2914-48be-96e9-cdc8ff535f04" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_fa684987-7233-4bbd-b268-2231c005f7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement_37166092-21c1-4918-914a-f9422c7fd26e" xlink:href="cybn-20250331.xsd#cybn_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_b039529f-2914-48be-96e9-cdc8ff535f04" xlink:to="loc_cybn_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement_37166092-21c1-4918-914a-f9422c7fd26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_8928f535-60d3-49fd-94c1-35469eb74738" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_b039529f-2914-48be-96e9-cdc8ff535f04" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_8928f535-60d3-49fd-94c1-35469eb74738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_a2faa14c-62d7-413a-b750-10d1a3a71230" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_b039529f-2914-48be-96e9-cdc8ff535f04" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_a2faa14c-62d7-413a-b750-10d1a3a71230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_8d0fde9e-59a1-4964-bb80-ace5fee3399b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_b039529f-2914-48be-96e9-cdc8ff535f04" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_8d0fde9e-59a1-4964-bb80-ace5fee3399b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_4c9a33ed-7e55-4ae2-8c7c-833fac40e29d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_b039529f-2914-48be-96e9-cdc8ff535f04" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_4c9a33ed-7e55-4ae2-8c7c-833fac40e29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement_3a5056c0-22b0-4837-99ce-ac9a8bf75ae6" xlink:href="cybn-20250331.xsd#cybn_WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_b039529f-2914-48be-96e9-cdc8ff535f04" xlink:to="loc_cybn_WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement_3a5056c0-22b0-4837-99ce-ac9a8bf75ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_30075fbd-c83d-4702-8912-1e1527b816b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_b039529f-2914-48be-96e9-cdc8ff535f04" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_30075fbd-c83d-4702-8912-1e1527b816b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_595afa63-1bc5-4397-a6a9-4070a09e1a8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_b039529f-2914-48be-96e9-cdc8ff535f04" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_595afa63-1bc5-4397-a6a9-4070a09e1a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_12357c9d-7817-4e54-8a2f-eeefed031245" xlink:href="cybn-20250331.xsd#cybn_ShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_39e6cf99-6c91-4d8c-9462-2eae6b740d5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract_12357c9d-7817-4e54-8a2f-eeefed031245" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_39e6cf99-6c91-4d8c-9462-2eae6b740d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodAxis_bd0d3872-060c-4bd8-9d83-45b54a5a6ad4" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_39e6cf99-6c91-4d8c-9462-2eae6b740d5b" xlink:to="loc_cybn_OptionExpirationPeriodAxis_bd0d3872-060c-4bd8-9d83-45b54a5a6ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodAxis_bd0d3872-060c-4bd8-9d83-45b54a5a6ad4" xlink:to="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyTwoMember_a6b41361-5322-4a23-9ee3-6f3f7e504b36" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodThirtyTwoMember_a6b41361-5322-4a23-9ee3-6f3f7e504b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyFourMember_95c3578d-b261-48ff-8313-3d6bf467211e" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyFourMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodThirtyFourMember_95c3578d-b261-48ff-8313-3d6bf467211e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyFiveMember_de78136e-648a-493b-af2a-8ce6afa0f252" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodThirtyFiveMember_de78136e-648a-493b-af2a-8ce6afa0f252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtySixMember_ec23ff4d-ea8d-4296-b034-81a7265cd115" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtySixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodThirtySixMember_ec23ff4d-ea8d-4296-b034-81a7265cd115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyNineMember_22ed1c6d-ac80-4bb7-ac12-ed0788c2aa6b" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyNineMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodTwentyNineMember_22ed1c6d-ac80-4bb7-ac12-ed0788c2aa6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyFourMember_3f488394-692c-413d-bc0c-dbb4e14c8dc8" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyFourMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodTwentyFourMember_3f488394-692c-413d-bc0c-dbb4e14c8dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyMember_a74ed0e1-2273-4e7f-9e46-920f5895e498" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodThirtyMember_a74ed0e1-2273-4e7f-9e46-920f5895e498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtySevenMember_ae42d48f-e9ca-459e-b27d-48dbea9d6dcd" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtySevenMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodThirtySevenMember_ae42d48f-e9ca-459e-b27d-48dbea9d6dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyEightMember_82c0666b-a84c-46d3-a38f-f4e6a8892aa7" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyEightMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodThirtyEightMember_82c0666b-a84c-46d3-a38f-f4e6a8892aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyOneMember_25d92c3d-c233-4622-8c37-d11764266bb4" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyOneMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_67cd9c6a-25ed-4ca3-83b7-c97018cbe30c" xlink:to="loc_cybn_OptionExpirationPeriodThirtyOneMember_25d92c3d-c233-4622-8c37-d11764266bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5798694e-b0d2-4271-a856-c82152a4488c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_39e6cf99-6c91-4d8c-9462-2eae6b740d5b" xlink:to="loc_srt_RangeAxis_5798694e-b0d2-4271-a856-c82152a4488c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fcc81119-2fa2-4fba-9209-96d8d83fcd8c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5798694e-b0d2-4271-a856-c82152a4488c" xlink:to="loc_srt_RangeMember_fcc81119-2fa2-4fba-9209-96d8d83fcd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f11f6559-2a68-4eaa-a067-f2d389415b34" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fcc81119-2fa2-4fba-9209-96d8d83fcd8c" xlink:to="loc_srt_MinimumMember_f11f6559-2a68-4eaa-a067-f2d389415b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_762c0ded-6c3e-400d-bcb2-9bab0b16558b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fcc81119-2fa2-4fba-9209-96d8d83fcd8c" xlink:to="loc_srt_MaximumMember_762c0ded-6c3e-400d-bcb2-9bab0b16558b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f53b3081-9a0c-4fc7-9174-e4acf370e2ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_39e6cf99-6c91-4d8c-9462-2eae6b740d5b" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f53b3081-9a0c-4fc7-9174-e4acf370e2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_dc003637-ddbf-4d0b-99e2-225531ca42af" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f53b3081-9a0c-4fc7-9174-e4acf370e2ec" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_dc003637-ddbf-4d0b-99e2-225531ca42af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_52254ec7-f618-408c-a038-a7019b824c93" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f53b3081-9a0c-4fc7-9174-e4acf370e2ec" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_52254ec7-f618-408c-a038-a7019b824c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_f904a1b6-c25c-47d0-a51b-eb6bf438c2a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f53b3081-9a0c-4fc7-9174-e4acf370e2ec" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_f904a1b6-c25c-47d0-a51b-eb6bf438c2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_aa072334-5c8e-4a71-921d-53345449efbe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f53b3081-9a0c-4fc7-9174-e4acf370e2ec" xlink:to="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_aa072334-5c8e-4a71-921d-53345449efbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted_f8cdafca-0da0-4548-8fcc-2f712c509adc" xlink:href="cybn-20250331.xsd#cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f53b3081-9a0c-4fc7-9174-e4acf370e2ec" xlink:to="loc_cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted_f8cdafca-0da0-4548-8fcc-2f712c509adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_329a1047-b5f2-4c0a-8644-1a45a708ba39" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f53b3081-9a0c-4fc7-9174-e4acf370e2ec" xlink:to="loc_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_329a1047-b5f2-4c0a-8644-1a45a708ba39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_6308bbe7-d22e-42fd-a312-5c2a4636f538" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_f53b3081-9a0c-4fc7-9174-e4acf370e2ec" xlink:to="loc_ifrs-full_ExercisePriceShareOptionsGranted2019_6308bbe7-d22e-42fd-a312-5c2a4636f538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SHARECAPITALSummaryofstockoptioninformationDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_680a7f79-4c65-41b9-bc38-f20b81ce371d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodAxis_8b35601a-d1a8-4c62-8ee1-e6e78fd7f3b9" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_680a7f79-4c65-41b9-bc38-f20b81ce371d" xlink:to="loc_cybn_OptionExpirationPeriodAxis_8b35601a-d1a8-4c62-8ee1-e6e78fd7f3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodAxis_8b35601a-d1a8-4c62-8ee1-e6e78fd7f3b9" xlink:to="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodOneMember_89945b29-03da-4f53-a0ec-2916ffb2a9ba" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodOneMember_89945b29-03da-4f53-a0ec-2916ffb2a9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwoMember_e19ba77e-4ce4-4fa1-a3d0-9da0ee317ffc" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwoMember_e19ba77e-4ce4-4fa1-a3d0-9da0ee317ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThreeMember_b76e7d7e-6f9a-400e-8e5c-916d59801374" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodThreeMember_b76e7d7e-6f9a-400e-8e5c-916d59801374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodFourMember_21ec41bd-4ae4-48c3-b1c3-a254660b1fb9" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodFourMember_21ec41bd-4ae4-48c3-b1c3-a254660b1fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodFiveMember_10aaa2d8-24ce-4406-80e3-2353528206e5" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodFiveMember_10aaa2d8-24ce-4406-80e3-2353528206e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodSixMember_3d9c4fa4-bffb-49e1-9fa0-f943ba045efe" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodSixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodSixMember_3d9c4fa4-bffb-49e1-9fa0-f943ba045efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodSevenMember_e7fd849f-e358-4210-800d-c3d4db15be73" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodSevenMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodSevenMember_e7fd849f-e358-4210-800d-c3d4db15be73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodEightMember_a978a60b-fc32-4113-a8dc-d0a1fd55ea03" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodEightMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodEightMember_a978a60b-fc32-4113-a8dc-d0a1fd55ea03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodNineMember_29ec9dcb-c36f-4eb7-9da5-3a6f0bbbed14" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodNineMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodNineMember_29ec9dcb-c36f-4eb7-9da5-3a6f0bbbed14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTenMember_ef6d5a56-94d1-4360-a7b3-d649b07b9d68" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTenMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTenMember_ef6d5a56-94d1-4360-a7b3-d649b07b9d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodElevenMember_a49f795c-27c0-46ff-8464-d821a6147f4f" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodElevenMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodElevenMember_a49f795c-27c0-46ff-8464-d821a6147f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwelveMember_72bf97ef-1b8f-4378-a1bd-d08c1e7188fa" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwelveMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwelveMember_72bf97ef-1b8f-4378-a1bd-d08c1e7188fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirteenMember_1ba05a0f-0eaa-409f-a5cc-8bbaafe70e14" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirteenMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodThirteenMember_1ba05a0f-0eaa-409f-a5cc-8bbaafe70e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodFourteenMember_d0986393-0b98-4769-b47a-ee3ada3c2281" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodFourteenMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodFourteenMember_d0986393-0b98-4769-b47a-ee3ada3c2281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodFifteenMember_099f1b16-f313-4781-967b-c7649b446a8d" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodFifteenMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodFifteenMember_099f1b16-f313-4781-967b-c7649b446a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodSixteenMember_e0c1923a-1651-4828-95c5-ca536c13217f" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodSixteenMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodSixteenMember_e0c1923a-1651-4828-95c5-ca536c13217f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodSeventeenMember_e9b9dc58-620a-4aa2-a3ba-13e233fd91e7" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodSeventeenMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodSeventeenMember_e9b9dc58-620a-4aa2-a3ba-13e233fd91e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodEighteenMember_289545a0-c74f-46b8-8c96-2c722247b0ce" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodEighteenMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodEighteenMember_289545a0-c74f-46b8-8c96-2c722247b0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodNineteenMember_ae40c267-36f1-4d67-9206-5f535aa42f95" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodNineteenMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodNineteenMember_ae40c267-36f1-4d67-9206-5f535aa42f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyMember_5d71c3a0-c640-436c-b950-8b56632ff6f8" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentyMember_5d71c3a0-c640-436c-b950-8b56632ff6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyOneMember_15c7ff6f-6f9f-482f-9c20-a16252b35d57" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyOneMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentyOneMember_15c7ff6f-6f9f-482f-9c20-a16252b35d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyTwoMember_e3ec032f-43f7-4589-96c5-49f8af0847ba" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyTwoMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentyTwoMember_e3ec032f-43f7-4589-96c5-49f8af0847ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyThreeMember_5b826138-34d4-4426-add6-1612f43d74e9" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyThreeMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentyThreeMember_5b826138-34d4-4426-add6-1612f43d74e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyFourMember_f058e294-ce6c-456f-9061-9ee5451a32a8" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyFourMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentyFourMember_f058e294-ce6c-456f-9061-9ee5451a32a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyFiveMember_00bd4cb9-1c9c-4642-9bbf-abd51875f968" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyFiveMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentyFiveMember_00bd4cb9-1c9c-4642-9bbf-abd51875f968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentySixMember_991570a4-f6c0-4e8e-a9ae-4aa8b295eee2" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentySixMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentySixMember_991570a4-f6c0-4e8e-a9ae-4aa8b295eee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentySevenMember_040b9671-996a-41fb-9a35-d89a090bdf28" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentySevenMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentySevenMember_040b9671-996a-41fb-9a35-d89a090bdf28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyEightMember_bbb1a3b5-4d6e-404c-865e-220e98f53f4f" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyEightMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentyEightMember_bbb1a3b5-4d6e-404c-865e-220e98f53f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodTwentyNineMember_0fead762-2c83-4230-aef4-bbf4a9092c79" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodTwentyNineMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodTwentyNineMember_0fead762-2c83-4230-aef4-bbf4a9092c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyMember_3f51ebb1-4d1a-453b-b4bf-b92de47a1861" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodThirtyMember_3f51ebb1-4d1a-453b-b4bf-b92de47a1861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyOneMember_38882e4a-df5e-44b9-abc4-7eb3cb69ad43" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyOneMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodThirtyOneMember_38882e4a-df5e-44b9-abc4-7eb3cb69ad43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyTwoMember_042b9db6-cef3-49f9-a603-0db532755210" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyTwoMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodThirtyTwoMember_042b9db6-cef3-49f9-a603-0db532755210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyThreeMember_2638d2f5-ef30-4f74-8aee-0ff9f6aadfea" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyThreeMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodThirtyThreeMember_2638d2f5-ef30-4f74-8aee-0ff9f6aadfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyFourMember_04b71c01-a0ed-45ee-80be-49d576681ecc" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyFourMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodThirtyFourMember_04b71c01-a0ed-45ee-80be-49d576681ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtyFiveMember_a1a8767b-731c-4958-99e5-b6c938671c66" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtyFiveMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodThirtyFiveMember_a1a8767b-731c-4958-99e5-b6c938671c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_OptionExpirationPeriodThirtySixMember_5da4eb7d-be0d-42de-aa4f-6357ac9be247" xlink:href="cybn-20250331.xsd#cybn_OptionExpirationPeriodThirtySixMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_OptionExpirationPeriodDomain_ae64601b-4f12-4541-a4b9-dac1166cb235" xlink:to="loc_cybn_OptionExpirationPeriodThirtySixMember_5da4eb7d-be0d-42de-aa4f-6357ac9be247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_db85a482-30e2-471c-a0ee-73413230d1e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_680a7f79-4c65-41b9-bc38-f20b81ce371d" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_db85a482-30e2-471c-a0ee-73413230d1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_85bf7935-1fa0-4c8c-a843-20c29b79c4e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_db85a482-30e2-471c-a0ee-73413230d1e2" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_85bf7935-1fa0-4c8c-a843-20c29b79c4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_eea00655-d2d7-41d7-8701-a85f957abfde" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_db85a482-30e2-471c-a0ee-73413230d1e2" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_eea00655-d2d7-41d7-8701-a85f957abfde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_4744dc1b-d1a3-421b-bd04-73e4bc898bf8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_db85a482-30e2-471c-a0ee-73413230d1e2" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_4744dc1b-d1a3-421b-bd04-73e4bc898bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_1b9f4db6-f100-470d-a0af-24a3734d0374" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_db85a482-30e2-471c-a0ee-73413230d1e2" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_1b9f4db6-f100-470d-a0af-24a3734d0374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_ee429980-df25-4189-bae8-6baf2eafc008" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_db85a482-30e2-471c-a0ee-73413230d1e2" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_ee429980-df25-4189-bae8-6baf2eafc008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_RelatedPartyAbstract_58a222eb-d1c8-43ce-a882-3b49427dc0a2" xlink:href="cybn-20250331.xsd#cybn_RelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_952751e7-0309-4130-a7de-16af201001b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_RelatedPartyAbstract_58a222eb-d1c8-43ce-a882-3b49427dc0a2" xlink:to="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_952751e7-0309-4130-a7de-16af201001b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4bb8fb84-1e09-494f-98e5-b6af9d7047d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_952751e7-0309-4130-a7de-16af201001b9" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4bb8fb84-1e09-494f-98e5-b6af9d7047d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_e19eb9c6-3116-460b-a70b-f0cef61e8930" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4bb8fb84-1e09-494f-98e5-b6af9d7047d9" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_e19eb9c6-3116-460b-a70b-f0cef61e8930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareBasedPaymentArrangementOptionMember_09dd2813-6c0e-4e17-92a5-8b90577a50fa" xlink:href="cybn-20250331.xsd#cybn_ShareBasedPaymentArrangementOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_e19eb9c6-3116-460b-a70b-f0cef61e8930" xlink:to="loc_cybn_ShareBasedPaymentArrangementOptionMember_09dd2813-6c0e-4e17-92a5-8b90577a50fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_876c1dfe-4d98-4b1d-8656-80682fc44b0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_e19eb9c6-3116-460b-a70b-f0cef61e8930" xlink:to="loc_ifrs-full_WarrantsMember_876c1dfe-4d98-4b1d-8656-80682fc44b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncomeStatementLocationAxis_f73ad67d-96a2-4dca-9df0-3a37026f3ae7" xlink:href="cybn-20250331.xsd#cybn_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_952751e7-0309-4130-a7de-16af201001b9" xlink:to="loc_cybn_IncomeStatementLocationAxis_f73ad67d-96a2-4dca-9df0-3a37026f3ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncomeStatementLocationDomain_e53c8ab8-9628-434a-9e27-a973cff471aa" xlink:href="cybn-20250331.xsd#cybn_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeStatementLocationAxis_f73ad67d-96a2-4dca-9df0-3a37026f3ae7" xlink:to="loc_cybn_IncomeStatementLocationDomain_e53c8ab8-9628-434a-9e27-a973cff471aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GeneralAndAdministrativeExpenseMember_56b6456e-7be6-4fb8-bc7e-afb9f2b3f55c" xlink:href="cybn-20250331.xsd#cybn_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeStatementLocationDomain_e53c8ab8-9628-434a-9e27-a973cff471aa" xlink:to="loc_cybn_GeneralAndAdministrativeExpenseMember_56b6456e-7be6-4fb8-bc7e-afb9f2b3f55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ResearchComponentMember_9e6168a9-0d69-474f-b1a4-12ee4a8eeb9b" xlink:href="cybn-20250331.xsd#cybn_ResearchComponentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeStatementLocationDomain_e53c8ab8-9628-434a-9e27-a973cff471aa" xlink:to="loc_cybn_ResearchComponentMember_9e6168a9-0d69-474f-b1a4-12ee4a8eeb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_4b3582b7-d939-42d7-a37b-9f057fd87afd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable_952751e7-0309-4130-a7de-16af201001b9" xlink:to="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_4b3582b7-d939-42d7-a37b-9f057fd87afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_303a7b4e-af29-4244-a030-1e61d8893e9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_4b3582b7-d939-42d7-a37b-9f057fd87afd" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_303a7b4e-af29-4244-a030-1e61d8893e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_3f114bbc-1b7e-4204-af04-392127273f2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_4b3582b7-d939-42d7-a37b-9f057fd87afd" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_3f114bbc-1b7e-4204-af04-392127273f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_5ee5a475-0329-4fdf-8561-69f2adba77a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems_4b3582b7-d939-42d7-a37b-9f057fd87afd" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_5ee5a475-0329-4fdf-8561-69f2adba77a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/RESEARCHEXPENSESDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#RESEARCHEXPENSESDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/RESEARCHEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_cc711ac6-b45d-4df0-ad20-0244470e70fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AdvancementOfDevelopmentPrograms_35405ec1-006c-4ace-a467-0b1a0aec9cc3" xlink:href="cybn-20250331.xsd#cybn_AdvancementOfDevelopmentPrograms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_cc711ac6-b45d-4df0-ad20-0244470e70fc" xlink:to="loc_cybn_AdvancementOfDevelopmentPrograms_35405ec1-006c-4ace-a467-0b1a0aec9cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PayrollAndBenefits_ad0e6f8b-f57f-4c9d-9e0f-5623d0f691f6" xlink:href="cybn-20250331.xsd#cybn_PayrollAndBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_cc711ac6-b45d-4df0-ad20-0244470e70fc" xlink:to="loc_cybn_PayrollAndBenefits_ad0e6f8b-f57f-4c9d-9e0f-5623d0f691f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LabAndAdministration_6e2942d4-e68d-48c2-919a-f3d335ebc69c" xlink:href="cybn-20250331.xsd#cybn_LabAndAdministration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_cc711ac6-b45d-4df0-ad20-0244470e70fc" xlink:to="loc_cybn_LabAndAdministration_6e2942d4-e68d-48c2-919a-f3d335ebc69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ProfessionalAndConsultingFees_0176ae67-768d-4912-8c35-fab9499799d4" xlink:href="cybn-20250331.xsd#cybn_ProfessionalAndConsultingFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_cc711ac6-b45d-4df0-ad20-0244470e70fc" xlink:to="loc_cybn_ProfessionalAndConsultingFees_0176ae67-768d-4912-8c35-fab9499799d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_238f9a99-0ac1-434a-b90c-6c56a11048a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_cc711ac6-b45d-4df0-ad20-0244470e70fc" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_238f9a99-0ac1-434a-b90c-6c56a11048a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#GENERALANDADMINISTRATIVEEXPENSESDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_dd143457-2e5c-4712-b11a-95a81f0fea14" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CapitalMarketExpense_8bb6a5bc-d6a2-4ba8-9801-09e6f2772742" xlink:href="cybn-20250331.xsd#cybn_CapitalMarketExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_dd143457-2e5c-4712-b11a-95a81f0fea14" xlink:to="loc_cybn_CapitalMarketExpense_8bb6a5bc-d6a2-4ba8-9801-09e6f2772742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_50e9c79e-5f3d-44f8-a290-7d74f1d37cf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_dd143457-2e5c-4712-b11a-95a81f0fea14" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_50e9c79e-5f3d-44f8-a290-7d74f1d37cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OccupancyExpense_0d268125-43ef-4b09-b79c-2e2c577b7c1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OccupancyExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_dd143457-2e5c-4712-b11a-95a81f0fea14" xlink:to="loc_ifrs-full_OccupancyExpense_0d268125-43ef-4b09-b79c-2e2c577b7c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfessionalFeesExpense_3253502c-5c25-4542-a8b7-cab56910f59b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfessionalFeesExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_dd143457-2e5c-4712-b11a-95a81f0fea14" xlink:to="loc_ifrs-full_ProfessionalFeesExpense_3253502c-5c25-4542-a8b7-cab56910f59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_BusinessDevelopmentExpense_9449f031-77e6-4758-8173-e208fb7602cf" xlink:href="cybn-20250331.xsd#cybn_BusinessDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_dd143457-2e5c-4712-b11a-95a81f0fea14" xlink:to="loc_cybn_BusinessDevelopmentExpense_9449f031-77e6-4758-8173-e208fb7602cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_InvestorRelationsSalesAndMarketingExpense_ceef5931-28b5-4b7a-8967-c72cab07f1fc" xlink:href="cybn-20250331.xsd#cybn_InvestorRelationsSalesAndMarketingExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_dd143457-2e5c-4712-b11a-95a81f0fea14" xlink:to="loc_cybn_InvestorRelationsSalesAndMarketingExpense_ceef5931-28b5-4b7a-8967-c72cab07f1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ListingFeesExpense_1fc3eda0-e5f8-4214-ac49-0ab74339b969" xlink:href="cybn-20250331.xsd#cybn_ListingFeesExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_dd143457-2e5c-4712-b11a-95a81f0fea14" xlink:to="loc_cybn_ListingFeesExpense_1fc3eda0-e5f8-4214-ac49-0ab74339b969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_b4be468c-073e-42f6-8df4-f3ffd352718e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_dd143457-2e5c-4712-b11a-95a81f0fea14" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_b4be468c-073e-42f6-8df4-f3ffd352718e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#CONTRACTSCOMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CommitmentsAbstract_4d32081b-ef56-459a-9d23-3f3df33f8fb3" xlink:href="cybn-20250331.xsd#cybn_CommitmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_COMMITMENTSTable_a8f96588-a3b8-4f5d-b9e9-1f4f3655712c" xlink:href="cybn-20250331.xsd#cybn_COMMITMENTSTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_CommitmentsAbstract_4d32081b-ef56-459a-9d23-3f3df33f8fb3" xlink:to="loc_cybn_COMMITMENTSTable_a8f96588-a3b8-4f5d-b9e9-1f4f3655712c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ItemsOfContingentLiabilitiesAxis_004d793c-ad92-4b00-b00b-cc92bd84e544" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ItemsOfContingentLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_COMMITMENTSTable_a8f96588-a3b8-4f5d-b9e9-1f4f3655712c" xlink:to="loc_ifrs-full_ItemsOfContingentLiabilitiesAxis_004d793c-ad92-4b00-b00b-cc92bd84e544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ItemsOfContingentLiabilitiesDomain_64e9996e-c0dc-4c14-8856-e9cede5381af" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ItemsOfContingentLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ItemsOfContingentLiabilitiesAxis_004d793c-ad92-4b00-b00b-cc92bd84e544" xlink:to="loc_ifrs-full_ItemsOfContingentLiabilitiesDomain_64e9996e-c0dc-4c14-8856-e9cede5381af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherContingentLiabilitiesMember_e06f60a7-4ec9-4af0-8ac9-77de9044f708" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherContingentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ItemsOfContingentLiabilitiesDomain_64e9996e-c0dc-4c14-8856-e9cede5381af" xlink:to="loc_ifrs-full_OtherContingentLiabilitiesMember_e06f60a7-4ec9-4af0-8ac9-77de9044f708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_COMMITMENTSLineItems_b5a3ca18-aece-411b-aef6-ef983cdf3f97" xlink:href="cybn-20250331.xsd#cybn_COMMITMENTSLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_COMMITMENTSTable_a8f96588-a3b8-4f5d-b9e9-1f4f3655712c" xlink:to="loc_cybn_COMMITMENTSLineItems_b5a3ca18-aece-411b-aef6-ef983cdf3f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractualCapitalCommitments_76f78418-8ccc-4768-b5df-2c8bf99051c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractualCapitalCommitments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_COMMITMENTSLineItems_b5a3ca18-aece-411b-aef6-ef983cdf3f97" xlink:to="loc_ifrs-full_ContractualCapitalCommitments_76f78418-8ccc-4768-b5df-2c8bf99051c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SalesRoyaltyPercentage_54d3f044-854c-4ac2-a8a5-8c64f07b52ea" xlink:href="cybn-20250331.xsd#cybn_SalesRoyaltyPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_COMMITMENTSLineItems_b5a3ca18-aece-411b-aef6-ef983cdf3f97" xlink:to="loc_cybn_SalesRoyaltyPercentage_54d3f044-854c-4ac2-a8a5-8c64f07b52ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/CAPITALMANAGEMENTDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#CAPITALMANAGEMENTDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/CAPITALMANAGEMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CapitalManagementAbstract_65fcb3dd-5d68-4a6a-b91b-95e4ba90d79f" xlink:href="cybn-20250331.xsd#cybn_CapitalManagementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_34f4341e-adc6-44ab-97f0-2b45ad262f87" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_CapitalManagementAbstract_65fcb3dd-5d68-4a6a-b91b-95e4ba90d79f" xlink:to="loc_ifrs-full_IssuedCapital_34f4341e-adc6-44ab-97f0-2b45ad262f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremium_8f3af206-5b6f-470a-8cac-6d3081f54623" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_CapitalManagementAbstract_65fcb3dd-5d68-4a6a-b91b-95e4ba90d79f" xlink:to="loc_ifrs-full_SharePremium_8f3af206-5b6f-470a-8cac-6d3081f54623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPayments_bb20fdea-ad4c-443d-a5f8-7de6a7c8f55d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_CapitalManagementAbstract_65fcb3dd-5d68-4a6a-b91b-95e4ba90d79f" xlink:to="loc_ifrs-full_ReserveOfSharebasedPayments_bb20fdea-ad4c-443d-a5f8-7de6a7c8f55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantReserve_0c61143b-0964-4c4b-b6cb-0fa4b8c8e156" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_CapitalManagementAbstract_65fcb3dd-5d68-4a6a-b91b-95e4ba90d79f" xlink:to="loc_ifrs-full_WarrantReserve_0c61143b-0964-4c4b-b6cb-0fa4b8c8e156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_67ceeea5-ab40-418c-b11c-9b813a4da2f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_CapitalManagementAbstract_65fcb3dd-5d68-4a6a-b91b-95e4ba90d79f" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_67ceeea5-ab40-418c-b11c-9b813a4da2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_abd78b38-3383-44e2-aab8-2a52100011a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_CapitalManagementAbstract_65fcb3dd-5d68-4a6a-b91b-95e4ba90d79f" xlink:to="loc_ifrs-full_RetainedEarnings_abd78b38-3383-44e2-aab8-2a52100011a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_f81ba503-25ef-4b36-bf1e-2c1aa25c0629" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_CapitalManagementAbstract_65fcb3dd-5d68-4a6a-b91b-95e4ba90d79f" xlink:to="loc_ifrs-full_Equity_f81ba503-25ef-4b36-bf1e-2c1aa25c0629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_FinancialInstrumentsAbstract_8a1417c3-23df-464b-aede-634fdc164301" xlink:href="cybn-20250331.xsd#cybn_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_7914a5fe-3fac-4110-9497-257b0ed808db" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_FinancialInstrumentsAbstract_8a1417c3-23df-464b-aede-634fdc164301" xlink:to="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_7914a5fe-3fac-4110-9497-257b0ed808db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_86b07139-1f5a-4984-80d7-e63544b1f4a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_7914a5fe-3fac-4110-9497-257b0ed808db" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_86b07139-1f5a-4984-80d7-e63544b1f4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_78eec2b6-6189-4f51-9e9f-a6e21d596cfe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsAxis_86b07139-1f5a-4984-80d7-e63544b1f4a9" xlink:to="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_78eec2b6-6189-4f51-9e9f-a6e21d596cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_db41c549-2608-42c1-a169-629a82f605a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_78eec2b6-6189-4f51-9e9f-a6e21d596cfe" xlink:to="loc_ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember_db41c549-2608-42c1-a169-629a82f605a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_5dfb721d-5aaa-4e68-a471-bb745f89a5ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialAssetsDomain_78eec2b6-6189-4f51-9e9f-a6e21d596cfe" xlink:to="loc_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_5dfb721d-5aaa-4e68-a471-bb745f89a5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsAxis_71f78bc3-40c6-4dfe-9385-6af92fa1e6fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_7914a5fe-3fac-4110-9497-257b0ed808db" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsAxis_71f78bc3-40c6-4dfe-9385-6af92fa1e6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialAssetsDomain_0c641725-5655-4558-9281-564e83ed57c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsAxis_71f78bc3-40c6-4dfe-9385-6af92fa1e6fa" xlink:to="loc_ifrs-full_ClassesOfFinancialAssetsDomain_0c641725-5655-4558-9281-564e83ed57c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CashMember_a9daacc2-f19c-453b-9e44-0d8981241bb2" xlink:href="cybn-20250331.xsd#cybn_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_0c641725-5655-4558-9281-564e83ed57c4" xlink:to="loc_cybn_CashMember_a9daacc2-f19c-453b-9e44-0d8981241bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember_c9b8a0cd-ecd2-4fb7-acf2-8d6e2cbaff85" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialAssetsDomain_0c641725-5655-4558-9281-564e83ed57c4" xlink:to="loc_ifrs-full_TradeReceivablesMember_c9b8a0cd-ecd2-4fb7-acf2-8d6e2cbaff85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_6b1b8360-0444-4295-8995-80bac112983b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_7914a5fe-3fac-4110-9497-257b0ed808db" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_6b1b8360-0444-4295-8995-80bac112983b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_eaac8f6e-7d73-4b21-97f5-c736811d74dd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_6b1b8360-0444-4295-8995-80bac112983b" xlink:to="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_eaac8f6e-7d73-4b21-97f5-c736811d74dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_4a22e53b-b8db-4324-b62e-ea2a56aca5ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CategoriesOfFinancialLiabilitiesDomain_eaac8f6e-7d73-4b21-97f5-c736811d74dd" xlink:to="loc_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_4a22e53b-b8db-4324-b62e-ea2a56aca5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_41209467-671f-4572-8f3c-7d29d7ccc0f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_7914a5fe-3fac-4110-9497-257b0ed808db" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_41209467-671f-4572-8f3c-7d29d7ccc0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f0d14633-e018-4b61-b4c5-d16f46cfa913" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesAxis_41209467-671f-4572-8f3c-7d29d7ccc0f7" xlink:to="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f0d14633-e018-4b61-b4c5-d16f46cfa913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AccountsPayableAndAccruedLiabilitiesMember_407697f8-30d9-4e7c-8fe0-017c578c2049" xlink:href="cybn-20250331.xsd#cybn_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f0d14633-e018-4b61-b4c5-d16f46cfa913" xlink:to="loc_cybn_AccountsPayableAndAccruedLiabilitiesMember_407697f8-30d9-4e7c-8fe0-017c578c2049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_59c699e8-fdbb-4545-baae-c71d57834d55" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfFinancialLiabilitiesDomain_f0d14633-e018-4b61-b4c5-d16f46cfa913" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_59c699e8-fdbb-4545-baae-c71d57834d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_6390f1b0-0cbb-4600-9682-6ec7d50f571f" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_7914a5fe-3fac-4110-9497-257b0ed808db" xlink:to="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_6390f1b0-0cbb-4600-9682-6ec7d50f571f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_dde08be9-bd56-4c29-be77-fa6d6c8abb7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_6390f1b0-0cbb-4600-9682-6ec7d50f571f" xlink:to="loc_ifrs-full_Cash_dde08be9-bd56-4c29-be77-fa6d6c8abb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentReceivables_65f79035-cf27-49d8-b198-8e30a425060d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_6390f1b0-0cbb-4600-9682-6ec7d50f571f" xlink:to="loc_ifrs-full_TradeAndOtherCurrentReceivables_65f79035-cf27-49d8-b198-8e30a425060d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_a2130a81-98c2-40eb-89a8-0afed941ca00" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_6390f1b0-0cbb-4600-9682-6ec7d50f571f" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_a2130a81-98c2-40eb-89a8-0afed941ca00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_2e948b32-397f-4e77-b9fd-281858335a23" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_6390f1b0-0cbb-4600-9682-6ec7d50f571f" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_2e948b32-397f-4e77-b9fd-281858335a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#FINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_FinancialInstrumentsAbstract_c350c791-5c6e-45ee-a004-b0c83deac823" xlink:href="cybn-20250331.xsd#cybn_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_54a39549-acef-4788-a565-6aa1a2a40c02" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_FinancialInstrumentsAbstract_c350c791-5c6e-45ee-a004-b0c83deac823" xlink:to="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_54a39549-acef-4788-a565-6aa1a2a40c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_63b1c960-8530-4d99-8777-b287d33359e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_54a39549-acef-4788-a565-6aa1a2a40c02" xlink:to="loc_ifrs-full_TypesOfRisksAxis_63b1c960-8530-4d99-8777-b287d33359e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksDomain_4cab5e24-4fb1-4d75-bccf-416a33a673d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_63b1c960-8530-4d99-8777-b287d33359e4" xlink:to="loc_ifrs-full_TypesOfRisksDomain_4cab5e24-4fb1-4d75-bccf-416a33a673d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_4349aa9b-d7f3-47e0-8dc0-cfa6729cd8b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksDomain_4cab5e24-4fb1-4d75-bccf-416a33a673d7" xlink:to="loc_ifrs-full_CurrencyRiskMember_4349aa9b-d7f3-47e0-8dc0-cfa6729cd8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable_54a39549-acef-4788-a565-6aa1a2a40c02" xlink:to="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Cash_60b118f7-74b1-4649-9aab-94d7941123b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:to="loc_ifrs-full_Cash_60b118f7-74b1-4649-9aab-94d7941123b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_23729e75-f7e1-4e54-92df-169864fe5fb2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:to="loc_ifrs-full_CurrentLiabilities_23729e75-f7e1-4e54-92df-169864fe5fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_afe4bbed-66aa-4441-bb99-cd4e416130c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:to="loc_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_afe4bbed-66aa-4441-bb99-cd4e416130c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent_9466682d-0c10-4aca-b113-19d532fe1784" xlink:href="cybn-20250331.xsd#cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:to="loc_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent_9466682d-0c10-4aca-b113-19d532fe1784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss_7b012ac3-2ded-4332-8adc-e181aa485f87" xlink:href="cybn-20250331.xsd#cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:to="loc_cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss_7b012ac3-2ded-4332-8adc-e181aa485f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash_6c7562eb-6fe8-44e3-b89f-0dfc80f34eb8" xlink:href="cybn-20250331.xsd#cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:to="loc_cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash_6c7562eb-6fe8-44e3-b89f-0dfc80f34eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_InterestRateRiskIncreaseDecreaseInInterestIncome_0ebf8d5e-9ce7-48c8-a7bf-e59496b1d697" xlink:href="cybn-20250331.xsd#cybn_InterestRateRiskIncreaseDecreaseInInterestIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:to="loc_cybn_InterestRateRiskIncreaseDecreaseInInterestIncome_0ebf8d5e-9ce7-48c8-a7bf-e59496b1d697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_InterestRateRiskTerm_c6058572-f529-4086-a04c-711cd83fd199" xlink:href="cybn-20250331.xsd#cybn_InterestRateRiskTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems_91af326d-9484-4d20-9f22-36341e3e57ab" xlink:to="loc_cybn_InterestRateRiskTerm_c6058572-f529-4086-a04c-711cd83fd199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_FinancialInstrumentsAbstract_6a40e574-779a-492e-8621-d8b48c4a47de" xlink:href="cybn-20250331.xsd#cybn_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c925c40d-1193-4196-83fd-95c00891334d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_FinancialInstrumentsAbstract_6a40e574-779a-492e-8621-d8b48c4a47de" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c925c40d-1193-4196-83fd-95c00891334d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_4c08c406-675b-4f4a-b6ed-a7de75784566" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c925c40d-1193-4196-83fd-95c00891334d" xlink:to="loc_srt_CurrencyAxis_4c08c406-675b-4f4a-b6ed-a7de75784566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_1efdd05f-1d11-4835-b8b9-7c9ae1f17148" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_4c08c406-675b-4f4a-b6ed-a7de75784566" xlink:to="loc_currency_AllCurrenciesDomain_1efdd05f-1d11-4835-b8b9-7c9ae1f17148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_dad29d3e-ced4-4ff8-bf38-b223ff33ff93" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1efdd05f-1d11-4835-b8b9-7c9ae1f17148" xlink:to="loc_currency_USD_dad29d3e-ced4-4ff8-bf38-b223ff33ff93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_762f56cc-0c5d-4dd5-b9a7-f5f0c5b49d87" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_GBP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1efdd05f-1d11-4835-b8b9-7c9ae1f17148" xlink:to="loc_currency_GBP_762f56cc-0c5d-4dd5-b9a7-f5f0c5b49d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_adca0c4d-a8c2-4b49-a054-73e61be3a4d2" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_1efdd05f-1d11-4835-b8b9-7c9ae1f17148" xlink:to="loc_currency_EUR_adca0c4d-a8c2-4b49-a054-73e61be3a4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis_1c4284d0-8174-4437-a0a5-f663838fd237" xlink:href="cybn-20250331.xsd#cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c925c40d-1193-4196-83fd-95c00891334d" xlink:to="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis_1c4284d0-8174-4437-a0a5-f663838fd237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain_af54d291-d2a3-4cb9-93c8-5a2a27b24e25" xlink:href="cybn-20250331.xsd#cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis_1c4284d0-8174-4437-a0a5-f663838fd237" xlink:to="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain_af54d291-d2a3-4cb9-93c8-5a2a27b24e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_CashMember_38b6140d-8438-4194-911a-9a59ce522fd5" xlink:href="cybn-20250331.xsd#cybn_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain_af54d291-d2a3-4cb9-93c8-5a2a27b24e25" xlink:to="loc_cybn_CashMember_38b6140d-8438-4194-911a-9a59ce522fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeReceivablesMember_3f81474f-08d5-4b97-8e05-f694696798d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain_af54d291-d2a3-4cb9-93c8-5a2a27b24e25" xlink:to="loc_ifrs-full_TradeReceivablesMember_3f81474f-08d5-4b97-8e05-f694696798d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_AccountsPayableAndAccruedLiabilitiesMember_4bc4b2c2-9fda-4998-a73d-55263439ccb8" xlink:href="cybn-20250331.xsd#cybn_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain_af54d291-d2a3-4cb9-93c8-5a2a27b24e25" xlink:to="loc_cybn_AccountsPayableAndAccruedLiabilitiesMember_4bc4b2c2-9fda-4998-a73d-55263439ccb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesMember_52596111-ff4b-4612-a48a-a2e097c4ce44" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain_af54d291-d2a3-4cb9-93c8-5a2a27b24e25" xlink:to="loc_ifrs-full_LeaseLiabilitiesMember_52596111-ff4b-4612-a48a-a2e097c4ce44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_c211eb95-98be-460c-8847-f5adc5f5c144" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_c925c40d-1193-4196-83fd-95c00891334d" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_c211eb95-98be-460c-8847-f5adc5f5c144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_FinancialAssetsAndLiabilities_129d9b50-6034-4f1a-bfaa-7b59c16bf086" xlink:href="cybn-20250331.xsd#cybn_FinancialAssetsAndLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_c211eb95-98be-460c-8847-f5adc5f5c144" xlink:to="loc_cybn_FinancialAssetsAndLiabilities_129d9b50-6034-4f1a-bfaa-7b59c16bf086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClosingForeignExchangeRate_69170b91-c973-4274-86be-cd875757e8b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClosingForeignExchangeRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_c211eb95-98be-460c-8847-f5adc5f5c144" xlink:to="loc_ifrs-full_ClosingForeignExchangeRate_69170b91-c973-4274-86be-cd875757e8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_a5e78a84-47d4-4faa-b0a7-b93a3d00c545" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_c211eb95-98be-460c-8847-f5adc5f5c144" xlink:to="loc_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_a5e78a84-47d4-4faa-b0a7-b93a3d00c545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#INCOMETAXIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncomeTaxesAbstract_aef8a2c1-0cad-448c-ab95-3bfe6504e356" xlink:href="cybn-20250331.xsd#cybn_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_a9ec87c7-166e-48d9-b7f4-73b7f022eb95" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeTaxesAbstract_aef8a2c1-0cad-448c-ab95-3bfe6504e356" xlink:to="loc_ifrs-full_ProfitLoss_a9ec87c7-166e-48d9-b7f4-73b7f022eb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_934d7ba1-1914-4afe-92b2-3f2556d7e377" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeTaxesAbstract_aef8a2c1-0cad-448c-ab95-3bfe6504e356" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_934d7ba1-1914-4afe-92b2-3f2556d7e377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset_f37278bf-29e0-41cc-a138-326d5c6d5b2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeTaxesAbstract_aef8a2c1-0cad-448c-ab95-3bfe6504e356" xlink:to="loc_ifrs-full_ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset_f37278bf-29e0-41cc-a138-326d5c6d5b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_TaxEffectOfShareBasedCompensation_65cac1b6-0021-4c58-9b5a-09e0ecb68add" xlink:href="cybn-20250331.xsd#cybn_TaxEffectOfShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeTaxesAbstract_aef8a2c1-0cad-448c-ab95-3bfe6504e356" xlink:to="loc_cybn_TaxEffectOfShareBasedCompensation_65cac1b6-0021-4c58-9b5a-09e0ecb68add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_TaxEffectOfShareIssuanceCosts_3cbc3af6-fb26-40c1-bfc1-782860ddfdd0" xlink:href="cybn-20250331.xsd#cybn_TaxEffectOfShareIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeTaxesAbstract_aef8a2c1-0cad-448c-ab95-3bfe6504e356" xlink:to="loc_cybn_TaxEffectOfShareIssuanceCosts_3cbc3af6-fb26-40c1-bfc1-782860ddfdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_7b172fb6-d604-45aa-a62b-327ca6f84836" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeTaxesAbstract_aef8a2c1-0cad-448c-ab95-3bfe6504e356" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_7b172fb6-d604-45aa-a62b-327ca6f84836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset_17153eeb-433a-4c29-a0a1-257d9661ff5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeTaxesAbstract_aef8a2c1-0cad-448c-ab95-3bfe6504e356" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset_17153eeb-433a-4c29-a0a1-257d9661ff5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_73903a49-291a-4c2f-a85c-78473bb9f3b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeTaxesAbstract_aef8a2c1-0cad-448c-ab95-3bfe6504e356" xlink:to="loc_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_73903a49-291a-4c2f-a85c-78473bb9f3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_TaxEffectOfChangeInDeferredTaxAssets_8898fb51-0c89-4634-ad3b-f1ce5d64a7a5" xlink:href="cybn-20250331.xsd#cybn_TaxEffectOfChangeInDeferredTaxAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeTaxesAbstract_aef8a2c1-0cad-448c-ab95-3bfe6504e356" xlink:to="loc_cybn_TaxEffectOfChangeInDeferredTaxAssets_8898fb51-0c89-4634-ad3b-f1ce5d64a7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_73ba71bd-ab5d-4f00-9da3-dacd9224fb50" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeTaxesAbstract_aef8a2c1-0cad-448c-ab95-3bfe6504e356" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_73ba71bd-ab5d-4f00-9da3-dacd9224fb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#INCOMETAXDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncomeTaxesAbstract_3e62341d-25b9-48da-991f-18cb6f9da53d" xlink:href="cybn-20250331.xsd#cybn_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f25e1188-3a25-4102-b940-012fcce5fb71" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeTaxesAbstract_3e62341d-25b9-48da-991f-18cb6f9da53d" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f25e1188-3a25-4102-b940-012fcce5fb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_7de7dd9f-9af4-4122-ad74-50ca10e223d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f25e1188-3a25-4102-b940-012fcce5fb71" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_7de7dd9f-9af4-4122-ad74-50ca10e223d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_25312568-bfe7-4d9d-83c2-c7bcb1096a89" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_7de7dd9f-9af4-4122-ad74-50ca10e223d5" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_25312568-bfe7-4d9d-83c2-c7bcb1096a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_1504a2a9-a6e6-4200-b6b9-824c472525c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_25312568-bfe7-4d9d-83c2-c7bcb1096a89" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_1504a2a9-a6e6-4200-b6b9-824c472525c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DeferredCompensationMember_4a9591b7-5774-4797-a956-c60e1ca9efa6" xlink:href="cybn-20250331.xsd#cybn_DeferredCompensationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_25312568-bfe7-4d9d-83c2-c7bcb1096a89" xlink:to="loc_cybn_DeferredCompensationMember_4a9591b7-5774-4797-a956-c60e1ca9efa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_RDExpendituresMember_c2bffc26-8b31-47e8-84fe-7c2e8765912e" xlink:href="cybn-20250331.xsd#cybn_RDExpendituresMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_25312568-bfe7-4d9d-83c2-c7bcb1096a89" xlink:to="loc_cybn_RDExpendituresMember_c2bffc26-8b31-47e8-84fe-7c2e8765912e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ShareIssuanceCostsMember_7cdfc7b9-4b47-480f-a6c2-f36f61fd181d" xlink:href="cybn-20250331.xsd#cybn_ShareIssuanceCostsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_25312568-bfe7-4d9d-83c2-c7bcb1096a89" xlink:to="loc_cybn_ShareIssuanceCostsMember_7cdfc7b9-4b47-480f-a6c2-f36f61fd181d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember_eec14e49-2dc0-4dba-b6a3-38cd9d3aad3d" xlink:href="cybn-20250331.xsd#cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_25312568-bfe7-4d9d-83c2-c7bcb1096a89" xlink:to="loc_cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember_eec14e49-2dc0-4dba-b6a3-38cd9d3aad3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8a4909a0-267d-40e9-b3d1-b484af43ab6d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f25e1188-3a25-4102-b940-012fcce5fb71" xlink:to="loc_srt_StatementGeographicalAxis_8a4909a0-267d-40e9-b3d1-b484af43ab6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e246ac3f-3251-40a7-9b08-f34859399b40" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8a4909a0-267d-40e9-b3d1-b484af43ab6d" xlink:to="loc_srt_SegmentGeographicalDomain_e246ac3f-3251-40a7-9b08-f34859399b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_ab99f890-8eb3-4814-bab8-ebd13c03460a" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e246ac3f-3251-40a7-9b08-f34859399b40" xlink:to="loc_country_CA_ab99f890-8eb3-4814-bab8-ebd13c03460a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ab615412-9443-4a3c-9079-18c86dda5a9e" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e246ac3f-3251-40a7-9b08-f34859399b40" xlink:to="loc_country_US_ab615412-9443-4a3c-9079-18c86dda5a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_8a9ffdb7-bbec-4c8e-b6c0-54abb1c448ea" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IE"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e246ac3f-3251-40a7-9b08-f34859399b40" xlink:to="loc_country_IE_8a9ffdb7-bbec-4c8e-b6c0-54abb1c448ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_1de04e4a-f19d-46cd-998d-3104937b648e" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e246ac3f-3251-40a7-9b08-f34859399b40" xlink:to="loc_country_GB_1de04e4a-f19d-46cd-998d-3104937b648e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_47a3475e-c99f-432e-992a-7fa3cddb641d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_f25e1188-3a25-4102-b940-012fcce5fb71" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_47a3475e-c99f-432e-992a-7fa3cddb641d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_GrossDeferredTaxAssets_8a1c1735-5c39-4abe-95f3-c40be3365508" xlink:href="cybn-20250331.xsd#cybn_GrossDeferredTaxAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_47a3475e-c99f-432e-992a-7fa3cddb641d" xlink:to="loc_cybn_GrossDeferredTaxAssets_8a1c1735-5c39-4abe-95f3-c40be3365508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DeferredTaxAssetsValuationAllowance_630bd1ce-ffe9-4094-b5ad-c83c4d60e1f8" xlink:href="cybn-20250331.xsd#cybn_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_47a3475e-c99f-432e-992a-7fa3cddb641d" xlink:to="loc_cybn_DeferredTaxAssetsValuationAllowance_630bd1ce-ffe9-4094-b5ad-c83c4d60e1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeferredTaxAssets_d0f44e2b-17af-46b1-ab01-507110909ad4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_47a3475e-c99f-432e-992a-7fa3cddb641d" xlink:to="loc_ifrs-full_DeferredTaxAssets_d0f44e2b-17af-46b1-ab01-507110909ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#INCOMETAXNoncapitalLossesExpirationDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncomeTaxesAbstract_660b4181-552c-41b1-83f3-8cf11b2c6095" xlink:href="cybn-20250331.xsd#cybn_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable_e5f785e9-8276-41cc-b6b3-ddb9e45f0268" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfNonCapitalLossesExpirationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeTaxesAbstract_660b4181-552c-41b1-83f3-8cf11b2c6095" xlink:to="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable_e5f785e9-8276-41cc-b6b3-ddb9e45f0268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LossCarryforwardExpirationAxis_3c2f4e85-c908-4f30-832b-1bb6604b79bf" xlink:href="cybn-20250331.xsd#cybn_LossCarryforwardExpirationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable_e5f785e9-8276-41cc-b6b3-ddb9e45f0268" xlink:to="loc_cybn_LossCarryforwardExpirationAxis_3c2f4e85-c908-4f30-832b-1bb6604b79bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:href="cybn-20250331.xsd#cybn_LossCarryforwardExpirationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_LossCarryforwardExpirationAxis_3c2f4e85-c908-4f30-832b-1bb6604b79bf" xlink:to="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2036Member_32bbee4a-d61d-4c70-809c-3c0c6fc285f3" xlink:href="cybn-20250331.xsd#cybn_A2036Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2036Member_32bbee4a-d61d-4c70-809c-3c0c6fc285f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2037Member_39c81b44-8ba4-4cb1-82b7-9dcf2262d033" xlink:href="cybn-20250331.xsd#cybn_A2037Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2037Member_39c81b44-8ba4-4cb1-82b7-9dcf2262d033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2038Member_ba60715e-2e01-4fd7-aaf6-ce587e1c2cad" xlink:href="cybn-20250331.xsd#cybn_A2038Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2038Member_ba60715e-2e01-4fd7-aaf6-ce587e1c2cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2039Member_260d3dca-b588-4075-805e-451c12889872" xlink:href="cybn-20250331.xsd#cybn_A2039Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2039Member_260d3dca-b588-4075-805e-451c12889872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2040Member_68f66e6e-a84e-4069-a79a-2e82cc6d3efc" xlink:href="cybn-20250331.xsd#cybn_A2040Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2040Member_68f66e6e-a84e-4069-a79a-2e82cc6d3efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2041Member_91b21b40-bbd2-404f-8b52-ef84a8b4ee46" xlink:href="cybn-20250331.xsd#cybn_A2041Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2041Member_91b21b40-bbd2-404f-8b52-ef84a8b4ee46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2042Member_f10ed48f-8b8d-4017-9b81-b3f38a4af6a6" xlink:href="cybn-20250331.xsd#cybn_A2042Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2042Member_f10ed48f-8b8d-4017-9b81-b3f38a4af6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2043Member_8f6ef45b-d26c-4634-a7c2-517a5685a2b1" xlink:href="cybn-20250331.xsd#cybn_A2043Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2043Member_8f6ef45b-d26c-4634-a7c2-517a5685a2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2044Member_0b38c33d-ba7d-427f-9146-454bddd9bccd" xlink:href="cybn-20250331.xsd#cybn_A2044Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2044Member_0b38c33d-ba7d-427f-9146-454bddd9bccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2045Member_d2c74987-6c74-4258-9d1f-8b4dee26f61e" xlink:href="cybn-20250331.xsd#cybn_A2045Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_6025003c-298b-4104-85ea-0a8930b911f5" xlink:to="loc_cybn_A2045Member_d2c74987-6c74-4258-9d1f-8b4dee26f61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_777a6f23-e94e-4633-ac4a-9ffbfbf4247a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable_e5f785e9-8276-41cc-b6b3-ddb9e45f0268" xlink:to="loc_srt_StatementGeographicalAxis_777a6f23-e94e-4633-ac4a-9ffbfbf4247a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ca930b70-8d81-4af2-a032-7dbedad9eaaf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_777a6f23-e94e-4633-ac4a-9ffbfbf4247a" xlink:to="loc_srt_SegmentGeographicalDomain_ca930b70-8d81-4af2-a032-7dbedad9eaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_287a7bfd-9966-41d0-bef4-0eeae4e125a9" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca930b70-8d81-4af2-a032-7dbedad9eaaf" xlink:to="loc_country_CA_287a7bfd-9966-41d0-bef4-0eeae4e125a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0cb6b2ce-cb3e-4d88-945c-0d69591cf823" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca930b70-8d81-4af2-a032-7dbedad9eaaf" xlink:to="loc_country_US_0cb6b2ce-cb3e-4d88-945c-0d69591cf823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_d7109f96-835e-4a8e-a9e3-ed46b430ffa4" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IE"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca930b70-8d81-4af2-a032-7dbedad9eaaf" xlink:to="loc_country_IE_d7109f96-835e-4a8e-a9e3-ed46b430ffa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_2083d2c1-a0f2-414c-95ab-ba55fd0aefc6" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ca930b70-8d81-4af2-a032-7dbedad9eaaf" xlink:to="loc_country_GB_2083d2c1-a0f2-414c-95ab-ba55fd0aefc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfNonCapitalLossesExpirationLineItems_00f90855-fe8f-438e-bde0-a5e7f7f6f753" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfNonCapitalLossesExpirationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable_e5f785e9-8276-41cc-b6b3-ddb9e45f0268" xlink:to="loc_cybn_DisclosureOfNonCapitalLossesExpirationLineItems_00f90855-fe8f-438e-bde0-a5e7f7f6f753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NonCapitalLossCarryforward_1bd84b2d-dafe-425b-9ac8-dc3ff22929a5" xlink:href="cybn-20250331.xsd#cybn_NonCapitalLossCarryforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationLineItems_00f90855-fe8f-438e-bde0-a5e7f7f6f753" xlink:to="loc_cybn_NonCapitalLossCarryforward_1bd84b2d-dafe-425b-9ac8-dc3ff22929a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/INCOMETAXAdditionalInformationDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#INCOMETAXAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/INCOMETAXAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_IncomeTaxesAbstract_71e2336d-9e02-4356-af0f-b8d575773e0e" xlink:href="cybn-20250331.xsd#cybn_IncomeTaxesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable_b57e1f2b-6e4e-436f-984a-06ba2002d232" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfNonCapitalLossesExpirationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_IncomeTaxesAbstract_71e2336d-9e02-4356-af0f-b8d575773e0e" xlink:to="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable_b57e1f2b-6e4e-436f-984a-06ba2002d232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4b42b825-bbae-41a5-acb7-bdd3863a8b44" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable_b57e1f2b-6e4e-436f-984a-06ba2002d232" xlink:to="loc_srt_StatementGeographicalAxis_4b42b825-bbae-41a5-acb7-bdd3863a8b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_94f2f334-8fcf-4767-81ad-907ff26f3395" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4b42b825-bbae-41a5-acb7-bdd3863a8b44" xlink:to="loc_srt_SegmentGeographicalDomain_94f2f334-8fcf-4767-81ad-907ff26f3395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_734f2450-d8e0-417c-93c2-b04d6f3452d9" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_94f2f334-8fcf-4767-81ad-907ff26f3395" xlink:to="loc_country_GB_734f2450-d8e0-417c-93c2-b04d6f3452d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_92f11202-a5a1-49e9-b3e6-5ab6f3c8a8c8" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_94f2f334-8fcf-4767-81ad-907ff26f3395" xlink:to="loc_country_US_92f11202-a5a1-49e9-b3e6-5ab6f3c8a8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LossCarryforwardExpirationAxis_8d9bdf84-b178-4402-8729-ac9381cc53db" xlink:href="cybn-20250331.xsd#cybn_LossCarryforwardExpirationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable_b57e1f2b-6e4e-436f-984a-06ba2002d232" xlink:to="loc_cybn_LossCarryforwardExpirationAxis_8d9bdf84-b178-4402-8729-ac9381cc53db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_LossCarryforwardExpirationDomain_8af9d68e-3ec6-488a-b9bc-00fb68a6bb98" xlink:href="cybn-20250331.xsd#cybn_LossCarryforwardExpirationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_LossCarryforwardExpirationAxis_8d9bdf84-b178-4402-8729-ac9381cc53db" xlink:to="loc_cybn_LossCarryforwardExpirationDomain_8af9d68e-3ec6-488a-b9bc-00fb68a6bb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A20402041Member_12b9b08b-85f0-4112-9b04-7f2d05f8b138" xlink:href="cybn-20250331.xsd#cybn_A20402041Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_8af9d68e-3ec6-488a-b9bc-00fb68a6bb98" xlink:to="loc_cybn_A20402041Member_12b9b08b-85f0-4112-9b04-7f2d05f8b138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_A2040Member_519e25ac-9e99-4237-aacf-a7ea6b7017e9" xlink:href="cybn-20250331.xsd#cybn_A2040Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_LossCarryforwardExpirationDomain_8af9d68e-3ec6-488a-b9bc-00fb68a6bb98" xlink:to="loc_cybn_A2040Member_519e25ac-9e99-4237-aacf-a7ea6b7017e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DisclosureOfNonCapitalLossesExpirationLineItems_d1ab2306-fabd-44cd-becf-a9439aa60b38" xlink:href="cybn-20250331.xsd#cybn_DisclosureOfNonCapitalLossesExpirationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationTable_b57e1f2b-6e4e-436f-984a-06ba2002d232" xlink:to="loc_cybn_DisclosureOfNonCapitalLossesExpirationLineItems_d1ab2306-fabd-44cd-becf-a9439aa60b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NonCapitalLossCarryforward_e489b5d5-84a7-4280-ba5c-9dc446287abb" xlink:href="cybn-20250331.xsd#cybn_NonCapitalLossCarryforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationLineItems_d1ab2306-fabd-44cd-becf-a9439aa60b38" xlink:to="loc_cybn_NonCapitalLossCarryforward_e489b5d5-84a7-4280-ba5c-9dc446287abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_Section382Limitation_346b2062-b2a4-4a0f-9174-4f2926a3b3f1" xlink:href="cybn-20250331.xsd#cybn_Section382Limitation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_DisclosureOfNonCapitalLossesExpirationLineItems_d1ab2306-fabd-44cd-becf-a9439aa60b38" xlink:to="loc_cybn_Section382Limitation_346b2062-b2a4-4a0f-9174-4f2926a3b3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cybin.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="cybn-20250331.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://cybin.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cybn_EventsAfterReportingPeriodAbstract_095f4621-8ea4-414d-92c5-8b30c3b19d0c" xlink:href="cybn-20250331.xsd#cybn_EventsAfterReportingPeriodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_41105518-258b-482a-a243-81ce2135017c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_EventsAfterReportingPeriodAbstract_095f4621-8ea4-414d-92c5-8b30c3b19d0c" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_41105518-258b-482a-a243-81ce2135017c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_5b810831-8268-4d55-8f5e-c14d91694d83" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_41105518-258b-482a-a243-81ce2135017c" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_5b810831-8268-4d55-8f5e-c14d91694d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_7df0c10b-3440-44b8-b020-a608e962a7ac" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_5b810831-8268-4d55-8f5e-c14d91694d83" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_7df0c10b-3440-44b8-b020-a608e962a7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_fb2b0c63-3fe4-4e06-94ca-391192444600" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_7df0c10b-3440-44b8-b020-a608e962a7ac" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_fb2b0c63-3fe4-4e06-94ca-391192444600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_0b3f848d-ce22-4502-a1bc-363ba96424da" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_41105518-258b-482a-a243-81ce2135017c" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_0b3f848d-ce22-4502-a1bc-363ba96424da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_8f38e12d-e846-4847-b34f-352d8735ce18" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_0b3f848d-ce22-4502-a1bc-363ba96424da" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_8f38e12d-e846-4847-b34f-352d8735ce18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OrdinarySharesMember_18efe883-af7f-43ea-9330-8992ecb2fa49" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_8f38e12d-e846-4847-b34f-352d8735ce18" xlink:to="loc_ifrs-full_OrdinarySharesMember_18efe883-af7f-43ea-9330-8992ecb2fa49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassesOfDebtInstrumentsAxis_0a9b4a6a-f441-4d71-8343-57f0a3adf377" xlink:href="cybn-20250331.xsd#cybn_ClassesOfDebtInstrumentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_41105518-258b-482a-a243-81ce2135017c" xlink:to="loc_cybn_ClassesOfDebtInstrumentsAxis_0a9b4a6a-f441-4d71-8343-57f0a3adf377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ClassesOfDebtInstrumentsDomain_fecf2630-af7b-4549-ade5-00a5f988c2b3" xlink:href="cybn-20250331.xsd#cybn_ClassesOfDebtInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ClassesOfDebtInstrumentsAxis_0a9b4a6a-f441-4d71-8343-57f0a3adf377" xlink:to="loc_cybn_ClassesOfDebtInstrumentsDomain_fecf2630-af7b-4549-ade5-00a5f988c2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ConvertibleDebenturesMember_3a5e54e2-a5f2-491d-b916-cc116fb7e305" xlink:href="cybn-20250331.xsd#cybn_ConvertibleDebenturesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ClassesOfDebtInstrumentsDomain_fecf2630-af7b-4549-ade5-00a5f988c2b3" xlink:to="loc_cybn_ConvertibleDebenturesMember_3a5e54e2-a5f2-491d-b916-cc116fb7e305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_ConvertibleDebenturePrivatePlacementMember_dc7a99ad-e519-40df-8c69-c46c3396141a" xlink:href="cybn-20250331.xsd#cybn_ConvertibleDebenturePrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cybn_ConvertibleDebenturesMember_3a5e54e2-a5f2-491d-b916-cc116fb7e305" xlink:to="loc_cybn_ConvertibleDebenturePrivatePlacementMember_dc7a99ad-e519-40df-8c69-c46c3396141a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_41105518-258b-482a-a243-81ce2135017c" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_NumberOfSharesIssuedThroughShareOfferingEquity_a5cd18e2-624f-4c09-8463-d1693b6fc9ce" xlink:href="cybn-20250331.xsd#cybn_NumberOfSharesIssuedThroughShareOfferingEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_NumberOfSharesIssuedThroughShareOfferingEquity_a5cd18e2-624f-4c09-8463-d1693b6fc9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_SharePricePerCommonShare_1408bb01-73f4-48c2-923d-1cf15d78e600" xlink:href="cybn-20250331.xsd#cybn_SharePricePerCommonShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_SharePricePerCommonShare_1408bb01-73f4-48c2-923d-1cf15d78e600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_986fa520-2430-430f-a912-ea8913dd4bde" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_986fa520-2430-430f-a912-ea8913dd4bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DebtSecurities_13ede7ad-b91b-4544-8106-a3092c041559" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_ifrs-full_DebtSecurities_13ede7ad-b91b-4544-8106-a3092c041559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentTerm_831be623-d32c-4cc0-b711-9bb0250c28b5" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_DebtInstrumentTerm_831be623-d32c-4cc0-b711-9bb0250c28b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentGuaranteedInterestPayableRate_5f13ff18-f045-4be6-9f4e-56553fbb6e6d" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentGuaranteedInterestPayableRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_DebtInstrumentGuaranteedInterestPayableRate_5f13ff18-f045-4be6-9f4e-56553fbb6e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate_5fa0baf5-f71b-4ed2-8c49-ac9b6948f80b" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate_5fa0baf5-f71b-4ed2-8c49-ac9b6948f80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentDefaultRate_118864a8-86dc-4e6e-b548-ebcd595c91ea" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentDefaultRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_DebtInstrumentDefaultRate_118864a8-86dc-4e6e-b548-ebcd595c91ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger_c006fe35-8aa9-4b8a-93ce-43f7edd02b0a" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger_c006fe35-8aa9-4b8a-93ce-43f7edd02b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays_c6e49b9e-1f7c-4109-9624-d9c3ab954f2e" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays_c6e49b9e-1f7c-4109-9624-d9c3ab954f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentPrepaymentPremiumYearOne_60eb6d48-ec59-4c69-a640-98afa6ae513c" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentPrepaymentPremiumYearOne"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_DebtInstrumentPrepaymentPremiumYearOne_60eb6d48-ec59-4c69-a640-98afa6ae513c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentPrepaymentPremiumYearTwo_359909f0-3e75-4f6f-9646-38d6dd0b8f06" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentPrepaymentPremiumYearTwo"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_DebtInstrumentPrepaymentPremiumYearTwo_359909f0-3e75-4f6f-9646-38d6dd0b8f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage_6eb25ccc-6a2d-4ed4-8869-ed9f659579da" xlink:href="cybn-20250331.xsd#cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_0cb24d35-d5fb-4f94-8e94-be2dd02f73b2" xlink:to="loc_cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage_6eb25ccc-6a2d-4ed4-8869-ed9f659579da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cybn-20250331_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cybn-20250331_g1.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /U3HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>Y_'"UX77@8IWJ,]_"?PD;/A&X-MX@L9%X99DQ_WT*^NQ]VODGP3:&^\3:?
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M1C9;GA/Q*\!1^"KJW2&=ITEBW[F4 @YP1Q7.^%YC#KU@Z\$7$?\ Z&*](_:
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M#@O_  J[K\K'^5<SH^D3^'YM-U+4X5CM%^U>8ZC#)G.W>?X@>U;/P;NHM?\
M!]Q8W2+<1POL9'&1AAG%=+:_#O1+6X646[R*ARD4LA9%/LIKUE%U4IKK_P
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MP/ZU-*//-1'4ER0<CWZTM8[.UA@B7;%$H15] !BK-%)7TI\T% SWIC.JC+,
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M;JSKZ***]\\$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=.[W9XV*J>TJ66R'4445VG&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %036L-QQ+$DG^^H-3
MT4 4ETFT7[MI /I&O^%6%C"KA5"CV&*EHH'<****!!1110 4444 %%%% #3\
MJY/05\S_ !9\7?\ "2>('2%LVEOF./T(SR?Q(_2O9_BAXH'AGPO.R/LN;G]S
M%Z\CD_@*^7YI#-*SDY+'O7E8RIM31ZN"I[U&,KJ_AWX5;Q3X@@@*GR V96]%
M')_P_&N7CC,TBHO4U]*?"7PA_P (WX?6:>/;>W(W-GJJ?PC^M<>'I>UG9[(Z
M\15]G"_4[F&%+>%(HP%1%"JH[ 5-117T)\^%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '@/QZUPW6M1:>K_);(,KVW-SG\L5
MY/7I/QLT2[M_%$]VT9,$V'1^Q& /T(K \#^ [[Q;J4:11[;<',DS#Y57U^OH
M*^?K*4ZK5M3Z&C*,**=]+'1?!WP*VMZH-0NH_P#0[=@3NZ.W4+_4U]$* %P.
ME9VBZ/;:#I\-E:)MAC&/<GN3[FM+I7KT*2I0MU/&KU75G?H+11172<X4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >??&;_D5
M7_WZ=\&?^1/A_P!XT45Y_P#S$?([_P#F'._HHHKT#@"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>cybn-20250331_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cybn-20250331_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MD^JW;3Z-GC.M_P#!1DZ-JUQ:GP["WDOMR;IA_P"R5Z#^S;^U2?C_ *Y?V?\
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M'JSBX)_BU/1?F?S7_P#!;?\ Y2C?&#_L-M_Z+2OUC_X-/_\ DQGQG_V-C_\
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M[S]L3]K+QS\1KMI=OB75);BUCD))M[8';#%SV2,*OX5](?\ !*;_ (+-Q_\
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M$H.X29@0YS[U_)G^WW^RSJW[&G[6_C;P#JEI):II.I2MI[$';<6;L7@D4_Q
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MK0Z//?BV9[*9(Y]OF%>&9&&<?[-%%=&5SE]7EKL</$U*'U^&BUWTW]3]B?\
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.AGPC3@J#FDK]^OWG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>cybn-20250331_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cybn-20250331_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !  0,# 2(  A$! Q$!_\0
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M6O\ 97AS1K:9K+2[8F6YNF4%VP6.68D\NQQE@"1D"O-_"G[=6IZGI'PNEO\
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H10 4444 )@4M%% "48%+10 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>cybn-20250331_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cybn-20250331_g4.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1"  %!98# 2(  A$! Q$!_\0
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MZN!_\M3_ .ZJ** #_ATC_P!7 _\ EJ?_ '51_P .D?\ JX'_ ,M3_P"ZJ**
M#_ATC_U<#_Y:G_W51_PZ1_ZN!_\ +4_^ZJ** #_ATC_U<#_Y:G_W51_PZ1_Z
MN!_\M3_[JHHH /\ ATC_ -7 _P#EJ?\ W51_PZ1_ZN!_\M3_ .ZJ** #_ATC
M_P!7 _\ EJ?_ '51_P .D?\ JX'_ ,M3_P"ZJ** #_ATC_U<#_Y:G_W51_PZ
M1_ZN!_\ +4_^ZJ** #_ATC_U<#_Y:G_W51_PZ1_ZN!_\M3_[JHHH /\ ATC_
M -7 _P#EJ?\ W51_PZ1_ZN!_\M3_ .ZJ** #_ATC_P!7 _\ EJ?_ '51_P .
MD?\ JX'_ ,M3_P"ZJ** #_ATC_U<#_Y:G_W51_PZ1_ZN!_\ +4_^ZJ** #_A
MTC_U<#_Y:G_W51_PZ1_ZN!_\M3_[JHHH /\ ATC_ -7 _P#EJ?\ W51_PZ1_
MZN!_\M3_ .ZJ** #_ATC_P!7 _\ EJ?_ '51_P .D?\ JX'_ ,M3_P"ZJ**
M#_ATC_U<#_Y:G_W51_PZ1_ZN!_\ +4_^ZJ** #_ATC_U<#_Y:G_W51_PZ1_Z
MN!_\M3_[JHHH /\ ATC_ -7 _P#EJ?\ W51_PZ1_ZN!_\M3_ .ZJ** #_ATC
M_P!7 _\ EJ?_ '51_P .D?\ JX'_ ,M3_P"ZJ** #_ATC_U<#_Y:G_W51_PZ
M1_ZN!_\ +4_^ZJ** #_ATC_U<#_Y:G_W51_PZ1_ZN!_\M3_[JHHH /\ ATC_
M -7 _P#EJ?\ W51_PZ1_ZN!_\M3_ .ZJ** #_ATC_P!7 _\ EJ?_ '51_P .
MD?\ JX'_ ,M3_P"ZJ** #_ATC_U<#_Y:G_W51_PZ1_ZN!_\ +4_^ZJ** #_A
MTC_U<#_Y:G_W51_PZ1_ZN!_\M3_[JHHH /\ ATC_ -7 _P#EJ?\ W51_PZ1_
MZN!_\M3_ .ZJ** #_ATC_P!7 _\ EJ?_ '51_P .D?\ JX'_ ,M3_P"ZJ**
M#_ATC_U<#_Y:G_W51_PZ1_ZN!_\ +4_^ZJ** #_ATC_U<#_Y:G_W51_PZ1_Z
MN!_\M3_[JHHH /\ ATC_ -7 _P#EJ?\ W51_PZ1_ZN!_\M3_ .ZJ** #_ATC
M_P!7 _\ EJ?_ '51_P .D?\ JX'_ ,M3_P"ZJ** #_ATC_U<#_Y:G_W51_PZ
M1_ZN!_\ +4_^ZJ** #_ATC_U<#_Y:G_W51_PZ1_ZN!_\M3_[JHHH /\ ATC_
M -7 _P#EJ?\ W51_PZ1_ZN!_\M3_ .ZJ** #_ATC_P!7 _\ EJ?_ '51_P .
MD?\ JX'_ ,M3_P"ZJ** #_ATC_U<#_Y:G_W51_PZ1_ZN!_\ +4_^ZJ** #_A
MTC_U<#_Y:G_W51_PZ1_ZN!_\M3_[JHHH /\ ATC_ -7 _P#EJ?\ W51_PZ1_
MZN!_\M3_ .ZJ** #_ATC_P!7 _\ EJ?_ '51_P .D?\ JX'_ ,M3_P"ZJ**
M#_ATC_U<#_Y:G_W51_PZ1_ZN!_\ +4_^ZJ** #_ATC_U<#_Y:G_W51_PZ1_Z
MN!_\M3_[JHHH /\ ATC_ -7 _P#EJ?\ W51_PZ1_ZN!_\M3_ .ZJ** #_ATC
M_P!7 _\ EJ?_ '51_P .D?\ JX'_ ,M3_P"ZJ** #_ATC_U<#_Y:G_W51_PZ
M1_ZN!_\ +4_^ZJ** #_ATC_U<#_Y:G_W51_PZ1_ZN!_\M3_[JHHH /\ ATC_
M -7 _P#EJ?\ W51_PZ1_ZN!_\M3_ .ZJ** #_ATC_P!7 _\ EJ?_ '51_P .
MD?\ JX'_ ,M3_P"ZJ** #_ATC_U<#_Y:G_W51_PZ1_ZN!_\ +4_^ZJ** #_A
MTC_U<#_Y:G_W51_PZ1_ZN!_\M3_[JHHH /\ ATC_ -7 _P#EJ?\ W51_PZ1_
MZN!_\M3_ .ZJ** #_ATC_P!7 _\ EJ?_ '51_P .D?\ JX'_ ,M3_P"ZJ**
M#_ATC_U<#_Y:G_W51_PZ1_ZN!_\ +4_^ZJ** #_ATC_U<#_Y:G_W51_PZ1_Z
MN!_\M3_[JHHH /\ ATC_ -7 _P#EJ?\ W51_PZ1_ZN!_\M3_ .ZJ** #_ATC
M_P!7 _\ EJ?_ '51_P .D?\ JX'_ ,M3_P"ZJ** #_ATC_U<#_Y:G_W51_PZ
M1_ZN!_\ +4_^ZJ** #_ATC_U<#_Y:G_W51_PZ1_ZN!_\M3_[JHHH /\ ATC_
M -7 _P#EJ?\ W51_PZ1_ZN!_\M3_ .ZJ** #_ATC_P!7 _\ EJ?_ '51_P .
MD?\ JX'_ ,M3_P"ZJ** #_ATC_U<#_Y:G_W51_PZ1_ZN!_\ +4_^ZJ** #_A
MTC_U<#_Y:G_W51_PZ1_ZN!_\M3_[JHHH /\ ATC_ -7 _P#EJ?\ W51_PZ1_
MZN!_\M3_ .ZJ** #_ATC_P!7 _\ EJ?_ '51_P .D?\ JX'_ ,M3_P"ZJ**
M#_ATC_U<#_Y:G_W51_PZ1_ZN!_\ +4_^ZJ** #_ATC_U<#_Y:G_W51_PZ1_Z
MN!_\M3_[JHHH /\ ATC_ -7 _P#EJ?\ W51_PZ1_ZN!_\M3_ .ZJ** #_ATC
M_P!7 _\ EJ?_ '51_P .D?\ JX'_ ,M3_P"ZJ** #_ATC_U<#_Y:G_W51_PZ
M1_ZN!_\ +4_^ZJ** #_ATC_U<#_Y:G_W51_PZ1_ZN!_\M3_[JHHH /\ ATC_
M -7 _P#EJ?\ W51_PZ1_ZN!_\M3_ .ZJ** #_ATC_P!7 _\ EJ?_ '51_P .
MD?\ JX'_ ,M3_P"ZJ** #_ATC_U<#_Y:G_W51_PZ1_ZN!_\ +4_^ZJ** #_A
MTC_U<#_Y:G_W51_PZ1_ZN!_\M3_[JHHH /\ ATC_ -7 _P#EJ?\ W51_PZ1_
MZN!_\M3_ .ZJ** #_ATC_P!7 _\ EJ?_ '51_P .D?\ JX'_ ,M3_P"ZJ**
M#_ATC_U<#_Y:G_W51_PZ1_ZN!_\ +4_^ZJ** #_ATC_U<#_Y:G_W51_PZ1_Z
MN!_\M3_[JHHH /\ ATC_ -7 _P#EJ?\ W51_PZ1_ZN!_\M3_ .ZJ** #_ATC
M_P!7 _\ EJ?_ '51_P .D?\ JX'_ ,M3_P"ZJ** #_ATC_U<#_Y:G_W51_PZ
M1_ZN!_\ +4_^ZJ** #_ATC_U<#_Y:G_W51_PZ1_ZN!_\M3_[JHHH /\ ATC_
M -7 _P#EJ?\ W51_PZ1_ZN!_\M3_ .ZJ** #_ATC_P!7 _\ EJ?_ '51_P .
MD?\ JX'_ ,M3_P"ZJ** #_ATC_U<#_Y:G_W51_PZ1_ZN!_\ +4_^ZJ** #_A
MTC_U<#_Y:G_W51_PZ1_ZN!_\M3_[JHHH /\ ATC_ -7 _P#EJ?\ W51_PZ1_
@ZN!_\M3_ .ZJ** #_ATC_P!7 _\ EJ?_ '51110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_0a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0a.jpg
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/[J#T     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_0b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0b.jpg
MB5!.1PT*&@H    -24A$4@  !V,   1P" 8   #7#?\P    !F)+1T0 _P#_
M /^@O:>3    "7!(67,   [$   .Q &5*PX;   @ $E$051XG.S=>[0EZ7G7
M]]_[OE6U:U_.V>?>IV=ZID<S&NLZ(]GXMI EI"B@(,<$7X)7\ 4"3HAQ6&#_
M!621%7!L EX$PF+9!ML0!#88@Q.%A>W LBW'B;&3V))EL"4[&EFC&?7T=/?I
M<]N7NKSOFS^J]CG[G.[ID::G>Y_3_?U(-57[5ONMFEX]M>MYG^>1
M
M
M
M                                              "?#[/H 0
M  !GFFO7L5T'2;+M"Z[=-CIYJRT>K8T=*\933[?RO*]B6K;[F"U&\_N+V7[S
MN= L-I[\UID@R4ORLX_:]H7Z-1PS    7A?NU=\"        /,3LJ<=1.HYV
MWAH\O55UM+4\[*G7ZRJ$(.^#ZCJTK]QA'[8\&D?JI,1*)AY_:GY845(\O:L@
M    + B9L0       , =.&62I'@4[FQ35'4< 'U%1MI^?%7[^_L:'_J3@=$H
MI7FFJJAU%#V-I[-L9\])BD%9GBIS5DY!\K5BK#0MJJ.Q>$GA=##6W\W1 P
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MG*)2165M>>1F;)67LF1TL=NM_Z'+7_Z G[ZHNCJ0"5.95]PK    [@>WZ $
M        9YIIEV@E9;*=H=8V'[5;%Q[[KK6UBS\^F5:/>V]E7:HDZ\A8JQ"#
M0H@RULC9.V2G?AY-Q&RTDF:+T^E;>B$4LJ:05?%4#./?*(K]WPK^4#%.12@6
M  !@L>@9"P       -Q13U(NN;YZ@T>UNGKYTO+PTH<ZG8WW&;NL&S='&@R'
MZB_U585:^Z,=E7ZLO)=H,!BHN)&W^VD#HV9N^Y;UK=O6[31;L:<8<X78:WO6
M-D7O?'6H/!TKS\:*]4N??OFE?_>F*R]\M K^NJ0@"A4#   LCEWT
M ("SSRC-<ZVNKOS!K:VMCZ^NK+[/6JO1:*1+ERXI29QV=G:TO[^O+$NULKJJ
M+,LT'M_;?K&2%$)05=7*TE0;&^MO6%]?_[HTS21):9K>\^\'  # *R,S%@
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M[[U":#JQ&GL_NH"94^N9)B4W29PFX[%ZW8%\6:FNO8;#U:^^?CWY01FZE $
M "P25V,       !XZ$5%3<NI9@'.?+"LC8V-MZ^LKOS;$,(S=5VI+$N592D?
MO)QUZG:[6EY:6NS )0T&2S+&:&EI(!FIJFMU\^X'57O=\QK*    N",R8P$
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M;^:LK*SJNI*\E[)4V<J*LD[V[6F2?+^U5L88&6,D(\48%4-8\.CORO:B!P
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M$DG*Y(,T*7))2_?[4%\3YYR,,8HQR@>OJ"!CHHPQ4UG;GC<    L L%8
M    G&^SJKQMT-:7LW\TM[YZO;[K=+(?-\;\GA""@@]-7U@9&?M 9[Z.%ST
M  " AQW!6        )P;4;6DHGWD)5-)B90DDHQ4EY)\*H6^Y'+EW<L:K@S_
M>K?;_6IK;5..V->*(<HD1M8Z2=7"CN?S$T^MI>/>L/-/MQLFJDF'K7=)BP4
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MU"1-U.WU_FZWVWW6&*/I=*JJJE37M6*(,K;)C+76*BK*>[_8P=];O[OH 0
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M;;G!8/#CG4YGVZ5=A9#(>Z^H*)<X/?!U>F.3$6N,E+A$UGB5WG]2,2YZ9
M  \]@K$        XXXQDFBQ0Q2"%5%)7LNNR^:/:7'_;7_)A_3UUM:'NH*_2
ME]H?[2K:L7J#GNK)0@?_.IB5:8[MYJQ><W-.0HCR/BA)HK).JJQ3J_+QM]2)
M4DP>^%@T  # 6687/0        #@\Q%".(I+REDMKZWIT4<>>7^OU_]+UEJ%
M&&6LE3%&95FJJBLY=]YK%']^O/>*,3:9L=;*>_\;BE$VRQ8]-   @(<:F;$
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M)5;R7BH*I8.!+EZ\^*7=7N\OEU6IHB@6/;K%BU'&F*:*L9'*LORWBQX2
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MRBB;^Y[S*\[R*4S;_-9$*1I)61-O#4;.!1FS+VOK7SLX>*&0BN;\G?-^N0
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MF,C$3#9*)A1*W51+@^EO_L+/_NC;I ,YNZ,8II+.>\=<  " \XVI@P
M %BX<A8O=4[R3?AP<_NB&4\F?U_2TL(&=D[$&%44Q<\M>AP    XB9ZQ
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M9\;&V9DR[59LHJTF)FW@U2K&^J>DB60K29(U4M2IC%H   #<=V3& @
M8*%2FRHJJM/IF$<>N?C#DOIE62K+,M5UO>CAG0<W8XR_=/0HWN&=    N*_(
MC 4      , ]E9<KDJ2H0RFIY3.IDIJ$S; D^74-'GF'MA]]]H]-M/K[?;1R
MR511GU"2>,5ZZ39[K8\S7\W)^&.S[<Y]1NQ,ENZIJBJ9<E59LJKH$Y730MY=
M5=:_(9==_9F/_=)/>&77U5_.-;HYU:B6\J2CLBX7/7P  ("'&IFQ
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M)<0H8XR,I8[NJXDQ*G%.W5Y7OO9:6EK2:#3ZL;J<R#FWZ.$!  #@#IA:"
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M71VEY<;2JPQ!QCK%LCA^L]5Q')E[(0   'A ):GDO6WG(CIM;EBUV3H  "
M241!5&X^L[P\_%/C:2W9N[P ?]@9H^O7K_^#_?W]HRAXC$$ND6)]IP\"  !@
MT0C& @!>$WN4[CD?70S-_.W;Q41/"?;6YXZ#E*'=]FJR8EVSGN6(1BOI$2G4
MQ\\=?9&5DDRJR[GG3@_ Z)EGOZ,G:7EN&;0O+NMDDZ5YI:2QI'&2/E],II.=
M_?W]F[N[-P_'^P=2-99\G.N!&R4YR:7-9EU)859'[/FY SX^?\>?"XKM_VZ;
M<6R/*RT;Z;@^LFX;>FZWCWO.TC$6    7YB>)"FHDE5SK1W-<8)GD#0MG%3G
MDE;47WU2>>_1_S%HW56QO/TN'R9F=KUNYW[WW*9<CIG])IC[;6"",AWHRN=^
M\T<F!R^J^4E2R/M*G3116==S>TG;G-K8]%0Q7/D#   L&L%8 ,#Y5,\U1W*)
M>LM#;6QL=C8W-B\-EI8N%45Q2=%<DLPER6Q)VI!TH5F;C:)P[FZ^OMOM*DT3
MY9V.5E=6JA##36?MYY+477'.?38J7G'67#'6O%17U4L'AP=7=F[<N'KCQHU"
MD]N4: 8   #.L6Y7FHS;P)]+-!P._Y"U[C^LJUK&W*X4+[X0UIB?V[UY\U-Q
M.I7IY(K%2#$$69?H1,EH    G#E<#0, 7A-GFHG6L[S4H[S,=G)WIYNHF)[L
M(W4DDS1-I>#:9JBSS%>G9IZ0DY1*+I=LVCQG4_7[RUI?7\^6E]?>G&3;;Y+,
M%TEZ4M)3DGFR";[*W%JF^-0 HE%E\[LZ?N,[IYXXW2OW=-;K47_9%Z3X.WWK
M?]NH^NVB+']G=_?:K[_\\I7G1_LO2YI(*IO3$0XEU5)J)#^5PBRCH%;:GZJJ
MO$XWB;)62E/)^Z9<60RW3U#F=@T   "^,*OMNKE>-;/\R_8BL]-=4C'.) WU
MIF??EVY??/._O[$3GIX63L/558V+T2(&?7:8V;6\;2O]S);F!!HCI:F3]Z4F
MDT,%5>IV4R6)4^T+U3<^^D>O7/G$/SG8O29I*ME"DI="D#&2:7]3A:,B/T$R
MU7'-'Q)D 0  %H;,6 # :V-T% 1TJ918J[(,DI4ZG43%I&[>XZ3^4E<Q1HT/
MITW4=KZ"\"MX],DG79X/WMCM+KW3N<X[8C1ODY*W)FGR9)KDMJA>^;-GW"5)
MEXJB>%^:2IU.1QL;&UI:[ET/_M%?=8G_U32-_^]SG_[$_WEX8*Z5DSVI*G44
M[DX2]0<#C0Y>;(+>O52=+%,,7I/Q5'4I%>U;33QYBJV5K).LF:OB#    +P.
MBFDA*5/:6Y*S[CNJLGI:QLE9)^^9"OAJ8HB*L?F!9:R1DY.U3I)1C.'&:#S^
MR;(\OH@WULK$IDU,C&1;    G&5<JP$ 7I/A<$63::D0@ER2JO9!OJQUU+?5
MS,WT-K,9WT9*$MEN7V'ODB0GI7TM+ZVXX7#UK4O+*U_>ZR]_69;F7WQP.'E[
MFG9[:9;+*%'M@^HJ*,K(&*-*LYGUMVM0VV['V[W6"+%_=R? 79_;W6VR8(]Z
M/LUGR1Z_QTPO*'&)7&(D50JAE$RA) E*TB#G:E75P;_W8?J1&*8_O[MW_>=?
M_-SO[I0[-R35DKFIXWSDT"PNRJ9.:2(5H_VC0TY<,]/>J,UFCB>K/ ,   "O
M;JE=3]1<C[8/HR0-) WE.A>U??$MZRMK3_Y_KK.T4L=$=6RNW^WM=ODPL=-F
M'5U;&6BV;DYD"%Y9YA15J:I',M:KDUN%X#4I]OZGG4]\^,_=W/V<HBI)M3JY
ME??UW'5]IN-L6TFJFF4N418   "+068L . UV=MK@WTRJGV0G;5@=59)WE/6
MR34>3:2JEIQK4C)E9/)<_7[_PK/O_ /OBM'\WACC5_B@+PE!O1",ZJI2509U
MNSWY6AJ-1BI+K^ EZQ)E:4=)FB[JL%\WSC7_":[K2B$4\KZ0#VW)-U.J/TA4
M%*.WA5B\K=/1=ZRNKL;A2O^7LS3]E[U^^N&/_*M_])N2FIK$3DT]XGJJ4$Q5
M%,<UR*P]#L+6-;.P    \#HYFN]HI- \6%];UX4+%_Z*C\G*M"CDLE1)DJ@H
M"F4)MZ#N),:H$)N2P]8ZN<3(&*FN"TW&DQ_<W]]7;".JUCDY:^0I/0P  ' N
M<$\6 / :;:B) DK-W)Y41W6)DX%4!\EVU5W;U/;%Q]ZX/%Q]K[79NUR2O*O3
MZ3^]<]7(&"MCC(QM2G 9ZV2,DS%6,1I5=5!5UPJA*<.5))F2))%U3M/JZMQ8
MYC)?X^SQ[?K&'K_7)B_<W>'[X=R#V&; MMNWK.>S9!LA;C1ER$R4-9)SM@V<
M!BEZ62=-QX>JZU+.&<7H556EG+/JYAWU<_^IO=UK'[[RTDO_=/?JB_^/JD,U
ML]_+YE_%_&-5DJDE^>/RTO/)N@   ,"KRMIUV12_,6TAFK LQ35)JWKCT^]^
M\_:C;_UW!Y/2[4^FROI=V2QH,IFH:WL+'/L98"?-.CI)B123=KM)7?6^5)I:
M&5LKJI!+O8RIM+>_^PO7=UY\[^33_T)2K2C))5+2L2J+T 1DHY74T7P/6JD0
MF;$   !G ],2 0"OT7&PL],;*,UR^6#EDER=?.F)RT^\\;U%&=\GF[Z_TQD\
M&F4UF4X50E"65@IA*"G*&"/Y(!FOXY+&5D59R=I$:=91M]=5FG840M1T.M5H
M/%::+^[(7P\N<?(^* ;?](1R3LXU":XA>.WO[TO1JYMW-%CJ23'H\&!?D^E$
MX_%8-H:G!DM+W_6VM;7OBF]Y^I.CP]U_=/WZYW[LVLLO?+K<OW[K%T9)SLJZ
M*&>LJH)I]    'CMC&8!6:,8C=;6MM3K][_/&./4MA:)H9D%F"2.8."K,&8N
MD&J:=577.CP\_/[#G9VC:; SWH?CS%AK.;\   !G&)FQ (#7Z"V2$G6Z?:UO
M; ^6A^O_0=99^D"O-_Q ;[#^5%%&[>^7&D^\HE*%Z.2#52?O:= ?J#;/2VI[
MF"JV9;G:;4G3HI0Q1BY)E.==I5DJ[X,.1X<:CR9:65[1K?\9,\?+48;L_//'
MDKN]61$[LXU77K]BMJQDAA.55:6JK"19.9?*1*NJ]*H*K\<>NZS1_EB322D3
MV]Y/P2C/NUI:&J@XW)-BK1!JQ3!5C*6,II*FOVA-\8,OOO [_[PJ]\OQY*;*
MR4VI;DH@RUDY%^3+@[L\ 0   '@HM5FQ,I)1)L4UA;"IM[WUO;^OTWWB(RY=
MU]27FOA",0UR>2%CK>PD>]5=/]#LN%G'1,>9L8F.4E>CETLDF5+1%+*NTK38
MN_K""Y]]?/+";Y<]]U%5/BA*,JZI#.V#I"@E65=U,0OFSG[W3"55LNWN \%:
M  " A2$S%@#PFGS5N]_SS+0(7QUC_$":]=X5HDNGTZ##PY&*TFA21'F?J),/
MU!^LRMJ.ID6MNIV];=K9WE%1BFU0-C9!V2AI^\*VIL54TZ)0556*BC+6*LLR
MF:-:6^=7[;V\K^5#D+-.B7-R-I4U059>+U^]JKJ*<C95-\^E($W&A79W=W5X
M>*!!QRF&6B%44BQE3*TTD9(D>7?BXKN??OKIOW5X>/V';UQW?_?&]>(STX.V
M+%K[O0   ,!K=A3SF]4JEEE96?T;1655EH6BE:RUJJ-7B$$=EY*X^2J,,2<F
M<X805-?UCQ1%44I2FJ;ROI!7\]LI!!W%7:T]_[^/    'F1DQ@+ HKS2[^57
MZ.=Y^NW!=N<^($FA^56NV-2Z59!K9ZV;V^PS9$TEJQ@EA;9?4>BHZ065'R^]
M=:VN7M3R<"/K=E?>FV7IUQC3_9HRY)>_T$/&ZVE6J"P>+Z;Y]RX%)8F12ZR<
M,Z&JRP_O[>W^M:LO7?F5Z4LO2;%4HM]4T%[[_FFSJW8R?9I*==7^N3FZ:Y9)
MZDK*9604-.M)&Q7E)?FC?=QRHRWJN#?6T;C'K^?)    P#UGU>\/-!J-E/9[
MJJ9>2M<D/]"7O.MKOJDL!_\XA!7%./N=$F1,+9GF6C/&ASLSUH:FSTJTA61J
MQ=E5<\REF,@IEPE1H\-K&O1+K:T7\;GG?OD-SW_J%S\CE5*@S0@  ,!Y168L
M #S 0I0ZB57>R21%E9-"5?L;WM=JIN1$M<%;VSQVB60R;5V\K"197N[DPP]V
M\I6O3[/>!XQ)EV*4?*B9SG/&C<9CI8E3FB76VOBUW;S[M1N;&Q\YZ'3^A\ET
M_+]7+_V&4I,H2:VF97.#+,^EVC>!6$E'+7Q-D"2K*-.&?6\S6P     /M,0E
M&HU&ZO2Z*B9C*5^6)H4>?=,[\O%D_#V)&RQZB.>:,48A>'4Z'25)T/[^]9\:
MC\>?6?2X    </<(Q@+ HK0SHX^=["MJ%.?BG;/GYAZ;R2OOVT@N2>7+2M,J
M:EJ5[0M.>;>K/.]I]Z;5<99BT[=H>>.2+EQX;&UYN/6'0DR_WMC\#UB79\;D
M"M&J]E9U%51[+Y>^U@/'ZV/^S\OIU&<C(]OTX0U!QEAE64<KR=I[EP;#]X90
M?]0//OA77KSRV__K>+0KF2TI[FL\GDJ:JK^4:G1X(&LD9R2;2M9,%?Q4O@WF
MG\Y^C6HKU,533YX0;O<D    S@-7-OU)4Z=B/)#&/:F[K8O;;_\S>_NZ[&PF
M&2^I^9TR:TIBHFVW'G9Q;FN^MVMS+6]M+1\+]7N)G/.Z<N5S/[B_MR,Y>U2$
M!@   .<3P5@ >$#YJKKM\]/)1-/)5-*:;-;3]H5M;6X].APLK7R=,?DW%F5\
M?U%520B2L4[&.UGK%)4HM/</K"4M]JQ;6AHH1*\0FB4JM(G/3HEQ7YROK?XO
M%Q_Y/;_R\K6K?^&3O_5K/R])-DEE7=3H8$\R;1\J-8G36=KTHO*>;E\    /
MH[J2DDP:[1_(YAL*4^FIIYY:#R'\-]UN7UPFWJ5V8F/6Z:@JP_/7KEW[J?)P
M7^HX@K$   #G',%8 %@0=^*OX-ME.9[.=CPYE]QJ+CLQZE39X$Q*NVT?6"OY
M61:L:YK(*M&7_]YO[7JO_Z2JZV^LO3ZXNV\SEW24IEUUNIEV=P\ED\BZ3,:E
M,B:1C)MK0CMZ?4X$7F?-71SG4LE+=?"J*Z\0O:PU<L[*6B<-WJ(K-W:^PN87
M?^XKWO>5/WMX</TO?N*W?O7_KD=7)$VD>"AIK*"Q0JPD+V5ID&E;$@>KT\G<
M<W]D$]U:QWK6@/9$(UH   "<%XG46Y'VKV8*TYY,=EG#_A?_Q>(P'?:7ES2:
MCB132ZZMX!.M3$RDT&D>/^3S.:.9NP:.=NY\1!E32='+)86,"DW&5__>Y.#E
M(%52C#J:%0L  (!SB6 L #RHZO:'>TPD6:G?T]K:EEU;7W__8##\UKKR7^M<
MVN_U>C(FD0]11>EU>'BHL@I:7=M4E%.058Q.448A6L78%,&-W \XTZ:3B7SP
M\KY2B+XI>VVLK+5RSNKJ2U=U86M+G8[3_M[5]\<8?^699Y[YT,'^YI^_\N)O
M7RFF7KX8'^TOA.:/DS&4F ,  'A8C492VN^I&GF]_>UO?WPZG?SI+._)!R;;
MW2T?O+(TU61R6-W8V?D1A;;242 M%@  X+Q[R.<E L#BI&V_UI.!K=@^#K=Y
M37.O-)FQQ\^E:N;7="1E[;HCV;YZFX]H?>/26Y>&Z]^:9OUOCM*CP2=*ZA55
M5:6B*%357M9:97FN;J^GK--16=5-S]&CY5174C\6%FF^Q]1L'=NLY:@80[MN
M'ALK66-EG9$U1B';UM[>GGQ=JY]GLC&HG.PI2^+AVC#YGA<_^\F_N;?SN\7>
MC><D[4DZ5)*64F@FYH?DY-<VBVU?<*?&Y]7\R:UO'38   #.AUQ2E*Q[3*E[
M4N]\YNO_P?Z^^^-Y?TU%74OIGF1'BO9 DF1B(A-R&;\D2?+VX0XJ&LWWSIV_
M& ZR\HJ^T/) VMUYX2=^][F/_I'IP8MJKL/'LC8HA/J^CQD   "O#S)C > !
M]<R7?^5*-/D?E>G\Y]'D7QIBU'0ZE8]1,20*(Z,\SS4<#M7)<T49%46AT62B
MF[N[2K-,4::Y36#,45:E=4[&,)?GK.MT.II%26,,"C$HAB!?>]4Q:C3>4YJE
MRK-,\LV-G<%@((5B<+"_^U<O77KTVSK)^+^NRFL_,S[8.]HO&=$    /I[0C
M55,IC,=ZZU>\]>TW;NS\L8W-IS4:UZI]I21=] C/MQ"\7-+1=#+Y@>G!H>2<
MG,WDJ[&LM2+Y&   X/PB& L "Q+EY[:/U\8VK5F=<_(^J Y1,DT -$9)/D@R
M<O9Q55YJ,@Y39?FJ-C8OF<T+C[U[:;CU;0=C_PTA=KI!F4+L*"I15"HC)V.E
M;'DD*6I45QH=ELT 3)1)H_(T;3,L0Y.K:XY'.+L'D(B[+8MUNF'KC)%D5);U
MJ=>-FHQ5*V,DURL48J48K:RSBM&J#(EL='*NHZHV3PV&V4]?3B_\Z.'^E>_<
MW[]R[6#_BD*82CJ0PFZS6VLEV>:/86CWGZ2*]?SW'_<_GOU1(J8+  !PMCCG
M9*U57==M=14I35,YYU37M:I1+<DI77Z#RFKP5R]LO\D<' 9-BJ"TTU/45))I
M_A]G5Z5-BQ-(UC45AV)H ZOM!;$U7M%,E'<K'1Y>^\W)],6/2-<E/Y7W8_6R
M3--RM,BA P  X"X1C 6 !<DZ31_.$"0_5[%KUINSKKS<[&]I[]O?ZE9R3LO+
M0^WO%#+*-1QN:&5U:VNPO/;'L\[RG[1)^D7C\5A-J6+@M9E,)TJMU._WOZG;
MV?I KQ>_,^_4_WCGQG55Y8$Z2ST5X[%4!\E:]88K<B;1P?YH+A +  " \\)[
M+V-,.PDT'CT70I#WONV*DFEY:?G=QIC_N"Q+28G2-)6QALEVKR+$>'1>K;%-
MT-H8&1/D3!,(/SP8_YW1:#1W*DUS[@$  '"N,3T1 !8DR=J9XD:*1HI!JKV.
M>V_:CN2MFKL>B;+E53F7:7)P(-62TC=K>7G]75L7MO[T^OJ%;\B[_:RNC0['
MI2;36EEGH!A3!26*:OIX1CG%]J]^D[RDD_F)LYZC<]NGLAJ/,V0E6P_NY>G!
M_\_>G4=+NIWU??_NO=^AQE-UQCX]W-O==]1P)2&$)4N @)  85P0!^)@C"&!
M,",C@:VP8@<#LE?L!$L"!8S",H-A!0/+9BW%"B3$3,*$8$"  ,W2';O[GM-G
MK.%]W[UW_GC?.D/?OAKZW*OJ[O/[]*I;=:KJ5.TZYU3=O=]G/\_S<9WL<%>5
M-KOKH\/<<+(1() Z2YI$#"73Z1Y[>YO_;F=G^[^=3+:?V+WV^T!59\;&$F)5
M?XT'4S7C"_77LUW_1_X;4)TU$1$1D=N-,0;G'#'&FP0!+]!;>S%GUQ]\5YZM
MO3J&96S2 9?@0R"8/; 3C)G4F;'18F*"#6T 2GNZYW_!E  86EB2N@T,!F,G
M.+N-M=L[CWWTW>>O//J>/<H-C*UPP6/J$C24\QV^B(B(B)R ,F-%1.8D-,<V
M(N!<'92U]O!Z?( DQ20MXL13[.Q VN+\I4N]"^<O_:V][95O39+62[,\PUK+
M=%I05N!]4"DP.;%VJTWT)64YP5=C8JAHM]K_>:?=_E-CE[[YW1M_\,ND>9W&
M713'OK?5ZS'9VYW3R$5$1$3D5ATM3PP<#\BZA*6EI2]?6EIZ]7AD&4T*VDF;
M-$D(I4*%'T\( 6LLQAJLL5AK,9B#;.3I=/HOM[>V]BCKN76KU:(<C>8\:A$1
M$1%Y+B@8*R(R)R%29Z%&J"H@)A!SZO+".=@>5 FQRB!;XN)]#]^_?O;>[\K2
M[!NF!?W62A?O Y.JHBKJ\F$Q4O>7S2S>1(PI,528. O.'@9I_9',1'/T4HQ-
M,-<<)L3>9/PJ0S9G1[*4#W\91W]3SW:YUBJ/3@%BT\,X !71&*9E_3=5^4"(
M*=BZ7UB2N"7KW"]]QJN^\:>?>NH#W_78HQ_<@0U@!'F%=5.FU2ZX\C"IVC0/
MC<,<3#VF)WKY(B(B(O+\B#$>](F=R;(,DWZV[>8/_6"6K#)Q^T2WCW<1YR;U
MCM(0FC5-[TC1G4A=/05F%5).JX@GFH@QMMZ%BR.&2, 3S82MK2=_=#*Z"F8'
MS!1G4CSE0>]=A;M%1$1$[EP*QHJ(S$F:@8]-)NS-*G:%BL[2.@\]]-+/7UH^
M]]UE:;YT=V]J=G=W(>84ML(8BW,.:QV)<Q#K_D[Q=%< D^? [NX.+DG)\HP\
MS3&V[E=55273Z93+9Y:_WMC1:R/5W[QZK?K]<F\,TRG!CL$4:H0@(B(B<H>Z
M68_2X7!(UEG[FB1-7EI5%<XYLBPEA$!1% >M4.39S3)@C3$8ZG5;\!65+R!.
M_L\GGWSR?<PRC&-DVE2?T4]61$1$Y,ZG8*R(R)SXV*H#L15 !DF7K+U$I[U,
MF@W;#S[X\J\=C<UW3R;FD2>?:)'E?0PM?%DR&H^I^B.<LZ0V(4L<UAI,#,00
MB+Z"&# $#!$3 Q"Q1_J_AMCGAIQ89MFPL\S8PXS:YKIX>$]O#W?*RYPU&=;'
MK[C9^>'EK.PP2UF()A!-()A -)Y@(,DB-O&0!((+1&.IHJ%R"1[#4X\7M/(+
ME\^M#W\[S]O?^^CCX<WE[IB#OL-'GS(>^?M29JR(B(C(;2E-4\HF&!A"((1Z
MAV>>YRPM+26M]DM_L"P\>WMCLDY"WIFP/]FEJ )IFF/H0,P@9,W\KZZZ@IFU
MM#C=F;'&@&E^!!$(/E*5GK*<$,/H1_W6-4@*R",4 5^" Q(<GF<&R$5$1$3D
MSJ%@K(C(G(2BH%Y>.P!:G3;+RZO+RROW?&NON_9=556N)DF'=CNC*"R3R01C
MH-7JTA\LL)=L-@=)/%7E(0:LB5@#SIK#WK,BMV!I:8FB*ID4):/QB!@M+DW)
MTA9))\%5^Q1E@;%5NKR\_,\7EU[R65L[_6]\XHF_W!WOC.<]?!$1$1'Y)%E[
M&"R-,1[K']OM=K^QT^W??VUSDV(RH=5MX[*,O?$^95&2)*DR.#^.65;L; -L
MC 'O/655?C#XXO]H[D2KW6)2',ZGG75X+>Y$1$1$[FB:*XO(*=9ISL.14P3C
M;\@R=(#%8CG<S>UHTP(@4A*9$B@(3;WAX"#:IOKPL<>R@ &30_EJ<#G9ZBJK
MJV<N#P;#[\FS]C<8;#=$F$[*YOZV?K"#=,/91[<6Y#(_66KP547PD%A'8BV^
M*-^_OW?]J\;[3__IXX^^&]@C2<=4Y15@AU8G@(')% AY_4 Q-N^1^HUBFO-G
MOFV:O_O9>54@(B(B(I^$K#GW8+W%D30KG7I>%8!^/V5CMR0D"U M DO<]Y+_
MM+VX?/&]HTFX,*>1WQ4*NT&:IG1XD+WKVQ2C+2[=,Z3P?_*&=_WNS_W/Q&V(
M8&.]3C7-&C4FS>]'A8E$1$1$[EC*C!41N44&VX1%+:$YC!$(=>'7""%0QTT/
MDE\=> ,^0(RTS]]+GK=>WNUT_UZGW?X;@"N**=Y'@H\XESW+,XO,7PB!&&/]
M/FAV^5MK'TB3]/=\EG_MZNH]__;:M;^B*B> )<DR)I,)6,A2*%2E6$1$1.2V
M4Q1-S]*JCOS9W@#GW+=4577AM)<9/BF#P1J#]YXD<22=#N/Q>+R]M_E3&'/#
M;D01$1$1N9LH&"LBI]@LLS0VEX]DFIHF!S5R[+:Z-:?#  5[==ZJ=1CG,%CP
M"56($!)(VU "50:D]:D]H#\<TNH,7[-R[O(_,+@O--9@L$T -Q)#),8;FV[.
MQOF,YJ B<U'&"DS$.$NTEF@=)C4D>:>;F_!OEI87O]\S_<>;UXH(EJI*FAT*
M!:6'^LT!F#J;G'B0-WX@TF27!]<<^U-!#Q$1$9%;%HZ?1WR]D939U[ _!9<F
MA#*'I,?%BP_WG!M\?U&&PX:G<DML;.'(\-6$+#7DG83MK0_^W.-/O/>Z<07Q
MX!=15TB*&, >_MY$1$1$Y(ZEF;2(R D$H H>[STQ-GV 9@$C?[2,L"5=&+!^
M[MP77+I\Z=\_\, #OYNFZ1<Z9R%&0O#$&'$NH=5JT>MUY_%R1#YAP8?#OWE3
M[UXPQI)F*>UVF[(J?_CR???]_ ,/O[B=MMIU735GP4%4B341$1&1VY9S#H!6
MM\>Y\^>_,TV295^I1<I)U>UB#;[RN"0ARS*N7]_ZL=W-IP_7D"(B(B)R5U)F
MK(B<6NX@$W;6+_8&L^34HUO% =-\7^&.W!X]5 [H4?>B[4+H@%UDN'K!+"]?
M^(K>PN(;7=)Z9?"&W1U/2,:$$)IRKV -F 1P#FL<=>:@.?+DYLBYR'Q5)F"M
MQ3A#92#$^A"2=3G.Y6QL[7+A_+G_ZL+PS&5O.E_VX8^\YUH<;]1ENMD%=^WP
MO66:K-CXS%UB]5^])P1+7>];?_\B(B(BMZ2:M4&)S;^*P)&Z.Q:J") #70;#
M\\-V>^WO[>Y88IS,8<!W%QNZF#+%FA'6>,IJ\[=V]]_W)W =V#\RS2TYJ*P$
M$)0<*R(B(G*G4S!61.06Y3E4 7QYXRUUH]BU"Q=-J[7R%;W^RC_L]I8^+4G;
M5)6A*BO*LB1)#=;6H:<0(B%&RK*D\J'IPZGB!7)[FV7%QABIJ@H3(;&6Q#GR
M5L[>_CZ+6?ZJ^^Z[[UTNF7[1^_]BZP-X3]+K4HVOS7OX(B(B(G*$<T %55FQ
ML+S"\O+RZZ;3Z<"8-HE+ZAOE1"I?X:S#5Q5;NQL_-AJ-  A*/!81$1&YJRD8
M*R*GEFT.)MS8@34>23Z-\(Q$O!@A&O NJ5?-)H78!]O'=L[2ZYZGE:]]\>7[
M7OS#59E_6E'"[CZ$",9:;)*0YI80G\!@2)P!9P@Q$GW$ATB(@21Q1P9Q\.S/
M^<]!Y%8$"]89HC5X'ZE\( 9#ECBP":W^&I/Q'AO;D<'"T@.#I4?>M7(^^^*G
MKUWYPZH:0WP<*(]EGL_>:D??<I99/G@@8I45("(B(G++6LUY"91$P#?5@ *0
M)PF4#GR/I;4'EA:&][QN<[/ V"%)TJ**6W,;^=W ^ISH/5F[I"H??^+IS3_^
M%<+CX'8."B =;L<M 4?$$.DTUXWF,6P1$1$1>0XH[4I$Y%9-*O!'@J.M-BLK
MJU]T\>+%W;W:J@  ( !)1$%4__#@@P^^HRS+3XLQDJ0)K59.WFKAG,/[BLET
M0E$45+X" TF2T,KK^[3RG"S+Y_>Z1#X!AL->L<2(#P%?57CO"2&0) F=3H>B
M*'CJJ:<((:P]^-"#OWGV_(4O9+(W[^&+B(B(R V,/=P2M["P\'V=3F>PN[M+
M).)F&T7E1(*O6WU4OOKQ[>WMBN#).JV/_XTB(B(B<D=3XS41.;6.E@8XVA8V
M L:!LY:R#-3[5I(CYX#-ZVQ8-Z1_YBQGSESZG(7^^IL2M_ :[S/*,J&J++'9
MS8R!2  3B$0P'G=L9[.YR>5G2\_51[?,7Y$6]87H,-$=G)OHFK_0B(EUCV5C
M/%#5_99-+ WEW_RSWWOS+_>&'?:V-H$"9P,A3+ T_6.;YYF]-^M^9@YP379L
M\:EZJ2(B(B)W!<L0AZ-BGT@!)I!DX)*,PD.<9N2#2]Q[\=-6VIWS'PYQH8M9
M))H.P0<PVE!W$CTWX/JUISES85*\]WV_=<^U1W__:KHPI1R-Z\FN 1LY:! ;
M#M:?LUZ_^OF+B(B(W*F4&2LBIU:69"3.W32T&3R499W=E[4.=RJG>0N:\L2]
M\^=8N7CQY2NK*^]LM]K_'GA-44P9C4:,]E5"2N19I, OOO*S7_NU>UO7Z0X&
M /A0D;B$5 T41$1$1)X7L?EGCZR ZG5/2:Q* %IY3I*XOV>,Z6*:+7818E2[
ME)/RP=/NM-G9V?GY\7A\%:"<3K775D1$1.04T)1/1$XMA\58@[46K"%&0X@&
M'X#@:/6&3/:FU+&C#&P'@B'O#3AW[O+#K>$C/VAM]E\ZYS V(4:+KR)E%? ^
MD.9UJ>$Z$W:6%5N? SA_TE)?^@B7^:F2NN<RT4!T@,5$VYS7-QUDR!* @)GE
MGAM/-[D:LG3R;;_[&[_V$RXW^.D&:1;)7,EHO/F,W6*'20*S:&WUO+X^$1$1
MD;M-0AL 8RJ\\808F@E;!F$ [;.LK;_P[.K: Q^T;JGE0P(V)6"H?$5J%) ]
MB98W=+*<#S[QCD^_<O4/_BB43T  :P$/^./SW'!0*F;6PF;ZJ1VPB(B(B#QG
ME!DK(J=6)!""IZQ*8HS8)C!KG05GF>SM8K(<DJ8L5(@\^*)'SK[B%:_XR:6E
MI3_/\SH0&V/$5Y[@/=8Y6JTV_7Y_OB].Y#9GC+'.VA__:Y_U.=_JIR-Z@T4
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M MMDVQXF#J1 UN3GSMIK3<&5AQ\-Y?/\ D5$1$0^56YV9.<FUZ70]"EUE.4
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ML]2'UF],Q@G0 KL#MCR6#1\!TWR4U#D+MGD\.&@8:YIC84KP$!$1D3O-T2I
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MRXE4546[U08@QOC$E:M7?XD8*(OBXWRGB(B(B)QVRHP5D5L6DVMU.#8V)Y]
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M>.1O.M[D]L.O8\R?DV>7VU,\Z!M\T"?VV"]M=S]GL/C@UR^O5#\RVMIZ-]&
M32%L4T685?\S,339#0F1C,.,DNU/T2L1$1$1J45#?12GS, NL+;V@G::GO_V
MW:T6!$>,[?J.IJS[Q)H*8^J^I@*6 DP@&G\P5XQ ) 52G&UC8JR7JP&LJ8C5
M%#_9BWZR\=:MR6/ /N I_90L#Q0EQ A9"L6-A5,,-UUSBXB(B,CIH\Q8$7EV
M!SUB$X;#X=GU]?7?7%E=^>96JT5553CG\%7%>#1F/![CO<=:>ZR'D8C(_,3#
M8U\W' 2;3"9TNUTS& Q^:':=LT8S(Q$1$;E]&0[G*DG"<#C\!N>2Y=%X="1M
M5FZ5M1:,.<B,#3'@@Z<JJW=.I\5? =@CD\4L.^P;ZY3J("(B(B(?@YOW $1D
M?IQK$KZ:Q$&3.9)L@5 Z\ -@B.U>Y-)]KWS5\LI#_T\(@Q=,QCF^ZF)=E]+4
MY8N=R[ V(6((,1()&!.!T&3"QN:<NEEC?0'BZ>Y9)"=U=)OYD8-/IM[?[JS%
M4/\]1NI^Q8: L1%KH"I:Q.!N^5158P"<LR3.89VM#]IX3^7KS0HR?W%VBL=/
M29:SLU>R,%AZN#=<_K6GG[SZ6*P\N!3"N&X=UK01PT"(@7K:E%,?!1W/[T6)
MB(C(Z90Y\!%89K#TL.WW+_^K5ON>)6N6V!L5I%E*- %L :; -#WN#19#TQ?U
M%$NH,,S6IQ"-(9(TF;$)15%/%//,,1UM44XW.+_>QS+ZCO>]Y__^ %PC,@)*
MH**H#C..JXK#B2>.>KX8U3-61$1$1 "5*18YU?P-U8)CX:GB"%P+LC9I-F1Y
MZ<Q_L[#0?UN6Y5E56&(3U8A1I8;E]F:LA1@Q 8*/A."),=0GH-=9.='C3Z=3
MK+'UR5JLLZ3IX0:#\7ARPE<@SZ<0 C9"698XY_YQ>[CXN>.M32A+2$P=L141
M$1&YG<SF)\XQ' Z_LM5N/S#:'S$M [U>EZ!V,"=B3)T=&T(@21(2VV(T&OW%
MYN;FK\][;"(B(B)R9U,P5N0T"Y F&;B<<FJ %M#&=<^RO'HQ[717W]SKKGUK
MN[L$L45%264"UGB,,1SV?CT2M# '>6@WG)J:6E'EL^2Y<O1O*=YP5:0JIV B
MQAK2S&*,Q=JFAZB!Z>[NB9Z]U^_5I<N:3-A8Q68(1F7B[@!%B#CGB 6X9.5S
MULZ\Y L^LC7^M;I?6 =?/55GQ,Y^E18(=1:$B(B(R%R4"= C[U]@N'CI]6FZ
MQM9V28B>I<4E]D9/@YV"W:_O'PT&@PDYL_ZHIUE=I,E@S*Q7K"60$'%-)#9@
MG,57([)\GVZK8'OSPV^Y^N2?1W@*F%)GQ89G]H&-0'0<9L4V@E<;#!$1$1%1
M,%;DM*NJBEA!'8@%V^VQ=F;MS-+RZB]F^>)KTZ2#L8:J\/BJ(L9Z\6J-5I1R
M>RNK"FOKOD[&U >B0CC<0'#2,L*5]WA?494595418\!@L*[)E+4J4WP["]Z3
M.$=9EF2MA-6UM3==?6KAU\?;UZ*U%O_Q'T)$1$3D4R_+6%M;>TV[U7YU57D,
MAB1)ZPV!<F+66JH02+($Y\+UC8V-G]G;VT0151$1$1$Y"05C14ZQS"Y0!@=D
M0(_>\#Y6UQ]X66_A_*_:=/'>HDPHJP1CH*H\/GBP'M(II"GX6;@BWG!^E*5I
MR--<;KX&4+A#GA=-ANJL/W'T>!\I0Q,\K4I\\*QVBQ,]RV2Z4/>(C75@U]H$
MYQR)2[#.,IE,3_I"Y'GDK<<[CZ\L@0[=?/"*P>"A+QYO;[^CK/8AC,%>/Y[U
M8'U]O8B(B,@\Q#[#Y1>PMO;PZTK?9KQOR=HY+LT93_:)=@QVC+&3)E,SA] &
MOU!_O]N;Z_#GS43;G,^N<43CB*;I[VH]T42,&V'LB.GTZ9_<V?[+$3Q*8B-5
M.+)^O;%(3[30])X]'K@U-+N?141$1.044S!6Y!2SUAY4&NYT!ZROKW_%\MK:
MO\)UNI,"IM,"8ZJZ9%-3;=A9BS&1J'Z*<IL+(9(DAB1-2-,$:PV10/">$#W)
M"5MJ=9(.=9DSZJ!L:$H65Q6^"$TI;[E=66LQ&)Q+FE+3AJ6EI?]A9VOE':.=
MZ_,>GHB(B,A-+2\OW=OK];YJ>]M3EB7==@^7INSL[6*S>8_NSA=\W2^VJBJ_
MO7GMQ_9VFP"VIO8B(B(B<@(*QHJ<8KY*Z*7+= >K+"Q>_OO=[L4WA6K9E$6/
MPN>$$.ORKLYCDP)G M9.B&9<=TTTZ0V/. O0FL-3A,.,6-OTT6EV"AMEQLI)
MW.R(R&&6MG6F#KB9.@CK0\17Y499EA^J?/DA8ZY_!'@:V "N =O I#F%YL%F
MJ>,=8 "L LO V>O7XZ4T22_G>7Y?FJ8]3%WVNY@6E%5)I]-]7E^]G(Q)(5I/
MDG8II@6[>R4+O0NO.K.V\T4?VGG\G3""L ^NR:">_;F9\N9% $1$1$2>9[W5
MBV39TG=ZGSEC<JQMX:M ,%.,K9I^L1.B*9NI2PL3$TQHUP]PZC-CFS8BD69N
M5U=M.IS:!7PH:+<]Q?[VKURY\OZ/PG4L(^I]EHZ#26$\O%@_@*,^Q)8<N2&I
M;U1FK(B(B,BIIV"LR"GFJ>CW^_G9\^??WNF?^5N3,F%_-,)'!VE*FJ9U,-9:
M;!)QQA,I"#[BO<>X&X.Q(K>-_7:K_4<A5G]2%,6[Q]O[?[*SL_6>K>N;NVQO
M0RR S1,^Q?U 1K:Z8E965BX-%@8OR[+L94F2OCJ&\)K*^_YS\#KD>>*L!6-(
M7$(Q&E--"U:' X;#X?<#[YSW^/Y_]NX\2-+T+NS\]WF>]\B[[KZF9WHNC20D
MA+$$@T$(&=8@C&QCV 4BP,NE!7&L@34@]HB0CW @-KQ@A$"LD+$66!,HUH@%
MM,) 2" C:219UHP$TLQHCI[I8[J[KJP\W^MYGOWC?3,KJZ>G9S39/3G=]?MT
M9%=65F;64UE9F<_S/K]#""&$$.)RZ^OK+>!-:9H2ABVB."++,W"*( JE"<R\
M/%CG,,90%,4O#[I= &IUR.;K<"*$$$(((0XY*;0BQ(VL"G#&L9_'Y\!4Y5>-
MU@0F9)07@ *E"-MM/)YB-.;EK_G?CP+O _[. D8O;G#&ULHS*B]/.@,RT#G3
MNM94$>@^K$Y!>4(SC%2YV8\JWXR\!^?!.93SU.,:WEIL;O'6HKS':%/V9=4:
MY5+P.<X7.#>^Z%WR8>=&?X4??01&]S_PV8]:&*-(T"0HL@-O>OF\#\"D_?$T
ME#X"ZN!KX!OFJ[[N#:\J;/2&(@^^N;#1UW@?:J7K!(%!J0;6K#%*$Y)TA-.6
ML&8((HVGH+ 9@5(8!\9#X!3&ZO*C*S/+^_&<=98/.:=4F:GOX^IYX5!8M-G%
MZ*V_^YF_^H]_@=G$-%("!_FPP !UFF3D),@1.2&$$$)\D2:QK-7Z3?L0-9U4
M@J<@C&+2+ 4\Q"VP&@H@[/#R5_^S'P/>L9"QWP2,*^LX.U7@M<5-FL=ZC0(&
MO5U.'EUE=_OQ3SWRT']^C4T>![8P!H(0TF1A0Q="""&$$#<XR8P5XB:7YBE@
MJ#>:C,<C\L$ :C5>_IK7O KX(^"V!0]1'%)IFI8;JR8@,*;LL>I=M1_K0('6
M!ATJ, :\1_FRA;%SWAKX:%[D'QB-!A_H][<>Z/6V_&"P"?2 \6)^J.G&K+?W
M_>4'/PWM3S=73_S\ZMK)C4YG_=O#,/@NK?7KO$=E68[SGB ,T6%($&N4]F1%
M@;66()"WZ 7ZW\S*\E_8WB8V*5!F?QO?(9O@0@@AA+A^G+-,)Y7605%VSF@L
M+6G@GRYP:#>]1J.!M8XD27_9%@=#-YVD'0LAA!!"B#E(9JP0-S(]28W-*<.E
M0<_T,G0>E*X11LMDB0(:4#O"K;??\8:-(_>\=YRM2AE5\;Q->RZI*K1?6<KL
MPDF:]N1ZLSV#JW[!WI 0X;W'>UMF)&I/:#R!\1AM&0V[: JT=AAM,=H76OD_
MT5J]5RG[QY_XV'_:Q=LJH[:@_!N8G&QU*LK[9C(V.WWCFSLS]@ -&%#!_D=7
M73;I'U5KT%Y99V5EY<YZL_W#*RLO_?YQHC?&:49A Y2IHTT3I6.\-W@'RH/&
M87R.IL#X EW]K2>Z=DU_@L/&ZZIWEZL#!KPJ-_OU@$!OL[WSX-\^]^C'/XW=
M I6BK)O^-@V&D10"%$(((<07JYH^3RH:Z>H"55W@ #^IO&+J8&.@!B;F]GON
M_9;ZTFO_>!'#OEGH*JC.8ZI3M3;!HE1.LPXVOW3AS.D'3FV=^6P&7<)PB"W*
M>9_SSW#'0@@AA!!"/ M)NQ'B)J>4*OL($=-86>>NE[SJAYOMSJ]V]T9&!:N+
M'IXXQ)K-%EF6D20C\CQ#*X>I!82UB%H<L]?=I%D/?:M5^W.CW>_U>[OO.W/V
MB9VM<Z<I-UPSF&8I3C((-*@ I11^$>'KWA_\"*#+,9'G])]ZBOY33ST&^BWW
MO'KCGSOJWZ>T^>D@".Y$&QR>(B]PSA(&T0L_?C&UL7'DIS<OM+X[ZVV!<P0!
M^&K_UA@#5C9CA1!""'%M1:$AS:LYAM%,8K_B5HOU]?6?'%[;:$)QF2B*V.J.
MWMGK];))<*G6&HR5J9\00@@AA)B+9,8*<0-3'*O^B!,@95*:U2G*O^Z@#ED3
MS!HG[[I7K:[?\POCI/TSSG?HM#LDV;E%#5W<!)R>' W2X$W9[\KK*A-VT@<6
M5)4YJZ;-C<L-U#CHX)W'^0SO4IQ/46H,I&B5G%U9K;UG>_O,NY]\\N$GNA<>
M!ZK>M'B(@: J13Q[MY.#)).]4#=I[3H9TR3Z'8HY<V,#HNI;^>I_MU_"=O)M
M%/O)L9.Q3L:FVK1:)UD_<DNPO'+'FZ+HZ%L+VSHV3B/2-":*6]7UJA],I2B5
MH51:?E_7F&O\AYT/>N49UP!7 Q]59;!S#"/:[<P^\O!]=UYZ\M-/PBXFR/%%
M@@&B$.1@J!!"""&^>+.31*KJ+=-/"6N09E0QADM0-($.1V]]Q2OO>LEK/KL[
M:K[ X[VY*%/._[SME-51?%Q>KL9HW:79&F9///')6R\\^>E+Y%T@(S(AWD+A
M++ZJ4".$$$(((<072S)CA;B9Y3FMM35.WO:J>F?I^&^/$__M>9X1A@IM]+/?
M7HCKJ-?K$T<1M7J ,8H\M[[7&[]_KWOA7:/Q]O\WW'["E@$&Z?Z-M *EP>5E
M8BSL;VY6B;%0'L_RUSEZ?3::R<\,8W)!4#,4A3VX 6L@;"GB.&9PH6"PO<U@
MD!91??SKS5;O=Y:7;W_KRMKM/[FQ<3RXM+EW?7\ <5766K.^OOX3_;V5?S;>
MV\46EE ##@HY#B>$$$*(Z\#-MJ:O2N,V5M=9WUC_B:*02+#K;7=W]S]L;VU?
M(LNGD_T\+S!*#IT)(8000HCY2&:L$#>PB#*2M\S) X_"H2GC+!I06^%EK_SJ
M(QM'[_E_M[OVJWI]1;UY'!,L,1J-:(8[BQR^N,$5P:@\XP.4#U$^!!>B?("B
M['>J %2.(D>IK,IL=2B5H=,12N4X[Y(\&_[6<+3WB[W>I8?ZO4V*K,M^QG<*
MNMIYG;QK*2!D?Q=T=L/3'SP_Z:-<WM1,<G8IYHQLCXGPU3]FLF(GWW[2'C>,
M((S+R]*L:F]+.2Y7S/R]TJ"Y?(K;3KWR;VT<N^O_ZO;R5UE?QQ/@5(A'XYBD
MO4/@4\0<@DU0X%T37 WEFF7?6*KGC._1:>>#,T]\^M8SC]W7G?8,LSEXZ1DF
MA!!"B.=CDMEJ410HBG)JIZOYXV2NZP&[!JQQZJ5?MW[+\5>=V>D.:ZHFE5'F
M$FR5'^T:RK91+D9YT+J'#I[B[%,?__*M,Q^]']U'A>!3P"H4J]6<7];/0@@A
MA!#B^9'4."%N8E]Y[[WW%$5QW]FS9[XJ" *.'#F*]]#O]Y%8#+%HR\O+VT:;
MM^[N[-YZ^O3I'W[BL4<>VMVZ0)&-F#X_M49'$6%<(ZP93+C_)2S[F[#5GJ8.
M(*@V/U\(:KJU^W2F*DV<YS :PGBXOQ$+,&EI&P8A)H@ P["[Q^<??/#^CWWL
MOJ\$WGD=ARZ>Q7B<T&@T6DM+G1^87*:U1LM+IQ!"""&N%T\YUU7[AVJ6EI;?
MW&PV:Z/Q>&'#.B0^W-O;NW_R21B:Z1<\$H4GA!!"""'F(X<4A;@!**70^F#L
MA/<>XQPHB&O@U1+#D0;:1,V3O/1+[KU7A>T_MM37+0%.*9Q2>$651PMQ_@+M
M6(F;4M3Q%(6ER#PV]WAG,"HDU"&!-O1[7>)(T6@$1*$ER_JDZ1[&Z.U&4_V;
M!^__HW<4>3I(DH0\'W.P^>ND >Q,(]C]I-"2"ZLS_AD^NJ=%',W>?-XJQE<J
M5N:?=K[L5>N>]G:K"*O1>6R5W>ZK; @#U,#7N>O+7O=#G>7;WSD8Q;I6/XZU
M'88C0ZO9Q!5/SOD3'&ZJRHSP/@87@Z^5?<-<^9OQ+J55]\31\+'''[WO)6>?
MN,_!%K76F&3$I/6Q$$(((<07H06 PJ+(H<J,]7I_'ADTH!C&X#:X]:6OCVZ[
M]2M/#_NMXWN#/K6V',*91]S)Z':[-(+C-*(.P[TARGGB>(_A^.%O>_BS[W\?
MP<5R"C\I=U,$P&IU#Y<6-G8AA!!""'%CD\Q8(6X WGN<<SCGL-9BK<55#86"
M ,9C&(Z& &P<NX4[[KSC6Y(T_1"POL!ABYO<SLX.H]$(I16-1H-FLTD8A&1Y
M3K_?I]EL4J_7R?.<;G</Y]QVO=[XGW=V=F[_V(<__+8\SP9YD5/8*VR+*CG0
M1!CPZ$,/O6NON_?MZVMK>9JD)$E*N]5B.!HM>G0W/07D>8XM[)WU1OV;RTUR
MR+.KWTX((8008A[3UK!A1!1%WU%8>]QY3QQ+(.V\BKS :(U24!0%2FOB.,8Y
M=[JWM_>'BQZ?$$(((82X>5TIL4<(\2*AM<9[/SU=SH4PME VSUPA;M_.B5-?
M_8.UQO%W[72=SFT;I\!K"SY'JP0F)P!N>0%_&G&SL:G&. 7:HW79\TKI%*_'
M:#-B97F5O=T+>#L:-FO\0K=[\9<>??3S Y^-(?#D^9-8"WY2C@VFI=F,4=AB
M]CEO+FNDI= LS=QHTCAV-JO67G89U[3 6#$)9YKM48N>.9GJ-'O9?GJOPP)Y
M-;8"77W9XW J1YL^+MMBZX+Z@[6E^'LB.K]KBT+[K$Y-S=?O5@"N!I2EIKUR
M0 ;XZG< 2FF2Q&!4C6;SQ(\OK]_Y_N[6&%MDX.?-JQ9"""'$X91-:Z-,^6H^
M/+V* =^DOG2"N+[VDVENR%Q(5&N2.\G,G$>:UM"ZA@?RO$\8Y#0:GKWND^_8
MV7K(PG!_60'5I-"#EV@\(8000@@Q'\F,%>)%3"F%NDJ&8+,9[I]?7N&NN^[Z
MYUKK=Z=IHMOM]@LQ1'&(==KM220YX_&8\7B,M98P#&FVFIP_?]XW&LW?U,:\
MY/X'[O]7CWS^KP<^2T"'4&2D*117V%/4BJMT8CT\7 X$(;V+%[G_@?O?F^7Y
M#P+L=;MT.IT%C^YP*(J"PEJ:S>8W;6QLW*W":-%#$D(((<3-;-*FU!A65U=?
M6ZO57ET4!=Y[HC"\ZDW%L\OS'&.J:B=59JQ2#(>CX;NS47_!HQ-"""&$$#<S
MR8P5XD5,*77%C-B)T?A+@!JMU15SRVTO^_6X?>1-PS$4+J)6#RBJ_2SE%1J/
MLA':*K0J%Z"26R?F43-M\![G4W CG!^!&^(8X>WH@^UF^C_=?_\''AAW-R%P
MQ'5-.AZ @S@.R-.GW^=^DNSE#3DGF8B3&"*%9G#9+<%/TU1]]=F5_WZN:;O/
MV5ZVOKIW/PFI+RZ[POXFLYV&W>?5!G09>*]]>1S.>6C4%?UL2+[W*.<>M^\Y
M=N+EQY::G9\/@PQY"Y^/LLTR"U9EY0.O\NKD\"[$8U!&X[Q"Z8YJM8__6*-Q
MXJ>&>RFP!USA"2R$$$((<16:RS,L#:"JR:D"4P,7$'6.T>D<_4EMZE@,:$UQ
ME76A>&Y\L8QR#;SK@1J@S)A1LON>7N_A/=@%TO)W,1L7JCRHLB70M5U$""&$
M$$*(PT0R8X5X$9OTBKU<$ 3$<8SWCCM><G?CE:]\Y>\WFXTWI6E"%,5$44RO
MWUO B,5A4F;".J(PI%ZO$P8!:9(\>>GBQ6\]??KT-WSZOH\^D"8IIE:#HB =
MCVEW.C2:3=(T><;[]1Z\'.B@5H/^8'_#>=C=9F=[^VU+G<Z_V^MV%SBRP\$Y
M1ZU6PVA#GN6$8?B]G:5.C)*IDQ!"""&N$^\ACEE=6[NUWFA\JW,.HS5!$# >
MCQ<]NAN>-F:ZQ@X"@W/.;VY>^I7M[>U%#TT((8000MSD)*U&B!>Q*V7%3C9B
M@R"@V?QOE]KM8W^H=/-U63(DLQE15(, =.'PNMC/MG,!VH<8!Z:ZVR*4WC=B
M#D4 7E/XC)R^'8TN_>+.SA/_8GOG\2&C"\ 8EPTQH6)Y-6;83QCVQBA@I6/8
MZY5O0?N!YV4VJ_-NOXW6Y0FE:G^75MEG[MLY>_/RO,97&:I^>F?Y\_[12Y-2
M<;[\(\,?&-\!5ZJZ/)--ZQQHM]]5%H"L1@@H @I2'#F][@-TN]F/$M1?!J__
MFCE_@,/-U\HGAW8HE>&G?7A3T![K#/5&&YL[1B-+%(<KK>;&MYGZZN_:48)D
MQ@HAA!#BBZ;WIXU -2\M9WP0@@MHMC=873G^(T'0,*/$H8, T.SN]5F23A5S
M"<PRM@#\+K6ZQ^5[?W)QZW,/D3]%5 _(Q@Z\ 3\)OO.@BV>>XPLAA!!""/$<
M27J'$"]B5\J*-<80! %A&&Z\Y)Y[_J(HBM=M;6UAC*'9:)*F*7F>L[:VMH 1
MB\.D7J^!@N%P^+'-S<V_?>&I"S^[O;4U9%25\:K%H!0V]W2["7D!403&0*]G
M,6@,!JT-6FN49!P>D+N<6$=X'!I-H]G&I@D//OA@%L?1=P";BQ[CS<Q[3QS'
M:&U(TW22*?NF.(H7/30AA!!"W*R<IU:OQ\UF\TU::XJBP!B#-H8D>>;*,N*Y
M"8S!>8?SGL $..?^;=;= Z#1:"QX=$(((800XF9VI5P=(<1S-;MW-(UP-M47
MJOX_3V\H.7/[!C@+C(&$N :AAJ(H3]Z7?2,]36 )6*'>N9,3)^XZM;Q^ZL]'
MA;G[>OYXXN:F7979J2PHBU<%7EG X15$<4R:YN2YQY@:M5H;K6ODF2--4^[N
M_'E_<_/2SYX]<^9=6SN;SE'>=I)_.OG\X$E<*\?O_.YO['3N^I/EY0WE59/!
MP#/*$G2HB!N*W'=!)2B5E[\35T/9.LJVRSM0DAE_-5F:$H0!S6:+/,](Q@G-
M9M-O;6_=??9O[G\,_I X]G@<>6K1&HRJ7M(!18A'X]!5&[@,M-U_WY@W,5L(
M(800-YQIOJ6&, *E(4T!&P(;P#%N?^GKOO?(L5>\9Y@6C*VEUFKB3$*WVV4E
M:"YN\"\&RK*_\/8'TXSWKU1EMDX^3AYUC7,=\CRG$>T1F9W/7SK_P"O.GK[/
M:_K4#12VW/!V@,7@T.7-)W=1R 1.""&$$$(\/Y*&),0BJ8/Q$-9"8<N/ /JR
MO]#.Z@9'CAY]111''QD-A[(1*ZZKO>X>Q@2LK*P0QS7V]O:X>/$"X_&89K/Y
MH;-GS[[RTJ6+O][K]YV;V6A5*)226)_KK=OM_JGS_NU**9(D(2\*&HTFM5J-
ML61.S$T;C5(*YRS66CP>%"H,PQ^ "("BL-BB?,'VCJ<?"Q1"""&$> ;>[P=Q
M343-%E$4_9A2"E?U-G7.X;W'&+.8@=Y$M%)$48C',QCTWSX:#J>S-VN+J]U4
M""&$$$*(N4C/6"'FX2_[./5,&8 ';V"TK19]Y2K<Y66RU+3?I8GPU($6<?LD
M&R?NOG=IY=3[LURO[?5S6E(M4\S!AOWRC ^JWD@QRAOP"@7$.L<EEB0?8 ++
M4C,E,;UQ?_#PS^YL[_YJ?OX+/DW'V&G6:QF9KI1"*0]^DCDXK%0  "  241!
M5!D[<Y1I=H]6-J[F,MY[F.3(L9_+"_6&--,OA26:C0:%U^SU'&%8EHE&56_U
MONPW)CVOGIO !"BM*(J"HB@/SBFEB./X^Z.-C;=FFS5K[;BZ=ID1;JN^OU7W
M8V:[%LOS70@AA! *C<=--V+M-+$S!M-@=?WHO;5Z\RL\'N<LSEJ<+= !1&$(
MAWV_T*LJH'DRO[K2@KRJ3.4OKU(%09 0&$,Z'NSN[)S[K>[>1<JUBL527%8Z
M;I*%"U+A1P@AA!!"S$LR8X58-'UPR3>[C+36 IIF9YECQXY__?+2\@>C*%HS
MQA"&X0LZ3''X!,;@G"<O"KSW**4^FF79EUVX<.$=>X\_YD?IJ-J(W:=0>.]Q
M3G:>KCMKV=K<3+:VMW_864<<17COL;:0S(EK0)NRE[&MLE\G/8W#,#RQL;'^
M#5&M=N7;R<Q*""&$$,] F_V)@IVMJJ$5<:/!ZNK:C\=Q#7S9O[Z<VUF\]X2!
MK/_FI;5&:TV:IK^QO;T]<MD8I;0\MD(((800XKJ3S%@AYN%G_X1FHW*OD@TX
M\WG@;=EC<.:6G@!/C*<!-&@MW\K16^[YA^WE$^_-=2,>C@U>Q]26 GPJ/6O$
M\U>8ZOGC--H%*!^"#]!>HSVX8D2G;C!!8OO],V\]?^'S;^MN/6JQ>Z#SJJZ:
M1Z&K#:@J@O_R_K#JLH\3LE\['WV)\<XGN,C%OSQU^Y>_I]ZH?U\R+DCS@&:]
M@746J('*47@4OGK,#WM*Q7.C5)D):ZO2@&5P0IG)TFEWOGO4.OFG69("%E2.
M\VF9>Z&KDL58GO:DOU);,R&$$$(<&DK9<BHPG0]H\$UTXRBMSO$CC?;J=R@=
M4C@+RF/*23G**@)M<(<^0U,_PUSJ:@N-_76Z47U\L6='PR=_U8_/ T.43M"F
M8+9*\?ZOQSW]KH400@@AA'@>)']#B 6RKJJL=-D"SV"(HSJ-9H?U]8WO7%]?
M_W\:C49LK25)QEAGB:)H(6,6A\?R\C)9GIT]<^;,ZQ]ZZ*%_W7WJG"7/RB\&
M 1I-%$34:C%!%4WN9:?IA1.4V:_)]C9)DOR<<VZ0IBEYGDGF_#7@G*MZ'WN4
MU@1A@"UL^?A&X;>OK*PT)M<]\'C+ 3LAA!!"/(,KSI65HM5JL;JZ^D.!"2+K
M'$51H+6>SK&==3++O@:<<^SU>K_?W=U]<GJ9]UA[V#>YA1!"""'$]29U#(68
M2XWRSVAR]+W*BIVTIM'LGW]ZRQH"7U8IWN\Q6,.Q1!#>0E2[E>,G_];WUEMW
M_!;A>I#:%JD-*8CP.L2BT%8RW,3S5Z@0[R.4-^534^48E:+5 *-W\/;"'V]>
M_,PWG3_S7Q[RV1E@A\ ,0 WQ-@5ET<:CM,/:#&LG'8\]00C.<_!OX')R1&D^
M)@4] %),' YK<:RUUE]O=(!2-;P+43X 'X$/4:BRQ98JJKZQ$H]U-<Y9@B"@
M*"Q::VJUF"S+2)*$.(ZCFDG_YN)39_\: J*X3I$G@$,;<-,DBO+ WO3 JYIY
MTLOS7P@AA#ATE*KFR  T@!:$&RROW16L'[W[=RR-3IKKL@^]T6598^]0. *E
M\?:P3R!F%]D:O*%<CT].U=?4[.+#E7,P98GU);8O_<T/=[<>/X/;!8; $(LC
MJ.9PDT(F;O+M9K^E[-D*(8000HCG28[$"K%@EV?&:C1A$!!%T8^<N.66]]3K
M=9TD8\;C,5HIXEH,"D:CT<+&+&YZ.?!3G_K4I_[AUM;63JO5IE9O 5#8 N?*
MOIC>>_(\)\]SBN)@8$!@I K^=3=3";VWMT=_T/^E( @O1%%$EF:+&]=-PE5'
MXY0"HS6F*E.<YSG..NKUQC]!E3%MTJ-7""&$$,^%OU)B;&"(X_A;&XW&+<Z6
M6;'6NC(SUAB44CCG<>ZP;\3.SSGWJ=%H^!&*%%"8.)KNO@:!'!X30@@AA!#7
MCQP]%&(N,>5.ZFS\K)]&T"XMQ7AOL7;_*L8<O)H)P/N0W+?QK!#5;N/$J2]_
MRQUW?^4O]88!F6OA51-O8CP&[Q5*:0*C,5Y"<\4S*XJ<*(II-!I566N/LPZE
M( @,/F\0^)@\'9&-MZC7QK2:_2=W=S_S30]]_@._3_8HMGB<+#E+4>R@R:J8
M<X7V"J?*)['WGLNSOPOW'/HKR?&D^4R#_W-<,J:W>2D_>NM)N[%QY T7+FQ1
MB]LP_8V9LF<L#J6RZKQLF%^-UJ8J5:Q!*?(\KS)D:]6CY^ZXY>2I__/\V7/#
MW#MP.:@4ZR@SPZ<OSQY_(*W"3RX60@@AQ"'C 10TVVOD11U\A^;R7=QVQY>]
M<YC&IW(?H72$,@;G'=Y9-)Y *92;S"D.L\FZ>W9N-3DI%(HH# %/D@PI;$(8
M01@J4"EN^+F?NW3Q<Y^Q>1?4B"#,<%6U*1WZ:=_8Z33N\@H_LOP60@@AA!#/
MDX3^"7$=C48IV4R"FC:@M4;K_3^]HH#"%2@42TMKG+CEQ+]HMUMORW,I02SF
MD^<Y69J2)&.29$R69=,^F$8;G+4,1R/B*.;4;;?1:#3^\K'''GO-Z2]\X;^0
MI8L>OG@VLW$@E;UN]UW#X6B[7J\O:E2'AK,N /]M -->RI4\7\2(A!!""'$C
MT!K2- %G 46CV?A2Y]SKE)+#,_/RWI>!HGBT5IB9M;=S[L)P./R]+*LF:DJA
M9\H9.WN%.Q1"""&$$.(:D<Q8(>82L)\1:SG0+Y:9!9T'T!C=0-/$VPA/ T<;
MQRJ>5>+FG1R[]<O>MG[\9?^KCM<99Q&%JN%4 $JC4&@<VEL"\BHK]K!'1HNK
MT4JAM<8[3U[D%'F!J[*IE5*$-J&F,EJU%,/V.[8N_?7WG'W\XWWRLZ!WP(SW
M^XLJC_*3)K Q$."4! PL4A14KS&.\O=$0>Y]7JO%C5:[_7KG !] U1,894%9
ME,ZKC5S)C)V'+Q2:H#'*BM]*1UW0%DB)FV"+_6SQ<J]\IH&RU^5)4BN$$$*(
MPT>7E9**/ *6:*Z]E)6UE_TKI==?K8(6A3=XI4$YE/)HRI-QH+W&J4.^_E-Y
MM3:9?'XP==5Y6[93H<"3H0-'&#F<STBSO7_3?^JC'QP.S@,IQN1$H2,O?'5;
M\%[C"2C7^0:\/;CDELHF0@@AA!#B>9+02R%>($:7L0]%46!GFSVB:+26.7;L
MZ-N6EY??$D412BG99Q5S:[5:Q+4:VNR_U'M?]L(LBH):7*/5:J5[>WO?_XF/
M?^)_?.0S#^38HJJE+5[L#OR:JD]&6YML;6W]6AB&DIMYG7GO<=Z__NBQ8ZM
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M'$HY\BQ9X,#%S<"X)MX6X!T!?7 ]DO'V)[8V'_[FG9V'=^B?!KTW::%$EHX
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M0JN'BB.($!!4E1 B(41BB&QL;-:5BZ/.+B%JW49*8514.!&<=SB!NNE4)$H
M5W%E3TA\&^\=ODV[E\7WMU:*]Z\5Q:]65?DWKES:?K*(N\1J1'TL*HE41$H<
M<;8D.:NE)M/<V&AS=V.,61*V&6O,"WC+6][RER:C[&/#X9"5M762K,6UW1W4
M35A;7V<RL3,B\^53K4O2..]0=<]%U7?E>?[Y\N" NIQL_7TQCT0%''@/P>(
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MIWD9Q3I+XS7S]]TDV-L88XPQ"R;+TOI&!)<TB_/.L;&YL=KI=/YREF5U51Q
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M,L88<_O89JRY-;.J&H!ZZE!6;1Y0(-396=($N6IS:9X8BOJQT8ZCO78OD]W
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M"CA/XK/7.Y>B.&(4P#>;@19E>VNN?]^5^<Q8Y^HTD9V=[6=P8GWFC#'&F#N
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M'I4&RE!05#EE*(@$Q"GB %'J_S5FV;$>-*DOYD3S/N7BA2L?^///_=FG**]
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MZ$A<*:64NF/RUN&>\R1),!@LAN65Y:Z(?%V=W7BV*D",37IBS>QT:Q'2) 7
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M9Z=>N:"IQWC=%O7$U&G&.IWNJ]]@I>XBQES7SS9_*VF6TN_WSY],JTX/:3)
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M [P=XZ6DC"70/>'&JQ,ET]14!J(TNPZ;R%@BKIK\SM7UIW_$#[>  N<&>'<
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M5DZ>YUAK\=Y33(H3;+BZ!VQ75?4M>]>N>HBDW1ZQK @.\A9H@*Q2=]0+)]V
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MV]OO7=]8G]66L5:GCY122BFEE+I=NMIVCYO.^4;JZ)U#GC MC"-''CA7T\Y
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M.8<QYM?V=G>? TBS'&LMHN^O4DHII912MTUG8^]Q1X-?FRA&(F&Z9W4^R!'
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M:Q8IDJ4GVS:EE%+JM)H;<JPL+[^E*(HD35.L,?B@YS?']*C;W0T 2=XZG$,
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M_.$"XVFT4Q8L+JY0# OZ>9OQ_@X)0QZ\F)6??.RW'[IRZ4/KR!:8YIPO@D2
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MP-[L]HT=A#YT9AD 4 'T%.VG:&,QE.#&&%7AJJ.#T>%SWW-T]/S/%I-]?#$
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MS=SC7),[UGO @DEYZ*&'OJ[3[7SU:%PL==W$O:^J+*U6BZH:[UV[=NV'*29
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MKST$-P_'4("]SF0$SSS%\)E/$7L(@X-@P?CXFFHA?&/Q^*,@"^";188X5AL
M%3*,3K$N#@N;U.!-17!EK-%.B4V HHT<_X000HB[3=WT9A0G5FUM/O1-A%PE
M21NO,X:3"5DKQWEWYB=4J1M.1F+#+Q#JS$B6LJC87E_CZ/J+/]W;OPZ4: 6)
M/IT996$Q)U]$SG.$$$(((81XE9WUMLQ](+:6\BQG9V?G/X'PIK(LR;*,RLI
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M;/M-._^^K"9_,!J/?[??/_JS7O\P]/M'5$'Z)H000@@A7HK,4;M3>B.V>/0
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MH?H-Q>3#G_@/OQ5@&+=3,@8U OH0ZN\-R_P+8>$]TAK2-':M-25JU>Q[K+F
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MQ1J#LWL#_^)&!Z2FIN9 J">S^T002LDJ&6%="BZCV;[ ZMH+_TIIVTTO5$C
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M/_7&V6\>] .R3-)HQ:B@0(H4OPE/-N/!D,5VE^W^A^W5*Y_X4<R3$&8N"=P
MUB!MB,M4!BBPC+'"9^1[/!Z/YS.GBK$*) *+0)=C&I<,)%29%V1!ZQK6A$ ,
M48-&]V7W1D'WOY+4,(5%YSD@$8%""N7*'<[G#]O*P^[N4<8BW!:T4\5P];T,
M HO1(Q %UFZ!'?Y"-KP*9$AC>9%5)#U'&&%+&V2JW/D$20\9+2%4CZ6U>Z.D
M<>[Q2=%^;)A9M!!$48O<&(;9A"0YU.:?>,2<IGG>,[82\(\F&4FMC3$QXXFB
MVSGS?4'C]%<4PZM@!CB5N^<SICJ 1 U,BR XHY)D_0VCL2*6%BO3F6>L==6F
M9CW*7.6%$XJREL!:R(O?=-4LG">;DC/-JI& *7![=2F7+;=B+ER98JP$TP":
MA,TUFHT-DF3Y+:LK]_V,M;7>9!Q0:($E($H4,I04QJOR/">=F3L\0I?J6*A*
MWA6%085-@L %+IK-^)T;Z_&_O73IV5_-!I>!/9 3]_K]=L[3MW4#"T55<67V
MN3ZC[X3CPUVWB IA. *(P$A6U\\^,IKHAA4!,@C+*A(P.]YLN=$M,\/GDXN8
M>L8J&O56Z+:7@NDZ K@8Q_QVJA:W/8>-Y-:L)ORO>'0XV6>B%TF[W7Y]DB0/
MCL=CBJ(@# .$],H1#Z1I1A2&='O=WWSR@Q_\D&JUII5GI(_3>SP>C^>04',C
M/..,8 $(HY!&H_$]4KKT?F,,VAB,<25[A1!^?$/IVV<MQMA+UMK?FMI9^*HH
M=P4W^AF54H1!0!2%T7WWW??X>#Q^[-*ERRBEZ/5Z&&L8CR=$47SG&^SY&[&W
MM\?RR@J[N[LTZG5V]W;_[GWWW?> 7PA_:0@"]4@8AEUKK5]I?A&4V^BOC35/
MS=__8D4]9@+,6>.I6HVEI>7:/??<\R\O7KSX*U$4]8I".TLEH-/IT.OU$$*P
MO;-S.[Z"QW/74A0%M:1&K5;#6DL4QZROK__,TN+2*;^4?4OL'G8#C@!^A? 6
M<56=9G2[W3>FI1>Z4CZ\<7.$2V(4$$51Z^!C'H_GSG#B.P,Q-Z *:P&(@&R2
M@TV )NOW?BZ6M6\>#)HTFC6TAO[> *DT]7I YI-+3S1!L$TZSGGVVOO_%V0?
M/=B<]F%25,/UF9+(W$5^>QZ/Q^,Y1,J^QEI*9>Q^+YPBK9XCZ?7.<.UJ"J;&
MN7L_?SEIG?[Z<1%CM%.$)G$,"+0Q:)TQK\#9G\E?^:H>_^Q^BRE]^9RON["N
M;Q9HA,@0<D@0:JS=_+F__JL_+6 $9$@-M5K"<#PYU/9[;HW*]M<@"(,EBJ).
MJMLL++X\NO^!SWU\>R]_+&KT"!J*P@IV]U*L@"2* 0.Z>,'W][RTB#*:;D7I
M&5N=CX3$6D6SU6,PS*@U%DFS(6&T++3FN^N+K_BFT>:'J=<S)I,)55G=>>N9
M6JTV#6)YGH>RF$"M>9KQMF1YZ95O$BR3)!.&DR$J5',]A$)8UV^X>;<YYKW'
MK5.,++W>XF^^[T_^ Q 0A'6*;)=\;% A!!+2E'+*J$$9@J1&831D&>0;0 .0
MA.UUUM?N?:C7/?7+4C4?W-D-080@(:ZY8V0PV7;5($1!W !KZB_4/(_GKJ8:
M[TV=QX4S7K8 %I)Z0E88LMP@C "C$+:VT%M\V<\O+MSW)>__BUV+N>;\Q\40
M1#Y].Z' 9I1#Y)#YX(;SJM4G^?QW@K_ZE.9A-^"X,QX6($+J"QN,MBRCB7[]
MXO)IKFUF3/(1M4:SW-%<>2@QMR+KYGTG>RU62(&P((5$"%G(^7.4E-YN[X@C
MYBOEWR!V7LUOE9PE^&E35E.!6?D5SZ%SLL]$@)S;!-98M)G?.P5Q%*V$0?A5
M2DIDJ181"*QEZJ_F.;DD2<)X//[CO7[_C[!FWQ'E$[,\'H_'<UBHN<%ZOS]P
MH_"D3A $WU%FG'E>@"1)T(6VX_'X_RCR_9EWNO"!N+N!0+EY0%IDU.MU7O;R
M!Z/U]?7'KUZ]^MAAM\US:U@SES BW*)3H(*WQ7'< <CS?,XG6^SS&=-^(>KF
ME M X_X @A@+;ZJVJ5+>4_%F)$G"]O;V[^C")?7,%Z/0&O(;=#'%9 *3M,K
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MK<'Y&H/ 3..IVAALEI6)BRX0:XS%6HCCA)>2P6#@1(>ZJCLMD%(@LVJ,F
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M<1AC&(_'[QT,!I^9/%:<\/*.%145%14+1D&>%]/;MBB F'JG@S'1#RVT;4<
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M$9P"T95-Q.*95>%!2F^HN0H+XW%!G*087:/=C!LB_+JU\N*KKO;WZ5]QV$W
MHE4#L'B[6[YFB#,\06T?F(P7NE3)'BY.Q&Q*:4T41]BYBBC=3B=MM5IO[%7B
MD1.-]PZCD^!'X#W&&)S+&8YZO[K;VZU,@RLJ*BHJ#C6=3D=W.NVW.NN)8DT<
MI^P,>B0G7+E@3)CN>1^\^R9K7>(]UKI?O';UVG1&+UZ((H.S&G_2ZZ<=$@;#
MC+0>8UU,GH])&LN<O^N^Y;75<[_7[_5O"^6,*BIND7(W5KR_M[VTI'I7C^?6
MZQ?*GO4]'Y9)6^WV"[SWZTI7&2D5AQNEP/N06"6$\WMD(N(X)HYCDB0ABH)B
M:#P>?7(TVOT_MK>??.?6YJ51-K@.Q0C((8ZIU5.4LF19#Y^-%OW1OB#B**:6
MM!"?,!I['!Y/SH5/?6J'QO(_65X^];/+2WQKJQ']:&3B^Y,DP>B8/'?3S5B4
M1VL5CEN:8(QA,*R62)Z)/,_1;3WUS6NU6E_;[79?M'6-CY]@9=_JHAMPB&@M
MN@&'GC+,< YJW39)DKY!:SWUD*UX9D0$79:8M\Z11 H1=G9W=S^QZ+;=#%KK
MITV,CNHIMM!0*-"&M-FBU6J^K-EL_G*CV?@*:P7G'<Y[/&$,-L:0)#%*:T;C
MJ@\=9I(TP3E'O]]'F0(OGN7EI1]M=UKWB9SYMDN?N-RSQ8AL.&)J35KB0_[9
MD>$8;L;NTRUJ<*(0%1&JF:506Z7=.?N-)FYWJ#9C3S96B&J@7([(F#BR>+LE
M_?ZE=^SN7J$T,SO@/U:#>$5%147%L\'$\T;-W2^]SPX,*!U0"YXX>I56Z[9O
MBI*E\X4U>!1&J[(DD0ZJV%+!H$2C)"I5)$<?-3T/3\[1>NI^J%"(TB 6H4"1
M8Y1%B:+(1Z/QX.([AEEO^G^=RXGC%&V"BF'.[>JIG-AUM&<9UPS7:@!FXG?$
M[-#[F.&H W1 K7'VS N3LV=?^"YK[7V7+V[27*XV8RMNA5(92]B,]5[2E>6U
MVWI7HR?V*):FYL7'C8,5;7M$"@[0,7B#3CNT.JNOLCY"5$)%Q2*1B>>]E.L[
MI5=\N*_Q5B->0FE[XXDB,!$8+2@UY-2I)^CWMA^Z=O7J3UR[=OEWQKUMP65@
M/!A!FP*1')&<\;  )1@%<1K*X"U^3W9>82AEA16F,6.2@HC'NP&#T3@HAE5"
MK!*T'I-Q!7J?86NG7FS1_=>USNW_^M2I>_[&Z=/W_.3*RFT/;&X7.!&<"!Z-
M&(]$GD)[G')SGHQSXX?:/W"6%U4J8^=]VN1H+T&J/4E[&IE^'ET*904G%E$>
M94!'*<WVZ@]$C=-OM<,"V.]=Z>:J$90<&&L>'J\[H.QO<S+>@]H\\PQ>#W.2
MYZQUAYFC_0.X9<I.X/<^)N7"_%09ZX$<VJMW$">=-ZA88>60_086@$!((B3<
MF#EV3WZ'H9R\,0:M<JP;H!.%8OBAW=T+"U_$GD74!L&4UW/>TQ84!9#-U+#S
M?^ZO0]RE<WJ=U=7;&JW&ZH\K7?_AHC#FZI8C3E.\%YSX4-'8:&*C4*5-4;6.
MOV!4>?Z<E..9=.CR"VXU.A2V(,]&H1]'#=*T3:<9?Y.)_ <;=T??<.'")Y_8
MSIX$1L"(J 9>AOAB4);F#F^AI_,X/_7R/4P<^Q.!UB$;)'SI02:RM+1$N]WY
M#F>KP?RDX[U'*XT7B_<>DQILYM_;Z_4_-QKL+KIY%145%145!Z,U[=556JW6
M]WOO0SPKGCS/2U7HR8YQ9,[WU1B-UAKG+/U^_S>N;U[?G'^NQU?9UH<-I:?K
M-;>?.Z?.WWGG.\3+:W9W=]%5F:F*6Z8LS3M9$Q1A:6GI[D?AB84VZY P3=E1
M88>@4:_3;K=?Y;U'&U4MJ%<<:D1DZIEGC,%HP;N"T2BCR =_E(\?_:GA</?W
M=G:VL;M;3$O<>0LB1+4(:PLDM^5F8OD,#<D16#T3"9[K846R3# 31V2"PC4K
MALQ^Q)[Q[A:7[*7?&X_B_]AHCM^RNG;[/T;K#:U-2 \4P;J,K!CCO:=&[>G>
MN@)(TY0\SS :(A-1%'T:]<9WK*ZM_>CEQY[HW_@5CB6G%MV 0\0)KUUT$\S9
M]'0ZG=4D25YFE"8K3O;<]F81+^@X'$1G+4HE(/)^MWOXU[?]TVR6:@-) F-O
MB!L-6LW67VNU6K_6:K;NTKJ!M1%%8<BMH)0&$;P((D)1%%AG44JA29_C3U3Q
MA6 B$^(WG:"41AM!*<MH-,:ZX8O/KJ]_:#2Z_+KMZ]<_%39C02EUE 2Q4XY
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M:>Z]]][_5L$_N';U&B+0[7:IU2I53L6SBR"D:7KW,=IM?78H#T<412MQ$K\
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MP3CVD.4\'>V5N"^$+ ^I%B)O3&LUK+-!,5MQHHE,1%[DI&G*<#CX%XR&N,$
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M14VLRS$^PBI;/KN*0(!]-<W#;26E#8QXO"O %(Q'O?>1]\&,.!2RP(C0#(E
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ML_>YT[7FK2H]MBCK+NL:6CETNYP_?^X'UM?7?[7=[F1**[R/7I^++BP-#;>
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M8X\COX5Q2PAV*2]=*^<EK@$$BU(!R_;(N8WWP 2C*VQE#TY9[Y>_79Z8 Y"
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M"2$DB!Z"V6%J-]^V/?S@9^$B*AG'7.#2E!WWKQ-.?$7^ :($= +5PMHG P;
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MR=(AQ>Q@C^5H9_( G /G:+5:;ZRL!1%ZO1XB0J][8KL_G!A""(3@T:I6O8:
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MN0N4O6A:JBE65]=(D^2=(H*SRUT"M.;.R;,,!)(D 1%&H]%O;FUO?W"XL^/
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M[&(3\S[Z-J0)I\^<ON_LV7,_KD14E;E+=2L7".K=?VNTKOPW/:[,*(TEJ6)
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MGU[KO^-W!H-.RQ9]G&\B1H-H'","XR@T6/;AO^OM^W$V30H*2!?ZW7UO H8
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MB@U+V>SN&G$^!X0F$E)DYME=(#(AFVSPYD<2/O_,)R^?.9W\\5__C5][$9E
M<)A$8Y>\^&8@P95Z8&,"A?4@4P@6O.7Z^N]=[?75=S6:[O\8;#JL-YP^>YX@
M*PSWUC'+F")T%W$!$F-(&ITO[:V<T]F5YQT2"WI42U>RKSJ6C^=?*-6Q"Y]U
M]*6EU6*1"/V5E<>!51'!AUH9>Q(HBIB)K\O% 1&%B)!ET^'FYM:O+;ZV\I6M
MJ:FIJ:DY;/IGSM)I=_Z2=8ZBL/$ZI@1?>VX T&RU*(J"$.*P='=W]T=V:E7L
M;>,=-PW(")HT;='IKK*VMO9_-IO--]O"DF<Y2@DF2>[YMAY'C#'X$-C;W?M?
M7[I\^:?RO1TH"E1R/&:IJK_">#)^QV@X0BL]J\"NC3GNRNKUP]Z >T'[[%E)
MDN11B-G_SD8_**54/-XU2X_SCN%P^)WK&QO/DT^CU[.NUTYJ:I:(9?04K3UC
M;Y\C7(;ZSI&%H.NIM;4S2JG[#V]KEH=PX+&(^M6\FA\+Y--Y0M7##S_<?."!
M!WYR;W>WT^_W&0SJ*N]WBK6.Z]>N7WG+6][R@=_]M5]]@3P#I=!I\]A4-@L$
M?#F7,X:8%I(DD*:,-S?8WM[YOM%X_$GG'-Y[K+4ST=M)QP>/UIHT37O]?O_=
M> _E?GFU>>Z'OAKHT64^C3OP/( &:8!O SW:[3-?YD.*QD2/+.V/@6?1R6;N
M(^!B]DXTO"'F"0@N#ZA&@E(:IS*,RM'BR*8O_:?MG4]FP"Q0:ZV=^1Q5I=1J
M:FIJ:FI>#U3I)^C)F<M<#=  W^/,N2<:*EG[IN$X(W>.5JN%P^(+H9&V]MM)
MGD!ZK2Z3T2Z)\4BR^<SNWJ=_TV<O A,0#=[-]G%4Q?JY6+:^O%?#I%)]H"!T
M@1XJ.4?2.,?Y"P__;:4>^+/C48(M/#I)R:<%P3LZG0Y9=DS*Z;Y&0GG."D2_
MG-(W1ZADQH($77J@:0@:":;T%((TV61O]_+/;6U<_F[RJ\ (PA3O"I0J9H+;
M^=^KJL L/'&85 GX5'U910HD//308TUKU>,A0+>W@M$)^(#2BBS/B.K9)29$
M7]SRAW+^X4!<5,;BXZ^])?;O1US*\7*;-SNVB]]7<?;T^?L;:;N3%P6@L;;
M6H\2@S;)O%1QN.F'U1PR7I4+($$A".(%%4#P*!R=IF(P>.X_;VU^]OO(GP?6
M079B%H]F+LBIJ3EZC&_]DA/#$0W&[BM=4XI>-8B!D)R.]\3K:G +/I7U->0
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M;EHW3===QY]9>M;7U]^KM2;+,K(\ Q$ZG3;F5"R6&UX),7-]-LA/M-:? ,!
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M]>P_Y_)]]O>(OTPV C1H%6.*9K_^:.#2S[Q"IF_L";>TM+2TG B.5ONJD'C
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M(,A00C,N;OX&C(.WHC?/HX)?VH%CY4KM+A0OZ[FO B_3L/Z4]5SF> ^_Q"G
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M@HW-M>N?_J/_[SWY9-<@1J%2@C>A7)FSC/;WCZQKN,/SEL5B<0@40H8J+D1
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MW>UG.-/;P)13M)'XHH>,4T)>C0-I0&2 0<X6+]T%GGQ+;,+<R\D2)PU>&IP
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M2OF^WQJ*HM@"[Q%^5LV <[ 8JRAR\Z12@!-8Z\LV*"GQ\S;UYCR]6<-$V+E
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M"W?&;W!*">PD.+4SK<+WB#UC9S'&3#QDI92LK*P 7'Z4;0@\6JRU1%%$7O@
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M&TQ#%QXI%<8:!()FJTD<P7 X*(Z.CKY[-!KKUWZ'P 7G0N\C0@BD$$BI0#I
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M6U>1"@;02XY4$IS!&/.IV>P:J:K@-! (! *!^1-6*$YAC''7KU_/E)(^@4I
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M*=HKY[X#8Q$?5;'+IK0&IQ5:"4:#T:#$$5R)E)Y&:X6=_9?^[NLO?NQ[\3>
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M&:N/0F(!J!),Q6C<>T'(%.?LPI@?8DB(?*SMXJUEI5:$S=BS2WO9#0@$ H%
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M1\[_=OK]3=8;#;)R;YF-7SHEEH<??HC=&R\M31E[6J:R@;O+X;(;$ @$ H'
M?<#N[NY^F[.V;#2:&&O16M-H-$B2A. I&W .XC@B3?UB?)9E3*=3$(+UM76&
MPR'C\>2GLBS["U55N6.F3$$-NQ+,_;VL+R,&0)02)\D? KYH6>T*@-::2"GB
M.*8L2WMX>/B.@X/]7RC+L) %,!R._G.2ID@ER?(,(2!.8JRSN-MN= 0^"U;'
M,[:6+I1E>5F((U]#$$=^D(' J\9[9E*K Y52J"A"U2K!T7#(Q8L7*<N*+,MH
MMIH\=.G2N-5J_;''?N.]?[_.9EM\NL *(:3\];6U-92*?&40I:ATQ7 XI"S/
MOA!'*84UED:C099EK&]L'+[XXHL_IZ+5WH2>45;E-:CW'9T%(8Y*5P=>D6:S
MB3$&8RQIFF*MM8?MPV\=# ;5*_]V('"Z*8J"V46[W6Y?CJ/H<#J=4)8E6H<Y
MV' XI-?OT>ZTB[L0;=\FW6Q>$_KE(B<W?ID?!%:;]K(;$ @$ H' _>#:M0]]
M,B]V_DZ:CI!B"$QII((D4A19@7 *82.$\P=.'6W>!,X 1V99PBF$BQ$V0=C8
MJXA<1"05L1(H46+M$&/:0!L9]3CL/OEONH//O&,\O6JJ\A"8  :$1,CH*,NT
M)H@[3B%"''TP)2#62-?/T6@TOML)PU%:NUCX%S[)NX*H0%0()Q V1=IF?2BD
MLR@Y0D4]+'L,1Y?_XN[>LS\Y[.SB2F@V3['IZWVB?7CC\69#32+EF(S[2&%I
MI@G6&*PQ?G2[I9N*LV/Y=\<XCODB>F_8[NU'ZE/XA@D%-F(Z&7Y:RHHH,BBE
M$3@BF=1*QQCA9M[C H? N:A6_ 0>9*R]4!\;.-?P?4-6.#7!J3%6#K%BB)53
MA#1$44P<K:'D%H(-+IXW[%S_&%L;!1MK)6DT^8RM.E_YR0^][U?1([ %N JL
M]HI8YV#A= LLF_K#N.UG81F/>K^F(H.U&64Y(6U$2!Q9EA/'R7UNZ]W'"5_Q
MR"'\.&E3A$OG<X!(""(AB)7#Z#Z-1O7#5U_\:!$E?JZXZF33WC5!B92^O*Y$
MH(0"-XMS_17C5N_@,Q) "(T3&B<,/M;WKT\@P"E?(>#8X>>%POFCV;0HF:%D
M1J1*LFGW!V_NOO3XN+>/+RII@,5]68/7LBW.*P*!T\"L&AA'M]7LG#<<[%RC
MV8@^-)WT,=44:_/E-/,4\<C#ZUP\!ZW&=+JLU,<PBIQ-@E]L(! (!!X,)@/:
M[<-_.)E,/J24(HECK+54N@H9P@&DDFBM*8H"(01K:VLTFTVR+./F[LU_<7AX
M^&>ZW:Z9CL=@%Y0",BB35H$HBF\]SQL-MK:VWM)HI-^PG%8%9J1I2I$7'.P?
M_-7=F[O_LA@<B19#9C8<'!R44LK'I!#D>8X4DKB^AMF@C'VUK(YGK "D9- ?
M/ [4BD6%M>ZX7V @\"KQ7HBU,C:*B*,8*23..;(\YY%''N'P\)!&(_VY3K?S
ME8\_^A\_,U_1G9DDSHZP [M2[.WM/95-LY>R/*,L2](D)4D2I)1L;FPLNWGW
M'&LMK;46D^F$)$GR?K__SP#*LD!%JY_,,AJ.K@&%$ )C3.V-Z\_MP"OCG%?$
MQG',9#*Y?'!P\#='O1[@P(3X-' &D KB&(J<-$T_J+5&2HE287VCT^FP<V/G
M<._99\J[<#6XW:"[&#2=#* <X$8AJ#J3A,W80" 0"#P@O,"HTS>'K<Z??OWK
M/O_CS<;FQGADT2:FD9Y#&XD3?D$* 4)H'""6;A87N!O,M^&<K)7/42V.\C^+
ME2 K>E@[9FU=L;XIR8L^G<[E?["_\])?)ROPF<\94/A;H;V"VDJP/H/\:+NO
M!&R(GD\)3@J,=4<*9K=)L_%:-K<N?:>*(V$KO=!)I/?3 \">!5W TA&BSJYV
M*<+&."\G0(@2Y)@TRCCL/?\#N[M/_R,]N 8B!TJPDBH/8[ ;[Y)GG?>MK6W]
M$25+I"P![;T9H>Z[BRH6$<:>8QA U?+AF5K%]F\Q^IYSRLYZ(X"47O?FIRZ>
M&W2C:/.\$0YG+)((:QO^<2X"Y\L7^^]K5?DI>SF!^XN=>28*C9A5*<!"71%"
M*(T3$BL,4B0HD>"<P&BOO-]L')(77?V&1YI_^3<?_:D?I.K3W&B0C3I  4XO
M'/6?FFONEF^Y')AM&+G;+.D:)I,.1=G[%:&B[Q82A*APKJJ5DZN?[&'%S.LU
MJCW5%=)&"/SXZ$S)UKE-=J_OLO4:\1///_/$/G1P;DR4+-A:K"BCT8X1XJ%G
M(NF^W!J#DBFQ2!%6(81$N-EU$9P X6R]([#Z&]$ 3M8)M&*F5ITA$"X&&]?7
M2EF'4@8_#U @"BISP,9:A*XR=W#SRK?N[U^>8@?X^6 .%,?#K_DYIL,62N#T
MXA>Y (C2"&V!LL39[ -)G!(K31P7/.AN,1>W8J08[A&/6-;6=(BASB:KXY43
M" 0"@<"=4A;L[^]=[O?[?U9KC>/((ROP@./-E##64E45>98S&HW^1K?;_>M,
MIO@)_$F;#\!9=,B,/O58:['V^'1F;6UM;7U]_5O#^;]\!L/!.SN=SM_4_:.I
M2=1H0%"=USBZG<YO5%7)6FL-(<2"EU_HOZ^2X;(;\%E3CUV3;L<:8_X# ,Y[
M+0<"=XJ4J@Z!O/6K YRU5%5)EF5$D7H1YW[_;_[G]_X@509 -NJSOGT.<&#K
M(VP\K"9"4NGJW\=Q3"--*8J2HL@QQC >CY;=NGO.K-2_,<8.!H/_>]PYG,<>
M9R&\=Y,AP%/'E+%2^CEP"!]>$:TU1ALFD\D_[G0ZCY%/\(-=B$\#9P"!K_!5
MQY.]7N]#29),XCC&V7!1KZJ*JBJO4U5W(SUEGJZVP$)M>#$K+\+1]\(-"64,
MSB)A,S80" 0"#P:M-A0',&VPOZ=_(5'%/]G8>/WW&*W(\P$J6L<YA9V[1,[2
M7,-,]2P@G)LK87'NZ'OJKTW%6L-BG2$O#JJ=SHT_V^M?^\EJ? !J J96D<B9
MKQ)^\=%(( +2^B\YO#-5Y9-.;\F4#BP#K35( :()9A,X3YJ^]D^GC7/;66%]
MYORL@SC)/$,^Y*/>'411^YJF7FWC:I\R62+H_^N7KG_DNR?3%R"ZZ1_OP%F0
MHH5%XI7F#S)#.NT7/WGQPMK.]O;K7S<8YA29)D[7<=(/3]X3>3ZJ >'J-4=8
M[UN,\..XL"!LWX_E)RN"G4*T@TCA]X\/?D:HQI_"-#$5B%@A1'.AY0*$JY=N
M9G[+U:W/&7A@<&K,3*OJ'+XZ"!'8!F")E,,Z[_LJ1(9@BB5#FPF%'OQL/AG^
M^4]\]-&!/S\T*A((H1GW#V@T(O*\N"5B%@NRFW 5738+21N+0YP%J,"-&(]W
M'UW?VAXVU-;FM!QBK:69M#"50ZWXA<2*6O5)7/N#QJC9-=*!=)IBNL.%+?U3
M5RY_]#)T::SGY)D?>E>??123IX6,*(U#L4Y$ C9"" GH!;_8&B>._,97_/-W
M0@/65P8X]AJ5]UEW4?UUO;DJK)^[.0'2$:5#)N/.9[KM]M^JBIOXZW .Y A1
M^N(:"_W$,0_%CNX(!):%J*_%\TZIF"O$Z[YIJART M5B;_=R^85?_-#[A>M\
M0UDT0:2W>=('!Z4KI"@_!?G2TB_"$'(V"9NQ@4 @$'@PD!*4GUB.#PX9#D=_
MK=EL/MIJM<BR?,F-"RP;8RR-1H.UM;5!659?LWO]QD]F[394%7)C Y0$I4 I
MI%((*5=^@>*!1-2?8Z1(XO@[XBC&V;!4O$3> WS[Y/# D><0R[G8P-3[1ZW6
MVM(:=YHH1R.TUN]NM5H( 67I_<Z#LOM5LUH7_CHQWEK['N?<#><LQIJ0+Q^X
M8Z24?AR9V[Y:K+732NL_5Q;EMWSD(Q\<-!HMFLUU$ JC*W15D20)>;Y:IU'@
M=EAZ_5Y15=6_4U&$,88HBMC<W"!)SOY"O%22\6ADMK>W_^ZDV_;W"4&KN>2&
MW5T^[9,QG$_+J,_WP"N3IJD9#H?OZ'2[N7/.^VO6M%JM);8L$+@[F+*><,41
MDTX;X->--11%L<QFG0HB%:&4^@3(N[$9>](3]OC]QE;XS)'9PRSGSFT/')8\
MG][YGP\L%2DDC4:*M98LR^>;L=9:TOCL!UN!0" 0>#"1>@)V F( =+AY_0G]
MS%./?M.P_\)SKWLD9:U9()EBJA'"Y;0:,>O-%A)%-@V+3:O.VEJ*T06C88>J
M'+*^YCBW'1&K"9/Q2UQZ"*IBY\6K+SS^7U][\?'_1'X#1!=$'YOM U-P.9@"
M6U4XK>O%\5GY8E%K*04@Y\HT)TYD2 >6@X1X8P/T.3#G>/-;_\!7O>ZUO^-+
MIQE8X7"RQ(ER_N C7V$;?*/O D4QH=F(:*:"X> ZV X;S>SQZ?#Y/_Z)#_YB
M"6V@!]H>\S&RVC*=9LML^BEA J++6K/ZM9WKS[#6%#13P;FM#?K=CG](K>AV
MU)ZA0N"$P]W6$_4!0QB4<DAER8L)0E@^^E\>S7'Z-DDUIZ\J1K.U5I>0Z_+L
M<X^9\>39?[ZQE;.]E6 JC7 )PB7^P<+B:E]0-^\/@0<9E1P@XSV$Z"'(D$X0
MN18-<9Z6>HC>7H&9"-;BF(VF!KOSX6[W0U]Q]>JO_NCAU5\$#BCRZ^39-:3K
M(!DCR='E%(77V<CZ$,>.</T\'6@$&HE%.N:'IT2JBE'_1?)B_V>+\H#SYQ.Z
M[0.<$3BS^M>/7!?(6)&D#8102"2-*":5#J'[7#H'97;]1S[PV+^[##U@S'14
MD$U?QE)\Y>AP<^<S'XI5P87M=2(1<?/&/N>W+C#LC1$X!!I$":+$">/G+D1G
MPC?6<10'+5:]$DXBG""?9#A=DD303!5I;(AD@9(9L9K0WO_T#W3;SWU4#U_$
MY3?!#D%XK]A\,CD:^VH+^M,3.00"+(2SBU?GA;APOCU8@IU"HFGO7W[W>JMD
M>_/L7[^M-2@EB>,865O Y'F&,1JE%)NM-8:=WB=@287)JZJL9%U;/K#:6.=/
M*"DE4:0&BSWJI)=6(! (! )GA9.7..L<95EV1Z/QU_5Z_3: 4@JE%-99BJ*@
M+$NDE*R%S->59S@8$$<1YR^<I]EL,AJ-Z+0[..>X]- EKE^_\;Z]O;W_JC_H
M/UV=S 0-,^LS095EH"3)QC9Q'']WI2N<<R'^O0]L;6TQ&HW9V]_G;6]]&TD2
M/[>WO__USSWS[)0H)(-^5CC'8#!X;YJFN=8:*259EI&DR;);MHH,EMV SX5L
M,IVK<?0TH]_OO]-HW8WC^!5^,Q#P7K!22.(D)DT2E%(88YA,)_3[ RY=ND1K
MK451E.7AP<'W[NSL_#<'^P?/,QXON^F!^X U%I <'AR^+XGCP^%PR(4+%ZFJ
MZDQ47E!*@?!KG=8:G+-SWU2E%-/))"_R_ >,UIP4+9V!EP\X>OW^0555SU=5
MA;..C8T-A!"L;VPLNW%+I[6VAHH45551Y+FW-:FK!!ACGYA.)]]?+LX+E4**
MF25$('!&\"5WH,RY>?/FE;V]O8_W^RL5*K\J?#60>D=:")22,S4L4DHFD\GU
M7J_W/-B[D9JRX$(^VQAWS/Y#+N:O2?_?9#J9^*I>83-VU3'&$->=2Y#T21*P
M)5C_L[#B& @$ H&SB*P%C#[&F2)=GV(:T7?Y"^/1_C<VFK_M?5*N-QN-A$K'
M5+K F(0X;I V6D&=M>)(85%*$REPHL2:#,L4ZPS:FG]Z]>KC?T7KH:F*/IB9
M'Y#WV8HLV%GX?%O!5,F1+D3.'Q@FZ:<(B<_(B"[P\*4O?U.LWO*-69:"LFA3
MHE1=HLDE4'M(^8_:JV6#NNS.:#;7V=N]P<7SYQD.K^QN;D9?\]$/_?*A5\-.
M@*%7ZBS8&/GRJ^9EG_.!0DX Q^'!E?&E2Z_]C2P;?4.LMAD/>ZPU6VCKY1AN
M87 *X\\"PO@2Y8#O4R;WE<#J58_;JF-/%XW88J6C+*[2&]CQ>'+^[VYN-GXP
M4@G"*E^!07I?/+#^>Y.<PE<2N-\HE_O2I%: LTBK$2B4!")+*Q9,)P>?'':O
M_)EV]]E/CD<O@3T Y2L5J%?Z S4KX+[\0"+1Q\<!-[L?+!4P A71/GC>O/FM
M;_VYR<1^Q^O?^%K:[0)BQ:J[_HI(804X8S"Z0DF#0J!4AHRZC(?7_D$^?>$Z
MU1X^3\?XH=3Z')C5?O4 (\K)=;!?^ 'G&I]OK&&CM<ET5)"HE-(4@*E]U6M<
M!&Z6[*-O]Z0KA/0>N,*K]1VN5CP+!(ZU5DR1Y13E!($F425"%I@RFY;5_I\<
M#U^J=-:FCAU(HQBKJUI1O.B3?;2M(MU9Z#>!,\6\@WIEK*Q%>K:^/XI!4X+)
MP YII).?OWCQC;]C?[B\)M\7G,-:AY0.*011%/FX)U)(*=!F_.[1> \H[_U*
MP$S]*F=U1I1B.!@.A1 ^JRBPTCA;7X#\KG]?2C6?G-H0-@<"@4#@K'+B$F>M
M83J=TNUV.=C?_V#[\/#KLVR:*:5(&RE1%&.MPU@3E'-G@.WM;9RUC$8CM#9L
M;FZROKX^&0P&?^JIIY[ZGFS8,]5T?&14N8 )^T&K3^T7W6PVN73IX?\U25)9
ME:572KAP?M]K!OT^G_=YG\=D/!GF>?YU[_^-]U[=W-ZN?QK>_U="1A%81__@
M$)S[A:JJO*)G.J61!F7QJV#EO >TUG7V/I33C+V]O1\:] >?3,/G'W@%G',8
M8Z@J[_7JG"..(M;66FQM;A4W;MSXOALW;ORNW=W=3XY[G;HD-KZ\_]GRS0R\
M'*8"4[&WO_]O(Q4AA"1)$HQ9]8TXYFO8UEB,M8O^VVBMKW<ZG7\X&HVX70J!
M/ /9+/'Z&AB-,>8#UOK*3U$4T>MU*<ORE9_@C&.,]?-\(8CBB"B.L=8R' Z_
M8V]__^GQ<'A47DLIE)0AR2EPMA#U/F"M^*Z*@JJJ?K[56EMRP^X/SEF<]7MD
M4101Q1%2R%E5D?=H70'R'A5M%S"_^,P*X\]&& F]7F>ZOF414N!LV+!;:6JS
M=NLL6-.WQD"]"!4N*H% (! XJZC9/ H?\1@[P<TRPFFR=V#>?\&^^8\GS;?]
M<JMU*8889P6F<N2F6))11.!N86V%$"515**B#&/[3XXF-[]Y[^#)9_+^#E"
M*$!:E/"+3\*"U3,Q;+TBZ;*YI^4\P=0!Y+6WTHG$15MGG0:6BQ1@'<VU2\UF
MXW7?/IUN8?04X@PA)$[X$F3>=U%Z=2P<*><"=X2@P7@TK+;/J;=_Y-%?^A1B
MR+#?8W-+,1ED?GA=>*LM$L=,M1.0HL+*"5C)>-3^56>WM10F<E8CI?##T'Q
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MC:/RAZC5OX$'FI9\ [)XF$G7N/V=W7]YX]JGO^#FS8_\R*CS(8?]!*C+(&^
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MWK:\>.?;CA\_\8KY[AW?-';CKY52?K[R^#$9>"L7!%KKYL]&AKLJA/@0\#^
M/WW/>][SB#9578%HIPR[0!!%,94.<I$;2E1723"6X>8FPV%>";'R3J>C=^)B
MOO"+O_J4=>85./-YSIKG.>2].'.7<V(9F)/8:";Y=P1F"Z'7$>82F+/'3QQ_
M(L_'#UZX</ZA"Q?.3*A&^-=+#G^)^T#@:"/V)#L7NF P&/P-B%>.!O9_24\M
M_K0@?HX4DBB*4:I%I%HHE2!%3)[-U!6_XL,=@^U:.$B$$A&2&"6\F8,$+ERX
MP/Q<Q.)B0J?7^WB6Y;^TTA^\_<*%<Z7)5Z_K=[UQP=AFC4+L>7*Z4&< $X*Q
M@4 @$ @<1JZJ4KI:RO">-]B]J= -^TDF]MG0M"S07L>>O8.OV4#A3F;<D6&7
M$KAYPI+F0V9]ORPE(-F:9(P>77],/_K 8Z!^AR2AO;#,XL+RO0L+R\_O=1=>
M%,>=%V9I>0]$=PNBNZ6([I JBF0<(9"^/".:W;]IH_[PCUOM!&LUQE08JU-K
MS1JXR\*)<\)RIKN@SQ9%^D0V&GUR,.B?&PZV*$9;=11 ,_7908.>V9:XFN]K
M('#MN/J8$OA28[H61.A<  G+QT_3FUM\@XHBH:U&&X>4D5=Z3M]P&U-7O!$X
MG*CWY;0(0HRTRSBK<=:" R4$<5(AXDVD@ZWAV7^RLO[8^[>*-6(,2I5HDP$5
M<2RI])Z WQ7]7.!@- N2UI\%L_UI_3N*-C@=0;;)ZLJCKM=9>OW<\>Z')5(I
MY^K*"0+AE"];ZP#A:A52G=TPO>9:!!K<45D(G5G$%_;\SM^!SXBK[#(I)<[:
MNJ1N<Y. 0]L2.?\D5FNH#/D$SJ=RZ_P9L87E 9ST=3)M<TPJB&*2I$VKU9)1
ME"P^Z[E?M 0L CT@!A;PZV(+3]-B"PR/G:XJI<1$")&559EN#[<'Z^MK@XWU
MU0%EQG1,M&OLN=.)G5JZAZ(<89D #H-#HA#3<4^S7@:[O'+#(18X$LPF0VBF
MOL<U:9KCSW?O%5WAV!B4# 8;]ZOHT_>?>L&S?U*A.LCH\V04/Q<5W2>EG!>"
M'C")HGA85>7*9#(Y.QP.'QT,!I?3X1#*)LC:>+[.5F1R=;+H5:J>[&ECX+-'
MB,(780(@ S?P<SHA041\Y,./KT'T+E#O\I6:ZK(=KEX?4 -V?'AGE,Q-G*$Y
M=#3^-VO5]XT==LAW"01N(4_=__LY1'/R"@R.K:QBG*U;Q:7_?-]="[^-B[Y%
M(%X/T:N%41@387T!<4333\R6$FG6_ISCY$D_-G16@!7UO9NJ8T^<K,ZGD_[;
M'W_B\MNWMRX_4*9]<*DO]YN4U[6TZZU6QJ[<XNT' H% (! ('#F*L@ 4$LFQ
MY1. 9&MK@,&@,75$$RA+\HUU\HW^^56B\R#_P@\/ZW+%K07FYY?%XN+RXL+"
M\F*O.[>8),G")-<1T %:?I$1<*3@2H0;5U55%D76'XV'_<'V5KX]V(+QD)U%
MZXQI&3"?H,>T9(TWXID&O%0<(S#HRK\^BJ *B>N!@U K6ZT#)21(6Z^?^P6>
MX\>/G^CUYKY+*46I+;8I8234]-0)7!TA!+91TPN_P"F%Q!DPQKQS]=*E7QB-
M?*G:"HV84;OOS8H.W!H<3,\'JHSU];6/]]KW_=+2\HDW4!V5H.IUX<*M;L!1
MPSG+;$<K44111*1BI)*,)Z.95\LZ.TO6B_E I=E)U .,I2PJRCRWR&AKZWWO
MW3I8"U-V&J= "; &S+4-3-8V=]05"DD2QSAG*$-E@$!@2KO5IITLX&Q"-C$4
M%*#AS,,/@9]$?,C?FBS-:_,R6.C-8ZQ!:Y\P:JT 8;W%F@VCNQN-F\VUDR"5
M0,@6('$NPA8S_:"K@^8.KGGD;8$21%<@A=L9VA^L.GT@$+@)7*WX3D5%1<ZG
MWO\!C6S]]L)]]_WV77?=^]RYWOS?U]K]G?$H?54Z&;>7EH^!FYE'"I_(Y\>#
MEK*LZI&A0CJ)0 VED.\5RKU;PKL??>23'RV+H2O233!#IFM5UNS,B:X3US$8
M:^"*^LSLB70W67ZUPD%4UU?G&P@$ H% X.;@9H<0>Q22S(RD]JZKUW^KSW@\
ML_N##,LSV]Q19.X$^^SNOQLIY5&99^_:?WO5Q,U$5F"!C:TQL\9'21Q3NK6=
M]SK!U&]6U('8QD>CD(P*Y48;8AOD]FX/X+U&O;._PU7^5LIG%\8I6 UZYHO,
M_#92U6->09/,B*J_I@WKE8$#4Q]L6N!47%<O4V![1 MWTIT__GUQTFT[!!:#
MPR%%K<VR>QW(;D-LV]\+C1 53O@@A' QN!92MW&5QIF*2#FBJ *W3EZ.5\MB
MY;M6-A]P7@7F;XZ*)!9()<CSXFD\R2&4FCL8;KHJV?BJUU7_T"! M20FL^!R
M;X1I+:.MC]-?'/W4XK$O^A;EEN[!UF, UTA.P+F9ZX,H9TK9&WRI^K+YW\/-
MK$\=]L+^LL4]<F,G]SQW&_.4!X"K8RO-N$U@L91:4^I:TM3.IF.#72+2FJ2G
M<-8'5FP]?A"U58(0"B.O5IGEVN@MM#'68+1&F\I7 % .$?OAC2D;U=95/L"V
MI@\-CLI&_C.N4%@W"VG1GN=#J?# 8696&>5VHG/-_##R"1EY,2 O1GB98X0B
M00B!CK8;@^;Z(YR?,#0+Y4KYYYS=MZ\93G8\GYN;=%Z%)9ZJ>M*AOW ]0W [
MW3<:K'8@\IW^<E;8-MN'-H]GYX#[%-#JS+>((D555>3C*JB: X%G%$_=_S?5
M=*0L_+J/-1B38Y' $.9:D&4,SSW"\)QZ'*=^MGOB],_>=^^SHN?<<_HE5;7U
M,N#9P)W $M@> @=N &XD$C4NR_)L.LX>'0Z&CVUOC<ZG@P&43<6$NCJ;J!")
M18@2:\L;4@#G5BMC0S#VZ!!FEX% (! (/$-HM]I46F/,E8MVSCF_D 'L!&'K
M^Z84E#[@9;W5JK,(-9BFG&,36:5>2*F3^*S9J4(H?-!U5F#2O+P9K\<QF%!F
M*G ]< YM#,AZ2J04)T^>["@5?;^4$F.I_4XELLX&,,:$=9VGP=6GN9!^WPDT
M15&PN;GYG</MBVL&0RP$TLGI!,*7"+R5K0XT**4PTS* S=%NZ/?[H[GN^O='
MBTM_>,L:]\SCW*UNP%'#>S[N9SM1<[58I/#Y9&5IKL@)VPF7:Y"] [4ORS)L
M53+[J>#S$LQLSLA5FM_K]JBJBK(N\:&-)E81290@E6223@[4OD#@,+//M 7P
M9UH416AGZWD%,VK8&9J!1%.NTNUY[3Z?;[%8 \*$B.L-Q_J^4DI?G>8*9HH:
M[!N,?9IQ8C:Z<H(H(NAT$W".="LD\P4"SWB<GW\+I7P2G?:)>2[+KGAINK[!
M(^N;&M0#(!^8?L#T?N;62?R]J<L3Z]G70GMAD:(8X8H25U8XZ<=I,H%V2Y(.
MKE_8ZP8$8YM>4OE5LUT=J /1^'Y9D/E*".$=&8:WN@&!0" 0N)DD]7VCA*VS
M^O>;0.V#/&!FOZ%9K-I17\J90<5^\[=FR^!=5 \WS?Z?'61"L\J0%Q/B1!(G
M$F.T5X8(7_FWLN5,6G)3L839L2C=A1;.B6FRN;46:[TJ$ ?*NID=.[/]6@EE
M]PN6.M\\*<%,8,<+;6=FK:1"2(DR%H?W](Q5C$2B;85 DM B9_!9[;5  $ I
MX1,5G((R@60.; R=4QP[^9SOK&SK!$[AA ,%2@HBY1,9C#9$ZC8/Q]:>L7Y>
M5R&P=97 "*Q"N#;*6)30),(@Q295>?X7MH<?^_^RK<>!$B/J^6"=95%4]<?-
M[MHK5+%-1G583#L(C8#5.8U7'<7^"1L#EK*H@UD"8 +*^[H5U19G+VS\T8L7
M[O@]A_M6A\*1X%P;)[PS+,2X>CP@:,J!.830=7*ZQ#S=:NHS'EVK8@T(<VY:
M:G]Z7=V/V[S/>"IV[;/FP*N5:OA$&"GDM(1Y69_^4DKLM&R</Z:DC;#&3=\K
MA*@K7 H:1V/$P8*=HNPB7%)_FF^\% (E)1)!4>7LKY;V5&+3Y[O-",DK4U(9
MGPCACZ<F(M'<9L^9H(P-'&::8]GAK^DSU8MF<S $_GE1@"VP3"@JV)G_7(7I
MZ;%?GRMHMR*<<_7-8JW!6)^]X?:>MT%5>=V1+((3Q"["8=&N!&>)E"1)(L;9
MB"OZN%WCPAY79KS,)AC[@T@189K^V42D>7.MN'S]OU0@$+A&KJW_MX V.4+D
MU%.'_8=5KOG,YK:W@MN>$BI%M-.&NB("0DS?5N6;2%=!7/FB"TTN3P59]8PM
M4_Q9L?;T+PD$ H% (! (?*94I:6:"9!+50="9]<ZK[)>F(YGHJG3Y,*=0:YM
MI";3%[A=KTT2A;5F5^6PI@U"L/]:HA"(VEO2"K]0 EXULK,B8DB+]-IW0B"P
M#THIK+57B"I4',OY^84?&0P-RAJ$< @A:M6F1!N#-=:7P0M<E>;<E4(BE0/X
M>%55_S0;C3:#\ X  "  241!5 'H=KJDF<_C['0Z6*<I"C_Q39*=8$O@%J$U
MJA5AG(5Z\4%UNYC*4 R' -\/?"5P_!:V\IF  9ZXU8TXRC@<QFCVUB.(XY@H
MBK#64A1^O**D(HD3,I/7[[73Q3:)'UN %T0<!%,GD @$<10C)%AKJ'0%N'H[
MS@L1@+T%Q,K2CX5:+9#2?X>J\LJ\_:J9! *W$TF\\]C59<:;A7CGY'1.(93W
MDI93):SO+\I\/W/0G07WO&C*48IZ23ZH86\V"H64$F-LO?<=E:EPI4%2RV9G
M^\W9/MOLE<[NOED@%C$@,<XG&_LT&8D.OMR!P*'![E,:6,:^>Y "(,(8@2EW
MQDUR.C^?"<:*G2COOK:O33DG7/U9&J$@4J!J.W)K]R_$<!!NH#+67S&%\ -+
MBP,)5N= PM+R(IM;ERZS>/U;$ @$ H% X$8SF]FV1PZR=Z%KGX#?['1(X*OD
M-M40&P7GU;<)LE-Z[]"9S[7X27P<0S;Q_S>UK$,BJ/U0 ;BRS,GA8K_5Q#T3
MUSTOF9:#$G!-\]$KO'AV/O_I!I"V'A@W>8I3IN/E*R?3T@FL%K4N)D)<H0B9
M_5+;U_ % H']J<J2=BM&NRY5F2#E*2R2E[ST2[]!VZ7G$U441@"E+Z?M++8P
M""=IQ0GN=E<F-4+XV7/2@7!>_BY<#M821093;4\NKWSLVRZ>>7^)N@P)I 73
MTSHKLN;#@)E [+Z)(F'1]'HP:^WJF5V\D& UIM SW;3%Y-O31/;[/_A[ZR]^
MV5?_T-+RB=\<C QQZSB&%GE6TNYV<$A?%W!:M<(AG$/6V>^'71F;Y2.44BPN
M]1Y[[__[NU62Q* E<60IRJN]*\BK]F7?4WJ_DW^F@@8)MH*R\E[$BA;>\@#*
M7*,:I??>&BG[QT8_8]3,YYKI8-6AIBH/9NYWM]U_@,8Z7PT -S,8VZ7\:!HY
MF_@3CJ' 4: YMIN#?>:X=D^7C&5ISB=G? #O2JYR?9F>6SOGG-W5GJLP.W<*
M7 <*#"6F_AEVQI$*8P301MB]9;9F=K[<IS+23$52Q<Y\M^D];3V8:>H.! *!
M6\53]_]7E+;;T^^*<EIHC:8O5],7VQF?JUE5["S-W 2N'&<Z7^D)OP'CAYB^
M&:*1!%P_;OA,:*HX%CX#L*$H2R9INGZCMQ\(! *!0. 6L\]@*DY\T#2*IK$.
M3#WPT;K.>I.ULFJ?F_4"!% 0MR!I>[%:6<(DV&T% H&G02E%59: P.836LO'
M*<KRQZP[X$I] .<<G78;$/3[_1_>VMKZU-27-P@3C@""2Y<N_=9P./I_VNT.
M1GO=XMS<'%5U]&7-4>15F<;8AYOGG+M2:1\(! *!0" 0" 0"L]P 96P3WVVR
MEOR"AI"@E,0*#4Z090,&P]6J>R<;P(GKWX[ 3>9PIS@' H% X#/$SMS7GK&S
M0===26<2B)'$"&) 4):S\I$9!:3P6DIC:X7.%26(/+UCACP?8=*,6ASAD:#B
MF<0X"=+Z;8C:0^QH,)N;M\\*\#X)A[-_2WNP_6 /FB*N9MKOFL_<A[WJW*?T
MY L$K@T).*.!+L@%L#U>^()7?<DH$U]2Z#8:5V?#^OY-UBHG0>. >7LCA ^X
M.2=\G^Z:C%N#$!DB'I&T(R;CE3_9Z/_U6]/!IR :$2=0[5=!L.%JR<H89G.A
M ]>;6<E@<TUG_]_#0A2O,^A_D$YG^WN?]=PO>%5E6Z>%A*3385R4"!'C]8,6
MZ7RG+1R(J3_3S?E6-XJD%2&5I2S33_JQC]GE+74E^V2DW<Y\5AWH;.6/J\J/
MKPEYT'P;\52=V#6PW_>_ZCYI^KRC,G8-!&;/W^; ESLJGJLI4:?SO .>?Y_M
M^7^[#_RN$S:>^?UFQQA-Q95=19X4OK+5SC5TWY]AO\OKKA>&),M X)G! ?O_
M7?C^89\Z;.S,9W;K6>6N:B/[+3(U:X^-_9:=%CNYWMRT49T E)0['DO6,O2>
M,\$W]FBP<*L;$ @$ H%G-A:'P6#0$$?^%M4W51N:BFM;J)WT^YBT+F^IZEO]
M/G.P=;I (' ;D!<:7]JR@J3+R9,G?S1)DCV)(H'/AB1.2+.TW^_WOWLTJ$O*
M:8VUOB)"X'!C:M.EE<LKZX/!X'OBJ$FR*DA:R:UMW$T@CF+B*&:23CX)@'-^
M+3DLU@<"@4 @$ @$ H&GX.#*V"L\9V8]8W>PM:&ZE 8K##B%-2G >> E!VY'
M(! (! *!FXB9N3=7"#^D!&N\(A9:0%+?>S\8JAX@(8I)%I986EJ>6UQ8?D&O
M-_?B)&F?*LMJ$2<70!8@4A!;.'D6> QX[/X/O+.""B()L@)1O\R,P:7@BFE;
MK 1LT]ZCDAU[M5J?L_ZJS)@#[O@Z0N.?T[!7_N3V>6[O?IM]_U.E+UXELN[V
M4;CM]]*K"8I"J=/  8@5: ,+O6,,)S&?<]]+GU^6W6]L=WMLC8?$G02$V?&.
M<18A!,+62:6WN\A-UOVK:X%M5 N S)%R@(PRUM8_^;UKFX^N("^!37UV<0[M
MN<27A[XB<+5?5O,,LW*)$/0Z&+.7!>?8Z5"M?SQC"2^:>P?^&@[6]OUKS#:7
M+O?^ZW-?T/E5H^WWCD9CCIVXD_&D4;[46>MN5AE[!! .A&8XW'X +-;MN2#M
M6\'AB'SW&\TU["9S38J)I_J  RZ!R:L,0*ZU7[JB,LE3C$O%/J\)_5_@,"/J
M\V?7<=QDU<Z<&V[/@R;;11VP0L:U]!?A'+MQ[)TB[JEZY,3.3RU=O<8P\WL8
M.U\_VJMJVWN_W_\#% 0"@5O$ ?M_,UU_;%08>Q>*]O8!;M=+5+T>Z/;QE-W;
M:WAFJ_3!]5R N@%EBG<CI<1:BS-@C-DO8_3BC6Y#(! (! *!F\P^$]F8F"1I
M$<DY[OS<+^@@Y%=+(;]22O554JJ72!DAA<1H[1?WQ6Q L5',"H#LY:]\]8>S
M?.L]@\'6'PX'*Q_-TA3* M#-JG$@$ CL2Q0KM/$^E\B$.^Z\XPW#T4A$[66$
M"$&3@S(<#M^^L;'Q7\KM 2@+2H+V$UYC0JGAHX"48"T,5E?H'^__B(R3OUWI
M]DND//KE5+76*$RZM;7U\/_/WIT'2;;EA7W_GG/NDEM5955U=?4RW6^;]]XP
M#)N'$8N,Q!)"(4>PV.$@, 0RH##@X0F-T0R;01 :"+"DL"V$D2Q  V9$F AD
MP["(0989"2QF@6'@S?[>FWGSIE^OM6?E<N\]B_\X-[.RJNNMU=U9U?7[=&3G
M6IFGLC+/O?><\_O] +P_<N)^(8000@@AQ"EPAR=CIP<_X\!IDB23=%]V>A)9
M.4RB :[>V3:(&<EGW0 AA!#WTGA O=ZX'QB)C%D,$R GTW.T&DMT6F=H=SIO
MRM.E-Z?SG_]?AZ Z$!>[A: ('AR*$#1%43&IW1 .K$H+JCG??.RO-3OFKRTO
MC'ZTLNN?VNE=_:6U]4_]PL;:,[<H;L::7FH(JHI1F'K<9O="2]].EL,6 4Z,
MWZ^#Y],K^Z97!A^RBG!??;9#7O^%BJZ]8+3;P0_(N+K!P2A<SUX85GT>PH$)
M]@/M$^(54O5G;KO?XZ&'O_!,FG2^8ZL7T'C2;"ZF4B>@5, $"/6R?9EPJ=4U
M8_$-" G4-7A4&*+4Z.JU&Q_[WF'Y:4AO0 !M(#'@"BB&@?TKFN'V3F8<*N'V
M[G[1/D^\(H?6Y 6H]NJ*3S\V@"('F@ 84Y"D4/A=\!F?>?;#P^4+YIL7EAYZ
M_Z@<-,8!L),:L6'Z^O3KG4Q55>)#]>>#G2T+ >]L_$2K.$GMY//YZKQ0=HR#
M_/2PPTM%1QWVN"/N/[CI5-R'90(YK%\[V($=LM\SN>Q?^&E ^C]QLNW+S,#4
MYUES>+33@>_Q43O8PVK.'GS*0[,;B#O"=J:N^*GSNA\,>W7KQ_?N7^(U/GX-
M!TY3_>:+94\XV;L?0IQL1^W_35VB+$Q'R(8#4Y%U?Z!N'\L*_O9,-OY%#^['
MM6SU[<TYHKN^=-68J0*YX_U, *U)8M&@*W>[#>*>:,ZZ 4(((8X?@Z:1-YB;
MF_OKR\O+[SFW>N[]%RY<^/9^O]\9# 8,!@.&PR&CT9"B*"B*DK(L,8G!F 1C
M3'UY?$HP24)95HR*$</A$.?<PYUV^Z<>>O#!Y][T)5_RO_R5K_S*Y5G_WD*(
MXRMX3Z,>3[]\Z?+WE675" 2&@R%9=O_7O+S+OF/GUJTMIB)@O8>Y3H.&O+?W
MA;P1%UF;M!Y*&/09#@9/SLUUGA@.#QGHOL]8:['._C'#(?M&D^K)6"&$$$((
M(80XS)$C8_<O3/+ <-_]P^'47?M^T%,,-N@DFU>"FJ,H*MIS2_2'CLWM;1:6
MNKC@<&%4UVP:UYI)4#Y%^W@P[[7D?)^I8.H5\1F0@L\.7UDVF?>72!8AA#@>
MQJO/8&\%VL%1Q ,K]=7>JM.T8:GLWMW:-"!T\5436  6:'<?X.RY2P_.SY_]
M6672KZN<Y[KUA%TPZ2%-FEJ9%K O6GJT4!:4(ZAQ)&4.Y WE5MZB+=^Q^NBY
MO]_?WOBEW?7/@KL.; -;H/LH P=+O)TX+[@R;RJJXFZ^ULM>6?Q";=EY>:\I
M*]/%(73='_A@B/N@C?J><4VQ$MP(ZIJOC4R1:(,M+=;#KOU\:)[AM?_9YW>&
MK?-/;*X/R-J!A6;.^MH-&HT6L3]LU/5M+$$5V+0?G]\MW+M?]FY01PL-*(TA
MSQM4?<>HM\/2PAS+"QT^^]RG_N7'/_('?P!K8#?W@O(#K&^.P(_?M^U7]H+W
M0S:#XV1?MWQ@8UB_U[?WW 7CB)3*U6, E2=O[%*,A@RNKO/TQD=^Z;6/O_$K
MDG3QOW6A3=!M5+J :C2Q9.R6CK*JR,PN!S,R[ L"# HPJ* 99\>87(:8^>((
MLG(QO@UF@-<%P0SPRN.UCZT**80$%4R]=Q10P:&41X>*S^W<X/JM9]^#OPH4
M-+(YG#,,JP%9;O"NCC .(^*^5@*D^,G:Y5?X^3\M#ON.'_J]G_7X3WEO7D;V
M@\3]Z-##@CIS$=6,7E_<,W[WE?_(OFLOT?_*_J(0Q]=1^__;#E_=[3>^R/?_
MMI=_V?W%G=]PS'SMYF PO.J<Q7L_J2FKE)J<A!!""''\5#:6 4SK255?5OBJ
M! Q9<X[EU?-J>7GY^SKMSD?3+/TZK35**;32W(.:<@O=A>XOKJRL_.;*A0N=
MQOQBS)-9"Y*B2(C[FCJP>L.Y@+46-WTLU6P2X+O*LEI,T@2E-&598<P=KN)R
M'PHAUG[5VI W&@0?V-[>NK*[N_NV6;=-W'W3WZ.X38_?M[*JZ._NOCE)DK](
MTQ1C#,XYAL-AS&+A/4ER\K]?SCL[' S^>'S=5I80XFB.LR=]I9<00@@AA!#B
M;IGYT=#V]OKS7=/&^4!5%4 V.:#3JH[:"0>3]LMREV.H\](/$4((<5R,IR;#
MU/_CE65Q*WN@=M5!'IP"8U+P&F@#<^1SJYP__]C2W/SJKR5I]V\F61M4BG>>
MH!5HT"A".-H*,X4AH%#!$Y2K]Q7B/0%(LR:MO/$-\^W\/^ZT^-JU6W:MMSD"
M7]:_IRR-%N*DFM1W">/O\GB%1>RWU"1J/MY2N>EULS&2=F'^3*9"^OW%R)*E
M<P274(Q*DB3;JPVCB%E@QC6,Y? C<AD^:#+C:;0]U>@FZQO/?L_&]B=WH!?K
M=<.!;E9S3Z)>Q%WGQW_& %H;M/)X2BJWP=;V\X/.POPW))G_4Y.H,]9"54#I
M,I*L0]YHX$+*[9&Q^[]<>_5E R@_V2>Y(TNUQS6/ZPP;DQK%=20L(=F+C V@
M\'$%>U HY2BKW3_:[JWOQL^SQ882'2J21&.MW;_</3@.+V(GA!!"""&$.&UF
M'AF[N;EYTSE7!A^HJ@I"0&L=5Y?*,<M),O.)?2&$$/>8@W*X-[BN\B:KJZN?
M>_;LV3^;FYO[FWF>$T*@LE6,%E&QEGR2WOU-QG 0)P/:G<X7+2TMOJN[T&TT
MVVU(4U1B7N*GA1 GWH'CB'U3/>TV"PL+WZ:4OEB6)4EB4%I15A5&^H>7%$+
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M%?=H*FQUE<Y\X.:-I]YR[=:?6;@%#"B&D*50VEDU7-P/]-3F.DDM6H,/)2Z
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MO:2U7K36-HDAKA!#7'O #>#CP)-/?OC)ORS+PI7#7;!#P (6E4*6*EQ50*C
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M#(<#E#HL,A:D)NDQHC1I8E!*0U K]6$J:9+BR^+ @PWR=Q-"B#M#USDC XZ
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MA20;/TF82JL;7J /A'$?>/]DU:F/@T) X0F$^#8$C2)@JR%I8M!JA+,C\FQ
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M8US4J-[#QWS!12D%C32%$#/)<B0(:1QCK:<L^W@V?GYSXS,9;((9,YQ4XV3
M$N36W[\HI9122BFEE%*'S=R3L5^(P:#_P<A59;B,,332E"S+GO8DN3HT'EI9
M63'65A,-<10A^UZS,L_GM5U**?6LXBJAA7/7G[CVWN.P-),&>9DS' X!6#IY
MDOOOO_\-:9K^*?#*F[S)MQ3O/8U& V,,&QL;?WMS<^LS-WHME%)'CW,P&D'2
M<)3C,29)P>?<_J)[7S<>C]\R[^T[[*J>VE55&F-,53G(.:;E:H:#X;N*8N\X
MNZXN &AE(:644DHII912:A[FGHPU=:^CJN\;8*;MH\KZMIR-C4N/W''NY(:7
M<@4;:'=:[/2'M%JMX[XP?NZDCAB) 1&'X.K;$T22WLKJV;NWKW[N,:1)L^78
MWMVJ7F!G04\&*:4.L:(H9J7QIY. (D((@1 "F2O(*0AT@=.X^'Y.G7C#W^AU
M[OC)<9''!3G!Y8BM$K06JD17OE3_A..]H"C8:K\O&""&:5K+>"QCC.N3I(9A
M?ODW-C8^_'.[6Y^CD0R(8\@RD!OU?I5KKI52A]*T%'L4=<F)D;P#\>V<.OVJ
M=^P,<J!-,+9.T/LZ#1M  D;?WP1*/ XK8#$X9TF,)4A!&8:_N[/Y^<^378)H
M %35'$H#02*R0I] I9122BFEE%+J9CL2R=C-C0WOO7\O@#&61J-!GN=5CSUU
MJ#72].5%D1/$'^B!&*7I_#9**:6^ "$$RK*<]2B<I8_JBPB$ '':X+X'7I:\
M\I6O?%<<Q?^BW^_'+M($YW/EK&4T&CVUN;GY/;N[NX!GDD\('NR1.'I12CV=
MLH0XAM%N'YM4QX3WONC>-XJ$KVHV6W/>NL-ONC!HNF]RUF&,I2P]V63R,UM;
M6W4?<L""L68V;@9=K:*44DHII9122MUTAR 9>_",JI&ZCYP!I !*BO$VH]'.
M[Z3-UK<9X[$(SAHDE,>^9]1A4*5BIWW_INDQAYB(TIM7@/EW'L=HG,V^QUK0
M:(-2ZJ@HZEZN!RU"XS3G[OW2TW?<^>K?R(OEUV]>V24O<[JA26E+,#G&%%@!
M(PX;8JR/ 2A==H/'/#[$UK]_2$$L8# "QDRP=H? =K&^]9F_NK'UZ";F,C#$
M$:" ;B-B.Y37)&"KQ]B['/AI7!^;U05=2LV-0+>3L#E)"7D3D]Q.KW??/QZ/
M$UH+70:3495^MQD0,%)6[^H0@[%[3:>/*RN("80@>R->"!23P?G18.,]9)O@
MAF"J8VZ1$FLA>%THI)122BFEE%)*S</ASY88"PB;FYOO"R%X$2'+,IK-YFS!
MMSK47C']9Y;E>Q,/15G.:WN44NH+TF@TB.,88VY\TM\T4AYX\8-?=N[<71\>
MC4>O7[NZAG..3K=+J6/<<[:UM?4#5Z^N?R#;W:5:[K/W.H@> "AUY V'.8UF
M&_!\R9>\[)LFD\F7Q4E,"+I0XMG8.N8J(K-+412,1J.?W]G9.5##/8AV!E%*
M*:644DHII>9M[I.Q9O:?G9UF-4PWS&,=0&!S\^IV".4?(9[Q>$BGT\9HLO)0
MJ%Z%Z;I\"U@$"SC:G=[+EY=/L9=8JK\GR\#IZGREU.$UG83=/_'GG*/=;K.X
MN,A=9[[O[9W&6_Z?T>3,V:W1A(E[$M-[$KOP)-*XC%@/H8?);\/FM^&*12)O
MB<TZL5F?UZ]U:(@IJ@L&) ))J@L"9O+N"Y<^\<^+_',070$98)W'4>U-LLS?
M(!4[O;AGN$R_?LQ3=4K-6>0@FP"2TNJ>M>W6Z1^!#M9V&6>.0(P8@YB F'(V
M7AB; 3>J5'"\&&O U)E_$<0'BKSPHV'_9P?;FT .#FP,!"B+JHJ-T?%/*:64
M4DHII92:B[E/QCX;8ZI)/#\:(B+O$8'))*/1:,Y[T]07H-OIGEM>65Z=?MYH
M)'OG@)XF;::44H?!>#P^4)XXBB*6EI8X<^9,<N[<N7?=====/SL:C9(K5ZZ0
MIBFK)TY4WS<:$\=S[P)PE/TY\%UA>QM\F.TS)$"G8XE-/->-4TH]=VE:+<B;
M3(:\]"4O_9:-C8U7+"XNS/ITJV=FK:T6#,E>_UA?EN_)\_P"Y( ECL'M^TNO
MFHS58V^EE%)**:644FH>YOX7^?[9X/T;(P:"V7>OT*.]^N"#+WGI&S_IW%FV
M-F-<'".N?_,V5EW'N$T )'1 &A#:U>V46'*BN(_X];=\]/_[K=\AG4"V 6Z,
M\0$7@5;R5$I]T0Z$ZVW==[2^OJZ?H%QS@8AV_;4<\. *RFD?40-)IT7>+T%:
M$#KTSC[ J=,ONBU-VK]1%(TOL_'I%^YW.P)LJ"=%;0Z4B)U.H%A$'$A25TFH
M7PN;(:8 4Y6LS[=/8\K ZHD&C63,<'">1C(:[6X_\=I''OF#3\ 8RP1S36]7
M[?BJU/Q-EYL(,4)"()W= @',!!-YQ->]G0VD$<3.498P\2^%WAENO_N>J--:
M_H21QOW6-#&DA&"0V1@>P)1 65V;^L#1+]S,7_?0"?DB29IRY<JG>."^%2;C
M\XP&3WW#)S[RA_\!)E3IX8)JI"S!^(/MM+5LL5)**:644DHI=5,=^F3L?MZ'
M3Q5%\7@( 5OWDE6'FU3+\%]7?W;@2BFEYJEA&[AZ1C<0*'VHSEL[< W(!Z/9
M?9/59997EK^\V^E\N-5J?5F[W7Z:1U5?J,A%G#AY@CS/Z??[M%HM+EVZ]-<?
M>>2CGSABAR=*J6N)(!(.K+3T'HK"4Q;53*!K-(A<]!W&V/OW[B=(T /%9V.L
MI2@*5E96V-G=(8[CQ]?6UMY7/>&Z5$4II9122BFEE#ILYEY'L5XL_RP"$/!E
MQGBT^Y[(3?YFY!*\:*QRWF063;MFJ;T11*ID@\&]EK0'(:?Z)V<0HW.R2JGG
MZ-I!1$)UHUQ[(GJ:ACUXNVOMXO.<(B\/?B4DA+(+)6![+)RXA]43]_S-7O?L
MCT=F*:9L4+4LSY_77^?(,=-HE0>S[QD4@Q&'B,/L2\9*B*I>[[;ZOK0Q)$B)
M#QLX.V0XW/GIBQ<?_248X9S'>\^UKUGUDKOZ6J-=2LW+WO ;J-Z+Y;ZO5,?M
M^("I#OL0#V68WBN"YA+=]E(S2=K_P)H$"1$8BX@AA*H,+U3?BSBJ05?TX+%F
M,03O63VUQ,7S3]"(_<]=O?+Y@,O!3ZB>Z>GX*7N[05WGHI122BFEE%)*S<61
M^I.\* KZ_?Z_+XH"YUR5NE2'6@B"P;QV87'1,$TZZ.NFE#H$^H,165YB &OW
MM;$.'IEDM):7.7OWW<US=]WU"ZNKJ__<61N/QV-&HQ%Y?LPG8I\'SCFN7KV*
MBQQ)'/^_CSW^^/=-1B/BI%E/Q"JECCH#Q+'!N8.W-U>6Z72[_VT2)W>8?0OT
MI.Z!JIY9$"%)4JPQ6&N+2Y<N_1Q%#EX7JBJEE%)**:644H?1H4C&0KWPG8,I
M62OUFFX#4$(^8-"_^@=+BSOK[69O-2LF0')3MU==*ZI>0U.71:L33XA@#(3@
MP":+BXNG[]^Y\L2?0UPG'+2$FE+J.0I/\\G^'<DSE%X(T_YYLS:R"9@NT $Z
MG+O]]?>V6J?_CV9K]:&R;#(9%DPR0^2:I,T&F*O/UV]R)(FI^Q!>FXS% @XC
MCJJQ;_4BF&E:+B1@)@@7:?<&Q$G\Y-;F^;^RO?W9W"9C6FW+3C[&7),\EOIQ
MPZPB@T[8*C4OLY:NX@&#P=3']/7[O,[ !@$;Q10^4(T-EBA98K%WMM=J+/\]
M:YKXTB#!@HTQN+JZ@=W[0=-QNEHZ<]-^QT/-%W2Z;0:[5V@V^<W/?OJ3:T1C
M"#O5L?AU;=+KB'*8OG"ZH$@II9122BFEE+J9CM89C5 RZ/=]412_I<G8HR'4
M_<(6%Q=?>VUM.7WUE%+S9*_= PK$C08K)T]R^]UW?6.[W?E0'$</E:4GSS)\
M\#CG2!LIS49S+MM\*\F+@E.G3HW[_?Y_\=E''UVS=71N9VMSSENFE'K>[*N4
M.[6XN$BKU?K^)$E60"B])X3JCL98C'GV!B;'G:EW8(/!@+(HWDD^@3BNOJCK
M'9522BFEE%)*J4-G[LE8N'$;([,_,@M@"I",,-Y _,ZO)_'.=UIRA/2F;JLZ
M2"3>.[]F M5*^RIN)E(G8Z5%IQW_!4A_$5(@KE_/>6VU4NI6$,WV&GMGGF7Z
MOVOZ4M_HW'2P!HH() +IX)HG6%R\RZVLW/4C[=:9'_)E2EFV$8D0(J+(@K48
M)^1^_(+]7D?%-!EK9L]NG8 5"V)!'&:Z$Q? !@QU'UB3(_8IUC<>^X[S%Q[]
M3XR?(L0"Q1 H,)08K@TV3U.QU]0[54K==-. I1&N>;]6R5@3P;3:N/<Q$AP0
M0]JFO73?B21:_'Y+DU *OB@ BXD<UKAZH<R^=[_8.AVKR=BI1E(R&:YCS>@S
MZVN/_P$,H=PD:GK*27VG67H9JN<M8>_YTV2L4DHII9122BEU,QV*R=@OR*RA
ME">$\'O&F%T1>O/>+/5LJNF0)$F_?,X;HI12!Y75^&0;#=KM57K=TRN]WNJO
M=MK=KTWB!J,QB \(@G4.ZR*"0)[GY$5.W)[S]A]QSKE_]+&/?.#=3,;@'!35
M!'>4Q(3<HRMVE#JZG+-X7RW4"%4C6 #B.*;=;O^0L;8-$$+ AX#! @9CJHN^
M^Y]9',=L[VS0["8_LW;UJA GX .=;IOMR7#>FZ>44DHII9122JEKS+\.V&S5
MMJW7:H<#&^5BF)Z375JYFZWU"=#C*[[J+;]8^-[;=HJEF[S!:K]@3!54,,6!
MVTU(JIZ_OB3!$$=C<69C]8/O_XU-V(1T&PJTE)I2ZHL6[TO&3D_<"WN]#$/=
M9]!%8$Q,F7NF/4R;[07&PZHW;'OE%*=/W_.E"[W3O^YLY\X\MQ2Y(XI;LX2M
M&-GKD6K*ZC:);^KO>^C8G*IO:_7L&Z:IV 03(D(9$<<QD3-(R"G]#I@)2</2
M:$Y^^X_^[Y_Z9B@#2-UWLJROJY[Q!P]0+ &'X-A+=HUNTB^JE+K.-* >]MZO
M^]^ST\ZQN!BD#=+!MD]RYNS==YXZ_>)'Q\5*O-<7UC+K!RO31]H?ZY2Z9(X<
MO.T8R[;6N?/VI>PSCW[P[,4G/K!).H#R"AAH-6$T'1X%"!:(.9B,W9G'9BNE
ME%)**:644L?6H:_U-2UQ!I#EV>SCP7#XF]HS]O SF&G%4 -\Y>P+^M(II5Y@
MC;J*O2^A+#VM;H<HK6X<#X?0:-%:/L'2TM)_TVPV_\@Y=V?U'::JQJ">DV:S
MB83 9#S&>T_::)"F":/1Z)/GSY__5G0YCE*W-&.!$*J+-70Z75JMUH_X$([Y
M2I;GKMUNL[.S\^[!8% UV0[[AE,]QE9**:644DHII0Z=0U6F. !5/G8O'2L!
MDACR$K+1)M  +-M;GWOOR9.M(2QKH<@Y$N*J\ER=%JM24H"Q"!&8E. #(A9A
M_%78SF\2^O5]YK752JE;P8TR4L$RZQGKTBY,QB )2,(X[P(IV!)"RKF[W]R)
MH];#:=K\UCAI$4@(8@E&P'F\]54RUI15^M^42'T-0+E\LW_E0T7JE/%LGRT
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MABBMJ^4Z(%H&OTC4O8=S][SF?XN2TZ_TM/ X2JE+DXLG^!(C0A(GZ/%W78G
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M]:YSY\[)5*L00@@AA!!"""$.D<E84G]1R%%H( = 44(,U#6TN@&E'?5X \K
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MA!!_9649T18PAA3%5*R>.G7G:#3^+N@<]>9=U\JRI-OI 'M8:Q^X_Y%'_P/
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M962YP>8.5$GM)OAZ1.T<!>UGX%D1SQ85>DURW:0T;+2HIGJ!BA!\B=%CK K
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MS6M;8F;7B<WK'C!2MRN$9/:6:-9?O9PMK924Y34&P]V?&@PN_>WA\/*TF&Y
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M($TP^R"+K8ELI=3QBK&BB<4B?A%B"^C177R#[2S>]SYCEI%H"#*M?\"$NEM
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M$F.!F J,QS9)M3H5Z^9^GT,/-BFECB(F>_45<1@<2(*1#,2!./*I08(@43"
M<XXD<3AGL09.G!@P'&R--C<WOG=S\^*/C/>N!9A0IY%*L!%K/<X:K''$"+ZJ
M]K=<.K-/*75LXMQ2'//31&4N-2EVEHIM[F("D$$\2=:]C].GWO+M,9QX]712
MT&Z?I-7NL;-QE86EC(.!M/7Y*$8"AD"]_Z;[<$=A8XH)*<Z )2?/=S_8WWOB
M"=B!9 RQ.2'HT =-!K2:FS09JY122BFEE%)*J>=.B[$O=<[N'PA*N@OX/$*
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MT_HW=Q*B']VVYZJ44B\EA@P#6.-)F_/21)H+#DN/LZ]X_3O6UN_[81]3IF7
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M[4!<!S9877GK YW\2]X_'%U9UF"E97U&8C,B$QPS"#.JNF R^]R/3D:?!ZZ
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MX8?/3";3[U[V^.YV,0:<=5AKB2'@G*/3[1 C[.SL_'19EI?JNCY0?(WQ!CV
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M[KVGS_ESC_W><\\\^@MPD6(R)$FFF A!X601$1$1$1$1D9NB8JR(B(B('+X
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M(B(B(B(B=QSUC!41$1&1FQ/:=6P7/!$P[0:70%67[6E_!FH'(0>7<?K4(\>
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MN7>#*Y=GJO:]!B(I "8:YHG5>1=?B!@J(&!-C3$5(8PIBG/_UVC\^0_-=B^
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>29(D29(D?;O^?_+8 F+O#=Q$     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_0c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0c.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /U3HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&=:NM8\.S_:I&E:&7:C,<D J#C/UKP2TT&\U+4OLL,#O*S ;5'//M7TO\/\
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ME4ITU>]C"^&OP]F\5:BLLZ-'8Q,#))T_X"/<U](V=G#8VL=O"BQPQJ%55'
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6*** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_0d.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0d.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /U3HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBN?\8^*H?">CRWDN&?[L<><;F_PJ)245=E1BY.R(?%_CK3?!
M]N&NG,D[#*01_>/N?05G> /B3!XX:>(P?9IX_F"[LAEKYS\0:]=>(-0FNKF4
MR/(V3_GTKTG]GZQ:36KNYYQ'#CV^8_\ UJ\V&*E4JI+8]*>%A3I-O<]ZHHHK
MU3RPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBL7Q%XKTWPQ;&:^N%CXRL8Y=OH*EM15V-)R=D;-96K^)]*T*,M?7L-OC
M^%F&3^%>(>+/C?J.J&2#3A]BMSP"A^<CW;M^%>;W6H7%Y(SRR,S,<DDY)_&O
M/J8R*T@KGHT\%*6LW8^A-0^.6AVK,L$<MR5[\(#],UG0_M!6$DVU]-E1/[WF
MK7@=%<;QE3N=BP=+L?5'AWXF:%XBD$4-UY,YZ13?*3]#WKK.,5\7Q3/"P9&*
MFO9?A9\5G:6+2]5EW(V$BF<\@] ">X_E771QG,^69QUL)RKF@>VT4WKR*=7I
MGFA1110 4444 %%%% !1110 4444 %%%% #68*I). .M?-/Q:\8GQ)KTD43Y
ML[<F.(#H0.K?B<_A7KWQ;\4CP]X:DBCDV75T#&F.H7^(_P!/QKYED<R,6/4U
MY.,J_P#+M'K8*E_R\8BJ78*O))P*^E/@UX=_L7PP+AP1+>-O&1@A!PH_F?QK
MP?P9H,GB/Q!:6:+E9'PWLO<_E7UE:VZ6MO%!&,1QJ$4>P&*G!4[R<WT*QM2T
M5!=2>BBBO8/'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?A^*T;F=CYDN#D;CV_  5Y6$YY5.9['K8ODC3Y5N=11117L'CA1110 4444
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MT<6/AN:\9-LEQ)M&>ZKW_$DUZ:/2O>PL.6FGW/G\5/GJ-=A:***[3D"BBB@
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MJIQ4$SPCX_Y_X2:#/3[,F/\ OIJ\IKZ%^,G@:Z\1PP7MC$9YH4\MD7[V,Y!
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M3N884MX4BC 5$4*JCL!4M%%?0GSP4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //_C-_R*;?[].^#/\
MR)T7^\:**X?^8GY'?_S#G?4445W' %%%% !1110 4444 %%%% !1110 4444
G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_1.jpg
MB5!.1PT*&@H    -24A$4@  !3$   -Q" 8    \>_VO     7-21T( KLX<
MZ0    1G04U!  "QCPO\804    )<$A9<P  #L,   [# <=OJ&0  /^E241!
M5'A>[-T)6%5EXL?QG[?&+/<4!%=$17.4,,T5MS+<TLPMF\Q)4[/RGUHN:=:4
M8Y1BBY--CCE6EA.9FDMFDIJ[YF@2D2D9XLKBCFCFU.U_S[GG(B@H*.#Q\OT\
M#\]YW_<>+O=>.)=S?^==BOSA(@        "P*8>U!0        !;(L0$
M    8&N$F         !LC1 3        @*T18@(       "P-4),
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M_[FZ60=PWJ^__D\[=Q]0Y.=;M?O02;.M3;"_1CUVCRKYW6K6 0  \A,A)@
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MY>KOK58  ( K1X@)  "\BM'K:]&&/68YK/7MYA9 P>MR3P-S.WO)=\R-"0
MKAHA)@  \"J>7E^=F]=4Z5+%S3* @F<LIF7,C6GTQOQNQUZK%0  X,H08@(
M *^R;%V<N6W>J):Y!7#MW-<NV-Q&+OG6W (  %PI0DP  . U#B8=,U=$+E_R
M)G-./@#7UFVU*IO;U3&)#"D'  !7A1 3  !XC6]C$LSM74UJF%L UY8QI4/#
M6KYF^:<]2>86  #@2A!B @  K_%3PF%S&Q3H;VX!7'OUZ[A[1>_=?\3< @
M7 E"3   X#6B=[E[>I4MS8(^@%W4JNYG;K?&[C>W    5X(0$P  > UC/DR#
ML2HR 'LH=M.?S.V>@R?,+0  P)4@Q 0  %[A^(DT<VLLZ@/ /CP7%3P7&0
M *X$(28  / *1X^[0\QZ->B%"0   '@;0DP         MD:("0       ,#6
M"#$!        V!HA)@        !;(\0$        8&N$F         !LC1 3
M        @*T18@(       "P-4),         +9&B D       # U@@Q 0
M     -@:(28         6R/$!        &!KA)@         ;(T0$P
M ("M$6("        L#5"3         "V1H@)        P-8(,0$       #8
M&B$F         %LCQ 0       !@:X28         &R-$!,       " K1%B
M @       + U0DP         MD:("0       ,#6"#$!        V!HA)@
M      !;(\0$        8&N$F         !LC1 3        @*T18@(
M  "P-4),         +9&B D  %!H.'4F?IVB(E]0WRHE%>3YZOV"YBU;JLWQ
MJ:Y=XK3HTQC];GU'CJ0LUNB,]Q<Z5;&7NX/3.S1O>!/7_MWT^H9$UR/+(Q<^
MEDQ?G30SYK2U(P   *XGA)@   "%P>DX185W5TCK3AHZ*D:W1WRNJ)TG%;?_
ME.+FCE2C4D>U[MF&"JK64&\=S56$*?EVU:MKWE:H5<V)WW_^2M/G[W"55FKZ
MI__547?SU7,]ELG[7<]EQF#Y6DV2GQH_][6B]W^A@<'%K38   !<3P@Q 0
MO-WIK9K9O[.&OK-2JM!/X:MG:U2?U@HH[CD5+*6 %OTTZKV/-;J9G]66.XX2
M953>*N?$#37NT9 >=5VENS6DUYTJYV[.(T55H6%K-;=J4BVU:7Z;;K%J
MN/X08@(  '@SYSY%O?BD)F]*<E7\%#IRF+K7*.6^[4+%&VG J\^KME7-5\7K
MJN>;WRAN_T(]W<*?DU(   !<$N>+    7LNIM$WO:4*D,6S;T$E][@J\Y F@
M(Z"IPLHYE;)LV,5S2@Y?K,/&3IGFG1RFJ)3?S._-R)F\59^%=W/OTVBP9J[;
MK3/F+;_I\ 7WW6[Z=O<<G+]OU\S0\^W&');_6K9&*]/G\&RBT>]NUN&KFD#S
MM&*G=\KP,UP__^W%BHYZ7Q&]:YGUT.$S%)-RSMK_/&?*=D5-'ZQ0S_<:<XEN
M\#PO    Y"="3    *]U7+%K5BC%JJE50P65O]&J9,,1I/MZ-91_Q[_KRXA^
MY^>5K#91"U[K*A^C;,P[N>-S#:HV6-/^&Z$PWPON\^PZ+5_[AT*?7:#HI:^H
M<?+'FOR7AS1QV3XY=:-\.DY25,3]ULX9W-!  ]=N4W@KSY#VG[0NQJG@WN,T
MT=Q_AQ9.&*8WEAOW<Z6*J]Z0!9E^_KXU/^ALR%_TS*O/F_-ZILQ_1D]$?*GD
M##_$F;18XSNUTM"9)?7"?P^[G]>F-S2N3W^]O2'/9O0$  ! -@@Q 0  O-7O
M^Q3[1;15<?$IH_1I,"^KE )[#]-P3Z"X=YMV[CWK+IL<*C_L,;7S*VK5,RC6
M4AU[W2D?AT.WU M3-_,^=FC>\^]IRRDC&;Q1Q4N7-7>]B.,6E?*YV:K44IN.
MC5WW4TQ5ZC945;-MA]9NWW.5O1\S__RJ=W70G;Y%Y:A67\VKN=M2OMZN/:>M
M%-.Y3RM>>UGSDB7?[EW5W*^8;JEQE[J9<WI64-F2EPF& 0  <-4(,0$  +S5
MT?V*VVN5KX2CICH\T=?JC?F9WHS\1FEF^9R2-^U1U98!ES^9=%12G9:UW.7D
M%5H7<]Q=O@HI*2?UBU7.-\G'E/J+.\1T)JQ6I#DDWT]!@?[N!8+2Y_2<IX'!
MI8T6    Y"-"3    &]U<VGY5+#*5\2A$L%M=)]U'RD+5BO6Z$GI3-#&O=75
M)*M>F)=T4H=3\SU^S&._Z>BN;5IOEF]6^=*W< (-  !P#7 .!@  X*V*^ZMZ
M;<_\DBZ'3\@S0CK'2C91KY'6_)')'VG&TMWZ/>%[G:A;5R7<K5[N5R7O_<DJ
M[]&W>P^[%R$"  ! @2+$!   \%:.JFK4I9E5<=FU1TFY3C&+J6KC=N:"-U*2
MUB]9J95;3NFVX&SFM+RDTO(IY9GO\GIQ@TJ4*6^5I;/'4O-_*#L    N0H@)
M  #@M8JI:IN>ZND94I[\A1:O/W#IE;V=QW7XR#FKXN8([*S!CX>X*VM':T)\
M==4KF=/3R+-*.W;**E=7=?_B5OEZ453EJ]1(7Z4]?4@]    "A0A)@  @!=S
M^'70B*GCU-BL[="\]^9H2TKFD#*=,U&;(R*T)O7"D*ZLZK5N9P5Y[?7(O2&7
M'DJ^-UZ'CO[F+CN/ZL /26;1]_%'U2&PF%F^?CA4(J2S'FEF#<N_:'&B5"7$
MQ.N,G#H3OU@1O6LIJ-%@O1>==.FP&    +E"B D  .#5BLJGQ3-Z8\EKZF;T
MR-P4KGY#)VK>AMTZX][!)54)&V8KXN&)^K']4^I^4=#H4(EF#VIX*S^I55>U
MJW>YU;@W:\6J.-?]G]/A3?.U<&V2U&R<I@QL9H6?O^GTR?-!8*8AVLXS2CWL
MJ9W2\5-G75NG?CEU0D;)=-FY/<\I>=L:;;1JTE'%[=B;X?EF\_//I.IX^@\Y
MKM0T*X@M?H?^,GZ8%01'Z]UA+VC>SZFNLO'\OE)<\?*ZQ74/\5'3]>XFUW--
M_EBOO+_%]5,!  "05XK\X6*5 0  KEN[]R2IY\A(M0FIHB?[M[=:D8DS2;$K
M-FOGUO<U[IV55J-+LQ$*[W^/&K5JH8#BV5WC/JN$R"<U06,TLT_0Q5?"4Q9K
M7/@>M1EPOV[71LV>^+P[T-/=&A0Q0KVZM+3N^S<=7O:,6@R>97Y;NAYSM.&U
M*EK4NI4F[[7:3"'JUJ."%LY?;M4MQOYO=I6/54WG>ARC&SZDA58ULY8:O?0]
M-=W87]U?7F>UN57M\:#JSO]87UIUMP&:MNTUA?G>Z"J?T^&8+[5HULN:/'^'
MJUY7W9Y[3OVZ=U ]7V.5=J,GYN=Z^]EG]&Y\6XV=.4%_#?&CQX"EU["9YC9Z
M_G!S"P  D%N$F   P"L08N8WI](VS-97_GUT_W4W)!S7&B$F  "X6EP<!@
M0 X<5^R.DFH00( )  " @D>("0  @(L9B_Q,ZJ:@1L\H*NF<=.HG)5:[4U4Y
M>P0  , UP&DH    +O9'DF*7K)22O]**[;L4&QDC_V:5.7D$  # -<%Y*
M "YV0PVU>VZD&FN/%CX_73OOZJ.F)3EU!   P+7!F2@   "R4$H!'?^FC_:?
M4MS6M]6S1BFK'0   "AXA)@         ;(T0$P       ("M$6("
ML#5"3   @&O"J3/Q*S5STJ=*<%I-USW7<XJ9IKY5>FIFS$FK#=E+5<*&I?IR
M^F"%/C0[YW\'SMV*>O=3Q::<LQH   "\'R$F  ! @3NGPQLF:>@_?E;C_O<I
MX*(S,B/<FJ^9PYLHJ$I)ZZN;(B(7:W-\JK4/TIW>K<W+WE=$[UKG7Z]&@S5S
M:91B4\[J3,Q"1<6?M7:VB[-*B!RJL#Y]]-3+'RO%:LT11Z!"[[Y)RT:,T'O1
M2?*:#!P  . 2"#$!   *E-%;<8;&?%I5XU\>J&#?HE:[FS-EL]X;?H_Z?GI
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M32Z:A_)RKULZXV=?^+OYU;HM(V-.U-D9YOB\U&M55O5:ARIAYE+%G+KH!P(
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MG'Q0GT5.4,^P.^1W-6?$>?ZZ&8L@3=+@UL8"0',U>]PCNCNX4LY>&YM.50
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M*M'A"3TSN*M\M4M;OMHCWQ89>UP:*Y^O5\# S@HNR:D]  #P7D7^<+'*
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M9,@-1Y#N'_.X6@26LAH   "\'Z?,         &R-$!,       " K1%B @
M     + U0DP         MD:("0       ,#6"#$!        V!HA)@
M  !;(\0$        8&N$F         !LC1 3        @*T18@(       "P
M-4),         +9&B D       # U@@Q 0       -@:(28         6R/$
M!        &!KA)@         ;(T0$P       ("M$6("        L#5"3
M      "V1H@)        P-8(,0$       #8&B$F         %LCQ 0
M  !@:X28         &R-$!,       " K1%B @       + U0DP
MMD:("0  O$(E_UO-[>KH_>86    @/<@Q 0  %[AYF)%K1( .]EW(,7<M@GV
M-[<   !7@A 3  !X#4](X@E- %Q[QT^>-K>E2Q8SMP   %>"$!,  'B-JOYE
MS.VAY./F%L"U%Q>?:&X;U:MB;@$  *X$(28  / :(74KF]N=N]VA"8!K[]L=
M!\WM;;4JFEL  ( K08@)  "\1NV:[N'D2S?NUJ^__L\L [AV3J:>UNY#)\UR
MS>I^YA8  .!*$&("  "O4<GO5@4'E#7+.W<?,+< KIUO8^+-;;_VMYE;  "
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M9_3HT1HX<*""@H*L%@   !1F#FL+         +9$B D       # U@@Q 0
M     -@:(28         6R/$!        &!KA)@         ;(T0$P
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M         &R-$!,       " K1%B @       + U0DP         MD:("0
M     ,#6"#$!        V!HA)@        !;(\0$        8&N$F
M  !LC1 3        @*T18@(       "P-4),         +9&B D       #
MU@@Q 0       -A:D3]<K#(   "R<##IF'[YY9Q50T&H%>BOG^(3K1KRV\TW
M%U4EOUNM&@  @/T08@(  &1@!);?QB1H:^Q^[3EX0C$)QZU;4)!.'HI1Z8K!
M5@T%Q;]L,=W3N+IJ!?CHCN  @DT  & ;A)@  *#0.WXB35^N_E[+UL5E&5K6
MK%A:E7U+637 ^QQ(2=7N0R>MVGG! 675L660.K2IK[)E2EBM    !8\0$P
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M$&("  "O-ORE3\P TUAU_*5A75AM',A#QFKF?YNZQ%S%W @RW_S; ]8M
M><MA;0$  +S.NW-6$V "^<@XIHQCRSC&C&/-..8   #R R$F  #P2IN__4EO
M+X@VRR/ZWT6 ">03X]@RCC&#<<RM6O^#608  ,A+A)@  ,#K'#^1II?>=L_5
M]T2O)@JJ4<DL \@?QC%F'&N&B/?6F<<@  ! 7B+$!   7N?-62N5>.*LVH14
M4=O0^E8K@/QD'&O&,6<<>\8Q"   D)<(,0$ @%<QAI$OVK#'G*.O;X]0JQ5
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M9-I9<PL  '"E"#$!        V!HA)@        !;(\0$        8&N$F
M      !LC1 3        @*T18@(       "P-4),         +9&B D
M  # U@@Q 0       -@:(28         6R/$!        &!KA)@
M;(T0$P       ("M$6("        L#5"3         "V1H@)        P-8(
M,0$       #8&B$F         %LCQ 0       !@:X28         &R-$!,
M      " K1%B @       + U0DP         MD:("0       ,#6"#$!
M    V!HA)@        !;(\0$        8&N$F         !LC1 3
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MQRDJO+M"6G?2T%$QNCWB<T7M/.EZSJ[G/7>D&I4ZJG7/-E10M89ZZR@1)@
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MFQ635ESFP/I-ZQ2;5.&"Y[I.DZ=^K<KCUBENY]<:W>R8%K[<37U?_%S)Y)@
M  !Y@A 3  #@.O/[GF@M]_3"U,TJ7_J6G)_4%:^K[D\]F1[2[5OWO?9G"MJJ
MZ<G'PU0ABSLLUO)^W1_BY_I9I54WK*O[/I)G:,*L34HSRHY;5,KG9J-T$4>)
M,BIOE56MK<*:^LOAJ*0Z+6NYVY*WZ+N?3[G+6?E]GV*_\ 2W+CYEE.7H^6PX
MD[[4U.=G*,4(?;N'J6[Q&W5+C=9J%UK=];-G:]P+"Y5@O0Z9'JM2E5;B=C4-
M;JDN_;O*MUDG-:WA>HZ9GFN(!@T;[!X^7[R>VG5O9K:F1$9H]J;<+:<$  "
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MNU.G*<IX[4_':L6"36:K;Y]1ZF>]-K__O$R3WUGI*NW0P@D?:_N1W\QV
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MWWQ(@<4Y'<R]R@I[,\9\#3-]O=E5/M8>    R%N<M0(       "P-4),
M     +9&B D       # U@@Q 0  "ERJ$M:]H]<_C9/3:KG^G53L])X*ZCU-
ML:>]YUGE#Z?.Q*]3U-*I&MVHG^;%YW1E\[-*6/9O?1:3Y$5_-P   #E#B D
M %"0G(G:/&FH_KFS@1[N$73!R9@[W/IR^F"%5BFI(/.KEOJ&OZ^H#;MUQMH+
M'E88&/F"^J:_7B45.GRJOHS:KL/.DXK]]$LEV"SQ<\9_I*&M.VGHD/%:F&PU
MYD@Q!;1JJ>*?C]:S[VYV/3^K&0  H! @Q 0  "@P)Q4[8[P65'M6+PYJ*I^,
M9V+.),6\.T1AO3_4@6J/Z[.]GE6OMVEBRS2M&-9 8<-G*";EG/4-5\BY6RNC
M=N=#3[[2JC=DGN+F#E6]@ECQW/-ZM1ZI%2=NU] U!]-7"5\[KI4<\>_H_FJ5
MU7W2-TJR6<]01V _S=J[3>&M_*R67#!6EW]VDKH?FZ(1,[82; , @$*#$!,
M *! G%/RL@D:_O-]>J9W7=UBM9J,WID10]3S7W_2\$^F:&#'!AD"SE(*:#E4
MKWX^1ZW6/Z.>0V=<Q7!MUV-8_JX^.7:]=^$SPN"AZCGA.[6:\:E>'=)#30-+
M6;>Y3G!]&RALR#1]%CE.C:TVVW&44^4_7T&(:7#XJ^G09]5FU>OZ3\Q)JQ$
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M34_/T22MG_*QMF1<0=QY6JG',_8DO8*AY]9C\.W>1O5*<EH/  "\&V<[
M^:ZLZK5N)]_L%N]Q5%78BQ]JVN._:7+GORKBTZTZ[-G-6.!EV50]>^\SVM=]
MCCYZ^4$%9NBYZ#Q]4L?-4JI23_]FEERM.IN6*C,B^U^JTGYQWUEZC]!M.UWW
M?U*QGWZI?>6,-BDE>J-B4US?8?R\SS[7%B,9-(9LIR1H2U2,TBX*W2[P2ZI.
M_,\HG-&)M%_-IO,![:W:\O)$O;TLSATXGHY3U%MOZ;M>$_1(LW+FGCJ]0_.&
M-U%0HR<U[^=4=UMVBC?2@&D?:FP/:>&H^S0X_'VMC$DZW]/17!0G4@O6_$FA
M[>N8@:_[N5_^>:;F]/7T+,R3O%T;8Y)=>QB+!2W5BLV)KIV,GI>'E+QII6+5
M1(],':?&R5,T\OF9BC%^MNN^X^=_HM5FY]3/-*ZUCT+#-^DFJ]?F=^MCS-^_
M,V6KED1]8[YF1@">DK39]3S=C\YD!<'WM:ZG$E83  " MR+$!   R'<.E0CI
MK$<"UVM=QA JH^)!"ALW5QN6/J'Z1V?H_FHE%53%]56MI5[=7EKMIB[3C'%=
M%9 >8)Y50F0_U;GS(<TS>A@FS]#0.^]6Q(:=VAS>6B&=QVJ+L=NFL>I>YQ'-
MBS\KE6R@7G\?J8#(A]3CZ4_D;'V7 DHWTR,S7U.W^'#U:]A2HV?\H!(=GM S
M@XT>E+NTY:L]*N>W34]5^[.&1NYPW6&TWNT3H*!&+VFSV;/0J;0-+RFT3EM-
MWF3T3%RNR9T;:4!DG#M4- +:28NTX/5@?3>XH4*,Y]3_(Z6V?E4SQK3-, S[
MC$X<.N9Z'K,U[H6%2DA/)+/F\&VJ_F]^I:A(UV/70CW>N9;J&/==I9;ZOOJE
MDOW:J'NO.\_??\G+/<\?=,)U6Z,<OY[%U7A@A,;V2-3T/D%J-7R&XDK<HP'/
M_I]Z&D'QYC7:7>%.U2M93#XMGM$;2]_5?8<BU+-A.07U?D.[&_905_]2:OSX
M6YKV[[7Z[-FV\F_VF/[Y0ELE3.NJ%HT':]:N,KIG\!@-Z%-7VK5>JWXJKV;!
M98U'X6*M?![X@#J&>-H   "\5Y$_7*PR  # =>EOKR_2H@U[]-JHKJI:^<K7
MKLY?1MCW=W686D[3WWM"]7(S#V2A<E2;WUTMOT=[Y'*8>2'CW*>H,4.T^J[I
MFMBQJFU[)NP[D*)G(A;KOA;5]=+3]UFM    N<>I(0  0(%PJ$2+X9I^UT:]
M.FW-^>'BR,"I,S&K=*!).P+,2TI5_-S7%%EC@L;;., $  #(2YSS    %)C2
MJC?X-0W5VQKQZF(E9#4_9F%U>K<V+UNFF!+MU3.XM-6(B[A>IPW3QVKBWFZ:
M-+A1GBWP!   8'>$F     7)X:^F8_ZC-SH=UH(O=KOGC814O*::=NRLIH&E
MK 9<[*P2OOA,/_YYA*9EFD\4  # ^W'J P  4."*RB?D43W=*XB3,>1",07T
M&J6!+6O2 Q,  !0ZG#<#        L#5"3         "V1H@)        P-8(
M,0$       #8&B$F         %LCQ 0       !@:X28         &R-$!,
M      " K1%B @       + U0DP         MD:("0       ,#6"#$!
M    V!HA)@        !;(\0$        8&N$F         !LC1 3
M@*T18@(       "P-4),         +9&B D       # U@@Q 0       -@:
M(28         6R/$!        &!KA)@         ;(T0$P       ("M$6("
M        L#5"3         "V1H@)        P-8(,0$ P'6O=(EBYO90\G%S
M"\ >CI\\;6X]QR@  ,"5(L0$  #7O5H!/N;VEU_.F5L ]G#L>)JY]1RC
M5XH0$P       ("M$6(" (#KGD_YDN9VQT^'S"T >_ <DYYC%   X$H18@(
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M  #D!T),  #@U1[OUU9M@OW-D.69B,4,+0?RB'$L&<>4<6P9Q]BS3W2T;@$
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MT#/"3*.WV:?+OT\?9GXAHZ<FX*TR]K3,*#B@K'JUKV_V4B:\!   UQ(A)@
M0 8'DXYIU^Y$1>\XH.A=2=F&FLA?WRT8H=N[OV'54%",T#*DMI]"ZE96[9K^
MJN1WJW4+  # M46("0  <!E&3\VCQ].L&@I"K4!__12?:-60W\J5+4%/2P
M8&N$F    +"=(D6*B--4    >#BL+0        #8$B$F         %LCQ 0
M      !@:X28         &R-$!,       " K1%B @       + U0DP   #8
MRB^__&*5     #="3    -C*_OW[-6K4**L&    $&("        L#E"3
M      "V1H@)        P-8(,0$       #8&B$F         %LCQ 0
M  !@:X28         &R-$!,       " K1%B @       + U0DP
MMD:("0       ,#6"#$!        V!HA)@        !;(\0$        8&N$
MF         !LC1 3        @*T18@(       "P-4),         +9&B D
M      # U@@Q 0       -@:(28         6R/$!        &!KA)@
M    ;(T0$P       ("M$6("        L#5"3         "V1H@)
MP-8(,0$       #8&B$F    ;"4A(4%5JU:U:@     A)@   &PF+2U-%2M6
MM&H     (28         FR/$!        &!KA)@         ;(T0$P
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M4X28L"5"3   "C?.!0  \%[&B" C/)X\>;+5 EP>"_L         L#5"3
M      "V1H@)        P-8(,0$       #8&B$F         %LCQ 0
M  !@:X28         &R-$!,       " K1%B @       + U0DP
MMD:("0       ,#6"#$!        V!HA)FSGV+%CNO/..ZT:        "CM"
M3-C.D2-'U*9-&ZL&      " PHX0$P       ("M$6("        L#5"3
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MRK4#7=M#BDXXXGH+\H2@&:0=TJ[O71]UZM=49<\0,N=>+1@Y7X'A0]20864
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M_E^J?,--JCSTE)Z.>MWJ'NY4VLY/](^]/32E>S7W'U!:G+Z:\E=5S.'JI@
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MJ0  >*<%"Q:8V^[=NYM;("<(,6$[A)@  ( 0$P  [T6(B2N1[05W
M + #0DP         MD:("0       ,#6"#$!        V!HA)@        !;
M(\2$[9PY<\8J 0       (28L*'X^'@U;=K4J@$      *"P(\0$
M8&N$F         !LC1 3        @*T18@(       "P-4),         +9&
MB D       # U@@Q 0       -A:D3]<K#*RL7M/DE4"O,_--Q=5);];K1H
M    %#Z_G#VG@XG'K!KR6]3R+\QM6/M.YA;YKUS9$BI;IH15NSX18F9@O&E]
MMV.OOO_QH XDG]2B#7NL6P#OYU^VF!K7]5>C>E5T6ZV*JEG=S[H%  HWXV+F
MD>.G=/C(*:6=^54[XU.L6P#O8IP#&'S*EU25BN6XR G :QT_D:;ML7OU\][#
M^F%WLE;')%JWH*"</!1C;DM7##:W*#C! 6454MM/(74KJW9-_^OJ_STAILOF
M;W_2QJWQFKW\1ZLELX:U?%6R^$U6#? N!U)2M?O02:MVGG^98NI^5QVU;5Z'
M0!- H>+Y8+-FRVXN:*+0Z]?^-O-#3H-ZU:[[WAL "C>CT]*FK3]I\<K8;$/+
M-B'NBSG(?X?V[32W%:O6,;?(?[$_I^C(J5^MVGE&J-FQ99 ZM*EO^__UA3;$
M--[ 5JR-U3\_V:+$$V>M5G=@V22DNFH$5% %G[*ZZ:8_6;< WBWE\ DEIAQ7
M7'RBOMUQ,%.P>5^+ZGKX_B:$F0"\FG%1<]GJ'1<%ES4KEE;M !]5JU3.K%?R
MOU7%.#^ ESG[Z__2AU'N^.E0EA]TC$"SZSVW<SX X+IB7)R<MW2KWEX0;;6X
M&8%EW5H5^>R/0F??@10=2CZNG;L3]<WW^S/]OS?^US_0]4[;]LXLE"&F\2'E
MI;=7IH>7QH>3L!9U=$=PH$J7*FZV 86=$6JNV;Q#<U?LL%K<8>;@O[1D>!D
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M@T>Z-##+QNK_!Y..F64 R _&5#$9.R\18 +YRP@R/1<LC8L'U^+_O->%F$:
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M"3%SA#<RP'XJ^]]J;K?&[C>W % 0]B6>,+=<V 3L@W," 'GA8*)[X1#/B"\
M]A!0I;RY+8B+E==]B.E9 <E8$0F ?90M7=PJ 4#!\2STQX5-P#X\YP0G3YTU
MMP!P)8X</V5N_7Q*F5L ]G!+L:+F-NW,K^8V/UWW(>8OO[@7#:E7@P\K@)U4
M\''W@EJT88^Y!8#\QD)B@#UY+BIX+C( P)4X?,0=8E:K5,[< K"'2M:(BYWQ
M*>8V/WG%<'( ]L."&@ *FF>8F6=>'@    #YJU@!?O8GQ 0       !@:X28
M         &R-$!,       " K1%B @       + U0DP         MD:("0
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MN_8+;JX[&C97/=^B[B;G/JUX[67-2[Y?PY_JIV!/>_&::MIGO-XP0D]W"P
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ML)A9SG<9Y_+,:F5UTTGM6'E(]1JXXUF/W]YY0S,NN7A/7?7LV^;RBQH!
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M]W^CR4-ZJ&E@*6NG#'S#U+^CT<NRE ):]'"]27Z3_GWK7<^O0XN:E^F%"@
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MZM8M-+W^BMU:1N6#!^NU&8/3YPA-B7Q9K\W=H3-6_=HXKD,[#UAEY"5"3
M    @(+BJ*I&79I9%9==>Y24ZQ2SF*HV;F<MMI.D]4M6:N664[HM..LY+2^I
MPJTJ=;/-XJ&C^[4[1^L$%56%]B,U9>C=5GV'%HYZ0?^).6G5\]BIC9H7=;F
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MRZZ;=%:/K9-FQIRV;G?JS,]S-+J1J[WW*]J<W9OQM92R6*,S/?Z,7QF?"P
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M?5!QZX>IW@V5%?9FC'9N6WS^BH.+;X_I^G+G2:T8TB!GW:]-KOMZ?9["C3?
MR[(>VX[/-2C+KN"_*/ZK.5IH7-G9]+$6;$MQ-]N);U=-WG]4ZS), BSC3?RY
MKQ6]_PL-#"YNM0$ D$.G=VOSLO<5T;M6A@MCW101N5!1YH>2LTJ8/S]W)ZL7
M7G0S+V):MV4K5?&13RJT2BWUG?2U#E_^$T4.7>[BZ1I%3^^4Y6T7?H4.GZHO
MH[9G>FR_QTQ5NRSV=7_E_@+CU=U??E^0O?S].Y.^U'N7G7<K)[+XO>7H[P@
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M%%3JP8V*M%$H\$=^\4JY#[DB*.$V!8DQ(@1(PB$D000"0:1U_<_,SH9-")!
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M[U9@4<MOY:BFEL->5A=W'M"MTS3QPZ\+=.AZ49/EPG2.(W.FJ97/Z6OL(0P
M ."="&(6!W?448@[<?RYDSISUH[H'3^D!'=E\:;U5.N.2^7Q<JA4Y0#5LI=T
M[*0*K^.$&9B<JL7+WU8'S=3 ARLI^(EI4O_W%#%O0@[Y/\S\(*]J9O3'ZFLF
MT3==8:A\_BFA.ZK>G1GL=0WI*FX]3 "@."FI:B$M/0KH)"GIJ%G!.F\<_@W5
MUKV?WK!6,5';=+)NW:L8 EQ>E<KE-<=BX3)S50]Z,^Q"^I=Q$_5)W"EKZ>HX
M=6;S?*VSJKKGA_Q^O/QU4YD*%W):>A[399$//80!  "\$$',XL!13?7;-7+-
M>Q:A.7-2KL%&?@IMU_"R>;>RG&#M25**.XIY-ETG,E,[76.>IQPY=39QM>;.
M_56]HD_9O0SVZJ/1O=2PAF< ,T/QD1_;P]+,RN1/JO^@GJZ3),\\H 7*H3+!
M3^A9=_#THMQDZ4J.2Z3'"0 4(0[_YNJ>.40Z5DN7;%;J9:]?G=?QM!-9"_@X
M[E&; ?8^2XOURJM)NC?H0N&8RSNG,S^=MN<#%%"YM#WOK4K(M_4@C<FW8>4G
M%+_ID$KGVWX^OQ\O?SDJ5=>][IZLJ?MU^)B[&KDGSQ["/^O'4V>S?M\  %<G
M8Y\VSYBBQ8GY?<Y[+<SSY8V*BARCGE5[:4&A;YMQCKMYA5;/"%-HCXA"&@%Y
M.=ZV/3DPOD?;5LW5E&Y!ZA.9P#XZCPABW@B<1[3SBVWV@N%<@G8G9\WSZ$SY
M6NLW7:A.?F[W+AW(/"$H*?]V+VE\9_.$89O6?I&@LSJE75'+K"(T/IU?TROM
M[G%]&3SS37H>^!HG6&U?'.0:IIVZ4LLV'9;3>53;/IZG;\PV2ZQF=7]&L^,R
MLCV.9W#S?\HX=2&PESGD.DLPU&,XGG.?5KXZ3+..E5:9*YU0G/Q8_5Y^7YNM
M8C[&\Z2;4S^%//>$@BXY).^\4G=$:XN])!U7PJX#'H'&/&YOZ8?TIU?L]\E\
M/P:-L7-RGM>QK9\KH?0=KHKE&;NT8' #U>H67@SS@0% $6(.D1XQ4?WL"UAI
MD7/T\=:CES@@-?8%FZ?I[2^.V<MN#I4):JZGK.#4E?9;A@.).G+<O9\\KL/?
MN7(D^O3_B]K4<%?LN]ZR[C^SR+=AY<:)6]RG"E]^\U7D^\Y)?C_>U<J:GB8+
MSQRJVJHE4?$>[YM39[Z+TT&G9P_A%"4D'K77<>KGTR>5>?ARR9Z< (#LG&E?
MZIVPJ4IH^(R>\C^H!3UJ6L7JKOQ7LT #5<[$CS2P65L-'#%5,79;X3FGY,B!
M:M6]NUX8]ZG2[-;K)[?;8XZZ>%VAV3^K^J]KV^FSQF/TRMIN_7D&B,WGR;:.
M==]<?,K.!"T(>UR]POZF65M)/G<UKN<1&J[H?SJV:I!J5;]/ R-WV6T&,\]C
M\[M4*W2:XG\]K*C!0:KS< ^["J5+VL)^:E.GO%K.V.DJ+E.ZKKJ,^U@14UKK
MR(@&"JY:19W&_4]]IWRFC\8];5?/-!YK:!>-=B>,-RNECNBBEU:9>94<*A44
MIJDK9JEOHY^,_WCWJ>G0Y2K5_ADU+_FH\3@?*GSF0BW:L43/!9W(]CAF<+.%
M1J[:K?@9G=1JQ&*[W=C.Z4^JP^ PO5#W2<W*W/[%&MWL14690[G<">PW/*]6
MU3U^)*R_FNHY/D+;W!7(*_;31V^VT<TQ;ZEGU8IJ$K9?3[WSJ::&U7<%#K-+
M6Z:1UGHS/7[@=FF)]?ZTU>RXU+QO;^;[]+%&FD%CZ[-Z3"-GK%;JW>W4ZJ+A
M[P" &YW#IX4&AW^H4=;%PG6:T;V_WHZ,5G+F12JSET2T%HQ_3E-V-=&0;K4N
M/@ KVT!=AW<T9AJI0ZO G/=;F=P7),T+9 M=>:(;C=9;SS7*'()^8;2%P3-8
ME>-%QFS!K5RDC;G\Q5-#1J*V;]MC+Q@V16MGRH5>@Q</*W]>K\W:IF/60UQ\
M@3'QA^-93P"=*8I?]4^]UF>48NH'R/=FNSU'5_EX>;T@:[R#%WK%>EP(=A[7
MD?W'K=8L+OGXGNEI?M:1 RDZD[9-ZZS1'145TF>$'0 VW[>QFK'9#)J;W[%M
MBK_5WQI9XZCQE(:^W-I<R<XI?MXX =^HR/E?66V6U+?4Z_%_&L>2]C( (&<9
MVS5GR!)5>V.">@?[R>&HI2X?[U7"[B\UTKR(Z3M<$;O<HP8]_@[LU8(QK72I
MI&WYP5&CE^8<V*'Q[E&3A:JD_+M':'?T>QZI=:ZGW&Z/613X[]KD_OP,/OT_
MT]?;_ZZ&94L9CS%7L>MGJ(-]L=6Z[5"$NF1>*'8]C^OS#U#(RU\JUKIO+L)K
MUG?G6T5-,8_Y<#5N^LU@S]^0]B6EJ,OP2#4/KJKG>[L.UE"$&#N,V;V?UN2M
M[H!H#AI-T*(/!BC0"L3"FW0=--N:QBX<;$T!H"!=_V."\SH6MUX[=VU21)8>
M$>;%OCYJ$M(\6RJ4K)R)$7KN56G,A[T\BM;9TI9I]/@D->_340]HBR+&OJI9
MUK[1?.PAZMJNB?S=^T'S(EV]'EKB6K+U4?A7/76PVQ\TV9T/VQ*L#IU]M63A
M&GO99E83?[>]*MF+%Y@73]MJX,(+ 4Q/U5[^3&]IDKJ-VVBW9&,6HXD>I$ K
M2'A042]VS7JA]BJ8)Q>K1S?+,8?HKW'3U/J)5W307LX-U^/=K2T7O<X =9BY
M3",T]4(U<%O.K]M<?YYZ'1BJ3A>U3U?+-?US>/R5FOQX%6,^7<FKINJ5L+>,
M[Y'Q&<^<K.<?KY49W':F;=?2V6/UXO1UQI*?0OJ_JH'=.V3]?IF!V87O:^)0
M\[M85QW&3-.0A[_2,^./JU_O^BIW<U4]V/)!52JDPR>."0!<J^517^O5?VW0
M@*X-U"+T?KNU@%G[JGY:_X<9&OMXM:P7(<U>=<\\H=%[>BKBRU=S#F*=WJ@/
M5OOJSUUSN("97]S;L:&1QD?/] BV%9+3T9K2XDG-JOV>HG(ZABELN=X>LT?F
MFVK3_2WIHF,)L[=EF-6AZ9+'&>;[WF>>JOQS=.X"F)G<C[U5H5-6:';W OQN
M%)*#A],T;,HR/=4X0*\/?<IN+1@$,>'US*[[[PX,TXQ+!C*;:.2*^7HNR-OS
M@!4_G+  *$PW_#%!89SH -<)QP0 KE7A!S'--"/O*ZS/<0W,*4B9FR!F82"(
MF55>ML>]KH9?_!E>[C:#>?&Y7V1UO9-3@/.R"&)>BQO]O4(1YTQ9IE?:OJ0?
M>Z_3[NS=\P\=UB)KJ%1-5?.[Q74'  !N2$Z=B=NOV^IEZ^4!  "N#^=A;?KP
M0R5W:J[ ? A0.M-V:MV*:1I9OXFF;#ZFLXGK--NLDU"UK$('SU1<6O9B;6:1
MF@A-Z6;GWZP?IMD;]^4AAW2V^U=MH)$SEBG>XWGRODUF^I+LZ_QBWW8EWK8]
M!G>NZ8N*\AHN=YO.Z6#,#M5L%I@U@&D6[;&*+-DI\,S/;-5..UU.;KA3$'6P
MWR,SA5YDEO?(&FDQWWX.X_$_B#VJ]*VK%9.;G)Q% ,?)\&+&?^#].[4A]2<=
MW!FK@QF>_RG-_]S;M6WW6768\E>%^A1DIA$  /*;6>1G@G$ VD"C5QTT]FHG
MM.M(53WB[RV%>0  *-Z<R>L5&?F3:M6H?(5<U3EQZHQG8.ETM-YNVU3]^[VB
M):G&,<"FQ5J3?I_ZO+O5RK_XR*9A&C![J\ZXUC:D*S%RE'H.^DH!$W8HX= I
MQ?Z[F1*&/*A@=X#LLM6WSRMUU>OJV7V9*KRRW;C_<6V.[* CXWJHG_MY\KQ-
MYOGYIWJMVS^5WG6)=AO;%/6"G]9^LE272?YF\[;M<:N@H"?_J!#%:FETO,=C
M&S*+)^9TVT%M7UU)38(JV T&,_7 :SW4:Y&/7MI]2@D'$A31-4V3PU[0W*TY
MY,:^B.OUC)V^1[6>F^?ZS*/?U@.QKZK3P)EV06#C?5PS5>\DMM#4 Z>5L#U<
M3VJYQH[XRKAW\4 0$U[,3+@[2HM7O*>>MW^FGG7*VU<CS+]&>BWJ)P7TF:.)
MW>M>Q4X% (#KZ;]*_7:C8K1+"]9\K8-QRQ5W9[!\.3(# , +.'7V:)(2Y*=[
MJU;,>^#$F:KX+4D7 DMEFVG$]F1%] \V%DJH4FAG=32+!!G_2@4\K)#:?DI;
MM%[QF4'/G5KX5H34J9O:6,5AC?7N[JP!5A' CAH??4P)'U]FJ+0S61L_6J8T
MW_L5&%#6:#">LU%G=6CJ\3QYW::,K_7)J$GZ<?AD#6Y<V;5>C2<5]@<??>51
M9#A'WK8]F8S[!+;*NATV9_(V1=W>0NU\S2)Y.=Q6JTF6'KJNH/<N^03?[\I3
M[JBLD*Z=%)I3$#0GSGU:^6:2VH]Y3D$^)8P&\_6T4M=.C:2MT_3.\GUR6N_C
MU[HW-,C.:6V\3\'/:MB80&/MXJ&XO$[<L(S_E$&MU*;?3&W*,I3\*TWNUU6/
M!ID_:@  W&AN58U6_=37K(JY<(+>WQ6B/S6N:-\&  "NK_/Z\=!^I2E  96O
M4'LA]2WUJNO9X<;XJUY+O3Y-LU?(.^>Q _K^HD!<"=U1]6[Y:*M6QIBC."[#
MX:LZ31Z03XL'%9 O!7"=.A.[0G.W!JMMB&?J&X=*50Y0+7OIDKQM>SPYJJE^
MNT;9AHW;P\6[#U77BX:4YSR4W.%;5X\T"E;3!P.NJI.5&1A=N6Y2MN]2):NX
MD)2BA,2C=BJ!9"V=OUJ)F2-52\BW56>%7*^<K(6L>+Q*    KV)>76^O$?/V
MNB[,,:H    ODJ&4Q"1[_@I\ARMBURF/#C?&GSF4^&D?>X5<2MVOP\=<N0]=
M 3$_I7UW0#]>%*W,3>_0\@KLMT";IK27K^.\CL6MUH*)(S5Z0^X'6ELRM^F$
MXJ/7*LWW;E6I9/82O,!1J;KN];47+LG;ML=3254+:9FUQV3F</%[%-BLI7QR
MO,UC*+FI='T]-V^CQIM5[,V\E5%S]?9+;VJ3??/EF8'1M=J4TW?)_MMD%A"R
M ZYI"_NI39U.FA(9K>0L:?>*/H*8        ^<7AJ\!' JX^X%+Z(?UIPFOJ
ML.<]O3]OEZL'7L9NK9Z_4FF-_JC'@[,%T')DUI$PB]X\JB&?I:A"VT$:V]3/
MOBV/,O-#7@MOVYX+'/X-U=8<4C[]_VEUXCF/X>*_4YF@YGK*8TAY3D/)+TA7
M\L9PC0SIIU4_^:GUH!$*M6_)%8] =LY*RK][N*)F#E>(UFG6B"?5R@QFKDK(
M0\&G&QM!3       @$REY5<CP)Z_&@Z5:=3F&H;X.E3J[G;J]^*?Y+=WM*N8
M3YW>BJGSLA:%ARGPBD.RS^O8YDD*:V86O9FGB-'/ZM&@NZYC ,C;MB<;]Y!R
M:ZA^@I(]AXMGJ5)^).>JY";G46V;U$NM_GE:G5;.TXCN;118.:\%&Y.4=#3#
MGK^4<O)__._Z:/=.14P9X@IFAHW6)W&G[-N+-H*8        F=SY)W,35+J"
MTQOUP?R$R^>PO(A9S?LMS2W348-?76(/*3;K0K17H%7TY0I.;]7<0>.5W'^(
MPJRB-]?(45%5[O/+14_!2_"V[;F(>TAYBC8M7Z8O]LHC%VJ%"T/*OYBG-3D-
M)3=S=&Z=J>'AQ]5W4)@:YN8SRL+]?8O5K&F?VI7(/9W3P;C=68L#E;Y'#;N_
MIIGK9ZB#[QK-_2SVRL6#B@""F-XD8Y\VSYBBQ8GG[(:BP.PROE%1*Z9I9/U>
M6E 47EO&=LWN%J2>,[87<)?M="5O7J'5,\(4VB-"R<4KU04 %%/F,*3I>B?/
M)SM7SYFV4^M6S=448]_6)_)*SVOOUR/'J&?5[/OU4XJ?T46UNH7G</!] S&.
MQ[;E^OTH -;SS]?LP4U<S^_<IZA9\Q6?EA\G:0" W''8PXA3]/VAX]>P+S#V
MC1]_KK+U/(O/Y()5A7JKRI8K?55!FYP+ UT+=R!OL=Z-_"I+L,R9<4KNDC>7
MXFW;DQ/WD')MF*3)N^NIOK^[%Z7[NR"ES?R[/LQQ*+F[$-35,GON/JW!YO-O
M':5^+[^OS8GI]FW&L=?^U8K)J*0RYC'!_)T><0A'9N7VXH(@II=PIGVI=\*F
M*J&.K_9TJ^11C:J+9E^B6[ S,4)],M>S_[PLV.5,_$@#F[75P'ZO:$F^_FBY
MG5-R9*^L[X'U5_.B$X\<WZ_ZKVO;:6\\T3)?UT"UZMY=+XS[]!I^# $ -PQK
M&-) O;_[03W3N9H.YKA_\_RKJ9[CYRIJ5=35![B<"5HTI)OZA_U-L[;^;#=>
M6N9^?<14Q=AMA>M2^WWC+S^.@8SW8T'8X^J5R_<CWV4^?Q]-7FCG^G+44.BC
MMVC5D"'Z(#:E\(.J %!<6<.(_3RJ0F?E_/$''?RO,7.IWH!6)Z41ZK?Q'E=
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M0F']@Y46N4 ;D^W.:!?=/YO$XSJ3VRO5]F.E?7= /Q:[J]LYX_@8      #
MVZ7NU^%CV8<ZYX+SH+8OWRJ?_I_IZT/F$//L?QLUHG%%Z72\-BZ*E<]]U75'
MEFA1[JN37W"' IJV5@??75HRXBF%Y9CW,7]X!OD<OG7U2*-+!?[\=&_5BG*8
M0[_CUFMIJGO90_;JY/9[)]^[5:52]ER>[N"N1W"T(.Q)4DIQ3#64 X*8
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M!LY4O!5<-9YCS52]D]A"4\W[;@_7DUJNL2,NSMEI]<:L'*!:J6NU,<Z57A<
M     -R@'+ZJTZ26-HT8J;<CHST*!IG2E;QQGM:DUU6(M_9N=.[3FOD)NO>%
M< UM7)F 70YX3W!%5F6UV6^[DO]NG:H7GVBB7N.S55B[$F>R-GZT3&F^]RLP
MH*S14$*5&G56AZ9^2ENT7O%7Z@UI7E%Y,TGMQSRG("MIKEFDIY6Z=FID;-,T
MO6,FYK6>XVO=&QJD2M8WVWB.X&<U;$Q@CE]T1Z7JNM<W5DNCXW7&;@,
M #<BNWA19!\%)$[UJ,#>05,BM^A,[4[JV,B+@X..6NKX8G\UKG&AX!.R(HB)
M7#"#@6&:N/)+3>K_J+%L5O1Z7KV:/::1,]9EN[IQ"=85D0?DT^)!!5Q%(1UG
M\C:M7#=)O>JZ?X3,OTIJ-6*Q<6N*$A*/VKDMD[5T_FJ/8>\EY-NJLZNG:':E
M*RN@MI_2OCN@'W/Q$@      @#<K)__&[=5E]!(E'#)'=YI_2S2B>QL%6AVB
M<",CB(E<<_C45\?1\[1YQ2SU;>1GM.S2DG$=U*KW^_9P[LLQKX@LT*8I[>7K
M.*]C<:NU8.)(C=YPZ6P5%YS3P9BUVN0[7!&[3GG\$%WXVS2ZF<HXJJE^NT:N
M8>]U.FG*1=W'+V%/DE)RLQX       "N"X*8R".SFE=WC9BW0U$SARO$;-HZ
M+9=5ONTDM8,?U9#/4E2A[2"--?-?YE;J?AT^YE'$YR(EY=\]W-ZN=9HUXDFU
M,H.9JQ*H0 X      ' #(XB)*SBGY*AU2KZHHV(Y^3_^JF:NF* 0<WCYQEU*
MNVQGQO,ZMGF2PIK]4^E=YREB]+-Z-.BN/'X!DY1T-,.>OQ1SN_ZNCW;O5,24
M(:Y@9MAH?1)WRKX]![4#Y'<50]P!      !0.(C<X,I^VJKMR>?L!4\.E0IL
M917GN:+36S5WT'@E]Q^BL#Q7V2JA.ZK>+1_%:M:T3W,8NGY.!^-V9RW.4_H>
M->S^FF:NGZ$.OFLT][/8BXOW9!Q5TIX4^=Q777?P/P$      ,!K$;I!+B1I
MR?RM.I933TLK$"B%-*DKG\M\FYS'#NC[5'LASQPJT^AI#3:#I5M'J=_+[VMS
M9F5TI\[N7ZV8C$HJX]RGJ/D[/8:..U0JX&&%U,XYR.K:IF ]U2Q09>PV
M    >!^"F,B%_RHFO+TZ#IVFJ+@4N6.9SK1M^N#5D9I58Y!>>N8AE;):W;TF
M]^CK/6ER9NS4XE7[I$K5=:^OE!:[1?%IYXT[IRA^\6>*,2..9J[+M&3%1,7I
MC*.BJMSG)^WY1@EIYW0V;HFB$L\9W]1[U/;%058.SK2%H]2[V5UVA?+R"AYU
M6'6"*ABW.)6^9)S>RRSHX]39I/\H9L\#>O;)X&R!2N.VHTE*\&VI)M9] 0
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M1>C]=BN Z^W@X30-F[),3S4.T.M#G[);"P9=T%#\9.S2HHE+5>/],00P 0
M    ;@ $,5&,.'4V<9UFOSQ1![N.S6&(.0       +P104P4'\Y]6C,_0?>^
M$*ZAC2OSY0<      +A!$,=!\>&HI8XO]E?C&N7L!@       -P("&("
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ML8>L*0#OD'SH1VM:O>H=UK0@%8D@9G!M/VMZ)-4U?!7 ]??M[A^L:6'\D &
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MA3GCTTW6O-F9L# O5!:I(*;YQHWHW<2:_[_%,70M!PJ1>>' ?;+2NUMCNQ4
MK@_S0HIY0<4TY]\;K"F PF&>W'RP8(LU;Y[<D%X&0'[SW,]_LF2;-050.#Y=
MLCDS%V:[5J[Z-(6E2 4Q37\(O<_J6FZ^H=,CUMFM  J2V<O)O'!@,B\D<+("
MP!N8%U3,"RMF!=,O-WUKMP(H:,NB_F.-C#)/;LR14@!0$/KW:I&YGY^_W'7A
M!$#!,H>1FWGG36,&MK:FA:G(!3%-@_L\RH\94$C,WA93YWQN73@P+R"8%Q(
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MDF-0$RBJ*E<HJ9"ZE54_L*KNK7GG#;5_)XAY!69@\_B),_82"D/-&I6U-Y$
M<F&ZJ_+M]*@ @!R8)SF'CAS7L1]/:WM\UEYI0%%4ODQ)U?2OI$IWE%5MXYC,
MVWMD $!^,??Y9D]TH"B[T2]($L2$U[GIIIO$UQ(       !N#GL*
M %Z)("8         KT80$P       (!7(X@)        P*L1Q 0       #@
MU0AB @       /!J!#$!        >#6"F         "\&D%,         %Z-
M("8         KT80$P       (!7(X@)        P*L1Q 0       #@U0AB
M @       /!J!#$!        >#6"F         "\&D%,         %Z-("8
M        KT80$P       (!7(X@)        P*L1Q 0       #@U0AB @
M     /!J!#$!        >#6"F         "\&D%,         %Z-("8
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M3]J-ACRL[TQ)5NQ1:]961E5JUY".1FG-]I_L-MN9&+TS^H ZCWQ4E?DV 0
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M        -_K* 0       /!J!#$!        >#6"F         "\&D%,
M     %Z-("8         KT80$P       (!7(X@)        P*L1Q 0
M  #@U0AB @       /!J!#$!        >#6"F         "\&D%,
M %Z-("8         KT80$P       (!7(X@)        P*L1Q 0       #@
MU0AB @       /!J!#$!        >#6"F         "\&D%,         %Z-
M("8         KT80$P       (!7(X@)        P*L1Q 0       #@U0AB
M @       /!J!#$!        >+6;?C/8\S#\D/*3OHY+UM[D8SIX]*36QQVU
M;T%A^6;1$#W0::J]A,)0N4))A=2MK"J^Y77_O7>I=HW*JG!;&?M6      "
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MMP       .2?(AG$G![QI>*23^B>.\M;.3 !%!PSD&D6RS*]MRC62N,
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M"F(&WNW*OP? .[B+;)G%?0       *Y%D1A.#L#[N(.8        UXH@)@
M      "O1A 3        @%<CB D       # JQ'$!        .#5"&("
M    \&H$,0$       !X-8*8         +P:0<RKYM29S:\KM/[KVG;::;?E
M4MHRC:Q:5K4\_EK.V*E?[9NOZ*+[#U)4VO_L&YTZN_]CC:QOM'>;H&UIY^WV
M:W%848.#/)XO-W_F-IU2_(RV6=KS]#J+,^=!1<V*TC%[T9*Q2PL&-S#>QPYZ
M9_-1XY,&       H'@AB7K43BH]>J[34M=H8=\)NRR6?]II\*%D1_8/MACPR
M[C\Q^CV%VHM9_:S$SS_6DE1C=NNG6K0CS=5\S0+5]YTOM?G :24<,OYV?*P.
M]BU2$XU<D>)J/_2#HCZ9H Z^9GMI!?9;I*@I':VUD%OGE;IFFM[X[IR][/+K
M_L\U8^$N8VZ=9LS_CXZ[F@$      (H\@IA7R9FX0C.GQQISL5JZ9+-2\]PM
MKJ3*W%[6GL\[1YG;=(<]G]6MJO%8#U<0L='3ZE3/Q]5\36Y6N=8OZ?FN]57I
MBM^8<O)O,D!CIH4:]S+]3J7+5[#FD!MF3]KY>OO5F<H>?K[Y[L?4KW-=8^Y1
M]>OZL"JZF@$      (H\@IA7Y9P.QJS5)GLI+7*!-B9G[35W_3A4ZNX>FKS]
MM!+FC5)#GQ)V^[6HK(:/!ZF4O71E#I5IW%6/^OS.7D;NF ',3_7:'_NY>M)F
M5[JNNKS[E1(.+='0QI7YSPL      (H-XB!7(R->:S>G*\0:,FW:JI4Q!R^?
MHS!CGS;/"%.HE1NR@4;.6*W=/_W7OC$'SA3%SQ^CGG8NR=#!X=J<F&[?>"G9
M<U>VU>RX#/LV4[J2-R_3@O$=+JQ3/TRS-^[367N-@G=229LC-*5;3>OY0P?/
M5-Q%>3O/ZUA<9.8Z%VUC]IR@@Y?IF!D 3%SFND^67*"Y>,W9'R_T'6W;8^<5
MS6G]3)??SE_CIJEEEL>=IOA?LW]&01JYZK"QMO%8FR<IK+E' '-A#S6VUOFK
M9D__J\=]<LHM:F[+,LVV<F::Z]14S_$1VI;YG3'?GW69MUOO>\J^B_-N @
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M>_::/*R$'\S@Y%5N9X'PW)8< JJVFP."U=J=PW7K6QK8K)>FK$HHQ%RH
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MW46)3NO$Z6LM.E- KSG?M_,:Y'I;S"'F3^NU>1^K;R/W^KNT9,1$K4RDN \
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M^4>%V$L7%7[*2%1\8KI^C8M41-PI5YM9F?QO0]37"I:75Z5R.52S!P
M\"($,:_HO([%SM9K?=[1$;OE(HX::M:SK;U@%O@9IF%3OM0Q*Y944O[M7M!(
M:PBO.\!I#G/^5(MB[:"2(6WZD^HP8Z=^546%]!FA+E: *44QX\9JQN:C<IJ!
MU,1MBK_57]6,3\UYYJ0N])_SZ.'I/*OT8^ZB,N[@HD.WEKW-V!+;D8-*34M4
M<ND'+N3SS-/0=6/[]W[G\7ZDZ)M-<?;KS>Y_RCAUH6=J9K#V;+I.9,8CW=OO
M4)E&O37&7?%]ZS1-#(]V/6[&/FV+^YUJ5'>]BBRO/\=MOX;7G/J1PO_YF9(S
M_J>S\5%:8A5:JJLN;_96B!7$SOUVZHY@M72O=V"'=A](S_;9_ZP?3YTU/EV7
M+#UQS6T^?5@Q47$Z<ZGWT=B64D'/Z*676UM+2GU+PU_]5(EF4-5Y5#$K$U3*
MURQ#E:H(XWLU>^,^*RCNS#AEO.N&1G_4X\$5S#D       "O=?-K!GO^AO33
MR3.:%Q4O?[_R"GGP'KLUO_Q/QU8-5^,_3=+NC#/Z8>/_:<;43;JU90<]Y%O"
MM4K:,HVL$Z*1RW>ZEBW&NC&?:L[BTFKQYX;RN>5.!3=[1%5O/JRE<]_2!Y\>
MDF^7/ZO-[_^CY,"A&A764^WZ3=*8)VKJ9N/>-Y6IK18=6EGKK]V^3ML7S%?,
MN0JJ'MA4#6N4LY[SQ49_493KR0R[M6[N<=7N>:_VO])1PU8?MMM3]/6"I3IT
M;SNU?B1(P>5^U/KH>)5NT$+!?K44'!*H:D9;U.??*"/C5MWA?Z?N"JBFVTK<
M9-\_!];K;:"1"S;J![LI\_6^&VD]UV,UC6VT9"A^1A<]^>H:>]EHV?Z)5AU,
MUO:!HS7/W2G5VOYMKO?5KY+N;ME.+:K]3DEKUBK&?-ROSJFR_P,*;7R/2IFK
M9W_]&5NT^+W-63\7@Z.2?^Y?\W\3]/G,1<:6&*J/T(115;5M4@\]\TJD?O!]
M6B-GO:/G'PU0YJ/?5/[*VVDRU@L(OE]EC^_0IN\W:MV>WU3[L<YJ_KO-FK?1
MK)-^1@<__UR'W>_;+=7T8,O[]>N>+?IZZU=*<@:I7=>&NFG=2+5XX5/78QK,
M]_%?!P/5O4UME59)^3S45"WJ^NJ7F"^TXS^?Z:/Y!W1KM7O5L%T35;GE)OV6
M^H,J].BC1S*^U-SA7=1G3)3*])JJ?[[24X$5KK90U)7-7^TJ4]7OCPVM*0
M    P-6XZ3>#/7]#VI>4HB[#(]4\N*J>[VWW1@/RR@S.UNNA)>:\614^>I "
MS8@RKDG70;.M:>S"P=84      #@:C"<'        (!7(X@)        P*L1
MQ 0,5RX4!       @.N%(":0MDPO-7M>F^Q%L\)WK[K!&KG*72 )
MUQ-!3,"GO28?.JV$+']QFOQX%7L%        7$\$,0$       !X-8*8
M     +P:04P         7HT@)@        "O1A 3U^A_.K9JD&I5+9OS7^@T
MQ?]JKPH       !<!8*8N$:_4Z7'IRGAP'<*[U[7;C.UUL@5AY6P:9 ";[:;
M        @*M $!/YPW&G'OQ#0WO!4+V)&MY7WEX         KAY!3
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M$ J"UTA+.Z6?K;ES.KA^@1:DFO,!"JA<VI@Z5.KN'IJ\_;02Y@U48&F^N@
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M=::G*P      0 $AZE(<."JKX8N?:&K;8UJTDKR-^<>A4C6:J-7C3>1/ !,
M     *# $'DI-DJH4O!?-)2<C0       +C!$,\"        X-4(8@(
M  #P:@0Q 0       '@U@I@         O!I!3'APZFQ<N'I6[:+9<:?LM@*2
ML4_;5LW7[,%-U"<RH5A43'<FKM '\[?K&.7A 0      \H0@IC=S)FA!CYJJ
M5;5LMK]>6I!XSE[)=$[)D;TN6B]T?+3.V&MX%?-UA3VN7F%]-'EABMUX><ZT
MG8J:$:90]^OK-D8+HG;JF/.X8E;]QSM?9S:.&DW4HLP*O3ATIN+2SMNM
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MWX/+R-5K=29KXT=?Z][0('N=$JH4_*R&C0G,X3^:G1,T=:TVQEUM]DX
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M:F3UB+R6UVINZQOJ5?>4UK[<R-C&\@H>M4>-YH2K3V:0U695;??-(;@)
M  " [&[ZS6#/WY#V):6HR_!(-0^NJN=[FSWE &]W7JFK1JG'%\WT\:3V\BW"
MEQ*Z#IIM36,7#K:F        5X.>F$"A,H?2S]?;'P7HW=>>+-(!3
M@/Q"" 4H-.E*WOB^7AMS4)VFAF7)70H      (!+(XH"%!)GXAHM^NY>#9CY
MHAKZE+!; 0      <"4$,8%"XJC154/[/2I_>F "      #D"=$4
M %Z-("8         KT80$T"!^.67_]IS        UZ;(!#$/IZ7;<P"\0>JQ
M$]:T>5!E:PH      '"U;O@@YCT!?M9TWY%3UA2 =SAG]\0L7[:D-04
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MF0LS[$]-K"D      $!^*%)!3%.[5@^I>5!E_7CZ%\W^Y N[%4!!,H>13_W
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M;]P*:_Z.LK=H2.\_J-;==UG+ *[,['VYY3^[K3RSIB#_"IHPHAU#R $
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M        P*L1Q 0       #@U0AB @       /!J!#$!        >#6"F
M      "\&D%,         %Z-("8         KT80$P       (!7(X@)
G    P*L1Q 0       #@Q:3_#YC=E8&E^Y4X     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_1a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_1a.jpg
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M[>!F,"%76(#'ODXTG,!3YIDUYA%PK4754Q9:><Y[^SPCU$:JGF>0=GDG^$P
MQWQ<1!>2O*MCQ7)"8:7WWM),VCY+@^.]IWW>4V>8/RP/@N&S.B"3O6V7,L_Z
M:.FESY0'V_9!D/R418;ZA?+S/FP?;-L'05L61%\:>M+PG#R8MJ!]'Y;GN07O
MP92WS]+Y 4;.&!B\""Q6FIMM#VG/)N 4)2-H=;W;0PJTV?/;%T9!X=R 3"@\
M2+T+X EJ"4ZF;VCO:3^>B3^_3(ZY#5&4(<IO<:*0-FD_([HM=AA!8T!H%(82
M>;::BL;G6$\>14]*P43D_1Q4=%A4N346TKD![232C\@]CT 04Y]!]R#L@_$;
M?N863QW^'V:EX"EOL<.(&P,G!8*$ DR)"42AI.('CH-$G=V,8PBR&K?[T7L:
M3!Y]2-%WG&=K O$5%. 3P/*L?KYM038&LU*\*&>+$X4Y:=-AQ(P!(5(42D/1
MW4,7"19UCA)1*JFCK?Q.W<TQ[RF#H3<W)@::K6+[8R7N SA?5L80B5\XU1 O
M4$?]\#,W>)I?X-[^]@5YK"<*(V<,H(BO&VUNPT7!I=Q_1TCY)9R;>NZ8._+)
MR@OG-H1/*[[^W%ITG(@'F%M]MC4,@[P.'48=1M(S<.;LQS51[BB9'\PX?V8(
M7$EUUDXA$R-01SJW 9_ZHN@N\?CQC'L.V1ZXU.3V77B3=N@PZC!RQL"1H1_M
M, )955T!=4[O_-X/DIP9QT!$,8/WAC&(@:+D^.+%Z->%%S<776B)<5+WWN"I
M0X?)PL@9 S?G7"?V$V(1>C]V<4I X?PO.S?2*&&K:-H%Y,UMT)]^\>'JKB--
M_UC#5>/V"#&\M?QUZ#"J,%+& %!F/Z9Q9N_W^NZ\^]L %(S+K;S%>0'ZC<+S
M7OPRSK^]<@^>D<JV)4:@&X,.\P.,I#&@2$DI4IZ'"C:OE P_,-L2:3R5& G/
M+:\=.HPZ=&,P!X ?V(U!AZD$(V<,.G3H,&^@&X,.'3I4Z,:@0X<.%;HQZ-"A
A0X5N##ITZ/!?*.7_ %]0_LB'O*=I     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_1b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_1b.jpg
MB5!.1PT*&@H    -24A$4@   ^@    %" 8   #6D<8E    "7!(67,  $SE
M  !,Y0%USO"5    .DE$051XVNW7L0T   C#L/S_-)P!@R/Y@6ZM&@   ."<
M$0   ,!!!P   !QT    ^'+0)4F2)$G2<0O]])%"ZBZ_)@    !)14Y$KD)@
!@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ziefmans3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ziefmans3.jpg
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M"_0& WB>1R:303*5PL;&!A*)!-A<#BJE$F:S&3J=KL+^9#*)[>UM<!P'@\$
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MP'$<7'U]Z.WMQ68B@<W-3;CZ^]'I<.PIA^-!\-P*AUZO%\O+RT@D$B@4"@
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ML]DP,C(BA'X"J H/)B%_8L0>?//S\\CG\S"93!6_B<2AB23TN%8;SP*#P0
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ML1:SV8PK$Q,P& QH;V^'5J/!E8D)N/K[R^WR/!Q.)US]_8)GMTZGP]#0$!@
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M *4"2:4"=Y-)>#,9L "V2R6\[NR$0>+]9U2I\$:[#;_E=.(OUM:P4BR *13
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MH\$%9V?#YZA0*,!Q')0J%4JEDO!9(I' S/0TK%8K3IPXL6L[#,- H5"@4"A
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M9&3D&5I3R</5(!)LIAQ"K%#L%#)10*?1XM43 QCK.0X <*C4.*;30)W-H@B
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M7NQ:+<ZWM.)<JQ6:7*Z\/2"$'&\6B_CSU55<CT1DCW5,K\=;'1WXB<,!$\,
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M14.::8?0B- E+6)S6/A\OJ;GX4'0;'CQTT*CT1R($"F'L]6**,L"A<).@12
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M/:_.,;_ZU:^4]ZFWMQ>CHZ,U]V&3L]@D9T$0X':[,3@XJ#2"KB<6B^'FS9L
M<"S;;*_MQ%Z;V6S&)Y]\LN_OW<3$A'+0R):GWJ;[^=G/?M;0_7[^\Y\?>END
M4BG,S\\C%HLA'H\KH^7-9C.<3B<"@< _RB$E['VN]SM*""&$O,UL-EM%'[-D
M,ME0GT/6YVMC8T,)UK$R6?9OIKV]';.SLP@&@THFT[-GSVJ&LNS'[_<C$HG
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MR602F4Q&.>$QF\UPN5S*20A+<653ZU*I5,7D+G9[-IM5EA>/QS6'5+"3$-;
MME@LPN/QU,WJ4)<BL>=2KW<T&L6U:]>.?#",%JO5JC0=KE>NS,I9O5XOEI:6
M:FYG#8X/6U:<2J64H"\+_ 0" 24;[K#E9/L%GK2H2Y;#X3!Z>WN5UW7__OV*
MP' C8K&8LOT.<X)Z4.SDO-&@YH]__&/-GU>7O=EL-N5W-)/)8&-C ]>O7Z_Y
M'2T6B\KGR&ZWP^5R*>\O^^RIUTVK+ \H_4ZP7J>93*9F>ZM[I+(2P'@\CO'Q
M\9KT=::Z;)#=+QZ/*V6  "AX2-X)K*6'V6S&J5.GE/8$6@YS(85]_NM=O;]R
MY<J!6ARP@[W>WE[-V[U>+Z+1:$VY"NN=U.@^3?U]4J]!_:N4[=Z^?1O)9!+]
M_?T5%_ZJQ6(Q -!LR&^SV>!VNQ&-1K&\O*R\-E:6[?%X-+___7X_XO%X13:^
MNO_PJ5.G:A[3U]>G]+O=KR4)(82\K1HI&2?_=+QJ_]*]"#H=SOM\^)=#9_!_
M/GF*Q6R^E,VG*Y>^<ASN;V[BQLH+#+8TX[3#4;.,<TU._$EW-\+9#)[E\R^S
M!L4") E8$0OX_Y:68>-X_+.N+EC*P4..X^ R&B$8!*#) >0+0"Z'%H,!IZQ6
M_'&@$P,Z [Y^^@Q_/3V#Z=6U<M"P/!1%E@'(.-/1C@]/G@"_3Y;;8;+@^OKZ
MD$JE$'SV#.NKJ\JD9?7RV,]$28)>IT-'1P=Z>WOQX,$#2)($J5Q:?//++S&\
MM863)T]6!!!E6<;N[BXV-S:PMK8&&:7C0'9,I2Y%#L[-X<Z=.XAO;8'G><BR
M#*O5B@\__!#I=!I34U/8W=T%S_.(1J/XZJNO8+%8T*]QS*2U?635O]5;2Y9E
M2.5A*8% 0(DI,2LK*QB_>Q?/GC^'#"B/I1Z'#6('T@<)B/7U]2DG/,O+RS7!
MJ6@T6E/2PP($T6A4N9H_-#2$H:$A)=.P.@!X__Y])=A1';1CRZO.#F"2R61%
M&=5>36)9JJQ6*5(L%L/X^#B2R21NW;IUK).8U7P^'Y+)9-URY5@L!D$0,# P
MH!DX9 $AA\-1T]2]D4;P<W-S %Y.TP9*96G!8%#)"CEH&6U?7]^A T"CHZ-*
MMAPK)0N%0DJ NM$29>!E(VB?SW?L :E8+*:<=#N=SGWN7=_4U%3==@+J0%]U
MU@M0^BP(@E"3R<N"B<%@L&)YZE+(Z@-"%KRLSI0)A4)*T'!P<% )#*O[:6IM
M&Q8T5#^F>OVJLYT(.4Y:F>^-8I^=1GNF'O1""@M&'56@:;]@G=845K9/$P1!
M^6[<;T +"[ZY7*XCO_C&]CTNEPLC(R.X<>-&W?NR]72[W9JWV^UV1*/1B@Q0
MEM&O'F"AQBYVJ!_#MIMZ );6<V4R&<UM3 @AA)!*7JL%_WKX/.9V$E@*/B_U
M.M3Q  ?(' _98,!O5]?08GZ._WKP/;14E;ZZ# ;\V.?'S?4UK$8B2/+\R^S!
M8BG(]_<O7B";R\-E,.!\2PL\9A-XCH.)Y^&U6&!=B\"HT\/K:<8%APN?-CGQ
M?5<S%I=?X'_X<@S?+H=1T'% O@@4)26 R!6+&.GNPL43VA=J&:U>>XWTWS,:
MC3AUZA0NOO\^QN_<P>;FIO:R6 :D3@>WVXV3_?W*' ,6&/R'+[]$)!+!AQ]^
MB!,G3L#A<"BEQ=%(!,%@$$^>/ %D&5>N7L4//_T4@B HP;=L-HN[=^_B_KU[
M2C#1:#2BN[L;/_B#/T BD4 FD\'CQX]1+!8ARS+&Q\?1V=F)-I\/#HV@;S46
MYK-8++#9[1 $09D0G<UF\;O?_0X<QRD7JSF.P^KJ*N[=O:OT0WQ3?0W5WKG
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M0A1%\#H==#P/N\T&?;D,NIK5:D5G9R>:FIHP/#R,1"*!G9T=% H%Z'0Z"((
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M>_9LQ>/8L*^%A058+!8E8*:^N& VFX_TV*):?W^_LOVJ+W#<NG5+V1;JP.3
MP(!2'GW__OV*X.KMV[>5GI"G3IVJ>*Z^OCX\>O0("PL+<#J=2J W' [C\>/'
M (Z^Y)P00HZ#NK\AZPW82)DQH-WCNE&L'^%Q8>NF+O&=G9U5@IFOJU]?M60R
M6?>UOTKEPE&[=.F24D[- LIO8IJSUVS&=]O:\.76!FZLK6%'$$KEQ+)<^L/S
M6"H6\(M(!+O%(BZWM."TS0:?V0*K3@<]SZ$H24A+$C9X";"9,6 VH:W)@8MM
M7FS&=Y#+Y5 H%I$7B]C-Y) I%&#4"^ATNQ!P-J'/X\:)5@\<KQ#XRN?SF)N;
M0R*10%-3$P8'!QO*EM/I=)B?GT<ZG<;%BQ</_?S'*9%(8.[I4YB,1G1T=BJQ
MC(V-#3Q__ASI=!KGSIU[K8%#69:1R624M@H__.$/7]MS,^]LX! H91ZRGH?Q
M>+RBK,CE<L'C\>#4J5-'?@)_[MPY3$Y.(IE,(I/)8'U]'8%  %>O7E4RC]0!
MO-[>7@P.#B(<#A]9J6P@$(#)9$(P&*PHX[7;[?#Y?*]]>K#:P,  9F9F#C1-
M&2@%]ZY?OXZIJ2DL+R]7;$./QU.15<K*H '4G #5PQKQ9S*9FJS0MPU[[<<]
M!7PO0T-#RLES]>>+E3Q69QHRHZ.C,)O-ROO(3K)]/A\&!P=A-IOQ^>>?(YE,
M5F3N'I3-9L/''W^,F9D9;&QL*.OH<KG@]_LQ-#2D#&]96UNKR)89&AJ"U6K%
MXN*B$N@VF\WHZ>F!T^FLZ47&3J39_=D)>&MK*[J[N]'7UX=X/(YD,JD,!R+D
MN!U%/\+CPO;;P6!0Z9MJL]F4"VI *6A8_?EG67B]O;U*H"\4"BF?[_UZ-+(^
M@4#I<[N[NZL,9(I&HS"93#7K4+WMAH:&D$PFL;R\C$>/'F%N;J[BXH(@")K?
MLT?Y?G@\'B7[6^L"1[UU.'?NG')AD5WDJ'Z]U<=% P,#6%M;0S0:Q=V[=S$[
M.UMSX:XZ(Y(00MXV2TM+2"021Q)$>Y4@XD&P3,6#4E] &QL;P\3$1,,7U8[:
MNS(X2UUJ/3T]C4@D J/16#%$YG4(F,WXXT G4D417ZRO*MF&2O"P4,"*+./_
MB*Q@;".&$:<+0XXF>$U&F'0ZI$41R]D,%C)IZ#D>Y^P.]#L<&#K1#:_!!+..
M1Z$@(I'+(B468=7Q:#69X3 >W?M4+!8Q,S.#E1<OT!D(X/3IT^!Y'K(L0Y(D
M%(M%%(M%Z/5Z)3M4EF5DTFE,34YB:VL+@^^]!Y/%4AHRHAI(PK+J9%FN>#Q;
M!OM;EF44BT7H=#KH]7KE-I:9)Y67:S 8*K(:V?J)Q2(D6890SBID]UE;6\.W
MWWX+A\,!"4!+2PMXGD<ZG<;:ZBIV$HF:@',^GU>&IA@,AHIS>+9->)ZO6#?6
MAU%=!BU)$D111*%0*/5J% 085!F/3YX\P:UOOJ' X6%X/)Y#!QWV*\>J=WN]
MTB.6"5C/P,! 39G/Z.CHGH_9Z_97>>U'X6<_^UG=VS[[[+.ZM^VWW8>&AO8-
MNC1RGVI]?7VO?"*WUVNN9[_W6,M1E0J^JOU^I_>RWWM4O2WW>W_JW>[Q>/8\
M4+IRY4K=$LV]GE/KY_NMXZ>??EKW-D+^*1H:&H+/YZL([E<'W!O!RG(/NP[L
M(@&["-+(.ERY<@5M;6TU%Q?<;K=FP/,XU+O X7:[ZY9JLPN+6MN\O[^_;N;@
MM6O7ZEZXHZ A(>1=D,N5RCZK@X;9;/9 V6_5TX.!E^6X]30W-V-A80%;6UN:
M0<MZM[.^BNH2ZX/JZ>G!PL*"YE 3A@T9T;)7V78C6!EW]6L[BC+EXW+FS!F,
MC8TIOS.ODX[G\:,V'^+Y/%YD,IC<CI?Z':HKL401D&6\D"2LKZWBRXT8> "<
M+$/F.(B2C&(Y4/9K00^.X^"SF##H<**G?,$PE<NCT^7$IVX/3AQAT%!1'@C"
ME3,-95E&.IU&.IW&HT>/$(_'T=K:JB24I--I3#YZA/F%!202"?QV; Q>KQ=^
MOU^9RY#-9K&TM(39V5F(HHCN[F[E(FFQ6$0JF03'\Q"+123*[5R:FYN5.0NR
M+&-C8P-/9F:PM;4%K]=;.EXJ_U[*LHQX/(Z%A04L+R\CD\G@9%\?3@T,H*FI
M"8E$ HN+BWBQL@++UE:I3%F6<>+D2;1W=,!NMR.12%0< Z;3:2PL+" 8#$*6
M99PX<0+OO?>>$CQD)<YFLQG;\3B>/GV*K7@<G9V=&!X>5@+OHBAB?7T=SYX]
MP]KJ*G0Z'0;>>P\]O;TPFTQ*L%2KQ^+K\,X'#@DAA)!_3 YRX> P%S.T'.;"
M2J//O5]POYK6ZS_,!1BUPUXX.NCC#OI^-/)>'V;=#[K-F<-<E".$D+<%Z__'
M)A #+Z<L'T1_?S\BD0BFIZ>5++6%A84]'V.WV^%VN[&PL%"1P7;GSAT8# 9<
MN'!!N;VYN5EIBQ.)1 XTS+)Z>C$ ;&YN5@Q,,9E,V-S<5-9C>GJZX>4?5O5K
M#P:#2"02;T4V(IM,W=/3HZP?ZSFI'ICRNEWWMD$"\#_/S^/!3ARBR03D<B\S
M#P$4 10Y#FF@E)7(<8!4&3C:E21 SV-K9P<KJ33,/ ^]7H=VBP5G]1XXCZF"
MC>-YF,QF6,L!Z;OW[N')]#0D649Z=Q>IW5V$GC]'*IG$^Q<OPF*Q(/CL&5:C
M4202"=P='T=W=S<$O1Y^OQ];6UMX\. !IJ:F8#0:D<EDL/+B!38W-S'ZP0=H
M<CH1C4;Q].E3K*ZN*EF)HZ.C*!:+>/3H$187%[$=CT.2).SN[F)I:0G1:!0?
M7[L&O]^/W=U=?//UUXA$H^ X#CJ.P_B]>PBOK."CCSY"*I7"UN8F-K>VD&&_
MN[(,O]\/H\F$K:TM1%96T-34!*?3B4@D@F^^_AHKD0@XCD,NET-X>1GS\_/X
MZ*./T-S<C-W=7=RZ=0M;6UM*MN'6UA9"H1"6EI9P_?IU.)U.[.SLX.;-F]C9
MV8&@TT&GU^.KW_X6R\O+^."##Z#3Z6 QF]]8"P *'!)"""&$$$((>:=YO5[L
M[.Q@86%!"?3Y_7XE@W"OC+QJUZY=P]C8F-(/CV7U[>7,F3,(!H,50UE8GT7U
M[1,3$\KMZF!6(\Z<.8/IZ>F*YS"93+ATZ9+R_\'!04Q,3%2L^U[9?UU=75A8
M6,#8V!C\?O^A)C17KY?)9(+;[7XKL@Y9-N?L[&S%>Z@>+A,,!A&)1%YKN7>K
MT8A_WMZ!G4(!%I['Q'8<J7*?0Q8XA"25_NQ%!)!':;B*5$!&%''2Z<0'+6Z,
MVAWP'D>V(4K3B4TF$TQF,T11Q,.)"7SSS3?H[.S$P,  7"X75EZ\P)T[=R (
M BZ,C,!NL\%BM:)8+,)BL<!D,D%7'JHY.3F)!P\>8'M[&Z,??(!L-HO%Q45\
M^9O?P&:U8NC<.213*=P9'\>+<!C=W=WH[.R$T^F$*(JX?_\^IJ>G83&;<?'B
M17@\'BPO+^/6K5MH\_G0Y'1"DB3L[.R YSAXV]K@L-MQY\X=K*RLH+FY&>WM
M[7 T-<%L-,)D-L-BM<)LM4(P&+"]O8WGSY]C:7$1O7U]R&0RN'__/AX^? B#
MP8"S9\\BG\_CV?/G>''K%IQ.)S[XX /D<CD\?/@0*R]>P-O6AN'A8=BL5CQ[
M_ARWOOD&?7U].'_^/"1)0C*1@,5D0IO/!X[C,#8VAMC&AM*^QF:W4^"0$$((
M(8000@@YK/[^?LV!%^J?:06'U(&W>O=K),!7[_D;O5UKW2Y<N%#Q?W6O/BUV
MNWW/==>Z?:__:SU?5U=7S?:HOM_T]/2^08[JYU6_#UK/H;7NU=.TM7ZF=1^U
M_=Z7XV+6Z?"G?2<PY&C"_[6TA/\WNE+*(&0]#QO!^O?Q'.P<CQ^U=^ _"73@
M>ZUMX(#CG5HLRX DH5@H()%(P&@TXO+ER_C.1Q_!Z71B<6$!?_9G?X;IF1GT
M]O7ATQ_]"(+1B)5P&'_T1W^$YI862)*$U=55?'/K%@2]'I_]Y"<8'!R$8#!@
M<G(2_\N_^W>X=^\>#$8C['8[BL4BVOU^_/-_\2_0U]<'J]6*[>UMK*VMP6PV
MX_V+%_'93W\*H]&()S,S^/,__W,\?OP83J<3P\/#^/333Y'+Y2 8#+#9;$@F
MD[AW]RX>/7J$TZ=/8WAX&(N+BS 8#!@>'L;%BQ?!<1S6UM:4WL]ZO1-#DD(
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"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVER<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">40-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cybin Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPrimarySicNumber', window );">Entity Primary SIC Number</a></td>
<td class="text">2834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 King Street West<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 5600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Toronto<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">ON<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">M5X 1C9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">764-8385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, no par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CYBN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AnnualInformationForm', window );">Annual Information Form</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditedAnnualFinancialStatements', window );">Audited Annual Financial Statements</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">21,601,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001833141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">C T Corporation System<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1015 15th Street N.W.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Washington<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">572-3133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AnnualInformationForm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag with value true on a form if it is an annual report containing an annual information form.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AnnualInformationForm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditedAnnualFinancialStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag with value true on a form if it is an annual report containing audited financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditedAnnualFinancialStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPrimarySicNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primary Standard Industrial Classification (SIC) Number for the Entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPrimarySicNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:sicNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AUDIT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Zeifmans LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Toronto, Ontario<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1149<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">$ 135,022<span></span>
</td>
<td class="nump">$ 208,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Accounts receivable</a></td>
<td class="nump">5,885<span></span>
</td>
<td class="nump">4,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">22,156<span></span>
</td>
<td class="nump">2,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">2,909<span></span>
</td>
<td class="nump">2,177<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total Current Assets</a></td>
<td class="nump">165,972<span></span>
</td>
<td class="nump">218,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Equipment</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">41,018<span></span>
</td>
<td class="nump">35,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="nump">51,487<span></span>
</td>
<td class="nump">47,475<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total Non-Current Assets</a></td>
<td class="nump">92,646<span></span>
</td>
<td class="nump">83,487<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">258,618<span></span>
</td>
<td class="nump">302,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">21,418<span></span>
</td>
<td class="nump">9,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total Liabilities</a></td>
<td class="nump">21,418<span></span>
</td>
<td class="nump">10,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">464,364<span></span>
</td>
<td class="nump">443,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Contributed surplus</a></td>
<td class="nump">44,414<span></span>
</td>
<td class="nump">11,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfSharebasedPayments', window );">Options reserve</a></td>
<td class="nump">47,427<span></span>
</td>
<td class="nump">39,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantReserve', window );">Warrants reserve</a></td>
<td class="nump">27,594<span></span>
</td>
<td class="nump">25,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(7,231)<span></span>
</td>
<td class="num">(2,285)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Deficit</a></td>
<td class="num">(339,368)<span></span>
</td>
<td class="num">(226,231)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="nump">237,200<span></span>
</td>
<td class="nump">291,927<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">$ 258,618<span></span>
</td>
<td class="nump">$ 302,023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from share-based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research</a></td>
<td class="nump">$ 54,910<span></span>
</td>
<td class="nump">$ 32,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative costs</a></td>
<td class="nump">45,368<span></span>
</td>
<td class="nump">32,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Share-based compensation</a></td>
<td class="nump">42,869<span></span>
</td>
<td class="nump">13,886<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">TOTAL EXPENSES</a></td>
<td class="nump">143,147<span></span>
</td>
<td class="nump">78,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_MiscellaneousIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSES)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax', window );">Foreign currency translation gain</a></td>
<td class="nump">21,749<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="nump">8,289<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Other loss</a></td>
<td class="num">(28)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">TOTAL OTHER INCOME</a></td>
<td class="nump">30,010<span></span>
</td>
<td class="nump">756<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">NET LOSS FOR THE YEAR</a></td>
<td class="num">(113,137)<span></span>
</td>
<td class="num">(78,080)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>OTHER COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Foreign currency translation differences for foreign operations</a></td>
<td class="num">(4,946)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">COMPREHENSIVE LOSS FOR THE YEAR</a></td>
<td class="num">$ (118,083)<span></span>
</td>
<td class="num">$ (78,330)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per share for the year (in dollars per share)</a></td>
<td class="num">$ (5.59)<span></span>
</td>
<td class="num">$ (9.41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of common shares outstanding - basic (in shares)</a></td>
<td class="nump">20,222,493<span></span>
</td>
<td class="nump">8,297,370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_MiscellaneousIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Miscellaneous Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_MiscellaneousIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNatureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNatureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - CAD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>LPC Purchase Agreement</div></th>
<th class="th"><div>Share capital</div></th>
<th class="th">
<div>Share capital </div>
<div>LPC Purchase Agreement</div>
</th>
<th class="th"><div>Warrants</div></th>
<th class="th"><div>Options</div></th>
<th class="th"><div>Contributed surplus</div></th>
<th class="th"><div>Deficit</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,279,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 48,234,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,162,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,873,000<span></span>
</td>
<td class="nump">$ 27,283,000<span></span>
</td>
<td class="nump">$ 2,102,000<span></span>
</td>
<td class="num">$ (148,151,000)<span></span>
</td>
<td class="num">$ (2,035,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesIssuedThroughShareOfferingEquity', window );">At-the-market offering - net of share issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">898,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_IncreaseDecreaseThroughShareOfferingEquity', window );">At-the-market offering - net of share issuance costs</a></td>
<td class="nump">14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesIssuedNetOfIssuanceCosts', window );">Shares issued through common share purchase agreement - net of share issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,572,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Shares issued through common share purchase agreement - net of share issuance costs</a></td>
<td class="nump">239,753,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217,311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,442,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity', window );">Share issuance on business acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,130,138<span></span>
</td>
<td class="nump">50,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary', window );">Share issuance on business acquisition</a></td>
<td class="nump">53,481,000<span></span>
</td>
<td class="nump">$ 147,000<span></span>
</td>
<td class="nump">$ 53,481,000<span></span>
</td>
<td class="nump">$ 147,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing', window );">Issuance of common shares as commitment fee for equity financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity', window );">Options expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,992,000)<span></span>
</td>
<td class="nump">1,992,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Warrants exercised</a></td>
<td class="nump">56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity', window );">Warrants expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,656,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation</a></td>
<td class="nump">13,886,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,886,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Unrealized gain (loss) on translation of foreign operations</a></td>
<td class="num">(250,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(250,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">(78,080,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,080,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,001,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">291,927,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 443,877,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,639,000<span></span>
</td>
<td class="nump">39,177,000<span></span>
</td>
<td class="nump">11,750,000<span></span>
</td>
<td class="num">(226,231,000)<span></span>
</td>
<td class="num">(2,285,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInEquityAbstract', window );"><strong>Changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesIssuedThroughShareOfferingEquity', window );">At-the-market offering - net of share issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,609,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_IncreaseDecreaseThroughShareOfferingEquity', window );">At-the-market offering - net of share issuance costs</a></td>
<td class="nump">20,983,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,983,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issuance costs</a></td>
<td class="num">(496,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(496,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_IncreaseDecreaseThroughShareConsolidationEquity', window );">Adjustment for fractional shares upon share consolidation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity', window );">Options forfeited/expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,664,000)<span></span>
</td>
<td class="nump">32,664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation</a></td>
<td class="nump">42,869,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,955,000<span></span>
</td>
<td class="nump">40,914,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Unrealized gain (loss) on translation of foreign operations</a></td>
<td class="num">(4,946,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,946,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">(113,137,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113,137,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,610,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">$ 237,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 464,364,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,594,000<span></span>
</td>
<td class="nump">$ 47,427,000<span></span>
</td>
<td class="nump">$ 44,414,000<span></span>
</td>
<td class="num">$ (339,368,000)<span></span>
</td>
<td class="num">$ (7,231,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Expiration Of Warrants, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_IncreaseDecreaseThroughShareConsolidationEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Share Consolidation, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_IncreaseDecreaseThroughShareConsolidationEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_IncreaseDecreaseThroughShareOfferingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Share Offering, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_IncreaseDecreaseThroughShareOfferingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Share Options Expired In Share Based Payment Award, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Share Options Forfeited And Expired In Share Based Payment Award, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfSharesIssuedNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Issued, Net Of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfSharesIssuedNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Issued Through Acquisition Of Subsidiary, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Issued Through Commitment Fee For Equity Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Issued Through Exercise Of Warrants, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfSharesIssuedThroughShareOfferingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Issued Through Share Offering, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfSharesIssuedThroughShareOfferingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the acquisition of subsidiaries. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF CASH FLOWS - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">$ (113,137)<span></span>
</td>
<td class="num">$ (78,080)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for items not affecting cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation</a></td>
<td class="nump">42,869<span></span>
</td>
<td class="nump">13,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_AdjustmentForLeaseInterest', window );">Lease interest accretion</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_AdjustmentsForOtherLossesGains', window );">Other loss</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Computer equipment write-down</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation', window );">Unrealized foreign currency translation gain</a></td>
<td class="num">(21,749)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Cash flows used in operating activities before net changes in non-cash working capital items</a></td>
<td class="num">(91,507)<span></span>
</td>
<td class="num">(63,881)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_AdjustmentsForWorkingCapitalAbstract', window );"><strong>Net changes in non-cash working capital items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,409)<span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(19,265)<span></span>
</td>
<td class="num">(986)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(732)<span></span>
</td>
<td class="num">(408)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">11,613<span></span>
</td>
<td class="num">(2,544)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="num">(101,300)<span></span>
</td>
<td class="num">(68,908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013', window );">Cash acquired on acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchase of equipment and intangible assets</a></td>
<td class="num">(1,966)<span></span>
</td>
<td class="num">(710)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash flows provided by (used in) investing activities</a></td>
<td class="num">(1,966)<span></span>
</td>
<td class="nump">6,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds on issuance of common shares, net</a></td>
<td class="nump">20,487<span></span>
</td>
<td class="nump">254,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds on exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Lease payments</a></td>
<td class="num">(290)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash flows provided by financing activities</a></td>
<td class="nump">20,197<span></span>
</td>
<td class="nump">254,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effects of exchange rate changes on cash</a></td>
<td class="nump">9,099<span></span>
</td>
<td class="num">(162)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net increase (decrease) in cash</a></td>
<td class="num">(73,970)<span></span>
</td>
<td class="nump">192,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash, beginning of year</a></td>
<td class="nump">208,992<span></span>
</td>
<td class="nump">16,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash, end of year</a></td>
<td class="nump">$ 135,022<span></span>
</td>
<td class="nump">$ 208,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_AdjustmentForLeaseInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment For Lease Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_AdjustmentForLeaseInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Increase (Decrease) In Accrued And Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_AdjustmentsForOtherLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Other Losses (Gains)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_AdjustmentsForOtherLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Unrealized Gain (Loss) On Foreign Currency Translation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_AdjustmentsForWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Working Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_AdjustmentsForWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Of Property, Plant, Equipment And Intangible Assets, Classified As Investing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) on property, plant and equipment recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents in subsidiaries or other businesses over which control is obtained or lost. [Refer: Total for all subsidiaries [member]; Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 40<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_40_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CORPORATE INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory', window );">CORPORATE INFORMATION</a></td>
<td class="text">CORPORATE INFORMATION<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Cybin Inc. (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Cybin</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;), was incorporated under the Business Corporations Act (British Columbia) on October 13, 2016. These consolidated financial statements include the accounts of Cybin&#8217;s seven subsidiaries (together with Cybin, the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Company</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;): Cybin Corp., Natures Journey Inc. (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Journey</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;), Serenity Life Sciences Inc. (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Serenity</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;), Cybin US Holdings Inc. (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Cybin</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">US</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;), Adelia Therapeutics Inc. (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Adelia</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;) Cybin IRL Limited (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Cybin</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">IRL</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;) and Cybin UK Ltd.  Cybin&#8217;s head office, principal address and registered address and records office is 100 King Street West, Suite 5600, Toronto, Ontario M5X 1C9. The Company acquired Small Pharma Inc. (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Small</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Pharma</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;) and its subsidiary Small Pharma Ltd. on October 23, 2023. On April 1, 2024, Small Pharma Inc. was amalgamated with Cybin Corp. and continued as Cybin Corp. Effective on December 16, 2023, Small Pharma Ltd.'s name was changed to Cybin UK Ltd. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit.  These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">These consolidated financial statements as at, and for the year ended March 31, 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">were approved and authorized for issue by the board of directors on June&#160;30, 2025.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%;text-decoration:underline">Stock exchange listings</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Cybin&#8217;s common shares (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Common Shares</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;) are listed for trading on Cboe Canada Inc. (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Cboe Canada</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">") and NYSE American LLC under the symbol &#8220;CYBN&#8221; and on the Frankfurt Stock Exchange under the symbol &#8220;R7E1&#8221;.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Share consolidation</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On September 19, 2024, the Company consolidated its outstanding Common Shares on the basis of one new Common Share for every 38 previously existing Common Shares (the "</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Consolidation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">"). As a result, the number of Common Shares, warrants, options and earnings per share presented in these consolidated financial statements have been restated retrospectively for all the years to reflect the Consolidation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfConsolidationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory', window );">MATERIAL ACCOUNTING POLICIES AND BASIS OF PREPARATION</a></td>
<td class="text">MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Statement of compliance </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%">The Company&#8217;s consolidated financial statements have been prepared in accordance with IFRS Accounting Standards (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:124%">IFRS</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%">&#8221;) as issued by the International Accounting Standards Board (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:124%">IASB</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%">&#8221;). </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%">The policies applied to these consolidated financial statements are based on IFRS, which have been applied consistently to all periods presented. These consolidated financial statements were issued and effective as at June&#160;30, 2025, the date the Board of Directors approved these consolidated financial statements.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company&#8217;s board of directors has the power to amend the consolidated financial statements after issuance.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Basis of measurement</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">These consolidated financial statements have been prepared on a going concern basis, under the historical cost convention, except for certain financial instruments classified at fair value upon initial recognition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Functional and presentation currency</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The functional currency of a company is the currency of the primary economic environment in which the company operates. The presentation currency for a company is the currency in which the company chooses to present its financial statements.</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">These consolidated financial statements are presented in Canadian dollars, the Company&#8217;s presentation currency. The subsidiaries&#8217; functional currencies are as follows:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:37.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Entity</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ownership</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cybin Corp.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollars</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Journey</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serenity</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybin US</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adelia</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cybin IRL </span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybin UK Ltd</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Great Britain pounds</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> For accounting purposes, Cybin US is a wholly-owned subsidiary of Cybin. Certain former Adelia Shareholders hold Class B Shares (defined below) in Cybin US.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"> Basis of consolidation </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company consolidates entities which it controls. Control exists when the Company has the power, directly and indirectly to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Intercompany balances, and any unrealized gains and losses or income and expenses arising from transactions with controlled entities are eliminated to the extent of the Company&#8217;s interest in the entity. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Cash and cash equivalents</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash and cash equivalents are comprised of cash on deposit and highly liquid short-term interest-bearing variable rate investments with an original maturity of three months or less, or which are readily convertible into a known amount of cash with no significant changes. As at March&#160;31, 2025 and March&#160;31, 2024 there were no cash equivalents.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Inventories</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inventories include raw materials and finished goods. Raw materials are stated at the lower of cost and replacement cost with cost determined on a first-in, first-out basis. The Company monitors the shelf life and expiry of finished goods to determine when inventory values are not recoverable and a write-down is necessary.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Equipment</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Equipment consists of lab and computer equipment and are recorded at cost less accumulated depreciation and accumulated impairment losses. Cost includes all expenditures incurred to bring the asset to the location and condition necessary for them to be operating in the manner intended by management. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Depreciation is recognized based on the cost of the item less its estimated residual value, over its estimated useful life on a straight-line basis at the following rates:</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Lab equipment &#8211; 5 years</span></div><div style="padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Computer equipment &#8211; 3 years</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">An item of equipment and any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the consolidated statement of loss and comprehensive loss when the asset is derecognized. The assets&#8217; residual values, useful lives and methods of depreciation are reviewed at each reporting date and adjusted prospectively if appropriate. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Intangible Assets</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Intangible assets include expenditures related to obtaining patents, software related items and in-process research and development (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">IPR&amp;D</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;). The amortization of software related items begins when the software is in use and will be amortized on a straight-line basis over a period of 3 years. The amortization of patent costs commences when the associated products are available for commercial sale and is amortized on a straight-line basis over its respective legal lives or economic life, if shorter. Patents have an estimated useful life of 17 years. Amortization methods, useful lives, and residual values are reviewed at each reporting date and adjusted if appropriate. Acquired IPR&amp;D is capitalized based on technical feasibility and remains on the balance sheet, subject to impairment. Acquired IPR&amp;D is initially measured at fair value and recognized as an indefinite-lived intangible asset until completion or abandonment of the related project. Amortization commences when the assets become available for use. Expenditures on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in operations as incurred. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Development activities involve a plan or design for the production of new, or substantially improved, products or processes related to the Company&#8217;s development of psychedelic-based therapeutics. Development expenditures are capitalized only if the relevant IFRS criteria are met. Capitalized development expenditures </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">are amortized from the beginning of commercial production and sales and are amortized on a straight-line basis over the remaining useful life of the related patents. Development expenditures, in relation to the Company&#8217;s psychedelic-based therapeutics, have not satisfied the above criteria and are recognized in operations as incurred. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Goodwill</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Goodwill represents the excess of the consideration transferred for the acquisition of an entity over the fair value of the net identifiable assets. Goodwill is initially measured at cost, and subsequently recorded at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Company&#8217;s cash-generating units (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">CGUs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those CGUs. The Company tests for impairment annually, or when indications of impairment exist.  Impairment is determined for goodwill by assessing if the carrying value of CGUs, including goodwill, exceeds its recoverable amount determined as the greater of the estimated fair value less costs of disposal and the value in use. Impairment losses recognized in respect of the CGUs are first allocated to the carrying value of goodwill and any excess is allocated to the carrying amount of assets in the CGUs. Any goodwill impairment is recorded in the consolidated statement of loss and comprehensive loss.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Impairment of long-lived assets</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Long-lived assets, including equipment and intangible assets, are reviewed for impairment at each consolidated statement of financial position date or whenever events or changes in circumstances indicate that the carrying amount of the asset exceeds its recoverable amount. Where the carrying value of an asset exceeds its recoverable amount, which is the higher of value in use and fair value less costs to sell, the asset is written down accordingly. Where it is not possible to estimate the recoverable amount of an individual asset, the impairment test is carried out on the asset&#8217;s cash-generating unit, which is the lowest group of assets in which the asset belongs for which there are separate cash inflows that are largely independent of the cash inflows from other assets. An impairment loss is charged to operations. </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Financial instruments</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Recognition and initial measurement</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company initially recognizes financial instruments on the trade date, which is the date on which the Company becomes a party to the contractual provisions of the instrument. A financial asset or financial liability is measured initially at fair value plus/minus, for an item not at fair value through profit or loss (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">FVTPL</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;), transaction costs that are directly attributable to its acquisition or use.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Classification</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Financial asset</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On initial recognition, a financial asset is classified as measured at: amortized cost, fair value through other comprehensive income (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">FVOCI</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;), or FVTPL.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">A financial asset is measured at amortized cost if it meets both of the following conditions and is not designated as at FVTPL:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company currently measures accounts receivable at amortized cost. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">A debt instrument is measured at FVOCI only if it meets both of the following conditions and is not designated as at FVTPL:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in FVOCI. This election is made on an investment-by-investment basis. The Company has not elected to present any assets as FVOCI.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash is measured at FVTPL.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In addition, on initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortized cost as FVOCI or FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Business model assessment</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company makes an assessment of the objective of a business model in which an asset is held at a portfolio level because this best reflects the way the business is managed and information is provided to management. The information considered includes:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The stated policies and objectives for the portfolio and the operation of those policies in practice. In particular, whether management&#8217;s strategy focuses on earning contractual interest revenue, maintaining a particular interest rate profile, matching the duration of the financial assets to the </span></div><div style="padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">duration of the liabilities that are funding those assets or realizing cash flows through the sale of the assets;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">How the performance of the portfolio is evaluated and reported to the Company&#8217;s management;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">How managers of the business are compensated (e.g. whether compensation is based on the fair value of the assets managed or the contractual cash flows collected); and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The frequency, volume and timing of sales in prior periods, the reasons for such sales and its expectation about future sales activity. However, information about sales activity is not considered in isolation, but as part of an overall assessment of the Company&#8217;s stated objective for managing the financial asset is achieved and how cash flows are realized. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Assessment whether contractual cash flows are solely payments of principal and interest</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">For the purpose of this assessment, &#8216;principal&#8217; is defined as the fair value of the financial asset on initial recognition. &#8216;Interest&#8217; is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g. liquidity risk and administrative costs), as well as profit margin. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In assessing whether the contractual cash flows are solely payments of principal and interest, the Company considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of the contractual cash flows such that it would not meet this condition. In making the assessment, the Company considers:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">contingent events that would change the amount and timing of cash flows;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">leverage features;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">prepayment and extension terms;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">terms that limit the Company&#8217;s claim to cash flows from specified assets (e.g. non-recourse asset arrangements); and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">features that modify consideration of the time value of money (e.g. periodical rest of interest rates).</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Reclassifications</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company would reclassify a financial asset when the Company changes its business model for managing the financial asset. All reclassifications are recorded at fair value at the date of the reclassification, which becomes the new carrying value. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Financial assets are not reclassified subsequent to their initial recognition, except in the period after the Company changes its business model for managing financial assets. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Financial liabilities</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company classifies its financial liabilities at amortized cost or FVTPL. The Company currently measures accounts payable, lease liabilities and accrued liabilities at amortized cost.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Derecognition </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Financial assets</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transition in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and it does not retain control of the financial asset. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On derecognition of a financial asset, the difference between the carrying amount of the asset (or the carrying amount allocated to the portion of the asset derecognized) and the sum of (i) the consideration received (including any new assets obtained less any new liability assumed) and (ii) cumulative gain or loss that had been recognized in other comprehensive income is recognized in profit or loss. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Financial liabilities </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled, or expire. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Modifications of financial assets and financial liabilities </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Financial assets</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If the terms of a financial asset are modified, the Company evaluates whether the cash flows of the modified asset are substantially different. If the cash flows are substantially different, then the contractual rights to cash flows from the original financial asset are deemed to have expired. In this case, the original financial asset is derecognized and a new financial asset is recognized at fair value. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If the cash flows of the modified asset carried at amortized cost are not substantially different, then the modification does not result in derecognition of the financial asset. In this case, the Company recalculates the gross carrying amount of the financial asset and recognizes the amount arising from adjusting the gross carrying amount as a modification gain or loss in profit or loss. If such a modification is carried out because of financial difficulties of the borrower, then the gain or loss is presented together with impairment losses. In other cases, it is presented as interest income. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Financial liabilities</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company derecognizes a financial liability when its terms are modified and the cash flows of the modified liability are substantially different. In this case, a new financial liability based on the modified terms is recognized at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognized in profit or loss. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Offsetting</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Financial assets and financial liabilities are offset and the net amount presented in the consolidated statement of financial position when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Income and expenses are presented on a net basis only when permitted under IFRS, or for gains and losses arising from a group of similar transactions. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Fair value measurement</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or, in its absence, the most advantageous market to which the Company has access at that date. The fair value of a liability reflects its non-performance risk. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">When one is available, the Company measures the fair value of an instrument using the quoted price in an active market for that instrument. A market is regarded as active if transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If there is no quoted price in an active market, then the Company uses valuation techniques that maximize the use of relevant observable inputs and minimize the use of unobservable inputs. The chosen valuation technique incorporates all of the factors that market participants would take into account in pricing a transaction. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The best evidence of the fair value of a financial instrument on initial recognition is normally the transaction price (i.e. the fair value of the consideration given or received). If the Company determines that the fair value on initial recognition differs from the transaction price and the fair value is evidenced neither by a quoted price in an active market for an identical asset or liability nor based on a valuation technique for which any observable inputs are judged to be insignificant in relation to the measurement, then the financial instrument is initially measured at fair value, adjusted to defer the difference between the fair value on initial recognition and the transaction price. Subsequently, that difference is recognized in profit or loss on an appropriate basis over the life of the instrument but no later than when the valuation is wholly supported by observable market data or the transaction is closed out. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If an asset or a liability at fair value has a bid price and an ask price, then the Company measures assets and long positions at bid price and liabilities and short positions at an ask price. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Portfolio of financial assets and financial liabilities that are exposed to market risk and credit risk that are managed by the Company on the basis of the net exposure to either market or credit risk are measured on the basis of a price that would be received to sell a net long position (or paid to transfer a net short position) for the particular risk exposure. Portfolio-level adjustment e.g. bid-ask adjustment or credit risk adjustments that reflect the measurement on the basis of the net exposure are allocated to the individual assets and liabilities on the basis of the relative risk adjustment of each of the individual instruments in the portfolio.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The fair value of a financial liability with a demand feature is not less than the amount payable on demand, discounted from the first date on which the amount could be required to be paid. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period during which the change has occurred.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:130%">  </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Impairment</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Credit-impaired financial assets</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">At each reporting date, the Company assesses whether financial assets carried at amortized costs and debt financial assets carried at FVOCI are credit-impaired. A financial asset is &#8216;credit-impaired&#8217; when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Evidence that a financial asset is credit-impaired includes the following observable data: </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">Significant financial difficulty of the borrower or issuer;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">A breach of contract such as a default of past due event;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The restructuring of a loan or advance by the Company on terms that the Company would not consider otherwise;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">It is becoming probable that the borrower will enter bankruptcy or other financial reorganization; or </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The disappearance of an active market for a security because of financial difficulties. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">A loan that has been renegotiated due to a deterioration in the borrower&#8217;s condition is usually considered to be credit-impaired unless there is evidence that the risk of not receiving contractual cash flows has reduced significantly and there are no other indicators of impairment. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Recognition of allowance of expected credit losses (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">ECL</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">&#8221;) in the consolidated statement of financial position</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company recognizes a loss allowance for ECL on trade receivables that are measured at amortized cost. The Company&#8217;s applied the simplified approach for trade receivables and recognizes the lifetime ECL for these assets. The ECL on trade receivables is estimated using a provision matrix based on the Company&#8217;s historical credit loss experience, adjusted for factors that are specific to the customers, general economic conditions and </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">an assessment of both the current as well as the forecast direction of conditions at the reporting date, including time value of money where appropriate. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">For all other financial assets measured at amortized cost of FVOCI, the Company recognizes lifetime ECL only when there has been a significant increase in credit risk since initial recognition. If the credit risk on such financial instruments has not increased significantly since initial recognition, the Company measures the loss allowance on those financial instruments at an amount equal to 12-months ECL. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Lifetime ECL represents the ECL that will result from all possible default events over the expected life of a financial asset. In contrast, 12-month ECL represents the portion of lifetime ECL that is expected to result from default events on a financial asset that are possible within 12 months after the reporting date. In assessing whether the credit risk on a financial asset has increased significantly since initial recognition, the Company compares the risk of default occurring on the financial asset at the reporting date with the risk of default occurring at the initial recognition. The Company considers both quantitative and qualitative factors that are supportable, including historical experience and forward-looking information that is available without undue cost or effort. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Irrespective of the above assessment, the Company presumes that the credit risk on a financial asset has increased significantly since initial recognition when contractual payments are more than 30 days past due, unless the Company has reasonable and supportable information that demonstrates otherwise. Despite the foregoing, the Company presumes that the credit risk on a financial asset has not increased significantly since initial recognition if the financial asset is determined to have low credit risk at the reporting date. </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company regularly monitors the effectiveness of the criteria used to identify whether there has been a significant increase in credit risk and revises them as appropriate to ensure that the criteria are capable of identifying significant increase in credit risk before the amount becomes pas due. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Definition of default</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">For internal credit risk management purposes, the Company considers a financial asset not recoverable if the customer balance owing is 180 days past due and information obtained from the customer and other external factors indicate that the customer is unlikely to pay its creditors in full.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Write-off</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Financial assets are written off (either partially or in full) when there is no realistic prospect of recovery. This is generally the case when the Company determines that the counterparty does not have assets or sources of income that could general sufficient cash flows to repay the amounts subject to the write-off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Company&#8217;s procedures for recovery of amounts due. </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Taxation</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Income tax comprises current and deferred tax. Income tax is recognized in the consolidated statement of loss and comprehensive loss except to the extent that it relates to items recognized directly in equity, in which case the income tax is also recognized directly in equity.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Current income tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted, at the end of the reporting period, and any adjustment to tax payable in respect of previous years.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from audits by taxing authorities. Where the outcome of these tax-related matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Deferred income tax is recorded using the asset and liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences do not result in deferred tax assets or liabilities: the initial recognized of assets or liabilities that affect neither accounting or taxable loss; or difference relating to investment in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the consolidated statement of financial position date.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its correct tax assets and liabilities on a net basis. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Share capital</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Equity instruments are contracts that give a residual interest in the net assets of the Company. Financial instruments issued by the Company are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Common Shares and the Company&#8217;s Common Share purchase warrants and options are classified as equity instruments. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Incremental costs directly attributable to the issue of new Common Shares or warrants are shown in equity as a deduction, net of tax, from the proceeds. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Share-based compensation</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Under the Company&#8217;s equity incentive plan, all stock options granted may have graded vesting periods and are exercisable up to a maximum of 10 years form the date of grant. Each tranche of an award with graded vesting periods is considered a separate grant at each grant date for the calculation of fair value, and the resulting fair value is amortized over the vesting period of the respective tranches. The fair value of the options granted is measured using the Black-Scholes option pricing model taking into account the terms and conditions upon which the options were granted, the estimated volatility, estimated risk free rate and estimated forfeitures. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If a grant of the share-based payments is cancelled or settled during the vesting period (other than a grant cancelled by forfeiture when the vesting conditions are not satisfied or options granted in error and cancelled retroactively), the Company accounts for the cancellation or settlement as an acceleration of vesting, and recognizes immediately the amount that otherwise would have been recognized for services over the remainder of the vesting period. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The amount recognized for goods or services received during the vesting period is based on the best available estimate of the number of equity instruments anticipated to vest. The Company revises that estimate, if necessary, if subsequent information indicates that the number of share options anticipated to vest differs from previous estimates. On the vesting date, the Company revises the estimate to equal the number of equity instrument that ultimately vested. After the vesting date, the Company makes no subsequent adjustment to total equity for goods or services received if the share options are later forfeited or they expire at the end of the share option&#8217;s life. Upon expiration of options, the amount applicable to expired options is moved to contributed surplus.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If a grant of the share based payment is modified during the vesting period (other than a grant cancelled by forfeiture when</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:130%">  </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">the vesting conditions are not satisfied) and the fair value of the new instruments is higher than the fair value of the original instrument, the incremental fair value granted is included in the measurement of the amount recognized for services received over the period from modification date until the date when the modified equity instruments vests, in addition to the amount based on the grant date fair value of the original equity instruments, which is recognized over the remainder of the original vesting period of the original instrument. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Warrants</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company follows the relative fair value method with respect to the measurement of Common Shares and warrants issued as units. The proceeds from the issuance of units are allocated between share capital and warrants. The warrant component is recorded in equity reserve. Unit proceeds are allocated to Common Shares and warrants using the Black-Scholes option pricing model and the share price at the time of financing. If and when the warrants are exercised, consideration paid by the warrant holder, together with the amount previously recognized in warrant reserve, is recorded as an increase to share capital. A forfeiture rate is estimated on the grant date and is adjusted to reflect the actual number of warrants that vest. When stock options or warrants are cancelled, they are treated as if they have vested on the date of collation and any cost </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">not yet recognized in profit or loss is immediately expensed. Upon expiration of warrants, the amount applicable to expired warrants is moved to contributed surplus. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Loss per share</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Basic loss per share is calculated using the weighted-average number of shares outstanding during the period. The diluted earnings (loss) per share reflects the potential dilution of Common Share equivalents, such as outstanding stock options and warrants, in the weighted average number of Common Shares outstanding during the period, if they are dilutive.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Currency translation</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">All figures presented in the consolidated financial statements are reflected in Canadian dollars unless otherwise noted.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Foreign currency transactions are translated into Canadian dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the consolidated statement of financial position date are translated to Canadian dollars at the foreign exchange rate applicable as that date. Realized and unrealized exchange gains and losses are recognized through profit or loss. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The assets and liabilities of foreign operations are translated into Canadian dollars at period-end exchange rates. Income and expenses, and cash flows of foreign operations are translated into Canadian dollars using average exchange rates. Exchange differences resulting from translating foreign operations are recognized in other comprehensive income (loss) and accumulated separately in shareholders&#8217; equity. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Foreign currency translation gains or losses arising from a monetary item receivable or payable to a foreign operation, the settlement of which is neither planned nor likely to occur in the foreseeable future and which in substance is considered to form part of the net investment in the foreign operation, are recognized in other comprehensive income (loss) in the translation reserve. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Provisions</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Provisions are recorded when a present legal or constructive obligation exists as a result of past events where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and a reliable estimate of the amount of the obligation can be made.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the consolidated statement of financial position date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows. When some or all of the economic benefits required to settle, a provision is expected to be recovered from a third party, the receivable is recognized as an asset if it is virtually certain that reimbursement will be received and the amount receivable can be measured reliably. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">New standards and interpretations</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The IASB has issued certain amendments to accounting and financial reporting standards effective for annual reporting periods beginning on or after January 1, 2024.</span></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">IAS 1, Presentation of Financial Statements ("IAS 1") - Classification of Liabilities as Current or Non-Current</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In January 2020, the IASB issued amendments to IAS 1. The amendments aim to promote consistency in applying the requirements by helping companies determine whether, in the consolidated statements of financial position, debt and other liabilities with an uncertain settlement date should be classified as current (due or potentially due to be settled within one year) or non-current. The amendments include clarifying the classification requirements for debt a company might settle by converting it into equity. The amendments are effective for annual reporting periods beginning on or after January 1, 2024.  The Company has determined that adoption of these amendments has no significant effect on the Company's consolidated financial statements.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">New standards and interpretations not yet adopted </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">IFRS 18, Presentation and Disclosure in Financial Statements</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In April 2024, the IASB issued IFRS 18 that is to replace IAS 1, Presentation of Financial Statements. The new standard aims to improve the quality of financial reporting by: (i) requiring defined subtotals in the statement of profit or loss; (ii) requiring disclosure about management defined performance measures; and (iii) adding new principles for aggregation and disaggregation of information.  The standard is effective for the annual reporting periods beginning on or after January 1, 2027, with early application permitted. The Company is in the process of assessing the impact of this new standard on its consolidated financial statements.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">IFRS 9, Financial Instruments (&#8220;IFRS 9&#8221;) and IFRS 7, Financial Instruments: Disclosures (&#8220;IFRS 7&#8221;)</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In May 2024, the IASB issued targeted amendments to IFRS 9 and IFRS 7 in response to practical implementation issues and to introduce new requirements applicable to both financial institutions and corporate entities. These amendments aim to enhance the clarity and consistency of financial reporting for various types of financial instruments and their related disclosures by (i) clarifying the date of recognition and derecognition for certain financial assets and liabilities, including a new exception for financial liabilities settled through an electronic cash transfer system (ii) providing help to determine whether a financial asset meets the Solely Payments of Principal and Interest criterion (iii) introducing new disclosures for instruments with contractual terms that may alter cash flows, such as financial instruments linked to the achievement of environmental, social, and governance targets, and (iv) updating the disclosure requirements for equity instruments designated at FVTOCI. The new standard is to be effective for annual periods beginning on or after January 1, 2026. The Company is in the process of assessing the impact of the standard on its consolidated financial statements.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">All other IFRSs and amendments issued but not yet effective have been assessed by the Company and are not expected to have a material impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of material accounting policy information applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_CriticalAccountingEstimatesAndJudgementsAbstract', window );"><strong>Critical Accounting Estimates and Judgements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS</a></td>
<td class="text">CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS <div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The preparation of these consolidated financial statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting year. Actual outcomes could differ from these estimates. These consolidated financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the year in which the estimate is revised and future years if the revision affects both current and future years. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Judgments, estimates and assumptions that have the most significant effect on the amounts recognized in the consolidated financial statements include warrants and fair value of share-based payments (note 9) and the fair value of financial instruments (note 15).</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Ability to continue as a going concern</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In order to assess whether it is appropriate for the Company to continue as a going concern, management is required to apply judgment and make estimates with respect to future cash flow projections. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In arriving at this judgment, there were a number of assumptions and estimates involved in calculating these future cash flow projections. This includes making estimates regarding the timing and amounts of future expenditures and the ability and timing of raising additional financing. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Business combinations</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">A business combination is a transaction or event in which an acquirer obtains control of one or more businesses and is accounted for using the acquisition method. The total consideration paid for the acquisition is the aggregate of the fair values of assets given, liabilities incurred or assumed, and equity instruments issued in exchange for control of the acquiree at the acquisition date. The acquisition date is the date where the Company obtains control of the acquiree. The identifiable assets acquired and liabilities assumed are recognized at their acquisition date fair values, except for deferred taxes and share-based payment awards where IFRS provides exceptions to recording the amounts at fair value. Acquisition costs are expensed to profit or loss.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combination. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as an asset or a liability is remeasured at subsequent reporting dates in accordance with IFRS 9, or IAS 37 Provisions, Contingent Liabilities and Contingent Assets, as appropriate, with the corresponding gain or loss being recognized in profit or loss.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Non-controlling interest in the acquiree, if any, is recognized either at fair value or at the non-controlling interest&#8217;s proportionate share of the acquiree&#8217;s net assets, determined on an acquisition-by-acquisition basis. For each acquisition, the excess of total consideration, the fair value of previously held equity interest prior to obtaining control and the non-controlling interest in the acquiree, over the fair value of the identifiable net asset acquired, is recorded as goodwill.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Certain fair values may be estimated at the acquisition date pending confirmation or completion of the valuation process. Where provisional values are used in accounting for a business combination, they may be adjusted retrospectively in subsequent periods. The measurement period is the period from the acquisition date to the date complete information about facts and circumstances that existed as of the acquisition date is received. However, the measurement period does not exceed one year from the acquisition date. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Acquisitions that do not meet the definition of a business combination are accounted for as an asset acquisition. Consideration paid for an asset acquisition is allocated to the individual identifiable assets acquired and liabilities assumed based on their relative fair values.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Share based payments</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The fair value of share-based compensation expenses are estimated using the Black-Scholes option pricing model and rely on a number of estimates, such as the expected life of the option, the volatility of the underlying share price, the risk-free rate of return, and the estimated rate of forfeiture of options or warrants granted.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Impairment of non-financial assets</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Impairment exists when the carrying value of an asset or cash generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The fair value less costs of disposal calculation is based on available data from binding sales transactions, conducted at arm&#8217;s length, for similar assets or observable market prices less incremental costs of disposing of the asset. The value in use calculation is based on a discounted cash flow (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">DCF</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) model. The cash flows are derived from the forecast for the next ten years and do not include restructuring activities that the Company is not yet committed to or significant future investments that will enhance the performance of the assets of the CGU being tested. The determination of the Company&#8217;s CGUs is based on management&#8217;s judgement. The recoverable amount is sensitive to the discount rate used for the DCF model as well as the expected future cash-inflows and the growth rate used for extrapolation purposes. These estimates are most relevant to goodwill and other intangibles with indefinite useful lives recognized by the Company.  Future events could cause the assumptions used in the impairment review to change with a consequential adverse effect on the results of the Company. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Income taxes</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company computed an income tax provision in accordance with the applicable income tax laws. However, actual amounts of income tax expense only become final upon filing and acceptance of the tax return by the relevant authorities, which occurs subsequent to the issuance of the consolidated financial statements. Additionally, estimation of income taxes includes evaluation the recoverability of deferred tax assets based on </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">an assessment of the ability to use the underlying future tax deductions before they expire against future taxable income. The assessment is based upon existing tax laws and estimates of future taxable income. The income tax provision is based on estimates of full-year earnings by jurisdiction. The average annual effective income tax rates are re-estimated at the end of each reporting period. To the extent that estimates and forecasts  differ from actual results, adjustments are recorded in subsequent periods. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">The useful life and recoverability of long-lived assets:</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Management estimates the useful life of long-lived assets based on the period during which the assets are expected to be available for use. The amounts and timing of recorded expenses for amortization and depreciation are affected by these estimated useful lives. The estimates are reviewed at least annually and are updated if expectations change as a result of technical or commercial obsolescence, and legal or other limits to use. It is possible that changes in these factors may cause significant changes in the estimated useful lives of the Company&#8217;s long-lived assets in the future. </span></div>The Company estimates the useful lives and selects methods used to allocate amortization and depreciation amounts of long-lived assets on a systematic basis. Technical obsolescence of intangible and tangible assets could significantly impact estimated residual useful lives and, in turn, carrying values being over or understated. The estimates of the useful lives of long-lived assets are reviewed on an annual basis. Amortization and depreciation are adjusted on a prospective basis, if and when required.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_CriticalAccountingEstimatesAndJudgementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Critical Accounting Estimates and Judgements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_CriticalAccountingEstimatesAndJudgementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract', window );"><strong>Disclosure of detailed information about business combination [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory', window );">ACQUISITION</a></td>
<td class="text">ACQUISITION<div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On October 23, 2023, Cybin completed the acquisition of Small Pharma and its wholly-owned subsidiary Small Pharma Ltd. (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Acquisition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) and issued 0.00634 Common Shares for every one common share of Small Pharma outstanding, resulting in a total of 2,130,138 Common Shares being issued to Small Pharma shareholders. As a result of the Acquisition, Small Pharma became a wholly-owned subsidiary of Cybin. On December 16, 2023 the Company changed the name of Small Pharma Ltd. to Cybin UK Ltd. </span></div><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In connection with the Acquisition, all unvested options of Small Pharma were vested and holders were able to exercise their options prior to the close of the Acquisition. All stock options of Small Pharma remaining unexercised at October 23, 2023 were cancelled and compensation of $0.001 per stock option was paid to the optionees.</span></div><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">As at October 23, 2023  Small Pharma&#8217;s patent portfolio consisted of 17 active patent families with 92 pending applications and 30 granted patents across its psychedelic and non-psychedelic portfolio.</span></div><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company determined that the Acquisition was a business combination under IFRS. The consideration for the acquisition and measurement of assets acquired and liabilities assumed, as well as goodwill, in accordance with IFRS 3 - Business Combinations, is as follows:</span></div><div style="padding-left:13.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:38.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.206%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.464%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acquisition Summary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Consideration</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,481&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of purchaser consideration</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53,481</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of Purchase Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,632&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,686)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total allocation of purchase price</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53,481</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="padding-left:13.5pt"><span><br/></span></div><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A professional valuator was engaged by the Company to estimate the value of the assets of Small Pharma for the purpose of the final purchase price allocation. Accordingly, the purchase price allocation was subject to change as at March 31, 2024. The final purchase price allocation was completed within the required one-year measurement period and did not result in any changes from the provisional amounts previously reported. As such, the allocation of the purchase consideration to the identifiable assets acquired and liabilities assumed remains unchanged.</span></div><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">As at February 28, 2023, Small Pharma had Canadian loss carry forwards of $9,393 and UK loss carry forwards (stated in Canadian dollars) of $46,631. No value has been ascribed to loss carry forwards in these  consolidated financial statements. Tax values of assets acquired may differ from their accounting values.</span></div><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The following revenue and net loss is attributable to Small Pharma for the period from the Acquisition date to March 31, 2024 and included in these consolidated financial statements for the comparative year.</span></div><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> </span></div><div style="padding-left:13.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:38.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,666)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS03_g59-63_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_PropertyPlantAndEquipment1Abstract', window );"><strong>Property, Plant and Equipment1 [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">EQUIPMENT</a></td>
<td class="text">EQUIPMENT<div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lab Equipment</span></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">664</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">239</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">903</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Small Pharma</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment write-down</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">664</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">930</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment write-down</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31,  2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">686</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">302</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">988</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at   March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">290</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">163</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation charge</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment write-down</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">430</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">664</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation charge</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment write-down</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31,  2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">587</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">260</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">847</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value as at March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">99</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_PropertyPlantAndEquipment1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant and Equipment [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_PropertyPlantAndEquipment1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_IntangibleAssetsAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">INTANGIBLE ASSETS</a></td>
<td class="text">INTANGIBLE ASSETS<div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:40.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IP Research &amp; Development </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patents</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">License</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,076</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">978</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,379</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,507</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Small Pharma</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,339&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,339&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,440</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,668</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,381</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,563</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,851</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,794</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,465</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,184</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization charge</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization charge</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">166</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,440</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,668</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,325</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,465</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value as at March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,851</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,794</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,367</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,018</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">IP Research &amp; Development</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Refer to note 4 for information on the Small Pharma Acquisition.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Patents</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Costs associated with patent procurement.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company performed its annual impairment test of intangible assets not yet in use at March 31, 2025. The recoverable amount was determined based on the relief from royalty method to arrive at the value-in-use (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">VIU</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;). The Company considered an estimate of future revenues and a reasonable royalty rate to apply to financial projections based on the current budget and future commercialization plans. In assessing the VIU, estimated future cash flows are discounted to their present value using a discount rate that reflects the assessment of royalty and business opportunities and risk as well as the market potential. The VIU calculations were performed using a pre-tax discount rate of 20.3% (2024 - 15.7%) and an estimated useful life of 15 year</span></div>s (2024 - 15 years). Based on the Company&#8217;s assessment, the recoverable amount is higher than the carrying value and therefore no impairment loss was recorded for the years ended March&#160;31, 2025 or 2024.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_IntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_IntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS38_g118-128_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RIGHT-OF-USE ASSETS AND LEASE LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfLeasesAndRightOfUseAssetsTextBlock', window );">RIGHT-OF-USE ASSETS AND LEASE LIABILITIES</a></td>
<td class="text">RIGHT-OF-USE ASSETS AND LEASE LIABILITIES<div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">During the year ended March&#160;31, 2025, the Company terminated its lease early, resulting in a loss on the derecognition of its right-of-use assets of $52 and a gain on derecognition of lease liabilities of $24. The loss on the derecognition of its right-of-use assets reflects the difference between the carrying value of the right-of-use asset and the recoverable amount at the time of derecognition. The gain on derecognition of lease liabilities was calculated as the difference between the carrying amount of the lease liability immediately before the termination and the payment made to settle the lease obligation. The net loss of $28 has been recognized as "other loss" in the consolidated statement of loss and comprehensive loss. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">a)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:9.96pt;text-decoration:underline">Right-of-use assets</span></div><div><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">424</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31,  2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">143</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value as at  March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">b)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.53pt;text-decoration:underline">Lease Liabilities</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest accretion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">291</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest accretion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on derecognition</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination penalty payment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DisclosureOfLeasesAndRightOfUseAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Leases And Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DisclosureOfLeasesAndRightOfUseAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_GoodwillAbstract', window );"><strong>Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGoodwillExplanatory', window );">GOODWILL</a></td>
<td class="text">GOODWILL<div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill is recognized at the acquisition date when total consideration exceeds the net identifiable assets acquired. </span></div><div><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,792</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition from Small Pharma</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,652&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31,  2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47,475</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31,  2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,487</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Impairment</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">For purposes of the Company&#8217;s goodwill impairment testing, the Company has grouped certain CGUs to test at the lowest level at which management monitors goodwill for internal management purposes, which is the Company wide level.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company performed its annual impairment test of goodwill at March&#160;31, 2025. The recoverable amount was determined based on value-in-use (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">VIU</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) and considered the cash flows of the group of CGUs based on the current budget and future commercialization plans. In assessing the VIU, estimated future cash flows are discounted to their present value using a discount rate that reflects market assessments of the time value of money and the risks specific to the CGUs. The VIU calculations were performed using a pre-tax discount rate of 20.3% (March&#160;31, 2024 - 15.7%). The Company utilized the run-off method, and no terminal period cash flows were considered. Based on the Company&#8217;s assessment, the recoverable amount is higher than the carrying value and therefore no impairment loss was recorded for the year ended March&#160;31, 2025 or March&#160;31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_GoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_GoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves, and Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">SHARE CAPITAL</a></td>
<td class="text">SHARE CAPITAL<div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">a)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:9.96pt;text-decoration:underline">Authorized share capital</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On September 19, 2024, the Company completed the Consolidation.  As a result, the number of Common Shares, warrants, options and earnings per share presented in these consolidated financial statements have been restated retrospectively for all the years to reflect the Consolidation.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The authorized share capital of Cybin consists of an unlimited number of Common Shares and an unlimited number of preferred shares without par value. The board of directors of Cybin would determine the designation, rights, privileges, and conditions attached to any preferred shares prior to issuance.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">b)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:9.53pt;text-decoration:underline">Issued share capital</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Common Shares</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As at March&#160;31, 2025, the Company had 23,364 Common Shares subject to transfer restrictions (March 31, 2024: 415,985). </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">During the year ended March 31, 2025, the Company completed the following share issuances:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On February 10, 2025, the Company established a new at-the-market equity program (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">2025 ATM Program</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221; and together with the 2023 ATM Program (see below), the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">ATM Programs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) that allow the Company to issue and sell up to US$100,000 of Common Shares from treasury to the public, from time to time. Distributions of Common Shares under the 2025 ATM Program are made pursuant to the terms and conditions of an at-the-market equity distribution agreement (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">2025 Distribution Agreement</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) dated February 10, 2025, among the Company, Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald &amp; Co. The 2025 ATM Program is to be effective until the earlier of the issuance and sale of all of the Common Shares issuable pursuant to the 2025 ATM Program and September 17, 2025, unless earlier terminated in accordance with the terms of the 2025 Distribution Agreement.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">During the year ended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">March&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, the Company sold 1,609,298 Common Shares under the ATM Programs at an average price of $13.62 (US$9.52) per Common Share, for aggregate gross proceeds of $21,924 (US$15,322). Share issuance costs related to the ATM Programs for the year were $941.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">There were two</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> Common Shares issued in connection with the Consolidation as a result of rounding.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">During the year ended March 31, 2024, the Company completed the following share issuances:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On August 23, 2023, the Company established a new at-the-market equity program (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">2023 ATM Program</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221; and together with the 2022 at-the-market equity program, the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Prior</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">ATM Programs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) that allows the Company to issue and sell up to US$35,000 of Common Shares from treasury to the public, from time to time. Distributions of Common Shares under the 2023 ATM Program are made pursuant to the terms and conditions of an at-the-market equity distribution agreement (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">2023 Distribution Agreement</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) dated August 23, 2023, among the Company, Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald &amp; Co. The 2023 ATM Program was terminated on February 10, 2025.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">During the year ended March 31, 2024, the Company sold 898,434 Common Shares under the Prior ATM Programs at an average price of $17.29 (US$12.82) per Common Share, for aggregate gross proceeds of $15,532 (US$11,518). Share issuance costs related to the ATM Programs for the year were $832.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On May 30, 2023, the Company entered into an agreement (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">LPC Agreement</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) with Lincoln Park Capital Fund, LLC (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">LPC</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;). Subject to the terms and conditions of the LPC Agreement, the Company has the right to sell, and LPC is obligated to purchase, up to US$30,000 of Common Shares over a 36-month period at prices that are based on the market price at the time of each sale to LPC. Cybin, in its sole discretion, controls the timing and amount of all sales of Common Shares under the LPC Agreement. During the year ended March 31, 2024, the Company sold 50,658 Common Shares, at an average price of $12.30 (US$9.18) per Common Shares, for aggregate gross proceeds of $623 (US$465) pursuant to the LPC Agreement. Share issuance costs related to the LPC Agreement for the year ended March  31, 2024 were $476 (US$351).</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cybin has the right to terminate the LPC Agreement at any time at no cost or penalty. LPC has agreed not to engage in any short selling or hedging activity of any kind in the Common Shares. As consideration for LPC&#8217;s obligation to purchase Common Shares from the Company at its direction under the LPC Agreement, Cybin issued 66,812 Common Shares to LPC as a commitment fee on May 30, 2023.  The LPC Agreement provides that Cybin may not issue or sell any Common Shares to LPC under the LPC Agreement which, when aggregated with all other Common Shares then beneficially owned by LPC and its affiliates (as calculated pursuant to Section 13(d) of the U.S. Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder), would result in LPC beneficially owning more than 9.99% of the outstanding Common Shares. On July 31, 2023, Cybin announced that it had suspended all sales under the LPC Agreement. On August 23, 2023, the Company filed a prospectus supplement to the base shelf prospectus dated August 17, 2023 to re-qualify sales of up to US$30,000 of the Company&#8217;s Common Shares pursuant to the LPC Agreement. On November 9, 2023, the Company announced that it has, again, suspended all sales under the LPC Agreement. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On August 4, 2023, the Company completed a public offering (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">August 2023 Offering</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) of 638,545 units of the Company (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">August 2023 Units</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) at a price of US$12.92 per August 2023 Unit for gross proceeds of $11,018 (US$8,250) pursuant to a supplement to the Company&#8217;s short form base shelf prospectus dated July 5, 2021. Each August 2023 Unit is comprised of one Common Share and one Common Share purchase warrant (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">August 2023 Warrants</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;). Each August 2023 Warrant is exercisable to acquire one Common Share at a price of $21.85 (US$15.20) for a period of 60 months from issuance, subject to acceleration in certain circumstances. In connection with the Offering, Cybin paid the underwriters a cash commission of $506 (US$379) and incurred additional share issuance costs, being professional fees of $622 (US$465).</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On November 14, 2023, the Company completed a public offering (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">November 2023 Offering</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) of 1,754,386 units of the Company (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">November 2023 Units</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) at a price of US$17.10 per November 2023 Unit for gross proceeds of $41,107 (US$30,000) pursuant to a supplement to the Company&#8217;s short form base shelf prospectus dated August 17, 2023. Each November 2023 Unit is comprised of one Common Share and one Common Share purchase warrant (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">November 2023 Warrants</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;). Each November 2023 Warrant is exercisable to acquire one Common Share at a price of $27.86 (US$19.38) between May 14, 2024 and May 14, 2029, subject to acceleration in certain circumstances. In connection with the November 2023 Offering, Cybin paid the underwriters a cash commission of $2,096 (US$1,530) and incurred additional share issuance costs being professional fees of $339 (US$247).</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On March 19, 2024, the Company completed a private placement (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">March 2024 Offering</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) of 9,179,927 Common Shares at a price of US$16.34 per Common Share for gross proceeds of $202,995 (US$150,000). 415,985 Common Shares issued in the March 2024 Offering were subject to resale restrictions until July 20, 2024. In connection with the March  2024 Offering, Cybin paid the agent a cash commission of $11,726 (US$8,665) and incurred additional share issuance costs being professional fees of $504 .</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Preferred</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Shares</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As at March&#160;31, 2025,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> the Company had no preferred shares outstanding (2024- nil).</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Cybin US Class B Shares</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:65.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Class B Shares</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530,542.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Converted into Common Shares</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(494,457.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,084.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,084.7&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As at March&#160;31, 2025, 36,084.7 class B common shares of Cybin US (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Class B Shares</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8221;) were outstanding, and are exchangeable for a total of 9,496 Common Shares. The Class B Shares are exchangeable at the holder&#8217;s option for Common Shares on the basis of 0.26316 Common Shares for 1 Class B Share. These consolidated financial statements reflect issued Class B Shares on an as-converted basis. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">During the year ended March 31, 2025, no Class B Shares were issued or converted.</span></div><div style="margin-top:10pt;padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">c)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%;padding-left:10.56pt;text-decoration:underline">Warrants</span></div><div style="text-align:justify;text-indent:0.15pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The continuity of the outstanding warrants for the years ended March 31, 2025 and 2024, are as follows: </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:61.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Warrants</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Common Share Purchase Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611,329&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.02</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.46</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,658)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.14</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205,404)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.86</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,796,197&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.74</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,796,197</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.03</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,796,197</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.03</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unit Purchase Warrants</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,862&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.50</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,862)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at March 31, 2024 and March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Certain warrants were issued in USD, the weighted average exercise price is calculated using the closing exchange rate in effect as at the respective dates.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">        </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Each unit consisted of one Common Share and one half of one Common Share purchase warrant, with each Common Share purchase warrant being exercisable to acquire one Common Share at an exercise price of $123.50 per Common Share.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">During the year ended March 31, 2024, the Company had the following movement in warrants:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended March 31, 2024, 2,658 Common Share purchase warrants were exercised by various holders for aggregate proceeds to the Company of $56. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended March 31, 2024, 205,404 warrants with a weighted average exercise price of $131.86 expired unexercised.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">During the year ended March 31, 2024, the Company completed the following warrant issuances: </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On August 4, 2023, Cybin issued 638,545 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">August 2023 Warrants in connection with the August 2023 Offering. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Each August 2023 Warrant is exercisable to acquire one Common Share at a price of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> US$15.20</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> per Common Share until August 4, 2028, subject to acceleration in certain circumstances. </span></div><div style="padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company estimated the aggregate fair value of the August 2023 Warrants using the Black-Scholes option pricing model to be $4,600 (US$3,442) with the following assumptions: </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:81.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$12.92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$15.20</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On November 14, 2023, Cybin issued 1,754,386 November 2023 Warrants in connection with the November 2023 Offering. Each November 2023 Warrant is exercisable from May 14, 2024 to May 14, 2029 to acquire one Common Share at a price of </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">US$19.38</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">, subject to acceleration in certain circumstances.  </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company estimated the aggregate fair value of the November 2023 Warrants using the Black-</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Scholes option pricing model to be $17,842 (US$12,299) with the following assumptions: </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:81.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$17.48</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$19.38</span></td></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes information about warrants outstanding as at March&#160;31, 2025:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:30.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Expiry</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants outstanding</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants exercisable</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average of exercisable price</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated fair value</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average remaining contractual life</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$000&#8217;s</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2028</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635,887&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635,887&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$15.20</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,578</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 14, 2029</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,754,386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,754,386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$19.38</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,842</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 15, 2030</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,843&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,843&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.50</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,891</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 20, 2030</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.32</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.39</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2030</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.50</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.63</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,796,197</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,796,197</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.03</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,594</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.11</span></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On August 27, 2024, the Company, upon receiving shareholder approval, extended the expiry dates of the warrants originally expiring on June 15, 2025, August 20 , 2025, and November 15, 2025 to June 15, 2030, August 20, 2030, and November 15, 2030, respectively. The Company extended the expiry date of 405,924 </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">warrants, of which 260,527 warrants related to officers and directors of the Company. No other changes to the terms of the warrants were made. As a result of the modification, the Company recorded an additional expense, related to the incremental fair value of the extended warrants, of $1,955 in the statements of loss and comprehensive loss as "Share-based compensation".</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">d</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">)  </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%;text-decoration:underline"> Stock options</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On November 5, 2020, Cybin adopted an equity incentive plan. Under the plan, the board of directors may grant share-based awards to acquire such number of Common Shares as is equal to up to 20% of the total number of issued and outstanding Common Shares at the time such awards are granted. Options granted under the plan vest over a period of time at the discretion of the board of directors. On August 27, 2024, the board of directors and the shareholders re-approved the equity incentive plan and approved certain amendments to the plan, including an increase to the fixed number of Incentive Stock Options (as defined in the plan), certain changes to the board of directors' authority to amend existing awards, and certain other housekeeping amendments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in options for the years ended March 31, 2025 and 2024 are as follow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s: </span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:66.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Options</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average exercise price</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778,163&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.68&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,735)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.08&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742,139&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.17</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,484,626&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.84</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,270,081)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,956,684</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.23</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable as at March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,591,976</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.19</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">During the year ended March 31, 2025, the Company completed the following option issuances:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On April 5, 2024, the Company granted options to purchase up to 308,294 Common Shares, of which 134,872 were granted to employees, 144,738 were granted to officers of the Company and 28,684 were granted to consultants. The granted options have an exercise price of $21.28 per Common Share and expire on April 5, 2029. The granted options have different vesting schedules; 38,536 options vested immediately and 269,758 options vest over two years. The aggregate estimated grant date fair value was determined to be $4,619 calculated using the Black-Scholes option pricing model with the following assumptions: </span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:81.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.62%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on historical share price of the Company</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.13%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested forfeiture rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0% - 3.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.28</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.28</span></td></tr></table></div><div style="margin-top:12pt;padding-left:17.85pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On May 5, 2024, the Company cancelled options to purchase up to 1,199,655 Common Shares (exercise prices ranged from $27.17 to $119.70). The unvested options were vested based on an accelerated cancellation criteria which resulted in $1,185 of share based compensation expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On August 15, 2024, the Company granted options to purchase up to 3,061,232 Common Shares, of which 940,168 were granted to employees, 1,980,888 were granted to officers and directors and 140,176 were granted to consultants. The granted options have an exercise price of $13.11 per Common Share and expire on August 15, 2034. Certain options vested immediately, while others vest over periods of up to two years. The aggregate estimated grant date fair value was determined to be $34,822 calculated using the Black-Scholes option pricing model with the following assumptions: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07%</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on historical share price of the Company</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.69%</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested forfeiture rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%  - 3.4%</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.30</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.11</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On November 27, 2024, the Company granted options to purchase up to 80,100 Common Shares, of which 73,100 were granted to employees and 7,000 was granted to a consultant. The granted options have an exercise price of $14.37 per Common Share and expire on November 27, 2034. The granted options vest over periods of up to two years. The aggregate estimated grant date fair value was determined to be $982 calculated using the Black-Scholes option pricing model with the following assumptions: </span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:74.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.23%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on historical share price of the Company</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.06%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested forfeiture rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0% - 3.4% </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.37</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.37</span></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">On March 7, 2025, the Company granted options to purchase up to 35,000 Common Shares to a consultant. The granted options have an exercise price of $10.45 per Common Share and expire on March 7, 2035. The granted options vest over period of one year. The aggregate estimated grant date fair value was determined to be $307 calculated using the Black-Scholes option pricing model with the following assumptions: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:74.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.03%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on historical share price of the Company</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.43%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested forfeiture rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">D</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">uring the year ended March 31, 2024, the Company completed the following option issuances:</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On June 29, 2023, the Company granted options to purchase up to 305,661 Common Shares, of which 105,026</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> were granted to employees, 99,027 were granted to officers of the Company, 80,949 were granted to consultants, and 20,659 were granted to directors of the Company. The granted options have an exercise price of $16.72 per Common Share and expire on June 30, 2028. The granted options have different vesting schedules; 39,474 options vested immediately, 18,422 options vest over three months, 2,632 options vest over one year, and 245,133 options vest over two years.  The aggregate estimated grant date fair value was determined to be $4,080, calculated using the Black-Scholes option pricing model with the following assumptions: </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:81.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.78%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.86</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.72</span></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On September 26, 2023, the Company granted options to purchase up to 31,842 Common Shares, of which 3,553 were granted to an employee and, 28,289 were granted to consultants. The granted options have an exercise price of $30.02 per Common Share, and 25,657 options expire on September 26, 2026 and the re</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">maining 6,185 options expire on September 26, 2028. The granted options have different vesting schedules. 9,868 options vest over three months, 5,263 options vest over six months, 10,526 options vest over one year, 2,632 options vest over fifteen months, and 3,553 options vest over 18 months.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> The aggregate estimated grant date fair value was determined to be $577, calculated using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> Options expiring on September 26, 2026</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:81.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.02</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.02</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Options  expiring on September 26, 2028</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:81.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Risk-free interest rate</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.02</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.02</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On November 16, 2023, the Company granted options to purchase up to 673,682 Common Shares, of which 584,211 were granted to officers, 42,104 were granted to directors, 34,209 were granted to employees and 13,158 were granted to a consultant. The granted options have an exercise price of $27.17 per Common Share, 13,158 options expire on November 16, 2026 and the remaining 660,524 options expire on November 16, 2028. The granted options have different vesting schedules. 496,052 options vest immediately and 177,630 options vest over two years. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The aggregate estimated grant date fair value was determined to be $10,907, calculated using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Options expiring on November 16, 2026</span></div><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:81.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.17</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Options expiring on November 16, 2028</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:81.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.17</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 20, 2024, the Company granted options to purchase up to 526 Common Shares to an employee with an exercise price of $21.28 per Common Share which expire on March 20, 2029 and vest over two years.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The aggregate estimated grant date fair value was determined to be $8, calculated using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:81.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.00%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.28</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.28</span></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">During the year ended March 31, 2024, the Company amended the expiry dates of certain options with former employees and consultants of the Company.  </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The following summarizes information about stock options outstanding on March&#160;31, 2025:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:26.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of options outstanding</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of options exercisable</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated  fair value</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average remaining life</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiry date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$000&#8217;s</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 6, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.11</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 6, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.72</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 6, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.28</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 7, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.12</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 15, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.50</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.20</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.50</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.50</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,869&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,869&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.50</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.58</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 11, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.24</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.70</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 14, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,829&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,829&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.12</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.11</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.72</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.28</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.14</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.82</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,895&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,895&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.90</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.16</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.99</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,342&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,342&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.11</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,339&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,339&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.72</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.28</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 28, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,475&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,475&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.20</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.24</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 26, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,657&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,657&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.02</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.17</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,896&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,896&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.00</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 4, 2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.94</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.92</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,526&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,526&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.76</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.94</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,949&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,949&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.72</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,710&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 26, 2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.02</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.49</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 20, 2029</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.28</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.97</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 5, 2029</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,873&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,994&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.28</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,742&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2032</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,895&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,895&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.20</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 15, 2034</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,784&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,877,860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.11</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,032&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.37</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 27, 2034</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,867&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.37</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.66</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 7, 2035</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.93</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,956,684</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,591,976</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47,427</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.13</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company recognized share-based payments expense related to the issuance of stock options for the year ended March 31, 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">of $40,914 (2024 - $13,886).</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The outstanding options and warrants disclosed above were anti-dilutive for the year ended March 31, 2025 and 2024 and did not impact the calculation of the loss per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves, and Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS AND BALANCES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_RelatedPartyAbstract', window );"><strong>Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">RELATED PARTY TRANSACTIONS AND BALANCES</a></td>
<td class="text">RELATED PARTY TRANSACTIONS AND BALANCES<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Key management personnel include persons having the authority and responsibility for planning, directing, and controlling the activities of the Company as a whole. The Company has determined its key management personnel to be certain executive officers and directors of the Company.</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The remuneration of key management personnel for the years ended March 31, 2025 and 2024 are as follows: </span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:67.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payroll, consulting and benefits</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,807</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,406&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 15.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,937</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,643&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 15.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,239</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,049&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%;padding-left:8pt"> For the year ended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">March&#160;31, 2025</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%">, includes $</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">6,640</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%"> (2024 - $5,145) presented in the consolidated statements of loss and comprehensive loss as a part of &#8220;General and administrative costs&#8221; and $</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">1,167 (2024 - $1,261)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%"> presented in the consolidated statements of loss and comprehensive loss as a part of &#8220;Research&#8221;.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_RelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_RelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory', window );">RESEARCH EXPENSES</a></td>
<td class="text">RESEARCH EXPENSES<div style="padding-left:13.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:67.546%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advancement of development programs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,547&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,799&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,319&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab and administration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional and consulting fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,910</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,362&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL AND ADMINISTRATIVE EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="text">GENERAL AND ADMINISTRATIVE EXPENSES<div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:70.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,694</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,519&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll, consulting and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,146</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,248&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and administration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,498</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional and consulting fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,156</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,918&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,305</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investor relations and Marketing media</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,286</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Listing fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">283</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,368</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,588&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of general and administrative expenses. [Refer: Administrative expenses]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONTRACTS, COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_CommitmentsAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">CONTRACTS, COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">CONTRACTS, COMMITMENTS AND CONTINGENCIES<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As at March&#160;31, 2025, the Company had entered into agreements for various studies which may require the Company to spend up to an additional $85,802. The Company expects to pay this amount within the 24 months ending March 31, 2027, however the timing and certainty of the payments are contingent on availability of materials and successful completion of certain milestones. The Company has the right to cancel the studies at its discretion, in which case a cancellation fee may apply, however the Company is not liable to pay the full amount of the studies. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition to the above, during the year ended March 31, 2022, the Company entered into an exclusive license agreement with Mindset Pharma Inc. to acquire access to a number of classes of tryptamine-based molecules to support Company&#8217;s early-stage research programs and a fully-paid, perpetual non-exclusive license to a separate class of tryptamine-based molecules. Upon the successful completion of certain milestones contemplated in the exclusive license, the Company may have to pay additional consideration of up to $13,657 (US$9,500). At the sole discretion of Cybin, the milestones may be paid in cash or in Common Shares, or a combination thereof, subject to the approval of Cboe Canada. Due to the nature of the arrangement, the timing and probability of future potential payments cannot be determined at this time, and no accrual has been recorded. Further, there is no assurance that the aforementioned milestones will be met at all. The agreement also contemplates a sales royalty of approximately 2% for all commercialized licensed products within the scope of the agreement. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company is party to certain employee and management contracts that contain severance obligations. These contracts contain clauses requiring additional payments to be made upon the occurrence of involuntary termination. As the likelihood of these events taking place is not determinable, no contingent liabilities have been recorded in the consolidated financial statements.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In the normal course of business, the Company may be subject to legal proceedings and claims. As at March&#160;31, 2025, there was no ongoing litigation and therefore no contingent liabilities have been recorded in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_CommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_CommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL MANAGEMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_CapitalManagementAbstract', window );"><strong>Capital Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory', window );">CAPITAL MANAGEMENT</a></td>
<td class="text">CAPITAL MANAGEMENT<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company&#8217;s objectives when managing capital are to safeguard the Company&#8217;s ability to continue as a going concern in order to pursue business opportunities and to maintain a flexible capital structure that optimizes the costs of capital at an acceptable risk. The Company&#8217;s intentions are to (i) provide financial capacity and flexibility in order to preserve its ability to meet its strategic objectives and financial obligations; (ii) maintain a capital structure which allows the Company to respond to changes in economic and marketplace conditions and affords the Company the ability to participate in new investments; (iii) optimize the use of its capital to provide an appropriate investment return to its shareholders equal with the level of risk; and (iv) maintain a flexible capital structure which optimizes the cost of capital at acceptable levels of risk.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company&#8217;s financial strategy is formulated and adapted according to market conditions in order to maintain a flexible capital structure that is consistent with its objectives and the risk characteristics of its underlying assets. The Company manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of its underlying assets. The Company maintains or adjusts its capital level to enable it to meet its objectives by raising capital through the issuance of securities.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company&#8217;s capital management objectives, policies and processes generally remained unchanged during the year ended March 31, 2025.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company requires capital to fund existing and future operations. The Company&#8217;s policy is to maintain adequate levels of capital at all times.</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company&#8217;s capital structure includes the following:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:59.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity comprised of:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share capital</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">464,364</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443,877&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributed surplus</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,414</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options reserve</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47,427</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants reserve</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,594</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,639&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,231)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,285)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deficit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(339,368)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226,231)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">237,200</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,927</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_CapitalManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital Management [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_CapitalManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 134<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_134&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text">FINANCIAL INSTRUMENTS<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company&#8217;s financial instruments are exposed to certain financial risks, which include currency risk, credit risk, liquidity risk and interest rate risk.</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company has classified its financial instruments as follows:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"><tr><td style="width:1.0%"></td><td style="width:50.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial assets, measured at fair value:</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">135,022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,992&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial assets, measured at amortized cost:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">706</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial liabilities, measured at amortized cost:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,418</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,805&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The carrying value of the Company&#8217;s financial instruments approximate their fair value.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%;text-decoration:underline">Fair value hierarchy of financial instruments</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company has categorized its financial instruments that are carried at fair value, based on the priority of the inputs to the valuation techniques used to measure fair value, into a three-level fair value hierarchy as follows:</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Level 1:  Fair value is based on unadjusted quoted prices for identical assets or liabilities in an active market. The types of assets and liabilities classified as Level 1 generally included cash. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Level 2: Fair value is based on quoted prices for similar assets or liabilities in active markets, valuation that is based on significant observable inputs, or inputs that are derived principally from or corroborated with observable market data through correlation or other means. Currently, the Company has no financial instruments that would be classified as Level 2. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Level 3: Fair value is based on valuation techniques that require one or more significant inputs that are not based on observable market inputs. These unobservable inputs reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability. Currently, the Company has no financial instruments that would be classified as Level 3. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">There were no transfers between levels of the fair value hierarchy for the year ended March 31, 2025.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%;text-decoration:underline">Financial risk management</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Credit risk</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company&#8217;s cash is exposed to credit risk.  The Company reduces its </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">credit risk on cash by placing these instruments with institutions of high creditworthiness. As at March&#160;31, 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">the Company&#8217;s maximum exposure to credit risk is the carrying value of its financial assets. </span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Liquidity risk</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Liquidity risk is the risk that an entity will encounter difficulty in raising funds to meet commitments associated with financial instruments. The Company manages liquidity by maintaining adequate cash balances to meet liabilities as they become due.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As at March&#160;31, 2025, the Company had cash of $135,022 (March&#160;31, 2024 - $208,992) in order to meet current liabilities. Current liabilities include accounts payable and accrued liabilities of $21,418</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:139%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(March&#160;31, 2024 - $9,805) and lease liabilities of $nil (March 31, 2024 - $291). All amounts are due within the next 12 months. </span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Market risk</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The significant market risks to which the Company is exposed are interest rate risk and currency risk.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%;text-decoration:underline">Interest rate risk</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Interest rate risk is the risk that the fair value or the future cash flows of a financial instrument will fluctuate because of changes in market interest rates. In seeking to minimize the risks from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities.  Assuming that all other variables remain constant, as at March&#160;31, 2025, a 1% decline on the interest rate generated on cash would have resulted in a reduction of interest income of $1,145 over a one-year period.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%;text-decoration:underline">Currency risk</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company is exposed to currency risk to the extent that monetary operational expenses are denominated in both CAD and USD while the functional currency of CAD is used for reporting.  The Company has not entered into any foreign currency contracts to mitigate this risk.</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">At March&#160;31, 2025 the Company had the following balances in monetary assets and monetary liabilities which are subject to fluctuation against CAD:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.673%"><tr><td style="width:1.0%"></td><td style="width:48.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominated in:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">US$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GBP</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EUR</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,416&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,841)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90,928</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(339)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">618</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4376</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8571</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5540&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equivalent in Canadian dollars</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">130,718</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(630)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">960</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Impact of 10% change in exchange rate</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,072</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(63)</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>Such analysis excludes any indirect economic or geo-political effects of such currency fluctuations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">INCOME TAX</a></td>
<td class="text">INCOME TAX <div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Major items causing the Company&#8217;s income tax rate to differ from the Canadian statutory rate of approximately 26.5% are as follows:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:47.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended March 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 3.77pt 0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 3.77pt 0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 3.77pt 0 1pt"></td><td colspan="3" style="padding:0 3.77pt 0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 3.75pt 0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(113,137)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(78,080)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected recovery at statutory rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,981</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,691</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital losses acquired on acquisition of subsidiary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,658&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,497)</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,680)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issuance costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,420</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Difference between Canadian and foreign tax rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,317)</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,440)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange on unbooked deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">351</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(103)</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrecognized deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,537)</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,405)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax recovery</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 3.77pt 0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 3.77pt 0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The significant components of the Company&#8217;s deferred tax assets resulting from temporary differences, unused tax credits and unused tax losses, that have not been included on the consolidated statement of financial position, are as follows:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:59.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital loss carryforwards - Canada</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,310</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,168</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital loss carryforwards - United States</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,533</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,344</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital loss carryforwards - Ireland</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,327</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,391</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital loss carryforwards - United Kingdom</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,767</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,282</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,653</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,474</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development expenditures</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,538</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,681</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issuance costs</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,102</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation/Capital cost allowance differences</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61,245</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,708</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(61,245)</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,708)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Non-capital loss balance</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As at March&#160;31, 2025, the Company has non-capital losses in Canada, which under certain circumstances can be used to reduce taxable income of future years. The non-capital losses expire as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year of expiry</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">863</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,856</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,704</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,397</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2045</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,105</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">84,154</span></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As at March&#160;31, 2025, the Company has non-capital losses in the United States and Massachusetts of $12,064, which under certain circumstances can be used to reduce the taxable income of future years. The federal losses have no expiry but are subject to limitations on utilization as laid out below. The Massachusetts non-capital losses, stated in Canadian dollars expire as follows:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.993%"><tr><td style="width:1.0%"></td><td style="width:82.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year of expiry</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,053</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,543</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,979</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,593</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,425</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2045</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,471</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,064</span></td></tr></table></div><div style="padding-left:18pt"><span style="background-color:#ffde0f;color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:139%"> </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Although the US federal losses carryforward indefinitely, they are subject to restrictions on their deductibility. For federal purposes the deductibility of $2,596 is restricted to 80% of taxable income in the year of deduction. The deductibility of $1,053 is further restricted to an annual limitation under Section 382. As at March&#160;31, 2025, the annual limitation was $153.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As at March&#160;31, 2025, the Company has non-capital losses in Ireland, which under certain circumstances can be used to reduce taxable income of future years. The non-capital losses in Ireland, stated in Canadian Dollars, expire as follows:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"> </span></div><div style="margin-bottom:10pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.275%"><tr><td style="width:1.0%"></td><td style="width:81.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.528%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year of expiry</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2042</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,965</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2043</span></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2044</span></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,857</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2045</span></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57,875</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">137,714</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">As at March&#160;31, 2025 the Company had $43,208 of non-capital losses in UK which under certain circumstances can be used to reduce the taxable income of future years. These losses do not expire.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_EventsAfterReportingPeriodAbstract', window );"><strong>Events after reporting period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">ATM Program</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">During the period from April 1, 2025 to June&#160;30, 2025, the Company sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">1,422,423 Common Shares, at an average price of US$7.36 per Common Share, for aggregate gross proceeds of US$10,465, through its 2025 ATM Program.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Convertible Debentures</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On June 30, 2025, the Company entered into a securities purchase agreement (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">SPA</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) with High Trail Special Situations LLC (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">High Trail</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;), pursuant to which the Company agreed to issue to High Trail up to US$500,000 of unsecured convertible debentures (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Convertible Debentures</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;). The sale and issuance of US$50,000 principal amount of Convertible Debentures was completed on June 30, 2025. </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Convertible Debentures have a two-year term (the &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Convertible Debenture Term</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;). The Company is to pay guaranteed interest equal to 11% of the amount issued for the Convertible Debenture Term (the equivalent of 5.5% per annum). Such interest is to be pre-paid on closing. Upon the occurrence of an event of default, interest would increase to 18% per annum on the outstanding principal balance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Subject to the terms of the SPA and the Convertible Debentures, High Trail is to be entitled to convert the principal amount of, and accrued and unpaid interest, if any, in whole or in part, from time to time, into Common Shares at a conversion price per Common Share equal to the lower of (a) 130% of the volume weighted average price (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">VWAP</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) of the Common Shares on the day prior to the initial issuance of the Convertible Debentures, or (b) the VWAP of the Common Shares during the <span style="-sec-ix-hidden:f-1169">five</span> trading days immediately prior to conversion.  </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company, in its sole discretion, may prepay any outstanding amount under the Convertible Debentures, in whole or in part, in cash by providing High Trail with advance written notice at least five trading days prior to such prepayment. The prepayment is to include, (i) if paid during the first year after closing, a 5% premium on the amount of the prepayment or (ii) if paid during the second year after closing, a 3% premium on the amount of the prepayment.  </span></div>The terms of the Convertible Debentures restrict the conversion of Convertible Debentures by High Trail if such a conversion or exercise would cause High Trail, together with any affiliate thereof, to beneficially own in excess of 4.99% of the number of Common Shares outstanding immediately after giving effect to such conversion.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_EventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Events after reporting period [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_EventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfIFRSCompliance', window );">Statement of compliance</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%">The Company&#8217;s consolidated financial statements have been prepared in accordance with IFRS Accounting Standards (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:124%">IFRS</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%">&#8221;) as issued by the International Accounting Standards Board (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:124%">IASB</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%">&#8221;). </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%">The policies applied to these consolidated financial statements are based on IFRS, which have been applied consistently to all periods presented. These consolidated financial statements were issued and effective as at June&#160;30, 2025, the date the Board of Directors approved these consolidated financial statements.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company&#8217;s board of directors has the power to amend the consolidated financial statements after issuance.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock', window );">Basis of measurement</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Basis of measurement</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">These consolidated financial statements have been prepared on a going concern basis, under the historical cost convention, except for certain financial instruments classified at fair value upon initial recognition.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory', window );">Functional and presentation currency</a></td>
<td class="text"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Functional and presentation currency</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The functional currency of a company is the currency of the primary economic environment in which the company operates. The presentation currency for a company is the currency in which the company chooses to present its financial statements.</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">These consolidated financial statements are presented in Canadian dollars, the Company&#8217;s presentation currency. The subsidiaries&#8217; functional currencies are as follows:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:37.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Entity</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ownership</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cybin Corp.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollars</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Journey</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serenity</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybin US</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adelia</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cybin IRL </span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybin UK Ltd</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Great Britain pounds</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> For accounting purposes, Cybin US is a wholly-owned subsidiary of Cybin. Certain former Adelia Shareholders hold Class B Shares (defined below) in Cybin US.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfBasisOfConsolidationPolicyTextBlock', window );">Basis of consolidation</a></td>
<td class="text">Basis of consolidation <div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company consolidates entities which it controls. Control exists when the Company has the power, directly and indirectly to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. </span></div>Intercompany balances, and any unrealized gains and losses or income and expenses arising from transactions with controlled entities are eliminated to the extent of the Company&#8217;s interest in the entity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Cash and cash equivalents</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash and cash equivalents are comprised of cash on deposit and highly liquid short-term interest-bearing variable rate investments with an original maturity of three months or less, or which are readily convertible into a known amount of cash with no significant changes. As at March&#160;31, 2025 and March&#160;31, 2024 there were no cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories', window );">Inventories</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Inventories</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Inventories include raw materials and finished goods. Raw materials are stated at the lower of cost and replacement cost with cost determined on a first-in, first-out basis. The Company monitors the shelf life and expiry of finished goods to determine when inventory values are not recoverable and a write-down is necessary.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Equipment</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Equipment</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Equipment consists of lab and computer equipment and are recorded at cost less accumulated depreciation and accumulated impairment losses. Cost includes all expenditures incurred to bring the asset to the location and condition necessary for them to be operating in the manner intended by management. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Depreciation is recognized based on the cost of the item less its estimated residual value, over its estimated useful life on a straight-line basis at the following rates:</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Lab equipment &#8211; 5 years</span></div><div style="padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt">Computer equipment &#8211; 3 years</span></div>An item of equipment and any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the consolidated statement of loss and comprehensive loss when the asset is derecognized. The assets&#8217; residual values, useful lives and methods of depreciation are reviewed at each reporting date and adjusted prospectively if appropriate.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory', window );">Intangible Assets</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Intangible Assets</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Intangible assets include expenditures related to obtaining patents, software related items and in-process research and development (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">IPR&amp;D</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;). The amortization of software related items begins when the software is in use and will be amortized on a straight-line basis over a period of 3 years. The amortization of patent costs commences when the associated products are available for commercial sale and is amortized on a straight-line basis over its respective legal lives or economic life, if shorter. Patents have an estimated useful life of 17 years. Amortization methods, useful lives, and residual values are reviewed at each reporting date and adjusted if appropriate. Acquired IPR&amp;D is capitalized based on technical feasibility and remains on the balance sheet, subject to impairment. Acquired IPR&amp;D is initially measured at fair value and recognized as an indefinite-lived intangible asset until completion or abandonment of the related project. Amortization commences when the assets become available for use. Expenditures on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in operations as incurred. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Development activities involve a plan or design for the production of new, or substantially improved, products or processes related to the Company&#8217;s development of psychedelic-based therapeutics. Development expenditures are capitalized only if the relevant IFRS criteria are met. Capitalized development expenditures </span></div>are amortized from the beginning of commercial production and sales and are amortized on a straight-line basis over the remaining useful life of the related patents. Development expenditures, in relation to the Company&#8217;s psychedelic-based therapeutics, have not satisfied the above criteria and are recognized in operations as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory', window );">Goodwill</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Goodwill</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Goodwill represents the excess of the consideration transferred for the acquisition of an entity over the fair value of the net identifiable assets. Goodwill is initially measured at cost, and subsequently recorded at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Company&#8217;s cash-generating units (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">CGUs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;) that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those CGUs. The Company tests for impairment annually, or when indications of impairment exist.  Impairment is determined for goodwill by assessing if the carrying value of CGUs, including goodwill, exceeds its recoverable amount determined as the greater of the estimated fair value less costs of disposal and the value in use. Impairment losses recognized in respect of the CGUs are first allocated to the carrying value of goodwill and any excess is allocated to the carrying amount of assets in the CGUs. Any goodwill impairment is recorded in the consolidated statement of loss and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory', window );">Impairment of long-lived assets</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Impairment of long-lived assets</span></div>Long-lived assets, including equipment and intangible assets, are reviewed for impairment at each consolidated statement of financial position date or whenever events or changes in circumstances indicate that the carrying amount of the asset exceeds its recoverable amount. Where the carrying value of an asset exceeds its recoverable amount, which is the higher of value in use and fair value less costs to sell, the asset is written down accordingly. Where it is not possible to estimate the recoverable amount of an individual asset, the impairment test is carried out on the asset&#8217;s cash-generating unit, which is the lowest group of assets in which the asset belongs for which there are separate cash inflows that are largely independent of the cash inflows from other assets. An impairment loss is charged to operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Financial instruments</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Recognition and initial measurement</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company initially recognizes financial instruments on the trade date, which is the date on which the Company becomes a party to the contractual provisions of the instrument. A financial asset or financial liability is measured initially at fair value plus/minus, for an item not at fair value through profit or loss (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">FVTPL</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;), transaction costs that are directly attributable to its acquisition or use.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">Classification</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Financial asset</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On initial recognition, a financial asset is classified as measured at: amortized cost, fair value through other comprehensive income (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">FVOCI</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">&#8221;), or FVTPL.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">A financial asset is measured at amortized cost if it meets both of the following conditions and is not designated as at FVTPL:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company currently measures accounts receivable at amortized cost. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">A debt instrument is measured at FVOCI only if it meets both of the following conditions and is not designated as at FVTPL:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in FVOCI. This election is made on an investment-by-investment basis. The Company has not elected to present any assets as FVOCI.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Cash is measured at FVTPL.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In addition, on initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortized cost as FVOCI or FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Business model assessment</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company makes an assessment of the objective of a business model in which an asset is held at a portfolio level because this best reflects the way the business is managed and information is provided to management. The information considered includes:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The stated policies and objectives for the portfolio and the operation of those policies in practice. In particular, whether management&#8217;s strategy focuses on earning contractual interest revenue, maintaining a particular interest rate profile, matching the duration of the financial assets to the </span></div><div style="padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">duration of the liabilities that are funding those assets or realizing cash flows through the sale of the assets;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">How the performance of the portfolio is evaluated and reported to the Company&#8217;s management;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">How managers of the business are compensated (e.g. whether compensation is based on the fair value of the assets managed or the contractual cash flows collected); and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The frequency, volume and timing of sales in prior periods, the reasons for such sales and its expectation about future sales activity. However, information about sales activity is not considered in isolation, but as part of an overall assessment of the Company&#8217;s stated objective for managing the financial asset is achieved and how cash flows are realized. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Assessment whether contractual cash flows are solely payments of principal and interest</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">For the purpose of this assessment, &#8216;principal&#8217; is defined as the fair value of the financial asset on initial recognition. &#8216;Interest&#8217; is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g. liquidity risk and administrative costs), as well as profit margin. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In assessing whether the contractual cash flows are solely payments of principal and interest, the Company considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of the contractual cash flows such that it would not meet this condition. In making the assessment, the Company considers:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">contingent events that would change the amount and timing of cash flows;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">leverage features;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">prepayment and extension terms;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">terms that limit the Company&#8217;s claim to cash flows from specified assets (e.g. non-recourse asset arrangements); and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">features that modify consideration of the time value of money (e.g. periodical rest of interest rates).</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Reclassifications</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company would reclassify a financial asset when the Company changes its business model for managing the financial asset. All reclassifications are recorded at fair value at the date of the reclassification, which becomes the new carrying value. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Financial assets are not reclassified subsequent to their initial recognition, except in the period after the Company changes its business model for managing financial assets. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Financial liabilities</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company classifies its financial liabilities at amortized cost or FVTPL. The Company currently measures accounts payable, lease liabilities and accrued liabilities at amortized cost.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Derecognition </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Financial assets</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transition in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and it does not retain control of the financial asset. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">On derecognition of a financial asset, the difference between the carrying amount of the asset (or the carrying amount allocated to the portion of the asset derecognized) and the sum of (i) the consideration received (including any new assets obtained less any new liability assumed) and (ii) cumulative gain or loss that had been recognized in other comprehensive income is recognized in profit or loss. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Financial liabilities </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled, or expire. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Modifications of financial assets and financial liabilities </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Financial assets</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If the terms of a financial asset are modified, the Company evaluates whether the cash flows of the modified asset are substantially different. If the cash flows are substantially different, then the contractual rights to cash flows from the original financial asset are deemed to have expired. In this case, the original financial asset is derecognized and a new financial asset is recognized at fair value. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If the cash flows of the modified asset carried at amortized cost are not substantially different, then the modification does not result in derecognition of the financial asset. In this case, the Company recalculates the gross carrying amount of the financial asset and recognizes the amount arising from adjusting the gross carrying amount as a modification gain or loss in profit or loss. If such a modification is carried out because of financial difficulties of the borrower, then the gain or loss is presented together with impairment losses. In other cases, it is presented as interest income. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Financial liabilities</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company derecognizes a financial liability when its terms are modified and the cash flows of the modified liability are substantially different. In this case, a new financial liability based on the modified terms is recognized at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognized in profit or loss. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Offsetting</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Financial assets and financial liabilities are offset and the net amount presented in the consolidated statement of financial position when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Income and expenses are presented on a net basis only when permitted under IFRS, or for gains and losses arising from a group of similar transactions. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Fair value measurement</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or, in its absence, the most advantageous market to which the Company has access at that date. The fair value of a liability reflects its non-performance risk. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">When one is available, the Company measures the fair value of an instrument using the quoted price in an active market for that instrument. A market is regarded as active if transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If there is no quoted price in an active market, then the Company uses valuation techniques that maximize the use of relevant observable inputs and minimize the use of unobservable inputs. The chosen valuation technique incorporates all of the factors that market participants would take into account in pricing a transaction. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The best evidence of the fair value of a financial instrument on initial recognition is normally the transaction price (i.e. the fair value of the consideration given or received). If the Company determines that the fair value on initial recognition differs from the transaction price and the fair value is evidenced neither by a quoted price in an active market for an identical asset or liability nor based on a valuation technique for which any observable inputs are judged to be insignificant in relation to the measurement, then the financial instrument is initially measured at fair value, adjusted to defer the difference between the fair value on initial recognition and the transaction price. Subsequently, that difference is recognized in profit or loss on an appropriate basis over the life of the instrument but no later than when the valuation is wholly supported by observable market data or the transaction is closed out. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If an asset or a liability at fair value has a bid price and an ask price, then the Company measures assets and long positions at bid price and liabilities and short positions at an ask price. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Portfolio of financial assets and financial liabilities that are exposed to market risk and credit risk that are managed by the Company on the basis of the net exposure to either market or credit risk are measured on the basis of a price that would be received to sell a net long position (or paid to transfer a net short position) for the particular risk exposure. Portfolio-level adjustment e.g. bid-ask adjustment or credit risk adjustments that reflect the measurement on the basis of the net exposure are allocated to the individual assets and liabilities on the basis of the relative risk adjustment of each of the individual instruments in the portfolio.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The fair value of a financial liability with a demand feature is not less than the amount payable on demand, discounted from the first date on which the amount could be required to be paid. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period during which the change has occurred.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:130%">  </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">Impairment</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Credit-impaired financial assets</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">At each reporting date, the Company assesses whether financial assets carried at amortized costs and debt financial assets carried at FVOCI are credit-impaired. A financial asset is &#8216;credit-impaired&#8217; when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Evidence that a financial asset is credit-impaired includes the following observable data: </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">Significant financial difficulty of the borrower or issuer;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">A breach of contract such as a default of past due event;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The restructuring of a loan or advance by the Company on terms that the Company would not consider otherwise;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">It is becoming probable that the borrower will enter bankruptcy or other financial reorganization; or </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt">The disappearance of an active market for a security because of financial difficulties. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">A loan that has been renegotiated due to a deterioration in the borrower&#8217;s condition is usually considered to be credit-impaired unless there is evidence that the risk of not receiving contractual cash flows has reduced significantly and there are no other indicators of impairment. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Recognition of allowance of expected credit losses (&#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%">ECL</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">&#8221;) in the consolidated statement of financial position</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company recognizes a loss allowance for ECL on trade receivables that are measured at amortized cost. The Company&#8217;s applied the simplified approach for trade receivables and recognizes the lifetime ECL for these assets. The ECL on trade receivables is estimated using a provision matrix based on the Company&#8217;s historical credit loss experience, adjusted for factors that are specific to the customers, general economic conditions and </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">an assessment of both the current as well as the forecast direction of conditions at the reporting date, including time value of money where appropriate. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">For all other financial assets measured at amortized cost of FVOCI, the Company recognizes lifetime ECL only when there has been a significant increase in credit risk since initial recognition. If the credit risk on such financial instruments has not increased significantly since initial recognition, the Company measures the loss allowance on those financial instruments at an amount equal to 12-months ECL. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Lifetime ECL represents the ECL that will result from all possible default events over the expected life of a financial asset. In contrast, 12-month ECL represents the portion of lifetime ECL that is expected to result from default events on a financial asset that are possible within 12 months after the reporting date. In assessing whether the credit risk on a financial asset has increased significantly since initial recognition, the Company compares the risk of default occurring on the financial asset at the reporting date with the risk of default occurring at the initial recognition. The Company considers both quantitative and qualitative factors that are supportable, including historical experience and forward-looking information that is available without undue cost or effort. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Irrespective of the above assessment, the Company presumes that the credit risk on a financial asset has increased significantly since initial recognition when contractual payments are more than 30 days past due, unless the Company has reasonable and supportable information that demonstrates otherwise. Despite the foregoing, the Company presumes that the credit risk on a financial asset has not increased significantly since initial recognition if the financial asset is determined to have low credit risk at the reporting date. </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company regularly monitors the effectiveness of the criteria used to identify whether there has been a significant increase in credit risk and revises them as appropriate to ensure that the criteria are capable of identifying significant increase in credit risk before the amount becomes pas due. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Definition of default</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">For internal credit risk management purposes, the Company considers a financial asset not recoverable if the customer balance owing is 180 days past due and information obtained from the customer and other external factors indicate that the customer is unlikely to pay its creditors in full.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%">Write-off</span></div>Financial assets are written off (either partially or in full) when there is no realistic prospect of recovery. This is generally the case when the Company determines that the counterparty does not have assets or sources of income that could general sufficient cash flows to repay the amounts subject to the write-off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Company&#8217;s procedures for recovery of amounts due.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Taxation</a></td>
<td class="text"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Taxation</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Income tax comprises current and deferred tax. Income tax is recognized in the consolidated statement of loss and comprehensive loss except to the extent that it relates to items recognized directly in equity, in which case the income tax is also recognized directly in equity.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Current income tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted, at the end of the reporting period, and any adjustment to tax payable in respect of previous years.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from audits by taxing authorities. Where the outcome of these tax-related matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Deferred income tax is recorded using the asset and liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences do not result in deferred tax assets or liabilities: the initial recognized of assets or liabilities that affect neither accounting or taxable loss; or difference relating to investment in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the consolidated statement of financial position date.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized. </span></div>Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its correct tax assets and liabilities on a net basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory', window );">Share capital</a></td>
<td class="text"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Share capital</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Equity instruments are contracts that give a residual interest in the net assets of the Company. Financial instruments issued by the Company are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Common Shares and the Company&#8217;s Common Share purchase warrants and options are classified as equity instruments. </span></div>Incremental costs directly attributable to the issue of new Common Shares or warrants are shown in equity as a deduction, net of tax, from the proceeds.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based compensation</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Share-based compensation</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Under the Company&#8217;s equity incentive plan, all stock options granted may have graded vesting periods and are exercisable up to a maximum of 10 years form the date of grant. Each tranche of an award with graded vesting periods is considered a separate grant at each grant date for the calculation of fair value, and the resulting fair value is amortized over the vesting period of the respective tranches. The fair value of the options granted is measured using the Black-Scholes option pricing model taking into account the terms and conditions upon which the options were granted, the estimated volatility, estimated risk free rate and estimated forfeitures. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If a grant of the share-based payments is cancelled or settled during the vesting period (other than a grant cancelled by forfeiture when the vesting conditions are not satisfied or options granted in error and cancelled retroactively), the Company accounts for the cancellation or settlement as an acceleration of vesting, and recognizes immediately the amount that otherwise would have been recognized for services over the remainder of the vesting period. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The amount recognized for goods or services received during the vesting period is based on the best available estimate of the number of equity instruments anticipated to vest. The Company revises that estimate, if necessary, if subsequent information indicates that the number of share options anticipated to vest differs from previous estimates. On the vesting date, the Company revises the estimate to equal the number of equity instrument that ultimately vested. After the vesting date, the Company makes no subsequent adjustment to total equity for goods or services received if the share options are later forfeited or they expire at the end of the share option&#8217;s life. Upon expiration of options, the amount applicable to expired options is moved to contributed surplus.</span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">If a grant of the share based payment is modified during the vesting period (other than a grant cancelled by forfeiture when</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:130%">  </span>the vesting conditions are not satisfied) and the fair value of the new instruments is higher than the fair value of the original instrument, the incremental fair value granted is included in the measurement of the amount recognized for services received over the period from modification date until the date when the modified equity instruments vests, in addition to the amount based on the grant date fair value of the original equity instruments, which is recognized over the remainder of the original vesting period of the original instrument.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory', window );">Warrants</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Warrants</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company follows the relative fair value method with respect to the measurement of Common Shares and warrants issued as units. The proceeds from the issuance of units are allocated between share capital and warrants. The warrant component is recorded in equity reserve. Unit proceeds are allocated to Common Shares and warrants using the Black-Scholes option pricing model and the share price at the time of financing. If and when the warrants are exercised, consideration paid by the warrant holder, together with the amount previously recognized in warrant reserve, is recorded as an increase to share capital. A forfeiture rate is estimated on the grant date and is adjusted to reflect the actual number of warrants that vest. When stock options or warrants are cancelled, they are treated as if they have vested on the date of collation and any cost </span></div>not yet recognized in profit or loss is immediately expensed. Upon expiration of warrants, the amount applicable to expired warrants is moved to contributed surplus.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss per share</a></td>
<td class="text"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Loss per share</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Basic loss per share is calculated using the weighted-average number of shares outstanding during the period. The diluted earnings (loss) per share reflects the potential dilution of Common Share equivalents, such as outstanding stock options and warrants, in the weighted average number of Common Shares outstanding during the period, if they are dilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Currency translation</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Currency translation</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">All figures presented in the consolidated financial statements are reflected in Canadian dollars unless otherwise noted.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Foreign currency transactions are translated into Canadian dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the consolidated statement of financial position date are translated to Canadian dollars at the foreign exchange rate applicable as that date. Realized and unrealized exchange gains and losses are recognized through profit or loss. </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The assets and liabilities of foreign operations are translated into Canadian dollars at period-end exchange rates. Income and expenses, and cash flows of foreign operations are translated into Canadian dollars using average exchange rates. Exchange differences resulting from translating foreign operations are recognized in other comprehensive income (loss) and accumulated separately in shareholders&#8217; equity. </span></div>Foreign currency translation gains or losses arising from a monetary item receivable or payable to a foreign operation, the settlement of which is neither planned nor likely to occur in the foreseeable future and which in substance is considered to form part of the net investment in the foreign operation, are recognized in other comprehensive income (loss) in the translation reserve.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">Provisions</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Provisions are recorded when a present legal or constructive obligation exists as a result of past events where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and a reliable estimate of the amount of the obligation can be made.</span></div>The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the consolidated statement of financial position date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows. When some or all of the economic benefits required to settle, a provision is expected to be recovered from a third party, the receivable is recognized as an asset if it is virtually certain that reimbursement will be received and the amount receivable can be measured reliably.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations', window );">New standards and interpretations not yet adopted</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">New standards and interpretations</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The IASB has issued certain amendments to accounting and financial reporting standards effective for annual reporting periods beginning on or after January 1, 2024.</span></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">IAS 1, Presentation of Financial Statements ("IAS 1") - Classification of Liabilities as Current or Non-Current</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In January 2020, the IASB issued amendments to IAS 1. The amendments aim to promote consistency in applying the requirements by helping companies determine whether, in the consolidated statements of financial position, debt and other liabilities with an uncertain settlement date should be classified as current (due or potentially due to be settled within one year) or non-current. The amendments include clarifying the classification requirements for debt a company might settle by converting it into equity. The amendments are effective for annual reporting periods beginning on or after January 1, 2024.  The Company has determined that adoption of these amendments has no significant effect on the Company's consolidated financial statements.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline">New standards and interpretations not yet adopted </span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">IFRS 18, Presentation and Disclosure in Financial Statements</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In April 2024, the IASB issued IFRS 18 that is to replace IAS 1, Presentation of Financial Statements. The new standard aims to improve the quality of financial reporting by: (i) requiring defined subtotals in the statement of profit or loss; (ii) requiring disclosure about management defined performance measures; and (iii) adding new principles for aggregation and disaggregation of information.  The standard is effective for the annual reporting periods beginning on or after January 1, 2027, with early application permitted. The Company is in the process of assessing the impact of this new standard on its consolidated financial statements.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%">IFRS 9, Financial Instruments (&#8220;IFRS 9&#8221;) and IFRS 7, Financial Instruments: Disclosures (&#8220;IFRS 7&#8221;)</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">In May 2024, the IASB issued targeted amendments to IFRS 9 and IFRS 7 in response to practical implementation issues and to introduce new requirements applicable to both financial institutions and corporate entities. These amendments aim to enhance the clarity and consistency of financial reporting for various types of financial instruments and their related disclosures by (i) clarifying the date of recognition and derecognition for certain financial assets and liabilities, including a new exception for financial liabilities settled through an electronic cash transfer system (ii) providing help to determine whether a financial asset meets the Solely Payments of Principal and Interest criterion (iii) introducing new disclosures for instruments with contractual terms that may alter cash flows, such as financial instruments linked to the achievement of environmental, social, and governance targets, and (iv) updating the disclosure requirements for equity instruments designated at FVTOCI. The new standard is to be effective for annual periods beginning on or after January 1, 2026. The Company is in the process of assessing the impact of the standard on its consolidated financial statements.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">All other IFRSs and amendments issued but not yet effective have been assessed by the Company and are not expected to have a material impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Accounting Policy For Basis Of Measurement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DisclosureOfBasisOfConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Basis Of Consolidation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DisclosureOfBasisOfConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the currency of the primary economic environment in which the entity operates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for warrants. Warrants are financial instruments that give the holder the right to purchase ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 46<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_46&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfIFRSCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An explicit and unreserved statement of compliance with all the requirements of IFRSs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfIFRSCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DetailDescriptionOfFunctionalCurrenciesTableTextBlock', window );">Schedule of subsidiaries and functional currencies</a></td>
<td class="text">The subsidiaries&#8217; functional currencies are as follows:<div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:37.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Entity</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ownership</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cybin Corp.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollars</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Journey</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serenity</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybin US</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adelia</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cybin IRL </span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. dollars</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybin UK Ltd</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Great Britain pounds</span></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:130%"> For accounting purposes, Cybin US is a wholly-owned subsidiary of Cybin. Certain former Adelia Shareholders hold Class B Shares (defined below) in Cybin US.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DetailDescriptionOfFunctionalCurrenciesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail Description Of Functional Currencies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DetailDescriptionOfFunctionalCurrenciesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract', window );"><strong>Disclosure of detailed information about business combination [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory', window );">Disclosure of detailed information about business combination</a></td>
<td class="text">The consideration for the acquisition and measurement of assets acquired and liabilities assumed, as well as goodwill, in accordance with IFRS 3 - Business Combinations, is as follows:<div style="padding-left:13.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:38.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.206%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.464%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acquisition Summary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Consideration</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,481&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair value of purchaser consideration</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53,481</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Allocation of Purchase Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,632&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,686)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total allocation of purchase price</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53,481</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The following revenue and net loss is attributable to Small Pharma for the period from the Acquisition date to March 31, 2024 and included in these consolidated financial statements for the comparative year.</span></div><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> </span></div><div style="padding-left:13.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:38.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,666)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about business combinations. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Section Disclosures application of paragraphs 59 and 61<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;doctype=Appendix&amp;subtype=B&amp;dita_xref=IFRS03_gB64-B67_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_PropertyPlantAndEquipment1Abstract', window );"><strong>Property, Plant and Equipment1 [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of equipment</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lab Equipment</span></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">664</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">239</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">903</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Small Pharma</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment write-down</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">664</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">930</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment write-down</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31,  2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">686</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">302</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">988</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at   March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">290</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">163</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation charge</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment write-down</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">430</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">664</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation charge</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment write-down</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31,  2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">587</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">260</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">847</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value as at March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">99</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_PropertyPlantAndEquipment1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant and Equipment [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_PropertyPlantAndEquipment1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_IntangibleAssetsAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Schedule of intangible assets</a></td>
<td class="text"><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:40.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.069%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IP Research &amp; Development </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patents</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">License</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Software</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,076</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">978</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,379</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,507</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of Small Pharma</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,339&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,339&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,440</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,668</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,381</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,563</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,851</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,794</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,465</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,184</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization charge</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization charge</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">166</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,440</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,668</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,325</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,465</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value as at March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,851</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,794</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,367</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,018</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_IntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_IntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Schedule of right-of-use assets</a></td>
<td class="text"><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">424</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31,  2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">143</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value as at  March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory', window );">Schedule of lease liabilities</a></td>
<td class="text"><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest accretion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">291</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest accretion</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on derecognition</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination penalty payment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 97<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_97&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_GoodwillAbstract', window );"><strong>Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory', window );">Schedule of goodwill</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill is recognized at the acquisition date when total consideration exceeds the net identifiable assets acquired. </span></div><div><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:38.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,792</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition from Small Pharma</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,652&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31,  2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47,475</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,012&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at  March 31,  2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,487</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_GoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_GoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of changes in goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves, and Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Summary of share capital</a></td>
<td class="text"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Cybin US Class B Shares</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:65.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Class B Shares</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530,542.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Converted into Common Shares</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(494,457.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,084.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as at March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,084.7&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Summary of warrants</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The continuity of the outstanding warrants for the years ended March 31, 2025 and 2024, are as follows: </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:61.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Warrants</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Common Share Purchase Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611,329&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.02</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.46</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,658)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.14</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205,404)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.86</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,796,197&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.74</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,796,197</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.03</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,796,197</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.03</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unit Purchase Warrants</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,862&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.50</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,862)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at March 31, 2024 and March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Certain warrants were issued in USD, the weighted average exercise price is calculated using the closing exchange rate in effect as at the respective dates.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">        </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%">Each unit consisted of one Common Share and one half of one Common Share purchase warrant, with each Common Share purchase warrant being exercisable to acquire one Common Share at an exercise price of $123.50 per Common Share.</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following summarizes information about warrants outstanding as at March&#160;31, 2025:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:30.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Expiry</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants outstanding</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants exercisable</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average of exercisable price</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated fair value</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average remaining contractual life</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$000&#8217;s</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 4, 2028</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635,887&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635,887&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$15.20</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,578</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 14, 2029</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,754,386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,754,386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$19.38</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,842</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 15, 2030</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,843&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,843&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.50</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,891</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 20, 2030</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,818&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.32</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.39</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2030</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.50</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.63</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,796,197</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,796,197</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.03</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,594</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.11</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory', window );">Summary of significant unobservable inputs used, equity</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company estimated the aggregate fair value of the August 2023 Warrants using the Black-Scholes option pricing model to be $4,600 (US$3,442) with the following assumptions: </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:81.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$12.92</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$15.20</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The Company estimated the aggregate fair value of the November 2023 Warrants using the Black-</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">Scholes option pricing model to be $17,842 (US$12,299) with the following assumptions: </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:81.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$17.48</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$19.38</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Summary of number and weighted average exercise prices of share options</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in options for the years ended March 31, 2025 and 2024 are as follow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s: </span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:66.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Options</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average exercise price</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at March 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778,163&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.68&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011,711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,735)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.08&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at March 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742,139&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.17</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,484,626&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.84</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,270,081)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as at March 31, 2025</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,956,684</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.23</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable as at March 31, 2025</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,591,976</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.19</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The following summarizes information about stock options outstanding on March&#160;31, 2025:</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:26.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of options outstanding</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of options exercisable</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated  fair value</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted average remaining life</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiry date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$000&#8217;s</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 6, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.11</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 6, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.72</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 6, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.28</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 7, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.12</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 15, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.50</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.20</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.50</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.50</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,869&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,869&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.50</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.58</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 11, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.24</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.70</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 14, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,829&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,829&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.12</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.71</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.11</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,947&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.72</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.28</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.14</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 10, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.82</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 15, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,895&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,895&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.90</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.16</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.99</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,342&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,342&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.11</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,339&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,339&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.72</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.28</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 28, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,475&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,475&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.20</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.24</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 26, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,657&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,657&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.02</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.49</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 15, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.17</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,896&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,896&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.00</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 4, 2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.94</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.92</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 8, 2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,526&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,526&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.76</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.94</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,949&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,949&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.72</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,710&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 26, 2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.02</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.49</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 20, 2029</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.28</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.97</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 5, 2029</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,873&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,994&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.28</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,742&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2032</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,895&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,895&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.20</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 15, 2034</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,784&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,877,860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.11</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,032&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.37</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 27, 2034</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,867&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.37</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.66</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 7, 2035</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.93</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,956,684</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,591,976</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47,427</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.13</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Summary of measurement of stock option fair value assumptions</a></td>
<td class="text">The aggregate estimated grant date fair value was determined to be $4,619 calculated using the Black-Scholes option pricing model with the following assumptions: <div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:81.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.62%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on historical share price of the Company</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.13%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested forfeiture rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0% - 3.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.28</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.28</span></td></tr></table></div>The aggregate estimated grant date fair value was determined to be $34,822 calculated using the Black-Scholes option pricing model with the following assumptions: <div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.07%</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on historical share price of the Company</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.69%</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested forfeiture rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%  - 3.4%</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.30</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.11</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div>The aggregate estimated grant date fair value was determined to be $982 calculated using the Black-Scholes option pricing model with the following assumptions: <div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:74.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.23%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on historical share price of the Company</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.06%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested forfeiture rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0% - 3.4% </span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.37</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.37</span></td></tr></table></div>The aggregate estimated grant date fair value was determined to be $307 calculated using the Black-Scholes option pricing model with the following assumptions: <div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:74.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.03%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on historical share price of the Company</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.43%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested forfeiture rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45</span></td></tr></table></div>The aggregate estimated grant date fair value was determined to be $4,080, calculated using the Black-Scholes option pricing model with the following assumptions: <div style="margin-top:10pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:81.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.78%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.86</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.72</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"> The aggregate estimated grant date fair value was determined to be $577, calculated using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> Options expiring on September 26, 2026</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:81.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.68%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.02</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.02</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Options  expiring on September 26, 2028</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">    </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:81.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle">Risk-free interest rate</td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.02</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.02</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%">The aggregate estimated grant date fair value was determined to be $10,907, calculated using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div style="padding-left:13.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">   Options expiring on November 16, 2026</span></div><div style="padding-left:13.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:81.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.17</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Options expiring on November 16, 2028</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:81.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.28%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.17</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The aggregate estimated grant date fair value was determined to be $8, calculated using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:81.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected annual volatility, based on comparable companies</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.00%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share price</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.28</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.28</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves, and Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of the entity's own equity instruments. [Refer: Classes of entity's own equity instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS AND BALANCES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_RelatedPartyAbstract', window );"><strong>Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Schedule of remuneration of key management personnel</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The remuneration of key management personnel for the years ended March 31, 2025 and 2024 are as follows: </span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:67.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-left:2.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payroll, consulting and benefits</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,807</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,406&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 15.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,937</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,643&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 15.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,239</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,049&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%;padding-left:8pt"> For the year ended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">March&#160;31, 2025</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%">, includes $</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">6,640</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%"> (2024 - $5,145) presented in the consolidated statements of loss and comprehensive loss as a part of &#8220;General and administrative costs&#8221; and $</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%">1,167 (2024 - $1,261)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%"> presented in the consolidated statements of loss and comprehensive loss as a part of &#8220;Research&#8221;.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_RelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_RelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_ScheduleOfResearchExpensesTableTextBlock', window );">Schedule Of Research Expenses</a></td>
<td class="text"><div style="padding-left:13.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"><tr><td style="width:1.0%"></td><td style="width:67.546%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advancement of development programs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,547&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,799&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,319&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab and administration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional and consulting fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,910</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,362&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ScheduleOfResearchExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Research Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ScheduleOfResearchExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL AND ADMINISTRATIVE EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory', window );">Schedule of General and Administrative Expenses</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:70.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital markets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,694</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,519&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll, consulting and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,146</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,248&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and administration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,498</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,945&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional and consulting fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,156</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,918&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,305</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investor relations and Marketing media</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,286</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Listing fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">283</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,368</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,588&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of attribution of expenses by nature to line items by function in the statement of profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL MANAGEMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_CapitalManagementAbstract', window );"><strong>Capital Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfCapitalStructureTableTextBlock', window );">Disclosure Of Capital Structure</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company&#8217;s capital structure includes the following:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:59.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.734%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity comprised of:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share capital</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">464,364</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443,877&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributed surplus</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,414</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options reserve</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47,427</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants reserve</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,594</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,639&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,231)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,285)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deficit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(339,368)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226,231)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">237,200</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,927</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_CapitalManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital Management [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_CapitalManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DisclosureOfCapitalStructureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Capital Structure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DisclosureOfCapitalStructureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory', window );">Schedule of Financial Assets</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company has classified its financial instruments as follows:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"><tr><td style="width:1.0%"></td><td style="width:50.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial assets, measured at fair value:</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">135,022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,992&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial assets, measured at amortized cost:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">706</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial liabilities, measured at amortized cost:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,418</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,805&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Schedule of Financial Liabilities</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The Company has classified its financial instruments as follows:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"><tr><td style="width:1.0%"></td><td style="width:50.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial assets, measured at fair value:</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">135,022</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,992&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial assets, measured at amortized cost:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">706</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial liabilities, measured at amortized cost:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,418</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,805&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory', window );">Disclosure of Monetary Assets and Liabilities Currency Risk Fluctuations</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">At March&#160;31, 2025 the Company had the following balances in monetary assets and monetary liabilities which are subject to fluctuation against CAD:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.673%"><tr><td style="width:1.0%"></td><td style="width:48.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominated in:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">US$</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GBP</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EUR</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,416&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,841)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90,928</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(339)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">618</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4376</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8571</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5540&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equivalent in Canadian dollars</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">130,718</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(630)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">960</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Impact of 10% change in exchange rate</span></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,072</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(63)</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information that enables users of financial statements to evaluate the nature and extent of risks arising from financial instruments to which the entity is exposed. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock', window );">Major items causing the income tax rate to differ from the Canadian statutory rate</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Major items causing the Company&#8217;s income tax rate to differ from the Canadian statutory rate of approximately 26.5% are as follows:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:47.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended March 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 3.77pt 0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 3.77pt 0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 3.77pt 0 1pt"></td><td colspan="3" style="padding:0 3.77pt 0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 3.75pt 0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(113,137)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(78,080)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected recovery at statutory rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,981</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,691</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital losses acquired on acquisition of subsidiary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,658&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,497)</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,680)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issuance costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,420</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Difference between Canadian and foreign tax rates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,317)</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,440)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange on unbooked deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">351</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(103)</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrecognized deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,537)</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,405)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax recovery</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 3.77pt 0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 3.77pt 0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Significant components of deferred tax assets</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The significant components of the Company&#8217;s deferred tax assets resulting from temporary differences, unused tax credits and unused tax losses, that have not been included on the consolidated statement of financial position, are as follows:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"><tr><td style="width:1.0%"></td><td style="width:59.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2024</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital loss carryforwards - Canada</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,310</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,168</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital loss carryforwards - United States</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,533</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,344</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital loss carryforwards - Ireland</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,327</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,391</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital loss carryforwards - United Kingdom</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,767</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,282</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,653</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,474</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development expenditures</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,538</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,681</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issuance costs</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,102</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,361</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation/Capital cost allowance differences</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61,245</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,708</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(61,245)</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,708)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfExpirationOfNonCapitalLossesTableTextBlock', window );">Non-capital losses expiration</a></td>
<td class="text">The non-capital losses expire as follows:<div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:82.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year of expiry</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">115</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">863</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,856</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,704</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,397</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2045</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,105</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">84,154</span></td></tr></table></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.993%"><tr><td style="width:1.0%"></td><td style="width:82.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year of expiry</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2040</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,053</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,543</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,979</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,593</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2044</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,425</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2045</span></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,471</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,064</span></td></tr></table></div>The non-capital losses in Ireland, stated in Canadian Dollars, expire as follows:<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"> </span></div><div style="margin-bottom:10pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.275%"><tr><td style="width:1.0%"></td><td style="width:81.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.528%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year of expiry</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2042</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,965</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2043</span></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2044</span></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,857</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:18pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2045</span></div></td><td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57,875</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">137,714</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DisclosureOfExpirationOfNonCapitalLossesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Expiration Of Non Capital Losses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DisclosureOfExpirationOfNonCapitalLossesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CORPORATE INFORMATION (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>CAD ($) </div>
<div>subsidiary</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Sep. 19, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSubsidiaries', window );">Number of subsidiaries | subsidiary</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OrdinarySharesConsolidationNewSharesIssued', window );">Share consolidation, new shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OrdinarySharesConsolidationSharesIssuedPreviously', window );">Share consolidation, shares issued previously (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Deficit</a></td>
<td class="nump">$ 339,368<span></span>
</td>
<td class="nump">$ 226,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">135,022<span></span>
</td>
<td class="nump">208,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="nump">113,137<span></span>
</td>
<td class="nump">78,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Cash flows from (used in) operating activities</a></td>
<td class="num">$ (101,300)<span></span>
</td>
<td class="num">$ (68,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OrdinarySharesConsolidationNewSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary Shares, Consolidation, New Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OrdinarySharesConsolidationNewSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OrdinarySharesConsolidationSharesIssuedPreviously">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary Shares, Consolidation, Shares Issued Previously</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OrdinarySharesConsolidationSharesIssuedPreviously</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Functional and presentation currency (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cybn_CybinCorpMember', window );">Cybin Corp.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="nump">10000.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cybn_JourneyMember', window );">Journey</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="nump">10000.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cybn_SerenityMember', window );">Serenity</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="nump">10000.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cybn_CybinUSMember', window );">Cybin US</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="nump">10000.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cybn_AdeliaMember', window );">Adelia</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="nump">10000.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cybn_CybinIRLLimitedMember', window );">Cybin IRL</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="nump">10000.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cybn_CybinUKLtd.Member', window );">Cybin UK Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Disclosure of subsidiaries [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership</a></td>
<td class="nump">10000.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cybn_CybinCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cybn_CybinCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cybn_JourneyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cybn_JourneyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cybn_SerenityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cybn_SerenityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cybn_CybinUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cybn_CybinUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cybn_AdeliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cybn_AdeliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cybn_CybinIRLLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cybn_CybinIRLLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cybn_CybinUKLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cybn_CybinUKLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Cash and cash equivalents (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Equipment and Intangible Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life of intangible assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life of intangible assets</a></td>
<td class="text">17 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cybn_LaboratoryEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life of equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Useful life of equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cybn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cybn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Share-based compensation (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_ShareBasedCompensationArrangementExpirationPeriod', window );">Exercisable period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ShareBasedCompensationArrangementExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement, Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ShareBasedCompensationArrangementExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Oct. 23, 2023 </div>
<div>shares </div>
<div>patent_family </div>
<div>patent </div>
<div>application </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (113,137)<span></span>
</td>
<td class="num">$ (78,080)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=cybn_SmallPharmaInc.Member', window );">Small Pharma Inc. ("Small Pharma")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding', window );">Ratio of common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.634%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable', window );">Number of instruments or interests issued or issuable (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,130,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation', window );">Unexercised stock options in subsidiary, compensation for cancellation (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfActivePatentFamilies', window );">Number of active patent families | patent_family</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfPendingPatentApplications', window );">Number of pending patent applications | application</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfGrantedPatents', window );">Number of granted patents | patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">$ (1,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=cybn_SmallPharmaInc.Member', window );">Small Pharma Inc. ("Small Pharma") | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=cybn_SmallPharmaInc.Member', window );">Small Pharma Inc. ("Small Pharma") | United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,631<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfActivePatentFamilies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Active Patent Families</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfActivePatentFamilies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfGrantedPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Granted Patents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfGrantedPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfPendingPatentApplications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Pending Patent Applications</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfPendingPatentApplications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio Of Common Shares Issued To Every One Share Of Subsidiary Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unexercised Stock Options In Subsidiary, Compensation For Cancellation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_f_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=cybn_SmallPharmaInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=cybn_SmallPharmaInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITION - Details of acquisition (Details) - Small Pharma Inc. ("Small Pharma")<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Oct. 23, 2023 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred', window );">Fair value of purchaser consideration</a></td>
<td class="nump">$ 53,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_CashRecognisedAsOfAcquisitionDate', window );">Cash</a></td>
<td class="nump">7,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate', window );">Current assets</a></td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate', window );">Net equipment</a></td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate', window );">Intellectual property</a></td>
<td class="nump">29,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate', window );">Right of use asset</a></td>
<td class="nump">412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate', window );">Lease liability</a></td>
<td class="num">(415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate', window );">Liabilities assumed</a></td>
<td class="num">(6,686)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate', window );">Goodwill</a></td>
<td class="nump">22,652<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed', window );">Total allocation of purchase price</a></td>
<td class="nump">$ 53,481<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_CashRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Recognised as of Acquisition Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_CashRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liabilities Recognised As Of Acquisition Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right Of Use Asset Recognised As Of Acquisition Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for current assets acquired in a business combination. [Refer: Current assets; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for financial liabilities assumed in a business combination. [Refer: Financial liabilities; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GoodwillRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GoodwillRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B64<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B64_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph IE72<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE72&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=cybn_SmallPharmaInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=cybn_SmallPharmaInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION - Results since acquisition (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (113,137)<span></span>
</td>
<td class="num">$ (78,080)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=cybn_SmallPharmaInc.Member', window );">Small Pharma Inc. ("Small Pharma")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (1,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=cybn_SmallPharmaInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=cybn_SmallPharmaInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUIPMENT (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of period</a></td>
<td class="nump">$ 266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of period</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Net book value</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cybn_LaboratoryEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of period</a></td>
<td class="nump">234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of period</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Net book value</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of period</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of period</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Net book value</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of period</a></td>
<td class="nump">930<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition from Small Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Equipment write-down</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Effect of foreign exchange</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of period</a></td>
<td class="nump">988<span></span>
</td>
<td class="nump">930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Net book value</a></td>
<td class="nump">988<span></span>
</td>
<td class="nump">930<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of period</a></td>
<td class="nump">664<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition from Small Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Equipment write-down</a></td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Effect of foreign exchange</a></td>
<td class="num">(41)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of period</a></td>
<td class="nump">686<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Net book value</a></td>
<td class="nump">686<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of period</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Acquisition from Small Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Equipment write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Effect of foreign exchange</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of period</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Net book value</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of period</a></td>
<td class="num">(664)<span></span>
</td>
<td class="num">(453)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Equipment write-down</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Effect of foreign exchange</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of period</a></td>
<td class="num">(847)<span></span>
</td>
<td class="num">(664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Net book value</a></td>
<td class="num">(847)<span></span>
</td>
<td class="num">(664)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated Amortization | Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of period</a></td>
<td class="num">(430)<span></span>
</td>
<td class="num">(290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Equipment write-down</a></td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Effect of foreign exchange</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of period</a></td>
<td class="num">(587)<span></span>
</td>
<td class="num">(430)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Net book value</a></td>
<td class="num">(587)<span></span>
</td>
<td class="num">(430)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated Amortization | Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at beginning of period</a></td>
<td class="num">(234)<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Equipment write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation charge</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Effect of foreign exchange</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance at end of period</a></td>
<td class="num">(260)<span></span>
</td>
<td class="num">(234)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Net book value</a></td>
<td class="num">$ (260)<span></span>
</td>
<td class="num">$ (234)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_v&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cybn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cybn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">$ 35,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">$ 41,018<span></span>
</td>
<td class="nump">$ 35,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible assets other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life of intangible assets</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible assets other than goodwill | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputAssets', window );">Significant unobservable input, assets</a></td>
<td class="nump">0.203<span></span>
</td>
<td class="nump">0.157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember', window );">IP Research &amp; Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">$ 32,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">35,851<span></span>
</td>
<td class="nump">$ 32,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">1,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">$ 3,794<span></span>
</td>
<td class="nump">1,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life of intangible assets</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">$ 1,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">1,367<span></span>
</td>
<td class="nump">1,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill', window );">Useful life of intangible assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">$ 35,563<span></span>
</td>
<td class="nump">5,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisition of Small Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">1,931<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Effect of foreign exchange</a></td>
<td class="nump">3,690<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">41,184<span></span>
</td>
<td class="nump">35,563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | IP Research &amp; Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">32,440<span></span>
</td>
<td class="nump">3,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisition of Small Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Effect of foreign exchange</a></td>
<td class="nump">3,411<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">35,851<span></span>
</td>
<td class="nump">32,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">1,668<span></span>
</td>
<td class="nump">978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisition of Small Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">1,931<span></span>
</td>
<td class="nump">689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Effect of foreign exchange</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">3,794<span></span>
</td>
<td class="nump">1,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">1,381<span></span>
</td>
<td class="nump">1,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisition of Small Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Effect of foreign exchange</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">1,465<span></span>
</td>
<td class="nump">1,381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost | Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Acquisition of Small Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Effect of foreign exchange</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="num">(98)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Effect of foreign exchange</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="num">(166)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated Amortization | IP Research &amp; Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Effect of foreign exchange</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated Amortization | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Effect of foreign exchange</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated Amortization | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Effect of foreign exchange</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="num">(98)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated Amortization | Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets other than goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill', window );">Effect of foreign exchange</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance</a></td>
<td class="num">$ (68)<span></span>
</td>
<td class="num">$ (42)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_IntangibleAssetsUnderDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_LicencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Narrative (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_GainLossOnDerecognitionOfRightOfUseAssets', window );">Loss on derecognition of right-of-use assets</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_GainLossOnDerecognitionOfLeaseLiability', window );">Gain on derecognition of lease liability</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Other loss</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_GainLossOnDerecognitionOfLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Derecognition of Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_GainLossOnDerecognitionOfLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_GainLossOnDerecognitionOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Derecognition of Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_GainLossOnDerecognitionOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Right of use assets (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, beginning of period</a></td>
<td class="nump">$ 281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, beginning of period</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_EffectOfForeignExchangeRightOfUseAssets', window );">Effect of foreign exchange</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsRightofuseAssets', window );">Disposals</a></td>
<td class="num">(448)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, beginning of period</a></td>
<td class="num">(143)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_EffectOfForeignExchangeRightOfUseAssets', window );">Effect of foreign exchange</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsRightofuseAssets', window );">Disposals</a></td>
<td class="num">(395)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Amortization</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (143)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_EffectOfForeignExchangeRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect Of Foreign Exchange, Right Of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_EffectOfForeignExchangeRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in right-of-use assets resulting from disposals. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Lease liabilities (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities, beginning of period</a></td>
<td class="nump">$ 291<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_AdditionsToLeaseLiabilities', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest accretion</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_EffectOfForeignExchangeLeaseLiabilities', window );">Effect of foreign exchange</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_GainLossOnDerecognitionOfLeaseLiability', window );">Gain on derecognition</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_PaymentForTerminationPenaltyLeaseLiability', window );">Termination penalty payment</a></td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_PaymentsOfLeaseLiabilities', window );">Payments</a></td>
<td class="num">(259)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments</a></td>
<td class="num">(290)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities, end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 291<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_AdditionsToLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions To Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_AdditionsToLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_EffectOfForeignExchangeLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect Of Foreign Exchange, Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_EffectOfForeignExchangeLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_GainLossOnDerecognitionOfLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Derecognition of Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_GainLossOnDerecognitionOfLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_PaymentForTerminationPenaltyLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Termination Penalty, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_PaymentForTerminationPenaltyLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_PaymentsOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Of Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_PaymentsOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets and goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Balance at beginning of period</a></td>
<td class="nump">$ 47,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Balance at end of period</a></td>
<td class="nump">51,487,000<span></span>
</td>
<td class="nump">$ 47,475,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill', window );">Impairment loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_GoodwillMember', window );">Goodwill | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets and goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputAssets', window );">Significant unobservable input, assets</a></td>
<td class="nump">0.203<span></span>
</td>
<td class="nump">0.157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract', window );"><strong>Reconciliation of changes in intangible assets and goodwill [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Balance at beginning of period</a></td>
<td class="nump">$ 47,475,000<span></span>
</td>
<td class="nump">$ 24,792,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill', window );">Acquisition from Small Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,652,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill', window );">Effect of foreign exchange</a></td>
<td class="nump">4,012,000<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Balance at end of period</a></td>
<td class="nump">$ 51,487,000<span></span>
</td>
<td class="nump">$ 47,475,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in intangible assets and goodwill resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2024-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for goodwill. [Refer: Impairment loss recognised in profit or loss; Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2024-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B67_d_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_GoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Narrative - Issued Share Capital (Details)<br> $ / shares in Units, $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 19, 2024 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 19, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 14, 2023 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 14, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 30, 2023 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>CAD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 10, 2025 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Nov. 14, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 23, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfCommonSharesHeldInEscrow', window );">Number of common shares held in escrow (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,364<span></span>
</td>
<td class="nump">23,364<span></span>
</td>
<td class="nump">415,985<span></span>
</td>
<td class="nump">415,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_CommonStockSharesAuthorizedValue', window );">Common stock shares, authorized value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Payments for share issue costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 941,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 832,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_PercentageOfOutstandingCommonSharesOwn', window );">Percentage of outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Professional and consulting fees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,918,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_CommonSharesExchangeRate', window );">Common shares exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.26316<span></span>
</td>
<td class="nump">0.26316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_LPCPurchaseAgreementMember', window );">LPC Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_CommonStockSharesAuthorizedValue', window );">Common stock shares, authorized value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 476,000<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_CommonSharesPurchasePeriodTerm', window );">Purchase period, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_August2023CompensationCommonShareWarrantMember', window );">August 2023 compensation common share warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_SharePricePerCommonShare', window );">Share price (in CAD/USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Payments for share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 506,000<span></span>
</td>
<td class="nump">$ 379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement', window );">Number of shares acquired upon exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement', window );">Exercise price of other equity instruments (in CAD/USD per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement', window );">Period to exercise warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Professional and consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 622,000<span></span>
</td>
<td class="nump">$ 465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfCommonShares', window );">Number of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfCommonSharePurchaseWarrants', window );">Number of common share purchase warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_November2023CompensationCommonShareWarrantMember', window );">November 2023 compensation common share warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_SharePricePerCommonShare', window );">Share price (in CAD/USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Payments for share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,096,000<span></span>
</td>
<td class="nump">1,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement', window );">Number of shares acquired upon exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement', window );">Exercise price of other equity instruments (in CAD/USD per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Professional and consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 339,000<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfCommonShares', window );">Number of common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfCommonSharePurchaseWarrants', window );">Number of common share purchase warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_March2024PrivatePlacementMember', window );">March 2024 private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Payments for share issue costs</a></td>
<td class="nump">$ 11,726,000<span></span>
</td>
<td class="nump">$ 8,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Professional and consulting fees | $</a></td>
<td class="nump">$ 504,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesIssuedThroughShareOfferingEquity', window );">At-the-market offering - net of share issuance costs (in shares)</a></td>
<td class="nump">9,179,927<span></span>
</td>
<td class="nump">9,179,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638,545<span></span>
</td>
<td class="nump">638,545<span></span>
</td>
<td class="nump">66,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">898,434<span></span>
</td>
<td class="nump">898,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_SharePricePerCommonShare', window );">Share price (in CAD/USD per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.62<span></span>
</td>
<td class="nump">$ 9.52<span></span>
</td>
<td class="nump">$ 17.29<span></span>
</td>
<td class="nump">$ 12.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,018,000<span></span>
</td>
<td class="nump">$ 8,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,924,000<span></span>
</td>
<td class="nump">$ 15,322<span></span>
</td>
<td class="nump">$ 15,532,000<span></span>
</td>
<td class="nump">$ 11,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | LPC Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesIssuedThroughShareOfferingEquity', window );">At-the-market offering - net of share issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,658<span></span>
</td>
<td class="nump">50,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_SharePricePerCommonShare', window );">Share price (in CAD/USD per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.3<span></span>
</td>
<td class="nump">$ 9.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 623,000<span></span>
</td>
<td class="nump">$ 465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | November 2023 compensation common share warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesIssuedThroughShareOfferingEquity', window );">At-the-market offering - net of share issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,754,386<span></span>
</td>
<td class="nump">1,754,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_SharePricePerCommonShare', window );">Share price (in CAD/USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,107,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | March 2024 private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_SharePricePerCommonShare', window );">Share price (in CAD/USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of ordinary shares</a></td>
<td class="nump">$ 202,995,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesSubjectToResaleRestrictions', window );">Number of shares subject to resale restrictions (in shares)</a></td>
<td class="nump">415,985<span></span>
</td>
<td class="nump">415,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember', window );">Preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=cybn_ClassBSharesMember', window );">Class B Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,084.7<span></span>
</td>
<td class="nump">36,084.7<span></span>
</td>
<td class="nump">36,084.7<span></span>
</td>
<td class="nump">36,084.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530,542.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments', window );">Number of shares issued upon conversion of convertible instruments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,496<span></span>
</td>
<td class="nump">9,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity', window );">Class B shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity', window );">Shares issued on Adelia milestones (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesIssuedThroughShareOfferingEquity', window );">At-the-market offering - net of share issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,609,298<span></span>
</td>
<td class="nump">1,609,298<span></span>
</td>
<td class="nump">898,434<span></span>
</td>
<td class="nump">898,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_IncreaseDecreaseThroughShareConsolidationEquity', window );">Adjustment for fractional shares upon share consolidation (in shares) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,610,704<span></span>
</td>
<td class="nump">21,610,704<span></span>
</td>
<td class="nump">20,001,404<span></span>
</td>
<td class="nump">20,001,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,279,846<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_CommonSharesExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Shares, Exchange Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_CommonSharesExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_CommonSharesPurchasePeriodTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Shares Purchase Period, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_CommonSharesPurchasePeriodTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_CommonStockSharesAuthorizedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Shares Authorized Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_CommonStockSharesAuthorizedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise Price of Other Equity Instruments in Share-based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_IncreaseDecreaseThroughShareConsolidationEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Share Consolidation, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_IncreaseDecreaseThroughShareConsolidationEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfCommonSharePurchaseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Common Share Purchase Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfCommonSharePurchaseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Common Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfCommonSharesHeldInEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Common Shares Held In Escrow</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfCommonSharesHeldInEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Acquired Upon Exercise Of Warrant In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Converted Through Contingent Consideration, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Issued Through Contingent Consideration, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfSharesIssuedThroughShareOfferingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Issued Through Share Offering, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfSharesIssuedThroughShareOfferingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Shares Issued Upon Conversion of Convertible Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfSharesSubjectToResaleRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Subject To Resale Restrictions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfSharesSubjectToResaleRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_PercentageOfOutstandingCommonSharesOwn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Outstanding Common Shares Own</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_PercentageOfOutstandingCommonSharesOwn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period To Exercise Warrants In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_SharePricePerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Price per Common Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_SharePricePerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_LPCPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_LPCPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_August2023CompensationCommonShareWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_August2023CompensationCommonShareWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_November2023CompensationCommonShareWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_November2023CompensationCommonShareWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_March2024PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_March2024PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=cybn_ClassBSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=cybn_ClassBSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Summary of share capital (Details) - Class B Shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract', window );"><strong>Reconciliation of number of shares outstanding [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in shares)</a></td>
<td class="nump">530,542.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares', window );">Converted into Common Shares (in shares)</a></td>
<td class="num">(494,457.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in shares)</a></td>
<td class="nump">36,084.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Conversion of Convertible Instruments, Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=cybn_ClassBSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=cybn_ClassBSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Summary of warrants (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_CommonSharePurchaseWarrantsMember', window );">Common Share Purchase Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_WarrantsNumberOfSharesRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding (in shares)</a></td>
<td class="nump">2,796,197<span></span>
</td>
<td class="nump">611,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,392,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Number of other equity instruments exercised or vested in share-based payment arrangement</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,658)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of other equity instruments expired in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(205,404)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding (in shares)</a></td>
<td class="nump">2,796,197<span></span>
</td>
<td class="nump">2,796,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of other equity instruments exercisable in share-based payment arrangement (in shares)</a></td>
<td class="nump">2,796,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_WarrantsWeightedAverageExercisePriceRollForward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 22.74<span></span>
</td>
<td class="nump">$ 49.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement', window );">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding (in CAD per share) | $ / shares</a></td>
<td class="nump">24.03<span></span>
</td>
<td class="nump">$ 22.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 24.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_UnitPurchaseWarrantsMember', window );">Unit Purchase Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_WarrantsNumberOfSharesRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,862)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_WarrantsWeightedAverageExercisePriceRollForward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 85.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement', window );">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfCommonShares', window );">Number of common shares (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfCommonSharePurchaseWarrants', window );">Number of common share purchase warrants (in shares)</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement', window );">Number of shares acquired upon exercise of warrant (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 123.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfCommonSharePurchaseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Common Share Purchase Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfCommonSharePurchaseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Common Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Other Equity Instruments Issued in Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Acquired Upon Exercise Of Warrant In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_WarrantsNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Number of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_WarrantsNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_WarrantsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_WarrantsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Of Other Equity Instruments Issued In Share-based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_CommonSharePurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_CommonSharePurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_UnitPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_UnitPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Narrative - Warrants (Details)<br> $ / shares in Units, $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 14, 2023 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 14, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CAD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds on exercise of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,869<span></span>
</td>
<td class="nump">$ 13,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_CommonSharePurchaseWarrantsMember', window );">Common Share Purchase Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds on exercise of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Number of other equity instruments expired in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,392,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended', window );">Number of warrants with extended expiry dates (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_August2023CompensationCommonShareWarrantMember', window );">August 2023 compensation common share warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds on exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="nump">$ 3,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638,545<span></span>
</td>
<td class="nump">638,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement', window );">Number of shares acquired upon exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_November2023CompensationCommonShareWarrantMember', window );">November 2023 compensation common share warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds on exercise of warrants</a></td>
<td class="nump">$ 17,842<span></span>
</td>
<td class="nump">$ 12,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement', window );">Issued (in shares)</a></td>
<td class="nump">1,754,386<span></span>
</td>
<td class="nump">1,754,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 19.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement', window );">Number of shares acquired upon exercise of warrant (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_GrantedToOfficersAndDirectorsMember', window );">Granted to officers and directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended', window );">Number of warrants with extended expiry dates (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Other Equity Instruments In Share-Based Payment Arrangement, Expiry Date Extended</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Other Equity Instruments Issued in Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Acquired Upon Exercise Of Warrant In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_CommonSharePurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_CommonSharePurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_August2023CompensationCommonShareWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_August2023CompensationCommonShareWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_November2023CompensationCommonShareWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_November2023CompensationCommonShareWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_GrantedToOfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_GrantedToOfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Summary of significant unobservable inputs used, equity (Details)<br> $ / shares in Units, $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 14, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Nov. 14, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds on exercise of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_August2023CompensationCommonShareWarrantMember', window );">August 2023 compensation common share warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds on exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="nump">$ 3,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.87%<span></span>
</td>
<td class="nump">3.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Expected annual volatility, based on comparable companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted', window );">Expected life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_SharePricePerCommonShare', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted', window );">Exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_November2023CompensationCommonShareWarrantMember', window );">November 2023 compensation common share warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds on exercise of warrants</a></td>
<td class="nump">$ 17,842<span></span>
</td>
<td class="nump">$ 12,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Expected annual volatility, based on comparable companies</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted', window );">Expected life (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_SharePricePerCommonShare', window );">Share price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted', window );">Exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Dividend As Percentage, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ExpectedVolatilityOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Volatility, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ExpectedVolatilityOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Equity Instruments Life, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk Free Interest Rate, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_SharePricePerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Price per Common Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_SharePricePerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_August2023CompensationCommonShareWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_August2023CompensationCommonShareWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_November2023CompensationCommonShareWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_November2023CompensationCommonShareWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHARE CAPITAL - Summary of warrants by expiry period (Details) - Common Share Purchase Warrants<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>CAD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">2,796,197<span></span>
</td>
<td class="nump">2,796,197<span></span>
</td>
<td class="nump">611,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Warrants exercisable (in shares)</a></td>
<td class="nump">2,796,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average of exercisable price (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 24.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="nump">$ 27,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments', window );">Weighted average remaining of outstanding contractual life</a></td>
<td class="text">4 years 1 month 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_CommonSharePurchaseWarrantsMember', window );">August 4, 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">635,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Warrants exercisable (in shares)</a></td>
<td class="nump">635,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average of exercisable price (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 15.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="nump">$ 4,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments', window );">Weighted average remaining of outstanding contractual life</a></td>
<td class="text">3 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_CommonSharePurchaseWarrantsMember', window );">May 14, 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">1,754,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Warrants exercisable (in shares)</a></td>
<td class="nump">1,754,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average of exercisable price (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 19.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="nump">$ 17,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments', window );">Weighted average remaining of outstanding contractual life</a></td>
<td class="text">4 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_CommonSharePurchaseWarrantsMember', window );">June 15, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">336,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Warrants exercisable (in shares)</a></td>
<td class="nump">336,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average of exercisable price (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="nump">$ 3,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments', window );">Weighted average remaining of outstanding contractual life</a></td>
<td class="text">5 years 2 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_CommonSharePurchaseWarrantsMember', window );">August 20, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">38,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Warrants exercisable (in shares)</a></td>
<td class="nump">38,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average of exercisable price (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 24.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="nump">$ 936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments', window );">Weighted average remaining of outstanding contractual life</a></td>
<td class="text">5 years 4 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_CommonSharePurchaseWarrantsMember', window );">November 15, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">30,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Warrants exercisable (in shares)</a></td>
<td class="nump">30,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average of exercisable price (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="nump">$ 347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments', window );">Weighted average remaining of outstanding contractual life</a></td>
<td class="text">5 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Life of Other Equity Instruments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_CommonSharePurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_CommonSharePurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_WarrantExpirationPeriodAxis=cybn_WarrantExpirationPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_WarrantExpirationPeriodAxis=cybn_WarrantExpirationPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_WarrantExpirationPeriodAxis=cybn_WarrantExpirationPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_WarrantExpirationPeriodAxis=cybn_WarrantExpirationPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_WarrantExpirationPeriodAxis=cybn_WarrantExpirationPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_WarrantExpirationPeriodAxis=cybn_WarrantExpirationPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_WarrantExpirationPeriodAxis=cybn_WarrantExpirationPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_WarrantExpirationPeriodAxis=cybn_WarrantExpirationPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_WarrantExpirationPeriodAxis=cybn_WarrantExpirationPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_WarrantExpirationPeriodAxis=cybn_WarrantExpirationPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Narrative - Stock options (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 07, 2025 </div>
<div>CAD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 27, 2024 </div>
<div>CAD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 15, 2024 </div>
<div>CAD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 05, 2024 </div>
<div>CAD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 05, 2024 </div>
<div>CAD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 20, 2024 </div>
<div>CAD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 16, 2023 </div>
<div>CAD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>CAD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 29, 2023 </div>
<div>CAD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Nov. 05, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding', window );">Shares available for grant, percent of total shares outstanding (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,484,626<span></span>
</td>
<td class="nump">1,011,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value at measurement date, share options granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Share-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,869<span></span>
</td>
<td class="nump">$ 13,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyTwoMember', window );">Option Expiration Period Thirty Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value at measurement date, share options granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyTwoMember', window );">Option Expiration Period Thirty Two | Share Options, Vesting, First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyTwoMember', window );">Option Expiration Period Thirty Two | Share Options, Vesting, Second Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFourMember', window );">Option Expiration Period Thirty Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value at measurement date, share options granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFiveMember', window );">Option Expiration Period Thirty Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value at measurement date, share options granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFiveMember', window );">Option Expiration Period Thirty Five | Share Options, Vesting, Second Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySixMember', window );">Option Expiration Period Thirty Six</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 10.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value at measurement date, share options granted | $</a></td>
<td class="nump">$ 307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySixMember', window );">Option Expiration Period Thirty Six | Share Options, Vesting, Second Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyNineMember', window );">Option Expiration Period Twenty Nine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value at measurement date, share options granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,080<span></span>
</td>
<td class="nump">3,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyNineMember', window );">Option Expiration Period Twenty Nine | Share Options, Vesting, First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyNineMember', window );">Option Expiration Period Twenty Nine | Share Options, Vesting, Second Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyNineMember', window );">Option Expiration Period Twenty Nine | Share Options, Vesting, Third Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyNineMember', window );">Option Expiration Period Twenty Nine | Share Options, Vesting, Fourth Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFourAndThirtyMember', window );">Option Expiration Period Twenty Four And Thirty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value at measurement date, share options granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFourAndThirtyMember', window );">Option Expiration Period Twenty Four And Thirty | Share Options, Vesting, First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFourAndThirtyMember', window );">Option Expiration Period Twenty Four And Thirty | Share Options, Vesting, Second Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFourAndThirtyMember', window );">Option Expiration Period Twenty Four And Thirty | Share Options, Vesting, Third Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFourAndThirtyMember', window );">Option Expiration Period Twenty Four And Thirty | Share Options, Vesting, Fourth Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFourAndThirtyMember', window );">Option Expiration Period Twenty Four And Thirty | Share Options, Vesting, Fifth Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFourMember', window );">Option Expiration Period Twenty Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value at measurement date, share options granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyMember', window );">Option Expiration Period Thirty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value at measurement date, share options granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember', window );">Option Expiration Period Thirty Seven And Thirty Eight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value at measurement date, share options granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember', window );">Option Expiration Period Thirty Seven And Thirty Eight | Share Options, Vesting, First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember', window );">Option Expiration Period Thirty Seven And Thirty Eight | Share Options, Vesting, Second Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement', window );">Number of options vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySevenMember', window );">Option Expiration Period Thirty Seven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyEightMember', window );">Option Expiration Period Thirty Eight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyOneMember', window );">Option Expiration Period Thirty One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value at measurement date, share options granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,100<span></span>
</td>
<td class="nump">3,061,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673,682<span></span>
</td>
<td class="nump">31,842<span></span>
</td>
<td class="nump">305,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Number of share options forfeited in share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,199,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options forfeited in share-based payment arrangement (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options forfeited in share-based payment arrangement (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | Option Expiration Period Thirty Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | Option Expiration Period Thirty Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | Option Expiration Period Thirty Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | Option Expiration Period Thirty Six</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="nump">$ 10.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | Option Expiration Period Twenty Nine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | Option Expiration Period Twenty Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | Option Expiration Period Thirty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | Option Expiration Period Thirty Seven And Thirty Eight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | Option Expiration Period Thirty Seven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | Option Expiration Period Thirty Eight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | Option Expiration Period Thirty One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | Granted to officers and directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,980,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | Granted to officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">584,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | Granted to directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | Granted to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted in share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,100<span></span>
</td>
<td class="nump">940,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,872<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="nump">34,209<span></span>
</td>
<td class="nump">3,553<span></span>
</td>
<td class="nump">105,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares | Granted to consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted in share-based payment arrangement (in shares)</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">140,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,158<span></span>
</td>
<td class="nump">28,289<span></span>
</td>
<td class="nump">80,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Options Vested In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant, Percent Of Total Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting Requirements For Share-Based Payment Arrangement, Vesting Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ShareBasedPaymentVestingPeriodAxis=cybn_ShareOptionsVestingFirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ShareBasedPaymentVestingPeriodAxis=cybn_ShareOptionsVestingFirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ShareBasedPaymentVestingPeriodAxis=cybn_ShareOptionsVestingSecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ShareBasedPaymentVestingPeriodAxis=cybn_ShareOptionsVestingSecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ShareBasedPaymentVestingPeriodAxis=cybn_ShareOptionsVestingThirdTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ShareBasedPaymentVestingPeriodAxis=cybn_ShareOptionsVestingThirdTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ShareBasedPaymentVestingPeriodAxis=cybn_ShareOptionsVestingFourthTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ShareBasedPaymentVestingPeriodAxis=cybn_ShareOptionsVestingFourthTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFourAndThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFourAndThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ShareBasedPaymentVestingPeriodAxis=cybn_ShareOptionsVestingFifthTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ShareBasedPaymentVestingPeriodAxis=cybn_ShareOptionsVestingFifthTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_GrantedToOfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_GrantedToOfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_GrantedToOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_GrantedToOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_GrantedToDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_GrantedToDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_GrantedToEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_GrantedToEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_GrantedToConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_GrantedToConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Summary of number and weighted average exercise prices of share options (Details)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>shares </div>
<div>option</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>option</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Share Capital, Reserves, and Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options, beginning balance (in shares) | shares</a></td>
<td class="nump">1,742,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">778,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted in share-based payment arrangement (in shares) | shares</a></td>
<td class="nump">3,484,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,011,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement', window );">Number of share options forfeited/expired in share-based payment arrangement (in shares) | shares</a></td>
<td class="num">(1,270,081)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,735)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options, ending balance (in shares)</a></td>
<td class="nump">3,956,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,956,684<span></span>
</td>
<td class="nump">1,742,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of share options exercisable in share-based payment arrangement</a></td>
<td class="nump">3,591,976<span></span>
</td>
<td class="nump">3,591,976<span></span>
</td>
<td class="nump">3,591,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,591,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options granted in share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement', window );">Weighted average exercise price of share options exercised in share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options exercisable in share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Share Options Forfeited And Expired In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Reserves, and Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Of Share Options Forfeited And Expired In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHARE CAPITAL - Summary of measurement of stock option fair value assumptions (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 07, 2025 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 27, 2024 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 15, 2024 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 05, 2024 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 20, 2024 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 16, 2023 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 29, 2023 </div>
<div>yr </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted', window );">Unvested forfeiture rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted', window );">Unvested forfeiture rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyTwoMember', window );">Option Expiration Period Thirty Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected annual volatility, based on historical share price of the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in CAD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in CAD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFourMember', window );">Option Expiration Period Thirty Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected annual volatility, based on historical share price of the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.69%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in CAD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in CAD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFiveMember', window );">Option Expiration Period Thirty Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected annual volatility, based on historical share price of the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.06%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in CAD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in CAD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySixMember', window );">Option Expiration Period Thirty Six</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">3.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected annual volatility, based on historical share price of the Company</a></td>
<td class="nump">83.43%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="nump">10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted', window );">Unvested forfeiture rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in CAD per share)</a></td>
<td class="nump">$ 10.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in CAD per share)</a></td>
<td class="nump">$ 10.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyNineMember', window );">Option Expiration Period Twenty Nine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.78%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected annual volatility, based on historical share price of the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in CAD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in CAD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFourMember', window );">Option Expiration Period Twenty Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected annual volatility, based on historical share price of the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in CAD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in CAD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyMember', window );">Option Expiration Period Thirty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected annual volatility, based on historical share price of the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in CAD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in CAD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySevenMember', window );">Option Expiration Period Thirty Seven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected annual volatility, based on historical share price of the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in CAD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in CAD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyEightMember', window );">Option Expiration Period Thirty Eight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected annual volatility, based on historical share price of the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in CAD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in CAD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyOneMember', window );">Option Expiration Period Thirty One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected annual volatility, based on historical share price of the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life (in years) | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Share price (in CAD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price (in CAD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unvested Forfeiture Rate, As Percentage, Share Options Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE CAPITAL - Summary of stock option information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="3"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>option</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 07, 2025 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Nov. 27, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Aug. 15, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Apr. 05, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 20, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Jun. 29, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="nump">3,956,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,956,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,742,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">778,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="nump">3,591,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,591,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">8 years 1 month 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodOneMember', window );">Option Expiration Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwoMember', window );">Option Expiration Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThreeMember', window );">Option Expiration Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodFourMember', window );">Option Expiration Period Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodFiveMember', window );">Option Expiration Period Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">2 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodSixMember', window );">Option Expiration Period Six</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodSevenMember', window );">Option Expiration Period Seven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodEightMember', window );">Option Expiration Period Eight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodNineMember', window );">Option Expiration Period Nine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTenMember', window );">Option Expiration Period Ten</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodElevenMember', window );">Option Expiration Period Eleven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwelveMember', window );">Option Expiration Period Twelve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirteenMember', window );">Option Expiration Period Thirteen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodFourteenMember', window );">Option Expiration Period Fourteen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodFifteenMember', window );">Option Expiration Period Fifteen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodSixteenMember', window );">Option Expiration Period Sixteen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">10 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodSeventeenMember', window );">Option Expiration Period Seventeen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodEighteenMember', window );">Option Expiration Period Eighteen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodNineteenMember', window );">Option Expiration Period Nineteen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyMember', window );">Option Expiration Period Twenty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyOneMember', window );">Option Expiration Period Twenty One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyTwoMember', window );">Option Expiration Period Twenty Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyThreeMember', window );">Option Expiration Period Twenty Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">1 year 2 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFourMember', window );">Option Expiration Period Twenty Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">1 year 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFiveMember', window );">Option Expiration Period Twenty Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">1 year 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentySixMember', window );">Option Expiration Period Twenty Six</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">1 year 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentySevenMember', window );">Option Expiration Period Twenty Seven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">1 year 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyEightMember', window );">Option Expiration Period Twenty Eight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">1 year 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyNineMember', window );">Option Expiration Period Twenty Nine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">3 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyMember', window );">Option Expiration Period Thirty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">3 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyOneMember', window );">Option Expiration Period Thirty One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">3 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyTwoMember', window );">Option Expiration Period Thirty Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">4 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyThreeMember', window );">Option Expiration Period Thirty Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">7 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFourMember', window );">Option Expiration Period Thirty Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,049,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,877,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">9 years 4 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFiveMember', window );">Option Expiration Period Thirty Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">9 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySixMember', window );">Option Expiration Period Thirty Six</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Estimated grant date fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining life</a></td>
<td class="text">9 years 11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_OptionExpirationPeriodAxis=cybn_OptionExpirationPeriodThirtySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS AND BALANCES - Schedule of Remuneration of Key Management Personnel (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems', window );"><strong>Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Payroll, consulting and benefits</a></td>
<td class="nump">$ 7,807<span></span>
</td>
<td class="nump">$ 6,406<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="nump">33,983<span></span>
</td>
<td class="nump">15,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_IncomeStatementLocationAxis=cybn_GeneralAndAdministrativeExpenseMember', window );">General and administrative costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems', window );"><strong>Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Payroll, consulting and benefits</a></td>
<td class="nump">6,640<span></span>
</td>
<td class="nump">5,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_IncomeStatementLocationAxis=cybn_ResearchComponentMember', window );">Research</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems', window );"><strong>Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Payroll, consulting and benefits</a></td>
<td class="nump">1,167<span></span>
</td>
<td class="nump">1,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_ShareBasedPaymentArrangementOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems', window );"><strong>Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based compensation</a></td>
<td class="nump">24,937<span></span>
</td>
<td class="nump">8,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems', window );"><strong>Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based compensation</a></td>
<td class="nump">$ 1,239<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_IncomeStatementLocationAxis=cybn_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_IncomeStatementLocationAxis=cybn_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_IncomeStatementLocationAxis=cybn_ResearchComponentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_IncomeStatementLocationAxis=cybn_ResearchComponentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_ShareBasedPaymentArrangementOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cybn_ShareBasedPaymentArrangementOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH EXPENSES (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_AdvancementOfDevelopmentPrograms', window );">Advancement of development programs</a></td>
<td class="nump">$ 39,547<span></span>
</td>
<td class="nump">$ 22,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_PayrollAndBenefits', window );">Payroll and benefits</a></td>
<td class="nump">13,146<span></span>
</td>
<td class="nump">8,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LabAndAdministration', window );">Lab and administration</a></td>
<td class="nump">1,933<span></span>
</td>
<td class="nump">1,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_ProfessionalAndConsultingFees', window );">Professional and consulting fees</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="nump">$ 54,910<span></span>
</td>
<td class="nump">$ 32,362<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_AdvancementOfDevelopmentPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advancement Of Development Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_AdvancementOfDevelopmentPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_LabAndAdministration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lab And Administration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_LabAndAdministration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_PayrollAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payroll And Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_PayrollAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ProfessionalAndConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Professional And Consulting Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ProfessionalAndConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL AND ADMINISTRATIVE EXPENSES (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_CapitalMarketExpense', window );">Capital markets</a></td>
<td class="nump">$ 16,694<span></span>
</td>
<td class="nump">$ 11,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Payroll, consulting and benefits</a></td>
<td class="nump">13,146<span></span>
</td>
<td class="nump">8,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OccupancyExpense', window );">Office and administration</a></td>
<td class="nump">4,498<span></span>
</td>
<td class="nump">2,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Professional and consulting fees</a></td>
<td class="nump">4,156<span></span>
</td>
<td class="nump">4,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_BusinessDevelopmentExpense', window );">Business development</a></td>
<td class="nump">3,305<span></span>
</td>
<td class="nump">896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_InvestorRelationsSalesAndMarketingExpense', window );">Investor relations and Marketing media</a></td>
<td class="nump">3,286<span></span>
</td>
<td class="nump">3,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_ListingFeesExpense', window );">Listing fees</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">Total</a></td>
<td class="nump">$ 45,368<span></span>
</td>
<td class="nump">$ 32,588<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_BusinessDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_BusinessDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_CapitalMarketExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital Market Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_CapitalMarketExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_InvestorRelationsSalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investor Relations, Sales and Marketing Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_InvestorRelationsSalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ListingFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Listing Fees Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ListingFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OccupancyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from occupancy services received by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OccupancyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONTRACTS, COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_COMMITMENTSLineItems', window );"><strong>COMMITMENTS [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCapitalCommitments', window );">Contractual commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_SalesRoyaltyPercentage', window );">Sales royalty percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ItemsOfContingentLiabilitiesAxis=ifrs-full_OtherContingentLiabilitiesMember', window );">Other contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_COMMITMENTSLineItems', window );"><strong>COMMITMENTS [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCapitalCommitments', window );">Contractual commitments</a></td>
<td class="nump">$ 13,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_COMMITMENTSLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>COMMITMENTS [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_COMMITMENTSLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_SalesRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Royalty, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_SalesRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractualCapitalCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractualCapitalCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ItemsOfContingentLiabilitiesAxis=ifrs-full_OtherContingentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ItemsOfContingentLiabilitiesAxis=ifrs-full_OtherContingentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CAPITAL MANAGEMENT (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_CapitalManagementAbstract', window );"><strong>Capital Management [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">$ 464,364<span></span>
</td>
<td class="nump">$ 443,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Contributed surplus</a></td>
<td class="nump">44,414<span></span>
</td>
<td class="nump">11,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfSharebasedPayments', window );">Options reserve</a></td>
<td class="nump">47,427<span></span>
</td>
<td class="nump">39,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantReserve', window );">Warrants reserve</a></td>
<td class="nump">27,594<span></span>
</td>
<td class="nump">25,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(7,231)<span></span>
</td>
<td class="num">(2,285)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Deficit</a></td>
<td class="num">(339,368)<span></span>
</td>
<td class="num">(226,231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="nump">$ 237,200<span></span>
</td>
<td class="nump">$ 291,927<span></span>
</td>
<td class="nump">$ 48,234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_CapitalManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital Management [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_CapitalManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from share-based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Financial Assets and Liabilities (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure of Financial Assets and Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">$ 135,022<span></span>
</td>
<td class="nump">$ 208,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Accounts receivable</a></td>
<td class="nump">5,885<span></span>
</td>
<td class="nump">4,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">21,418<span></span>
</td>
<td class="nump">9,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">Financial liabilities, measured at amortized cost: | Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure of Financial Assets and Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">21,418<span></span>
</td>
<td class="nump">9,805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">Financial liabilities, measured at amortized cost: | Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure of Financial Assets and Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember', window );">Financial assets, measured at fair value: | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure of Financial Assets and Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">135,022<span></span>
</td>
<td class="nump">208,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets, measured at amortized cost: | Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure of Financial Assets and Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Accounts receivable</a></td>
<td class="nump">$ 706<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Financial Assets and Liabilities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=cybn_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=cybn_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=cybn_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=cybn_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems', window );"><strong>Disclosure of Financial Assets and Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">$ 135,022<span></span>
</td>
<td class="nump">$ 208,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">21,418<span></span>
</td>
<td class="nump">10,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 21,418<span></span>
</td>
<td class="nump">$ 9,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash', window );">Decrease in interest rate generated on cash</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_InterestRateRiskIncreaseDecreaseInInterestIncome', window );">Reduction in interest income due to interest rate decline</a></td>
<td class="nump">$ 1,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_InterestRateRiskTerm', window );">Interest rate risk, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Financial Assets and Liabilities [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_InterestRateRiskIncreaseDecreaseInInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Rate Risk, Increase (Decrease) In Interest Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_InterestRateRiskIncreaseDecreaseInInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Rate Risk, Increase (Decrease) In Interest Rate Generated On Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_InterestRateRiskTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Rate Risk, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_InterestRateRiskTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Monetary Assets and Liabilities Currency Risk Fluctuations (Details)<br> &#8364; in Thousands, &#163; in Thousands, $ in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>GBP (&#163;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">United States of America, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_FinancialAssetsAndLiabilities', window );">Financial assets and liabilities</a></td>
<td class="nump">$ 90,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Foreign currency rate | shares</a></td>
<td class="nump">1.4376<span></span>
</td>
<td class="nump">1.4376<span></span>
</td>
<td class="nump">1.4376<span></span>
</td>
<td class="nump">1.4376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Impact of 10% change in foreign currency rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">United States of America, Dollars | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_FinancialAssetsAndLiabilities', window );">Financial assets and liabilities</a></td>
<td class="nump">$ 92,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">United States of America, Dollars | Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_FinancialAssetsAndLiabilities', window );">Financial assets and liabilities</a></td>
<td class="nump">353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">United States of America, Dollars | Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_FinancialAssetsAndLiabilities', window );">Financial assets and liabilities</a></td>
<td class="num">$ (1,841)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">United Kingdom, Pounds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_FinancialAssetsAndLiabilities', window );">Financial assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#163; (339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (630)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Foreign currency rate | shares</a></td>
<td class="nump">1.8571<span></span>
</td>
<td class="nump">1.8571<span></span>
</td>
<td class="nump">1.8571<span></span>
</td>
<td class="nump">1.8571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Impact of 10% change in foreign currency rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (63)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">United Kingdom, Pounds | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_FinancialAssetsAndLiabilities', window );">Financial assets and liabilities | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">United Kingdom, Pounds | Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_FinancialAssetsAndLiabilities', window );">Financial assets and liabilities | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">United Kingdom, Pounds | Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_FinancialAssetsAndLiabilities', window );">Financial assets and liabilities | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#163; (415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro Member Countries, Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_FinancialAssetsAndLiabilities', window );">Financial assets and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 618<span></span>
</td>
<td class="nump">$ 960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Foreign currency rate | shares</a></td>
<td class="nump">1.5540<span></span>
</td>
<td class="nump">1.5540<span></span>
</td>
<td class="nump">1.5540<span></span>
</td>
<td class="nump">1.5540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Impact of 10% change in foreign currency rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro Member Countries, Euro | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_FinancialAssetsAndLiabilities', window );">Financial assets and liabilities | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro Member Countries, Euro | Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_FinancialAssetsAndLiabilities', window );">Financial assets and liabilities | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro Member Countries, Euro | Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_FinancialAssetsAndLiabilities', window );">Financial assets and liabilities | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_FinancialAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Assets And Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_FinancialAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of risk exposure associated with financial instruments with a shared characteristic that identifies a concentration of risks. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph B8<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B8_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis=cybn_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis=cybn_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis=cybn_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis=cybn_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX - Income Tax Rate Reconciliation (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_IncomeTaxesAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">$ (113,137)<span></span>
</td>
<td class="num">$ (78,080)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Expected recovery at statutory rate</a></td>
<td class="nump">29,981<span></span>
</td>
<td class="nump">20,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset', window );">Non-capital loss acquired on acquisition of subsidiary</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_TaxEffectOfShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="num">(10,497)<span></span>
</td>
<td class="num">(3,680)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_TaxEffectOfShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">4,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfForeignTaxRates', window );">Difference between Canadian and foreign tax rates</a></td>
<td class="num">(9,317)<span></span>
</td>
<td class="num">(5,440)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset', window );">Effect of exchange on unbooked deferred tax assets</a></td>
<td class="nump">351<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss', window );">Non-deductible expenses</a></td>
<td class="num">(103)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_TaxEffectOfChangeInDeferredTaxAssets', window );">Change in unrecognized deferred tax assets</a></td>
<td class="num">(10,537)<span></span>
</td>
<td class="num">(27,405)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax recovery</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_IncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_IncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_TaxEffectOfChangeInDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Change In Deferred Tax Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_TaxEffectOfChangeInDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_TaxEffectOfShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Share Based Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_TaxEffectOfShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_TaxEffectOfShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Share Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_TaxEffectOfShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a pre-acquisition deferred tax asset of the acquirer as a result of a business combination that changes the probability of realising the asset by the acquirer. [Refer: Deferred tax assets; Total for all business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_j&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in deferred tax liability (asset) resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Deferred tax liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAX - Deferred Tax Assets (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_GrossDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">$ 61,245<span></span>
</td>
<td class="nump">$ 50,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(61,245)<span></span>
</td>
<td class="num">(50,708)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Net deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember', window );">Non-capital loss carryforwards - Canada | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_GrossDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">22,310<span></span>
</td>
<td class="nump">20,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember', window );">Non-capital loss carryforwards - Canada | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_GrossDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">2,533<span></span>
</td>
<td class="nump">2,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember', window );">Non-capital loss carryforwards - Canada | Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_GrossDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">18,327<span></span>
</td>
<td class="nump">10,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember', window );">Non-capital loss carryforwards - Canada | United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_GrossDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">10,767<span></span>
</td>
<td class="nump">10,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cybn_DeferredCompensationMember', window );">Deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_GrossDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">1,653<span></span>
</td>
<td class="nump">1,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cybn_RDExpendituresMember', window );">Research and Development expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_GrossDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">2,538<span></span>
</td>
<td class="nump">1,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cybn_ShareIssuanceCostsMember', window );">Share issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_GrossDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">3,102<span></span>
</td>
<td class="nump">4,361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember', window );">Depreciation/Capital cost allowance differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_GrossDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_GrossDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross Deferred Tax Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_GrossDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cybn_DeferredCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cybn_DeferredCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cybn_RDExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cybn_RDExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cybn_ShareIssuanceCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cybn_ShareIssuanceCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAX - Non-capital Losses Expiration (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">$ 84,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">12,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">137,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">43,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2036Member', window );">2036 | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2037Member', window );">2037 | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2038Member', window );">2038 | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2039Member', window );">2039 | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2040Member', window );">2040 | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">863<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2040Member', window );">2040 | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">1,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2041Member', window );">2041 | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">21,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2041Member', window );">2041 | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">1,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2042Member', window );">2042 | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">16,019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2042Member', window );">2042 | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">4,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2042Member', window );">2042 | Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">22,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2043Member', window );">2043 | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">10,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2043Member', window );">2043 | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">1,593<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2043Member', window );">2043 | Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">23,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2044Member', window );">2044 | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">24,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2044Member', window );">2044 | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">1,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2044Member', window );">2044 | Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">33,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2045Member', window );">2045 | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">10,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2045Member', window );">2045 | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">1,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_LossCarryforwardExpirationAxis=cybn_A2045Member', window );">2045 | Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">$ 57,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Non-Capital Losses Expiration [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DisclosureOfNonCapitalLossesExpirationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NonCapitalLossCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Capital Loss Carryforward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NonCapitalLossCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_LossCarryforwardExpirationAxis=cybn_A2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_LossCarryforwardExpirationAxis=cybn_A2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_LossCarryforwardExpirationAxis=cybn_A2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_LossCarryforwardExpirationAxis=cybn_A2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_LossCarryforwardExpirationAxis=cybn_A2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_LossCarryforwardExpirationAxis=cybn_A2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_LossCarryforwardExpirationAxis=cybn_A2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_LossCarryforwardExpirationAxis=cybn_A2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_LossCarryforwardExpirationAxis=cybn_A2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_LossCarryforwardExpirationAxis=cybn_A2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_LossCarryforwardExpirationAxis=cybn_A2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_LossCarryforwardExpirationAxis=cybn_A2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_LossCarryforwardExpirationAxis=cybn_A2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_LossCarryforwardExpirationAxis=cybn_A2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_LossCarryforwardExpirationAxis=cybn_A2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_LossCarryforwardExpirationAxis=cybn_A2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_LossCarryforwardExpirationAxis=cybn_A2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_LossCarryforwardExpirationAxis=cybn_A2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_LossCarryforwardExpirationAxis=cybn_A2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_LossCarryforwardExpirationAxis=cybn_A2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAX - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_Section382Limitation', window );">Section 382 limitation</a></td>
<td class="nump">$ 153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">43,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">12,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | 2040 - 2041</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">2,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | 2040</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems', window );"><strong>Disclosure Of Non-Capital Losses Expiration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NonCapitalLossCarryforward', window );">Non-capital losses</a></td>
<td class="nump">$ 1,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DisclosureOfNonCapitalLossesExpirationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Non-Capital Losses Expiration [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DisclosureOfNonCapitalLossesExpirationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NonCapitalLossCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Capital Loss Carryforward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NonCapitalLossCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_Section382Limitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Section 382 Limitation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_Section382Limitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_LossCarryforwardExpirationAxis=cybn_A20402041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_LossCarryforwardExpirationAxis=cybn_A20402041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_LossCarryforwardExpirationAxis=cybn_A2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_LossCarryforwardExpirationAxis=cybn_A2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br> $ / shares in Units, $ / shares in Units, $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 19, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>CAD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesIssuedThroughShareOfferingEquity', window );">At-the-market offering - net of share issuance costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,179,927<span></span>
</td>
<td class="nump">638,545<span></span>
</td>
<td class="nump">638,545<span></span>
</td>
<td class="nump">66,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">898,434<span></span>
</td>
<td class="nump">898,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_SharePricePerCommonShare', window );">Share price (in USD per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.62<span></span>
</td>
<td class="nump">$ 9.52<span></span>
</td>
<td class="nump">$ 17.29<span></span>
</td>
<td class="nump">$ 12.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,018<span></span>
</td>
<td class="nump">$ 8,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,924<span></span>
</td>
<td class="nump">$ 15,322<span></span>
</td>
<td class="nump">$ 15,532<span></span>
</td>
<td class="nump">$ 11,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember', window );">Major ordinary share transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage', window );">Maximum affiliate ownership percentage</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember', window );">Major ordinary share transactions | Convertible Debentures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DebtSecurities', window );">Debt instruments issued</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DebtInstrumentGuaranteedInterestPayableRate', window );">Debt instrument, guaranteed interest payable</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate', window );">Debt instrument, annual interest rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DebtInstrumentDefaultRate', window );">Debt instrument, default rate</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of stock price trigger</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays', window );">Threshold trading days</a></td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DebtInstrumentPrepaymentPremiumYearOne', window );">Prepayment premium, if paid year one</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_DebtInstrumentPrepaymentPremiumYearTwo', window );">Prepayment premium, if paid year two</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember', window );">Major ordinary share transactions | Convertible Debenture Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DebtSecurities', window );">Debt instruments issued</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember', window );">Major ordinary share transactions | Common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_NumberOfSharesIssuedThroughShareOfferingEquity', window );">At-the-market offering - net of share issuance costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,422,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cybn_SharePricePerCommonShare', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debenture, Maximum Affiliate Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debenture, Threshold Percentage of Stock Price Trigger</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debenture, Threshold Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DebtInstrumentDefaultRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Default Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DebtInstrumentDefaultRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Guaranteed Interest Payable, Annual Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DebtInstrumentGuaranteedInterestPayableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Guaranteed Interest Payable, Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DebtInstrumentGuaranteedInterestPayableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DebtInstrumentPrepaymentPremiumYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DebtInstrumentPrepaymentPremiumYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DebtInstrumentPrepaymentPremiumYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Premium, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DebtInstrumentPrepaymentPremiumYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_NumberOfSharesIssuedThroughShareOfferingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Issued Through Share Offering, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_NumberOfSharesIssuedThroughShareOfferingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_SharePricePerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Price per Common Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_SharePricePerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cybn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of instruments issued by the entity that represent indebtedness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ClassesOfDebtInstrumentsAxis=cybn_ConvertibleDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ClassesOfDebtInstrumentsAxis=cybn_ConvertibleDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cybn_ClassesOfDebtInstrumentsAxis=cybn_ConvertibleDebenturePrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cybn_ClassesOfDebtInstrumentsAxis=cybn_ConvertibleDebenturePrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>428</ContextCount>
  <ElementCount>323</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>137</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - COVER</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/COVER</Role>
      <ShortName>COVER</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - AUDIT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/AUDITINFORMATION</Role>
      <ShortName>AUDIT INFORMATION</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENT OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Disclosure - CORPORATE INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/CORPORATEINFORMATION</Role>
      <ShortName>CORPORATE INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATION</Role>
      <ShortName>MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/CRITICALACCOUNTINGESTIMATESANDJUDGEMENTS</Role>
      <ShortName>CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - ACQUISITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/ACQUISITION</Role>
      <ShortName>ACQUISITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/EQUIPMENT</Role>
      <ShortName>EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/INTANGIBLEASSETS</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIES</Role>
      <ShortName>RIGHT-OF-USE ASSETS AND LEASE LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/GOODWILL</Role>
      <ShortName>GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - SHARE CAPITAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/SHARECAPITAL</Role>
      <ShortName>SHARE CAPITAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - RELATED PARTY TRANSACTIONS AND BALANCES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCES</Role>
      <ShortName>RELATED PARTY TRANSACTIONS AND BALANCES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - RESEARCH EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/RESEARCHEXPENSES</Role>
      <ShortName>RESEARCH EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSES</Role>
      <ShortName>GENERAL AND ADMINISTRATIVE EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - CONTRACTS, COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>CONTRACTS, COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - CAPITAL MANAGEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/CAPITALMANAGEMENT</Role>
      <ShortName>CAPITAL MANAGEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/FINANCIALINSTRUMENTS</Role>
      <ShortName>FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - INCOME TAX</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/INCOMETAX</Role>
      <ShortName>INCOME TAX</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies</Role>
      <ShortName>MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONTables</Role>
      <ShortName>MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATION</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - ACQUISITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/ACQUISITIONTables</Role>
      <ShortName>ACQUISITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cybin.com/role/ACQUISITION</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/EQUIPMENTTables</Role>
      <ShortName>EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cybin.com/role/EQUIPMENT</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/INTANGIBLEASSETSTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cybin.com/role/INTANGIBLEASSETS</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESTables</Role>
      <ShortName>RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIES</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/GOODWILLTables</Role>
      <ShortName>GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cybin.com/role/GOODWILL</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - SHARE CAPITAL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/SHARECAPITALTables</Role>
      <ShortName>SHARE CAPITAL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cybin.com/role/SHARECAPITAL</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - RELATED PARTY TRANSACTIONS AND BALANCES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESTables</Role>
      <ShortName>RELATED PARTY TRANSACTIONS AND BALANCES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - RESEARCH EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/RESEARCHEXPENSESTables</Role>
      <ShortName>RESEARCH EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cybin.com/role/RESEARCHEXPENSES</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESTables</Role>
      <ShortName>GENERAL AND ADMINISTRATIVE EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSES</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - CAPITAL MANAGEMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/CAPITALMANAGEMENTTables</Role>
      <ShortName>CAPITAL MANAGEMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cybin.com/role/CAPITALMANAGEMENT</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/FINANCIALINSTRUMENTSTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cybin.com/role/FINANCIALINSTRUMENTS</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - INCOME TAX (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/INCOMETAXTables</Role>
      <ShortName>INCOME TAX (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cybin.com/role/INCOMETAX</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - CORPORATE INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/CORPORATEINFORMATIONDetails</Role>
      <ShortName>CORPORATE INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cybin.com/role/CORPORATEINFORMATION</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Functional and presentation currency (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails</Role>
      <ShortName>MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Functional and presentation currency (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Cash and cash equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONCashandcashequivalentsDetails</Role>
      <ShortName>MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Cash and cash equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Equipment and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails</Role>
      <ShortName>MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Equipment and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Share-based compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONSharebasedcompensationDetails</Role>
      <ShortName>MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Share-based compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - ACQUISITION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/ACQUISITIONNarrativeDetails</Role>
      <ShortName>ACQUISITION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - ACQUISITION - Details of acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails</Role>
      <ShortName>ACQUISITION - Details of acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - ACQUISITION - Results since acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/ACQUISITIONResultssinceacquisitionDetails</Role>
      <ShortName>ACQUISITION - Results since acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/EQUIPMENTDetails</Role>
      <ShortName>EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cybin.com/role/EQUIPMENTTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/INTANGIBLEASSETSDetails</Role>
      <ShortName>INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cybin.com/role/INTANGIBLEASSETSTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESNarrativeDetails</Role>
      <ShortName>RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Right of use assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails</Role>
      <ShortName>RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Right of use assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESLeaseliabilitiesDetails</Role>
      <ShortName>RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - GOODWILL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/GOODWILLDetails</Role>
      <ShortName>GOODWILL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cybin.com/role/GOODWILLTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - SHARE CAPITAL - Narrative - Issued Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails</Role>
      <ShortName>SHARE CAPITAL - Narrative - Issued Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - SHARE CAPITAL - Summary of share capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/SHARECAPITALSummaryofsharecapitalDetails</Role>
      <ShortName>SHARE CAPITAL - Summary of share capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - SHARE CAPITAL - Summary of warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails</Role>
      <ShortName>SHARE CAPITAL - Summary of warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - SHARE CAPITAL - Narrative - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails</Role>
      <ShortName>SHARE CAPITAL - Narrative - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - SHARE CAPITAL - Summary of significant unobservable inputs used, equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails</Role>
      <ShortName>SHARE CAPITAL - Summary of significant unobservable inputs used, equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - SHARE CAPITAL - Summary of warrants by expiry period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails</Role>
      <ShortName>SHARE CAPITAL - Summary of warrants by expiry period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - SHARE CAPITAL - Narrative - Stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails</Role>
      <ShortName>SHARE CAPITAL - Narrative - Stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - SHARE CAPITAL - Summary of number and weighted average exercise prices of share options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/SHARECAPITALSummaryofnumberandweightedaverageexercisepricesofshareoptionsDetails</Role>
      <ShortName>SHARE CAPITAL - Summary of number and weighted average exercise prices of share options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - SHARE CAPITAL - Summary of measurement of stock option fair value assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails</Role>
      <ShortName>SHARE CAPITAL - Summary of measurement of stock option fair value assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - SHARE CAPITAL - Summary of stock option information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails</Role>
      <ShortName>SHARE CAPITAL - Summary of stock option information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - RELATED PARTY TRANSACTIONS AND BALANCES - Schedule of Remuneration of Key Management Personnel (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS AND BALANCES - Schedule of Remuneration of Key Management Personnel (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - RESEARCH EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/RESEARCHEXPENSESDetails</Role>
      <ShortName>RESEARCH EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cybin.com/role/RESEARCHEXPENSESTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails</Role>
      <ShortName>GENERAL AND ADMINISTRATIVE EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - CONTRACTS, COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>CONTRACTS, COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - CAPITAL MANAGEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/CAPITALMANAGEMENTDetails</Role>
      <ShortName>CAPITAL MANAGEMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cybin.com/role/CAPITALMANAGEMENTTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Monetary Assets and Liabilities Currency Risk Fluctuations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Monetary Assets and Liabilities Currency Risk Fluctuations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - INCOME TAX - Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails</Role>
      <ShortName>INCOME TAX - Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - INCOME TAX - Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails</Role>
      <ShortName>INCOME TAX - Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - INCOME TAX - Non-capital Losses Expiration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails</Role>
      <ShortName>INCOME TAX - Non-capital Losses Expiration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - INCOME TAX - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/INCOMETAXAdditionalInformationDetails</Role>
      <ShortName>INCOME TAX - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="cybn-20250331_d2.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cybin.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cybin.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>74</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="40-F" isDefinitelyFs="true" isIfrs="true" original="cybn-20250331_d2.htm">cybn-20250331_d2.htm</File>
    <File doctype="40-F" isDefinitelyFs="true" isIfrs="true" original="cybn-20250331.htm">cybn-20250331.htm</File>
    <File>cybn-20250331.xsd</File>
    <File>cybn-20250331_cal.xml</File>
    <File>cybn-20250331_def.xml</File>
    <File>cybn-20250331_lab.xml</File>
    <File>cybn-20250331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cybn-20250331_g1.jpg</File>
    <File>cybn-20250331_g2.jpg</File>
    <File>cybn-20250331_g3.jpg</File>
    <File>cybn-20250331_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="43">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="893">https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>110
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cybn-20250331_d2.htm cybn-20250331.htm": {
   "nsprefix": "cybn",
   "nsuri": "http://cybin.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "cybn-20250331.htm",
      "cybn-20250331_d2.htm"
     ]
    },
    "schema": {
     "local": [
      "cybn-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2024-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd",
      "https://xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cybn-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cybn-20250331_def.xml"
     ],
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/dim_full_ifrs_2024-03-27_role-995000.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cybn-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cybn-20250331_pre.xml"
     ]
    }
   },
   "keyStandard": 221,
   "keyCustom": 102,
   "axisStandard": 23,
   "axisCustom": 7,
   "memberStandard": 37,
   "memberCustom": 93,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://cybin.com/20250331": 2
   },
   "contextCount": 428,
   "entityCount": 1,
   "segmentCount": 137,
   "elementCount": 596,
   "unitCount": 14,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 893,
    "http://xbrl.sec.gov/dei/2024": 43
   },
   "report": {
    "R1": {
     "role": "http://cybin.com/role/COVER",
     "longName": "0000001 - Document - COVER",
     "shortName": "COVER",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331_d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331_d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cybin.com/role/AUDITINFORMATION",
     "longName": "0000002 - Document - AUDIT INFORMATION",
     "shortName": "AUDIT INFORMATION",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
     "longName": "9952151 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:Cash",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CurrentPrepaidExpenses",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
     "longName": "9952152 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:OperatingExpense",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
     "longName": "9952153 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "ifrs-full:Equity",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS",
     "longName": "9952154 - Statement - CONSOLIDATED STATEMENT OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENT OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://cybin.com/role/CORPORATEINFORMATION",
     "longName": "9952155 - Disclosure - CORPORATE INFORMATION",
     "shortName": "CORPORATE INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATION",
     "longName": "9952156 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION",
     "shortName": "MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://cybin.com/role/CRITICALACCOUNTINGESTIMATESANDJUDGEMENTS",
     "longName": "9952157 - Disclosure - CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS",
     "shortName": "CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cybin.com/role/ACQUISITION",
     "longName": "9952158 - Disclosure - ACQUISITION",
     "shortName": "ACQUISITION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cybin.com/role/EQUIPMENT",
     "longName": "9952159 - Disclosure - EQUIPMENT",
     "shortName": "EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://cybin.com/role/INTANGIBLEASSETS",
     "longName": "9952160 - Disclosure - INTANGIBLE ASSETS",
     "shortName": "INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIES",
     "longName": "9952161 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES",
     "shortName": "RIGHT-OF-USE ASSETS AND LEASE LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cybn:DisclosureOfLeasesAndRightOfUseAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cybn:DisclosureOfLeasesAndRightOfUseAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://cybin.com/role/GOODWILL",
     "longName": "9952162 - Disclosure - GOODWILL",
     "shortName": "GOODWILL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://cybin.com/role/SHARECAPITAL",
     "longName": "9952163 - Disclosure - SHARE CAPITAL",
     "shortName": "SHARE CAPITAL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCES",
     "longName": "9952164 - Disclosure - RELATED PARTY TRANSACTIONS AND BALANCES",
     "shortName": "RELATED PARTY TRANSACTIONS AND BALANCES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://cybin.com/role/RESEARCHEXPENSES",
     "longName": "9952165 - Disclosure - RESEARCH EXPENSES",
     "shortName": "RESEARCH EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSES",
     "longName": "9952166 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES",
     "shortName": "GENERAL AND ADMINISTRATIVE EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIES",
     "longName": "9952167 - Disclosure - CONTRACTS, COMMITMENTS AND CONTINGENCIES",
     "shortName": "CONTRACTS, COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://cybin.com/role/CAPITALMANAGEMENT",
     "longName": "9952168 - Disclosure - CAPITAL MANAGEMENT",
     "shortName": "CAPITAL MANAGEMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://cybin.com/role/FINANCIALINSTRUMENTS",
     "longName": "9952169 - Disclosure - FINANCIAL INSTRUMENTS",
     "shortName": "FINANCIAL INSTRUMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://cybin.com/role/INCOMETAX",
     "longName": "9952170 - Disclosure - INCOME TAX",
     "shortName": "INCOME TAX",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://cybin.com/role/SUBSEQUENTEVENTS",
     "longName": "9952171 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies",
     "longName": "9955511 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION (Policies)",
     "shortName": "MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONTables",
     "longName": "9955512 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION (Tables)",
     "shortName": "MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cybn:DetailDescriptionOfFunctionalCurrenciesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cybn:DetailDescriptionOfFunctionalCurrenciesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://cybin.com/role/ACQUISITIONTables",
     "longName": "9955513 - Disclosure - ACQUISITION (Tables)",
     "shortName": "ACQUISITION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://cybin.com/role/EQUIPMENTTables",
     "longName": "9955514 - Disclosure - EQUIPMENT (Tables)",
     "shortName": "EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://cybin.com/role/INTANGIBLEASSETSTables",
     "longName": "9955515 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESTables",
     "longName": "9955516 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Tables)",
     "shortName": "RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://cybin.com/role/GOODWILLTables",
     "longName": "9955517 - Disclosure - GOODWILL (Tables)",
     "shortName": "GOODWILL (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://cybin.com/role/SHARECAPITALTables",
     "longName": "9955518 - Disclosure - SHARE CAPITAL (Tables)",
     "shortName": "SHARE CAPITAL (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESTables",
     "longName": "9955519 - Disclosure - RELATED PARTY TRANSACTIONS AND BALANCES (Tables)",
     "shortName": "RELATED PARTY TRANSACTIONS AND BALANCES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://cybin.com/role/RESEARCHEXPENSESTables",
     "longName": "9955520 - Disclosure - RESEARCH EXPENSES (Tables)",
     "shortName": "RESEARCH EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cybn:ScheduleOfResearchExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cybn:ScheduleOfResearchExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESTables",
     "longName": "9955521 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)",
     "shortName": "GENERAL AND ADMINISTRATIVE EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://cybin.com/role/CAPITALMANAGEMENTTables",
     "longName": "9955522 - Disclosure - CAPITAL MANAGEMENT (Tables)",
     "shortName": "CAPITAL MANAGEMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cybn:DisclosureOfCapitalStructureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cybn:DisclosureOfCapitalStructureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://cybin.com/role/FINANCIALINSTRUMENTSTables",
     "longName": "9955523 - Disclosure - FINANCIAL INSTRUMENTS (Tables)",
     "shortName": "FINANCIAL INSTRUMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://cybin.com/role/INCOMETAXTables",
     "longName": "9955524 - Disclosure - INCOME TAX (Tables)",
     "shortName": "INCOME TAX (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cybn:DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cybn:DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://cybin.com/role/CORPORATEINFORMATIONDetails",
     "longName": "9955525 - Disclosure - CORPORATE INFORMATION (Details)",
     "shortName": "CORPORATE INFORMATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "cybn:NumberOfSubsidiaries",
      "unitRef": "subsidiary",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "cybn:NumberOfSubsidiaries",
      "unitRef": "subsidiary",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails",
     "longName": "9955526 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Functional and presentation currency (Details)",
     "shortName": "MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Functional and presentation currency (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-40",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-40",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONCashandcashequivalentsDetails",
     "longName": "9955527 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Cash and cash equivalents (Details)",
     "shortName": "MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Cash and cash equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CashEquivalents",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ifrs-full:CashEquivalents",
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:CashEquivalents",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ifrs-full:CashEquivalents",
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails",
     "longName": "9955528 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Equipment and Intangible Assets (Details)",
     "shortName": "MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Equipment and Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-49",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-47",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONSharebasedcompensationDetails",
     "longName": "9955529 - Disclosure - MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Share-based compensation (Details)",
     "shortName": "MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION - Share-based compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cybn:ShareBasedCompensationArrangementExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cybn:ShareBasedCompensationArrangementExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://cybin.com/role/ACQUISITIONNarrativeDetails",
     "longName": "9955530 - Disclosure - ACQUISITION - Narrative (Details)",
     "shortName": "ACQUISITION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-51",
      "name": "cybn:RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails",
     "longName": "9955531 - Disclosure - ACQUISITION - Details of acquisition (Details)",
     "shortName": "ACQUISITION - Details of acquisition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-51",
      "name": "ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-51",
      "name": "ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://cybin.com/role/ACQUISITIONResultssinceacquisitionDetails",
     "longName": "9955532 - Disclosure - ACQUISITION - Results since acquisition (Details)",
     "shortName": "ACQUISITION - Results since acquisition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-54",
      "name": "ifrs-full:Revenue",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://cybin.com/role/EQUIPMENTDetails",
     "longName": "9955533 - Disclosure - EQUIPMENT (Details)",
     "shortName": "EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-57",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://cybin.com/role/INTANGIBLEASSETSDetails",
     "longName": "9955534 - Disclosure - INTANGIBLE ASSETS (Details)",
     "shortName": "INTANGIBLE ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-139",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESNarrativeDetails",
     "longName": "9955535 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Narrative (Details)",
     "shortName": "RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cybn:GainLossOnDerecognitionOfRightOfUseAssets",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cybn:GainLossOnDerecognitionOfRightOfUseAssets",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails",
     "longName": "9955536 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Right of use assets (Details)",
     "shortName": "RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Right of use assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-57",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESLeaseliabilitiesDetails",
     "longName": "9955537 - Disclosure - RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Lease liabilities (Details)",
     "shortName": "RIGHT-OF-USE ASSETS AND LEASE LIABILITIES - Lease liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:LeaseLiabilities",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "ifrs-full:LeaseLiabilities",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://cybin.com/role/GOODWILLDetails",
     "longName": "9955538 - Disclosure - GOODWILL (Details)",
     "shortName": "GOODWILL (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:Goodwill",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
     "longName": "9955539 - Disclosure - SHARE CAPITAL - Narrative - Issued Share Capital (Details)",
     "shortName": "SHARE CAPITAL - Narrative - Issued Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "cybn:NumberOfCommonSharesHeldInEscrow",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-148",
      "name": "cybn:CommonStockSharesAuthorizedValue",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://cybin.com/role/SHARECAPITALSummaryofsharecapitalDetails",
     "longName": "9955540 - Disclosure - SHARE CAPITAL - Summary of share capital (Details)",
     "shortName": "SHARE CAPITAL - Summary of share capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-170",
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "1",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-171",
      "name": "cybn:IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "1",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails",
     "longName": "9955541 - Disclosure - SHARE CAPITAL - Summary of warrants (Details)",
     "shortName": "SHARE CAPITAL - Summary of warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-177",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-175",
      "name": "ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019",
      "unitRef": "cadPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails",
     "longName": "9955542 - Disclosure - SHARE CAPITAL - Narrative - Warrants (Details)",
     "shortName": "SHARE CAPITAL - Narrative - Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProceedsFromExerciseOfWarrants",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-178",
      "name": "ifrs-full:ProceedsFromExerciseOfWarrants",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails",
     "longName": "9955543 - Disclosure - SHARE CAPITAL - Summary of significant unobservable inputs used, equity (Details)",
     "shortName": "SHARE CAPITAL - Summary of significant unobservable inputs used, equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProceedsFromExerciseOfWarrants",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-161",
      "name": "cybn:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails",
     "longName": "9955544 - Disclosure - SHARE CAPITAL - Summary of warrants by expiry period (Details)",
     "shortName": "SHARE CAPITAL - Summary of warrants by expiry period (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-179",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-179",
      "name": "ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
     "longName": "9955545 - Disclosure - SHARE CAPITAL - Narrative - Stock options (Details)",
     "shortName": "SHARE CAPITAL - Narrative - Stock options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-191",
      "name": "cybn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-191",
      "name": "cybn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://cybin.com/role/SHARECAPITALSummaryofnumberandweightedaverageexercisepricesofshareoptionsDetails",
     "longName": "9955546 - Disclosure - SHARE CAPITAL - Summary of number and weighted average exercise prices of share options (Details)",
     "shortName": "SHARE CAPITAL - Summary of number and weighted average exercise prices of share options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cybn:NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails",
     "longName": "9955547 - Disclosure - SHARE CAPITAL - Summary of measurement of stock option fair value assumptions (Details)",
     "shortName": "SHARE CAPITAL - Summary of measurement of stock option fair value assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-224",
      "name": "cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-224",
      "name": "cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails",
     "longName": "9955548 - Disclosure - SHARE CAPITAL - Summary of stock option information (Details)",
     "shortName": "SHARE CAPITAL - Summary of stock option information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails",
     "longName": "9955549 - Disclosure - RELATED PARTY TRANSACTIONS AND BALANCES - Schedule of Remuneration of Key Management Personnel (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS AND BALANCES - Schedule of Remuneration of Key Management Personnel (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://cybin.com/role/RESEARCHEXPENSESDetails",
     "longName": "9955550 - Disclosure - RESEARCH EXPENSES (Details)",
     "shortName": "RESEARCH EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cybn:AdvancementOfDevelopmentPrograms",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "cybn:ScheduleOfResearchExpensesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cybn:AdvancementOfDevelopmentPrograms",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "cybn:ScheduleOfResearchExpensesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails",
     "longName": "9955551 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Details)",
     "shortName": "GENERAL AND ADMINISTRATIVE EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cybn:CapitalMarketExpense",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cybn:CapitalMarketExpense",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIESDetails",
     "longName": "9955552 - Disclosure - CONTRACTS, COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "CONTRACTS, COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:ContractualCapitalCommitments",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:ContractualCapitalCommitments",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://cybin.com/role/CAPITALMANAGEMENTDetails",
     "longName": "9955553 - Disclosure - CAPITAL MANAGEMENT (Details)",
     "shortName": "CAPITAL MANAGEMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:IssuedCapital",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R67": {
     "role": "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails",
     "longName": "9955554 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Financial Assets and Liabilities (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Financial Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:Cash",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-368",
      "name": "ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
       "ifrs-full:DisclosureOfFinancialAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
     "longName": "9955555 - Disclosure - FINANCIAL INSTRUMENTS - Narrative (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "ifrs-full:Cash",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "cybn:InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails",
     "longName": "9955556 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Monetary Assets and Liabilities Currency Risk Fluctuations (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Monetary Assets and Liabilities Currency Risk Fluctuations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-379",
      "name": "cybn:FinancialAssetsAndLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-379",
      "name": "cybn:FinancialAssetsAndLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails",
     "longName": "9955557 - Disclosure - INCOME TAX - Income Tax Rate Reconciliation (Details)",
     "shortName": "INCOME TAX - Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:TaxExpenseIncomeAtApplicableTaxRate",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cybn:DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails",
     "longName": "9955558 - Disclosure - INCOME TAX - Deferred Tax Assets (Details)",
     "shortName": "INCOME TAX - Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "cybn:GrossDeferredTaxAssets",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "cybn:GrossDeferredTaxAssets",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails",
     "longName": "9955559 - Disclosure - INCOME TAX - Non-capital Losses Expiration (Details)",
     "shortName": "INCOME TAX - Non-capital Losses Expiration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-408",
      "name": "cybn:NonCapitalLossCarryforward",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-408",
      "name": "cybn:NonCapitalLossCarryforward",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://cybin.com/role/INCOMETAXAdditionalInformationDetails",
     "longName": "9955560 - Disclosure - INCOME TAX - Additional Information (Details)",
     "shortName": "INCOME TAX - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "cybn:Section382Limitation",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "cybn:Section382Limitation",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://cybin.com/role/SUBSEQUENTEVENTSDetails",
     "longName": "9955561 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-165",
      "name": "cybn:NumberOfSharesIssuedThroughShareOfferingEquity",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-427",
      "name": "cybn:DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cybn-20250331.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "cybn_A2036Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "A2036Member",
     "presentation": [
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2036",
        "label": "2036 [Member]",
        "documentation": "2036"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_A2037Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "A2037Member",
     "presentation": [
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2037",
        "label": "2037 [Member]",
        "documentation": "2037"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_A2038Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "A2038Member",
     "presentation": [
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2038",
        "label": "2038 [Member]",
        "documentation": "2038"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_A2039Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "A2039Member",
     "presentation": [
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2039",
        "label": "2039 [Member]",
        "documentation": "2039"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_A20402041Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "A20402041Member",
     "presentation": [
      "http://cybin.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2040 - 2041",
        "label": "2040 - 2041 [Member]",
        "documentation": "2040 - 2041"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_A2040Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "A2040Member",
     "presentation": [
      "http://cybin.com/role/INCOMETAXAdditionalInformationDetails",
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2040",
        "label": "2040 [Member]",
        "documentation": "2040"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_A2041Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "A2041Member",
     "presentation": [
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2041",
        "label": "2041 [Member]",
        "documentation": "2041"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_A2042Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "A2042Member",
     "presentation": [
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2042",
        "label": "2042 [Member]",
        "documentation": "2042"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_A2043Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "A2043Member",
     "presentation": [
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2043",
        "label": "2043 [Member]",
        "documentation": "2043"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_A2044Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "A2044Member",
     "presentation": [
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2044",
        "label": "2044 [Member]",
        "documentation": "2044"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_A2045Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "A2045Member",
     "presentation": [
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2045",
        "label": "2045 [Member]",
        "documentation": "2045"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "documentation": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_AccountsPayableAndAccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "AccountsPayableAndAccruedLiabilitiesMember",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails",
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Accounts Payable And Accrued Liabilities [Member]",
        "documentation": "Accounts Payable And Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "presentation": [
      "http://cybin.com/role/EQUIPMENTDetails",
      "http://cybin.com/role/INTANGIBLEASSETSDetails",
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Amortization",
        "verboseLabel": "Accumulated amortization",
        "label": "Accumulated depreciation and amortisation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r49",
      "r231",
      "r234",
      "r239",
      "r240"
     ]
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CAPITALMANAGEMENTDetails",
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated other comprehensive income [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of purchaser consideration",
        "label": "Consideration transferred, acquisition-date fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/GOODWILLDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition from Small Pharma",
        "label": "Acquisitions through business combinations, intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in intangible assets and goodwill resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of Small Pharma",
        "label": "Acquisitions through business combinations, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ifrs-full_AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/EQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition from Small Pharma",
        "label": "Acquisitions through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in property, plant and equipment resulting from acquisitions through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additions other than through business combinations, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/EQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additions other than through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "cybn_AdditionsToLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "AdditionsToLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additions To Lease Liabilities",
        "documentation": "Additions To Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsToRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additions to right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Address Type [Domain]",
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "cybn_AdeliaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "AdeliaMember",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adelia",
        "label": "Adelia [Member]",
        "documentation": "Adelia"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_AdjustmentForLeaseInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "AdjustmentForLeaseInterest",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease interest accretion",
        "label": "Adjustment For Lease Interest",
        "documentation": "Adjustment For Lease Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Adjustments for decrease (increase) in other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Adjustments for decrease (increase) in prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Adjustments for decrease (increase) in trade accounts receivable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Adjustments for depreciation and amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment write-down",
        "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for impairment loss (reversal of impairment loss) on property, plant and equipment recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Adjustments For Increase (Decrease) In Accrued And Other Liabilities",
        "documentation": "Adjustments For Increase (Decrease) In Accrued And Other Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_AdjustmentsForOtherLossesGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "AdjustmentsForOtherLossesGains",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other loss",
        "label": "Adjustments For Other Losses (Gains)",
        "documentation": "Adjustments For Other Losses (Gains)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments for items not affecting cash:",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized foreign currency translation gain",
        "label": "Adjustments For Unrealized Gain (Loss) On Foreign Currency Translation",
        "documentation": "Adjustments For Unrealized Gain (Loss) On Foreign Currency Translation"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_AdjustmentsForWorkingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "AdjustmentsForWorkingCapitalAbstract",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net changes in non-cash working capital items:",
        "label": "Adjustments For Working Capital [Abstract]",
        "documentation": "Adjustments For Working Capital"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_AdvancementOfDevelopmentPrograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "AdvancementOfDevelopmentPrograms",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/RESEARCHEXPENSESDetails": {
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/RESEARCHEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advancement of development programs",
        "label": "Advancement Of Development Programs",
        "documentation": "Advancement Of Development Programs"
       }
      }
     },
     "auth_ref": []
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Currencies [Domain]",
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://cybin.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization charge",
        "label": "Amortisation, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AnalysisOfIncomeAndExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Analysis of income and expense [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual Information Form",
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r108",
      "r109",
      "r111",
      "r171",
      "r174"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Audited Annual Financial Statements",
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://cybin.com/role/AUDITINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://cybin.com/role/AUDITINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://cybin.com/role/AUDITINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215"
     ]
    },
    "cybn_August2023CompensationCommonShareWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "August2023CompensationCommonShareWarrantMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 2023 compensation common share warrant",
        "label": "August 2023 Compensation Common Share Warrant [Member]",
        "documentation": "August 2023 Compensation Common Share Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per share for the year (in dollars per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BusinessCombinationsAxis",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails",
      "http://cybin.com/role/ACQUISITIONNarrativeDetails",
      "http://cybin.com/role/ACQUISITIONResultssinceacquisitionDetails",
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combinations [axis]",
        "label": "Business combinations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_BusinessCombinationsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BusinessCombinationsDomain",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails",
      "http://cybin.com/role/ACQUISITIONNarrativeDetails",
      "http://cybin.com/role/ACQUISITIONResultssinceacquisitionDetails",
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combinations [domain]",
        "label": "Business combinations [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r145"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215"
     ]
    },
    "cybn_BusinessDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "BusinessDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails": {
       "parentTag": "ifrs-full_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business development",
        "label": "Business Development Expense",
        "documentation": "Business Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "country_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "CA",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONNarrativeDetails",
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails",
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canada",
        "label": "CANADA"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_COMMITMENTSLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "COMMITMENTSLineItems",
     "presentation": [
      "http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS [Line Items]",
        "label": "COMMITMENTS [Line Items]",
        "documentation": "COMMITMENTS [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_COMMITMENTSTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "COMMITMENTSTable",
     "presentation": [
      "http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS [Table]",
        "label": "COMMITMENTS [Table]",
        "documentation": "COMMITMENTS [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_CapitalManagementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "CapitalManagementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Management [Abstract]",
        "documentation": "Capital Management [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_CapitalMarketExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "CapitalMarketExpense",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails": {
       "parentTag": "ifrs-full_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital markets",
        "label": "Capital Market Expense",
        "documentation": "Capital Market Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://cybin.com/role/EQUIPMENTDetails",
      "http://cybin.com/role/INTANGIBLEASSETSDetails",
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r46",
      "r72",
      "r76",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r144",
      "r154",
      "r155"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://cybin.com/role/EQUIPMENTDetails",
      "http://cybin.com/role/INTANGIBLEASSETSDetails",
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount [member]",
        "label": "Carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r76",
      "r80",
      "r82",
      "r83",
      "r144",
      "r154",
      "r155"
     ]
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://cybin.com/role/CORPORATEINFORMATIONDetails",
      "http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, beginning of year",
        "periodEndLabel": "Cash, end of year",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r90",
      "r104"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash acquired on acquisition",
        "label": "Cash and cash equivalents in subsidiary or businesses acquired or disposed"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents in subsidiaries or other businesses over which control is obtained or lost. [Refer: Total for all subsidiaries [member]; Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ifrs-full_CashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONCashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows provided by financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r92"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCING ACTIVITIES",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows provided by (used in) investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r92"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVESTING ACTIVITIES",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://cybin.com/role/CORPORATEINFORMATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows used in operating activities",
        "terseLabel": "Cash flows from (used in) operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r85",
      "r92"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING ACTIVITIES",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash flows used in operating activities before net changes in non-cash working capital items",
        "label": "Cash flows from (used in) operations before changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r244"
     ]
    },
    "cybn_CashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "CashMember",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails",
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash [Member]",
        "documentation": "Cash"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_CashRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "CashRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash Recognised as of Acquisition Date",
        "documentation": "Cash Recognised as of Acquisition Date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAxis",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial assets [axis]",
        "label": "Categories of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_CategoriesOfFinancialAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsDomain",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial assets [domain]",
        "label": "Categories of financial assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial liabilities [axis]",
        "label": "Categories of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesDomain",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial liabilities [domain]",
        "label": "Categories of financial liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-capital loss acquired on acquisition of subsidiary",
        "label": "Increase (decrease) in amount recognised for pre-acquisition deferred tax asset"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a pre-acquisition deferred tax asset of the acquirer as a result of a business combination that changes the probability of realising the asset by the acquirer. [Refer: Deferred tax assets; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ifrs-full_ChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ChangesInEquityAbstract",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in equity [abstract]",
        "label": "Changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_ClassBSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ClassBSharesMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofsharecapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class B Shares",
        "label": "Class B Shares [Member]",
        "documentation": "Class B Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://cybin.com/role/GOODWILLDetails",
      "http://cybin.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of assets [axis]",
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r112",
      "r119"
     ]
    },
    "ifrs-full_ClassesOfAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfAssetsDomain",
     "presentation": [
      "http://cybin.com/role/GOODWILLDetails",
      "http://cybin.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of assets [domain]",
        "label": "Classes of assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r112",
      "r119"
     ]
    },
    "cybn_ClassesOfDebtInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ClassesOfDebtInstrumentsAxis",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes Of Debt Instruments [Axis]",
        "label": "Classes Of Debt Instruments [Axis]",
        "documentation": "Classes Of Debt Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_ClassesOfDebtInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ClassesOfDebtInstrumentsDomain",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes Of Debt Instruments [Domain]",
        "label": "Classes Of Debt Instruments [Domain]",
        "documentation": "Classes Of Debt Instruments [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_ClassesOfFinancialAssetsAndLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ClassesOfFinancialAssetsAndLiabilitiesAxis",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes Of Financial Assets And Liabilities [Axis]",
        "label": "Classes Of Financial Assets And Liabilities [Axis]",
        "documentation": "Classes Of Financial Assets And Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_ClassesOfFinancialAssetsAndLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ClassesOfFinancialAssetsAndLiabilitiesDomain",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes Of Financial Assets And Liabilities [Domain]",
        "label": "Classes Of Financial Assets And Liabilities [Domain]",
        "documentation": "Classes Of Financial Assets And Liabilities [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsAxis",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial assets [axis]",
        "label": "Classes of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r158",
      "r159",
      "r180",
      "r181"
     ]
    },
    "ifrs-full_ClassesOfFinancialAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsDomain",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial assets [domain]",
        "label": "Classes of financial assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r126",
      "r158",
      "r159",
      "r180",
      "r181"
     ]
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial liabilities [axis]",
        "label": "Classes of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r180",
      "r181"
     ]
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesDomain",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of financial liabilities [domain]",
        "label": "Classes of financial liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r180",
      "r181"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis",
     "presentation": [
      "http://cybin.com/role/GOODWILLDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets and goodwill [axis]",
        "label": "Classes of intangible assets and goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsAndGoodwillDomain",
     "presentation": [
      "http://cybin.com/role/GOODWILLDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets and goodwill [domain]",
        "label": "Classes of intangible assets and goodwill [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "presentation": [
      "http://cybin.com/role/INTANGIBLEASSETSDetails",
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets other than goodwill [axis]",
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain",
     "presentation": [
      "http://cybin.com/role/INTANGIBLEASSETSDetails",
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of intangible assets other than goodwill [domain]",
        "label": "Classes of intangible assets other than goodwill [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://cybin.com/role/EQUIPMENTDetails",
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [axis]",
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentDomain",
     "presentation": [
      "http://cybin.com/role/EQUIPMENTDetails",
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [domain]",
        "label": "Classes of property, plant and equipment [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofsharecapitalDetails",
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of share capital [axis]",
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalDomain",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofsharecapitalDetails",
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of share capital [domain]",
        "label": "Classes of share capital [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_ClosingForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClosingForeignExchangeRate",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency rate",
        "label": "Closing foreign exchange rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "cybn_CommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "CommitmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments [Abstract]",
        "documentation": "Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_CommonSharePurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "CommonSharePurchaseWarrantsMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Share Purchase Warrants",
        "label": "Common Share Purchase Warrants [Member]",
        "documentation": "Common Share Purchase Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_CommonSharesExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "CommonSharesExchangeRate",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares exchange rate",
        "label": "Common Shares, Exchange Rate",
        "documentation": "Common Shares, Exchange Rate"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_CommonSharesPurchasePeriodTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "CommonSharesPurchasePeriodTerm",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase period, term",
        "label": "Common Shares Purchase Period, Term",
        "documentation": "Common Shares Purchase Period, Term"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_CommonStockSharesAuthorizedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "CommonStockSharesAuthorizedValue",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares, authorized value",
        "label": "Common Stock Shares Authorized Value",
        "documentation": "Common Stock Shares Authorized Value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [axis]",
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [domain]",
        "label": "Components of equity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "COMPREHENSIVE LOSS FOR THE YEAR",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r24",
      "r95",
      "r97",
      "r102",
      "r200"
     ]
    },
    "ifrs-full_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://cybin.com/role/EQUIPMENTDetails",
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Equipment",
        "label": "Computer equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "ifrs-full_ComputerSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComputerSoftwareMember",
     "presentation": [
      "http://cybin.com/role/INTANGIBLEASSETSDetails",
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software",
        "verboseLabel": "Software",
        "label": "Computer software [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Name",
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContractualCapitalCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ContractualCapitalCommitments",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual commitments",
        "label": "Contractual capital commitments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]"
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "cybn_ConvertibleDebenturePrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ConvertibleDebenturePrivatePlacementMember",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debenture Private Placement",
        "label": "Convertible Debenture Private Placement [Member]",
        "documentation": "Convertible Debenture Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_ConvertibleDebenturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ConvertibleDebenturesMember",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debentures",
        "label": "Convertible Debentures [Member]",
        "documentation": "Convertible Debentures"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember",
     "presentation": [
      "http://cybin.com/role/INTANGIBLEASSETSDetails",
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "verboseLabel": "Patents",
        "label": "Copyrights, patents and other industrial property rights, service and operating rights [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing copyrights, patents and other industrial property rights, service and operating rights. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate information and statement of IFRS compliance [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "cybn_CriticalAccountingEstimatesAndJudgementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "CriticalAccountingEstimatesAndJudgementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Critical Accounting Estimates and Judgements [Abstract]",
        "documentation": "Critical Accounting Estimates and Judgements"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency [Axis]",
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrencyRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrencyRiskMember",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency risk",
        "label": "Currency risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r166"
     ]
    },
    "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Current accrued expenses and other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r99",
      "r200"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Current assets recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for current assets acquired in a business combination. [Refer: Current assets; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "terseLabel": "Current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r101",
      "r200"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Current prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "cybn_CybinCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "CybinCorpMember",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybin Corp.",
        "label": "Cybin Corp [Member]",
        "documentation": "Cybin Corp"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_CybinIRLLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "CybinIRLLimitedMember",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybin IRL",
        "label": "Cybin IRL Limited [Member]",
        "documentation": "Cybin IRL Limited"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_CybinUKLtd.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "CybinUKLtd.Member",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybin UK Ltd.",
        "label": "Cybin UK Ltd. [Member]",
        "documentation": "Cybin UK Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "cybn_CybinUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "CybinUSMember",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybin US",
        "label": "Cybin US [Member]",
        "documentation": "Cybin US"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum affiliate ownership percentage",
        "label": "Debt Instrument, Convertible Debenture, Maximum Affiliate Ownership Percentage",
        "documentation": "Debt Instrument, Convertible Debenture, Maximum Affiliate Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold percentage of stock price trigger",
        "label": "Debt Instrument, Convertible Debenture, Threshold Percentage of Stock Price Trigger",
        "documentation": "Debt Instrument, Convertible Debenture, Threshold Percentage of Stock Price Trigger"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_DebtInstrumentConvertibleDebentureThresholdTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DebtInstrumentConvertibleDebentureThresholdTradingDays",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold trading days",
        "label": "Debt Instrument, Convertible Debenture, Threshold Trading Days",
        "documentation": "Debt Instrument, Convertible Debenture, Threshold Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_DebtInstrumentDefaultRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DebtInstrumentDefaultRate",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, default rate",
        "label": "Debt Instrument, Default Rate",
        "documentation": "Debt Instrument, Default Rate"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_DebtInstrumentGuaranteedInterestPayableAnnualRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DebtInstrumentGuaranteedInterestPayableAnnualRate",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, annual interest rate",
        "label": "Debt Instrument, Guaranteed Interest Payable, Annual Rate",
        "documentation": "Debt Instrument, Guaranteed Interest Payable, Annual Rate"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_DebtInstrumentGuaranteedInterestPayableRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DebtInstrumentGuaranteedInterestPayableRate",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, guaranteed interest payable",
        "label": "Debt Instrument, Guaranteed Interest Payable, Rate",
        "documentation": "Debt Instrument, Guaranteed Interest Payable, Rate"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_DebtInstrumentPrepaymentPremiumYearOne": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DebtInstrumentPrepaymentPremiumYearOne",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment premium, if paid year one",
        "label": "Debt Instrument, Prepayment Premium, Year One",
        "documentation": "Debt Instrument, Prepayment Premium, Year One"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_DebtInstrumentPrepaymentPremiumYearTwo": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DebtInstrumentPrepaymentPremiumYearTwo",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment premium, if paid year two",
        "label": "Debt Instrument, Prepayment Premium, Year Two",
        "documentation": "Debt Instrument, Prepayment Premium, Year Two"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, term",
        "label": "Debt Instrument, Term",
        "documentation": "Debt Instrument, Term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DebtSecurities",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instruments issued",
        "label": "Debt instruments issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of instruments issued by the entity that represent indebtedness."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "cybn_DeferredCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DeferredCompensationMember",
     "presentation": [
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation",
        "label": "Deferred compensation [Member]",
        "documentation": "Deferred compensation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r14",
      "r35"
     ]
    },
    "cybn_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails": {
       "parentTag": "ifrs-full_DeferredTaxAssets",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Deferred Tax Assets, Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeferredTaxLiabilityAsset",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss carryforwards",
        "label": "Deferred tax liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipment",
     "presentation": [
      "http://cybin.com/role/EQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation charge",
        "label": "Depreciation, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r44",
      "r48"
     ]
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationRightofuseAssets",
     "presentation": [
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization",
        "label": "Depreciation, right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share",
        "label": "Description of accounting policy for earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial instruments",
        "label": "Description of accounting policy for financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation",
        "label": "Description of accounting policy for foreign currency translation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Functional and presentation currency",
        "label": "Description of accounting policy for functional currency [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the currency of the primary economic environment in which the entity operates."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForGoodwillExplanatory",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Description of accounting policy for goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Description of accounting policy for impairment of assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of assets."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxation",
        "label": "Description of accounting policy for income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for income tax."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Description of accounting policy for intangible assets other than goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Description of accounting policy for issued capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForMeasuringInventories",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Description of accounting policy for measuring inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment",
        "label": "Description of accounting policy for property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions",
        "label": "Description of accounting policy for provisions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Description of accounting policy for share-based payment transactions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForWarrantsExplanatory",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Description of accounting policy for warrants [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for warrants. Warrants are financial instruments that give the holder the right to purchase ordinary shares."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected annual volatility, based on historical share price of the Company",
        "label": "Expected volatility, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfInitialApplicationOfStandardsOrInterpretations",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New standards and interpretations not yet adopted",
        "label": "Disclosure of initial application of standards or interpretations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life (in years)",
        "label": "Option life, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Risk free interest rate, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "cybn_DetailDescriptionOfFunctionalCurrenciesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DetailDescriptionOfFunctionalCurrenciesTableTextBlock",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of subsidiaries and functional currencies",
        "label": "Detail Description Of Functional Currencies [Table Text Block]",
        "documentation": "Detail Description Of Functional Currencies"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://cybin.com/role/CRITICALACCOUNTINGESTIMATESANDJUDGEMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS",
        "label": "Disclosure of accounting judgements and estimates [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "cybn_DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of measurement",
        "label": "Disclosure Of Accounting Policy For Basis Of Measurement [Policy Text Block]",
        "documentation": "Disclosure Of Accounting Policy For Basis Of Measurement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesLineItems",
     "presentation": [
      "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]",
        "label": "Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAmountsIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntitiesTable",
     "presentation": [
      "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [table]",
        "label": "Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the amounts incurred by the entity for provision of key management personnel services that are provided by separate management entities."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory",
     "presentation": [
      "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of General and Administrative Expenses",
        "label": "Disclosure of attribution of expenses by nature to their function [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of attribution of expenses by nature to line items by function in the statement of profit or loss."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r223"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfConsolidationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfBasisOfConsolidationExplanatory",
     "presentation": [
      "http://cybin.com/role/CORPORATEINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "CORPORATE INFORMATION",
        "label": "Disclosure of basis of consolidation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for consolidation."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "cybn_DisclosureOfBasisOfConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DisclosureOfBasisOfConsolidationPolicyTextBlock",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of consolidation",
        "label": "Disclosure Of Basis Of Consolidation [Policy Text Block]",
        "documentation": "Disclosure Of Basis Of Consolidation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBusinessCombinationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsExplanatory",
     "presentation": [
      "http://cybin.com/role/ACQUISITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACQUISITION",
        "label": "Disclosure of business combinations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for business combinations."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "ifrs-full_DisclosureOfBusinessCombinationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsLineItems",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails",
      "http://cybin.com/role/ACQUISITIONNarrativeDetails",
      "http://cybin.com/role/ACQUISITIONResultssinceacquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about business combination [line items]",
        "label": "Disclosure of detailed information about business combination [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBusinessCombinationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsTable",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails",
      "http://cybin.com/role/ACQUISITIONNarrativeDetails",
      "http://cybin.com/role/ACQUISITIONResultssinceacquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about business combination [table]",
        "label": "Disclosure of detailed information about business combination [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of business combinations."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "cybn_DisclosureOfCapitalStructureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DisclosureOfCapitalStructureTableTextBlock",
     "presentation": [
      "http://cybin.com/role/CAPITALMANAGEMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Capital Structure",
        "label": "Disclosure Of Capital Structure [Table Text Block]",
        "documentation": "Disclosure Of Capital Structure"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of share capital",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]"
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofsharecapitalDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [line items]",
        "label": "Disclosure of classes of share capital [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofsharecapitalDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [table]",
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTRACTS, COMMITMENTS AND CONTINGENCIES",
        "label": "Disclosure of commitments and contingent liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about business combination",
        "label": "Disclosure of detailed information about business combination [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about business combinations. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
     "presentation": [
      "http://cybin.com/role/INTANGIBLEASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of intangible assets",
        "label": "Disclosure of detailed information about intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://cybin.com/role/EQUIPMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of equipment",
        "label": "Disclosure of detailed information about property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "cybn_DisclosureOfExpirationOfNonCapitalLossesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DisclosureOfExpirationOfNonCapitalLossesTableTextBlock",
     "presentation": [
      "http://cybin.com/role/INCOMETAXTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-capital losses expiration",
        "label": "Disclosure Of Expiration Of Non Capital Losses [Table Text Block]",
        "documentation": "Disclosure Of Expiration Of Non Capital Losses"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_DisclosureOfFinancialAssetsAndLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DisclosureOfFinancialAssetsAndLiabilitiesLineItems",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Financial Assets and Liabilities [Line Items]",
        "label": "Disclosure of Financial Assets and Liabilities [Line Items]",
        "documentation": "Disclosure of Financial Assets and Liabilities [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_DisclosureOfFinancialAssetsAndLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DisclosureOfFinancialAssetsAndLiabilitiesTable",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails",
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Financial Assets and Liabilities [Table]",
        "label": "Disclosure of Financial Assets and Liabilities [Table]",
        "documentation": "Disclosure of Financial Assets and Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsExplanatory",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets",
        "label": "Disclosure of financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL INSTRUMENTS",
        "label": "Disclosure of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Liabilities",
        "label": "Disclosure of financial liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
     "presentation": [
      "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL AND ADMINISTRATIVE EXPENSES",
        "label": "Disclosure of general and administrative expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of general and administrative expenses. [Refer: Administrative expenses]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DisclosureOfGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGoodwillExplanatory",
     "presentation": [
      "http://cybin.com/role/GOODWILL"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GOODWILL",
        "label": "Disclosure of goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://cybin.com/role/INCOMETAX"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAX",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of measurement of stock option fair value assumptions",
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsExplanatory",
     "presentation": [
      "http://cybin.com/role/INTANGIBLEASSETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTANGIBLE ASSETS",
        "label": "Disclosure of intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for intangible assets."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://cybin.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [line items]",
        "label": "Disclosure of detailed information about intangible assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsTable",
     "presentation": [
      "http://cybin.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about intangible assets [table]",
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "cybn_DisclosureOfLeasesAndRightOfUseAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DisclosureOfLeasesAndRightOfUseAssetsTextBlock",
     "presentation": [
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RIGHT-OF-USE ASSETS AND LEASE LIABILITIES",
        "label": "Disclosure Of Leases And Right-Of-Use Assets [Text Block]",
        "documentation": "Disclosure Of Leases And Right-Of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MATERIAL ACCOUNTING POLICIES AND BASIS OF PREPARATION",
        "label": "Disclosure of material accounting policy information [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure of material accounting policy information applied by the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
     "presentation": [
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of lease liabilities",
        "label": "Disclosure of maturity analysis of operating lease payments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems",
     "presentation": [
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of maturity analysis of operating lease payments [line items]",
        "label": "Disclosure of maturity analysis of operating lease payments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable",
     "presentation": [
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of maturity analysis of operating lease payments [table]",
        "label": "Disclosure of maturity analysis of operating lease payments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Monetary Assets and Liabilities Currency Risk Fluctuations",
        "label": "Disclosure of nature and extent of risks arising from financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information that enables users of financial statements to evaluate the nature and extent of risks arising from financial instruments to which the entity is exposed. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [line items]",
        "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [table]",
        "label": "Disclosure of nature and extent of risks arising from financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152"
     ]
    },
    "cybn_DisclosureOfNonCapitalLossesExpirationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DisclosureOfNonCapitalLossesExpirationLineItems",
     "presentation": [
      "http://cybin.com/role/INCOMETAXAdditionalInformationDetails",
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Non-Capital Losses Expiration [Line Items]",
        "label": "Disclosure Of Non-Capital Losses Expiration [Line Items]",
        "documentation": "Disclosure Of Non-Capital Losses Expiration [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_DisclosureOfNonCapitalLossesExpirationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DisclosureOfNonCapitalLossesExpirationTable",
     "presentation": [
      "http://cybin.com/role/INCOMETAXAdditionalInformationDetails",
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Non-Capital Losses Expiration [Table]",
        "label": "Disclosure Of Non-Capital Losses Expiration [Table]",
        "documentation": "Disclosure Of Non-Capital Losses Expiration [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Disclosure of non-adjusting events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [domain]]"
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]",
        "label": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [table]",
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of warrants",
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of number and weighted average exercise prices of share options",
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]",
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]",
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
     "presentation": [
      "http://cybin.com/role/CAPITALMANAGEMENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CAPITAL MANAGEMENT",
        "label": "Disclosure of objectives, policies and processes for managing capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://cybin.com/role/EQUIPMENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUIPMENT",
        "label": "Disclosure of property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://cybin.com/role/EQUIPMENTDetails",
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]",
        "label": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://cybin.com/role/EQUIPMENTDetails",
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]",
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "presentation": [
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of right-of-use assets",
        "label": "Disclosure of quantitative information about right-of-use assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "cybn_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock",
     "presentation": [
      "http://cybin.com/role/INCOMETAXTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major items causing the income tax rate to differ from the Canadian statutory rate",
        "label": "Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates [Table Text Block]",
        "documentation": "Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInGoodwillExplanatory",
     "presentation": [
      "http://cybin.com/role/GOODWILLTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of goodwill",
        "label": "Disclosure of reconciliation of changes in goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of changes in goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInGoodwillLineItems",
     "presentation": [
      "http://cybin.com/role/GOODWILLDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of changes in goodwill [line items]",
        "label": "Disclosure of reconciliation of changes in goodwill [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfChangesInGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfReconciliationOfChangesInGoodwillTable",
     "presentation": [
      "http://cybin.com/role/GOODWILLDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of reconciliation of changes in goodwill [table]",
        "label": "Disclosure of reconciliation of changes in goodwill [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the reconciliation of changes in goodwill."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS AND BALANCES",
        "label": "Disclosure of related party [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://cybin.com/role/RESEARCHEXPENSES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESEARCH EXPENSES",
        "label": "Disclosure of research and development expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://cybin.com/role/SHARECAPITAL"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE CAPITAL",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of subsidiaries [line items]",
        "label": "Disclosure of subsidiaries [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of subsidiaries [table]",
        "label": "Disclosure of subsidiaries [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to subsidiaries."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r63",
      "r107"
     ]
    },
    "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of significant unobservable inputs used, equity",
        "label": "Disclosure of significant unobservable inputs used in fair value measurement of equity [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of the entity's own equity instruments. [Refer: Classes of entity's own equity instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
     "presentation": [
      "http://cybin.com/role/INCOMETAXTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant components of deferred tax assets",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
     "presentation": [
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "presentation": [
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of remuneration of key management personnel",
        "label": "Disclosure of transactions between related parties [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ifrs-full_DiscountRateMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DiscountRateMeasurementInputMember",
     "presentation": [
      "http://cybin.com/role/GOODWILLDetails",
      "http://cybin.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Discount rate, measurement input [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a discount rate used as a measurement input used in valuation techniques based on a present value calculation."
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "ifrs-full_DisposalsRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisposalsRightofuseAssets",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Disposals",
        "label": "Disposals, right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in right-of-use assets resulting from disposals. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Registration Statement",
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "currency_EUR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "EUR",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Euro Member Countries, Euro",
        "label": "Euro Member Countries, Euro"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effects of exchange rate changes on cash",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88"
     ]
    },
    "cybn_EffectOfForeignExchangeLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "EffectOfForeignExchangeLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of foreign exchange",
        "label": "Effect Of Foreign Exchange, Lease Liabilities",
        "documentation": "Effect Of Foreign Exchange, Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_EffectOfForeignExchangeRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "EffectOfForeignExchangeRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of foreign exchange",
        "label": "Effect Of Foreign Exchange, Right Of Use Assets",
        "documentation": "Effect Of Foreign Exchange, Right Of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails": {
       "parentTag": "ifrs-full_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payroll, consulting and benefits",
        "label": "Employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r30",
      "r183"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Addresses, Address Type [Axis]",
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Addresses [Line Items]",
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Addresses [Table]",
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Primary SIC Number",
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CAPITALMANAGEMENTDetails",
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL SHAREHOLDERS' EQUITY",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r19",
      "r94",
      "r96",
      "r108",
      "r109",
      "r111"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHAREHOLDERS' EQUITY",
        "label": "Equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "cybn_EventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "EventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Events after reporting period [Abstract]",
        "documentation": "Events after reporting period [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of other equity instruments (in CAD/USD per share)",
        "label": "Exercise Price of Other Equity Instruments in Share-based Payment Arrangement",
        "documentation": "Exercise Price of Other Equity Instruments in Share-based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in dollars per share)",
        "label": "Exercise price of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExercisePriceShareOptionsGranted2019",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price, share options granted (in CAD per share)",
        "verboseLabel": "Exercise price (in CAD per share)",
        "label": "Exercise price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ExpectedDividendAsPercentageOtherEquityInstrumentsGranted",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Expected Dividend As Percentage, Other Equity Instruments Granted",
        "documentation": "Expected Dividend As Percentage, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Expected dividend as percentage, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "cybn_ExpectedVolatilityOtherEquityInstrumentsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ExpectedVolatilityOtherEquityInstrumentsGranted",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected annual volatility, based on comparable companies",
        "label": "Expected Volatility, Other Equity Instruments Granted",
        "documentation": "Expected Volatility, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseByNatureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseByNatureAbstract",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EXPENSES",
        "label": "Expenses by nature [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Expense from share-based payment transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "cybn_FinancialAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "FinancialAssetsAndLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets and liabilities",
        "label": "Financial Assets And Liabilities",
        "documentation": "Financial Assets And Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCostCategoryMember",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets, measured at amortized cost:",
        "label": "Financial assets at amortised cost, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets, measured at fair value:",
        "label": "Financial assets at fair value through other comprehensive income, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at fair value through other comprehensive income category. [Refer: Financial assets at fair value through other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "cybn_FinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "FinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Abstract]",
        "documentation": "Financial Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities, measured at amortized cost:",
        "label": "Financial liabilities at amortised cost, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ifrs-full_FinancialLiabilitiesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Liabilities assumed",
        "label": "Financial liabilities recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for financial liabilities assumed in a business combination. [Refer: Financial liabilities; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r207"
     ]
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "GB",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONNarrativeDetails",
      "http://cybin.com/role/INCOMETAXAdditionalInformationDetails",
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails",
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United Kingdom",
        "label": "UNITED KINGDOM"
       }
      }
     },
     "auth_ref": []
    },
    "currency_GBP": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "GBP",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United Kingdom, Pounds",
        "label": "United Kingdom, Pounds"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_GainLossOnDerecognitionOfLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "GainLossOnDerecognitionOfLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESLeaseliabilitiesDetails",
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on derecognition of lease liability",
        "negatedTerseLabel": "Gain on derecognition",
        "label": "Gain (Loss) On Derecognition of Lease Liability",
        "documentation": "Gain (Loss) On Derecognition of Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_GainLossOnDerecognitionOfRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "GainLossOnDerecognitionOfRightOfUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on derecognition of right-of-use assets",
        "label": "Gain (Loss) On Derecognition of Right-Of-Use Assets",
        "documentation": "Gain (Loss) On Derecognition of Right-Of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation gain",
        "label": "Gains (losses) on exchange differences on translation of foreign operations, before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative costs",
        "totalLabel": "Total",
        "label": "General and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "cybn_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative costs",
        "label": "General And Administrative Expense [Member]",
        "documentation": "General And Administrative Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [axis]",
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r189",
      "r201",
      "r204"
     ]
    },
    "ifrs-full_GeographicalAreasDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeographicalAreasDomain",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [domain]",
        "label": "Geographical areas [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r189",
      "r201",
      "r204"
     ]
    },
    "ifrs-full_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://cybin.com/role/GOODWILLDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r69",
      "r70",
      "r144"
     ]
    },
    "cybn_GoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "GoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [Abstract]",
        "documentation": "Goodwill [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GoodwillMember",
     "presentation": [
      "http://cybin.com/role/GOODWILLDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ifrs-full_GoodwillRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GoodwillRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the business combination's acquisition date for goodwill. [Refer: Goodwill; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207"
     ]
    },
    "cybn_GrantedToConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "GrantedToConsultantsMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted to consultants",
        "label": "Granted To Consultants [Member]",
        "documentation": "Granted To Consultants"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_GrantedToDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "GrantedToDirectorsMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted to directors",
        "label": "Granted To Directors [Member]",
        "documentation": "Granted To Directors"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_GrantedToEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "GrantedToEmployeesMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted to employees",
        "label": "Granted To Employees [Member]",
        "documentation": "Granted To Employees"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_GrantedToOfficersAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "GrantedToOfficersAndDirectorsMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted to officers and directors",
        "label": "Granted To Officers And Directors [Member]",
        "documentation": "Granted To Officers And Directors"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_GrantedToOfficersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "GrantedToOfficersMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted to officers",
        "label": "Granted To Officers [Member]",
        "documentation": "Granted To Officers"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GrossCarryingAmountMember",
     "presentation": [
      "http://cybin.com/role/EQUIPMENTDetails",
      "http://cybin.com/role/INTANGIBLEASSETSDetails",
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "label": "Gross carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r40",
      "r72",
      "r81",
      "r84",
      "r144",
      "r155",
      "r157",
      "r208"
     ]
    },
    "cybn_GrossDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "GrossDeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails": {
       "parentTag": "ifrs-full_DeferredTaxAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Gross Deferred Tax Assets",
        "documentation": "Gross Deferred Tax Assets"
       }
      }
     },
     "auth_ref": []
    },
    "country_IE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "IE",
     "presentation": [
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails",
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ireland",
        "label": "IRELAND"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IdentifiableAssetsAcquiredLiabilitiesAssumed",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total allocation of purchase price",
        "label": "Identifiable assets acquired (liabilities assumed)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r207"
     ]
    },
    "ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intellectual property",
        "label": "Identifiable intangible assets recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r207"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossGoodwill",
     "presentation": [
      "http://cybin.com/role/GOODWILLDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss",
        "label": "Impairment loss recognised in profit or loss, goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for goodwill. [Refer: Impairment loss recognised in profit or loss; Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "presentation": [
      "http://cybin.com/role/EQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Equipment write-down",
        "label": "Impairment loss recognised in profit or loss, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r29",
      "r43"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Income Statement Location"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Income Statement Location [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Income tax recovery",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r26",
      "r32",
      "r33",
      "r34",
      "r59",
      "r106",
      "r170"
     ]
    },
    "cybn_IncomeTaxesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "IncomeTaxesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]",
        "documentation": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughAcquisitionOfSubsidiary",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issuance on business acquisition",
        "label": "Increase (decrease) through acquisition of subsidiary, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the acquisition of subsidiaries. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofsharecapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted into Common Shares (in shares)",
        "label": "Increase (Decrease) Through Conversion of Convertible Instruments, Equity, Shares",
        "documentation": "Increase (Decrease) Through Conversion of Convertible Instruments, Equity, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised",
        "label": "Increase (decrease) through exercise of warrants, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "cybn_IncreaseDecreaseThroughExpirationOfWarrantsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "IncreaseDecreaseThroughExpirationOfWarrantsEquity",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants expired",
        "label": "Increase (Decrease) Through Expiration Of Warrants, Equity",
        "documentation": "Increase (Decrease) Through Expiration Of Warrants, Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange on unbooked deferred tax assets",
        "label": "Increase (decrease) through net exchange differences, deferred tax liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in deferred tax liability (asset) resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Deferred tax liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/GOODWILLDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of foreign exchange",
        "label": "Increase (decrease) through net exchange differences, intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets and goodwill resulting from the net exchange differences arising when the financial statements are translated from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of foreign exchange",
        "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/EQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Effect of foreign exchange",
        "label": "Increase (decrease) through net exchange differences, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "cybn_IncreaseDecreaseThroughShareConsolidationEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "IncreaseDecreaseThroughShareConsolidationEquity",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment for fractional shares upon share consolidation (in shares)",
        "label": "Increase (Decrease) Through Share Consolidation, Equity",
        "documentation": "Increase (Decrease) Through Share Consolidation, Equity"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_IncreaseDecreaseThroughShareOfferingEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "IncreaseDecreaseThroughShareOfferingEquity",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-market offering - net of share issuance costs",
        "label": "Increase (Decrease) Through Share Offering, Equity",
        "documentation": "Increase (Decrease) Through Share Offering, Equity"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options expired",
        "label": "Increase (Decrease) Through Share Options Expired In Share Based Payment Award, Equity",
        "documentation": "Increase (Decrease) Through Share Options Expired In Share Based Payment Award, Equity"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options forfeited/expired",
        "label": "Increase (Decrease) Through Share Options Forfeited And Expired In Share Based Payment Award, Equity",
        "documentation": "Increase (Decrease) Through Share Options Forfeited And Expired In Share Based Payment Award, Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Increase (decrease) through share-based payment transactions, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cybn_IntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "IntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Abstract]",
        "documentation": "Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://cybin.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r76"
     ]
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "presentation": [
      "http://cybin.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets other than goodwill",
        "label": "Intangible assets other than goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r190",
      "r202"
     ]
    },
    "ifrs-full_IntangibleAssetsUnderDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IntangibleAssetsUnderDevelopmentMember",
     "presentation": [
      "http://cybin.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IP Research &amp; Development",
        "label": "Intangible assets under development [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing such assets under development. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest accretion",
        "label": "Interest expense on lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "cybn_InterestRateRiskIncreaseDecreaseInInterestIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "InterestRateRiskIncreaseDecreaseInInterestIncome",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reduction in interest income due to interest rate decline",
        "label": "Interest Rate Risk, Increase (Decrease) In Interest Income",
        "documentation": "Interest Rate Risk, Increase (Decrease) In Interest Income"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease in interest rate generated on cash",
        "label": "Interest Rate Risk, Increase (Decrease) In Interest Rate Generated On Cash",
        "documentation": "Interest Rate Risk, Increase (Decrease) In Interest Rate Generated On Cash"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_InterestRateRiskTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "InterestRateRiskTerm",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate risk, term",
        "label": "Interest Rate Risk, Term",
        "documentation": "Interest Rate Risk, Term"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_InvestorRelationsSalesAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "InvestorRelationsSalesAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails": {
       "parentTag": "ifrs-full_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor relations and Marketing media",
        "label": "Investor Relations, Sales and Marketing Expense",
        "documentation": "Investor Relations, Sales and Marketing Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssueOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssueOfEquity",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued through common share purchase agreement - net of share issuance costs",
        "label": "Issue of equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CAPITALMANAGEMENTDetails",
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_ItemsOfContingentLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ItemsOfContingentLiabilitiesAxis",
     "presentation": [
      "http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Items of contingent liabilities [axis]",
        "label": "Items of contingent liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "ifrs-full_ItemsOfContingentLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ItemsOfContingentLiabilitiesDomain",
     "presentation": [
      "http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Items of contingent liabilities [domain]",
        "label": "Items of contingent liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated individual items of contingent liabilities. It also represents the standard value for the 'Items of contingent liabilities' axis if no other member is used. [Refer: Classes of contingent liabilities [domain]]"
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "cybn_JourneyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "JourneyMember",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Journey",
        "label": "Journey [Member]",
        "documentation": "Journey"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Key management personnel compensation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Key management personnel compensation, share-based payment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payroll, consulting and benefits",
        "label": "Key management personnel compensation, short-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "cybn_LPCPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "LPCPurchaseAgreementMember",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LPC Purchase Agreement",
        "label": "LPC Purchase Agreement [Member]",
        "documentation": "LPC Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_LabAndAdministration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "LabAndAdministration",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/RESEARCHEXPENSESDetails": {
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/RESEARCHEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab and administration",
        "label": "Lab And Administration",
        "documentation": "Lab And Administration"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://cybin.com/role/EQUIPMENTDetails",
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab Equipment",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Lease liabilities, beginning of period",
        "periodEndLabel": "Lease liabilities, end of period",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilitiesMember",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails",
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Lease liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r199"
     ]
    },
    "cybn_LeaseLiabilitiesRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "LeaseLiabilitiesRecognisedAsOfAcquisitionDate",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Lease liability",
        "label": "Lease Liabilities Recognised As Of Acquisition Date",
        "documentation": "Lease Liabilities Recognised As Of Acquisition Date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES",
        "label": "Liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LicencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LicencesMember",
     "presentation": [
      "http://cybin.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "Licences [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "cybn_ListingFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ListingFeesExpense",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails": {
       "parentTag": "ifrs-full_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Listing fees",
        "label": "Listing Fees Expense",
        "documentation": "Listing Fees Expense"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "cybn_LossCarryforwardExpirationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "LossCarryforwardExpirationAxis",
     "presentation": [
      "http://cybin.com/role/INCOMETAXAdditionalInformationDetails",
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Carryforward Expiration [Axis]",
        "label": "Loss Carryforward Expiration [Axis]",
        "documentation": "Loss Carryforward Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_LossCarryforwardExpirationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "LossCarryforwardExpirationDomain",
     "presentation": [
      "http://cybin.com/role/INCOMETAXAdditionalInformationDetails",
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Carryforward Expiration [Domain]",
        "label": "Loss Carryforward Expiration [Domain]",
        "documentation": "Loss Carryforward Expiration [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorOrdinaryShareTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MajorOrdinaryShareTransactionsMember",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major ordinary share transactions",
        "label": "Major ordinary share transactions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "cybn_March2024PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "March2024PrivatePlacementMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2024 private placement",
        "label": "March 2024 Private Placement [Member]",
        "documentation": "March 2024 Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_MiscellaneousIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "MiscellaneousIncomeExpenseAbstract",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER INCOME (EXPENSES)",
        "label": "Miscellaneous Income (Expense) [Abstract]",
        "documentation": "Miscellaneous Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_NonCapitalLossCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NonCapitalLossCarryforward",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/INCOMETAXAdditionalInformationDetails",
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-capital losses",
        "label": "Non-Capital Loss Carryforward",
        "documentation": "Non-Capital Loss Carryforward"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [axis]",
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodDomain",
     "presentation": [
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [domain]",
        "label": "Non-adjusting events after reporting period [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Non-Current Assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r100",
      "r200"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current",
        "label": "Non-current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_November2023CompensationCommonShareWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "November2023CompensationCommonShareWarrantMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "November 2023 compensation common share warrant",
        "label": "November 2023 Compensation Common Share Warrant [Member]",
        "documentation": "November 2023 Compensation Common Share Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_NumberOfActivePatentFamilies": {
     "xbrltype": "integerItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfActivePatentFamilies",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of active patent families",
        "label": "Number Of Active Patent Families",
        "documentation": "Number Of Active Patent Families"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_NumberOfCommonSharePurchaseWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfCommonSharePurchaseWarrants",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common share purchase warrants (in shares)",
        "label": "Number Of Common Share Purchase Warrants",
        "documentation": "Number Of Common Share Purchase Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_NumberOfCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfCommonShares",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common shares (in shares)",
        "label": "Number of Common Shares",
        "documentation": "Number of Common Shares"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_NumberOfCommonSharesHeldInEscrow": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfCommonSharesHeldInEscrow",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common shares held in escrow (in shares)",
        "label": "Number of Common Shares Held In Escrow",
        "documentation": "Number of Common Shares Held In Escrow"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_NumberOfGrantedPatents": {
     "xbrltype": "integerItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfGrantedPatents",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of granted patents",
        "label": "Number Of Granted Patents",
        "documentation": "Number Of Granted Patents"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuable",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of instruments or interests issued or issuable (in shares)",
        "label": "Number of instruments or interests issued or issuable"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of other equity instruments exercisable in share-based payment arrangement (in shares)",
        "verboseLabel": "Warrants exercisable (in shares)",
        "label": "Number of other equity instruments exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Number of other equity instruments exercised or vested in share-based payment arrangement",
        "terseLabel": "Exercised (in shares)",
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Number of other equity instruments expired in share-based payment arrangement (in shares)",
        "terseLabel": "Number of other equity instruments expired in share-based payment arrangement (in shares)",
        "label": "Number of other equity instruments expired in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "cybn_NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants with extended expiry dates (in shares)",
        "label": "Number Of Other Equity Instruments In Share-Based Payment Arrangement, Expiry Date Extended",
        "documentation": "Number Of Other Equity Instruments In Share-Based Payment Arrangement, Expiry Date Extended"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issued (in shares)",
        "label": "Number of Other Equity Instruments Issued in Share-Based Payment Arrangement",
        "documentation": "Number of Other Equity Instruments Issued in Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding (in shares)",
        "periodEndLabel": "Outstanding (in shares)",
        "terseLabel": "Warrants outstanding (in shares)",
        "label": "Number of other equity instruments outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOutstandingShareOptions",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofnumberandweightedaverageexercisepricesofshareoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options, beginning balance (in shares)",
        "periodEndLabel": "Number of options, ending balance (in shares)",
        "terseLabel": "Number of share options outstanding (in shares)",
        "label": "Number of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r130",
      "r133"
     ]
    },
    "cybn_NumberOfPendingPatentApplications": {
     "xbrltype": "integerItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfPendingPatentApplications",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of pending patent applications",
        "label": "Number Of Pending Patent Applications",
        "documentation": "Number Of Pending Patent Applications"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofnumberandweightedaverageexercisepricesofshareoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share options exercisable in share-based payment arrangement",
        "verboseLabel": "Number of options exercisable (in shares)",
        "label": "Number of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "cybn_NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofnumberandweightedaverageexercisepricesofshareoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of share options forfeited/expired in share-based payment arrangement (in shares)",
        "label": "Number Of Share Options Forfeited And Expired In Share-Based Payment Arrangement",
        "documentation": "Number Of Share Options Forfeited And Expired In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share options forfeited in share-based payment arrangement",
        "label": "Number of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofnumberandweightedaverageexercisepricesofshareoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of share options granted in share-based payment arrangement (in shares)",
        "label": "Number of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "cybn_NumberOfShareOptionsVestedInShareBasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfShareOptionsVestedInShareBasedPaymentArrangement",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options vested (in shares)",
        "label": "Number Of Share Options Vested In Share-Based Payment Arrangement",
        "documentation": "Number Of Share Options Vested In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares acquired upon exercise of warrant (in shares)",
        "label": "Number Of Shares Acquired Upon Exercise Of Warrant In Share-Based Payment Arrangement",
        "documentation": "Number Of Shares Acquired Upon Exercise Of Warrant In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_NumberOfSharesConvertedThroughContingentConsiderationEquity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfSharesConvertedThroughContingentConsiderationEquity",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class B shares converted (in shares)",
        "label": "Number of Shares Converted Through Contingent Consideration, Equity",
        "documentation": "Number of Shares Converted Through Contingent Consideration, Equity"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_NumberOfSharesIssuedNetOfIssuanceCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfSharesIssuedNetOfIssuanceCosts",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued through common share purchase agreement - net of share issuance costs (in shares)",
        "label": "Number Of Shares Issued, Net Of Issuance Costs",
        "documentation": "Number Of Shares Issued, Net Of Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issuance on business acquisition (in shares)",
        "label": "Number Of Shares Issued Through Acquisition Of Subsidiary, Equity",
        "documentation": "Number Of Shares Issued Through Acquisition Of Subsidiary, Equity"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares as commitment fee for equity financing (in shares)",
        "label": "Number Of Shares Issued Through Commitment Fee For Equity Financing",
        "documentation": "Number Of Shares Issued Through Commitment Fee For Equity Financing"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfSharesIssuedThroughContingentConsiderationEquity",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued on Adelia milestones (in shares)",
        "label": "Number of Shares Issued Through Contingent Consideration, Equity",
        "documentation": "Number of Shares Issued Through Contingent Consideration, Equity"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfSharesIssuedThroughExerciseOfWarrantsEquity",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised (in shares)",
        "label": "Number Of Shares Issued Through Exercise Of Warrants, Equity",
        "documentation": "Number Of Shares Issued Through Exercise Of Warrants, Equity"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_NumberOfSharesIssuedThroughShareOfferingEquity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfSharesIssuedThroughShareOfferingEquity",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-market offering - net of share issuance costs (in shares)",
        "label": "Number Of Shares Issued Through Share Offering, Equity",
        "documentation": "Number Of Shares Issued Through Share Offering, Equity"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfSharesIssuedUponConversionOfConvertibleInstruments",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued upon conversion of convertible instruments (in shares)",
        "label": "Number of Shares Issued Upon Conversion of Convertible Instruments",
        "documentation": "Number of Shares Issued Upon Conversion of Convertible Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofsharecapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "terseLabel": "Number of shares outstanding (in shares)",
        "label": "Number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "cybn_NumberOfSharesSubjectToResaleRestrictions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfSharesSubjectToResaleRestrictions",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares subject to resale restrictions (in shares)",
        "label": "Number Of Shares Subject To Resale Restrictions",
        "documentation": "Number Of Shares Subject To Resale Restrictions"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_NumberOfSubsidiaries": {
     "xbrltype": "integerItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "NumberOfSubsidiaries",
     "presentation": [
      "http://cybin.com/role/CORPORATEINFORMATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of subsidiaries",
        "label": "Number Of Subsidiaries",
        "documentation": "Number Of Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OccupancyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OccupancyExpense",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails": {
       "parentTag": "ifrs-full_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office and administration",
        "label": "Occupancy expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from occupancy services received by the entity."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_OperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL EXPENSES",
        "label": "Operating expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all operating expenses."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "cybn_OptionExpirationPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodAxis",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period [Axis]",
        "label": "Option Expiration Period [Axis]",
        "documentation": "Option Expiration Period"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodDomain",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period [Domain]",
        "label": "Option Expiration Period [Domain]",
        "documentation": "Option Expiration Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodEightMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Eight",
        "label": "Option Expiration Period Eight [Member]",
        "documentation": "Option Expiration Period Eight"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodEighteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodEighteenMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Eighteen",
        "label": "Option Expiration Period Eighteen [Member]",
        "documentation": "Option Expiration Period Eighteen"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodElevenMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Eleven",
        "label": "Option Expiration Period Eleven [Member]",
        "documentation": "Option Expiration Period Eleven"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodFifteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodFifteenMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Fifteen",
        "label": "Option Expiration Period Fifteen [Member]",
        "documentation": "Option Expiration Period Fifteen"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodFiveMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Five",
        "label": "Option Expiration Period Five [Member]",
        "documentation": "Option Expiration Period Five"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodFourMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Four",
        "label": "Option Expiration Period Four [Member]",
        "documentation": "Option Expiration Period Four"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodFourteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodFourteenMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Fourteen",
        "label": "Option Expiration Period Fourteen [Member]",
        "documentation": "Option Expiration Period Fourteen"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodNineMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Nine",
        "label": "Option Expiration Period Nine [Member]",
        "documentation": "Option Expiration Period Nine"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodNineteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodNineteenMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Nineteen",
        "label": "Option Expiration Period Nineteen [Member]",
        "documentation": "Option Expiration Period Nineteen"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodOneMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period One",
        "label": "Option Expiration Period One [Member]",
        "documentation": "Option Expiration Period One"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodSevenMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Seven",
        "label": "Option Expiration Period Seven [Member]",
        "documentation": "Option Expiration Period Seven"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodSeventeenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodSeventeenMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Seventeen",
        "label": "Option Expiration Period Seventeen [Member]",
        "documentation": "Option Expiration Period Seventeen"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodSixMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Six",
        "label": "Option Expiration Period Six [Member]",
        "documentation": "Option Expiration Period Six"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodSixteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodSixteenMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Sixteen",
        "label": "Option Expiration Period Sixteen [Member]",
        "documentation": "Option Expiration Period Sixteen"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodTenMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Ten",
        "label": "Option Expiration Period Ten [Member]",
        "documentation": "Option Expiration Period Ten"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodThirteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodThirteenMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Thirteen",
        "label": "Option Expiration Period Thirteen [Member]",
        "documentation": "Option Expiration Period Thirteen"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodThirtyEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodThirtyEightMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Thirty Eight",
        "label": "Option Expiration Period Thirty Eight [Member]",
        "documentation": "Option Expiration Period Thirty Eight"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodThirtyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodThirtyFiveMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Thirty Five",
        "label": "Option Expiration Period Thirty Five [Member]",
        "documentation": "Option Expiration Period Thirty Five"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodThirtyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodThirtyFourMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Thirty Four",
        "label": "Option Expiration Period Thirty Four [Member]",
        "documentation": "Option Expiration Period Thirty Four"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodThirtyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodThirtyMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Thirty",
        "label": "Option Expiration Period Thirty [Member]",
        "documentation": "Option Expiration Period Thirty"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodThirtyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodThirtyOneMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Thirty One",
        "label": "Option Expiration Period Thirty One [Member]",
        "documentation": "Option Expiration Period Thirty One"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodThirtySevenAndThirtyEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodThirtySevenAndThirtyEightMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Thirty Seven And Thirty Eight",
        "label": "Option Expiration Period Thirty Seven And Thirty Eight [Member]",
        "documentation": "Option Expiration Period Thirty Seven And Thirty Eight"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodThirtySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodThirtySevenMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Thirty Seven",
        "label": "Option Expiration Period Thirty Seven [Member]",
        "documentation": "Option Expiration Period Thirty Seven"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodThirtySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodThirtySixMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Thirty Six",
        "label": "Option Expiration Period Thirty Six [Member]",
        "documentation": "Option Expiration Period Thirty Six"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodThirtyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodThirtyThreeMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Thirty Three",
        "label": "Option Expiration Period Thirty Three [Member]",
        "documentation": "Option Expiration Period Thirty Three"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodThirtyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodThirtyTwoMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Thirty Two",
        "label": "Option Expiration Period Thirty Two [Member]",
        "documentation": "Option Expiration Period Thirty Two"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodThreeMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Three",
        "label": "Option Expiration Period Three [Member]",
        "documentation": "Option Expiration Period Three"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodTwelveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodTwelveMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Twelve",
        "label": "Option Expiration Period Twelve [Member]",
        "documentation": "Option Expiration Period Twelve"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodTwentyEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodTwentyEightMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Twenty Eight",
        "label": "Option Expiration Period Twenty Eight [Member]",
        "documentation": "Option Expiration Period Twenty Eight"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodTwentyFiveMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Twenty Five",
        "label": "Option Expiration Period Twenty Five [Member]",
        "documentation": "Option Expiration Period Twenty Five"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodTwentyFourAndThirtyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodTwentyFourAndThirtyMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Twenty Four And Thirty",
        "label": "Option Expiration Period Twenty Four And Thirty [Member]",
        "documentation": "Option Expiration Period Twenty Four And Thirty"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodTwentyFourMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Twenty Four",
        "label": "Option Expiration Period Twenty Four [Member]",
        "documentation": "Option Expiration Period Twenty Four"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodTwentyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodTwentyMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Twenty",
        "label": "Option Expiration Period Twenty [Member]",
        "documentation": "Option Expiration Period Twenty"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodTwentyNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodTwentyNineMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Twenty Nine",
        "label": "Option Expiration Period Twenty Nine [Member]",
        "documentation": "Option Expiration Period Twenty Nine"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodTwentyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodTwentyOneMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Twenty One",
        "label": "Option Expiration Period Twenty One [Member]",
        "documentation": "Option Expiration Period Twenty One"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodTwentySevenMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Twenty Seven",
        "label": "Option Expiration Period Twenty Seven [Member]",
        "documentation": "Option Expiration Period Twenty Seven"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodTwentySixMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Twenty Six",
        "label": "Option Expiration Period Twenty Six [Member]",
        "documentation": "Option Expiration Period Twenty Six"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodTwentyThreeMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Twenty Three",
        "label": "Option Expiration Period Twenty Three [Member]",
        "documentation": "Option Expiration Period Twenty Three"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodTwentyTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodTwentyTwoMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Twenty Two",
        "label": "Option Expiration Period Twenty Two [Member]",
        "documentation": "Option Expiration Period Twenty Two"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OptionExpirationPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OptionExpirationPeriodTwoMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Expiration Period Two",
        "label": "Option Expiration Period Two [Member]",
        "documentation": "Option Expiration Period Two"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OrdinarySharesConsolidationNewSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OrdinarySharesConsolidationNewSharesIssued",
     "presentation": [
      "http://cybin.com/role/CORPORATEINFORMATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share consolidation, new shares issued (in shares)",
        "label": "Ordinary Shares, Consolidation, New Shares Issued",
        "documentation": "Ordinary Shares, Consolidation, New Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_OrdinarySharesConsolidationSharesIssuedPreviously": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OrdinarySharesConsolidationSharesIssuedPreviously",
     "presentation": [
      "http://cybin.com/role/CORPORATEINFORMATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share consolidation, shares issued previously (in shares)",
        "label": "Ordinary Shares, Consolidation, Shares Issued Previously",
        "documentation": "Ordinary Shares, Consolidation, Shares Issued Previously"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares",
        "label": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER COMPREHENSIVE LOSS",
        "label": "Other comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation differences for foreign operations",
        "verboseLabel": "Unrealized gain (loss) on translation of foreign operations",
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r27"
     ]
    },
    "ifrs-full_OtherContingentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherContingentLiabilitiesMember",
     "presentation": [
      "http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other contingent liabilities",
        "label": "Other contingent liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for contingent liabilities that the entity does not separately disclose in the same statement or note. [Refer: Classes of contingent liabilities [domain]]"
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "ifrs-full_OtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life (in years)",
        "label": "Other Equity Instruments Life, Other Equity Instruments Granted",
        "documentation": "Other Equity Instruments Life, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherExpenseByNature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherExpenseByNature",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_OtherIncome",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other loss",
        "terseLabel": "Other loss",
        "label": "Other expenses, by nature"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]"
       }
      }
     },
     "auth_ref": [
      "r30",
      "r183"
     ]
    },
    "ifrs-full_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL OTHER INCOME",
        "label": "Other income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r183",
      "r184"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_PaymentForTerminationPenaltyLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "PaymentForTerminationPenaltyLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Termination penalty payment",
        "label": "Payment For Termination Penalty, Lease Liability",
        "documentation": "Payment For Termination Penalty, Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PaymentsForShareIssueCosts",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for share issue costs",
        "label": "Payments for share issue costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "cybn_PaymentsOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "PaymentsOfLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments",
        "label": "Payments Of Lease Liabilities",
        "documentation": "Payments Of Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESLeaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Lease payments",
        "negatedLabel": "Payments",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "cybn_PayrollAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "PayrollAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/RESEARCHEXPENSESDetails": {
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cybin.com/role/RESEARCHEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payroll and benefits",
        "label": "Payroll And Benefits",
        "documentation": "Payroll And Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_PercentageOfOutstandingCommonSharesOwn": {
     "xbrltype": "pureItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "PercentageOfOutstandingCommonSharesOwn",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding common shares",
        "label": "Percentage Of Outstanding Common Shares Own",
        "documentation": "Percentage Of Outstanding Common Shares Own"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_PeriodToExerciseWarrantsInShareBasedPaymentArrangement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "PeriodToExerciseWarrantsInShareBasedPaymentArrangement",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period to exercise warrant",
        "label": "Period To Exercise Warrants In Share-Based Payment Arrangement",
        "documentation": "Period To Exercise Warrants In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PreferenceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PreferenceSharesMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred shares",
        "label": "Preference shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Presentation of leases for lessee [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds on exercise of warrants",
        "label": "Proceeds from exercise of warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issue of ordinary shares",
        "label": "Proceeds from issue of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds on issuance of common shares, net",
        "label": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "cybn_ProfessionalAndConsultingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ProfessionalAndConsultingFees",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/RESEARCHEXPENSESDetails": {
       "parentTag": "ifrs-full_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cybin.com/role/RESEARCHEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional and consulting fees",
        "label": "Professional And Consulting Fees",
        "documentation": "Professional And Consulting Fees"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfessionalFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfessionalFeesExpense",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails": {
       "parentTag": "ifrs-full_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/GENERALANDADMINISTRATIVEEXPENSESDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional and consulting fees",
        "label": "Professional fees expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable for professional services."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/ACQUISITIONNarrativeDetails",
      "http://cybin.com/role/ACQUISITIONResultssinceacquisitionDetails",
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://cybin.com/role/CORPORATEINFORMATIONDetails",
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS FOR THE YEAR",
        "terseLabel": "Net loss for the year",
        "negatedLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r23",
      "r86",
      "r95",
      "r97",
      "r171",
      "r173",
      "r200",
      "r203"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://cybin.com/role/EQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equipment",
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "terseLabel": "Net book value",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r46"
     ]
    },
    "cybn_PropertyPlantAndEquipment1Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "PropertyPlantAndEquipment1Abstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment1 [Abstract]",
        "documentation": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net equipment",
        "label": "Property, plant and equipment recognised as of acquisition date"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as of the acquisition date for plant, property and equipment acquired in a business combination. [Refer: Property, plant and equipment; Total for all business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r207"
     ]
    },
    "cybn_PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember",
     "presentation": [
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation/Capital cost allowance differences",
        "label": "Property, Plant And Equipment Related Temporary Differences [Member]",
        "documentation": "Property, Plant And Equipment Related Temporary Differences"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership",
        "label": "Proportion of ownership interest in subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r98"
     ]
    },
    "cybn_PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of equipment and intangible assets",
        "label": "Purchase Of Property, Plant, Equipment And Intangible Assets, Classified As Investing Activities",
        "documentation": "Purchase Of Property, Plant, Equipment And Intangible Assets, Classified As Investing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_RDExpendituresMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "RDExpendituresMember",
     "presentation": [
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development expenditures",
        "label": "R&amp;D expenditures [Member]",
        "documentation": "R&amp;D expenditures"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ratio of common shares issued",
        "label": "Ratio Of Common Shares Issued To Every One Share Of Subsidiary Outstanding",
        "documentation": "Ratio Of Common Shares Issued To Every One Share Of Subsidiary Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReconciliationOfChangesInIntangibleAssetsAndGoodwillAbstract",
     "presentation": [
      "http://cybin.com/role/GOODWILLDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of changes in intangible assets and goodwill [abstract]",
        "label": "Reconciliation of changes in intangible assets and goodwill [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract",
     "presentation": [
      "http://cybin.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of changes in intangible assets other than goodwill [abstract]",
        "label": "Reconciliation of changes in intangible assets other than goodwill [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract",
     "presentation": [
      "http://cybin.com/role/EQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of changes in property, plant and equipment [abstract]",
        "label": "Reconciliation of changes in property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReconciliationOfNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofsharecapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of number of shares outstanding [abstract]",
        "label": "Reconciliation of number of shares outstanding [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_RelatedPartyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "RelatedPartyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Abstract]",
        "documentation": "Related Party Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cybin.com/role/RESEARCHEXPENSESDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://cybin.com/role/RESEARCHEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research",
        "totalLabel": "Total",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "cybn_ResearchComponentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ResearchComponentMember",
     "presentation": [
      "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research",
        "label": "Research Component [Member]",
        "documentation": "Research Component"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReserveOfSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPayments",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CAPITALMANAGEMENTDetails",
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options reserve",
        "label": "Reserve of share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Reserve of share-based payments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CAPITALMANAGEMENTDetails",
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://cybin.com/role/CORPORATEINFORMATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deficit",
        "negatedLabel": "Deficit",
        "label": "Retained earnings"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deficit",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r185"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONResultssinceacquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r103",
      "r148",
      "r168",
      "r172",
      "r176",
      "r177",
      "r179",
      "r183",
      "r184",
      "r200"
     ]
    },
    "ifrs-full_RevenueFromInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromInterest",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_OtherIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r169",
      "r175",
      "r223"
     ]
    },
    "cybn_RightOfUseAssetRecognisedAsOfAcquisitionDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "RightOfUseAssetRecognisedAsOfAcquisitionDate",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails": {
       "parentTag": "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use asset",
        "label": "Right Of Use Asset Recognised As Of Acquisition Date",
        "documentation": "Right Of Use Asset Recognised As Of Acquisition Date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://cybin.com/role/RIGHTOFUSEASSETSANDLEASELIABILITIESRightofuseassetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset",
        "periodStartLabel": "Right-of-use assets, beginning of period",
        "periodEndLabel": "Right-of-use assets, end of period",
        "label": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r118"
     ]
    },
    "ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RiskExposureAssociatedWithInstrumentsSharingCharacteristic",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of 10% change in foreign currency rate",
        "label": "Risk exposure associated with instruments sharing characteristic"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of risk exposure associated with financial instruments with a shared characteristic that identifies a concentration of risks. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "RiskFreeInterestRateOtherEquityInstrumentsGranted",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Risk Free Interest Rate, Other Equity Instruments Granted",
        "documentation": "Risk Free Interest Rate, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_SalesRoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "SalesRoyaltyPercentage",
     "presentation": [
      "http://cybin.com/role/CONTRACTSCOMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales royalty percentage",
        "label": "Sales Royalty, Percentage",
        "documentation": "Sales Royalty, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_ScheduleOfResearchExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ScheduleOfResearchExpensesTableTextBlock",
     "presentation": [
      "http://cybin.com/role/RESEARCHEXPENSESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Research Expenses",
        "label": "Schedule Of Research Expenses [Table Text Block]",
        "documentation": "Schedule Of Research Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_Section382Limitation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "Section382Limitation",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/INCOMETAXAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Section 382 limitation",
        "label": "Section 382 Limitation",
        "documentation": "Section 382 Limitation"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://cybin.com/role/INCOMETAXAdditionalInformationDetails",
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails",
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariableImpactOnProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reasonably possible change in risk variable, impact on net loss",
        "label": "Sensitivity Analysis For Types Of Risks, Reasonably Possible Change In Risk Variable, Impact On Profit (Loss)",
        "documentation": "Sensitivity Analysis For Types Of Risks, Reasonably Possible Change In Risk Variable, Impact On Profit (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent": {
     "xbrltype": "pureItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "SensitivityAnalysisForTypesOfRisksReasonablyPossibleChangeInRiskVariablePercent",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reasonably possible change in risk variable, percent",
        "label": "Sensitivity Analysis For Types Of Risks, Reasonably Possible Change In Risk Variable, Percent",
        "documentation": "Sensitivity Analysis For Types Of Risks, Reasonably Possible Change In Risk Variable, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_SerenityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "SerenityMember",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONFunctionalandpresentationcurrencyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Serenity",
        "label": "Serenity [Member]",
        "documentation": "Serenity"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for grant, percent of total shares outstanding (up to)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant, Percent Of Total Shares Outstanding",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant, Percent Of Total Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_ShareBasedCompensationArrangementExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ShareBasedCompensationArrangementExpirationPeriod",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONSharebasedcompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable period",
        "label": "Share-Based Compensation Arrangement, Expiration Period",
        "documentation": "Share-Based Compensation Arrangement, Expiration Period"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_ShareBasedPaymentArrangementOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ShareBasedPaymentArrangementOptionMember",
     "presentation": [
      "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Options"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_ShareBasedPaymentVestingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ShareBasedPaymentVestingPeriodAxis",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Share-based Payment, Vesting Period [Axis]",
        "documentation": "Share-based Payment, Vesting Period"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_ShareBasedPaymentVestingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ShareBasedPaymentVestingPeriodDomain",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment, Vesting Period [Domain]",
        "label": "Share-based Payment, Vesting Period [Domain]",
        "documentation": "Share-based Payment, Vesting Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_ShareCapitalReservesAndOtherEquityInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ShareCapitalReservesAndOtherEquityInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Capital, Reserves, and Other Equity Interest [Abstract]",
        "documentation": "Share Capital, Reserves, and Other Equity Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_ShareIssuanceCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ShareIssuanceCostsMember",
     "presentation": [
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issuance costs",
        "label": "Share Issuance Costs [Member]",
        "documentation": "Share Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShareIssueRelatedCost",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Share issuance costs",
        "label": "Share issue related cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "cybn_ShareOptionsVestingFifthTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ShareOptionsVestingFifthTrancheMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Options, Vesting, Fifth Tranche",
        "label": "Share Options, Vesting, Fifth Tranche [Member]",
        "documentation": "Share Options, Vesting, Fifth Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_ShareOptionsVestingFirstTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ShareOptionsVestingFirstTrancheMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Options, Vesting, First Tranche",
        "label": "Share Options, Vesting, First Tranche [Member]",
        "documentation": "Share Options, Vesting, First Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_ShareOptionsVestingFourthTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ShareOptionsVestingFourthTrancheMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Options, Vesting, Fourth Tranche",
        "label": "Share Options, Vesting, Fourth Tranche [Member]",
        "documentation": "Share Options, Vesting, Fourth Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_ShareOptionsVestingSecondTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ShareOptionsVestingSecondTrancheMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Options, Vesting, Second Tranche",
        "label": "Share Options, Vesting, Second Tranche [Member]",
        "documentation": "Share Options, Vesting, Second Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_ShareOptionsVestingThirdTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "ShareOptionsVestingThirdTrancheMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Options, Vesting, Third Tranche",
        "label": "Share Options, Vesting, Third Tranche [Member]",
        "documentation": "Share Options, Vesting, Third Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharePremium",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CAPITALMANAGEMENTDetails",
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributed surplus",
        "label": "Share premium"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributed surplus",
        "label": "Share premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "cybn_SharePricePerCommonShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "SharePricePerCommonShare",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails",
      "http://cybin.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in CAD/USD per share)",
        "verboseLabel": "Share price (in USD per share)",
        "label": "Share Price per Common Share",
        "documentation": "Share Price per Common Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SignificantUnobservableInputAssets": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SignificantUnobservableInputAssets",
     "presentation": [
      "http://cybin.com/role/GOODWILLDetails",
      "http://cybin.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant unobservable input, assets",
        "label": "Significant unobservable input, assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The value of significant unobservable input used in the measurement of the fair value of assets."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "cybn_SmallPharmaInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "SmallPharmaInc.Member",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONDetailsofacquisitionDetails",
      "http://cybin.com/role/ACQUISITIONNarrativeDetails",
      "http://cybin.com/role/ACQUISITIONResultssinceacquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Small Pharma Inc. (\"Small Pharma\")",
        "label": "Small Pharma Inc. [Member]",
        "documentation": "Small Pharma Inc."
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://cybin.com/role/INCOMETAXAdditionalInformationDetails",
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails",
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [line items]",
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [table]",
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfIFRSCompliance": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfIFRSCompliance",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of compliance",
        "label": "Statement of IFRS compliance [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "An explicit and unreserved statement of compliance with all the requirements of IFRSs."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "cybn_TaxEffectOfChangeInDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "TaxEffectOfChangeInDeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in unrecognized deferred tax assets",
        "label": "Tax Effect Of Change In Deferred Tax Assets",
        "documentation": "Tax Effect Of Change In Deferred Tax Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-deductible expenses",
        "label": "Tax effect of expense not deductible in determining taxable profit (tax loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ifrs-full_TaxEffectOfForeignTaxRates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxEffectOfForeignTaxRates",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Difference between Canadian and foreign tax rates",
        "label": "Tax effect of foreign tax rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "cybn_TaxEffectOfShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "TaxEffectOfShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Share-based compensation",
        "label": "Tax Effect Of Share Based Compensation",
        "documentation": "Tax Effect Of Share Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_TaxEffectOfShareIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "TaxEffectOfShareIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issuance costs",
        "label": "Tax Effect Of Share Issuance Costs",
        "documentation": "Tax Effect Of Share Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cybin.com/role/INCOMETAXIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expected recovery at statutory rate",
        "label": "Tax expense (income) at applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "presentation": [
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]",
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain",
     "presentation": [
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [domain]",
        "label": "Temporary difference, unused tax losses and unused tax credits [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Trade and other current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r18"
     ]
    },
    "ifrs-full_TradeReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeReceivablesMember",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofFinancialAssetsandLiabilitiesDetails",
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Trade receivables [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r156",
      "r208",
      "r223"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cybin.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfRisksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfRisksAxis",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of risks [axis]",
        "label": "Types of risks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r125",
      "r149",
      "r151",
      "r152",
      "r182"
     ]
    },
    "ifrs-full_TypesOfRisksDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfRisksDomain",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of risks [domain]",
        "label": "Types of risks [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r125",
      "r149",
      "r151",
      "r152",
      "r182"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements [axis]",
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsDomain",
     "presentation": [
      "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeIssuedShareCapitalDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements",
        "label": "Types of share-based payment arrangements [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://cybin.com/role/INCOMETAXAdditionalInformationDetails",
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails",
      "http://cybin.com/role/INCOMETAXNoncapitalLossesExpirationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "USD",
     "presentation": [
      "http://cybin.com/role/FINANCIALINSTRUMENTSScheduleofMonetaryAssetsandLiabilitiesCurrencyRiskFluctuationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States of America, Dollars",
        "label": "United States of America, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "UnexercisedStockOptionsInSubsidiaryCompensationForCancellation",
     "presentation": [
      "http://cybin.com/role/ACQUISITIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unexercised stock options in subsidiary, compensation for cancellation (in CAD per share)",
        "label": "Unexercised Stock Options In Subsidiary, Compensation For Cancellation",
        "documentation": "Unexercised Stock Options In Subsidiary, Compensation For Cancellation"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_UnitPurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "UnitPurchaseWarrantsMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unit Purchase Warrants",
        "label": "Unit Purchase Warrants [Member]",
        "documentation": "Unit Purchase Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnobservableInputsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "UnobservableInputsAxis",
     "presentation": [
      "http://cybin.com/role/GOODWILLDetails",
      "http://cybin.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable inputs [axis]",
        "label": "Unobservable inputs [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r247"
     ]
    },
    "ifrs-full_UnobservableInputsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "UnobservableInputsDomain",
     "presentation": [
      "http://cybin.com/role/GOODWILLDetails",
      "http://cybin.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable inputs [domain]",
        "label": "Unobservable inputs [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r247"
     ]
    },
    "ifrs-full_UnusedTaxLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "UnusedTaxLossesMember",
     "presentation": [
      "http://cybin.com/role/INCOMETAXDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-capital loss carryforwards - Canada",
        "label": "Unused tax losses [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "cybn_UnvestedForfeitureRateAsPercentageShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "UnvestedForfeitureRateAsPercentageShareOptionsGranted",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested forfeiture rate",
        "label": "Unvested Forfeiture Rate, As Percentage, Share Options Granted",
        "documentation": "Unvested Forfeiture Rate, As Percentage, Share Options Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://cybin.com/role/INTANGIBLEASSETSDetails",
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life of intangible assets",
        "label": "Useful life measured as period of time, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
     "presentation": [
      "http://cybin.com/role/MATERIALACCOUNTINGPOLICYINFORMATIONANDBASISOFPREPARATIONEquipmentandIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life of equipment",
        "label": "Useful life measured as period of time, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "VestingRequirementsForShareBasedPaymentArrangementVestingPeriod",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Period",
        "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Period"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_WarrantExpirationPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "WarrantExpirationPeriodAxis",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Expiration Period [Axis]",
        "label": "Warrant Expiration Period [Axis]",
        "documentation": "Warrant Expiration Period"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_WarrantExpirationPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "WarrantExpirationPeriodDomain",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Expiration Period [Domain]",
        "label": "Warrant Expiration Period [Domain]",
        "documentation": "Warrant Expiration Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_WarrantExpirationPeriodFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "WarrantExpirationPeriodFiveMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "November 15, 2030",
        "label": "Warrant Expiration Period Five [Member]",
        "documentation": "Warrant Expiration Period Five"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_WarrantExpirationPeriodFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "WarrantExpirationPeriodFourMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 20, 2030",
        "label": "Warrant Expiration Period Four [Member]",
        "documentation": "Warrant Expiration Period Four"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_WarrantExpirationPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "WarrantExpirationPeriodOneMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 4, 2028",
        "label": "Warrant Expiration Period One [Member]",
        "documentation": "Warrant Expiration Period One"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_WarrantExpirationPeriodThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "WarrantExpirationPeriodThreeMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 15, 2030",
        "label": "Warrant Expiration Period Three [Member]",
        "documentation": "Warrant Expiration Period Three"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_WarrantExpirationPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "WarrantExpirationPeriodTwoMember",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "May 14, 2029",
        "label": "Warrant Expiration Period Two [Member]",
        "documentation": "Warrant Expiration Period Two"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WarrantReserve",
     "crdr": "credit",
     "calculation": {
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cybin.com/role/CAPITALMANAGEMENTDetails",
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants reserve",
        "label": "Warrant reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]"
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_WarrantReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WarrantReserveMember",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant reserve [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments [member]]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WarrantsMember",
     "presentation": [
      "http://cybin.com/role/RELATEDPARTYTRANSACTIONSANDBALANCESScheduleofRemunerationofKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrants [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for warrants."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "cybn_WarrantsNumberOfSharesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "WarrantsNumberOfSharesRollForward",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants",
        "label": "Warrants, Number of Shares [Roll Forward]",
        "documentation": "Warrants, Number of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_WarrantsWeightedAverageExercisePriceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "WarrantsWeightedAverageExercisePriceRollForward",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price",
        "label": "Warrants, Weighted Average Exercise Price [Roll Forward]",
        "documentation": "Warrants, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement (in CAD per share)",
        "verboseLabel": "Weighted average of exercisable price (in CAD per share)",
        "label": "Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement",
        "label": "Weighted Average Exercise Price Of Other Equity Instruments Exercised Or Vested In Share-based Payment Arrangement",
        "documentation": "Weighted Average Exercise Price Of Other Equity Instruments Issued In Share-based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement",
        "label": "Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeWarrantsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement (in CAD per share)",
        "label": "Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding (in CAD per share)",
        "periodEndLabel": "Outstanding (in CAD per share)",
        "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofnumberandweightedaverageexercisepricesofshareoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price of share options exercisable in share-based payment arrangement",
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "cybn_WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofnumberandweightedaverageexercisepricesofshareoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price of share options exercised in share-based payment arrangement",
        "label": "Weighted Average Exercise Price Of Share Options Forfeited And Expired In Share-Based Payment Arrangement",
        "documentation": "Weighted Average Exercise Price Of Share Options Forfeited And Expired In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price of share options forfeited in share-based payment arrangement (in CAD per share)",
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofnumberandweightedaverageexercisepricesofshareoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price of share options granted in share-based payment arrangement",
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofnumberandweightedaverageexercisepricesofshareoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, beginning balance (in dollars per share)",
        "periodEndLabel": "Weighted average exercise price, ending balance (in dollars per share)",
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r130"
     ]
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated grant date fair value",
        "label": "Weighted average fair value at measurement date, other equity instruments granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted",
     "crdr": "credit",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALNarrativeStockoptionsDetails",
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value at measurement date, share options granted",
        "verboseLabel": "Estimated grant date fair value",
        "label": "Weighted average fair value at measurement date, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofsignificantunobservableinputsusedequityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price (in USD per share)",
        "label": "Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted",
        "documentation": "Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "WeightedAverageRemainingContractualLifeOfOtherEquityInstruments",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofwarrantsbyexpiryperiodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining of outstanding contractual life",
        "label": "Weighted Average Remaining Contractual Life of Other Equity Instruments",
        "documentation": "Weighted Average Remaining Contractual Life of Other Equity Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofstockoptioninformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining life",
        "label": "Weighted average remaining contractual life of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageSharePriceShareOptionsGranted2019",
     "presentation": [
      "http://cybin.com/role/SHARECAPITALSummaryofmeasurementofstockoptionfairvalueassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in CAD per share)",
        "label": "Weighted average share price, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://cybin.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of common shares outstanding - basic (in shares)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "cybn_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cybin.com/20250331",
     "localname": "WorkingCapital",
     "crdr": "debit",
     "presentation": [
      "http://cybin.com/role/CORPORATEINFORMATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital",
        "label": "Working Capital",
        "documentation": "Working Capital"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "134",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_134&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "91",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_98_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_j&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2024-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_v&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_viii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2024-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_36_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "18A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2024-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "134",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "135",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_135_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI",
   "URIDate": "2024-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "40",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_40_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "46",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_46&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2024-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_j&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_d_v&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS03_g59-63_TI",
   "URIDate": "2024-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Section": "Disclosures application of paragraphs 59 and 61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&doctype=Appendix&subtype=B&dita_xref=IFRS03_gB64-B67_TI",
   "URIDate": "2024-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35M",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B8",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B8_c&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "Defined terms",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2024-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2024-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2024-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2024-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2024-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2024-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2025-01-01",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "A19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_A19_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "22",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_22_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2024-01-01",
   "Paragraph": "88",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_88&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "119",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_119_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "119",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_119_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "119",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_119_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2024-03-27"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI",
   "URIDate": "2024-03-27"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE72",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_IE72&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B64",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>111
<FILENAME>0001628280-25-033606-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-033606-xbrl.zip
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MTESD$:/Y*LUEB-K=+Z:*30,_26<8J6<CK_3&;1;TR(.''[[F@7\A:;-Z&^&
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M4#,O^!GP<,_8_OK3*/P*.FLQJ#.5\\4+;\(H6OPL@PV.@L5/0U E<?5IY8*
MB@W]< ;OLOB3&;BC\*5<>L(L36#[U=(S0/>&<.*5'8-AELN W.ANT;M;# '6
MY9@RD'3M.)53E!C(AM<R#;4WBW=0R<C#15N;3AMKQ#60EE@Y1=8-0OYAM6_+
MKXT[9SZ=@(>M8KH_T"P(,[_(,N-(5UREC=\U!WY#/:Z/Z\4R'W<[F$),O.X0
MJ]K%0 :@#<ERX)4LQ/POFF!9!K(C,.>*34'V-=:&+S*5H_<G*$G^0EX%W?$G
M]"=#_QZ[^$G%L/I('%4BQKS%!RV>&J 07C H^L#].U*9GX9DXS=PWVR!99V/
M4F/]^,/._ONUI[^6T]Q;??CY(_ RX,8_;?5V7PF8I=]X]X5LJI70F-IV];JM
M#J5[26YH'Q"YF/6FEA<!<<_06"O+UH./YB-J%5F%8V?@[ODF=FHT5P:D/'"D
M?%92KB)0C9QU2U &[/NS.H*?^21:C>*W*9HF,?SM\_%TE&P:)<$,^JK8K)YE
M893XE(L"J@6%K^FUWH9R!'M9@EF>-KI1XR*2E?0%R:EB2I59<3NR *>8(<.4
M"/\7B.N##L<K\7>91"MPM);\COK/37WP=-+DFK,DFJI).A?#) C9_YUE<W\"
MOBR0F#+#N:3,564 5;3SRL1BGBJ9&Z,7/;>DR,1$R2B?6/Z8(_&+D)CWW4=O
M%78*-@[H:_+=DAVU6CJ1/SI5Z&9'F'#D#P8%>/E*QG@Q1ML:DM$9?&F 0_#.
M$\<H^2@2%-A;^@O0)$BFK,R<-GM^>38,HS"?H_ZA9 G18R93$]-"S@]KB QM
MA20SU%!%3'%E)YE>FE@4TT?J8-P.-5 ^29-B/!%1 C\%>DU!^\QFT9Q"T2D8
M_13<*S-RMU/,1A\_:[&#A5Q_I>3=:B[HK-V:=2N\ S:^T1!P=X"?X !K0UW
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MZ$P7P]\(':G+@DC1P:HK^4C)9@4[AA$W.JQAJN,45A&9;9IXE/I5E'/V]%/
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M:\6='%.5S9*86$H+86<0/E:G\F#01E!Y8Q3K_:>IRA735)L)@OK3U[=WVJ[
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M GP!E!_],>QK4PP!Q[F.<V_CW)/^49.*DI#<)_";<3)5Z7RKGX&E.0:>F*5
M?XS87T@V77T9N>*A1Q.=PA9@O6^#L%*Q/W<RR\FLC63?L]$([M$,J*1C6\>V
MM[/M')FVA\7_V4SY>>$@>XYMF\^V+E_YTN5&KECSB3C7%1LY ;L!;.KR[D[
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MN@.6Q)HPN*GY"O_HS7Y.94[:\1])D<9JOECP[JU_7X]HB9N[DHIE<'374''
MF5?0HY2EW2;]OG.;?K\&#85G>BZ","-UI9WDA54O/!Z=$R <3G'+.9,2)_%6
M GJ9. ;! 2 F4N0-C%1:]]Y0PZG6TVI#2%COP_5D!-Q(^K'\0>0X$F]4(.TP
M^9<"%6\3.6OH%\D;<^&E*4@X5=<Z:W&D?*8J4Z_=HERB#..%FY<:>VA<H9(
M&=JX^!."421BEH6@L>DE4KOW;F#Y58B'@7?"&23$&FE2C$VRC3#S]['J7MT_
M6=R\.NO78AB2\K=I.&26EU4Y<35W%.E1N3Q=OFFG,3&,0_L%&A7$L%*UGLU$
MR'7H@VE6MC+WS8&E]#%UJ;MUZ;4U8DNQVHF7!G9[*F<*Z.YGS8DS\^(:L54W
ML$&JC,PSY^'Q"&JH^C(SO8+B-I=JJ"$%(2SHE?X5!RLP&%%FL@RN[3"2()8_
MF&S*6Q L@1J%:*;B A%CTS"F;U9+B7<M\:74FJN%G;>>@*#0R$*)F.P+Q"AF
M.I&5^)PV8Z2HKW4MO!0XLDF,82B9V75#Z]>R[ BMOJ[$IF2Z1=*:*+MNE5&7
MGNM>MRF,U,2V3^_6<TD*!@/8RX'8W]WW]GN]U]RZ5YV[CA;\=9)K3"F=%)]S
MP96 HVRHG&'\OD+T$6>^51)MRB8P8.V<-X/Y.%9! DFK",*7H9I8P+P3?K?]
M/*ONWFO5KUKPW=WM=79?\^U?]0C6L1?('9VZUF+\MH=A5])<M>9;&@"+N0J5
MC"BJ\!OE-A+A@UL&R\-)DP&Z:"B6;VFC\L"2P<WQX'6;C#NZ1M[MP/.WB OM
M<Z. ;KNS70I(Q(;RG?3S\%2?R#F':;J=%ICL*T&054:V%*[EBFTWEG#7(Y6F
M94E-KB+,8Q44><$P  YMS,!HR=@2*8,U]&Q,:'!HUG]P9(%Z:48%&<"# I^%
MJ(TJ\("O6\48,!;% %IZ29Q(EQ1PD8\U]Z'/Z&>@5NC#RLN?V<AQY/9;(A,;
MW?CD97!(%=IF 4CP?$ #! K.TC 2'9,C7L2;+,-Y,*ZX\$2[ZF"2I.%_8$>!
M3VKMY"Q(..4'O*5/8.&FFJBJ43"G86D',*&P(GOQY1?Q.9Q2OY 0HYTW]]@'
M_?BWETV%5US"FM7O!?H=@^M7MM2SRN7;R+-\1?([BI(;9"\P\L %(OF+7B/R
M]"KYBMFP%(LA2^ZASC694?"(H!)&G\,'82I^*](P"T)== .L%MJUO(M5#^63
M=.4,?HT8!OJ'MO9#<CDS\FW)BN<#F:G:JAS@83W@8<<!'AY>V!].QW N\K^]
M":?PCO_7:?TV&[\16>HO?E+CLEYW?_;M??T1N.9K++<"(T(_A1[(7^O=V#[8
MG7U[\_CE/BEC[=\/AY[DBNKTGD4N+ZYAC3]TM29N@O\MS4<K=F#53-4C!*\%
M/MQ_I'+\OH8\KTBR[RQC>M7.&Y\&IX.+_F=Q-/CGX//9^<G@]$J<?117/P_$
MAR^7QZ>#R\N-M [.EBMPO:726G3E;NM:_(C6R P#MTLOZS!P&XFO#V&]=[/I
M352SN>]GS"\D8>[ _\CZ%8LVC;&VQ5T@'_&O>Y44KJAUT?Z-J5K$%,[JRL(J
M#F N6%N50VM?4PXYDC[.9C>UU+I <D/-W[X.*8# #!3HA(B A#(-C.ME[[TQ
M4JOP0KW@%^O#AFA.%W%@HBJ?8?<890C\P4F43(S"2.?H!T?]B_^N86(.-'KB
M(=MI6YB=UOYKH Y[O5M1AR^D:?9:G9W[K'39WL>]V^JU]E<894.9*7Z+SBOE
M!V#)5HBW:0?L@0;*K[I] 9P T[" 8TA-?;\[:TNMD%'7,U8G>*2ANM8AL#(K
M*T)L,AF.0A[X2'L!O_G?KG@;7K^CE"VB>Q2H *D5W9+*7)?$[?MP\E!P17,/
M0:[;W?U6;S%]/)'7*(Y0;8W'*.K 4[^644%)9#D#E?@M1%4&*NLOW>X!*P$-
M)# HV66SVK/[%E&[HEKX'WL0==JM+G<ARI8 !BLS3!*>IQ-V.]Y!N[N8<DJ5
MKJC0[Z-*#"$MUVJBU-MO[>TN=5$RX6Q0R#H*7.(?*G(9*M((3UDI"SG%:/F*
M/=O!.!LN@-YC85<H(ZFK4D'=*#2/N!Y$$NVHLT895K\'T=G&6-OYX1:E/(3'
MJ=2<J79K9WN6"RHA$>;0+'NKMIY!+SR9@2V0SW_J&-=]>YMTST)7QB<[DSLL
MG^\ZE>O%>^<5Q/O!_1S6?A2)WPN9 M6QO$>E/#_6U IE.NFBLVEL/L!+@" %
M$8(M8;;4;?D$%^W:==&N3=.I^T:GWM(3!+_Z5Y)& 4T7*].)YR:=>&:W<Z+F
M?=F$0'$<0(Y+Y+=NK<W"5+?[N>8>?U)0<HG#UA/)%3/D&L$%<S%5^00+\Z1/
MK?>FF*L!%T[,LKD/SU+8+W":P,H*;*3T5C?Q/DS*]"-X&4K"6IN ACP_O&H"
M^&05/>*D)6!Y/_ZPO?=^<(XI:?JSO;?7WMG3I>/P?>TW&D>G-_9$4PJ#>D>&
M?&<C<6Y1ZD0%^L=@H<R!JTJ"][%2? [>\)3O<*Y2C $@A^"C]<U+%QJ3*ED]
M :[G1*D5;\<IZ$RIKQB7R+6X1XNDY"?B/?;QV3!8S6!T+"CYS&TUHKE.)9I$
MM<:$:A0]&C?X%#EGLT1_:$S/LF\E^[.C BMD-C9OK6WUWNV"A;7=-=J0JDSS
M!S*7' 61XOP76'L1S(5"VUER/BJGKIOP ,5U*0K4)->B'9U<E?3QQ.&O']KM
M;<_(#_C^&LSI2K"TQ.5,^503'J$I;\C.OX.?3;$-&=\YLZK'97 -_P%5!+R!
M(3B@P40<_Y.>S@DTO@_\VT9#1 F(ME0$15IB.$P#/OK5%,-DR ]A(J]E&,DA
MAG_F?-QX%V24)?5U<;NF^L*S27+#G?A"(*[$#H\$3S6],YDIDXP"<Q@BP?/"
MZS=^ ]$ .=4@4"F,E^!9PG0DGA9+0&-"$O>6+'$*:$617?]2"O",#K4VM0U"
MW3Y=3]6[_-4XOMNYARH-<YH[, ,CE ?@,20!#P!0/1-':3&NY14.K6AG$W17
MN=0F:#!$:XVC9"@CCTJO\'[7Z D2!\(16PT<XDU7W]!ZX=)]@48IIG2 *-<(
M0]+L&B YK%(HCR!S,L7@<I&O3*>?4_T J\VNK"!,.67S,6:/1[7GW2;,K*(L
M"893,F[I7\'*P8<9<LO+49AF^?*UVOG58I-]WX5%V<5=QB'/T3XRJ:RI_ T^
M#LC]SU!*!V%&WFPC>/#DJ GC6#<5CG+&B,/>G>**4![3D(8DZ?X_Q_&U@K6/
MC46/2R*1U02V.#YM!%O4;6..Y^DT=\)6(>U8/P"K-B1E3K*](34:'X_ZC=A$
MLC/R)7%*,F\+W?P"GK4H72U3T4A9>6\9ZZT6A2!L-M84ITKO.PQQ,DM6!=1/
MRC*GQ8BZB::#_GU[C?]+G_2HI;*G ^[B?[>IAS3R.WW2$__;T;\)]?^&3QF-
M_YX@O-?N;9LD;U"8\/'#0_(O'GS>:,;<NYLQO1+3C;)@#:K66P3$AXO%<E8)
M-U)']W5&)Y.E"_EO[&>1]SF(84E AP]A,J50160 NPV0T'IQC9#2M)F^BDBF
M,K2B].4M&W,F@>6II$G[Y:L,YWLX]M54B-(?K<EJ&7^#&\Q+:[4YI8]]K+BP
MF\\U@7P<7RAKGLML'HF[Q05CTNTO'1RG0DHU24TD@RO8C&."S@7%=BHY!^X9
M";Z9G),06QY)L/RP)ART0UYD,RA5J\VQ!2:&:F!G13'#T_B7[7V>G8)95UW0
MH)WB3"LF@F0%!FYD1!TWO-<-\) N?+_\1D7@_DUAI9/,0K'KO2G;KW,/C6_8
M42];0U+TG",,/2%C@+CNM44@YUFM&FT9G&5PI%CE8W5M3(:FAPD"Z&,%KY=1
M$1MJ=M#S&ZX:#^X?2BJKE(_UX 3VS"[4=0AK^I#(-&B,%#R^:$8C=L,E?"+&
M)NY>]RUN#^2L<#4>$M#YHSH;W7L8=4N<6P),29;Q5"T!(@!VSP9+@G]?SQU&
MX%>09BF!D^"]/I'GJ/M853 5G /,HBV, ]CKM+)<.!"'\%P1@QR-5L?DR"1=
M:1^U>*R[ Q:L!1;L.6#!'U$0W!IV6!5UZ'$$X3Y! WWO>\4.>GM>;W>WU?VN
M( (87D^&Y-MK[3P6R'> K4H>#^3K[L.CEX%\FZN4@#:=^V3F5ANMM9H(#7_0
M,0.*%WB8O[[&RG5X3IUA!Q\N_KW5:7=(=V%9,+8M-9G:K4&K-+TE%:_#+V#?
M$"T3&>/=S'JV5TW4KG%>IVW,<Y)?JU_DA5IWW-&\9C.YIWLODZ9,ZGI5.M>C
MX4E@819PY&),B9.A1U/P[ITGK%)]MQ@7WYOP0\/S#BNDX;32PR16XMFP[;N%
M2I/Y%GR[->4Y50H.24YVYSB5T\;X2O@6K^DLO5"[FS7ALJL3A!<B01KA,#+>
M"X,?JCXZ$-O8D@9E9%D4Z;C)E\N_]'9H]O#R\&+V5D(>YHC_-5V@4-G\7L!Y
M(A5B%^#-]+0"1"84X )Q*+LV1:5B_)K"*)V4;()@'BJH0W S_%M%(_O&?#<2
M>3L-:V9*B_F J[ZD59^7JVX"=[!9L'Z-1-?*XF)[K0JT=7>T_O:P9$<7%=:&
MJ8$S>H298FW&9DL\9=4=(@\(Z_BP33J5@5I3)$I]=JK@&N?Y-<U7"4KCD0?6
MBJST2H-8YL\K/FUN:5:WQ34RJSY!B@=&<8O+6L>M0^!>.#T?P_P_8ZS #TS=
M[>%"3?#RA3_^T-M_#]>5AW7AE-2.*(\QK9]!'F(:@AHHL&%:SM!1P4E>8W;=
MF>9=31DKL(X717*6Z0XO^F?KA<O&>F9Z=SNKX@0:%EO9U+9)O<)O(W@-H6H&
MV#Y"#S5<1-@T0"H=#9J!KL'PZQCG)U'T]1(QN)A>/191Z*LX(\O$QO\^*#1N
M^2[W1]]H-RK3./H*([_LKFQRD%QS?:]]SX@$.W[Y34(G(?3#&04%JI%6".8F
MT;,BY+TFM/W'2SV87;U/G$<'Y/ $U.*.HQ C+VNKB#'ZN$TSXY\\^-CS.@?M
M5N=[@H_;N_M/6$:\W>H\-OJX[^WUMA\??=SIM7;V5Y01;RIC6@,B5L;#U\*4
M[$D3NF_A21@'&-5KV@Q9O:Y&Z#4;W$5-]Z."X.N66J//<_@7?@YJ:4S=;GQB
M<QJ#/)_E$G%[6UP#7!9]L>58>3I<WH-G NL<0T(CF>>,%,%=Z+JRS0T\W- 0
M'O3E\B\[[3:2&6MFB-Q5[?M*%%4EF_2MLPJG 7<[\'80FU.UC"75L?0CSY29
M5?7UO!2O!.A0__LZ#*."RM65/<@R5E09;!/ZA'Y:_D:/^*A5^V>F"&XF0U);
MOLRP.$-03\QZO^N4YK!,AV$L35^>I?;%]"(FFX_/K)KQ$+U()(HXP9:W!2>+
M2]TJ0781*>'F2.AJC0;,-%7Y(M6I#LN2_UC_E$FL"4R3N8SR^;)T[OY7.5^2
MAFZG/FP<<'=@V"58+]]<ZG??I7XW1-\!SV,CYLP O$@L^&#$ESV)*^U6CNBK
M^H_C&:%Z*SX59"N8'V1E!]Y8;G1Q;-F#JG,?#P!M>I,O+ 7PDE4?8NG:M8JQ
M;JT)!L'Q/QMA"R!P>%)K:1<PZ!09;904*97P 5^-J RY<J_@%Q@KSW0S,JTM
M+N4(H<4:5X>Z*LQS4//\B!BT+69WXZ14D"#Y[=+AC']/H^^^A=C3A:U?;5>L
M(?,-N2EDT2P -D.=GD0FVMCC\ \9%WCV=8[UEA[G%6PL4]B  C[4;3A)D_8U
M\ONH276*G_K-*$@CDQ 8#_^+/ ^N/MJ;Y+62 6R&5YMV" ^LL]]8]ONHABGS
MW_W9KT(M&K.3&Q;@B0S4##TV>!<%RLHGV:/%A-:'IPJM6"Q3(60'^PWY4H M
M*.'Q]R2%:0!@RF4H\)8GL)?L19K2%[Q=$H^3,AJT)'(T\+$T\ZGE@8ZH5AA(
M'9<*IXSX7[TF8T;7D GT@BQ;3<]?D&T%XM/)82@3EGASL$>W>"6Z4/X/PF_=
M.^0=^!08G)M&C'$'3R,6,D0%(Y$*X%J$_PGKV9%RWW3+&YQD@$.Y0Q7[G%!!
MYQ?3#(L)[%$"1AA596!IF6^[G\0161WE#]Z'(L]X 8:T\U^&7V^2]"N%X?G@
M6 BIB8H"<)3*%BH4LXH3+MZI'DLC8D/6EN4EW)H>85;Q=1)=F]X)N*0U,TH6
MXM+ZL,'AW>!>$Q4+[:]BH;*X@SHOA5,,:Z*_D548Z25^T>+@@7AW9HKR]K76
M)&5SEV2(Q2?+XV&PV],LY&IH B9L83\4Y'2KW4ZJLAGV+T&I84>_6^+<CH67
M AE%)I8781\'#(MG52:"IM&CAP]$))!/ ZR#:2,JBSS1FXX]L8__@]3HM/$O
MW'H.T48Z&8?1"]Y4.I#4YR5/(BWVZ22"[8N+H2D^ ?>J5M>*2829) 10GB2$
M8T,X%F(GZW3DB\14291ZHR+BD4')L* ^%Q5G< "YG(6QC_,"]-IYD9XQR9G9
MC L@IO.,)1PU_PAILN.-E0DP4>^ETV.Q-TLNTX\#+8(Z*PMF9<;^H;C%T4:Z
MHP^Q<B2SJ1011O8R3T]%DMPR:L5;XDOB7?1[@>,<(9X#5F@*H,BUJ+KO5%2I
M==KA?C_/@P-=T1/X84TC;^\)W/VC"VO0[L6,\_VU1%YEHBT)8=UT"@TJ):-\
M,M?CVA6<NQ:V35MK G()2ZBK9T,*,J.C6E\;FKHUV*3@[N\SFEY#I=)DOU(,
MG 2RZ(NWY:I&!78- >E"WWPHOQG"(C/QW]45Q+=TT:%XRZ_[;O5;>7:EZ4I#
MYFYKVK3)2I*8\%)5Z![L"K2R8I0!1V4;,GQ #.R "\0L&&%+C+FA/71<#FHY
M+OPOP@@W:YJ D-22Z_P7?LDC^!1.-EZ&X_G A%/<BXL]6H-=08A>4?8_K.-V
MN35<I9N1$#B!!X=5P:I6\)NF3&W)*]FH)HMMV#N+*-/DC"5N9='3"U#K1OY5
MO449 9/7B*<ZFGZ!TY'].+6]W:XO#<'-_$ZZEQF^AH[S3!59S^:2#Z_>G'=%
MJ/J9A-(S]^WM/@^>[7Z->Y%/RGE8(U"O2<H.)"9UICSIDAOAS]DI"FDPXXU,
M@ZTH2;Y2$70U',!N[PLL19Q%W I+QH?;\PD6&X!9\UK1HR_2N+H7:/$LB;D5
M7KFP3$^T8:" ;A<IOL;)3:2"L=)= ZN9-[K_'W?FL^1;2UP6\.#R-3*]AO+>
MG@;,)>128P!^3*GW,<J2!&3"N @#_7X4:N>78@N"7I.,.!VFU((%RUL2D!U8
MB)W V9KEU3>X\EEX39E__2'=&.4EW<^NU;0Z2>F6)A0[\2HRJDRWG/)]/?<A
MG&J@<X7KXW%\]&W&V\'/I2ZDAGHZF,7 #>#W+,3M',[Y)]4V>'JO3#TG&(42
M'ZG?;96O9',"F&<4)08ZH>J^1=:X)-Z!2^(UQVJE.W[_,(GM3;7*=8/:.U,.
M",2%OVGJX>#D0__B%W$V4S&BMT!"T;B"),8G\#@:TQ,/;!]VS/RD0!^8W,4$
M?#E06K9[IX?\:&R#^1%*4+9]?13PZ+8IDILR8ITW4PDW*N;1C&SNT.W+^ EL
MY9C-0X9P;FR\%/L4'CQT^JTV"9E^8'X;M$AI%1IC>+7IN79,%/]XW3KT'&<<
M:$MH<9,R,#Y)L.R%F 4=VHZ-L:S1X%YTEE";PP['6?TF4E!3=.K@PJY<2UQH
M14E>3-U[80C?C'-HV"Z;O=!7<%I6]HY)=" (_IIMT>E*[7>QZ ++7R+A4LB7
MW9Y)F ;EZ <T9NRI#EQBLXF!D8V=YT,-2-OW3[K5<9+DZJ%129#5LG]5\XJ0
M/I\?BG.SO&;5X9"Q_QDG!$<DAKZ*0SE#FT!\++"'WN?/AXV(DL,6-F&_T/VJ
M@0[7%<_A=ZO)OAQ?PW^3"4GE%BK2[A#^'#S89!AAHUTMI/7M/*N^M,T)#2QM
MJ:?B#O^RW3'?O5LN%M2MOGJ[6U1W:$H1*5/'?<+,=(/2M24,)U<!,EA;QX$H
M 8S=Y7$X-,(@<6VP_IIL]TQYP@)&U!.Z47QF[L7X\, >_83!-8)7WE+SN'J_
M=?=\7-2#?ULA0!<+)W%Y#Z_1M>5=8Z03V2NXH&:5TSYI!3./@2PQT5;_5()F
M9)D.T=CCS=DBHM%0% =0*?PD2<W<X@I<+%;L(*>3$"2\\.C+ZM%XUX$NHF D
M&4=&FB!O+P>-D+="#TG@HX5V;UG'5T7RX!\?D1L^;B&:LJJA#Y0?2307JD(3
M7:0#;X>_.O/S!$&8'"7O>.M*-T^P@^)O0+8L"'WMWAV!_(J2#"U:'E132Y,,
M57Z#95FZ+M7$D;Z %P#?TH32304?7-VFO<HRV-N$*FH5S-00:B@GK"2F@\%%
M +<:L?,M^B659N&/ L)]4.NTL1Q3Q!5_SW( ]27Y4^@O!V-2'4CK4$/PX<*O
M834DMB;_*5^R/)<0'EZA(EC[ZL:5I8U95R.+F JA,;L,52G#TO<V"G3UUNZN
MM]]9&,:H%2L/7&%8&3M82K$L6K/GVKO+*B"KW3@4]Y=KL.#UJ7T%?K/RP7>K
M3#Q_'I=)EQ5K!J0#=^9@Z\*]\>*ABA4"E60UQ!F.*[VLK@*6(Q"F(55;O,5,
MCXS\@HOO;-5\J?>\TWL;O#.RG$J#+=E;RMV^3\*E<]#;MHNM&J.=[84V02*S
M;7J!N+Y.+]CJ<3D.<05\=Y,4D0G/XY%#ZBW2%8\HA1@H[WK0.CCX+T.EI,A!
MB'+WBX63:MHP]>Z-T<3>X-F,J5G9CW?R+S>9C343E3I UY:2FC_3839BF !>
MCGA51<D-K=-<VENY4K0)ZG$K9&J."*VS'M=80K>9/_6Z^N98F[28QO9PP4P9
MF_7S=;C*-6RCO:,,9P=HIQ#E&H;(:E&+I![UT XXNDIG2Z/)[Q,3 1X<2ZRO
M>PRS;Z@)8II+[MR^2RPX,X-WSA #BZ7</NB\& P)/EI*3G$FB]UX0\/ 3$G\
MBK+P[#L&5GCB!#2D5)$XE]$H57-NI= Z:I%H_0!><2X^P<4Q=81*Q&\)"1C[
M)>N-0G1]]U4*>VH&RI'G&BEL$ "7A*F&V\*R#^'E1N*".J$<H2P#1S[EH#!]
M<PP;J+&:YMM52, <GZ9;PB-C.XC%TT L>J^(L  +Z7F5Q,$CDX\78?95?&3(
MQRONCVEZQ>F,5,,&2M2&FPF]=N>Z;9?ZWQ#M*H-KK)Z;&XU1<Q?!98[4-W$:
M7B=I\I_)UU"K+D]@;P'0>ZR+JI[H"=D@F59(J#+#N" ?'N%9^(A*)UU6&MJH
MI7I)QX;;*[KYQZU);#F;@;HOV_%<2A0OX'"UL/<56@KD^3.R<@P;I:FUL;E]
MWIA[9/<7-J8O4YS,)-,\0LXK>>BL+'NR6$@/AHI]X-,J&,AM?4UKQ9.T5=V.
M"TS3:P:/W77GDMLIRK \D>K+I?@YB0*&XO$J,@PL:R -QAXWF;.CAQ3N!A9
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MFJZ<7(C+V"^-!Z*NNS,-W6&0/)])S7E$S]8M9WGMC^P"35/%LK$8!VL V!T
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M/.)7> 9M8^Z#+8NO&!8&1B(F(IA.3=!L'ZZ.FA##,)V#%_*0AJ5D\!ML-EN
M2\X4GD=XC2J;2L8'.&"4>L=*3%@K'-C)C9S74I/D>=' '<DC4&$12$0<6$IR
ME(#[]KSNTM.WH&\)>VIJ>7)M.2!U<Y62/@+;MQ\!61GH@QC,W-&6T3D&%E=N
M'.[OHH=]:S;]/BRPX;N[4L"4;G2YM:.D2/4 *33:AH@.-3$+,Q9#[[M<4/8]
MG60U'L2"$\.."C4VQ_"<+G);GTH.IWC6]%1D0B24X88RL2QS6K#IFL,,L"X
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M*S&5M Q'M79[<? FE/C.V-X\;1U&@\*HMT.BKE3XAR<:5+Q>V"B7'0#B@;D
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M<[G=\YS930,F</,<:0^SK+GX6*/Q;9";Q.-IY/0%8W@?3--LY# S#6N'H6E
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M^,SN22O-0RHU.'B];M/1%.+",0E7THTESY(14$?5YS3+E->(]0'S$4"0FH?
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MU]I^CJ% 0^.+P0P6BRB^Y+/\!,)GP\7 $@T)GTF;!D U1WB\"&#PTS>D@C:
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M1KL^_ AU;"5<GQBV=Q^]3Z1NWEDMW-7HG1KVM;BJ' ;7:E/?*@+ET2 =4LH
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MN-Z+&R;.CT"^?X*NBW27DH&:T&J.Y5H70( 8JM89Q;J1BP'CLEG173'-<''
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MJO27$S18M$+@\_=2M]JBCI&+EF_9(<E"H_6L-2!&<U*)L40Q743DJN'Q;_;
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MQ"DZ1"'+P$A214DST^PKKGK/J!!TO^3/I%6[%3:]I4[K:=W9 YM1IK'"AD&
M0%I;,K<1;6MV3Z>8O-; L<&>FRK>Z+$NGGU:>YS'"[;7R!\=KJ\*NTPF=&T"
MO[W_NDN/<1A$(&L%(PY,@3!3!C?.1B,:EF!;%WP2JHJ[)].M/<RF7'ZG!FLD
M3_)E>8YG8YC%$KGT:9D=B0Z[DCPY:&X4QC>@1T*:B]M[KA(XU/>B[NZUM3>]
MW,9)+_KM\K^.]O9"TH\ *-[IZ_L@N#Z:!RS]0>AI;WKTO)Y/^PHSZ\R7>G92
MXS&94,%0>O@$AZ_#%MXS]T;32*'[0O1%50#CF%;#TGV'9]UK]U\ (G" T4@3
MSV%<P>K"/VGCQ_3-2Y)MCO"67'HYIH=H8ME*SJPQLBI"BTCS.P=%HK!CXZ%-
M49S&@6KM+P:+L:,X+1BCX2;'2=W>=?9MH$X36AZ&0,91%:-*H2SNXTP[Q#6
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M+1&JE)\'>).1@^Z$5*< ] 5\9$E^(P4Z-ZX\!R0X,(N$S,K]"./GBIX^TD]
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M=Q1ATX6QT.;+Q5A%OUWRYI 0R3+O/HN*>6;NVX.]M3S))R$;DW('A!REC@A
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MT-5RET)<N'H5^(5!L<9C.![)\$8-%"7KL=PDLJ%,*1_VT5C<51),:(_#EJ3
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M8MSKRXLF%.,R]X 9_&ZK95;9M#M@T".H6TZU\Z1/"%#@Y'=>;;UGC(HO];1
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MX91T#JO@;;Q.DVKB)P*XR#AI )E(^+<>RPTUE@H"\-,PA=G.]/6[0&=K, V
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M"ET!#!5;&>5Z"5(1074.N!3L;ZKF.C T]"HQS 97AI:JJ>_V<'GFU;FI,(G
MO%^2YUF*#!:L"J8 DH>T9]M,F7@:M(OJ8OP:9:",M H2+YXXKVZMS5XNN.:H
M,K@J*3HTI:($2]]0<RX,+[@-G6J>IER1 +=(\\(5TM%C*W!=^ 6@MC(0D=;V
M%S^?T]-"PVJ$<]Z@?#[27&'Z?:G%9?=5'7YHUJE4X6:78VJ;/M+'JS3PC![>
MP7IY^-^B9L2Q9J11,0DDKL+ZIZCF!R@^5)]1L4N4=4$5542B;,B]VWL7<+YF
MT-&Q")2'&&?,TP=)W'M258TZ$K#2,T@30.D1M6+5O*L"XX3:*6\Z-U"GJ5N7
MT;)WO9?,B\W_*MJ3G9T.Y=HOX#KI,3M<^SRS#A;PY'$7"S;QZ-MW]_#F3:%0
M]0:;XX#9%LFC.PM@8RS\)?3:,+9/O[!*=!H8HI6ZS597ZF\R4B:F-'1O97&,
MQJ+^/F=[;BAVQ(=/7S3;K,%7S(B#>C^Y7U#[FD5@T9#_M9'@3W^$)8KLS >E
MW#]<@OHI=(>/6E2[<(PBMZ6V>8O5TV[4+O_B9YS1&@NK)0KP=<$\POYF[=1)
M&W0)D!&U$9*9.V(7(717'!>)4%[?QM^29K'U'S9RZY72C9Y%"!XF@++O"M4R
M2DT^4R_PW"8R*3^(WH#/H-.]5-&6P0@A,!3MVU/2$%I7N-6"7[D<P>!BA3F!
M3^GQB=8!7V#+:0*#C?MU!UJ<7.\9MC@' *N)Y8A4L(-46J7AL+5$.,R'P 6U
M>^P?N[J2)@"LYC%%3)G(I&#)K=T)I67"4!F7&N'.!#Z&%1+FZ!#8W*;8Q;UJ
M]J5^Q++M /K*]#-R+X?./9GM:F+;%MG''%2<*82NWR'XNIK:8 EM)W L5[?4
M[6#7A*S7]#I:[KHLK!S&2&YL'0*?6XA<LE;?Z[(O\];+,,BP^\W$772/&207
MJ2T2F#%F'S J%2HI)MN0U2%Y;11>AO>\QZ!BF@NV=#%DK2/I'P.@JW!0G7)G
M(^08=.J O@@*%@ ^AO%Y9*QGNV5[LT"IPR#CZ><:LT!C[=VLU);*=3:\33-3
MZJ53&248U<WQM;5V<;S/57A;6C2\+]-Q5TJ4314+'$'-TU.Y3V7!U3KOL=JM
MK?"FLU*;"%BG=^QZ\B5T;7OEP=_S:<-2->2QA-@GQ\OVJ@UUQ9N<0NIVCB>A
MDA_3$4QID$J%/$:LU2V3K78)DBS<N[NZG3=+DMOC!5,UG]:;E!PX'!-I>MMT
M;0Z%(:VO8_=)K"S&^=:VR2#_&:C=LX1H.H@90H_815%0@NF.M+Q@Z#(-D@!G
MF O9N40Y*</]QJ31Z/JDQM$CM%U0_2MT6O0O967ATS@QZHD*,26X8QZ@=;4K
MW))A9N\U- +AE_YE=IVNL\4]OW.#>3B+@]1R#/9=+5F=Z2NVM:L9C)?Y;B]%
MO>6ND< $+Q EV0J#OI?;6R#R5]OH_S9)'IC>'QIIBD&O8M\R:<>5L6/,2K+/
MSN4/Y0X/PUM7ZQE-@XS8I/A)34TT[. E3V6$SXQJ9*,,$B!AF$.%:\2_R>Z3
MT@;8_0>PX93-#J@,R:B9'UNL28WBJVN-":>*#8$R>',[!^6CL2FQDD!6OZ!>
M.=+M2NP)Z?(]&HX"/D=66+P@LF#^/\1%LQ+6%_6300\LMDAG$L_?'\\?2CR_
M)1BF5 9&VAW#DL!%!Y7CANBAK$U*1/)I0$6))!QP1N%_K<$@?-48&HAOC8_)
MK:9% AL*FE.B\52PI#E3D/XF-[E5"J/@\2QJ>^T*"5TQTDY'[4WQ)EC^P^D-
M--"L8#>Z#&SB&E^YUFJKJSJTB^WB: 9M!>3#E5RZPM<KAZW92E[3URIM$P"?
M_Z.>WG+:O%;1* ,AR\ 9+X9Q$$SK&%EYV,8>8_&*2BVYF3@*2^^'?#>955J$
MOBN*(M1.R+XX*L<OX?+V)>FM[$$S#SBT>SM+M+E6ZHZVXAW8$LS+?$\Y1KF2
MOHC(@#F!%DET0[WGO A@LY,=_E#@W*E4EX50KC"CDT\M*V1FS+#&AF.WIJS.
MM!?0X#\V*)AWHV V,R6@4 BG(STE)D][8JB.,19S$V@][&8:W6F$?3A Z5'I
M@($M< .+CZXX%/H7] .E%:":?^9ZUV/:H9R)8R+)AY S)Z6OH6FORPLJS>8?
MBR(^DEJL? Y,@]2UY+00Q.X;'_3S'\![";BN_/MY]KR%K_?#C^^+]N9G/__Q
MO/,NZ0QZ0]R-ONOU89]71Y&J'V$1,:[OI5V!^"MRT/^A=E!3BNE?7;]O0C$]
MMJ$5&!<@AO]#F2)P2'N>T_%=WX=T4 I=G']J6P.4C6,K.V[4!@8U.I\?N0@N
MLPMIU<9\B\4(6C55"0U-"MKD)NK9_C7&:E8Z0-9*BQ'0@IC-4"I'I8$$"IBZ
M1UF!$3)0/X*W>L=3 ;_BK-<=P]>QY5V]#I]%<!;I</=Z)VU&V5E"5$=4R$43
M>BBY;,5CJTR4U6-[H7Z3W$I,JM+WJ=T5DI !EY5@^6/GTF)*P(M=OW?JMVU/
M,]U1="I11MTM><^HDVH>Y(W%XWN%P=+.LU?75V^>6ZE^-+J*T01.)01'H1J3
MPZS;F)K2Y \3"/\94D&OKM]<4>XD7VRR#O'.<P4?F(!Q>!9",79GG43,PU,\
M!B8&B]=E-B=;66.W'16X5P)BR,^!TM'E%_HZ&.S2-7K$%L,-Q,]T&/JY?BMK
M+MOU>[@LOH]Z*KTJ:D4&;52T/_S(HY II/3S!CH) J-IU&W.P1#:-F*HYL]O
M&]&BI?97LF:N]-]G>0)P,:!#Z=@EJ<"K!T$PW"O7L-&468W"?*\K*;"N:$4D
M-]EBAVU["JT*U1-64&WK/ C<0%FUB:X[9L3BNSD=)3=HKL+$"M'<</.4H4C4
M)(9QG-R!\:[/",;<8V#F9D,4&+]+?>],T%.P0&W61()7T!\5#<E(QGG#E7SX
M.L"!N@H_*<<LT3-B26@I)50)7 DG<K!M,59G"ZEZ?YK#1!4NVUV$(M]P9^ZG
M)E,$.YYN/0TA<62;#^H&_]BLPHXWQL7N.Q9M4F XCN)@LRIH9^%ZN/Y8IA4C
M/)D"I&R90(Y%ERS2A +D(U.KAPA61_-)89(=@+<434EY8&Q\RJREMQN@*%L%
MH,EXE_ZB?H0>H0X17YN[U^'[GKMG-;>O_$)A\NJ=_TR[COWG'9I(_S9 *.V#
MX<:' G*B^/]:B:ZX]EH3<N\/;$(T #+*_$ 613</0/QJDV5,TAM^6L?4#_3,
M[H91)E7XD:R$-<PAL^W,RGH]QZQJ1]DKLP^\^NQ"TR[G@+:F.RTLV?VK!S6U
M<;%_[OE%]&Q*;@WR9Y"1RYO L&Q8"ZZ3[-5+OTK4T>%B(6I+F"NP@&/^BP+"
M=2-TU*OK\U\:H:24B"["&1FS!%@]BGPDV# /!U5#+NZ$B"B"F<6P9&W99/+9
MX;L)3";FC\ "$.#1H5P[4U67W*(:"RZT[^AT0,1T6HH=4X:Y_]]PL/_U+[WQ
M2Z5CLCO(;S[[%P..\F*>4]2I&'P/>5ON_M.\)T4]D_W*U-G,'^PY!?7&]INK
MYT3"F:Q@Y0#HJ>!OF<QMD\"N4KVE9.P425S($#6\\UKE0-R(O"PL3;W5)5\
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M#("$=P)G-E:G)Z1BSNAC$#/_4W6OV'3_2EZO@I7:NF9/ELJ'+.V%\VQXHFM
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MPP?AZFIK55 &7"^GPUE8Z:]?K%3]?+!1YYA1!7"]#9E9"$)TAV+U'<J4P6G
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MU6OZ%,W$NCM0:@(]]T./5*97H,?S>IZXW0(]8E.U&MA&8CY4@<WO2;&[ )L
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M!])R)<:XP/FQ&+N#%81/SE?14MG@&!,'1CJQP/> MH!1O07NN\[$%XTF%KA
M]E'%=EVA)M=,I);9+=!=CU32O_D(>WO4%XXML;<%O(\CMC29A5D6<O-]&JZ#
M%"I0*CPMW^TTP\<BN41ZZXWPGNOTI'A0C'#!\2,;X59#3QUVUQCE$@N_%\"D
MX&(OHO>_>*SCMR8<071!=&%*;#RFG]80;=EL1P;\L3]P/"N._B7#';^U,]H<
MV&_9WJKJA"?:5,?0#"V3[!,X M_5C.3'J@X)0==KAW'/\8>296VJ7FB>;,0=
MD!D8)\9RZ1*MQ_*!Z_0&$O<2+!<L/ZK8A#']=/./I-]T#_;[CB=9;,%^P?[C
MBLUF"%"0_R[*4R!D_/U3- \1V@=GOU[[YYWWX2Q<YPK>SV^3591)^?L^0#]M
M VK+HH,:[8<CQ^]YG08$]5LFP'J-(.*3N/^))7N%[W419>LPS>YA;Y?@?HT.
M.6W\NF4[S9OP?#W7<2<#P4!1(:)"O@G)?E&*0?1*C5Z1,LE:U>&Y0V<P$.8@
M"39]4\&FEL%]M6\7VKL.*"T]%/"G29XGR_M$_EVHA -:?D\BL>:=?:TTO(G3
M<P\HPQ+Q?8E:$>E]GN+Y<KF):JKV/CR!>OH;$GSJGUMOS/<=^>K!])5?I&&,
M'L_+NVB>+_BA[&_I52Z^$DS58BC_:>]7ED%Z&ZUP\3R_;ML_N4;R'I*UCP,,
M1V69/6(W_/CW*8BT)&GKST6J+[ .;L.S:1H&'\Z"&_7]%T%\%VRSBF"45.Q5
M>$" +'K4M[SCZ4@-NJ.!]3,Z1O3#AYX;_R *V/)I5HL0!^LL?*'_\G(>9>LX
MV+Z(5BA*_-++\J/!4U0-#I D?5R\7]>E=V33B>_,'W?Q(XTWI<_ZW8&[_U.W
MZ^W][+ZK>I/NH'^$R_:Z0_\(EU4?#I_^LGVU7\:/N^Q#5F\P^W"; FJ=\4F>
M3^"_I]*>+D#\#_=KI",_ N@9O]L;GTZ'[QC=HWIUHDP?=5=KMF'GW68Y#=/'
MJ'41(@GQ'YLTRN;13%<NO([B1QI&(D%.T2D3?/,H$_P+)?8D%F0K1'H19K,T
M6L.>E/J8^H"#U/35AQ-&KM/SA9E&8M 2@Y:4X[<#]Z=MWVG9]AOVF.+ =R:6
MY*060TI9I)2ES9)]&ZPV-\$LWZ1A40<9*;\5&JZ,RC$_O@KBO&[_BEXQ>D4L
MY;) 1I/>0.: 5(0"5_EO&,3*:!/)M,]Y:)[8A/7@Z1!<&&S* AE[OB\,_(+@
M@N""X.U <.&MJ0IDU)\(]UAEG'&6!F$L0A'P%O!N$'CWA'BF(A#/'XTE.2W@
M+> MX-UT\)9>Q:I 1J/^0((G%6ZG8!7, Q&*H+>@=Y/06T($E2#O*]_U?6)Q
M<;WA4/C;=TCZ8J#I$R@7*!<H;Q242\5%I=#I/PCC ?Y9H+K7'[H26ZFR;G^*
M9HD(12!=(+U)D"Y1A/LAO<^&^K _E"),@72!=('TID.ZF)[5J2.^[_:\B:01
M*G&6112'(A.!;X'O)L&WC("K4 :X9X#@9R.WK\QQ"4&5I?,^7&^F,+),':K?
MDC24J+D N@!ZHP!=X@9U@-Y7@*YL<AGM+8 N@"Z WB9 %\@J"^3G2]\;N^/^
ML-\5T51$LTF3=1BL.LR"^?O-3323H(M ND!ZHR!=FCNKDS*\T6#@"Z +H N@
M"Z"W#M#[TO"YDP15-KK;&WK#7E>"Z#N9T)7$603#!<,;A>%2L+&#X7W/'?GC
MP<#MBL<B&"X8+AC>< R7YL9*\M/#<D2_-Q@.)+92ELU/:?!G)/PK@N&"X8W"
M< D7[,92_-%P.)!2S;)@SM763=5CB!TN&"X8WB@,ES[/W5B*[_8F(Q&,8+A@
MN&!X"S!<&COK8BF#_J#G7HMHRM..U9,&ZR25RA1!<4'Q1J&X! VJ[4!@B[O>
MP/?^(Z(1%!<4%Q1O/HI+4^<NR8K7\R4D7H7P9),O.N<WJ7H>$8V@N*!XDU!<
M*C J*.Z[ZB^C_D12OF7!7"^"2,9R"H0+A#<-PJ4.NA).(;:LP:#G"1-D%:X6
M41RMU^KGF4A&@%R O$% /CAMQR9<<N_.FD<?]1/L;,<3HGQ?H;S7\XN0BWI.
M$=_G*@(1WF?JBB<2W#$T1LLD^T7JI%@&42I&J4@+Z6Z8WA^YP\%H) P)E>G/
M"M4D1"]NP:EQ7!"\A.#20+J+X&>#D>>-)+I3ELP_ O7R(A,!< 'P)@&XI!)W
M.X_.W+'KN>*<"( +@ N -QS I4.R+) AT+>XHW'/=[M2[EB6S:_)ZK;S6_*4
M@/5-R$5@7&#\Q#!^VG!!RS(Q?>Q)FDS&[K#K2XKPR]6 B$ZRJY)=_<94BEB_
ME3$BWGC8&TAK6(69-U@%<\FLBD/P)'T8"L'7"LBC6>=R$:X46&]C O)7R7*=
M9%$>)2MQ"QZ/X8)6==-)>V<CU^V-/<FQEJ4C$TD%R@7*&PKETLVZR]/;\T=>
M3_P4X7@4)!<D;PV22U/K#I+WS@:>[PZEFDAJ9@3&!<;; .-#:;&IP+@'4S/&
MG@RODZG2 NL"ZRV%=:G;KBV(G(R\85>*1:4@4L#\VP#S:9+GR?(^F7X7<']
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MNLV3S4]I\&<4BU#$27@2SFI"<+'YZW%H)"W0.\D#7TG%'X]]Z=\HB^:-@J!
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M]R?*^BCKO[BLC]66O<+"EZ9._N3B_#26-O62F_":=02D1$,]"N\'%]Y1-@T
M*6?/3TZ>/ST].3V.>80!*J6*4CM*[2BU'UAJ/RS,^<!<X[.GIR^>7EP\/[[X
MW-[Q'^(FQGYH4<I_!2D?Y?K=@NHTIOC"%7G*'=">G)V_>. ^E@>F\X8-TJ+*
MB](\2O.O*LUCGJ^W(B^>GY[%"LW89"<*Z"B@'X. CC4L8_0G3^ =Y\]C[#O2
MGT1)'27UXY#4L0QSA/ $!/6S%Q?_.RY-9(>-DOKK2NHHJ"<$=30;>X+Z@H"
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M6+25B,RC/,W";4H)HN4(XP*2%\]F10G7F.S^,;,Q#./S#K3.B>!8 Z<.\,R
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M=X.\K%2(C[N! 9)?98MV,98_'<M_'F/Y!R+YQRY.ZYB;?-^*@/K<EYC-P0!
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M1TE Q -4F5AQJVVX01IC.02!1CK^O8<<>JFVXU]KOOO@I9<!>9#]PMK:XPQ
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M\&5)A42]+Z6.-ZXIUM9YROI97BF'4])1++W3%RVI-87KCW[90ZYQ<;@&)<-
M)+Y]5B"QW*J"*T*UMN1^.CYJ1%904C&H!\Z[&1@7?'"X@'A('KO@8'X)'Z2^
M,NY(-*@D?112C@V)Q!*/+LP3M8B3_%C[SAU!=($(@->@H3!J$SO6(N*RN5GE
MH@Y&SC.G>O1N2!39'VO7^GN,NY8@!YJ.&>D88'#UQK_?RQT8:8*%&[O._E$S
MRUMPOS&/3=SVM,,U6("J1U#O5MBU\SXOY]BI-16X99N-O%Z1$2N3"R3;7=9\
MZLUY,>4]Z?>X5-2>/,*'&J9 PS)C+GA,A.E%,>JNDE#(<-8)108%WG5+;E![
M2CLDI5F4P\RXO"R'W-!!R[,FEXRN=NQ!L>GR+S9PSLB43;U1TAF.+SFJ8[NF
MF"?1JL5D; RSG8IS;B--%HY&*[P\$ZR@U-XOW2<66\DW+Z7;:BMFHJD28:^)
M#HDBV$0TI/PZ-[F2B7Z(DI9_,E.)4?W)J/Z3&-4_$#$@Y65T.TKT'A=3UIL+
MZ1M%04$!SM$OB#S0Y<JL!5,%MX@E2;\:1A&AE$%41Q%1P,CC)L'H=M2MHF9H
M1(J7"V;?=TDC39^U\CC"NW*<H=>^AY+$C1$O(M1:%B'2#,E.GGQYX9!S0H<1
M+5FRKDF8*@0D,&MP6$)[4>"B.7^:VJ;*0*8L2N7+2!K"2^><<PY#]K[KDI.%
M2M:AIJMA7C%X60S;Z?.%X0_KG@W#!_%_:,R(1#OU!0G+D?WO78L0J2J><'6P
M63 N)VL-6:TY HX1\>P?YW89/EV6]8WUI8ZQ_&SBRR5O7YG-N#.D;:B'IV'1
M9#?<3CQL?N(8\Q2:W:,]&%:!R:DS.';7Z 6Q2CWZ&[R%/$+XH Z$X7NH;,*3
MWAL,<?,,Z72$9,\'\0.%M6CJC3/_G?Y6U(LR0(3%MDM&V.)QF.SZ%2Y;YMQ>
MO(]F,.AP:&P8C(NML+K+@,R\< UF.?E>9BF1&F];=$' F#I,*O6SQ>"T7@)Q
M9&B1"ZD.A]==9PTW[=LV-DT&]!2.I(=$C(-7*7.ZN%RN#L:SG&L4((B0/_X@
MC3/5/IH&;B][,XPAF\\3LD$%UHO4',50S=ZAFN%:Q5C-8XO5( ;^3Q*KV>.[
M7!J*!$3,A\$=D1H_ 4[\$+.&F--73L;HQ9.DWZ&$AUP\Z"L'?0I++)@S./[^
M42 JA3,QH,-4>1^'#IC*)[V ]*?>!91\\%5!Y.#B-PKG"=*]"),3M=794D)L
MD;I2@YEWC2BZHWV$ S3U6!9.3Z ]<&QYT7,];2*E<6WRUK=[G?>TU7%0P=N7
MWOPU-B")BSWG&ZXTY O.UHY7>K-E3[AU(5OCWBSC3<+VNG"4/RZ%-,S6>N)Z
M-P&IDY=B,S9K@EH('C$3\V.A1S%>EAU4TYM+_1N'KP4<Y A07^G?V';],".N
M! C!E5.655,HHNVM)MKN_18SLI_XYXB%MS)$I5AW"CUQE $23$UAXZFMV.1R
M!\&RB_'5YE\5U&GWNZ,GS[Z""W,+-.O95T*GC0TAC"T^.3L^I3BB8AEFNRG/
M@K@""6^"X6JJ#95R2<1TDDL+!AL[Q+T&B!55.5.#I1BOGHQ7/XWQZGBK/^^M
M;K<M.<&,CP_@\D,Y;Z^^@V[NQD2T"VT*2:0DW[S+,(ZG=YJ#4%OJ6N\"[*+!
M']8->;X8,\PY\EZX,*]B+&^7*?$,?88S1+:W!*LG:AU#W*"X@$'IJN].BT#*
MO"W(&O?% P9*)YUN??B$*93(<:*#<Q<-6J\3+OOGO<,>S\T7/S=[F8<^8D(1
M3A?R&8D^B)\S"(-ICXI HHD+C9Z=)#]<H$I#<>Z\-!F'B$;>J8(N'I<O?ES<
MWDD Y(K5$$4#N*Y2V_/V+_Z(N2G@WHJK8-'']PX^)J"XP&#;<;R4OD>>/S?+
MI; [@]X5(*Z,U[Y/4^BE*[EH0*+2UV8CW1GZ\R.B%.TO+$5,2I02@*R)PG6^
M;3ANAX#K>$:_FI,TH8%<?9)KC1*6)F$$@^KW=W) ;<?>Q9;9=QLN;' \ XL\
M6Q!7?-S?+[Z_1<7,A-+/L'?'D5"XG7:0X_Y\\?V9B$R@X :I.J=PY+KH.NQV
MOBRTA9[[SG51:PD4V:8BGX.@*=Q1RBA0(I":\3%M4S:W@4%) ]SJ7E$BHV$8
M#A\=QYJNP8I>N@Z#)%KKBK@(H@'9+J*3\^5/EMVL^YRR)O\'MQU/Y3 LA)#!
M'08Q6F@C.7-F+!QI'%$@50/!^]F_SJL&3  MBS)$.@HX32UL2($<+K.E*3F4
M6MS5O&[N$ZR.)^HSV@J4ZD5Z7E=W/T9[PH:EYA:&  J6((>;<O@2:33GY#7F
MZ"O/G1/HF H,&/+HCE-L:13E2)UT))N(?5'T[F&O PV#A$G[L*DOM0G#'BJY
M@2L.NQ41Y$.RE-D:&=M90O@N!71PEJ50B&%W"WX[# H_OS8MST;5&&JJV;K@
M"K_1A]]#F1(@\ CY)47#I09?+RQM"D)+T4?1K@<!G[U),G$-)B[Y<?+*A8%T
MWQ>W'!"7UOP"?!%[)/<>S;5ZAY0_+H];C69>7&-QACG_4E%YPH?.%^7]\C?^
M[T^4:(=COS"N:J]&GI)WU6Z_Q)]LW*"=3VJ0T;83(F]IE;SYZ57R#1Y"^!/<
M:-CW;[F,(B-\Y]TH%KIIVIG7JTYX;LLT2=RY"7XO02<D/?&?NY7>P'$<NB)O
M<M@I-JG7K% ..0Q<U@U_#$:CM>^](1%U%BN"*3-T;'0.5$9(I)5'0!PG/]8W
M,,8F-22NC( ?75O%GH54?C^\NNQ]T@J);QD!@#-:,G)\*$9KQ68@!1H1-\//
M6Y ;U%-;BI&1,)O7DE9L0I*)967-*FU<T]NL^]_:D5348[SLH1[*I6E9DY?Y
M=59U4[*<3 X?LQJ#/0:=1?J;V.8$BJ<6'W)^?%_PT3<2)(Z;^79"]F^48\#^
M=IS\X$TD456PPR0'?%,>NB/],RN8A35333:>K=$S%0?,NKTZBT*UHN='IW/F
M^+L%K/79CU/,<9_''/>C!-8'MIF'V9,8.$BGX[(=-0'W@XA)EVM2Z[;J7CT.
M-+IZOW,6/HHX;M9&,@@)<*C#J;@;!#_SE5F_#O-95OD%8$:."ICFS#B4D6HQ
MSKOFTJH&+)8K1=C"S,E@UNJI(NPOX7@[I')5:-ZE]T.A(GP4B#Y"]N(AL3)R
M ORZ!W7>-7,0^Y%4CLMX4)%@'YXI[:VD4F] N#S.KDJ#<0/!4B':''@'5G<1
MJ5'I^(.$*C\E7!I^UF#3$F1HI>@.0A#QTV":F 3!L"HY#?:#2R8(F(DD.[([
M#G G>2E1VZ,Z.@TVS70$]/!]?)HW&S40J=-/T2^>Y]275]J;5(;<>/\JC'ZG
M(OCY&O2[+'R:E/4\\RDM\@IU&29"[8=0D.0!WG]MLD6NQ4>&JP]OST%*T/&P
MS<0Y\/1<AH"(*OC;-981^K:8RBTW7A\S@DGR^5)+4 7N/E%;.M[S,3@P#2V4
MJ$[F6**D>="_D\ZDD'TQ] 3K3JBC#YJ]!<,5ZH$@/$[>4O0##'-J%8Z=4ON7
MUD4LE#-ML\(PUYLW;XAH=%-<UQT&;>'?P:M<T2Q69)E6VJZ(80'W%>NFS504
MAV,XY^?4A+)'\R719_ZP(W4C,9!U6,\*"SK@%E/R-'KD GG,\ M@H),P6$@P
MR(Y%R=+"ZD[ODKMO*#(9=1JOQU#E2 Q!"U<Y;X^] YIB<668W1ULQ,G3?OV9
M\RNXYHP*M(ZXM,5M5G"\@G-/@7C+U$#A24[S2(A!N&E[T2\=S1:^6 :G#5N;
ML.0LI;BV1W>Y'#NONIQN5; J7%A:42JDJI6O\V;7JXT3'RTT!K0UF^D;V4-F
MD_:C_3^"[?<\9@(,MN@+,V Y@^Z\K3+BWFNT39LY1M)(-2MWTCR=,!G!7[6(
M?>Y1C>B)SLWQ!\F1K9%C(X#]N(7+.ND[K<T=,+T'6^6_WVLOYE^?--MJR+KG
M2LAH&_KG1AL"Z@YS5;.T)R;1.'7DQ\P:ZX57_<M/QF</@!]P$U"_AGUBKG@,
MBZ\4>?4M-O@JF2:Z:HLP:^3CMPY^<L;@>[]/EZYJ_0]C%?3;S\T'O1=-ZRG>
M['V\L";O!6[DM'-(V5:17"$E0T7AK)(RYURRMS^GJV.!LIRNQW;;/-E UIC
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M)BI "AZKG+[^VM1MGQN!LXEN]IZ=/'R<#%3*^F"H;K%=^JMN@A"3HZ6O-XA
MV%8L, _RP+X<4S1,JXHKJ!&R'I60H>9@=Q+!RWFK6)J%$ 9:"H3LIAUTSI-H
MG28V-4Z8^<VUVH_#^!S=PFC_+?4?[E9@);K^0!=BY72,/4%(JH-^-@%]X+Q<
M<X'5DE,GEF=8.RH[]"C/I]@XP DG G-*?;P9<G[VUD2Z*+A;W*=X;$*6(-3X
MJQK$<5=RK=5572\P)R0)#%G1&:Y7_PH=$,0-BZT11ORSTTH'>;F,-O!<;UP
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M"#  *)FY^F^=WA,(4)3;,DD)-34=62*!][B.SWI6I*Z'Y.-P$2ZMG=[P636
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M];PKL5>+H/MV^-[T*>/F'1C"2:@M#JGE<]%IC[78(XD=C68)04HEG'P7"3J
M##2-OS#2I-",\N:8^&[;Q]QI.)>-6/S88LL)P;AI ]2X\"XX%'&!\]O*VVJY
MJAANB]/ <57MS/4?=[[0)PGR7,)&.@JG4?D+)2TN3*MR-_^@<EI)D]A5]404
MXXY\T?K0S,%P.E15C:OEQ%Z[G05DKZIBVB3178!="$ET%] K$"2#6<@JJL2^
ML'6Z$.N;!E&4<OS?7$/S1"I&+:C28L@5,6A;$'.+CNWF6J_IWY$X1$VJ$1[!
M$B-OB^^'LKU(0*BI2?T+J"D!I(C B;GM#'P$SN<XGBX8;);4$9-M(<YCPL96
MY)<;GW&GI]".18AYO1"$MQPS)C@UM3?JN6&FDMTL7#FR;,>C'9W .(]:4,BJ
M"4^_HCJ9K@(L(3INH(ZF*E0K5$%4/XYV;Q[M6!+*Q\A0N4,^'_SI+H[NY0OZ
MT>JW*4R-")L45B:,L,^VD7,1'EEN%D:52-0*E!QZ=U%]&VAC?U/MB_+G&VUS
M_+Z2':XE8@.%E,U:&MDLXI&M5Y:AK&#-90W;X/F2X'FO#9YOD<2U/<(G,P!J
M=*6)I<C%M2N_;;$U)5K0H;KPEI-0C8 XSY=(%0>M*'QEU E(7O$6%[ZG%02&
M@I.Y;@KXE;ZJP@/80H;%A)'39F"5X/'CS'R.Q6M(P3*7V=8$@6DITX!EHHRG
M$Y(U1?4/@ ]]2CC<PJ1R!C;4Z4\>*+KZ9H>:#M7C1J[Z&&#SR)A$/_@6X(SH
M,EA)M)JZ6BG%;9B9%2E[>#\ZGO&RK::GC0]ML@T56=18<["14[.3W:<*I.)L
MSX)[&N.95MDBMG=1BVN4KG&C,UI3.MIVNDI>9JZEI@ZL"R'6&>CT(?T8W=%"
MQJ3?3RT##7:Z-AWPB+/7>(@L=*Q"EQ$LK";!S@]INJ$+89)(>L)J#UC8D=2R
MFC60/(Q:.1NY[535Z^-1)^-XCO)D\T:[6E\0YW:]((%";C,.<JT&EUVVC#8&
MU[?ZH]0@:G658X4'RG\.H+,W J:JS:PR0MXDYQB^CYV%LI"V!>'[;FZ%MA8%
M1QY-*"R6B4)B1;)2AJ$F'K DCMP8(<A4C =^JP!SB[%^*S!C)]<49Q"U@ZV5
MU.+TW(^C2@AC3'4]#(,CC\>@X.1-578*)5-(NB%9AQ7AK1@$U?.L<Q'60$R]
M 2TQ!B/O]<K.!;%KIU?80Z%(<J0\E+J7280TE"X\U7<-HC0:X6Z)SXYW;0;Z
M/=?)H@<DT<#ADW*DN6E%;.!8=4,T"H)%%CC*33JL5@^2(@HL@37G,V2\65JL
MBE^VXBA,5GBUP2RN$"6(<8EU.'NF,L8-3S"*4:;3H,>:G[&Q6JU5#D^L'$X*
ME<'&/+E=S#2(LXKA6T$W:EAO?:V/JH2 QX^CX Z&[IDJ'1)(RU(#= *1JSQ/
ME/ &"_+"*:%@J6M#1<4>)8=:%0ZE$8)YL>4X&-94_">MUA$F9&70&&2 SR6$
M,:4+&%TE 6W!@C0,8>D[]?@*86OQ6;&Z1"YQ.HX$K&UE.:^B(<6))8O I3,6
MFYY<!\VC7E)EAM6!6I/$X)[DY/"H"UU)@BU+\RZD4ZN*>)EOK&2#DS'!8-J(
M!--BY/Y1;Q0'5IV2S:^+5J50(%YN7=+8!1#YM@H5!74*I33QB8'G],1?L( I
M'JXPP+=1,<SCJ7WNWZBBNYUU8N0W;)V6'LEUK(^_6>OSU-NU].55AX20@J#2
MTMED@/4*(T,6J6L17+&,5,(J6</,J;5Q$O(2^>D4).1R^IAI>]%R=,G]1+$L
M>[,JRVCF!V8U8#*;#?XK]Q>0F@9RY-@IX\]VO&LT>:T"-?[H-QB0%0I$(3&V
M ["A"JU:\2V3=/.7>0:55)V=EW'3OUPWQ^QMPVQB-0"/4R?E13H4+-U@.%9%
MY6ZN*DTEZ<P6G[N#59!B78%99K'JZ<-@ Y_;E-*2E%*_32EMB2TCMEIB;+48
MQ4X8%5-88YU,K_A&VLFH>,4J'J;:37/8)A9!)G6PA'4W' MD\,/#8""WR/:1
M($9LR"AX9I30Y!]E1,S@E&RVJ[6M$F,10UQ&99E!83Z[5=PU=JY"(9")_<+.
M]TO9PD)8GR53X8@F!A.K%:QFYVU!I5,808BL]#1M\M6- /-U31B6DR;40FJ6
MJ\)QBF)RB4QD.1ZRG#)S\OIT$WE8*;@S+">)NC6-$AU.=%LVP:$%$Z@!ED.@
M9H:/B3(SRV=JV#@^J:(,>KZP%]DL9WY"51ACQ=R5MQ1:6H>S1]J;LJOB)%EA
M&%P#P?Y;",L&7:3HB]3C#<[ (L&J?QV&1RBNR7@@U%:$Y%2AWPJ84W08DELK
MTF-K#\-@@NA%!6\0"I75%;=FT7"5+M=!-75#KPOT=+Q:&4#96#F!X8P(E^Q*
M'NSNR(3@=D4#(E,#:NP<3:;\*PX!UVRI(AJ;SO)IQEZR"3X(T3T&7BEM>!<D
M C'B_>MX_U3!8BY_I50/""GN%U$!)5:X5G0VB(*:N=6*05<$2#WS*(Z2D)9K
M5D12X.NS.8$/,%$$/7_<P 0%IV[98<!-(PD2E+'&SRS/&@9W61Q::50;]K)X
M)FMBT;H5ABJ7"7B**);4?4O=;5$]/7-CW3G '6T"FY@408/$&%4G[)MLT"L*
MC"?6J<YF)5XBE92OG%&A!E;E@2;>1.:L*8]9 JPN9@A@BCGVI$24IF=FR]SN
MMV:'T17 C2K.D&S,JE1V&\K8D7>Q]BL"7WH%5@0]A[6XM@HELRW+.76%.UB6
M)@FB:>QK7F-3VCYN9[8S3$,47*X2<6$(S6'!^N@M+QU+;I*S7$%"055"P.+O
M'!Y@C,8OR1G5E;4IE2C1=TTXLA2$(O>=1L$VB59*V$6'RMU4[2"!'SO7'?=
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MEY2?8.$5<_-QO@ N'Y/&$L*2ZL$H/HAA[;B<?;%"%U;$7H/Q%!WO4+Q!; +
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MJ@>=NWE0DUG4TJ3O9JG2>-@O"HX"XKZ)M1JSE6@U&Q^]5AFJ@1*SO%8YU:I
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M'@^]Z^P/59*MU8BI\U>^-SC[!3DQ.J2W9=;2]EC=5M"T=5<>9T.EP2TZ*.K
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M]%'R:',Z3E&2BB, +V#CF-QQR_ LK902/#T,8U9PF!>G_( L3NC=Y#.XE'F
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MT'INO?AVX&N (]CL$4%W0BV!O?F5)AS(XK7)!>,>]Z*ZR_U;5OK^1HGP1&Q
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M8"N$?Z1P-^6MI0MCX"WR3@LKZ)/)''Z_XA63)=*=:1IAC% 2ODL7) ==<('
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M.3F]_1K>F8>?%<?^)\E_4$L#!!0    ( %6NWEHA &_@)14  !V9   >
M8WEB:6XM:6YC96YT:79E8V]M<&5N<V%T:6\N:'1M[3UK4]M(MM_OK^B;U)V!
M*MMK&1L#R::*)<P4M3M)*F1W:SYMM:2VW1,]/-T2QOOK[SFGN_6P)4. !)%
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MXKA!,<\6J8+6]LQ&NUJWR4-G"C>Y5PX;,64]+.:?!9W+O'&T,] A$!E7P*G
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M[7>DL^@P!Q (\D5<(02^VU0G84A?*NN!!^;>PA[#[W3/7M*7XL=*&IC^+@X
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M'F6,2]=[32^F@R%@^TFV/2*-0+))"U\8+0B_C]/R8J0BLC(Q4# ]GQ'&*<"
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MD_/W'S^\_WAV_=J[NO[XV_GU;Q]?>^__^?KC/R]?_^M)BI1KQT$!V2!LRN^
MT&\>&1+9+"%VBV2>Q-0H70F4W'H(#U"&GVO;6@0WV$T)R"/"5YS*2$.WB>;%
M@G281H(LO;E$ UBE<_@P L'%.:H8:"_5J) XBV$K4M8I&,Q3E(T$FYK5,:H^
M]!.PA,"N3/GT:UIN&$]U\LMT5$8+M?32CDZV"323E;%+U4/H/*%0\0-G@FP!
M9:KT4$:=:D/.D,"&K$DS@E,L$B4SQ*7-XU#Z><A@PQ"9"PUB<P?>'\K5F40
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M@U_HY "F_1EV',4W/-?%(A^LWL +%S(&O82Z&U0VX9,(E$0@/F K*<)L5@)
MT-M;>-TTAJNH2<--S'-ZU+\QU%+ZO4_ Q]3TY..DLH U9K=Q0L4]\-\P./!#
M 6^#O4 BF9C:<FKMR%Q.)8]^/(UH3)-;OVJ %<#*4]P2*BEWX!.,TE2I'S/
M&I0J2A>*--L-TE#.,CJ"D84,,,&?Z HCQD,*?Z9!%<7F)G(*JXG2[92Q''?[
MA_>JIUKQS+)X\>)@2+5E+^$%J:Q;LQ.BV_$./_RUO\O W]<$T)Z2R'#JN4VR
MA. XA8(F=F!$5,IR@J$6"Q6& GU-+ *9+AG>%V*:FKJ,U>%>_3CA^!W8G!&.
M1$%5ZW;*,82OX0#V<V<]&H]O'ZOYEQ](8FO3N,6=1P )]OJA$:%L!^7F(L;J
M>NAHT53 R98=$P9DT<9;7G=>?(V8IT[^[/Q_7O5Z0\0$!: XJ(H(G.]4A;$/
M!&&081V^;E2Y#G$0^GGO.MZ[@P V)YLM0U!GBPPV+)*-..2+M]=-.&6]B8<=
M;S$#I8T;Q7L$]J9B'6.[$B/@3G#Q$J;TJ>#8;6-E$7N(YA$^UI.CD:#+@%:*
M#F)BS#RBQ.M>^]F;TQ=E+]M-5E1S%$4DOA+=*$6FN!*O_$,&8MPCW+$2)A&5
M/BLU&%A'.J0S.-*#(*]B8.W4#L>@FVPPV,JK0!)A&6!DA? 3;/:!27/-RV]4
MDKJ&IXO7T9=<27Q$S35D\$JTHGR$W28@S$(5=[WJ/<L76E\:W^L6=,D!5L]%
M'EF$RB]?S(?"(DZF6ICACG<\D 3,8;\N@<2F"#?P%>A89;@Q:(;$^O7JH@D2
M"XBC>HYKSP6+%,CN*&)'<-T<Q56(^.2 *T5L$A9L<OPA^AISW:1$)?5(Y8>6
M5^,X 9%KT018 H6A*L]L;-EE1X-8?X(V<K\'_XX70#?9\D7?Q.@/>]2280>B
M\9!-]HV'VC_<8/'W-UO\V\DFGMYCR5A! %*1!./: A&F.:>X5]<+N06OXV49
ML-K@6F*"2OE)KJS@-IW/V!NG>19F7H&*5MOAH?:7"TG-0E!A&'R56P/TF!7+
M7U7C"!LU5;I)#O>O EE.EB8.=<0#=I2<PJ)#$/38KURKZ_*N=#RWJQD)('Z<
M;5I&=RLZORH]5])L/0TH\26<?N 4>[D=E=@ IQ(MVC\^V95^EVR,\%#ICMDT
M>LT.D)[O@*^I9-)L@6O.TQOQ$MM:T$>L!6T3WM8Z.&X3W@^VE_]"KA0&X4[1
MTB+D2U'%CC61 M?V.F ![H9\.P:3!::N#;WHC$4U]<U/0,V*VHY;L3J1U$XU
M<FU<$9Y&4%3+Q1I\2Q&)DL\!J@IN/)V3U%CO?5S/I-L\DCA1OX,L![^LL\!*
MA#(ZQJ.C^R=+4]B'L\&\.;8JQ-AUR?EUMM?-#U&(*P9'.UU&Z!A\E9?\V,2#
MA%Z3BO\JM]8 GHLB;"Q]IGJOTYXWQ8PR$B U/=/=.6[(S>YY:&V0HG'Z=Z#G
M\%@HBB\LY;IT@Y$?=#"R =[6/H1EZKQ9EM0!.)+,;2\HP<K>Q1F5]%H@[EL6
M$[_8K- >;,F]:J/U@ +DHK7!?]B?:L*OFD(L)P!ITAY[V2836&0!;0N\>T:)
MR!5#89O(F?:$5C(3BB8H&/,,[<(LP;%""44L YJ=EAF@*@=PG$@Q=Q5>%QBE
MN@TJBS:A@DI9M,DK*%L#/4<OK*B"5M38P$PD-+_&0%O7\_8XMW16Q.]P$!Z?
MW5HJ,V$_HP_@3"68\C@:BGR)6U2MB# B):(M%%":L,$9A=/<W37=H>&G2!>D
M.IH07CO[<-D @?_<-L_0I00ZM^S4U=^5?782.3<*H[<SP?GGCOXW6&<W,L(
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ME^6!(HF:Q@DV@\ VL5WO?>2=@449>OU!W=P?-Z,M]5'@?NE%OE](^#UG3YL
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M&GQE%E8>DT(I-V>R:>WRG+&;/$V)%BB#2F]NS/=3C9%3Z05DBCG(4,V5EEI
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M3\%Y/[<FH99T%5H_-[1^C;2^UPY0Y<V9N1'U)#SL8133'-".%\3Y. 2JA9O
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MX+?71-3(UK9FE!$_/O; HK820.-HF'OH;^C"OWF<9J;N--#UBIFN%H5;$:J
M[DD/QLG?DSA4L8$AN">WXH6D$LLV.XRBI ?C_>,%.C/_9D"E>[GIJL%R8&$0
M(==LR':\8E^*UY[@.E?J2+D9T23.$W@_>/<<I 'WV]0W?W;Y3]JIYQWOZL.O
MO<$)?D+O>OFV],61^P5_CN\ ?ZL.K">/Y #^G_%(8*U6<L#&V]GUIJ=N''7
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MRRT#>*[B@#)H<@[ZFG@21Z@-*KR #'=,F?0B!]?=#XM]XD_(F=<-5!WP+J*
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M3;=)N*<O/]W/XW?/+4D@>/YT2W91,HM+W-7>+%;1*O?F409; R8!YGOFNJ;
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MHF%=H6&%?F<22L10-"R!J#L5VZ<M:EM+V^>H50)5-]"G1OV;$-S\$'(2?4K
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MS<U'(3Q]G>817O\LTWBC+_KY>30OEN;)[E5VMNI+U!2$6A;[+[ES N8@N$J
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M'[A%U8%M[RO*6@4F!28%)A^1J$,_'!P-0OA%W) W$-NO"B33 E1LWX*2$(I
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M406E.+VC=*A8H=&X9[P'?,ZBDOD&G52\5& )O(,]G%(]DSDLO9]3!5IO&T[
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M5;E2&;/?&RPFX#*L'920DU?JJ"VCV('2!(^&W-HIUZN.%ZS1)=K NHS1)._
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M@FVLYV;J*C-OU0^/,L> ,SNWV*S=8G+>$D\B>)+#NT1%W-9]U#A@*0NBLN?
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M'CK8JN)X-RV;Z1524?'\9A-24"_9TB/!'M&N(O%004]_[YER7ZOS.#<]%BP
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M9ID9KT314 :+8H0(8Q&W  (IW%L<;8E[0H,I]),KP35[P8T?2EBZ,J^8<SB
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M*$C5!O[;P'\;^&\#_X?^Z',+_+_Q4QZU/L5_X,C.&S_$L1;/+>#O>'V[Z[:
M0,<N\QUO8+OC-L:S!\7Z/=MS1BW%=J?8"..(+<3-/IF1D3T>NRW%=@<V0X*U
MX?U]+J7MM%)LKQR2UWM\!GMN!O77./-#ZW5*8_N>(2Z0VQ_9 Z>MFCEVZ>#V
M/;O?:PL9]J#8P+6]L=-2;'>*C7KVH-?6?>QA%79=N^MZ+<7V*"\:V\,677.?
MFH^A/7#;2[D[P7I]>_ $<O\')W7QPTYE6!>;V7_$T<6;59((6,'O@3\)PB +
M'FR"U]T4.Q8.?8@A7KOSSX..N7AFA]#2NJ5U2^N6UBVM#T[KWO9T14OFEJ5;
M6M_7C_E+YD]"H<K:Z;]X-1NXIT:A_L)/KH*(YH -BK3^URK-@OGZH>GJ.(JL
M],27 3@=P72[>^*-:;IT**;43QM%*W!4/D3S.%GX61!'&[O;9>=/N=4Z#J*-
M?;T6UCP.P_@6V,"B0[26B4C! Z-?P)_?Q NX1VOBM>&KU(*_KL(LM>*Y%?/H
ML3A*+1_^7T:51T 9^EYVG0AA+>(T@Z],X8'A&B[E8AD*).0\B/QH&@ MU\)/
M4DM$R(B6FLYNI=?Q*IQ9$P%?]F=6$,%WHW^MHBF^SKH-LFMZR7O]F,O,S\0"
M2YUH%8D(?7Q/%&= +?AH(K*X<_R'53Z-5'%F3M @9\Z'.!;XK3H5V\(NEG2U
M@)L+ZY[AXYE[TE]^[H]>[4_"[927NQ^Z0)YEG :XI9=TLL&->'4;S+)K*0G-
M;TE1U\V_XD] YJVR^J\8ZT.2B.1 )]SOE?J#C/^^UG6I2_]*7$S@7GR[\.>P
MV)=^>.NOT^*6%B!93?K5;5T*846TCK--$E?A6.]TUBQ9BBH)B!KZRU2\5/]X
M-0O29>BO7P81D8:^]*JX0%2,)75$+^0_RUV.QYU1;X@;E?$U^6))@P[1H*0G
M^6_>J#,>CVO_#.2I_=NVQSJCSF@P.*K'[D:$4RD'&-]I&-24I+_Q(W\6^)$U
M0R8&B0F:*@/=!6^9I;8EOD\%;"]O 411S/^:!U<KT*7UD<T]"L1S\AW8<AWO
M%.U]+W41ZAA6,2A7<BWC=MW^#F0YF=U;A:WWGM/6-P[>*^S^!Y,D.XX8;H3D
MV4JX+^)&1*L'2X4T?-CT;C21WN^CE":55_"0A4GMD/$?I?JA1XRW-'Y\&I^<
M9?F,A[CO1@.GY]E.;WAT\OQY5,_L1L'AR!YY;97IKN3J.W;_"9H<GI<L/<4Q
MOKOM_,QQ0(1ZM2 5K0C;):0#,JP[>N;H%3N2JC>T>X\[#;,=\-@B(SR 9'PF
M<Q!W(X;;M5W7A9OKM;;V$4O?D>V.A[;7 F#N3+&>/1J.[6'W\=M'GI=TW8"Y
M_'^VI+5.4J2>]3O]<6MV_X@M.>[TG-;HWHE0PT<%C'O&*&C/2VP_FRDAK5G\
MC.1C:Q:W9G$S!$IK%K=F<6L6MV9Q:Q8?E=@^>0S='<LQ'A%!M[6%GX:"+4[G
M?O1R!O; >WPXIN<E3T\50G''J,(C BBV8O1I*-C"M.U9UN;9H_'C0XX]"P2M
M?63L<\?/>A9](RUJQE-U-K24/GY*5Z.3J-??$Y=@KY[Y!Z/Z_B@1UK6?(@*&
MM?2!IK"!8":B66K%D4+V6, _9=8/(QZS6/ 7_ A(&BS]3%@S,0W]!%M3\(GY
M0P)^2(2MG/-5MDK$)KS&#]*YF8@PQ-SLSCP,AQPSLY'=X;-O!YR2"#\5,VNR
MME[T/+O7[5OS)%Y8KY=)$%JRO=G*8FYX9LF@&KZMA1]$X9H@2R3(#&+,^/JQ
M! )#L;G4!*9!8)@LH.98>/ RB:_@R\">"%&C\6DZ%EZ+_$DI7 F0&GX(+XSG
M<U@^KMF/X!WR(_#J92+HX@C9DM4!)Q;A5"H6;Q=6=.W/-KZL$6E@D7Q=K"G0
M$P67=1LGW_"%+YR!W>T[UMF?ER\<QW8&_?,'OU//#U.E7Z3%,6*J'%H&["X<
MB>1?<HBH3SE$U(]+N&-!D>GU.Y[K/CPNB]MQG?JO_L!C1\-'0)%Q.]U>[W$>
M.WP2<)K:=-G@A^;8LS3\44O]#7QMD@0_%C606&!1=KT!]54;,#B5S?^S"G[E
M<<%'3*=FE]3O3@WV1P3_LB.NSRGN>Q=0GU/<=WO>6VI'>O>I'7ETZ?+LGO.\
MTK'O_K_/[_ZX?'>Y!\K82<[TWOF,:CT5AV":#11CMS,P&X?W:B8>ZU[BIPO3
M*F=-H/US1_?R<>0C:TJ91O9X,&YJPJ?-'!LGY=BC7IMHWY6Q^SU[['2?"V/O
M*>,;:3#6%)BXMC=P'\3Y;+5<I9;[340BP51%-+/\V2*(@C1+*.8-U$VS<G3R
MI*2$X]KN\Y$2QW%2==,M[>ZH57^[,G:O#V*SL:65K?K;0_WU1Z-6_3V>^J,:
MCXL))>=QVH>(4AX0<L)J#V1I<UNYGZ<8K]%ZMCL8M]3:5>FY]NCY!#-.5^DY
MGCT:#1XM3=#,V.T3A'EWBO\?5\C^ZZ>OKW^W[@S<[P!%7Z;!<8@\S[/=87,[
M4?=EN$<>-]#T,ZYI5>W;SKC?$OK9P^RWA_PT./R/3NBVZ*')SWE>10^?OO[M
MW1?KPQ]O/GU\9YTI2VJ7V7NG91RWX;'*\-C[.($?(VM*S;/3M94E\+"00V17
M?A"=<)C,L=U^8VWKYQGXJ8F2V_WNXS?5'Q^U:J*_CCWLM6&R$PB3#=O$T.-I
MO@_8CB'2#!L?XX4X:3W7ZSG/11X<QT'5Z+E>"UBV*U./;'?4*KFC5W(#9_P8
M2DXYY_T*?5?2/@VA!NFD3]FU2&B$WPZICN.[LPW''WJ>XO7^$#;/DUXU>-_N
MJ,6J;@Y;/7@*_4BCOYP_+\2 GU\2W;4'S2V':[-^#Q,A'/6V%](UC<Z-)G)-
M,4K7[C:WFV(_T=W>HJK<>;]-G#<H47U?S(AF9,UG8_S/*18E_O'NJ_7[I\M+
MZ_VG+Q:85M;G=U\^?'K[ $##QR=(:KPA4!7]X?[SCPZEI$_N6&HF!;F.[?4&
M[;$T[+8XCF<[WK ]EX9=E^'([HZZS3N6^YA)A[$:3O4YSZN&\%<_#::4EC"&
M.L[CA*!_X3=!O,O W"8+@#K!W*G7EFU8MT"H8:WZ>IZ$NL=8T.=)J --_WR,
M$3I(D1/T=_6T=/^&IZ5'J\4$]$ \QXYZ'*20\B"%>)6EF1_A%JT+:X):8_=L
M0_4DC%.*G[I=>S0&D])K+'#' QS%HP183XDWZO%O>GV[-]A>Y]P>T $OK^NZ
M=J_QF<26-Y[\6$:V.Q[:WK#;U//9/@NJ6-T]*!+[L29LN#L5Q#W Z(R'7;:S
M:U>5E57)B5JS\JE6!@Y[EL\^D,[[QC  FDJ$@('HX*^KQ@7PZ)]'$84[[N3-
M>A+0U"+L7)M9D<@H0B%H^,H+3D#0'E[(\*J-LY668HK0A^':)C0H/^&Y1*5O
M<YR<O\U!P/*79RL:#(;T2?V%BH+HV6!+^"DARO'\)>/Y'#=I)',HWJ"3OQ7A
M39%-TD,>-YYTN)J)1A+.\JTHCBYH1A>R51R)J/+^/]F"C)E;:1T"&G$Z0H4Q
MHS.\TK9;\H+PJN2E(A"?^U^+8YZ8MY7T;W,2;)&<YM"T6Q^EPG2%!P3'H@:Y
MX5-PEMN-#U1;X1@UABOG#_B+U+9N [B</G\9OXH??RM6&4Z>@H=]3H,PG@+M
M7T=^&%]9G_F+UMF;?_[:[7KG=)+&Y]\"';+K=9@EZV4&M(E$Z2N]<YN^D_@!
M+<^_!=:(<.@<\)*Y)?P0+B:(9G 8R;IC2;*DJZD2)[8%RON:OT;KT1J'WY5/
MB5,;MJ[]&Z'I0SP)"YCQ4#PX2I%F</-HCB-&*R;QC>A8ER#0L.S4[3Y.X?D.
ML\*J&05G%G\1-R):"8M!>C.D$%#\7W"A#BILB5[.J\U+VL[9JYJS-RC2XOCG
M[)%U;C9X[F)</X46KKUBU>/XY P^N%5J&.6._H33F!W?[6=L,^D/*40JAH4V
MTGBSU;14@TU LP"/ 0%?')*"]>AO!R>:=48#;2\.2R"&3FLD@<[9\:M@+>G(
M5/H,9),?E*)UT,$')V@S.(X\H$;2YWP7GX^9,A$X<1J9LH(];T4B\K */FNU
M7,9)IHW^J;]$!6SG#LDO/WNC5]8,;-DP7BZ0C94E'V/&, P+?RNZ"IU=0WQ'
MII*W^'Y-53=;\!$/3M9FW'X&%VPD@8Y4W]1C>A^<HLU@N2)8=J,(=.H:YQBF
MS1<&&#[UJAXU9[<]R'34MD'KKO^0NV[<9<(3&+XR@N,-,ZEJYV\>G([%S,Y!
MB42C+YM)I.J$5E6:]\L&!\[KKSL6T"/]DX"2/G/+G]WXT528ZLK48#H#<FA[
MS>G97E,9NA'VVLAVN\VDS[EM+?UU$H-QI.PVS:J'9JN>/1HVDVK-X"K/]IR&
M.@&V%?J3C>FB<51@K@-S5Z^RXOK@M&L&;[G]QG(6<A6HOCE60\21'&([C:-T
M%9(+.1<-D%UG0S?O?6H4!9O!7P/WO+[:YZC]N-WJ>YKNH]2/4C\XH9OCHQ3G
ME#>+2 _AHQ K'ZU7XHWM?INXV*;C77LX;J:!W62W! O'>\VTCIK!5R/P2QK+
M5HWW2QQ[[#4T[M4([G+LKM=K)'W.C\,U<4?-)!^QEW=H]G(;:O6>FKOTU4C+
M!M$T$7Z*^5[3'SHD&[ VL,D4UAT)VQNA;"M(P>P6Z):PC2U;-KBKILKYV]+%
M ?8VG"MLS,RGXS-*YC<V5.B>B"P)_##-%_WXK1\=ZU=\4<W^8#NP#Y'YR7JS
M<<,V.SSX<38W<Z37\6UD<<T_]G9<(V^XX,?,1<9M)&(^AV=-D3@H6]..]7Z5
MX)R$19P(]6#;NKT.@*CP=6LB1&3!:R/<U_NWKZU?O[ZUZ2^PJBR@[?)[/&"U
MU2P0Z:X7;L>*@ 96PG.#"6NIUT5[Z$V< N\\?=*^0<1LL_:/KO&O# 8T#7*X
M],5"H,-:G*[=5*N@.;$PQ"H9-=1OV3T6]ML.#+E/!G]K$*-G]WI>[E1Y]FC@
M@(<J"]LL$(S?1%;\BFL/NV/S*V-G#%^9K-* .B[-0%SABX[=<[KY%UW0]O9N
MKHICNYZCO@D_C;P1?!6(=X.=E0EO#1Z1TA-XT?B A9@%?N$QCILOP+&]P0">
M$Z,B%W=YY/!QI]?+OSWJX?+I6R%\@]=[2.Z7RQPX^1K[GJJ^K;!R=Q%\6_C,
M2"\4Q7S)!%6OANMWNV&E/7BW]7%K\MJ\S1Y:JM<'MAX5A;+GVOW1Z)%D4'6$
M?IL$<0;V8&Q<)<>Q^R1#MHHJCGD:%]!V>Z/=KR](NO'(D#[VN-<ORY^V=5CG
MWH9%6AQ_Z_"QR((Z'=BSG;[F_A>8&AWMI'4]V^OVC5LS1I6WK^;T;'<T,'7^
M<.QL:C]E((P,B\(=.JB##JD8'T#_-=*FK-<6AZ0V:/\0+IX(U\H*\*,"W4N:
M(052SQB78Y,IY1_3 H8'W Y@N!65*5 KAM@'[^-#9"%P&3Y_B\*A&)!:]4SM
M1$?A_.G_K@*6Z?C&RP4RU^=K/UGX&PT?S]SPV3,>=$GM.K\2U=\8[3IM[\:)
M1(&VP;<U-TQ4!$9*Q!1A$6?U$%9:D!R2^@?%T6JFSD1G.%=&N:HJ)3@B>%N\
M9!U$$7O889JN^ /2.L/?*N\C@7_- F +4%]L2HG%,HS78O<0_I&(&R3@75Q/
MP&'ZCO#G8F:0N1\DUHT?@CY=,5*7]6L(>[(NI]=Q",O\&,]$V+$^X<-$,D7E
M#FP,ZIU/ 4FK#@:?)T /9Y2"$0EH[(D?8F(*?.$ -.\$Y>&-T0:J;(^.9>W5
MW7\*B$,TP?M#!.<EK+-W4CR='Y\]L84[>8$S9#SBQY>P$)'@ITA-P@<CZ]WW
MZ;4?70GK-Q]D5FM5/ .K0I8^-U(?%<P*W6H^E\Q*/T;3M06.:92R4V1= >."
M9YK$"]6SKMSW1*!DE;\ J2FE(<@^ 8Z6GZ9"2M P\"=!".X+>CHBI!!@Z9U!
M ZJ$P!KINVR-N(X][)5LEP:;&.I$0:>!<51#>2#Z&S_R9P$XR#/P0GVT(O[L
M7';RG]ZMDCCE=I-?$_A6"K<0MY:>%CK--L'] :.@(LVD[KH_SNK!&>-.F7H_
MN5;MF02*; &K?)F ZSE\GT:V.]KN"G@]>?4&SL8']P29OL/@-N-#B!6K5HX%
M0*DF@)KQ0C@Q2K+!*PB\0WUGR[5X?B'\T3,+X3]"@.PP]CJ2]?< /)L9^#8V
M* D.F'X1:;Q*IO).O,%[\#Z,;S>A0[>1XZ__AZ8MY/Q-XQVFJ'"6J7BI_O%J
M%J3+T%^_#"):&WWI59&&_>7&= <B*/]9,LEXW.D[/>03.=-*OEBR4(=8J#20
M@O_FCCJ]WKCVSW""M7_;]MA1ISNJ_V:SGCKL])AV#_K406?8&SP"!7I._TB>
M.@0*C!Z#KOW=>.".&6]W3@@=[#W0\]6&5FK2#*.ON464EHV<\M":"B(<U5[?
M4/AAAUV=QM'^L\IN?09GNN,5K]C> :8LUMHF-3,PRVXK&_[Q"MXR2S>&8U9L
M?^>I4@T9KU4W>BW/5CV'S?8>:[/-N]$OGL]6_^,YL7![7T^3B9_M?;UK7'3E
MGB<#_,^V;1]NU'.UR?&'R#CR1\.HP-S(X7I]#$M21+V6!S9&?]Y-CZ8-^*P9
MV^XZMN-X=?/(]SG]AY^O>GQ$KC%WW:X][ Z;1N0-]W VP?_43&P]7NKWNH-:
MTO\P#=HSN<^9N-OG"1_B5 Y A7K#^01$88V^<;J.[76[39.%QTKE&I$W&-GC
M[JAI1'XFPNT,(?7&;JMSFG4LO6&K=/;U_N[KX.D<\J&\O#/IYIUSG1MW!M4X
M>UPY4']!FLSJ=5K6[HYZ=0+H\41)DRE5YYHY_:>G4ZVL.4("C@;CO35=2]E=
M]%6W=S^%=>PZZ?AD2ZT4'@]J0P^M%,XI-;#'[O:00"LQ=I+%]FA4[_6UTOA'
M:.NX3T[9@TOB4_4.R">8!Y$?39^-3^!V[?'(>91NG-VH?R#YWN23JB:4,^XB
MBEJK#W]<9@_&H!'K@\VM1OPA:^/)';^#*\3C$S&URL 95XX5:95!L_C/[??L
M?G=[Z+H55SM%^KR>[3FM,G@<ZMXCWW7LRN!>E7-C%_]S3)5S'U1K[=E,\+_.
M&84MO;YW_4(%%9K&Y[4Q/=>I+R?:X\@?O7KA"&A<X_^ U3[VQMN#WP>B]'Y)
MXJ,]@C-GZ-A.OS8U]N-T:,_E?N?2=1IU)@=7PB<F$6NTSLBSNUORK*W:>9"P
MFVOWW>UAMU:\/;*/-NS;_?'^/EI[+H^L=GKU+2+/4NT<57?VG4DQ!=TF%+;A
M+)C/!:*XU>,,'$=0K4:?]FNC%6WL,2=3?WL!4AL8V\UBW[_[J*7L3I0=/SEE
M#ZYWCD^T5$O@L=VMGMK>YI^:Q7YGSN  NO*$Q-38=N^HY6C5P \Q:'_HU+=6
MGZH>.!W_@V H:685_@/A^&_\4-!HA(FX"B*"9\4IE 01>Y+*T/$&MCNN',[:
MJL-FW4)O9(_'VU-3K=3>12L.@>-;M?B(=4.].Q*HIZH9CT_2U)7HH:AQ6Z70
MI*.J*UBP!Y[7*H6'R,!Y_</(K6="8:<_>)YJ8;=B/37SI(#NAZL\E6*^+=X6
M#DK=Q\]Z,)(U[>K4.6E]N^LV5A\_) ,_?(W(Z3%)C=7-1MM1GM0=>?SG<H1G
M0\\>#^]=@M(>:T./U;MW,>M!CO3@!M,SD^>MTF^5?JOTGZUV:)7^21YKJ_3O
M$27Y"\WJ^^MNXP#5<G>>COCDTP-'O>&]I@=V.][@X6?G>:..,Q@^SF-WFW7X
MH[/C=JHR>,JI%TYW)UN.9\1]C"MFQ.T^^T/S=W]#,!P7-2K&JNT5+]VAZG]/
M(E6%2N$Q!Z+/C\T+&93YYA[TD"+S$"394!4.DN1S$H $#O3LY11G+^<TFL>)
M023Q?2FBE(:43\,5[A%'0 MB-8P_S\2-"./E FZ&_JQMI7X(;Q!R8GF<78O$
MNA(1/#2DW_BS11 %:<93OO47.SS,=H[#; N#[0NGA>T-L!21KRV*,\N?SW$N
M-7P2MP)+6.$*4RN]]A-A37S<&LZUAF\47FK#%I:)F ;\6UK=(H:C^C?]PK9"
MGE@M!TO;UBI*!!SAOYE4Q7Z+*S^(4@L(&,9IJK8?(0O2WVD^7A1'%^;LZI2/
M 5<.YR W'$?F9/<?N<@/HP?J+_4^D]>?BL-W&[!N3$Z_4T)8M\!*+WC(CC5+
M@AL169.UY=/AXF'3M:&9Y_P>'+/N=>W^<,Q,X.?G?A<#X7=Q1KO;=VUKZ0/-
M_1 N:SR?I_ R>"N^9@X65GR+B]3/#3*Q2'_YN3]Z59BD#@^\C9-O?#-X@#0N
M;F3W!YYM\?VXJ+@?^"'7[HX]><^W7!+Z[,#MW &[]^.<]N3LU#79:5TUPG0O
M!I)3,W;F(. VV_&&]O[L ZPZ[&G>4X@?=<PPMH=C9(;[<=M6%NJY]F@POD/*
M\B>'0$C6%40/8L 1?;8H@^DOPRIN:ZV=DK6S%3#_3BOY0>EQ>HJBBKATS_/K
M3?=Y!<] _@6V!1:&BQJ@Z^R#A9"EQ-Z8OV<3BBX]@O[O+DN?VUGM*H4?[73&
M@\$CR)XM'NDCG?"!1=1]P7OW\>4?EG(F\'%CK\=^HJSV$$HW!8V491)/A9B!
M8H[H34&:KM"!P6L!:A]>R98 :6YVN_1'IG&:28U.^,5[B[?VD/>1@8]SK.K\
M>J-AM6/"9MK27Z.TE,<][M8*RXT =2D(S2=:&X&N#V8_:*#[8<_95>=,3WR)
M%G@PW7[RWIBG.+O6ZZ\?K<])?)7XB]I][4FJ)V1QYRX6IXU^BJS7JRM8@C4B
ME@8?&+GR#?@5?K2V0*4#TP3I-; ^>+E^=@%_O8##_,:LC+2QSG[Y>>2Z>1+W
M<?>QH>>V'M@A:$KD<%Z= R7]S/+1EP/RF63-8KKW@@R>5(2AM5KB+_^\?(&E
M$^"RPF5^P]+@DJ5!P.+"<"/-!Y($RM#I7"7T>+:UX.BFMOPC[)#^ /]K6[?7
M 8@QE$[_NP(VG >P0) HMS[*%_!@X6C3I9AFJ]1*5\ME*,@@F_D9?&Z#7V)S
M*;AY9_@*(X'@<*+/O*!P(/PLPKGY8'[:WU<@TT"0UEX52=HA7N5EG ;HP+[D
M&-Z-D/DJMG7,;RE!DW_%GX"B6F7U7]G(/!SH2O;')0EN_/=UDL=TKL3%!$[\
MVX4_A\6^]$,XO;2XI06(7)-^=5O?2SI72+;FRC=@4<<Z0_YLAI!RK%_Q,ES2
M9?BL+T,3Q%7'^@IDJE\CB0O!<?\;0?$SWXB>N7TV@[DFGMJ/M6[IDZSP&G,0
MOV.V_) TMPZY^[<@>!O!< ]C+3;2\-R-$F\Q*1=,5I2!VM3Y*W YV ,IFS?6
MK0!_;^'/***"'D2F]##H@@5'4J8QW$/]:/R;^3[K]16XKJC7]<4OO:)PW5=1
M%H3E^WQ[#8Y- #;."HCKDU\'VAQ7 ,Y0QH$A?SH%CY%<G-L O.1\C5L7903!
M\4-T8RWD7/6U>D'%^U&F$6X#,Y8Q&$-7M"@@U,+_AL;7&E.G8B_*\\-OP)18
ML/D&!I7$6I@53O.NPYL)IA-3Z<UZ$D2Y[12'B":73A.A _@UI*P[TM<I[:^X
M+;U">.E=ZR,#=<86:AS"/S(V*A-QXP<A;EF[ 0$L2/Z9S$QY0CX8CL 25+@$
M9+;YDZEU@\EJRDC 0U1 ,$DQEA*OKGA;LU6B4Q7UQZ#.F!8X G]\.'9VOT-H
MG -1;T0"MI3<!CG1;F<PM,[ &'<&G='X')5<X:DV*[\KH#9RE'658 (E]^PQ
M;CFRAZCP\"&>/>Z-SSOU)FYSG<A[^,]D7/[^^4W.C$>X[YV=YX_@,7E=%H<E
MUYG29WAO0=[X!?[)H^"^%G>-,8W@Y#ZKY6T<X4'=:9)YOP<1O#BR/H/PL=Y(
M;_@]W'+;^OWW-XV(10 )FT"OCG6YFOP+-.(NED'UL1<Y&OY&/U,U+CX4(Q><
M\\:O!VE1QRHFMXW@1K<ZN!&##(8[X@TN"I%T/U,J@R,INK)(QDZW*2#A3Z])
M[>"K87D=5K$VY:JR#15K(TVR) Y3]12*Y'+B?,7)*#!N[K87J@DIW[Y)0FTK
M;?DR*ZHU;PW^'<44X,?"IZ6(_#!;=^B;^' 2*#,R>.#I(KI"U8:F VI)BLC@
MH9'!DEC78G9E!*PY]@,?_!:PO2$//]\GF15 J#28R;HITH3P<FVZ2!; /QD\
M4"(71Z0,UH)=X:',@@3-3?C@702U)4&EE3(8V"/'+;V%#QZKTGP*K0<9&Y9"
M( .9DKMCD3E10WY0[#>P8<F%_-X%?!N)S&$\H %%\38M+KF&N[;# 3F;#6IM
M6,Q8Y"'?<:%&Z=GXX8F(Q#R8RMS ;<2!/-HW'B(F5>=SL->H\O ,: $V^G05
MTM--U^%2$M[QSF;G2BK\V;GLX%]6":<SWJG*E]=3NA'.V.O91. %I4=8&'Q9
MP=5RO-F%AP])!&W^'#87K\!,@Y6OP@S9"Q=97C[9E7&"UP%LLW%G//X/M9AX
ME:69SZ&%$E>"(J8XHLS+>(H[_"B"RSNEZ"NQ&-P1,&=7X"A0-B>_T7<>$,[N
MB:-(4DF;W](A(F_H$Z(_X^J0S#/8%AX&$B"(SFF-ZL->E;W@AVE<6+"PYFQG
M;XG(%JQ;K]H=LH'D'.5=:V^J>H]2K*;^0BL+Y+(8/E2P9N*RW<.:&84L[/(/
MD.:+"2QK7+G-BB/!RDVLI;)W.!I#I)ZL7?EVE:B3*J<>N5TNSS^"+B@*!=-W
MNULKH9>853^YK/G)Q^IW[4%_5'RE7>=(@1?D=KPN.4'CCC.ZCR.%A8[L1O4&
M_?.-8$?=OAZ:-9Y=$F+0;9,0C^@?D[3>);_<Z/#E/:[9X?+;-5IW3X7;%#==
M\HY:X:5>81,\SYW,$A3A"5A_MV2D8E@QB%=I6*HY*!0<8&D@>"FZ[J A9U%W
MF0]Z! ]9>[!?=4''VB>MX?U@6F.C*D4RB1F,-\)LA1(&)1)D*-J@$C@0\&ZP
M3=X'V;^OL)%JAK_Q9QC(2Y9QDA?6;W[PEY^]T2OX7*=9'%J=*6@$LZH$E'=G
M NJ]F"0K'[C08>>CKW-0^.D],T];R++%A'PNR<GW>+$WE.=$*-=D9B3C0A^4
MZ'6!KN9)PAW>/#A3*)%SX8!OX=F>V]U97M2Z'B^<?J?7X_2+T^GV[Y7# 2^H
M[SG\D)'M@O_1D?'[4J$M-W;.E*BJEFHO<#3HF)XV<C$=M(>75T&JKM>S^\Y@
M=]%:2ZE>ISN2/MK(O5^R"Y8RX*W!Z3K]P=.D]IMMW_>?2_WHQLTN\BN+!D$]
MF?#.8['H*H_OL!9=S/;<KM8<<.+>YES'^E =YRQ39%NN<S^+[/'/W-W]S!ML
M(['E6G'9'LMX_5IQ[)CD@R.>B W##-\/6BP,0'U(,T!K2>)-3,7))%I>O&P6
M...GL5:D;/EOK $?=RF6&4>9G:$BQ"H*!:@FM8K]C<&Z\W_X>&+S#;\*1MO1
M].N73;\*DV;3HND/>_9P5$[A%>R9_HZFG]L9<=!YU!G?KWIG:'O]/CVB;SN#
MP>YV7[_"[NMWV1#U^CU\D'@J#;=GR\OE:I*"I$:1_.X&&XH:(/7JS<@VCK]C
M'-]IX_B/:.>_8]-&97[31U84M$ZC7<]MDMK(0^V]JD@[0E6$(B-'@(U-;&64
M"?.&V/U5V?P&B$&JQQAX([O?ZX-*#++4,*&(N,TBX+/MK"#&^1,/J!%<@Q92
M;ABA2^AVQBX91":GXX+))MJTA-"(LMU^=\,H+W?[[= PJ&MS<G.IKM.H8[W#
M\KV-108IB9$DH"+ N15'12^"\<_*O]1%:+=^DOC*Y3PDG\B;:N[O'[RV1C!.
M!?GE\O $Q'>13(.4?#5T]Z>@ Q-1<18;W-?ON-T-<WRCD6S0E8UD'*A0-C<6
M!^ER5O#F1*A*$+$T2R09@C%-@V2Z6F"9V!3KPFJ"&55B7I6,+?V \V7D>MPF
M08:M"3XW^E,589K*O@2TZ8=CV9PQ7248 4'T WR9'U9C,A@N UR9N:"'P8?G
M0J@+UQOT[V'W'D#;ZT(OYV@5OMY"(U6^8P_[/=L;#9JM](M$;++Z&W8<%D";
M2ZY1@"]ZCNUTN1N(J]<WB]#TPRH+,@I9H9I^-1*W%6MZ2'W7.$9IH,:K7.#]
M==X+=]B!RTMYL7''JRB M"8BNQ6"ZVFE&.W1J1J_&#^@ZJL6>/=0?@16*?=F
M]SVX%@^J!U]X'B<4W=YP2S;QF--G7=5!AHA"#A=+][:HT"2XP7#E,O2GS:E%
MPTWP#HAS#ZU!NR4-.K:=X=@>N\-27'E3-0PZ7J_:-JVJ#.BZ]GC,$6*GSVJA
M@X7(%25+4FE7$,DFA 1812C!5$JG+YLJ=JBCDQTJ7/1%)?QYSP;]#MM5)H+M
M+]G4*VO$\PX-$!)A*(&G1:F9>;*FKMT8W3O9/R1?L;:NXQ"^#2+G_2K!IQG;
MDKF9TK[F02@YNLIGO%-=4@L7@9#A9V5G ^<PR8< .Q..6*:;1O9P@/VWY;9@
MM?M8RT^$6J4L6> K-,,8A%]9V5><8ZVPK3SSDJ3UKPB\JUK&.F !NBQD1_8
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M3:?*E\"FXB!A&UJ*M^K,4+ 4> *V!%W*E2^L;2$$MAU?Q=1VI:$#Y"@7A&<
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M;+1:"AKRXF%CY>7194\Y\V"WK7^]%L]UZR7=A[:O^,XEVY1QP+Q4N12)BQ!
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M;>SY-/ <3N(2>[Q3B>Z\U@+%_*2>TCI5$V3^V!A"0L<B"&N#$%6J(A\%DH#
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MNJVTV%M:](<=[[!D.SUI\5Y,$DZ?]JKE1<^QN^"IN8\K+]*RP "[Y;][UEF
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M93(V;* %\AF+-,#6/F%-\*$Z?5F>-O&'+\L[/N LWA5YZGWWPNF.2<(YK]Z
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M,YP"-]10EOMX:G(MDGZ[#O9(VF[1"-PIZM<L ETOW"28+;(&89;]@><N%)=
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M*^:M1EME*Y_4*--K*U/7+GI_PW-?Y^WZ$74@BNZQXF@8,5)?-=55<6@US#.
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MV_WVE-M]9X/Y1+?,='4F6SZN56Q%^S M6?G"S\:WYQ@"SY7+3DLBP;30EAO
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M;6Z@J%96M2.B<DI%L 0KUJ+TQO1QP3OB-EF\V20'@*6]+K:L-MT7$2!RU!.
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M$Y,4<4;LZGUVD^\8,[R*G1T_.CYG;;.\UPT*-YK=/X/2)>I,>)2]"DXBLWV
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M= ^77!/_'7TA1"(P/&O)EOEG49*]M*\[YA[L&XK$)K>,QV/J-4FR1%O6&=I
MHA1MN;YPD@$&JS';/6[;LP"*6_70V/:(6X)LLI+EE2Q[9(4\O07RMUP2DUR*
ML'*/TH/Z-$/X8I6L-A+H82M=25O]B'MW,[=>=3AM5(@/0OBIR2ADZEA>%>U^
MU%(HP6CJSZHBIU-:'2'1<=)B_A^%Z8_\=P)J]@ 5]\"R!FV]7>;@;&Q5G=,M
M(]$YSJL]M^HQ;"7YJ])7K")(ET+NE5O^P7+D6R(F26!1-G!Y+QKTJAI"I= P
M5?'[(Z''>/M%.]13MD9KO<,TC->-ZL#J##.?@:B'PS(>6O)S+I1/-]3CS8_X
M:=1PD+"20 CDF*0T+</R Z6FHW8+;R6G<:U^#Y/8WN=S]XZ>R,_FP;Z,$WYN
MQ!?W>23N[(&,54=7$WU?)P+(*^N8K$5;C-)ALK4X4>];="Z(^:5&DK "I('[
M*F]ELYY2>9EW_N+ITS,_M9'3)&]=.<".2B3]1^[Y7!X!3; 1)(Y P.#>\2:Q
M6G(@;6B]>PG)"[?4QX8$SW@MP%(]>9VSE<6D#P-2LYC69!,!=AQ\8-VL!LO&
M9FQK>H!9,^E"K@IW\-QEOL,'R=!O6?Z#F6=YE.;:F*6EKV2FJ=35S(^YHRAU
MD#B$K^[(+>-]A-?J0!H91,#2+XK#@T[D?K\3,JT>VKVNZ3^2$\TZ5\>RS9]#
M$$-PFL01;\6=J-\9]YQ?A')VXLD=T4E8'9LR'*EF_4L6,BXD[WX0C);J9>"
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MEE)DRW"]9JJA(3"-26KINDB:?N.CW^ $"O/IG?F7:*5NBFLRE@(C5X,4C83
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M053S=FW2%I&7(BK>*U_0"&HVNKWYH'&BW&T.:3'>?CV 6Y=CCI*RWE0#Y3,
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MXD%\2"/>6IP?YF*)'C?.!/D$RKVBX&"4>=5S+JWAHYI(_)PVF$@>7I/:I0+
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MB6IVT>JRX:/XAJPCN5?Q&%[>WX B#R-_-VM?,(P1I.%W:24([$K>HG+N0M:
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M%?"J](25H++"#27*%O8V@K^@D!):RK!]80)^T2/5S2'>Q'&XOL?9P;8"1-O
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MIF<3ID%V@TAMZ?K2W>(-PAUNTEBN>%=3DV),4H?3>RTO_,TG%MHWZ+/<)7R
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MOCA=7]QY)3B[RB<V-YUK?FFG7W:S7;43NF6UG\P[GH$Z ZMR#.\PC+4RT0S
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M JQ65!*8^[T"QXA@AEV/RL63.2"'Q_&D2'?_-8=)LXX%,$@>&P2J4<#/T=:
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M4JE\0#<KS@Z!HU\TA\ H'ONLE?Q4_4T[4;*PX?PR(\>!>' Y2DS]&X[SBC@
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M B(E%JP.Z.^6V&Q'] ZN4X^<*M_,F0+3C(/F,($KG7F:T7]0LF9JN195%#-
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MPP$'"AZ!_A-X:IJIVBL_+7X=%L7R/'[U4%XOVT$AT B<CCF5."0K&?/AO=L
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MJ8]'"'I=1-21_41;Q3U.</UVVJ[M?M.J:V&#WL"22:W&=7?3)+,>OC4#G,X
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MZ11ZJ2J%SI.>8L:)9JD?!R:\:C?W#E96^Q00Y#B](FZ2D&$&YJ%@"T@\<O*
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MW0N21B5@CW+/&VB:*SWYDS\P6'A)<5;B-1^!J1Q[M,DKDQXR6Z\5/8)BDWY
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M'8]>!*R+DKNT2TDW-?0X33I.CL+9I7(6J<:+.R#T8\ V^&TP%AAU?0!9$,+
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MLUYE-R(5(V3;%=5H)$NN#J4 &L:5!YP'D2K\9[LV%4:=#= #A=4_[B\*K,U
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MW?W-']=XIZ^_?G3^^\?'W^.;FX4/V5D]L#%ALFU$QFL3,MYQ*Z$,+L1%&*G
MQ/+R-FF\1+I7$!1,!'>,+=H8C[+D_ DDDAC3H+;.QK*^5&_6QV$SM-#)3;&L
M>Z',%1UDTDZ7U.41O&O^':H(1R]33;P%&-,J.]=L9,KNFY%LX,DU-#$X4R1T
M(,[[%?=3Q</B1YD'E:1F[X5P%[%.@LL8XF@>6VNLQM,RR+Y-!B'X)!$^N53;
M()T Z,Q=?;/0CI:GG0KCQY"=&NRJK.6@6@^N*L+"-)6!GLX#2$\RW\89MSSI
M)#K5<4HI\13Q2SE55+Z50;X]!8 M<UR9M")V.^E-I?6GU#FEYQ0OZ]&+@(V1
M#PS))/1P:273:'$.K@Z"& =F96]:W9/#UIF,.:$'2H[#2?5\.7 J8H2NB"1-
MUXT"GR'88P3XOA?V9V.NFSF+IL/_K9A*23\X$W\ANY>1%J/I@B"KX@=+FHHO
MO,&I3EAI$$8C&/<;+/MUND7(F&9'%3]4;;X]7??)6K'>BZMKV=Q,XH:@+.9Z
MA8= @I("RSR'EA WZ-LCGA!(_U#LL.6<?'<R"8-)Z.D]"93C:/'NE71I[Z7K
M"RCW)9;S4G+\3 FT##*B9'6Q=Q9=C'\*5:-]'B<%O,)[(G$ZY2BAVD"*WR#L
M,!>B)/@:.F_3FQT@ WH*1D_,LN(>$ZS)1&+);M\_)H"XJ-/]3$MHC,N&<:4,
M?*H2^30%2DDNU*,&W',A*>20EY/^YJ<Q-N)R6:K6'%U#==P#8SM^](V+J]^P
MV@@O,:B</=E$/9^ \5JOP+73,ZR/>^AJF T8K2"5*%$(J84#L1^X%KTI53Q3
M)"B@@BA,1(.'Q@$J3_(5DB!Q<%9#)9ZSUH8=1Y1598SGR@HV(](;\$/CY /M
M05G)I=(98MLDD>NZ48/=18&QZG8-W,,9]1[&& U>=\3?I+N>#Q#)0(&GX40,
MN8Y3[40\/>R1XDYSTV7XB'O#IVHE"JPZ%"E98=AU_5W2-,&;!,J61*Q@.ZXO
MQ4;.H./%9@T"GK07YB>H;6GL(>(TP:1[LSQU@^[%77Y4Z2I%OV6W]2B)K<K<
M'JR;C:E$,CWLQ!U/ *W#9';<MM-5_#!B&9F!UCA9U6WAE?] ^L6#(-AA_4+I
M)9;4^#S2#_PR"VK.27L2PAUT%1T3(#VP"G"'?%%<(\\I.X434TE>YE:VG"J(
M<=QD[EIKB\2',(CM$UR:]A,M(S?'FV1>K<IB77..<4$F<A*M S#I;BM.V*->
M.4#^%-XF)4XE\<"HF.U6;SM)G7E)G^.73.MR[:MKX@4EFF6BD)82Q&7J/(YI
M*'3O$-(B!B'L"?QH$4[ATOBDC4>^/![9M,6?-K)H(XLVLF@CB\< 34PA)U,@
MJG[T@2@L19-FQ$B">'!RH/2^*IN"$$/!]BAEL"<D\E1*(2>=1[96*Q@^;O.%
M^@<J/8'/%5'4"2QMSL2_1;PI5RHO6HD/Y7>F%-;>_%(W6,#T\**R\QE-6>P,
MJGTG.UW^4@EV!G.S9' -:\TH'L5(,P_EYH%*%9 ;D"TUZ<@C6TTY9HIV)K_Q
M<2^@?%^AE(T7;T]LYN5Z86 [-\3\.%<#2"7\:OX #++U]&:G!8:Z0\XU/LBA
MI[H)!@QB-A):%)=&EIX*3MU4L#8Q_@NV;^+74TQ1<DLM1$<YI$9K2?8#D=..
MVY!0BT[5>5:B^B66A<Q#9<> WA,G:> X?4SWT#+N@4S/I?^6ZQ:I[HI<KS*D
MF"BE@^N1,3:5"-"*R5&_Z!GOAT*D*3M_#Y[%$[6&,<]]$(A(IEMB;YRX$+)X
M&7OQ<!XA^6MN$@5@&M#.8?(X'RQ6%WF*ELT$R+V'4J:R;N]JFTU&L\EO9_HQ
M&>!Z1R/B;W#EGKP!AOXW<F?I'=I4$4&Z>=3I^X+,SNV[?.O&,X92* X6ZUWM
MDTP5<B_&$F/M!ELA<FB\27JKUR1E1U5*L&HB<\BQ'VJZ<3ASQ*0WM_J6BVVI
M'D;KXE6*(=DNDY[=5"8SG85^T@!=Z^\M?Z$UR$K:KZ8:5LG6CF=ZE6[&P-A"
M5:N">EVVH.C4]Z4@R)KLBP2QC/O$Q1!\\9W3_:44*7T0/LD-^!'VV9/2/7(\
MF22"^,HD"LA0U+IHXOBR>RG6LF*%3W*[1RS,(@Z<HK,JB&19%/Z2?P2Z$ZAD
MK"PM?S8.^+(,BT5.TO\:= Z7M9&>)QL]N,@?=&ATZI$WF/6E!NJ&XZ03LO ?
MIH\E;H#JP0&YH1* V,*]AZ"X])ZQ&_X44[[N$4]7[\6:F;H,!4\5 C>O5]^!
MXJ51,954 )*XMJK^W&ZSWM4NX<</GW?[6C.-QX6RQ-QY"S5H2NJN 2,_"4VK
M1H#D/N*WJA"F#S?5F<+5X#PZ*E9DQ4QE-J%AB-BPG""))//$BD[<PUPK&U-E
M2R"ZN'Z:#-$PE7PE4P82]&8Y% %"ZK6=>IVY3BVQ\O[A]Q\R*C"5K<CO29%D
M\US/;E5SC D;'HU2=)7DN,2_^5-E./.X^9N/ T2(($V*G3)0)'FR#"/[2FTV
M$(J2Q,"0Q&B4D[1:OL8EV#9\D%(Z/H3!,^;2I(:%XPO=22 ORF06PNT2!9F-
ME 8'\E\\N9RWJTQR+5G1@^OJ/WB]D4K=P:P(4LSII<,9%IH^B90?)EV&5G:<
MSZET1LZ7[;MXJ^49QKDLL]A9Q_FLDF>CBT,\4UX21[<9T(:<(VQ6DH ;P'%$
M(I/-QT#%4>;@3]_N*E 0&-B<(N*GO@/+N_FB1DV-E;@QJ]P9'1LW'_8DDDUJ
MV;7'1BX"\\8^ EF,K"5':;^5ZCL0Z0B=)_3YD)IES["%VM ;Q<E5?71,ZTP/
MGV=565VU^!*[L^EC$,I*<59#* T[%6E6!JW6/GBEY-:R<QWG:(WF<;IMC-21
M4%:21"82!]14YYFQE: G:2AV'C/A->*W9Q9U;=FHJXVZVJBKC;K:J.N11%T-
M_6#ATZ- P%VH#[D*0$)YC?14;5 5E)JNN?*D58(2>R#044"Z>T^@-<DA(>[H
MZKC4@VBJ/:#I3#+=-'EW;'[-)JK9"-ER4K7*)+HGR>:F8<W:G*9:9 8:C2XI
M4!-WV.QA&4/H10.OS_$#FJSLI"4A51(P#NUUH5;-=ID+Y6$3,/2P8NPW"U(&
M[PBD^3<E/8U"5*F:)F6O1TZJX%"JFM+4*:7*\E(=7PI"<8>P!/:G-E5K4NV/
M#=:AD+[OK#8Z"G"*W'Z"=-%W9U"!\D=2SI-0VS2S7Z;-2<6TXA@H.X:2@DT5
M( M%ML](XI;D!'S%$E1F=;I.1-%P'/F@\-T8K]"_-0A! =('#)<D/$B7-'9+
M1.EH2>+!X'=GZU'1[\"W=R303\8W?Y2 ZQ"N$]ZL8;J*4SHJ,KV2IJ+_Z%,)
M*4?KQR(D(RM JT-$?2XII1"B:L:DT'S''D.UT3;=<(>E((J\N,,2OU%!-6&Q
M#Q>:4GR>W2VZVRW]\X)-*7*7Y4E!=5PCEFQJU;>'S-LCO%L+%(9&VA=1</6>
M5.6"X/[.7) B/658<2?CU,MN0N*%R)\=N=$9]PU^W5=)2O<)L6KDR;:^\@KR
M)8W_X/'8PZ<1&R:!,,B4%M(3$4?3LTME_&L*!*9C,RKEFY*0D&&@1L*:8/;R
MJO!CAI3S2T_=<IF]Q<)=;L+U<@:C\EX";J86I[[P$#);379;4\62^VQA/U@9
M$*I9K5]H3^T-C(3,?$3/?@D4B:J1^Z"5R!GA1SH&3;V3AQ^Y_O _/V[N;NYO
M;K\N!1=9'R^D8\0+Z2S&"ZF7F\? U&Y]YQ9$"V8+U.IDI<(_/\Q[6'(J,[$&
MN6PGN'YW8VQ4]@W,N[$;QSF?'\%\FU\&SQ*K&+B"ATB$J1]_F<(5?X-#'C"N
MI^4L'32^Q^6+5/$G[\OG4%9(8GB:;@LG<UQD;E 3:&X S NV-OJOBZ:Z3_UY
MSW_W'>GS=@BW9QSXE)(3W=!+[H-/P'#GM[Z@3V^'=_$AW<ZF!/4(%'KA<.8=
MW,Y?TW?P^LM!0+CK^+(+!VX6[E$EN87=BRMT\+7J#76[U"JN')Z$P[/@N!9.
M@?+I^OQ=G)Z;HI,@F5!):V5,]5Z<3PM/%&X:C1DMWK1&G@E]I;W&ECIQ1:9L
MH ,"26XB?(#N=A"2ZVY4HW)Q52L!"<#_[RS;*A:0"NLW2&^.WEH9!%M&,X6[
M=:TG(Z<>[8'5B7VJ"V\K>G>0 90=8 X?15]0+E&UQ=PA%19FQ5-F'N.HV4.D
MRX[MK(FC_/B__,&*TG$)BUQ+@SP2=GN#;-7WN4P_"4*E3@NW;T81=%1$5%Y4
M9F,)1D#^!IF(I 4)+R"1F<4OM$G8Z>.%\5AQ&CF%BD;DCLM1#5#5""-&0?]G
MX21"4#(Y#7WFJW>1@945*3RM/H:H1B,YXU0*'(S\E\*[W'<'WT1(UV+QA:ZG
MN."/9$YWN(Q;7L6-GS"]#]H</@?A!YX@_;GVW:XR$ZSF[S4Y0K6-=)ZINM6+
M\U'Y8[%ZUN@)WHSKR$@X*8)+RCM<\JJASVT8C+P@Q@<?+!0*_-C_\KP7D]+-
MU\\I8E*"X9K,@6\TT&<<QT,IDZ<&T/VJ[3PIN&Q-R/D/Y0#," JGK74OV&S2
MW[C&@&>MM8DSSAS,AF[-1,2<8Z9-AJW9);N]V8Q_Y]1/GK%QFF!RUROY:<J<
M4;G#F,L=8H$Q:J>3:-Y_% ,!TZ>)8TJE_EE,36=\"W4O1K;=449 $!<KR.5G
M##.L*B^_R [\**:N!P+C)JD%N<92D%7MPT8S;Y@UFGG[\#X',6#" 2$()*U2
M1 ,R7%(Q4-*SPE1J5JFP$K_N7#HQ3(R^1JJ\0K![T-R"9_1H+S)FUW#5O8R4
MSRQAHVT3-FS"ADW8L D;-F'C*!(VV--:\"V+>X,2L*EW=K^<N-LN5ZO-=1EQ
MO5-NM3H+&?&J0U4;Y4K'_,@AA^J4:Y765H;JEANMQHMDEMO_^1 BF5_*NSZD
M_ZTKK$ B[4^=J62\X,[=; SD.8_O(][$#==;P=7*#7W5SV]Z\)(KH(JAJ3!X
MAD=$$CD#L)(4\*8*K%]"$H7Z',Y^^39M>I+',O)V"*7B'"VY_"5+'%M:L;Y2
M4@D/O]1%[NG%3J[+>M[+H;%>3#KZ['KA/S QXG9XC[&MU 6\3^ .5_-*UQ,'
M2.OBJEDO-3IYMS1KNKLY/_QJ]7,LXK2M$^&T9N'[.0W],P/CPXU$F/9#;8'W
M6B:XZY,\229H7NKK9(+M0B:XY^2/"B=_'!_CS7ARJ^S&>*4,QX[\8@OFZ*7G
M->?*RMR!;U)Z8DOBOK V['G;L!_<Z/$4%">KDEF[=#]V*>5>X+7YSM ?D1A<
M1YCL$NMG'T$_6UOOZEQ<M4NM>CZ;Y!A5H-<L(POXH&IGET8+.Q&IN,[QG!*G
M.@=^E)B(DH:YN<02[I1G0%TP_*KY++'-V(]E,J;C_BJFA%,]P90HRV..\HPL
MCUG(8[Z%P016-/\V<H'3^(-/BIS7Y3?-RL55/9_U:]G-]DX>:W%&6#Z+=9T3
M>7"6[1SE65FVLY#MW&C0XS=Q%?9*FLYZ=AA,Y:K6+=7K7<N:=D@=W_&_T1N)
M\ QD<UF^=)0'9?E2D0N(2/AV^"-B-K2V_E.[N&I4M^7NL5S&=-9?!,8YXLZ/
MEL4<Y2F='(MYLS4>0P2L]1%=F\G4D<DT<TSFK>4O6^$O^>HURV..\J0LCUEL
M7WU6N->K,YLU[:K&Q56KU.JT+"_:#4'\+BME=Y:!;KF3Y4Z'<?XHTMXN0VI>
M7-5JI5;S>$VPU7.Z-ZT9.8(;84Y9HYQ6!?(H$]=4VC=W5WJ]E3;;>.T>Z.(H
M^.5VD\A?M!TGGV&N^]C9LWXMH3HTI?":S9RUN6UQ;<VK2RM_(;/=0#!D"KS7
MA"IYG1 [5,A]C6'+H8BTALT(6D-P.L)_<!]R;;<(RDWBX<:=H U]TU+8; K
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M,MTVR-=\BJ--$MO*@2[/--C^@7;V>J GP+-M_M,J"GVAZ;NSC(HN!@JM]GA
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M/3@.9C#DLQN!CC 5X1AF-G!Z;@3_E(PG%"-/#)UA&(R=,)B[H^G<&8OI8S!
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M=5ER8""%$.(?Q2046"()8ZZ@)-<0\\, AFO-->M0V#J5OM"S4*O9IES6GWQ
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M2HYA/XH(SIV?GJ]*O]-<JXS5YND^6'@OX.4QE)=4W_ K37\S1D0UZ0NK0NV
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M!(_G/78$Q,']TMY@A*Q6>S5K2[TM>>;,IPV(+$K8)@D.0$K6_/HWLPH@0:)
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M'\8HX"\@W[M8O-_RP'2VCY*!X;^^E0V%_:543O5,+!5.7G":HWVB9MA%ZRU
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M-16E(!PR"Y4ZG.^ZX<(AJVDXA+$E4ZR>:N"0W1H<NJC8DBW@$!B;TT1LR77
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M+=U28"NW^ZJ@I><*N@% 92&)2O2BJ@I1M49+MVB(:CU&Z%P1U>]>.'R55$7
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MT5SHBVXE3Z]$N@FF<,</*23#X&4&/QXQ^5_10YTT9Z<ZJE4R \G3+17^8A&
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MYP0B!:N^WA!H6=MV<9B"[.H-4WPO2H>[O%,E.L11##*=NBC\T\'0*0S&)(I
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MM!P.212!J.@8CPFA$H>OQ;>0P-0P6#$CT>8+OGH1O3/U@_B:0VQQ.J&?)48
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M;>,2_B]K KB9^V-G_*P 2AL]@YD8S^/GH:9IMN>IS_K8<L;D?PQL,GQH@PZ
M ;#/?;K*;TJBC<RQJ]:PUZE6GRV&[#^/Z4[!VLX\>7]R.TXX!J>I@&-D.TZ
MKWSX_59ZNOY_4K8MPE8C#2X"8Q?EW4OK%6R_0:.6Z7?[AF!MZ$]\>JN'<<R9
M!KU^#8.QO_A].5GX\XE/1K]\7,_A#T,T<I %9@:C)_H?<)]?)L'P>THFYOFU
MV_C=^U^<TK0@TXC.N4AFXFSW7(Y;)2V\/UGO)3K= G!OR+IDT9\DC@W]TA+-
MB7T5NW>M)_)-/B3-ZIM_H2ZHR!@T7D^@AMM:6'W5+-_6PNX;>S!8X082:M_6
M]?.^E*OL;@%2D'C$)=E:AWZ-@V[9<:<3T9)_\F8H;00%CA%:&2:"(NET;K34
MH2NA[N)K=3KFE6[KOX,==58O;-1@I64MZ-#O'R#FYI-Q/Y3DVYW8"[5 G6J%
M#W>/\P1PUM@SP39V*12VH[ZOG+NMPE^;>:OG?"@66ND<5R8[D9OA8F>2WT#/
MY1.RR Q5=5G5[8ZQ:P[8N<SN[%S\\$,I_6<*JFO1O]T;V(ZL./O(5;''W$H4
M8$"N5T!O"K:^*E/6)JZROLH9E4S@A(<AQAQ#,L0FPQ_8=WKSN%\">!0&:#MW
MEM/8/TJGMXMO'RR$ARUW64CO>I$):97W*W0B@^PZ^14'G<EWU[-K=10=EZR;
M.&I?JL6P7#P RA9WVD?Y,^$I.,W[8'8U].;8<IR">206#.DT==JXGOZ9Y=T9
M@^ Y\D>^%WX(3UJ3)\T4"5%^ZMWLFB;;,'?P,O,C,OH2A%]#DM+/9S(F(:@-
MC)]2H\NTOG&5_-8W9^U2.VY?33K4B@RM@)MUD:BKRA:G18;HLU3,!) 72*Z>
M/<SAP^Z'^R#-)C;DECN/1"J@ >\J0D'P07EU#V.JB5]0$3<I/91?$S@'4I$-
MMT"HY'344+9'3Q$'5J\:L$F&;!6-6)R-*Y'\*%KBE IXFVA1)'Q[P6ZD+B]R
M%^O@!E7 M4X#G 1G4.RY.8BZ_,.6@,OZ!K,W,&1#RR\E/#?7\)F2: BZA6>R
M>"<D521/A\3%34H2XHWP&[7#C\T 2&S<<0>)A")6WK(M'&2KJP)[%/(M]>C
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MG:X%5K'X#XG:<8P, W-91O/IBK:*Q7U(4(XC6JTWV!/OJ")=WT:'^&ZOC0:
MKZ;W!I8J:\9!2^?D=%+!HFI )T9O8"JRK5Q.;OOOWB0>([3:($_7<U=0GK5K
MY6<,;"6\ZT1VY4W.S'4#EUV=M6NYUZ((*W?M-U^<=5$U0;5MUZE"C-U;P^X"
M$LT6!4#U[^-5*<NIKMHG.VGY<B<$NV)"L)@0+"8$BPG!-6M%+?38ES,A>,>P
M5XT_[%4_K7I0_J:3H5\]>Y.-LVG.].'.OB:_[)66XTF<12BG:UZE5R^29MGA
M!W[<XM*38U,#JP-S'L)^@%8X],/A<@J6BY%N:0AO]4PD5N,:2"'VRJ&M%>@F
M&\]#P[+5)2:^I0\"%@Z>^;"QP;=_SOTP'AD,JHP#\:S,.6<HL*JY67N&#[.#
MDK%6F",-@O?<*J_=-4:9#[$V[6#P'\_A7[=^E[,BXT?EO8'6ZUYQ[P%S>!VM
MKU4UIM;LF];NXM[SJT/;,7N6MI4$\RW1WJ1TJ6IWJG,OL^!04W3K'"/[560B
M=Q&(-_>/FQ0-FW?^U[&?WL5$[\&F[-.-$E=A.;OHSR4M1^T-K,MA.(/I.)=L
M.B"5ZDP'$!ZG<>09FXY[V::SBY!=TG2PKF4??>:L; >[QE^R[>S*,)>T':,W
M<*P]Q1+G93OJ9=O.KJ3X+MLIF0O731"V*CNF=4FVI5VV;>VB@E=I6UAH9,F*
MZEZ2;>F7;5N[N.Y5VI;-BH25RZEB ]LR+MNV=K'8J[0M['MDR#IGZ.49VU:1
MWHEG;%N[:/Q5VI9+_9;*:0POJ(==MY%#8]<E;<10X+!GR*I99&_+\MIR>6P7
MFCC';VVT;:,TCM^]*/*&K\N(+%CGZ1_*V<*AT>BRMH E5YJL6%E;.((*\+J?
M#H"I]S&!*Z]E&;?'CO.7TO-R01DOT?+Y?W%@'EQ_XD_AK6G?=CHS;^%/_'_'
M-0>1-/' 1P1+;*\]"=[9+3;5D%6@G.+C;'-\N#R @OE[#J,&/]YBU'0@?V_V
M7?>0_+UN:U7E[XT]?;XO):TK\O<7HNB"D>M+Q$#JH:FTLOL>]J&3E7W]@<[K
M"';9(6_UT%1;6=/"/)QL&A=E6I<=\58/S<25-2T#NW"XM@AX7XYI-92H,VC#
M/-.]**]UV?%NM:$\G<$: FH714VY['"WVE":SK!9K\GC>+HBVMU&M+NI"*>3
M&^$\*MK-B]VEA?WL#;^_A%B^=Q7+?3P>$67\\PXM//E3$DGWY%WZ%DR]68XV
M]$)Q[8(%I!T)PD^PJ/'EE073'[<CP^F.Z9(_&Y&QCP'WR0>-T7]LAXE#$BU"
M?[B*$\-W_!",C<UT]R?^XJ,O?0G"U6WFRW >X(WP]AO?*Q^Y5QO*(AML=HF;
M)59)?K02 8O+.\I?Z/#+S9A\G+OXB,..\7L',Q8Y/U8,#05R3"4OD(-B&"]#
M++S=$@?8M3>#-3U))13B-,<C8>^F.UI?VI,:RE[CW8O*B6G7N3%^%'B2WU9W
MX$J =LW+OG]_7X7K66?EXF$J]=:SYF5_='[VQ\BM.$T_,"<A]7E==,ZM3-W<
MI(KFJ S^4YJY34-*FT*Q_<PJA*FW]C/.:XL>*TF/%5,1/59$CQ718T7T6*E9
M*Z+'2N$>*WIOYV9L<EU FDO5 ;*(W==LLS191(5?5406L?JF((L(LDC%9)$C
M]NB\2>Q:7\WN&=TX6FUD:]<^37!05J&+AKC:ID:G4KM6I8F16HS9ZK QZX6-
M^8Q-MB'JN DH1M-E1:VT=.7B3-80)FNH#>5_3*,WT'79,87)'F.RIC!90VLJ
MIP&'0=.6'5L4<9V>C33$,C615*/;LJW64\75U>20LBLYM)4;&I7,66H-T3A-
MNS<P=%GC#(C (ST_/_3'?]5=CQ61Y':C !YB$6>;^OL2+V@\^&K^V!D_*ZKB
MC)X5S3">Q\]#3=-LSU.?];'EC,G_6-BCZ.!\)";^9XM/5QRR16QQVL@<NVH-
M6175+MK -C5\(-7%%HS'&]'%,GNY?8.WB*XQU_*-S(,0/_L*EPQ&MW_.)][,
M6P3A1\I8'$Z:SG2RS6P?__CE\?:__[B]?Y)N_X[A[=U-:_-BD>S2O#MJN5F*
M]AU%5FW443S]+GT-@Y?0FU;3L;=DA+9]5_EY&<(340\PIS8FC<-@*EW/0W\B
MK;QF(/UM.2.Q+U5XB7;8NT>)*"I-_F92"/SWD$K>O!+AY6X>- 419?>/#:ZV
MLKE]+*?/)'P8T\&QT5T4P=IZ>@V1]$0_>L!)DN@=_K7T%Q_%MA0EY25<QK'5
MX/\Y5!A0XQ1>@-U<QMT3.3" K#!;#+8PI#O"'X_Y^^4R&H&3HA?8\][:)HL%
M?_$5[P _9X\17Z3D&UI*;V#W=0[="9-"Z1>4\=*2]_(2DA=O0:07'.D&;QD,
M"6&9ICTONN<%>9-FOL97_P*KBRKW8?P0@C/PPH_'V%A*@@1+I9T<#$YT$)<F
MM1S)7T1L":<\73[OIV,>&C?6FV!&\3U"D\_D&7;&C5GI1[S!'O?=05_],*-N
M6.)[8$HFH4E-9+!)$1F":U_XX&+G2P#"'J W#RR>T,'S/^(O<7B1IOQ<K^?D
M;[R/7Z_;<-CTC=6??Y+>_<6K])_P-])3Z,%.]SC'4;[P;W^QC/L'_/;;C?1C
MBR):/UV;DI+1>G"(.27.L@-&VNJH2=&S!,XZ)_B'E%B7<_Q@ES?E'K-RZD[2
M<[N>%X\K R_O.C4<P*?((#KN 6LYHZN'8$1C[7Y&*_?3^O+9[17;L!/&"8Y
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M*3C"39X].7H6AO;6_QW[9W#!D^4(_.2/_D_H6ZFW31G>V _A-K34DU;Y),!
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M#0.U?3#PK\_!Z /^];J83@;_/U!+ P04    " !5KMY:H/I0@ED<  #I9 $
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M$W-3['V_=@+3#XQ:08S]U2STC5P43*;!QQ*5M?=8*HV)I:7E:J5C;8YE#UR
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M#Y3<?_,AS(XR+M2G5O0H>NULLH$8;1  $ +!P,40(XTU.H+AT)]JWG0VP_(
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M:(2+@LD\'" ._F:$(6!Q0R%O(\R[)NXKL<LN]=?=Z6\>VXV@N#&X8FB6I0"
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M_])I]IJ-+JNU+EGC:_W76NM3@]7;GS\WN]UFN[5Q\/S&@Q&H&Z'GYMAEH5X
M1>&H>K;-2+C:XOZ=\=_+KVHMDB7VM0U46CT" %VU.Y_9>_OQW/7<%JB5OCV0
MHN$Q[(@AS",/LM#E8Y@22+-SK7M*&8),;)@OE4XJ>Q?58O[J_6%JH"RF&_*^
M(_0B^YYO"3\/:W7X)!#G^I=WEAU,'#X]EZ(Z3R\]A]F"*"D4I3@)??C?TE]6
MMPMPZW#^>K50+&??@<W+O+YHI+-*X>1T^5"'-#,Y.P  0NS#7B66-A-NH2&
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M'D7@]0;,9%B4""K'AH"KWH.D+D\KDM(W1%]]\-!_J] 5""VP@7=KVLCI&P2
MV8OB<0+@".9ISO)@VABUD$_,OF<'ZH:P9F_U(PO .7LU&(R$!4)F[G$!?&Z,
M0)J]@2)ZP(-P[@;Z2UUK[C( 7<-[R7*2I^+WDZ?ZPK%AYP/SUCWW;8E-B @4
M4Y;PQEV;C'P>R/V===H,A$\,3Z;& )K!P(1-?HRKZJO 'F?7,O B9PY2#UD7
MQTB7\^M]L($R^X >_$ZXL^]X V"&\^_T4=,8(0 LXR8E5HE;KAQ#^'<@ QJ!
M2I$"7"8>B]=L%W@0DAOJ+8NY%REF@3"!IKV:&7YTVI9A(!5% -Y$99XH8E6
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M6LQ?O9OS3>KQ/$IU3[Q?2=D0S=UVY'E64A-71UG!O7AD,.KM $\LQ20DTW"
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M&J>4,M(<QE3?)ODQ$ZTW!!_RS?<4"O4>9U<7\QGI*&'GT5!;/KRC@*A=IG"
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M91!2-C2?DED-O<B0),OD8A;+V' ]-[N=VP])]P/2HY>KQMLI$-O%-4$C.F=
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MBURC&#C/Q7O5B "[C7NLI.A1^UWO"F\G7Q="-!8V><N)T RB#)I<@B A9L[
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MS/; \OQ(LYB%M-C#SU56KM1K@QR]!A5]A("I%E?UD@7'M+3#I2GL,X,C9.>
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MIY,I+%S5$E5TBG:J-MC?&^^8P6^CVJXKQS\F8CV93L9+LJZ.J$B<#,("&L]
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M)X2[7\O;7?T6RK\/7PO-=6BLW1>'Y: \V@P^)UGOK1F)XZLX40C.C4^(SP'
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MQ>&(PQF.^GO=/;KA:%5T[,$.]^+Z1'_S;D[2ELC#8M7B7(7@2G *>*[+\ZJ
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MPO$):+>?4A-P@UMC.P"/97QU1&\SM6G!32_'W"Z0KDB7N4B072W,=\I"D*J
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M0.+>$_>Q]D6?9)DC6;?NHS=(IFM':9)6[S*]XO("!";]A9?Z08QV2ZN#)Z#
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M@=<B?[!?PL-=_WMG9Q_EP*E2_>];L&\@\HTKV.7]/,MODOM16>X;IK08C)M
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M^.NF63M;D$X#W=VH"+'@@0>%I_$F4Q'N1^7][KFT6NR]IMM/%F@IU9<R?"F
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M?UM5=5H;^G)Y?Y#T..=<X<8[;FR=UUO\<>X_#?(!F9/#@QNMQ6.U"H74#,J
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MW3R@<JJ9+/BCT/KB6/ VG'_5RW+X[?Y?%V>[-7; !EQ#L%$.WC.#VO'WN/.
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MOAX50C7@[D;V1;1(M1>DI8*;E3-NU?J'';H+=XR>_X <@B+-Y35XS]8^(<Y
M!(JSE8(H4/(@^6<8S:=ZKI-]!#+Z*)..ODK\=.>L?-B0*45W7BQ^V6R$^DQ=
M:?6WK\M;O5SYF\_G>(!*Y$Z)R? /LF^?)MC=OITZ4QUHEIBM5XRL;'4JL?"\
M&TGBTXCM?/L'+QY0AGT!=U(J,8AJ+L']Y $^UOG<."F=R:?MM5D7GT@S%I->
M^C()+\RSY.PCD:PJ\#,QEUE2__XB5QQ<.8C[.*( U;2XYLN,7?]Z2S<[84IE
MO%WP9JY:I:/#S2H_7\D#9!/FO;S\'+-LJ ,Q*Z8%9 G5\H#ODKC6T3CTQ)4^
M].R, U=XD(5AIL,8H3@>,"<9Q@-RE"B)E!W@Y_XWX& ?:4.*O,*_EPWJ]C$A
MZAT<^AM<2:$]Y0%+2:2[%-;>/SQ@PUH:GXOD10SXY5^:L*R)!QS+;BA!6. B
M#_AB0MC, W[$(R.F=YU;2N8HJO* ?5U$N+5#DKOISA*#!RP&<' %*ZY$3IP/
M+/F-8XE,= :_8!H$D7G,5\B\\Z%<9PY"U"G;QW%L8!2<-GW"*0 ;-=&3*J.;
M$*O#>\"5$A.XD(!P9[L(D\R-"J:L9-NLZ)'&+39FPNM0\"QV< 6=Z,<#W B5
M7#S\D;1TB0>((E-=2I$-T<1]1@1E,=H-;@ O.*P? N^#+"T7'O#G27%Y=[12
M$9U&HO>MX#(X@T@0 WG Y+Y16?2<X>B&MN9J,BR.Y@&I<DP2-S&9![SZ-C@Q
MQ9$9A9T2F3%P$S(XIX>"W(J&U#/K!TERB$L(%6_8BSNCN2WXA#+TNF+W )BQ
M1FH!?[C3%MMP<O9T73F\ 0.,-6@?/_FJH4__S^_G_9MWR"B;2FBD-P<GC@J"
MM"R*<-%\:.?%3Q0)4]W\ES(FUZ6)A[U#Q$32KE81_K3:XY%X"R*ACFY'8B$P
MS@@DW:_;(YY6P+1H3IO7+CL59I'S\;I@\UNSY6UF9U7\!%:DH=N,[33K-H0*
MR?,6!EEW7N?1N[<.(_[,?!@H/A*9BHG*"O[G[KWS"1I[)[)HH6VD^Q^[BM'^
M;L[19C&'N@K&"MEBJ@8:Y++%D:%J[OD_(*T*546*X0'!:&H<N\U3T,,!EEKM
M"=3__*HARD*K6S*CYM.F:_F@W.'Q%^1O9$C?%CX!)I!6V?G(KF\;_.W'D59F
MB<?#(AUL.PO&F*GYB%KFT6V]3N_K#4?]SFA1U_:6_#Z"#>)35Z?F$3*0J.3@
MEI0Y2$S)OY!H'$NKM_/;^W$H>\"9_7WY\)&WRX6#SD\F07>]R6[(1!-V<AIE
MZ2!A4"/C$5ED09D(@K[S $^W8#@ANTX2ED!.PN/'U=SX*G1[X2B:]FUQ7:%!
M'QQ,0S)-KGK1+/BY=H*B'W@? 232XW"I1YM@B68$!"@&EIOHCVS:TN!$-T<*
M#3OE,QS@5FD$8D[862..(J(&U!"V9LLC:,!,DMM)T%Z0D^= (W$3-!&DO,KE
M@^FP5S;X>4;I'><[EP]L1)*PUT]T,.H'MME3H7?/<MV9%P<&;THK^M3<=S\(
M4D\.G>!GMP2L$Z#(\<5MA&Z2=,7HULMA87=VQIEJ$ZIE>O=1M8N81M<BA1N%
MAN7AKX7,+;#$ 008QE7Q$07P-Y1815J YH/E.ER>6QNIO&86'X>^1UJ-NB;9
M^;'SNH]Q"VK8P:]Z'=_M'E>6T6>K8$%/8HUT^"UQZB4KP ND(>H8FK/S",NQ
MNK=A=WB893_>?JS&.[592;%&J./!Q*9M,WNRGI+44;]4"J:[D=JK>NXNHY=E
M5]ZO#>^"T-:,+#=JFRJC-($\E. 5'=1^F%K/A)GD2076 >X[CA=;'$_XCH^D
M45L?L.T?;WF&O3AQY0"*(O BU!GUJ%%1<Z.,FT@)D!2#J>AR,I&@'.YT8>A6
MC>3B"QUYVRWWZ2XH[JN@(Y>VWI'O./3))F9-82+RB%XAL=PFO)_=5U_DS.I'
M4M04<CXX((*"=Y0 W/QB;(,H9/3Z5Q"QB35*S:R[W.Q-#T[;$3(J)3X.?\!V
MC3*").<>H_TEH7V^Z60<-;8"]:"JLV0XV/Y[?1>^]J89.R,+'-18#V#]X;Y>
M1%]U&.IH0TN5#'DTJ/:KOJ],,L=45PE=/7CCI[(HY7XD4HX)O$9BT=F&7-1#
MP71[=7OH1CZ4>HYIN>'A,7,&9ZKEG6C8(O--^%/:HW+X5P0*6^ @,E= OC.:
M/?69>^<^?G#6F'A9G;"A3;'8""(C0(M."C=S0!$:1V4JPO'=A]::=KYM<.D(
MD0L2&L,]Y@',G:>0M'"":(T<F5<DCGUD([+T$V1:'E+("UYA6#<+AX)"0^&^
M5$L1[VG!7GO6XVQ#\>=-"6)P*,V6WS-YT;?">2:Y-O_YA=+$L8)3"YAB4K#%
M>F)U1G&P<HJA!O.]CU??UCN#"/^;<T,=HF&I&M>T,;_O5R>VQ;S'/-TZ9;;*
MR8!'P;*N8K8\80 V9$@4^*N^]3=Y7)Q?*A38\JPT7.4,YUCKL<\+LK?(W\D_
M2+#$O1C6'>YC?91 >-/80@$=MRW<K6U.YLZ3DIQ'%K?EQ4[X.CLU1GU4O?&/
M";]GEQ\Q>V^6JBT.4O]\;<0D;5.]6WA^1V_)S-1W4E4U9U=Q 'LWW&=V  H:
M%?L]\.Q3]>NO(R6OE+?_\V(J2,)D7*E_;7$.RSZI.Q_!UH)TZ4[3P3GD^"*S
M(:U,AX/%<)A];2UW&#;@9.&MF)18RE74T!GGP=?5 3Q &G]L4&EJCC7C_O7]
M^_2]^HHA::)' 6FN+R*Y!$FLF]S'!"5(Z8)@]X,53?<C_YB(-%_H2 X^4'E[
M/4WFB>@U1\_ET86C(ZC.@\9?+;%&X=H5'IZDNU9L5A2D'G!;*TQI/T1(S97:
M6]_?0/NUW'F3M(6@AC=C#N3>V!E3F2PV@SW=*A_:JQ9G?:);L.I6=S%!GW/R
M"3$Y-#F#,CYS"EY='>1(1<;C'9A!&#13.YG,O5DRYR=TX=K3V]X%>9W2H0LE
M'VYZ^M'.2XXO^#QG*J'4BN_GR_:EQJ=<_U!Q::6VVF)A,8&R=-(4RP,N1%"X
M6U<Y@5 N;%5L 3<@!/TM$;Q$D@,G_@DGPQ_7P(T]LQ#U[U,LM_]XBM7]+P'!
M+4^LSEOF2LZZPR((5>Z;AA1X@+?.7]8,P7Y!,VZF<W)-4&P%+?2*R.S,(J2&
MYN3FTX*Y#S^@X4<MN'T(9GMP2PE_P+FK[Y!%U<FZDC"+TK)!LGP*?GZ-HW$E
MFW&0JA_GU3,:CILL[P _:</U![>-KN\Q,^ ![\37X-1VW)=TSK9RV,F>H0NW
M):KS )MQ\DSU^"+G'Y(\PLV;V4ABGB!;'(;UT27Y\<CI6*B,!"V@ 7 U?Q8W
MV#TG@F1P!Z3L;HE'<;=5<F+0&[VKY-DIE@"2_M4A9'N\6Y+A6#>J*;1GIDM'
M!-9VL%PG=8+_$T5 . 7^7\5%/Z*HAK&?.Y1YP*-AKM\ZZ1&:X>*0L$92!&F(
MPI(.?598H.-5/9#76U0=;?HL7#)='K@#[%PU8-LBM?4GO%B/F1+8:#2/]P@0
MLR\*7\/6U=23@A<-J5]9W]M("W>EKM[L2!VAR%-H%12@4O+G."QJS32R_5"9
M,M+MW(]RZ76MV>XVC#HHBRKP6G5;6X000S@[^RFTYSC!4$DB09N1N!9?9Z38
MESYD\>.7RDX9!_5.E< ZZ4N^ZW=E=Y?.F/C'YVJ\/]F:G/[KHAAYI\.6S+Z"
M^%Y731:B.XEZ(.V/P[J-=#<W;B-X.?.O@HPY09FPAMIY .X#"-_5)EP &^W
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MPN?F4*7H.<K8:-2(UH#.BFLEQJ>NTB7+PR;A15"W@B/HMH_\YFOAV7",NGJ
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ME-3_I9I2C#*P&W1F82;_6NB_#CGZ]F]02P,$%     @ 5:[>6BRQP?\W @
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M?VU^N[FT+HY=J)8-?_W//]Y_9H_BB<!B42_)@FD"=?'7NOGA^Y*198/Z6;[
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M$YS%G) $A62VW-1PF*3T'Q"QTCLGJE+Z<K#T+6"'GG4YPQ%8@I"G(D&02I9
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MM+"=[;$T<%]&1<A2K^S8LKO,'#%HVY]_'!]!"P=C5"3=? C?B-KY!\Z ]+H
M]JM.9^4[2[QGR+NOXB.5X?>RY-^+^5P14>^2?KXO,R*01"BG,,XXA0B3!&+*
M<AA&48B#D(>I&)# <(3BR&KX][N[MW^_??]^2-+!,9Q,K3>/TMNIV/T$@X>.
M-/BZ%#^6@*KW^!^C90[TR#EIOL Q/BZ8)= #2W]N0-^-#H;:)]U=\TY^J<5U
M78OE)\'*AT6A=-!U?2>OF3((ZT)K'!TCF&6,8$$P@PRE$B))",0\DY"@/(M"
M&F$9Y,8VF@WED?5"PXK>&:M: -W,:6EA7%@A:&"9C86+G<9H(;F30/$!&D;
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ML%'TW(;HR'I\S8#%W TKR$P/POP"8:F&=S&X D];\J#0],'7IS-6KF,!A9G
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M;(W\G?C[:3=3NY:VGPLO#\+T2S UO'9*O@=9*P?>I_[WB=CHJMT+LQ-K;9\
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M38&GG=YX-5NG!BU3H.,*[+#57+13H7)CD>,Y#%G7D48C(>QEBI%'I >,+7)
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M&4!",8&1[HV?Q1SQV*B&X?7"(W\,-"$+1;,KL8&*=I3#3MUJ&BY)PKNR6"A
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M,+87/LIWY_^G.L ?_!ALC^V'$W0U%Z[K6NS.Q@HQ8PE#ZK.>9!")5'T <)Q
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M_(3ATM$QW(^(CD_.U8G02PE%41&?OQ-"IQTK9L5,9FF:19& :8@91&'"E=?
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M(4\$AR1*<HAHE$"2):ERMFF$4YI3B<WK!@V)7LKE;AD!#2>#_<Q#*)W][T$
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MOJ X5Q<<EG.H9&#/")/6 1R6Y&UQ/XLW I>LN/LY[XZ>J;8*,(<YT.> 0A_
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M Z0L"4E9#H1B$" I$* 4YD"1*LMP 6F.K92:!:WICE%M%"]O28\]0QU YGR
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M1]^H3U(;)CNW[?<YK3 KE00\A95>Z*8'*D4,( 4K!&E9%C*[G\D'DQMS9VE
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MH\]QR.F,03]9]XQ$SR%"M/!X&[OQJ9[)ZY5\,AV5JPI5' .15:9)!^6 2E(
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M7Y?U]=,SK1?F^S Q$%];A;$T-VC:TE+UZF9A?K[N/G0/)2\5%!5@2E* ."(
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M'1Z#]XD5?43X#W>#F,1"7'A^D"M:/QJR:KYX:@+T+MC\9?5E,7^6B]7K%[W
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MG3GEI54.2"4+(-(J@YRP7%*K,A.NA*>[C[A1B>8%=,PD+3>[7H]O=P[W#<X
M6[C-(L'F?5]P9L0</&F1D//SIX5$T,V_Y@%#KY?-9;SI?&T>4NYYW'S>#W<E
MH0&7:U<QJB@3#&J=:VH,EUK[$@89@%FI*D@+Q<7HZX@MN;-=11@6QKO9=W#S
MOX'P0R/4[8.A'O#B8?=+&GWIX(=,Z N'WD\ER%W#H9P^]PP[HYS]CN%0(IO[
MA2-O>>BXKM+EW?QR/EN^/*Y,7:YU2R-)"1,4 I$AD]QC&F;*C )",R7TJ3.K
M2KM2./UT(FNUCG"RFION9FO2#FNW!R$+-19&;C?]M1;Y;I[L4/716SVR.RBL
M,!CX::KC6 324,."]:JFGM>GTTG#,NPI(XO'1Y2,V&U!KA7<_.7ANVGI5L\>
M],0;BK7HK@7:*F#WI.((HSPUI5D$0#E7@.0X TC(4G)5L-(N?7H4%Y$U6%<7
MH&[X2?1>>R'D8TV3I_I1+E?SF?[=N/(2SJA;Z+TIL'33BMMZ"QV@+5-)QU6R
M92O9X^M=TG(V!; >!2QB CRVL$5@H/U*7O@"9%4*PWGPZ4MD^,I_M'2&]V Q
MZZ._?UG66@LN+^=/K)ZUM\:[%5Y9E@F.TP*D*"\!RC 'C*42D)031CC/L+*J
M-Q24J^G<IOW5NUG'IJE?M.8S1O7TH4FRO8^9&'IOUZL[ZF<ME6X)V6]1)7V(
MU]^P0+HEO'ZUT6T']S#,O\JEU&]H)?_TK"W-V:H[_96,*VUM(R!SI54JPP5@
M10E!KE)(&".2IMS:[CY!)+*&7%-UL.M.H6%A#P>0T4T5K0DF&XH^#H!3$CL8
MJ@$D][-##Q$(9%D.2-1K.)YZ=SJ[<(#[/;-OZ%D/C?*FZ\[QDMY=XYWWQQOO
MW)>28<XH!1F4IEAO5IHL$ B8I#G-<U0H$]!LJ7T",!194UT==,XZ69_?. (N
M+S[\][]N/R3/^I'&*>#B$P@Q/1;J<&+0W53G!N\O:[S;$G8M@\D.AR;2[W:G
M65G'97+AVF N&/8.BGGB.?!3XM/,A9O^#PA<[UX1@LYT^TI 5/;VH)#C^GHA
MVCI[>A-<R.]RMJQ_F&C/^9/\+%<WZH[^6O=5_U K)4TFNUS>S.XT_>5CNQ I
M%U6>X0Q 5@B ),\!8;G>NZ2$)<IPB95C%\^Q+$7>L[J&\UV12OZ:K+:D$['E
MJ8FA5MW#VP015P_$Z E*N5(Y(AQDRF3[9U4*:(4*4!05+F!.*UIDKB7?IYPB
MKT+Q?\T6DC[6_Z6UY0/5ZK,ML6ZN&'9G2^O<WV"";/U#4X+N9E9T=7!W6=-[
MEN'M79.(IG%>T5_O$MEQN+=,1LV)A\\H%(S1'4:C&9W86Q0*V$-74;"1?7=)
M4R?@ZM=SXZVZ6"[GO#;=._Y5K[[O[-1FGS;Y6_H/RO7&4B]7-;^OJ()IP3 H
M"WV.0T1F@)4R-Z$G,F<%XJ4I).NR/_HS$WEGO'YZUK3,"H;I_]%E0!K;5;W=
M,?6J=JXP.V(*;!7L-, Z.KLT3R;5JG6]TPU7R4_-UMX!>=DR9G#?X2RDYAR/
M3W2=.8+%B;7E># /]62 ,3W\7G_-UGT6Q>UJSO_==9K>+09G=+=6W(TRUO;S
M)=4@/7;F#X.55H*, :F(.384!6!84&VN(@Y5A@2VJT85@)?(^G&'N61IN-MT
MB-\KCOBNL:36+#;'"+[#Y-H3YN<%&SE9%@ZPZ:; 39/NHM\PEG2<F98DMSOH
M[W*7:/:27?ZF@]K!WS4=Y'ZNKLC0N_FXPH#5Z]X:26(ZSU88+/:<6H&&#!%5
M<_%D>DMJTHWA*=Z_7LU6]>I5D_RRF/^HE[4I8OH?\O5/.J.M.^V+5NKSV4P^
MWLK%#].9M7E0F'=OY3,U=NOVX6:T6G8U^21+19EC;>(KGFL['U< EU""/,=E
M6F'3$COU#\694I1)XW=H*YAQ%S22)>PUD8ULS<;WO);.//MO^9H\;7@V^U\K
M8;+L1&P?%^THRT[*W5=D)V>(^HV3?EVV1YC_';X9MVW[?XO/963HTCEF:M)X
MITD%/&.0U#DFLC^RZBP<^6[>>[&XG>'079*9\;NK,';B@AA"S JJ]UU8-F4"
M( 28$ QRA4C*,554.N[ H_B)O(UN8]';.AKKHZ3<\I>L<R>Z>^/G[MZ8NM[A
MAYHA0DMM$D$"%.9$VTBB BRM%%!EI2>(0]/3QO4J:K(Y\FM8O)FE8_/CG-P2
M:B)LS8G)P'6S"2)_^QZ[>1"@HF_)X[B<>%\- NGAYAAFV!#'T_=T62]-S];9
M<OY8"]KE0F_R!@J:DHRD"F2Y<8SJ#0Q0ABE(!2YPGF8P*Z2KMG2@'UTW7MY\
M_7+S]>+N*KG^_/'FZY\7=]<WG\><R(8 ]3E$!01IS+F'&3;:7MP[C$R25V&)
MP*3GB2&>SG@$L(2KWVJW'22$&C(]H^NVYM_%3&QSWG8:'>XN(I2F,A>IU!,$
M"VUE%Y6IG:#M[4J8!O<BKTCN[^=R8R:RB7UY\_GNZ\7EW>V[Y/+FSS^O[_Z\
M^GQWFUQ\_I"87UU__N/J\^7UU>T8G>6(OH\*BX?I&(W&MUPU+3_X-G=VMZ?J
M%!K.#Z!)%9XCBV?4?WY@]JM#SS$#]^KX6/]8US124C(,:0KRDI7Z()MBP""J
M "92E3E$%#D49["C&5G7#35:,(P$ZD>Q@Z/%=7)X=-RTE@TPH3MV[" 4J&6'
M'U)Q>G;T?DKAFG8<BNS=M6-GJ+.7U#HAFW7?CB.O!M.35_7#]Y64L^[;33DN
M6*;/KCQ5""!$H3G IJ" 3 JH\:!V5Z+6%,^E(]=<C%[^;P#T5H_^L 12CFL&
MPFG&-]",UHO^$ 76BH,?3PB5>%Q:#X7X9J!SJ\/C<EDHPQ,O^AZH_]7XE3<E
MY&"9XC)/S<T&U9HOUR=EAA0%)"VHX%E)J:K<#LG[!"(KNC4QUX/M&Q1L#ZO^
MLKEIJS6=Y-O3@%+R.% >%R+Z(?$-V8D/?L>%/CS,G7AN;#V]SGW_3[E<F=HA
MO>G#+%49PAK%DDJLCVPD WH5:E )SR0C.<72OJ"Q+Q>3W0FO;\1^-$R%J*+G
M@K6%W3(%@EZ7BC==<;=-B&K+51.IVMPGO@^0#^^-K&\9O4@(CRJC%P'I$77T
M/!"RKZ/G,OB9ZNAYR'^ZCI[/8+ZFUUX6_2[UKJ!KED)R+THB82DX2*$QR"#D
M@&5E!3C-69I+J$IBI?W=R$96]_O54]Z]"89XZ.H#^Z:+."*<(B8A8@I(PIDV
M>1D%C%<"Y(*BG*("FOW5\;8Z-,9>U]1O:M1,!*>M[1P:(K<]T^H+#&EENX@;
MW?:V8F9BB]P%H$,[W>EM[\:4_#]?ZF7=C-M56CU6Y^]:FQ6SAYH]FE1&V=S\
M_#&?BY^U'H)FN"!900 O& 1(F_2 "%P"*O(L+3/%6.JHSL<S%5G9[S#8=I^]
M?:*/C\D7/4E/U+F7Y?@IL%50TP+KIKYV>4M671'G8P5,E^^2>L.@R<*6W:WU
M0\=CT":8P1"+WQ=S/*M3M\H,!NZ1[IGAQAX;07^\EI1]@# F&.<%ER"ELC*Q
MAQBPJJ(@90+# F4YSQT5;"#.IO.@G"I$Z!9D'"+&>^QD(DHSJ(0 TCB\D*A4
MXX@&5,E<E!QGI&2^8?<33J>7];[Q^0:.NQ\[)[;;YQEP]G*;A5LQ,<+R Z$W
M68#^6'[/%*H?".;30?NA"/ANK\W@7Q;RJ7YYZBZYB"IHI:0$O"PR?13)!2!E
M7H$4<I)!3'FJ'.L['1*)'><ZGZT6-7LQWJ+ER^+Y\<7YYN\(,+8:;IRX;LJJ
M]3<_M\2B7 .>EB:Z\CA">F(]<%KXPR7=\^S(=M(?M:$]XS5]W)C7.W&B;3I]
M)824*L\!0KC0%A%"@)D.6YED):(5SDENU3?%@W;DM;P?9+UA)[G8GED_[897
MC^J2;(&TQ55@//S<E,/O!IUGC^FP$(YN,QT"2O].T_9@6#>;MACR//VF[64]
MV7+:80COU"/)5K>2ORR:,>]Y6A0I-;T.L'$T4)8#0J2YF).2RK)$>94YIA/M
M$8BM;C6QO;-.V\O0.2-H'Q1;T\E?5$?-Z"BE3S[.45'BY]CLDYTZ;^:HT$=R
M88X_%R+[[ZLTW.H5WBCX&W795&U=7L_6+LE/]4Q>K^33\C['"J8E*D%>0 %0
MH8\[5)D2#DP9_Q(6JAC1;,Z>D4DMJ,4>6TWB6LN8\62LO?_)-SVT3&K#W:B:
M4@ZS8:TCHF,\QLH*"._()$!W;"9- '1@[XS)?^X@]B?^>8SGJQ3_FKTLI;BC
MOS[-M>VS#F&FE!&H$ 60\=2DL"B ):L P3A#C B6NG:W.$HG]JW&?*8-JN=Z
MI4UPTP@AX72Q>%7SQ4^Z$,L$F#*;5#C?(A^'S%8QC0;"3>^TY$P?@@8"&2<*
MO%>HZ KC./6)]4$O!(?+O?_QP"F\3=9']YWB',LB53G@2I;:G.$%((I34*"*
M5#E&2)7V/B!+HI'7^5#F9<-)H!S572@MG#P1 ');_U;8A$[DW04I4":O)UAQ
M4GG[/ZAPN;Q'A/9.YMT=Z]SI:R>ELT[G/?:NA]*\GO&%I$OY0;9_;CN@_]!J
MJ+6]FK^OZN:6;7OWUES&M<W3[PL%A<3&A<-3?4)$# ,"&02\S&4J*YEERKXL
M0A"6XM^<&0::1MBKN2E?_C3OLA>6GDDW86;"0B-/CJ^;OEZSE_QMS>#?DX[%
M9,NC.3'N<+G;-?%=UTGQ73<?D\^!@\*??"[\MH/IYL1MZP@*7^_&$H;2=-M.
M4&3V-J6P(X=P9?Y)33<;^GC!N:EY7,\>OLP?:_ZZTU1^MY26U$?XK,#:X!>8
MZ<VJJ@#+<@4RFI:(",1R9=5J.00SD;>I/R_NKKY>7WQ*+BXO;_YJ*I<E7VX^
M79OB94TYL_<7M]>WR<W'Y,O7JR\77T=78G2<"A]?9CR Q_@SGSJN$KIA*WEN
M^-(6PH:Q2:J:^0$TJ5/3D<4S.C;]P.QW;GJ.Z6'=&]?*Y8[+;WN4^#!_HO7L
MGC.A4%%20$A! :J* F#!*% 9S$I:Z%_APMIP'Z(66=D9\LDN_=WCZ[>6!9?S
M_2!X%K9V2$C<U-/D:#A8O2%1\3-HQZ'C9J3:2MMK?PX.,IUI:2O/GM5H_9+W
M-<Y2ZC\_U4K^J:U2K6?%Q;+UE]RHN_I)?EF8KL*KUR_Z.UA=S(2Q1I^;B'Q%
M"\@P%*#"* 6(<@IPB@7@:8IACGE:0<>4%V]>(FO(EJ_D43-F;!:Y)NM\_^.-
MM?4=T10(.MXC[8#WU#&5T*7)!S>.4=/JNC9]KY\[UO3?#'--S-LPTCY73F,Q
MBG\MY<WAU%=78Z$\<KTU>D@O;ZZI^S-??)5M5[WE+7V4)IKO3[KXMS26IM:[
M<K:4]R51!12E I4L)4"F. 8M&0:\PAG$1855:56HS(UL9/VVYB-9K!EI5M^&
M"[UN16UYV^V(IY7?-0)*KK[5#J -#^^2AHLW.'6,1$'*R3L: 3%?#V@8Y%S]
MFXX #/@P;4>;TD_I*.$;7Z3KV_ZU*_17\_)HVFHWN6BFE>E"?M=CUS_D]8S/
MG^2]Y$H@2C&0>:D-R2)3@.(\ QE!I&"YK'#I7)QBD&IDE;K#09?GR7=Y:$)J
MW(M0#&-I:R@&1LA-G0Z!4S?TPY:(L!9W@AH0P[Q,7N3!&IYC51SL7_:PS?XE
MF\JSXN*'7- '^9'6BW_2QY>VY,[%JK,2S<[T0;-P/.&UJ\9S7RHJ,2\J  71
MFD9F%6 "9T!EHLPS!!$O4[O$_M"LN2RV4%6Y_KIUK\H5?$HL#, SP>RFT]9,
M)AV7B6$S:?A,&D:3BU6RPVIB>'V7--QVE[R[%[_)'P.UP.+.BH.Q>:;9\3-'
MIYXE-[,U I2]AFU(>M.9OA%0VC..8XSODZ$ME30=B._HKS:YT##1?.T7CX_S
MGU0#=8_RE-%*"+V?-='V.0140@P*+AFJ$&8<I_<S^6#VYCO;[.QANE;KE+3K
M]("Z]5K=T$WHFK!+[K %?!9[3R@T/-,(6^*)IMZE K]+MK!<1(+%)8\Z+#R>
MR=-C87),E[:7N3]'VF*<"1.C[:7:SX9V>"]$T-*=?'J>+^CB]4.M-&6IQW^3
M$7$Q$YN?7&K.ZE57'R#%7 I1(<!25 '$2@YHI@A(%2D@Q%E*Q@0P^3,6V16Q
M'W"S6K.9B V?[Y*7@V0?XY[;^2EO^4V^K1R*. 2?05OOQO3SXJC8IYR2D6%1
MX_&;-$1J!+MG#)<:#W)_Z%2 \6,%&+RM[MD8U'??Z29E]5Y28FHP8L!AIHQ_
M6 )6I!6H<BDRD3&"N&/)B]$\31MP<%!*-W3@P? <A I "(ILG$"$P\+%K8]Z
MI;F,4K\X&&9G#TP8YO0W"U"PAM8]4,%^: _GP$66HJS+DZQH63"50@"5J<U6
MI0J02ENY>2X4%J4HM9%K'9*P,W!D'6<(.1Q<=R6V.+=[RN&F40P-GPS875D<
M#MN>,OD=JGNGQ^W ?(3OWH/Q[O/3'8"/<+EWT#WV^Q 'VL_S&17_ZV79W+K_
M,,[#"Z67TU>I#;8FQKW1*9\V=6P0KTA:('UVY14'B&J["(N" 8DR3BHAD*"Y
M_RG6D9M)CZZS^0QLF$MDPUU"#7O)8LW?>C</56#(=79\3J@1,1]S+ T.]\B#
MJ"=,DYX^77D\XY'3$\[^<Z;OH-YM9/?O:O;:\9RJ?OUQOE"RWO99.U'[NNDJ
M13)<4E*DH&2P!(BEIIQ1+@&$$*4Y1X+DCLHV,L>1%?+F_I1V]Z=R/ZR@KZJ]
M6DMAVP5B7->PV)^&K:;_C2;<,Z(A\EP';2H\#=CQNQ1'EF/JML?33,N1/LH3
M$0YQ$'CK,-A-^"X11BFJ,*BPRDW5WPJP0B"@.$8XQVE998YE]2PI1]Y/KC_?
M77S^X_K]IZODXO;VZNYVC*W>!Z"/71X(EC$V^*$O<HI,> O!)[6J^_@YHP5M
M 5._M6PS@(=S\&2*%+Q@6LM1;M5P?'B4>(O@RR87\,LF%W!+/_FVYL#%Z6:!
MBH,O+BPZ?BZZ7I1L0')SX]F+W.O=LQAF.J>?O4Q[OD"'U]S6KY#U_840>M*7
M=_K-KD0 8[2B%$H@\M2T3,($D%))4"DH<X;*DI16U2:.CAYYA^_H)8:@8_V$
MXV#TJZ[1(KHI*C?IK-=;KQ1'MMZEY/_M8?[CO^OWFDW7_,4L/=0LN^.C3;+(
M>@59+ZG^AWQ-Z[>M.5:;0-ZN\M:I9)5+NI(/>@ON+FA@FJHBK:!>?$H!!#$&
M5)K^R2E/5260(-@Q^B 09Y$7[K8)#>U"*K>7YJM$F;CY'X;G_]O59 \U,;8F
M_1G@=E,B;Y'>QW?39_ETIMR[A'>L1JG1'1C Z$>'4/Q.?+0(#//AT2,T@7"U
MQK_7VIBZF<EU1 /C$M(T!5650H J:-+T4@XDKB1.:2I35HZM-+Y/,K(N/5T6
MNF$CT7R,+Z#]!D2+(UYP:-STG@4J >N+OX%G?'5Q?YA"UQ8?_HB"5!8_+K!/
M7?$W(YV]JOAQR6QJBI]X,YAJ_%S/Y$K*V?JKQ65>*JI P14%*,<,D#SG0'$%
M,5$XK91]K)<-Q7,IQC47H]?]&P"]M:(_+(&4XIJ!<"KQ[;<U5B/Z0Q18(0Y^
M/"'4X7%I/;3AFX'.K0R/RV6A"T^\Z*$*+V_^_//Z[L^KSW>W;=X/X[ RQVT@
MBT)HM8<R@%F!0"DPJR IRBRWNOXZ.GID%;=#SJ,%[@$4%@ILC(!NRBJP; X:
M:(R,?MK&158W_7)*EEY=<O#2='KC%+][.N+D0[[^O!O.7Y[U^?5U71 M@X4R
M[F^@BJ("*"L5P,+DPA<E+CDN.$ZYFV/N+8G8QH]2)H[&7-M0\53/:G-U8+Y)
M5X_: 32VKK$Q CN:-6M*B0Q5Z6U8C.B>I@/"$[N,3@E^Z/LY^:1?[Z/YD[RC
MO^32Y4+YR&OQOK>66-)0\[LO/B:E6X>:,=)Z]YMQDMJY:\PID89ZP!R\-VE'
MEU-<O^W/<O(Y'QOVT3CSES?*]*+>B2Z[^%4O[W&9%8AF%>!9R@"250&(*+11
MRW&&<%GF5%K=*0U2BFW;MJ23&Y4T+<]W2R-],_2=S,$^Q&S,WD X.)K DT'@
M8AT'@L+34CX-22B+V4*^?NNY;X )+6D+.?:M:IL7?/))7T2]VNFCXK*OGWHW
M8M2%H9A<[_8'\MGA3PKMDI,90'B_5>8%@F/BYH!P_5F<IUZ>,*5S@/_]_,ZA
MA[U+( L]L"FR?#?_:J+1Y^IEV05\WJ>F4ALFIFQ;I<^P-!> 45D"7J29@I 6
MC#K&=?=0BVP,;"@[US7N <CV)!M(;$<]M"::K.;)PI %<P4TX:$R'3X5C(<%
MC%^YN(>'J2L6#\-QI%*QQ4N^JWRS,Y^,#6V,.%)R!C'+@.!8 "0( EA5&.1Y
M!G&*"&;,JHFZ*^&)#@)SU=_')?E&[4UB9W!ME45XR/S.#&/1\E C;J)'URB6
M[$RL7-Q .M0SCN\'*8NXH+.EME:,=GLO5S^EG#7-'4SFVF)5R[UDJ )"3@EE
M(,\(!R@7&&#,"D P+Y1 N"I3J_BJ\:Q$5DNW_+L4+X]-*M5"/KW,9'=1K/_]
M;_F:/&DVNH1C/4_+^6PF3U=V"CT+MMIJ"FS=]->;\H4[/"6L9:KM)-3D^S9L
M39*VY@/.M+4)71@\9S5"#R 'Z@_ZC!BH*,0FRM6Q!GZF%&-$0* (50 QE@)*
M<PD(K*H<"8&YL&KU%9JQR#KS:KFJGYJU^V#H)4+_?2<<?609!M_)L%66TT/L
MICH/BBKL!/K3U3K%HMF11--ZX&2)A8=0K0=B@3=UD01?=L];"V$DR(,E#\:.
M[WT>ILOO'Q_G/Y<?-09_+4TUA;;K6#U[N- ;P8_:J/V-RQ7R2A)",T 80@"E
MN5:V94D 8[Q$%:*P)%:!K;X,1%:JUY__>75[=_WYC^3B\N[ZG]=WUU?.I0X<
M$;4^#$?#R?%0K/E(E&$D,<LF^5M3Z+J>_5W_KV,GH1M^]-$XG+-[+!CQC\EN
M;$U]7/8"[<BQV6\<]PSK3_I+>/SR?3Z3GU^:T.>,"29RDH$RQZG6/ECK(20%
M$%5&I62$83NOW+'!(VN6AES2T$M:@O;)U0<X].N,L=*YZ0,'P9SRJD])X)56
M?3#89%G5I\383:H^^8RWQVG;[.-335G]J&V'QG]^7Q4YUZ<B#*K&I:04!I3E
M D"B_U/)DA)9.70BLB!I]>6-;D)DBN,GG"X6KVJ^^$D7POEVZS1FU@Z@41",
MZSS4M)]8$TW^UMQKG2[%Y^/ &1(NOH?F) =3NV"&H#CB8QE\Q7>I=P7/EC?J
MDSXVR/7H>@-NO-NUJDW!\RZE>'=_OJ^DR+$L"U"FJ@0(*:HWTR(#4O*T*@BE
M*!=>JL";I8E4A6%J7>#064WXXUUBPJ7,(4 9$0 550$8-JH7Z_,4@8PJFJ_Q
M_AVA=D/YR^3XVJKIN)CYU='J6#)N^L?F\WS<<O4NX1N^3!\,M>9LYY@54M./
MQB?Z3N#/X<0[Q6@H#W>2\4/ZMXC_SY=ZV05FM(4HWK\LZYE<+B_G3TQ3;'XU
MW*,&45%5C%5 D+0 2"@&"!12*T*5YA@7VD3%KGWDP[ 6._)JRZ99Z;=/]-&<
MG.CBB;KWF \T&;9:\QP0NRG170XWQ7A8QZ.IQ[-A\@R]@T+#%S^&+!3#4P><
M!0;Z2'1:: H><>!-P>/W.P6/_]FZW]H,[ZX"7Z4D@8A#D$%!M9Y-.<!IP4%9
M08(+F)806Q7%MZ88.TIDISYYQ\2[I&-C75+ K7*A/9;]:C(*0F[:[YS@.,3A
MAP;)+R8_"%AN,?HN@O?&ZUL--%WLOHM<>W'\3B]ZAY@T_0M67^52+G[(^ZK(
M**X@ KFYN$05+0&MBAQ@*E"E!*X$<[R]W"<060%VQ);)HB7G'..QCX:MZ><O
MHYL*Z^@,2N<3,7%4A/B1#_MDIXY@."KTD4B$X\\%C"@XYJY!A80,<PPDT= A
MR!$@+"M!A@A1.,]+5K#[U7Q%'VW7HAUAIS6Z(6_]$7^6JX1OK\B?%_,?M=#;
M#'MU<]R, ]=V:8>'S&W)GPXFB.WE<I/\')$#OX'_R@TDJTB!&)ZISUJ>E\7"
MQ.NW%5/7L35I02"4 @/$!00(52F@B%6 YJ@J,T92S!Q#0T^1BKSS:[*@H^NJ
M,4Z"8ZLC0HCLIA5VI-VT4XD21C0D6O1E?Y*!B1?Z$!"'2WOP#?\T7-.7<-WA
MZ?KIF=8+\R]SP_]5_M!KAS[>J+<_Y_.'6=THF"^+N:I7-POS\Y-Y/?>0$U:E
MJ=8'$FGU0&D!*"LD('E!"92*Y1ES3>B=@._(:L;4E'Y9=7',;6K;ST6]DD#,
M?SI7NYIF(JW]U[_;]#@ZM[?LFZ9]2;UA-'DTH2]_6W0R--VH]G_Y=WVB6@MB
M^OP]-Z+H9=G\]EU_;F/8W.@)YV""+.LII)D\7WO"*3J6^3TE>=\MZ@\Y?UC0
MY^\UIWHV)&WK_C"&C!,I ]KJ3 %B.01$4 Q4GA8L2X7^;^JVI1RE$WD+V*69
M4$/4,Q?\.$BVZGJTZ&[JU5UJ#_77*U-T=76<^L3JI1>"0W70_[C'O9E>"_-%
MD[VXT0;KJMI4"27*$A04:H.PY!10#B7(,I(2R$LH*V1]67:23.3%JY_>=I9S
MN.4Y#8O%O5<08=V6ZY;D;B,]]WKK/9^#_956$/G][K&.X1#HOFI0JMY+JM-O
M3W<S-2C!WG74\-,ARC]L*DXTMU^7]+E>T<?=8@-$:%,!%@ID BJ ,H$ QFFF
MU1"NE%)554 K->1'/O8%_LO3$]7?JCZB-+W&$]YR,*:4PR"BMA9'+)S<--M^
MR0:^+4"S!]@D91IL09BT-,,@4V<LQV +6'\)!NM10NBC__&BST:UV75,#[&=
MFGKSE]7;TEN[BZK"N(1"5@!Q<WDG6 %P):2ID65:WV1,XA%]SCVYBJV]=HO4
M.!21BS@-/KIM G#'J+S_W&$OJ7>J9E+#X#'@)U&&(U&;5$?Z\GI&U3D2WGZ-
M.G9P7T7;UFS8W+=A5.0%22F I<FW8I0#4F4"*,ZK+"MA19EPTYG[!&*KOW]<
M?+WZQ\VG#U=?;_^OY.I__'5]]S]===X;1&S5E[^<;IJHI1/IKO&X$-$5PQNR
M$Z_QXT(?+M<3SWF'(.W>3-YSB<J"RDP?IWANJ@900$2FL9)9*CE4C'#D&&FT
M.W[D@*([\TK244PNO&R-?3QLEYVWE&ZK[G+OIC]HC,\Q >*'\NQ1G3IBYYC(
M1P)SCC[FXU"=+Y>7.VGWVV9SC;N_R!!"HE1 R1("1"NBSPEI"3!A!<^+2E1V
M=;,M:,5VK9I;UEWJN_T,G1M(#,!FXW4-!H:CZW5*'%R\L,'P\'3%]N 2RB5K
M)6*_7[9_B F=LU:R['MH[5YQ+S-T94X'KU>_FN*7];91YGVE4,D81H!)F+?%
MSH@L,%"LHJI2N<I+ZW)#IXA$5ELM6?TM)EO"78:+??VADP#UZZE08CL:\1X2
M.Q4F&A+)JT#1R4$G*U0T)-9NP:+!9[VKF2Q,H12IF6V\G\M-.VVB"(("R"*7
M $G. >4E MJ * 3D2J6NT7K'"45>C"U14ZZG\>:[U\8XCHZM/3]>9K>5N*77
MR9M\>QJXHO4I5]$K5?Q:%,?)3UUHHA>$(U4D^I_W7;YW\NEYOJ"+UP^UZL;_
M:V92.DS=H[FYUKB8B<U/+O5*J+NF:1"EJJ DTWMK4;3WGH0I!BHDBE(1(E+F
M&#SES4MD);#A*Q$;QMXE+PTC;1FOAKDF"G/GI[QET#,8RW]B;)7+)'"[Z9^X
M2'NHJM$81==F_AQ.K/!&0WFH$\</.>)&]GF^I(_+P[YCF2(5HCG0U@\!B%!L
M<I<RP)% 99:6+!78KUSC*9)6RW%T#;8->8];TQ-0V2JJ<9+[WG"V)-_%[CXV
M*-P4%Y$G.)C^>K$?BJ.7A@.O^*[P8P5BNN(92A0XE1D')"\K@$I* (60@XK2
M#/,4E8PZ5L,Z32RR:?/^6+&EY)MPJ3IBA9GM6@^#A-MB]P3!8[$/2Q=]M?>P
M,/%R'P;C<+U;O..[X+LT9_JX4Z!OFZARL;Q1.V6D3)>'^S)#%%9, 2*Y!*@J
M&" I(D"K (A%43&3/N*SU3NS,HT)L,.-V0A?GGIZI 0#V59QQ,',2Y]L6-FM
M";J;T4>;^%"Z4UO0=*0)J6B\T8BN?]PYFU@M>4-WJ*W\A_*OY+*2#_-%;:)1
M-]1;BZC;B G&2N;,-"?,M/&2J@)@KBC(B@SR'"')F%6).0>:D6V8+7VSJM1F
M\:UC#3V-F6$H;5534(#<5-%8;+S*M%A*.T&%EB%.)B_.8@G-L;HLMJ_ZJ@ZC
MF/2H>LLRVNA&77[7'Y)<-AFZ)UJM;N(D"T)86G' *TP *DH,<$49J+(*8UQP
MQ2O'(FW^S$16-ON,-1D?+6M=FGYOR^'!(,7P4V.KHZ8!W$UYQ<7:0[6-!RFZ
MSAO!XL3*<#R8AUHRP)C>P2A/<O%0SQ[^6,Q_KKZ;LBQT]GJ/2U7@ @IM:!$%
M4)E7@'',@:A$F4$*\SR5CO$HQ^A,%)+2D4Y:VDE'W#DJY2A2_8HJH/QN.LA3
M=)_PE#[!QD2H'!UWZB"5/N&.Q*GT/NX1]-KUWKR;WRA5<[T"M [X4.LCN9Z5
M=5 &+0G6RY( R"H3>5Z6@#&9@T*0@FA+AF-E7WS;@F#D1=MQD*SF>N=L>6@V
M2;'FPB'HTP:^_@4< Q2WE;S&XVZ>K,DGFGZR8<"G'($-, XAL8$!\HN+'00J
M4'"L@["]$;(VXTP7)NL@U5ZLK,M['@KP3>_BJU]RP>NE_++0M&[4\8;%ZX?$
MS<)4^C;5F@Y*@%^80L0/3>?C>\S3#!<5 TQ4&"!$$,"I)(!5-,T43BF7W%J!
M3L!P9 5\T)!<=NSILXL6PIQG3K8@7S\J3,VW'XTLYM"SW*F"W[5#2^A6( ?%
M-<7W8+$C_&:S[+:C;":XXSY9<Y8T_&OMF302)%V6XHX,FT=%<K-(6C'T[Y,C
M;0Z2B]]V@AUVMM]LHOUVQC$3?KU<OHR;8[?==4+ >W?G*?B8;G>?$-4]ZV!*
MNA[61=L$^4;ID]K3O*7R1:^A[YK2N@/&?492"JM*FP.J(*:3!P$48PC25&0Y
M-N7;D%5&@"W!R+M[RT'CE&QXZ,K]/'=<)#_7G3_^MMZWEZ>[^_HA:K&_!L;)
M;7_L(-):L27?:KYDS4"RYB P+ Z[4F!X_':5T3"Y;0P.,O<J=IMQIE/,#E+M
M*5:7]WQ=PY?ZDUC0Q^N9D+_^0[[>PU125)(*9$@J@#@NM36 "U 6"F625Q)F
M5ID3)RE,XP[NB"8-U423=74$O\7%U@4\0EHOYZ^]H!YNWQ/"C'#XOAUQ8E?O
M"8$.G;RG'G1?9MNH0*U[^;H@*..XX+(4("U3O<PJR0"#1 $B*ICE1<585M@N
MLZ,4(B^S35AJ1]1^>1W'8WAYC9;2;7F]%7#8 >NTOGJE\5I?QT><;'WU"K2[
MOOH?]&E>*INDX1^FXL^,/KXN:U/L_4Z/M+Q17^OEOY=?)5W.9Y0]OGZ9+Y>F
MAVI[]WH],[_^)UW4^G?RBSZ1&,=!B5"%< 4!-!T\D*HHP$55 ,1XQ7!*N"JM
M=L 8S$4/(%GSDCQWS'1A#<;!M]#\)#\ZAMXESRU++MT_ \^4Q1GCC/B[Z9L=
M1I,UIXEF-6EX-09XP^V[9&>.U@PG+<?&?V,>2OZYF:,O9Y\CEV:NYYLKS[ZO
M9YDSQT:Q<4#M[RD;F.:$[6?CH+7?J382#8^M\X[^NE)*\E57'KCQOIF(!LUB
MNV"5WO-(FDD@:5'JS=!TM\T@ A@QS#/$LY)QAS02.ZI6*W=TQLBNJYOO4'=0
MEL/X66Q18>#P2VFGOY*6ME%6K6NG(9]<Q@+$83\("HR?AA\)D)NJMI:W5_D.
MCS*=.K66:$]!VK_E&T[^J>8F'W\=!$,$@SCE!!2%UG2(0 D(*DL *69566(J
M7,N/[Q.(;+4WQ);.[;O?@-"OJ4*(YJ:;UG2B5/DY+D3T .@W9"<.:CXN]&&@
M\HGG0C0(.!GJO%N&'E4"BE)20(H" E3ILS?-) *$9T(B*(K2M7B/*PNQ?=3_
MXZ_K+W]>?;X;4^3?"DK;11T3(+=EOU^^?R"18H)*_2YH3%J6WXJQ,];@=P&N
MO^"^TTB.IZ"F<#%_O?_K]L,]H;F A20@13D'B/(,$$@I2"7$2I852:6=XV]G
MT,B:Y*]9;4)^;K59VV917CS)1<WIN^3#_/&16L=1[\(P<&3Q%,Y-"_C+96]R
M'Q&DQ_&^?KSUOJ__M77![PTWC85]1("-'7WL=R$V\#_IZF6QX[FX43=Z;6JK
M?/;P26H[O0O=67ZJ9_)Z)9^6]TQ;T4(R8;IBIP"A- 6,P1244/!*V]<*(^*_
MFSOS$WE![F]?3QUW>M_JO(,FKG;-8/)H.%S'RFI#5Y.026VX=,["'#='/F9"
M5.3'V P10!]I0WA#-:E!X<[E&:T+;TC[30W_8;V5JWQ>2-[FA!X4H2NH2(G*
M%< IUA:)+!5@!4OU2:C$D#(L<4G\ZO7U4)W&^WKQ-%^LZO]R<#!:8F:MR\9"
MX*>J=JC&+]]G(6)\%=/'Q-0:Q *0(PK"YBV/VY<WI3+TR6:G%,]]I2!3:='<
MO&CCB2-]&N$" IR5*4&RR')AG[#42RJR2?3Q;6$7<XC?*3[E<+W0CYC%74LP
M'-Q6_1:"EFZ3LO@I @0.MRO!H/"[6?&&Q.U.Q4K*WON4_A&FNTNQDF3O'L7N
M#5_#I<GK,$%<VC;2L[\S='>AP"$O2LP9R'!%31Q5!C!"%)!4YB2O)*?0\> W
M1#*R(FO3I_B&OKL2<T#/UHP)B8F;4NN#(\JEC:VHT4V:048F-FML@3DT;:S?
M]._ <L)W>X]IGJ4L4Z"0B@#$&->GG+0$L$J+,A-E4:;9_0^Y8'.7-BPGJ+FL
M@EV:]E<Z:TKN35A. 41AR?*2Y( J4@%4\0I0T\BBR*I"D@JF/)?WSTVCG-L5
M7:PF!>DM76N@WE/]3ZY/.ZN$R8=Z-C,^&7/3X]!$R@8]KK&CHE  $2RU^6Q*
M2>H3,X!"8%9)_:E!WJ%WI3?&Z;%;4_5!3FI;*0)F*2L4I24$E5(:,U96@%0Y
M!$BB*D<%(3)U[HL4 "^?!$BI/Z_YW(0K/[XX1T:<1LAV5PXBM]MV_*7OJC1L
MAZ0!V29HDG2*@\G[) U <:Q5TM K'IZ$FV=S]MIV,&S;I]W*'W+6F9-Z0\T+
MQ(3&4S& 4"D PTS#BR 30J2HS*R,<3MRL0WQAOYNI]"6@Z1AP>$P/8R;A4\A
M*!J.)G@O$#XUHX81<7 Q!$7&S\W@^:FX.1FLY>QU- R/,IVSP5JB/8>#_5L>
M.NZ2+K]WGV J,U9@RH%2%)F\+ JP5#G@B)$45AQR85\,;SMN9*UE"#FLQ!UY
M+920GQ1NVL;0\-$I.Y(X* \_B?RT1._4N.F"0[9[%_W.X].M[D,>]Y;QD5_[
M'O^O]4S,'DP&2^N#_&NFW_Z@%<+CO#%ZUM9)D<$4"0DJD5%]W& *8"85X!F5
MN5 F ,LJ&]J5<.05?_TE^2J74N/V/?D_Z=/S_Y/L<.!Z*+&$TO:$$AX@-V6R
MI;^^%GHQ'"1BRT(4)Z*;W-&/,I;L3'RN<0/I\)#C^/Z(HDYMO]FV?MG=]\7\
MY>'[NK34C5H726FK3]U758FXR'( H3(M1DH&6*'_KX09+=+L_^_N;9OCUI$U
MP>_S*QCS8:=OA#%#$@ )[$9,A"S+IW7'Q_+8ZNZ]ZP\5>)5YNU2EK2KY'-U?
MOP#)>E.Q6 !(4+[;'=V65"0R\V$AF9G(ES13L/1N\N3!0&1MLR5VT)]Q6'LG
M'VP=3)3(B/FIGWU?HX:=;0N\EJ%]\SQSQ9:G=VWKO,A0!K2(B@3IT)91(T(;
MUD8J !>GME(^ZT[?9BI ZLZV4R'K!,^&JA.6-^U)]79 ",RR/&>R +Q4QBXT
MRAO0E$' M88Z4UH6"GG.@^JB$]OQ:VAZSWCJA,35OALLJ*=OV)#;S6Z*,N*D
M5Z;X$YLZJ4\]I:D/@H[)3+V7A\PJ6"[E']5\[OA][+PGWK=P2RGY?N4WSJA;
M-I_F^ -D#.R$[R&K9^_[,[+T-[I_?=.$7>W/\'O<PO[<10&;X"I/$=XV<DL)
M4EI(@#(( 2IP"2A*": $P904JBRX>^?8@X4COY,L(8^M<2BQPXX/E,-OLUL:
M(>'(0UD\=GB@3&&;N_?Q^.WF#KY[-_+A]=/MX0XNC[9OU^>A+4]O%^8]_[1L
MSBCJ$L/KY?-BLWJY7DHU*[G@L,PS0'2> R3+$K",:) 3#EEJY&(J]VN VDLO
M\CYONX0>L?"NJ:NTTQM:1A++B6^'U'X8^[5$!'#\E,<8N 0T5'62=D![U?[U
M)VZVZB3L:>M5M]L"7ML?%-_L6]!_6:FV"-#\]%@]/_Z;8JN[A9I1K0I2FC<Z
M+(1Q.J'2MN45 QP5G$"6:9QESF]T-YJ1E<">;/+4T'V75#IY8I5,7@P'R7+A
MN/M]<'2P$\9'QT\+6/H'@S#>)0=(?=DB9;E([F(@Y&%]C(]4F&$R#F)^%HR?
M[+W&C>-2T]D]?K(=F42>MP:E7#Q5&S;_G:W^J6RS#=ME:I:GA(JR+$"1YAJ@
MG%- F,) "R4893+31'HD7YQ2B)Z&49-,'FN:/J57G7 X:+FA0GI&XEKY&G))
M2V^HF%Z)&\/$#4WA\!+;-ZGCO$@7TCLZ;IPRT>,\WZ]2/GHN#(WI?UXNF/SW
MY[4M+KGY:<OFK[39L%_5DRW]7CPTZ6'-A/A9P:%..<F RM(2H$*5@*0\ UEA
M_L-HFN:99PJ(#_G(.L>P G:\)*IF)F&6FV2U9:?-YD^^RYHC[PX@7FB[GB+$
MPM!/I8T*7\"Y0P@*T8\CO)B:^)0B!+#3PXN@53S-G,:SG-W>S$K-J;*'BRD7
M&""184!Q3H!094E*!DM9:B>[9K=D9*5RNU+F=\?RGP-!+U@L0>S[[>?;KS>?
MKCY_&.'E?,)L7P>OYN*V@5?SRT'_KOU2T[R?3UC?O9!//PD*=FBU6AWWS=VF
M3W.8:<0+D'-[;I%C#7BJ),@+)6G)4YIF3J?J%^A$_OIO"8?V[NX!R"ER,8;8
MOM&*#HE#3D!Z1/<*28P!06@8PN?A^X8;+LEU(<1P]O8IPPJ79'@52KAX^6A5
M:?=_F*?]TG[=6)I10K(2B,R\:E%*&"!2::"HDCF3>:G<F@,ZTHNLDLX6&S4\
M#"[#.H+.04F-"XB?LKJ Q7BU:4>@#"Y."P5GY.JT"U^8,<K3NB0-J$\[6N:M
M"]2Z9'*H4.N\S?]T^=HV#EPI5I]_%@QSA$D*"E4:(ZN '!!>*%!FC&$JN,9N
M1M;KA6-'1^M91H:6YY'PD>S]JFF(1)ZA4#=AO,YQNS@/.K ]6FBRD]DN]@^/
M8#L_'Z-Q\+?J85'I2K#%YG;Q4ZTW=1_-V\6W9[ZN9,56E5K?V[%&LT()K6E&
M08J1+09#$M!24<!1B8E N13*,Q(8Q$=L]^6H9^WZ@'KR?6/I#VH![(ZV:R0P
M.H:>OE X? .;^7H+/VD37W?NWK!YKS>$_4U[_9?S?[=?/<O*?$L^V2^+-2T+
MJ44)F7%7A'FSHTPJP$N>@1(2JFE9<,B=HH4=:T=6/"VU9$O._1W_&H/+K_D!
MDOFI V>AO-[U9]@/>MV_7FNR-_X9(0Y?^N<N"4F-EFI>L=8;4QG7 M(<0$D@
M0#DJ 2=VTG6JE#;_8RAU;V%[N'+L+5*3\DDI/I3:P3$/E<5S4]14@E*D#^7Q
MR9$.E"O,>[[PF#S3I#M8[\^3/KQAPD3I#CZ/,Z6[+HB3+7G_QW*6\1)GHA0@
M+40*4(HXH+G4 '$%$2I*G;L-Z_*@&7GW7\R6W/RQ'#<7T.+H=.8P-CJ^YP^N
MN7_W,1 :-UO2$ZG8V9)]B(V>+7D@^]!L2;O4+Y4M>2";;[;DX:W!=<S+IY=Z
MJL/Z"]O4*0L+63?9O5W(9T.]8O-M!\!ZE,#ZFUK]K(2REVTGC30?;$](,BQ1
M#B$HE; V5%H PK'MIYV1G!O%2[%G3\ZQ68RMCALFO:NGQWX0>8%%SC4"7'($
M$,HX("I/09II!%.8TZQ,??L5O^6C"&IS_*L\#->HU5L"[!FKWG'ZSI@:FR;%
MS;;YK;NL5SMV=R,QD^W5ZX;EYNK=F*OFTR@ME&*!&K^"?VS&IR[^CP1\1]^
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M8%K=V'!Z9MB%X=&?:N>YYH0Y=V'2'B??!:XQ9M.!^4^U;=G.<JB8\7T*@B%
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M>$M?\PU6ZTV;_'FW^&33?0ZSUU(,-8:$ [."<2]DF@&&S4^IS* 0E&4Z=PK
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ML1%9*QIB0?,'@Q!UMM BX^1IHSEUOZI92HS)\W:=KWI0>?-\Q4[F?K&$Q3X
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M[! ZN+#P<*U?HY2P0SKGXL&N>P.49GLX=+^\T[H21O.T7UJB48YR HT5PS!
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MTW4M7,2P3$&7A^?93*U;A/Z^::_NF;!%6C>WQ]W0SEPSJ!%YFXNF2YUGD&M
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M4;XH@A +(;QXW5(@^]%]-IX/YS].8D1!SM+LQOE1&E!FB632@)6<@\!E@VL
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M/GO*2+UN&!O?<9BF&-58:JPWQM*Q>0#E P))4H$IQ(=VG&+0[S@"QWD@9:(
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MJ4$'K14S0)DK*=&RU(9)!49$$R5#OUBSUN#;3H/<H[NF:57)>\/Z6YKZ26/
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M;LDH,$D]"];B^JI6<+;Y'5U75!\6,DT*N#\X*9):7($L9]$OQM(/= @^&^]
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MT>+6OB/QW9QI]@6Q=31Y%%!=IO(N//#YR6R6YK.!$Y9)FPE(78: .^N+4Z+
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MC.KG[<^WVNY'C^[FVN8 ]GM?<?7B>F_7XX?WPW$ZGZ=;C$$S]YI$Y(U;E)K
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MLX@Q[5LWG/[-C>Z0T9O)W(U.D;MA3,L2S)NI&\^6= Z8SRE%M/+44C3UI6[
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M_+P64BRSR/TBA\9@^&0B6+MH%AU#,B9J)[K)Q'R=]CXU0CBH7W= E?8"LJ5
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MJ?F7&WL\SBJ<28Q-0/2)Y#(?6:R3RH%%7M]@C0<O,8/@++DD?7!^.5MP@GS
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MZ^OS=_QS\MLTL@*L5E@J1A8[ZAC!A8!8LF5YE+WR\VK=(/,K!&H'\[A-T-2
MX@V"$O/.2"^!!4_.G34>@K((.4M,**,0CH\ S<^K=0/-KQ&T'<CC1D&S*3?H
M8=X7'KB!4ENP*EOSWHPE8]Y6PTPI0S[?J-AMZ0N97R%^.Y3#;2+FW>8_-^C)
M+'(O) (WNK;O%0[(4-,044L3N13<CC%]?UJL&V)^B5CN0 XWBIAJRM^DR).#
M%[4#(QA=M8@"4 8B4&8A94F>C+2Q,=V^J/E% KL#N=PF;@[QQQ\$">>U(A.-
M=*4BL]X$!RYZ R):(82R@<4Q+T8_K]8--;](C'<8C]L$38U%WB (LV)1& O2
ME-IN@K[S@AG0=:X9HA+%CWF-_GFU;J#Y->*] WG<)FBN&O8>R=')\BCK&3"*
MU>!DA. U(T]0&R-%*::,[XG<)WGN%XC\#N5ORW#YD3?*=;1UVS7/JU03K8"/
M@@%R([0(4B<]JC_IS\MU \WIAX#'<+EEW-Q()94Y,D(\'8)BB6&NMN&JPRY]
M<5B8H_MV9"!XVW<TD?@E8L&#N=PT;FYDENK@A.'2@51)@5+" *9DR$?DHBB9
MK,ICDC'O+-@-.[] 4'@4IUM&SXUTT\*TR\(KB)GN7J5)I7IF>)W81<8_1REP
M\:$/XO1CPZ/XW#1T?F2@,A:2BL0C'GUM$*YJR\=0 $/2W%E=_+B4B%OK=8/.
MZ<>(1_&Y9>C\2$OUGFO+4$$Q]0T_NPSHL?:M01>$USGG44/1?EZN&W!./U0\
MALM-X^9&]@=3+'A3NQMY@Z!X">!1:DC.(_-T4(H8KW/Z)@*+TP\8C^-TR^BY
MF;@:0J";-N@:EZJ=BE4$9W0&(5CVKF@Y+C?KSH+=T'/Z@>-QG&X9/3>R65G)
MF&SM3ASK9&4A&6 N"N@J5NB9%]&.=[-ZI@N+TX\?C^)SH]"Y.<!+%LTSG08Z
M";S.8)(!@B+K+7B1LK+(G1F3>M-[/IK\!2+(0_G;,EQ^Q#:E<TYDA9"*KI5]
MQ"@,48'-0<9@/"8UIG9ER)@B^0M$D$=PN67<_(AM,B6"3[5S;2ZR1C2)(L,D
ML!2T%%9K\:-N8*'A]O(7B""/X'+3N+D1UQ1&NB2*!B*)/,5B%3C,&5@IOAC$
M1%?R>.3T;?_P"T201W&Z9?3<B&PR%2R/C-?V.(EX1M0X%DBE^J2M,8[G.*JY
MS*WUNF'G%X@@C^%ST]#Y$=E$CL[6C%<K>21"M*L3+30$$[UTAL@U9CQT^D60
MY2\001[#YY:A\R.VJ1/6>M($(3,Z#&3J Z(J8*2V&'W(0HV? MLO@BQ_@0CR
M""XWT2)YEA:5+[\W $[!:51.@&29V$WGIBKC3,=*<2DD2_SVN\6I]4A]V6N"
MV$*3;!IH-MHDQ)HX<E<\>)"R<Z<#\5IJX+7QC(IU[(]3A&<6A0_6QSO9*3.>
MF2<V^TMVV!V(K3O GU+032'W)A7')NU53[S8'OXBX#ZG-_CM$TGP[.*B3L^L
MWY[GC(P9K2&)9$F+T!=GV6%@;O%T/8:2EANC,XJ47U+53XWZ^4$R83O_R:9,
M/,C>P[ "995*D:S/Q+&^U-!W(3%%G,TJ1.==N)T<O]2LB4?WW=+4L^;P/I/X
MFU#XMWC\!VXN_H$?O^2SRS\S5GG4,_O[ ],WR4PLJL9]"V=TO5ERB)!A :%0
M$FL3N],<=[DI0+TH:6F&6G/P7PPBC6C[L7P_*(*<E?#>,4A%5(?*D4.%V8$)
M6$3&$AE;[AZ8@J*6IKVU?D3FA\QD=\=44X[>/G]Y]O[Y[V_.WK[_?]^_/7OU
M[NS9^Q>OZ9=7O_]V]O+LU;/G[][%OW+Z\C'O"O'GRS9?1=EVY?_*W_[$+5Z9
MAV]H?[OM-G\<,0MIMKV,FYBT#(M&SE4Z1$+?YH^DSLEXO[C\=A;V!PB?:X="
MB%Q-F^A R9C)9*\')BBOA$V18;<$Y?L^?=HPY]FGW9?MY?[%-GZI!^.W;\^W
MEYOZ<'3QYF+W=;/?U)&W]_/T7;[X2E;>_O"#J?[;=YE4%&WXQP\?/FV3CZ$S
MKX75/%O2O,S3L:VY639EX(:.+:-;C]_N^[Y0 '1)+JPX"F4T6!^/9S:+I2;<
MA_?TD]>S 1]P^/>'J44J!%>"4\!SI<RK MX=GMNP^&29LFFY4])UURW%/MO%
MX9WC,PLH3@;NQV?(S'T./AJ0G!M0M34TVMH?FL5<#,_.2]84X-><>38W=@9!
M=( @UTX4.-#SV_WT7+D:W]NLI20<EV BRZ RKRU)4(,+GFEK4;..+5:[KG@*
MN!HB\-W<W&]"[_T3*R67^^LY<-9$G@IM/=6VCH&G6LE2AZT8)TI4*C!<3+?]
MO+>U'VYFQMDD(EE;2Y$-L_N4WY%8#OQX67^Z"JBJ]6(E)F,3>(."B(D(/A4&
M$J5EPA2)'7O?/;+(VA@Y*;-N4HDUBKSK ZEE=!@<42*JTZB(DBPLH+<REJ(L
MQVZ7XJ/+K.@J3R;&#M@8P-.UT?&W7"-N'\^VZ2Q]VFPW-99PN?F:G__G<][N
MOS<\,<$H;3+8D$EMDPT*(=H,6((O(LBB=;?<[D[+M8>6(8+=S<KEM7'SEH1"
MJ__U;/?I\VY+K+IN-I --PX]L&1(W=:.D8$C>2PB9X4NT^T?.D9,[UU@Q=&R
M,V%C"DXV83"O<,7_>,M206HG@H7DI:\IRL1Y:0/X0MY%2<YB28N9YVMRHJ6L
MEN8-O39$U@N\31SU^XFO&HRNLP/8WOVUN[BD)3\]__3YX^Y;SK_1%5@VE_MS
MR23:H.JU)BJQ2@&2R("3ODN.',#LESNI(PA9.[IS.HB]<]B6@L_)G)5;@9-S
M63A7(43@H0Z5%XR(+/1%>L&%%586T=89N47 ?\-HPY)G8PQ<3N1,G.N<-2JK
M"9+UG)=4P&G#P9 KA"F@M<@;.@+_#<VNY1#?"PS# ;Z[Q(^SI(F]>W[V]ME_
M/?]_WCQ_]>[YNU%97O=_U-@DK0X;')EC]4/<9UO\^&V_V;\N5P[UV38=PR#?
M,UEBM)QC-!"43J!J2 Z38$#'4RG+LF4E+G;VG][OJ$#*6?J*VWCU7E9^SU_S
MQ]WGPT&XV'VX0#I<4BNF<^3 6.T8BS6M1QER<P)'ACGZ&+NU 7IJI;4-VHF!
M\5.095(NKQU[HVN?/JY&$[];Q9A8-L4%**1P046?P&=60!LA$RO&\]*M@\+=
MSU[;EIL3%B,YN380Z!-NA93IKC2UO;1("K)QQ P7!7CN$8I,4NH<HO'=8O7W
M??K:9LZ<8!C-S;7A0,JLY'TU[PY/#<]VV_V7CY>;[8<_<MZ?,VX-9E)I]D")
MYP)<E!H*!J^\M]ZG;@-C'UUF[:JB6;7%9/QMP@F[?G@@4F[<B$=NG0OIBD?O
M@6'D5^\9P;,()FJ#G#/E<+E<OD>WNG:5SDR0FT-0S?E&?WO^ZOG;6@CR^]GO
M?[YX]>+=^[=G[U_\X_D$OE+7CQ[G.PTB8$E?*B5.F- 61-:Q%GD)"(1%\!H=
M+[7)[NTYX:?K2SW#SQO"Z9]X\:_\_7RX$ SJ$"$=DCP".O".D:'OR<X3U@JK
MNM7PW/?I)^ S]0' 3]?=:&XV<<O=?D"X)D2S[*/U&329<J!4<8#",[#)JL*3
MM+'HQ<[% YL\ ==K"+JF%4X3*'L=XY?/N(W?KBE@21C':TVKS.1&!N:A]KXA
M-HFHK0TV\N72A6_O[@2\N'&X&B6.)@!UT]>H[L4U(5)HJ9F(H&.E1BL!Z(*%
MB$$;SUG1M_.K9L35 YL\ 1]P'+RF$,[:P8+?ONPW6R+B'H_"*^4+DQRLK7F(
M5CMPW$K(@KD2K"$*NXU'>7B-$_#9!MM-$W%V;8"\V'[->_K[0ZUQ;=CP#C_F
M/3'JRB#<;#]<4Q5S)F035<+522_!(CAO"/96$/*9+?SV<\V#.>0=E^P$G\G[
ML"X#GWGXOC::7F[VUY&RZ^W3[F1.R"!KLN^4X HPJAK'"%9)Z8,WW0;IW/WL
M3OB8?%K7,O@8R<DFK)LG\N'/@PI9&1>!65D36HH!EXJ"(DM)4@O+W7)-%9_8
M;">L33[;:T%K9TIA-1> ?/;ZU?NW9\_>OWOV^L\_7[S_\_FK][4Y3?WC%Z_^
M]OS5LQ>C@I!]/GY<('(P(5,TSWFV^_1I<WE5J'X-.I4D634\ %U29.MH7XNK
MA 1)+GV1LI#!TRUOX9X/'Q<E_,&@J\QQ=,4;[1R@#*0^BTX0?/; BRK2:$WG
MI9O]<ON35RQD&BN1GR.!8SC6Q(5SR%-[76IO,KH[:_7.!L/FXR&/[5 *R)A*
MULL(F'R-:S(&]/\ ,7H1DE-9J^7"Y$_M=DU<C8+"G;ME4KDTC[1CJ9A1V7MO
M,D26Z#J.9*XY1R<R^YA3UM)Q+$U@K8WV*--BI!<$!PBL"1"^OOPK7]Q+T;&X
M,#-3#$,+*D</"@L#A_2=M2E[IE2Q"[;J?&JW+0-P"$+NAJNG%-?:GOZ-&^+E
M]PSQH%%&Y'1+Y$@^ B<C!#,Y"KEX)R-9'\5W:W%QWZ>O6!,\R74X#=N:4#PW
MFK\>GX]O&*+GUA3K%)'C8JQ^J'$0="IUPF\HWC/-XW)S<Q[=:AL6UD @W-$O
MTTEE;>5RB(6^W7W#CY??WN2+6*7R(9]K<FT*Z4%P6AVRM^O#2VTN%8TJS 8M
M.@ZNO/_SVU PX] P%?N:Z\+\[.S-B_=G+_\\>W7VM^>546/"-0]]ULC83*<M
M3A*(N<[9N:ZG^N[\&UUBD"F!3G3 %9J:)DC \3JK@)Z1!=WM4>_!)2;PG?;[
M+SD=%SB7JBBI>":S/AI0"FFSEBP?$93&)(PHSBYV6_RTM35OATD$?(\7-)CU
M3=@=AYK8-Q?YT^;+IW-79&WY8$ '4^K\!21-AA%,DLSQHI41<C'@W-S9FO?(
M3+@9S/@F8%,SJR^^YGMZ%](E&P0K*2.=@7HI*ID Z_,:N5P&;71%Z^5J\!_9
MZ#K)7+.":BJQ-(&Q8]/*(TWG+!K.E0S O%&@H@IU_"[]MJ *+KK,M5D,5C_O
M;9V\K5F1-(+Y38#G+,8OG[X<FOT?@T2?:#-_Y>U^\S5?O?>>&QMSSF2N8U"L
MSE")]74W@@^.2U0)Q8*9S!TVO$[NUZPPFUI,36#O;752MCD]QXLZUV=_CB%9
M%Z0#*9TDU9O)3:P=[P1JP1ECG.-R;V2W=[=.2MC,U^ ( 30!H>?_Y\OF\MMY
M<3R@KE+4A^QK:2 4\BY$Y(A"1V;$<H,PKO:T3H;8K' 9P.SFTG'^>/'J[-6S
M%V<O7[QZ]_[MWP]QKQ\#HO[8;'$;-_CQ;+_/EWO<IILO,</#/A.L.BY -#79
M4X22OJ_Z8DOP_/)S*HE#KKB-!#*9"&1&U0ADRF"D*BERHR3C3W']R55&18IO
M-D2ZQ<"SGQAX]6YC/5?D1V20A1Q6Q3D#K[RE0V0#R\DQE[KUK>VW[HJ1I,GD
M^U.$>4:V-W&C/2,;[\/N8E,''MRFK^8B.!.8Y;(^^&D$Y9T"1WH;LI%:J<"+
MPN6NNB<VNR+XYH3)W>>O"676.@B/^0C6Y1Q%,&#J2$U5- >??0$T6?"DO8EE
MN03J)[>[=H+'I #I [\!TFH"@+>9=/E]0/+[ORYV7S[\]9 7?.3%MV->2PJ*
M1ZT\",-JX4+D@-QX(!,5G2B&Z06UY41$-0SF(7"[ ^<U9-\FZ,\^[2XN-_N<
MGNWVE[>HTZD$2]P$C4@J(Y,_A\IR",$J79Q'C<NU,.RS\[5[#BP.WZFDV 1&
MGWU$(NN!:\SR8ET@HUZQ^JI;)V=YZ334Z8&B(,_F]@"\.8V"1W:ZXCOILH;I
M5-)J&GO'8TM4D$LI-&BC:W&\=N"%X_1;E9W,2=NX7/3X\;VN?H5/AHO.D!L@
MI+5S 9_A_J^CGD:?$&,44+BG8ZAEH"M!D>B3\XX+Q4/HVN/I^C-;Q< 00>W&
M<ZT)#?/^ E-^FV/>?*W:]SH[/OK@D,4$.291YV99P%@$N$0600Q8BEON ?3^
M/:YN54V/IDG%T@2\[C4];Q<;F<"#DX8!4W14E/ :G*]?6,#(N?!.+M> I\N.
M5\P/6C_*-T9Z)X')Z^ESI,A=J:,#DR7+( A>$S8U1"N-XSQ9E99+5NNVY]4O
MV,GQTAN2 X37!"CO9=>CCK1"(7(U, *=85"2D!.,R)!1H#88R9%>#I^]M]\Z
M5(?@Z.' R"Q";0*W=ZV@V^==<<%\G?M@R,TB0\B2N5)D)(X*GVR,D97E:@Z>
MW.Z*"9LKQTG&R*U]*![/<V&)*R,E9,;K?'O#(:BH(7%3E(D%/5^NCJ'#AE=7
MD]/"I!\,!\AL[0#*68R'06%O\%L]I+7!4XP77W*Z6X"NF#5TESB0+'E0V49B
M7":SB-NHK8N"J6Z]VKJOV32:ADA[-S_KFU!M+S/29]VA0_MHO,\.2@JA-D?5
M$! S62<\$1U2);U<E.;^/;87I9D&<I/*9FVMU=GR>/F]7MI(SPH/=&9B)<\P
MLCZ,$V!RM$FSHNDVF#:Y[V6OWA3S%#LL8*(M(9 F=%J-FI^GE)D+V4-(M7]:
M%/1=MA8*FF2BPQ#L<GV;ZHY.(8%OH-#OB:7TE$ 3N#F$QHDA5SDQ=1QK+4;[
M'BFO&?_6,TD^>A$6E$\. O<.7)8,%:D?PY:+BSRQV5-XE9\*;5/*K0D@'FDX
M6IG'UJW[6Q3>8.0Y"DZD. Z^SKQ3+ =P'ATP+#EYQ2.RY>9_]=W]*;QY3*88
MYY1L2]B];;N>B^R5"U* ]'549[T(@B\)A.-..RDU+MCGX8%-GD*(;F(DCI)3
M<^V%[BO->E6KRFL+[(EKSNY\[O1598]O??:ZL2@UB^1I@(XFDZ.9,Y"V41!8
M=#)EC.[VD6V\;DPKE+YF,6.LU9:V=O[3IF9C(4>!BD76+?/HUZ@;ZR/?,75C
M?=C>Q!WVGGYR_[J\W>S_=7Q9EH%';Q@X+1FHY#TX6S6C<#9)4HH^+Y<.>7MW
MI^!8#@#"73-_C%2:P]4Q0JCJN*E,DE8E<*+!:@@Q$G.X02G16)F6>\.\N[^U
MX_KC9/XHA 8(H D071EN\5LEXOK502J/Z ,D6R2=JTSL29&1OTO[%SXF=WMZ
MP^RV]<W]M02B(5)_P'8>+((3#,I[CD4*DX"< V):'8?MBR GP=3.@S)KBQ-7
MW/<+RC=17S+D>EM"(&VHK1H2-BQP[HH%J^JQ,\0K.C6!B$C6*\Z%# O&J4XN
M*-]+Z/<'Y?M(H W<W(V)"4D:-9/*+C83#5DK\"(5X,8[HTK6Y78!R0*AI)Y1
MI&9"[R,Q-4XZ+2&L1TRV9!5"3F!,+315JM:8DB$:D\ID0'!)7O7_1-O;0><\
MDEW;BGM7R_4O-U\WE]^NIPK^L;NX:>N^S;C?;<DT^?9FM]]OR$1Y]A=N/^07
MV_K7_\"+335;CJWES[TRQCB1@$7.:E]YK"T/)7"?M!0E<^M4)Q-OXHV=5E!^
M"&!7%^>O N47GSYCO'R]K2._-Y<OZ2?/;6!<8.V-E>A8*RD%.$P1,G<<43E]
MIR_]S*B^N\=3R#IJ". CA;PVUE]LZ8/R_O(M7N9*UHMMO*AO<+_GJU]?;&_^
MQ-4XU]JI=GMEOD>KC<@!3,FN-A65$)POP%*)CA6I<G"=X#QJ&RNV;UT2L<N)
MJC\H_14HM_E#7?+]TM@\MDEF.127= 8?LP7EH@.TH4#67GD3_O_RKJVYC5M)
MO^]_Z3VX7UZV2K85EZL2VQO)9W>?6(V;S+.2J%!4$O_[;5"4+>M"#X<SQ,A;
MJ<C'RJD!T-\'H+O1%YY,QTYANX[<L"+L-!G8 Y")DHX^>S&+AFE7,SZ*%AX4
M<P:0J0B6\YB<+(G[;BD,3WV]31/PYN396; O(KSC6^7=WQ:7>87++T\5WKWO
ML?_E_*9V5ZNS&*\.\3Z3&;,\\6!"&CWZQ*!B1&X%UOI:QU%D<$9P2"[0N:90
MV?1#C$:+/OGF8[B_H]_CBOZDC7Q<A;.Z>[=<SJ_GEV>_T$GPU%1NWPZB%SHJ
MEH!S+T%Q;Z#N1O Z,N8\EU(=+K9XF#5-->QE%V(]]BDUP+NAR7*]7'U][;Q-
MRHR,9,0,&*L#J*(0@B&C"TEH5ENGM-G6$:?@=5A/DCZ\IN@_\OGJNOZM;ERU
MYN'#,5L_'[= ?#& ^%M:NILYSX[.SS?S_Y84QW-)B>D"/'%..JK49!@%#S9Z
MS+QPR]6V=M;7.?[[V>+/?]R-<4NCN[]]H]&V.;2AU'YH+@86[13H\>GDS2QA
MS>>6&6).-1ZC. A%T@\A9"F2_O7;@E=VI@.-V>AF&@RYAU3858Q3@/[MJX\S
M:T31)D9@42<R;1(MVJ,EVZ30;T+-U-GVD+8S]#1FH\?9T:#?58Q3@/[XT^\S
M3!%95'36K?-:0HV:89IT,ID-#[GVV-KVAK\S]#1FHY?/T:#?58RM/=_/%DK]
MS@A=7XP\*N%48N XZ>E*24O+0@W%&.FD*TG(;G[%[F.V+B?04,L<$YV70;K-
M=L2B:;]X,@4%DO B[40OHP.- H4-0F6A!Z1=2UUT5,QWYU4/ )HSZUMM7NF"
MX773.44:%VTZ!9YS!(_:QZR%**DC;QI7-!X9L6=*&^\BODE$C#U30U<6QY55
M!9@C%4P%;\%E5O>(5\8;ZUTZ7'3KE$H;'X96@^+3^G39I>94B"H(4O]\2=6?
MZ>N;GTR@M3!221]CQYB @<M]C=3&_""GTTCBG\3I]5Q9*:&]X62&E*)J.CD7
M@,HAH,C,VZAB5H?+<=RCY-=(/<\/=WH-@,\D>+:W1?/M#3P*SG/P&KP+N98Z
MB."<JAX.,H!UT9$?D)O#K:O-,3H)F[,Y35I?\%O/D1D7/OF@&1@FJS>7M.%0
M$,$&4HFY"84YT^E.WSK,BW]9ZPG]8A0<)G'HOB9Y5H$MEGE^=GG\=UQ'T-80
MH)GQW+) MU+TM>*X(#O>&1)63,YJ^B>[AWKBJ!6*GYOGBW?$[4?*P:&<!"VK
MW([_OEJ+E3;:@D2VRNF_YJO/]P1W\AF7M.#7] =&&GU^O9K'&>IL'=;0-[M^
MV*+=%QC6JD0296(L:G6X4K3]U_'B[_JA:'T@*DPN>/'=^]<??CL^/?KOVU#=
M4_Q['9B9XX(D?3Y??WB/<,1=/K]?@&'OA0P1,OAUS/PMH MS<5A;TK*("91R
M$;#24X:2C68J2]U-67KBX_L????R5-#GZ&RTP$TMN.22AV!+?:VC/Y@0=5,=
M["C;,0%I'%_SOG ^/EYZBGL2MR3)89.D>BN7H]71U=7Y/%8K:[/-9IZ,*1N0
M _><SD"L'25%$""+T-HDFZ4]8,&@'T^XH<=Y>'(-#5#[%(Q[ZN8FU^[HHGH^
MZW%^=EE["9'^^7&9,?YQ,Z_Y>_5LOYTH+7AM,\V*M,*Z4$#XS,C^CR13+AW4
MK 4=Z=\@#M<^N_<R&OJTAR?J8<!L3]^U^.JN+"5'4F2KWIA?X;H%UD7=J&L
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M_H]_^S]02P$"% ,4    " !5KMY:OC?4SCH$   (#@  &P
M@ $     8WEB:6XM-#!X9GAE>#DY-GAC96\Y,#8N:'1M4$L! A0#%     @
M5:[>6F>263M=!   -1   !L              ( !<P0  &-Y8FEN+30P>&9X
M97@Y.3=X8V9O.3 V+FAT;5!+ 0(4 Q0    ( %6NWEK9IR8\UP8  +4@   =
M              "  0D)  !C>6)I;BTT,'AF>&5X:&EB:70Y.31X8V5O+FAT
M;5!+ 0(4 Q0    ( %6NWEJ.W?S5X@8   4A   <              "  1L0
M  !C>6)I;BTT,'AF>&5X:&EB:70Y.35C9F\N:'1M4$L! A0#%     @ 5:[>
M6OL-UFR[80( 9.\7 !X              ( !-Q<  &-Y8FEN+6%N;G5A;&EN
M9F]R;6%T:6]N9F]R+FAT;5!+ 0(4 Q0    ( %6NWEH(H(K%@ ,  "L1   >
M              "  2YY @!C>6)I;BUC;VYS96YT9F]R;30P>&9A;FYU82YH
M=&U02P$"% ,4    " !5KMY:(0!OX"45   =F0  '@              @ 'J
M? ( 8WEB:6XM:6YC96YT:79E8V]M<&5N<V%T:6\N:'1M4$L! A0#%     @
M5:[>6EG?0AZE^P$ A@43 !X              ( !2Y(" &-Y8FEN+6UD87AQ
M-'@R-7AM87)C:#,Q,C R+FAT;5!+ 0(4 Q0    ( %6NWEJ@[1Q134 ! #J'
M$@ 1              "  2R.! !C>6)N+3(P,C4P,S,Q+FAT;5!+ 0(4 Q0
M   ( %6NWEJ@^E""61P  .ED 0 1              "  :C.!0!C>6)N+3(P
M,C4P,S,Q+GAS9%!+ 0(4 Q0    ( %6NWEH;?Q]@^A<  ,?=   5
M      "  3#K!0!C>6)N+3(P,C4P,S,Q7V-A;"YX;6Q02P$"% ,4    " !5
MKMY:&=#B@>$Q   \;0$ %               @ %= P8 8WEB;BTR,#(U,#,S
M,5]D,BYH=&U02P$"% ,4    " !5KMY:1E&V*#5[  #!E04 %0
M    @ %P-08 8WEB;BTR,#(U,#,S,5]D968N>&UL4$L! A0#%     @ 5:[>
M6G5<5ZY<*   (RP  !0              ( !V+ & &-Y8FXM,C R-3 S,S%?
M9S$N:G!G4$L! A0#%     @ 5:[>6O=A_# Q)0  %"<  !0
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M" !C>6)N+3(P,C4P,S,Q7W!R92YX;6Q02P4&     !, $P K!0  0M@(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>cybn-20250331_d2_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:cybn="http://cybin.com/20250331"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cybn-20250331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cybn:LPCPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cybn:LPCPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
        </entity>
        <period>
            <instant>2024-09-19</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cybn:CybinCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cybn:JourneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cybn:SerenityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cybn:CybinUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cybn:AdeliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cybn:CybinIRLLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cybn:CybinUKLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cybn:SmallPharmaInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-23</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cybn:SmallPharmaInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cybn:SmallPharmaInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">cybn:SmallPharmaInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-23</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cybn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:GoodwillMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
        </entity>
        <period>
            <instant>2025-02-10</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
        </entity>
        <period>
            <instant>2023-08-23</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:LPCPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-30</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:LPCPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-30</startDate>
            <endDate>2023-05-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:LPCPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:LPCPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-30</startDate>
            <endDate>2023-05-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
        </entity>
        <period>
            <startDate>2023-05-30</startDate>
            <endDate>2023-05-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:LPCPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-23</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-04</startDate>
            <endDate>2023-08-04</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:August2023CompensationCommonShareWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:August2023CompensationCommonShareWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-04</startDate>
            <endDate>2023-08-04</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:November2023CompensationCommonShareWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-14</startDate>
            <endDate>2023-11-14</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:November2023CompensationCommonShareWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-14</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:November2023CompensationCommonShareWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-04</startDate>
            <endDate>2023-08-04</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-19</startDate>
            <endDate>2024-03-19</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:March2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-19</startDate>
            <endDate>2024-03-19</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:March2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-19</startDate>
            <endDate>2024-03-19</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">cybn:ClassBSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">cybn:ClassBSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">cybn:ClassBSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">cybn:ClassBSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">cybn:ClassBSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:UnitPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:UnitPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:UnitPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:UnitPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:November2023CompensationCommonShareWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-14</startDate>
            <endDate>2023-11-14</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:WarrantExpirationPeriodAxis">cybn:WarrantExpirationPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:WarrantExpirationPeriodAxis">cybn:WarrantExpirationPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:WarrantExpirationPeriodAxis">cybn:WarrantExpirationPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:WarrantExpirationPeriodAxis">cybn:WarrantExpirationPeriodFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:WarrantExpirationPeriodAxis">cybn:WarrantExpirationPeriodFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:CommonSharePurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToOfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
        </entity>
        <period>
            <instant>2020-11-05</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-05</startDate>
            <endDate>2024-04-05</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-05</startDate>
            <endDate>2024-04-05</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-05</startDate>
            <endDate>2024-04-05</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-05</startDate>
            <endDate>2024-04-05</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-05</startDate>
            <endDate>2024-04-05</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-05</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-05</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-05</startDate>
            <endDate>2024-04-05</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-05</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-05</startDate>
            <endDate>2024-04-05</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-05</startDate>
            <endDate>2024-04-05</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-05</startDate>
            <endDate>2024-04-05</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-05</startDate>
            <endDate>2024-05-05</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-05</startDate>
            <endDate>2024-05-05</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-05</startDate>
            <endDate>2024-05-05</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
        </entity>
        <period>
            <startDate>2024-05-05</startDate>
            <endDate>2024-05-05</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToOfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-15</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-27</startDate>
            <endDate>2024-11-27</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-27</startDate>
            <endDate>2024-11-27</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-27</startDate>
            <endDate>2024-11-27</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-27</startDate>
            <endDate>2024-11-27</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-27</startDate>
            <endDate>2024-11-27</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-27</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-27</startDate>
            <endDate>2024-11-27</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-27</startDate>
            <endDate>2024-11-27</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-27</startDate>
            <endDate>2024-11-27</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-07</startDate>
            <endDate>2025-03-07</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-07</startDate>
            <endDate>2025-03-07</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-07</startDate>
            <endDate>2025-03-07</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-07</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-07</startDate>
            <endDate>2025-03-07</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-29</startDate>
            <endDate>2023-06-29</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-29</startDate>
            <endDate>2023-06-29</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-29</startDate>
            <endDate>2023-06-29</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-29</startDate>
            <endDate>2023-06-29</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-29</startDate>
            <endDate>2023-06-29</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-29</startDate>
            <endDate>2023-06-29</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-29</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-29</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-29</startDate>
            <endDate>2023-06-29</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingThirdTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-29</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingThirdTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-29</startDate>
            <endDate>2023-06-29</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFourthTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-29</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFourthTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-29</startDate>
            <endDate>2023-06-29</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-29</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-29</startDate>
            <endDate>2023-06-29</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingThirdTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingThirdTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFourthTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFourthTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFifthTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFifthTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourAndThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-16</startDate>
            <endDate>2023-11-16</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToOfficersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-16</startDate>
            <endDate>2023-11-16</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-16</startDate>
            <endDate>2023-11-16</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-16</startDate>
            <endDate>2023-11-16</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-16</startDate>
            <endDate>2023-11-16</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySevenAndThirtyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-16</startDate>
            <endDate>2023-11-16</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-16</startDate>
            <endDate>2023-11-16</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-16</startDate>
            <endDate>2023-11-16</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySevenAndThirtyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-16</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySevenAndThirtyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-16</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySevenAndThirtyEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cybn:ShareBasedPaymentVestingPeriodAxis">cybn:ShareOptionsVestingSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-16</startDate>
            <endDate>2023-11-16</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySevenAndThirtyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-16</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-16</startDate>
            <endDate>2023-11-16</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-16</startDate>
            <endDate>2023-11-16</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:GrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-20</startDate>
            <endDate>2024-03-20</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodSeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodSeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodTwentyNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:OptionExpirationPeriodAxis">cybn:OptionExpirationPeriodThirtySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:ShareBasedPaymentArrangementOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cybn:ShareBasedPaymentArrangementOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:IncomeStatementLocationAxis">cybn:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:IncomeStatementLocationAxis">cybn:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:IncomeStatementLocationAxis">cybn:ResearchComponentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:IncomeStatementLocationAxis">cybn:ResearchComponentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ItemsOfContingentLiabilitiesAxis">ifrs-full:OtherContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">cybn:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">cybn:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">cybn:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">cybn:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:ClassesOfFinancialAssetsAndLiabilitiesAxis">cybn:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:ClassesOfFinancialAssetsAndLiabilitiesAxis">cybn:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:ClassesOfFinancialAssetsAndLiabilitiesAxis">cybn:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:ClassesOfFinancialAssetsAndLiabilitiesAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:ClassesOfFinancialAssetsAndLiabilitiesAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:ClassesOfFinancialAssetsAndLiabilitiesAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:ClassesOfFinancialAssetsAndLiabilitiesAxis">cybn:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:ClassesOfFinancialAssetsAndLiabilitiesAxis">cybn:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:ClassesOfFinancialAssetsAndLiabilitiesAxis">cybn:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cybn:DeferredCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cybn:DeferredCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cybn:RDExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cybn:RDExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cybn:ShareIssuanceCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cybn:ShareIssuanceCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cybn:PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">cybn:PropertyPlantAndEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A20402041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:LossCarryforwardExpirationAxis">cybn:A2045Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:ClassesOfDebtInstrumentsAxis">cybn:ConvertibleDebenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:ClassesOfDebtInstrumentsAxis">cybn:ConvertibleDebenturePrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cybn:ClassesOfDebtInstrumentsAxis">cybn:ConvertibleDebenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001833141</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="cadPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="subsidiary">
        <measure>cybn:subsidiary</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="patent_family">
        <measure>cybn:patent_family</measure>
    </unit>
    <unit id="application">
        <measure>cybn:application</measure>
    </unit>
    <unit id="patent">
        <measure>cybn:patent</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="y">
        <measure>utr:Y</measure>
    </unit>
    <unit id="option">
        <measure>cybn:option</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:DocumentType contextRef="c-1" id="f-1173">40-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c-1" id="f-1174">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-1175">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-1176">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-1177">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFileNumber contextRef="c-1" id="f-1178">001-40673</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-1179">Cybin Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-1180">A6</dei:EntityIncorporationStateCountryCode>
    <dei:EntityPrimarySicNumber contextRef="c-1" id="f-1181">2834</dei:EntityPrimarySicNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-1182">100 King Street West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-1183">Suite 5600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-1184">Toronto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-1185">ON</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="c-1" id="f-1186">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-1187">M5X 1C9</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-1188">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-1189">764-8385</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName contextRef="c-428" id="f-1190">C T Corporation System</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c-428" id="f-1191">1015 15th Street N.W.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-428" id="f-1192">Suite 1000</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-428" id="f-1193">Washington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-428" id="f-1194">DC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-428" id="f-1195">20005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-428" id="f-1196">202</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-428" id="f-1197">572-3133</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-1198">Common Shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-1199">CYBN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-1200">NYSEAMER</dei:SecurityExchangeName>
    <dei:AnnualInformationForm contextRef="c-1" id="f-1201">true</dei:AnnualInformationForm>
    <dei:AuditedAnnualFinancialStatements contextRef="c-1" id="f-1202">true</dei:AuditedAnnualFinancialStatements>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c-2"
      decimals="INF"
      id="f-1203"
      unitRef="shares">21601208</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-1204">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-1205">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-1206">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-1207">false</dei:EntityExTransitionPeriod>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-1208">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <cybn:NumberOfCommonSharePurchaseWarrants
      contextRef="c-183"
      decimals="INF"
      id="f-969"
      unitRef="shares">0.5</cybn:NumberOfCommonSharePurchaseWarrants>
    <cybn:DebtInstrumentConvertibleDebentureThresholdTradingDays contextRef="c-426" id="f-1169">P5D</cybn:DebtInstrumentConvertibleDebentureThresholdTradingDays>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-1209">0001833141</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-1210">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-1211">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-1212">false</dei:AmendmentFlag>
    <dei:AuditorName contextRef="c-1" id="f-1">Zeifmans LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-2">Toronto, Ontario</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="c-1" id="f-3">1149</dei:AuditorFirmId>
    <ifrs-full:Cash contextRef="c-2" decimals="-3" id="f-4" unitRef="cad">135022000</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c-3" decimals="-3" id="f-5" unitRef="cad">208992000</ifrs-full:Cash>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c-2" decimals="-3" id="f-6" unitRef="cad">5885000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c-3" decimals="-3" id="f-7" unitRef="cad">4476000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-2" decimals="-3" id="f-8" unitRef="cad">22156000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-3" decimals="-3" id="f-9" unitRef="cad">2891000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:OtherCurrentAssets contextRef="c-2" decimals="-3" id="f-10" unitRef="cad">2909000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c-3" decimals="-3" id="f-11" unitRef="cad">2177000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c-2" decimals="-3" id="f-12" unitRef="cad">165972000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c-3" decimals="-3" id="f-13" unitRef="cad">218536000</ifrs-full:CurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-2" decimals="-3" id="f-14" unitRef="cad">141000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-15" unitRef="cad">266000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2" decimals="-3" id="f-16" unitRef="cad">41018000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-3" decimals="-3" id="f-17" unitRef="cad">35465000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:RightofuseAssets contextRef="c-2" decimals="-3" id="f-18" unitRef="cad">0</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-3" decimals="-3" id="f-19" unitRef="cad">281000</ifrs-full:RightofuseAssets>
    <ifrs-full:Goodwill contextRef="c-2" decimals="-3" id="f-20" unitRef="cad">51487000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill contextRef="c-3" decimals="-3" id="f-21" unitRef="cad">47475000</ifrs-full:Goodwill>
    <ifrs-full:NoncurrentAssets contextRef="c-2" decimals="-3" id="f-22" unitRef="cad">92646000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c-3" decimals="-3" id="f-23" unitRef="cad">83487000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="c-2" decimals="-3" id="f-24" unitRef="cad">258618000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c-3" decimals="-3" id="f-25" unitRef="cad">302023000</ifrs-full:Assets>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c-2" decimals="-3" id="f-26" unitRef="cad">21418000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c-3" decimals="-3" id="f-27" unitRef="cad">9805000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-2" decimals="-3" id="f-28" unitRef="cad">0</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-3" decimals="-3" id="f-29" unitRef="cad">291000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-4" decimals="-3" id="f-30" unitRef="cad">291000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-2" decimals="-3" id="f-31" unitRef="cad">21418000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-3" decimals="-3" id="f-32" unitRef="cad">10096000</ifrs-full:CurrentLiabilities>
    <ifrs-full:IssuedCapital contextRef="c-2" decimals="-3" id="f-33" unitRef="cad">464364000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c-3" decimals="-3" id="f-34" unitRef="cad">443877000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c-3" decimals="-3" id="f-35" unitRef="cad">443877000</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium contextRef="c-2" decimals="-3" id="f-36" unitRef="cad">44414000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c-3" decimals="-3" id="f-37" unitRef="cad">11750000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c-3" decimals="-3" id="f-38" unitRef="cad">11750000</ifrs-full:SharePremium>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c-2" decimals="-3" id="f-39" unitRef="cad">47427000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c-3" decimals="-3" id="f-40" unitRef="cad">39177000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c-3" decimals="-3" id="f-41" unitRef="cad">39177000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:WarrantReserve contextRef="c-2" decimals="-3" id="f-42" unitRef="cad">27594000</ifrs-full:WarrantReserve>
    <ifrs-full:WarrantReserve contextRef="c-3" decimals="-3" id="f-43" unitRef="cad">25639000</ifrs-full:WarrantReserve>
    <ifrs-full:WarrantReserve contextRef="c-3" decimals="-3" id="f-44" unitRef="cad">25639000</ifrs-full:WarrantReserve>
    <ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="c-2" decimals="-3" id="f-45" unitRef="cad">-7231000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="c-3" decimals="-3" id="f-46" unitRef="cad">-2285000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="c-3" decimals="-3" id="f-47" unitRef="cad">-2285000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:RetainedEarnings contextRef="c-2" decimals="-3" id="f-48" unitRef="cad">-339368000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c-3" decimals="-3" id="f-49" unitRef="cad">-226231000</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity contextRef="c-2" decimals="-3" id="f-50" unitRef="cad">237200000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-3" id="f-51" unitRef="cad">291927000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="c-2" decimals="-3" id="f-52" unitRef="cad">258618000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-3" decimals="-3" id="f-53" unitRef="cad">302023000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-54" unitRef="cad">54910000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-55" unitRef="cad">32362000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-56" unitRef="cad">45368000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-57" unitRef="cad">32588000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-1" decimals="-3" id="f-58" unitRef="cad">42869000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-5" decimals="-3" id="f-59" unitRef="cad">13886000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:OperatingExpense contextRef="c-1" decimals="-3" id="f-60" unitRef="cad">143147000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense contextRef="c-5" decimals="-3" id="f-61" unitRef="cad">78836000</ifrs-full:OperatingExpense>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax contextRef="c-1" decimals="-3" id="f-62" unitRef="cad">21749000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax contextRef="c-5" decimals="-3" id="f-63" unitRef="cad">137000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:RevenueFromInterest contextRef="c-1" decimals="-3" id="f-64" unitRef="cad">8289000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="c-5" decimals="-3" id="f-65" unitRef="cad">619000</ifrs-full:RevenueFromInterest>
    <ifrs-full:OtherExpenseByNature contextRef="c-1" decimals="-3" id="f-66" unitRef="cad">28000</ifrs-full:OtherExpenseByNature>
    <ifrs-full:OtherExpenseByNature contextRef="c-5" decimals="-3" id="f-67" unitRef="cad">0</ifrs-full:OtherExpenseByNature>
    <ifrs-full:OtherIncome contextRef="c-1" decimals="-3" id="f-68" unitRef="cad">30010000</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c-5" decimals="-3" id="f-69" unitRef="cad">756000</ifrs-full:OtherIncome>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-70" unitRef="cad">-113137000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-5" decimals="-3" id="f-71" unitRef="cad">-78080000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-1" decimals="-3" id="f-72" unitRef="cad">-4946000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-5" decimals="-3" id="f-73" unitRef="cad">-250000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-3" id="f-74" unitRef="cad">-118083000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-5" decimals="-3" id="f-75" unitRef="cad">-78330000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-76"
      unitRef="cadPerShare">-5.59</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-5"
      decimals="2"
      id="f-77"
      unitRef="cadPerShare">-9.41</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="0" id="f-78" unitRef="shares">20222493</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-5" decimals="0" id="f-79" unitRef="shares">8297370</ifrs-full:WeightedAverageShares>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c-6" decimals="0" id="f-80" unitRef="shares">5279846</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c-6" decimals="-3" id="f-81" unitRef="cad">158162000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-7" decimals="-3" id="f-82" unitRef="cad">10873000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-8" decimals="-3" id="f-83" unitRef="cad">27283000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-9" decimals="-3" id="f-84" unitRef="cad">2102000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-10" decimals="-3" id="f-85" unitRef="cad">-148151000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-11" decimals="-3" id="f-86" unitRef="cad">-2035000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-12" decimals="-3" id="f-87" unitRef="cad">48234000</ifrs-full:Equity>
    <cybn:NumberOfSharesIssuedThroughShareOfferingEquity contextRef="c-13" decimals="0" id="f-88" unitRef="shares">898434</cybn:NumberOfSharesIssuedThroughShareOfferingEquity>
    <cybn:IncreaseDecreaseThroughShareOfferingEquity contextRef="c-13" decimals="-3" id="f-89" unitRef="cad">14700000</cybn:IncreaseDecreaseThroughShareOfferingEquity>
    <cybn:IncreaseDecreaseThroughShareOfferingEquity contextRef="c-5" decimals="-3" id="f-90" unitRef="cad">14700000</cybn:IncreaseDecreaseThroughShareOfferingEquity>
    <cybn:NumberOfSharesIssuedNetOfIssuanceCosts contextRef="c-13" decimals="0" id="f-91" unitRef="shares">11572858</cybn:NumberOfSharesIssuedNetOfIssuanceCosts>
    <ifrs-full:IssueOfEquity contextRef="c-13" decimals="-3" id="f-92" unitRef="cad">217311000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-14" decimals="-3" id="f-93" unitRef="cad">22442000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-5" decimals="-3" id="f-94" unitRef="cad">239753000</ifrs-full:IssueOfEquity>
    <cybn:NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity contextRef="c-13" decimals="0" id="f-95" unitRef="shares">2130138</cybn:NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity>
    <ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary contextRef="c-13" decimals="-3" id="f-96" unitRef="cad">53481000</ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary>
    <ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary contextRef="c-5" decimals="-3" id="f-97" unitRef="cad">53481000</ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary>
    <cybn:NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing contextRef="c-13" decimals="0" id="f-98" unitRef="shares">66812</cybn:NumberOfSharesIssuedThroughCommitmentFeeForEquityFinancing>
    <cybn:NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity contextRef="c-15" decimals="0" id="f-99" unitRef="shares">50658</cybn:NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity>
    <ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary contextRef="c-15" decimals="-3" id="f-100" unitRef="cad">147000</ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary>
    <ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary contextRef="c-16" decimals="-3" id="f-101" unitRef="cad">147000</ifrs-full:IncreaseDecreaseThroughAcquisitionOfSubsidiary>
    <cybn:IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity contextRef="c-17" decimals="-3" id="f-102" unitRef="cad">-1992000</cybn:IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity>
    <cybn:IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity contextRef="c-18" decimals="-3" id="f-103" unitRef="cad">1992000</cybn:IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity>
    <cybn:IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity contextRef="c-5" decimals="-3" id="f-104" unitRef="cad">0</cybn:IncreaseDecreaseThroughShareOptionsExpiredInShareBasedPaymentAwardEquity>
    <cybn:NumberOfSharesIssuedThroughExerciseOfWarrantsEquity contextRef="c-13" decimals="0" id="f-105" unitRef="shares">2658</cybn:NumberOfSharesIssuedThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-13" decimals="-3" id="f-106" unitRef="cad">76000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-14" decimals="-3" id="f-107" unitRef="cad">-20000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-5" decimals="-3" id="f-108" unitRef="cad">56000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <cybn:IncreaseDecreaseThroughExpirationOfWarrantsEquity contextRef="c-14" decimals="-3" id="f-109" unitRef="cad">-7656000</cybn:IncreaseDecreaseThroughExpirationOfWarrantsEquity>
    <cybn:IncreaseDecreaseThroughExpirationOfWarrantsEquity contextRef="c-18" decimals="-3" id="f-110" unitRef="cad">7656000</cybn:IncreaseDecreaseThroughExpirationOfWarrantsEquity>
    <cybn:IncreaseDecreaseThroughExpirationOfWarrantsEquity contextRef="c-5" decimals="-3" id="f-111" unitRef="cad">0</cybn:IncreaseDecreaseThroughExpirationOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-17" decimals="-3" id="f-112" unitRef="cad">13886000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-5" decimals="-3" id="f-113" unitRef="cad">13886000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-19" decimals="-3" id="f-114" unitRef="cad">-250000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-5" decimals="-3" id="f-115" unitRef="cad">-250000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ProfitLoss contextRef="c-20" decimals="-3" id="f-116" unitRef="cad">-78080000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-5" decimals="-3" id="f-117" unitRef="cad">-78080000</ifrs-full:ProfitLoss>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c-21" decimals="0" id="f-118" unitRef="shares">20001404</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c-21" decimals="-3" id="f-119" unitRef="cad">443877000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-22" decimals="-3" id="f-120" unitRef="cad">25639000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-23" decimals="-3" id="f-121" unitRef="cad">39177000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-24" decimals="-3" id="f-122" unitRef="cad">11750000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-25" decimals="-3" id="f-123" unitRef="cad">-226231000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-26" decimals="-3" id="f-124" unitRef="cad">-2285000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-3" id="f-125" unitRef="cad">291927000</ifrs-full:Equity>
    <cybn:IncreaseDecreaseThroughShareConsolidationEquity contextRef="c-27" decimals="0" id="f-126" unitRef="cad">2</cybn:IncreaseDecreaseThroughShareConsolidationEquity>
    <cybn:NumberOfSharesIssuedThroughShareOfferingEquity contextRef="c-27" decimals="0" id="f-127" unitRef="shares">1609298</cybn:NumberOfSharesIssuedThroughShareOfferingEquity>
    <cybn:IncreaseDecreaseThroughShareOfferingEquity contextRef="c-27" decimals="-3" id="f-128" unitRef="cad">20983000</cybn:IncreaseDecreaseThroughShareOfferingEquity>
    <cybn:IncreaseDecreaseThroughShareOfferingEquity contextRef="c-1" decimals="-3" id="f-129" unitRef="cad">20983000</cybn:IncreaseDecreaseThroughShareOfferingEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-27" decimals="-3" id="f-130" unitRef="cad">496000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-1" decimals="-3" id="f-131" unitRef="cad">496000</ifrs-full:ShareIssueRelatedCost>
    <cybn:IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity contextRef="c-28" decimals="-3" id="f-132" unitRef="cad">-32664000</cybn:IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity>
    <cybn:IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity contextRef="c-29" decimals="-3" id="f-133" unitRef="cad">32664000</cybn:IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity>
    <cybn:IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity contextRef="c-1" decimals="-3" id="f-134" unitRef="cad">0</cybn:IncreaseDecreaseThroughShareOptionsForfeitedAndExpiredInShareBasedPaymentAwardEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-30" decimals="-3" id="f-135" unitRef="cad">1955000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-28" decimals="-3" id="f-136" unitRef="cad">40914000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-1" decimals="-3" id="f-137" unitRef="cad">42869000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-31" decimals="-3" id="f-138" unitRef="cad">-4946000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-1" decimals="-3" id="f-139" unitRef="cad">-4946000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ProfitLoss contextRef="c-32" decimals="-3" id="f-140" unitRef="cad">-113137000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-141" unitRef="cad">-113137000</ifrs-full:ProfitLoss>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c-33" decimals="0" id="f-142" unitRef="shares">21610704</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c-33" decimals="-3" id="f-143" unitRef="cad">464364000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-34" decimals="-3" id="f-144" unitRef="cad">27594000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-35" decimals="-3" id="f-145" unitRef="cad">47427000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-36" decimals="-3" id="f-146" unitRef="cad">44414000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-37" decimals="-3" id="f-147" unitRef="cad">-339368000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-38" decimals="-3" id="f-148" unitRef="cad">-7231000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-2" decimals="-3" id="f-149" unitRef="cad">237200000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-150" unitRef="cad">-113137000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-5" decimals="-3" id="f-151" unitRef="cad">-78080000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-1" decimals="-3" id="f-152" unitRef="cad">475000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-5" decimals="-3" id="f-153" unitRef="cad">424000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-1" decimals="-3" id="f-154" unitRef="cad">42869000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-5" decimals="-3" id="f-155" unitRef="cad">13886000</ifrs-full:AdjustmentsForSharebasedPayments>
    <cybn:AdjustmentForLeaseInterest contextRef="c-1" decimals="-3" id="f-156" unitRef="cad">7000</cybn:AdjustmentForLeaseInterest>
    <cybn:AdjustmentForLeaseInterest contextRef="c-5" decimals="-3" id="f-157" unitRef="cad">8000</cybn:AdjustmentForLeaseInterest>
    <cybn:AdjustmentsForOtherLossesGains contextRef="c-1" decimals="-3" id="f-158" unitRef="cad">28000</cybn:AdjustmentsForOtherLossesGains>
    <cybn:AdjustmentsForOtherLossesGains contextRef="c-5" decimals="-3" id="f-159" unitRef="cad">0</cybn:AdjustmentsForOtherLossesGains>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-160" unitRef="cad">0</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-161" unitRef="cad">18000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <cybn:AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation contextRef="c-1" decimals="-3" id="f-162" unitRef="cad">21749000</cybn:AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation>
    <cybn:AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation contextRef="c-5" decimals="-3" id="f-163" unitRef="cad">137000</cybn:AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-1" decimals="-3" id="f-164" unitRef="cad">-91507000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="c-5" decimals="-3" id="f-165" unitRef="cad">-63881000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-1" decimals="-3" id="f-166" unitRef="cad">-1409000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="c-5" decimals="-3" id="f-167" unitRef="cad">-1089000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses contextRef="c-1" decimals="-3" id="f-168" unitRef="cad">-19265000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses contextRef="c-5" decimals="-3" id="f-169" unitRef="cad">-986000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="c-1" decimals="-3" id="f-170" unitRef="cad">-732000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="c-5" decimals="-3" id="f-171" unitRef="cad">-408000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <cybn:AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities contextRef="c-1" decimals="-3" id="f-172" unitRef="cad">11613000</cybn:AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities>
    <cybn:AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities contextRef="c-5" decimals="-3" id="f-173" unitRef="cad">-2544000</cybn:AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-174" unitRef="cad">-101300000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c-5" decimals="-3" id="f-175" unitRef="cad">-68908000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013 contextRef="c-1" decimals="-3" id="f-176" unitRef="cad">0</ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013>
    <ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013 contextRef="c-5" decimals="-3" id="f-177" unitRef="cad">7632000</ifrs-full:CashAndCashEquivalentsInSubsidiaryOrBusinessesAcquiredOrDisposed2013>
    <cybn:PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-178" unitRef="cad">1966000</cybn:PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities>
    <cybn:PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities contextRef="c-5" decimals="-3" id="f-179" unitRef="cad">710000</cybn:PurchaseOfPropertyPlantEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-180" unitRef="cad">-1966000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-5" decimals="-3" id="f-181" unitRef="cad">6922000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-1" decimals="-3" id="f-182" unitRef="cad">20487000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-5" decimals="-3" id="f-183" unitRef="cad">254600000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-1" decimals="-3" id="f-184" unitRef="cad">0</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-5" decimals="-3" id="f-185" unitRef="cad">56000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-1" decimals="-3" id="f-186" unitRef="cad">290000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c-5" decimals="-3" id="f-187" unitRef="cad">149000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-188" unitRef="cad">20197000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-5" decimals="-3" id="f-189" unitRef="cad">254507000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-190" unitRef="cad">9099000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-5" decimals="-3" id="f-191" unitRef="cad">-162000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-192" unitRef="cad">-73970000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-5" decimals="-3" id="f-193" unitRef="cad">192359000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-194" unitRef="cad">208992000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-12" decimals="-3" id="f-195" unitRef="cad">16633000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-2" decimals="-3" id="f-196" unitRef="cad">135022000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-197" unitRef="cad">208992000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfBasisOfConsolidationExplanatory contextRef="c-1" id="f-198">CORPORATE INFORMATION&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;Cybin Inc. (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;Cybin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;&#x201d;), was incorporated under the Business Corporations Act (British Columbia) on October 13, 2016. These consolidated financial statements include the accounts of Cybin&#x2019;s seven subsidiaries (together with Cybin, the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;&#x201d;): Cybin Corp., Natures Journey Inc. (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;Journey&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;&#x201d;), Serenity Life Sciences Inc. (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;Serenity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;&#x201d;), Cybin US Holdings Inc. (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;Cybin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;US&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;&#x201d;), Adelia Therapeutics Inc. (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;Adelia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;&#x201d;) Cybin IRL Limited (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;Cybin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;IRL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;&#x201d;) and Cybin UK Ltd.  Cybin&#x2019;s head office, principal address and registered address and records office is 100 King Street West, Suite 5600, Toronto, Ontario M5X 1C9. The Company acquired Small Pharma Inc. (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;Small&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;Pharma&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;&#x201d;) and its subsidiary Small Pharma Ltd. on October 23, 2023. On April 1, 2024, Small Pharma Inc. was amalgamated with Cybin Corp. and continued as Cybin Corp. Effective on December 16, 2023, Small Pharma Ltd.'s name was changed to Cybin UK Ltd. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit.  These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;These consolidated financial statements as at, and for the year ended March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;were approved and authorized for issue by the board of directors on June&#160;30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%;text-decoration:underline"&gt;Stock exchange listings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;Cybin&#x2019;s common shares (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;Common Shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;&#x201d;) are listed for trading on Cboe Canada Inc. (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;Cboe Canada&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;") and NYSE American LLC under the symbol &#x201c;CYBN&#x201d; and on the Frankfurt Stock Exchange under the symbol &#x201c;R7E1&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;Share consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On September 19, 2024, the Company consolidated its outstanding Common Shares on the basis of one new Common Share for every 38 previously existing Common Shares (the "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;"). As a result, the number of Common Shares, warrants, options and earnings per share presented in these consolidated financial statements have been restated retrospectively for all the years to reflect the Consolidation.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfConsolidationExplanatory>
    <cybn:NumberOfSubsidiaries
      contextRef="c-2"
      decimals="INF"
      id="f-199"
      unitRef="subsidiary">7</cybn:NumberOfSubsidiaries>
    <cybn:OrdinarySharesConsolidationNewSharesIssued
      contextRef="c-39"
      decimals="INF"
      id="f-200"
      unitRef="shares">1</cybn:OrdinarySharesConsolidationNewSharesIssued>
    <cybn:OrdinarySharesConsolidationSharesIssuedPreviously
      contextRef="c-39"
      decimals="INF"
      id="f-201"
      unitRef="shares">38</cybn:OrdinarySharesConsolidationSharesIssuedPreviously>
    <ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory contextRef="c-1" id="f-202">MATERIAL ACCOUNTING POLICY INFORMATION AND BASIS OF PREPARATION&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Statement of compliance &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%"&gt;The Company&#x2019;s consolidated financial statements have been prepared in accordance with IFRS Accounting Standards (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:124%"&gt;IFRS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%"&gt;&#x201d;) as issued by the International Accounting Standards Board (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:124%"&gt;IASB&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%"&gt;&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%"&gt;The policies applied to these consolidated financial statements are based on IFRS, which have been applied consistently to all periods presented. These consolidated financial statements were issued and effective as at June&#160;30, 2025, the date the Board of Directors approved these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company&#x2019;s board of directors has the power to amend the consolidated financial statements after issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Basis of measurement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;These consolidated financial statements have been prepared on a going concern basis, under the historical cost convention, except for certain financial instruments classified at fair value upon initial recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Functional and presentation currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The functional currency of a company is the currency of the primary economic environment in which the company operates. The presentation currency for a company is the currency in which the company chooses to present its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;These consolidated financial statements are presented in Canadian dollars, the Company&#x2019;s presentation currency. The subsidiaries&#x2019; functional currencies are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ownership&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cybin Corp.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canadian dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Journey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canadian dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Serenity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canadian dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cybin US&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canadian dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adelia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cybin IRL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cybin UK Ltd&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Great Britain pounds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; For accounting purposes, Cybin US is a wholly-owned subsidiary of Cybin. Certain former Adelia Shareholders hold Class B Shares (defined below) in Cybin US.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt; Basis of consolidation &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company consolidates entities which it controls. Control exists when the Company has the power, directly and indirectly to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Intercompany balances, and any unrealized gains and losses or income and expenses arising from transactions with controlled entities are eliminated to the extent of the Company&#x2019;s interest in the entity. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash and cash equivalents are comprised of cash on deposit and highly liquid short-term interest-bearing variable rate investments with an original maturity of three months or less, or which are readily convertible into a known amount of cash with no significant changes. As at March&#160;31, 2025 and March&#160;31, 2024 there were no cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Inventories include raw materials and finished goods. Raw materials are stated at the lower of cost and replacement cost with cost determined on a first-in, first-out basis. The Company monitors the shelf life and expiry of finished goods to determine when inventory values are not recoverable and a write-down is necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Equipment consists of lab and computer equipment and are recorded at cost less accumulated depreciation and accumulated impairment losses. Cost includes all expenditures incurred to bring the asset to the location and condition necessary for them to be operating in the manner intended by management. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Depreciation is recognized based on the cost of the item less its estimated residual value, over its estimated useful life on a straight-line basis at the following rates:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt"&gt;Lab equipment &#x2013; 5 years&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt"&gt;Computer equipment &#x2013; 3 years&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;An item of equipment and any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the consolidated statement of loss and comprehensive loss when the asset is derecognized. The assets&#x2019; residual values, useful lives and methods of depreciation are reviewed at each reporting date and adjusted prospectively if appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Intangible assets include expenditures related to obtaining patents, software related items and in-process research and development (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;). The amortization of software related items begins when the software is in use and will be amortized on a straight-line basis over a period of 3 years. The amortization of patent costs commences when the associated products are available for commercial sale and is amortized on a straight-line basis over its respective legal lives or economic life, if shorter. Patents have an estimated useful life of 17 years. Amortization methods, useful lives, and residual values are reviewed at each reporting date and adjusted if appropriate. Acquired IPR&amp;amp;D is capitalized based on technical feasibility and remains on the balance sheet, subject to impairment. Acquired IPR&amp;amp;D is initially measured at fair value and recognized as an indefinite-lived intangible asset until completion or abandonment of the related project. Amortization commences when the assets become available for use. Expenditures on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in operations as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Development activities involve a plan or design for the production of new, or substantially improved, products or processes related to the Company&#x2019;s development of psychedelic-based therapeutics. Development expenditures are capitalized only if the relevant IFRS criteria are met. Capitalized development expenditures &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;are amortized from the beginning of commercial production and sales and are amortized on a straight-line basis over the remaining useful life of the related patents. Development expenditures, in relation to the Company&#x2019;s psychedelic-based therapeutics, have not satisfied the above criteria and are recognized in operations as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Goodwill represents the excess of the consideration transferred for the acquisition of an entity over the fair value of the net identifiable assets. Goodwill is initially measured at cost, and subsequently recorded at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Company&#x2019;s cash-generating units (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;CGUs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;) that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those CGUs. The Company tests for impairment annually, or when indications of impairment exist.  Impairment is determined for goodwill by assessing if the carrying value of CGUs, including goodwill, exceeds its recoverable amount determined as the greater of the estimated fair value less costs of disposal and the value in use. Impairment losses recognized in respect of the CGUs are first allocated to the carrying value of goodwill and any excess is allocated to the carrying amount of assets in the CGUs. Any goodwill impairment is recorded in the consolidated statement of loss and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Long-lived assets, including equipment and intangible assets, are reviewed for impairment at each consolidated statement of financial position date or whenever events or changes in circumstances indicate that the carrying amount of the asset exceeds its recoverable amount. Where the carrying value of an asset exceeds its recoverable amount, which is the higher of value in use and fair value less costs to sell, the asset is written down accordingly. Where it is not possible to estimate the recoverable amount of an individual asset, the impairment test is carried out on the asset&#x2019;s cash-generating unit, which is the lowest group of assets in which the asset belongs for which there are separate cash inflows that are largely independent of the cash inflows from other assets. An impairment loss is charged to operations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%"&gt;Recognition and initial measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company initially recognizes financial instruments on the trade date, which is the date on which the Company becomes a party to the contractual provisions of the instrument. A financial asset or financial liability is measured initially at fair value plus/minus, for an item not at fair value through profit or loss (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;FVTPL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;), transaction costs that are directly attributable to its acquisition or use.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%"&gt;Classification&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Financial asset&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On initial recognition, a financial asset is classified as measured at: amortized cost, fair value through other comprehensive income (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;FVOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;), or FVTPL.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;A financial asset is measured at amortized cost if it meets both of the following conditions and is not designated as at FVTPL:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;The asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company currently measures accounts receivable at amortized cost. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;A debt instrument is measured at FVOCI only if it meets both of the following conditions and is not designated as at FVTPL:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;The asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in FVOCI. This election is made on an investment-by-investment basis. The Company has not elected to present any assets as FVOCI.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash is measured at FVTPL.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;In addition, on initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortized cost as FVOCI or FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Business model assessment&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company makes an assessment of the objective of a business model in which an asset is held at a portfolio level because this best reflects the way the business is managed and information is provided to management. The information considered includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;The stated policies and objectives for the portfolio and the operation of those policies in practice. In particular, whether management&#x2019;s strategy focuses on earning contractual interest revenue, maintaining a particular interest rate profile, matching the duration of the financial assets to the &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;duration of the liabilities that are funding those assets or realizing cash flows through the sale of the assets;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;How the performance of the portfolio is evaluated and reported to the Company&#x2019;s management;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;The risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;How managers of the business are compensated (e.g. whether compensation is based on the fair value of the assets managed or the contractual cash flows collected); and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;The frequency, volume and timing of sales in prior periods, the reasons for such sales and its expectation about future sales activity. However, information about sales activity is not considered in isolation, but as part of an overall assessment of the Company&#x2019;s stated objective for managing the financial asset is achieved and how cash flows are realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Assessment whether contractual cash flows are solely payments of principal and interest&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;For the purpose of this assessment, &#x2018;principal&#x2019; is defined as the fair value of the financial asset on initial recognition. &#x2018;Interest&#x2019; is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g. liquidity risk and administrative costs), as well as profit margin. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;In assessing whether the contractual cash flows are solely payments of principal and interest, the Company considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of the contractual cash flows such that it would not meet this condition. In making the assessment, the Company considers:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;contingent events that would change the amount and timing of cash flows;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;leverage features;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;prepayment and extension terms;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;terms that limit the Company&#x2019;s claim to cash flows from specified assets (e.g. non-recourse asset arrangements); and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;features that modify consideration of the time value of money (e.g. periodical rest of interest rates).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company would reclassify a financial asset when the Company changes its business model for managing the financial asset. All reclassifications are recorded at fair value at the date of the reclassification, which becomes the new carrying value. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Financial assets are not reclassified subsequent to their initial recognition, except in the period after the Company changes its business model for managing financial assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company classifies its financial liabilities at amortized cost or FVTPL. The Company currently measures accounts payable, lease liabilities and accrued liabilities at amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Derecognition &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transition in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and it does not retain control of the financial asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On derecognition of a financial asset, the difference between the carrying amount of the asset (or the carrying amount allocated to the portion of the asset derecognized) and the sum of (i) the consideration received (including any new assets obtained less any new liability assumed) and (ii) cumulative gain or loss that had been recognized in other comprehensive income is recognized in profit or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Financial liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled, or expire. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Modifications of financial assets and financial liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;If the terms of a financial asset are modified, the Company evaluates whether the cash flows of the modified asset are substantially different. If the cash flows are substantially different, then the contractual rights to cash flows from the original financial asset are deemed to have expired. In this case, the original financial asset is derecognized and a new financial asset is recognized at fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;If the cash flows of the modified asset carried at amortized cost are not substantially different, then the modification does not result in derecognition of the financial asset. In this case, the Company recalculates the gross carrying amount of the financial asset and recognizes the amount arising from adjusting the gross carrying amount as a modification gain or loss in profit or loss. If such a modification is carried out because of financial difficulties of the borrower, then the gain or loss is presented together with impairment losses. In other cases, it is presented as interest income. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company derecognizes a financial liability when its terms are modified and the cash flows of the modified liability are substantially different. In this case, a new financial liability based on the modified terms is recognized at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognized in profit or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Offsetting&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Financial assets and financial liabilities are offset and the net amount presented in the consolidated statement of financial position when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Income and expenses are presented on a net basis only when permitted under IFRS, or for gains and losses arising from a group of similar transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Fair value measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or, in its absence, the most advantageous market to which the Company has access at that date. The fair value of a liability reflects its non-performance risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;When one is available, the Company measures the fair value of an instrument using the quoted price in an active market for that instrument. A market is regarded as active if transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;If there is no quoted price in an active market, then the Company uses valuation techniques that maximize the use of relevant observable inputs and minimize the use of unobservable inputs. The chosen valuation technique incorporates all of the factors that market participants would take into account in pricing a transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The best evidence of the fair value of a financial instrument on initial recognition is normally the transaction price (i.e. the fair value of the consideration given or received). If the Company determines that the fair value on initial recognition differs from the transaction price and the fair value is evidenced neither by a quoted price in an active market for an identical asset or liability nor based on a valuation technique for which any observable inputs are judged to be insignificant in relation to the measurement, then the financial instrument is initially measured at fair value, adjusted to defer the difference between the fair value on initial recognition and the transaction price. Subsequently, that difference is recognized in profit or loss on an appropriate basis over the life of the instrument but no later than when the valuation is wholly supported by observable market data or the transaction is closed out. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;If an asset or a liability at fair value has a bid price and an ask price, then the Company measures assets and long positions at bid price and liabilities and short positions at an ask price. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Portfolio of financial assets and financial liabilities that are exposed to market risk and credit risk that are managed by the Company on the basis of the net exposure to either market or credit risk are measured on the basis of a price that would be received to sell a net long position (or paid to transfer a net short position) for the particular risk exposure. Portfolio-level adjustment e.g. bid-ask adjustment or credit risk adjustments that reflect the measurement on the basis of the net exposure are allocated to the individual assets and liabilities on the basis of the relative risk adjustment of each of the individual instruments in the portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The fair value of a financial liability with a demand feature is not less than the amount payable on demand, discounted from the first date on which the amount could be required to be paid. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period during which the change has occurred.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:130%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Credit-impaired financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;At each reporting date, the Company assesses whether financial assets carried at amortized costs and debt financial assets carried at FVOCI are credit-impaired. A financial asset is &#x2018;credit-impaired&#x2019; when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Evidence that a financial asset is credit-impaired includes the following observable data: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;Significant financial difficulty of the borrower or issuer;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;A breach of contract such as a default of past due event;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;The restructuring of a loan or advance by the Company on terms that the Company would not consider otherwise;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;It is becoming probable that the borrower will enter bankruptcy or other financial reorganization; or &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;The disappearance of an active market for a security because of financial difficulties. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;A loan that has been renegotiated due to a deterioration in the borrower&#x2019;s condition is usually considered to be credit-impaired unless there is evidence that the risk of not receiving contractual cash flows has reduced significantly and there are no other indicators of impairment. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Recognition of allowance of expected credit losses (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%"&gt;ECL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;&#x201d;) in the consolidated statement of financial position&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company recognizes a loss allowance for ECL on trade receivables that are measured at amortized cost. The Company&#x2019;s applied the simplified approach for trade receivables and recognizes the lifetime ECL for these assets. The ECL on trade receivables is estimated using a provision matrix based on the Company&#x2019;s historical credit loss experience, adjusted for factors that are specific to the customers, general economic conditions and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;an assessment of both the current as well as the forecast direction of conditions at the reporting date, including time value of money where appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;For all other financial assets measured at amortized cost of FVOCI, the Company recognizes lifetime ECL only when there has been a significant increase in credit risk since initial recognition. If the credit risk on such financial instruments has not increased significantly since initial recognition, the Company measures the loss allowance on those financial instruments at an amount equal to 12-months ECL. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Lifetime ECL represents the ECL that will result from all possible default events over the expected life of a financial asset. In contrast, 12-month ECL represents the portion of lifetime ECL that is expected to result from default events on a financial asset that are possible within 12 months after the reporting date. In assessing whether the credit risk on a financial asset has increased significantly since initial recognition, the Company compares the risk of default occurring on the financial asset at the reporting date with the risk of default occurring at the initial recognition. The Company considers both quantitative and qualitative factors that are supportable, including historical experience and forward-looking information that is available without undue cost or effort. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Irrespective of the above assessment, the Company presumes that the credit risk on a financial asset has increased significantly since initial recognition when contractual payments are more than 30 days past due, unless the Company has reasonable and supportable information that demonstrates otherwise. Despite the foregoing, the Company presumes that the credit risk on a financial asset has not increased significantly since initial recognition if the financial asset is determined to have low credit risk at the reporting date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company regularly monitors the effectiveness of the criteria used to identify whether there has been a significant increase in credit risk and revises them as appropriate to ensure that the criteria are capable of identifying significant increase in credit risk before the amount becomes pas due. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Definition of default&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;For internal credit risk management purposes, the Company considers a financial asset not recoverable if the customer balance owing is 180 days past due and information obtained from the customer and other external factors indicate that the customer is unlikely to pay its creditors in full.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Write-off&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Financial assets are written off (either partially or in full) when there is no realistic prospect of recovery. This is generally the case when the Company determines that the counterparty does not have assets or sources of income that could general sufficient cash flows to repay the amounts subject to the write-off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Company&#x2019;s procedures for recovery of amounts due. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Taxation&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Income tax comprises current and deferred tax. Income tax is recognized in the consolidated statement of loss and comprehensive loss except to the extent that it relates to items recognized directly in equity, in which case the income tax is also recognized directly in equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Current income tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted, at the end of the reporting period, and any adjustment to tax payable in respect of previous years.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from audits by taxing authorities. Where the outcome of these tax-related matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Deferred income tax is recorded using the asset and liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences do not result in deferred tax assets or liabilities: the initial recognized of assets or liabilities that affect neither accounting or taxable loss; or difference relating to investment in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the consolidated statement of financial position date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its correct tax assets and liabilities on a net basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Share capital&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Equity instruments are contracts that give a residual interest in the net assets of the Company. Financial instruments issued by the Company are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Common Shares and the Company&#x2019;s Common Share purchase warrants and options are classified as equity instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Incremental costs directly attributable to the issue of new Common Shares or warrants are shown in equity as a deduction, net of tax, from the proceeds. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Under the Company&#x2019;s equity incentive plan, all stock options granted may have graded vesting periods and are exercisable up to a maximum of 10 years form the date of grant. Each tranche of an award with graded vesting periods is considered a separate grant at each grant date for the calculation of fair value, and the resulting fair value is amortized over the vesting period of the respective tranches. The fair value of the options granted is measured using the Black-Scholes option pricing model taking into account the terms and conditions upon which the options were granted, the estimated volatility, estimated risk free rate and estimated forfeitures. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;If a grant of the share-based payments is cancelled or settled during the vesting period (other than a grant cancelled by forfeiture when the vesting conditions are not satisfied or options granted in error and cancelled retroactively), the Company accounts for the cancellation or settlement as an acceleration of vesting, and recognizes immediately the amount that otherwise would have been recognized for services over the remainder of the vesting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The amount recognized for goods or services received during the vesting period is based on the best available estimate of the number of equity instruments anticipated to vest. The Company revises that estimate, if necessary, if subsequent information indicates that the number of share options anticipated to vest differs from previous estimates. On the vesting date, the Company revises the estimate to equal the number of equity instrument that ultimately vested. After the vesting date, the Company makes no subsequent adjustment to total equity for goods or services received if the share options are later forfeited or they expire at the end of the share option&#x2019;s life. Upon expiration of options, the amount applicable to expired options is moved to contributed surplus.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;If a grant of the share based payment is modified during the vesting period (other than a grant cancelled by forfeiture when&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:130%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;the vesting conditions are not satisfied) and the fair value of the new instruments is higher than the fair value of the original instrument, the incremental fair value granted is included in the measurement of the amount recognized for services received over the period from modification date until the date when the modified equity instruments vests, in addition to the amount based on the grant date fair value of the original equity instruments, which is recognized over the remainder of the original vesting period of the original instrument. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company follows the relative fair value method with respect to the measurement of Common Shares and warrants issued as units. The proceeds from the issuance of units are allocated between share capital and warrants. The warrant component is recorded in equity reserve. Unit proceeds are allocated to Common Shares and warrants using the Black-Scholes option pricing model and the share price at the time of financing. If and when the warrants are exercised, consideration paid by the warrant holder, together with the amount previously recognized in warrant reserve, is recorded as an increase to share capital. A forfeiture rate is estimated on the grant date and is adjusted to reflect the actual number of warrants that vest. When stock options or warrants are cancelled, they are treated as if they have vested on the date of collation and any cost &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;not yet recognized in profit or loss is immediately expensed. Upon expiration of warrants, the amount applicable to expired warrants is moved to contributed surplus. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Loss per share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Basic loss per share is calculated using the weighted-average number of shares outstanding during the period. The diluted earnings (loss) per share reflects the potential dilution of Common Share equivalents, such as outstanding stock options and warrants, in the weighted average number of Common Shares outstanding during the period, if they are dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Currency translation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;All figures presented in the consolidated financial statements are reflected in Canadian dollars unless otherwise noted.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Foreign currency transactions are translated into Canadian dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the consolidated statement of financial position date are translated to Canadian dollars at the foreign exchange rate applicable as that date. Realized and unrealized exchange gains and losses are recognized through profit or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The assets and liabilities of foreign operations are translated into Canadian dollars at period-end exchange rates. Income and expenses, and cash flows of foreign operations are translated into Canadian dollars using average exchange rates. Exchange differences resulting from translating foreign operations are recognized in other comprehensive income (loss) and accumulated separately in shareholders&#x2019; equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Foreign currency translation gains or losses arising from a monetary item receivable or payable to a foreign operation, the settlement of which is neither planned nor likely to occur in the foreseeable future and which in substance is considered to form part of the net investment in the foreign operation, are recognized in other comprehensive income (loss) in the translation reserve. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Provisions are recorded when a present legal or constructive obligation exists as a result of past events where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and a reliable estimate of the amount of the obligation can be made.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the consolidated statement of financial position date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows. When some or all of the economic benefits required to settle, a provision is expected to be recovered from a third party, the receivable is recognized as an asset if it is virtually certain that reimbursement will be received and the amount receivable can be measured reliably. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;New standards and interpretations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The IASB has issued certain amendments to accounting and financial reporting standards effective for annual reporting periods beginning on or after January 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;IAS 1, Presentation of Financial Statements ("IAS 1") - Classification of Liabilities as Current or Non-Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;In January 2020, the IASB issued amendments to IAS 1. The amendments aim to promote consistency in applying the requirements by helping companies determine whether, in the consolidated statements of financial position, debt and other liabilities with an uncertain settlement date should be classified as current (due or potentially due to be settled within one year) or non-current. The amendments include clarifying the classification requirements for debt a company might settle by converting it into equity. The amendments are effective for annual reporting periods beginning on or after January 1, 2024.  The Company has determined that adoption of these amendments has no significant effect on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;New standards and interpretations not yet adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;IFRS 18, Presentation and Disclosure in Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;In April 2024, the IASB issued IFRS 18 that is to replace IAS 1, Presentation of Financial Statements. The new standard aims to improve the quality of financial reporting by: (i) requiring defined subtotals in the statement of profit or loss; (ii) requiring disclosure about management defined performance measures; and (iii) adding new principles for aggregation and disaggregation of information.  The standard is effective for the annual reporting periods beginning on or after January 1, 2027, with early application permitted. The Company is in the process of assessing the impact of this new standard on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;IFRS 9, Financial Instruments (&#x201c;IFRS 9&#x201d;) and IFRS 7, Financial Instruments: Disclosures (&#x201c;IFRS 7&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;In May 2024, the IASB issued targeted amendments to IFRS 9 and IFRS 7 in response to practical implementation issues and to introduce new requirements applicable to both financial institutions and corporate entities. These amendments aim to enhance the clarity and consistency of financial reporting for various types of financial instruments and their related disclosures by (i) clarifying the date of recognition and derecognition for certain financial assets and liabilities, including a new exception for financial liabilities settled through an electronic cash transfer system (ii) providing help to determine whether a financial asset meets the Solely Payments of Principal and Interest criterion (iii) introducing new disclosures for instruments with contractual terms that may alter cash flows, such as financial instruments linked to the achievement of environmental, social, and governance targets, and (iv) updating the disclosure requirements for equity instruments designated at FVTOCI. The new standard is to be effective for annual periods beginning on or after January 1, 2026. The Company is in the process of assessing the impact of the standard on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;All other IFRSs and amendments issued but not yet effective have been assessed by the Company and are not expected to have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory>
    <ifrs-full:StatementOfIFRSCompliance contextRef="c-1" id="f-203">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%"&gt;The Company&#x2019;s consolidated financial statements have been prepared in accordance with IFRS Accounting Standards (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:124%"&gt;IFRS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%"&gt;&#x201d;) as issued by the International Accounting Standards Board (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:124%"&gt;IASB&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%"&gt;&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:124%"&gt;The policies applied to these consolidated financial statements are based on IFRS, which have been applied consistently to all periods presented. These consolidated financial statements were issued and effective as at June&#160;30, 2025, the date the Board of Directors approved these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company&#x2019;s board of directors has the power to amend the consolidated financial statements after issuance.&lt;/span&gt;&lt;/div&gt;</ifrs-full:StatementOfIFRSCompliance>
    <cybn:DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock contextRef="c-1" id="f-204">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Basis of measurement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;These consolidated financial statements have been prepared on a going concern basis, under the historical cost convention, except for certain financial instruments classified at fair value upon initial recognition.&lt;/span&gt;&lt;/div&gt;</cybn:DisclosureOfAccountingPolicyForBasisOfMeasurementPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory contextRef="c-1" id="f-205">&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Functional and presentation currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The functional currency of a company is the currency of the primary economic environment in which the company operates. The presentation currency for a company is the currency in which the company chooses to present its financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;These consolidated financial statements are presented in Canadian dollars, the Company&#x2019;s presentation currency. The subsidiaries&#x2019; functional currencies are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ownership&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cybin Corp.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canadian dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Journey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canadian dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Serenity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canadian dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cybin US&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canadian dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adelia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cybin IRL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cybin UK Ltd&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Great Britain pounds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; For accounting purposes, Cybin US is a wholly-owned subsidiary of Cybin. Certain former Adelia Shareholders hold Class B Shares (defined below) in Cybin US.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFunctionalCurrencyExplanatory>
    <cybn:DetailDescriptionOfFunctionalCurrenciesTableTextBlock contextRef="c-1" id="f-206">The subsidiaries&#x2019; functional currencies are as follows:&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ownership&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cybin Corp.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canadian dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Journey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canadian dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Serenity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canadian dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cybin US&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canadian dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adelia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cybin IRL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cybin UK Ltd&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Great Britain pounds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:130%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:130%"&gt; For accounting purposes, Cybin US is a wholly-owned subsidiary of Cybin. Certain former Adelia Shareholders hold Class B Shares (defined below) in Cybin US.&lt;/span&gt;&lt;/div&gt;</cybn:DetailDescriptionOfFunctionalCurrenciesTableTextBlock>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-40"
      decimals="INF"
      id="f-207"
      unitRef="number">100</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-41"
      decimals="INF"
      id="f-208"
      unitRef="number">100</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-42"
      decimals="INF"
      id="f-209"
      unitRef="number">100</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-43"
      decimals="INF"
      id="f-210"
      unitRef="number">100</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-44"
      decimals="INF"
      id="f-211"
      unitRef="number">100</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-45"
      decimals="INF"
      id="f-212"
      unitRef="number">100</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="c-46"
      decimals="INF"
      id="f-213"
      unitRef="number">100</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <cybn:DisclosureOfBasisOfConsolidationPolicyTextBlock contextRef="c-1" id="f-214">Basis of consolidation &lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company consolidates entities which it controls. Control exists when the Company has the power, directly and indirectly to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. &lt;/span&gt;&lt;/div&gt;Intercompany balances, and any unrealized gains and losses or income and expenses arising from transactions with controlled entities are eliminated to the extent of the Company&#x2019;s interest in the entity.</cybn:DisclosureOfBasisOfConsolidationPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents contextRef="c-1" id="f-215">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash and cash equivalents are comprised of cash on deposit and highly liquid short-term interest-bearing variable rate investments with an original maturity of three months or less, or which are readily convertible into a known amount of cash with no significant changes. As at March&#160;31, 2025 and March&#160;31, 2024 there were no cash equivalents.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents>
    <ifrs-full:CashEquivalents contextRef="c-3" decimals="INF" id="f-216" unitRef="cad">0</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents contextRef="c-2" decimals="INF" id="f-217" unitRef="cad">0</ifrs-full:CashEquivalents>
    <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories contextRef="c-1" id="f-218">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Inventories include raw materials and finished goods. Raw materials are stated at the lower of cost and replacement cost with cost determined on a first-in, first-out basis. The Company monitors the shelf life and expiry of finished goods to determine when inventory values are not recoverable and a write-down is necessary.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-219">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Equipment consists of lab and computer equipment and are recorded at cost less accumulated depreciation and accumulated impairment losses. Cost includes all expenditures incurred to bring the asset to the location and condition necessary for them to be operating in the manner intended by management. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Depreciation is recognized based on the cost of the item less its estimated residual value, over its estimated useful life on a straight-line basis at the following rates:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt"&gt;Lab equipment &#x2013; 5 years&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.15pt"&gt;Computer equipment &#x2013; 3 years&lt;/span&gt;&lt;/div&gt;An item of equipment and any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the consolidated statement of loss and comprehensive loss when the asset is derecognized. The assets&#x2019; residual values, useful lives and methods of depreciation are reviewed at each reporting date and adjusted prospectively if appropriate.</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-47" id="f-220">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c-48" id="f-221">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory contextRef="c-1" id="f-222">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Intangible assets include expenditures related to obtaining patents, software related items and in-process research and development (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;). The amortization of software related items begins when the software is in use and will be amortized on a straight-line basis over a period of 3 years. The amortization of patent costs commences when the associated products are available for commercial sale and is amortized on a straight-line basis over its respective legal lives or economic life, if shorter. Patents have an estimated useful life of 17 years. Amortization methods, useful lives, and residual values are reviewed at each reporting date and adjusted if appropriate. Acquired IPR&amp;amp;D is capitalized based on technical feasibility and remains on the balance sheet, subject to impairment. Acquired IPR&amp;amp;D is initially measured at fair value and recognized as an indefinite-lived intangible asset until completion or abandonment of the related project. Amortization commences when the assets become available for use. Expenditures on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in operations as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Development activities involve a plan or design for the production of new, or substantially improved, products or processes related to the Company&#x2019;s development of psychedelic-based therapeutics. Development expenditures are capitalized only if the relevant IFRS criteria are met. Capitalized development expenditures &lt;/span&gt;&lt;/div&gt;are amortized from the beginning of commercial production and sales and are amortized on a straight-line basis over the remaining useful life of the related patents. Development expenditures, in relation to the Company&#x2019;s psychedelic-based therapeutics, have not satisfied the above criteria and are recognized in operations as incurred.</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-49" id="f-223">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-50" id="f-224">P17Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory contextRef="c-1" id="f-225">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Goodwill represents the excess of the consideration transferred for the acquisition of an entity over the fair value of the net identifiable assets. Goodwill is initially measured at cost, and subsequently recorded at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Company&#x2019;s cash-generating units (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;CGUs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;) that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those CGUs. The Company tests for impairment annually, or when indications of impairment exist.  Impairment is determined for goodwill by assessing if the carrying value of CGUs, including goodwill, exceeds its recoverable amount determined as the greater of the estimated fair value less costs of disposal and the value in use. Impairment losses recognized in respect of the CGUs are first allocated to the carrying value of goodwill and any excess is allocated to the carrying amount of assets in the CGUs. Any goodwill impairment is recorded in the consolidated statement of loss and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForGoodwillExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory contextRef="c-1" id="f-226">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;Long-lived assets, including equipment and intangible assets, are reviewed for impairment at each consolidated statement of financial position date or whenever events or changes in circumstances indicate that the carrying amount of the asset exceeds its recoverable amount. Where the carrying value of an asset exceeds its recoverable amount, which is the higher of value in use and fair value less costs to sell, the asset is written down accordingly. Where it is not possible to estimate the recoverable amount of an individual asset, the impairment test is carried out on the asset&#x2019;s cash-generating unit, which is the lowest group of assets in which the asset belongs for which there are separate cash inflows that are largely independent of the cash inflows from other assets. An impairment loss is charged to operations.</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="c-1" id="f-227">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%"&gt;Recognition and initial measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company initially recognizes financial instruments on the trade date, which is the date on which the Company becomes a party to the contractual provisions of the instrument. A financial asset or financial liability is measured initially at fair value plus/minus, for an item not at fair value through profit or loss (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;FVTPL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;), transaction costs that are directly attributable to its acquisition or use.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%"&gt;Classification&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Financial asset&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On initial recognition, a financial asset is classified as measured at: amortized cost, fair value through other comprehensive income (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;FVOCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;), or FVTPL.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;A financial asset is measured at amortized cost if it meets both of the following conditions and is not designated as at FVTPL:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;The asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company currently measures accounts receivable at amortized cost. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;A debt instrument is measured at FVOCI only if it meets both of the following conditions and is not designated as at FVTPL:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;The asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in FVOCI. This election is made on an investment-by-investment basis. The Company has not elected to present any assets as FVOCI.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cash is measured at FVTPL.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;In addition, on initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortized cost as FVOCI or FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Business model assessment&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company makes an assessment of the objective of a business model in which an asset is held at a portfolio level because this best reflects the way the business is managed and information is provided to management. The information considered includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;The stated policies and objectives for the portfolio and the operation of those policies in practice. In particular, whether management&#x2019;s strategy focuses on earning contractual interest revenue, maintaining a particular interest rate profile, matching the duration of the financial assets to the &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;duration of the liabilities that are funding those assets or realizing cash flows through the sale of the assets;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;How the performance of the portfolio is evaluated and reported to the Company&#x2019;s management;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;The risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;How managers of the business are compensated (e.g. whether compensation is based on the fair value of the assets managed or the contractual cash flows collected); and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;The frequency, volume and timing of sales in prior periods, the reasons for such sales and its expectation about future sales activity. However, information about sales activity is not considered in isolation, but as part of an overall assessment of the Company&#x2019;s stated objective for managing the financial asset is achieved and how cash flows are realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Assessment whether contractual cash flows are solely payments of principal and interest&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;For the purpose of this assessment, &#x2018;principal&#x2019; is defined as the fair value of the financial asset on initial recognition. &#x2018;Interest&#x2019; is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g. liquidity risk and administrative costs), as well as profit margin. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;In assessing whether the contractual cash flows are solely payments of principal and interest, the Company considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of the contractual cash flows such that it would not meet this condition. In making the assessment, the Company considers:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;contingent events that would change the amount and timing of cash flows;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;leverage features;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;prepayment and extension terms;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;terms that limit the Company&#x2019;s claim to cash flows from specified assets (e.g. non-recourse asset arrangements); and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;features that modify consideration of the time value of money (e.g. periodical rest of interest rates).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company would reclassify a financial asset when the Company changes its business model for managing the financial asset. All reclassifications are recorded at fair value at the date of the reclassification, which becomes the new carrying value. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Financial assets are not reclassified subsequent to their initial recognition, except in the period after the Company changes its business model for managing financial assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company classifies its financial liabilities at amortized cost or FVTPL. The Company currently measures accounts payable, lease liabilities and accrued liabilities at amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Derecognition &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transition in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and it does not retain control of the financial asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On derecognition of a financial asset, the difference between the carrying amount of the asset (or the carrying amount allocated to the portion of the asset derecognized) and the sum of (i) the consideration received (including any new assets obtained less any new liability assumed) and (ii) cumulative gain or loss that had been recognized in other comprehensive income is recognized in profit or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Financial liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled, or expire. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Modifications of financial assets and financial liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;If the terms of a financial asset are modified, the Company evaluates whether the cash flows of the modified asset are substantially different. If the cash flows are substantially different, then the contractual rights to cash flows from the original financial asset are deemed to have expired. In this case, the original financial asset is derecognized and a new financial asset is recognized at fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;If the cash flows of the modified asset carried at amortized cost are not substantially different, then the modification does not result in derecognition of the financial asset. In this case, the Company recalculates the gross carrying amount of the financial asset and recognizes the amount arising from adjusting the gross carrying amount as a modification gain or loss in profit or loss. If such a modification is carried out because of financial difficulties of the borrower, then the gain or loss is presented together with impairment losses. In other cases, it is presented as interest income. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company derecognizes a financial liability when its terms are modified and the cash flows of the modified liability are substantially different. In this case, a new financial liability based on the modified terms is recognized at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognized in profit or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Offsetting&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Financial assets and financial liabilities are offset and the net amount presented in the consolidated statement of financial position when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Income and expenses are presented on a net basis only when permitted under IFRS, or for gains and losses arising from a group of similar transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Fair value measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or, in its absence, the most advantageous market to which the Company has access at that date. The fair value of a liability reflects its non-performance risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;When one is available, the Company measures the fair value of an instrument using the quoted price in an active market for that instrument. A market is regarded as active if transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;If there is no quoted price in an active market, then the Company uses valuation techniques that maximize the use of relevant observable inputs and minimize the use of unobservable inputs. The chosen valuation technique incorporates all of the factors that market participants would take into account in pricing a transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The best evidence of the fair value of a financial instrument on initial recognition is normally the transaction price (i.e. the fair value of the consideration given or received). If the Company determines that the fair value on initial recognition differs from the transaction price and the fair value is evidenced neither by a quoted price in an active market for an identical asset or liability nor based on a valuation technique for which any observable inputs are judged to be insignificant in relation to the measurement, then the financial instrument is initially measured at fair value, adjusted to defer the difference between the fair value on initial recognition and the transaction price. Subsequently, that difference is recognized in profit or loss on an appropriate basis over the life of the instrument but no later than when the valuation is wholly supported by observable market data or the transaction is closed out. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;If an asset or a liability at fair value has a bid price and an ask price, then the Company measures assets and long positions at bid price and liabilities and short positions at an ask price. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Portfolio of financial assets and financial liabilities that are exposed to market risk and credit risk that are managed by the Company on the basis of the net exposure to either market or credit risk are measured on the basis of a price that would be received to sell a net long position (or paid to transfer a net short position) for the particular risk exposure. Portfolio-level adjustment e.g. bid-ask adjustment or credit risk adjustments that reflect the measurement on the basis of the net exposure are allocated to the individual assets and liabilities on the basis of the relative risk adjustment of each of the individual instruments in the portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The fair value of a financial liability with a demand feature is not less than the amount payable on demand, discounted from the first date on which the amount could be required to be paid. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period during which the change has occurred.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:130%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Credit-impaired financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;At each reporting date, the Company assesses whether financial assets carried at amortized costs and debt financial assets carried at FVOCI are credit-impaired. A financial asset is &#x2018;credit-impaired&#x2019; when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Evidence that a financial asset is credit-impaired includes the following observable data: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;Significant financial difficulty of the borrower or issuer;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;A breach of contract such as a default of past due event;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;The restructuring of a loan or advance by the Company on terms that the Company would not consider otherwise;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;It is becoming probable that the borrower will enter bankruptcy or other financial reorganization; or &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%;padding-left:14.15pt"&gt;The disappearance of an active market for a security because of financial difficulties. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;A loan that has been renegotiated due to a deterioration in the borrower&#x2019;s condition is usually considered to be credit-impaired unless there is evidence that the risk of not receiving contractual cash flows has reduced significantly and there are no other indicators of impairment. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Recognition of allowance of expected credit losses (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%"&gt;ECL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;&#x201d;) in the consolidated statement of financial position&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company recognizes a loss allowance for ECL on trade receivables that are measured at amortized cost. The Company&#x2019;s applied the simplified approach for trade receivables and recognizes the lifetime ECL for these assets. The ECL on trade receivables is estimated using a provision matrix based on the Company&#x2019;s historical credit loss experience, adjusted for factors that are specific to the customers, general economic conditions and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;an assessment of both the current as well as the forecast direction of conditions at the reporting date, including time value of money where appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;For all other financial assets measured at amortized cost of FVOCI, the Company recognizes lifetime ECL only when there has been a significant increase in credit risk since initial recognition. If the credit risk on such financial instruments has not increased significantly since initial recognition, the Company measures the loss allowance on those financial instruments at an amount equal to 12-months ECL. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Lifetime ECL represents the ECL that will result from all possible default events over the expected life of a financial asset. In contrast, 12-month ECL represents the portion of lifetime ECL that is expected to result from default events on a financial asset that are possible within 12 months after the reporting date. In assessing whether the credit risk on a financial asset has increased significantly since initial recognition, the Company compares the risk of default occurring on the financial asset at the reporting date with the risk of default occurring at the initial recognition. The Company considers both quantitative and qualitative factors that are supportable, including historical experience and forward-looking information that is available without undue cost or effort. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Irrespective of the above assessment, the Company presumes that the credit risk on a financial asset has increased significantly since initial recognition when contractual payments are more than 30 days past due, unless the Company has reasonable and supportable information that demonstrates otherwise. Despite the foregoing, the Company presumes that the credit risk on a financial asset has not increased significantly since initial recognition if the financial asset is determined to have low credit risk at the reporting date. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company regularly monitors the effectiveness of the criteria used to identify whether there has been a significant increase in credit risk and revises them as appropriate to ensure that the criteria are capable of identifying significant increase in credit risk before the amount becomes pas due. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Definition of default&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;For internal credit risk management purposes, the Company considers a financial asset not recoverable if the customer balance owing is 180 days past due and information obtained from the customer and other external factors indicate that the customer is unlikely to pay its creditors in full.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:130%"&gt;Write-off&lt;/span&gt;&lt;/div&gt;Financial assets are written off (either partially or in full) when there is no realistic prospect of recovery. This is generally the case when the Company determines that the counterparty does not have assets or sources of income that could general sufficient cash flows to repay the amounts subject to the write-off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Company&#x2019;s procedures for recovery of amounts due.</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="c-1" id="f-228">&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Taxation&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Income tax comprises current and deferred tax. Income tax is recognized in the consolidated statement of loss and comprehensive loss except to the extent that it relates to items recognized directly in equity, in which case the income tax is also recognized directly in equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Current income tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted, at the end of the reporting period, and any adjustment to tax payable in respect of previous years.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from audits by taxing authorities. Where the outcome of these tax-related matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Deferred income tax is recorded using the asset and liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences do not result in deferred tax assets or liabilities: the initial recognized of assets or liabilities that affect neither accounting or taxable loss; or difference relating to investment in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the consolidated statement of financial position date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized. &lt;/span&gt;&lt;/div&gt;Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Company intends to settle its correct tax assets and liabilities on a net basis.</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory contextRef="c-1" id="f-229">&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Share capital&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Equity instruments are contracts that give a residual interest in the net assets of the Company. Financial instruments issued by the Company are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Common Shares and the Company&#x2019;s Common Share purchase warrants and options are classified as equity instruments. &lt;/span&gt;&lt;/div&gt;Incremental costs directly attributable to the issue of new Common Shares or warrants are shown in equity as a deduction, net of tax, from the proceeds.</ifrs-full:DescriptionOfAccountingPolicyForIssuedCapitalExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="c-1" id="f-230">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Under the Company&#x2019;s equity incentive plan, all stock options granted may have graded vesting periods and are exercisable up to a maximum of 10 years form the date of grant. Each tranche of an award with graded vesting periods is considered a separate grant at each grant date for the calculation of fair value, and the resulting fair value is amortized over the vesting period of the respective tranches. The fair value of the options granted is measured using the Black-Scholes option pricing model taking into account the terms and conditions upon which the options were granted, the estimated volatility, estimated risk free rate and estimated forfeitures. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;If a grant of the share-based payments is cancelled or settled during the vesting period (other than a grant cancelled by forfeiture when the vesting conditions are not satisfied or options granted in error and cancelled retroactively), the Company accounts for the cancellation or settlement as an acceleration of vesting, and recognizes immediately the amount that otherwise would have been recognized for services over the remainder of the vesting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The amount recognized for goods or services received during the vesting period is based on the best available estimate of the number of equity instruments anticipated to vest. The Company revises that estimate, if necessary, if subsequent information indicates that the number of share options anticipated to vest differs from previous estimates. On the vesting date, the Company revises the estimate to equal the number of equity instrument that ultimately vested. After the vesting date, the Company makes no subsequent adjustment to total equity for goods or services received if the share options are later forfeited or they expire at the end of the share option&#x2019;s life. Upon expiration of options, the amount applicable to expired options is moved to contributed surplus.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;If a grant of the share based payment is modified during the vesting period (other than a grant cancelled by forfeiture when&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:130%"&gt;  &lt;/span&gt;the vesting conditions are not satisfied) and the fair value of the new instruments is higher than the fair value of the original instrument, the incremental fair value granted is included in the measurement of the amount recognized for services received over the period from modification date until the date when the modified equity instruments vests, in addition to the amount based on the grant date fair value of the original equity instruments, which is recognized over the remainder of the original vesting period of the original instrument.</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <cybn:ShareBasedCompensationArrangementExpirationPeriod contextRef="c-1" id="f-231">P10Y</cybn:ShareBasedCompensationArrangementExpirationPeriod>
    <ifrs-full:DescriptionOfAccountingPolicyForWarrantsExplanatory contextRef="c-1" id="f-232">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company follows the relative fair value method with respect to the measurement of Common Shares and warrants issued as units. The proceeds from the issuance of units are allocated between share capital and warrants. The warrant component is recorded in equity reserve. Unit proceeds are allocated to Common Shares and warrants using the Black-Scholes option pricing model and the share price at the time of financing. If and when the warrants are exercised, consideration paid by the warrant holder, together with the amount previously recognized in warrant reserve, is recorded as an increase to share capital. A forfeiture rate is estimated on the grant date and is adjusted to reflect the actual number of warrants that vest. When stock options or warrants are cancelled, they are treated as if they have vested on the date of collation and any cost &lt;/span&gt;&lt;/div&gt;not yet recognized in profit or loss is immediately expensed. Upon expiration of warrants, the amount applicable to expired warrants is moved to contributed surplus.</ifrs-full:DescriptionOfAccountingPolicyForWarrantsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="c-1" id="f-233">&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Loss per share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Basic loss per share is calculated using the weighted-average number of shares outstanding during the period. The diluted earnings (loss) per share reflects the potential dilution of Common Share equivalents, such as outstanding stock options and warrants, in the weighted average number of Common Shares outstanding during the period, if they are dilutive.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c-1" id="f-234">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Currency translation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;All figures presented in the consolidated financial statements are reflected in Canadian dollars unless otherwise noted.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Foreign currency transactions are translated into Canadian dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the consolidated statement of financial position date are translated to Canadian dollars at the foreign exchange rate applicable as that date. Realized and unrealized exchange gains and losses are recognized through profit or loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The assets and liabilities of foreign operations are translated into Canadian dollars at period-end exchange rates. Income and expenses, and cash flows of foreign operations are translated into Canadian dollars using average exchange rates. Exchange differences resulting from translating foreign operations are recognized in other comprehensive income (loss) and accumulated separately in shareholders&#x2019; equity. &lt;/span&gt;&lt;/div&gt;Foreign currency translation gains or losses arising from a monetary item receivable or payable to a foreign operation, the settlement of which is neither planned nor likely to occur in the foreseeable future and which in substance is considered to form part of the net investment in the foreign operation, are recognized in other comprehensive income (loss) in the translation reserve.</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="c-1" id="f-235">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Provisions are recorded when a present legal or constructive obligation exists as a result of past events where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and a reliable estimate of the amount of the obligation can be made.&lt;/span&gt;&lt;/div&gt;The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the consolidated statement of financial position date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows. When some or all of the economic benefits required to settle, a provision is expected to be recovered from a third party, the receivable is recognized as an asset if it is virtually certain that reimbursement will be received and the amount receivable can be measured reliably.</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations contextRef="c-1" id="f-236">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;New standards and interpretations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The IASB has issued certain amendments to accounting and financial reporting standards effective for annual reporting periods beginning on or after January 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;IAS 1, Presentation of Financial Statements ("IAS 1") - Classification of Liabilities as Current or Non-Current&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;In January 2020, the IASB issued amendments to IAS 1. The amendments aim to promote consistency in applying the requirements by helping companies determine whether, in the consolidated statements of financial position, debt and other liabilities with an uncertain settlement date should be classified as current (due or potentially due to be settled within one year) or non-current. The amendments include clarifying the classification requirements for debt a company might settle by converting it into equity. The amendments are effective for annual reporting periods beginning on or after January 1, 2024.  The Company has determined that adoption of these amendments has no significant effect on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%;text-decoration:underline"&gt;New standards and interpretations not yet adopted &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;IFRS 18, Presentation and Disclosure in Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;In April 2024, the IASB issued IFRS 18 that is to replace IAS 1, Presentation of Financial Statements. The new standard aims to improve the quality of financial reporting by: (i) requiring defined subtotals in the statement of profit or loss; (ii) requiring disclosure about management defined performance measures; and (iii) adding new principles for aggregation and disaggregation of information.  The standard is effective for the annual reporting periods beginning on or after January 1, 2027, with early application permitted. The Company is in the process of assessing the impact of this new standard on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;IFRS 9, Financial Instruments (&#x201c;IFRS 9&#x201d;) and IFRS 7, Financial Instruments: Disclosures (&#x201c;IFRS 7&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;In May 2024, the IASB issued targeted amendments to IFRS 9 and IFRS 7 in response to practical implementation issues and to introduce new requirements applicable to both financial institutions and corporate entities. These amendments aim to enhance the clarity and consistency of financial reporting for various types of financial instruments and their related disclosures by (i) clarifying the date of recognition and derecognition for certain financial assets and liabilities, including a new exception for financial liabilities settled through an electronic cash transfer system (ii) providing help to determine whether a financial asset meets the Solely Payments of Principal and Interest criterion (iii) introducing new disclosures for instruments with contractual terms that may alter cash flows, such as financial instruments linked to the achievement of environmental, social, and governance targets, and (iv) updating the disclosure requirements for equity instruments designated at FVTOCI. The new standard is to be effective for annual periods beginning on or after January 1, 2026. The Company is in the process of assessing the impact of the standard on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;All other IFRSs and amendments issued but not yet effective have been assessed by the Company and are not expected to have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="c-1" id="f-237">CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS &lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The preparation of these consolidated financial statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting year. Actual outcomes could differ from these estimates. These consolidated financial statements include estimates which, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the year in which the estimate is revised and future years if the revision affects both current and future years. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Judgments, estimates and assumptions that have the most significant effect on the amounts recognized in the consolidated financial statements include warrants and fair value of share-based payments (note 9) and the fair value of financial instruments (note 15).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%"&gt;Ability to continue as a going concern&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;In order to assess whether it is appropriate for the Company to continue as a going concern, management is required to apply judgment and make estimates with respect to future cash flow projections. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;In arriving at this judgment, there were a number of assumptions and estimates involved in calculating these future cash flow projections. This includes making estimates regarding the timing and amounts of future expenditures and the ability and timing of raising additional financing. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%"&gt;Business combinations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;A business combination is a transaction or event in which an acquirer obtains control of one or more businesses and is accounted for using the acquisition method. The total consideration paid for the acquisition is the aggregate of the fair values of assets given, liabilities incurred or assumed, and equity instruments issued in exchange for control of the acquiree at the acquisition date. The acquisition date is the date where the Company obtains control of the acquiree. The identifiable assets acquired and liabilities assumed are recognized at their acquisition date fair values, except for deferred taxes and share-based payment awards where IFRS provides exceptions to recording the amounts at fair value. Acquisition costs are expensed to profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combination. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as an asset or a liability is remeasured at subsequent reporting dates in accordance with IFRS 9, or IAS 37 Provisions, Contingent Liabilities and Contingent Assets, as appropriate, with the corresponding gain or loss being recognized in profit or loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Non-controlling interest in the acquiree, if any, is recognized either at fair value or at the non-controlling interest&#x2019;s proportionate share of the acquiree&#x2019;s net assets, determined on an acquisition-by-acquisition basis. For each acquisition, the excess of total consideration, the fair value of previously held equity interest prior to obtaining control and the non-controlling interest in the acquiree, over the fair value of the identifiable net asset acquired, is recorded as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Certain fair values may be estimated at the acquisition date pending confirmation or completion of the valuation process. Where provisional values are used in accounting for a business combination, they may be adjusted retrospectively in subsequent periods. The measurement period is the period from the acquisition date to the date complete information about facts and circumstances that existed as of the acquisition date is received. However, the measurement period does not exceed one year from the acquisition date. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Acquisitions that do not meet the definition of a business combination are accounted for as an asset acquisition. Consideration paid for an asset acquisition is allocated to the individual identifiable assets acquired and liabilities assumed based on their relative fair values.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Share based payments&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The fair value of share-based compensation expenses are estimated using the Black-Scholes option pricing model and rely on a number of estimates, such as the expected life of the option, the volatility of the underlying share price, the risk-free rate of return, and the estimated rate of forfeiture of options or warrants granted.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Impairment of non-financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Impairment exists when the carrying value of an asset or cash generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The fair value less costs of disposal calculation is based on available data from binding sales transactions, conducted at arm&#x2019;s length, for similar assets or observable market prices less incremental costs of disposing of the asset. The value in use calculation is based on a discounted cash flow (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;DCF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;) model. The cash flows are derived from the forecast for the next ten years and do not include restructuring activities that the Company is not yet committed to or significant future investments that will enhance the performance of the assets of the CGU being tested. The determination of the Company&#x2019;s CGUs is based on management&#x2019;s judgement. The recoverable amount is sensitive to the discount rate used for the DCF model as well as the expected future cash-inflows and the growth rate used for extrapolation purposes. These estimates are most relevant to goodwill and other intangibles with indefinite useful lives recognized by the Company.  Future events could cause the assumptions used in the impairment review to change with a consequential adverse effect on the results of the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company computed an income tax provision in accordance with the applicable income tax laws. However, actual amounts of income tax expense only become final upon filing and acceptance of the tax return by the relevant authorities, which occurs subsequent to the issuance of the consolidated financial statements. Additionally, estimation of income taxes includes evaluation the recoverability of deferred tax assets based on &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;an assessment of the ability to use the underlying future tax deductions before they expire against future taxable income. The assessment is based upon existing tax laws and estimates of future taxable income. The income tax provision is based on estimates of full-year earnings by jurisdiction. The average annual effective income tax rates are re-estimated at the end of each reporting period. To the extent that estimates and forecasts  differ from actual results, adjustments are recorded in subsequent periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;The useful life and recoverability of long-lived assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Management estimates the useful life of long-lived assets based on the period during which the assets are expected to be available for use. The amounts and timing of recorded expenses for amortization and depreciation are affected by these estimated useful lives. The estimates are reviewed at least annually and are updated if expectations change as a result of technical or commercial obsolescence, and legal or other limits to use. It is possible that changes in these factors may cause significant changes in the estimated useful lives of the Company&#x2019;s long-lived assets in the future. &lt;/span&gt;&lt;/div&gt;The Company estimates the useful lives and selects methods used to allocate amortization and depreciation amounts of long-lived assets on a systematic basis. Technical obsolescence of intangible and tangible assets could significantly impact estimated residual useful lives and, in turn, carrying values being over or understated. The estimates of the useful lives of long-lived assets are reviewed on an annual basis. Amortization and depreciation are adjusted on a prospective basis, if and when required.</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <ifrs-full:DisclosureOfBusinessCombinationsExplanatory contextRef="c-1" id="f-238">ACQUISITION&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On October 23, 2023, Cybin completed the acquisition of Small Pharma and its wholly-owned subsidiary Small Pharma Ltd. (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Acquisition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;) and issued 0.00634 Common Shares for every one common share of Small Pharma outstanding, resulting in a total of 2,130,138 Common Shares being issued to Small Pharma shareholders. As a result of the Acquisition, Small Pharma became a wholly-owned subsidiary of Cybin. On December 16, 2023 the Company changed the name of Small Pharma Ltd. to Cybin UK Ltd. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;In connection with the Acquisition, all unvested options of Small Pharma were vested and holders were able to exercise their options prior to the close of the Acquisition. All stock options of Small Pharma remaining unexercised at October 23, 2023 were cancelled and compensation of $0.001 per stock option was paid to the optionees.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;As at October 23, 2023  Small Pharma&#x2019;s patent portfolio consisted of 17 active patent families with 92 pending applications and 30 granted patents across its psychedelic and non-psychedelic portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company determined that the Acquisition was a business combination under IFRS. The consideration for the acquisition and measurement of assets acquired and liabilities assumed, as well as goodwill, in accordance with IFRS 3 - Business Combinations, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.668%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.206%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.464%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Acquisition Summary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair value of purchaser consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;53,481&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allocation of Purchase Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total allocation of purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;53,481&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A professional valuator was engaged by the Company to estimate the value of the assets of Small Pharma for the purpose of the final purchase price allocation. Accordingly, the purchase price allocation was subject to change as at March 31, 2024. The final purchase price allocation was completed within the required one-year measurement period and did not result in any changes from the provisional amounts previously reported. As such, the allocation of the purchase consideration to the identifiable assets acquired and liabilities assumed remains unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;As at February 28, 2023, Small Pharma had Canadian loss carry forwards of $9,393 and UK loss carry forwards (stated in Canadian dollars) of $46,631. No value has been ascribed to loss carry forwards in these  consolidated financial statements. Tax values of assets acquired may differ from their accounting values.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The following revenue and net loss is attributable to Small Pharma for the period from the Acquisition date to March 31, 2024 and included in these consolidated financial statements for the comparative year.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.668%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBusinessCombinationsExplanatory>
    <cybn:RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding contextRef="c-51" decimals="5" id="f-239" unitRef="number">0.00634</cybn:RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding>
    <ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable contextRef="c-51" decimals="4" id="f-240" unitRef="shares">2130138</ifrs-full:NumberOfInstrumentsOrInterestsIssuedOrIssuable>
    <cybn:UnexercisedStockOptionsInSubsidiaryCompensationForCancellation
      contextRef="c-51"
      decimals="3"
      id="f-241"
      unitRef="cadPerShare">0.001</cybn:UnexercisedStockOptionsInSubsidiaryCompensationForCancellation>
    <cybn:NumberOfActivePatentFamilies
      contextRef="c-51"
      decimals="INF"
      id="f-242"
      unitRef="patent_family">17</cybn:NumberOfActivePatentFamilies>
    <cybn:NumberOfPendingPatentApplications
      contextRef="c-51"
      decimals="INF"
      id="f-243"
      unitRef="application">92</cybn:NumberOfPendingPatentApplications>
    <cybn:NumberOfGrantedPatents
      contextRef="c-51"
      decimals="INF"
      id="f-244"
      unitRef="patent">30</cybn:NumberOfGrantedPatents>
    <ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory contextRef="c-1" id="f-245">The consideration for the acquisition and measurement of assets acquired and liabilities assumed, as well as goodwill, in accordance with IFRS 3 - Business Combinations, is as follows:&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.668%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.206%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.464%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Acquisition Summary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair value of purchaser consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;53,481&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Allocation of Purchase Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,686)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total allocation of purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;53,481&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The following revenue and net loss is attributable to Small Pharma for the period from the Acquisition date to March 31, 2024 and included in these consolidated financial statements for the comparative year.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.668%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="c-51" decimals="-3" id="f-246" unitRef="cad">53481000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred contextRef="c-51" decimals="-3" id="f-247" unitRef="cad">53481000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <cybn:CashRecognisedAsOfAcquisitionDate contextRef="c-51" decimals="-3" id="f-248" unitRef="cad">7632000</cybn:CashRecognisedAsOfAcquisitionDate>
    <ifrs-full:CurrentAssetsRecognisedAsOfAcquisitionDate contextRef="c-51" decimals="-3" id="f-249" unitRef="cad">510000</ifrs-full:CurrentAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate contextRef="c-51" decimals="-3" id="f-250" unitRef="cad">37000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate contextRef="c-51" decimals="-3" id="f-251" unitRef="cad">29339000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <cybn:RightOfUseAssetRecognisedAsOfAcquisitionDate contextRef="c-51" decimals="-3" id="f-252" unitRef="cad">412000</cybn:RightOfUseAssetRecognisedAsOfAcquisitionDate>
    <cybn:LeaseLiabilitiesRecognisedAsOfAcquisitionDate contextRef="c-51" decimals="-3" id="f-253" unitRef="cad">415000</cybn:LeaseLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate contextRef="c-51" decimals="-3" id="f-254" unitRef="cad">6686000</ifrs-full:FinancialLiabilitiesRecognisedAsOfAcquisitionDate>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate contextRef="c-51" decimals="-3" id="f-255" unitRef="cad">22652000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed contextRef="c-51" decimals="-3" id="f-256" unitRef="cad">53481000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-52" decimals="-3" id="f-257" unitRef="cad">-9393000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset contextRef="c-53" decimals="-3" id="f-258" unitRef="cad">-46631000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:Revenue contextRef="c-54" decimals="-3" id="f-259" unitRef="cad">0</ifrs-full:Revenue>
    <ifrs-full:ProfitLoss contextRef="c-54" decimals="-3" id="f-260" unitRef="cad">-1666000</ifrs-full:ProfitLoss>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-261">EQUIPMENT&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lab Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Computer Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at  March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;664&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;239&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;903&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of Small Pharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment write-down&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at  March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;664&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;930&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment write-down&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at  March 31,  2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;686&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;302&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;988&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at   March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;290&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment write-down&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at  March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;430&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;664&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment write-down&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31,  2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;587&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;847&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value as at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;99&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;141&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-262">&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lab Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Computer Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at  March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;664&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;239&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;903&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of Small Pharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment write-down&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at  March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;664&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;930&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment write-down&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at  March 31,  2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;686&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;302&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;988&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at   March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;290&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment write-down&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at  March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;430&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;664&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment write-down&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31,  2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;587&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;847&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value as at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;99&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;141&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-55" decimals="-3" id="f-263" unitRef="cad">664000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-56" decimals="-3" id="f-264" unitRef="cad">239000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-57" decimals="-3" id="f-265" unitRef="cad">903000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-58" decimals="-3" id="f-266" unitRef="cad">0</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-59" decimals="-3" id="f-267" unitRef="cad">37000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-60" decimals="-3" id="f-268" unitRef="cad">37000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-58" decimals="-3" id="f-269" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-59" decimals="-3" id="f-270" unitRef="cad">21000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-60" decimals="-3" id="f-271" unitRef="cad">21000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="c-59" decimals="-3" id="f-272" unitRef="cad">33000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="c-60" decimals="-3" id="f-273" unitRef="cad">33000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-58" decimals="-3" id="f-274" unitRef="cad">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-59" decimals="-3" id="f-275" unitRef="cad">2000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-60" decimals="-3" id="f-276" unitRef="cad">2000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-61" decimals="-3" id="f-277" unitRef="cad">664000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-62" decimals="-3" id="f-278" unitRef="cad">266000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-63" decimals="-3" id="f-279" unitRef="cad">930000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-64" decimals="-3" id="f-280" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-65" decimals="-3" id="f-281" unitRef="cad">35000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-66" decimals="-3" id="f-282" unitRef="cad">35000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="c-64" decimals="-3" id="f-283" unitRef="cad">19000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="c-66" decimals="-3" id="f-284" unitRef="cad">19000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-64" decimals="-3" id="f-285" unitRef="cad">41000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-65" decimals="-3" id="f-286" unitRef="cad">1000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-66" decimals="-3" id="f-287" unitRef="cad">42000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-67" decimals="-3" id="f-288" unitRef="cad">686000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-68" decimals="-3" id="f-289" unitRef="cad">302000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-69" decimals="-3" id="f-290" unitRef="cad">988000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-70" decimals="-3" id="f-291" unitRef="cad">-290000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-71" decimals="-3" id="f-292" unitRef="cad">-163000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-72" decimals="-3" id="f-293" unitRef="cad">-453000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-73" decimals="-3" id="f-294" unitRef="cad">137000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-74" decimals="-3" id="f-295" unitRef="cad">86000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-75" decimals="-3" id="f-296" unitRef="cad">223000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="c-74" decimals="-3" id="f-297" unitRef="cad">15000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="c-75" decimals="-3" id="f-298" unitRef="cad">15000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-73" decimals="-3" id="f-299" unitRef="cad">-3000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-74" decimals="-3" id="f-300" unitRef="cad">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-75" decimals="-3" id="f-301" unitRef="cad">-3000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-76" decimals="-3" id="f-302" unitRef="cad">-430000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-77" decimals="-3" id="f-303" unitRef="cad">-234000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-78" decimals="-3" id="f-304" unitRef="cad">-664000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-79" decimals="-3" id="f-305" unitRef="cad">146000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-80" decimals="-3" id="f-306" unitRef="cad">26000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-81" decimals="-3" id="f-307" unitRef="cad">172000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="c-79" decimals="-3" id="f-308" unitRef="cad">19000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment contextRef="c-81" decimals="-3" id="f-309" unitRef="cad">19000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-79" decimals="-3" id="f-310" unitRef="cad">-30000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-80" decimals="-3" id="f-311" unitRef="cad">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c-81" decimals="-3" id="f-312" unitRef="cad">-30000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-82" decimals="-3" id="f-313" unitRef="cad">-587000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-83" decimals="-3" id="f-314" unitRef="cad">-260000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-84" decimals="-3" id="f-315" unitRef="cad">-847000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-85" decimals="-3" id="f-316" unitRef="cad">234000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-86" decimals="-3" id="f-317" unitRef="cad">32000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-318" unitRef="cad">266000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-87" decimals="-3" id="f-319" unitRef="cad">99000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-88" decimals="-3" id="f-320" unitRef="cad">42000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-2" decimals="-3" id="f-321" unitRef="cad">141000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="c-1" id="f-322">INTANGIBLE ASSETS&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;IP Research &amp;amp; Development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,379&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,507&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of Small Pharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,440&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,668&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,381&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35,563&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35,851&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,794&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,465&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41,184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;68&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;166&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value as at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,440&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,668&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,325&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35,465&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35,851&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,794&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,367&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41,018&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%"&gt;IP Research &amp;amp; Development&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Refer to note 4 for information on the Small Pharma Acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%"&gt;Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Costs associated with patent procurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company performed its annual impairment test of intangible assets not yet in use at March 31, 2025. The recoverable amount was determined based on the relief from royalty method to arrive at the value-in-use (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;VIU&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;). The Company considered an estimate of future revenues and a reasonable royalty rate to apply to financial projections based on the current budget and future commercialization plans. In assessing the VIU, estimated future cash flows are discounted to their present value using a discount rate that reflects the assessment of royalty and business opportunities and risk as well as the market potential. The VIU calculations were performed using a pre-tax discount rate of 20.3% (2024 - 15.7%) and an estimated useful life of 15 year&lt;/span&gt;&lt;/div&gt;s (2024 - 15 years). Based on the Company&#x2019;s assessment, the recoverable amount is higher than the carrying value and therefore no impairment loss was recorded for the years ended March&#160;31, 2025 or 2024.</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory contextRef="c-1" id="f-323">&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;IP Research &amp;amp; Development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;978&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,379&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,507&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of Small Pharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,440&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,668&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,381&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35,563&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35,851&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,794&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,465&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41,184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization charge&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;98&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;68&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;166&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value as at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,440&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,668&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,325&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35,465&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;35,851&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,794&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,367&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41,018&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-89" decimals="-3" id="f-324" unitRef="cad">3076000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-90" decimals="-3" id="f-325" unitRef="cad">978000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-91" decimals="-3" id="f-326" unitRef="cad">1379000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-92" decimals="-3" id="f-327" unitRef="cad">74000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-57" decimals="-3" id="f-328" unitRef="cad">5507000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-93" decimals="-3" id="f-329" unitRef="cad">29339000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-94" decimals="-3" id="f-330" unitRef="cad">0</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-95" decimals="-3" id="f-331" unitRef="cad">0</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-96" decimals="-3" id="f-332" unitRef="cad">0</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-60" decimals="-3" id="f-333" unitRef="cad">29339000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-93" decimals="-3" id="f-334" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-94" decimals="-3" id="f-335" unitRef="cad">689000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-95" decimals="-3" id="f-336" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-96" decimals="-3" id="f-337" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-60" decimals="-3" id="f-338" unitRef="cad">689000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-93" decimals="-3" id="f-339" unitRef="cad">25000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-94" decimals="-3" id="f-340" unitRef="cad">1000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-95" decimals="-3" id="f-341" unitRef="cad">2000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-96" decimals="-3" id="f-342" unitRef="cad">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-60" decimals="-3" id="f-343" unitRef="cad">28000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-97" decimals="-3" id="f-344" unitRef="cad">32440000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-98" decimals="-3" id="f-345" unitRef="cad">1668000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-99" decimals="-3" id="f-346" unitRef="cad">1381000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-100" decimals="-3" id="f-347" unitRef="cad">74000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-63" decimals="-3" id="f-348" unitRef="cad">35563000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-101" decimals="-3" id="f-349" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-102" decimals="-3" id="f-350" unitRef="cad">1931000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-103" decimals="-3" id="f-351" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-104" decimals="-3" id="f-352" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c-66" decimals="-3" id="f-353" unitRef="cad">1931000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-101" decimals="-3" id="f-354" unitRef="cad">3411000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-102" decimals="-3" id="f-355" unitRef="cad">195000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-103" decimals="-3" id="f-356" unitRef="cad">84000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-104" decimals="-3" id="f-357" unitRef="cad">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-66" decimals="-3" id="f-358" unitRef="cad">3690000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-105" decimals="-3" id="f-359" unitRef="cad">35851000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-106" decimals="-3" id="f-360" unitRef="cad">3794000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-107" decimals="-3" id="f-361" unitRef="cad">1465000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-108" decimals="-3" id="f-362" unitRef="cad">74000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-69" decimals="-3" id="f-363" unitRef="cad">41184000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-109" decimals="-3" id="f-364" unitRef="cad">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-110" decimals="-3" id="f-365" unitRef="cad">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-111" decimals="-3" id="f-366" unitRef="cad">-19000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-112" decimals="-3" id="f-367" unitRef="cad">-18000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-72" decimals="-3" id="f-368" unitRef="cad">-37000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-113" decimals="-3" id="f-369" unitRef="cad">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-114" decimals="-3" id="f-370" unitRef="cad">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-115" decimals="-3" id="f-371" unitRef="cad">-37000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-116" decimals="-3" id="f-372" unitRef="cad">-24000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-75" decimals="-3" id="f-373" unitRef="cad">-61000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-117" decimals="-3" id="f-374" unitRef="cad">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-118" decimals="-3" id="f-375" unitRef="cad">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-119" decimals="-3" id="f-376" unitRef="cad">-56000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-120" decimals="-3" id="f-377" unitRef="cad">-42000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-78" decimals="-3" id="f-378" unitRef="cad">-98000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-121" decimals="-3" id="f-379" unitRef="cad">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-122" decimals="-3" id="f-380" unitRef="cad">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-123" decimals="-3" id="f-381" unitRef="cad">-39000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-124" decimals="-3" id="f-382" unitRef="cad">-26000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c-81" decimals="-3" id="f-383" unitRef="cad">-65000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-121" decimals="-3" id="f-384" unitRef="cad">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-122" decimals="-3" id="f-385" unitRef="cad">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-123" decimals="-3" id="f-386" unitRef="cad">-3000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-124" decimals="-3" id="f-387" unitRef="cad">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill contextRef="c-81" decimals="-3" id="f-388" unitRef="cad">-3000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-125" decimals="-3" id="f-389" unitRef="cad">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-126" decimals="-3" id="f-390" unitRef="cad">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-127" decimals="-3" id="f-391" unitRef="cad">-98000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-128" decimals="-3" id="f-392" unitRef="cad">-68000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-84" decimals="-3" id="f-393" unitRef="cad">-166000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-129" decimals="-3" id="f-394" unitRef="cad">32440000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-130" decimals="-3" id="f-395" unitRef="cad">1668000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-131" decimals="-3" id="f-396" unitRef="cad">1325000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-132" decimals="-3" id="f-397" unitRef="cad">32000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-3" decimals="-3" id="f-398" unitRef="cad">35465000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-133" decimals="-3" id="f-399" unitRef="cad">35851000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-134" decimals="-3" id="f-400" unitRef="cad">3794000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-135" decimals="-3" id="f-401" unitRef="cad">1367000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-136" decimals="-3" id="f-402" unitRef="cad">6000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="c-2" decimals="-3" id="f-403" unitRef="cad">41018000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:SignificantUnobservableInputAssets contextRef="c-137" decimals="3" id="f-404" unitRef="number">0.203</ifrs-full:SignificantUnobservableInputAssets>
    <ifrs-full:SignificantUnobservableInputAssets contextRef="c-138" decimals="3" id="f-405" unitRef="number">0.157</ifrs-full:SignificantUnobservableInputAssets>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-139" id="f-406">P15Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="c-140" id="f-407">P15Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <cybn:DisclosureOfLeasesAndRightOfUseAssetsTextBlock contextRef="c-1" id="f-408">RIGHT-OF-USE ASSETS AND LEASE LIABILITIES&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;During the year ended March&#160;31, 2025, the Company terminated its lease early, resulting in a loss on the derecognition of its right-of-use assets of $52 and a gain on derecognition of lease liabilities of $24. The loss on the derecognition of its right-of-use assets reflects the difference between the carrying value of the right-of-use asset and the recoverable amount at the time of derecognition. The gain on derecognition of lease liabilities was calculated as the difference between the carrying amount of the lease liability immediately before the termination and the payment made to settle the lease obligation. The net loss of $28 has been recognized as "other loss" in the consolidated statement of loss and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:9.96pt;text-decoration:underline"&gt;Right-of-use assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;424&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(448)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at  March 31,  2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(395)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value as at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value as at  March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:9.53pt;text-decoration:underline"&gt;Lease Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;291&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on derecognition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination penalty payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cybn:DisclosureOfLeasesAndRightOfUseAssetsTextBlock>
    <cybn:GainLossOnDerecognitionOfRightOfUseAssets contextRef="c-1" decimals="-3" id="f-409" unitRef="cad">-52000</cybn:GainLossOnDerecognitionOfRightOfUseAssets>
    <cybn:GainLossOnDerecognitionOfLeaseLiability contextRef="c-1" decimals="-3" id="f-410" unitRef="cad">24000</cybn:GainLossOnDerecognitionOfLeaseLiability>
    <ifrs-full:OtherExpenseByNature contextRef="c-1" decimals="-3" id="f-411" unitRef="cad">28000</ifrs-full:OtherExpenseByNature>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory contextRef="c-1" id="f-412">&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;424&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(448)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at  March 31,  2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(395)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value as at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;281&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value as at  March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <ifrs-full:RightofuseAssets contextRef="c-57" decimals="-3" id="f-413" unitRef="cad">0</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c-60" decimals="-3" id="f-414" unitRef="cad">412000</ifrs-full:AdditionsToRightofuseAssets>
    <cybn:EffectOfForeignExchangeRightOfUseAssets contextRef="c-60" decimals="-3" id="f-415" unitRef="cad">12000</cybn:EffectOfForeignExchangeRightOfUseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-63" decimals="-3" id="f-416" unitRef="cad">424000</ifrs-full:RightofuseAssets>
    <cybn:EffectOfForeignExchangeRightOfUseAssets contextRef="c-66" decimals="-3" id="f-417" unitRef="cad">24000</cybn:EffectOfForeignExchangeRightOfUseAssets>
    <ifrs-full:DisposalsRightofuseAssets contextRef="c-66" decimals="-3" id="f-418" unitRef="cad">448000</ifrs-full:DisposalsRightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-69" decimals="-3" id="f-419" unitRef="cad">0</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-72" decimals="-3" id="f-420" unitRef="cad">0</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-75" decimals="-3" id="f-421" unitRef="cad">-140000</ifrs-full:DepreciationRightofuseAssets>
    <cybn:EffectOfForeignExchangeRightOfUseAssets contextRef="c-75" decimals="-3" id="f-422" unitRef="cad">-3000</cybn:EffectOfForeignExchangeRightOfUseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-78" decimals="-3" id="f-423" unitRef="cad">-143000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-81" decimals="-3" id="f-424" unitRef="cad">-238000</ifrs-full:DepreciationRightofuseAssets>
    <cybn:EffectOfForeignExchangeRightOfUseAssets contextRef="c-81" decimals="-3" id="f-425" unitRef="cad">-14000</cybn:EffectOfForeignExchangeRightOfUseAssets>
    <ifrs-full:DisposalsRightofuseAssets contextRef="c-81" decimals="-3" id="f-426" unitRef="cad">395000</ifrs-full:DisposalsRightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-84" decimals="-3" id="f-427" unitRef="cad">0</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-3" decimals="-3" id="f-428" unitRef="cad">281000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-2" decimals="-3" id="f-429" unitRef="cad">0</ifrs-full:RightofuseAssets>
    <ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory contextRef="c-1" id="f-430">&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;291&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on derecognition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination penalty payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory>
    <ifrs-full:LeaseLiabilities contextRef="c-12" decimals="-3" id="f-431" unitRef="cad">0</ifrs-full:LeaseLiabilities>
    <cybn:AdditionsToLeaseLiabilities contextRef="c-5" decimals="-3" id="f-432" unitRef="cad">415000</cybn:AdditionsToLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-5" decimals="-3" id="f-433" unitRef="cad">8000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <cybn:EffectOfForeignExchangeLeaseLiabilities contextRef="c-5" decimals="-3" id="f-434" unitRef="cad">17000</cybn:EffectOfForeignExchangeLeaseLiabilities>
    <cybn:PaymentsOfLeaseLiabilities contextRef="c-5" decimals="-3" id="f-435" unitRef="cad">149000</cybn:PaymentsOfLeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-3" decimals="-3" id="f-436" unitRef="cad">291000</ifrs-full:LeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-1" decimals="-3" id="f-437" unitRef="cad">7000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <cybn:EffectOfForeignExchangeLeaseLiabilities contextRef="c-1" decimals="-3" id="f-438" unitRef="cad">16000</cybn:EffectOfForeignExchangeLeaseLiabilities>
    <cybn:GainLossOnDerecognitionOfLeaseLiability contextRef="c-1" decimals="-3" id="f-439" unitRef="cad">24000</cybn:GainLossOnDerecognitionOfLeaseLiability>
    <cybn:PaymentForTerminationPenaltyLeaseLiability contextRef="c-1" decimals="-3" id="f-440" unitRef="cad">31000</cybn:PaymentForTerminationPenaltyLeaseLiability>
    <cybn:PaymentsOfLeaseLiabilities contextRef="c-1" decimals="-3" id="f-441" unitRef="cad">259000</cybn:PaymentsOfLeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-2" decimals="-3" id="f-442" unitRef="cad">0</ifrs-full:LeaseLiabilities>
    <ifrs-full:DisclosureOfGoodwillExplanatory contextRef="c-1" id="f-443">GOODWILL&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill is recognized at the acquisition date when total consideration exceeds the net identifiable assets acquired. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at  March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24,792&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition from Small Pharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at  March 31,  2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47,475&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at  March 31,  2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;51,487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;For purposes of the Company&#x2019;s goodwill impairment testing, the Company has grouped certain CGUs to test at the lowest level at which management monitors goodwill for internal management purposes, which is the Company wide level.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company performed its annual impairment test of goodwill at March&#160;31, 2025. The recoverable amount was determined based on value-in-use (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;VIU&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;) and considered the cash flows of the group of CGUs based on the current budget and future commercialization plans. In assessing the VIU, estimated future cash flows are discounted to their present value using a discount rate that reflects market assessments of the time value of money and the risks specific to the CGUs. The VIU calculations were performed using a pre-tax discount rate of 20.3% (March&#160;31, 2024 - 15.7%). The Company utilized the run-off method, and no terminal period cash flows were considered. Based on the Company&#x2019;s assessment, the recoverable amount is higher than the carrying value and therefore no impairment loss was recorded for the year ended March&#160;31, 2025 or March&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGoodwillExplanatory>
    <ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory contextRef="c-1" id="f-444">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill is recognized at the acquisition date when total consideration exceeds the net identifiable assets acquired. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at  March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24,792&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition from Small Pharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at  March 31,  2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47,475&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at  March 31,  2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;51,487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfReconciliationOfChangesInGoodwillExplanatory>
    <ifrs-full:Goodwill contextRef="c-141" decimals="-3" id="f-445" unitRef="cad">24792000</ifrs-full:Goodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill contextRef="c-142" decimals="-3" id="f-446" unitRef="cad">22652000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsAndGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-142" decimals="-3" id="f-447" unitRef="cad">31000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:Goodwill contextRef="c-143" decimals="-3" id="f-448" unitRef="cad">47475000</ifrs-full:Goodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill contextRef="c-144" decimals="-3" id="f-449" unitRef="cad">4012000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsAndGoodwill>
    <ifrs-full:Goodwill contextRef="c-145" decimals="-3" id="f-450" unitRef="cad">51487000</ifrs-full:Goodwill>
    <ifrs-full:SignificantUnobservableInputAssets contextRef="c-146" decimals="3" id="f-451" unitRef="number">0.203</ifrs-full:SignificantUnobservableInputAssets>
    <ifrs-full:SignificantUnobservableInputAssets contextRef="c-147" decimals="3" id="f-452" unitRef="number">0.157</ifrs-full:SignificantUnobservableInputAssets>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill contextRef="c-1" decimals="INF" id="f-453" unitRef="cad">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill contextRef="c-5" decimals="INF" id="f-454" unitRef="cad">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c-1" id="f-455">SHARE CAPITAL&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:9.96pt;text-decoration:underline"&gt;Authorized share capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On September 19, 2024, the Company completed the Consolidation.  As a result, the number of Common Shares, warrants, options and earnings per share presented in these consolidated financial statements have been restated retrospectively for all the years to reflect the Consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The authorized share capital of Cybin consists of an unlimited number of Common Shares and an unlimited number of preferred shares without par value. The board of directors of Cybin would determine the designation, rights, privileges, and conditions attached to any preferred shares prior to issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%;padding-left:9.53pt;text-decoration:underline"&gt;Issued share capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%"&gt;Common Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;As at March&#160;31, 2025, the Company had 23,364 Common Shares subject to transfer restrictions (March 31, 2024: 415,985). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;During the year ended March 31, 2025, the Company completed the following share issuances:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On February 10, 2025, the Company established a new at-the-market equity program (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;2025 ATM Program&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d; and together with the 2023 ATM Program (see below), the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;ATM Programs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;) that allow the Company to issue and sell up to US$100,000 of Common Shares from treasury to the public, from time to time. Distributions of Common Shares under the 2025 ATM Program are made pursuant to the terms and conditions of an at-the-market equity distribution agreement (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;2025 Distribution Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;) dated February 10, 2025, among the Company, Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald &amp;amp; Co. The 2025 ATM Program is to be effective until the earlier of the issuance and sale of all of the Common Shares issuable pursuant to the 2025 ATM Program and September 17, 2025, unless earlier terminated in accordance with the terms of the 2025 Distribution Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;During the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;March&#160;31, 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;, the Company sold 1,609,298 Common Shares under the ATM Programs at an average price of $13.62 (US$9.52) per Common Share, for aggregate gross proceeds of $21,924 (US$15,322). Share issuance costs related to the ATM Programs for the year were $941.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;There were two&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt; Common Shares issued in connection with the Consolidation as a result of rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:130%"&gt;During the year ended March 31, 2024, the Company completed the following share issuances:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On August 23, 2023, the Company established a new at-the-market equity program (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;2023 ATM Program&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d; and together with the 2022 at-the-market equity program, the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Prior&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;ATM Programs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;) that allows the Company to issue and sell up to US$35,000 of Common Shares from treasury to the public, from time to time. Distributions of Common Shares under the 2023 ATM Program are made pursuant to the terms and conditions of an at-the-market equity distribution agreement (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;2023 Distribution Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;) dated August 23, 2023, among the Company, Cantor Fitzgerald Canada Corporation and Cantor Fitzgerald &amp;amp; Co. The 2023 ATM Program was terminated on February 10, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;During the year ended March 31, 2024, the Company sold 898,434 Common Shares under the Prior ATM Programs at an average price of $17.29 (US$12.82) per Common Share, for aggregate gross proceeds of $15,532 (US$11,518). Share issuance costs related to the ATM Programs for the year were $832.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On May 30, 2023, the Company entered into an agreement (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;LPC Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;) with Lincoln Park Capital Fund, LLC (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;LPC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;). Subject to the terms and conditions of the LPC Agreement, the Company has the right to sell, and LPC is obligated to purchase, up to US$30,000 of Common Shares over a 36-month period at prices that are based on the market price at the time of each sale to LPC. Cybin, in its sole discretion, controls the timing and amount of all sales of Common Shares under the LPC Agreement. During the year ended March 31, 2024, the Company sold 50,658 Common Shares, at an average price of $12.30 (US$9.18) per Common Shares, for aggregate gross proceeds of $623 (US$465) pursuant to the LPC Agreement. Share issuance costs related to the LPC Agreement for the year ended March  31, 2024 were $476 (US$351).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Cybin has the right to terminate the LPC Agreement at any time at no cost or penalty. LPC has agreed not to engage in any short selling or hedging activity of any kind in the Common Shares. As consideration for LPC&#x2019;s obligation to purchase Common Shares from the Company at its direction under the LPC Agreement, Cybin issued 66,812 Common Shares to LPC as a commitment fee on May 30, 2023.  The LPC Agreement provides that Cybin may not issue or sell any Common Shares to LPC under the LPC Agreement which, when aggregated with all other Common Shares then beneficially owned by LPC and its affiliates (as calculated pursuant to Section 13(d) of the U.S. Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder), would result in LPC beneficially owning more than 9.99% of the outstanding Common Shares. On July 31, 2023, Cybin announced that it had suspended all sales under the LPC Agreement. On August 23, 2023, the Company filed a prospectus supplement to the base shelf prospectus dated August 17, 2023 to re-qualify sales of up to US$30,000 of the Company&#x2019;s Common Shares pursuant to the LPC Agreement. On November 9, 2023, the Company announced that it has, again, suspended all sales under the LPC Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On August 4, 2023, the Company completed a public offering (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;August 2023 Offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;) of 638,545 units of the Company (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;August 2023 Units&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;) at a price of US$12.92 per August 2023 Unit for gross proceeds of $11,018 (US$8,250) pursuant to a supplement to the Company&#x2019;s short form base shelf prospectus dated July 5, 2021. Each August 2023 Unit is comprised of one Common Share and one Common Share purchase warrant (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;August 2023 Warrants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;). Each August 2023 Warrant is exercisable to acquire one Common Share at a price of $21.85 (US$15.20) for a period of 60 months from issuance, subject to acceleration in certain circumstances. In connection with the Offering, Cybin paid the underwriters a cash commission of $506 (US$379) and incurred additional share issuance costs, being professional fees of $622 (US$465).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On November 14, 2023, the Company completed a public offering (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;November 2023 Offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;) of 1,754,386 units of the Company (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;November 2023 Units&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;) at a price of US$17.10 per November 2023 Unit for gross proceeds of $41,107 (US$30,000) pursuant to a supplement to the Company&#x2019;s short form base shelf prospectus dated August 17, 2023. Each November 2023 Unit is comprised of one Common Share and one Common Share purchase warrant (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;November 2023 Warrants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;). Each November 2023 Warrant is exercisable to acquire one Common Share at a price of $27.86 (US$19.38) between May 14, 2024 and May 14, 2029, subject to acceleration in certain circumstances. In connection with the November 2023 Offering, Cybin paid the underwriters a cash commission of $2,096 (US$1,530) and incurred additional share issuance costs being professional fees of $339 (US$247).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On March 19, 2024, the Company completed a private placement (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;March 2024 Offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;) of 9,179,927 Common Shares at a price of US$16.34 per Common Share for gross proceeds of $202,995 (US$150,000). 415,985 Common Shares issued in the March 2024 Offering were subject to resale restrictions until July 20, 2024. In connection with the March  2024 Offering, Cybin paid the agent a cash commission of $11,726 (US$8,665) and incurred additional share issuance costs being professional fees of $504 .&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Preferred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;As at March&#160;31, 2025,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt; the Company had no preferred shares outstanding (2024- nil).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Cybin US Class B Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Class B Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530,542.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Converted into Common Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(494,457.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,084.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,084.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;As at March&#160;31, 2025, 36,084.7 class B common shares of Cybin US (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;Class B Shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;&#x201d;) were outstanding, and are exchangeable for a total of 9,496 Common Shares. The Class B Shares are exchangeable at the holder&#x2019;s option for Common Shares on the basis of 0.26316 Common Shares for 1 Class B Share. These consolidated financial statements reflect issued Class B Shares on an as-converted basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;During the year ended March 31, 2025, no Class B Shares were issued or converted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:35.7pt;text-align:justify;text-indent:-17.85pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%;padding-left:10.56pt;text-decoration:underline"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0.15pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The continuity of the outstanding warrants for the years ended March 31, 2025 and 2024, are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Common Share Purchase Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.46&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.86&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,796,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,796,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24.03&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,796,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24.03&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unit Purchase Warrants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,862)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at March 31, 2024 and March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%"&gt;Certain warrants were issued in USD, the weighted average exercise price is calculated using the closing exchange rate in effect as at the respective dates.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%"&gt;        &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%"&gt;Each unit consisted of one Common Share and one half of one Common Share purchase warrant, with each Common Share purchase warrant being exercisable to acquire one Common Share at an exercise price of $123.50 per Common Share.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;During the year ended March 31, 2024, the Company had the following movement in warrants:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended March 31, 2024, 2,658 Common Share purchase warrants were exercised by various holders for aggregate proceeds to the Company of $56. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the year ended March 31, 2024, 205,404 warrants with a weighted average exercise price of $131.86 expired unexercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;During the year ended March 31, 2024, the Company completed the following warrant issuances: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On August 4, 2023, Cybin issued 638,545 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;August 2023 Warrants in connection with the August 2023 Offering. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Each August 2023 Warrant is exercisable to acquire one Common Share at a price of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt; US$15.20&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt; per Common Share until August 4, 2028, subject to acceleration in certain circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company estimated the aggregate fair value of the August 2023 Warrants using the Black-Scholes option pricing model to be $4,600 (US$3,442) with the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.87%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on comparable companies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$12.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$15.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On November 14, 2023, Cybin issued 1,754,386 November 2023 Warrants in connection with the November 2023 Offering. Each November 2023 Warrant is exercisable from May 14, 2024 to May 14, 2029 to acquire one Common Share at a price of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;US$19.38&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;, subject to acceleration in certain circumstances.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company estimated the aggregate fair value of the November 2023 Warrants using the Black-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Scholes option pricing model to be $17,842 (US$12,299) with the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on comparable companies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$17.48&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$19.38&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;   &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes information about warrants outstanding as at March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Date of Expiry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted average of exercisable price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$000&#x2019;s&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 4, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$15.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,578&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.35&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 14, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,754,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,754,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$19.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 15, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,891&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 20, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 15, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,796,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,796,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27,594&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;On August 27, 2024, the Company, upon receiving shareholder approval, extended the expiry dates of the warrants originally expiring on June 15, 2025, August 20 , 2025, and November 15, 2025 to June 15, 2030, August 20, 2030, and November 15, 2030, respectively. The Company extended the expiry date of 405,924 &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;warrants, of which 260,527 warrants related to officers and directors of the Company. No other changes to the terms of the warrants were made. As a result of the modification, the Company recorded an additional expense, related to the incremental fair value of the extended warrants, of $1,955 in the statements of loss and comprehensive loss as "Share-based compensation".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;d&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%;text-decoration:underline"&gt; Stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;On November 5, 2020, Cybin adopted an equity incentive plan. Under the plan, the board of directors may grant share-based awards to acquire such number of Common Shares as is equal to up to 20% of the total number of issued and outstanding Common Shares at the time such awards are granted. Options granted under the plan vest over a period of time at the discretion of the board of directors. On August 27, 2024, the board of directors and the shareholders re-approved the equity incentive plan and approved certain amendments to the plan, including an increase to the fixed number of Incentive Stock Options (as defined in the plan), certain changes to the board of directors' authority to amend existing awards, and certain other housekeeping amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in options for the years ended March 31, 2025 and 2024 are as follow&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,742,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,484,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,270,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,956,684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15.23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,591,976&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15.19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;During the year ended March 31, 2025, the Company completed the following option issuances:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On April 5, 2024, the Company granted options to purchase up to 308,294 Common Shares, of which 134,872 were granted to employees, 144,738 were granted to officers of the Company and 28,684 were granted to consultants. The granted options have an exercise price of $21.28 per Common Share and expire on April 5, 2029. The granted options have different vesting schedules; 38,536 options vested immediately and 269,758 options vest over two years. The aggregate estimated grant date fair value was determined to be $4,619 calculated using the Black-Scholes option pricing model with the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.62%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on historical share price of the Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.13%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0% - 3.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.28&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.28&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:17.85pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;On May 5, 2024, the Company cancelled options to purchase up to 1,199,655 Common Shares (exercise prices ranged from $27.17 to $119.70). The unvested options were vested based on an accelerated cancellation criteria which resulted in $1,185 of share based compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;On August 15, 2024, the Company granted options to purchase up to 3,061,232 Common Shares, of which 940,168 were granted to employees, 1,980,888 were granted to officers and directors and 140,176 were granted to consultants. The granted options have an exercise price of $13.11 per Common Share and expire on August 15, 2034. Certain options vested immediately, while others vest over periods of up to two years. The aggregate estimated grant date fair value was determined to be $34,822 calculated using the Black-Scholes option pricing model with the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.187%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.07%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on historical share price of the Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.69%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%  - 3.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;On November 27, 2024, the Company granted options to purchase up to 80,100 Common Shares, of which 73,100 were granted to employees and 7,000 was granted to a consultant. The granted options have an exercise price of $14.37 per Common Share and expire on November 27, 2034. The granted options vest over periods of up to two years. The aggregate estimated grant date fair value was determined to be $982 calculated using the Black-Scholes option pricing model with the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.23%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on historical share price of the Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.06%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0% - 3.4% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;On March 7, 2025, the Company granted options to purchase up to 35,000 Common Shares to a consultant. The granted options have an exercise price of $10.45 per Common Share and expire on March 7, 2035. The granted options vest over period of one year. The aggregate estimated grant date fair value was determined to be $307 calculated using the Black-Scholes option pricing model with the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.03%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on historical share price of the Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.43%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.45&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.45&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;uring the year ended March 31, 2024, the Company completed the following option issuances:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On June 29, 2023, the Company granted options to purchase up to 305,661 Common Shares, of which 105,026&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt; were granted to employees, 99,027 were granted to officers of the Company, 80,949 were granted to consultants, and 20,659 were granted to directors of the Company. The granted options have an exercise price of $16.72 per Common Share and expire on June 30, 2028. The granted options have different vesting schedules; 39,474 options vested immediately, 18,422 options vest over three months, 2,632 options vest over one year, and 245,133 options vest over two years.  The aggregate estimated grant date fair value was determined to be $4,080, calculated using the Black-Scholes option pricing model with the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.78%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on comparable companies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.86&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On September 26, 2023, the Company granted options to purchase up to 31,842 Common Shares, of which 3,553 were granted to an employee and, 28,289 were granted to consultants. The granted options have an exercise price of $30.02 per Common Share, and 25,657 options expire on September 26, 2026 and the re&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;maining 6,185 options expire on September 26, 2028. The granted options have different vesting schedules. 9,868 options vest over three months, 5,263 options vest over six months, 10,526 options vest over one year, 2,632 options vest over fifteen months, and 3,553 options vest over 18 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt; The aggregate estimated grant date fair value was determined to be $577, calculated using the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; Options expiring on September 26, 2026&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.68%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on comparable companies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Options  expiring on September 26, 2028&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;    &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;Risk-free interest rate&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.28%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on comparable companies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On November 16, 2023, the Company granted options to purchase up to 673,682 Common Shares, of which 584,211 were granted to officers, 42,104 were granted to directors, 34,209 were granted to employees and 13,158 were granted to a consultant. The granted options have an exercise price of $27.17 per Common Share, 13,158 options expire on November 16, 2026 and the remaining 660,524 options expire on November 16, 2028. The granted options have different vesting schedules. 496,052 options vest immediately and 177,630 options vest over two years. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The aggregate estimated grant date fair value was determined to be $10,907, calculated using the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;   Options expiring on November 16, 2026&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.28%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on comparable companies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Options expiring on November 16, 2028&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.28%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on comparable companies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On March 20, 2024, the Company granted options to purchase up to 526 Common Shares to an employee with an exercise price of $21.28 per Common Share which expire on March 20, 2029 and vest over two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The aggregate estimated grant date fair value was determined to be $8, calculated using the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.52%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on comparable companies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.28&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.28&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;During the year ended March 31, 2024, the Company amended the expiry dates of certain options with former employees and consultants of the Company.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The following summarizes information about stock options outstanding on March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of options outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of options exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated  fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted average remaining life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiry date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$000&#x2019;s&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 6, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 6, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 6, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 4, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 11, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 14, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 15, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 10, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 15, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.90&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 29, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.99&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 28, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 26, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 15, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 4, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 8, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 26, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 20, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.97&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 5, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 15, 2034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,877,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 27, 2034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.66&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 7, 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.93&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,956,684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,591,976&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47,427&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The Company recognized share-based payments expense related to the issuance of stock options for the year ended March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;of $40,914 (2024 - $13,886).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The outstanding options and warrants disclosed above were anti-dilutive for the year ended March 31, 2025 and 2024 and did not impact the calculation of the loss per share.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <cybn:NumberOfCommonSharesHeldInEscrow contextRef="c-2" decimals="INF" id="f-456" unitRef="shares">23364</cybn:NumberOfCommonSharesHeldInEscrow>
    <cybn:NumberOfCommonSharesHeldInEscrow contextRef="c-3" decimals="INF" id="f-457" unitRef="shares">415985</cybn:NumberOfCommonSharesHeldInEscrow>
    <cybn:CommonStockSharesAuthorizedValue contextRef="c-148" decimals="-3" id="f-458" unitRef="cad">100000</cybn:CommonStockSharesAuthorizedValue>
    <cybn:NumberOfSharesIssuedThroughShareOfferingEquity contextRef="c-27" decimals="0" id="f-459" unitRef="shares">1609298</cybn:NumberOfSharesIssuedThroughShareOfferingEquity>
    <cybn:SharePricePerCommonShare
      contextRef="c-149"
      decimals="2"
      id="f-460"
      unitRef="cadPerShare">13.62</cybn:SharePricePerCommonShare>
    <cybn:SharePricePerCommonShare
      contextRef="c-149"
      decimals="2"
      id="f-461"
      unitRef="usdPerShare">9.52</cybn:SharePricePerCommonShare>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-149" decimals="-3" id="f-462" unitRef="cad">21924000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-149" decimals="-3" id="f-463" unitRef="usd">15322000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c-1" decimals="-3" id="f-464" unitRef="cad">941000</ifrs-full:PaymentsForShareIssueCosts>
    <cybn:IncreaseDecreaseThroughShareConsolidationEquity contextRef="c-27" decimals="0" id="f-465" unitRef="cad">2</cybn:IncreaseDecreaseThroughShareConsolidationEquity>
    <cybn:CommonStockSharesAuthorizedValue contextRef="c-150" decimals="-3" id="f-466" unitRef="cad">35000</cybn:CommonStockSharesAuthorizedValue>
    <cybn:NumberOfSharesIssuedThroughShareOfferingEquity contextRef="c-151" decimals="0" id="f-467" unitRef="shares">898434</cybn:NumberOfSharesIssuedThroughShareOfferingEquity>
    <cybn:SharePricePerCommonShare
      contextRef="c-151"
      decimals="2"
      id="f-468"
      unitRef="cadPerShare">17.29</cybn:SharePricePerCommonShare>
    <cybn:SharePricePerCommonShare
      contextRef="c-151"
      decimals="2"
      id="f-469"
      unitRef="usdPerShare">12.82</cybn:SharePricePerCommonShare>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-151" decimals="-3" id="f-470" unitRef="cad">15532000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-151" decimals="-3" id="f-471" unitRef="usd">11518000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c-5" decimals="-3" id="f-472" unitRef="cad">832000</ifrs-full:PaymentsForShareIssueCosts>
    <cybn:CommonStockSharesAuthorizedValue contextRef="c-152" decimals="-3" id="f-473" unitRef="cad">30000000</cybn:CommonStockSharesAuthorizedValue>
    <cybn:CommonSharesPurchasePeriodTerm contextRef="c-153" id="f-474">P36M</cybn:CommonSharesPurchasePeriodTerm>
    <cybn:NumberOfSharesIssuedThroughShareOfferingEquity contextRef="c-154" decimals="0" id="f-475" unitRef="shares">50658</cybn:NumberOfSharesIssuedThroughShareOfferingEquity>
    <cybn:SharePricePerCommonShare
      contextRef="c-154"
      decimals="2"
      id="f-476"
      unitRef="cadPerShare">12.3</cybn:SharePricePerCommonShare>
    <cybn:SharePricePerCommonShare
      contextRef="c-154"
      decimals="2"
      id="f-477"
      unitRef="usdPerShare">9.18</cybn:SharePricePerCommonShare>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-154" decimals="-3" id="f-478" unitRef="cad">623000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-154" decimals="-3" id="f-479" unitRef="usd">465000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-155" decimals="-3" id="f-480" unitRef="cad">476000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-155" decimals="-3" id="f-481" unitRef="usd">351000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <cybn:NumberOfSharesIssuedThroughShareOfferingEquity contextRef="c-156" decimals="0" id="f-482" unitRef="shares">66812</cybn:NumberOfSharesIssuedThroughShareOfferingEquity>
    <cybn:PercentageOfOutstandingCommonSharesOwn contextRef="c-157" decimals="4" id="f-483" unitRef="number">0.0999</cybn:PercentageOfOutstandingCommonSharesOwn>
    <cybn:CommonStockSharesAuthorizedValue contextRef="c-158" decimals="-3" id="f-484" unitRef="cad">30000000</cybn:CommonStockSharesAuthorizedValue>
    <cybn:NumberOfSharesIssuedThroughShareOfferingEquity contextRef="c-159" decimals="0" id="f-485" unitRef="shares">638545</cybn:NumberOfSharesIssuedThroughShareOfferingEquity>
    <cybn:SharePricePerCommonShare
      contextRef="c-159"
      decimals="2"
      id="f-486"
      unitRef="usdPerShare">12.92</cybn:SharePricePerCommonShare>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-159" decimals="-3" id="f-487" unitRef="cad">11018000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-159" decimals="-3" id="f-488" unitRef="usd">8250000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <cybn:NumberOfCommonShares contextRef="c-160" decimals="0" id="f-489" unitRef="shares">1</cybn:NumberOfCommonShares>
    <cybn:NumberOfCommonSharePurchaseWarrants contextRef="c-160" decimals="0" id="f-490" unitRef="shares">1</cybn:NumberOfCommonSharePurchaseWarrants>
    <cybn:NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement
      contextRef="c-160"
      decimals="INF"
      id="f-491"
      unitRef="shares">1</cybn:NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement>
    <cybn:ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement
      contextRef="c-160"
      decimals="2"
      id="f-492"
      unitRef="cadPerShare">21.85</cybn:ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement>
    <cybn:ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement
      contextRef="c-160"
      decimals="2"
      id="f-493"
      unitRef="usdPerShare">15.2</cybn:ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement>
    <cybn:PeriodToExerciseWarrantsInShareBasedPaymentArrangement contextRef="c-161" id="f-494">P60M</cybn:PeriodToExerciseWarrantsInShareBasedPaymentArrangement>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c-161" decimals="-3" id="f-495" unitRef="cad">506000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c-161" decimals="-3" id="f-496" unitRef="usd">379000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:ProfessionalFeesExpense contextRef="c-161" decimals="-3" id="f-497" unitRef="cad">622000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense contextRef="c-161" decimals="-3" id="f-498" unitRef="usd">465000</ifrs-full:ProfessionalFeesExpense>
    <cybn:NumberOfSharesIssuedThroughShareOfferingEquity contextRef="c-162" decimals="0" id="f-499" unitRef="shares">1754386</cybn:NumberOfSharesIssuedThroughShareOfferingEquity>
    <cybn:SharePricePerCommonShare
      contextRef="c-162"
      decimals="2"
      id="f-500"
      unitRef="usdPerShare">17.1</cybn:SharePricePerCommonShare>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-162" decimals="-3" id="f-501" unitRef="cad">41107000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-162" decimals="-3" id="f-502" unitRef="usd">30000000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <cybn:NumberOfCommonShares contextRef="c-163" decimals="0" id="f-503" unitRef="shares">1</cybn:NumberOfCommonShares>
    <cybn:NumberOfCommonSharePurchaseWarrants contextRef="c-163" decimals="0" id="f-504" unitRef="shares">1</cybn:NumberOfCommonSharePurchaseWarrants>
    <cybn:NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement
      contextRef="c-163"
      decimals="INF"
      id="f-505"
      unitRef="shares">1</cybn:NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement>
    <cybn:ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement
      contextRef="c-163"
      decimals="2"
      id="f-506"
      unitRef="cadPerShare">27.86</cybn:ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement>
    <cybn:ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement
      contextRef="c-163"
      decimals="2"
      id="f-507"
      unitRef="usdPerShare">19.38</cybn:ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c-164" decimals="-3" id="f-508" unitRef="cad">2096000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c-164" decimals="-3" id="f-509" unitRef="usd">1530000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:ProfessionalFeesExpense contextRef="c-164" decimals="-3" id="f-510" unitRef="cad">339000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense contextRef="c-164" decimals="-3" id="f-511" unitRef="usd">247000</ifrs-full:ProfessionalFeesExpense>
    <cybn:NumberOfSharesIssuedThroughShareOfferingEquity contextRef="c-165" decimals="0" id="f-512" unitRef="shares">9179927</cybn:NumberOfSharesIssuedThroughShareOfferingEquity>
    <cybn:SharePricePerCommonShare
      contextRef="c-166"
      decimals="2"
      id="f-513"
      unitRef="usdPerShare">16.34</cybn:SharePricePerCommonShare>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-166" decimals="-3" id="f-514" unitRef="cad">202995000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-166" decimals="-3" id="f-515" unitRef="usd">150000000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <cybn:NumberOfSharesSubjectToResaleRestrictions contextRef="c-166" decimals="1" id="f-516" unitRef="shares">415985</cybn:NumberOfSharesSubjectToResaleRestrictions>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c-167" decimals="-3" id="f-517" unitRef="cad">11726000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c-167" decimals="-3" id="f-518" unitRef="usd">8665000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:ProfessionalFeesExpense contextRef="c-167" decimals="-3" id="f-519" unitRef="cad">504000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-168"
      decimals="INF"
      id="f-520"
      unitRef="shares">0</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c-169"
      decimals="INF"
      id="f-521"
      unitRef="shares">0</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c-1" id="f-522">&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Cybin US Class B Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Class B Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;530,542.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Converted into Common Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(494,457.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,084.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,084.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c-170" decimals="1" id="f-523" unitRef="shares">530542.1</ifrs-full:NumberOfSharesOutstanding>
    <cybn:IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares contextRef="c-171" decimals="1" id="f-524" unitRef="shares">-494457.4</cybn:IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c-172" decimals="1" id="f-525" unitRef="shares">36084.7</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c-173" decimals="1" id="f-526" unitRef="shares">36084.7</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c-173" decimals="1" id="f-527" unitRef="shares">36084.7</ifrs-full:NumberOfSharesOutstanding>
    <cybn:NumberOfSharesIssuedUponConversionOfConvertibleInstruments contextRef="c-173" decimals="0" id="f-528" unitRef="shares">9496</cybn:NumberOfSharesIssuedUponConversionOfConvertibleInstruments>
    <cybn:CommonSharesExchangeRate contextRef="c-2" decimals="5" id="f-529" unitRef="shares">0.26316</cybn:CommonSharesExchangeRate>
    <cybn:NumberOfSharesConvertedThroughContingentConsiderationEquity contextRef="c-174" decimals="1" id="f-530" unitRef="shares">0</cybn:NumberOfSharesConvertedThroughContingentConsiderationEquity>
    <cybn:NumberOfSharesIssuedThroughContingentConsiderationEquity contextRef="c-174" decimals="1" id="f-531" unitRef="shares">0</cybn:NumberOfSharesIssuedThroughContingentConsiderationEquity>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory contextRef="c-1" id="f-532">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The continuity of the outstanding warrants for the years ended March 31, 2025 and 2024, are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.067%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:2.77pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt;Common Share Purchase Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;611,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,392,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.46&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.86&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,796,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,796,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24.03&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,796,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24.03&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unit Purchase Warrants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,862)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at March 31, 2024 and March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%"&gt;Certain warrants were issued in USD, the weighted average exercise price is calculated using the closing exchange rate in effect as at the respective dates.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%"&gt;        &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:130%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:130%"&gt;Each unit consisted of one Common Share and one half of one Common Share purchase warrant, with each Common Share purchase warrant being exercisable to acquire one Common Share at an exercise price of $123.50 per Common Share.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The following summarizes information about warrants outstanding as at March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Date of Expiry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted average of exercisable price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$000&#x2019;s&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 4, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$15.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,578&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.35&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 14, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,754,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,754,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$19.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 15, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,891&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 20, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.39&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 15, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,796,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,796,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27,594&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="c-175" decimals="0" id="f-533" unitRef="shares">611329</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-175"
      decimals="2"
      id="f-534"
      unitRef="cadPerShare">49.02</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <cybn:NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement contextRef="c-176" decimals="0" id="f-535" unitRef="shares">2392931</cybn:NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement>
    <cybn:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement
      contextRef="c-176"
      decimals="2"
      id="f-536"
      unitRef="cadPerShare">25.46</cybn:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="c-176" decimals="0" id="f-537" unitRef="shares">2658</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="c-176"
      decimals="2"
      id="f-538"
      unitRef="cadPerShare">20.14</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement contextRef="c-176" decimals="0" id="f-539" unitRef="shares">205404</ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c-176"
      decimals="2"
      id="f-540"
      unitRef="cadPerShare">131.86</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="c-177" decimals="0" id="f-541" unitRef="shares">2796197</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-177"
      decimals="2"
      id="f-542"
      unitRef="cadPerShare">22.74</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="c-178" decimals="0" id="f-543" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="c-178"
      decimals="2"
      id="f-544"
      unitRef="cadPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="c-179" decimals="0" id="f-545" unitRef="shares">2796197</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-179"
      decimals="2"
      id="f-546"
      unitRef="cadPerShare">24.03</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement contextRef="c-179" decimals="0" id="f-547" unitRef="shares">2796197</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-179"
      decimals="2"
      id="f-548"
      unitRef="cadPerShare">24.03</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="c-180" decimals="0" id="f-549" unitRef="shares">22862</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-180"
      decimals="2"
      id="f-550"
      unitRef="cadPerShare">85.50</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <cybn:NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement contextRef="c-181" decimals="0" id="f-551" unitRef="shares">-22862</cybn:NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement>
    <cybn:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement
      contextRef="c-181"
      decimals="2"
      id="f-552"
      unitRef="cadPerShare">85.50</cybn:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="c-182" decimals="0" id="f-553" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="c-183" decimals="0" id="f-554" unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-183"
      decimals="2"
      id="f-555"
      unitRef="cadPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-182"
      decimals="2"
      id="f-556"
      unitRef="cadPerShare">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <cybn:NumberOfCommonShares
      contextRef="c-183"
      decimals="INF"
      id="f-557"
      unitRef="shares">1</cybn:NumberOfCommonShares>
    <cybn:NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement
      contextRef="c-183"
      decimals="INF"
      id="f-558"
      unitRef="shares">1</cybn:NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-183"
      decimals="2"
      id="f-559"
      unitRef="cadPerShare">123.5</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="c-176" decimals="0" id="f-560" unitRef="shares">2658</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-178" decimals="-3" id="f-561" unitRef="cad">56000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement contextRef="c-176" decimals="0" id="f-562" unitRef="shares">205404</ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c-176"
      decimals="2"
      id="f-563"
      unitRef="cadPerShare">131.86</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019>
    <cybn:NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement contextRef="c-161" decimals="0" id="f-564" unitRef="shares">638545</cybn:NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement>
    <cybn:NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement
      contextRef="c-160"
      decimals="INF"
      id="f-565"
      unitRef="shares">1</cybn:NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-161"
      decimals="2"
      id="f-566"
      unitRef="cadPerShare">15.2</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory contextRef="c-1" id="f-567">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company estimated the aggregate fair value of the August 2023 Warrants using the Black-Scholes option pricing model to be $4,600 (US$3,442) with the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.87%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on comparable companies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$12.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$15.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company estimated the aggregate fair value of the November 2023 Warrants using the Black-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Scholes option pricing model to be $17,842 (US$12,299) with the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on comparable companies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$17.48&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$19.38&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfEquityExplanatory>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-161" decimals="-3" id="f-568" unitRef="cad">4600000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-161" decimals="-3" id="f-569" unitRef="usd">3442000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <cybn:RiskFreeInterestRateOtherEquityInstrumentsGranted contextRef="c-161" decimals="4" id="f-570" unitRef="number">0.0387</cybn:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <cybn:ExpectedVolatilityOtherEquityInstrumentsGranted contextRef="c-161" decimals="4" id="f-571" unitRef="number">0.9500</cybn:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <cybn:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted contextRef="c-161" id="f-572">P5Y</cybn:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted>
    <cybn:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted contextRef="c-161" decimals="4" id="f-573" unitRef="number">0.0000</cybn:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <cybn:SharePricePerCommonShare
      contextRef="c-161"
      decimals="2"
      id="f-574"
      unitRef="usdPerShare">12.92</cybn:SharePricePerCommonShare>
    <cybn:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="c-161"
      decimals="2"
      id="f-575"
      unitRef="usdPerShare">15.2</cybn:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted>
    <cybn:NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement contextRef="c-184" decimals="0" id="f-576" unitRef="shares">1754386</cybn:NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement>
    <cybn:NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement
      contextRef="c-163"
      decimals="INF"
      id="f-577"
      unitRef="shares">1</cybn:NumberOfSharesAcquiredUponExerciseOfWarrantInShareBasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-184"
      decimals="2"
      id="f-578"
      unitRef="cadPerShare">19.38</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-184" decimals="-3" id="f-579" unitRef="cad">17842000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-184" decimals="-3" id="f-580" unitRef="usd">12299000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <cybn:RiskFreeInterestRateOtherEquityInstrumentsGranted contextRef="c-184" decimals="4" id="f-581" unitRef="number">0.0376</cybn:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <cybn:ExpectedVolatilityOtherEquityInstrumentsGranted contextRef="c-184" decimals="4" id="f-582" unitRef="number">0.9500</cybn:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <cybn:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted contextRef="c-184" id="f-583">P5Y6M</cybn:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted>
    <cybn:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted contextRef="c-184" decimals="4" id="f-584" unitRef="number">0.0000</cybn:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <cybn:SharePricePerCommonShare
      contextRef="c-184"
      decimals="2"
      id="f-585"
      unitRef="usdPerShare">17.48</cybn:SharePricePerCommonShare>
    <cybn:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="c-184"
      decimals="2"
      id="f-586"
      unitRef="usdPerShare">19.38</cybn:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="c-185" decimals="0" id="f-587" unitRef="shares">635887</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement contextRef="c-185" decimals="0" id="f-588" unitRef="shares">635887</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-185"
      decimals="2"
      id="f-589"
      unitRef="cadPerShare">15.2</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted contextRef="c-185" decimals="-3" id="f-590" unitRef="cad">4578000</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <cybn:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments contextRef="c-185" id="f-591">P3Y4M6D</cybn:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="c-186" decimals="0" id="f-592" unitRef="shares">1754386</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement contextRef="c-186" decimals="0" id="f-593" unitRef="shares">1754386</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-186"
      decimals="2"
      id="f-594"
      unitRef="cadPerShare">19.38</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted contextRef="c-186" decimals="-3" id="f-595" unitRef="cad">17842000</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <cybn:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments contextRef="c-186" id="f-596">P4Y1M13D</cybn:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="c-187" decimals="0" id="f-597" unitRef="shares">336843</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement contextRef="c-187" decimals="0" id="f-598" unitRef="shares">336843</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-187"
      decimals="2"
      id="f-599"
      unitRef="cadPerShare">9.50</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted contextRef="c-187" decimals="-3" id="f-600" unitRef="cad">3891000</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <cybn:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments contextRef="c-187" id="f-601">P5Y2M15D</cybn:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="c-188" decimals="0" id="f-602" unitRef="shares">38818</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement contextRef="c-188" decimals="0" id="f-603" unitRef="shares">38818</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-188"
      decimals="2"
      id="f-604"
      unitRef="cadPerShare">24.32</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted contextRef="c-188" decimals="-3" id="f-605" unitRef="cad">936000</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <cybn:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments contextRef="c-188" id="f-606">P5Y4M20D</cybn:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="c-189" decimals="0" id="f-607" unitRef="shares">30263</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement contextRef="c-189" decimals="0" id="f-608" unitRef="shares">30263</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-189"
      decimals="2"
      id="f-609"
      unitRef="cadPerShare">9.50</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted contextRef="c-189" decimals="-3" id="f-610" unitRef="cad">347000</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <cybn:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments contextRef="c-189" id="f-611">P5Y7M17D</cybn:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="c-179" decimals="0" id="f-612" unitRef="shares">2796197</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement contextRef="c-179" decimals="0" id="f-613" unitRef="shares">2796197</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-179"
      decimals="2"
      id="f-614"
      unitRef="cadPerShare">24.03</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted contextRef="c-179" decimals="-3" id="f-615" unitRef="cad">27594000</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <cybn:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments contextRef="c-179" id="f-616">P4Y1M9D</cybn:WeightedAverageRemainingContractualLifeOfOtherEquityInstruments>
    <cybn:NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended contextRef="c-179" decimals="0" id="f-617" unitRef="shares">405924</cybn:NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended>
    <cybn:NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended contextRef="c-190" decimals="0" id="f-618" unitRef="shares">260527</cybn:NumberOfOtherEquityInstrumentsInShareBasedPaymentArrangementExpiryDateExtended>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-30" decimals="-3" id="f-619" unitRef="cad">1955000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <cybn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding contextRef="c-191" decimals="2" id="f-620" unitRef="number">0.20</cybn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="c-1" id="f-621">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in options for the years ended March 31, 2025 and 2024 are as follow&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,742,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,484,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,270,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,956,684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15.23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable as at March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,591,976&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15.19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The following summarizes information about stock options outstanding on March&#160;31, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of options outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of options exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated  fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted average remaining life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiry date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$000&#x2019;s&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 6, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 6, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 6, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 7, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 4, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 11, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 14, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.71&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 15, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 10, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.82&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 15, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.90&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 29, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.99&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 28, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 26, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 15, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 4, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 8, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 26, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 20, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.97&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 5, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 15, 2034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,877,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 27, 2034&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.66&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 7, 2035&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.93&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,956,684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,591,976&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47,427&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8.13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-12" decimals="0" id="f-622" unitRef="shares">778163</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-12"
      decimals="2"
      id="f-623"
      unitRef="cadPerShare">51.68</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c-5" decimals="0" id="f-624" unitRef="shares">1011711</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c-5"
      decimals="2"
      id="f-625"
      unitRef="cadPerShare">26.22</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <cybn:NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement contextRef="c-5" decimals="0" id="f-626" unitRef="shares">47735</cybn:NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement>
    <cybn:WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement
      contextRef="c-5"
      decimals="2"
      id="f-627"
      unitRef="cadPerShare">44.08</cybn:WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-3" decimals="0" id="f-628" unitRef="shares">1742139</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-3"
      decimals="2"
      id="f-629"
      unitRef="cadPerShare">35.17</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c-1" decimals="0" id="f-630" unitRef="shares">3484626</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c-1"
      decimals="2"
      id="f-631"
      unitRef="cadPerShare">13.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <cybn:NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement contextRef="c-1" decimals="0" id="f-632" unitRef="shares">1270081</cybn:NumberOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement>
    <cybn:WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement
      contextRef="c-1"
      decimals="2"
      id="f-633"
      unitRef="cadPerShare">38.76</cybn:WeightedAverageExercisePriceOfShareOptionsForfeitedAndExpiredInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-2" decimals="0" id="f-634" unitRef="shares">3956684</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-2"
      decimals="2"
      id="f-635"
      unitRef="cadPerShare">15.23</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-2" decimals="0" id="f-636" unitRef="shares">3591976</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-2"
      decimals="2"
      id="f-637"
      unitRef="cadPerShare">15.19</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-192"
      decimals="INF"
      id="f-638"
      unitRef="shares">308294</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-193"
      decimals="INF"
      id="f-639"
      unitRef="shares">134872</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-194"
      decimals="INF"
      id="f-640"
      unitRef="shares">144738</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-195"
      decimals="INF"
      id="f-641"
      unitRef="shares">28684</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-196"
      decimals="2"
      id="f-642"
      unitRef="cadPerShare">21.28</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-197"
      decimals="INF"
      id="f-643"
      unitRef="shares">38536</cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-198"
      decimals="INF"
      id="f-644"
      unitRef="shares">269758</cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-199" id="f-645">P2Y</cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="c-1" id="f-646">The aggregate estimated grant date fair value was determined to be $4,619 calculated using the Black-Scholes option pricing model with the following assumptions: &lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.62%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on historical share price of the Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.13%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0% - 3.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.28&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.28&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The aggregate estimated grant date fair value was determined to be $34,822 calculated using the Black-Scholes option pricing model with the following assumptions: &lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.187%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.07%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on historical share price of the Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.69%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%  - 3.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The aggregate estimated grant date fair value was determined to be $982 calculated using the Black-Scholes option pricing model with the following assumptions: &lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.23%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on historical share price of the Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.06%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0% - 3.4% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.37&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The aggregate estimated grant date fair value was determined to be $307 calculated using the Black-Scholes option pricing model with the following assumptions: &lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.03%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on historical share price of the Company&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.43%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.45&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.45&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The aggregate estimated grant date fair value was determined to be $4,080, calculated using the Black-Scholes option pricing model with the following assumptions: &lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.78%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on comparable companies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.86&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt; The aggregate estimated grant date fair value was determined to be $577, calculated using the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt; Options expiring on September 26, 2026&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.68%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on comparable companies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Options  expiring on September 26, 2028&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;    &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;Risk-free interest rate&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.28%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on comparable companies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The aggregate estimated grant date fair value was determined to be $10,907, calculated using the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;   Options expiring on November 16, 2026&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.28%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on comparable companies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Options expiring on November 16, 2028&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.28%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on comparable companies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The aggregate estimated grant date fair value was determined to be $8, calculated using the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.52%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected annual volatility, based on comparable companies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.28&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 3.77pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.28&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-200" decimals="-3" id="f-647" unitRef="cad">4619000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c-201" decimals="4" id="f-648" unitRef="number">0.0362</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c-201" decimals="4" id="f-649" unitRef="number">0.8813</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-201" decimals="2" id="f-650" unitRef="y">5.00</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c-201" decimals="4" id="f-651" unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted contextRef="c-202" decimals="3" id="f-652" unitRef="number">0</cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted>
    <cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted contextRef="c-203" decimals="3" id="f-653" unitRef="number">0.034</cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-201"
      decimals="2"
      id="f-654"
      unitRef="cadPerShare">21.28</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-201"
      decimals="2"
      id="f-655"
      unitRef="cadPerShare">21.28</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="c-204"
      decimals="INF"
      id="f-656"
      unitRef="shares">1199655</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c-205"
      decimals="2"
      id="f-657"
      unitRef="cadPerShare">27.17</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c-206"
      decimals="2"
      id="f-658"
      unitRef="cadPerShare">119.7</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-207" decimals="-3" id="f-659" unitRef="cad">1185000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-208"
      decimals="INF"
      id="f-660"
      unitRef="shares">3061232</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-209"
      decimals="INF"
      id="f-661"
      unitRef="shares">940168</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-210"
      decimals="INF"
      id="f-662"
      unitRef="shares">1980888</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-211"
      decimals="INF"
      id="f-663"
      unitRef="shares">140176</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-212"
      decimals="2"
      id="f-664"
      unitRef="cadPerShare">13.11</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-213" id="f-665">P2Y</cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-214" decimals="-3" id="f-666" unitRef="cad">34822000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c-213" decimals="4" id="f-667" unitRef="number">0.0307</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c-213" decimals="4" id="f-668" unitRef="number">0.8669</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-213" decimals="2" id="f-669" unitRef="y">10.00</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c-213" decimals="4" id="f-670" unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted contextRef="c-215" decimals="3" id="f-671" unitRef="number">0</cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted>
    <cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted contextRef="c-216" decimals="3" id="f-672" unitRef="number">0.034</cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-213"
      decimals="2"
      id="f-673"
      unitRef="cadPerShare">13.30</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-213"
      decimals="2"
      id="f-674"
      unitRef="cadPerShare">13.11</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-217"
      decimals="INF"
      id="f-675"
      unitRef="shares">80100</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-218"
      decimals="INF"
      id="f-676"
      unitRef="shares">73100</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-219"
      decimals="INF"
      id="f-677"
      unitRef="shares">7000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-220"
      decimals="2"
      id="f-678"
      unitRef="cadPerShare">14.37</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-221" id="f-679">P2Y</cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-222" decimals="-3" id="f-680" unitRef="cad">982000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c-223" decimals="4" id="f-681" unitRef="number">0.0323</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c-223" decimals="4" id="f-682" unitRef="number">0.8606</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-223" decimals="2" id="f-683" unitRef="y">10.00</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c-223" decimals="4" id="f-684" unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted contextRef="c-224" decimals="3" id="f-685" unitRef="number">0</cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted>
    <cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted contextRef="c-225" decimals="3" id="f-686" unitRef="number">0.034</cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-223"
      decimals="2"
      id="f-687"
      unitRef="cadPerShare">14.37</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-223"
      decimals="2"
      id="f-688"
      unitRef="cadPerShare">14.37</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-226"
      decimals="INF"
      id="f-689"
      unitRef="shares">35000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-227"
      decimals="2"
      id="f-690"
      unitRef="cadPerShare">10.45</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-228" id="f-691">P1Y</cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-229" decimals="-3" id="f-692" unitRef="cad">307000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c-230" decimals="4" id="f-693" unitRef="number">0.0303</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c-230" decimals="4" id="f-694" unitRef="number">0.8343</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-230" decimals="2" id="f-695" unitRef="y">10.00</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c-230" decimals="4" id="f-696" unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted contextRef="c-230" decimals="2" id="f-697" unitRef="number">0.02</cybn:UnvestedForfeitureRateAsPercentageShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-230"
      decimals="2"
      id="f-698"
      unitRef="cadPerShare">10.45</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-230"
      decimals="2"
      id="f-699"
      unitRef="cadPerShare">10.45</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-231"
      decimals="INF"
      id="f-700"
      unitRef="shares">305661</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-232"
      decimals="INF"
      id="f-701"
      unitRef="shares">105026</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-233"
      decimals="INF"
      id="f-702"
      unitRef="shares">99027</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-234"
      decimals="INF"
      id="f-703"
      unitRef="shares">80949</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-235"
      decimals="INF"
      id="f-704"
      unitRef="shares">20659</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-236"
      decimals="2"
      id="f-705"
      unitRef="cadPerShare">16.72</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-237"
      decimals="INF"
      id="f-706"
      unitRef="shares">39474</cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-238"
      decimals="INF"
      id="f-707"
      unitRef="shares">18422</cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-239" id="f-708">P3M</cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-240"
      decimals="INF"
      id="f-709"
      unitRef="shares">2632</cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-241" id="f-710">P1Y</cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-242"
      decimals="INF"
      id="f-711"
      unitRef="shares">245133</cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-243" id="f-712">P2Y</cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-244" decimals="-3" id="f-713" unitRef="cad">4080000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c-245" decimals="4" id="f-714" unitRef="number">0.0378</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c-245" decimals="4" id="f-715" unitRef="number">0.9500</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-245" decimals="2" id="f-716" unitRef="y">5.00</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c-245" decimals="4" id="f-717" unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-245"
      decimals="2"
      id="f-718"
      unitRef="cadPerShare">17.86</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-245"
      decimals="2"
      id="f-719"
      unitRef="cadPerShare">16.72</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-246"
      decimals="INF"
      id="f-720"
      unitRef="shares">31842</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-247"
      decimals="INF"
      id="f-721"
      unitRef="shares">3553</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-248"
      decimals="INF"
      id="f-722"
      unitRef="shares">28289</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-246"
      decimals="2"
      id="f-723"
      unitRef="cadPerShare">30.02</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-249"
      decimals="INF"
      id="f-724"
      unitRef="shares">25657</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-250"
      decimals="INF"
      id="f-725"
      unitRef="shares">6185</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-251"
      decimals="INF"
      id="f-726"
      unitRef="shares">9868</cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-252" id="f-727">P3M</cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-253"
      decimals="INF"
      id="f-728"
      unitRef="shares">5263</cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-254" id="f-729">P6M</cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-255"
      decimals="INF"
      id="f-730"
      unitRef="shares">10526</cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-256" id="f-731">P1Y</cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-257"
      decimals="INF"
      id="f-732"
      unitRef="shares">2632</cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-258" id="f-733">P15M</cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-259"
      decimals="INF"
      id="f-734"
      unitRef="shares">3553</cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-260" id="f-735">P18M</cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-261" decimals="-3" id="f-736" unitRef="cad">577000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c-262" decimals="4" id="f-737" unitRef="number">0.0468</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c-262" decimals="4" id="f-738" unitRef="number">0.8500</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-262" decimals="2" id="f-739" unitRef="y">3.00</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c-262" decimals="4" id="f-740" unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-262"
      decimals="2"
      id="f-741"
      unitRef="cadPerShare">30.02</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-262"
      decimals="2"
      id="f-742"
      unitRef="cadPerShare">30.02</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c-263" decimals="4" id="f-743" unitRef="number">0.0428</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c-263" decimals="4" id="f-744" unitRef="number">0.9500</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-263" decimals="2" id="f-745" unitRef="y">5.00</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c-263" decimals="4" id="f-746" unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-263"
      decimals="2"
      id="f-747"
      unitRef="cadPerShare">30.02</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-263"
      decimals="2"
      id="f-748"
      unitRef="cadPerShare">30.02</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-264"
      decimals="INF"
      id="f-749"
      unitRef="shares">673682</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-265"
      decimals="INF"
      id="f-750"
      unitRef="shares">584211</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-266"
      decimals="INF"
      id="f-751"
      unitRef="shares">42104</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-267"
      decimals="INF"
      id="f-752"
      unitRef="shares">34209</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-268"
      decimals="INF"
      id="f-753"
      unitRef="shares">13158</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-269"
      decimals="2"
      id="f-754"
      unitRef="cadPerShare">27.17</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-270"
      decimals="INF"
      id="f-755"
      unitRef="shares">13158</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-271"
      decimals="INF"
      id="f-756"
      unitRef="shares">660524</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-272"
      decimals="INF"
      id="f-757"
      unitRef="shares">496052</cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement
      contextRef="c-273"
      decimals="INF"
      id="f-758"
      unitRef="shares">177630</cybn:NumberOfShareOptionsVestedInShareBasedPaymentArrangement>
    <cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-274" id="f-759">P2Y</cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-275" decimals="-3" id="f-760" unitRef="cad">10907000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c-276" decimals="4" id="f-761" unitRef="number">0.0428</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c-276" decimals="4" id="f-762" unitRef="number">0.8500</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-276" decimals="2" id="f-763" unitRef="y">3.00</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c-276" decimals="4" id="f-764" unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-276"
      decimals="2"
      id="f-765"
      unitRef="cadPerShare">22.80</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-276"
      decimals="2"
      id="f-766"
      unitRef="cadPerShare">27.17</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c-277" decimals="4" id="f-767" unitRef="number">0.0428</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c-277" decimals="4" id="f-768" unitRef="number">0.9500</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-277" decimals="2" id="f-769" unitRef="y">5.00</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c-277" decimals="4" id="f-770" unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-277"
      decimals="2"
      id="f-771"
      unitRef="cadPerShare">22.80</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-277"
      decimals="2"
      id="f-772"
      unitRef="cadPerShare">27.17</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="c-278"
      decimals="INF"
      id="f-773"
      unitRef="shares">526</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-279"
      decimals="2"
      id="f-774"
      unitRef="cadPerShare">21.28</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod contextRef="c-280" id="f-775">P2Y</cybn:VestingRequirementsForShareBasedPaymentArrangementVestingPeriod>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-281" decimals="-3" id="f-776" unitRef="cad">8000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c-280" decimals="4" id="f-777" unitRef="number">0.0352</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c-280" decimals="4" id="f-778" unitRef="number">0.9500</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-280" decimals="2" id="f-779" unitRef="y">5.00</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c-280" decimals="4" id="f-780" unitRef="number">0.0000</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="c-280"
      decimals="2"
      id="f-781"
      unitRef="cadPerShare">21.28</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="c-280"
      decimals="2"
      id="f-782"
      unitRef="cadPerShare">21.28</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-282" decimals="0" id="f-783" unitRef="option">986</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-282" decimals="0" id="f-784" unitRef="option">986</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-282"
      decimals="2"
      id="f-785"
      unitRef="cadPerShare">13.11</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-282" decimals="-3" id="f-786" unitRef="cad">11000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-283" id="f-787">P0Y7D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-284" decimals="0" id="f-788" unitRef="option">2372</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-284" decimals="0" id="f-789" unitRef="option">2372</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-284"
      decimals="2"
      id="f-790"
      unitRef="cadPerShare">16.72</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-284" decimals="-3" id="f-791" unitRef="cad">32000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-285" id="f-792">P0Y7D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-286" decimals="0" id="f-793" unitRef="option">986</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-286" decimals="0" id="f-794" unitRef="option">986</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-286"
      decimals="2"
      id="f-795"
      unitRef="cadPerShare">21.28</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-286" decimals="-3" id="f-796" unitRef="cad">15000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-287" id="f-797">P0Y7D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-288" decimals="0" id="f-798" unitRef="option">1161</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-288" decimals="0" id="f-799" unitRef="option">1161</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-288"
      decimals="2"
      id="f-800"
      unitRef="cadPerShare">66.12</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-288" decimals="-3" id="f-801" unitRef="cad">55000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-289" id="f-802">P0Y7D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-290" decimals="0" id="f-803" unitRef="option">27631</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-290" decimals="0" id="f-804" unitRef="option">27631</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-290"
      decimals="2"
      id="f-805"
      unitRef="cadPerShare">9.50</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-290" decimals="-3" id="f-806" unitRef="cad">188000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-291" id="f-807">P0Y2M15D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-292" decimals="0" id="f-808" unitRef="option">5263</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-292" decimals="0" id="f-809" unitRef="option">5263</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-292"
      decimals="2"
      id="f-810"
      unitRef="cadPerShare">34.20</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-292" decimals="-3" id="f-811" unitRef="cad">73000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-293" id="f-812">P0Y3M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-294" decimals="0" id="f-813" unitRef="option">7106</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-294" decimals="0" id="f-814" unitRef="option">7106</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-294"
      decimals="2"
      id="f-815"
      unitRef="cadPerShare">28.50</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-294" decimals="-3" id="f-816" unitRef="cad">97000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-295" id="f-817">P0Y6M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-296" decimals="0" id="f-818" unitRef="option">25000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-296" decimals="0" id="f-819" unitRef="option">25000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-296"
      decimals="2"
      id="f-820"
      unitRef="cadPerShare">28.50</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-296" decimals="-3" id="f-821" unitRef="cad">509000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-297" id="f-822">P0Y7M6D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-298" decimals="0" id="f-823" unitRef="option">9869</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-298" decimals="0" id="f-824" unitRef="option">9869</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-298"
      decimals="2"
      id="f-825"
      unitRef="cadPerShare">28.50</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-298" decimals="-3" id="f-826" unitRef="cad">110000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-299" id="f-827">P0Y7M17D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-300" decimals="0" id="f-828" unitRef="option">5263</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-300" decimals="0" id="f-829" unitRef="option">5263</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-300"
      decimals="2"
      id="f-830"
      unitRef="cadPerShare">34.58</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-300" decimals="-3" id="f-831" unitRef="cad">53000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-301" id="f-832">P0Y7M17D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-302" decimals="0" id="f-833" unitRef="option">5263</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-302" decimals="0" id="f-834" unitRef="option">5263</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-302"
      decimals="2"
      id="f-835"
      unitRef="cadPerShare">56.24</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-302" decimals="-3" id="f-836" unitRef="cad">211000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-303" id="f-837">P0Y8M12D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-304" decimals="0" id="f-838" unitRef="option">2829</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-304" decimals="0" id="f-839" unitRef="option">2829</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-304"
      decimals="2"
      id="f-840"
      unitRef="cadPerShare">66.12</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-304" decimals="-3" id="f-841" unitRef="cad">131000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-305" id="f-842">P0Y8M15D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-306" decimals="0" id="f-843" unitRef="option">2500</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-306" decimals="0" id="f-844" unitRef="option">2500</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-306"
      decimals="2"
      id="f-845"
      unitRef="cadPerShare">13.11</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-306" decimals="-3" id="f-846" unitRef="cad">28000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-307" id="f-847">P0Y9M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-308" decimals="0" id="f-848" unitRef="option">3947</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-308" decimals="0" id="f-849" unitRef="option">3947</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-308"
      decimals="2"
      id="f-850"
      unitRef="cadPerShare">16.72</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-308" decimals="-3" id="f-851" unitRef="cad">53000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-309" id="f-852">P0Y9M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-310" decimals="0" id="f-853" unitRef="option">5263</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-310" decimals="0" id="f-854" unitRef="option">5263</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-310"
      decimals="2"
      id="f-855"
      unitRef="cadPerShare">21.28</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-310" decimals="-3" id="f-856" unitRef="cad">79000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-311" id="f-857">P0Y9M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-312" decimals="0" id="f-858" unitRef="option">1974</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-312" decimals="0" id="f-859" unitRef="option">1974</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-312"
      decimals="2"
      id="f-860"
      unitRef="cadPerShare">77.14</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-312" decimals="-3" id="f-861" unitRef="cad">109000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-313" id="f-862">P0Y10M17D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-314" decimals="0" id="f-863" unitRef="option">5725</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-314" decimals="0" id="f-864" unitRef="option">5725</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-314"
      decimals="2"
      id="f-865"
      unitRef="cadPerShare">52.82</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-314" decimals="-3" id="f-866" unitRef="cad">217000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-315" id="f-867">P0Y11M8D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-316" decimals="0" id="f-868" unitRef="option">7895</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-316" decimals="0" id="f-869" unitRef="option">7895</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-316"
      decimals="2"
      id="f-870"
      unitRef="cadPerShare">58.90</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-316" decimals="-3" id="f-871" unitRef="cad">360000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-317" id="f-872">P0Y11M15D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-318" decimals="0" id="f-873" unitRef="option">987</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-318" decimals="0" id="f-874" unitRef="option">987</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-318"
      decimals="2"
      id="f-875"
      unitRef="cadPerShare">50.16</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-318" decimals="-3" id="f-876" unitRef="cad">35000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-319" id="f-877">P0Y11M26D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-320" decimals="0" id="f-878" unitRef="option">4342</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-320" decimals="0" id="f-879" unitRef="option">4342</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-320"
      decimals="2"
      id="f-880"
      unitRef="cadPerShare">13.11</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-320" decimals="-3" id="f-881" unitRef="cad">49000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-321" id="f-882">P1Y</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-322" decimals="0" id="f-883" unitRef="option">3339</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-322" decimals="0" id="f-884" unitRef="option">3339</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-322"
      decimals="2"
      id="f-885"
      unitRef="cadPerShare">16.72</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-322" decimals="-3" id="f-886" unitRef="cad">44000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-323" id="f-887">P1Y</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-324" decimals="0" id="f-888" unitRef="option">986</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-324" decimals="0" id="f-889" unitRef="option">986</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-324"
      decimals="2"
      id="f-890"
      unitRef="cadPerShare">21.28</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-324" decimals="-3" id="f-891" unitRef="cad">15000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-325" id="f-892">P1Y</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-326" decimals="0" id="f-893" unitRef="option">4475</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-326" decimals="0" id="f-894" unitRef="option">4475</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-326"
      decimals="2"
      id="f-895"
      unitRef="cadPerShare">110.20</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-326" decimals="-3" id="f-896" unitRef="cad">355000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-327" id="f-897">P1Y2M26D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-328" decimals="0" id="f-898" unitRef="option">25657</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-328" decimals="0" id="f-899" unitRef="option">25657</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-328"
      decimals="2"
      id="f-900"
      unitRef="cadPerShare">30.02</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-328" decimals="-3" id="f-901" unitRef="cad">439000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-329" id="f-902">P1Y5M26D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-330" decimals="0" id="f-903" unitRef="option">13158</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-330" decimals="0" id="f-904" unitRef="option">9868</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-330"
      decimals="2"
      id="f-905"
      unitRef="cadPerShare">27.17</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-330" decimals="-3" id="f-906" unitRef="cad">150000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-331" id="f-907">P1Y7M17D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-332" decimals="0" id="f-908" unitRef="option">32896</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-332" decimals="0" id="f-909" unitRef="option">32896</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-332"
      decimals="2"
      id="f-910"
      unitRef="cadPerShare">57.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-332" decimals="-3" id="f-911" unitRef="cad">1352000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-333" id="f-912">P1Y9M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-334" decimals="0" id="f-913" unitRef="option">526</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-334" decimals="0" id="f-914" unitRef="option">526</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-334"
      decimals="2"
      id="f-915"
      unitRef="cadPerShare">42.94</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-334" decimals="-3" id="f-916" unitRef="cad">16000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-335" id="f-917">P1Y11M1D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-336" decimals="0" id="f-918" unitRef="option">10526</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-336" decimals="0" id="f-919" unitRef="option">10526</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-336"
      decimals="2"
      id="f-920"
      unitRef="cadPerShare">38.76</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-336" decimals="-3" id="f-921" unitRef="cad">295000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-337" id="f-922">P1Y11M8D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-338" decimals="0" id="f-923" unitRef="option">277949</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-338" decimals="0" id="f-924" unitRef="option">277949</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-338"
      decimals="2"
      id="f-925"
      unitRef="cadPerShare">16.72</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-338" decimals="-3" id="f-926" unitRef="cad">3710000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-339" id="f-927">P3Y3M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-340" decimals="0" id="f-928" unitRef="option">2632</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-340" decimals="0" id="f-929" unitRef="option">2632</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-340"
      decimals="2"
      id="f-930"
      unitRef="cadPerShare">30.02</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-340" decimals="-3" id="f-931" unitRef="cad">59000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-341" id="f-932">P3Y5M26D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-342" decimals="0" id="f-933" unitRef="option">526</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-342" decimals="0" id="f-934" unitRef="option">394</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-342"
      decimals="2"
      id="f-935"
      unitRef="cadPerShare">21.28</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-342" decimals="-3" id="f-936" unitRef="cad">8000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-343" id="f-937">P3Y11M19D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-344" decimals="0" id="f-938" unitRef="option">284873</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-344" decimals="0" id="f-939" unitRef="option">177994</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-344"
      decimals="2"
      id="f-940"
      unitRef="cadPerShare">21.28</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-344" decimals="-3" id="f-941" unitRef="cad">3742000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-345" id="f-942">P4Y3D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-346" decimals="0" id="f-943" unitRef="option">7895</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-346" decimals="0" id="f-944" unitRef="option">7895</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-346"
      decimals="2"
      id="f-945"
      unitRef="cadPerShare">34.20</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-346" decimals="-3" id="f-946" unitRef="cad">179000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-347" id="f-947">P7Y3M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-348" decimals="0" id="f-948" unitRef="option">3049784</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-348" decimals="0" id="f-949" unitRef="option">2877860</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-348"
      decimals="2"
      id="f-950"
      unitRef="cadPerShare">13.11</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-348" decimals="-3" id="f-951" unitRef="cad">34032000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-349" id="f-952">P9Y4M13D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-350" decimals="0" id="f-953" unitRef="option">80100</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-350" decimals="0" id="f-954" unitRef="option">23867</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-350"
      decimals="2"
      id="f-955"
      unitRef="cadPerShare">14.37</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-350" decimals="-3" id="f-956" unitRef="cad">507000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-351" id="f-957">P9Y7M28D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-352" decimals="0" id="f-958" unitRef="option">35000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-352" decimals="0" id="f-959" unitRef="option">8750</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-352"
      decimals="2"
      id="f-960"
      unitRef="cadPerShare">10.45</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-352" decimals="-3" id="f-961" unitRef="cad">109000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-353" id="f-962">P9Y11M4D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-2" decimals="0" id="f-963" unitRef="option">3956684</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-2" decimals="0" id="f-964" unitRef="option">3591976</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-2" decimals="-3" id="f-965" unitRef="cad">47427000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-1" id="f-966">P8Y1M17D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-28" decimals="-3" id="f-967" unitRef="cad">40914000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-5" decimals="-3" id="f-968" unitRef="cad">13886000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="c-1" id="f-970">RELATED PARTY TRANSACTIONS AND BALANCES&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;Key management personnel include persons having the authority and responsibility for planning, directing, and controlling the activities of the Company as a whole. The Company has determined its key management personnel to be certain executive officers and directors of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The remuneration of key management personnel for the years ended March 31, 2025 and 2024 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-left:2.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payroll, consulting and benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,807&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 15.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24,937&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 15.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,239&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;33,983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%;padding-left:8pt"&gt; For the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%"&gt;March&#160;31, 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%"&gt;, includes $&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%"&gt;6,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%"&gt; (2024 - $5,145) presented in the consolidated statements of loss and comprehensive loss as a part of &#x201c;General and administrative costs&#x201d; and $&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%"&gt;1,167 (2024 - $1,261)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%"&gt; presented in the consolidated statements of loss and comprehensive loss as a part of &#x201c;Research&#x201d;.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c-1" id="f-971">&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The remuneration of key management personnel for the years ended March 31, 2025 and 2024 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-left:2.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payroll, consulting and benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,807&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 15.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24,937&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 15.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,239&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;33,983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%;padding-left:8pt"&gt; For the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%"&gt;March&#160;31, 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%"&gt;, includes $&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%"&gt;6,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%"&gt; (2024 - $5,145) presented in the consolidated statements of loss and comprehensive loss as a part of &#x201c;General and administrative costs&#x201d; and $&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:139%"&gt;1,167 (2024 - $1,261)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:139%"&gt; presented in the consolidated statements of loss and comprehensive loss as a part of &#x201c;Research&#x201d;.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-1" decimals="-3" id="f-972" unitRef="cad">7807000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-5" decimals="-3" id="f-973" unitRef="cad">6406000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-354" decimals="-3" id="f-974" unitRef="cad">24937000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-355" decimals="-3" id="f-975" unitRef="cad">8643000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-356" decimals="-3" id="f-976" unitRef="cad">1239000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-357" decimals="-3" id="f-977" unitRef="cad">0</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-1" decimals="-3" id="f-978" unitRef="cad">33983000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-5" decimals="-3" id="f-979" unitRef="cad">15049000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-358" decimals="-3" id="f-980" unitRef="cad">6640000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-359" decimals="-3" id="f-981" unitRef="cad">5145000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-360" decimals="-3" id="f-982" unitRef="cad">1167000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-361" decimals="-3" id="f-983" unitRef="cad">1261000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory contextRef="c-1" id="f-984">RESEARCH EXPENSES&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.246%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.248%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advancement of development programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab and administration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional and consulting fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;54,910&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory>
    <cybn:ScheduleOfResearchExpensesTableTextBlock contextRef="c-1" id="f-985">&lt;div style="padding-left:13.5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.115%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.460%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.246%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.248%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advancement of development programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab and administration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional and consulting fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;54,910&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cybn:ScheduleOfResearchExpensesTableTextBlock>
    <cybn:AdvancementOfDevelopmentPrograms contextRef="c-1" decimals="-3" id="f-986" unitRef="cad">39547000</cybn:AdvancementOfDevelopmentPrograms>
    <cybn:AdvancementOfDevelopmentPrograms contextRef="c-5" decimals="-3" id="f-987" unitRef="cad">22799000</cybn:AdvancementOfDevelopmentPrograms>
    <cybn:PayrollAndBenefits contextRef="c-1" decimals="-3" id="f-988" unitRef="cad">13146000</cybn:PayrollAndBenefits>
    <cybn:PayrollAndBenefits contextRef="c-5" decimals="-3" id="f-989" unitRef="cad">8319000</cybn:PayrollAndBenefits>
    <cybn:LabAndAdministration contextRef="c-1" decimals="-3" id="f-990" unitRef="cad">1933000</cybn:LabAndAdministration>
    <cybn:LabAndAdministration contextRef="c-5" decimals="-3" id="f-991" unitRef="cad">1034000</cybn:LabAndAdministration>
    <cybn:ProfessionalAndConsultingFees contextRef="c-1" decimals="-3" id="f-992" unitRef="cad">284000</cybn:ProfessionalAndConsultingFees>
    <cybn:ProfessionalAndConsultingFees contextRef="c-5" decimals="-3" id="f-993" unitRef="cad">210000</cybn:ProfessionalAndConsultingFees>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-994" unitRef="cad">54910000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-995" unitRef="cad">32362000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory contextRef="c-1" id="f-996">GENERAL AND ADMINISTRATIVE EXPENSES&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.068%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,694&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll, consulting and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office and administration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional and consulting fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,156&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Business development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,305&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investor relations and Marketing media&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,286&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Listing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;45,368&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory>
    <ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory contextRef="c-1" id="f-997">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.066%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.068%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,694&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll, consulting and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office and administration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional and consulting fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,156&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Business development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,305&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investor relations and Marketing media&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,286&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Listing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;45,368&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory>
    <cybn:CapitalMarketExpense contextRef="c-1" decimals="-3" id="f-998" unitRef="cad">16694000</cybn:CapitalMarketExpense>
    <cybn:CapitalMarketExpense contextRef="c-5" decimals="-3" id="f-999" unitRef="cad">11519000</cybn:CapitalMarketExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-1" decimals="-3" id="f-1000" unitRef="cad">13146000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-5" decimals="-3" id="f-1001" unitRef="cad">8248000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:OccupancyExpense contextRef="c-1" decimals="-3" id="f-1002" unitRef="cad">4498000</ifrs-full:OccupancyExpense>
    <ifrs-full:OccupancyExpense contextRef="c-5" decimals="-3" id="f-1003" unitRef="cad">2945000</ifrs-full:OccupancyExpense>
    <ifrs-full:ProfessionalFeesExpense contextRef="c-1" decimals="-3" id="f-1004" unitRef="cad">4156000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense contextRef="c-5" decimals="-3" id="f-1005" unitRef="cad">4918000</ifrs-full:ProfessionalFeesExpense>
    <cybn:BusinessDevelopmentExpense contextRef="c-1" decimals="-3" id="f-1006" unitRef="cad">3305000</cybn:BusinessDevelopmentExpense>
    <cybn:BusinessDevelopmentExpense contextRef="c-5" decimals="-3" id="f-1007" unitRef="cad">896000</cybn:BusinessDevelopmentExpense>
    <cybn:InvestorRelationsSalesAndMarketingExpense contextRef="c-1" decimals="-3" id="f-1008" unitRef="cad">3286000</cybn:InvestorRelationsSalesAndMarketingExpense>
    <cybn:InvestorRelationsSalesAndMarketingExpense contextRef="c-5" decimals="-3" id="f-1009" unitRef="cad">3791000</cybn:InvestorRelationsSalesAndMarketingExpense>
    <cybn:ListingFeesExpense contextRef="c-1" decimals="-3" id="f-1010" unitRef="cad">283000</cybn:ListingFeesExpense>
    <cybn:ListingFeesExpense contextRef="c-5" decimals="-3" id="f-1011" unitRef="cad">271000</cybn:ListingFeesExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-1012" unitRef="cad">45368000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-1013" unitRef="cad">32588000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="c-1" id="f-1014">CONTRACTS, COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;As at March&#160;31, 2025, the Company had entered into agreements for various studies which may require the Company to spend up to an additional $85,802. The Company expects to pay this amount within the 24 months ending March 31, 2027, however the timing and certainty of the payments are contingent on availability of materials and successful completion of certain milestones. The Company has the right to cancel the studies at its discretion, in which case a cancellation fee may apply, however the Company is not liable to pay the full amount of the studies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;In addition to the above, during the year ended March 31, 2022, the Company entered into an exclusive license agreement with Mindset Pharma Inc. to acquire access to a number of classes of tryptamine-based molecules to support Company&#x2019;s early-stage research programs and a fully-paid, perpetual non-exclusive license to a separate class of tryptamine-based molecules. Upon the successful completion of certain milestones contemplated in the exclusive license, the Company may have to pay additional consideration of up to $13,657 (US$9,500). At the sole discretion of Cybin, the milestones may be paid in cash or in Common Shares, or a combination thereof, subject to the approval of Cboe Canada. Due to the nature of the arrangement, the timing and probability of future potential payments cannot be determined at this time, and no accrual has been recorded. Further, there is no assurance that the aforementioned milestones will be met at all. The agreement also contemplates a sales royalty of approximately 2% for all commercialized licensed products within the scope of the agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The Company is party to certain employee and management contracts that contain severance obligations. These contracts contain clauses requiring additional payments to be made upon the occurrence of involuntary termination. As the likelihood of these events taking place is not determinable, no contingent liabilities have been recorded in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;In the normal course of business, the Company may be subject to legal proceedings and claims. As at March&#160;31, 2025, there was no ongoing litigation and therefore no contingent liabilities have been recorded in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <ifrs-full:ContractualCapitalCommitments contextRef="c-2" decimals="-3" id="f-1015" unitRef="cad">85802000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:ContractualCapitalCommitments contextRef="c-362" decimals="-3" id="f-1016" unitRef="cad">13657000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:ContractualCapitalCommitments contextRef="c-362" decimals="-3" id="f-1017" unitRef="usd">9500000</ifrs-full:ContractualCapitalCommitments>
    <cybn:SalesRoyaltyPercentage
      contextRef="c-363"
      decimals="2"
      id="f-1018"
      unitRef="number">0.02</cybn:SalesRoyaltyPercentage>
    <ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory contextRef="c-1" id="f-1019">CAPITAL MANAGEMENT&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The Company&#x2019;s objectives when managing capital are to safeguard the Company&#x2019;s ability to continue as a going concern in order to pursue business opportunities and to maintain a flexible capital structure that optimizes the costs of capital at an acceptable risk. The Company&#x2019;s intentions are to (i) provide financial capacity and flexibility in order to preserve its ability to meet its strategic objectives and financial obligations; (ii) maintain a capital structure which allows the Company to respond to changes in economic and marketplace conditions and affords the Company the ability to participate in new investments; (iii) optimize the use of its capital to provide an appropriate investment return to its shareholders equal with the level of risk; and (iv) maintain a flexible capital structure which optimizes the cost of capital at acceptable levels of risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The Company&#x2019;s financial strategy is formulated and adapted according to market conditions in order to maintain a flexible capital structure that is consistent with its objectives and the risk characteristics of its underlying assets. The Company manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of its underlying assets. The Company maintains or adjusts its capital level to enable it to meet its objectives by raising capital through the issuance of securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The Company&#x2019;s capital management objectives, policies and processes generally remained unchanged during the year ended March 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The Company requires capital to fund existing and future operations. The Company&#x2019;s policy is to maintain adequate levels of capital at all times.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The Company&#x2019;s capital structure includes the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shareholders&#x2019; equity comprised of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;464,364&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contributed surplus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;44,414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47,427&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27,594&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(339,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;237,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,927&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory>
    <cybn:DisclosureOfCapitalStructureTableTextBlock contextRef="c-1" id="f-1020">&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The Company&#x2019;s capital structure includes the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shareholders&#x2019; equity comprised of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;464,364&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contributed surplus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;44,414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;47,427&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27,594&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(339,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;237,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291,927&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cybn:DisclosureOfCapitalStructureTableTextBlock>
    <ifrs-full:IssuedCapital contextRef="c-2" decimals="-3" id="f-1021" unitRef="cad">464364000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c-3" decimals="-3" id="f-1022" unitRef="cad">443877000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c-3" decimals="-3" id="f-1023" unitRef="cad">443877000</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium contextRef="c-2" decimals="-3" id="f-1024" unitRef="cad">44414000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c-3" decimals="-3" id="f-1025" unitRef="cad">11750000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c-3" decimals="-3" id="f-1026" unitRef="cad">11750000</ifrs-full:SharePremium>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c-2" decimals="-3" id="f-1027" unitRef="cad">47427000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c-3" decimals="-3" id="f-1028" unitRef="cad">39177000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="c-3" decimals="-3" id="f-1029" unitRef="cad">39177000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:WarrantReserve contextRef="c-2" decimals="-3" id="f-1030" unitRef="cad">27594000</ifrs-full:WarrantReserve>
    <ifrs-full:WarrantReserve contextRef="c-3" decimals="-3" id="f-1031" unitRef="cad">25639000</ifrs-full:WarrantReserve>
    <ifrs-full:WarrantReserve contextRef="c-3" decimals="-3" id="f-1032" unitRef="cad">25639000</ifrs-full:WarrantReserve>
    <ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="c-2" decimals="-3" id="f-1033" unitRef="cad">-7231000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="c-3" decimals="-3" id="f-1034" unitRef="cad">-2285000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="c-3" decimals="-3" id="f-1035" unitRef="cad">-2285000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:RetainedEarnings contextRef="c-2" decimals="-3" id="f-1036" unitRef="cad">-339368000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c-3" decimals="-3" id="f-1037" unitRef="cad">-226231000</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity contextRef="c-2" decimals="-3" id="f-1038" unitRef="cad">237200000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-3" id="f-1039" unitRef="cad">291927000</ifrs-full:Equity>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="c-1" id="f-1040">FINANCIAL INSTRUMENTS&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The Company&#x2019;s financial instruments are exposed to certain financial risks, which include currency risk, credit risk, liquidity risk and interest rate risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The Company has classified its financial instruments as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.129%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.010%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial assets, measured at fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;135,022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial assets, measured at amortized cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;706&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial liabilities, measured at amortized cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,418&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The carrying value of the Company&#x2019;s financial instruments approximate their fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%;text-decoration:underline"&gt;Fair value hierarchy of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The Company has categorized its financial instruments that are carried at fair value, based on the priority of the inputs to the valuation techniques used to measure fair value, into a three-level fair value hierarchy as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;Level 1:  Fair value is based on unadjusted quoted prices for identical assets or liabilities in an active market. The types of assets and liabilities classified as Level 1 generally included cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;Level 2: Fair value is based on quoted prices for similar assets or liabilities in active markets, valuation that is based on significant observable inputs, or inputs that are derived principally from or corroborated with observable market data through correlation or other means. Currently, the Company has no financial instruments that would be classified as Level 2. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;Level 3: Fair value is based on valuation techniques that require one or more significant inputs that are not based on observable market inputs. These unobservable inputs reflect the Company&#x2019;s assumptions about the assumptions market participants would use in pricing the asset or liability. Currently, the Company has no financial instruments that would be classified as Level 3. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;There were no transfers between levels of the fair value hierarchy for the year ended March 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%;text-decoration:underline"&gt;Financial risk management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;Credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company&#x2019;s cash is exposed to credit risk.  The Company reduces its &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;credit risk on cash by placing these instruments with institutions of high creditworthiness. As at March&#160;31, 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:139%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;the Company&#x2019;s maximum exposure to credit risk is the carrying value of its financial assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;Liquidity risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;Liquidity risk is the risk that an entity will encounter difficulty in raising funds to meet commitments associated with financial instruments. The Company manages liquidity by maintaining adequate cash balances to meet liabilities as they become due.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;As at March&#160;31, 2025, the Company had cash of $135,022 (March&#160;31, 2024 - $208,992) in order to meet current liabilities. Current liabilities include accounts payable and accrued liabilities of $21,418&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:139%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;(March&#160;31, 2024 - $9,805) and lease liabilities of $nil (March 31, 2024 - $291). All amounts are due within the next 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;Market risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The significant market risks to which the Company is exposed are interest rate risk and currency risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%;text-decoration:underline"&gt;Interest rate risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;Interest rate risk is the risk that the fair value or the future cash flows of a financial instrument will fluctuate because of changes in market interest rates. In seeking to minimize the risks from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities.  Assuming that all other variables remain constant, as at March&#160;31, 2025, a 1% decline on the interest rate generated on cash would have resulted in a reduction of interest income of $1,145 over a one-year period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%;text-decoration:underline"&gt;Currency risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The Company is exposed to currency risk to the extent that monetary operational expenses are denominated in both CAD and USD while the functional currency of CAD is used for reporting.  The Company has not entered into any foreign currency contracts to mitigate this risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;At March&#160;31, 2025 the Company had the following balances in monetary assets and monetary liabilities which are subject to fluctuation against CAD:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.673%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.481%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.817%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.652%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominated in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;US$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;GBP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;EUR&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,841)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(415)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;90,928&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;618&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4376&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8571&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Equivalent in Canadian dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;130,718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;960&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Impact of 10% change in exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;Such analysis excludes any indirect economic or geo-political effects of such currency fluctuations.</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfFinancialAssetsExplanatory contextRef="c-1" id="f-1042">&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The Company has classified its financial instruments as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.129%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.010%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial assets, measured at fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;135,022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial assets, measured at amortized cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;706&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial liabilities, measured at amortized cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,418&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialAssetsExplanatory>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory contextRef="c-1" id="f-1041">&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The Company has classified its financial instruments as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.129%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.010%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial assets, measured at fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;135,022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial assets, measured at amortized cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;706&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial liabilities, measured at amortized cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,418&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 9.77pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <ifrs-full:Cash contextRef="c-364" decimals="-3" id="f-1043" unitRef="cad">135022000</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c-365" decimals="-3" id="f-1044" unitRef="cad">208992000</ifrs-full:Cash>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c-366" decimals="-3" id="f-1045" unitRef="cad">706000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="c-367" decimals="-3" id="f-1046" unitRef="cad">42000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c-368" decimals="-3" id="f-1047" unitRef="cad">21418000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c-369" decimals="-3" id="f-1048" unitRef="cad">9805000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-2" decimals="-3" id="f-1049" unitRef="cad">0</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-3" decimals="-3" id="f-1050" unitRef="cad">291000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-4" decimals="-3" id="f-1051" unitRef="cad">291000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:Cash contextRef="c-2" decimals="-3" id="f-1052" unitRef="cad">135022000</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c-3" decimals="-3" id="f-1053" unitRef="cad">208992000</ifrs-full:Cash>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c-2" decimals="-3" id="f-1054" unitRef="cad">21418000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c-369" decimals="-3" id="f-1055" unitRef="cad">9805000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-2" decimals="-3" id="f-1056" unitRef="cad">0</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-3" decimals="-3" id="f-1057" unitRef="cad">291000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-4" decimals="-3" id="f-1058" unitRef="cad">291000</ifrs-full:CurrentLeaseLiabilities>
    <cybn:InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash contextRef="c-2" decimals="2" id="f-1059" unitRef="number">-0.01</cybn:InterestRateRiskIncreaseDecreaseInInterestRateGeneratedOnCash>
    <cybn:InterestRateRiskIncreaseDecreaseInInterestIncome contextRef="c-2" decimals="-3" id="f-1060" unitRef="cad">-1145000</cybn:InterestRateRiskIncreaseDecreaseInInterestIncome>
    <cybn:InterestRateRiskTerm contextRef="c-1" id="f-1061">P1Y</cybn:InterestRateRiskTerm>
    <ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory contextRef="c-1" id="f-1062">&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;At March&#160;31, 2025 the Company had the following balances in monetary assets and monetary liabilities which are subject to fluctuation against CAD:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.673%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.481%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.817%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.652%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominated in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;US$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;GBP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;EUR&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,841)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(415)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;90,928&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;618&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4376&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8571&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Equivalent in Canadian dollars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;130,718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;960&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Impact of 10% change in exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsExplanatory>
    <cybn:FinancialAssetsAndLiabilities contextRef="c-370" decimals="-3" id="f-1063" unitRef="usd">92416000</cybn:FinancialAssetsAndLiabilities>
    <cybn:FinancialAssetsAndLiabilities contextRef="c-371" decimals="-3" id="f-1064" unitRef="gbp">76000</cybn:FinancialAssetsAndLiabilities>
    <cybn:FinancialAssetsAndLiabilities contextRef="c-372" decimals="-3" id="f-1065" unitRef="eur">676000</cybn:FinancialAssetsAndLiabilities>
    <cybn:FinancialAssetsAndLiabilities contextRef="c-373" decimals="-3" id="f-1066" unitRef="usd">353000</cybn:FinancialAssetsAndLiabilities>
    <cybn:FinancialAssetsAndLiabilities contextRef="c-374" decimals="-3" id="f-1067" unitRef="gbp">0</cybn:FinancialAssetsAndLiabilities>
    <cybn:FinancialAssetsAndLiabilities contextRef="c-375" decimals="-3" id="f-1068" unitRef="eur">0</cybn:FinancialAssetsAndLiabilities>
    <cybn:FinancialAssetsAndLiabilities contextRef="c-376" decimals="-3" id="f-1069" unitRef="usd">-1841000</cybn:FinancialAssetsAndLiabilities>
    <cybn:FinancialAssetsAndLiabilities contextRef="c-377" decimals="-3" id="f-1070" unitRef="gbp">-415000</cybn:FinancialAssetsAndLiabilities>
    <cybn:FinancialAssetsAndLiabilities contextRef="c-378" decimals="-3" id="f-1071" unitRef="eur">-58000</cybn:FinancialAssetsAndLiabilities>
    <cybn:FinancialAssetsAndLiabilities contextRef="c-379" decimals="-3" id="f-1072" unitRef="usd">90928000</cybn:FinancialAssetsAndLiabilities>
    <cybn:FinancialAssetsAndLiabilities contextRef="c-380" decimals="-3" id="f-1073" unitRef="gbp">-339000</cybn:FinancialAssetsAndLiabilities>
    <cybn:FinancialAssetsAndLiabilities contextRef="c-381" decimals="-3" id="f-1074" unitRef="eur">618000</cybn:FinancialAssetsAndLiabilities>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="c-379"
      decimals="4"
      id="f-1075"
      unitRef="shares">1.4376</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="c-380"
      decimals="4"
      id="f-1076"
      unitRef="shares">1.8571</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="c-381"
      decimals="4"
      id="f-1077"
      unitRef="shares">1.5540</ifrs-full:ClosingForeignExchangeRate>
    <cybn:FinancialAssetsAndLiabilities contextRef="c-379" decimals="-3" id="f-1078" unitRef="cad">130718000</cybn:FinancialAssetsAndLiabilities>
    <cybn:FinancialAssetsAndLiabilities contextRef="c-380" decimals="-3" id="f-1079" unitRef="cad">-630000</cybn:FinancialAssetsAndLiabilities>
    <cybn:FinancialAssetsAndLiabilities contextRef="c-381" decimals="-3" id="f-1080" unitRef="cad">960000</cybn:FinancialAssetsAndLiabilities>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic contextRef="c-379" decimals="-3" id="f-1081" unitRef="cad">13072000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic contextRef="c-380" decimals="-3" id="f-1082" unitRef="cad">-63000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic contextRef="c-381" decimals="-3" id="f-1083" unitRef="cad">96000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c-1" id="f-1084">INCOME TAX &lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;Major items causing the Company&#x2019;s income tax rate to differ from the Canadian statutory rate of approximately 26.5% are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended March 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 3.77pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 3.77pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 3.77pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 3.77pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 3.75pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(113,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(78,080)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected recovery at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,981&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,691&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-capital losses acquired on acquisition of subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10,497)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,680)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;122&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,420&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Difference between Canadian and foreign tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,317)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,440)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange on unbooked deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;351&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in unrecognized deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10,537)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,405)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income tax recovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 3.77pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 3.77pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The significant components of the Company&#x2019;s deferred tax assets resulting from temporary differences, unused tax credits and unused tax losses, that have not been included on the consolidated statement of financial position, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.928%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.127%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-capital loss carryforwards - Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,310&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,168&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-capital loss carryforwards - United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,533&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,344&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-capital loss carryforwards - Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,327&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,391&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-capital loss carryforwards - United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,767&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,282&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,653&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,474&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and Development expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,538&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,681&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,102&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation/Capital cost allowance differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;61,245&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,708&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(61,245)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,708)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;Non-capital loss balance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;As at March&#160;31, 2025, the Company has non-capital losses in Canada, which under certain circumstances can be used to reduce taxable income of future years. The non-capital losses expire as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year of expiry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2037&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;115&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;863&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,856&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2043&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,704&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24,397&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,105&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;84,154&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;As at March&#160;31, 2025, the Company has non-capital losses in the United States and Massachusetts of $12,064, which under certain circumstances can be used to reduce the taxable income of future years. The federal losses have no expiry but are subject to limitations on utilization as laid out below. The Massachusetts non-capital losses, stated in Canadian dollars expire as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.993%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year of expiry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,053&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,543&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,979&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2043&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,593&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,425&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,471&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,064&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="background-color:#ffde0f;color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:139%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;Although the US federal losses carryforward indefinitely, they are subject to restrictions on their deductibility. For federal purposes the deductibility of $2,596 is restricted to 80% of taxable income in the year of deduction. The deductibility of $1,053 is further restricted to an annual limitation under Section 382. As at March&#160;31, 2025, the annual limitation was $153.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;As at March&#160;31, 2025, the Company has non-capital losses in Ireland, which under certain circumstances can be used to reduce taxable income of future years. The non-capital losses in Ireland, stated in Canadian Dollars, expire as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.272%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.528%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year of expiry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-right:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,965&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23,017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;2044&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;33,857&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57,875&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;137,714&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;As at March&#160;31, 2025 the Company had $43,208 of non-capital losses in UK which under certain circumstances can be used to reduce the taxable income of future years. These losses do not expire.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <cybn:DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock contextRef="c-1" id="f-1085">&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;Major items causing the Company&#x2019;s income tax rate to differ from the Canadian statutory rate of approximately 26.5% are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.733%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended March 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 3.77pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 3.77pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 3.77pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 3.77pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 3.75pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(113,137)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.75pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(78,080)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected recovery at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,981&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,691&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-capital losses acquired on acquisition of subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10,497)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,680)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;122&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,420&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Difference between Canadian and foreign tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,317)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,440)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange on unbooked deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;351&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in unrecognized deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10,537)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,405)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income tax recovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 3.77pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 3.77pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cybn:DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTableTextBlock>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-1086" unitRef="cad">-113137000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-5" decimals="-3" id="f-1087" unitRef="cad">-78080000</ifrs-full:ProfitLoss>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="c-1" decimals="-3" id="f-1088" unitRef="cad">-29981000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="c-5" decimals="-3" id="f-1089" unitRef="cad">-20691000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset contextRef="c-1" decimals="-3" id="f-1090" unitRef="cad">0</ifrs-full:ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset>
    <ifrs-full:ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset contextRef="c-5" decimals="-3" id="f-1091" unitRef="cad">-11658000</ifrs-full:ChangeInAmountRecognisedForPreacquisitionDeferredTaxAsset>
    <cybn:TaxEffectOfShareBasedCompensation contextRef="c-1" decimals="-3" id="f-1092" unitRef="cad">10497000</cybn:TaxEffectOfShareBasedCompensation>
    <cybn:TaxEffectOfShareBasedCompensation contextRef="c-5" decimals="-3" id="f-1093" unitRef="cad">3680000</cybn:TaxEffectOfShareBasedCompensation>
    <cybn:TaxEffectOfShareIssuanceCosts contextRef="c-1" decimals="-3" id="f-1094" unitRef="cad">122000</cybn:TaxEffectOfShareIssuanceCosts>
    <cybn:TaxEffectOfShareIssuanceCosts contextRef="c-5" decimals="-3" id="f-1095" unitRef="cad">4420000</cybn:TaxEffectOfShareIssuanceCosts>
    <ifrs-full:TaxEffectOfForeignTaxRates contextRef="c-1" decimals="-3" id="f-1096" unitRef="cad">9317000</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates contextRef="c-5" decimals="-3" id="f-1097" unitRef="cad">5440000</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset contextRef="c-1" decimals="-3" id="f-1098" unitRef="cad">351000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset contextRef="c-5" decimals="-3" id="f-1099" unitRef="cad">-112000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesDeferredTaxLiabilityAsset>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="c-1" decimals="-3" id="f-1100" unitRef="cad">103000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss contextRef="c-5" decimals="-3" id="f-1101" unitRef="cad">132000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <cybn:TaxEffectOfChangeInDeferredTaxAssets contextRef="c-1" decimals="-3" id="f-1102" unitRef="cad">10537000</cybn:TaxEffectOfChangeInDeferredTaxAssets>
    <cybn:TaxEffectOfChangeInDeferredTaxAssets contextRef="c-5" decimals="-3" id="f-1103" unitRef="cad">27405000</cybn:TaxEffectOfChangeInDeferredTaxAssets>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-3" id="f-1104" unitRef="cad">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-5" decimals="-3" id="f-1105" unitRef="cad">0</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory contextRef="c-1" id="f-1106">&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;The significant components of the Company&#x2019;s deferred tax assets resulting from temporary differences, unused tax credits and unused tax losses, that have not been included on the consolidated statement of financial position, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.634%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.928%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.127%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.645%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:1.65pt;padding-right:2.75pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;March 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-capital loss carryforwards - Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,310&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,168&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-capital loss carryforwards - United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,533&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,344&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-capital loss carryforwards - Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,327&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,391&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-capital loss carryforwards - United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,767&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,282&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,653&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,474&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and Development expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,538&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,681&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,102&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,361&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation/Capital cost allowance differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;61,245&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,708&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(61,245)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,708)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
    <cybn:GrossDeferredTaxAssets contextRef="c-382" decimals="-3" id="f-1107" unitRef="cad">22310000</cybn:GrossDeferredTaxAssets>
    <cybn:GrossDeferredTaxAssets contextRef="c-383" decimals="-3" id="f-1108" unitRef="cad">20168000</cybn:GrossDeferredTaxAssets>
    <cybn:GrossDeferredTaxAssets contextRef="c-384" decimals="-3" id="f-1109" unitRef="cad">2533000</cybn:GrossDeferredTaxAssets>
    <cybn:GrossDeferredTaxAssets contextRef="c-385" decimals="-3" id="f-1110" unitRef="cad">2344000</cybn:GrossDeferredTaxAssets>
    <cybn:GrossDeferredTaxAssets contextRef="c-386" decimals="-3" id="f-1111" unitRef="cad">18327000</cybn:GrossDeferredTaxAssets>
    <cybn:GrossDeferredTaxAssets contextRef="c-387" decimals="-3" id="f-1112" unitRef="cad">10391000</cybn:GrossDeferredTaxAssets>
    <cybn:GrossDeferredTaxAssets contextRef="c-388" decimals="-3" id="f-1113" unitRef="cad">10767000</cybn:GrossDeferredTaxAssets>
    <cybn:GrossDeferredTaxAssets contextRef="c-389" decimals="-3" id="f-1114" unitRef="cad">10282000</cybn:GrossDeferredTaxAssets>
    <cybn:GrossDeferredTaxAssets contextRef="c-390" decimals="-3" id="f-1115" unitRef="cad">1653000</cybn:GrossDeferredTaxAssets>
    <cybn:GrossDeferredTaxAssets contextRef="c-391" decimals="-3" id="f-1116" unitRef="cad">1474000</cybn:GrossDeferredTaxAssets>
    <cybn:GrossDeferredTaxAssets contextRef="c-392" decimals="-3" id="f-1117" unitRef="cad">2538000</cybn:GrossDeferredTaxAssets>
    <cybn:GrossDeferredTaxAssets contextRef="c-393" decimals="-3" id="f-1118" unitRef="cad">1681000</cybn:GrossDeferredTaxAssets>
    <cybn:GrossDeferredTaxAssets contextRef="c-394" decimals="-3" id="f-1119" unitRef="cad">3102000</cybn:GrossDeferredTaxAssets>
    <cybn:GrossDeferredTaxAssets contextRef="c-395" decimals="-3" id="f-1120" unitRef="cad">4361000</cybn:GrossDeferredTaxAssets>
    <cybn:GrossDeferredTaxAssets contextRef="c-396" decimals="-3" id="f-1121" unitRef="cad">15000</cybn:GrossDeferredTaxAssets>
    <cybn:GrossDeferredTaxAssets contextRef="c-397" decimals="-3" id="f-1122" unitRef="cad">7000</cybn:GrossDeferredTaxAssets>
    <cybn:GrossDeferredTaxAssets contextRef="c-2" decimals="-3" id="f-1123" unitRef="cad">61245000</cybn:GrossDeferredTaxAssets>
    <cybn:GrossDeferredTaxAssets contextRef="c-3" decimals="-3" id="f-1124" unitRef="cad">50708000</cybn:GrossDeferredTaxAssets>
    <cybn:DeferredTaxAssetsValuationAllowance contextRef="c-2" decimals="-3" id="f-1125" unitRef="cad">61245000</cybn:DeferredTaxAssetsValuationAllowance>
    <cybn:DeferredTaxAssetsValuationAllowance contextRef="c-3" decimals="-3" id="f-1126" unitRef="cad">50708000</cybn:DeferredTaxAssetsValuationAllowance>
    <ifrs-full:DeferredTaxAssets contextRef="c-2" decimals="-3" id="f-1127" unitRef="cad">0</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets contextRef="c-3" decimals="-3" id="f-1128" unitRef="cad">0</ifrs-full:DeferredTaxAssets>
    <cybn:DisclosureOfExpirationOfNonCapitalLossesTableTextBlock contextRef="c-1" id="f-1129">The non-capital losses expire as follows:&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year of expiry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2036&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2037&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2038&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;115&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;863&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,856&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2043&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,704&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24,397&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,105&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;84,154&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.993%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year of expiry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2040&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,053&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,543&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,979&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2043&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,593&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2044&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,425&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,471&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,064&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The non-capital losses in Ireland, stated in Canadian Dollars, expire as follows:&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.275%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.272%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.528%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year of expiry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.15pt;padding-right:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,965&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23,017&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;2044&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;33,857&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:1.5pt;margin-top:2.65pt;padding-right:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:139%"&gt;2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57,875&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;137,714&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cybn:DisclosureOfExpirationOfNonCapitalLossesTableTextBlock>
    <cybn:NonCapitalLossCarryforward contextRef="c-398" decimals="-3" id="f-1130" unitRef="cad">1000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-399" decimals="-3" id="f-1131" unitRef="cad">62000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-400" decimals="-3" id="f-1132" unitRef="cad">32000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-401" decimals="-3" id="f-1133" unitRef="cad">115000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-402" decimals="-3" id="f-1134" unitRef="cad">863000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-403" decimals="-3" id="f-1135" unitRef="cad">21856000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-404" decimals="-3" id="f-1136" unitRef="cad">16019000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-405" decimals="-3" id="f-1137" unitRef="cad">10704000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-406" decimals="-3" id="f-1138" unitRef="cad">24397000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-407" decimals="-3" id="f-1139" unitRef="cad">10105000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-408" decimals="-3" id="f-1140" unitRef="cad">84154000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-409" decimals="-3" id="f-1141" unitRef="cad">12064000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-410" decimals="-3" id="f-1142" unitRef="cad">1053000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-411" decimals="-3" id="f-1143" unitRef="cad">1543000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-412" decimals="-3" id="f-1144" unitRef="cad">4979000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-413" decimals="-3" id="f-1145" unitRef="cad">1593000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-414" decimals="-3" id="f-1146" unitRef="cad">1425000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-415" decimals="-3" id="f-1147" unitRef="cad">1471000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-409" decimals="-3" id="f-1148" unitRef="cad">12064000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-416" decimals="-3" id="f-1149" unitRef="cad">2596000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-410" decimals="-3" id="f-1150" unitRef="cad">1053000</cybn:NonCapitalLossCarryforward>
    <cybn:Section382Limitation contextRef="c-2" decimals="-3" id="f-1151" unitRef="cad">153000</cybn:Section382Limitation>
    <cybn:NonCapitalLossCarryforward contextRef="c-417" decimals="-3" id="f-1152" unitRef="cad">22965000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-418" decimals="-3" id="f-1153" unitRef="cad">23017000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-419" decimals="-3" id="f-1154" unitRef="cad">33857000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-420" decimals="-3" id="f-1155" unitRef="cad">57875000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-421" decimals="-3" id="f-1156" unitRef="cad">137714000</cybn:NonCapitalLossCarryforward>
    <cybn:NonCapitalLossCarryforward contextRef="c-422" decimals="-3" id="f-1157" unitRef="cad">43208000</cybn:NonCapitalLossCarryforward>
    <ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory contextRef="c-1" id="f-1158">SUBSEQUENT EVENTS&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;ATM Program&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;During the period from April 1, 2025 to June&#160;30, 2025, the Company sold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:130%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;1,422,423 Common Shares, at an average price of US$7.36 per Common Share, for aggregate gross proceeds of US$10,465, through its 2025 ATM Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:139%"&gt;Convertible Debentures&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;On June 30, 2025, the Company entered into a securities purchase agreement (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;SPA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;) with High Trail Special Situations LLC (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;High Trail&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;), pursuant to which the Company agreed to issue to High Trail up to US$500,000 of unsecured convertible debentures (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Convertible Debentures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;). The sale and issuance of US$50,000 principal amount of Convertible Debentures was completed on June 30, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Convertible Debentures have a two-year term (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;Convertible Debenture Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;). The Company is to pay guaranteed interest equal to 11% of the amount issued for the Convertible Debenture Term (the equivalent of 5.5% per annum). Such interest is to be pre-paid on closing. Upon the occurrence of an event of default, interest would increase to 18% per annum on the outstanding principal balance. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;Subject to the terms of the SPA and the Convertible Debentures, High Trail is to be entitled to convert the principal amount of, and accrued and unpaid interest, if any, in whole or in part, from time to time, into Common Shares at a conversion price per Common Share equal to the lower of (a) 130% of the volume weighted average price (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:130%"&gt;VWAP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;&#x201d;) of the Common Shares on the day prior to the initial issuance of the Convertible Debentures, or (b) the VWAP of the Common Shares during the &lt;span style="-sec-ix-hidden:f-1169"&gt;five&lt;/span&gt; trading days immediately prior to conversion.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:130%"&gt;The Company, in its sole discretion, may prepay any outstanding amount under the Convertible Debentures, in whole or in part, in cash by providing High Trail with advance written notice at least five trading days prior to such prepayment. The prepayment is to include, (i) if paid during the first year after closing, a 5% premium on the amount of the prepayment or (ii) if paid during the second year after closing, a 3% premium on the amount of the prepayment.  &lt;/span&gt;&lt;/div&gt;The terms of the Convertible Debentures restrict the conversion of Convertible Debentures by High Trail if such a conversion or exercise would cause High Trail, together with any affiliate thereof, to beneficially own in excess of 4.99% of the number of Common Shares outstanding immediately after giving effect to such conversion.</ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory>
    <cybn:NumberOfSharesIssuedThroughShareOfferingEquity
      contextRef="c-423"
      decimals="0"
      id="f-1159"
      unitRef="shares">1422423</cybn:NumberOfSharesIssuedThroughShareOfferingEquity>
    <cybn:SharePricePerCommonShare
      contextRef="c-423"
      decimals="2"
      id="f-1160"
      unitRef="usdPerShare">7.36</cybn:SharePricePerCommonShare>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-423" decimals="-3" id="f-1161" unitRef="usd">10465000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:DebtSecurities contextRef="c-424" decimals="-3" id="f-1162" unitRef="cad">500000000</ifrs-full:DebtSecurities>
    <ifrs-full:DebtSecurities contextRef="c-425" decimals="-3" id="f-1163" unitRef="cad">50000000</ifrs-full:DebtSecurities>
    <cybn:DebtInstrumentTerm contextRef="c-426" id="f-1164">P2Y</cybn:DebtInstrumentTerm>
    <cybn:DebtInstrumentGuaranteedInterestPayableRate
      contextRef="c-424"
      decimals="2"
      id="f-1165"
      unitRef="number">0.11</cybn:DebtInstrumentGuaranteedInterestPayableRate>
    <cybn:DebtInstrumentGuaranteedInterestPayableAnnualRate
      contextRef="c-424"
      decimals="3"
      id="f-1166"
      unitRef="number">0.055</cybn:DebtInstrumentGuaranteedInterestPayableAnnualRate>
    <cybn:DebtInstrumentDefaultRate
      contextRef="c-424"
      decimals="2"
      id="f-1167"
      unitRef="number">0.18</cybn:DebtInstrumentDefaultRate>
    <cybn:DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger
      contextRef="c-426"
      decimals="2"
      id="f-1168"
      unitRef="number">1.30</cybn:DebtInstrumentConvertibleDebentureThresholdPercentageOfStockPriceTrigger>
    <cybn:DebtInstrumentPrepaymentPremiumYearOne
      contextRef="c-426"
      decimals="2"
      id="f-1170"
      unitRef="number">0.05</cybn:DebtInstrumentPrepaymentPremiumYearOne>
    <cybn:DebtInstrumentPrepaymentPremiumYearTwo
      contextRef="c-426"
      decimals="2"
      id="f-1171"
      unitRef="number">0.03</cybn:DebtInstrumentPrepaymentPremiumYearTwo>
    <cybn:DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage
      contextRef="c-427"
      decimals="4"
      id="f-1172"
      unitRef="number">0.0499</cybn:DebtInstrumentConvertibleDebentureMaximumAffiliateOwnershipPercentage>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
